[{"PMID": 23313376, "id": 0, "text": "Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 13], "name": "Pterostilbene", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"ent_type": "GENE", "char_span": [91, 95], "name": "JAK2", "tok_span": [16, 18], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [96, 101], "name": "STAT3", "tok_span": [19, 21], "new_tok_span": [27, 29]}], "relation_list": [{"subject": "Pterostilbene", "sbj_char_span": [0, 13], "object": "JAK2", "obj_char_span": [91, 95], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [16, 18], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [22, 24]}, {"subject": "Pterostilbene", "sbj_char_span": [0, 13], "object": "STAT3", "obj_char_span": [96, 101], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [19, 21], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [27, 29]}], "umls_entity_list": [{"mention": "Pterostilbene", "char_span": [0, 13], "sem_type": "Pharmacologic Substance", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"mention": "osteosarcoma", "char_span": [54, 66], "sem_type": "Gene or Genome", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"mention": "JAK2", "char_span": [91, 95], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 18], "new_tok_span": [22, 24]}, {"mention": "JAK2", "char_span": [91, 95], "sem_type": "Gene or Genome", "tok_span": [16, 18], "new_tok_span": [22, 24]}], "new_text": "<START=Pharmacologic Substance> Pterostilbene <END=Pharmacologic Substance> exerts antitumor activity against human <START=Gene or Genome> osteosarcoma <END=Gene or Genome> cells by inhibiting the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> JAK2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> / STAT3 signaling pathway."}, {"PMID": 23295227, "id": 10, "text": "Overall, these changes could contribute to the difference in inhibitory potency of fidarestat between AR and AKR1B10.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [83, 93], "name": "fidarestat", "tok_span": [13, 17], "new_tok_span": [14, 18]}, {"ent_type": "GENE", "char_span": [102, 104], "name": "AR", "tok_span": [18, 19], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [109, 116], "name": "AKR1B10", "tok_span": [20, 25], "new_tok_span": [22, 27]}], "relation_list": [{"subject": "fidarestat", "sbj_char_span": [83, 93], "object": "AR", "obj_char_span": [102, 104], "rel_type": "inhibitor", "sbj_tok_span": [13, 17], "obj_tok_span": [18, 19], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [20, 21]}, {"subject": "fidarestat", "sbj_char_span": [83, 93], "object": "AKR1B10", "obj_char_span": [109, 116], "rel_type": "inhibitor", "sbj_tok_span": [13, 17], "obj_tok_span": [20, 25], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [22, 27]}], "umls_entity_list": [{"mention": "fidarestat", "char_span": [83, 93], "sem_type": "Pharmacologic Substance", "tok_span": [13, 17], "new_tok_span": [14, 18]}], "new_text": "Overall, these changes could contribute to the difference in inhibitory potency of <START=Pharmacologic Substance> fidarestat <END=Pharmacologic Substance> between AR and AKR1B10."}, {"PMID": 10730683, "id": 4, "text": "Orlistat treatment also results in modest improvements in total cholesterol, low-density lipoprotein, blood pressure, and fasting glucose and insulin concentrations.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "Orlistat", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [64, 75], "name": "cholesterol", "tok_span": [11, 12], "new_tok_span": [13, 14]}, {"ent_type": "CHEMICAL", "char_span": [130, 137], "name": "glucose", "tok_span": [23, 24], "new_tok_span": [26, 27]}, {"ent_type": "GENE", "char_span": [77, 100], "name": "low-density lipoprotein", "tok_span": [13, 17], "new_tok_span": [15, 19]}, {"ent_type": "GENE", "char_span": [142, 149], "name": "insulin", "tok_span": [25, 26], "new_tok_span": [29, 30]}], "relation_list": [{"subject": "Orlistat", "sbj_char_span": [0, 8], "object": "low-density lipoprotein", "obj_char_span": [77, 100], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [13, 17], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [15, 19]}, {"subject": "Orlistat", "sbj_char_span": [0, 8], "object": "insulin", "obj_char_span": [142, 149], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [25, 26], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [29, 30]}], "umls_entity_list": [{"mention": "Orlistat", "char_span": [0, 8], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "glucose", "char_span": [130, 137], "sem_type": "Pharmacologic Substance", "tok_span": [23, 24], "new_tok_span": [26, 27]}], "new_text": "<START=Pharmacologic Substance> Orlistat <END=Pharmacologic Substance> treatment also results in modest improvements in total cholesterol, low - density lipoprotein, blood pressure, and fasting <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> and insulin concentrations."}, {"PMID": 2994716, "id": 0, "text": "Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Two different human genomic DNA libraries were screened for the gene for blood coagulation factor IX by employing a cDNA for the human protein as a hybridization probe.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Nucleotide", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [158, 179], "name": "coagulation factor IX", "tok_span": [31, 34], "new_tok_span": [40, 43]}, {"ent_type": "GENE", "char_span": [36, 51], "name": "human factor IX", "tok_span": [7, 10], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [53, 76], "name": "antihemophilic factor B", "tok_span": [11, 16], "new_tok_span": [16, 21]}], "relation_list": [{"subject": "Nucleotide", "sbj_char_span": [0, 10], "object": "human factor IX", "obj_char_span": [36, 51], "rel_type": "part of", "sbj_tok_span": [0, 2], "obj_tok_span": [7, 10], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [7, 10]}, {"subject": "Nucleotide", "sbj_char_span": [0, 10], "object": "antihemophilic factor B", "obj_char_span": [53, 76], "rel_type": "part of", "sbj_tok_span": [0, 2], "obj_tok_span": [11, 16], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [16, 21]}], "umls_entity_list": [{"mention": "factor IX", "char_span": [42, 51], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 10], "new_tok_span": [10, 12]}, {"mention": "factor IX", "char_span": [170, 179], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 34], "new_tok_span": [43, 45]}, {"mention": "factor IX", "char_span": [42, 51], "sem_type": "Gene or Genome", "tok_span": [8, 10], "new_tok_span": [10, 12]}, {"mention": "factor IX", "char_span": [170, 179], "sem_type": "Gene or Genome", "tok_span": [32, 34], "new_tok_span": [43, 45]}, {"mention": "antihemophilic factor B", "char_span": [53, 76], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 16], "new_tok_span": [16, 21]}, {"mention": "genomic DNA libraries", "char_span": [99, 120], "sem_type": "Gene or Genome", "tok_span": [21, 24], "new_tok_span": [28, 31]}, {"mention": "blood coagulation factor IX", "char_span": [152, 179], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 34], "new_tok_span": [39, 43]}, {"mention": "human protein", "char_span": [208, 221], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [40, 42], "new_tok_span": [55, 57]}], "new_text": "Nucleotide sequence of the gene for human <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> factor IX <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( <START=Amino Acid, Peptide, or Protein> antihemophilic factor B <END=Amino Acid, Peptide, or Protein> ). Two different human <START=Gene or Genome> genomic DNA libraries <END=Gene or Genome> were screened for the gene for <START=Amino Acid, Peptide, or Protein> blood coagulation <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> factor IX <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> by employing a cDNA for the <START=Amino Acid, Peptide, or Protein> human protein <END=Amino Acid, Peptide, or Protein> as a hybridization probe."}, {"PMID": 23394205, "id": 3, "text": "Optimization from a high quality screening hit within tight SAR space led to compound 6 (AZ20) which inhibits ATR immunoprecipitated from HeLa nuclear extracts with an IC50 of 5 nM and ATR mediated phosphorylation of Chk1 in HT29 colorectal adenocarcinoma tumor cells with an IC50 of 50 nM.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [89, 93], "name": "AZ20", "tok_span": [16, 18], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [110, 113], "name": "ATR", "tok_span": [21, 23], "new_tok_span": [23, 25]}, {"ent_type": "GENE", "char_span": [185, 188], "name": "ATR", "tok_span": [37, 39], "new_tok_span": [39, 41]}, {"ent_type": "GENE", "char_span": [217, 221], "name": "Chk1", "tok_span": [42, 45], "new_tok_span": [45, 48]}], "relation_list": [{"subject": "AZ20", "sbj_char_span": [89, 93], "object": "ATR", "obj_char_span": [110, 113], "rel_type": "inhibitor", "sbj_tok_span": [16, 18], "obj_tok_span": [21, 23], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [23, 25]}, {"subject": "AZ20", "sbj_char_span": [89, 93], "object": "ATR", "obj_char_span": [185, 188], "rel_type": "inhibitor", "sbj_tok_span": [16, 18], "obj_tok_span": [37, 39], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [39, 41]}, {"subject": "AZ20", "sbj_char_span": [89, 93], "object": "Chk1", "obj_char_span": [217, 221], "rel_type": "inhibitor", "sbj_tok_span": [16, 18], "obj_tok_span": [42, 45], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [45, 48]}], "umls_entity_list": [{"mention": "SAR", "char_span": [60, 63], "sem_type": "Gene or Genome", "tok_span": [9, 10], "new_tok_span": [10, 11]}, {"mention": "Chk1", "char_span": [217, 221], "sem_type": "Gene or Genome", "tok_span": [42, 45], "new_tok_span": [45, 48]}], "new_text": "Optimization from a high quality screening hit within tight <START=Gene or Genome> SAR <END=Gene or Genome> space led to compound 6 ( AZ20 ) which inhibits ATR immunoprecipitated from HeLa nuclear extracts with an IC50 of 5 nM and ATR mediated phosphorylation of <START=Gene or Genome> Chk1 <END=Gene or Genome> in HT29 colorectal adenocarcinoma tumor cells with an IC50 of 50 nM."}, {"PMID": 15655513, "id": 4, "text": "In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515). 4.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [48, 59], "name": "lumiracoxib", "tok_span": [13, 17], "new_tok_span": [13, 17]}, {"ent_type": "GENE", "char_span": [81, 86], "name": "COX-2", "tok_span": [24, 27], "new_tok_span": [26, 29]}, {"ent_type": "GENE", "char_span": [105, 110], "name": "COX-1", "tok_span": [32, 35], "new_tok_span": [36, 39]}, {"ent_type": "GENE", "char_span": [112, 117], "name": "COX-1", "tok_span": [36, 39], "new_tok_span": [40, 43]}, {"ent_type": "GENE", "char_span": [118, 123], "name": "COX-2", "tok_span": [40, 43], "new_tok_span": [46, 49]}], "relation_list": [{"subject": "lumiracoxib", "sbj_char_span": [48, 59], "object": "COX-2", "obj_char_span": [81, 86], "rel_type": "inhibitor", "sbj_tok_span": [13, 17], "obj_tok_span": [24, 27], "new_sbj_tok_span": [13, 17], "new_obj_tok_span": [26, 29]}, {"subject": "lumiracoxib", "sbj_char_span": [48, 59], "object": "COX-1", "obj_char_span": [105, 110], "rel_type": "inhibitor", "sbj_tok_span": [13, 17], "obj_tok_span": [32, 35], "new_sbj_tok_span": [13, 17], "new_obj_tok_span": [36, 39]}, {"subject": "lumiracoxib", "sbj_char_span": [48, 59], "object": "COX-1", "obj_char_span": [112, 117], "rel_type": "inhibitor", "sbj_tok_span": [13, 17], "obj_tok_span": [36, 39], "new_sbj_tok_span": [13, 17], "new_obj_tok_span": [40, 43]}, {"subject": "lumiracoxib", "sbj_char_span": [48, 59], "object": "COX-2", "obj_char_span": [118, 123], "rel_type": "inhibitor", "sbj_tok_span": [13, 17], "obj_tok_span": [40, 43], "new_sbj_tok_span": [13, 17], "new_obj_tok_span": [46, 49]}], "umls_entity_list": [{"mention": "COX-2", "char_span": [81, 86], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 27], "new_tok_span": [26, 29]}, {"mention": "COX-2", "char_span": [118, 123], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [40, 43], "new_tok_span": [46, 49]}, {"mention": "COX-2", "char_span": [81, 86], "sem_type": "Gene or Genome", "tok_span": [24, 27], "new_tok_span": [26, 29]}, {"mention": "COX-2", "char_span": [118, 123], "sem_type": "Gene or Genome", "tok_span": [40, 43], "new_tok_span": [46, 49]}], "new_text": "In a human whole blood assay, IC ( 50 ) values for lumiracoxib were 0. 13 microM for <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> COX - 2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and 67 microM for COX - 1 ( COX - 1 / <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> COX - 2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> selectivity ratio 515 ). 4."}, {"PMID": 11118042, "id": 0, "text": "Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 16], "name": "Sulindac sulfone", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "GENE", "char_span": [26, 31], "name": "K-ras", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [42, 58], "name": "cyclooxygenase-2", "tok_span": [12, 16], "new_tok_span": [12, 16]}], "relation_list": [{"subject": "Sulindac sulfone", "sbj_char_span": [0, 16], "object": "K-ras", "obj_char_span": [26, 31], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [6, 10], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [6, 10]}, {"subject": "Sulindac sulfone", "sbj_char_span": [0, 16], "object": "cyclooxygenase-2", "obj_char_span": [42, 58], "rel_type": "regulator", "sbj_tok_span": [0, 5], "obj_tok_span": [12, 16], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [12, 16]}], "umls_entity_list": [], "new_text": "Sulindac sulfone inhibits K - ras - dependent cyclooxygenase - 2 expression in human colon cancer cells."}, {"PMID": 19663609, "id": 1, "text": "Conivaptan, the first vasopressin receptor antagonist approved by the FDA, is available for the treatment of hyponatremia in euvolemic and hypervolemic patients.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Conivaptan", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [22, 33], "name": "vasopressin", "tok_span": [7, 10], "new_tok_span": [10, 13]}, {"ent_type": "GENE", "char_span": [22, 42], "name": "vasopressin receptor", "tok_span": [7, 11], "new_tok_span": [10, 14]}], "relation_list": [{"subject": "Conivaptan", "sbj_char_span": [0, 10], "object": "vasopressin receptor", "obj_char_span": [22, 42], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 4], "obj_tok_span": [7, 11], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [10, 14]}], "umls_entity_list": [{"mention": "Conivaptan", "char_span": [0, 10], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "vasopressin receptor antagonist", "char_span": [22, 53], "sem_type": "Pharmacologic Substance", "tok_span": [7, 12], "new_tok_span": [10, 15]}], "new_text": "<START=Pharmacologic Substance> Conivaptan <END=Pharmacologic Substance>, the first <START=Pharmacologic Substance> vasopressin receptor antagonist <END=Pharmacologic Substance> approved by the FDA, is available for the treatment of hyponatremia in euvolemic and hypervolemic patients."}, {"PMID": 18336310, "id": 1, "text": "Inhibition of carbonic anhydrase (CA, EC 4.2.1.1) isoforms present in the eyes (CA I, II, IV and XII), with sulfonamides such as acetazolamide, methazolamide, ethoxzolamide and dichlorophenamide, is still widely used for the systemic treatment of glaucoma.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [108, 120], "name": "sulfonamides", "tok_span": [37, 41], "new_tok_span": [41, 45]}, {"ent_type": "CHEMICAL", "char_span": [129, 142], "name": "acetazolamide", "tok_span": [43, 46], "new_tok_span": [50, 53]}, {"ent_type": "CHEMICAL", "char_span": [144, 157], "name": "methazolamide", "tok_span": [47, 50], "new_tok_span": [55, 58]}, {"ent_type": "CHEMICAL", "char_span": [159, 172], "name": "ethoxzolamide", "tok_span": [51, 55], "new_tok_span": [60, 64]}, {"ent_type": "CHEMICAL", "char_span": [177, 194], "name": "dichlorophenamide", "tok_span": [56, 59], "new_tok_span": [67, 70]}, {"ent_type": "GENE", "char_span": [14, 32], "name": "carbonic anhydrase", "tok_span": [2, 7], "new_tok_span": [2, 7]}, {"ent_type": "GENE", "char_span": [34, 36], "name": "CA", "tok_span": [8, 9], "new_tok_span": [8, 9]}, {"ent_type": "GENE", "char_span": [38, 48], "name": "EC 4.2.1.1", "tok_span": [10, 18], "new_tok_span": [10, 18]}, {"ent_type": "GENE", "char_span": [80, 100], "name": "CA I, II, IV and XII", "tok_span": [25, 34], "new_tok_span": [27, 36]}], "relation_list": [{"subject": "sulfonamides", "sbj_char_span": [108, 120], "object": "carbonic anhydrase", "obj_char_span": [14, 32], "rel_type": "inhibitor", "sbj_tok_span": [37, 41], "obj_tok_span": [2, 7], "new_sbj_tok_span": [41, 45], "new_obj_tok_span": [2, 7]}, {"subject": "sulfonamides", "sbj_char_span": [108, 120], "object": "CA", "obj_char_span": [34, 36], "rel_type": "inhibitor", "sbj_tok_span": [37, 41], "obj_tok_span": [8, 9], "new_sbj_tok_span": [41, 45], "new_obj_tok_span": [8, 9]}, {"subject": "sulfonamides", "sbj_char_span": [108, 120], "object": "EC 4.2.1.1", "obj_char_span": [38, 48], "rel_type": "inhibitor", "sbj_tok_span": [37, 41], "obj_tok_span": [10, 18], "new_sbj_tok_span": [41, 45], "new_obj_tok_span": [10, 18]}, {"subject": "acetazolamide", "sbj_char_span": [129, 142], "object": "carbonic anhydrase", "obj_char_span": [14, 32], "rel_type": "inhibitor", "sbj_tok_span": [43, 46], "obj_tok_span": [2, 7], "new_sbj_tok_span": [50, 53], "new_obj_tok_span": [2, 7]}, {"subject": "acetazolamide", "sbj_char_span": [129, 142], "object": "CA", "obj_char_span": [34, 36], "rel_type": "inhibitor", "sbj_tok_span": [43, 46], "obj_tok_span": [8, 9], "new_sbj_tok_span": [50, 53], "new_obj_tok_span": [8, 9]}, {"subject": "acetazolamide", "sbj_char_span": [129, 142], "object": "EC 4.2.1.1", "obj_char_span": [38, 48], "rel_type": "inhibitor", "sbj_tok_span": [43, 46], "obj_tok_span": [10, 18], "new_sbj_tok_span": [50, 53], "new_obj_tok_span": [10, 18]}, {"subject": "methazolamide", "sbj_char_span": [144, 157], "object": "carbonic anhydrase", "obj_char_span": [14, 32], "rel_type": "inhibitor", "sbj_tok_span": [47, 50], "obj_tok_span": [2, 7], "new_sbj_tok_span": [55, 58], "new_obj_tok_span": [2, 7]}, {"subject": "methazolamide", "sbj_char_span": [144, 157], "object": "CA", "obj_char_span": [34, 36], "rel_type": "inhibitor", "sbj_tok_span": [47, 50], "obj_tok_span": [8, 9], "new_sbj_tok_span": [55, 58], "new_obj_tok_span": [8, 9]}, {"subject": "methazolamide", "sbj_char_span": [144, 157], "object": "EC 4.2.1.1", "obj_char_span": [38, 48], "rel_type": "inhibitor", "sbj_tok_span": [47, 50], "obj_tok_span": [10, 18], "new_sbj_tok_span": [55, 58], "new_obj_tok_span": [10, 18]}, {"subject": "ethoxzolamide", "sbj_char_span": [159, 172], "object": "carbonic anhydrase", "obj_char_span": [14, 32], "rel_type": "inhibitor", "sbj_tok_span": [51, 55], "obj_tok_span": [2, 7], "new_sbj_tok_span": [60, 64], "new_obj_tok_span": [2, 7]}, {"subject": "ethoxzolamide", "sbj_char_span": [159, 172], "object": "CA", "obj_char_span": [34, 36], "rel_type": "inhibitor", "sbj_tok_span": [51, 55], "obj_tok_span": [8, 9], "new_sbj_tok_span": [60, 64], "new_obj_tok_span": [8, 9]}, {"subject": "ethoxzolamide", "sbj_char_span": [159, 172], "object": "EC 4.2.1.1", "obj_char_span": [38, 48], "rel_type": "inhibitor", "sbj_tok_span": [51, 55], "obj_tok_span": [10, 18], "new_sbj_tok_span": [60, 64], "new_obj_tok_span": [10, 18]}, {"subject": "dichlorophenamide", "sbj_char_span": [177, 194], "object": "carbonic anhydrase", "obj_char_span": [14, 32], "rel_type": "inhibitor", "sbj_tok_span": [56, 59], "obj_tok_span": [2, 7], "new_sbj_tok_span": [67, 70], "new_obj_tok_span": [2, 7]}, {"subject": "dichlorophenamide", "sbj_char_span": [177, 194], "object": "CA", "obj_char_span": [34, 36], "rel_type": "inhibitor", "sbj_tok_span": [56, 59], "obj_tok_span": [8, 9], "new_sbj_tok_span": [67, 70], "new_obj_tok_span": [8, 9]}, {"subject": "dichlorophenamide", "sbj_char_span": [177, 194], "object": "EC 4.2.1.1", "obj_char_span": [38, 48], "rel_type": "inhibitor", "sbj_tok_span": [56, 59], "obj_tok_span": [10, 18], "new_sbj_tok_span": [67, 70], "new_obj_tok_span": [10, 18]}], "umls_entity_list": [{"mention": "isoforms", "char_span": [50, 58], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 20], "new_tok_span": [20, 21]}, {"mention": "sulfonamides", "char_span": [108, 120], "sem_type": "Pharmacologic Substance", "tok_span": [37, 41], "new_tok_span": [41, 45]}, {"mention": "acetazolamide", "char_span": [129, 142], "sem_type": "Pharmacologic Substance", "tok_span": [43, 46], "new_tok_span": [50, 53]}, {"mention": "sulfonamides", "char_span": [108, 120], "sem_type": "Organic Chemical", "tok_span": [37, 41], "new_tok_span": [41, 45]}, {"mention": "ethoxzolamide", "char_span": [159, 172], "sem_type": "Pharmacologic Substance", "tok_span": [51, 55], "new_tok_span": [60, 64]}, {"mention": "dichlorophenamide", "char_span": [177, 194], "sem_type": "Pharmacologic Substance", "tok_span": [56, 59], "new_tok_span": [67, 70]}, {"mention": "treatment of glaucoma", "char_span": [234, 255], "sem_type": "Pharmacologic Substance", "tok_span": [67, 70], "new_tok_span": [80, 83]}], "new_text": "Inhibition of carbonic anhydrase ( CA, EC 4. 2. 1. 1 ) <START=Amino Acid, Peptide, or Protein> isoforms <END=Amino Acid, Peptide, or Protein> present in the eyes ( CA I, II, IV and XII ), with <START=Pharmacologic Substance> <START=Organic Chemical> sulfonamides <END=Pharmacologic Substance> <END=Organic Chemical> such as <START=Pharmacologic Substance> acetazolamide <END=Pharmacologic Substance>, methazolamide, <START=Pharmacologic Substance> ethoxzolamide <END=Pharmacologic Substance> and <START=Pharmacologic Substance> dichlorophenamide <END=Pharmacologic Substance>, is still widely used for the systemic <START=Pharmacologic Substance> treatment of glaucoma <END=Pharmacologic Substance>."}, {"PMID": 17075268, "id": 10, "text": "Repression of HDC gene expression and HDC activity by dexamethasone may underlie its therapeutic effect in the treatment of allergy.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [54, 67], "name": "dexamethasone", "tok_span": [12, 13], "new_tok_span": [15, 16]}, {"ent_type": "GENE", "char_span": [14, 17], "name": "HDC", "tok_span": [3, 5], "new_tok_span": [4, 6]}, {"ent_type": "GENE", "char_span": [38, 41], "name": "HDC", "tok_span": [8, 10], "new_tok_span": [10, 12]}], "relation_list": [{"subject": "dexamethasone", "sbj_char_span": [54, 67], "object": "HDC", "obj_char_span": [14, 17], "rel_type": "regulator", "sbj_tok_span": [12, 13], "obj_tok_span": [3, 5], "new_sbj_tok_span": [15, 16], "new_obj_tok_span": [4, 6]}, {"subject": "dexamethasone", "sbj_char_span": [54, 67], "object": "HDC", "obj_char_span": [38, 41], "rel_type": "inhibitor", "sbj_tok_span": [12, 13], "obj_tok_span": [8, 10], "new_sbj_tok_span": [15, 16], "new_obj_tok_span": [10, 12]}], "umls_entity_list": [{"mention": "HDC gene", "char_span": [14, 22], "sem_type": "Gene or Genome", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "dexamethasone", "char_span": [54, 67], "sem_type": "Pharmacologic Substance", "tok_span": [12, 13], "new_tok_span": [15, 16]}], "new_text": "Repression of <START=Gene or Genome> HDC gene <END=Gene or Genome> expression and HDC activity by <START=Pharmacologic Substance> dexamethasone <END=Pharmacologic Substance> may underlie its therapeutic effect in the treatment of allergy."}, {"PMID": 19281809, "id": 2, "text": "We discovered sergliflozin etabonate, a novel selective SGLT2 inhibitor, and found that selective inhibition of SGLT2 increased urinary glucose excretion and consequently decreased plasma glucose levels.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 36], "name": "sergliflozin etabonate", "tok_span": [2, 10], "new_tok_span": [2, 10]}, {"ent_type": "CHEMICAL", "char_span": [136, 143], "name": "glucose", "tok_span": [30, 31], "new_tok_span": [33, 34]}, {"ent_type": "CHEMICAL", "char_span": [188, 195], "name": "glucose", "tok_span": [36, 37], "new_tok_span": [43, 44]}, {"ent_type": "GENE", "char_span": [56, 61], "name": "SGLT2", "tok_span": [14, 17], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [112, 117], "name": "SGLT2", "tok_span": [25, 28], "new_tok_span": [27, 30]}], "relation_list": [{"subject": "sergliflozin etabonate", "sbj_char_span": [14, 36], "object": "SGLT2", "obj_char_span": [56, 61], "rel_type": "inhibitor", "sbj_tok_span": [2, 10], "obj_tok_span": [14, 17], "new_sbj_tok_span": [2, 10], "new_obj_tok_span": [15, 18]}, {"subject": "sergliflozin etabonate", "sbj_char_span": [14, 36], "object": "SGLT2", "obj_char_span": [112, 117], "rel_type": "inhibitor", "sbj_tok_span": [2, 10], "obj_tok_span": [25, 28], "new_sbj_tok_span": [2, 10], "new_obj_tok_span": [27, 30]}], "umls_entity_list": [{"mention": "SGLT2 inhibitor", "char_span": [56, 71], "sem_type": "Pharmacologic Substance", "tok_span": [14, 18], "new_tok_span": [15, 19]}, {"mention": "glucose", "char_span": [136, 143], "sem_type": "Pharmacologic Substance", "tok_span": [30, 31], "new_tok_span": [33, 34]}, {"mention": "glucose", "char_span": [188, 195], "sem_type": "Pharmacologic Substance", "tok_span": [36, 37], "new_tok_span": [43, 44]}, {"mention": "plasma", "char_span": [181, 187], "sem_type": "Pharmacologic Substance", "tok_span": [35, 36], "new_tok_span": [40, 41]}], "new_text": "We discovered sergliflozin etabonate, a novel selective <START=Pharmacologic Substance> SGLT2 inhibitor <END=Pharmacologic Substance>, and found that selective inhibition of SGLT2 increased urinary <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> excretion and consequently decreased <START=Pharmacologic Substance> plasma <END=Pharmacologic Substance> <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> levels."}, {"PMID": 23220037, "id": 4, "text": "The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (DOX), a known P-gp inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [101, 112], "name": "doxorubicin", "tok_span": [20, 21], "new_tok_span": [22, 23]}, {"ent_type": "CHEMICAL", "char_span": [114, 117], "name": "DOX", "tok_span": [22, 23], "new_tok_span": [24, 25]}, {"ent_type": "GENE", "char_span": [128, 132], "name": "P-gp", "tok_span": [27, 30], "new_tok_span": [29, 32]}], "relation_list": [{"subject": "doxorubicin", "sbj_char_span": [101, 112], "object": "P-gp", "obj_char_span": [128, 132], "rel_type": "activator", "sbj_tok_span": [20, 21], "obj_tok_span": [27, 30], "new_sbj_tok_span": [22, 23], "new_obj_tok_span": [29, 32]}, {"subject": "DOX", "sbj_char_span": [114, 117], "object": "P-gp", "obj_char_span": [128, 132], "rel_type": "activator", "sbj_tok_span": [22, 23], "obj_tok_span": [27, 30], "new_sbj_tok_span": [24, 25], "new_obj_tok_span": [29, 32]}], "umls_entity_list": [{"mention": "antidote", "char_span": [73, 81], "sem_type": "Pharmacologic Substance", "tok_span": [14, 17], "new_tok_span": [15, 18]}], "new_text": "The aim of the present work was to evaluate the effectiveness of such an <START=Pharmacologic Substance> antidote <END=Pharmacologic Substance> by testing whether doxorubicin ( DOX ), a known P - gp inducer, could efficiently protect Caco - 2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real - life intoxication scenario."}, {"PMID": 23160090, "id": 4, "text": "HSYA treatment also decreased NF-κB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen-activated protein kinase (p38 MAPK). These findings suggest that HSYA effectively inhibits LPS-induced inflammatory signal transduction in A549 cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 4], "name": "HSYA", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [176, 180], "name": "HSYA", "tok_span": [36, 39], "new_tok_span": [36, 39]}, {"ent_type": "GENE", "char_span": [30, 35], "name": "NF-κB", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [36, 39], "name": "p65", "tok_span": [10, 12], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [99, 102], "name": "p38", "tok_span": [19, 21], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [103, 135], "name": "mitogen-activated protein kinase", "tok_span": [21, 26], "new_tok_span": [21, 26]}, {"ent_type": "GENE", "char_span": [137, 140], "name": "p38", "tok_span": [27, 29], "new_tok_span": [27, 29]}, {"ent_type": "GENE", "char_span": [141, 145], "name": "MAPK", "tok_span": [29, 30], "new_tok_span": [29, 30]}], "relation_list": [{"subject": "HSYA", "sbj_char_span": [0, 4], "object": "p38", "obj_char_span": [99, 102], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [19, 21], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [19, 21]}, {"subject": "HSYA", "sbj_char_span": [0, 4], "object": "mitogen-activated protein kinase", "obj_char_span": [103, 135], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 26], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [21, 26]}, {"subject": "HSYA", "sbj_char_span": [0, 4], "object": "p38", "obj_char_span": [137, 140], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [27, 29], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [27, 29]}, {"subject": "HSYA", "sbj_char_span": [0, 4], "object": "MAPK", "obj_char_span": [141, 145], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [29, 30], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [29, 30]}], "umls_entity_list": [], "new_text": "HSYA treatment also decreased NF - κB p65 nuclear translocation and inhibited the phosphorylation of p38 mitogen - activated protein kinase ( p38 MAPK ). These findings suggest that HSYA effectively inhibits LPS - induced inflammatory signal transduction in A549 cells."}, {"PMID": 23146691, "id": 0, "text": "Emodin-6-O-β-D-glucoside inhibits HMGB1-induced inflammatory responses in vitro and in vivo.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 24], "name": "Emodin-6-O-β-D-glucoside", "tok_span": [0, 14], "new_tok_span": [1, 15]}, {"ent_type": "GENE", "char_span": [34, 39], "name": "HMGB1", "tok_span": [15, 18], "new_tok_span": [21, 24]}], "relation_list": [{"subject": "Emodin-6-O-β-D-glucoside", "sbj_char_span": [0, 24], "object": "HMGB1", "obj_char_span": [34, 39], "rel_type": "inhibitor", "sbj_tok_span": [0, 14], "obj_tok_span": [15, 18], "new_sbj_tok_span": [1, 15], "new_obj_tok_span": [21, 24]}], "umls_entity_list": [{"mention": "Emodin", "char_span": [0, 6], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "glucoside", "char_span": [15, 24], "sem_type": "Organic Chemical", "tok_span": [12, 14], "new_tok_span": [15, 17]}, {"mention": "HMGB1", "char_span": [34, 39], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 18], "new_tok_span": [21, 24]}, {"mention": "HMGB1", "char_span": [34, 39], "sem_type": "Gene or Genome", "tok_span": [15, 18], "new_tok_span": [21, 24]}], "new_text": "<START=Pharmacologic Substance> Emodin <END=Pharmacologic Substance> - 6 - O - β - D - <START=Organic Chemical> glucoside <END=Organic Chemical> inhibits <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> HMGB1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - induced inflammatory responses in vitro and in vivo."}, {"PMID": 8836913, "id": 1, "text": "Consensus interferon (Infergen) is a wholly synthetic type I interferon (IFN), developed by scanning several interferon-alpha nonallelic subtypes and assigning the most frequently observed amino acid in each position, resulting in a consensus sequence.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [189, 199], "name": "amino acid", "tok_span": [38, 40], "new_tok_span": [45, 47]}, {"ent_type": "GENE", "char_span": [10, 20], "name": "interferon", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"ent_type": "GENE", "char_span": [109, 125], "name": "interferon-alpha", "tok_span": [25, 28], "new_tok_span": [30, 33]}, {"ent_type": "GENE", "char_span": [54, 71], "name": "type I interferon", "tok_span": [14, 17], "new_tok_span": [17, 20]}, {"ent_type": "GENE", "char_span": [73, 76], "name": "IFN", "tok_span": [18, 19], "new_tok_span": [22, 23]}], "relation_list": [{"subject": "amino acid", "sbj_char_span": [189, 199], "object": "interferon-alpha", "obj_char_span": [109, 125], "rel_type": "part of", "sbj_tok_span": [38, 40], "obj_tok_span": [25, 28], "new_sbj_tok_span": [45, 47], "new_obj_tok_span": [30, 33]}], "umls_entity_list": [{"mention": "Consensus interferon", "char_span": [0, 20], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "type I interferon", "char_span": [54, 71], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 17], "new_tok_span": [17, 20]}, {"mention": "interferon-alpha", "char_span": [109, 125], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 28], "new_tok_span": [30, 33]}, {"mention": "amino acid", "char_span": [189, 199], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [38, 40], "new_tok_span": [45, 47]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Consensus interferon <END=Amino Acid, Peptide, or Protein> ( Infergen ) is a wholly synthetic <START=Amino Acid, Peptide, or Protein> type I interferon <END=Amino Acid, Peptide, or Protein> ( IFN ), developed by scanning several <START=Amino Acid, Peptide, or Protein> interferon - alpha <END=Amino Acid, Peptide, or Protein> nonallelic subtypes and assigning the most frequently observed <START=Amino Acid, Peptide, or Protein> amino acid <END=Amino Acid, Peptide, or Protein> in each position, resulting in a consensus sequence."}, {"PMID": 23605691, "id": 10, "text": "Simultaneous inhibition of both CYP3A and CYP2D6 results in increased oxycodone concentrations and such a combination should be avoided.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [70, 79], "name": "oxycodone", "tok_span": [15, 19], "new_tok_span": [16, 20]}, {"ent_type": "GENE", "char_span": [32, 37], "name": "CYP3A", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [42, 48], "name": "CYP2D6", "tok_span": [8, 12], "new_tok_span": [8, 12]}], "relation_list": [{"subject": "oxycodone", "sbj_char_span": [70, 79], "object": "CYP3A", "obj_char_span": [32, 37], "rel_type": "product or substrate", "sbj_tok_span": [15, 19], "obj_tok_span": [4, 7], "new_sbj_tok_span": [16, 20], "new_obj_tok_span": [4, 7]}, {"subject": "oxycodone", "sbj_char_span": [70, 79], "object": "CYP2D6", "obj_char_span": [42, 48], "rel_type": "product or substrate", "sbj_tok_span": [15, 19], "obj_tok_span": [8, 12], "new_sbj_tok_span": [16, 20], "new_obj_tok_span": [8, 12]}], "umls_entity_list": [{"mention": "oxycodone", "char_span": [70, 79], "sem_type": "Pharmacologic Substance", "tok_span": [15, 19], "new_tok_span": [16, 20]}], "new_text": "Simultaneous inhibition of both CYP3A and CYP2D6 results in increased <START=Pharmacologic Substance> oxycodone <END=Pharmacologic Substance> concentrations and such a combination should be avoided."}, {"PMID": 23339663, "id": 4, "text": "Also, the inhibition of AChE by CBDP is unexpected, from a structural standpoint, i.e., considering the narrowness of AChE active site and the bulkiness of CBDP. In the following, we report on kinetic X-ray crystallography experiments that provided 2.7-3.3 Å snapshots of the reaction of CBDP with mouse AChE and human BChE.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [32, 36], "name": "CBDP", "tok_span": [8, 10], "new_tok_span": [11, 13]}, {"ent_type": "CHEMICAL", "char_span": [156, 160], "name": "CBDP", "tok_span": [38, 40], "new_tok_span": [45, 47]}, {"ent_type": "CHEMICAL", "char_span": [288, 292], "name": "CBDP", "tok_span": [71, 73], "new_tok_span": [80, 82]}, {"ent_type": "GENE", "char_span": [24, 28], "name": "AChE", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"ent_type": "GENE", "char_span": [118, 122], "name": "AChE", "tok_span": [29, 31], "new_tok_span": [34, 36]}, {"ent_type": "GENE", "char_span": [298, 308], "name": "mouse AChE", "tok_span": [74, 77], "new_tok_span": [84, 87]}, {"ent_type": "GENE", "char_span": [313, 323], "name": "human BChE", "tok_span": [78, 82], "new_tok_span": [90, 94]}], "relation_list": [{"subject": "CBDP", "sbj_char_span": [32, 36], "object": "AChE", "obj_char_span": [24, 28], "rel_type": "inhibitor", "sbj_tok_span": [8, 10], "obj_tok_span": [5, 7], "new_sbj_tok_span": [11, 13], "new_obj_tok_span": [6, 8]}, {"subject": "CBDP", "sbj_char_span": [156, 160], "object": "AChE", "obj_char_span": [118, 122], "rel_type": "regulator", "sbj_tok_span": [38, 40], "obj_tok_span": [29, 31], "new_sbj_tok_span": [45, 47], "new_obj_tok_span": [34, 36]}], "umls_entity_list": [{"mention": "CBDP", "char_span": [32, 36], "sem_type": "Pharmacologic Substance", "tok_span": [8, 10], "new_tok_span": [11, 13]}, {"mention": "CBDP", "char_span": [156, 160], "sem_type": "Pharmacologic Substance", "tok_span": [38, 40], "new_tok_span": [45, 47]}, {"mention": "CBDP", "char_span": [288, 292], "sem_type": "Pharmacologic Substance", "tok_span": [71, 73], "new_tok_span": [80, 82]}, {"mention": "BChE", "char_span": [319, 323], "sem_type": "Gene or Genome", "tok_span": [79, 82], "new_tok_span": [93, 96]}, {"mention": "ChE", "char_span": [25, 28], "sem_type": "Gene or Genome", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"mention": "ChE", "char_span": [119, 122], "sem_type": "Gene or Genome", "tok_span": [29, 31], "new_tok_span": [34, 36]}, {"mention": "ChE", "char_span": [305, 308], "sem_type": "Gene or Genome", "tok_span": [75, 77], "new_tok_span": [86, 88]}, {"mention": "ChE", "char_span": [320, 323], "sem_type": "Gene or Genome", "tok_span": [79, 82], "new_tok_span": [93, 96]}], "new_text": "Also, the inhibition of <START=Gene or Genome> AChE <END=Gene or Genome> by <START=Pharmacologic Substance> CBDP <END=Pharmacologic Substance> is unexpected, from a structural standpoint, i. e., considering the narrowness of <START=Gene or Genome> AChE <END=Gene or Genome> active site and the bulkiness of <START=Pharmacologic Substance> CBDP <END=Pharmacologic Substance>. In the following, we report on kinetic X - ray crystallography experiments that provided 2. 7 - 3. 3 Å snapshots of the reaction of <START=Pharmacologic Substance> CBDP <END=Pharmacologic Substance> with mouse <START=Gene or Genome> AChE <END=Gene or Genome> and human <START=Gene or Genome> <START=Gene or Genome> BChE <END=Gene or Genome> <END=Gene or Genome>."}, {"PMID": 23154533, "id": 7, "text": "This case indicated that MPO-ANCA vasculitis occurred within several weeks after the initiation of PTU and that this side effect could be caused by the change from MMI to PTU. Thus, our clinical observation suggests that patients treated with PTU should be carefully monitored for MPO-ANCA titers and variable manifestations of MPO-ANCA-associated vasculitis regardless of the period of administration.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [99, 102], "name": "PTU", "tok_span": [19, 21], "new_tok_span": [21, 23]}, {"ent_type": "CHEMICAL", "char_span": [164, 167], "name": "MMI", "tok_span": [33, 35], "new_tok_span": [35, 37]}, {"ent_type": "CHEMICAL", "char_span": [171, 174], "name": "PTU", "tok_span": [36, 38], "new_tok_span": [38, 40]}, {"ent_type": "CHEMICAL", "char_span": [243, 246], "name": "PTU", "tok_span": [49, 51], "new_tok_span": [51, 53]}, {"ent_type": "GENE", "char_span": [25, 28], "name": "MPO", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"ent_type": "GENE", "char_span": [281, 284], "name": "MPO", "tok_span": [56, 58], "new_tok_span": [59, 61]}, {"ent_type": "GENE", "char_span": [328, 331], "name": "MPO", "tok_span": [66, 68], "new_tok_span": [71, 73]}], "relation_list": [{"subject": "PTU", "sbj_char_span": [99, 102], "object": "MPO", "obj_char_span": [25, 28], "rel_type": "regulator", "sbj_tok_span": [19, 21], "obj_tok_span": [4, 6], "new_sbj_tok_span": [21, 23], "new_obj_tok_span": [5, 7]}], "umls_entity_list": [{"mention": "MPO", "char_span": [25, 28], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"mention": "MPO", "char_span": [281, 284], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 58], "new_tok_span": [59, 61]}, {"mention": "MPO", "char_span": [328, 331], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [66, 68], "new_tok_span": [71, 73]}], "new_text": "This case indicated that <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> - ANCA vasculitis occurred within several weeks after the initiation of PTU and that this side effect could be caused by the change from MMI to PTU. Thus, our clinical observation suggests that patients treated with PTU should be carefully monitored for <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> - ANCA titers and variable manifestations of <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> - ANCA - associated vasculitis regardless of the period of administration."}, {"PMID": 21143836, "id": 4, "text": "RESULTS: Here, we present further evidence for the physiological correlation between AGM and ASIC3. Among arginine metabolites, only AGM and its analog arcaine (ARC) activated ASIC3 channels at neutral pH in a sustained manner similar to GMQ. In addition to the homomeric ASIC3 channels, AGM also activated heteromeric ASIC3 plus ASIC1b channels, extending its potential physiological relevance.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [106, 114], "name": "arginine", "tok_span": [21, 22], "new_tok_span": [24, 25]}, {"ent_type": "CHEMICAL", "char_span": [152, 159], "name": "arcaine", "tok_span": [30, 32], "new_tok_span": [35, 37]}, {"ent_type": "CHEMICAL", "char_span": [238, 241], "name": "GMQ", "tok_span": [50, 52], "new_tok_span": [58, 60]}, {"ent_type": "GENE", "char_span": [93, 98], "name": "ASIC3", "tok_span": [16, 19], "new_tok_span": [17, 20]}, {"ent_type": "GENE", "char_span": [176, 181], "name": "ASIC3", "tok_span": [37, 40], "new_tok_span": [44, 47]}, {"ent_type": "GENE", "char_span": [272, 277], "name": "ASIC3", "tok_span": [59, 62], "new_tok_span": [68, 71]}, {"ent_type": "GENE", "char_span": [319, 324], "name": "ASIC3", "tok_span": [70, 73], "new_tok_span": [81, 84]}, {"ent_type": "GENE", "char_span": [330, 336], "name": "ASIC1b", "tok_span": [74, 78], "new_tok_span": [86, 90]}], "relation_list": [{"subject": "arcaine", "sbj_char_span": [152, 159], "object": "ASIC3", "obj_char_span": [176, 181], "rel_type": "activator", "sbj_tok_span": [30, 32], "obj_tok_span": [37, 40], "new_sbj_tok_span": [35, 37], "new_obj_tok_span": [44, 47]}, {"subject": "arginine", "sbj_char_span": [106, 114], "object": "ASIC3", "obj_char_span": [176, 181], "rel_type": "activator", "sbj_tok_span": [21, 22], "obj_tok_span": [37, 40], "new_sbj_tok_span": [24, 25], "new_obj_tok_span": [44, 47]}, {"subject": "GMQ", "sbj_char_span": [238, 241], "object": "ASIC3", "obj_char_span": [176, 181], "rel_type": "activator", "sbj_tok_span": [50, 52], "obj_tok_span": [37, 40], "new_sbj_tok_span": [58, 60], "new_obj_tok_span": [44, 47]}], "umls_entity_list": [{"mention": "ASIC3", "char_span": [93, 98], "sem_type": "Gene or Genome", "tok_span": [16, 19], "new_tok_span": [17, 20]}, {"mention": "ASIC3", "char_span": [176, 181], "sem_type": "Gene or Genome", "tok_span": [37, 40], "new_tok_span": [44, 47]}, {"mention": "ASIC3", "char_span": [272, 277], "sem_type": "Gene or Genome", "tok_span": [59, 62], "new_tok_span": [68, 71]}, {"mention": "ASIC3", "char_span": [319, 324], "sem_type": "Gene or Genome", "tok_span": [70, 73], "new_tok_span": [81, 84]}, {"mention": "arginine", "char_span": [106, 114], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [24, 25]}, {"mention": "arcaine", "char_span": [152, 159], "sem_type": "Pharmacologic Substance", "tok_span": [30, 32], "new_tok_span": [35, 37]}], "new_text": "RESULTS : Here, we present further evidence for the physiological correlation between AGM and <START=Gene or Genome> ASIC3 <END=Gene or Genome>. Among <START=Amino Acid, Peptide, or Protein> arginine <END=Amino Acid, Peptide, or Protein> metabolites, only AGM and its analog <START=Pharmacologic Substance> arcaine <END=Pharmacologic Substance> ( ARC ) activated <START=Gene or Genome> ASIC3 <END=Gene or Genome> channels at neutral pH in a sustained manner similar to GMQ. In addition to the homomeric <START=Gene or Genome> ASIC3 <END=Gene or Genome> channels, AGM also activated heteromeric <START=Gene or Genome> ASIC3 <END=Gene or Genome> plus ASIC1b channels, extending its potential physiological relevance."}, {"PMID": 23401472, "id": 6, "text": "The UGT1A1 promoter in human kidney-derived HK-2 cells that do not express UGT1A1 was fully methylated, but was relatively unmethylated in human liver-derived HuH-7 cells that express UGT1A1. Treatment with 5-aza-2'-deoxycytidine (5-Aza-dC), an inhibitor of DNA methylation, resulted in an increase of UGT1A1 mRNA expression in both cell types, but the increase was much larger in HK-2 cells than in HuH-7 cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [207, 229], "name": "5-aza-2'-deoxycytidine", "tok_span": [55, 66], "new_tok_span": [80, 91]}, {"ent_type": "CHEMICAL", "char_span": [231, 239], "name": "5-Aza-dC", "tok_span": [67, 74], "new_tok_span": [94, 101]}, {"ent_type": "GENE", "char_span": [184, 190], "name": "UGT1A1", "tok_span": [47, 52], "new_tok_span": [69, 74]}, {"ent_type": "GENE", "char_span": [302, 308], "name": "UGT1A1", "tok_span": [87, 92], "new_tok_span": [121, 126]}, {"ent_type": "GENE", "char_span": [4, 19], "name": "UGT1A1 promoter", "tok_span": [1, 7], "new_tok_span": [3, 9]}, {"ent_type": "GENE", "char_span": [75, 81], "name": "UGT1A1", "tok_span": [20, 25], "new_tok_span": [32, 37]}], "relation_list": [{"subject": "5-aza-2'-deoxycytidine", "sbj_char_span": [207, 229], "object": "UGT1A1", "obj_char_span": [302, 308], "rel_type": "regulator", "sbj_tok_span": [55, 66], "obj_tok_span": [87, 92], "new_sbj_tok_span": [80, 91], "new_obj_tok_span": [121, 126]}, {"subject": "5-Aza-dC", "sbj_char_span": [231, 239], "object": "UGT1A1", "obj_char_span": [302, 308], "rel_type": "regulator", "sbj_tok_span": [67, 74], "obj_tok_span": [87, 92], "new_sbj_tok_span": [94, 101], "new_obj_tok_span": [121, 126]}], "umls_entity_list": [{"mention": "UGT1A1", "char_span": [4, 10], "sem_type": "Gene or Genome", "tok_span": [1, 6], "new_tok_span": [3, 8]}, {"mention": "UGT1A1", "char_span": [75, 81], "sem_type": "Gene or Genome", "tok_span": [20, 25], "new_tok_span": [32, 37]}, {"mention": "UGT1A1", "char_span": [184, 190], "sem_type": "Gene or Genome", "tok_span": [47, 52], "new_tok_span": [69, 74]}, {"mention": "UGT1A1", "char_span": [302, 308], "sem_type": "Gene or Genome", "tok_span": [87, 92], "new_tok_span": [121, 126]}, {"mention": "HK", "char_span": [44, 46], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 13], "new_tok_span": [20, 21]}, {"mention": "HK", "char_span": [381, 383], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [106, 107], "new_tok_span": [144, 145]}, {"mention": "HK", "char_span": [44, 46], "sem_type": "Gene or Genome", "tok_span": [12, 13], "new_tok_span": [20, 21]}, {"mention": "HK", "char_span": [381, 383], "sem_type": "Gene or Genome", "tok_span": [106, 107], "new_tok_span": [144, 145]}, {"mention": "UGT1A1", "char_span": [4, 10], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 6], "new_tok_span": [3, 8]}, {"mention": "UGT1A1", "char_span": [75, 81], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 25], "new_tok_span": [32, 37]}, {"mention": "UGT1A1", "char_span": [184, 190], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [47, 52], "new_tok_span": [69, 74]}, {"mention": "UGT1A1", "char_span": [302, 308], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [87, 92], "new_tok_span": [121, 126]}, {"mention": "methylated", "char_span": [92, 102], "sem_type": "Pharmacologic Substance", "tok_span": [27, 28], "new_tok_span": [42, 43]}, {"mention": "methylated", "char_span": [125, 135], "sem_type": "Pharmacologic Substance", "tok_span": [32, 35], "new_tok_span": [49, 52]}, {"mention": "5-aza", "char_span": [207, 212], "sem_type": "Pharmacologic Substance", "tok_span": [55, 59], "new_tok_span": [80, 84]}, {"mention": "5-Aza", "char_span": [231, 236], "sem_type": "Pharmacologic Substance", "tok_span": [67, 71], "new_tok_span": [94, 98]}, {"mention": "an", "char_span": [26, 28], "sem_type": "Gene or Genome", "tok_span": [8, 9], "new_tok_span": [13, 14]}, {"mention": "an", "char_span": [142, 144], "sem_type": "Gene or Genome", "tok_span": [36, 37], "new_tok_span": [55, 56]}, {"mention": "an", "char_span": [242, 244], "sem_type": "Gene or Genome", "tok_span": [76, 77], "new_tok_span": [105, 106]}, {"mention": "an", "char_span": [287, 289], "sem_type": "Gene or Genome", "tok_span": [84, 85], "new_tok_span": [115, 116]}, {"mention": "an", "char_span": [394, 396], "sem_type": "Gene or Genome", "tok_span": [110, 111], "new_tok_span": [151, 152]}], "new_text": "The <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> UGT1A1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> promoter in <START=Gene or Genome> human <END=Gene or Genome> kidney - derived <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> HK <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - 2 cells that don't express <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> UGT1A1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> was fully <START=Pharmacologic Substance> methylated <END=Pharmacologic Substance>, but was relatively <START=Pharmacologic Substance> unmethylated <END=Pharmacologic Substance> in <START=Gene or Genome> human <END=Gene or Genome> liver - derived HuH - 7 cells that express <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> UGT1A1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. Treatment with <START=Pharmacologic Substance> 5 - aza <END=Pharmacologic Substance> - 2'- deoxycytidine ( <START=Pharmacologic Substance> 5 - Aza <END=Pharmacologic Substance> - dC ), <START=Gene or Genome> an <END=Gene or Genome> inhibitor of DNA methylation, resulted in <START=Gene or Genome> an <END=Gene or Genome> increase of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> UGT1A1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> mRNA expression in both cell types, but the increase was much larger in <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> HK <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - 2 cells <START=Gene or Genome> than <END=Gene or Genome> in HuH - 7 cells."}, {"PMID": 23414802, "id": 2, "text": "In this study, a novel series of 2-hydroxydiarylamide derivatives were synthesized and evaluated for inhibiting TMPRSS4 serine protease activity and suppressing cancer cell invasion.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [33, 53], "name": "2-hydroxydiarylamide", "tok_span": [8, 14], "new_tok_span": [8, 14]}, {"ent_type": "CHEMICAL", "char_span": [120, 126], "name": "serine", "tok_span": [25, 26], "new_tok_span": [29, 30]}, {"ent_type": "GENE", "char_span": [112, 119], "name": "TMPRSS4", "tok_span": [21, 25], "new_tok_span": [23, 27]}, {"ent_type": "GENE", "char_span": [120, 135], "name": "serine protease", "tok_span": [25, 27], "new_tok_span": [29, 31]}], "relation_list": [{"subject": "2-hydroxydiarylamide", "sbj_char_span": [33, 53], "object": "TMPRSS4", "obj_char_span": [112, 119], "rel_type": "inhibitor", "sbj_tok_span": [8, 14], "obj_tok_span": [21, 25], "new_sbj_tok_span": [8, 14], "new_obj_tok_span": [23, 27]}, {"subject": "2-hydroxydiarylamide", "sbj_char_span": [33, 53], "object": "serine protease", "obj_char_span": [120, 135], "rel_type": "inhibitor", "sbj_tok_span": [8, 14], "obj_tok_span": [25, 27], "new_sbj_tok_span": [8, 14], "new_obj_tok_span": [29, 31]}], "umls_entity_list": [{"mention": "TMPRSS4", "char_span": [112, 119], "sem_type": "Gene or Genome", "tok_span": [21, 25], "new_tok_span": [23, 27]}, {"mention": "TMPRSS4", "char_span": [112, 119], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 25], "new_tok_span": [23, 27]}], "new_text": "In this study, a novel series of 2 - hydroxydiarylamide derivatives were synthesized and evaluated for inhibiting <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> TMPRSS4 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> serine protease activity and suppressing cancer cell invasion."}, {"PMID": 23063590, "id": 7, "text": "Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) α gene.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [171, 182], "name": "cholesterol", "tok_span": [30, 31], "new_tok_span": [36, 37]}, {"ent_type": "CHEMICAL", "char_span": [223, 248], "name": "hydroxymethylglutaryl CoA", "tok_span": [36, 42], "new_tok_span": [42, 48]}, {"ent_type": "CHEMICAL", "char_span": [250, 257], "name": "HMG CoA", "tok_span": [43, 47], "new_tok_span": [49, 53]}, {"ent_type": "CHEMICAL", "char_span": [68, 84], "name": "artemisinic acid", "tok_span": [10, 15], "new_tok_span": [11, 16]}, {"ent_type": "CHEMICAL", "char_span": [116, 132], "name": "artemisinic acid", "tok_span": [20, 25], "new_tok_span": [25, 30]}, {"ent_type": "GENE", "char_span": [223, 268], "name": "hydroxymethylglutaryl CoA (HMG CoA) reductase", "tok_span": [36, 49], "new_tok_span": [42, 55]}, {"ent_type": "GENE", "char_span": [328, 368], "name": "CCAAT/enhancer-binding protein (C/EBP) α", "tok_span": [59, 73], "new_tok_span": [67, 81]}], "relation_list": [{"subject": "artemisinic acid", "sbj_char_span": [116, 132], "object": "hydroxymethylglutaryl CoA (HMG CoA) reductase", "obj_char_span": [223, 268], "rel_type": "regulator", "sbj_tok_span": [20, 25], "obj_tok_span": [36, 49], "new_sbj_tok_span": [25, 30], "new_obj_tok_span": [42, 55]}, {"subject": "artemisinic acid", "sbj_char_span": [116, 132], "object": "CCAAT/enhancer-binding protein (C/EBP) α", "obj_char_span": [328, 368], "rel_type": "regulator", "sbj_tok_span": [20, 25], "obj_tok_span": [59, 73], "new_sbj_tok_span": [25, 30], "new_obj_tok_span": [67, 81]}], "umls_entity_list": [{"mention": "artemisinic acid", "char_span": [68, 84], "sem_type": "Pharmacologic Substance", "tok_span": [10, 15], "new_tok_span": [11, 16]}, {"mention": "artemisinic acid", "char_span": [116, 132], "sem_type": "Pharmacologic Substance", "tok_span": [20, 25], "new_tok_span": [25, 30]}, {"mention": "mediated", "char_span": [85, 93], "sem_type": "Pharmacologic Substance", "tok_span": [16, 17], "new_tok_span": [19, 20]}, {"mention": "mediated", "char_span": [285, 293], "sem_type": "Pharmacologic Substance", "tok_span": [53, 54], "new_tok_span": [60, 61]}], "new_text": "Moreover, attempts to elucidate a possible mechanism underlying the <START=Pharmacologic Substance> artemisinic acid <END=Pharmacologic Substance> - <START=Pharmacologic Substance> mediated <END=Pharmacologic Substance> effects revealed that <START=Pharmacologic Substance> artemisinic acid <END=Pharmacologic Substance> regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA ( HMG CoA ) reductase gene, which was <START=Pharmacologic Substance> mediated <END=Pharmacologic Substance> through reduced expression of the CCAAT / enhancer - binding protein ( C / EBP ) α gene."}, {"PMID": 8740147, "id": 11, "text": "The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [78, 87], "name": "amezinium", "tok_span": [12, 16], "new_tok_span": [12, 16]}, {"ent_type": "CHEMICAL", "char_span": [124, 136], "name": "debrisoquine", "tok_span": [23, 26], "new_tok_span": [23, 26]}, {"ent_type": "GENE", "char_span": [171, 174], "name": "MAO", "tok_span": [33, 35], "new_tok_span": [33, 35]}, {"ent_type": "GENE", "char_span": [368, 375], "name": "uptake1", "tok_span": [70, 72], "new_tok_span": [70, 72]}], "relation_list": [{"subject": "amezinium", "sbj_char_span": [78, 87], "object": "MAO", "obj_char_span": [171, 174], "rel_type": "inhibitor", "sbj_tok_span": [12, 16], "obj_tok_span": [33, 35], "new_sbj_tok_span": [12, 16], "new_obj_tok_span": [33, 35]}, {"subject": "debrisoquine", "sbj_char_span": [124, 136], "object": "MAO", "obj_char_span": [171, 174], "rel_type": "inhibitor", "sbj_tok_span": [23, 26], "obj_tok_span": [33, 35], "new_sbj_tok_span": [23, 26], "new_obj_tok_span": [33, 35]}, {"subject": "amezinium", "sbj_char_span": [78, 87], "object": "uptake1", "obj_char_span": [368, 375], "rel_type": "product or substrate", "sbj_tok_span": [12, 16], "obj_tok_span": [70, 72], "new_sbj_tok_span": [12, 16], "new_obj_tok_span": [70, 72]}, {"subject": "debrisoquine", "sbj_char_span": [124, 136], "object": "uptake1", "obj_char_span": [368, 375], "rel_type": "product or substrate", "sbj_tok_span": [23, 26], "obj_tok_span": [70, 72], "new_sbj_tok_span": [23, 26], "new_obj_tok_span": [70, 72]}], "umls_entity_list": [], "new_text": "The results when considered with previous reports in the literature show that amezinium is about 1000 times more potent and debrisoquine is about 20 times more potent for MAO inhibition in rat lungs than in tissue homogenates, and the reason for their high potencies in the intact lungs is transport and accumulation of the drugs in the pulmonary endothelial cells by uptake1."}, {"PMID": 17234158, "id": 0, "text": "Pirfenidone inhibits TGF-beta expression in malignant glioma cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Pirfenidone", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "GENE", "char_span": [21, 29], "name": "TGF-beta", "tok_span": [5, 8], "new_tok_span": [8, 11]}], "relation_list": [{"subject": "Pirfenidone", "sbj_char_span": [0, 11], "object": "TGF-beta", "obj_char_span": [21, 29], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [5, 8], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [8, 11]}], "umls_entity_list": [{"mention": "Pirfenidone", "char_span": [0, 11], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "TGF-beta", "char_span": [21, 29], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 8], "new_tok_span": [8, 11]}], "new_text": "<START=Pharmacologic Substance> Pirfenidone <END=Pharmacologic Substance> inhibits <START=Amino Acid, Peptide, or Protein> TGF - beta <END=Amino Acid, Peptide, or Protein> expression in malignant glioma cells."}, {"PMID": 19480470, "id": 13, "text": "Duloxetine is a substrate for CYP1A2 and CYP2D6 and a moderate inhibitor of CYP2D6. Concomitant use of duloxetine and potent CYP1A2 inhibitors should be avoided and duloxetine should be used with caution in patients receiving drugs that are extensively metabolized by CYP2D6, particularly those with a narrow therapeutic index.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Duloxetine", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [103, 113], "name": "duloxetine", "tok_span": [31, 35], "new_tok_span": [42, 46]}, {"ent_type": "CHEMICAL", "char_span": [165, 175], "name": "duloxetine", "tok_span": [46, 50], "new_tok_span": [59, 63]}, {"ent_type": "GENE", "char_span": [30, 36], "name": "CYP1A2", "tok_span": [7, 11], "new_tok_span": [9, 13]}, {"ent_type": "GENE", "char_span": [41, 47], "name": "CYP2D6", "tok_span": [12, 16], "new_tok_span": [16, 20]}, {"ent_type": "GENE", "char_span": [76, 82], "name": "CYP2D6", "tok_span": [21, 25], "new_tok_span": [29, 33]}, {"ent_type": "GENE", "char_span": [125, 131], "name": "CYP1A2", "tok_span": [37, 41], "new_tok_span": [49, 53]}, {"ent_type": "GENE", "char_span": [268, 274], "name": "CYP2D6", "tok_span": [65, 69], "new_tok_span": [81, 85]}], "relation_list": [{"subject": "Duloxetine", "sbj_char_span": [0, 10], "object": "CYP1A2", "obj_char_span": [30, 36], "rel_type": "product or substrate", "sbj_tok_span": [0, 3], "obj_tok_span": [7, 11], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [9, 13]}, {"subject": "Duloxetine", "sbj_char_span": [0, 10], "object": "CYP2D6", "obj_char_span": [41, 47], "rel_type": "product or substrate", "sbj_tok_span": [0, 3], "obj_tok_span": [12, 16], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [16, 20]}, {"subject": "Duloxetine", "sbj_char_span": [0, 10], "object": "CYP2D6", "obj_char_span": [76, 82], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 25], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [29, 33]}, {"subject": "duloxetine", "sbj_char_span": [165, 175], "object": "CYP2D6", "obj_char_span": [268, 274], "rel_type": "product or substrate", "sbj_tok_span": [46, 50], "obj_tok_span": [65, 69], "new_sbj_tok_span": [59, 63], "new_obj_tok_span": [81, 85]}], "umls_entity_list": [{"mention": "Duloxetine", "char_span": [0, 10], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "duloxetine", "char_span": [103, 113], "sem_type": "Pharmacologic Substance", "tok_span": [31, 35], "new_tok_span": [42, 46]}, {"mention": "duloxetine", "char_span": [165, 175], "sem_type": "Pharmacologic Substance", "tok_span": [46, 50], "new_tok_span": [59, 63]}, {"mention": "CYP2D6", "char_span": [41, 47], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 16], "new_tok_span": [16, 20]}, {"mention": "CYP2D6", "char_span": [76, 82], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 25], "new_tok_span": [29, 33]}, {"mention": "CYP2D6", "char_span": [268, 274], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [65, 69], "new_tok_span": [81, 85]}, {"mention": "CYP2D6", "char_span": [41, 47], "sem_type": "Gene or Genome", "tok_span": [12, 16], "new_tok_span": [16, 20]}, {"mention": "CYP2D6", "char_span": [76, 82], "sem_type": "Gene or Genome", "tok_span": [21, 25], "new_tok_span": [29, 33]}, {"mention": "CYP2D6", "char_span": [268, 274], "sem_type": "Gene or Genome", "tok_span": [65, 69], "new_tok_span": [81, 85]}], "new_text": "<START=Pharmacologic Substance> Duloxetine <END=Pharmacologic Substance> is a substrate for CYP1A2 and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> CYP2D6 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and a moderate inhibitor of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> CYP2D6 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>. Concomitant use of <START=Pharmacologic Substance> duloxetine <END=Pharmacologic Substance> and potent CYP1A2 inhibitors should be avoided and <START=Pharmacologic Substance> duloxetine <END=Pharmacologic Substance> should be used with caution in patients receiving drugs that are extensively metabolized by <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> CYP2D6 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, particularly those with a narrow therapeutic index."}, {"PMID": 14757145, "id": 3, "text": "Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [90, 100], "name": "bisoprolol", "tok_span": [18, 21], "new_tok_span": [25, 28]}, {"ent_type": "CHEMICAL", "char_span": [200, 210], "name": "salbutamol", "tok_span": [49, 53], "new_tok_span": [62, 66]}, {"ent_type": "GENE", "char_span": [57, 77], "name": "beta(1)-adrenoceptor", "tok_span": [8, 16], "new_tok_span": [10, 18]}, {"ent_type": "GENE", "char_span": [171, 191], "name": "beta(2)-adrenoceptor", "tok_span": [40, 48], "new_tok_span": [50, 58]}, {"ent_type": "GENE", "char_span": [249, 269], "name": "beta(2)-adrenoceptor", "tok_span": [67, 75], "new_tok_span": [81, 89]}], "relation_list": [{"subject": "bisoprolol", "sbj_char_span": [90, 100], "object": "beta(1)-adrenoceptor", "obj_char_span": [57, 77], "rel_type": "agonist or antagonist", "sbj_tok_span": [18, 21], "obj_tok_span": [8, 16], "new_sbj_tok_span": [25, 28], "new_obj_tok_span": [10, 18]}, {"subject": "salbutamol", "sbj_char_span": [200, 210], "object": "beta(2)-adrenoceptor", "obj_char_span": [171, 191], "rel_type": "agonist or antagonist", "sbj_tok_span": [49, 53], "obj_tok_span": [40, 48], "new_sbj_tok_span": [62, 66], "new_obj_tok_span": [50, 58]}], "umls_entity_list": [{"mention": "antagonist", "char_span": [78, 88], "sem_type": "Pharmacologic Substance", "tok_span": [16, 17], "new_tok_span": [21, 22]}, {"mention": "bisoprolol", "char_span": [90, 100], "sem_type": "Pharmacologic Substance", "tok_span": [18, 21], "new_tok_span": [25, 28]}, {"mention": "selective", "char_span": [47, 56], "sem_type": "Pharmacologic Substance", "tok_span": [7, 8], "new_tok_span": [8, 9]}, {"mention": "selective", "char_span": [161, 170], "sem_type": "Pharmacologic Substance", "tok_span": [39, 40], "new_tok_span": [48, 49]}, {"mention": "adrenoceptor", "char_span": [65, 77], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"mention": "adrenoceptor", "char_span": [179, 191], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [45, 48], "new_tok_span": [56, 59]}, {"mention": "adrenoceptor", "char_span": [257, 269], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [72, 75], "new_tok_span": [87, 90]}, {"mention": "salbutamol", "char_span": [200, 210], "sem_type": "Pharmacologic Substance", "tok_span": [49, 53], "new_tok_span": [62, 66]}], "new_text": "Rats received a concomitant treatment with the <START=Pharmacologic Substance> selective <END=Pharmacologic Substance> beta ( 1 ) - <START=Amino Acid, Peptide, or Protein> adrenoceptor <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> antagonist <END=Pharmacologic Substance>, <START=Pharmacologic Substance> bisoprolol <END=Pharmacologic Substance> ( 50 mg / kg / day p. o. ) or were chronically pretreated with the <START=Pharmacologic Substance> selective <END=Pharmacologic Substance> beta ( 2 ) - <START=Amino Acid, Peptide, or Protein> adrenoceptor <END=Amino Acid, Peptide, or Protein> agonist <START=Pharmacologic Substance> salbutamol <END=Pharmacologic Substance> ( 40 microg / kg / h ) for 1 week to induce beta ( 2 ) - <START=Amino Acid, Peptide, or Protein> adrenoceptor <END=Amino Acid, Peptide, or Protein> desensitization."}, {"PMID": 17567713, "id": 9, "text": "We also found that TRPV1 receptors are activated by CuSO(4), ZnSO(4), and FeSO(4), three salts known to produce a metallic taste sensation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [52, 59], "name": "CuSO(4)", "tok_span": [11, 16], "new_tok_span": [13, 18]}, {"ent_type": "CHEMICAL", "char_span": [61, 68], "name": "ZnSO(4)", "tok_span": [17, 22], "new_tok_span": [19, 24]}, {"ent_type": "CHEMICAL", "char_span": [74, 81], "name": "FeSO(4)", "tok_span": [24, 29], "new_tok_span": [27, 32]}, {"ent_type": "GENE", "char_span": [19, 24], "name": "TRPV1", "tok_span": [4, 7], "new_tok_span": [5, 8]}], "relation_list": [{"subject": "CuSO(4)", "sbj_char_span": [52, 59], "object": "TRPV1", "obj_char_span": [19, 24], "rel_type": "activator", "sbj_tok_span": [11, 16], "obj_tok_span": [4, 7], "new_sbj_tok_span": [13, 18], "new_obj_tok_span": [5, 8]}, {"subject": "ZnSO(4)", "sbj_char_span": [61, 68], "object": "TRPV1", "obj_char_span": [19, 24], "rel_type": "activator", "sbj_tok_span": [17, 22], "obj_tok_span": [4, 7], "new_sbj_tok_span": [19, 24], "new_obj_tok_span": [5, 8]}, {"subject": "FeSO(4)", "sbj_char_span": [74, 81], "object": "TRPV1", "obj_char_span": [19, 24], "rel_type": "activator", "sbj_tok_span": [24, 29], "obj_tok_span": [4, 7], "new_sbj_tok_span": [27, 32], "new_obj_tok_span": [5, 8]}], "umls_entity_list": [{"mention": "TRPV1", "char_span": [19, 24], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"mention": "FeSO", "char_span": [74, 78], "sem_type": "Pharmacologic Substance", "tok_span": [24, 26], "new_tok_span": [27, 29]}], "new_text": "We also found that <START=Amino Acid, Peptide, or Protein> TRPV1 <END=Amino Acid, Peptide, or Protein> receptors are activated by CuSO ( 4 ), ZnSO ( 4 ), and <START=Pharmacologic Substance> FeSO <END=Pharmacologic Substance> ( 4 ), three salts known to produce a metallic taste sensation."}, {"PMID": 23429912, "id": 6, "text": "We discovered that each RSPO alone or in combination partially rescues TCDD inhibition of both canonical Wnt signaling and prostatic bud formation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [71, 75], "name": "TCDD", "tok_span": [13, 15], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [24, 28], "name": "RSPO", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"ent_type": "GENE", "char_span": [105, 108], "name": "Wnt", "tok_span": [19, 20], "new_tok_span": [21, 22]}], "relation_list": [{"subject": "TCDD", "sbj_char_span": [71, 75], "object": "Wnt", "obj_char_span": [105, 108], "rel_type": "regulator", "sbj_tok_span": [13, 15], "obj_tok_span": [19, 20], "new_sbj_tok_span": [15, 17], "new_obj_tok_span": [21, 22]}], "umls_entity_list": [{"mention": "RSPO", "char_span": [24, 28], "sem_type": "Gene or Genome", "tok_span": [4, 6], "new_tok_span": [5, 7]}], "new_text": "We discovered that each <START=Gene or Genome> RSPO <END=Gene or Genome> alone or in combination partially rescues TCDD inhibition of both canonical Wnt signaling and prostatic bud formation."}, {"PMID": 12606421, "id": 19, "text": "Cetrorelix completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the GnRH-R mRNA, during both the infantile and the juvenile periods.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Cetrorelix", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [109, 113], "name": "GnRH", "tok_span": [29, 30], "new_tok_span": [32, 33]}, {"ent_type": "GENE", "char_span": [109, 115], "name": "GnRH-R", "tok_span": [29, 32], "new_tok_span": [32, 35]}], "relation_list": [{"subject": "Cetrorelix", "sbj_char_span": [0, 10], "object": "GnRH-R", "obj_char_span": [109, 115], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [29, 32], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [32, 35]}], "umls_entity_list": [{"mention": "Cetrorelix", "char_span": [0, 10], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "GnRH-R", "char_span": [109, 115], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 32], "new_tok_span": [32, 35]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Cetrorelix <END=Amino Acid, Peptide, or Protein> completely blocked the rise of levels of the two most abundant species, 5. 0 kb and 4. 5 kb, of the <START=Amino Acid, Peptide, or Protein> GnRH - R <END=Amino Acid, Peptide, or Protein> mRNA, during both the infantile and the juvenile periods."}, {"PMID": 10224140, "id": 2, "text": "Degenerate primers were designed based on the sequences conserved among OAT1, OAT2, and organic cation transporter 1 (OCT1), and reverse transcription-polymerase chain reaction was performed using rat brain poly(A)+ RNA. The 536-amino acid protein sequence encoded by OAT3 showed 49, 39, and 36% identity to those of OAT1, OAT2, and OCT1, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [229, 239], "name": "amino acid", "tok_span": [53, 55], "new_tok_span": [66, 68]}, {"ent_type": "GENE", "char_span": [72, 76], "name": "OAT1", "tok_span": [12, 15], "new_tok_span": [13, 16]}, {"ent_type": "GENE", "char_span": [78, 82], "name": "OAT2", "tok_span": [16, 19], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [88, 116], "name": "organic cation transporter 1", "tok_span": [21, 25], "new_tok_span": [28, 32]}, {"ent_type": "GENE", "char_span": [118, 122], "name": "OCT1", "tok_span": [26, 28], "new_tok_span": [37, 39]}, {"ent_type": "GENE", "char_span": [268, 272], "name": "OAT3", "tok_span": [59, 62], "new_tok_span": [76, 79]}, {"ent_type": "GENE", "char_span": [317, 321], "name": "OAT1", "tok_span": [74, 77], "new_tok_span": [93, 96]}, {"ent_type": "GENE", "char_span": [323, 327], "name": "OAT2", "tok_span": [78, 81], "new_tok_span": [99, 102]}, {"ent_type": "GENE", "char_span": [333, 337], "name": "OCT1", "tok_span": [83, 85], "new_tok_span": [106, 108]}], "relation_list": [{"subject": "amino acid", "sbj_char_span": [229, 239], "object": "OAT3", "obj_char_span": [268, 272], "rel_type": "part of", "sbj_tok_span": [53, 55], "obj_tok_span": [59, 62], "new_sbj_tok_span": [66, 68], "new_obj_tok_span": [76, 79]}, {"subject": "amino acid", "sbj_char_span": [229, 239], "object": "OAT1", "obj_char_span": [317, 321], "rel_type": "part of", "sbj_tok_span": [53, 55], "obj_tok_span": [74, 77], "new_sbj_tok_span": [66, 68], "new_obj_tok_span": [93, 96]}, {"subject": "amino acid", "sbj_char_span": [229, 239], "object": "OAT2", "obj_char_span": [323, 327], "rel_type": "part of", "sbj_tok_span": [53, 55], "obj_tok_span": [78, 81], "new_sbj_tok_span": [66, 68], "new_obj_tok_span": [99, 102]}, {"subject": "amino acid", "sbj_char_span": [229, 239], "object": "OCT1", "obj_char_span": [333, 337], "rel_type": "part of", "sbj_tok_span": [53, 55], "obj_tok_span": [83, 85], "new_sbj_tok_span": [66, 68], "new_obj_tok_span": [106, 108]}], "umls_entity_list": [{"mention": "OAT1", "char_span": [72, 76], "sem_type": "Gene or Genome", "tok_span": [12, 15], "new_tok_span": [13, 16]}, {"mention": "OAT1", "char_span": [317, 321], "sem_type": "Gene or Genome", "tok_span": [74, 77], "new_tok_span": [93, 96]}, {"mention": "OAT2", "char_span": [78, 82], "sem_type": "Gene or Genome", "tok_span": [16, 19], "new_tok_span": [19, 22]}, {"mention": "OAT2", "char_span": [323, 327], "sem_type": "Gene or Genome", "tok_span": [78, 81], "new_tok_span": [99, 102]}, {"mention": "organic", "char_span": [88, 95], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [28, 29]}, {"mention": "organic cation transporter 1", "char_span": [88, 116], "sem_type": "Gene or Genome", "tok_span": [21, 25], "new_tok_span": [28, 32]}, {"mention": "organic cation transporter 1", "char_span": [88, 116], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 25], "new_tok_span": [28, 32]}, {"mention": "OCT1", "char_span": [118, 122], "sem_type": "Gene or Genome", "tok_span": [26, 28], "new_tok_span": [37, 39]}, {"mention": "OCT1", "char_span": [333, 337], "sem_type": "Gene or Genome", "tok_span": [83, 85], "new_tok_span": [106, 108]}, {"mention": "protein", "char_span": [240, 247], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [55, 56], "new_tok_span": [69, 70]}, {"mention": "amino acid protein", "char_span": [229, 247], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [53, 56], "new_tok_span": [66, 69]}, {"mention": "OAT3", "char_span": [268, 272], "sem_type": "Gene or Genome", "tok_span": [59, 62], "new_tok_span": [76, 79]}], "new_text": "Degenerate primers were designed based on the sequences conserved among <START=Gene or Genome> OAT1 <END=Gene or Genome>, <START=Gene or Genome> OAT2 <END=Gene or Genome>, and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> organic <END=Amino Acid, Peptide, or Protein> cation transporter 1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( <START=Gene or Genome> OCT1 <END=Gene or Genome> ), and reverse transcription - polymerase chain reaction was performed using rat brain poly ( A ) + RNA. The 536 - <START=Amino Acid, Peptide, or Protein> amino acid <START=Amino Acid, Peptide, or Protein> protein <END=Amino Acid, Peptide, or Protein> <END=Amino Acid, Peptide, or Protein> sequence encoded by <START=Gene or Genome> OAT3 <END=Gene or Genome> showed 49, 39, and 36 % identity to those of <START=Gene or Genome> OAT1 <END=Gene or Genome>, <START=Gene or Genome> OAT2 <END=Gene or Genome>, and <START=Gene or Genome> OCT1 <END=Gene or Genome>, respectively."}, {"PMID": 7739347, "id": 0, "text": "Opioid receptor interaction and adenylyl cyclase inhibition of dihydroetorphine: direct comparison with etorphine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [104, 113], "name": "etorphine", "tok_span": [22, 25], "new_tok_span": [33, 36]}, {"ent_type": "CHEMICAL", "char_span": [32, 40], "name": "adenylyl", "tok_span": [6, 9], "new_tok_span": [12, 15]}, {"ent_type": "CHEMICAL", "char_span": [63, 79], "name": "dihydroetorphine", "tok_span": [12, 18], "new_tok_span": [19, 25]}, {"ent_type": "GENE", "char_span": [0, 15], "name": "Opioid receptor", "tok_span": [0, 4], "new_tok_span": [2, 6]}, {"ent_type": "GENE", "char_span": [32, 48], "name": "adenylyl cyclase", "tok_span": [6, 10], "new_tok_span": [12, 16]}], "relation_list": [{"subject": "dihydroetorphine", "sbj_char_span": [63, 79], "object": "adenylyl cyclase", "obj_char_span": [32, 48], "rel_type": "inhibitor", "sbj_tok_span": [12, 18], "obj_tok_span": [6, 10], "new_sbj_tok_span": [19, 25], "new_obj_tok_span": [12, 16]}], "umls_entity_list": [{"mention": "Opioid", "char_span": [0, 6], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"mention": "Opioid", "char_span": [0, 6], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"mention": "receptor interaction", "char_span": [7, 27], "sem_type": "Pharmacologic Substance", "tok_span": [3, 5], "new_tok_span": [8, 10]}, {"mention": "dihydroetorphine", "char_span": [63, 79], "sem_type": "Pharmacologic Substance", "tok_span": [12, 18], "new_tok_span": [19, 25]}, {"mention": "etorphine", "char_span": [70, 79], "sem_type": "Pharmacologic Substance", "tok_span": [14, 18], "new_tok_span": [22, 26]}, {"mention": "etorphine", "char_span": [104, 113], "sem_type": "Pharmacologic Substance", "tok_span": [22, 25], "new_tok_span": [33, 36]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> Opioid <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> <START=Pharmacologic Substance> receptor interaction <END=Pharmacologic Substance> and adenylyl cyclase inhibition of <START=Pharmacologic Substance> dihydro <START=Pharmacologic Substance>etorphine <END=Pharmacologic Substance> <END=Pharmacologic Substance> : direct comparison with <START=Pharmacologic Substance> etorphine <END=Pharmacologic Substance>."}, {"PMID": 23117572, "id": 10, "text": "In NTERA cells treated with the histone deacetylase inhibitors SAHA and valproic acid, a significant increase in NIS mRNA (about 60- and 30-fold vs control, P<0.001 and P<0.01 respectively) and protein levels, resulting in enhanced ability to uptake radioiodine, was observed.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [63, 67], "name": "SAHA", "tok_span": [13, 15], "new_tok_span": [16, 18]}, {"ent_type": "CHEMICAL", "char_span": [72, 85], "name": "valproic acid", "tok_span": [16, 20], "new_tok_span": [20, 24]}, {"ent_type": "CHEMICAL", "char_span": [250, 261], "name": "radioiodine", "tok_span": [63, 66], "new_tok_span": [71, 74]}, {"ent_type": "GENE", "char_span": [32, 51], "name": "histone deacetylase", "tok_span": [8, 12], "new_tok_span": [9, 13]}, {"ent_type": "GENE", "char_span": [113, 116], "name": "NIS", "tok_span": [25, 27], "new_tok_span": [31, 33]}], "relation_list": [{"subject": "SAHA", "sbj_char_span": [63, 67], "object": "histone deacetylase", "obj_char_span": [32, 51], "rel_type": "inhibitor", "sbj_tok_span": [13, 15], "obj_tok_span": [8, 12], "new_sbj_tok_span": [16, 18], "new_obj_tok_span": [9, 13]}, {"subject": "valproic acid", "sbj_char_span": [72, 85], "object": "histone deacetylase", "obj_char_span": [32, 51], "rel_type": "inhibitor", "sbj_tok_span": [16, 20], "obj_tok_span": [8, 12], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [9, 13]}, {"subject": "SAHA", "sbj_char_span": [63, 67], "object": "NIS", "obj_char_span": [113, 116], "rel_type": "regulator", "sbj_tok_span": [13, 15], "obj_tok_span": [25, 27], "new_sbj_tok_span": [16, 18], "new_obj_tok_span": [31, 33]}, {"subject": "valproic acid", "sbj_char_span": [72, 85], "object": "NIS", "obj_char_span": [113, 116], "rel_type": "regulator", "sbj_tok_span": [16, 20], "obj_tok_span": [25, 27], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [31, 33]}, {"subject": "radioiodine", "sbj_char_span": [250, 261], "object": "NIS", "obj_char_span": [113, 116], "rel_type": "product or substrate", "sbj_tok_span": [63, 66], "obj_tok_span": [25, 27], "new_sbj_tok_span": [71, 74], "new_obj_tok_span": [31, 33]}], "umls_entity_list": [{"mention": "histone deacetylase inhibitors", "char_span": [32, 62], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 13], "new_tok_span": [9, 14]}, {"mention": "SAHA", "char_span": [63, 67], "sem_type": "Pharmacologic Substance", "tok_span": [13, 15], "new_tok_span": [16, 18]}, {"mention": "NIS", "char_span": [113, 116], "sem_type": "Gene or Genome", "tok_span": [25, 27], "new_tok_span": [31, 33]}, {"mention": "NIS", "char_span": [113, 116], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 27], "new_tok_span": [31, 33]}], "new_text": "In NTERA cells treated with the <START=Amino Acid, Peptide, or Protein> histone deacetylase inhibitors <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> SAHA <END=Pharmacologic Substance> and valproic acid, a significant increase in <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NIS <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> mRNA ( about 60 - and 30 - fold vs control, P < 0. 001 and P < 0. 01 respectively ) and protein levels, resulting in enhanced ability to uptake radioiodine, was observed."}, {"PMID": 23523780, "id": 8, "text": "Administration of bicuculline, a GABAA inhibitor, isolated a single response to ω-agatoxin, which was characterized by a reduction in network activity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 29], "name": "bicuculline", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"ent_type": "GENE", "char_span": [33, 38], "name": "GABAA", "tok_span": [8, 10], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [80, 90], "name": "ω-agatoxin", "tok_span": [17, 22], "new_tok_span": [19, 24]}], "relation_list": [{"subject": "bicuculline", "sbj_char_span": [18, 29], "object": "GABAA", "obj_char_span": [33, 38], "rel_type": "inhibitor", "sbj_tok_span": [2, 6], "obj_tok_span": [8, 10], "new_sbj_tok_span": [3, 7], "new_obj_tok_span": [10, 12]}, {"subject": "bicuculline", "sbj_char_span": [18, 29], "object": "ω-agatoxin", "obj_char_span": [80, 90], "rel_type": "inhibitor", "sbj_tok_span": [2, 6], "obj_tok_span": [17, 22], "new_sbj_tok_span": [3, 7], "new_obj_tok_span": [19, 24]}], "umls_entity_list": [{"mention": "bicuculline", "char_span": [18, 29], "sem_type": "Pharmacologic Substance", "tok_span": [2, 6], "new_tok_span": [3, 7]}], "new_text": "Administration of <START=Pharmacologic Substance> bicuculline <END=Pharmacologic Substance>, a GABAA inhibitor, isolated a single response to ω - agatoxin, which was characterized by a reduction in network activity."}, {"PMID": 23584948, "id": 3, "text": "Vandetanib (Caprelsa(®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60 % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Vandetanib", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [12, 20], "name": "Caprelsa", "tok_span": [5, 8], "new_tok_span": [8, 11]}, {"ent_type": "CHEMICAL", "char_span": [59, 67], "name": "tyrosine", "tok_span": [24, 25], "new_tok_span": [28, 29]}, {"ent_type": "CHEMICAL", "char_span": [157, 165], "name": "tyrosine", "tok_span": [37, 38], "new_tok_span": [41, 42]}, {"ent_type": "GENE", "char_span": [59, 74], "name": "tyrosine kinase", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"ent_type": "GENE", "char_span": [134, 172], "name": "growth-factor receptor tyrosine kinase", "tok_span": [33, 39], "new_tok_span": [37, 43]}, {"ent_type": "GENE", "char_span": [173, 176], "name": "RET", "tok_span": [39, 40], "new_tok_span": [44, 45]}, {"ent_type": "GENE", "char_span": [233, 285], "name": "vascular endothelial growth-factor receptors 2 and 3", "tok_span": [53, 62], "new_tok_span": [60, 69]}, {"ent_type": "GENE", "char_span": [291, 324], "name": "epidermal growth-factor receptors", "tok_span": [64, 69], "new_tok_span": [72, 77]}], "relation_list": [{"subject": "Vandetanib", "sbj_char_span": [0, 10], "object": "tyrosine kinase", "obj_char_span": [59, 74], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [24, 26], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [28, 30]}, {"subject": "Caprelsa", "sbj_char_span": [12, 20], "object": "tyrosine kinase", "obj_char_span": [59, 74], "rel_type": "inhibitor", "sbj_tok_span": [5, 8], "obj_tok_span": [24, 26], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [28, 30]}, {"subject": "Vandetanib", "sbj_char_span": [0, 10], "object": "growth-factor receptor tyrosine kinase", "obj_char_span": [134, 172], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [33, 39], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [37, 43]}, {"subject": "Caprelsa", "sbj_char_span": [12, 20], "object": "growth-factor receptor tyrosine kinase", "obj_char_span": [134, 172], "rel_type": "inhibitor", "sbj_tok_span": [5, 8], "obj_tok_span": [33, 39], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [37, 43]}, {"subject": "Vandetanib", "sbj_char_span": [0, 10], "object": "RET", "obj_char_span": [173, 176], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [39, 40], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [44, 45]}, {"subject": "Caprelsa", "sbj_char_span": [12, 20], "object": "RET", "obj_char_span": [173, 176], "rel_type": "inhibitor", "sbj_tok_span": [5, 8], "obj_tok_span": [39, 40], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [44, 45]}, {"subject": "Vandetanib", "sbj_char_span": [0, 10], "object": "epidermal growth-factor receptors", "obj_char_span": [291, 324], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [64, 69], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [72, 77]}, {"subject": "Caprelsa", "sbj_char_span": [12, 20], "object": "epidermal growth-factor receptors", "obj_char_span": [291, 324], "rel_type": "inhibitor", "sbj_tok_span": [5, 8], "obj_tok_span": [64, 69], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [72, 77]}], "umls_entity_list": [{"mention": "Vandetanib", "char_span": [0, 10], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "Caprelsa", "char_span": [12, 20], "sem_type": "Pharmacologic Substance", "tok_span": [5, 8], "new_tok_span": [8, 11]}, {"mention": "RET", "char_span": [173, 176], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 40], "new_tok_span": [44, 45]}, {"mention": "vascular", "char_span": [233, 241], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [53, 54], "new_tok_span": [60, 61]}], "new_text": "<START=Pharmacologic Substance> Vandetanib <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> Caprelsa <END=Pharmacologic Substance> ( ® ), AstraZeneca ) is a once - daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth - factor receptor tyrosine kinase <START=Amino Acid, Peptide, or Protein> RET <END=Amino Acid, Peptide, or Protein> ( constitutively activated in roughly 60 % of all MTCs ), <START=Amino Acid, Peptide, or Protein> vascular <END=Amino Acid, Peptide, or Protein> endothelial growth - factor receptors 2 and 3, and epidermal growth - factor receptors."}, {"PMID": 23305921, "id": 5, "text": "In addition, derivatives of caffeic acid and sinapic acid efficiently inhibited tyrosinase activity and reduced melanin content in melanocytes Mel-Ab cell.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 40], "name": "caffeic acid", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"ent_type": "CHEMICAL", "char_span": [45, 57], "name": "sinapic acid", "tok_span": [9, 13], "new_tok_span": [12, 16]}, {"ent_type": "GENE", "char_span": [80, 90], "name": "tyrosinase", "tok_span": [15, 18], "new_tok_span": [19, 22]}], "relation_list": [{"subject": "caffeic acid", "sbj_char_span": [28, 40], "object": "tyrosinase", "obj_char_span": [80, 90], "rel_type": "inhibitor", "sbj_tok_span": [5, 8], "obj_tok_span": [15, 18], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [19, 22]}, {"subject": "sinapic acid", "sbj_char_span": [45, 57], "object": "tyrosinase", "obj_char_span": [80, 90], "rel_type": "inhibitor", "sbj_tok_span": [9, 13], "obj_tok_span": [15, 18], "new_sbj_tok_span": [12, 16], "new_obj_tok_span": [19, 22]}], "umls_entity_list": [{"mention": "caffeic acid", "char_span": [28, 40], "sem_type": "Pharmacologic Substance", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"mention": "sinapic acid", "char_span": [45, 57], "sem_type": "Pharmacologic Substance", "tok_span": [9, 13], "new_tok_span": [12, 16]}, {"mention": "melanin", "char_span": [112, 119], "sem_type": "Organic Chemical", "tok_span": [21, 23], "new_tok_span": [28, 30]}, {"mention": "mel", "char_span": [112, 115], "sem_type": "Pharmacologic Substance", "tok_span": [21, 22], "new_tok_span": [28, 29]}, {"mention": "mel", "char_span": [131, 134], "sem_type": "Pharmacologic Substance", "tok_span": [25, 26], "new_tok_span": [37, 38]}, {"mention": "Mel", "char_span": [143, 146], "sem_type": "Pharmacologic Substance", "tok_span": [27, 28], "new_tok_span": [43, 44]}, {"mention": "mel", "char_span": [112, 115], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [28, 29]}, {"mention": "mel", "char_span": [131, 134], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 26], "new_tok_span": [37, 38]}, {"mention": "Mel", "char_span": [143, 146], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [43, 44]}], "new_text": "In addition, derivatives of <START=Pharmacologic Substance> caffeic acid <END=Pharmacologic Substance> and <START=Pharmacologic Substance> sinapic acid <END=Pharmacologic Substance> efficiently inhibited tyrosinase activity and reduced <START=Organic Chemical> <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> melan <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein>in <END=Organic Chemical> content in <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> melan <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein>ocytes <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> Mel <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> - Ab cell."}, {"PMID": 9626023, "id": 5, "text": "Blood was assayed for serum-generated thromboxane B2 synthesis (COX-1 assay) and for lipopolysaccharide-stimulated prostaglandin E2 synthesis (COX-2 assay).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [115, 131], "name": "prostaglandin E2", "tok_span": [25, 28], "new_tok_span": [27, 30]}, {"ent_type": "GENE", "char_span": [64, 69], "name": "COX-1", "tok_span": [14, 17], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [143, 148], "name": "COX-2", "tok_span": [30, 33], "new_tok_span": [34, 37]}], "relation_list": [{"subject": "prostaglandin E2", "sbj_char_span": [115, 131], "object": "COX-2", "obj_char_span": [143, 148], "rel_type": "product or substrate", "sbj_tok_span": [25, 28], "obj_tok_span": [30, 33], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [34, 37]}], "umls_entity_list": [{"mention": "prostaglandin E2", "char_span": [115, 131], "sem_type": "Pharmacologic Substance", "tok_span": [25, 28], "new_tok_span": [27, 30]}, {"mention": "prostaglandin", "char_span": [115, 128], "sem_type": "Organic Chemical", "tok_span": [25, 26], "new_tok_span": [27, 28]}], "new_text": "Blood was assayed for serum - generated thromboxane B2 synthesis ( COX - 1 assay ) and for lipopolysaccharide - stimulated <START=Pharmacologic Substance> <START=Organic Chemical> prostaglandin <END=Organic Chemical> E2 <END=Pharmacologic Substance> synthesis ( COX - 2 assay )."}, {"PMID": 9626023, "id": 9, "text": "Inhibitory effects of NSAIDs on gastric prostaglandin E2 synthesis correlated with COX-1 inhibitory potency in blood (P < 0.001) and with COX-1 selectivity (P < 0.01), but not with COX-2 inhibitory potency.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [40, 56], "name": "prostaglandin E2", "tok_span": [8, 11], "new_tok_span": [12, 15]}, {"ent_type": "GENE", "char_span": [83, 88], "name": "COX-1", "tok_span": [14, 17], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [138, 143], "name": "COX-1", "tok_span": [31, 34], "new_tok_span": [37, 40]}, {"ent_type": "GENE", "char_span": [181, 186], "name": "COX-2", "tok_span": [46, 49], "new_tok_span": [52, 55]}], "relation_list": [{"subject": "prostaglandin E2", "sbj_char_span": [40, 56], "object": "COX-1", "obj_char_span": [83, 88], "rel_type": "product or substrate", "sbj_tok_span": [8, 11], "obj_tok_span": [14, 17], "new_sbj_tok_span": [12, 15], "new_obj_tok_span": [20, 23]}, {"subject": "prostaglandin E2", "sbj_char_span": [40, 56], "object": "COX-1", "obj_char_span": [138, 143], "rel_type": "product or substrate", "sbj_tok_span": [8, 11], "obj_tok_span": [31, 34], "new_sbj_tok_span": [12, 15], "new_obj_tok_span": [37, 40]}], "umls_entity_list": [{"mention": "NSAIDs", "char_span": [22, 28], "sem_type": "Pharmacologic Substance", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"mention": "prostaglandin E2", "char_span": [40, 56], "sem_type": "Pharmacologic Substance", "tok_span": [8, 11], "new_tok_span": [12, 15]}, {"mention": "prostaglandin", "char_span": [40, 53], "sem_type": "Organic Chemical", "tok_span": [8, 9], "new_tok_span": [12, 13]}], "new_text": "Inhibitory effects of <START=Pharmacologic Substance> NSAIDs <END=Pharmacologic Substance> on gastric <START=Pharmacologic Substance> <START=Organic Chemical> prostaglandin <END=Organic Chemical> E2 <END=Pharmacologic Substance> synthesis correlated with COX - 1 inhibitory potency in blood ( P < 0. 001 ) and with COX - 1 selectivity ( P < 0. 01 ), but not with COX - 2 inhibitory potency."}, {"PMID": 20624440, "id": 1, "text": "Rasagiline is a propargylamine and irreversible monoamine oxidase (MAO) B inhibitor used for the treatment of Parkinson's disease (PD). It has demonstrated neuroprotective properties in laboratory studies.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Rasagiline", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [16, 30], "name": "propargylamine", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"ent_type": "CHEMICAL", "char_span": [48, 57], "name": "monoamine", "tok_span": [11, 13], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [48, 73], "name": "monoamine oxidase (MAO) B", "tok_span": [11, 19], "new_tok_span": [13, 21]}], "relation_list": [{"subject": "Rasagiline", "sbj_char_span": [0, 10], "object": "monoamine oxidase (MAO) B", "obj_char_span": [48, 73], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [11, 19], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [13, 21]}, {"subject": "propargylamine", "sbj_char_span": [16, 30], "object": "monoamine oxidase (MAO) B", "obj_char_span": [48, 73], "rel_type": "inhibitor", "sbj_tok_span": [5, 9], "obj_tok_span": [11, 19], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [13, 21]}], "umls_entity_list": [{"mention": "propargylamine", "char_span": [16, 30], "sem_type": "Organic Chemical", "tok_span": [5, 9], "new_tok_span": [6, 10]}], "new_text": "Rasagiline is a <START=Organic Chemical> propargylamine <END=Organic Chemical> and irreversible monoamine oxidase ( MAO ) B inhibitor used for the treatment of Parkinson's disease ( PD ). It has demonstrated neuroprotective properties in laboratory studies."}, {"PMID": 23508685, "id": 5, "text": "Disruption of 5-HT2A receptor-dependent signaling in mice was associated with decreased acetylation of histone H3 (H3ac) and H4 (H4ac), and increased tri-methylation of histone H3 at lysine 27 (H3K27me3) at the mGlu2 promoter-epigenetic changes that correlate with transcriptional repression.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [183, 189], "name": "lysine", "tok_span": [47, 48], "new_tok_span": [59, 60]}, {"ent_type": "GENE", "char_span": [14, 20], "name": "5-HT2A", "tok_span": [3, 8], "new_tok_span": [3, 8]}, {"ent_type": "GENE", "char_span": [103, 113], "name": "histone H3", "tok_span": [20, 23], "new_tok_span": [23, 26]}, {"ent_type": "GENE", "char_span": [115, 119], "name": "H3ac", "tok_span": [24, 27], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [125, 127], "name": "H4", "tok_span": [29, 31], "new_tok_span": [34, 36]}, {"ent_type": "GENE", "char_span": [129, 133], "name": "H4ac", "tok_span": [32, 35], "new_tok_span": [39, 42]}, {"ent_type": "GENE", "char_span": [169, 179], "name": "histone H3", "tok_span": [43, 46], "new_tok_span": [54, 57]}, {"ent_type": "GENE", "char_span": [211, 225], "name": "mGlu2 promoter", "tok_span": [59, 63], "new_tok_span": [73, 77]}], "relation_list": [{"subject": "lysine", "sbj_char_span": [183, 189], "object": "histone H3", "obj_char_span": [169, 179], "rel_type": "product or substrate", "sbj_tok_span": [47, 48], "obj_tok_span": [43, 46], "new_sbj_tok_span": [59, 60], "new_obj_tok_span": [54, 57]}, {"subject": "lysine", "sbj_char_span": [183, 189], "object": "mGlu2 promoter", "obj_char_span": [211, 225], "rel_type": "part of", "sbj_tok_span": [47, 48], "obj_tok_span": [59, 63], "new_sbj_tok_span": [59, 60], "new_obj_tok_span": [73, 77]}], "umls_entity_list": [{"mention": "HT2A", "char_span": [16, 20], "sem_type": "Gene or Genome", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"mention": "H4", "char_span": [125, 127], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 31], "new_tok_span": [34, 36]}, {"mention": "H4", "char_span": [129, 131], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 34], "new_tok_span": [39, 41]}, {"mention": "histone", "char_span": [103, 110], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 21], "new_tok_span": [23, 24]}, {"mention": "histone", "char_span": [169, 176], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [43, 44], "new_tok_span": [54, 55]}, {"mention": "tri", "char_span": [150, 153], "sem_type": "Gene or Genome", "tok_span": [39, 40], "new_tok_span": [48, 49]}, {"mention": "H3K27me3", "char_span": [194, 202], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 56], "new_tok_span": [63, 69]}], "new_text": "Disruption of 5 - <START=Gene or Genome> HT2A <END=Gene or Genome> receptor - dependent signaling in mice was associated with decreased acetylation of <START=Amino Acid, Peptide, or Protein> histone <END=Amino Acid, Peptide, or Protein> H3 ( H3ac ) and <START=Amino Acid, Peptide, or Protein> H4 <END=Amino Acid, Peptide, or Protein> ( <START=Amino Acid, Peptide, or Protein> H4 <END=Amino Acid, Peptide, or Protein>ac ), and increased <START=Gene or Genome> tri <END=Gene or Genome> - methylation of <START=Amino Acid, Peptide, or Protein> histone <END=Amino Acid, Peptide, or Protein> H3 at lysine 27 ( <START=Amino Acid, Peptide, or Protein> H3K27me3 <END=Amino Acid, Peptide, or Protein> ) at the mGlu2 promoter - epigenetic changes that correlate with transcriptional repression."}, {"PMID": 23473053, "id": 2, "text": "The initial effort led to the first-generation PARP1 inhibitor 26 bearing a terminal phthalazin-1(2H)-one framework and showing remarkably high PARP1 inhibitory activity (0.31 nM) but only moderate potency in the cell.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [85, 105], "name": "phthalazin-1(2H)-one", "tok_span": [16, 28], "new_tok_span": [22, 34]}, {"ent_type": "GENE", "char_span": [47, 52], "name": "PARP1", "tok_span": [9, 11], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [144, 149], "name": "PARP1", "tok_span": [33, 35], "new_tok_span": [41, 43]}], "relation_list": [{"subject": "phthalazin-1(2H)-one", "sbj_char_span": [85, 105], "object": "PARP1", "obj_char_span": [47, 52], "rel_type": "inhibitor", "sbj_tok_span": [16, 28], "obj_tok_span": [9, 11], "new_sbj_tok_span": [22, 34], "new_obj_tok_span": [13, 15]}, {"subject": "phthalazin-1(2H)-one", "sbj_char_span": [85, 105], "object": "PARP1", "obj_char_span": [144, 149], "rel_type": "inhibitor", "sbj_tok_span": [16, 28], "obj_tok_span": [33, 35], "new_sbj_tok_span": [22, 34], "new_obj_tok_span": [41, 43]}], "umls_entity_list": [{"mention": "led", "char_span": [19, 22], "sem_type": "Gene or Genome", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"mention": "PARP1", "char_span": [47, 52], "sem_type": "Gene or Genome", "tok_span": [9, 11], "new_tok_span": [13, 15]}, {"mention": "PARP1", "char_span": [144, 149], "sem_type": "Gene or Genome", "tok_span": [33, 35], "new_tok_span": [41, 43]}, {"mention": "PARP1", "char_span": [47, 52], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 11], "new_tok_span": [13, 15]}, {"mention": "PARP1", "char_span": [144, 149], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 35], "new_tok_span": [41, 43]}], "new_text": "The initial effort <START=Gene or Genome> led <END=Gene or Genome> to the first - generation <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PARP1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> inhibitor 26 bearing a terminal phthalazin - 1 ( 2H ) - one framework and showing remarkably high <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PARP1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> inhibitory activity ( 0. 31 nM ) but only moderate potency in the cell."}, {"PMID": 15765929, "id": 5, "text": "Inhibition by piclamilast was largely reversed through pretreatment of cells with the adenylcyclase inhibitor SQ22536.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 25], "name": "piclamilast", "tok_span": [2, 6], "new_tok_span": [2, 6]}, {"ent_type": "CHEMICAL", "char_span": [110, 117], "name": "SQ22536", "tok_span": [20, 24], "new_tok_span": [20, 24]}, {"ent_type": "GENE", "char_span": [86, 99], "name": "adenylcyclase", "tok_span": [15, 19], "new_tok_span": [15, 19]}], "relation_list": [{"subject": "SQ22536", "sbj_char_span": [110, 117], "object": "adenylcyclase", "obj_char_span": [86, 99], "rel_type": "inhibitor", "sbj_tok_span": [20, 24], "obj_tok_span": [15, 19], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [15, 19]}], "umls_entity_list": [], "new_text": "Inhibition by piclamilast was largely reversed through pretreatment of cells with the adenylcyclase inhibitor SQ22536."}, {"PMID": 17015817, "id": 1, "text": "CONTEXT: Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved for insomnia treatment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 18], "name": "Ramelteon", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [30, 33], "name": "MT1", "tok_span": [10, 12], "new_tok_span": [11, 13]}, {"ent_type": "GENE", "char_span": [38, 60], "name": "MT2 melatonin receptor", "tok_span": [13, 17], "new_tok_span": [15, 19]}], "relation_list": [{"subject": "Ramelteon", "sbj_char_span": [9, 18], "object": "MT1", "obj_char_span": [30, 33], "rel_type": "agonist or antagonist", "sbj_tok_span": [4, 7], "obj_tok_span": [10, 12], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [11, 13]}, {"subject": "Ramelteon", "sbj_char_span": [9, 18], "object": "MT2 melatonin receptor", "obj_char_span": [38, 60], "rel_type": "agonist or antagonist", "sbj_tok_span": [4, 7], "obj_tok_span": [13, 17], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [15, 19]}], "umls_entity_list": [{"mention": "MT1", "char_span": [30, 33], "sem_type": "Gene or Genome", "tok_span": [10, 12], "new_tok_span": [11, 13]}, {"mention": "melatonin", "char_span": [42, 51], "sem_type": "Pharmacologic Substance", "tok_span": [15, 16], "new_tok_span": [18, 19]}], "new_text": "CONTEXT : Ramelteon is a novel <START=Gene or Genome> MT1 <END=Gene or Genome> and MT2 <START=Pharmacologic Substance> melatonin <END=Pharmacologic Substance> receptor selective agonist recently approved for insomnia treatment."}, {"PMID": 19503773, "id": 3, "text": "In the last 10 years, the catechol-O-methyltransferase (COMT) inhibitor tolcapone has been studied for its efficacy as an adjunctive treatment to levodopa plus a dopa decarboxylase inhibitor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [26, 34], "name": "catechol", "tok_span": [7, 8], "new_tok_span": [8, 9]}, {"ent_type": "CHEMICAL", "char_span": [35, 36], "name": "O", "tok_span": [9, 10], "new_tok_span": [10, 11]}, {"ent_type": "CHEMICAL", "char_span": [72, 81], "name": "tolcapone", "tok_span": [18, 22], "new_tok_span": [21, 25]}, {"ent_type": "CHEMICAL", "char_span": [146, 154], "name": "levodopa", "tok_span": [34, 37], "new_tok_span": [39, 42]}, {"ent_type": "CHEMICAL", "char_span": [162, 166], "name": "dopa", "tok_span": [39, 41], "new_tok_span": [46, 48]}, {"ent_type": "GENE", "char_span": [26, 54], "name": "catechol-O-methyltransferase", "tok_span": [7, 13], "new_tok_span": [8, 14]}, {"ent_type": "GENE", "char_span": [56, 60], "name": "COMT", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [162, 180], "name": "dopa decarboxylase", "tok_span": [39, 44], "new_tok_span": [46, 51]}], "relation_list": [{"subject": "tolcapone", "sbj_char_span": [72, 81], "object": "catechol-O-methyltransferase", "obj_char_span": [26, 54], "rel_type": "inhibitor", "sbj_tok_span": [18, 22], "obj_tok_span": [7, 13], "new_sbj_tok_span": [21, 25], "new_obj_tok_span": [8, 14]}, {"subject": "tolcapone", "sbj_char_span": [72, 81], "object": "COMT", "obj_char_span": [56, 60], "rel_type": "inhibitor", "sbj_tok_span": [18, 22], "obj_tok_span": [14, 16], "new_sbj_tok_span": [21, 25], "new_obj_tok_span": [16, 18]}, {"subject": "tolcapone", "sbj_char_span": [72, 81], "object": "dopa decarboxylase", "obj_char_span": [162, 180], "rel_type": "inhibitor", "sbj_tok_span": [18, 22], "obj_tok_span": [39, 44], "new_sbj_tok_span": [21, 25], "new_obj_tok_span": [46, 51]}], "umls_entity_list": [{"mention": "catechol-O-methyltransferase", "char_span": [26, 54], "sem_type": "Pharmacologic Substance", "tok_span": [7, 13], "new_tok_span": [8, 14]}, {"mention": "tolcapone", "char_span": [72, 81], "sem_type": "Pharmacologic Substance", "tok_span": [18, 22], "new_tok_span": [21, 25]}, {"mention": "levodopa", "char_span": [146, 154], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 37], "new_tok_span": [39, 42]}, {"mention": "dopa decarboxylase inhibitor", "char_span": [162, 190], "sem_type": "Pharmacologic Substance", "tok_span": [39, 45], "new_tok_span": [46, 52]}], "new_text": "In the last 10 years, the <START=Pharmacologic Substance> catechol - O - methyltransferase <END=Pharmacologic Substance> ( COMT ) inhibitor <START=Pharmacologic Substance> tolcapone <END=Pharmacologic Substance> has been studied for its efficacy as an adjunctive treatment to <START=Amino Acid, Peptide, or Protein> levodopa <END=Amino Acid, Peptide, or Protein> plus a <START=Pharmacologic Substance> dopa decarboxylase inhibitor <END=Pharmacologic Substance>."}, {"PMID": 23541125, "id": 7, "text": "TRPA1 activation by wood smoke particles occurred through the electrophile/oxidant-sensing domain (i.e., C621/C641/C665/K710), based on the inhibition of cellular responses when the particles were pretreated with glutathione; a role for the menthol-binding site of TRPA1 (S873/T874) was demonstrated for 3,5-ditert-butylphenol.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [213, 224], "name": "glutathione", "tok_span": [55, 56], "new_tok_span": [60, 61]}, {"ent_type": "CHEMICAL", "char_span": [241, 248], "name": "menthol", "tok_span": [61, 63], "new_tok_span": [68, 70]}, {"ent_type": "CHEMICAL", "char_span": [304, 326], "name": "3,5-ditert-butylphenol", "tok_span": [82, 94], "new_tok_span": [94, 106]}, {"ent_type": "GENE", "char_span": [0, 5], "name": "TRPA1", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"ent_type": "GENE", "char_span": [62, 97], "name": "electrophile/oxidant-sensing domain", "tok_span": [11, 19], "new_tok_span": [15, 23]}, {"ent_type": "GENE", "char_span": [265, 270], "name": "TRPA1", "tok_span": [67, 70], "new_tok_span": [77, 80]}], "relation_list": [{"subject": "menthol", "sbj_char_span": [241, 248], "object": "TRPA1", "obj_char_span": [265, 270], "rel_type": "regulator", "sbj_tok_span": [61, 63], "obj_tok_span": [67, 70], "new_sbj_tok_span": [68, 70], "new_obj_tok_span": [77, 80]}], "umls_entity_list": [{"mention": "glutathion", "char_span": [213, 223], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [55, 56], "new_tok_span": [60, 61]}, {"mention": "menthol", "char_span": [241, 248], "sem_type": "Pharmacologic Substance", "tok_span": [61, 63], "new_tok_span": [68, 70]}, {"mention": "TRPA1", "char_span": [0, 5], "sem_type": "Gene or Genome", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"mention": "TRPA1", "char_span": [265, 270], "sem_type": "Gene or Genome", "tok_span": [67, 70], "new_tok_span": [77, 80]}, {"mention": "TRPA1", "char_span": [0, 5], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"mention": "TRPA1", "char_span": [265, 270], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [67, 70], "new_tok_span": [77, 80]}], "new_text": "<START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> TRPA1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> activation by wood smoke particles occurred through the electrophile / oxidant - sensing domain ( i. e., C621 / C641 / C665 / K710 ), based on the inhibition of cellular responses when the particles were pretreated with <START=Amino Acid, Peptide, or Protein> glutathione <END=Amino Acid, Peptide, or Protein> ; a role for the <START=Pharmacologic Substance> menthol <END=Pharmacologic Substance> - binding site of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> TRPA1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( S873 / T874 ) was demonstrated for 3, 5 - ditert - butylphenol."}, {"PMID": 17602574, "id": 4, "text": "In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [57, 67], "name": "l-cysteine", "tok_span": [11, 14], "new_tok_span": [11, 14]}, {"ent_type": "CHEMICAL", "char_span": [77, 79], "name": "NO", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"ent_type": "CHEMICAL", "char_span": [96, 98], "name": "O2", "tok_span": [20, 22], "new_tok_span": [23, 25]}, {"ent_type": "CHEMICAL", "char_span": [133, 137], "name": "2H1C", "tok_span": [29, 33], "new_tok_span": [33, 37]}, {"ent_type": "CHEMICAL", "char_span": [156, 160], "name": "iron", "tok_span": [38, 39], "new_tok_span": [42, 43]}, {"ent_type": "GENE", "char_span": [22, 25], "name": "CDO", "tok_span": [4, 6], "new_tok_span": [4, 6]}, {"ent_type": "GENE", "char_span": [133, 168], "name": "2H1C class of non-heme iron enzymes", "tok_span": [29, 40], "new_tok_span": [33, 44]}], "relation_list": [{"subject": "l-cysteine", "sbj_char_span": [57, 67], "object": "CDO", "obj_char_span": [22, 25], "rel_type": "regulator", "sbj_tok_span": [11, 14], "obj_tok_span": [4, 6], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [4, 6]}, {"subject": "NO", "sbj_char_span": [77, 79], "object": "CDO", "obj_char_span": [22, 25], "rel_type": "regulator", "sbj_tok_span": [16, 17], "obj_tok_span": [4, 6], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [4, 6]}, {"subject": "O2", "sbj_char_span": [96, 98], "object": "CDO", "obj_char_span": [22, 25], "rel_type": "regulator", "sbj_tok_span": [20, 22], "obj_tok_span": [4, 6], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [4, 6]}, {"subject": "l-cysteine", "sbj_char_span": [57, 67], "object": "2H1C class of non-heme iron enzymes", "obj_char_span": [133, 168], "rel_type": "regulator", "sbj_tok_span": [11, 14], "obj_tok_span": [29, 40], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [33, 44]}, {"subject": "NO", "sbj_char_span": [77, 79], "object": "2H1C class of non-heme iron enzymes", "obj_char_span": [133, 168], "rel_type": "regulator", "sbj_tok_span": [16, 17], "obj_tok_span": [29, 40], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [33, 44]}, {"subject": "O2", "sbj_char_span": [96, 98], "object": "2H1C class of non-heme iron enzymes", "obj_char_span": [133, 168], "rel_type": "regulator", "sbj_tok_span": [20, 22], "obj_tok_span": [29, 40], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [33, 44]}], "umls_entity_list": [{"mention": "cysteine", "char_span": [59, 67], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 14], "new_tok_span": [14, 15]}, {"mention": "O2", "char_span": [96, 98], "sem_type": "Pharmacologic Substance", "tok_span": [20, 22], "new_tok_span": [23, 25]}], "new_text": "In these experiments, CDO exhibits an ordered binding of l - <START=Amino Acid, Peptide, or Protein> cysteine <END=Amino Acid, Peptide, or Protein> prior to NO ( and presumably <START=Pharmacologic Substance> O2 <END=Pharmacologic Substance> ) similar to that observed for the 2H1C class of non - heme iron enzymes."}, {"PMID": 17234158, "id": 2, "text": "Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, PFD) elicits growth-inhibitory effects and reduces TGF-beta2 protein levels in human glioma cell lines.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [43, 76], "name": "5-methyl-1-phenyl-2-(1H)-pyridone", "tok_span": [10, 27], "new_tok_span": [10, 27]}, {"ent_type": "CHEMICAL", "char_span": [78, 89], "name": "pirfenidone", "tok_span": [28, 32], "new_tok_span": [30, 34]}, {"ent_type": "CHEMICAL", "char_span": [91, 94], "name": "PFD", "tok_span": [33, 35], "new_tok_span": [36, 38]}, {"ent_type": "GENE", "char_span": [142, 151], "name": "TGF-beta2", "tok_span": [44, 48], "new_tok_span": [50, 54]}], "relation_list": [{"subject": "5-methyl-1-phenyl-2-(1H)-pyridone", "sbj_char_span": [43, 76], "object": "TGF-beta2", "obj_char_span": [142, 151], "rel_type": "regulator", "sbj_tok_span": [10, 27], "obj_tok_span": [44, 48], "new_sbj_tok_span": [10, 27], "new_obj_tok_span": [50, 54]}, {"subject": "pirfenidone", "sbj_char_span": [78, 89], "object": "TGF-beta2", "obj_char_span": [142, 151], "rel_type": "regulator", "sbj_tok_span": [28, 32], "obj_tok_span": [44, 48], "new_sbj_tok_span": [30, 34], "new_obj_tok_span": [50, 54]}, {"subject": "PFD", "sbj_char_span": [91, 94], "object": "TGF-beta2", "obj_char_span": [142, 151], "rel_type": "regulator", "sbj_tok_span": [33, 35], "obj_tok_span": [44, 48], "new_sbj_tok_span": [36, 38], "new_obj_tok_span": [50, 54]}], "umls_entity_list": [{"mention": "pyridone", "char_span": [68, 76], "sem_type": "Organic Chemical", "tok_span": [25, 27], "new_tok_span": [26, 28]}, {"mention": "PFD", "char_span": [91, 94], "sem_type": "Gene or Genome", "tok_span": [33, 35], "new_tok_span": [36, 38]}, {"mention": "TGF-beta2", "char_span": [142, 151], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [44, 48], "new_tok_span": [50, 54]}, {"mention": "protein", "char_span": [152, 159], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [48, 49], "new_tok_span": [58, 59]}, {"mention": "TGF-beta2", "char_span": [142, 151], "sem_type": "Gene or Genome", "tok_span": [44, 48], "new_tok_span": [50, 54]}, {"mention": "beta2 protein", "char_span": [146, 159], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [46, 49], "new_tok_span": [53, 56]}], "new_text": "Here, we report that the antifibrotic drug 5 - methyl - 1 - phenyl - 2 - ( 1H ) - <START=Organic Chemical> pyridone <END=Organic Chemical> ( pirfenidone, <START=Gene or Genome> PFD <END=Gene or Genome> ) elicits growth - inhibitory effects and reduces <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> TGF - <START=Amino Acid, Peptide, or Protein> beta2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <START=Amino Acid, Peptide, or Protein> protein <END=Amino Acid, Peptide, or Protein> <END=Amino Acid, Peptide, or Protein> levels in human glioma cell lines."}, {"PMID": 12652111, "id": 11, "text": "However, the lower level of PDE4 activity in failing human heart suggests that factors other than inhibition of PDE4 by milrinone may contribute to differences in cardiotonic action when compared to cilostazol.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [120, 129], "name": "milrinone", "tok_span": [23, 26], "new_tok_span": [27, 30]}, {"ent_type": "CHEMICAL", "char_span": [199, 209], "name": "cilostazol", "tok_span": [37, 41], "new_tok_span": [43, 47]}, {"ent_type": "GENE", "char_span": [28, 32], "name": "PDE4", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"ent_type": "GENE", "char_span": [112, 116], "name": "PDE4", "tok_span": [20, 22], "new_tok_span": [23, 25]}], "relation_list": [{"subject": "milrinone", "sbj_char_span": [120, 129], "object": "PDE4", "obj_char_span": [112, 116], "rel_type": "inhibitor", "sbj_tok_span": [23, 26], "obj_tok_span": [20, 22], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [23, 25]}, {"subject": "cilostazol", "sbj_char_span": [199, 209], "object": "PDE4", "obj_char_span": [112, 116], "rel_type": "inhibitor", "sbj_tok_span": [37, 41], "obj_tok_span": [20, 22], "new_sbj_tok_span": [43, 47], "new_obj_tok_span": [23, 25]}], "umls_entity_list": [{"mention": "PDE4", "char_span": [28, 32], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"mention": "PDE4", "char_span": [112, 116], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 22], "new_tok_span": [23, 25]}, {"mention": "cardiotonic", "char_span": [163, 174], "sem_type": "Pharmacologic Substance", "tok_span": [31, 33], "new_tok_span": [36, 38]}], "new_text": "However, the lower level of <START=Amino Acid, Peptide, or Protein> PDE4 <END=Amino Acid, Peptide, or Protein> activity in failing human heart suggests that factors other than inhibition of <START=Amino Acid, Peptide, or Protein> PDE4 <END=Amino Acid, Peptide, or Protein> by milrinone may contribute to differences in <START=Pharmacologic Substance> cardiotonic <END=Pharmacologic Substance> action when compared to cilostazol."}, {"PMID": 23485614, "id": 6, "text": "Similarly, substantial elevations of blood glucose, distorted lipid profile (total cholesterol: TC, triglycerides: TGs, high density lipoprotein cholesterol: HDL-C and low density lipoprotein cholesterol: LDL-C) and kidney function signs (creatinine and urea) have been refurbished to the desirable levels on par with the standard antidiabetic glibenclamide.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [83, 94], "name": "cholesterol", "tok_span": [13, 14], "new_tok_span": [15, 16]}, {"ent_type": "CHEMICAL", "char_span": [100, 113], "name": "triglycerides", "tok_span": [17, 18], "new_tok_span": [21, 22]}, {"ent_type": "CHEMICAL", "char_span": [145, 156], "name": "cholesterol", "tok_span": [25, 26], "new_tok_span": [31, 32]}, {"ent_type": "CHEMICAL", "char_span": [192, 203], "name": "cholesterol", "tok_span": [34, 35], "new_tok_span": [42, 43]}, {"ent_type": "CHEMICAL", "char_span": [239, 249], "name": "creatinine", "tok_span": [45, 46], "new_tok_span": [54, 55]}, {"ent_type": "CHEMICAL", "char_span": [254, 258], "name": "urea", "tok_span": [47, 48], "new_tok_span": [58, 59]}, {"ent_type": "CHEMICAL", "char_span": [344, 357], "name": "glibenclamide", "tok_span": [65, 69], "new_tok_span": [82, 86]}, {"ent_type": "CHEMICAL", "char_span": [43, 50], "name": "glucose", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "GENE", "char_span": [120, 144], "name": "high density lipoprotein", "tok_span": [22, 25], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [158, 161], "name": "HDL", "tok_span": [27, 28], "new_tok_span": [34, 35]}, {"ent_type": "GENE", "char_span": [168, 191], "name": "low density lipoprotein", "tok_span": [31, 34], "new_tok_span": [39, 42]}, {"ent_type": "GENE", "char_span": [205, 208], "name": "LDL", "tok_span": [36, 37], "new_tok_span": [44, 45]}], "relation_list": [{"subject": "glibenclamide", "sbj_char_span": [344, 357], "object": "high density lipoprotein", "obj_char_span": [120, 144], "rel_type": "regulator", "sbj_tok_span": [65, 69], "obj_tok_span": [22, 25], "new_sbj_tok_span": [82, 86], "new_obj_tok_span": [28, 31]}, {"subject": "glibenclamide", "sbj_char_span": [344, 357], "object": "HDL", "obj_char_span": [158, 161], "rel_type": "regulator", "sbj_tok_span": [65, 69], "obj_tok_span": [27, 28], "new_sbj_tok_span": [82, 86], "new_obj_tok_span": [34, 35]}, {"subject": "glibenclamide", "sbj_char_span": [344, 357], "object": "low density lipoprotein", "obj_char_span": [168, 191], "rel_type": "regulator", "sbj_tok_span": [65, 69], "obj_tok_span": [31, 34], "new_sbj_tok_span": [82, 86], "new_obj_tok_span": [39, 42]}, {"subject": "glibenclamide", "sbj_char_span": [344, 357], "object": "LDL", "obj_char_span": [205, 208], "rel_type": "regulator", "sbj_tok_span": [65, 69], "obj_tok_span": [36, 37], "new_sbj_tok_span": [82, 86], "new_obj_tok_span": [44, 45]}], "umls_entity_list": [{"mention": "lipid", "char_span": [62, 67], "sem_type": "Organic Chemical", "tok_span": [9, 10], "new_tok_span": [10, 11]}, {"mention": "TC", "char_span": [96, 98], "sem_type": "Gene or Genome", "tok_span": [15, 16], "new_tok_span": [18, 19]}, {"mention": "TGs", "char_span": [115, 118], "sem_type": "Gene or Genome", "tok_span": [19, 21], "new_tok_span": [24, 26]}, {"mention": "HDL", "char_span": [158, 161], "sem_type": "Gene or Genome", "tok_span": [27, 28], "new_tok_span": [34, 35]}, {"mention": "creatinine", "char_span": [239, 249], "sem_type": "Organic Chemical", "tok_span": [45, 46], "new_tok_span": [54, 55]}, {"mention": "urea", "char_span": [254, 258], "sem_type": "Pharmacologic Substance", "tok_span": [47, 48], "new_tok_span": [58, 59]}, {"mention": "par", "char_span": [309, 312], "sem_type": "Gene or Genome", "tok_span": [59, 60], "new_tok_span": [72, 73]}, {"mention": "antidiabetic", "char_span": [331, 343], "sem_type": "Pharmacologic Substance", "tok_span": [63, 65], "new_tok_span": [78, 80]}, {"mention": "glibenclamide", "char_span": [344, 357], "sem_type": "Pharmacologic Substance", "tok_span": [65, 69], "new_tok_span": [82, 86]}], "new_text": "Similarly, substantial elevations of blood glucose, distorted <START=Organic Chemical> lipid <END=Organic Chemical> profile ( total cholesterol : <START=Gene or Genome> TC <END=Gene or Genome>, triglycerides : <START=Gene or Genome> TGs <END=Gene or Genome>, high density lipoprotein cholesterol : <START=Gene or Genome> HDL <END=Gene or Genome> - C and low density lipoprotein cholesterol : LDL - C ) and kidney function signs ( <START=Organic Chemical> creatinine <END=Organic Chemical> and <START=Pharmacologic Substance> urea <END=Pharmacologic Substance> ) have been refurbished to the desirable levels on <START=Gene or Genome> par <END=Gene or Genome> with the standard <START=Pharmacologic Substance> antidiabetic <END=Pharmacologic Substance> <START=Pharmacologic Substance> glibenclamide <END=Pharmacologic Substance>."}, {"PMID": 15494548, "id": 9, "text": "Valdecoxib showed similar activity in the human whole-blood COX assay (COX-2 IC(50) = 0.24 microM; COX-1 IC(50) = 21.9 microM). We also determined whether this in vitro potency and selectivity translated to significant potency in vivo.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Valdecoxib", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "GENE", "char_span": [42, 63], "name": "human whole-blood COX", "tok_span": [9, 14], "new_tok_span": [11, 16]}, {"ent_type": "GENE", "char_span": [71, 76], "name": "COX-2", "tok_span": [16, 19], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [99, 104], "name": "COX-1", "tok_span": [30, 33], "new_tok_span": [36, 39]}], "relation_list": [{"subject": "Valdecoxib", "sbj_char_span": [0, 10], "object": "human whole-blood COX", "obj_char_span": [42, 63], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [9, 14], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [11, 16]}, {"subject": "Valdecoxib", "sbj_char_span": [0, 10], "object": "COX-2", "obj_char_span": [71, 76], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [16, 19], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [20, 23]}, {"subject": "Valdecoxib", "sbj_char_span": [0, 10], "object": "COX-1", "obj_char_span": [99, 104], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [30, 33], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [36, 39]}], "umls_entity_list": [{"mention": "COX-2", "char_span": [71, 76], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 19], "new_tok_span": [20, 23]}, {"mention": "COX-2", "char_span": [71, 76], "sem_type": "Gene or Genome", "tok_span": [16, 19], "new_tok_span": [20, 23]}, {"mention": "coxi", "char_span": [5, 9], "sem_type": "Gene or Genome", "tok_span": [1, 4], "new_tok_span": [2, 5]}], "new_text": "Val <START=Gene or Genome>decoxib <END=Gene or Genome> showed similar activity in the human whole - blood COX assay ( <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> COX - 2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> IC ( 50 ) = 0. 24 microM ; COX - 1 IC ( 50 ) = 21. 9 microM ). We also determined whether this in vitro potency and selectivity translated to significant potency in vivo."}, {"PMID": 17499824, "id": 6, "text": "The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian serine racemase activity is increased by ATP. In addition to the results regarding the effect of ATP on enzyme activity and the phylogenetic analysis of eukaryotic serine racemases, the antiserum against Arabidopsis serine racemase did not form a precipitate with barley and rice serine racemases.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [20, 23], "name": "PLP", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [53, 59], "name": "Ca(2+)", "tok_span": [12, 17], "new_tok_span": [12, 17]}, {"ent_type": "CHEMICAL", "char_span": [61, 67], "name": "Mg(2+)", "tok_span": [18, 23], "new_tok_span": [18, 23]}, {"ent_type": "CHEMICAL", "char_span": [72, 78], "name": "Mn(2+)", "tok_span": [25, 30], "new_tok_span": [25, 30]}, {"ent_type": "CHEMICAL", "char_span": [88, 91], "name": "ATP", "tok_span": [33, 34], "new_tok_span": [34, 35]}, {"ent_type": "CHEMICAL", "char_span": [111, 117], "name": "serine", "tok_span": [37, 38], "new_tok_span": [42, 43]}, {"ent_type": "CHEMICAL", "char_span": [152, 155], "name": "ATP", "tok_span": [45, 46], "new_tok_span": [54, 55]}, {"ent_type": "CHEMICAL", "char_span": [208, 211], "name": "ATP", "tok_span": [56, 57], "new_tok_span": [67, 68]}, {"ent_type": "CHEMICAL", "char_span": [275, 281], "name": "serine", "tok_span": [66, 67], "new_tok_span": [81, 82]}, {"ent_type": "CHEMICAL", "char_span": [327, 333], "name": "serine", "tok_span": [75, 76], "new_tok_span": [98, 99]}, {"ent_type": "CHEMICAL", "char_span": [391, 397], "name": "serine", "tok_span": [88, 89], "new_tok_span": [121, 122]}, {"ent_type": "GENE", "char_span": [111, 126], "name": "serine racemase", "tok_span": [37, 41], "new_tok_span": [42, 46]}, {"ent_type": "GENE", "char_span": [275, 291], "name": "serine racemases", "tok_span": [66, 70], "new_tok_span": [81, 85]}, {"ent_type": "GENE", "char_span": [315, 342], "name": "Arabidopsis serine racemase", "tok_span": [74, 79], "new_tok_span": [94, 99]}, {"ent_type": "GENE", "char_span": [391, 407], "name": "serine racemases", "tok_span": [88, 92], "new_tok_span": [121, 125]}], "relation_list": [{"subject": "ATP", "sbj_char_span": [152, 155], "object": "serine racemase", "obj_char_span": [111, 126], "rel_type": "activator", "sbj_tok_span": [45, 46], "obj_tok_span": [37, 41], "new_sbj_tok_span": [54, 55], "new_obj_tok_span": [42, 46]}], "umls_entity_list": [{"mention": "ATP", "char_span": [88, 91], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 34], "new_tok_span": [34, 35]}, {"mention": "ATP", "char_span": [152, 155], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [45, 46], "new_tok_span": [54, 55]}, {"mention": "ATP", "char_span": [208, 211], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 57], "new_tok_span": [67, 68]}, {"mention": "serine", "char_span": [111, 117], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 38], "new_tok_span": [42, 43]}, {"mention": "serine", "char_span": [275, 281], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [66, 67], "new_tok_span": [81, 82]}, {"mention": "serine", "char_span": [327, 333], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [75, 76], "new_tok_span": [98, 99]}, {"mention": "serine", "char_span": [391, 397], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [88, 89], "new_tok_span": [121, 122]}, {"mention": "serine racemase", "char_span": [111, 126], "sem_type": "Gene or Genome", "tok_span": [37, 41], "new_tok_span": [42, 46]}, {"mention": "serine racemase", "char_span": [275, 290], "sem_type": "Gene or Genome", "tok_span": [66, 70], "new_tok_span": [81, 85]}, {"mention": "serine racemase", "char_span": [327, 342], "sem_type": "Gene or Genome", "tok_span": [75, 79], "new_tok_span": [98, 102]}, {"mention": "serine racemase", "char_span": [391, 406], "sem_type": "Gene or Genome", "tok_span": [88, 92], "new_tok_span": [121, 125]}, {"mention": "serine racemase", "char_span": [111, 126], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 41], "new_tok_span": [42, 46]}, {"mention": "serine racemase", "char_span": [275, 290], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [66, 70], "new_tok_span": [81, 85]}, {"mention": "serine racemase", "char_span": [327, 342], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [75, 79], "new_tok_span": [98, 102]}, {"mention": "serine racemase", "char_span": [391, 406], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [88, 92], "new_tok_span": [121, 125]}, {"mention": "antiserum", "char_span": [297, 306], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [72, 73], "new_tok_span": [91, 92]}, {"mention": "barley", "char_span": [375, 381], "sem_type": "Pharmacologic Substance", "tok_span": [85, 86], "new_tok_span": [112, 113]}, {"mention": "rice", "char_span": [386, 390], "sem_type": "Pharmacologic Substance", "tok_span": [87, 88], "new_tok_span": [116, 117]}], "new_text": "The enzyme requires PLP and divalent cations such as Ca ( 2 + ), Mg ( 2 + ), or Mn ( 2 + ), but not <START=Amino Acid, Peptide, or Protein> ATP <END=Amino Acid, Peptide, or Protein>, whereas mammalian <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> serine <END=Amino Acid, Peptide, or Protein> racemase <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> activity is increased by <START=Amino Acid, Peptide, or Protein> ATP <END=Amino Acid, Peptide, or Protein>. In addition to the results regarding the effect of <START=Amino Acid, Peptide, or Protein> ATP <END=Amino Acid, Peptide, or Protein> on enzyme activity and the phylogenetic analysis of eukaryotic <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> serine <END=Amino Acid, Peptide, or Protein> racemases <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, the <START=Amino Acid, Peptide, or Protein> antiserum <END=Amino Acid, Peptide, or Protein> against Arabidopsis <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> serine <END=Amino Acid, Peptide, or Protein> racemase <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> did not form a precipitate with <START=Pharmacologic Substance> barley <END=Pharmacologic Substance> and <START=Pharmacologic Substance> rice <END=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> serine <END=Amino Acid, Peptide, or Protein> racemases <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 18290715, "id": 1, "text": "The vitamin D hormone, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], binds with high affinity to the nuclear vitamin D receptor (VDR), which recruits its retinoid X receptor (RXR) heterodimeric partner to recognize vitamin D responsive elements (VDREs) in target genes. 1,25(OH)(2)D(3) is known primarily as a regulator of calcium, but it also controls phosphate (re)absorption at the intestine and kidney.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [109, 118], "name": "vitamin D", "tok_span": [40, 42], "new_tok_span": [49, 51]}, {"ent_type": "CHEMICAL", "char_span": [154, 162], "name": "retinoid", "tok_span": [52, 54], "new_tok_span": [64, 66]}, {"ent_type": "CHEMICAL", "char_span": [215, 224], "name": "vitamin D", "tok_span": [66, 68], "new_tok_span": [81, 83]}, {"ent_type": "CHEMICAL", "char_span": [23, 49], "name": "1,25-dihydroxyvitamin D(3)", "tok_span": [5, 17], "new_tok_span": [9, 21]}, {"ent_type": "CHEMICAL", "char_span": [270, 285], "name": "1,25(OH)(2)D(3)", "tok_span": [79, 92], "new_tok_span": [95, 108]}, {"ent_type": "CHEMICAL", "char_span": [323, 330], "name": "calcium", "tok_span": [99, 100], "new_tok_span": [116, 117]}, {"ent_type": "CHEMICAL", "char_span": [353, 362], "name": "phosphate", "tok_span": [105, 106], "new_tok_span": [123, 124]}, {"ent_type": "CHEMICAL", "char_span": [4, 13], "name": "vitamin D", "tok_span": [1, 3], "new_tok_span": [2, 4]}, {"ent_type": "CHEMICAL", "char_span": [51, 66], "name": "1,25(OH)(2)D(3)", "tok_span": [18, 31], "new_tok_span": [24, 37]}, {"ent_type": "GENE", "char_span": [109, 127], "name": "vitamin D receptor", "tok_span": [40, 43], "new_tok_span": [49, 52]}, {"ent_type": "GENE", "char_span": [129, 132], "name": "VDR", "tok_span": [44, 46], "new_tok_span": [56, 58]}, {"ent_type": "GENE", "char_span": [154, 173], "name": "retinoid X receptor", "tok_span": [52, 56], "new_tok_span": [64, 68]}, {"ent_type": "GENE", "char_span": [175, 178], "name": "RXR", "tok_span": [57, 59], "new_tok_span": [70, 72]}, {"ent_type": "GENE", "char_span": [215, 244], "name": "vitamin D responsive elements", "tok_span": [66, 70], "new_tok_span": [81, 85]}, {"ent_type": "GENE", "char_span": [246, 251], "name": "VDREs", "tok_span": [71, 74], "new_tok_span": [87, 90]}], "relation_list": [{"subject": "1,25-dihydroxyvitamin D(3)", "sbj_char_span": [23, 49], "object": "vitamin D receptor", "obj_char_span": [109, 127], "rel_type": "regulator", "sbj_tok_span": [5, 17], "obj_tok_span": [40, 43], "new_sbj_tok_span": [9, 21], "new_obj_tok_span": [49, 52]}, {"subject": "1,25(OH)(2)D(3)", "sbj_char_span": [51, 66], "object": "vitamin D receptor", "obj_char_span": [109, 127], "rel_type": "regulator", "sbj_tok_span": [18, 31], "obj_tok_span": [40, 43], "new_sbj_tok_span": [24, 37], "new_obj_tok_span": [49, 52]}, {"subject": "1,25-dihydroxyvitamin D(3)", "sbj_char_span": [23, 49], "object": "VDR", "obj_char_span": [129, 132], "rel_type": "regulator", "sbj_tok_span": [5, 17], "obj_tok_span": [44, 46], "new_sbj_tok_span": [9, 21], "new_obj_tok_span": [56, 58]}, {"subject": "1,25(OH)(2)D(3)", "sbj_char_span": [51, 66], "object": "VDR", "obj_char_span": [129, 132], "rel_type": "regulator", "sbj_tok_span": [18, 31], "obj_tok_span": [44, 46], "new_sbj_tok_span": [24, 37], "new_obj_tok_span": [56, 58]}], "umls_entity_list": [{"mention": "vitamin D", "char_span": [4, 13], "sem_type": "Pharmacologic Substance", "tok_span": [1, 3], "new_tok_span": [2, 4]}, {"mention": "vitamin D", "char_span": [37, 46], "sem_type": "Pharmacologic Substance", "tok_span": [11, 14], "new_tok_span": [16, 19]}, {"mention": "vitamin D", "char_span": [109, 118], "sem_type": "Pharmacologic Substance", "tok_span": [40, 42], "new_tok_span": [49, 51]}, {"mention": "vitamin D", "char_span": [215, 224], "sem_type": "Pharmacologic Substance", "tok_span": [66, 68], "new_tok_span": [81, 83]}, {"mention": "hormone", "char_span": [14, 21], "sem_type": "Pharmacologic Substance", "tok_span": [3, 4], "new_tok_span": [6, 7]}, {"mention": "vitamin D receptor", "char_span": [109, 127], "sem_type": "Gene or Genome", "tok_span": [40, 43], "new_tok_span": [49, 52]}, {"mention": "vitamin D receptor", "char_span": [109, 127], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [40, 43], "new_tok_span": [49, 52]}, {"mention": "RXR", "char_span": [175, 178], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [57, 59], "new_tok_span": [70, 72]}, {"mention": "calcium", "char_span": [323, 330], "sem_type": "Pharmacologic Substance", "tok_span": [99, 100], "new_tok_span": [116, 117]}], "new_text": "The <START=Pharmacologic Substance> vitamin D <END=Pharmacologic Substance> <START=Pharmacologic Substance> hormone <END=Pharmacologic Substance>, 1, 25 - dihydroxy <START=Pharmacologic Substance>vitamin D <END=Pharmacologic Substance> ( 3 ) [ 1, 25 ( OH ) ( 2 ) D ( 3 ) ], binds with high affinity to the nuclear <START=Pharmacologic Substance> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> vitamin D <END=Pharmacologic Substance> receptor <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( VDR ), which recruits its retinoid X receptor ( <START=Amino Acid, Peptide, or Protein> RXR <END=Amino Acid, Peptide, or Protein> ) heterodimeric partner to recognize <START=Pharmacologic Substance> vitamin D <END=Pharmacologic Substance> responsive elements ( VDREs ) in target genes. 1, 25 ( OH ) ( 2 ) D ( 3 ) is known primarily as a regulator of <START=Pharmacologic Substance> calcium <END=Pharmacologic Substance>, but it also controls phosphate ( re ) absorption at the intestine and kidney."}, {"PMID": 23237828, "id": 8, "text": "Moreover, cycloheximide was observed to up-regulate expression of other SOCS family members, such as SOCS-1, -2, -4, -5, -6, -7, and cytokine-inducible SH2-containing protein (CIS)-1 mRNAs. Such effects varied with the dosage and duration of cycloheximide treatment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [242, 255], "name": "cycloheximide", "tok_span": [67, 70], "new_tok_span": [87, 90]}, {"ent_type": "CHEMICAL", "char_span": [10, 23], "name": "cycloheximide", "tok_span": [2, 5], "new_tok_span": [2, 5]}, {"ent_type": "GENE", "char_span": [101, 127], "name": "SOCS-1, -2, -4, -5, -6, -7", "tok_span": [21, 40], "new_tok_span": [29, 48]}, {"ent_type": "GENE", "char_span": [133, 182], "name": "cytokine-inducible SH2-containing protein (CIS)-1", "tok_span": [42, 56], "new_tok_span": [57, 71]}, {"ent_type": "GENE", "char_span": [72, 76], "name": "SOCS", "tok_span": [14, 16], "new_tok_span": [16, 18]}], "relation_list": [{"subject": "cycloheximide", "sbj_char_span": [10, 23], "object": "SOCS", "obj_char_span": [72, 76], "rel_type": "regulator", "sbj_tok_span": [2, 5], "obj_tok_span": [14, 16], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [16, 18]}, {"subject": "cycloheximide", "sbj_char_span": [10, 23], "object": "cytokine-inducible SH2-containing protein (CIS)-1", "obj_char_span": [133, 182], "rel_type": "regulator", "sbj_tok_span": [2, 5], "obj_tok_span": [42, 56], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [57, 71]}], "umls_entity_list": [{"mention": "SOCS", "char_span": [72, 76], "sem_type": "Gene or Genome", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"mention": "SOCS", "char_span": [101, 105], "sem_type": "Gene or Genome", "tok_span": [21, 23], "new_tok_span": [29, 31]}, {"mention": "SOCS", "char_span": [72, 76], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"mention": "SOCS", "char_span": [101, 105], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 23], "new_tok_span": [29, 31]}, {"mention": "SOCS-1", "char_span": [101, 107], "sem_type": "Gene or Genome", "tok_span": [21, 25], "new_tok_span": [29, 33]}, {"mention": "SOCS-1", "char_span": [101, 107], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 25], "new_tok_span": [29, 33]}, {"mention": "cytokine", "char_span": [133, 141], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 43], "new_tok_span": [57, 58]}, {"mention": "cytokine-inducible SH2-containing protein", "char_span": [133, 174], "sem_type": "Gene or Genome", "tok_span": [42, 50], "new_tok_span": [57, 65]}, {"mention": "cytokine-inducible SH2-containing protein", "char_span": [133, 174], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 50], "new_tok_span": [57, 65]}, {"mention": "CIS", "char_span": [176, 179], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [51, 53], "new_tok_span": [70, 72]}], "new_text": "Moreover, cycloheximide was observed to up - regulate expression of other <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> SOCS <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> family members, such as <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> SOCS <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - 1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, - 2, - 4, - 5, - 6, - 7, and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> cytokine <END=Amino Acid, Peptide, or Protein> - inducible SH2 - containing protein <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( <START=Amino Acid, Peptide, or Protein> CIS <END=Amino Acid, Peptide, or Protein> ) - 1 mRNAs. Such effects varied with the dosage and duration of cycloheximide treatment."}, {"PMID": 23296142, "id": 1, "text": "Regulation of sexual reproduction by estradiol involves the activation of estrogen receptors (ERs) in the hypothalamus.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [37, 46], "name": "estradiol", "tok_span": [5, 6], "new_tok_span": [5, 6]}, {"ent_type": "CHEMICAL", "char_span": [74, 82], "name": "estrogen", "tok_span": [10, 11], "new_tok_span": [10, 11]}, {"ent_type": "GENE", "char_span": [74, 92], "name": "estrogen receptors", "tok_span": [10, 12], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [94, 97], "name": "ERs", "tok_span": [13, 15], "new_tok_span": [13, 15]}], "relation_list": [{"subject": "estradiol", "sbj_char_span": [37, 46], "object": "estrogen receptors", "obj_char_span": [74, 92], "rel_type": "activator", "sbj_tok_span": [5, 6], "obj_tok_span": [10, 12], "new_sbj_tok_span": [5, 6], "new_obj_tok_span": [10, 12]}, {"subject": "estradiol", "sbj_char_span": [37, 46], "object": "ERs", "obj_char_span": [94, 97], "rel_type": "activator", "sbj_tok_span": [5, 6], "obj_tok_span": [13, 15], "new_sbj_tok_span": [5, 6], "new_obj_tok_span": [13, 15]}], "umls_entity_list": [], "new_text": "Regulation of sexual reproduction by estradiol involves the activation of estrogen receptors ( ERs ) in the hypothalamus."}, {"PMID": 18604229, "id": 2, "text": "The principal aim of the study was to find amiodarone analogues that retained human ether-a-go-go-related protein (hERG) channel inhibition but with reduced cytotoxicity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [43, 53], "name": "amiodarone", "tok_span": [9, 13], "new_tok_span": [10, 14]}, {"ent_type": "GENE", "char_span": [78, 128], "name": "human ether-a-go-go-related protein (hERG) channel", "tok_span": [16, 32], "new_tok_span": [18, 34]}], "relation_list": [{"subject": "amiodarone", "sbj_char_span": [43, 53], "object": "human ether-a-go-go-related protein (hERG) channel", "obj_char_span": [78, 128], "rel_type": "inhibitor", "sbj_tok_span": [9, 13], "obj_tok_span": [16, 32], "new_sbj_tok_span": [10, 14], "new_obj_tok_span": [18, 34]}], "umls_entity_list": [{"mention": "amiodarone", "char_span": [43, 53], "sem_type": "Pharmacologic Substance", "tok_span": [9, 13], "new_tok_span": [10, 14]}], "new_text": "The principal aim of the study was to find <START=Pharmacologic Substance> amiodarone <END=Pharmacologic Substance> analogues that retained human ether - a - go - go - related protein ( hERG ) channel inhibition but with reduced cytotoxicity."}, {"PMID": 17929114, "id": 12, "text": "Instead, ATP noncompetitive inhibitors, such as ON012380, Aurora kinase inhibitor MK0457 (VX-680), and p38 MAP kinase inhibitor BIRB-796, have been developed to address this problem.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 12], "name": "ATP", "tok_span": [2, 3], "new_tok_span": [2, 3]}, {"ent_type": "CHEMICAL", "char_span": [48, 56], "name": "ON012380", "tok_span": [11, 15], "new_tok_span": [12, 16]}, {"ent_type": "CHEMICAL", "char_span": [82, 88], "name": "MK0457", "tok_span": [20, 23], "new_tok_span": [25, 28]}, {"ent_type": "CHEMICAL", "char_span": [90, 96], "name": "VX-680", "tok_span": [24, 29], "new_tok_span": [31, 36]}, {"ent_type": "CHEMICAL", "char_span": [128, 136], "name": "BIRB-796", "tok_span": [37, 42], "new_tok_span": [48, 53]}, {"ent_type": "GENE", "char_span": [58, 71], "name": "Aurora kinase", "tok_span": [16, 19], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [103, 106], "name": "p38", "tok_span": [32, 34], "new_tok_span": [41, 43]}, {"ent_type": "GENE", "char_span": [107, 117], "name": "MAP kinase", "tok_span": [34, 36], "new_tok_span": [43, 45]}], "relation_list": [{"subject": "MK0457", "sbj_char_span": [82, 88], "object": "Aurora kinase", "obj_char_span": [58, 71], "rel_type": "inhibitor", "sbj_tok_span": [20, 23], "obj_tok_span": [16, 19], "new_sbj_tok_span": [25, 28], "new_obj_tok_span": [19, 22]}, {"subject": "VX-680", "sbj_char_span": [90, 96], "object": "Aurora kinase", "obj_char_span": [58, 71], "rel_type": "inhibitor", "sbj_tok_span": [24, 29], "obj_tok_span": [16, 19], "new_sbj_tok_span": [31, 36], "new_obj_tok_span": [19, 22]}, {"subject": "BIRB-796", "sbj_char_span": [128, 136], "object": "p38", "obj_char_span": [103, 106], "rel_type": "inhibitor", "sbj_tok_span": [37, 42], "obj_tok_span": [32, 34], "new_sbj_tok_span": [48, 53], "new_obj_tok_span": [41, 43]}, {"subject": "BIRB-796", "sbj_char_span": [128, 136], "object": "MAP kinase", "obj_char_span": [107, 117], "rel_type": "inhibitor", "sbj_tok_span": [37, 42], "obj_tok_span": [34, 36], "new_sbj_tok_span": [48, 53], "new_obj_tok_span": [43, 45]}], "umls_entity_list": [{"mention": "ON012380", "char_span": [48, 56], "sem_type": "Organic Chemical", "tok_span": [11, 15], "new_tok_span": [12, 16]}, {"mention": "Aurora", "char_span": [58, 64], "sem_type": "Pharmacologic Substance", "tok_span": [16, 18], "new_tok_span": [19, 21]}, {"mention": "MK0457", "char_span": [82, 88], "sem_type": "Pharmacologic Substance", "tok_span": [20, 23], "new_tok_span": [25, 28]}, {"mention": "VX-680", "char_span": [90, 96], "sem_type": "Pharmacologic Substance", "tok_span": [24, 29], "new_tok_span": [31, 36]}, {"mention": "p38 MAP kinase", "char_span": [103, 117], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 36], "new_tok_span": [41, 45]}, {"mention": "BIRB", "char_span": [128, 132], "sem_type": "Pharmacologic Substance", "tok_span": [37, 39], "new_tok_span": [48, 50]}], "new_text": "Instead, ATP noncompetitive inhibitors, such as <START=Organic Chemical> ON012380 <END=Organic Chemical>, <START=Pharmacologic Substance> Aurora <END=Pharmacologic Substance> kinase inhibitor <START=Pharmacologic Substance> MK0457 <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> VX - 680 <END=Pharmacologic Substance> ), and <START=Amino Acid, Peptide, or Protein> p38 MAP kinase <END=Amino Acid, Peptide, or Protein> inhibitor <START=Pharmacologic Substance> BIRB <END=Pharmacologic Substance> - 796, have been developed to address this problem."}, {"PMID": 23473803, "id": 7, "text": "Our data suggest that moexipril is a bona fide PDE4 inhibitor that may provide the starting point for development of novel PDE4 inhibitors with an improved therapeutic window.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [22, 31], "name": "moexipril", "tok_span": [4, 8], "new_tok_span": [4, 8]}, {"ent_type": "GENE", "char_span": [47, 51], "name": "PDE4", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [123, 127], "name": "PDE4", "tok_span": [27, 29], "new_tok_span": [33, 35]}], "relation_list": [{"subject": "moexipril", "sbj_char_span": [22, 31], "object": "PDE4", "obj_char_span": [47, 51], "rel_type": "inhibitor", "sbj_tok_span": [4, 8], "obj_tok_span": [14, 16], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [16, 18]}, {"subject": "moexipril", "sbj_char_span": [22, 31], "object": "PDE4", "obj_char_span": [123, 127], "rel_type": "inhibitor", "sbj_tok_span": [4, 8], "obj_tok_span": [27, 29], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [33, 35]}], "umls_entity_list": [{"mention": "PDE4 inhibitor", "char_span": [47, 61], "sem_type": "Pharmacologic Substance", "tok_span": [14, 17], "new_tok_span": [16, 19]}, {"mention": "PDE4 inhibitor", "char_span": [123, 137], "sem_type": "Pharmacologic Substance", "tok_span": [27, 30], "new_tok_span": [33, 36]}, {"mention": "PDE4", "char_span": [47, 51], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"mention": "PDE4", "char_span": [123, 127], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 29], "new_tok_span": [33, 35]}], "new_text": "Our data suggest that moexipril is a bona fide <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> PDE4 <END=Amino Acid, Peptide, or Protein> inhibitor <END=Pharmacologic Substance> that may provide the starting point for development of novel <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> PDE4 <END=Amino Acid, Peptide, or Protein> inhibitors <END=Pharmacologic Substance> with an improved therapeutic window."}, {"PMID": 23434322, "id": 4, "text": "Interactions are dynamic during differentiation, as for example evidenced by the mESC-specific binding of Klf4 to mC and the NPC-specific binding of Uhrf2 to hmC, suggesting specific biological roles for mC and hmC.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [158, 161], "name": "hmC", "tok_span": [36, 39], "new_tok_span": [42, 45]}, {"ent_type": "CHEMICAL", "char_span": [211, 214], "name": "hmC", "tok_span": [48, 51], "new_tok_span": [54, 57]}, {"ent_type": "GENE", "char_span": [106, 110], "name": "Klf4", "tok_span": [18, 21], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [149, 154], "name": "Uhrf2", "tok_span": [31, 35], "new_tok_span": [36, 40]}], "relation_list": [{"subject": "hmC", "sbj_char_span": [158, 161], "object": "Uhrf2", "obj_char_span": [149, 154], "rel_type": "regulator", "sbj_tok_span": [36, 39], "obj_tok_span": [31, 35], "new_sbj_tok_span": [42, 45], "new_obj_tok_span": [36, 40]}], "umls_entity_list": [{"mention": "Klf4", "char_span": [106, 110], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 21], "new_tok_span": [20, 23]}, {"mention": "Klf4", "char_span": [106, 110], "sem_type": "Gene or Genome", "tok_span": [18, 21], "new_tok_span": [20, 23]}, {"mention": "Uhrf2", "char_span": [149, 154], "sem_type": "Gene or Genome", "tok_span": [31, 35], "new_tok_span": [36, 40]}], "new_text": "Interactions are dynamic during differentiation, as for example evidenced by the mESC - specific binding of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Klf4 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> to mC and the NPC - specific binding of <START=Gene or Genome> Uhrf2 <END=Gene or Genome> to hmC, suggesting specific biological roles for mC and hmC."}, {"PMID": 16472148, "id": 6, "text": "Cilostazol suppressed TNF-alpha-induced decrease in viability of SK-N-SH (human neuroblastoma) cells and HCN-1A (human cortical neuron) cells in association with decrease in PTEN phosphorylation and increase in Akt/CREB phosphorylation with suppression of DNA fragmentation, all of which were antagonized by iberiotoxin, a maxi-K(+) channel blocker.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Cilostazol", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [328, 332], "name": "K(+)", "tok_span": [72, 76], "new_tok_span": [80, 84]}, {"ent_type": "GENE", "char_span": [22, 31], "name": "TNF-alpha", "tok_span": [5, 8], "new_tok_span": [5, 8]}, {"ent_type": "GENE", "char_span": [174, 178], "name": "PTEN", "tok_span": [42, 43], "new_tok_span": [46, 47]}, {"ent_type": "GENE", "char_span": [211, 214], "name": "Akt", "tok_span": [47, 48], "new_tok_span": [53, 54]}, {"ent_type": "GENE", "char_span": [215, 219], "name": "CREB", "tok_span": [49, 50], "new_tok_span": [55, 56]}, {"ent_type": "GENE", "char_span": [323, 340], "name": "maxi-K(+) channel", "tok_span": [69, 77], "new_tok_span": [77, 85]}], "relation_list": [{"subject": "Cilostazol", "sbj_char_span": [0, 10], "object": "TNF-alpha", "obj_char_span": [22, 31], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [5, 8], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [5, 8]}, {"subject": "Cilostazol", "sbj_char_span": [0, 10], "object": "PTEN", "obj_char_span": [174, 178], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [42, 43], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [46, 47]}, {"subject": "Cilostazol", "sbj_char_span": [0, 10], "object": "Akt", "obj_char_span": [211, 214], "rel_type": "activator", "sbj_tok_span": [0, 4], "obj_tok_span": [47, 48], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [53, 54]}, {"subject": "Cilostazol", "sbj_char_span": [0, 10], "object": "CREB", "obj_char_span": [215, 219], "rel_type": "activator", "sbj_tok_span": [0, 4], "obj_tok_span": [49, 50], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [55, 56]}, {"subject": "Cilostazol", "sbj_char_span": [0, 10], "object": "maxi-K(+) channel", "obj_char_span": [323, 340], "rel_type": "activator", "sbj_tok_span": [0, 4], "obj_tok_span": [69, 77], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [77, 85]}], "umls_entity_list": [{"mention": "HCN", "char_span": [105, 108], "sem_type": "Gene or Genome", "tok_span": [26, 28], "new_tok_span": [27, 29]}, {"mention": "PTEN", "char_span": [174, 178], "sem_type": "Gene or Genome", "tok_span": [42, 43], "new_tok_span": [46, 47]}, {"mention": "PTEN", "char_span": [174, 178], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 43], "new_tok_span": [46, 47]}, {"mention": "iberiotoxin", "char_span": [308, 319], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [64, 67], "new_tok_span": [71, 74]}], "new_text": "Cilostazol suppressed TNF - alpha - induced decrease in viability of SK - N - SH ( human neuroblastoma ) cells and <START=Gene or Genome> HCN <END=Gene or Genome> - 1A ( human cortical neuron ) cells in association with decrease in <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PTEN <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> phosphorylation and increase in Akt / CREB phosphorylation with suppression of DNA fragmentation, all of which were antagonized by <START=Amino Acid, Peptide, or Protein> iberiotoxin <END=Amino Acid, Peptide, or Protein>, a maxi - K ( + ) channel blocker."}, {"PMID": 6706930, "id": 3, "text": "This was shown to be attributable to catalase-like activity of these enzymes, resulting in unproductive cleavage of H2O2. This catalatic activity was completely iodide-dependent.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [116, 120], "name": "H2O2", "tok_span": [23, 27], "new_tok_span": [28, 32]}, {"ent_type": "CHEMICAL", "char_span": [161, 167], "name": "iodide", "tok_span": [34, 35], "new_tok_span": [40, 41]}, {"ent_type": "GENE", "char_span": [37, 45], "name": "catalase", "tok_span": [7, 8], "new_tok_span": [9, 10]}], "relation_list": [{"subject": "H2O2", "sbj_char_span": [116, 120], "object": "catalase", "obj_char_span": [37, 45], "rel_type": "product or substrate", "sbj_tok_span": [23, 27], "obj_tok_span": [7, 8], "new_sbj_tok_span": [28, 32], "new_obj_tok_span": [9, 10]}], "umls_entity_list": [{"mention": "catalase", "char_span": [37, 45], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 8], "new_tok_span": [9, 10]}, {"mention": "catalase", "char_span": [37, 45], "sem_type": "Gene or Genome", "tok_span": [7, 8], "new_tok_span": [9, 10]}, {"mention": "H2O2", "char_span": [116, 120], "sem_type": "Pharmacologic Substance", "tok_span": [23, 27], "new_tok_span": [28, 32]}], "new_text": "This was shown to be attributable to <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> catalase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - like activity of these enzymes, resulting in unproductive cleavage of <START=Pharmacologic Substance> H2O2 <END=Pharmacologic Substance>. This catalatic activity was completely iodide - dependent."}, {"PMID": 12652111, "id": 8, "text": "Therefore, in rabbit heart, partial inhibition of PDE4 by milrinone contributed to greater increases in cardiomyocyte cAMP and calcium levels than cilostazol.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [58, 67], "name": "milrinone", "tok_span": [12, 15], "new_tok_span": [14, 17]}, {"ent_type": "CHEMICAL", "char_span": [118, 122], "name": "cAMP", "tok_span": [22, 23], "new_tok_span": [24, 25]}, {"ent_type": "CHEMICAL", "char_span": [127, 134], "name": "calcium", "tok_span": [24, 25], "new_tok_span": [26, 27]}, {"ent_type": "CHEMICAL", "char_span": [147, 157], "name": "cilostazol", "tok_span": [27, 31], "new_tok_span": [29, 33]}, {"ent_type": "GENE", "char_span": [50, 54], "name": "PDE4", "tok_span": [9, 11], "new_tok_span": [10, 12]}], "relation_list": [{"subject": "milrinone", "sbj_char_span": [58, 67], "object": "PDE4", "obj_char_span": [50, 54], "rel_type": "inhibitor", "sbj_tok_span": [12, 15], "obj_tok_span": [9, 11], "new_sbj_tok_span": [14, 17], "new_obj_tok_span": [10, 12]}, {"subject": "cilostazol", "sbj_char_span": [147, 157], "object": "PDE4", "obj_char_span": [50, 54], "rel_type": "inhibitor", "sbj_tok_span": [27, 31], "obj_tok_span": [9, 11], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [10, 12]}], "umls_entity_list": [{"mention": "PDE4", "char_span": [50, 54], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 11], "new_tok_span": [10, 12]}], "new_text": "Therefore, in rabbit heart, partial inhibition of <START=Amino Acid, Peptide, or Protein> PDE4 <END=Amino Acid, Peptide, or Protein> by milrinone contributed to greater increases in cardiomyocyte cAMP and calcium levels than cilostazol."}, {"PMID": 16874462, "id": 4, "text": "We conclude that in the presence of proline, high POX activity is sufficient to induce mitochondria-mediated apoptosis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [36, 43], "name": "proline", "tok_span": [7, 8], "new_tok_span": [8, 9]}, {"ent_type": "GENE", "char_span": [50, 53], "name": "POX", "tok_span": [10, 12], "new_tok_span": [12, 14]}], "relation_list": [{"subject": "proline", "sbj_char_span": [36, 43], "object": "POX", "obj_char_span": [50, 53], "rel_type": "product or substrate", "sbj_tok_span": [7, 8], "obj_tok_span": [10, 12], "new_sbj_tok_span": [8, 9], "new_obj_tok_span": [12, 14]}], "umls_entity_list": [{"mention": "proline", "char_span": [36, 43], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 8], "new_tok_span": [8, 9]}], "new_text": "We conclude that in the presence of <START=Amino Acid, Peptide, or Protein> proline <END=Amino Acid, Peptide, or Protein>, high POX activity is sufficient to induce mitochondria - mediated apoptosis."}, {"PMID": 19029287, "id": 4, "text": "To address this question and to determine whether DHPs can discriminate between Ca(v)1.2 and Ca(v)1.3 binding pockets, we combined radioreceptor assays and quantitative polymerase chain reaction (qPCR). We bred double mutants (Ca(v)-DM) from mice expressing mutant Ca(v)1.2 channels [Ca(v)1.2DHP(-/-)] lacking high affinity for DHPs and from Ca(v)1.3 knockouts [Ca(v)1.3(-/-)]. (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [378, 398], "name": "(+)-[(3)H]isradipine", "tok_span": [119, 132], "new_tok_span": [125, 138]}, {"ent_type": "GENE", "char_span": [646, 650], "name": "LTCC", "tok_span": [224, 226], "new_tok_span": [234, 236]}, {"ent_type": "GENE", "char_span": [80, 88], "name": "Ca(v)1.2", "tok_span": [13, 20], "new_tok_span": [15, 22]}, {"ent_type": "GENE", "char_span": [93, 101], "name": "Ca(v)1.3", "tok_span": [21, 28], "new_tok_span": [23, 30]}, {"ent_type": "GENE", "char_span": [227, 232], "name": "Ca(v)", "tok_span": [52, 56], "new_tok_span": [54, 58]}, {"ent_type": "GENE", "char_span": [265, 273], "name": "Ca(v)1.2", "tok_span": [63, 70], "new_tok_span": [67, 74]}, {"ent_type": "GENE", "char_span": [284, 292], "name": "Ca(v)1.2", "tok_span": [72, 79], "new_tok_span": [76, 83]}, {"ent_type": "GENE", "char_span": [342, 350], "name": "Ca(v)1.3", "tok_span": [95, 102], "new_tok_span": [101, 108]}, {"ent_type": "GENE", "char_span": [362, 370], "name": "Ca(v)1.3", "tok_span": [105, 112], "new_tok_span": [111, 118]}, {"ent_type": "GENE", "char_span": [410, 418], "name": "Ca(v)1.2", "tok_span": [134, 141], "new_tok_span": [142, 149]}, {"ent_type": "GENE", "char_span": [431, 436], "name": "Ca(v)", "tok_span": [149, 153], "new_tok_span": [157, 161]}, {"ent_type": "GENE", "char_span": [520, 528], "name": "Ca(v)1.3", "tok_span": [175, 182], "new_tok_span": [185, 192]}, {"ent_type": "GENE", "char_span": [557, 562], "name": "LTCCs", "tok_span": [190, 193], "new_tok_span": [200, 203]}, {"ent_type": "GENE", "char_span": [583, 591], "name": "Ca(v)1.1", "tok_span": [197, 204], "new_tok_span": [207, 214]}, {"ent_type": "GENE", "char_span": [596, 613], "name": "Ca(v)1.4 alpha(1)", "tok_span": [205, 216], "new_tok_span": [215, 226]}], "relation_list": [{"subject": "(+)-[(3)H]isradipine", "sbj_char_span": [378, 398], "object": "Ca(v)", "obj_char_span": [431, 436], "rel_type": "regulator", "sbj_tok_span": [119, 132], "obj_tok_span": [149, 153], "new_sbj_tok_span": [125, 138], "new_obj_tok_span": [157, 161]}, {"subject": "(+)-[(3)H]isradipine", "sbj_char_span": [378, 398], "object": "Ca(v)1.3", "obj_char_span": [520, 528], "rel_type": "regulator", "sbj_tok_span": [119, 132], "obj_tok_span": [175, 182], "new_sbj_tok_span": [125, 138], "new_obj_tok_span": [185, 192]}, {"subject": "(+)-[(3)H]isradipine", "sbj_char_span": [378, 398], "object": "LTCCs", "obj_char_span": [557, 562], "rel_type": "regulator", "sbj_tok_span": [119, 132], "obj_tok_span": [190, 193], "new_sbj_tok_span": [125, 138], "new_obj_tok_span": [200, 203]}], "umls_entity_list": [{"mention": "DHPs", "char_span": [50, 54], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 10], "new_tok_span": [9, 11]}, {"mention": "DHPs", "char_span": [328, 332], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [91, 93], "new_tok_span": [96, 98]}, {"mention": "DM", "char_span": [233, 235], "sem_type": "Pharmacologic Substance", "tok_span": [57, 58], "new_tok_span": [60, 61]}, {"mention": "DM", "char_span": [437, 439], "sem_type": "Pharmacologic Substance", "tok_span": [154, 155], "new_tok_span": [163, 164]}, {"mention": "isradipine", "char_span": [388, 398], "sem_type": "Pharmacologic Substance", "tok_span": [129, 132], "new_tok_span": [136, 139]}], "new_text": "To address this question and to determine whether <START=Amino Acid, Peptide, or Protein> DHPs <END=Amino Acid, Peptide, or Protein> can discriminate between Ca ( v ) 1. 2 and Ca ( v ) 1. 3 binding pockets, we combined radioreceptor assays and quantitative polymerase chain reaction ( qPCR ). We bred double mutants ( Ca ( v ) - <START=Pharmacologic Substance> DM <END=Pharmacologic Substance> ) from mice expressing mutant Ca ( v ) 1. 2 channels [ Ca ( v ) 1. 2DHP ( - / - ) ] lacking high affinity for <START=Amino Acid, Peptide, or Protein> DHPs <END=Amino Acid, Peptide, or Protein> and from Ca ( v ) 1. 3 knockouts [ Ca ( v ) 1. 3 ( - / - ) ]. ( + ) - [ ( 3 ) H ] <START=Pharmacologic Substance> isradipine <END=Pharmacologic Substance> binding to Ca ( v ) 1. 2DHP ( - / - ) and Ca ( v ) - <START=Pharmacologic Substance> DM <END=Pharmacologic Substance> brains was reduced to 15. 1 and 4. 4 % of wild type, respectively, indicating that Ca ( v ) 1. 3 accounts for 10. 7 % of brain LTCCs. qPCR revealed that Ca ( v ) 1. 1 and Ca ( v ) 1. 4 alpha ( 1 ) subunits comprised 0. 08 % of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding."}, {"PMID": 15078100, "id": 3, "text": "QR2 catalyzes the two-electron reduction of menadione via the oxidation of N-alkylated or N-ribosylated nicotinamides.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [44, 53], "name": "menadione", "tok_span": [10, 13], "new_tok_span": [10, 13]}, {"ent_type": "CHEMICAL", "char_span": [75, 86], "name": "N-alkylated", "tok_span": [17, 21], "new_tok_span": [17, 21]}, {"ent_type": "CHEMICAL", "char_span": [90, 117], "name": "N-ribosylated nicotinamides", "tok_span": [22, 30], "new_tok_span": [22, 30]}, {"ent_type": "GENE", "char_span": [0, 3], "name": "QR2", "tok_span": [0, 2], "new_tok_span": [0, 2]}], "relation_list": [{"subject": "menadione", "sbj_char_span": [44, 53], "object": "QR2", "obj_char_span": [0, 3], "rel_type": "product or substrate", "sbj_tok_span": [10, 13], "obj_tok_span": [0, 2], "new_sbj_tok_span": [10, 13], "new_obj_tok_span": [0, 2]}, {"subject": "N-alkylated", "sbj_char_span": [75, 86], "object": "QR2", "obj_char_span": [0, 3], "rel_type": "product or substrate", "sbj_tok_span": [17, 21], "obj_tok_span": [0, 2], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [0, 2]}, {"subject": "N-ribosylated nicotinamides", "sbj_char_span": [90, 117], "object": "QR2", "obj_char_span": [0, 3], "rel_type": "product or substrate", "sbj_tok_span": [22, 30], "obj_tok_span": [0, 2], "new_sbj_tok_span": [22, 30], "new_obj_tok_span": [0, 2]}], "umls_entity_list": [], "new_text": "QR2 catalyzes the two - electron reduction of menadione via the oxidation of N - alkylated or N - ribosylated nicotinamides."}, {"PMID": 23535185, "id": 9, "text": "Our results showed that galangin down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory cytokines.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [24, 32], "name": "galangin", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"ent_type": "CHEMICAL", "char_span": [110, 119], "name": "histamine", "tok_span": [19, 20], "new_tok_span": [21, 22]}, {"ent_type": "GENE", "char_span": [163, 172], "name": "cytokines", "tok_span": [27, 28], "new_tok_span": [31, 32]}], "relation_list": [{"subject": "galangin", "sbj_char_span": [24, 32], "object": "cytokines", "obj_char_span": [163, 172], "rel_type": "regulator", "sbj_tok_span": [4, 7], "obj_tok_span": [27, 28], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [31, 32]}], "umls_entity_list": [{"mention": "galangin", "char_span": [24, 32], "sem_type": "Pharmacologic Substance", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"mention": "pro", "char_span": [146, 149], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 25], "new_tok_span": [27, 28]}], "new_text": "Our results showed that <START=Pharmacologic Substance> galangin <END=Pharmacologic Substance> down - regulates mast cell - derived allergic inflammatory reactions by blocking histamine release and expression of <START=Amino Acid, Peptide, or Protein> pro <END=Amino Acid, Peptide, or Protein> - inflammatory cytokines."}, {"PMID": 15037867, "id": 4, "text": "Another 5-HT(2A) receptor polymorphism consists of the silent thymidine-cytosine substitution (102T>C), which has been controversially associated with schizophrenia.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [62, 71], "name": "thymidine", "tok_span": [14, 16], "new_tok_span": [14, 16]}, {"ent_type": "CHEMICAL", "char_span": [72, 80], "name": "cytosine", "tok_span": [17, 19], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [8, 16], "name": "5-HT(2A)", "tok_span": [1, 8], "new_tok_span": [1, 8]}, {"ent_type": "GENE", "char_span": [95, 101], "name": "102T>C", "tok_span": [21, 25], "new_tok_span": [23, 27]}], "relation_list": [{"subject": "thymidine", "sbj_char_span": [62, 71], "object": "5-HT(2A)", "obj_char_span": [8, 16], "rel_type": "part of", "sbj_tok_span": [14, 16], "obj_tok_span": [1, 8], "new_sbj_tok_span": [14, 16], "new_obj_tok_span": [1, 8]}, {"subject": "cytosine", "sbj_char_span": [72, 80], "object": "5-HT(2A)", "obj_char_span": [8, 16], "rel_type": "part of", "sbj_tok_span": [17, 19], "obj_tok_span": [1, 8], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [1, 8]}], "umls_entity_list": [{"mention": "cytosine", "char_span": [72, 80], "sem_type": "Organic Chemical", "tok_span": [17, 19], "new_tok_span": [18, 20]}], "new_text": "Another 5 - HT ( 2A ) receptor polymorphism consists of the silent thymidine - <START=Organic Chemical> cytosine <END=Organic Chemical> substitution ( 102T > C ), which has been controversially associated with schizophrenia."}, {"PMID": 23327877, "id": 6, "text": "Cytotoxicity assays demonstrated that epigallocatechin 3-O-gallate (EGCG) and most of compounds 1-6 killed preferentially OATP-expressing CHO cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [38, 66], "name": "epigallocatechin 3-O-gallate", "tok_span": [5, 17], "new_tok_span": [5, 17]}, {"ent_type": "CHEMICAL", "char_span": [68, 72], "name": "EGCG", "tok_span": [18, 20], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [122, 126], "name": "OATP", "tok_span": [30, 32], "new_tok_span": [30, 32]}], "relation_list": [{"subject": "epigallocatechin 3-O-gallate", "sbj_char_span": [38, 66], "object": "OATP", "obj_char_span": [122, 126], "rel_type": "product or substrate", "sbj_tok_span": [5, 17], "obj_tok_span": [30, 32], "new_sbj_tok_span": [5, 17], "new_obj_tok_span": [30, 32]}, {"subject": "EGCG", "sbj_char_span": [68, 72], "object": "OATP", "obj_char_span": [122, 126], "rel_type": "product or substrate", "sbj_tok_span": [18, 20], "obj_tok_span": [30, 32], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [30, 32]}], "umls_entity_list": [], "new_text": "Cytotoxicity assays demonstrated that epigallocatechin 3 - O - gallate ( EGCG ) and most of compounds 1 - 6 killed preferentially OATP - expressing CHO cells."}, {"PMID": 23017408, "id": 4, "text": "BASO673 isolates with high levels of total phenols (66.0±1.2μg/mg, 78.1±1.8μg/mg, respectively) also showed high levels of PAL activities (20.5±3.1U/mg protein, 17.2±2.3U/mg protein, respectively) and strong antioxidant activities.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [43, 50], "name": "phenols", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [123, 126], "name": "PAL", "tok_span": [42, 44], "new_tok_span": [50, 52]}], "relation_list": [{"subject": "phenols", "sbj_char_span": [43, 50], "object": "PAL", "obj_char_span": [123, 126], "rel_type": "regulator", "sbj_tok_span": [10, 12], "obj_tok_span": [42, 44], "new_sbj_tok_span": [13, 15], "new_obj_tok_span": [50, 52]}], "umls_entity_list": [{"mention": "phenols", "char_span": [43, 50], "sem_type": "Pharmacologic Substance", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"mention": "isolate", "char_span": [8, 15], "sem_type": "Pharmacologic Substance", "tok_span": [4, 5], "new_tok_span": [5, 6]}, {"mention": "mg", "char_span": [63, 65], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 23], "new_tok_span": [27, 28]}, {"mention": "mg", "char_span": [78, 80], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 34], "new_tok_span": [40, 41]}, {"mention": "mg", "char_span": [149, 151], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [55, 56], "new_tok_span": [64, 65]}, {"mention": "mg", "char_span": [171, 173], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [67, 68], "new_tok_span": [78, 79]}], "new_text": "BASO673 <START=Pharmacologic Substance> isolates <END=Pharmacologic Substance> with high levels of total <START=Pharmacologic Substance> phenols <END=Pharmacologic Substance> ( 66. 0±1. 2μg / <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein>, 78. 1±1. 8μg / <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein>, respectively ) also showed high levels of PAL activities ( 20. 5±3. 1U / <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein> protein, 17. 2±2. 3U / <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein> protein, respectively ) and strong antioxidant activities."}, {"PMID": 23522182, "id": 1, "text": "AIM: To assess the glucose-lowering effects of monotherapy with the glucokinase activator AZD1656 in Japanese patients with type 2 diabetes mellitus.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [90, 97], "name": "AZD1656", "tok_span": [17, 21], "new_tok_span": [18, 22]}, {"ent_type": "GENE", "char_span": [68, 79], "name": "glucokinase", "tok_span": [13, 16], "new_tok_span": [13, 16]}], "relation_list": [{"subject": "AZD1656", "sbj_char_span": [90, 97], "object": "glucokinase", "obj_char_span": [68, 79], "rel_type": "activator", "sbj_tok_span": [17, 21], "obj_tok_span": [13, 16], "new_sbj_tok_span": [18, 22], "new_obj_tok_span": [13, 16]}], "umls_entity_list": [{"mention": "AZD1656", "char_span": [90, 97], "sem_type": "Pharmacologic Substance", "tok_span": [17, 21], "new_tok_span": [18, 22]}], "new_text": "AIM : To assess the glucose - lowering effects of monotherapy with the glucokinase activator <START=Pharmacologic Substance> AZD1656 <END=Pharmacologic Substance> in Japanese patients with type 2 diabetes mellitus."}, {"PMID": 23587660, "id": 11, "text": "Therefore, Korean pear juice may alleviate alcohol-hangover and its detoxification of alcohol seems to be modified by the genetic variation of ALDH2.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [86, 93], "name": "alcohol", "tok_span": [17, 18], "new_tok_span": [17, 18]}, {"ent_type": "GENE", "char_span": [143, 148], "name": "ALDH2", "tok_span": [27, 30], "new_tok_span": [29, 32]}], "relation_list": [{"subject": "alcohol", "sbj_char_span": [86, 93], "object": "ALDH2", "obj_char_span": [143, 148], "rel_type": "product or substrate", "sbj_tok_span": [17, 18], "obj_tok_span": [27, 30], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [29, 32]}], "umls_entity_list": [{"mention": "ALDH2", "char_span": [143, 148], "sem_type": "Gene or Genome", "tok_span": [27, 30], "new_tok_span": [29, 32]}, {"mention": "ALDH2", "char_span": [143, 148], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 30], "new_tok_span": [29, 32]}], "new_text": "Therefore, Korean pear juice may alleviate alcohol - hangover and its detoxification of alcohol seems to be modified by the genetic variation of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ALDH2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 10697523, "id": 2, "text": "Thymidylate synthase is inhibited by 5-fluorodeoxyuridine monophosphate, forming an inactive ternary complex with intracellular folate.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Thymidylate", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [37, 71], "name": "5-fluorodeoxyuridine monophosphate", "tok_span": [8, 21], "new_tok_span": [8, 21]}, {"ent_type": "CHEMICAL", "char_span": [128, 134], "name": "folate", "tok_span": [29, 30], "new_tok_span": [32, 33]}, {"ent_type": "GENE", "char_span": [0, 20], "name": "Thymidylate synthase", "tok_span": [0, 5], "new_tok_span": [0, 5]}], "relation_list": [{"subject": "5-fluorodeoxyuridine monophosphate", "sbj_char_span": [37, 71], "object": "Thymidylate synthase", "obj_char_span": [0, 20], "rel_type": "inhibitor", "sbj_tok_span": [8, 21], "obj_tok_span": [0, 5], "new_sbj_tok_span": [8, 21], "new_obj_tok_span": [0, 5]}], "umls_entity_list": [{"mention": "fluorodeoxyuridine", "char_span": [39, 57], "sem_type": "Pharmacologic Substance", "tok_span": [10, 16], "new_tok_span": [11, 17]}, {"mention": "folate", "char_span": [128, 134], "sem_type": "Pharmacologic Substance", "tok_span": [29, 30], "new_tok_span": [32, 33]}], "new_text": "Thymidylate synthase is inhibited by 5 - <START=Pharmacologic Substance> fluorodeoxyuridine <END=Pharmacologic Substance> monophosphate, forming an inactive ternary complex with intracellular <START=Pharmacologic Substance> folate <END=Pharmacologic Substance>."}, {"PMID": 17088426, "id": 2, "text": "Such organization results in the local activation of PKA subsets through the generation of confined intracellular gradients of cAMP, but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [127, 131], "name": "cAMP", "tok_span": [18, 19], "new_tok_span": [20, 21]}, {"ent_type": "CHEMICAL", "char_span": [194, 198], "name": "cAMP", "tok_span": [29, 30], "new_tok_span": [31, 32]}, {"ent_type": "GENE", "char_span": [53, 56], "name": "PKA", "tok_span": [8, 9], "new_tok_span": [9, 10]}], "relation_list": [{"subject": "cAMP", "sbj_char_span": [127, 131], "object": "PKA", "obj_char_span": [53, 56], "rel_type": "activator", "sbj_tok_span": [18, 19], "obj_tok_span": [8, 9], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [9, 10]}], "umls_entity_list": [{"mention": "PKA", "char_span": [53, 56], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [9, 10]}], "new_text": "Such organization results in the local activation of <START=Amino Acid, Peptide, or Protein> PKA <END=Amino Acid, Peptide, or Protein> subsets through the generation of confined intracellular gradients of cAMP, but the mechanisms responsible for limiting the diffusion of cAMP largely remain to be clarified."}, {"PMID": 11246672, "id": 0, "text": "Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Minocycline", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [49, 61], "name": "nitric oxide", "tok_span": [9, 11], "new_tok_span": [12, 14]}, {"ent_type": "GENE", "char_span": [39, 70], "name": "inducible nitric oxide synthase", "tok_span": [8, 12], "new_tok_span": [11, 15]}], "relation_list": [{"subject": "Minocycline", "sbj_char_span": [0, 11], "object": "inducible nitric oxide synthase", "obj_char_span": [39, 70], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [8, 12], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [11, 15]}], "umls_entity_list": [{"mention": "Minocyclin", "char_span": [0, 10], "sem_type": "Organic Chemical", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "inducible nitric oxide synthase", "char_span": [39, 70], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 12], "new_tok_span": [11, 15]}], "new_text": "<START=Organic Chemical> Minocyclin <END=Organic Chemical>e inhibits the production of <START=Amino Acid, Peptide, or Protein> inducible nitric oxide synthase <END=Amino Acid, Peptide, or Protein> in articular chondrocytes."}, {"PMID": 7858879, "id": 2, "text": "This study was designed to test the effect of a new nonpeptide antagonist of endothelin ETA and ETB receptors, bosentan, on myocardial infarct size, ventricular arrhythmias, and coronary endothelial dysfunction after ischaemia and reperfusion. 2.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [111, 119], "name": "bosentan", "tok_span": [24, 27], "new_tok_span": [27, 30]}, {"ent_type": "GENE", "char_span": [77, 87], "name": "endothelin", "tok_span": [15, 17], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [88, 91], "name": "ETA", "tok_span": [17, 19], "new_tok_span": [17, 19]}, {"ent_type": "GENE", "char_span": [96, 99], "name": "ETB", "tok_span": [20, 22], "new_tok_span": [21, 23]}], "relation_list": [{"subject": "bosentan", "sbj_char_span": [111, 119], "object": "ETA", "obj_char_span": [88, 91], "rel_type": "agonist or antagonist", "sbj_tok_span": [24, 27], "obj_tok_span": [17, 19], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [17, 19]}, {"subject": "bosentan", "sbj_char_span": [111, 119], "object": "ETB", "obj_char_span": [96, 99], "rel_type": "agonist or antagonist", "sbj_tok_span": [24, 27], "obj_tok_span": [20, 22], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [21, 23]}], "umls_entity_list": [{"mention": "ETB", "char_span": [96, 99], "sem_type": "Gene or Genome", "tok_span": [20, 22], "new_tok_span": [21, 23]}, {"mention": "bosentan", "char_span": [111, 119], "sem_type": "Pharmacologic Substance", "tok_span": [24, 27], "new_tok_span": [27, 30]}], "new_text": "This study was designed to test the effect of a new nonpeptide antagonist of endothelin ETA and <START=Gene or Genome> ETB <END=Gene or Genome> receptors, <START=Pharmacologic Substance> bosentan <END=Pharmacologic Substance>, on myocardial infarct size, ventricular arrhythmias, and coronary endothelial dysfunction after ischaemia and reperfusion. 2."}, {"PMID": 23582273, "id": 0, "text": "Synthesis and antitumor activity of 1,3,4-oxadiazole possessing 1,4-benzodioxan moiety as a novel class of potent methionine aminopeptidase type II inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [114, 124], "name": "methionine", "tok_span": [30, 31], "new_tok_span": [33, 34]}, {"ent_type": "CHEMICAL", "char_span": [36, 52], "name": "1,3,4-oxadiazole", "tok_span": [5, 14], "new_tok_span": [5, 14]}, {"ent_type": "CHEMICAL", "char_span": [64, 79], "name": "1,4-benzodioxan", "tok_span": [15, 23], "new_tok_span": [17, 25]}, {"ent_type": "GENE", "char_span": [114, 147], "name": "methionine aminopeptidase type II", "tok_span": [30, 37], "new_tok_span": [33, 40]}], "relation_list": [{"subject": "1,4-benzodioxan", "sbj_char_span": [64, 79], "object": "methionine aminopeptidase type II", "obj_char_span": [114, 147], "rel_type": "inhibitor", "sbj_tok_span": [15, 23], "obj_tok_span": [30, 37], "new_sbj_tok_span": [17, 25], "new_obj_tok_span": [33, 40]}, {"subject": "1,3,4-oxadiazole", "sbj_char_span": [36, 52], "object": "methionine aminopeptidase type II", "obj_char_span": [114, 147], "rel_type": "inhibitor", "sbj_tok_span": [5, 14], "obj_tok_span": [30, 37], "new_sbj_tok_span": [5, 14], "new_obj_tok_span": [33, 40]}], "umls_entity_list": [{"mention": "oxadiazole", "char_span": [42, 52], "sem_type": "Organic Chemical", "tok_span": [11, 14], "new_tok_span": [12, 15]}, {"mention": "methionine", "char_span": [114, 124], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 31], "new_tok_span": [33, 34]}, {"mention": "II", "char_span": [145, 147], "sem_type": "Gene or Genome", "tok_span": [36, 37], "new_tok_span": [42, 43]}, {"mention": "II", "char_span": [145, 147], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 37], "new_tok_span": [42, 43]}], "new_text": "Synthesis and antitumor activity of 1, 3, 4 - <START=Organic Chemical> oxadiazole <END=Organic Chemical> possessing 1, 4 - benzodioxan moiety as a novel class of potent <START=Amino Acid, Peptide, or Protein> methionine <END=Amino Acid, Peptide, or Protein> aminopeptidase type <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> II <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> inhibitors."}, {"PMID": 23544613, "id": 5, "text": "The highest DPmax of 15 was achieved in a one-step and two-step synthesis of oligo(p-xylylene sebacamide) catalyzed by CLEA cutinase.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [77, 105], "name": "oligo(p-xylylene sebacamide)", "tok_span": [19, 31], "new_tok_span": [20, 32]}, {"ent_type": "GENE", "char_span": [119, 132], "name": "CLEA cutinase", "tok_span": [33, 37], "new_tok_span": [35, 39]}], "relation_list": [{"subject": "oligo(p-xylylene sebacamide)", "sbj_char_span": [77, 105], "object": "CLEA cutinase", "obj_char_span": [119, 132], "rel_type": "product or substrate", "sbj_tok_span": [19, 31], "obj_tok_span": [33, 37], "new_sbj_tok_span": [20, 32], "new_obj_tok_span": [35, 39]}], "umls_entity_list": [{"mention": "oligo", "char_span": [77, 82], "sem_type": "Pharmacologic Substance", "tok_span": [19, 21], "new_tok_span": [20, 22]}, {"mention": "cutinase", "char_span": [124, 132], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 37], "new_tok_span": [38, 40]}], "new_text": "The highest DPmax of 15 was achieved in a one - step and two - step synthesis of <START=Pharmacologic Substance> oligo <END=Pharmacologic Substance> ( p - xylylene sebacamide ) catalyzed by CLEA <START=Amino Acid, Peptide, or Protein> cutinase <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 16517606, "id": 3, "text": "Similar to nSMase2, nSMase3 is Mg2+-dependent and shows optimal activity at pH 7, which is enhanced in the presence of phosphatidylserine and inhibited by scyphostatin. nSMase3 is ubiquitously expressed as a 4.6-kb mRNA species. nSMase3 lacks an N-terminal signal peptide, yet contains a 23-amino-acid transmembrane domain close to the C terminus, which is indicative for the family of C-tail-anchored integral membrane proteins.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [31, 35], "name": "Mg2+", "tok_span": [12, 15], "new_tok_span": [22, 25]}, {"ent_type": "CHEMICAL", "char_span": [119, 137], "name": "phosphatidylserine", "tok_span": [32, 35], "new_tok_span": [45, 48]}, {"ent_type": "CHEMICAL", "char_span": [246, 247], "name": "N", "tok_span": [66, 67], "new_tok_span": [90, 91]}, {"ent_type": "CHEMICAL", "char_span": [291, 301], "name": "amino-acid", "tok_span": [77, 80], "new_tok_span": [101, 104]}, {"ent_type": "CHEMICAL", "char_span": [336, 337], "name": "C", "tok_span": [85, 86], "new_tok_span": [109, 110]}, {"ent_type": "CHEMICAL", "char_span": [386, 387], "name": "C", "tok_span": [95, 96], "new_tok_span": [119, 120]}, {"ent_type": "GENE", "char_span": [11, 18], "name": "nSMase2", "tok_span": [2, 6], "new_tok_span": [4, 8]}, {"ent_type": "GENE", "char_span": [20, 27], "name": "nSMase3", "tok_span": [7, 11], "new_tok_span": [13, 17]}, {"ent_type": "GENE", "char_span": [169, 176], "name": "nSMase3", "tok_span": [42, 46], "new_tok_span": [60, 64]}, {"ent_type": "GENE", "char_span": [229, 236], "name": "nSMase3", "tok_span": [60, 64], "new_tok_span": [82, 86]}, {"ent_type": "GENE", "char_span": [246, 271], "name": "N-terminal signal peptide", "tok_span": [66, 71], "new_tok_span": [90, 95]}, {"ent_type": "GENE", "char_span": [386, 428], "name": "C-tail-anchored integral membrane proteins", "tok_span": [95, 104], "new_tok_span": [119, 128]}], "relation_list": [{"subject": "phosphatidylserine", "sbj_char_span": [119, 137], "object": "nSMase2", "obj_char_span": [11, 18], "rel_type": "activator", "sbj_tok_span": [32, 35], "obj_tok_span": [2, 6], "new_sbj_tok_span": [45, 48], "new_obj_tok_span": [4, 8]}, {"subject": "phosphatidylserine", "sbj_char_span": [119, 137], "object": "nSMase3", "obj_char_span": [20, 27], "rel_type": "activator", "sbj_tok_span": [32, 35], "obj_tok_span": [7, 11], "new_sbj_tok_span": [45, 48], "new_obj_tok_span": [13, 17]}, {"subject": "amino-acid", "sbj_char_span": [291, 301], "object": "nSMase3", "obj_char_span": [229, 236], "rel_type": "part of", "sbj_tok_span": [77, 80], "obj_tok_span": [60, 64], "new_sbj_tok_span": [101, 104], "new_obj_tok_span": [82, 86]}, {"subject": "C", "sbj_char_span": [336, 337], "object": "nSMase3", "obj_char_span": [229, 236], "rel_type": "part of", "sbj_tok_span": [85, 86], "obj_tok_span": [60, 64], "new_sbj_tok_span": [109, 110], "new_obj_tok_span": [82, 86]}], "umls_entity_list": [{"mention": "nSMase2", "char_span": [11, 18], "sem_type": "Gene or Genome", "tok_span": [2, 6], "new_tok_span": [4, 8]}, {"mention": "nSMase2", "char_span": [11, 18], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 6], "new_tok_span": [4, 8]}, {"mention": "nSMase3", "char_span": [20, 27], "sem_type": "Gene or Genome", "tok_span": [7, 11], "new_tok_span": [13, 17]}, {"mention": "nSMase3", "char_span": [169, 176], "sem_type": "Gene or Genome", "tok_span": [42, 46], "new_tok_span": [60, 64]}, {"mention": "nSMase3", "char_span": [229, 236], "sem_type": "Gene or Genome", "tok_span": [60, 64], "new_tok_span": [82, 86]}, {"mention": "nSMase3", "char_span": [20, 27], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 11], "new_tok_span": [13, 17]}, {"mention": "nSMase3", "char_span": [169, 176], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 46], "new_tok_span": [60, 64]}, {"mention": "nSMase3", "char_span": [229, 236], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [60, 64], "new_tok_span": [82, 86]}, {"mention": "Mg2", "char_span": [31, 34], "sem_type": "Gene or Genome", "tok_span": [12, 14], "new_tok_span": [22, 24]}, {"mention": "Mg2+", "char_span": [31, 35], "sem_type": "Pharmacologic Substance", "tok_span": [12, 15], "new_tok_span": [22, 25]}, {"mention": "phosphatidylserine", "char_span": [119, 137], "sem_type": "Organic Chemical", "tok_span": [32, 35], "new_tok_span": [45, 48]}, {"mention": "scyphostatin", "char_span": [155, 167], "sem_type": "Organic Chemical", "tok_span": [38, 41], "new_tok_span": [53, 56]}, {"mention": "integral", "char_span": [402, 410], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [101, 102], "new_tok_span": [126, 127]}], "new_text": "Similar to <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> nSMase2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> nSMase3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> is <START=Gene or Genome> <START=Pharmacologic Substance> Mg2 <END=Gene or Genome> + <END=Pharmacologic Substance> - dependent and shows optimal activity at pH 7, which is enhanced in the presence of <START=Organic Chemical> phosphatidylserine <END=Organic Chemical> and inhibited by <START=Organic Chemical> scyphostatin <END=Organic Chemical>. <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> nSMase3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> is ubiquitously expressed as a 4. 6 - kb mRNA species. <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> nSMase3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> lacks an N - terminal signal peptide, yet contains a 23 - amino - acid transmembrane domain close to the C terminus, which is indicative for the family of C - tail - anchored <START=Amino Acid, Peptide, or Protein> integral <END=Amino Acid, Peptide, or Protein> membrane proteins."}, {"PMID": 12898700, "id": 11, "text": "The oxidative stress conditions following DEM treatment activate L-cystine transport in TR-MUL cells due to the enhanced transcription of the xCT gene.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 45], "name": "DEM", "tok_span": [5, 6], "new_tok_span": [5, 6]}, {"ent_type": "CHEMICAL", "char_span": [65, 74], "name": "L-cystine", "tok_span": [8, 12], "new_tok_span": [8, 12]}, {"ent_type": "GENE", "char_span": [65, 84], "name": "L-cystine transport", "tok_span": [8, 13], "new_tok_span": [8, 13]}, {"ent_type": "GENE", "char_span": [142, 145], "name": "xCT", "tok_span": [26, 28], "new_tok_span": [30, 32]}], "relation_list": [{"subject": "DEM", "sbj_char_span": [42, 45], "object": "L-cystine transport", "obj_char_span": [65, 84], "rel_type": "activator", "sbj_tok_span": [5, 6], "obj_tok_span": [8, 13], "new_sbj_tok_span": [5, 6], "new_obj_tok_span": [8, 13]}, {"subject": "DEM", "sbj_char_span": [42, 45], "object": "xCT", "obj_char_span": [142, 145], "rel_type": "regulator", "sbj_tok_span": [5, 6], "obj_tok_span": [26, 28], "new_sbj_tok_span": [5, 6], "new_obj_tok_span": [30, 32]}], "umls_entity_list": [{"mention": "MUL", "char_span": [91, 94], "sem_type": "Gene or Genome", "tok_span": [16, 18], "new_tok_span": [17, 19]}, {"mention": "xCT", "char_span": [142, 145], "sem_type": "Gene or Genome", "tok_span": [26, 28], "new_tok_span": [30, 32]}, {"mention": "gene", "char_span": [146, 150], "sem_type": "Gene or Genome", "tok_span": [28, 29], "new_tok_span": [35, 36]}, {"mention": "xCT", "char_span": [142, 145], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 28], "new_tok_span": [30, 32]}], "new_text": "The oxidative stress conditions following DEM treatment activate L - cystine transport in TR - <START=Gene or Genome> MUL <END=Gene or Genome> cells due to the enhanced transcription of the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> xCT <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> gene <END=Gene or Genome>."}, {"PMID": 10328230, "id": 4, "text": "Both BB-94 and captopril also prevented substrate degradation by gelatinase A and B released in conditioned medium by cultured cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [5, 10], "name": "BB-94", "tok_span": [1, 4], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [65, 83], "name": "gelatinase A and B", "tok_span": [13, 18], "new_tok_span": [14, 19]}], "relation_list": [{"subject": "BB-94", "sbj_char_span": [5, 10], "object": "gelatinase A and B", "obj_char_span": [65, 83], "rel_type": "regulator", "sbj_tok_span": [1, 4], "obj_tok_span": [13, 18], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [14, 19]}], "umls_entity_list": [{"mention": "gelatinase", "char_span": [65, 75], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 15], "new_tok_span": [14, 16]}], "new_text": "Both BB - 94 and captopril also prevented substrate degradation by <START=Amino Acid, Peptide, or Protein> gelatinase <END=Amino Acid, Peptide, or Protein> A and B released in conditioned medium by cultured cells."}, {"PMID": 17603555, "id": 1, "text": "BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR). We have completed an extensive study of the pharmacological effects of these drugs on AMPK activation, adenine nucleotide concentration, transepithelial amiloride-sensitive (I(amiloride)) and ouabain-sensitive basolateral (I(ouabain)) short circuit current in H441 lung epithelial cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [107, 110], "name": "AMP", "tok_span": [22, 23], "new_tok_span": [32, 33]}, {"ent_type": "CHEMICAL", "char_span": [120, 174], "name": "5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside", "tok_span": [27, 49], "new_tok_span": [39, 61]}, {"ent_type": "CHEMICAL", "char_span": [176, 181], "name": "AICAR", "tok_span": [50, 52], "new_tok_span": [64, 66]}, {"ent_type": "CHEMICAL", "char_span": [24, 27], "name": "AMP", "tok_span": [4, 5], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [287, 305], "name": "adenine nucleotide", "tok_span": [71, 73], "new_tok_span": [90, 92]}, {"ent_type": "CHEMICAL", "char_span": [337, 346], "name": "amiloride", "tok_span": [77, 81], "new_tok_span": [98, 102]}, {"ent_type": "CHEMICAL", "char_span": [360, 369], "name": "amiloride", "tok_span": [86, 90], "new_tok_span": [109, 113]}, {"ent_type": "CHEMICAL", "char_span": [376, 383], "name": "ouabain", "tok_span": [93, 96], "new_tok_span": [118, 121]}, {"ent_type": "CHEMICAL", "char_span": [409, 416], "name": "ouabain", "tok_span": [103, 106], "new_tok_span": [130, 133]}, {"ent_type": "CHEMICAL", "char_span": [76, 85], "name": "metformin", "tok_span": [15, 16], "new_tok_span": [23, 24]}, {"ent_type": "CHEMICAL", "char_span": [87, 97], "name": "phenformin", "tok_span": [17, 19], "new_tok_span": [25, 27]}, {"ent_type": "GENE", "char_span": [24, 52], "name": "AMP-activated protein kinase", "tok_span": [4, 9], "new_tok_span": [6, 11]}, {"ent_type": "GENE", "char_span": [270, 274], "name": "AMPK", "tok_span": [68, 69], "new_tok_span": [84, 85]}, {"ent_type": "GENE", "char_span": [54, 58], "name": "AMPK", "tok_span": [10, 11], "new_tok_span": [16, 17]}], "relation_list": [{"subject": "metformin", "sbj_char_span": [76, 85], "object": "AMP-activated protein kinase", "obj_char_span": [24, 52], "rel_type": "activator", "sbj_tok_span": [15, 16], "obj_tok_span": [4, 9], "new_sbj_tok_span": [23, 24], "new_obj_tok_span": [6, 11]}, {"subject": "metformin", "sbj_char_span": [76, 85], "object": "AMPK", "obj_char_span": [54, 58], "rel_type": "activator", "sbj_tok_span": [15, 16], "obj_tok_span": [10, 11], "new_sbj_tok_span": [23, 24], "new_obj_tok_span": [16, 17]}, {"subject": "phenformin", "sbj_char_span": [87, 97], "object": "AMP-activated protein kinase", "obj_char_span": [24, 52], "rel_type": "activator", "sbj_tok_span": [17, 19], "obj_tok_span": [4, 9], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [6, 11]}, {"subject": "phenformin", "sbj_char_span": [87, 97], "object": "AMPK", "obj_char_span": [54, 58], "rel_type": "activator", "sbj_tok_span": [17, 19], "obj_tok_span": [10, 11], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [16, 17]}, {"subject": "5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside", "sbj_char_span": [120, 174], "object": "AMP-activated protein kinase", "obj_char_span": [24, 52], "rel_type": "activator", "sbj_tok_span": [27, 49], "obj_tok_span": [4, 9], "new_sbj_tok_span": [39, 61], "new_obj_tok_span": [6, 11]}, {"subject": "5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside", "sbj_char_span": [120, 174], "object": "AMPK", "obj_char_span": [54, 58], "rel_type": "activator", "sbj_tok_span": [27, 49], "obj_tok_span": [10, 11], "new_sbj_tok_span": [39, 61], "new_obj_tok_span": [16, 17]}, {"subject": "AICAR", "sbj_char_span": [176, 181], "object": "AMP-activated protein kinase", "obj_char_span": [24, 52], "rel_type": "activator", "sbj_tok_span": [50, 52], "obj_tok_span": [4, 9], "new_sbj_tok_span": [64, 66], "new_obj_tok_span": [6, 11]}, {"subject": "AICAR", "sbj_char_span": [176, 181], "object": "AMPK", "obj_char_span": [54, 58], "rel_type": "activator", "sbj_tok_span": [50, 52], "obj_tok_span": [10, 11], "new_sbj_tok_span": [64, 66], "new_obj_tok_span": [16, 17]}], "umls_entity_list": [{"mention": "AMP", "char_span": [24, 27], "sem_type": "Gene or Genome", "tok_span": [4, 5], "new_tok_span": [6, 7]}, {"mention": "AMP", "char_span": [54, 57], "sem_type": "Gene or Genome", "tok_span": [10, 11], "new_tok_span": [16, 17]}, {"mention": "AMP", "char_span": [107, 110], "sem_type": "Gene or Genome", "tok_span": [22, 23], "new_tok_span": [32, 33]}, {"mention": "AMP", "char_span": [270, 273], "sem_type": "Gene or Genome", "tok_span": [68, 69], "new_tok_span": [84, 85]}, {"mention": "aminoimidazole", "char_span": [122, 136], "sem_type": "Pharmacologic Substance", "tok_span": [29, 32], "new_tok_span": [42, 45]}, {"mention": "AMP", "char_span": [24, 27], "sem_type": "Pharmacologic Substance", "tok_span": [4, 5], "new_tok_span": [6, 7]}, {"mention": "AMP", "char_span": [54, 57], "sem_type": "Pharmacologic Substance", "tok_span": [10, 11], "new_tok_span": [16, 17]}, {"mention": "AMP", "char_span": [107, 110], "sem_type": "Pharmacologic Substance", "tok_span": [22, 23], "new_tok_span": [32, 33]}, {"mention": "AMP", "char_span": [270, 273], "sem_type": "Pharmacologic Substance", "tok_span": [68, 69], "new_tok_span": [84, 85]}, {"mention": "adenine nucleotide", "char_span": [287, 305], "sem_type": "Pharmacologic Substance", "tok_span": [71, 73], "new_tok_span": [90, 92]}, {"mention": "amiloride", "char_span": [337, 346], "sem_type": "Pharmacologic Substance", "tok_span": [77, 81], "new_tok_span": [98, 102]}, {"mention": "amiloride", "char_span": [360, 369], "sem_type": "Pharmacologic Substance", "tok_span": [86, 90], "new_tok_span": [109, 113]}, {"mention": "ouabain", "char_span": [376, 383], "sem_type": "Pharmacologic Substance", "tok_span": [93, 96], "new_tok_span": [118, 121]}, {"mention": "ouabain", "char_span": [409, 416], "sem_type": "Pharmacologic Substance", "tok_span": [103, 106], "new_tok_span": [130, 133]}], "new_text": "BACKGROUND AND PURPOSE : <START=Gene or Genome> <START=Pharmacologic Substance> AMP <END=Gene or Genome> <END=Pharmacologic Substance> - activated protein kinase ( <START=Gene or Genome> <START=Pharmacologic Substance> AMPK <END=Gene or Genome> <END=Pharmacologic Substance> ) is activated by metformin, phenformin, and the <START=Gene or Genome> <START=Pharmacologic Substance> AMP <END=Gene or Genome> <END=Pharmacologic Substance> mimetic, 5 - <START=Pharmacologic Substance> aminoimidazole <END=Pharmacologic Substance> - 4 - carboxamide - 1 - beta - D - ribofuranoside ( AICAR ). We have completed an extensive study of the pharmacological effects of these drugs on <START=Gene or Genome> <START=Pharmacologic Substance> AMPK <END=Gene or Genome> <END=Pharmacologic Substance> activation, <START=Pharmacologic Substance> adenine nucleotide <END=Pharmacologic Substance> concentration, transepithelial <START=Pharmacologic Substance> amiloride <END=Pharmacologic Substance> - sensitive ( I ( <START=Pharmacologic Substance> amiloride <END=Pharmacologic Substance> ) ) and <START=Pharmacologic Substance> ouabain <END=Pharmacologic Substance> - sensitive basolateral ( I ( <START=Pharmacologic Substance> ouabain <END=Pharmacologic Substance> ) ) short circuit current in H441 lung epithelial cells."}, {"PMID": 14757700, "id": 7, "text": "Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively). 5.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [23, 27], "name": "BCTC", "tok_span": [6, 8], "new_tok_span": [8, 10]}, {"ent_type": "CHEMICAL", "char_span": [29, 38], "name": "thio-BCTC", "tok_span": [9, 14], "new_tok_span": [12, 17]}, {"ent_type": "CHEMICAL", "char_span": [43, 54], "name": "capsazepine", "tok_span": [15, 18], "new_tok_span": [20, 23]}, {"ent_type": "CHEMICAL", "char_span": [105, 112], "name": "menthol", "tok_span": [31, 33], "new_tok_span": [37, 39]}, {"ent_type": "GENE", "char_span": [6, 9], "name": "VR1", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"ent_type": "GENE", "char_span": [96, 101], "name": "TRPM8", "tok_span": [27, 30], "new_tok_span": [33, 36]}], "relation_list": [{"subject": "BCTC", "sbj_char_span": [23, 27], "object": "VR1", "obj_char_span": [6, 9], "rel_type": "agonist or antagonist", "sbj_tok_span": [6, 8], "obj_tok_span": [2, 4], "new_sbj_tok_span": [8, 10], "new_obj_tok_span": [3, 5]}, {"subject": "thio-BCTC", "sbj_char_span": [29, 38], "object": "VR1", "obj_char_span": [6, 9], "rel_type": "agonist or antagonist", "sbj_tok_span": [9, 14], "obj_tok_span": [2, 4], "new_sbj_tok_span": [12, 17], "new_obj_tok_span": [3, 5]}, {"subject": "capsazepine", "sbj_char_span": [43, 54], "object": "VR1", "obj_char_span": [6, 9], "rel_type": "agonist or antagonist", "sbj_tok_span": [15, 18], "obj_tok_span": [2, 4], "new_sbj_tok_span": [20, 23], "new_obj_tok_span": [3, 5]}, {"subject": "BCTC", "sbj_char_span": [23, 27], "object": "TRPM8", "obj_char_span": [96, 101], "rel_type": "inhibitor", "sbj_tok_span": [6, 8], "obj_tok_span": [27, 30], "new_sbj_tok_span": [8, 10], "new_obj_tok_span": [33, 36]}, {"subject": "thio-BCTC", "sbj_char_span": [29, 38], "object": "TRPM8", "obj_char_span": [96, 101], "rel_type": "inhibitor", "sbj_tok_span": [9, 14], "obj_tok_span": [27, 30], "new_sbj_tok_span": [12, 17], "new_obj_tok_span": [33, 36]}, {"subject": "capsazepine", "sbj_char_span": [43, 54], "object": "TRPM8", "obj_char_span": [96, 101], "rel_type": "inhibitor", "sbj_tok_span": [15, 18], "obj_tok_span": [27, 30], "new_sbj_tok_span": [20, 23], "new_obj_tok_span": [33, 36]}, {"subject": "menthol", "sbj_char_span": [105, 112], "object": "TRPM8", "obj_char_span": [96, 101], "rel_type": "activator", "sbj_tok_span": [31, 33], "obj_tok_span": [27, 30], "new_sbj_tok_span": [37, 39], "new_obj_tok_span": [33, 36]}], "umls_entity_list": [{"mention": "VR1", "char_span": [6, 9], "sem_type": "Gene or Genome", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"mention": "thio", "char_span": [29, 33], "sem_type": "Gene or Genome", "tok_span": [9, 11], "new_tok_span": [12, 14]}, {"mention": "capsazepine", "char_span": [43, 54], "sem_type": "Pharmacologic Substance", "tok_span": [15, 18], "new_tok_span": [20, 23]}], "new_text": "Known <START=Gene or Genome> VR1 <END=Gene or Genome> antagonists ( BCTC, <START=Gene or Genome> thio <END=Gene or Genome> - BCTC and <START=Pharmacologic Substance> capsazepine <END=Pharmacologic Substance> ) were also able to block the response of TRPM8 to menthol ( IC ( 50 ) : 0. 8 + / - 1. 0, 3. 5 + / - 1. 1 and 18 + / - 1. 1 microM, respectively ). 5."}, {"PMID": 15695169, "id": 0, "text": "Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 37], "name": "ramelteon", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"ent_type": "CHEMICAL", "char_span": [39, 46], "name": "TAK-375", "tok_span": [8, 12], "new_tok_span": [11, 15]}, {"ent_type": "GENE", "char_span": [61, 64], "name": "MT1", "tok_span": [16, 18], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [65, 77], "name": "MT2 receptor", "tok_span": [19, 22], "new_tok_span": [23, 26]}], "relation_list": [{"subject": "ramelteon", "sbj_char_span": [28, 37], "object": "MT1", "obj_char_span": [61, 64], "rel_type": "agonist or antagonist", "sbj_tok_span": [4, 7], "obj_tok_span": [16, 18], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [20, 22]}, {"subject": "TAK-375", "sbj_char_span": [39, 46], "object": "MT1", "obj_char_span": [61, 64], "rel_type": "agonist or antagonist", "sbj_tok_span": [8, 12], "obj_tok_span": [16, 18], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [20, 22]}, {"subject": "ramelteon", "sbj_char_span": [28, 37], "object": "MT2 receptor", "obj_char_span": [65, 77], "rel_type": "agonist or antagonist", "sbj_tok_span": [4, 7], "obj_tok_span": [19, 22], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [23, 26]}, {"subject": "TAK-375", "sbj_char_span": [39, 46], "object": "MT2 receptor", "obj_char_span": [65, 77], "rel_type": "agonist or antagonist", "sbj_tok_span": [8, 12], "obj_tok_span": [19, 22], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [23, 26]}], "umls_entity_list": [{"mention": "ramelteon", "char_span": [28, 37], "sem_type": "Pharmacologic Substance", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"mention": "TAK-375", "char_span": [39, 46], "sem_type": "Pharmacologic Substance", "tok_span": [8, 12], "new_tok_span": [11, 15]}], "new_text": "Neurochemical properties of <START=Pharmacologic Substance> ramelteon <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> TAK - 375 <END=Pharmacologic Substance> ), a selective MT1 / MT2 receptor agonist."}, {"PMID": 23411318, "id": 6, "text": "C. pilosula also reversed Ca(2+) influx, MOMP and apoptosis increased by AngII plus Leu(27)-IGFII. Molecular markers in IGFIIR apoptotic pathway (IGFIIR, calcineurin, etc.) and IGFIIR-Gαq association were downregulated by C. pilosula.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [26, 32], "name": "Ca(2+)", "tok_span": [7, 12], "new_tok_span": [7, 12]}, {"ent_type": "CHEMICAL", "char_span": [84, 87], "name": "Leu", "tok_span": [23, 24], "new_tok_span": [24, 25]}, {"ent_type": "GENE", "char_span": [73, 78], "name": "AngII", "tok_span": [20, 22], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [92, 97], "name": "IGFII", "tok_span": [28, 30], "new_tok_span": [30, 32]}, {"ent_type": "GENE", "char_span": [120, 126], "name": "IGFIIR", "tok_span": [34, 37], "new_tok_span": [36, 39]}, {"ent_type": "GENE", "char_span": [146, 152], "name": "IGFIIR", "tok_span": [40, 43], "new_tok_span": [42, 45]}, {"ent_type": "GENE", "char_span": [154, 165], "name": "calcineurin", "tok_span": [44, 47], "new_tok_span": [47, 50]}, {"ent_type": "GENE", "char_span": [177, 183], "name": "IGFIIR", "tok_span": [52, 55], "new_tok_span": [56, 59]}, {"ent_type": "GENE", "char_span": [184, 187], "name": "Gαq", "tok_span": [56, 59], "new_tok_span": [60, 63]}], "relation_list": [{"subject": "Leu", "sbj_char_span": [84, 87], "object": "IGFII", "obj_char_span": [92, 97], "rel_type": "part of", "sbj_tok_span": [23, 24], "obj_tok_span": [28, 30], "new_sbj_tok_span": [24, 25], "new_obj_tok_span": [30, 32]}], "umls_entity_list": [{"mention": "Leu", "char_span": [84, 87], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [23, 24], "new_tok_span": [24, 25]}, {"mention": "calcineurin", "char_span": [154, 165], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [44, 47], "new_tok_span": [47, 50]}], "new_text": "C. pilosula also reversed Ca ( 2 + ) influx, MOMP and apoptosis increased by AngII plus <START=Amino Acid, Peptide, or Protein> Leu <END=Amino Acid, Peptide, or Protein> ( 27 ) - IGFII. Molecular markers in IGFIIR apoptotic pathway ( IGFIIR, <START=Amino Acid, Peptide, or Protein> calcineurin <END=Amino Acid, Peptide, or Protein>, etc. ) and IGFIIR - Gαq association were downregulated by C. pilosula."}, {"PMID": 8626538, "id": 0, "text": "Molecular cloning of a novel diacylglycerol kinase isozyme with a pleckstrin homology domain and a C-terminal tail similar to those of the EPH family of protein-tyrosine kinases.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [161, 169], "name": "tyrosine", "tok_span": [35, 36], "new_tok_span": [43, 44]}, {"ent_type": "CHEMICAL", "char_span": [29, 43], "name": "diacylglycerol", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"ent_type": "CHEMICAL", "char_span": [99, 100], "name": "C", "tok_span": [20, 21], "new_tok_span": [24, 25]}, {"ent_type": "GENE", "char_span": [139, 142], "name": "EPH", "tok_span": [29, 31], "new_tok_span": [35, 37]}, {"ent_type": "GENE", "char_span": [153, 177], "name": "protein-tyrosine kinases", "tok_span": [33, 37], "new_tok_span": [41, 45]}, {"ent_type": "GENE", "char_span": [29, 50], "name": "diacylglycerol kinase", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [66, 92], "name": "pleckstrin homology domain", "tok_span": [13, 18], "new_tok_span": [17, 22]}], "relation_list": [{"subject": "C", "sbj_char_span": [99, 100], "object": "diacylglycerol kinase", "obj_char_span": [29, 50], "rel_type": "part of", "sbj_tok_span": [20, 21], "obj_tok_span": [5, 9], "new_sbj_tok_span": [24, 25], "new_obj_tok_span": [6, 10]}, {"subject": "C", "sbj_char_span": [99, 100], "object": "pleckstrin homology domain", "obj_char_span": [66, 92], "rel_type": "part of", "sbj_tok_span": [20, 21], "obj_tok_span": [13, 18], "new_sbj_tok_span": [24, 25], "new_obj_tok_span": [17, 22]}], "umls_entity_list": [{"mention": "diacylglycerol", "char_span": [29, 43], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"mention": "isozyme", "char_span": [51, 58], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 11], "new_tok_span": [12, 14]}, {"mention": "EPH", "char_span": [139, 142], "sem_type": "Gene or Genome", "tok_span": [29, 31], "new_tok_span": [35, 37]}, {"mention": "EPH", "char_span": [139, 142], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 31], "new_tok_span": [35, 37]}], "new_text": "Molecular cloning of a novel <START=Amino Acid, Peptide, or Protein> diacylglycerol <END=Amino Acid, Peptide, or Protein> kinase <START=Amino Acid, Peptide, or Protein> isozyme <END=Amino Acid, Peptide, or Protein> with a pleckstrin homology domain and a C - terminal tail similar to those of the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> EPH <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> family of protein - tyrosine kinases."}, {"PMID": 1346768, "id": 10, "text": "All three subtypes have been shown to inhibit the activation of adenylate cyclase and thus reduce the levels of cAMP. Three alpha 2-adrenergic receptor subtypes have been identified by molecular cloning in both the human and rat species.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [64, 73], "name": "adenylate", "tok_span": [11, 13], "new_tok_span": [11, 13]}, {"ent_type": "CHEMICAL", "char_span": [112, 116], "name": "cAMP", "tok_span": [20, 21], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [64, 81], "name": "adenylate cyclase", "tok_span": [11, 14], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [124, 151], "name": "alpha 2-adrenergic receptor", "tok_span": [23, 29], "new_tok_span": [23, 29]}], "relation_list": [{"subject": "cAMP", "sbj_char_span": [112, 116], "object": "adenylate cyclase", "obj_char_span": [64, 81], "rel_type": "product or substrate", "sbj_tok_span": [20, 21], "obj_tok_span": [11, 14], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [11, 14]}], "umls_entity_list": [], "new_text": "All three subtypes have been shown to inhibit the activation of adenylate cyclase and thus reduce the levels of cAMP. Three alpha 2 - adrenergic receptor subtypes have been identified by molecular cloning in both the human and rat species."}, {"PMID": 23200255, "id": 2, "text": "N-alkylation of the pyridazinone ring markedly enhances potency against PDE4 but suppresses PDE3 inhibition.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 1], "name": "N", "tok_span": [0, 1], "new_tok_span": [0, 1]}, {"ent_type": "CHEMICAL", "char_span": [20, 32], "name": "pyridazinone", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [72, 76], "name": "PDE4", "tok_span": [15, 17], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [92, 96], "name": "PDE3", "tok_span": [19, 21], "new_tok_span": [23, 25]}], "relation_list": [{"subject": "pyridazinone", "sbj_char_span": [20, 32], "object": "PDE4", "obj_char_span": [72, 76], "rel_type": "inhibitor", "sbj_tok_span": [6, 10], "obj_tok_span": [15, 17], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [18, 20]}, {"subject": "pyridazinone", "sbj_char_span": [20, 32], "object": "PDE3", "obj_char_span": [92, 96], "rel_type": "inhibitor", "sbj_tok_span": [6, 10], "obj_tok_span": [19, 21], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [23, 25]}, {"subject": "N", "sbj_char_span": [0, 1], "object": "PDE4", "obj_char_span": [72, 76], "rel_type": "inhibitor", "sbj_tok_span": [0, 1], "obj_tok_span": [15, 17], "new_sbj_tok_span": [0, 1], "new_obj_tok_span": [18, 20]}, {"subject": "N", "sbj_char_span": [0, 1], "object": "PDE3", "obj_char_span": [92, 96], "rel_type": "inhibitor", "sbj_tok_span": [0, 1], "obj_tok_span": [19, 21], "new_sbj_tok_span": [0, 1], "new_obj_tok_span": [23, 25]}], "umls_entity_list": [{"mention": "pyridazinone", "char_span": [20, 32], "sem_type": "Organic Chemical", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"mention": "PDE4", "char_span": [72, 76], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 17], "new_tok_span": [18, 20]}], "new_text": "N - alkylation of the <START=Organic Chemical> pyridazinone <END=Organic Chemical> ring markedly enhances potency against <START=Amino Acid, Peptide, or Protein> PDE4 <END=Amino Acid, Peptide, or Protein> but suppresses PDE3 inhibition."}, {"PMID": 23145773, "id": 2, "text": "We report here the optimization of human 17β-HSD2 inhibitors in the 2,5-thiophene amide class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [68, 87], "name": "2,5-thiophene amide", "tok_span": [16, 24], "new_tok_span": [18, 26]}, {"ent_type": "CHEMICAL", "char_span": [159, 164], "name": "amide", "tok_span": [41, 42], "new_tok_span": [45, 46]}, {"ent_type": "CHEMICAL", "char_span": [180, 186], "name": "phenyl", "tok_span": [45, 46], "new_tok_span": [49, 50]}, {"ent_type": "GENE", "char_span": [35, 49], "name": "human 17β-HSD2", "tok_span": [6, 13], "new_tok_span": [6, 13]}], "relation_list": [{"subject": "2,5-thiophene amide", "sbj_char_span": [68, 87], "object": "human 17β-HSD2", "obj_char_span": [35, 49], "rel_type": "inhibitor", "sbj_tok_span": [16, 24], "obj_tok_span": [6, 13], "new_sbj_tok_span": [18, 26], "new_obj_tok_span": [6, 13]}], "umls_entity_list": [{"mention": "HSD2", "char_span": [45, 49], "sem_type": "Gene or Genome", "tok_span": [10, 13], "new_tok_span": [11, 14]}, {"mention": "thiophene", "char_span": [72, 81], "sem_type": "Pharmacologic Substance", "tok_span": [20, 23], "new_tok_span": [23, 26]}], "new_text": "We report here the optimization of human 17β - <START=Gene or Genome> HSD2 <END=Gene or Genome> inhibitors in the 2, 5 - <START=Pharmacologic Substance> thiophene <END=Pharmacologic Substance> amide class by varying the size of the linker ( n equals 0 and 2 ) between the amide moiety and the phenyl group."}, {"PMID": 15714982, "id": 3, "text": "Docetaxel is a semisynthetic taxane that inhibit tumor growth by induction of microtubule stabilization and promotion of bcl-2 inactivation, which induce apoptosis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Docetaxel", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [29, 35], "name": "taxane", "tok_span": [9, 11], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [121, 126], "name": "bcl-2", "tok_span": [23, 27], "new_tok_span": [29, 33]}], "relation_list": [{"subject": "taxane", "sbj_char_span": [29, 35], "object": "bcl-2", "obj_char_span": [121, 126], "rel_type": "regulator", "sbj_tok_span": [9, 11], "obj_tok_span": [23, 27], "new_sbj_tok_span": [13, 15], "new_obj_tok_span": [29, 33]}, {"subject": "Docetaxel", "sbj_char_span": [0, 9], "object": "bcl-2", "obj_char_span": [121, 126], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [23, 27], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [29, 33]}], "umls_entity_list": [{"mention": "Docetaxel", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "taxane", "char_span": [29, 35], "sem_type": "Pharmacologic Substance", "tok_span": [9, 11], "new_tok_span": [13, 15]}, {"mention": "taxane", "char_span": [29, 35], "sem_type": "Organic Chemical", "tok_span": [9, 11], "new_tok_span": [13, 15]}], "new_text": "<START=Pharmacologic Substance> Docetaxel <END=Pharmacologic Substance> is a semisynthetic <START=Pharmacologic Substance> <START=Organic Chemical> taxane <END=Pharmacologic Substance> <END=Organic Chemical> that inhibit tumor growth by induction of microtubule stabilization and promotion of bcl - 2 inactivation, which induce apoptosis."}, {"PMID": 15287725, "id": 3, "text": "We observed that the closed conformation of apo(a) is maintained by intramolecular interaction(s) between sequences within the amino- and carboxyl-terminal halves of the molecule.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [127, 132], "name": "amino", "tok_span": [23, 24], "new_tok_span": [25, 26]}, {"ent_type": "CHEMICAL", "char_span": [138, 146], "name": "carboxyl", "tok_span": [26, 27], "new_tok_span": [29, 30]}, {"ent_type": "GENE", "char_span": [44, 50], "name": "apo(a)", "tok_span": [7, 11], "new_tok_span": [8, 12]}], "relation_list": [{"subject": "amino", "sbj_char_span": [127, 132], "object": "apo(a)", "obj_char_span": [44, 50], "rel_type": "regulator", "sbj_tok_span": [23, 24], "obj_tok_span": [7, 11], "new_sbj_tok_span": [25, 26], "new_obj_tok_span": [8, 12]}, {"subject": "carboxyl", "sbj_char_span": [138, 146], "object": "apo(a)", "obj_char_span": [44, 50], "rel_type": "regulator", "sbj_tok_span": [26, 27], "obj_tok_span": [7, 11], "new_sbj_tok_span": [29, 30], "new_obj_tok_span": [8, 12]}], "umls_entity_list": [{"mention": "apo(a)", "char_span": [44, 50], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 11], "new_tok_span": [8, 12]}, {"mention": "carboxyl", "char_span": [138, 146], "sem_type": "Organic Chemical", "tok_span": [26, 27], "new_tok_span": [29, 30]}], "new_text": "We observed that the closed conformation of <START=Amino Acid, Peptide, or Protein> apo ( a ) <END=Amino Acid, Peptide, or Protein> is maintained by intramolecular interaction ( s ) between sequences within the amino - and <START=Organic Chemical> carboxyl <END=Organic Chemical> - terminal halves of the molecule."}, {"PMID": 6150080, "id": 7, "text": "Positive staining of mitochondria was achieved in the presence of the MAO substrate, tryptamine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [85, 95], "name": "tryptamine", "tok_span": [15, 19], "new_tok_span": [16, 20]}, {"ent_type": "GENE", "char_span": [70, 73], "name": "MAO", "tok_span": [11, 13], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "tryptamine", "sbj_char_span": [85, 95], "object": "MAO", "obj_char_span": [70, 73], "rel_type": "product or substrate", "sbj_tok_span": [15, 19], "obj_tok_span": [11, 13], "new_sbj_tok_span": [16, 20], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [{"mention": "tryptamine", "char_span": [85, 95], "sem_type": "Organic Chemical", "tok_span": [15, 19], "new_tok_span": [16, 20]}], "new_text": "Positive staining of mitochondria was achieved in the presence of the MAO substrate, <START=Organic Chemical> tryptamine <END=Organic Chemical>."}, {"PMID": 23244065, "id": 4, "text": "The three-step approach of CliEn-seq involves in vivo synthesis of S-adenosyl-L-methionine (SAM) analogues from cell-permeable methionine analogues by engineered SAM synthetase (methionine adenosyltransferase or MAT), in situ chromatin modification by engineered PMTs, subsequent enrichment and sequencing of the uniquely modified chromatins.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [67, 90], "name": "S-adenosyl-L-methionine", "tok_span": [17, 25], "new_tok_span": [17, 25]}, {"ent_type": "CHEMICAL", "char_span": [92, 95], "name": "SAM", "tok_span": [26, 27], "new_tok_span": [28, 29]}, {"ent_type": "CHEMICAL", "char_span": [127, 137], "name": "methionine", "tok_span": [34, 35], "new_tok_span": [37, 38]}, {"ent_type": "CHEMICAL", "char_span": [162, 165], "name": "SAM", "tok_span": [38, 39], "new_tok_span": [42, 43]}, {"ent_type": "CHEMICAL", "char_span": [178, 188], "name": "methionine", "tok_span": [42, 43], "new_tok_span": [49, 50]}, {"ent_type": "GENE", "char_span": [162, 176], "name": "SAM synthetase", "tok_span": [38, 41], "new_tok_span": [42, 45]}, {"ent_type": "GENE", "char_span": [178, 208], "name": "methionine adenosyltransferase", "tok_span": [42, 46], "new_tok_span": [49, 53]}, {"ent_type": "GENE", "char_span": [212, 215], "name": "MAT", "tok_span": [47, 48], "new_tok_span": [55, 56]}, {"ent_type": "GENE", "char_span": [263, 267], "name": "PMTs", "tok_span": [56, 58], "new_tok_span": [67, 69]}], "relation_list": [{"subject": "S-adenosyl-L-methionine", "sbj_char_span": [67, 90], "object": "SAM synthetase", "obj_char_span": [162, 176], "rel_type": "product or substrate", "sbj_tok_span": [17, 25], "obj_tok_span": [38, 41], "new_sbj_tok_span": [17, 25], "new_obj_tok_span": [42, 45]}, {"subject": "SAM", "sbj_char_span": [92, 95], "object": "SAM synthetase", "obj_char_span": [162, 176], "rel_type": "product or substrate", "sbj_tok_span": [26, 27], "obj_tok_span": [38, 41], "new_sbj_tok_span": [28, 29], "new_obj_tok_span": [42, 45]}, {"subject": "S-adenosyl-L-methionine", "sbj_char_span": [67, 90], "object": "methionine adenosyltransferase", "obj_char_span": [178, 208], "rel_type": "product or substrate", "sbj_tok_span": [17, 25], "obj_tok_span": [42, 46], "new_sbj_tok_span": [17, 25], "new_obj_tok_span": [49, 53]}, {"subject": "SAM", "sbj_char_span": [92, 95], "object": "methionine adenosyltransferase", "obj_char_span": [178, 208], "rel_type": "product or substrate", "sbj_tok_span": [26, 27], "obj_tok_span": [42, 46], "new_sbj_tok_span": [28, 29], "new_obj_tok_span": [49, 53]}, {"subject": "S-adenosyl-L-methionine", "sbj_char_span": [67, 90], "object": "MAT", "obj_char_span": [212, 215], "rel_type": "product or substrate", "sbj_tok_span": [17, 25], "obj_tok_span": [47, 48], "new_sbj_tok_span": [17, 25], "new_obj_tok_span": [55, 56]}, {"subject": "SAM", "sbj_char_span": [92, 95], "object": "MAT", "obj_char_span": [212, 215], "rel_type": "product or substrate", "sbj_tok_span": [26, 27], "obj_tok_span": [47, 48], "new_sbj_tok_span": [28, 29], "new_obj_tok_span": [55, 56]}], "umls_entity_list": [{"mention": "synthetase", "char_span": [166, 176], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 41], "new_tok_span": [44, 46]}, {"mention": "methionine", "char_span": [80, 90], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 25], "new_tok_span": [25, 26]}, {"mention": "methionine", "char_span": [127, 137], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 35], "new_tok_span": [37, 38]}, {"mention": "methionine", "char_span": [178, 188], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 43], "new_tok_span": [49, 50]}, {"mention": "chromatin", "char_span": [226, 235], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [52, 53], "new_tok_span": [61, 62]}, {"mention": "chromatin", "char_span": [331, 340], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [67, 68], "new_tok_span": [81, 82]}, {"mention": "PMTs", "char_span": [263, 267], "sem_type": "Organic Chemical", "tok_span": [56, 58], "new_tok_span": [67, 69]}, {"mention": "chromatins", "char_span": [331, 341], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [67, 69], "new_tok_span": [81, 83]}], "new_text": "The three - step approach of CliEn - seq involves in vivo synthesis of S - adenosyl - L - <START=Amino Acid, Peptide, or Protein> methionine <END=Amino Acid, Peptide, or Protein> ( SAM ) analogues from cell - permeable <START=Amino Acid, Peptide, or Protein> methionine <END=Amino Acid, Peptide, or Protein> analogues by engineered SAM <START=Amino Acid, Peptide, or Protein> synthetase <END=Amino Acid, Peptide, or Protein> ( <START=Amino Acid, Peptide, or Protein> methionine <END=Amino Acid, Peptide, or Protein> adenosyltransferase or MAT ), in situ <START=Amino Acid, Peptide, or Protein> chromatin <END=Amino Acid, Peptide, or Protein> modification by engineered <START=Organic Chemical> PMTs <END=Organic Chemical>, subsequent enrichment and sequencing of the uniquely modified <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> chromatin <END=Amino Acid, Peptide, or Protein>s <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23415902, "id": 4, "text": "Org 214444-0 is shown to be a stereoselective, nanomolar potent FSHR agonist and selective over the structurally related LHR and TSHR. Org 214444-0 is an allosteric agonist interacting with the transmembrane region of the FSHR. When co-incubated with FSH, Org 214444-0 augments FSH's potency in binding (6.5-fold) and adenylyl cyclase/cAMP activation (3.5-fold) in a concentration-dependent manner.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Org 214444-0", "tok_span": [0, 6], "new_tok_span": [0, 6]}, {"ent_type": "CHEMICAL", "char_span": [135, 147], "name": "Org 214444-0", "tok_span": [32, 38], "new_tok_span": [44, 50]}, {"ent_type": "CHEMICAL", "char_span": [256, 268], "name": "Org 214444-0", "tok_span": [61, 67], "new_tok_span": [81, 87]}, {"ent_type": "CHEMICAL", "char_span": [335, 339], "name": "cAMP", "tok_span": [88, 89], "new_tok_span": [110, 111]}, {"ent_type": "GENE", "char_span": [64, 68], "name": "FSHR", "tok_span": [17, 19], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [121, 124], "name": "LHR", "tok_span": [26, 28], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [129, 133], "name": "TSHR", "tok_span": [29, 31], "new_tok_span": [39, 41]}, {"ent_type": "GENE", "char_span": [222, 226], "name": "FSHR", "tok_span": [51, 53], "new_tok_span": [65, 67]}, {"ent_type": "GENE", "char_span": [251, 254], "name": "FSH", "tok_span": [59, 60], "new_tok_span": [78, 79]}, {"ent_type": "GENE", "char_span": [278, 283], "name": "FSH's", "tok_span": [69, 72], "new_tok_span": [90, 93]}, {"ent_type": "GENE", "char_span": [318, 334], "name": "adenylyl cyclase", "tok_span": [83, 87], "new_tok_span": [105, 109]}], "relation_list": [{"subject": "Org 214444-0", "sbj_char_span": [0, 12], "object": "FSHR", "obj_char_span": [64, 68], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 6], "obj_tok_span": [17, 19], "new_sbj_tok_span": [0, 6], "new_obj_tok_span": [19, 21]}, {"subject": "Org 214444-0", "sbj_char_span": [256, 268], "object": "adenylyl cyclase", "obj_char_span": [318, 334], "rel_type": "activator", "sbj_tok_span": [61, 67], "obj_tok_span": [83, 87], "new_sbj_tok_span": [81, 87], "new_obj_tok_span": [105, 109]}, {"subject": "Org 214444-0", "sbj_char_span": [256, 268], "object": "FSH's", "obj_char_span": [278, 283], "rel_type": "activator", "sbj_tok_span": [61, 67], "obj_tok_span": [69, 72], "new_sbj_tok_span": [81, 87], "new_obj_tok_span": [90, 93]}, {"subject": "Org 214444-0", "sbj_char_span": [256, 268], "object": "adenylyl cyclase", "obj_char_span": [318, 334], "rel_type": "regulator", "sbj_tok_span": [61, 67], "obj_tok_span": [83, 87], "new_sbj_tok_span": [81, 87], "new_obj_tok_span": [105, 109]}], "umls_entity_list": [{"mention": "FSHR", "char_span": [64, 68], "sem_type": "Gene or Genome", "tok_span": [17, 19], "new_tok_span": [19, 21]}, {"mention": "FSHR", "char_span": [222, 226], "sem_type": "Gene or Genome", "tok_span": [51, 53], "new_tok_span": [65, 67]}, {"mention": "LHR", "char_span": [121, 124], "sem_type": "Gene or Genome", "tok_span": [26, 28], "new_tok_span": [32, 34]}, {"mention": "LHR", "char_span": [121, 124], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 28], "new_tok_span": [32, 34]}, {"mention": "TSHR", "char_span": [129, 133], "sem_type": "Gene or Genome", "tok_span": [29, 31], "new_tok_span": [39, 41]}, {"mention": "TSHR", "char_span": [129, 133], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 31], "new_tok_span": [39, 41]}, {"mention": "co", "char_span": [233, 235], "sem_type": "Gene or Genome", "tok_span": [55, 56], "new_tok_span": [72, 73]}, {"mention": "co", "char_span": [367, 369], "sem_type": "Gene or Genome", "tok_span": [99, 100], "new_tok_span": [122, 123]}, {"mention": "FSH", "char_span": [64, 67], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 18], "new_tok_span": [19, 20]}, {"mention": "FSH", "char_span": [222, 225], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [51, 52], "new_tok_span": [65, 66]}, {"mention": "FSH", "char_span": [251, 254], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [59, 60], "new_tok_span": [78, 79]}, {"mention": "FSH", "char_span": [278, 281], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [69, 70], "new_tok_span": [90, 91]}], "new_text": "Org 214444 - 0 is shown to be a stereoselective, nanomolar potent <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> FSH <END=Amino Acid, Peptide, or Protein>R <END=Gene or Genome> agonist and selective over the structurally related <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> LHR <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> TSHR <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. Org 214444 - 0 is an allosteric agonist interacting with the transmembrane region of the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> FSH <END=Amino Acid, Peptide, or Protein>R <END=Gene or Genome>. When <START=Gene or Genome> co <END=Gene or Genome> - incubated with <START=Amino Acid, Peptide, or Protein> FSH <END=Amino Acid, Peptide, or Protein>, Org 214444 - 0 augments <START=Amino Acid, Peptide, or Protein> FSH <END=Amino Acid, Peptide, or Protein>'s potency in binding ( 6. 5 - fold ) and adenylyl cyclase / cAMP activation ( 3. 5 - fold ) in a <START=Gene or Genome> concentration <END=Gene or Genome> - dependent manner."}, {"PMID": 23115325, "id": 5, "text": "The concentration response to levcromakalim (LEVC), a K(ATP) channel opener, was significantly shifted to the left in the inflamed smooth-muscle cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [30, 43], "name": "levcromakalim", "tok_span": [4, 9], "new_tok_span": [5, 10]}, {"ent_type": "CHEMICAL", "char_span": [45, 49], "name": "LEVC", "tok_span": [10, 12], "new_tok_span": [12, 14]}, {"ent_type": "CHEMICAL", "char_span": [54, 55], "name": "K", "tok_span": [15, 16], "new_tok_span": [17, 18]}, {"ent_type": "CHEMICAL", "char_span": [56, 59], "name": "ATP", "tok_span": [17, 18], "new_tok_span": [19, 20]}, {"ent_type": "GENE", "char_span": [54, 68], "name": "K(ATP) channel", "tok_span": [15, 20], "new_tok_span": [17, 22]}], "relation_list": [{"subject": "levcromakalim", "sbj_char_span": [30, 43], "object": "K(ATP) channel", "obj_char_span": [54, 68], "rel_type": "activator", "sbj_tok_span": [4, 9], "obj_tok_span": [15, 20], "new_sbj_tok_span": [5, 10], "new_obj_tok_span": [17, 22]}, {"subject": "LEVC", "sbj_char_span": [45, 49], "object": "K(ATP) channel", "obj_char_span": [54, 68], "rel_type": "activator", "sbj_tok_span": [10, 12], "obj_tok_span": [15, 20], "new_sbj_tok_span": [12, 14], "new_obj_tok_span": [17, 22]}], "umls_entity_list": [{"mention": "levcromakalim", "char_span": [30, 43], "sem_type": "Pharmacologic Substance", "tok_span": [4, 9], "new_tok_span": [5, 10]}], "new_text": "The concentration response to <START=Pharmacologic Substance> levcromakalim <END=Pharmacologic Substance> ( LEVC ), a K ( ATP ) channel opener, was significantly shifted to the left in the inflamed smooth - muscle cells."}, {"PMID": 23397054, "id": 5, "text": "The brain-to-plasma partition coefficient of elacridar in the wild-type mice was 0.82, as compared with 3.5 in Mdr1a/b(-/-) mice, 6.6 in Bcrp1(-/-) mice, and 15 in Mdr1a/b(-/-)Bcrp1(-/-) mice, indicating that both P-gp and Bcrp limit the brain distribution of elacridar.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [260, 269], "name": "elacridar", "tok_span": [99, 103], "new_tok_span": [106, 110]}, {"ent_type": "CHEMICAL", "char_span": [45, 54], "name": "elacridar", "tok_span": [9, 13], "new_tok_span": [10, 14]}, {"ent_type": "GENE", "char_span": [164, 171], "name": "Mdr1a/b", "tok_span": [62, 68], "new_tok_span": [66, 72]}, {"ent_type": "GENE", "char_span": [176, 181], "name": "Bcrp1", "tok_span": [73, 77], "new_tok_span": [78, 82]}, {"ent_type": "GENE", "char_span": [214, 218], "name": "P-gp", "tok_span": [87, 90], "new_tok_span": [93, 96]}, {"ent_type": "GENE", "char_span": [223, 227], "name": "Bcrp", "tok_span": [91, 94], "new_tok_span": [97, 100]}, {"ent_type": "GENE", "char_span": [111, 118], "name": "Mdr1a/b", "tok_span": [31, 37], "new_tok_span": [33, 39]}, {"ent_type": "GENE", "char_span": [137, 142], "name": "Bcrp1", "tok_span": [48, 52], "new_tok_span": [51, 55]}], "relation_list": [{"subject": "elacridar", "sbj_char_span": [260, 269], "object": "P-gp", "obj_char_span": [214, 218], "rel_type": "product or substrate", "sbj_tok_span": [99, 103], "obj_tok_span": [87, 90], "new_sbj_tok_span": [106, 110], "new_obj_tok_span": [93, 96]}, {"subject": "elacridar", "sbj_char_span": [260, 269], "object": "Bcrp", "obj_char_span": [223, 227], "rel_type": "product or substrate", "sbj_tok_span": [99, 103], "obj_tok_span": [91, 94], "new_sbj_tok_span": [106, 110], "new_obj_tok_span": [97, 100]}], "umls_entity_list": [{"mention": "elacridar", "char_span": [45, 54], "sem_type": "Pharmacologic Substance", "tok_span": [9, 13], "new_tok_span": [10, 14]}, {"mention": "elacridar", "char_span": [260, 269], "sem_type": "Pharmacologic Substance", "tok_span": [99, 103], "new_tok_span": [106, 110]}, {"mention": "Bcrp1", "char_span": [137, 142], "sem_type": "Gene or Genome", "tok_span": [48, 52], "new_tok_span": [51, 55]}, {"mention": "Bcrp1", "char_span": [176, 181], "sem_type": "Gene or Genome", "tok_span": [73, 77], "new_tok_span": [78, 82]}], "new_text": "The brain - to - plasma partition coefficient of <START=Pharmacologic Substance> elacridar <END=Pharmacologic Substance> in the wild - type mice was 0. 82, as compared with 3. 5 in Mdr1a / b ( - / - ) mice, 6. 6 in <START=Gene or Genome> Bcrp1 <END=Gene or Genome> ( - / - ) mice, and 15 in Mdr1a / b ( - / - ) <START=Gene or Genome> Bcrp1 <END=Gene or Genome> ( - / - ) mice, indicating that both P - gp and Bcrp limit the brain distribution of <START=Pharmacologic Substance> elacridar <END=Pharmacologic Substance>."}, {"PMID": 23354536, "id": 5, "text": "The data suggest that the decrease in tissue levels of 5-HT produced by MDMA is accompanied by a decrease in tryptophan hydroxylase activity but cannot be explained by supersensitivity of the 5-HT1a autoreceptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [55, 59], "name": "5-HT", "tok_span": [10, 13], "new_tok_span": [10, 13]}, {"ent_type": "CHEMICAL", "char_span": [72, 76], "name": "MDMA", "tok_span": [15, 17], "new_tok_span": [16, 18]}, {"ent_type": "CHEMICAL", "char_span": [109, 119], "name": "tryptophan", "tok_span": [23, 24], "new_tok_span": [25, 26]}, {"ent_type": "GENE", "char_span": [109, 131], "name": "tryptophan hydroxylase", "tok_span": [23, 26], "new_tok_span": [25, 28]}, {"ent_type": "GENE", "char_span": [192, 198], "name": "5-HT1a", "tok_span": [36, 41], "new_tok_span": [38, 43]}], "relation_list": [{"subject": "5-HT", "sbj_char_span": [55, 59], "object": "tryptophan hydroxylase", "obj_char_span": [109, 131], "rel_type": "inhibitor", "sbj_tok_span": [10, 13], "obj_tok_span": [23, 26], "new_sbj_tok_span": [10, 13], "new_obj_tok_span": [25, 28]}], "umls_entity_list": [{"mention": "MDMA", "char_span": [72, 76], "sem_type": "Pharmacologic Substance", "tok_span": [15, 17], "new_tok_span": [16, 18]}, {"mention": "autoreceptor", "char_span": [199, 211], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 43], "new_tok_span": [44, 46]}], "new_text": "The data suggest that the decrease in tissue levels of 5 - HT produced by <START=Pharmacologic Substance> MDMA <END=Pharmacologic Substance> is accompanied by a decrease in tryptophan hydroxylase activity but cannot be explained by supersensitivity of the 5 - HT1a <START=Amino Acid, Peptide, or Protein> autoreceptor <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 12023506, "id": 4, "text": "Probenecid, but not KW-3902, betamipron, and cilastatin, significantly inhibited hOAT2-mediated PGF(2alpha) uptake.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Probenecid", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [20, 27], "name": "KW-3902", "tok_span": [7, 12], "new_tok_span": [8, 13]}, {"ent_type": "CHEMICAL", "char_span": [29, 39], "name": "betamipron", "tok_span": [13, 17], "new_tok_span": [15, 19]}, {"ent_type": "CHEMICAL", "char_span": [45, 55], "name": "cilastatin", "tok_span": [19, 22], "new_tok_span": [21, 24]}, {"ent_type": "GENE", "char_span": [81, 86], "name": "hOAT2", "tok_span": [25, 29], "new_tok_span": [27, 31]}], "relation_list": [{"subject": "Probenecid", "sbj_char_span": [0, 10], "object": "hOAT2", "obj_char_span": [81, 86], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [25, 29], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [27, 31]}], "umls_entity_list": [{"mention": "KW", "char_span": [20, 22], "sem_type": "Pharmacologic Substance", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"mention": "PGF", "char_span": [96, 99], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [31, 33], "new_tok_span": [34, 36]}], "new_text": "Probenecid, but not <START=Pharmacologic Substance> KW <END=Pharmacologic Substance> - 3902, betamipron, and cilastatin, significantly inhibited hOAT2 - mediated <START=Amino Acid, Peptide, or Protein> PGF <END=Amino Acid, Peptide, or Protein> ( 2alpha ) uptake."}, {"PMID": 23195954, "id": 3, "text": "Analogous to the active site of Zn(2+) carboxypeptidases, calnuc has two high affinity (K(d) ∼ 20 nm), well conserved Zn(2+)-binding sites near its N terminus, although it is inactive as a peptidase.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [32, 38], "name": "Zn(2+)", "tok_span": [7, 12], "new_tok_span": [7, 12]}, {"ent_type": "CHEMICAL", "char_span": [118, 124], "name": "Zn(2+)", "tok_span": [37, 42], "new_tok_span": [45, 50]}, {"ent_type": "CHEMICAL", "char_span": [148, 149], "name": "N", "tok_span": [47, 48], "new_tok_span": [55, 56]}, {"ent_type": "GENE", "char_span": [32, 56], "name": "Zn(2+) carboxypeptidases", "tok_span": [7, 17], "new_tok_span": [7, 17]}, {"ent_type": "GENE", "char_span": [58, 64], "name": "calnuc", "tok_span": [18, 21], "new_tok_span": [24, 27]}, {"ent_type": "GENE", "char_span": [118, 138], "name": "Zn(2+)-binding sites", "tok_span": [37, 45], "new_tok_span": [45, 53]}, {"ent_type": "GENE", "char_span": [189, 198], "name": "peptidase", "tok_span": [56, 58], "new_tok_span": [65, 67]}], "relation_list": [{"subject": "N", "sbj_char_span": [148, 149], "object": "calnuc", "obj_char_span": [58, 64], "rel_type": "part of", "sbj_tok_span": [47, 48], "obj_tok_span": [18, 21], "new_sbj_tok_span": [55, 56], "new_obj_tok_span": [24, 27]}], "umls_entity_list": [{"mention": "carboxypeptidases", "char_span": [39, 56], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 17], "new_tok_span": [13, 18]}, {"mention": "calnuc", "char_span": [58, 64], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 21], "new_tok_span": [24, 27]}, {"mention": "calnuc", "char_span": [58, 64], "sem_type": "Gene or Genome", "tok_span": [18, 21], "new_tok_span": [24, 27]}, {"mention": "peptidase", "char_span": [46, 55], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 16], "new_tok_span": [15, 18]}, {"mention": "peptidase", "char_span": [189, 198], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 58], "new_tok_span": [65, 67]}], "new_text": "Analogous to the active site of Zn ( 2 + ) <START=Amino Acid, Peptide, or Protein> carb <START=Amino Acid, Peptide, or Protein>oxypeptidase <END=Amino Acid, Peptide, or Protein>s <END=Amino Acid, Peptide, or Protein>, <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> calnuc <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> has two high affinity ( K ( d ) ∼ 20 nm ), well conserved Zn ( 2 + ) - binding sites near its N terminus, although it is inactive as a <START=Amino Acid, Peptide, or Protein> peptidase <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23486447, "id": 2, "text": "Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 13], "name": "Amitriptyline", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "CHEMICAL", "char_span": [15, 27], "name": "clomipramine", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "CHEMICAL", "char_span": [29, 36], "name": "doxepin", "tok_span": [11, 14], "new_tok_span": [12, 15]}, {"ent_type": "CHEMICAL", "char_span": [38, 48], "name": "imipramine", "tok_span": [15, 19], "new_tok_span": [17, 21]}, {"ent_type": "CHEMICAL", "char_span": [54, 66], "name": "trimipramine", "tok_span": [21, 25], "new_tok_span": [24, 28]}, {"ent_type": "GENE", "char_span": [87, 94], "name": "CYP2C19", "tok_span": [30, 34], "new_tok_span": [36, 40]}], "relation_list": [{"subject": "Amitriptyline", "sbj_char_span": [0, 13], "object": "CYP2C19", "obj_char_span": [87, 94], "rel_type": "product or substrate", "sbj_tok_span": [0, 5], "obj_tok_span": [30, 34], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [36, 40]}, {"subject": "clomipramine", "sbj_char_span": [15, 27], "object": "CYP2C19", "obj_char_span": [87, 94], "rel_type": "product or substrate", "sbj_tok_span": [6, 10], "obj_tok_span": [30, 34], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [36, 40]}, {"subject": "doxepin", "sbj_char_span": [29, 36], "object": "CYP2C19", "obj_char_span": [87, 94], "rel_type": "product or substrate", "sbj_tok_span": [11, 14], "obj_tok_span": [30, 34], "new_sbj_tok_span": [12, 15], "new_obj_tok_span": [36, 40]}, {"subject": "imipramine", "sbj_char_span": [38, 48], "object": "CYP2C19", "obj_char_span": [87, 94], "rel_type": "product or substrate", "sbj_tok_span": [15, 19], "obj_tok_span": [30, 34], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [36, 40]}, {"subject": "trimipramine", "sbj_char_span": [54, 66], "object": "CYP2C19", "obj_char_span": [87, 94], "rel_type": "product or substrate", "sbj_tok_span": [21, 25], "obj_tok_span": [30, 34], "new_sbj_tok_span": [24, 28], "new_obj_tok_span": [36, 40]}], "umls_entity_list": [{"mention": "doxepin", "char_span": [29, 36], "sem_type": "Pharmacologic Substance", "tok_span": [11, 14], "new_tok_span": [12, 15]}, {"mention": "trimipramine", "char_span": [54, 66], "sem_type": "Pharmacologic Substance", "tok_span": [21, 25], "new_tok_span": [24, 28]}, {"mention": "CYP2C19", "char_span": [87, 94], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 34], "new_tok_span": [36, 40]}, {"mention": "CYP2C19", "char_span": [87, 94], "sem_type": "Gene or Genome", "tok_span": [30, 34], "new_tok_span": [36, 40]}], "new_text": "Amitriptyline, clomipramine, <START=Pharmacologic Substance> doxepin <END=Pharmacologic Substance>, imipramine, and <START=Pharmacologic Substance> trimipramine <END=Pharmacologic Substance> are demethylated by <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> CYP2C19 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> to pharmacologically active metabolites."}, {"PMID": 15627430, "id": 6, "text": "The excellent correlation between in vitro antagonist activities of antipsychotics at muscarinic M2 receptors and their in vivo potencies to increase acetylcholine release, suggests that olanzapine, clozapine, as well as thioridazine and chlorpromazine, increase acetylcholine release via blockade of terminal muscarinic M2 autoreceptors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [150, 163], "name": "acetylcholine", "tok_span": [26, 27], "new_tok_span": [31, 32]}, {"ent_type": "CHEMICAL", "char_span": [187, 197], "name": "olanzapine", "tok_span": [31, 34], "new_tok_span": [37, 40]}, {"ent_type": "CHEMICAL", "char_span": [199, 208], "name": "clozapine", "tok_span": [35, 38], "new_tok_span": [41, 44]}, {"ent_type": "CHEMICAL", "char_span": [221, 233], "name": "thioridazine", "tok_span": [42, 47], "new_tok_span": [48, 53]}, {"ent_type": "CHEMICAL", "char_span": [238, 252], "name": "chlorpromazine", "tok_span": [48, 51], "new_tok_span": [54, 57]}, {"ent_type": "CHEMICAL", "char_span": [263, 276], "name": "acetylcholine", "tok_span": [53, 54], "new_tok_span": [60, 61]}, {"ent_type": "GENE", "char_span": [86, 109], "name": "muscarinic M2 receptors", "tok_span": [12, 18], "new_tok_span": [15, 21]}, {"ent_type": "GENE", "char_span": [310, 337], "name": "muscarinic M2 autoreceptors", "tok_span": [59, 67], "new_tok_span": [70, 78]}], "relation_list": [{"subject": "olanzapine", "sbj_char_span": [187, 197], "object": "muscarinic M2 autoreceptors", "obj_char_span": [310, 337], "rel_type": "inhibitor", "sbj_tok_span": [31, 34], "obj_tok_span": [59, 67], "new_sbj_tok_span": [37, 40], "new_obj_tok_span": [70, 78]}, {"subject": "clozapine", "sbj_char_span": [199, 208], "object": "muscarinic M2 autoreceptors", "obj_char_span": [310, 337], "rel_type": "inhibitor", "sbj_tok_span": [35, 38], "obj_tok_span": [59, 67], "new_sbj_tok_span": [41, 44], "new_obj_tok_span": [70, 78]}, {"subject": "thioridazine", "sbj_char_span": [221, 233], "object": "muscarinic M2 autoreceptors", "obj_char_span": [310, 337], "rel_type": "inhibitor", "sbj_tok_span": [42, 47], "obj_tok_span": [59, 67], "new_sbj_tok_span": [48, 53], "new_obj_tok_span": [70, 78]}, {"subject": "chlorpromazine", "sbj_char_span": [238, 252], "object": "muscarinic M2 autoreceptors", "obj_char_span": [310, 337], "rel_type": "inhibitor", "sbj_tok_span": [48, 51], "obj_tok_span": [59, 67], "new_sbj_tok_span": [54, 57], "new_obj_tok_span": [70, 78]}], "umls_entity_list": [{"mention": "antipsychotics", "char_span": [68, 82], "sem_type": "Pharmacologic Substance", "tok_span": [9, 11], "new_tok_span": [10, 12]}, {"mention": "acetylcholine", "char_span": [150, 163], "sem_type": "Pharmacologic Substance", "tok_span": [26, 27], "new_tok_span": [31, 32]}, {"mention": "acetylcholine", "char_span": [263, 276], "sem_type": "Pharmacologic Substance", "tok_span": [53, 54], "new_tok_span": [60, 61]}, {"mention": "muscarinic", "char_span": [86, 96], "sem_type": "Pharmacologic Substance", "tok_span": [12, 15], "new_tok_span": [15, 18]}, {"mention": "muscarinic", "char_span": [310, 320], "sem_type": "Pharmacologic Substance", "tok_span": [59, 62], "new_tok_span": [70, 73]}, {"mention": "autoreceptors", "char_span": [324, 337], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [64, 67], "new_tok_span": [77, 80]}, {"mention": "blockade", "char_span": [289, 297], "sem_type": "Pharmacologic Substance", "tok_span": [56, 57], "new_tok_span": [65, 66]}], "new_text": "The excellent correlation between in vitro antagonist activities of <START=Pharmacologic Substance> antipsychotics <END=Pharmacologic Substance> at <START=Pharmacologic Substance> muscarinic <END=Pharmacologic Substance> M2 receptors and their in vivo potencies to increase <START=Pharmacologic Substance> acetylcholine <END=Pharmacologic Substance> release, suggests that olanzapine, clozapine, as well as thioridazine and chlorpromazine, increase <START=Pharmacologic Substance> acetylcholine <END=Pharmacologic Substance> release via <START=Pharmacologic Substance> blockade <END=Pharmacologic Substance> of terminal <START=Pharmacologic Substance> muscarinic <END=Pharmacologic Substance> M2 <START=Amino Acid, Peptide, or Protein> autoreceptors <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23493374, "id": 3, "text": "Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3). 5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [29, 38], "name": "bisulfite", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"ent_type": "CHEMICAL", "char_span": [81, 84], "name": "CpG", "tok_span": [14, 15], "new_tok_span": [16, 17]}, {"ent_type": "CHEMICAL", "char_span": [86, 92], "name": "(m)CpG", "tok_span": [16, 20], "new_tok_span": [18, 22]}, {"ent_type": "CHEMICAL", "char_span": [401, 408], "name": "(m)CpGs", "tok_span": [86, 91], "new_tok_span": [100, 105]}, {"ent_type": "GENE", "char_span": [108, 113], "name": "glut3", "tok_span": [24, 26], "new_tok_span": [27, 29]}, {"ent_type": "GENE", "char_span": [193, 218], "name": "DNA methyl transferase 3a", "tok_span": [46, 52], "new_tok_span": [52, 58]}, {"ent_type": "GENE", "char_span": [306, 311], "name": "glut3", "tok_span": [72, 74], "new_tok_span": [83, 85]}, {"ent_type": "GENE", "char_span": [417, 422], "name": "glut3", "tok_span": [92, 94], "new_tok_span": [107, 109]}], "relation_list": [{"subject": "CpG", "sbj_char_span": [81, 84], "object": "DNA methyl transferase 3a", "obj_char_span": [193, 218], "rel_type": "regulator", "sbj_tok_span": [14, 15], "obj_tok_span": [46, 52], "new_sbj_tok_span": [16, 17], "new_obj_tok_span": [52, 58]}, {"subject": "(m)CpG", "sbj_char_span": [86, 92], "object": "DNA methyl transferase 3a", "obj_char_span": [193, 218], "rel_type": "regulator", "sbj_tok_span": [16, 20], "obj_tok_span": [46, 52], "new_sbj_tok_span": [18, 22], "new_obj_tok_span": [52, 58]}, {"subject": "(m)CpGs", "sbj_char_span": [401, 408], "object": "glut3", "obj_char_span": [417, 422], "rel_type": "regulator", "sbj_tok_span": [86, 91], "obj_tok_span": [92, 94], "new_sbj_tok_span": [100, 105], "new_obj_tok_span": [107, 109]}], "umls_entity_list": [{"mention": "glut3", "char_span": [108, 113], "sem_type": "Gene or Genome", "tok_span": [24, 26], "new_tok_span": [27, 29]}, {"mention": "glut3", "char_span": [306, 311], "sem_type": "Gene or Genome", "tok_span": [72, 74], "new_tok_span": [83, 85]}, {"mention": "glut3", "char_span": [417, 422], "sem_type": "Gene or Genome", "tok_span": [92, 94], "new_tok_span": [107, 109]}, {"mention": "gene", "char_span": [114, 118], "sem_type": "Gene or Genome", "tok_span": [26, 27], "new_tok_span": [31, 32]}, {"mention": "bisulfite", "char_span": [29, 38], "sem_type": "Pharmacologic Substance", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"mention": "transferase", "char_span": [204, 215], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [48, 50], "new_tok_span": [55, 57]}, {"mention": "PN3", "char_span": [278, 281], "sem_type": "Gene or Genome", "tok_span": [62, 64], "new_tok_span": [71, 73]}, {"mention": "luciferase", "char_span": [312, 322], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [75, 76], "new_tok_span": [88, 89]}], "new_text": "Methylation - specific PCR and <START=Pharmacologic Substance> bisulfite <END=Pharmacologic Substance> sequencing identified methylation of this CpG ( ( m ) CpG ) island of the <START=Gene or Genome> glut3 <END=Gene or Genome> <START=Gene or Genome> gene <END=Gene or Genome>, frequency of methylation increasing 2. 5 - fold with a 1. 6 - fold increase in DNA methyl <START=Amino Acid, Peptide, or Protein> transferase <END=Amino Acid, Peptide, or Protein> 3a concentrations noted with advancing postnatal age ( PN14 vs <START=Gene or Genome> PN3 <END=Gene or Genome> ). 5'- flanking region of <START=Gene or Genome> glut3 <END=Gene or Genome> - <START=Amino Acid, Peptide, or Protein> luciferase <END=Amino Acid, Peptide, or Protein> reporter transient transfection in HT22 hippocampal neurons demonstrated that ( m ) CpGs inhibit <START=Gene or Genome> glut3 <END=Gene or Genome> transcription."}, {"PMID": 23300056, "id": 0, "text": "Determination of key receptor-ligand interactions of dopaminergic arylpiperazines and the dopamine D2 receptor homology model.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [66, 81], "name": "arylpiperazines", "tok_span": [9, 14], "new_tok_span": [13, 18]}, {"ent_type": "CHEMICAL", "char_span": [90, 98], "name": "dopamine", "tok_span": [16, 17], "new_tok_span": [22, 23]}, {"ent_type": "GENE", "char_span": [90, 110], "name": "dopamine D2 receptor", "tok_span": [16, 20], "new_tok_span": [22, 26]}], "relation_list": [{"subject": "arylpiperazines", "sbj_char_span": [66, 81], "object": "dopamine D2 receptor", "obj_char_span": [90, 110], "rel_type": "regulator", "sbj_tok_span": [9, 14], "obj_tok_span": [16, 20], "new_sbj_tok_span": [13, 18], "new_obj_tok_span": [22, 26]}], "umls_entity_list": [{"mention": "dopaminergic", "char_span": [53, 65], "sem_type": "Pharmacologic Substance", "tok_span": [8, 9], "new_tok_span": [10, 11]}, {"mention": "dopamine", "char_span": [53, 61], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [10, 11]}, {"mention": "dopamine", "char_span": [90, 98], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 17], "new_tok_span": [22, 23]}, {"mention": "homology", "char_span": [111, 119], "sem_type": "Gene or Genome", "tok_span": [20, 21], "new_tok_span": [29, 30]}, {"mention": "dopamine D2 receptor", "char_span": [90, 110], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 20], "new_tok_span": [22, 26]}], "new_text": "Determination of key receptor - ligand interactions of <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> dopaminergic <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> arylpiperazines and the <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> dopamine <END=Amino Acid, Peptide, or Protein> D2 receptor <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> homology <END=Gene or Genome> model."}, {"PMID": 18055877, "id": 3, "text": "Using primary human T-lymphocytes, we show that the heterocyclic thionamides carbimazole and propylthiouracil inhibit synthesis of the proinflammatory cytokines tumor necrosis factor (TNF)alpha and interferon (IFN)gamma.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [52, 76], "name": "heterocyclic thionamides", "tok_span": [11, 19], "new_tok_span": [11, 19]}, {"ent_type": "CHEMICAL", "char_span": [77, 88], "name": "carbimazole", "tok_span": [19, 23], "new_tok_span": [20, 24]}, {"ent_type": "CHEMICAL", "char_span": [93, 109], "name": "propylthiouracil", "tok_span": [24, 29], "new_tok_span": [26, 31]}, {"ent_type": "GENE", "char_span": [151, 160], "name": "cytokines", "tok_span": [34, 35], "new_tok_span": [37, 38]}, {"ent_type": "GENE", "char_span": [161, 193], "name": "tumor necrosis factor (TNF)alpha", "tok_span": [35, 42], "new_tok_span": [39, 46]}, {"ent_type": "GENE", "char_span": [198, 219], "name": "interferon (IFN)gamma", "tok_span": [43, 48], "new_tok_span": [50, 55]}], "relation_list": [{"subject": "heterocyclic thionamides", "sbj_char_span": [52, 76], "object": "cytokines", "obj_char_span": [151, 160], "rel_type": "regulator", "sbj_tok_span": [11, 19], "obj_tok_span": [34, 35], "new_sbj_tok_span": [11, 19], "new_obj_tok_span": [37, 38]}, {"subject": "carbimazole", "sbj_char_span": [77, 88], "object": "cytokines", "obj_char_span": [151, 160], "rel_type": "regulator", "sbj_tok_span": [19, 23], "obj_tok_span": [34, 35], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [37, 38]}, {"subject": "propylthiouracil", "sbj_char_span": [93, 109], "object": "cytokines", "obj_char_span": [151, 160], "rel_type": "regulator", "sbj_tok_span": [24, 29], "obj_tok_span": [34, 35], "new_sbj_tok_span": [26, 31], "new_obj_tok_span": [37, 38]}, {"subject": "heterocyclic thionamides", "sbj_char_span": [52, 76], "object": "tumor necrosis factor (TNF)alpha", "obj_char_span": [161, 193], "rel_type": "regulator", "sbj_tok_span": [11, 19], "obj_tok_span": [35, 42], "new_sbj_tok_span": [11, 19], "new_obj_tok_span": [39, 46]}, {"subject": "carbimazole", "sbj_char_span": [77, 88], "object": "tumor necrosis factor (TNF)alpha", "obj_char_span": [161, 193], "rel_type": "regulator", "sbj_tok_span": [19, 23], "obj_tok_span": [35, 42], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [39, 46]}, {"subject": "propylthiouracil", "sbj_char_span": [93, 109], "object": "tumor necrosis factor (TNF)alpha", "obj_char_span": [161, 193], "rel_type": "regulator", "sbj_tok_span": [24, 29], "obj_tok_span": [35, 42], "new_sbj_tok_span": [26, 31], "new_obj_tok_span": [39, 46]}, {"subject": "heterocyclic thionamides", "sbj_char_span": [52, 76], "object": "interferon (IFN)gamma", "obj_char_span": [198, 219], "rel_type": "regulator", "sbj_tok_span": [11, 19], "obj_tok_span": [43, 48], "new_sbj_tok_span": [11, 19], "new_obj_tok_span": [50, 55]}, {"subject": "carbimazole", "sbj_char_span": [77, 88], "object": "interferon (IFN)gamma", "obj_char_span": [198, 219], "rel_type": "regulator", "sbj_tok_span": [19, 23], "obj_tok_span": [43, 48], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [50, 55]}, {"subject": "propylthiouracil", "sbj_char_span": [93, 109], "object": "interferon (IFN)gamma", "obj_char_span": [198, 219], "rel_type": "regulator", "sbj_tok_span": [24, 29], "obj_tok_span": [43, 48], "new_sbj_tok_span": [26, 31], "new_obj_tok_span": [50, 55]}], "umls_entity_list": [{"mention": "carbimazole", "char_span": [77, 88], "sem_type": "Pharmacologic Substance", "tok_span": [19, 23], "new_tok_span": [20, 24]}, {"mention": "cytokines", "char_span": [151, 160], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 35], "new_tok_span": [37, 38]}, {"mention": "alpha", "char_span": [188, 193], "sem_type": "Pharmacologic Substance", "tok_span": [41, 42], "new_tok_span": [46, 47]}, {"mention": "interferon", "char_span": [198, 208], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [43, 44], "new_tok_span": [50, 51]}], "new_text": "Using primary human T - lymphocytes, we show that the heterocyclic thionamides <START=Pharmacologic Substance> carbimazole <END=Pharmacologic Substance> and propylthiouracil inhibit synthesis of the proinflammatory <START=Amino Acid, Peptide, or Protein> cytokines <END=Amino Acid, Peptide, or Protein> tumor necrosis factor ( TNF ) <START=Pharmacologic Substance> alpha <END=Pharmacologic Substance> and <START=Amino Acid, Peptide, or Protein> interferon <END=Amino Acid, Peptide, or Protein> ( IFN ) gamma."}, {"PMID": 23077105, "id": 0, "text": "Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [129, 137], "name": "estrogen", "tok_span": [26, 27], "new_tok_span": [36, 37]}, {"ent_type": "CHEMICAL", "char_span": [66, 82], "name": "ethynylestradiol", "tok_span": [11, 17], "new_tok_span": [18, 24]}, {"ent_type": "GENE", "char_span": [129, 146], "name": "estrogen receptor", "tok_span": [26, 28], "new_tok_span": [36, 38]}, {"ent_type": "GENE", "char_span": [21, 62], "name": "multidrug resistance-associated protein 3", "tok_span": [3, 10], "new_tok_span": [6, 13]}], "relation_list": [{"subject": "ethynylestradiol", "sbj_char_span": [66, 82], "object": "multidrug resistance-associated protein 3", "obj_char_span": [21, 62], "rel_type": "activator", "sbj_tok_span": [11, 17], "obj_tok_span": [3, 10], "new_sbj_tok_span": [18, 24], "new_obj_tok_span": [6, 13]}], "umls_entity_list": [{"mention": "multidrug", "char_span": [21, 30], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 5], "new_tok_span": [6, 8]}, {"mention": "multidrug resistance-associated protein 3", "char_span": [21, 62], "sem_type": "Gene or Genome", "tok_span": [3, 10], "new_tok_span": [6, 13]}, {"mention": "multidrug resistance-associated protein 3", "char_span": [21, 62], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 10], "new_tok_span": [6, 13]}, {"mention": "ethynylestradiol", "char_span": [66, 82], "sem_type": "Pharmacologic Substance", "tok_span": [11, 17], "new_tok_span": [18, 24]}, {"mention": "estrogen receptor", "char_span": [129, 146], "sem_type": "Gene or Genome", "tok_span": [26, 28], "new_tok_span": [36, 38]}, {"mention": "estrogen receptor", "char_span": [129, 146], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 28], "new_tok_span": [36, 38]}], "new_text": "Induction of hepatic <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> multidrug <END=Amino Acid, Peptide, or Protein> resistance - associated protein 3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> by <START=Pharmacologic Substance> ethynylestradiol <END=Pharmacologic Substance> is independent of cholestasis and mediated by <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> estrogen receptor <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23403272, "id": 0, "text": "Paeoniflorin protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/heme oxygenase-1 pathway.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Paeoniflorin", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"ent_type": "CHEMICAL", "char_span": [145, 149], "name": "heme", "tok_span": [33, 34], "new_tok_span": [44, 45]}, {"ent_type": "GENE", "char_span": [122, 144], "name": "NF-E2-related factor 2", "tok_span": [24, 32], "new_tok_span": [31, 39]}, {"ent_type": "GENE", "char_span": [145, 161], "name": "heme oxygenase-1", "tok_span": [33, 38], "new_tok_span": [44, 49]}], "relation_list": [{"subject": "Paeoniflorin", "sbj_char_span": [0, 12], "object": "NF-E2-related factor 2", "obj_char_span": [122, 144], "rel_type": "activator", "sbj_tok_span": [0, 5], "obj_tok_span": [24, 32], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [31, 39]}, {"subject": "Paeoniflorin", "sbj_char_span": [0, 12], "object": "heme oxygenase-1", "obj_char_span": [145, 161], "rel_type": "activator", "sbj_tok_span": [0, 5], "obj_tok_span": [33, 38], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [44, 49]}], "umls_entity_list": [{"mention": "Paeoniflorin", "char_span": [0, 12], "sem_type": "Pharmacologic Substance", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"mention": "EA", "char_span": [28, 30], "sem_type": "Pharmacologic Substance", "tok_span": [7, 8], "new_tok_span": [10, 11]}, {"mention": "NF-E2-related", "char_span": [122, 135], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 30], "new_tok_span": [31, 37]}, {"mention": "heme oxygenase-1", "char_span": [145, 161], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 38], "new_tok_span": [44, 49]}, {"mention": "NF-E2-related factor 2", "char_span": [122, 144], "sem_type": "Gene or Genome", "tok_span": [24, 32], "new_tok_span": [31, 39]}, {"mention": "NF-E2-related factor 2", "char_span": [122, 144], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 32], "new_tok_span": [31, 39]}], "new_text": "<START=Pharmacologic Substance> Paeoniflorin <END=Pharmacologic Substance> protects human <START=Pharmacologic Substance> EA <END=Pharmacologic Substance>. hy926 endothelial cells against gamma - radiation induced oxidative injury by activating the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NF - E2 - related <END=Amino Acid, Peptide, or Protein> factor 2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> / <START=Amino Acid, Peptide, or Protein> heme oxygenase - 1 <END=Amino Acid, Peptide, or Protein> pathway."}, {"PMID": 12927775, "id": 6, "text": "This led to the discovery of aliskiren, a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [29, 38], "name": "aliskiren", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"ent_type": "CHEMICAL", "char_span": [143, 152], "name": "aliskiren", "tok_span": [32, 35], "new_tok_span": [41, 44]}, {"ent_type": "CHEMICAL", "char_span": [195, 201], "name": "sodium", "tok_span": [42, 43], "new_tok_span": [58, 59]}, {"ent_type": "GENE", "char_span": [83, 94], "name": "human renin", "tok_span": [17, 19], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [161, 166], "name": "renin", "tok_span": [36, 37], "new_tok_span": [49, 50]}], "relation_list": [{"subject": "aliskiren", "sbj_char_span": [29, 38], "object": "human renin", "obj_char_span": [83, 94], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [17, 19], "new_sbj_tok_span": [7, 10], "new_obj_tok_span": [19, 21]}, {"subject": "aliskiren", "sbj_char_span": [143, 152], "object": "renin", "obj_char_span": [161, 166], "rel_type": "inhibitor", "sbj_tok_span": [32, 35], "obj_tok_span": [36, 37], "new_sbj_tok_span": [41, 44], "new_obj_tok_span": [49, 50]}], "umls_entity_list": [{"mention": "aliskiren", "char_span": [29, 38], "sem_type": "Pharmacologic Substance", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"mention": "aliskiren", "char_span": [143, 152], "sem_type": "Pharmacologic Substance", "tok_span": [32, 35], "new_tok_span": [41, 44]}, {"mention": "renin", "char_span": [89, 94], "sem_type": "Pharmacologic Substance", "tok_span": [18, 19], "new_tok_span": [23, 24]}, {"mention": "renin", "char_span": [161, 166], "sem_type": "Pharmacologic Substance", "tok_span": [36, 37], "new_tok_span": [49, 50]}, {"mention": "renin", "char_span": [89, 94], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 19], "new_tok_span": [23, 24]}, {"mention": "renin", "char_span": [161, 166], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 37], "new_tok_span": [49, 50]}, {"mention": "renin", "char_span": [89, 94], "sem_type": "Gene or Genome", "tok_span": [18, 19], "new_tok_span": [23, 24]}, {"mention": "renin", "char_span": [161, 166], "sem_type": "Gene or Genome", "tok_span": [36, 37], "new_tok_span": [49, 50]}], "new_text": "This led to the discovery of <START=Pharmacologic Substance> aliskiren <END=Pharmacologic Substance>, a highly potent and selective inhibitor of human <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> renin <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> in vitro, and in vivo ; once - daily oral doses of <START=Pharmacologic Substance> aliskiren <END=Pharmacologic Substance> inhibit <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> renin <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and lower blood pressure in sodium - depleted marmosets and hypertensive human patients."}, {"PMID": 9666414, "id": 3, "text": "Two mechanisms of action have been identified for A77 1726: inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of tyrosine kinases.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [50, 58], "name": "A77 1726", "tok_span": [8, 12], "new_tok_span": [9, 13]}, {"ent_type": "CHEMICAL", "char_span": [74, 88], "name": "dihydroorotate", "tok_span": [15, 20], "new_tok_span": [17, 22]}, {"ent_type": "CHEMICAL", "char_span": [129, 137], "name": "tyrosine", "tok_span": [29, 30], "new_tok_span": [31, 32]}, {"ent_type": "GENE", "char_span": [74, 102], "name": "dihydroorotate dehydrogenase", "tok_span": [15, 21], "new_tok_span": [17, 23]}, {"ent_type": "GENE", "char_span": [104, 109], "name": "DHODH", "tok_span": [22, 25], "new_tok_span": [24, 27]}, {"ent_type": "GENE", "char_span": [129, 145], "name": "tyrosine kinases", "tok_span": [29, 31], "new_tok_span": [31, 33]}], "relation_list": [{"subject": "A77 1726", "sbj_char_span": [50, 58], "object": "dihydroorotate dehydrogenase", "obj_char_span": [74, 102], "rel_type": "inhibitor", "sbj_tok_span": [8, 12], "obj_tok_span": [15, 21], "new_sbj_tok_span": [9, 13], "new_obj_tok_span": [17, 23]}, {"subject": "A77 1726", "sbj_char_span": [50, 58], "object": "tyrosine kinases", "obj_char_span": [129, 145], "rel_type": "inhibitor", "sbj_tok_span": [8, 12], "obj_tok_span": [29, 31], "new_sbj_tok_span": [9, 13], "new_obj_tok_span": [31, 33]}], "umls_entity_list": [{"mention": "A77 1726", "char_span": [50, 58], "sem_type": "Pharmacologic Substance", "tok_span": [8, 12], "new_tok_span": [9, 13]}], "new_text": "Two mechanisms of action have been identified for <START=Pharmacologic Substance> A77 1726 <END=Pharmacologic Substance> : inhibition of dihydroorotate dehydrogenase ( DHODH ) and inhibition of tyrosine kinases."}, {"PMID": 17408613, "id": 11, "text": "In conclusion, the present study demonstrates a hypophagic effect of the angiotensin AT(1) receptor antagonist irbesartan that cannot be attributed to sedation or antidipsic effects of the drug.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 84], "name": "angiotensin", "tok_span": [14, 15], "new_tok_span": [14, 15]}, {"ent_type": "CHEMICAL", "char_span": [111, 121], "name": "irbesartan", "tok_span": [21, 24], "new_tok_span": [22, 25]}, {"ent_type": "GENE", "char_span": [73, 99], "name": "angiotensin AT(1) receptor", "tok_span": [14, 20], "new_tok_span": [14, 20]}], "relation_list": [{"subject": "irbesartan", "sbj_char_span": [111, 121], "object": "angiotensin AT(1) receptor", "obj_char_span": [73, 99], "rel_type": "agonist or antagonist", "sbj_tok_span": [21, 24], "obj_tok_span": [14, 20], "new_sbj_tok_span": [22, 25], "new_obj_tok_span": [14, 20]}], "umls_entity_list": [{"mention": "irbesartan", "char_span": [111, 121], "sem_type": "Pharmacologic Substance", "tok_span": [21, 24], "new_tok_span": [22, 25]}], "new_text": "In conclusion, the present study demonstrates a hypophagic effect of the angiotensin AT ( 1 ) receptor antagonist <START=Pharmacologic Substance> irbesartan <END=Pharmacologic Substance> that cannot be attributed to sedation or antidipsic effects of the drug."}, {"PMID": 9843368, "id": 2, "text": "Here we present the crystal structure of the dimeric catalytic domain (residues 117-424) of human phenylalanine hydroxylase (hPheOH), cocrystallized with various potent and well-known catechol inhibitors and refined at a resolution of 2.0 A.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [98, 111], "name": "phenylalanine", "tok_span": [21, 23], "new_tok_span": [23, 25]}, {"ent_type": "CHEMICAL", "char_span": [184, 192], "name": "catechol", "tok_span": [41, 42], "new_tok_span": [47, 48]}, {"ent_type": "GENE", "char_span": [92, 123], "name": "human phenylalanine hydroxylase", "tok_span": [20, 25], "new_tok_span": [20, 25]}, {"ent_type": "GENE", "char_span": [125, 131], "name": "hPheOH", "tok_span": [26, 29], "new_tok_span": [30, 33]}], "relation_list": [{"subject": "catechol", "sbj_char_span": [184, 192], "object": "human phenylalanine hydroxylase", "obj_char_span": [92, 123], "rel_type": "inhibitor", "sbj_tok_span": [41, 42], "obj_tok_span": [20, 25], "new_sbj_tok_span": [47, 48], "new_obj_tok_span": [20, 25]}, {"subject": "catechol", "sbj_char_span": [184, 192], "object": "hPheOH", "obj_char_span": [125, 131], "rel_type": "inhibitor", "sbj_tok_span": [41, 42], "obj_tok_span": [26, 29], "new_sbj_tok_span": [47, 48], "new_obj_tok_span": [30, 33]}], "umls_entity_list": [{"mention": "phenylalanine", "char_span": [98, 111], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 23], "new_tok_span": [23, 25]}, {"mention": "phenylalanine hydroxylase", "char_span": [98, 123], "sem_type": "Gene or Genome", "tok_span": [21, 25], "new_tok_span": [23, 27]}, {"mention": "catechol", "char_span": [184, 192], "sem_type": "Organic Chemical", "tok_span": [41, 42], "new_tok_span": [47, 48]}, {"mention": "catechol", "char_span": [184, 192], "sem_type": "Pharmacologic Substance", "tok_span": [41, 42], "new_tok_span": [47, 48]}], "new_text": "Here we present the crystal structure of the dimeric catalytic domain ( residues 117 - 424 ) of human <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> phenylalanine <END=Amino Acid, Peptide, or Protein> hydroxylase <END=Gene or Genome> ( hPheOH ), cocrystallized with various potent and well - known <START=Organic Chemical> <START=Pharmacologic Substance> catechol <END=Organic Chemical> <END=Pharmacologic Substance> inhibitors and refined at a resolution of 2. 0 A."}, {"PMID": 15871445, "id": 0, "text": "Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [52, 61], "name": "celecoxib", "tok_span": [9, 13], "new_tok_span": [11, 15]}, {"ent_type": "GENE", "char_span": [26, 40], "name": "cyclooxygenase", "tok_span": [5, 7], "new_tok_span": [6, 8]}], "relation_list": [{"subject": "celecoxib", "sbj_char_span": [52, 61], "object": "cyclooxygenase", "obj_char_span": [26, 40], "rel_type": "inhibitor", "sbj_tok_span": [9, 13], "obj_tok_span": [5, 7], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [6, 8]}], "umls_entity_list": [{"mention": "cyclooxygenase inhibitor", "char_span": [26, 50], "sem_type": "Pharmacologic Substance", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"mention": "analgesic", "char_span": [80, 89], "sem_type": "Pharmacologic Substance", "tok_span": [17, 18], "new_tok_span": [20, 21]}], "new_text": "Tolerability of selective <START=Pharmacologic Substance> cyclooxygenase inhibitor <END=Pharmacologic Substance>, celecoxib, in patients with <START=Pharmacologic Substance> analgesic <END=Pharmacologic Substance> intolerance."}, {"PMID": 12085361, "id": 9, "text": "Direct transport of rifampicin could be shown for OATP-C (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L). In conclusion, these results show that rifamycin SV and rifampicin interact with OATP-mediated substrate transport to different extents.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [20, 30], "name": "rifampicin", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [160, 172], "name": "rifamycin SV", "tok_span": [48, 51], "new_tok_span": [58, 61]}, {"ent_type": "CHEMICAL", "char_span": [177, 187], "name": "rifampicin", "tok_span": [52, 55], "new_tok_span": [63, 66]}, {"ent_type": "GENE", "char_span": [50, 56], "name": "OATP-C", "tok_span": [10, 14], "new_tok_span": [14, 18]}, {"ent_type": "GENE", "char_span": [97, 102], "name": "OATP8", "tok_span": [28, 31], "new_tok_span": [36, 39]}, {"ent_type": "GENE", "char_span": [202, 206], "name": "OATP", "tok_span": [57, 59], "new_tok_span": [71, 73]}], "relation_list": [{"subject": "rifampicin", "sbj_char_span": [20, 30], "object": "OATP-C", "obj_char_span": [50, 56], "rel_type": "product or substrate", "sbj_tok_span": [3, 6], "obj_tok_span": [10, 14], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [14, 18]}, {"subject": "rifampicin", "sbj_char_span": [20, 30], "object": "OATP8", "obj_char_span": [97, 102], "rel_type": "product or substrate", "sbj_tok_span": [3, 6], "obj_tok_span": [28, 31], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [36, 39]}], "umls_entity_list": [{"mention": "rifampicin", "char_span": [20, 30], "sem_type": "Organic Chemical", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "rifampicin", "char_span": [177, 187], "sem_type": "Organic Chemical", "tok_span": [52, 55], "new_tok_span": [63, 66]}, {"mention": "OATP", "char_span": [50, 54], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 12], "new_tok_span": [14, 16]}, {"mention": "OATP", "char_span": [97, 101], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 30], "new_tok_span": [36, 38]}, {"mention": "OATP", "char_span": [202, 206], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [57, 59], "new_tok_span": [71, 73]}, {"mention": "OATP", "char_span": [50, 54], "sem_type": "Gene or Genome", "tok_span": [10, 12], "new_tok_span": [14, 16]}, {"mention": "OATP", "char_span": [97, 101], "sem_type": "Gene or Genome", "tok_span": [28, 30], "new_tok_span": [36, 38]}, {"mention": "OATP", "char_span": [202, 206], "sem_type": "Gene or Genome", "tok_span": [57, 59], "new_tok_span": [71, 73]}], "new_text": "Direct transport of <START=Organic Chemical> rifampicin <END=Organic Chemical> could be shown for <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> OATP <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - C ( apparent K ( m ) value 13 micromol / L ) and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> OATP <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>8 ( 2. 3 micromol / L ). In conclusion, these results show that rifamycin SV and <START=Organic Chemical> rifampicin <END=Organic Chemical> interact with <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> OATP <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - mediated substrate transport to different extents."}, {"PMID": 3139361, "id": 5, "text": "For the cytosolic progesterone receptor, the same order is found with the exception that similar RBAs are found for gestodene and 3-keto-desogestrel.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 30], "name": "progesterone", "tok_span": [3, 4], "new_tok_span": [8, 9]}, {"ent_type": "CHEMICAL", "char_span": [116, 125], "name": "gestodene", "tok_span": [21, 24], "new_tok_span": [30, 33]}, {"ent_type": "CHEMICAL", "char_span": [130, 148], "name": "3-keto-desogestrel", "tok_span": [25, 34], "new_tok_span": [35, 44]}, {"ent_type": "GENE", "char_span": [18, 39], "name": "progesterone receptor", "tok_span": [3, 5], "new_tok_span": [8, 10]}], "relation_list": [{"subject": "gestodene", "sbj_char_span": [116, 125], "object": "progesterone receptor", "obj_char_span": [18, 39], "rel_type": "regulator", "sbj_tok_span": [21, 24], "obj_tok_span": [3, 5], "new_sbj_tok_span": [30, 33], "new_obj_tok_span": [8, 10]}, {"subject": "3-keto-desogestrel", "sbj_char_span": [130, 148], "object": "progesterone receptor", "obj_char_span": [18, 39], "rel_type": "regulator", "sbj_tok_span": [25, 34], "obj_tok_span": [3, 5], "new_sbj_tok_span": [35, 44], "new_obj_tok_span": [8, 10]}], "umls_entity_list": [{"mention": "cytosolic", "char_span": [8, 17], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"mention": "progesterone", "char_span": [18, 30], "sem_type": "Pharmacologic Substance", "tok_span": [3, 4], "new_tok_span": [8, 9]}, {"mention": "progesterone receptor", "char_span": [18, 39], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 5], "new_tok_span": [8, 10]}, {"mention": "progesterone receptor", "char_span": [18, 39], "sem_type": "Gene or Genome", "tok_span": [3, 5], "new_tok_span": [8, 10]}, {"mention": "gestodene", "char_span": [116, 125], "sem_type": "Pharmacologic Substance", "tok_span": [21, 24], "new_tok_span": [30, 33]}], "new_text": "For the <START=Amino Acid, Peptide, or Protein> cytosolic <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> progesterone <END=Pharmacologic Substance> receptor <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, the same order is found with the exception that similar RBAs are found for <START=Pharmacologic Substance> gestodene <END=Pharmacologic Substance> and 3 - keto - desogestrel."}, {"PMID": 15563582, "id": 1, "text": "In addition to PGD2, CRTH2 can be activated by indomethacin, a nonselective cyclooxygenase inhibitor and widely used nonsteroidal anti-inflammatory drug (NSAID). To evaluate the structural features that confer CRTH2 binding selectivity, structure-activity relationship analysis of arylacetic acid class NSAIDs as CRTH2 receptor ligands was performed.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [15, 19], "name": "PGD2", "tok_span": [3, 6], "new_tok_span": [3, 6]}, {"ent_type": "CHEMICAL", "char_span": [47, 59], "name": "indomethacin", "tok_span": [14, 17], "new_tok_span": [17, 20]}, {"ent_type": "CHEMICAL", "char_span": [281, 296], "name": "arylacetic acid", "tok_span": [59, 62], "new_tok_span": [67, 70]}, {"ent_type": "GENE", "char_span": [21, 26], "name": "CRTH2", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [76, 90], "name": "cyclooxygenase", "tok_span": [22, 24], "new_tok_span": [27, 29]}, {"ent_type": "GENE", "char_span": [210, 215], "name": "CRTH2", "tok_span": [47, 50], "new_tok_span": [54, 57]}, {"ent_type": "GENE", "char_span": [313, 318], "name": "CRTH2", "tok_span": [66, 69], "new_tok_span": [77, 80]}], "relation_list": [{"subject": "PGD2", "sbj_char_span": [15, 19], "object": "CRTH2", "obj_char_span": [21, 26], "rel_type": "activator", "sbj_tok_span": [3, 6], "obj_tok_span": [7, 10], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [8, 11]}, {"subject": "indomethacin", "sbj_char_span": [47, 59], "object": "CRTH2", "obj_char_span": [21, 26], "rel_type": "activator", "sbj_tok_span": [14, 17], "obj_tok_span": [7, 10], "new_sbj_tok_span": [17, 20], "new_obj_tok_span": [8, 11]}, {"subject": "indomethacin", "sbj_char_span": [47, 59], "object": "cyclooxygenase", "obj_char_span": [76, 90], "rel_type": "inhibitor", "sbj_tok_span": [14, 17], "obj_tok_span": [22, 24], "new_sbj_tok_span": [17, 20], "new_obj_tok_span": [27, 29]}], "umls_entity_list": [{"mention": "indomethacin", "char_span": [47, 59], "sem_type": "Pharmacologic Substance", "tok_span": [14, 17], "new_tok_span": [17, 20]}, {"mention": "cyclooxygenase inhibitor", "char_span": [76, 100], "sem_type": "Pharmacologic Substance", "tok_span": [22, 25], "new_tok_span": [27, 30]}, {"mention": "CRTH2", "char_span": [21, 26], "sem_type": "Gene or Genome", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "CRTH2", "char_span": [210, 215], "sem_type": "Gene or Genome", "tok_span": [47, 50], "new_tok_span": [54, 57]}, {"mention": "CRTH2", "char_span": [313, 318], "sem_type": "Gene or Genome", "tok_span": [66, 69], "new_tok_span": [77, 80]}, {"mention": "NSAIDs", "char_span": [303, 309], "sem_type": "Pharmacologic Substance", "tok_span": [63, 65], "new_tok_span": [72, 74]}], "new_text": "In addition to PGD2, <START=Gene or Genome> CRTH2 <END=Gene or Genome> can be activated by <START=Pharmacologic Substance> indomethacin <END=Pharmacologic Substance>, a nonselective <START=Pharmacologic Substance> cyclooxygenase inhibitor <END=Pharmacologic Substance> and widely used nonsteroidal anti - inflammatory drug ( NSAID ). To evaluate the structural features that confer <START=Gene or Genome> CRTH2 <END=Gene or Genome> binding selectivity, structure - activity relationship analysis of arylacetic acid class <START=Pharmacologic Substance> NSAIDs <END=Pharmacologic Substance> as <START=Gene or Genome> CRTH2 <END=Gene or Genome> receptor ligands was performed."}, {"PMID": 11153163, "id": 10, "text": "COX-1 was more inhibited by indomethacin and piroxicam and COX-2 by 6-MNA (active metabolite of nabumetone), diclofenac and ibuprofen.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 40], "name": "indomethacin", "tok_span": [7, 10], "new_tok_span": [7, 10]}, {"ent_type": "CHEMICAL", "char_span": [45, 54], "name": "piroxicam", "tok_span": [11, 15], "new_tok_span": [11, 15]}, {"ent_type": "CHEMICAL", "char_span": [68, 73], "name": "6-MNA", "tok_span": [20, 24], "new_tok_span": [20, 24]}, {"ent_type": "CHEMICAL", "char_span": [96, 106], "name": "nabumetone", "tok_span": [28, 32], "new_tok_span": [29, 33]}, {"ent_type": "CHEMICAL", "char_span": [109, 119], "name": "diclofenac", "tok_span": [34, 38], "new_tok_span": [36, 40]}, {"ent_type": "CHEMICAL", "char_span": [124, 133], "name": "ibuprofen", "tok_span": [39, 43], "new_tok_span": [41, 45]}, {"ent_type": "GENE", "char_span": [0, 5], "name": "COX-1", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "GENE", "char_span": [59, 64], "name": "COX-2", "tok_span": [16, 19], "new_tok_span": [16, 19]}], "relation_list": [{"subject": "indomethacin", "sbj_char_span": [28, 40], "object": "COX-1", "obj_char_span": [0, 5], "rel_type": "inhibitor", "sbj_tok_span": [7, 10], "obj_tok_span": [0, 3], "new_sbj_tok_span": [7, 10], "new_obj_tok_span": [0, 3]}, {"subject": "piroxicam", "sbj_char_span": [45, 54], "object": "COX-1", "obj_char_span": [0, 5], "rel_type": "inhibitor", "sbj_tok_span": [11, 15], "obj_tok_span": [0, 3], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [0, 3]}, {"subject": "6-MNA", "sbj_char_span": [68, 73], "object": "COX-2", "obj_char_span": [59, 64], "rel_type": "inhibitor", "sbj_tok_span": [20, 24], "obj_tok_span": [16, 19], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [16, 19]}, {"subject": "nabumetone", "sbj_char_span": [96, 106], "object": "COX-2", "obj_char_span": [59, 64], "rel_type": "inhibitor", "sbj_tok_span": [28, 32], "obj_tok_span": [16, 19], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [16, 19]}, {"subject": "diclofenac", "sbj_char_span": [109, 119], "object": "COX-2", "obj_char_span": [59, 64], "rel_type": "inhibitor", "sbj_tok_span": [34, 38], "obj_tok_span": [16, 19], "new_sbj_tok_span": [36, 40], "new_obj_tok_span": [16, 19]}, {"subject": "ibuprofen", "sbj_char_span": [124, 133], "object": "COX-2", "obj_char_span": [59, 64], "rel_type": "inhibitor", "sbj_tok_span": [39, 43], "obj_tok_span": [16, 19], "new_sbj_tok_span": [41, 45], "new_obj_tok_span": [16, 19]}], "umls_entity_list": [{"mention": "nabumetone", "char_span": [96, 106], "sem_type": "Pharmacologic Substance", "tok_span": [28, 32], "new_tok_span": [29, 33]}], "new_text": "COX - 1 was more inhibited by indomethacin and piroxicam and COX - 2 by 6 - MNA ( active metabolite of <START=Pharmacologic Substance> nabumetone <END=Pharmacologic Substance> ), diclofenac and ibuprofen."}, {"PMID": 22634360, "id": 5, "text": "Thus, in order to examine the anatomical substrates and physiological effects of group III mGluRs activation upon striatal and pallidal neurons in monkeys, we used electron microscopy immunohistochemistry to localize mGluR4, combined with local administration of the group III mGluR agonist L-AP4, or the mGluR4 positive allosteric modulator VU0155041, to assess the effects of group III mGluR activation on the firing rate and pattern of striatal and pallidal neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated parkinsonian monkeys.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [472, 516], "name": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "tok_span": [99, 119], "new_tok_span": [113, 133]}, {"ent_type": "CHEMICAL", "char_span": [518, 522], "name": "MPTP", "tok_span": [120, 122], "new_tok_span": [134, 136]}, {"ent_type": "CHEMICAL", "char_span": [291, 296], "name": "L-AP4", "tok_span": [53, 57], "new_tok_span": [57, 61]}, {"ent_type": "CHEMICAL", "char_span": [342, 351], "name": "VU0155041", "tok_span": [69, 74], "new_tok_span": [82, 87]}, {"ent_type": "GENE", "char_span": [217, 223], "name": "mGluR4", "tok_span": [36, 40], "new_tok_span": [38, 42]}, {"ent_type": "GENE", "char_span": [267, 282], "name": "group III mGluR", "tok_span": [47, 52], "new_tok_span": [51, 56]}, {"ent_type": "GENE", "char_span": [305, 311], "name": "mGluR4", "tok_span": [60, 64], "new_tok_span": [70, 74]}, {"ent_type": "GENE", "char_span": [378, 393], "name": "group III mGluR", "tok_span": [80, 85], "new_tok_span": [94, 99]}], "relation_list": [{"subject": "L-AP4", "sbj_char_span": [291, 296], "object": "group III mGluR", "obj_char_span": [267, 282], "rel_type": "agonist or antagonist", "sbj_tok_span": [53, 57], "obj_tok_span": [47, 52], "new_sbj_tok_span": [57, 61], "new_obj_tok_span": [51, 56]}], "umls_entity_list": [{"mention": "mGluR4", "char_span": [217, 223], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 40], "new_tok_span": [38, 42]}, {"mention": "mGluR4", "char_span": [305, 311], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [60, 64], "new_tok_span": [70, 74]}, {"mention": "mGluR4", "char_span": [217, 223], "sem_type": "Gene or Genome", "tok_span": [36, 40], "new_tok_span": [38, 42]}, {"mention": "mGluR4", "char_span": [305, 311], "sem_type": "Gene or Genome", "tok_span": [60, 64], "new_tok_span": [70, 74]}, {"mention": "AP4", "char_span": [293, 296], "sem_type": "Pharmacologic Substance", "tok_span": [55, 57], "new_tok_span": [61, 63]}, {"mention": "AP4", "char_span": [293, 296], "sem_type": "Gene or Genome", "tok_span": [55, 57], "new_tok_span": [61, 63]}, {"mention": "VU0155041", "char_span": [342, 351], "sem_type": "Organic Chemical", "tok_span": [69, 74], "new_tok_span": [82, 87]}], "new_text": "Thus, in order to examine the anatomical substrates and physiological effects of group III mGluRs activation upon striatal and pallidal neurons in monkeys, we used electron microscopy immunohistochemistry to localize <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> mGluR4 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, combined with local administration of the group III mGluR agonist L - <START=Pharmacologic Substance> <START=Gene or Genome> AP4 <END=Pharmacologic Substance> <END=Gene or Genome>, or the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> mGluR4 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> positive allosteric modulator <START=Organic Chemical> VU0155041 <END=Organic Chemical>, to assess the effects of group III mGluR activation on the firing rate and pattern of striatal and pallidal neurons in 1 - methyl - 4 - phenyl - 1, 2, 3, 6 - tetrahydropyridine ( MPTP ) - treated parkinsonian monkeys."}, {"PMID": 15562257, "id": 9, "text": "When selectively applied to channels after inducing slow inactivation with a 60-s pulse to -10 mV, mibefradil (1 microM) produced 45% fractional block in Nav1.5 and greater block (88%) in an isoform (Nav1.4) that slow-inactivates more completely.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [99, 109], "name": "mibefradil", "tok_span": [20, 25], "new_tok_span": [20, 25]}, {"ent_type": "GENE", "char_span": [154, 160], "name": "Nav1.5", "tok_span": [36, 40], "new_tok_span": [37, 41]}, {"ent_type": "GENE", "char_span": [200, 206], "name": "Nav1.4", "tok_span": [51, 55], "new_tok_span": [53, 57]}], "relation_list": [{"subject": "mibefradil", "sbj_char_span": [99, 109], "object": "Nav1.5", "obj_char_span": [154, 160], "rel_type": "inhibitor", "sbj_tok_span": [20, 25], "obj_tok_span": [36, 40], "new_sbj_tok_span": [20, 25], "new_obj_tok_span": [37, 41]}, {"subject": "mibefradil", "sbj_char_span": [99, 109], "object": "Nav1.4", "obj_char_span": [200, 206], "rel_type": "inhibitor", "sbj_tok_span": [20, 25], "obj_tok_span": [51, 55], "new_sbj_tok_span": [20, 25], "new_obj_tok_span": [53, 57]}], "umls_entity_list": [{"mention": "Nav1.5", "char_span": [154, 160], "sem_type": "Gene or Genome", "tok_span": [36, 40], "new_tok_span": [37, 41]}], "new_text": "When selectively applied to channels after inducing slow inactivation with a 60 - s pulse to - 10 mV, mibefradil ( 1 microM ) produced 45 % fractional block in <START=Gene or Genome> Nav1. 5 <END=Gene or Genome> and greater block ( 88 % ) in an isoform ( Nav1. 4 ) that slow - inactivates more completely."}, {"PMID": 15899831, "id": 0, "text": "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 7], "name": "AZD2171", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [93, 101], "name": "tyrosine", "tok_span": [20, 21], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [47, 92], "name": "vascular endothelial growth factor receptor-2", "tok_span": [13, 20], "new_tok_span": [13, 20]}, {"ent_type": "GENE", "char_span": [93, 108], "name": "tyrosine kinase", "tok_span": [20, 22], "new_tok_span": [20, 22]}], "relation_list": [{"subject": "AZD2171", "sbj_char_span": [0, 7], "object": "vascular endothelial growth factor receptor-2", "obj_char_span": [47, 92], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 20], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [13, 20]}, {"subject": "AZD2171", "sbj_char_span": [0, 7], "object": "tyrosine kinase", "obj_char_span": [93, 108], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [20, 22], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [20, 22]}], "umls_entity_list": [], "new_text": "AZD2171 : a highly potent, orally bioavailable, vascular endothelial growth factor receptor - 2 tyrosine kinase inhibitor for the treatment of cancer."}, {"PMID": 23643752, "id": 9, "text": "As seen with phagocytotic microglia, the CB2 antagonist, AM630, increased Iba-1 positive microglia in the absence of URB597 treatment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [57, 62], "name": "AM630", "tok_span": [13, 16], "new_tok_span": [13, 16]}, {"ent_type": "CHEMICAL", "char_span": [117, 123], "name": "URB597", "tok_span": [28, 32], "new_tok_span": [29, 33]}, {"ent_type": "GENE", "char_span": [41, 44], "name": "CB2", "tok_span": [9, 11], "new_tok_span": [9, 11]}, {"ent_type": "GENE", "char_span": [74, 79], "name": "Iba-1", "tok_span": [18, 22], "new_tok_span": [18, 22]}], "relation_list": [{"subject": "AM630", "sbj_char_span": [57, 62], "object": "CB2", "obj_char_span": [41, 44], "rel_type": "agonist or antagonist", "sbj_tok_span": [13, 16], "obj_tok_span": [9, 11], "new_sbj_tok_span": [13, 16], "new_obj_tok_span": [9, 11]}, {"subject": "AM630", "sbj_char_span": [57, 62], "object": "Iba-1", "obj_char_span": [74, 79], "rel_type": "regulator", "sbj_tok_span": [13, 16], "obj_tok_span": [18, 22], "new_sbj_tok_span": [13, 16], "new_obj_tok_span": [18, 22]}], "umls_entity_list": [{"mention": "URB597", "char_span": [117, 123], "sem_type": "Organic Chemical", "tok_span": [28, 32], "new_tok_span": [29, 33]}], "new_text": "As seen with phagocytotic microglia, the CB2 antagonist, AM630, increased Iba - 1 positive microglia in the absence of <START=Organic Chemical> URB597 <END=Organic Chemical> treatment."}, {"PMID": 18593927, "id": 9, "text": "The direct inhibition of stathmin by CCNU is likely a contributing factor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [37, 41], "name": "CCNU", "tok_span": [8, 11], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [25, 33], "name": "stathmin", "tok_span": [4, 7], "new_tok_span": [6, 9]}], "relation_list": [{"subject": "CCNU", "sbj_char_span": [37, 41], "object": "stathmin", "obj_char_span": [25, 33], "rel_type": "inhibitor", "sbj_tok_span": [8, 11], "obj_tok_span": [4, 7], "new_sbj_tok_span": [14, 17], "new_obj_tok_span": [6, 9]}], "umls_entity_list": [{"mention": "stathmin", "char_span": [25, 33], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 7], "new_tok_span": [6, 9]}, {"mention": "stathmin", "char_span": [25, 33], "sem_type": "Gene or Genome", "tok_span": [4, 7], "new_tok_span": [6, 9]}, {"mention": "CCNU", "char_span": [37, 41], "sem_type": "Pharmacologic Substance", "tok_span": [8, 11], "new_tok_span": [14, 17]}, {"mention": "CCNU", "char_span": [37, 41], "sem_type": "Gene or Genome", "tok_span": [8, 11], "new_tok_span": [14, 17]}], "new_text": "The direct inhibition of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> stathmin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> by <START=Pharmacologic Substance> <START=Gene or Genome> CCNU <END=Pharmacologic Substance> <END=Gene or Genome> is likely a contributing factor."}, {"PMID": 12697717, "id": 13, "text": "All-trans-retinoic acid did not affect 17 beta HSDXI expression or activity, but addition of the retinoid together with cAMP significantly decreased activity over cAMP alone (32% vs. 23%, P < 0.05).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 23], "name": "All-trans-retinoic acid", "tok_span": [0, 7], "new_tok_span": [0, 7]}, {"ent_type": "CHEMICAL", "char_span": [97, 105], "name": "retinoid", "tok_span": [24, 26], "new_tok_span": [25, 27]}, {"ent_type": "CHEMICAL", "char_span": [120, 124], "name": "cAMP", "tok_span": [28, 29], "new_tok_span": [30, 31]}, {"ent_type": "CHEMICAL", "char_span": [163, 167], "name": "cAMP", "tok_span": [33, 34], "new_tok_span": [35, 36]}, {"ent_type": "GENE", "char_span": [39, 52], "name": "17 beta HSDXI", "tok_span": [10, 16], "new_tok_span": [10, 16]}], "relation_list": [{"subject": "retinoid", "sbj_char_span": [97, 105], "object": "17 beta HSDXI", "obj_char_span": [39, 52], "rel_type": "inhibitor", "sbj_tok_span": [24, 26], "obj_tok_span": [10, 16], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [10, 16]}, {"subject": "cAMP", "sbj_char_span": [120, 124], "object": "17 beta HSDXI", "obj_char_span": [39, 52], "rel_type": "inhibitor", "sbj_tok_span": [28, 29], "obj_tok_span": [10, 16], "new_sbj_tok_span": [30, 31], "new_obj_tok_span": [10, 16]}, {"subject": "cAMP", "sbj_char_span": [163, 167], "object": "17 beta HSDXI", "obj_char_span": [39, 52], "rel_type": "inhibitor", "sbj_tok_span": [33, 34], "obj_tok_span": [10, 16], "new_sbj_tok_span": [35, 36], "new_obj_tok_span": [10, 16]}], "umls_entity_list": [{"mention": "retinoid", "char_span": [97, 105], "sem_type": "Pharmacologic Substance", "tok_span": [24, 26], "new_tok_span": [25, 27]}], "new_text": "All - trans - retinoic acid did not affect 17 beta HSDXI expression or activity, but addition of the <START=Pharmacologic Substance> retinoid <END=Pharmacologic Substance> together with cAMP significantly decreased activity over cAMP alone ( 32 % vs. 23 %, P < 0. 05 )."}, {"PMID": 12137927, "id": 4, "text": "Chronic treatment with the NET inhibitor, desipramine (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 53], "name": "desipramine", "tok_span": [7, 11], "new_tok_span": [13, 17]}, {"ent_type": "CHEMICAL", "char_span": [133, 135], "name": "NE", "tok_span": [33, 34], "new_tok_span": [52, 53]}, {"ent_type": "GENE", "char_span": [27, 30], "name": "NET", "tok_span": [4, 5], "new_tok_span": [7, 8]}, {"ent_type": "GENE", "char_span": [69, 72], "name": "NET", "tok_span": [17, 18], "new_tok_span": [30, 31]}, {"ent_type": "GENE", "char_span": [100, 103], "name": "Dbh", "tok_span": [23, 26], "new_tok_span": [40, 43]}, {"ent_type": "GENE", "char_span": [174, 177], "name": "NET", "tok_span": [41, 42], "new_tok_span": [64, 65]}], "relation_list": [{"subject": "desipramine", "sbj_char_span": [42, 53], "object": "NET", "obj_char_span": [27, 30], "rel_type": "inhibitor", "sbj_tok_span": [7, 11], "obj_tok_span": [4, 5], "new_sbj_tok_span": [13, 17], "new_obj_tok_span": [7, 8]}, {"subject": "desipramine", "sbj_char_span": [42, 53], "object": "NET", "obj_char_span": [69, 72], "rel_type": "regulator", "sbj_tok_span": [7, 11], "obj_tok_span": [17, 18], "new_sbj_tok_span": [13, 17], "new_obj_tok_span": [30, 31]}], "umls_entity_list": [{"mention": "NET", "char_span": [27, 30], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 5], "new_tok_span": [7, 8]}, {"mention": "NET", "char_span": [69, 72], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 18], "new_tok_span": [30, 31]}, {"mention": "NET", "char_span": [174, 177], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 42], "new_tok_span": [64, 65]}, {"mention": "NET", "char_span": [27, 30], "sem_type": "Gene or Genome", "tok_span": [4, 5], "new_tok_span": [7, 8]}, {"mention": "NET", "char_span": [69, 72], "sem_type": "Gene or Genome", "tok_span": [17, 18], "new_tok_span": [30, 31]}, {"mention": "NET", "char_span": [174, 177], "sem_type": "Gene or Genome", "tok_span": [41, 42], "new_tok_span": [64, 65]}, {"mention": "DMI", "char_span": [55, 58], "sem_type": "Pharmacologic Substance", "tok_span": [12, 14], "new_tok_span": [21, 23]}, {"mention": "Dbh", "char_span": [100, 103], "sem_type": "Gene or Genome", "tok_span": [23, 26], "new_tok_span": [40, 43]}, {"mention": "NE", "char_span": [27, 29], "sem_type": "Gene or Genome", "tok_span": [4, 5], "new_tok_span": [7, 8]}, {"mention": "ne", "char_span": [51, 53], "sem_type": "Gene or Genome", "tok_span": [10, 11], "new_tok_span": [17, 18]}, {"mention": "NE", "char_span": [69, 71], "sem_type": "Gene or Genome", "tok_span": [17, 18], "new_tok_span": [30, 31]}, {"mention": "NE", "char_span": [133, 135], "sem_type": "Gene or Genome", "tok_span": [33, 34], "new_tok_span": [52, 53]}, {"mention": "NE", "char_span": [174, 176], "sem_type": "Gene or Genome", "tok_span": [41, 42], "new_tok_span": [64, 65]}, {"mention": "antidepressant drugs", "char_span": [181, 201], "sem_type": "Pharmacologic Substance", "tok_span": [43, 45], "new_tok_span": [70, 72]}], "new_text": "Chronic treatment with the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Gene or Genome> NET <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Gene or Genome> inhibitor, desipram <START=Gene or Genome>ine <END=Gene or Genome> ( <START=Pharmacologic Substance> DMI <END=Pharmacologic Substance> ), reduced <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Gene or Genome> NET <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Gene or Genome> levels in both control and <START=Gene or Genome> Dbh <END=Gene or Genome> - / - mice, demonstrating that <START=Gene or Genome> NE <END=Gene or Genome> is not required for the regulation of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Gene or Genome> NET <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Gene or Genome> by <START=Pharmacologic Substance> antidepressant drugs <END=Pharmacologic Substance>."}, {"PMID": 23394555, "id": 1, "text": "Thymidylate kinase (TMPK) is a key enzyme for pyrimidine synthesis that catalyzes the phosphorylation of thymidine 5'-monophosphate (dTMP) in the presence of ATP and Mg(2+) to form thymidine 5'-diphosphate (dTDP), which is then converted to thymidine 5'-triphosphate (dTTP) by nucleoside-diphosphate kinase (NDK). TMPK has an important function in cell proliferation and its enzyme kinetics and related structures have been determined in various organisms.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Thymidylate", "tok_span": [0, 4], "new_tok_span": [2, 6]}, {"ent_type": "CHEMICAL", "char_span": [105, 131], "name": "thymidine 5'-monophosphate", "tok_span": [24, 34], "new_tok_span": [28, 38]}, {"ent_type": "CHEMICAL", "char_span": [133, 137], "name": "dTMP", "tok_span": [35, 37], "new_tok_span": [39, 41]}, {"ent_type": "CHEMICAL", "char_span": [158, 161], "name": "ATP", "tok_span": [42, 43], "new_tok_span": [46, 47]}, {"ent_type": "CHEMICAL", "char_span": [166, 172], "name": "Mg(2+)", "tok_span": [44, 49], "new_tok_span": [48, 53]}, {"ent_type": "CHEMICAL", "char_span": [181, 205], "name": "thymidine 5'-diphosphate", "tok_span": [51, 58], "new_tok_span": [55, 62]}, {"ent_type": "CHEMICAL", "char_span": [207, 211], "name": "dTDP", "tok_span": [59, 61], "new_tok_span": [63, 65]}, {"ent_type": "CHEMICAL", "char_span": [241, 266], "name": "thymidine 5'-triphosphate", "tok_span": [68, 78], "new_tok_span": [72, 82]}, {"ent_type": "CHEMICAL", "char_span": [268, 272], "name": "dTTP", "tok_span": [79, 81], "new_tok_span": [83, 85]}, {"ent_type": "CHEMICAL", "char_span": [277, 299], "name": "nucleoside-diphosphate", "tok_span": [83, 88], "new_tok_span": [89, 94]}, {"ent_type": "CHEMICAL", "char_span": [46, 56], "name": "pyrimidine", "tok_span": [14, 17], "new_tok_span": [18, 21]}, {"ent_type": "GENE", "char_span": [0, 18], "name": "Thymidylate kinase", "tok_span": [0, 5], "new_tok_span": [2, 7]}, {"ent_type": "GENE", "char_span": [20, 24], "name": "TMPK", "tok_span": [6, 8], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [314, 318], "name": "TMPK", "tok_span": [94, 96], "new_tok_span": [102, 104]}], "relation_list": [{"subject": "pyrimidine", "sbj_char_span": [46, 56], "object": "Thymidylate kinase", "obj_char_span": [0, 18], "rel_type": "product or substrate", "sbj_tok_span": [14, 17], "obj_tok_span": [0, 5], "new_sbj_tok_span": [18, 21], "new_obj_tok_span": [2, 7]}, {"subject": "pyrimidine", "sbj_char_span": [46, 56], "object": "TMPK", "obj_char_span": [20, 24], "rel_type": "product or substrate", "sbj_tok_span": [14, 17], "obj_tok_span": [6, 8], "new_sbj_tok_span": [18, 21], "new_obj_tok_span": [10, 12]}, {"subject": "thymidine 5'-monophosphate", "sbj_char_span": [105, 131], "object": "Thymidylate kinase", "obj_char_span": [0, 18], "rel_type": "product or substrate", "sbj_tok_span": [24, 34], "obj_tok_span": [0, 5], "new_sbj_tok_span": [28, 38], "new_obj_tok_span": [2, 7]}, {"subject": "dTMP", "sbj_char_span": [133, 137], "object": "Thymidylate kinase", "obj_char_span": [0, 18], "rel_type": "product or substrate", "sbj_tok_span": [35, 37], "obj_tok_span": [0, 5], "new_sbj_tok_span": [39, 41], "new_obj_tok_span": [2, 7]}, {"subject": "thymidine 5'-monophosphate", "sbj_char_span": [105, 131], "object": "TMPK", "obj_char_span": [20, 24], "rel_type": "product or substrate", "sbj_tok_span": [24, 34], "obj_tok_span": [6, 8], "new_sbj_tok_span": [28, 38], "new_obj_tok_span": [10, 12]}, {"subject": "dTMP", "sbj_char_span": [133, 137], "object": "TMPK", "obj_char_span": [20, 24], "rel_type": "product or substrate", "sbj_tok_span": [35, 37], "obj_tok_span": [6, 8], "new_sbj_tok_span": [39, 41], "new_obj_tok_span": [10, 12]}, {"subject": "thymidine 5'-diphosphate", "sbj_char_span": [181, 205], "object": "Thymidylate kinase", "obj_char_span": [0, 18], "rel_type": "product or substrate", "sbj_tok_span": [51, 58], "obj_tok_span": [0, 5], "new_sbj_tok_span": [55, 62], "new_obj_tok_span": [2, 7]}, {"subject": "thymidine 5'-diphosphate", "sbj_char_span": [181, 205], "object": "TMPK", "obj_char_span": [20, 24], "rel_type": "product or substrate", "sbj_tok_span": [51, 58], "obj_tok_span": [6, 8], "new_sbj_tok_span": [55, 62], "new_obj_tok_span": [10, 12]}, {"subject": "dTDP", "sbj_char_span": [207, 211], "object": "Thymidylate kinase", "obj_char_span": [0, 18], "rel_type": "product or substrate", "sbj_tok_span": [59, 61], "obj_tok_span": [0, 5], "new_sbj_tok_span": [63, 65], "new_obj_tok_span": [2, 7]}, {"subject": "dTDP", "sbj_char_span": [207, 211], "object": "TMPK", "obj_char_span": [20, 24], "rel_type": "product or substrate", "sbj_tok_span": [59, 61], "obj_tok_span": [6, 8], "new_sbj_tok_span": [63, 65], "new_obj_tok_span": [10, 12]}], "umls_entity_list": [{"mention": "Thymidylate", "char_span": [0, 11], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 4], "new_tok_span": [2, 6]}, {"mention": "Thymidylate kinase", "char_span": [0, 18], "sem_type": "Gene or Genome", "tok_span": [0, 5], "new_tok_span": [2, 7]}, {"mention": "nucleoside-diphosphate kinase", "char_span": [277, 306], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [83, 89], "new_tok_span": [89, 95]}, {"mention": "nucleoside-diphosphate kinase", "char_span": [277, 306], "sem_type": "Gene or Genome", "tok_span": [83, 89], "new_tok_span": [89, 95]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Thymidylate <END=Amino Acid, Peptide, or Protein> kinase <END=Gene or Genome> ( TMPK ) is a key enzyme for pyrimidine synthesis that catalyzes the phosphorylation of thymidine 5'- monophosphate ( dTMP ) in the presence of ATP and Mg ( 2 + ) to form thymidine 5'- diphosphate ( dTDP ), which is then converted to thymidine 5'- triphosphate ( dTTP ) by <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> nucleoside - diphosphate kinase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( NDK ). TMPK has an important function in cell proliferation and its enzyme kinetics and related structures have been determined in various organisms."}, {"PMID": 23473803, "id": 0, "text": "Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [45, 54], "name": "moexipril", "tok_span": [9, 13], "new_tok_span": [10, 14]}, {"ent_type": "CHEMICAL", "char_span": [79, 83], "name": "cAMP", "tok_span": [18, 19], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [105, 109], "name": "PDE4", "tok_span": [26, 28], "new_tok_span": [28, 30]}, {"ent_type": "GENE", "char_span": [79, 103], "name": "cAMP phosphodiesterase-4", "tok_span": [18, 25], "new_tok_span": [20, 27]}], "relation_list": [{"subject": "moexipril", "sbj_char_span": [45, 54], "object": "cAMP phosphodiesterase-4", "obj_char_span": [79, 103], "rel_type": "inhibitor", "sbj_tok_span": [9, 13], "obj_tok_span": [18, 25], "new_sbj_tok_span": [10, 14], "new_obj_tok_span": [20, 27]}, {"subject": "moexipril", "sbj_char_span": [45, 54], "object": "PDE4", "obj_char_span": [105, 109], "rel_type": "inhibitor", "sbj_tok_span": [9, 13], "obj_tok_span": [26, 28], "new_sbj_tok_span": [10, 14], "new_obj_tok_span": [28, 30]}], "umls_entity_list": [{"mention": "moexipril", "char_span": [45, 54], "sem_type": "Pharmacologic Substance", "tok_span": [9, 13], "new_tok_span": [10, 14]}], "new_text": "Chemical informatics uncovers a new role for <START=Pharmacologic Substance> moexipril <END=Pharmacologic Substance> as a novel inhibitor of cAMP phosphodiesterase - 4 ( PDE4 )."}, {"PMID": 14720519, "id": 2, "text": "The EGFR has been recently described to play a transduction role of uPAR stimuli, mediating uPA-induced proliferation in highly malignant cells that overexpress uPAR. In the present work, we found for the first time that uPAR stimulation with the amino-terminal fragment (ATF) of urokinase devoid of proteolytic activity transactivates the EGFR in mammary MCF-7 cells through a mechanism involving Src and a metalloproteinase, as indicated by its sensitivity to selected inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [247, 252], "name": "amino", "tok_span": [49, 50], "new_tok_span": [65, 66]}, {"ent_type": "GENE", "char_span": [4, 8], "name": "EGFR", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"ent_type": "GENE", "char_span": [68, 72], "name": "uPAR", "tok_span": [12, 14], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [92, 95], "name": "uPA", "tok_span": [17, 19], "new_tok_span": [24, 26]}, {"ent_type": "GENE", "char_span": [161, 165], "name": "uPAR", "tok_span": [29, 31], "new_tok_span": [39, 41]}, {"ent_type": "GENE", "char_span": [221, 225], "name": "uPAR", "tok_span": [44, 46], "new_tok_span": [58, 60]}, {"ent_type": "GENE", "char_span": [280, 289], "name": "urokinase", "tok_span": [58, 60], "new_tok_span": [76, 78]}, {"ent_type": "GENE", "char_span": [340, 344], "name": "EGFR", "tok_span": [69, 70], "new_tok_span": [90, 91]}, {"ent_type": "GENE", "char_span": [398, 401], "name": "Src", "tok_span": [80, 81], "new_tok_span": [102, 103]}, {"ent_type": "GENE", "char_span": [408, 425], "name": "metalloproteinase", "tok_span": [83, 85], "new_tok_span": [106, 108]}], "relation_list": [{"subject": "amino", "sbj_char_span": [247, 252], "object": "urokinase", "obj_char_span": [280, 289], "rel_type": "part of", "sbj_tok_span": [49, 50], "obj_tok_span": [58, 60], "new_sbj_tok_span": [65, 66], "new_obj_tok_span": [76, 78]}], "umls_entity_list": [{"mention": "uPAR", "char_span": [68, 72], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 14], "new_tok_span": [16, 18]}, {"mention": "uPAR", "char_span": [161, 165], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 31], "new_tok_span": [39, 41]}, {"mention": "uPAR", "char_span": [221, 225], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [44, 46], "new_tok_span": [58, 60]}, {"mention": "urokinase", "char_span": [280, 289], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [58, 60], "new_tok_span": [76, 78]}, {"mention": "uPA", "char_span": [68, 71], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 14], "new_tok_span": [16, 18]}, {"mention": "uPA", "char_span": [92, 95], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 19], "new_tok_span": [24, 26]}, {"mention": "uPA", "char_span": [161, 164], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 31], "new_tok_span": [39, 41]}, {"mention": "uPA", "char_span": [221, 224], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [44, 46], "new_tok_span": [58, 60]}, {"mention": "urokinase", "char_span": [280, 289], "sem_type": "Gene or Genome", "tok_span": [58, 60], "new_tok_span": [76, 78]}, {"mention": "EGFR", "char_span": [4, 8], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"mention": "EGFR", "char_span": [340, 344], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [69, 70], "new_tok_span": [90, 91]}, {"mention": "metalloproteinase", "char_span": [408, 425], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [83, 85], "new_tok_span": [106, 108]}], "new_text": "The <START=Amino Acid, Peptide, or Protein> EGFR <END=Amino Acid, Peptide, or Protein> has been recently described to play a transduction role of <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> uPAR <END=Amino Acid, Peptide, or Protein> <END=Amino Acid, Peptide, or Protein> stimuli, mediating <START=Amino Acid, Peptide, or Protein> uPA <END=Amino Acid, Peptide, or Protein> - induced proliferation in highly malignant cells that overexpress <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> uPAR <END=Amino Acid, Peptide, or Protein> <END=Amino Acid, Peptide, or Protein>. In the present work, we found for the first time that <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> uPAR <END=Amino Acid, Peptide, or Protein> <END=Amino Acid, Peptide, or Protein> stimulation with the amino - terminal fragment ( ATF ) of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> urokinase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> devoid of proteolytic activity transactivates the <START=Amino Acid, Peptide, or Protein> EGFR <END=Amino Acid, Peptide, or Protein> in mammary MCF - 7 cells through a mechanism involving Src and a <START=Amino Acid, Peptide, or Protein> metalloproteinase <END=Amino Acid, Peptide, or Protein>, as indicated by its sensitivity to selected inhibitors."}, {"PMID": 23628333, "id": 1, "text": "A novel 2-thio-6-oxo-1,6-dihydropyrimidine-containing inhibitor of human lactate dehydrogenase (LDH) was identified by high-throughput screening (IC50=8.1μM). Biochemical, surface plasmon resonance, and saturation transfer difference NMR experiments indicated that the compound specifically associated with human LDHA in a manner that required simultaneous binding of the NADH co-factor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [372, 376], "name": "NADH", "tok_span": [80, 81], "new_tok_span": [92, 93]}, {"ent_type": "CHEMICAL", "char_span": [73, 80], "name": "lactate", "tok_span": [26, 27], "new_tok_span": [32, 33]}, {"ent_type": "CHEMICAL", "char_span": [8, 42], "name": "2-thio-6-oxo-1,6-dihydropyrimidine", "tok_span": [2, 21], "new_tok_span": [2, 21]}, {"ent_type": "GENE", "char_span": [307, 317], "name": "human LDHA", "tok_span": [68, 71], "new_tok_span": [76, 79]}, {"ent_type": "GENE", "char_span": [67, 94], "name": "human lactate dehydrogenase", "tok_span": [25, 28], "new_tok_span": [31, 34]}, {"ent_type": "GENE", "char_span": [96, 99], "name": "LDH", "tok_span": [29, 30], "new_tok_span": [35, 36]}], "relation_list": [{"subject": "2-thio-6-oxo-1,6-dihydropyrimidine", "sbj_char_span": [8, 42], "object": "human lactate dehydrogenase", "obj_char_span": [67, 94], "rel_type": "inhibitor", "sbj_tok_span": [2, 21], "obj_tok_span": [25, 28], "new_sbj_tok_span": [2, 21], "new_obj_tok_span": [31, 34]}, {"subject": "2-thio-6-oxo-1,6-dihydropyrimidine", "sbj_char_span": [8, 42], "object": "LDH", "obj_char_span": [96, 99], "rel_type": "inhibitor", "sbj_tok_span": [2, 21], "obj_tok_span": [29, 30], "new_sbj_tok_span": [2, 21], "new_obj_tok_span": [35, 36]}, {"subject": "NADH", "sbj_char_span": [372, 376], "object": "human LDHA", "obj_char_span": [307, 317], "rel_type": "regulator", "sbj_tok_span": [80, 81], "obj_tok_span": [68, 71], "new_sbj_tok_span": [92, 93], "new_obj_tok_span": [76, 79]}], "umls_entity_list": [{"mention": "thio", "char_span": [10, 14], "sem_type": "Gene or Genome", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"mention": "oxo", "char_span": [17, 20], "sem_type": "Pharmacologic Substance", "tok_span": [9, 11], "new_tok_span": [12, 14]}, {"mention": "LDHA", "char_span": [313, 317], "sem_type": "Gene or Genome", "tok_span": [69, 71], "new_tok_span": [79, 81]}, {"mention": "LDHA", "char_span": [313, 317], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [69, 71], "new_tok_span": [79, 81]}, {"mention": "co", "char_span": [43, 45], "sem_type": "Gene or Genome", "tok_span": [22, 23], "new_tok_span": [27, 28]}, {"mention": "co", "char_span": [269, 271], "sem_type": "Gene or Genome", "tok_span": [64, 65], "new_tok_span": [71, 72]}, {"mention": "co", "char_span": [377, 379], "sem_type": "Gene or Genome", "tok_span": [81, 82], "new_tok_span": [94, 95]}], "new_text": "A novel 2 - <START=Gene or Genome> thio <END=Gene or Genome> - 6 - <START=Pharmacologic Substance> oxo <END=Pharmacologic Substance> - 1, 6 - dihydropyrimidine - <START=Gene or Genome> containing <END=Gene or Genome> inhibitor of human lactate dehydrogenase ( LDH ) was identified by high - throughput screening ( IC50 = 8. 1μM ). Biochemical, surface plasmon resonance, and saturation transfer difference NMR experiments indicated that the <START=Gene or Genome> compound <END=Gene or Genome> specifically associated with human <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> LDHA <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> in a manner that required simultaneous binding of the NADH <START=Gene or Genome> co <END=Gene or Genome> - factor."}, {"PMID": 16897483, "id": 6, "text": "Cm-ADH1 has strong preference for NAPDH as a co-factor, whereas Cm-ADH2 preferentially uses NADH. Both Cm-ADH proteins are much more active as reductases with K (m)s 10-20 times lower for the conversion of aldehydes to alcohols than for the dehydrogenation of alcohols to aldehydes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [34, 39], "name": "NAPDH", "tok_span": [9, 12], "new_tok_span": [11, 14]}, {"ent_type": "CHEMICAL", "char_span": [92, 96], "name": "NADH", "tok_span": [26, 27], "new_tok_span": [36, 37]}, {"ent_type": "CHEMICAL", "char_span": [206, 215], "name": "aldehydes", "tok_span": [56, 60], "new_tok_span": [77, 81]}, {"ent_type": "CHEMICAL", "char_span": [219, 227], "name": "alcohols", "tok_span": [61, 63], "new_tok_span": [85, 87]}, {"ent_type": "CHEMICAL", "char_span": [260, 268], "name": "alcohols", "tok_span": [69, 71], "new_tok_span": [97, 99]}, {"ent_type": "CHEMICAL", "char_span": [272, 281], "name": "aldehydes", "tok_span": [72, 76], "new_tok_span": [103, 107]}, {"ent_type": "GENE", "char_span": [0, 7], "name": "Cm-ADH1", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "GENE", "char_span": [64, 71], "name": "Cm-ADH2", "tok_span": [19, 24], "new_tok_span": [23, 28]}, {"ent_type": "GENE", "char_span": [103, 109], "name": "Cm-ADH", "tok_span": [29, 33], "new_tok_span": [41, 45]}], "relation_list": [{"subject": "alcohols", "sbj_char_span": [260, 268], "object": "Cm-ADH", "obj_char_span": [103, 109], "rel_type": "product or substrate", "sbj_tok_span": [69, 71], "obj_tok_span": [29, 33], "new_sbj_tok_span": [97, 99], "new_obj_tok_span": [41, 45]}, {"subject": "aldehydes", "sbj_char_span": [272, 281], "object": "Cm-ADH", "obj_char_span": [103, 109], "rel_type": "product or substrate", "sbj_tok_span": [72, 76], "obj_tok_span": [29, 33], "new_sbj_tok_span": [103, 107], "new_obj_tok_span": [41, 45]}], "umls_entity_list": [{"mention": "co", "char_span": [45, 47], "sem_type": "Gene or Genome", "tok_span": [14, 15], "new_tok_span": [17, 18]}, {"mention": "co", "char_span": [192, 194], "sem_type": "Gene or Genome", "tok_span": [54, 55], "new_tok_span": [73, 74]}, {"mention": "co", "char_span": [221, 223], "sem_type": "Gene or Genome", "tok_span": [61, 62], "new_tok_span": [85, 86]}, {"mention": "co", "char_span": [262, 264], "sem_type": "Gene or Genome", "tok_span": [69, 70], "new_tok_span": [97, 98]}, {"mention": "ADH2", "char_span": [67, 71], "sem_type": "Gene or Genome", "tok_span": [21, 24], "new_tok_span": [27, 30]}, {"mention": "NADH", "char_span": [92, 96], "sem_type": "Pharmacologic Substance", "tok_span": [26, 27], "new_tok_span": [36, 37]}, {"mention": "ADH", "char_span": [3, 6], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"mention": "ADH", "char_span": [67, 70], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 23], "new_tok_span": [27, 29]}, {"mention": "ADH", "char_span": [93, 96], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 27], "new_tok_span": [36, 37]}, {"mention": "ADH", "char_span": [106, 109], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [31, 33], "new_tok_span": [44, 46]}, {"mention": "proteins", "char_span": [110, 118], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 34], "new_tok_span": [48, 49]}, {"mention": "reductases", "char_span": [143, 153], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 41], "new_tok_span": [56, 58]}, {"mention": "aldehydes", "char_span": [206, 215], "sem_type": "Organic Chemical", "tok_span": [56, 60], "new_tok_span": [77, 81]}, {"mention": "aldehydes", "char_span": [272, 281], "sem_type": "Organic Chemical", "tok_span": [72, 76], "new_tok_span": [103, 107]}, {"mention": "alcohols", "char_span": [219, 227], "sem_type": "Pharmacologic Substance", "tok_span": [61, 63], "new_tok_span": [85, 87]}, {"mention": "alcohols", "char_span": [260, 268], "sem_type": "Pharmacologic Substance", "tok_span": [69, 71], "new_tok_span": [97, 99]}], "new_text": "Cm - <START=Amino Acid, Peptide, or Protein> ADH <END=Amino Acid, Peptide, or Protein>1 has strong preference for NAPDH as a <START=Gene or Genome> co <END=Gene or Genome> - factor, whereas Cm - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ADH <END=Amino Acid, Peptide, or Protein>2 <END=Gene or Genome> preferentially uses <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> NADH <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein>. Both Cm - <START=Amino Acid, Peptide, or Protein> ADH <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> proteins <END=Amino Acid, Peptide, or Protein> are much more active as <START=Amino Acid, Peptide, or Protein> reductases <END=Amino Acid, Peptide, or Protein> with K ( m ) s 10 - 20 times lower for the <START=Gene or Genome> conversion <END=Gene or Genome> of <START=Organic Chemical> aldehydes <END=Organic Chemical> to <START=Gene or Genome> <START=Pharmacologic Substance> alcohol <END=Gene or Genome>s <END=Pharmacologic Substance> than for the dehydrogenation of <START=Gene or Genome> <START=Pharmacologic Substance> alcohol <END=Gene or Genome>s <END=Pharmacologic Substance> to <START=Organic Chemical> aldehydes <END=Organic Chemical>."}, {"PMID": 17561443, "id": 8, "text": "Though T3 exerted a positive stimulatory effect on glucose-6-phosphate dehydrogenase, it was not sufficient to compensate for massive glutathione depletion and impaired activities of GPx-1, GR and GST, disturbing the cellular redox status in the process.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [134, 145], "name": "glutathione", "tok_span": [25, 26], "new_tok_span": [30, 31]}, {"ent_type": "CHEMICAL", "char_span": [7, 9], "name": "T3", "tok_span": [1, 3], "new_tok_span": [1, 3]}, {"ent_type": "CHEMICAL", "char_span": [51, 70], "name": "glucose-6-phosphate", "tok_span": [10, 15], "new_tok_span": [12, 17]}, {"ent_type": "GENE", "char_span": [183, 188], "name": "GPx-1", "tok_span": [31, 35], "new_tok_span": [38, 42]}, {"ent_type": "GENE", "char_span": [190, 192], "name": "GR", "tok_span": [36, 37], "new_tok_span": [44, 45]}, {"ent_type": "GENE", "char_span": [197, 200], "name": "GST", "tok_span": [38, 39], "new_tok_span": [46, 47]}, {"ent_type": "GENE", "char_span": [51, 84], "name": "glucose-6-phosphate dehydrogenase", "tok_span": [10, 16], "new_tok_span": [12, 18]}], "relation_list": [{"subject": "T3", "sbj_char_span": [7, 9], "object": "glucose-6-phosphate dehydrogenase", "obj_char_span": [51, 84], "rel_type": "activator", "sbj_tok_span": [1, 3], "obj_tok_span": [10, 16], "new_sbj_tok_span": [1, 3], "new_obj_tok_span": [12, 18]}], "umls_entity_list": [{"mention": "glucose-6-phosphate dehydrogenase", "char_span": [51, 84], "sem_type": "Gene or Genome", "tok_span": [10, 16], "new_tok_span": [12, 18]}, {"mention": "glucose-6-phosphate dehydrogenase", "char_span": [51, 84], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 16], "new_tok_span": [12, 18]}, {"mention": "glutathion", "char_span": [134, 144], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 26], "new_tok_span": [30, 31]}, {"mention": "GPx-1", "char_span": [183, 188], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [31, 35], "new_tok_span": [38, 42]}], "new_text": "Though T3 exerted a positive stimulatory effect on <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> glucose - 6 - phosphate dehydrogenase <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, it was not sufficient to compensate for massive <START=Amino Acid, Peptide, or Protein> glutathione <END=Amino Acid, Peptide, or Protein> depletion and impaired activities of <START=Amino Acid, Peptide, or Protein> GPx - 1 <END=Amino Acid, Peptide, or Protein>, GR and GST, disturbing the cellular redox status in the process."}, {"PMID": 11330337, "id": 10, "text": "However, fasciculin-2, a potent peptide inhibitor of acetylcholinesterase (IC50 24 nM), did prevent catabolism of acetylcholine in rat brain membranes with an atypical inhibition isotherm of [3H]-oxotremorine-M binding, thus permitting an estimation of the \"global affinity\" of acetylcholine (Ki 85 nM) for [3H]-oxotremorine-M-labelled muscarinic receptors in rat brain.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [114, 127], "name": "acetylcholine", "tok_span": [28, 29], "new_tok_span": [33, 34]}, {"ent_type": "CHEMICAL", "char_span": [191, 210], "name": "[3H]-oxotremorine-M", "tok_span": [40, 52], "new_tok_span": [46, 58]}, {"ent_type": "CHEMICAL", "char_span": [278, 291], "name": "acetylcholine", "tok_span": [66, 67], "new_tok_span": [75, 76]}, {"ent_type": "CHEMICAL", "char_span": [307, 326], "name": "[3H]-oxotremorine-M", "tok_span": [73, 85], "new_tok_span": [85, 97]}, {"ent_type": "GENE", "char_span": [53, 73], "name": "acetylcholinesterase", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [336, 356], "name": "muscarinic receptors", "tok_span": [87, 91], "new_tok_span": [102, 106]}], "relation_list": [{"subject": "[3H]-oxotremorine-M", "sbj_char_span": [307, 326], "object": "muscarinic receptors", "obj_char_span": [336, 356], "rel_type": "regulator", "sbj_tok_span": [73, 85], "obj_tok_span": [87, 91], "new_sbj_tok_span": [85, 97], "new_obj_tok_span": [102, 106]}, {"subject": "[3H]-oxotremorine-M", "sbj_char_span": [191, 210], "object": "muscarinic receptors", "obj_char_span": [336, 356], "rel_type": "regulator", "sbj_tok_span": [40, 52], "obj_tok_span": [87, 91], "new_sbj_tok_span": [46, 58], "new_obj_tok_span": [102, 106]}], "umls_entity_list": [{"mention": "fasciculin", "char_span": [9, 19], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"mention": "acetylcholine", "char_span": [53, 66], "sem_type": "Pharmacologic Substance", "tok_span": [13, 14], "new_tok_span": [16, 17]}, {"mention": "acetylcholine", "char_span": [114, 127], "sem_type": "Pharmacologic Substance", "tok_span": [28, 29], "new_tok_span": [33, 34]}, {"mention": "acetylcholine", "char_span": [278, 291], "sem_type": "Pharmacologic Substance", "tok_span": [66, 67], "new_tok_span": [75, 76]}, {"mention": "Ki", "char_span": [293, 295], "sem_type": "Pharmacologic Substance", "tok_span": [68, 69], "new_tok_span": [79, 80]}, {"mention": "oxotremorine", "char_span": [196, 208], "sem_type": "Pharmacologic Substance", "tok_span": [45, 50], "new_tok_span": [52, 57]}, {"mention": "oxotremorine", "char_span": [312, 324], "sem_type": "Pharmacologic Substance", "tok_span": [78, 83], "new_tok_span": [91, 96]}, {"mention": "muscarinic receptors", "char_span": [336, 356], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [87, 91], "new_tok_span": [102, 106]}], "new_text": "However, <START=Amino Acid, Peptide, or Protein> fasciculin <END=Amino Acid, Peptide, or Protein> - 2, a potent peptide inhibitor of <START=Pharmacologic Substance> acetylcholine <END=Pharmacologic Substance>sterase ( IC50 24 nM ), did prevent catabolism of <START=Pharmacologic Substance> acetylcholine <END=Pharmacologic Substance> in rat brain membranes with an atypical inhibition isotherm of [ 3H ] - <START=Pharmacologic Substance> oxotremorine <END=Pharmacologic Substance> - M binding, thus permitting an estimation of the \" global affinity \" of <START=Pharmacologic Substance> acetylcholine <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> Ki <END=Pharmacologic Substance> 85 nM ) for [ 3H ] - <START=Pharmacologic Substance> oxotremorine <END=Pharmacologic Substance> - M - labelled <START=Amino Acid, Peptide, or Protein> muscarinic receptors <END=Amino Acid, Peptide, or Protein> in rat brain."}, {"PMID": 12713596, "id": 0, "text": "Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [25, 38], "name": "prostaglandin", "tok_span": [9, 10], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [0, 16], "name": "Cyclooxygenase-1", "tok_span": [0, 7], "new_tok_span": [1, 8]}], "relation_list": [{"subject": "prostaglandin", "sbj_char_span": [25, 38], "object": "Cyclooxygenase-1", "obj_char_span": [0, 16], "rel_type": "product or substrate", "sbj_tok_span": [9, 10], "obj_tok_span": [0, 7], "new_sbj_tok_span": [11, 12], "new_obj_tok_span": [1, 8]}], "umls_entity_list": [{"mention": "Cyclooxygenase-1", "char_span": [0, 16], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 7], "new_tok_span": [1, 8]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Cyclooxygenase - 1 <END=Amino Acid, Peptide, or Protein> - coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair."}, {"PMID": 17537429, "id": 0, "text": "Participation of glucose transporters on atrial natriuretic peptide-induced glucose uptake by adult and neonatal cardiomyocytes under oxygenation and hypoxia.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [17, 24], "name": "glucose", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"ent_type": "CHEMICAL", "char_span": [76, 83], "name": "glucose", "tok_span": [13, 14], "new_tok_span": [18, 19]}, {"ent_type": "GENE", "char_span": [17, 37], "name": "glucose transporters", "tok_span": [3, 5], "new_tok_span": [4, 6]}], "relation_list": [{"subject": "glucose", "sbj_char_span": [76, 83], "object": "glucose transporters", "obj_char_span": [17, 37], "rel_type": "product or substrate", "sbj_tok_span": [13, 14], "obj_tok_span": [3, 5], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [4, 6]}], "umls_entity_list": [{"mention": "glucose", "char_span": [17, 24], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"mention": "glucose", "char_span": [76, 83], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 14], "new_tok_span": [18, 19]}, {"mention": "atrial natriuretic peptide", "char_span": [41, 67], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 11], "new_tok_span": [9, 14]}], "new_text": "Participation of <START=Amino Acid, Peptide, or Protein> glucose <END=Amino Acid, Peptide, or Protein> transporters on <START=Amino Acid, Peptide, or Protein> atrial natriuretic peptide <END=Amino Acid, Peptide, or Protein> - induced <START=Amino Acid, Peptide, or Protein> glucose <END=Amino Acid, Peptide, or Protein> uptake by adult and neonatal cardiomyocytes under oxygenation and hypoxia."}, {"PMID": 11092898, "id": 8, "text": "A strong shift in TCA affinity (IC(50)) was also observed for double mutants F316C/D336T (35-fold) and S399P/G400L (80-fold for nortriptyline and 1000-fold for desipramine).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [128, 141], "name": "nortriptyline", "tok_span": [46, 50], "new_tok_span": [47, 51]}, {"ent_type": "CHEMICAL", "char_span": [160, 171], "name": "desipramine", "tok_span": [55, 59], "new_tok_span": [57, 61]}, {"ent_type": "GENE", "char_span": [77, 82], "name": "F316C", "tok_span": [18, 22], "new_tok_span": [18, 22]}, {"ent_type": "GENE", "char_span": [83, 88], "name": "D336T", "tok_span": [23, 27], "new_tok_span": [23, 27]}, {"ent_type": "GENE", "char_span": [103, 108], "name": "S399P", "tok_span": [33, 37], "new_tok_span": [33, 37]}, {"ent_type": "GENE", "char_span": [109, 114], "name": "G400L", "tok_span": [38, 41], "new_tok_span": [38, 41]}], "relation_list": [{"subject": "nortriptyline", "sbj_char_span": [128, 141], "object": "F316C", "obj_char_span": [77, 82], "rel_type": "regulator", "sbj_tok_span": [46, 50], "obj_tok_span": [18, 22], "new_sbj_tok_span": [47, 51], "new_obj_tok_span": [18, 22]}, {"subject": "nortriptyline", "sbj_char_span": [128, 141], "object": "D336T", "obj_char_span": [83, 88], "rel_type": "regulator", "sbj_tok_span": [46, 50], "obj_tok_span": [23, 27], "new_sbj_tok_span": [47, 51], "new_obj_tok_span": [23, 27]}, {"subject": "nortriptyline", "sbj_char_span": [128, 141], "object": "S399P", "obj_char_span": [103, 108], "rel_type": "regulator", "sbj_tok_span": [46, 50], "obj_tok_span": [33, 37], "new_sbj_tok_span": [47, 51], "new_obj_tok_span": [33, 37]}, {"subject": "nortriptyline", "sbj_char_span": [128, 141], "object": "G400L", "obj_char_span": [109, 114], "rel_type": "regulator", "sbj_tok_span": [46, 50], "obj_tok_span": [38, 41], "new_sbj_tok_span": [47, 51], "new_obj_tok_span": [38, 41]}, {"subject": "desipramine", "sbj_char_span": [160, 171], "object": "F316C", "obj_char_span": [77, 82], "rel_type": "regulator", "sbj_tok_span": [55, 59], "obj_tok_span": [18, 22], "new_sbj_tok_span": [57, 61], "new_obj_tok_span": [18, 22]}, {"subject": "desipramine", "sbj_char_span": [160, 171], "object": "D336T", "obj_char_span": [83, 88], "rel_type": "regulator", "sbj_tok_span": [55, 59], "obj_tok_span": [23, 27], "new_sbj_tok_span": [57, 61], "new_obj_tok_span": [23, 27]}, {"subject": "desipramine", "sbj_char_span": [160, 171], "object": "S399P", "obj_char_span": [103, 108], "rel_type": "regulator", "sbj_tok_span": [55, 59], "obj_tok_span": [33, 37], "new_sbj_tok_span": [57, 61], "new_obj_tok_span": [33, 37]}, {"subject": "desipramine", "sbj_char_span": [160, 171], "object": "G400L", "obj_char_span": [109, 114], "rel_type": "regulator", "sbj_tok_span": [55, 59], "obj_tok_span": [38, 41], "new_sbj_tok_span": [57, 61], "new_obj_tok_span": [38, 41]}], "umls_entity_list": [{"mention": "nortriptyline", "char_span": [128, 141], "sem_type": "Pharmacologic Substance", "tok_span": [46, 50], "new_tok_span": [47, 51]}], "new_text": "A strong shift in TCA affinity ( IC ( 50 ) ) was also observed for double mutants F316C / D336T ( 35 - fold ) and S399P / G400L ( 80 - fold for <START=Pharmacologic Substance> nortriptyline <END=Pharmacologic Substance> and 1000 - fold for desipramine )."}, {"PMID": 17015480, "id": 12, "text": "Finally, TReP-132 gene expression levels increased following progesterone treatment, indicating the existence of a positive auto-regulatory loop between PR and TReP-132.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [61, 73], "name": "progesterone", "tok_span": [12, 13], "new_tok_span": [14, 15]}, {"ent_type": "GENE", "char_span": [9, 17], "name": "TReP-132", "tok_span": [2, 7], "new_tok_span": [3, 8]}, {"ent_type": "GENE", "char_span": [153, 155], "name": "PR", "tok_span": [26, 27], "new_tok_span": [28, 29]}, {"ent_type": "GENE", "char_span": [160, 168], "name": "TReP-132", "tok_span": [28, 33], "new_tok_span": [31, 36]}], "relation_list": [{"subject": "progesterone", "sbj_char_span": [61, 73], "object": "TReP-132", "obj_char_span": [9, 17], "rel_type": "regulator", "sbj_tok_span": [12, 13], "obj_tok_span": [2, 7], "new_sbj_tok_span": [14, 15], "new_obj_tok_span": [3, 8]}], "umls_entity_list": [{"mention": "TReP-132", "char_span": [9, 17], "sem_type": "Gene or Genome", "tok_span": [2, 7], "new_tok_span": [3, 8]}, {"mention": "TReP-132", "char_span": [160, 168], "sem_type": "Gene or Genome", "tok_span": [28, 33], "new_tok_span": [31, 36]}], "new_text": "Finally, <START=Gene or Genome> TReP - 132 <END=Gene or Genome> gene expression levels increased following progesterone treatment, indicating the existence of a positive auto - regulatory loop between PR and <START=Gene or Genome> TReP - 132 <END=Gene or Genome>."}, {"PMID": 23204517, "id": 2, "text": "We show here that the acidic sequence of PEP-19 has intrinsic Ca(2+) binding activity, which may modulate Ca(2+) binding to CaM by stabilizing an initial Ca(2+)-CaM complex or by electrostatically steering Ca(2+) to and from CaM.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [62, 68], "name": "Ca(2+)", "tok_span": [13, 18], "new_tok_span": [15, 20]}, {"ent_type": "CHEMICAL", "char_span": [106, 112], "name": "Ca(2+)", "tok_span": [24, 29], "new_tok_span": [26, 31]}, {"ent_type": "CHEMICAL", "char_span": [154, 160], "name": "Ca(2+)", "tok_span": [37, 42], "new_tok_span": [45, 50]}, {"ent_type": "CHEMICAL", "char_span": [206, 212], "name": "Ca(2+)", "tok_span": [51, 56], "new_tok_span": [65, 70]}, {"ent_type": "GENE", "char_span": [41, 47], "name": "PEP-19", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [124, 127], "name": "CaM", "tok_span": [31, 33], "new_tok_span": [36, 38]}, {"ent_type": "GENE", "char_span": [161, 164], "name": "CaM", "tok_span": [43, 45], "new_tok_span": [54, 56]}, {"ent_type": "GENE", "char_span": [225, 228], "name": "CaM", "tok_span": [59, 61], "new_tok_span": [76, 78]}], "relation_list": [{"subject": "Ca(2+)", "sbj_char_span": [62, 68], "object": "PEP-19", "obj_char_span": [41, 47], "rel_type": "regulator", "sbj_tok_span": [13, 18], "obj_tok_span": [8, 11], "new_sbj_tok_span": [15, 20], "new_obj_tok_span": [9, 12]}, {"subject": "Ca(2+)", "sbj_char_span": [106, 112], "object": "CaM", "obj_char_span": [124, 127], "rel_type": "regulator", "sbj_tok_span": [24, 29], "obj_tok_span": [31, 33], "new_sbj_tok_span": [26, 31], "new_obj_tok_span": [36, 38]}, {"subject": "Ca(2+)", "sbj_char_span": [154, 160], "object": "CaM", "obj_char_span": [161, 164], "rel_type": "regulator", "sbj_tok_span": [37, 42], "obj_tok_span": [43, 45], "new_sbj_tok_span": [45, 50], "new_obj_tok_span": [54, 56]}, {"subject": "Ca(2+)", "sbj_char_span": [206, 212], "object": "CaM", "obj_char_span": [225, 228], "rel_type": "regulator", "sbj_tok_span": [51, 56], "obj_tok_span": [59, 61], "new_sbj_tok_span": [65, 70], "new_obj_tok_span": [76, 78]}], "umls_entity_list": [{"mention": "PEP-19", "char_span": [41, 47], "sem_type": "Gene or Genome", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"mention": "CaM", "char_span": [124, 127], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [31, 33], "new_tok_span": [36, 38]}, {"mention": "CaM", "char_span": [161, 164], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [43, 45], "new_tok_span": [54, 56]}, {"mention": "CaM", "char_span": [225, 228], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [59, 61], "new_tok_span": [76, 78]}, {"mention": "CaM", "char_span": [124, 127], "sem_type": "Gene or Genome", "tok_span": [31, 33], "new_tok_span": [36, 38]}, {"mention": "CaM", "char_span": [161, 164], "sem_type": "Gene or Genome", "tok_span": [43, 45], "new_tok_span": [54, 56]}, {"mention": "CaM", "char_span": [225, 228], "sem_type": "Gene or Genome", "tok_span": [59, 61], "new_tok_span": [76, 78]}, {"mention": "CaM", "char_span": [124, 127], "sem_type": "Pharmacologic Substance", "tok_span": [31, 33], "new_tok_span": [36, 38]}, {"mention": "CaM", "char_span": [161, 164], "sem_type": "Pharmacologic Substance", "tok_span": [43, 45], "new_tok_span": [54, 56]}, {"mention": "CaM", "char_span": [225, 228], "sem_type": "Pharmacologic Substance", "tok_span": [59, 61], "new_tok_span": [76, 78]}], "new_text": "We show here that the acidic sequence of <START=Gene or Genome> PEP - 19 <END=Gene or Genome> has intrinsic Ca ( 2 + ) binding activity, which may modulate Ca ( 2 + ) binding to <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Pharmacologic Substance> CaM <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Pharmacologic Substance> by stabilizing an initial Ca ( 2 + ) - <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Pharmacologic Substance> CaM <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Pharmacologic Substance> complex or by electrostatically steering Ca ( 2 + ) to and from <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Pharmacologic Substance> CaM <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Pharmacologic Substance>."}, {"PMID": 23570914, "id": 6, "text": "To confirm this novel mechanism of bleomycin-induced fibrogenesis, we attempted to upregulate Nrf2 and related antioxidant proteins in bleomycin-treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that bleomycin-induced fibroblast proliferation and collagen content were attenuated through improved redox balance.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [198, 226], "name": "caffeic acid phenethyl ester", "tok_span": [37, 43], "new_tok_span": [43, 49]}, {"ent_type": "CHEMICAL", "char_span": [256, 265], "name": "bleomycin", "tok_span": [49, 51], "new_tok_span": [56, 58]}, {"ent_type": "CHEMICAL", "char_span": [35, 44], "name": "bleomycin", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"ent_type": "GENE", "char_span": [94, 98], "name": "Nrf2", "tok_span": [18, 20], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [182, 186], "name": "Nrf2", "tok_span": [33, 35], "new_tok_span": [39, 41]}, {"ent_type": "GENE", "char_span": [303, 311], "name": "collagen", "tok_span": [56, 57], "new_tok_span": [64, 65]}], "relation_list": [{"subject": "caffeic acid phenethyl ester", "sbj_char_span": [198, 226], "object": "Nrf2", "obj_char_span": [182, 186], "rel_type": "activator", "sbj_tok_span": [37, 43], "obj_tok_span": [33, 35], "new_sbj_tok_span": [43, 49], "new_obj_tok_span": [39, 41]}], "umls_entity_list": [{"mention": "bleomycin", "char_span": [35, 44], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"mention": "bleomycin", "char_span": [135, 144], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 27], "new_tok_span": [30, 32]}, {"mention": "bleomycin", "char_span": [256, 265], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [49, 51], "new_tok_span": [56, 58]}, {"mention": "antioxidant", "char_span": [111, 122], "sem_type": "Pharmacologic Substance", "tok_span": [22, 23], "new_tok_span": [25, 26]}], "new_text": "To confirm this novel mechanism of <START=Amino Acid, Peptide, or Protein> bleomycin <END=Amino Acid, Peptide, or Protein> - induced fibrogenesis, we attempted to upregulate Nrf2 and related <START=Pharmacologic Substance> antioxidant <END=Pharmacologic Substance> proteins in <START=Amino Acid, Peptide, or Protein> bleomycin <END=Amino Acid, Peptide, or Protein> - treated fibroblasts using a putative Nrf2 activator, caffeic acid phenethyl ester, and the results showed that <START=Amino Acid, Peptide, or Protein> bleomycin <END=Amino Acid, Peptide, or Protein> - induced fibroblast proliferation and collagen content were attenuated through improved redox balance."}, {"PMID": 23615073, "id": 7, "text": "Result showed that vitamin C treatment resulted in markedly reduced c-Rel nuclear translocation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [19, 28], "name": "vitamin C", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"ent_type": "GENE", "char_span": [68, 73], "name": "c-Rel", "tok_span": [10, 13], "new_tok_span": [14, 17]}], "relation_list": [{"subject": "vitamin C", "sbj_char_span": [19, 28], "object": "c-Rel", "obj_char_span": [68, 73], "rel_type": "regulator", "sbj_tok_span": [3, 5], "obj_tok_span": [10, 13], "new_sbj_tok_span": [5, 7], "new_obj_tok_span": [14, 17]}], "umls_entity_list": [{"mention": "vitamin C", "char_span": [19, 28], "sem_type": "Pharmacologic Substance", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"mention": "vitamin C", "char_span": [19, 28], "sem_type": "Organic Chemical", "tok_span": [3, 5], "new_tok_span": [5, 7]}], "new_text": "Result showed that <START=Pharmacologic Substance> <START=Organic Chemical> vitamin C <END=Pharmacologic Substance> <END=Organic Chemical> treatment resulted in markedly reduced c - Rel nuclear translocation."}, {"PMID": 12388748, "id": 4, "text": "Culture of HepG2 cells with griseofulvin has now been shown to induce both the formation of intracellular aggregates containing K18 as well as an increase in the abundance of K18 mRNA. Overexpression of K18 in HepG2, HeLa, or COS-7 cells also induced the formation of intracellular aggregates that stained with antibodies to ubiquitin and with rhodamine B (characteristics of MBs formed in vivo), eventually leading to cell death.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 40], "name": "griseofulvin", "tok_span": [6, 11], "new_tok_span": [7, 12]}, {"ent_type": "CHEMICAL", "char_span": [344, 355], "name": "rhodamine B", "tok_span": [69, 72], "new_tok_span": [86, 89]}, {"ent_type": "GENE", "char_span": [128, 131], "name": "K18", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"ent_type": "GENE", "char_span": [175, 178], "name": "K18", "tok_span": [35, 37], "new_tok_span": [43, 45]}, {"ent_type": "GENE", "char_span": [203, 206], "name": "K18", "tok_span": [41, 43], "new_tok_span": [53, 55]}, {"ent_type": "GENE", "char_span": [325, 334], "name": "ubiquitin", "tok_span": [66, 67], "new_tok_span": [81, 82]}], "relation_list": [{"subject": "griseofulvin", "sbj_char_span": [28, 40], "object": "K18", "obj_char_span": [175, 178], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [35, 37], "new_sbj_tok_span": [7, 12], "new_obj_tok_span": [43, 45]}, {"subject": "griseofulvin", "sbj_char_span": [28, 40], "object": "K18", "obj_char_span": [128, 131], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [24, 26], "new_sbj_tok_span": [7, 12], "new_obj_tok_span": [28, 30]}], "umls_entity_list": [{"mention": "griseofulvin", "char_span": [28, 40], "sem_type": "Pharmacologic Substance", "tok_span": [6, 11], "new_tok_span": [7, 12]}, {"mention": "K18", "char_span": [128, 131], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"mention": "K18", "char_span": [175, 178], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 37], "new_tok_span": [43, 45]}, {"mention": "K18", "char_span": [203, 206], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 43], "new_tok_span": [53, 55]}, {"mention": "K18", "char_span": [128, 131], "sem_type": "Gene or Genome", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"mention": "K18", "char_span": [175, 178], "sem_type": "Gene or Genome", "tok_span": [35, 37], "new_tok_span": [43, 45]}, {"mention": "K18", "char_span": [203, 206], "sem_type": "Gene or Genome", "tok_span": [41, 43], "new_tok_span": [53, 55]}, {"mention": "ubiquitin", "char_span": [325, 334], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [66, 67], "new_tok_span": [81, 82]}, {"mention": "rhodamine B", "char_span": [344, 355], "sem_type": "Organic Chemical", "tok_span": [69, 72], "new_tok_span": [86, 89]}, {"mention": "MBs", "char_span": [376, 379], "sem_type": "Organic Chemical", "tok_span": [75, 77], "new_tok_span": [95, 97]}, {"mention": "MBs", "char_span": [376, 379], "sem_type": "Gene or Genome", "tok_span": [75, 77], "new_tok_span": [95, 97]}], "new_text": "Culture of HepG2 cells with <START=Pharmacologic Substance> griseofulvin <END=Pharmacologic Substance> has now been shown to induce both the formation of intracellular aggregates containing <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> K18 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> as well as an increase in the abundance of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> K18 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> mRNA. Overexpression of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> K18 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> in HepG2, HeLa, or COS - 7 cells also induced the formation of intracellular aggregates that stained with antibodies to <START=Amino Acid, Peptide, or Protein> ubiquitin <END=Amino Acid, Peptide, or Protein> and with <START=Organic Chemical> rhodamine B <END=Organic Chemical> ( characteristics of <START=Organic Chemical> <START=Gene or Genome> MBs <END=Organic Chemical> <END=Gene or Genome> formed in vivo ), eventually leading to cell death."}, {"PMID": 6319437, "id": 9, "text": "Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [128, 140], "name": "Promethazine", "tok_span": [23, 26], "new_tok_span": [25, 28]}, {"ent_type": "CHEMICAL", "char_span": [144, 157], "name": "phenothiazine", "tok_span": [28, 32], "new_tok_span": [31, 35]}, {"ent_type": "CHEMICAL", "char_span": [224, 227], "name": "TFP", "tok_span": [47, 49], "new_tok_span": [54, 56]}, {"ent_type": "CHEMICAL", "char_span": [433, 436], "name": "W-7", "tok_span": [93, 96], "new_tok_span": [105, 108]}, {"ent_type": "CHEMICAL", "char_span": [584, 593], "name": "rhodamine", "tok_span": [127, 129], "new_tok_span": [142, 144]}, {"ent_type": "CHEMICAL", "char_span": [641, 644], "name": "W-7", "tok_span": [142, 145], "new_tok_span": [160, 163]}, {"ent_type": "CHEMICAL", "char_span": [890, 899], "name": "rhodamine", "tok_span": [199, 201], "new_tok_span": [222, 224]}, {"ent_type": "GENE", "char_span": [37, 47], "name": "calmodulin", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [300, 310], "name": "calmodulin", "tok_span": [63, 66], "new_tok_span": [72, 75]}, {"ent_type": "GENE", "char_span": [380, 390], "name": "calmodulin", "tok_span": [82, 85], "new_tok_span": [93, 96]}, {"ent_type": "GENE", "char_span": [510, 520], "name": "calmodulin", "tok_span": [112, 115], "new_tok_span": [125, 128]}, {"ent_type": "GENE", "char_span": [602, 623], "name": "alpha 2-macroglobulin", "tok_span": [131, 137], "new_tok_span": [148, 154]}, {"ent_type": "GENE", "char_span": [759, 770], "name": "calcineurin", "tok_span": [166, 169], "new_tok_span": [184, 187]}, {"ent_type": "GENE", "char_span": [774, 800], "name": "calmodulin-binding protein", "tok_span": [171, 177], "new_tok_span": [190, 196]}, {"ent_type": "GENE", "char_span": [908, 929], "name": "alpha 2-macroglobulin", "tok_span": [203, 209], "new_tok_span": [228, 234]}], "relation_list": [{"subject": "Promethazine", "sbj_char_span": [128, 140], "object": "calmodulin", "obj_char_span": [300, 310], "rel_type": "inhibitor", "sbj_tok_span": [23, 26], "obj_tok_span": [63, 66], "new_sbj_tok_span": [25, 28], "new_obj_tok_span": [72, 75]}, {"subject": "phenothiazine", "sbj_char_span": [144, 157], "object": "calmodulin", "obj_char_span": [300, 310], "rel_type": "inhibitor", "sbj_tok_span": [28, 32], "obj_tok_span": [63, 66], "new_sbj_tok_span": [31, 35], "new_obj_tok_span": [72, 75]}, {"subject": "TFP", "sbj_char_span": [224, 227], "object": "calmodulin", "obj_char_span": [300, 310], "rel_type": "inhibitor", "sbj_tok_span": [47, 49], "obj_tok_span": [63, 66], "new_sbj_tok_span": [54, 56], "new_obj_tok_span": [72, 75]}], "umls_entity_list": [{"mention": "phenothiazine", "char_span": [144, 157], "sem_type": "Pharmacologic Substance", "tok_span": [28, 32], "new_tok_span": [31, 35]}, {"mention": "calmodulin", "char_span": [37, 47], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"mention": "calmodulin", "char_span": [186, 196], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [38, 41], "new_tok_span": [43, 46]}, {"mention": "calmodulin", "char_span": [300, 310], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [63, 66], "new_tok_span": [72, 75]}, {"mention": "calmodulin", "char_span": [380, 390], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [82, 85], "new_tok_span": [93, 96]}, {"mention": "calmodulin", "char_span": [510, 520], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [112, 115], "new_tok_span": [125, 128]}, {"mention": "calmodulin", "char_span": [774, 784], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [171, 174], "new_tok_span": [190, 193]}, {"mention": "TFP", "char_span": [224, 227], "sem_type": "Gene or Genome", "tok_span": [47, 49], "new_tok_span": [54, 56]}, {"mention": "rhodamine", "char_span": [584, 593], "sem_type": "Organic Chemical", "tok_span": [127, 129], "new_tok_span": [142, 144]}, {"mention": "rhodamine", "char_span": [890, 899], "sem_type": "Organic Chemical", "tok_span": [199, 201], "new_tok_span": [222, 224]}, {"mention": "binding protein", "char_span": [785, 800], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [175, 177], "new_tok_span": [196, 198]}, {"mention": "lpha", "char_span": [603, 607], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [131, 132], "new_tok_span": [148, 149]}, {"mention": "lpha", "char_span": [909, 913], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [203, 204], "new_tok_span": [228, 229]}], "new_text": "Three lines of evidence suggest that <START=Amino Acid, Peptide, or Protein> calmodulin <END=Amino Acid, Peptide, or Protein> inhibition is not responsible for the inhibition of binding and endocytosis : 1 ) Promethazine, a <START=Pharmacologic Substance> phenothiazine <END=Pharmacologic Substance> that is a poor inhibitor of <START=Amino Acid, Peptide, or Protein> calmodulin <END=Amino Acid, Peptide, or Protein>, is nearly as effective as <START=Gene or Genome> TFP <END=Gene or Genome> at inhibiting endocytosis ; calmidazolium, a potent inhibitor of several <START=Amino Acid, Peptide, or Protein> calmodulin <END=Amino Acid, Peptide, or Protein> functions, did not cause a loss of binding ; 2 ) the microinjection of <START=Amino Acid, Peptide, or Protein> calmodulin <END=Amino Acid, Peptide, or Protein> into cells did not reverse the effects of W - 7 ; using pressure microinjection, we introduced up to a 100 - fold excess of <START=Amino Acid, Peptide, or Protein> calmodulin <END=Amino Acid, Peptide, or Protein> over native levels into individual gerbil fibroma cells ; using <START=Organic Chemical> rhodamine <END=Organic Chemical> - labeled <START=Amino Acid, Peptide, or Protein> alpha <END=Amino Acid, Peptide, or Protein> 2 - macroglobulin, we saw that the W - 7 induced inhibition of receptor - mediated endocytosis was the same in injected and uninjected cells ; 3 ) we injected calcineurin, a <START=Amino Acid, Peptide, or Protein> calmodulin <END=Amino Acid, Peptide, or Protein> - <START=Amino Acid, Peptide, or Protein> binding protein <END=Amino Acid, Peptide, or Protein>, into cells ( 1 - 3 pg / cell ) and observed no effect on the receptor - mediated endocytosis of <START=Organic Chemical> rhodamine <END=Organic Chemical> - labeled <START=Amino Acid, Peptide, or Protein> alpha <END=Amino Acid, Peptide, or Protein> 2 - macroglobulin."}, {"PMID": 16230360, "id": 3, "text": "We report here that procainamide specifically inhibits the hemimethylase activity of DNA methyltransferase 1 (DNMT1), the mammalian enzyme thought to be responsible for maintaining DNA methylation patterns during replication.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [20, 32], "name": "procainamide", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [59, 72], "name": "hemimethylase", "tok_span": [10, 15], "new_tok_span": [10, 15]}, {"ent_type": "GENE", "char_span": [85, 108], "name": "DNA methyltransferase 1", "tok_span": [17, 21], "new_tok_span": [17, 21]}, {"ent_type": "GENE", "char_span": [110, 115], "name": "DNMT1", "tok_span": [22, 25], "new_tok_span": [22, 25]}], "relation_list": [{"subject": "procainamide", "sbj_char_span": [20, 32], "object": "hemimethylase", "obj_char_span": [59, 72], "rel_type": "inhibitor", "sbj_tok_span": [4, 7], "obj_tok_span": [10, 15], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [10, 15]}, {"subject": "procainamide", "sbj_char_span": [20, 32], "object": "DNA methyltransferase 1", "obj_char_span": [85, 108], "rel_type": "inhibitor", "sbj_tok_span": [4, 7], "obj_tok_span": [17, 21], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [17, 21]}, {"subject": "procainamide", "sbj_char_span": [20, 32], "object": "DNMT1", "obj_char_span": [110, 115], "rel_type": "inhibitor", "sbj_tok_span": [4, 7], "obj_tok_span": [22, 25], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [22, 25]}], "umls_entity_list": [], "new_text": "We report here that procainamide specifically inhibits the hemimethylase activity of DNA methyltransferase 1 ( DNMT1 ), the mammalian enzyme thought to be responsible for maintaining DNA methylation patterns during replication."}, {"PMID": 16690332, "id": 0, "text": "Dynamics of NO rebinding to the heme domain of NO synthase-like proteins from bacterial pathogens.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [12, 14], "name": "NO", "tok_span": [2, 3], "new_tok_span": [2, 3]}, {"ent_type": "CHEMICAL", "char_span": [47, 49], "name": "NO", "tok_span": [10, 11], "new_tok_span": [13, 14]}, {"ent_type": "GENE", "char_span": [32, 72], "name": "heme domain of NO synthase-like proteins", "tok_span": [7, 15], "new_tok_span": [8, 16]}], "relation_list": [{"subject": "NO", "sbj_char_span": [12, 14], "object": "heme domain of NO synthase-like proteins", "obj_char_span": [32, 72], "rel_type": "regulator", "sbj_tok_span": [2, 3], "obj_tok_span": [7, 15], "new_sbj_tok_span": [2, 3], "new_obj_tok_span": [8, 16]}], "umls_entity_list": [{"mention": "heme", "char_span": [32, 36], "sem_type": "Organic Chemical", "tok_span": [7, 8], "new_tok_span": [8, 9]}, {"mention": "NO synthase", "char_span": [47, 58], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"mention": "bacterial", "char_span": [78, 87], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 17], "new_tok_span": [21, 22]}], "new_text": "Dynamics of NO rebinding to the <START=Organic Chemical> heme <END=Organic Chemical> domain of <START=Amino Acid, Peptide, or Protein> NO synthase <END=Amino Acid, Peptide, or Protein> - like proteins from <START=Amino Acid, Peptide, or Protein> bacterial <END=Amino Acid, Peptide, or Protein> pathogens."}, {"PMID": 16997906, "id": 2, "text": "These pyridoxal-5'-phosphate-dependent decarboxylases belong to the alanine racemase (AR) structural family together with diaminopimelate decarboxylase (DapDC), which catalyzes the final step of lysine biosynthesis in bacteria.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [6, 28], "name": "pyridoxal-5'-phosphate", "tok_span": [1, 10], "new_tok_span": [1, 10]}, {"ent_type": "CHEMICAL", "char_span": [68, 75], "name": "alanine", "tok_span": [18, 19], "new_tok_span": [21, 22]}, {"ent_type": "CHEMICAL", "char_span": [122, 137], "name": "diaminopimelate", "tok_span": [29, 34], "new_tok_span": [34, 39]}, {"ent_type": "CHEMICAL", "char_span": [195, 201], "name": "lysine", "tok_span": [50, 51], "new_tok_span": [56, 57]}, {"ent_type": "GENE", "char_span": [39, 53], "name": "decarboxylases", "tok_span": [12, 15], "new_tok_span": [13, 16]}, {"ent_type": "GENE", "char_span": [68, 84], "name": "alanine racemase", "tok_span": [18, 22], "new_tok_span": [21, 25]}, {"ent_type": "GENE", "char_span": [86, 88], "name": "AR", "tok_span": [23, 24], "new_tok_span": [27, 28]}, {"ent_type": "GENE", "char_span": [122, 151], "name": "diaminopimelate decarboxylase", "tok_span": [29, 37], "new_tok_span": [34, 42]}, {"ent_type": "GENE", "char_span": [153, 158], "name": "DapDC", "tok_span": [38, 41], "new_tok_span": [44, 47]}], "relation_list": [{"subject": "lysine", "sbj_char_span": [195, 201], "object": "diaminopimelate decarboxylase", "obj_char_span": [122, 151], "rel_type": "product or substrate", "sbj_tok_span": [50, 51], "obj_tok_span": [29, 37], "new_sbj_tok_span": [56, 57], "new_obj_tok_span": [34, 42]}, {"subject": "lysine", "sbj_char_span": [195, 201], "object": "DapDC", "obj_char_span": [153, 158], "rel_type": "product or substrate", "sbj_tok_span": [50, 51], "obj_tok_span": [38, 41], "new_sbj_tok_span": [56, 57], "new_obj_tok_span": [44, 47]}], "umls_entity_list": [{"mention": "decarboxylases", "char_span": [39, 53], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 15], "new_tok_span": [13, 16]}, {"mention": "alanine", "char_span": [68, 75], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 19], "new_tok_span": [21, 22]}, {"mention": "diaminopimelate", "char_span": [122, 137], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 34], "new_tok_span": [34, 39]}], "new_text": "These pyridoxal - 5'- phosphate - dependent <START=Amino Acid, Peptide, or Protein> decarboxylases <END=Amino Acid, Peptide, or Protein> belong to the <START=Amino Acid, Peptide, or Protein> alanine <END=Amino Acid, Peptide, or Protein> racemase ( AR ) structural family together with <START=Amino Acid, Peptide, or Protein> diaminopimelate <END=Amino Acid, Peptide, or Protein> decarboxylase ( DapDC ), which catalyzes the final step of lysine biosynthesis in bacteria."}, {"PMID": 23603058, "id": 6, "text": "TNF-alpha plasma peak concentrations were significantly higher in the LPS compared to the DON+LPS group (94.3±17.2ng/mL vs. 79.2±15.7ng/mL) while IL-6 climaxed earlier in the latter group (3h p.i. vs. 2h p.i.).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [90, 93], "name": "DON", "tok_span": [15, 17], "new_tok_span": [24, 26]}, {"ent_type": "GENE", "char_span": [0, 9], "name": "TNF-alpha", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [146, 150], "name": "IL-6", "tok_span": [45, 48], "new_tok_span": [67, 70]}], "relation_list": [{"subject": "DON", "sbj_char_span": [90, 93], "object": "TNF-alpha", "obj_char_span": [0, 9], "rel_type": "regulator", "sbj_tok_span": [15, 17], "obj_tok_span": [0, 3], "new_sbj_tok_span": [24, 26], "new_obj_tok_span": [1, 4]}, {"subject": "DON", "sbj_char_span": [90, 93], "object": "IL-6", "obj_char_span": [146, 150], "rel_type": "regulator", "sbj_tok_span": [15, 17], "obj_tok_span": [45, 48], "new_sbj_tok_span": [24, 26], "new_obj_tok_span": [67, 70]}], "umls_entity_list": [{"mention": "plasma", "char_span": [10, 16], "sem_type": "Pharmacologic Substance", "tok_span": [3, 4], "new_tok_span": [6, 7]}, {"mention": "TNF-alpha", "char_span": [0, 9], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "DON", "char_span": [90, 93], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 17], "new_tok_span": [24, 26]}, {"mention": "LPS", "char_span": [70, 73], "sem_type": "Organic Chemical", "tok_span": [11, 12], "new_tok_span": [17, 18]}, {"mention": "LPS", "char_span": [94, 97], "sem_type": "Organic Chemical", "tok_span": [18, 19], "new_tok_span": [30, 31]}, {"mention": "LPS", "char_span": [70, 73], "sem_type": "Gene or Genome", "tok_span": [11, 12], "new_tok_span": [17, 18]}, {"mention": "LPS", "char_span": [94, 97], "sem_type": "Gene or Genome", "tok_span": [18, 19], "new_tok_span": [30, 31]}, {"mention": "mL", "char_span": [117, 119], "sem_type": "Gene or Genome", "tok_span": [30, 31], "new_tok_span": [46, 47]}, {"mention": "mL", "char_span": [136, 138], "sem_type": "Gene or Genome", "tok_span": [42, 43], "new_tok_span": [62, 63]}, {"mention": "mL", "char_span": [117, 119], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 31], "new_tok_span": [46, 47]}, {"mention": "mL", "char_span": [136, 138], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 43], "new_tok_span": [62, 63]}], "new_text": "<START=Amino Acid, Peptide, or Protein> TNF - alpha <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> plasma <END=Pharmacologic Substance> peak concentrations were significantly higher in the <START=Organic Chemical> <START=Gene or Genome> LPS <END=Organic Chemical> <END=Gene or Genome> compared to the <START=Amino Acid, Peptide, or Protein> DON <END=Amino Acid, Peptide, or Protein> + <START=Organic Chemical> <START=Gene or Genome> LPS <END=Organic Chemical> <END=Gene or Genome> group ( 94. 3±17. 2ng / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> mL <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> vs. 79. 2±15. 7ng / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> mL <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ) while IL - 6 climaxed earlier in the latter group ( 3h p. i. vs. 2h p. i. )."}, {"PMID": 9584217, "id": 1, "text": "Dihydropyridines (DHPs) block L-type Ca2+ channels more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 16], "name": "Dihydropyridines", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "CHEMICAL", "char_span": [18, 22], "name": "DHPs", "tok_span": [6, 8], "new_tok_span": [6, 8]}, {"ent_type": "CHEMICAL", "char_span": [37, 41], "name": "Ca2+", "tok_span": [13, 16], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [30, 50], "name": "L-type Ca2+ channels", "tok_span": [10, 17], "new_tok_span": [10, 17]}], "relation_list": [{"subject": "Dihydropyridines", "sbj_char_span": [0, 16], "object": "L-type Ca2+ channels", "obj_char_span": [30, 50], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [10, 17], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [10, 17]}, {"subject": "DHPs", "sbj_char_span": [18, 22], "object": "L-type Ca2+ channels", "obj_char_span": [30, 50], "rel_type": "inhibitor", "sbj_tok_span": [6, 8], "obj_tok_span": [10, 17], "new_sbj_tok_span": [6, 8], "new_obj_tok_span": [10, 17]}], "umls_entity_list": [{"mention": "Ca2+", "char_span": [37, 41], "sem_type": "Pharmacologic Substance", "tok_span": [13, 16], "new_tok_span": [14, 17]}], "new_text": "Dihydropyridines ( DHPs ) block L - type <START=Pharmacologic Substance> Ca2 + <END=Pharmacologic Substance> channels more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state."}, {"PMID": 10516958, "id": 2, "text": "While it is an antagonist at these latter receptors, ziprasidone behaves as a 5-HT1A agonist in vitro in adenylate cyclase measurements.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [53, 64], "name": "ziprasidone", "tok_span": [10, 15], "new_tok_span": [10, 15]}, {"ent_type": "CHEMICAL", "char_span": [105, 114], "name": "adenylate", "tok_span": [27, 29], "new_tok_span": [29, 31]}, {"ent_type": "GENE", "char_span": [78, 84], "name": "5-HT1A", "tok_span": [18, 23], "new_tok_span": [18, 23]}, {"ent_type": "GENE", "char_span": [105, 122], "name": "adenylate cyclase", "tok_span": [27, 30], "new_tok_span": [29, 32]}], "relation_list": [{"subject": "ziprasidone", "sbj_char_span": [53, 64], "object": "5-HT1A", "obj_char_span": [78, 84], "rel_type": "agonist or antagonist", "sbj_tok_span": [10, 15], "obj_tok_span": [18, 23], "new_sbj_tok_span": [10, 15], "new_obj_tok_span": [18, 23]}], "umls_entity_list": [{"mention": "adenylate", "char_span": [105, 114], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 29], "new_tok_span": [29, 31]}, {"mention": "adenylate cyclase", "char_span": [105, 122], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 30], "new_tok_span": [29, 32]}], "new_text": "While it is an antagonist at these latter receptors, ziprasidone behaves as a 5 - HT1A agonist in vitro in <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> adenylate <END=Amino Acid, Peptide, or Protein> cyclase <END=Amino Acid, Peptide, or Protein> measurements."}, {"PMID": 11451212, "id": 0, "text": "In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [37, 57], "name": "olmesartan medoxomil", "tok_span": [8, 15], "new_tok_span": [9, 16]}, {"ent_type": "CHEMICAL", "char_span": [62, 76], "name": "angiotensin II", "tok_span": [17, 19], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [62, 94], "name": "angiotensin II type AT1 receptor", "tok_span": [17, 23], "new_tok_span": [19, 25]}], "relation_list": [{"subject": "olmesartan medoxomil", "sbj_char_span": [37, 57], "object": "angiotensin II type AT1 receptor", "obj_char_span": [62, 94], "rel_type": "agonist or antagonist", "sbj_tok_span": [8, 15], "obj_tok_span": [17, 23], "new_sbj_tok_span": [9, 16], "new_obj_tok_span": [19, 25]}], "umls_entity_list": [{"mention": "olmesartan medoxomil", "char_span": [37, 57], "sem_type": "Pharmacologic Substance", "tok_span": [8, 15], "new_tok_span": [9, 16]}, {"mention": "AT1", "char_span": [82, 85], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 22], "new_tok_span": [24, 26]}, {"mention": "AT1", "char_span": [82, 85], "sem_type": "Gene or Genome", "tok_span": [20, 22], "new_tok_span": [24, 26]}], "new_text": "In vitro and in vivo pharmacology of <START=Pharmacologic Substance> olmesartan medoxomil <END=Pharmacologic Substance>, an angiotensin II type <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> AT1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> receptor antagonist."}, {"PMID": 23611809, "id": 8, "text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 86], "name": "amitriptyline", "tok_span": [17, 22], "new_tok_span": [19, 24]}, {"ent_type": "CHEMICAL", "char_span": [88, 98], "name": "imipramine", "tok_span": [23, 27], "new_tok_span": [25, 29]}, {"ent_type": "CHEMICAL", "char_span": [104, 119], "name": "diphenhydramine", "tok_span": [29, 34], "new_tok_span": [31, 36]}, {"ent_type": "GENE", "char_span": [61, 68], "name": "UGT2B10", "tok_span": [11, 16], "new_tok_span": [12, 17]}, {"ent_type": "GENE", "char_span": [178, 184], "name": "UGT1A4", "tok_span": [42, 47], "new_tok_span": [45, 50]}, {"ent_type": "GENE", "char_span": [189, 195], "name": "UGT1A3", "tok_span": [48, 53], "new_tok_span": [52, 57]}, {"ent_type": "GENE", "char_span": [225, 231], "name": "UGT1A4", "tok_span": [60, 65], "new_tok_span": [65, 70]}], "relation_list": [{"subject": "amitriptyline", "sbj_char_span": [73, 86], "object": "UGT2B10", "obj_char_span": [61, 68], "rel_type": "regulator", "sbj_tok_span": [17, 22], "obj_tok_span": [11, 16], "new_sbj_tok_span": [19, 24], "new_obj_tok_span": [12, 17]}, {"subject": "imipramine", "sbj_char_span": [88, 98], "object": "UGT2B10", "obj_char_span": [61, 68], "rel_type": "regulator", "sbj_tok_span": [23, 27], "obj_tok_span": [11, 16], "new_sbj_tok_span": [25, 29], "new_obj_tok_span": [12, 17]}, {"subject": "diphenhydramine", "sbj_char_span": [104, 119], "object": "UGT2B10", "obj_char_span": [61, 68], "rel_type": "regulator", "sbj_tok_span": [29, 34], "obj_tok_span": [11, 16], "new_sbj_tok_span": [31, 36], "new_obj_tok_span": [12, 17]}, {"subject": "amitriptyline", "sbj_char_span": [73, 86], "object": "UGT2B10", "obj_char_span": [61, 68], "rel_type": "product or substrate", "sbj_tok_span": [17, 22], "obj_tok_span": [11, 16], "new_sbj_tok_span": [19, 24], "new_obj_tok_span": [12, 17]}, {"subject": "imipramine", "sbj_char_span": [88, 98], "object": "UGT2B10", "obj_char_span": [61, 68], "rel_type": "product or substrate", "sbj_tok_span": [23, 27], "obj_tok_span": [11, 16], "new_sbj_tok_span": [25, 29], "new_obj_tok_span": [12, 17]}, {"subject": "diphenhydramine", "sbj_char_span": [104, 119], "object": "UGT2B10", "obj_char_span": [61, 68], "rel_type": "product or substrate", "sbj_tok_span": [29, 34], "obj_tok_span": [11, 16], "new_sbj_tok_span": [31, 36], "new_obj_tok_span": [12, 17]}], "umls_entity_list": [{"mention": "UGT2B10", "char_span": [61, 68], "sem_type": "Gene or Genome", "tok_span": [11, 16], "new_tok_span": [12, 17]}, {"mention": "UGT1A4", "char_span": [178, 184], "sem_type": "Gene or Genome", "tok_span": [42, 47], "new_tok_span": [45, 50]}, {"mention": "UGT1A4", "char_span": [225, 231], "sem_type": "Gene or Genome", "tok_span": [60, 65], "new_tok_span": [65, 70]}], "new_text": "Kinetic analyses revealed that the affinity and clearance of <START=Gene or Genome> UGT2B10 <END=Gene or Genome> for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of <START=Gene or Genome> UGT1A4 <END=Gene or Genome> and UGT1A3, although the Vmax values of <START=Gene or Genome> UGT1A4 <END=Gene or Genome> toward these drugs are considerably higher."}, {"PMID": 7500004, "id": 4, "text": "Whole-cell voltage-clamp of hNET-293 cells reveals NE-induced, Na(+)-dependent currents blocked by antidepressants and cocaine that are absent in parental cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [51, 53], "name": "NE", "tok_span": [13, 14], "new_tok_span": [13, 14]}, {"ent_type": "CHEMICAL", "char_span": [63, 68], "name": "Na(+)", "tok_span": [17, 21], "new_tok_span": [17, 21]}, {"ent_type": "CHEMICAL", "char_span": [119, 126], "name": "cocaine", "tok_span": [29, 30], "new_tok_span": [31, 32]}, {"ent_type": "GENE", "char_span": [28, 32], "name": "hNET", "tok_span": [7, 9], "new_tok_span": [7, 9]}], "relation_list": [{"subject": "NE", "sbj_char_span": [51, 53], "object": "hNET", "obj_char_span": [28, 32], "rel_type": "activator", "sbj_tok_span": [13, 14], "obj_tok_span": [7, 9], "new_sbj_tok_span": [13, 14], "new_obj_tok_span": [7, 9]}, {"subject": "cocaine", "sbj_char_span": [119, 126], "object": "hNET", "obj_char_span": [28, 32], "rel_type": "inhibitor", "sbj_tok_span": [29, 30], "obj_tok_span": [7, 9], "new_sbj_tok_span": [31, 32], "new_obj_tok_span": [7, 9]}], "umls_entity_list": [{"mention": "antidepressants", "char_span": [99, 114], "sem_type": "Pharmacologic Substance", "tok_span": [26, 28], "new_tok_span": [27, 29]}], "new_text": "Whole - cell voltage - clamp of hNET - 293 cells reveals NE - induced, Na ( + ) - dependent currents blocked by <START=Pharmacologic Substance> antidepressants <END=Pharmacologic Substance> and cocaine that are absent in parental cells."}, {"PMID": 10085232, "id": 2, "text": "The resulting models highlight two residues, at positions 208 and 108, that could be important for determining, either directly or indirectly, substrate specificity for aflatoxin-exo-8,9-epoxide among the Alpha-class GSTs. Residues at these positions were mutated in human GSTA1-1 (Met-208, Leu-108), rat GSTA3-3 (Glu-208, His-108) and rat GSTA5-5 (Asp-208, Tyr-108): in the active rat GSTA5-5 to those in the inactive GSTA1-1; and in the inactive human GSTA1-1 and rat GSTA3-3 to those in the active rat GSTA5-5.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [169, 194], "name": "aflatoxin-exo-8,9-epoxide", "tok_span": [28, 41], "new_tok_span": [29, 42]}, {"ent_type": "GENE", "char_span": [205, 221], "name": "Alpha-class GSTs", "tok_span": [43, 48], "new_tok_span": [47, 52]}, {"ent_type": "GENE", "char_span": [267, 280], "name": "human GSTA1-1", "tok_span": [57, 63], "new_tok_span": [61, 67]}, {"ent_type": "GENE", "char_span": [301, 312], "name": "rat GSTA3-3", "tok_span": [73, 79], "new_tok_span": [83, 89]}, {"ent_type": "GENE", "char_span": [336, 347], "name": "rat GSTA5-5", "tok_span": [89, 95], "new_tok_span": [103, 109]}, {"ent_type": "GENE", "char_span": [382, 393], "name": "rat GSTA5-5", "tok_span": [108, 114], "new_tok_span": [128, 134]}, {"ent_type": "GENE", "char_span": [419, 426], "name": "GSTA1-1", "tok_span": [119, 124], "new_tok_span": [143, 148]}, {"ent_type": "GENE", "char_span": [448, 461], "name": "human GSTA1-1", "tok_span": [129, 135], "new_tok_span": [155, 161]}, {"ent_type": "GENE", "char_span": [466, 477], "name": "rat GSTA3-3", "tok_span": [136, 142], "new_tok_span": [166, 172]}, {"ent_type": "GENE", "char_span": [501, 512], "name": "rat GSTA5-5", "tok_span": [147, 153], "new_tok_span": [179, 185]}], "relation_list": [{"subject": "aflatoxin-exo-8,9-epoxide", "sbj_char_span": [169, 194], "object": "Alpha-class GSTs", "obj_char_span": [205, 221], "rel_type": "product or substrate", "sbj_tok_span": [28, 41], "obj_tok_span": [43, 48], "new_sbj_tok_span": [29, 42], "new_obj_tok_span": [47, 52]}], "umls_entity_list": [{"mention": "aflatoxin", "char_span": [169, 178], "sem_type": "Organic Chemical", "tok_span": [28, 31], "new_tok_span": [29, 32]}, {"mention": "epoxide", "char_span": [187, 194], "sem_type": "Organic Chemical", "tok_span": [39, 41], "new_tok_span": [42, 44]}, {"mention": "GSTA1-1", "char_span": [273, 280], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [58, 63], "new_tok_span": [64, 69]}, {"mention": "GSTA1-1", "char_span": [419, 426], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [119, 124], "new_tok_span": [143, 148]}, {"mention": "GSTA1-1", "char_span": [454, 461], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [130, 135], "new_tok_span": [158, 163]}, {"mention": "GSTA1-1", "char_span": [273, 280], "sem_type": "Gene or Genome", "tok_span": [58, 63], "new_tok_span": [64, 69]}, {"mention": "GSTA1-1", "char_span": [419, 426], "sem_type": "Gene or Genome", "tok_span": [119, 124], "new_tok_span": [143, 148]}, {"mention": "GSTA1-1", "char_span": [454, 461], "sem_type": "Gene or Genome", "tok_span": [130, 135], "new_tok_span": [158, 163]}, {"mention": "Leu", "char_span": [291, 294], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [68, 69], "new_tok_span": [77, 78]}, {"mention": "GSTA3", "char_span": [305, 310], "sem_type": "Gene or Genome", "tok_span": [74, 77], "new_tok_span": [85, 88]}, {"mention": "GSTA3", "char_span": [470, 475], "sem_type": "Gene or Genome", "tok_span": [137, 140], "new_tok_span": [168, 171]}, {"mention": "Glu", "char_span": [314, 317], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [80, 81], "new_tok_span": [93, 94]}, {"mention": "GSTA5", "char_span": [340, 345], "sem_type": "Gene or Genome", "tok_span": [90, 93], "new_tok_span": [105, 108]}, {"mention": "GSTA5", "char_span": [386, 391], "sem_type": "Gene or Genome", "tok_span": [109, 112], "new_tok_span": [130, 133]}, {"mention": "GSTA5", "char_span": [505, 510], "sem_type": "Gene or Genome", "tok_span": [148, 151], "new_tok_span": [181, 184]}, {"mention": "Asp", "char_span": [349, 352], "sem_type": "Gene or Genome", "tok_span": [96, 97], "new_tok_span": [114, 115]}, {"mention": "Asp", "char_span": [349, 352], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [96, 97], "new_tok_span": [114, 115]}], "new_text": "The resulting models highlight two residues, at positions 208 and 108, that could be important for determining, either directly or indirectly, substrate specificity for <START=Organic Chemical> aflatoxin <END=Organic Chemical> - exo - 8, 9 - <START=Organic Chemical> epoxide <END=Organic Chemical> among the Alpha - class GSTs. Residues at these positions were mutated in human <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> GSTA1 - 1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( Met - 208, <START=Amino Acid, Peptide, or Protein> Leu <END=Amino Acid, Peptide, or Protein> - 108 ), rat <START=Gene or Genome> GSTA3 <END=Gene or Genome> - 3 ( <START=Amino Acid, Peptide, or Protein> Glu <END=Amino Acid, Peptide, or Protein> - 208, His - 108 ) and rat <START=Gene or Genome> GSTA5 <END=Gene or Genome> - 5 ( <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Asp <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - 208, Tyr - 108 ) : in the active rat <START=Gene or Genome> GSTA5 <END=Gene or Genome> - 5 to those in the inactive <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> GSTA1 - 1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ; and in the inactive human <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> GSTA1 - 1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and rat <START=Gene or Genome> GSTA3 <END=Gene or Genome> - 3 to those in the active rat <START=Gene or Genome> GSTA5 <END=Gene or Genome> - 5."}, {"PMID": 12907245, "id": 8, "text": "Inhibition of ERK signaling by the MEK inhibitor, U0126, potentiated the cytotoxic effects of vinblastine and doxorubicin, but not that of VP-16.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [50, 55], "name": "U0126", "tok_span": [9, 12], "new_tok_span": [11, 14]}, {"ent_type": "CHEMICAL", "char_span": [94, 105], "name": "vinblastine", "tok_span": [19, 23], "new_tok_span": [22, 26]}, {"ent_type": "CHEMICAL", "char_span": [110, 121], "name": "doxorubicin", "tok_span": [24, 25], "new_tok_span": [28, 29]}, {"ent_type": "CHEMICAL", "char_span": [139, 144], "name": "VP-16", "tok_span": [30, 33], "new_tok_span": [35, 38]}, {"ent_type": "GENE", "char_span": [14, 17], "name": "ERK", "tok_span": [2, 3], "new_tok_span": [2, 3]}, {"ent_type": "GENE", "char_span": [35, 38], "name": "MEK", "tok_span": [6, 7], "new_tok_span": [7, 8]}], "relation_list": [{"subject": "U0126", "sbj_char_span": [50, 55], "object": "ERK", "obj_char_span": [14, 17], "rel_type": "regulator", "sbj_tok_span": [9, 12], "obj_tok_span": [2, 3], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [2, 3]}, {"subject": "U0126", "sbj_char_span": [50, 55], "object": "MEK", "obj_char_span": [35, 38], "rel_type": "inhibitor", "sbj_tok_span": [9, 12], "obj_tok_span": [6, 7], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [7, 8]}], "umls_entity_list": [{"mention": "MEK inhibitor", "char_span": [35, 48], "sem_type": "Pharmacologic Substance", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"mention": "vinblastine", "char_span": [94, 105], "sem_type": "Pharmacologic Substance", "tok_span": [19, 23], "new_tok_span": [22, 26]}, {"mention": "VP-16", "char_span": [139, 144], "sem_type": "Pharmacologic Substance", "tok_span": [30, 33], "new_tok_span": [35, 38]}], "new_text": "Inhibition of ERK signaling by the <START=Pharmacologic Substance> MEK inhibitor <END=Pharmacologic Substance>, U0126, potentiated the cytotoxic effects of <START=Pharmacologic Substance> vinblastine <END=Pharmacologic Substance> and doxorubicin, but not that of <START=Pharmacologic Substance> VP - 16 <END=Pharmacologic Substance>."}, {"PMID": 23643664, "id": 8, "text": "Resistance of TIDA neurons to MPTP toxicity was correlated with a transient increase in UCHL-1 and a sustained elevation in parkin in the arcuate nucleus.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [30, 34], "name": "MPTP", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"ent_type": "GENE", "char_span": [88, 94], "name": "UCHL-1", "tok_span": [16, 20], "new_tok_span": [18, 22]}, {"ent_type": "GENE", "char_span": [124, 130], "name": "parkin", "tok_span": [25, 27], "new_tok_span": [29, 31]}], "relation_list": [{"subject": "MPTP", "sbj_char_span": [30, 34], "object": "UCHL-1", "obj_char_span": [88, 94], "rel_type": "regulator", "sbj_tok_span": [6, 8], "obj_tok_span": [16, 20], "new_sbj_tok_span": [7, 9], "new_obj_tok_span": [18, 22]}, {"subject": "MPTP", "sbj_char_span": [30, 34], "object": "parkin", "obj_char_span": [124, 130], "rel_type": "regulator", "sbj_tok_span": [6, 8], "obj_tok_span": [25, 27], "new_sbj_tok_span": [7, 9], "new_obj_tok_span": [29, 31]}], "umls_entity_list": [{"mention": "MPTP", "char_span": [30, 34], "sem_type": "Organic Chemical", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"mention": "parkin", "char_span": [124, 130], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 27], "new_tok_span": [29, 31]}, {"mention": "parkin", "char_span": [124, 130], "sem_type": "Gene or Genome", "tok_span": [25, 27], "new_tok_span": [29, 31]}], "new_text": "Resistance of TIDA neurons to <START=Organic Chemical> MPTP <END=Organic Chemical> toxicity was correlated with a transient increase in UCHL - 1 and a sustained elevation in <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> parkin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> in the arcuate nucleus."}, {"PMID": 23050902, "id": 0, "text": "Ribavirin-induced intracellular GTP depletion activates transcription elongation in coagulation factor VII gene expression.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Ribavirin", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [32, 35], "name": "GTP", "tok_span": [6, 7], "new_tok_span": [8, 9]}, {"ent_type": "GENE", "char_span": [84, 106], "name": "coagulation factor VII", "tok_span": [12, 15], "new_tok_span": [16, 19]}], "relation_list": [{"subject": "Ribavirin", "sbj_char_span": [0, 9], "object": "coagulation factor VII", "obj_char_span": [84, 106], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [12, 15], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [16, 19]}], "umls_entity_list": [{"mention": "Ribavirin", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "coagulation factor VII", "char_span": [84, 106], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 15], "new_tok_span": [16, 19]}, {"mention": "coagulation factor VII", "char_span": [84, 106], "sem_type": "Gene or Genome", "tok_span": [12, 15], "new_tok_span": [16, 19]}], "new_text": "<START=Pharmacologic Substance> Ribavirin <END=Pharmacologic Substance> - induced intracellular GTP depletion activates transcription elongation in <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> coagulation factor VII <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> gene expression."}, {"PMID": 23536519, "id": 5, "text": "Moreover, resveratrol downregulated the expressions of leptin and c-Myc, and decreased the content of vascular endothelial growth factor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [10, 21], "name": "resveratrol", "tok_span": [2, 4], "new_tok_span": [2, 4]}, {"ent_type": "GENE", "char_span": [55, 61], "name": "leptin", "tok_span": [8, 9], "new_tok_span": [8, 9]}, {"ent_type": "GENE", "char_span": [66, 71], "name": "c-Myc", "tok_span": [10, 13], "new_tok_span": [10, 13]}, {"ent_type": "GENE", "char_span": [102, 136], "name": "vascular endothelial growth factor", "tok_span": [19, 23], "new_tok_span": [20, 24]}], "relation_list": [{"subject": "resveratrol", "sbj_char_span": [10, 21], "object": "leptin", "obj_char_span": [55, 61], "rel_type": "regulator", "sbj_tok_span": [2, 4], "obj_tok_span": [8, 9], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [8, 9]}, {"subject": "resveratrol", "sbj_char_span": [10, 21], "object": "c-Myc", "obj_char_span": [66, 71], "rel_type": "regulator", "sbj_tok_span": [2, 4], "obj_tok_span": [10, 13], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [10, 13]}, {"subject": "resveratrol", "sbj_char_span": [10, 21], "object": "vascular endothelial growth factor", "obj_char_span": [102, 136], "rel_type": "regulator", "sbj_tok_span": [2, 4], "obj_tok_span": [19, 23], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [20, 24]}], "umls_entity_list": [{"mention": "vascular endothelial growth factor", "char_span": [102, 136], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 23], "new_tok_span": [20, 24]}], "new_text": "Moreover, resveratrol downregulated the expressions of leptin and c - Myc, and decreased the content of <START=Amino Acid, Peptide, or Protein> vascular endothelial growth factor <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 2886642, "id": 1, "text": "ORF 17583, a histamine H2-receptor antagonist, inhibited gastric acid secretion in pylorus-ligated rats (ED50 = 4.9 mg/kg intraduodenal; 3.4 mg/kg p.o.; and 0.21 mg/kg i.p.) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole (ED50 = 0.12 mg/kg p.o. and 0.08 mg/kg i.v.), histamine, tetragastrin, bethanechol, 2-deoxy-D-glucose or a meal (ED50 values ranged from 0.11-0.26 mg/kg p.o.).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "ORF 17583", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [13, 22], "name": "histamine", "tok_span": [5, 6], "new_tok_span": [7, 8]}, {"ent_type": "CHEMICAL", "char_span": [242, 250], "name": "betazole", "tok_span": [75, 78], "new_tok_span": [77, 80]}, {"ent_type": "CHEMICAL", "char_span": [297, 306], "name": "histamine", "tok_span": [105, 106], "new_tok_span": [107, 108]}, {"ent_type": "CHEMICAL", "char_span": [308, 320], "name": "tetragastrin", "tok_span": [107, 110], "new_tok_span": [110, 113]}, {"ent_type": "CHEMICAL", "char_span": [322, 333], "name": "bethanechol", "tok_span": [111, 115], "new_tok_span": [116, 120]}, {"ent_type": "CHEMICAL", "char_span": [335, 352], "name": "2-deoxy-D-glucose", "tok_span": [116, 123], "new_tok_span": [122, 129]}, {"ent_type": "GENE", "char_span": [13, 34], "name": "histamine H2-receptor", "tok_span": [5, 10], "new_tok_span": [7, 12]}], "relation_list": [{"subject": "ORF 17583", "sbj_char_span": [0, 9], "object": "histamine H2-receptor", "obj_char_span": [13, 34], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 3], "obj_tok_span": [5, 10], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [7, 12]}], "umls_entity_list": [{"mention": "ORF", "char_span": [0, 3], "sem_type": "Pharmacologic Substance", "tok_span": [0, 1], "new_tok_span": [1, 2]}, {"mention": "tetragastrin", "char_span": [308, 320], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [107, 110], "new_tok_span": [110, 113]}, {"mention": "bethanechol", "char_span": [322, 333], "sem_type": "Pharmacologic Substance", "tok_span": [111, 115], "new_tok_span": [116, 120]}], "new_text": "<START=Pharmacologic Substance> ORF <END=Pharmacologic Substance> 17583, a histamine H2 - receptor antagonist, inhibited gastric acid secretion in pylorus - ligated rats ( ED50 = 4. 9 mg / kg intraduodenal ; 3. 4 mg / kg p. o. ; and 0. 21 mg / kg i. p. ) and in total gastric fistula or Heidenhain pouch dogs stimulated by betazole ( ED50 = 0. 12 mg / kg p. o. and 0. 08 mg / kg i. v. ), histamine, <START=Amino Acid, Peptide, or Protein> tetragastrin <END=Amino Acid, Peptide, or Protein>, <START=Pharmacologic Substance> bethanechol <END=Pharmacologic Substance>, 2 - deoxy - D - glucose or a meal ( ED50 values ranged from 0. 11 - 0. 26 mg / kg p. o. )."}, {"PMID": 23389878, "id": 4, "text": "RESULTS: We found that a putative transcription repression domain in the NH2-terminus of FOXO1 is dispensable for FOXO1 inhibition of the AR. In vitro protein binding assays showed that FOXO1 binds to the transcription activation unit 5 (TAU5) motif in the AR NH2-terminal domain (NTD), a region required for recruitment of p160 activators including SRC-1.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 76], "name": "NH2", "tok_span": [12, 14], "new_tok_span": [14, 16]}, {"ent_type": "CHEMICAL", "char_span": [260, 263], "name": "NH2", "tok_span": [58, 60], "new_tok_span": [70, 72]}, {"ent_type": "GENE", "char_span": [350, 355], "name": "SRC-1", "tok_span": [79, 83], "new_tok_span": [98, 102]}, {"ent_type": "GENE", "char_span": [34, 65], "name": "transcription repression domain", "tok_span": [7, 10], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [89, 94], "name": "FOXO1", "tok_span": [17, 20], "new_tok_span": [22, 25]}, {"ent_type": "GENE", "char_span": [114, 119], "name": "FOXO1", "tok_span": [24, 27], "new_tok_span": [31, 34]}, {"ent_type": "GENE", "char_span": [138, 140], "name": "AR", "tok_span": [30, 31], "new_tok_span": [38, 39]}, {"ent_type": "GENE", "char_span": [186, 191], "name": "FOXO1", "tok_span": [39, 42], "new_tok_span": [48, 51]}, {"ent_type": "GENE", "char_span": [205, 236], "name": "transcription activation unit 5", "tok_span": [45, 49], "new_tok_span": [55, 59]}, {"ent_type": "GENE", "char_span": [238, 242], "name": "TAU5", "tok_span": [50, 53], "new_tok_span": [60, 63]}, {"ent_type": "GENE", "char_span": [257, 279], "name": "AR NH2-terminal domain", "tok_span": [57, 63], "new_tok_span": [67, 73]}, {"ent_type": "GENE", "char_span": [324, 328], "name": "p160", "tok_span": [74, 76], "new_tok_span": [90, 92]}], "relation_list": [{"subject": "NH2", "sbj_char_span": [73, 76], "object": "FOXO1", "obj_char_span": [89, 94], "rel_type": "part of", "sbj_tok_span": [12, 14], "obj_tok_span": [17, 20], "new_sbj_tok_span": [14, 16], "new_obj_tok_span": [22, 25]}], "umls_entity_list": [{"mention": "NH2", "char_span": [73, 76], "sem_type": "Organic Chemical", "tok_span": [12, 14], "new_tok_span": [14, 16]}, {"mention": "NH2", "char_span": [260, 263], "sem_type": "Organic Chemical", "tok_span": [58, 60], "new_tok_span": [70, 72]}, {"mention": "FOXO1", "char_span": [89, 94], "sem_type": "Gene or Genome", "tok_span": [17, 20], "new_tok_span": [22, 25]}, {"mention": "FOXO1", "char_span": [114, 119], "sem_type": "Gene or Genome", "tok_span": [24, 27], "new_tok_span": [31, 34]}, {"mention": "FOXO1", "char_span": [186, 191], "sem_type": "Gene or Genome", "tok_span": [39, 42], "new_tok_span": [48, 51]}, {"mention": "NH2", "char_span": [73, 76], "sem_type": "Pharmacologic Substance", "tok_span": [12, 14], "new_tok_span": [14, 16]}, {"mention": "NH2", "char_span": [260, 263], "sem_type": "Pharmacologic Substance", "tok_span": [58, 60], "new_tok_span": [70, 72]}, {"mention": "p160", "char_span": [324, 328], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [74, 76], "new_tok_span": [90, 92]}, {"mention": "p160", "char_span": [324, 328], "sem_type": "Gene or Genome", "tok_span": [74, 76], "new_tok_span": [90, 92]}, {"mention": "SRC-1", "char_span": [350, 355], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [79, 83], "new_tok_span": [98, 102]}], "new_text": "RESULTS : We found that a putative transcription repression domain in the <START=Organic Chemical> <START=Pharmacologic Substance> NH2 <END=Organic Chemical> <END=Pharmacologic Substance> - terminus of <START=Gene or Genome> FOXO1 <END=Gene or Genome> is dispensable for <START=Gene or Genome> FOXO1 <END=Gene or Genome> inhibition of the AR. In vitro protein binding assays showed that <START=Gene or Genome> FOXO1 <END=Gene or Genome> binds to the transcription activation unit 5 ( TAU5 ) motif in the AR <START=Organic Chemical> <START=Pharmacologic Substance> NH2 <END=Organic Chemical> <END=Pharmacologic Substance> - terminal domain ( NTD ), a region required for recruitment of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> p160 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> activators including <START=Amino Acid, Peptide, or Protein> SRC - 1 <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23220609, "id": 5, "text": "Molecular docking analysis showed that BzP fits well into the agonist pocket of hERα. The lowest observed effect dose (LOED) (0.16 mg/kg/day) of BzP is much lower than the documented LOEDs of other parabens.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [39, 42], "name": "BzP", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"ent_type": "CHEMICAL", "char_span": [145, 148], "name": "BzP", "tok_span": [39, 42], "new_tok_span": [42, 45]}, {"ent_type": "CHEMICAL", "char_span": [198, 206], "name": "parabens", "tok_span": [52, 54], "new_tok_span": [57, 59]}, {"ent_type": "GENE", "char_span": [80, 84], "name": "hERα", "tok_span": [15, 18], "new_tok_span": [17, 20]}], "relation_list": [{"subject": "BzP", "sbj_char_span": [39, 42], "object": "hERα", "obj_char_span": [80, 84], "rel_type": "regulator", "sbj_tok_span": [5, 8], "obj_tok_span": [15, 18], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [17, 20]}], "umls_entity_list": [{"mention": "BzP", "char_span": [39, 42], "sem_type": "Gene or Genome", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"mention": "BzP", "char_span": [145, 148], "sem_type": "Gene or Genome", "tok_span": [39, 42], "new_tok_span": [42, 45]}, {"mention": "parabens", "char_span": [198, 206], "sem_type": "Pharmacologic Substance", "tok_span": [52, 54], "new_tok_span": [57, 59]}], "new_text": "Molecular docking analysis showed that <START=Gene or Genome> BzP <END=Gene or Genome> fits well into the agonist pocket of hERα. The lowest observed effect dose ( LOED ) ( 0. 16 mg / kg / day ) of <START=Gene or Genome> BzP <END=Gene or Genome> is much lower than the documented LOEDs of other <START=Pharmacologic Substance> parabens <END=Pharmacologic Substance>."}, {"PMID": 15123288, "id": 1, "text": "Ligand-dependent nuclear hormone receptor (NR) signaling requires direct interaction between NR and the steroid receptor coactivators (SRC). Herein we utilize a library of SRC2 peptidomimetics to select for specific inhibitors of the interaction of SRC2 with the two estrogen receptor (ER) isoforms, ERalpha and ERbeta, in the presence of three different ligands: 17beta-estradiol, diethylstilbesterol, and genistein.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [104, 111], "name": "steroid", "tok_span": [18, 19], "new_tok_span": [20, 21]}, {"ent_type": "CHEMICAL", "char_span": [267, 275], "name": "estrogen", "tok_span": [56, 57], "new_tok_span": [68, 69]}, {"ent_type": "CHEMICAL", "char_span": [364, 380], "name": "17beta-estradiol", "tok_span": [77, 81], "new_tok_span": [93, 97]}, {"ent_type": "CHEMICAL", "char_span": [382, 401], "name": "diethylstilbesterol", "tok_span": [82, 89], "new_tok_span": [98, 105]}, {"ent_type": "CHEMICAL", "char_span": [407, 416], "name": "genistein", "tok_span": [91, 94], "new_tok_span": [107, 110]}, {"ent_type": "GENE", "char_span": [104, 133], "name": "steroid receptor coactivators", "tok_span": [18, 23], "new_tok_span": [20, 25]}, {"ent_type": "GENE", "char_span": [135, 138], "name": "SRC", "tok_span": [24, 26], "new_tok_span": [26, 28]}, {"ent_type": "GENE", "char_span": [172, 176], "name": "SRC2", "tok_span": [34, 37], "new_tok_span": [39, 42]}, {"ent_type": "GENE", "char_span": [17, 41], "name": "nuclear hormone receptor", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"ent_type": "GENE", "char_span": [249, 253], "name": "SRC2", "tok_span": [50, 53], "new_tok_span": [59, 62]}, {"ent_type": "GENE", "char_span": [267, 284], "name": "estrogen receptor", "tok_span": [56, 58], "new_tok_span": [68, 70]}, {"ent_type": "GENE", "char_span": [286, 288], "name": "ER", "tok_span": [59, 60], "new_tok_span": [73, 74]}, {"ent_type": "GENE", "char_span": [300, 307], "name": "ERalpha", "tok_span": [63, 65], "new_tok_span": [79, 81]}, {"ent_type": "GENE", "char_span": [312, 318], "name": "ERbeta", "tok_span": [66, 68], "new_tok_span": [82, 84]}, {"ent_type": "GENE", "char_span": [43, 45], "name": "NR", "tok_span": [8, 9], "new_tok_span": [10, 11]}, {"ent_type": "GENE", "char_span": [93, 95], "name": "NR", "tok_span": [15, 16], "new_tok_span": [17, 18]}], "relation_list": [{"subject": "17beta-estradiol", "sbj_char_span": [364, 380], "object": "estrogen receptor", "obj_char_span": [267, 284], "rel_type": "regulator", "sbj_tok_span": [77, 81], "obj_tok_span": [56, 58], "new_sbj_tok_span": [93, 97], "new_obj_tok_span": [68, 70]}, {"subject": "17beta-estradiol", "sbj_char_span": [364, 380], "object": "ER", "obj_char_span": [286, 288], "rel_type": "regulator", "sbj_tok_span": [77, 81], "obj_tok_span": [59, 60], "new_sbj_tok_span": [93, 97], "new_obj_tok_span": [73, 74]}, {"subject": "diethylstilbesterol", "sbj_char_span": [382, 401], "object": "estrogen receptor", "obj_char_span": [267, 284], "rel_type": "regulator", "sbj_tok_span": [82, 89], "obj_tok_span": [56, 58], "new_sbj_tok_span": [98, 105], "new_obj_tok_span": [68, 70]}, {"subject": "diethylstilbesterol", "sbj_char_span": [382, 401], "object": "ER", "obj_char_span": [286, 288], "rel_type": "regulator", "sbj_tok_span": [82, 89], "obj_tok_span": [59, 60], "new_sbj_tok_span": [98, 105], "new_obj_tok_span": [73, 74]}, {"subject": "genistein", "sbj_char_span": [407, 416], "object": "estrogen receptor", "obj_char_span": [267, 284], "rel_type": "regulator", "sbj_tok_span": [91, 94], "obj_tok_span": [56, 58], "new_sbj_tok_span": [107, 110], "new_obj_tok_span": [68, 70]}, {"subject": "genistein", "sbj_char_span": [407, 416], "object": "ER", "obj_char_span": [286, 288], "rel_type": "regulator", "sbj_tok_span": [91, 94], "obj_tok_span": [59, 60], "new_sbj_tok_span": [107, 110], "new_obj_tok_span": [73, 74]}, {"subject": "17beta-estradiol", "sbj_char_span": [364, 380], "object": "ERalpha", "obj_char_span": [300, 307], "rel_type": "regulator", "sbj_tok_span": [77, 81], "obj_tok_span": [63, 65], "new_sbj_tok_span": [93, 97], "new_obj_tok_span": [79, 81]}, {"subject": "diethylstilbesterol", "sbj_char_span": [382, 401], "object": "ERalpha", "obj_char_span": [300, 307], "rel_type": "regulator", "sbj_tok_span": [82, 89], "obj_tok_span": [63, 65], "new_sbj_tok_span": [98, 105], "new_obj_tok_span": [79, 81]}, {"subject": "genistein", "sbj_char_span": [407, 416], "object": "ERalpha", "obj_char_span": [300, 307], "rel_type": "regulator", "sbj_tok_span": [91, 94], "obj_tok_span": [63, 65], "new_sbj_tok_span": [107, 110], "new_obj_tok_span": [79, 81]}, {"subject": "17beta-estradiol", "sbj_char_span": [364, 380], "object": "ERbeta", "obj_char_span": [312, 318], "rel_type": "regulator", "sbj_tok_span": [77, 81], "obj_tok_span": [66, 68], "new_sbj_tok_span": [93, 97], "new_obj_tok_span": [82, 84]}, {"subject": "diethylstilbesterol", "sbj_char_span": [382, 401], "object": "ERbeta", "obj_char_span": [312, 318], "rel_type": "regulator", "sbj_tok_span": [82, 89], "obj_tok_span": [66, 68], "new_sbj_tok_span": [98, 105], "new_obj_tok_span": [82, 84]}, {"subject": "genistein", "sbj_char_span": [407, 416], "object": "ERbeta", "obj_char_span": [312, 318], "rel_type": "regulator", "sbj_tok_span": [91, 94], "obj_tok_span": [66, 68], "new_sbj_tok_span": [107, 110], "new_obj_tok_span": [82, 84]}], "umls_entity_list": [{"mention": "nuclear hormone receptor", "char_span": [17, 41], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"mention": "SRC2", "char_span": [172, 176], "sem_type": "Gene or Genome", "tok_span": [34, 37], "new_tok_span": [39, 42]}, {"mention": "SRC2", "char_span": [249, 253], "sem_type": "Gene or Genome", "tok_span": [50, 53], "new_tok_span": [59, 62]}, {"mention": "peptidomimetics", "char_span": [177, 192], "sem_type": "Pharmacologic Substance", "tok_span": [37, 41], "new_tok_span": [44, 48]}, {"mention": "library", "char_span": [161, 168], "sem_type": "Gene or Genome", "tok_span": [32, 33], "new_tok_span": [35, 36]}, {"mention": "isoforms", "char_span": [290, 298], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [61, 62], "new_tok_span": [76, 77]}, {"mention": "estrogen receptor", "char_span": [267, 284], "sem_type": "Gene or Genome", "tok_span": [56, 58], "new_tok_span": [68, 70]}, {"mention": "estrogen receptor", "char_span": [267, 284], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 58], "new_tok_span": [68, 70]}], "new_text": "Ligand - dependent <START=Amino Acid, Peptide, or Protein> nuclear hormone receptor <END=Amino Acid, Peptide, or Protein> ( NR ) signaling requires direct interaction between NR and the steroid receptor coactivators ( SRC ). Herein we utilize a <START=Gene or Genome> library <END=Gene or Genome> of <START=Gene or Genome> SRC2 <END=Gene or Genome> <START=Pharmacologic Substance> peptidomimetics <END=Pharmacologic Substance> to select for specific inhibitors of the interaction of <START=Gene or Genome> SRC2 <END=Gene or Genome> with the two <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> estrogen receptor <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( ER ) <START=Amino Acid, Peptide, or Protein> isoforms <END=Amino Acid, Peptide, or Protein>, ERalpha and ERbeta, in the presence of three different ligands : 17beta - estradiol, diethylstilbesterol, and genistein."}, {"PMID": 16232421, "id": 3, "text": "When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [43, 50], "name": "glucose", "tok_span": [9, 10], "new_tok_span": [10, 11]}, {"ent_type": "CHEMICAL", "char_span": [87, 106], "name": "alpha-ketoglutarate", "tok_span": [19, 25], "new_tok_span": [24, 30]}, {"ent_type": "CHEMICAL", "char_span": [170, 179], "name": "succinate", "tok_span": [35, 37], "new_tok_span": [45, 47]}, {"ent_type": "CHEMICAL", "char_span": [223, 232], "name": "succinate", "tok_span": [50, 52], "new_tok_span": [67, 69]}, {"ent_type": "CHEMICAL", "char_span": [301, 310], "name": "succinate", "tok_span": [63, 65], "new_tok_span": [87, 89]}, {"ent_type": "GENE", "char_span": [81, 85], "name": "KGD1", "tok_span": [15, 18], "new_tok_span": [18, 21]}, {"ent_type": "GENE", "char_span": [87, 120], "name": "alpha-ketoglutarate dehydrogenase", "tok_span": [19, 26], "new_tok_span": [24, 31]}, {"ent_type": "GENE", "char_span": [217, 221], "name": "SDH1", "tok_span": [46, 49], "new_tok_span": [59, 62]}, {"ent_type": "GENE", "char_span": [223, 246], "name": "succinate dehydrogenase", "tok_span": [50, 53], "new_tok_span": [67, 70]}], "relation_list": [{"subject": "succinate", "sbj_char_span": [170, 179], "object": "KGD1", "obj_char_span": [81, 85], "rel_type": "product or substrate", "sbj_tok_span": [35, 37], "obj_tok_span": [15, 18], "new_sbj_tok_span": [45, 47], "new_obj_tok_span": [18, 21]}, {"subject": "succinate", "sbj_char_span": [170, 179], "object": "alpha-ketoglutarate dehydrogenase", "obj_char_span": [87, 120], "rel_type": "product or substrate", "sbj_tok_span": [35, 37], "obj_tok_span": [19, 26], "new_sbj_tok_span": [45, 47], "new_obj_tok_span": [24, 31]}, {"subject": "succinate", "sbj_char_span": [301, 310], "object": "SDH1", "obj_char_span": [217, 221], "rel_type": "product or substrate", "sbj_tok_span": [63, 65], "obj_tok_span": [46, 49], "new_sbj_tok_span": [87, 89], "new_obj_tok_span": [59, 62]}, {"subject": "succinate", "sbj_char_span": [301, 310], "object": "succinate dehydrogenase", "obj_char_span": [223, 246], "rel_type": "product or substrate", "sbj_tok_span": [63, 65], "obj_tok_span": [50, 53], "new_sbj_tok_span": [87, 89], "new_obj_tok_span": [67, 70]}], "umls_entity_list": [{"mention": "glucose", "char_span": [43, 50], "sem_type": "Pharmacologic Substance", "tok_span": [9, 10], "new_tok_span": [10, 11]}, {"mention": "KGD1", "char_span": [81, 85], "sem_type": "Gene or Genome", "tok_span": [15, 18], "new_tok_span": [18, 21]}, {"mention": "alpha-ketoglutarate dehydrogenase", "char_span": [87, 120], "sem_type": "Gene or Genome", "tok_span": [19, 26], "new_tok_span": [24, 31]}, {"mention": "succinate", "char_span": [170, 179], "sem_type": "Organic Chemical", "tok_span": [35, 37], "new_tok_span": [45, 47]}, {"mention": "succinate", "char_span": [223, 232], "sem_type": "Organic Chemical", "tok_span": [50, 52], "new_tok_span": [67, 69]}, {"mention": "succinate", "char_span": [301, 310], "sem_type": "Organic Chemical", "tok_span": [63, 65], "new_tok_span": [87, 89]}, {"mention": "SDH1", "char_span": [217, 221], "sem_type": "Gene or Genome", "tok_span": [46, 49], "new_tok_span": [59, 62]}, {"mention": "succinate", "char_span": [170, 179], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 37], "new_tok_span": [45, 47]}, {"mention": "succinate", "char_span": [223, 232], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 52], "new_tok_span": [67, 69]}, {"mention": "succinate", "char_span": [301, 310], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [63, 65], "new_tok_span": [87, 89]}, {"mention": "succinate dehydrogenase", "char_span": [223, 246], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 53], "new_tok_span": [67, 70]}, {"mention": "gene", "char_span": [122, 126], "sem_type": "Gene or Genome", "tok_span": [27, 28], "new_tok_span": [34, 35]}, {"mention": "gene", "char_span": [248, 252], "sem_type": "Gene or Genome", "tok_span": [54, 55], "new_tok_span": [75, 76]}], "new_text": "When cultured in YPD medium containing 15 % <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> under aerobic conditions, the <START=Gene or Genome> KGD1 <END=Gene or Genome> ( <START=Gene or Genome> alpha - ketoglutarate dehydrogenase <END=Gene or Genome> ) <START=Gene or Genome> gene <END=Gene or Genome> disrupted mutant produced a lower level of <START=Organic Chemical> <START=Amino Acid, Peptide, or Protein> succinate <END=Organic Chemical> <END=Amino Acid, Peptide, or Protein> than the wild - type strain, while the <START=Gene or Genome> SDH1 <END=Gene or Genome> ( <START=Organic Chemical> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> succinate <END=Organic Chemical> <END=Amino Acid, Peptide, or Protein> dehydrogenase <END=Amino Acid, Peptide, or Protein> ) <START=Gene or Genome> gene <END=Gene or Genome> - disrupted mutant produced an increased level of <START=Organic Chemical> <START=Amino Acid, Peptide, or Protein> succinate <END=Organic Chemical> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 1315825, "id": 11, "text": "RESULTS: Plasma ANF concentrations rose significantly in all patients within 2 h of candoxatril administration compared with placebo although peak and integrated ANF levels were similar at all three doses.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [84, 95], "name": "candoxatril", "tok_span": [15, 20], "new_tok_span": [18, 23]}, {"ent_type": "GENE", "char_span": [9, 19], "name": "Plasma ANF", "tok_span": [2, 5], "new_tok_span": [2, 5]}, {"ent_type": "GENE", "char_span": [162, 165], "name": "ANF", "tok_span": [28, 30], "new_tok_span": [32, 34]}], "relation_list": [{"subject": "candoxatril", "sbj_char_span": [84, 95], "object": "Plasma ANF", "obj_char_span": [9, 19], "rel_type": "regulator", "sbj_tok_span": [15, 20], "obj_tok_span": [2, 5], "new_sbj_tok_span": [18, 23], "new_obj_tok_span": [2, 5]}], "umls_entity_list": [{"mention": "rose", "char_span": [35, 39], "sem_type": "Pharmacologic Substance", "tok_span": [6, 7], "new_tok_span": [7, 8]}, {"mention": "candoxatril", "char_span": [84, 95], "sem_type": "Pharmacologic Substance", "tok_span": [15, 20], "new_tok_span": [18, 23]}], "new_text": "RESULTS : Plasma ANF concentrations <START=Pharmacologic Substance> rose <END=Pharmacologic Substance> significantly in all patients within 2 h of <START=Pharmacologic Substance> candoxatril <END=Pharmacologic Substance> administration compared with placebo although peak and integrated ANF levels were similar at all three doses."}, {"PMID": 23583259, "id": 3, "text": "The present study investigated the effects of rilpivirine and etravirine on the activity of human PXR (hPXR), including the mode of activation, and compared them to those of efavirenz, nevirapine, and delavirdine, which are first generation non-nucleoside reverse transcriptase inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [46, 57], "name": "rilpivirine", "tok_span": [7, 12], "new_tok_span": [8, 13]}, {"ent_type": "CHEMICAL", "char_span": [62, 72], "name": "etravirine", "tok_span": [13, 17], "new_tok_span": [16, 20]}, {"ent_type": "CHEMICAL", "char_span": [174, 183], "name": "efavirenz", "tok_span": [42, 45], "new_tok_span": [47, 50]}, {"ent_type": "CHEMICAL", "char_span": [185, 195], "name": "nevirapine", "tok_span": [46, 49], "new_tok_span": [53, 56]}, {"ent_type": "CHEMICAL", "char_span": [201, 212], "name": "delavirdine", "tok_span": [51, 55], "new_tok_span": [60, 64]}, {"ent_type": "CHEMICAL", "char_span": [245, 255], "name": "nucleoside", "tok_span": [62, 64], "new_tok_span": [72, 74]}, {"ent_type": "GENE", "char_span": [92, 101], "name": "human PXR", "tok_span": [21, 24], "new_tok_span": [25, 28]}, {"ent_type": "GENE", "char_span": [103, 107], "name": "hPXR", "tok_span": [25, 28], "new_tok_span": [29, 32]}, {"ent_type": "GENE", "char_span": [256, 277], "name": "reverse transcriptase", "tok_span": [64, 66], "new_tok_span": [74, 76]}], "relation_list": [{"subject": "efavirenz", "sbj_char_span": [174, 183], "object": "reverse transcriptase", "obj_char_span": [256, 277], "rel_type": "inhibitor", "sbj_tok_span": [42, 45], "obj_tok_span": [64, 66], "new_sbj_tok_span": [47, 50], "new_obj_tok_span": [74, 76]}, {"subject": "nevirapine", "sbj_char_span": [185, 195], "object": "reverse transcriptase", "obj_char_span": [256, 277], "rel_type": "inhibitor", "sbj_tok_span": [46, 49], "obj_tok_span": [64, 66], "new_sbj_tok_span": [53, 56], "new_obj_tok_span": [74, 76]}, {"subject": "delavirdine", "sbj_char_span": [201, 212], "object": "reverse transcriptase", "obj_char_span": [256, 277], "rel_type": "inhibitor", "sbj_tok_span": [51, 55], "obj_tok_span": [64, 66], "new_sbj_tok_span": [60, 64], "new_obj_tok_span": [74, 76]}], "umls_entity_list": [{"mention": "rilpivirine", "char_span": [46, 57], "sem_type": "Pharmacologic Substance", "tok_span": [7, 12], "new_tok_span": [8, 13]}, {"mention": "etravirine", "char_span": [62, 72], "sem_type": "Pharmacologic Substance", "tok_span": [13, 17], "new_tok_span": [16, 20]}, {"mention": "efavirenz", "char_span": [174, 183], "sem_type": "Pharmacologic Substance", "tok_span": [42, 45], "new_tok_span": [47, 50]}, {"mention": "nevirapine", "char_span": [185, 195], "sem_type": "Pharmacologic Substance", "tok_span": [46, 49], "new_tok_span": [53, 56]}, {"mention": "delavirdine", "char_span": [201, 212], "sem_type": "Pharmacologic Substance", "tok_span": [51, 55], "new_tok_span": [60, 64]}], "new_text": "The present study investigated the effects of <START=Pharmacologic Substance> rilpivirine <END=Pharmacologic Substance> and <START=Pharmacologic Substance> etravirine <END=Pharmacologic Substance> on the activity of human PXR ( hPXR ), including the mode of activation, and compared them to those of <START=Pharmacologic Substance> efavirenz <END=Pharmacologic Substance>, <START=Pharmacologic Substance> nevirapine <END=Pharmacologic Substance>, and <START=Pharmacologic Substance> delavirdine <END=Pharmacologic Substance>, which are first generation non - nucleoside reverse transcriptase inhibitors."}, {"PMID": 23404443, "id": 4, "text": "Three variables of cardiac vagal effects (the root mean square of successive differences [rMSSD] in the interbeat interval of the heart rate [IBI], heart-rate variability [HRV] caused by peak-valley respiratory sinus arrhythmia [pvRSA], and high-frequency power [HF]) and heart rate (HR) were obtained at seven time points during the clamps, characterised by increasing levels of insulin (achieved by administering insulin plus glucose, glucose only, glucose and GLP-1, and glucose and GLP-1 combined with arginine).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [428, 435], "name": "glucose", "tok_span": [98, 99], "new_tok_span": [98, 99]}, {"ent_type": "CHEMICAL", "char_span": [437, 444], "name": "glucose", "tok_span": [100, 101], "new_tok_span": [100, 101]}, {"ent_type": "CHEMICAL", "char_span": [451, 458], "name": "glucose", "tok_span": [103, 104], "new_tok_span": [103, 104]}, {"ent_type": "CHEMICAL", "char_span": [474, 481], "name": "glucose", "tok_span": [110, 111], "new_tok_span": [114, 115]}, {"ent_type": "CHEMICAL", "char_span": [506, 514], "name": "arginine", "tok_span": [117, 118], "new_tok_span": [125, 126]}, {"ent_type": "GENE", "char_span": [380, 387], "name": "insulin", "tok_span": [90, 91], "new_tok_span": [90, 91]}, {"ent_type": "GENE", "char_span": [415, 422], "name": "insulin", "tok_span": [96, 97], "new_tok_span": [96, 97]}, {"ent_type": "GENE", "char_span": [463, 468], "name": "GLP-1", "tok_span": [105, 108], "new_tok_span": [107, 110]}, {"ent_type": "GENE", "char_span": [486, 491], "name": "GLP-1", "tok_span": [112, 115], "new_tok_span": [118, 121]}], "relation_list": [{"subject": "glucose", "sbj_char_span": [428, 435], "object": "insulin", "obj_char_span": [380, 387], "rel_type": "regulator", "sbj_tok_span": [98, 99], "obj_tok_span": [90, 91], "new_sbj_tok_span": [98, 99], "new_obj_tok_span": [90, 91]}, {"subject": "glucose", "sbj_char_span": [437, 444], "object": "insulin", "obj_char_span": [380, 387], "rel_type": "regulator", "sbj_tok_span": [100, 101], "obj_tok_span": [90, 91], "new_sbj_tok_span": [100, 101], "new_obj_tok_span": [90, 91]}, {"subject": "glucose", "sbj_char_span": [451, 458], "object": "insulin", "obj_char_span": [380, 387], "rel_type": "regulator", "sbj_tok_span": [103, 104], "obj_tok_span": [90, 91], "new_sbj_tok_span": [103, 104], "new_obj_tok_span": [90, 91]}, {"subject": "glucose", "sbj_char_span": [474, 481], "object": "insulin", "obj_char_span": [380, 387], "rel_type": "regulator", "sbj_tok_span": [110, 111], "obj_tok_span": [90, 91], "new_sbj_tok_span": [114, 115], "new_obj_tok_span": [90, 91]}, {"subject": "arginine", "sbj_char_span": [506, 514], "object": "insulin", "obj_char_span": [380, 387], "rel_type": "regulator", "sbj_tok_span": [117, 118], "obj_tok_span": [90, 91], "new_sbj_tok_span": [125, 126], "new_obj_tok_span": [90, 91]}], "umls_entity_list": [{"mention": "GLP-1", "char_span": [463, 468], "sem_type": "Gene or Genome", "tok_span": [105, 108], "new_tok_span": [107, 110]}, {"mention": "GLP-1", "char_span": [486, 491], "sem_type": "Gene or Genome", "tok_span": [112, 115], "new_tok_span": [118, 121]}, {"mention": "GLP-1", "char_span": [463, 468], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [105, 108], "new_tok_span": [107, 110]}, {"mention": "GLP-1", "char_span": [486, 491], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [112, 115], "new_tok_span": [118, 121]}], "new_text": "Three variables of cardiac vagal effects ( the root mean square of successive differences [ rMSSD ] in the interbeat interval of the heart rate [ IBI ], heart - rate variability [ HRV ] caused by peak - valley respiratory sinus arrhythmia [ pvRSA ], and high - frequency power [ HF ] ) and heart rate ( HR ) were obtained at seven time points during the clamps, characterised by increasing levels of insulin ( achieved by administering insulin plus glucose, glucose only, glucose and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> GLP - 1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, and glucose and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> GLP - 1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> combined with arginine )."}, {"PMID": 23583259, "id": 1, "text": "Rilpivirine and etravirine are second generation non-nucleoside reverse transcriptase inhibitors approved recently by the United States Food and Drug Administration for the treatment of human immunodeficiency virus-1 infection.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Rilpivirine", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "CHEMICAL", "char_span": [16, 26], "name": "etravirine", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "CHEMICAL", "char_span": [53, 63], "name": "nucleoside", "tok_span": [15, 17], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [64, 85], "name": "reverse transcriptase", "tok_span": [17, 19], "new_tok_span": [19, 21]}], "relation_list": [{"subject": "Rilpivirine", "sbj_char_span": [0, 11], "object": "reverse transcriptase", "obj_char_span": [64, 85], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [17, 19], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [19, 21]}, {"subject": "etravirine", "sbj_char_span": [16, 26], "object": "reverse transcriptase", "obj_char_span": [64, 85], "rel_type": "inhibitor", "sbj_tok_span": [6, 10], "obj_tok_span": [17, 19], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [19, 21]}], "umls_entity_list": [{"mention": "non-nucleoside", "char_span": [49, 63], "sem_type": "Pharmacologic Substance", "tok_span": [13, 17], "new_tok_span": [14, 18]}], "new_text": "Rilpivirine and etravirine are second generation <START=Pharmacologic Substance> non - nucleoside <END=Pharmacologic Substance> reverse transcriptase inhibitors approved recently by the United States Food and Drug Administration for the treatment of human immunodeficiency virus - 1 infection."}, {"PMID": 23297412, "id": 4, "text": "In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as resveratrol, both of which down-regulated p300 protein levels but not p300 mRNA levels.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [82, 95], "name": "phenylephrine", "tok_span": [16, 19], "new_tok_span": [17, 20]}, {"ent_type": "CHEMICAL", "char_span": [152, 163], "name": "resveratrol", "tok_span": [30, 32], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [135, 140], "name": "SIRT1", "tok_span": [25, 27], "new_tok_span": [27, 29]}, {"ent_type": "GENE", "char_span": [194, 198], "name": "p300", "tok_span": [39, 41], "new_tok_span": [43, 45]}, {"ent_type": "GENE", "char_span": [222, 226], "name": "p300", "tok_span": [45, 47], "new_tok_span": [53, 55]}], "relation_list": [{"subject": "resveratrol", "sbj_char_span": [152, 163], "object": "p300", "obj_char_span": [194, 198], "rel_type": "regulator", "sbj_tok_span": [30, 32], "obj_tok_span": [39, 41], "new_sbj_tok_span": [32, 34], "new_obj_tok_span": [43, 45]}, {"subject": "phenylephrine", "sbj_char_span": [82, 95], "object": "p300", "obj_char_span": [194, 198], "rel_type": "regulator", "sbj_tok_span": [16, 19], "obj_tok_span": [39, 41], "new_sbj_tok_span": [17, 20], "new_obj_tok_span": [43, 45]}], "umls_entity_list": [{"mention": "phenylephrine", "char_span": [82, 95], "sem_type": "Pharmacologic Substance", "tok_span": [16, 19], "new_tok_span": [17, 20]}, {"mention": "p300", "char_span": [194, 198], "sem_type": "Gene or Genome", "tok_span": [39, 41], "new_tok_span": [43, 45]}, {"mention": "p300", "char_span": [222, 226], "sem_type": "Gene or Genome", "tok_span": [45, 47], "new_tok_span": [53, 55]}, {"mention": "p300", "char_span": [194, 198], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 41], "new_tok_span": [43, 45]}, {"mention": "p300", "char_span": [222, 226], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [45, 47], "new_tok_span": [53, 55]}], "new_text": "In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the α ( 1 ) - agonist <START=Pharmacologic Substance> phenylephrine <END=Pharmacologic Substance> was inhibited by the overexpression of SIRT1 as well as resveratrol, both of which down - regulated <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> p300 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> protein levels but not <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> p300 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> mRNA levels."}, {"PMID": 17916059, "id": 5, "text": "Caution is necessary only when it is coadministered with drugs metabolised by CYP2D6, such as metoprolol, or administered to the elderly or patients with severe hepatic or renal impairment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [94, 104], "name": "metoprolol", "tok_span": [22, 25], "new_tok_span": [24, 27]}, {"ent_type": "GENE", "char_span": [78, 84], "name": "CYP2D6", "tok_span": [15, 19], "new_tok_span": [17, 21]}], "relation_list": [{"subject": "metoprolol", "sbj_char_span": [94, 104], "object": "CYP2D6", "obj_char_span": [78, 84], "rel_type": "product or substrate", "sbj_tok_span": [22, 25], "obj_tok_span": [15, 19], "new_sbj_tok_span": [24, 27], "new_obj_tok_span": [17, 21]}], "umls_entity_list": [{"mention": "drugs", "char_span": [57, 62], "sem_type": "Pharmacologic Substance", "tok_span": [11, 12], "new_tok_span": [12, 13]}], "new_text": "Caution is necessary only when it is coadministered with <START=Pharmacologic Substance> drugs <END=Pharmacologic Substance> metabolised by CYP2D6, such as metoprolol, or administered to the elderly or patients with severe hepatic or renal impairment."}, {"PMID": 6441926, "id": 1, "text": "Deprenyl is a selective, irreversible inhibitor of monoamine oxidase type-B (MAO-B). In prolonged treatment (0.05-0.25 mg/kg, sc daily) in spite of the irreversible blocking, selective inhibition pattern of MAO was maintained. 14C-Deprenyl is well absorbed after oral or subcutaneous administration and penetrates rapidly to the central nervous system.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "Deprenyl", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [227, 239], "name": "14C-Deprenyl", "tok_span": [57, 63], "new_tok_span": [59, 65]}, {"ent_type": "CHEMICAL", "char_span": [51, 60], "name": "monoamine", "tok_span": [10, 12], "new_tok_span": [12, 14]}, {"ent_type": "GENE", "char_span": [207, 210], "name": "MAO", "tok_span": [52, 54], "new_tok_span": [54, 56]}, {"ent_type": "GENE", "char_span": [51, 75], "name": "monoamine oxidase type-B", "tok_span": [10, 16], "new_tok_span": [12, 18]}, {"ent_type": "GENE", "char_span": [77, 82], "name": "MAO-B", "tok_span": [17, 21], "new_tok_span": [19, 23]}], "relation_list": [{"subject": "Deprenyl", "sbj_char_span": [0, 8], "object": "monoamine oxidase type-B", "obj_char_span": [51, 75], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [10, 16], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [12, 18]}, {"subject": "Deprenyl", "sbj_char_span": [0, 8], "object": "MAO-B", "obj_char_span": [77, 82], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [17, 21], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [19, 23]}], "umls_entity_list": [{"mention": "Deprenyl", "char_span": [0, 8], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "Deprenyl", "char_span": [231, 239], "sem_type": "Pharmacologic Substance", "tok_span": [60, 63], "new_tok_span": [63, 66]}], "new_text": "<START=Pharmacologic Substance> Deprenyl <END=Pharmacologic Substance> is a selective, irreversible inhibitor of monoamine oxidase type - B ( MAO - B ). In prolonged treatment ( 0. 05 - 0. 25 mg / kg, sc daily ) in spite of the irreversible blocking, selective inhibition pattern of MAO was maintained. 14C - <START=Pharmacologic Substance> Deprenyl <END=Pharmacologic Substance> is well absorbed after oral or subcutaneous administration and penetrates rapidly to the central nervous system."}, {"PMID": 17324065, "id": 6, "text": "The temporal and anatomical determinants of cocaine-induced CREB activity may indicate functional differences among NAc shell subregions and suggest the involvement of CREB in early and late cocaine effects.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [44, 51], "name": "cocaine", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [191, 198], "name": "cocaine", "tok_span": [32, 33], "new_tok_span": [34, 35]}, {"ent_type": "GENE", "char_span": [60, 64], "name": "CREB", "tok_span": [9, 10], "new_tok_span": [9, 10]}, {"ent_type": "GENE", "char_span": [168, 172], "name": "CREB", "tok_span": [27, 28], "new_tok_span": [29, 30]}], "relation_list": [{"subject": "cocaine", "sbj_char_span": [44, 51], "object": "CREB", "obj_char_span": [60, 64], "rel_type": "activator", "sbj_tok_span": [6, 7], "obj_tok_span": [9, 10], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [9, 10]}], "umls_entity_list": [{"mention": "NAc", "char_span": [116, 119], "sem_type": "Gene or Genome", "tok_span": [16, 18], "new_tok_span": [17, 19]}], "new_text": "The temporal and anatomical determinants of cocaine - induced CREB activity may indicate functional differences among <START=Gene or Genome> NAc <END=Gene or Genome> shell subregions and suggest the involvement of CREB in early and late cocaine effects."}, {"PMID": 16763553, "id": 5, "text": "Further, cholesterol metabolites, predominantly the oxysterols, the natural ligands for liver X receptor (LXR), induced these genes via upregulation of sterol regulatory element binding protein-1c (SREBP-1c) that bound to the regulatory regions of these genes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 20], "name": "cholesterol", "tok_span": [2, 3], "new_tok_span": [4, 5]}, {"ent_type": "CHEMICAL", "char_span": [52, 62], "name": "oxysterols", "tok_span": [7, 10], "new_tok_span": [12, 15]}, {"ent_type": "CHEMICAL", "char_span": [152, 158], "name": "sterol", "tok_span": [29, 31], "new_tok_span": [42, 44]}, {"ent_type": "GENE", "char_span": [88, 104], "name": "liver X receptor", "tok_span": [15, 18], "new_tok_span": [24, 27]}, {"ent_type": "GENE", "char_span": [106, 109], "name": "LXR", "tok_span": [19, 21], "new_tok_span": [29, 31]}, {"ent_type": "GENE", "char_span": [152, 196], "name": "sterol regulatory element binding protein-1c", "tok_span": [29, 38], "new_tok_span": [42, 51]}, {"ent_type": "GENE", "char_span": [198, 206], "name": "SREBP-1c", "tok_span": [39, 44], "new_tok_span": [53, 58]}], "relation_list": [{"subject": "oxysterols", "sbj_char_span": [52, 62], "object": "liver X receptor", "obj_char_span": [88, 104], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [15, 18], "new_sbj_tok_span": [12, 15], "new_obj_tok_span": [24, 27]}, {"subject": "oxysterols", "sbj_char_span": [52, 62], "object": "LXR", "obj_char_span": [106, 109], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [19, 21], "new_sbj_tok_span": [12, 15], "new_obj_tok_span": [29, 31]}, {"subject": "cholesterol", "sbj_char_span": [9, 20], "object": "liver X receptor", "obj_char_span": [88, 104], "rel_type": "regulator", "sbj_tok_span": [2, 3], "obj_tok_span": [15, 18], "new_sbj_tok_span": [4, 5], "new_obj_tok_span": [24, 27]}, {"subject": "cholesterol", "sbj_char_span": [9, 20], "object": "LXR", "obj_char_span": [106, 109], "rel_type": "regulator", "sbj_tok_span": [2, 3], "obj_tok_span": [19, 21], "new_sbj_tok_span": [4, 5], "new_obj_tok_span": [29, 31]}, {"subject": "cholesterol", "sbj_char_span": [9, 20], "object": "sterol regulatory element binding protein-1c", "obj_char_span": [152, 196], "rel_type": "regulator", "sbj_tok_span": [2, 3], "obj_tok_span": [29, 38], "new_sbj_tok_span": [4, 5], "new_obj_tok_span": [42, 51]}, {"subject": "oxysterols", "sbj_char_span": [52, 62], "object": "sterol regulatory element binding protein-1c", "obj_char_span": [152, 196], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [29, 38], "new_sbj_tok_span": [12, 15], "new_obj_tok_span": [42, 51]}, {"subject": "cholesterol", "sbj_char_span": [9, 20], "object": "SREBP-1c", "obj_char_span": [198, 206], "rel_type": "regulator", "sbj_tok_span": [2, 3], "obj_tok_span": [39, 44], "new_sbj_tok_span": [4, 5], "new_obj_tok_span": [53, 58]}, {"subject": "oxysterols", "sbj_char_span": [52, 62], "object": "SREBP-1c", "obj_char_span": [198, 206], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [39, 44], "new_sbj_tok_span": [12, 15], "new_obj_tok_span": [53, 58]}], "umls_entity_list": [{"mention": "cholesterol", "char_span": [9, 20], "sem_type": "Organic Chemical", "tok_span": [2, 3], "new_tok_span": [4, 5]}, {"mention": "oxysterols", "char_span": [52, 62], "sem_type": "Organic Chemical", "tok_span": [7, 10], "new_tok_span": [12, 15]}, {"mention": "liver X receptor", "char_span": [88, 104], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 18], "new_tok_span": [24, 27]}, {"mention": "genes", "char_span": [126, 131], "sem_type": "Gene or Genome", "tok_span": [25, 26], "new_tok_span": [36, 37]}, {"mention": "genes", "char_span": [254, 259], "sem_type": "Gene or Genome", "tok_span": [53, 54], "new_tok_span": [68, 69]}, {"mention": "sterol", "char_span": [14, 20], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 3], "new_tok_span": [4, 5]}, {"mention": "sterol", "char_span": [55, 61], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 10], "new_tok_span": [14, 16]}, {"mention": "sterol", "char_span": [152, 158], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 31], "new_tok_span": [42, 44]}], "new_text": "Further, <START=Organic Chemical> <START=Amino Acid, Peptide, or Protein> cholesterol <END=Organic Chemical> <END=Amino Acid, Peptide, or Protein> metabolites, predominantly the <START=Organic Chemical> ox <START=Amino Acid, Peptide, or Protein>ysterols <END=Organic Chemical> <END=Amino Acid, Peptide, or Protein>, the natural ligands for <START=Amino Acid, Peptide, or Protein> liver X receptor <END=Amino Acid, Peptide, or Protein> ( LXR ), induced these <START=Gene or Genome> genes <END=Gene or Genome> via upregulation of <START=Amino Acid, Peptide, or Protein> sterol <END=Amino Acid, Peptide, or Protein> regulatory element binding protein - 1c ( SREBP - 1c ) that bound to the regulatory regions of these <START=Gene or Genome> genes <END=Gene or Genome>."}, {"PMID": 23074173, "id": 7, "text": "We demonstrated that deferasirox increased expression of the metastasis suppressor protein N-myc downstream-regulated gene 1 and upregulated the cyclin-dependent kinase inhibitor p21(CIP1/WAF1) while decreasing cyclin D1 levels.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [21, 32], "name": "deferasirox", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [83, 124], "name": "protein N-myc downstream-regulated gene 1", "tok_span": [12, 21], "new_tok_span": [15, 24]}, {"ent_type": "GENE", "char_span": [145, 182], "name": "cyclin-dependent kinase inhibitor p21", "tok_span": [24, 31], "new_tok_span": [30, 37]}, {"ent_type": "GENE", "char_span": [183, 187], "name": "CIP1", "tok_span": [32, 35], "new_tok_span": [40, 43]}, {"ent_type": "GENE", "char_span": [188, 192], "name": "WAF1", "tok_span": [36, 39], "new_tok_span": [45, 48]}, {"ent_type": "GENE", "char_span": [211, 220], "name": "cyclin D1", "tok_span": [42, 45], "new_tok_span": [54, 57]}], "relation_list": [{"subject": "deferasirox", "sbj_char_span": [21, 32], "object": "protein N-myc downstream-regulated gene 1", "obj_char_span": [83, 124], "rel_type": "regulator", "sbj_tok_span": [3, 6], "obj_tok_span": [12, 21], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [15, 24]}, {"subject": "deferasirox", "sbj_char_span": [21, 32], "object": "cyclin-dependent kinase inhibitor p21", "obj_char_span": [145, 182], "rel_type": "regulator", "sbj_tok_span": [3, 6], "obj_tok_span": [24, 31], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [30, 37]}, {"subject": "deferasirox", "sbj_char_span": [21, 32], "object": "CIP1", "obj_char_span": [183, 187], "rel_type": "regulator", "sbj_tok_span": [3, 6], "obj_tok_span": [32, 35], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [40, 43]}, {"subject": "deferasirox", "sbj_char_span": [21, 32], "object": "WAF1", "obj_char_span": [188, 192], "rel_type": "regulator", "sbj_tok_span": [3, 6], "obj_tok_span": [36, 39], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [45, 48]}, {"subject": "deferasirox", "sbj_char_span": [21, 32], "object": "cyclin D1", "obj_char_span": [211, 220], "rel_type": "regulator", "sbj_tok_span": [3, 6], "obj_tok_span": [42, 45], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [54, 57]}], "umls_entity_list": [{"mention": "deferasirox", "char_span": [21, 32], "sem_type": "Pharmacologic Substance", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "protein N", "char_span": [83, 92], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 14], "new_tok_span": [15, 17]}, {"mention": "cyclin-dependent kinase inhibitor p21", "char_span": [145, 182], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 31], "new_tok_span": [30, 37]}, {"mention": "WAF1", "char_span": [188, 192], "sem_type": "Gene or Genome", "tok_span": [36, 39], "new_tok_span": [45, 48]}, {"mention": "cyclin", "char_span": [145, 151], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 25], "new_tok_span": [30, 31]}, {"mention": "cyclin", "char_span": [211, 217], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 43], "new_tok_span": [54, 55]}, {"mention": "cyclin D1", "char_span": [211, 220], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 45], "new_tok_span": [54, 57]}], "new_text": "We demonstrated that <START=Pharmacologic Substance> deferasirox <END=Pharmacologic Substance> increased expression of the metastasis suppressor <START=Amino Acid, Peptide, or Protein> protein N <END=Amino Acid, Peptide, or Protein> - myc downstream - regulated gene 1 and upregulated the <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> cyclin <END=Amino Acid, Peptide, or Protein> - dependent kinase inhibitor p21 <END=Amino Acid, Peptide, or Protein> ( CIP1 / <START=Gene or Genome> WAF1 <END=Gene or Genome> ) while decreasing <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> cyclin <END=Amino Acid, Peptide, or Protein> D1 <END=Amino Acid, Peptide, or Protein> levels."}, {"PMID": 10229494, "id": 7, "text": "This increase in FAME (45%) was possibly due to the hydrolysis of phospholipids by activated PLA2, liberating fatty acids which were methylated.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [110, 121], "name": "fatty acids", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"ent_type": "GENE", "char_span": [93, 97], "name": "PLA2", "tok_span": [19, 21], "new_tok_span": [22, 24]}], "relation_list": [{"subject": "fatty acids", "sbj_char_span": [110, 121], "object": "PLA2", "obj_char_span": [93, 97], "rel_type": "product or substrate", "sbj_tok_span": [24, 26], "obj_tok_span": [19, 21], "new_sbj_tok_span": [28, 30], "new_obj_tok_span": [22, 24]}], "umls_entity_list": [{"mention": "phospholipids", "char_span": [66, 79], "sem_type": "Organic Chemical", "tok_span": [16, 17], "new_tok_span": [17, 18]}, {"mention": "PLA2", "char_span": [93, 97], "sem_type": "Gene or Genome", "tok_span": [19, 21], "new_tok_span": [22, 24]}], "new_text": "This increase in FAME ( 45 % ) was possibly due to the hydrolysis of <START=Organic Chemical> phospholipids <END=Organic Chemical> by activated <START=Gene or Genome> PLA2 <END=Gene or Genome>, liberating fatty acids which were methylated."}, {"PMID": 23532918, "id": 4, "text": "We had previously reported a fluorescein conjugate that was shown (by confocal microscopy imaging of DS-red-labelled cortical neurons) to bind specifically to GluN2B.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [29, 40], "name": "fluorescein", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"ent_type": "GENE", "char_span": [159, 165], "name": "GluN2B", "tok_span": [28, 32], "new_tok_span": [32, 36]}], "relation_list": [{"subject": "fluorescein", "sbj_char_span": [29, 40], "object": "GluN2B", "obj_char_span": [159, 165], "rel_type": "regulator", "sbj_tok_span": [5, 6], "obj_tok_span": [28, 32], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [32, 36]}], "umls_entity_list": [{"mention": "fluorescein", "char_span": [29, 40], "sem_type": "Pharmacologic Substance", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"mention": "GluN2B", "char_span": [159, 165], "sem_type": "Gene or Genome", "tok_span": [28, 32], "new_tok_span": [32, 36]}, {"mention": "GluN2B", "char_span": [159, 165], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 32], "new_tok_span": [32, 36]}], "new_text": "We had previously reported a <START=Pharmacologic Substance> fluorescein <END=Pharmacologic Substance> conjugate that was shown ( by confocal microscopy imaging of DS - red - labelled cortical neurons ) to bind specifically to <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> GluN2B <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23592780, "id": 3, "text": "Human albumin serum (HSA) is the most abundant protein in plasma and is glycated by glucose.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [84, 91], "name": "glucose", "tok_span": [19, 20], "new_tok_span": [23, 24]}, {"ent_type": "GENE", "char_span": [0, 19], "name": "Human albumin serum", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [21, 24], "name": "HSA", "tok_span": [4, 6], "new_tok_span": [6, 8]}], "relation_list": [{"subject": "glucose", "sbj_char_span": [84, 91], "object": "Human albumin serum", "obj_char_span": [0, 19], "rel_type": "regulator", "sbj_tok_span": [19, 20], "obj_tok_span": [0, 3], "new_sbj_tok_span": [23, 24], "new_obj_tok_span": [1, 4]}, {"subject": "glucose", "sbj_char_span": [84, 91], "object": "HSA", "obj_char_span": [21, 24], "rel_type": "regulator", "sbj_tok_span": [19, 20], "obj_tok_span": [4, 6], "new_sbj_tok_span": [23, 24], "new_obj_tok_span": [6, 8]}], "umls_entity_list": [{"mention": "Human albumin serum", "char_span": [0, 19], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "glycate", "char_span": [72, 79], "sem_type": "Pharmacologic Substance", "tok_span": [16, 18], "new_tok_span": [19, 21]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Human albumin serum <END=Amino Acid, Peptide, or Protein> ( HSA ) is the most abundant protein in plasma and is <START=Pharmacologic Substance> glycated <END=Pharmacologic Substance> by glucose."}, {"PMID": 10411647, "id": 0, "text": "Tyrosine hydroxylase binds tetrahydrobiopterin cofactor with negative cooperativity, as shown by kinetic analyses and surface plasmon resonance detection.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "Tyrosine", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "CHEMICAL", "char_span": [27, 46], "name": "tetrahydrobiopterin", "tok_span": [5, 11], "new_tok_span": [6, 12]}, {"ent_type": "GENE", "char_span": [0, 20], "name": "Tyrosine hydroxylase", "tok_span": [0, 4], "new_tok_span": [0, 4]}], "relation_list": [{"subject": "tetrahydrobiopterin", "sbj_char_span": [27, 46], "object": "Tyrosine hydroxylase", "obj_char_span": [0, 20], "rel_type": "regulator", "sbj_tok_span": [5, 11], "obj_tok_span": [0, 4], "new_sbj_tok_span": [6, 12], "new_obj_tok_span": [0, 4]}], "umls_entity_list": [{"mention": "tetrahydrobiopterin", "char_span": [27, 46], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 11], "new_tok_span": [6, 12]}], "new_text": "Tyrosine hydroxylase binds <START=Amino Acid, Peptide, or Protein> tetrahydrobiopterin <END=Amino Acid, Peptide, or Protein> cofactor with negative cooperativity, as shown by kinetic analyses and surface plasmon resonance detection."}, {"PMID": 10796070, "id": 6, "text": "The equilibrium dissociation constant (Kd) and density of binding sites (Bmax) for [3H]dexamethasone determined from saturation isotherms were 4.4 nM x/divided by 0.95 (SEM) and 30.1 fmol/mg protein +/-6.4 (SEM). Glucocorticoid receptors were activated by dexamethasone as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT. Transfection of primary human bronchial epithelial cells with this reporter plasmid resulted in 35-fold activation of transcription following dexamethasone stimulation (10(-6) M). The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [487, 500], "name": "dexamethasone", "tok_span": [106, 107], "new_tok_span": [127, 128]}, {"ent_type": "CHEMICAL", "char_span": [564, 570], "name": "RU-486", "tok_span": [121, 125], "new_tok_span": [151, 155]}, {"ent_type": "CHEMICAL", "char_span": [572, 584], "name": "mifepristone", "tok_span": [126, 130], "new_tok_span": [157, 161]}, {"ent_type": "CHEMICAL", "char_span": [627, 640], "name": "dexamethasone", "tok_span": [137, 138], "new_tok_span": [170, 171]}, {"ent_type": "CHEMICAL", "char_span": [700, 713], "name": "dexamethasone", "tok_span": [146, 147], "new_tok_span": [189, 190]}, {"ent_type": "CHEMICAL", "char_span": [83, 100], "name": "[3H]dexamethasone", "tok_span": [17, 22], "new_tok_span": [17, 22]}, {"ent_type": "CHEMICAL", "char_span": [256, 269], "name": "dexamethasone", "tok_span": [68, 69], "new_tok_span": [83, 84]}, {"ent_type": "GENE", "char_span": [529, 552], "name": "glucocorticoid receptor", "tok_span": [118, 120], "new_tok_span": [144, 146]}, {"ent_type": "GENE", "char_span": [644, 667], "name": "glucocorticoid receptor", "tok_span": [139, 141], "new_tok_span": [177, 179]}, {"ent_type": "GENE", "char_span": [761, 784], "name": "glucocorticoid receptor", "tok_span": [155, 157], "new_tok_span": [203, 205]}, {"ent_type": "GENE", "char_span": [213, 237], "name": "Glucocorticoid receptors", "tok_span": [61, 65], "new_tok_span": [71, 75]}], "relation_list": [{"subject": "dexamethasone", "sbj_char_span": [256, 269], "object": "Glucocorticoid receptors", "obj_char_span": [213, 237], "rel_type": "activator", "sbj_tok_span": [68, 69], "obj_tok_span": [61, 65], "new_sbj_tok_span": [83, 84], "new_obj_tok_span": [71, 75]}, {"subject": "RU-486", "sbj_char_span": [564, 570], "object": "glucocorticoid receptor", "obj_char_span": [529, 552], "rel_type": "agonist or antagonist", "sbj_tok_span": [121, 125], "obj_tok_span": [118, 120], "new_sbj_tok_span": [151, 155], "new_obj_tok_span": [144, 146]}, {"subject": "mifepristone", "sbj_char_span": [572, 584], "object": "glucocorticoid receptor", "obj_char_span": [529, 552], "rel_type": "agonist or antagonist", "sbj_tok_span": [126, 130], "obj_tok_span": [118, 120], "new_sbj_tok_span": [157, 161], "new_obj_tok_span": [144, 146]}], "umls_entity_list": [{"mention": "protein", "char_span": [191, 198], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 51], "new_tok_span": [55, 56]}, {"mention": "mg", "char_span": [188, 190], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [49, 50], "new_tok_span": [52, 53]}, {"mention": "Glucocorticoid receptor", "char_span": [213, 236], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [61, 65], "new_tok_span": [71, 75]}, {"mention": "glucocorticoid receptor", "char_span": [529, 552], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [118, 120], "new_tok_span": [144, 146]}, {"mention": "glucocorticoid receptor", "char_span": [644, 667], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [139, 141], "new_tok_span": [177, 179]}, {"mention": "glucocorticoid receptor", "char_span": [761, 784], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [155, 157], "new_tok_span": [203, 205]}, {"mention": "dexamethasone", "char_span": [87, 100], "sem_type": "Pharmacologic Substance", "tok_span": [21, 22], "new_tok_span": [22, 23]}, {"mention": "dexamethasone", "char_span": [256, 269], "sem_type": "Pharmacologic Substance", "tok_span": [68, 69], "new_tok_span": [83, 84]}, {"mention": "dexamethasone", "char_span": [487, 500], "sem_type": "Pharmacologic Substance", "tok_span": [106, 107], "new_tok_span": [127, 128]}, {"mention": "dexamethasone", "char_span": [627, 640], "sem_type": "Pharmacologic Substance", "tok_span": [137, 138], "new_tok_span": [170, 171]}, {"mention": "dexamethasone", "char_span": [700, 713], "sem_type": "Pharmacologic Substance", "tok_span": [146, 147], "new_tok_span": [189, 190]}, {"mention": "Glucocorticoid", "char_span": [213, 227], "sem_type": "Organic Chemical", "tok_span": [61, 64], "new_tok_span": [71, 74]}, {"mention": "glucocorticoid", "char_span": [290, 304], "sem_type": "Organic Chemical", "tok_span": [73, 74], "new_tok_span": [91, 92]}, {"mention": "glucocorticoid", "char_span": [529, 543], "sem_type": "Organic Chemical", "tok_span": [118, 119], "new_tok_span": [144, 145]}, {"mention": "glucocorticoid", "char_span": [644, 658], "sem_type": "Organic Chemical", "tok_span": [139, 140], "new_tok_span": [177, 178]}, {"mention": "glucocorticoid", "char_span": [761, 775], "sem_type": "Organic Chemical", "tok_span": [155, 156], "new_tok_span": [203, 204]}, {"mention": "mifepristone", "char_span": [572, 584], "sem_type": "Pharmacologic Substance", "tok_span": [126, 130], "new_tok_span": [157, 161]}, {"mention": "Glucocorticoid", "char_span": [213, 227], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [61, 64], "new_tok_span": [71, 74]}, {"mention": "glucocorticoid", "char_span": [290, 304], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [73, 74], "new_tok_span": [91, 92]}, {"mention": "glucocorticoid", "char_span": [529, 543], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [118, 119], "new_tok_span": [144, 145]}, {"mention": "glucocorticoid", "char_span": [644, 658], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [139, 140], "new_tok_span": [177, 178]}, {"mention": "glucocorticoid", "char_span": [761, 775], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [155, 156], "new_tok_span": [203, 204]}, {"mention": "Glucocorticoid receptor", "char_span": [213, 236], "sem_type": "Gene or Genome", "tok_span": [61, 65], "new_tok_span": [71, 75]}, {"mention": "glucocorticoid receptor", "char_span": [529, 552], "sem_type": "Gene or Genome", "tok_span": [118, 120], "new_tok_span": [144, 146]}, {"mention": "glucocorticoid receptor", "char_span": [644, 667], "sem_type": "Gene or Genome", "tok_span": [139, 141], "new_tok_span": [177, 179]}, {"mention": "glucocorticoid receptor", "char_span": [761, 784], "sem_type": "Gene or Genome", "tok_span": [155, 157], "new_tok_span": [203, 205]}], "new_text": "The equilibrium dissociation constant ( Kd ) and density of binding sites ( Bmax ) for [ 3H ] <START=Pharmacologic Substance> dexamethasone <END=Pharmacologic Substance> determined from saturation isotherms were 4. 4 nM x / divided by 0. 95 ( SEM ) and 30. 1 fmol / <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> protein <END=Amino Acid, Peptide, or Protein> + / - 6. 4 ( SEM ). <START=Amino Acid, Peptide, or Protein> <START=Organic Chemical> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Glucocorticoid <END=Organic Chemical> <END=Amino Acid, Peptide, or Protein> receptors <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> were activated by <START=Pharmacologic Substance> dexamethasone <END=Pharmacologic Substance> as assessed using a <START=Organic Chemical> <START=Amino Acid, Peptide, or Protein> glucocorticoid <END=Organic Chemical> <END=Amino Acid, Peptide, or Protein> - responsive reporter plasmid, pTAT3 - CAT. Transfection of primary human bronchial epithelial cells with this reporter plasmid resulted in 35 - fold activation of transcription following <START=Pharmacologic Substance> dexamethasone <END=Pharmacologic Substance> stimulation ( 10 ( - 6 ) M ). The <START=Amino Acid, Peptide, or Protein> <START=Organic Chemical> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> glucocorticoid <END=Organic Chemical> <END=Amino Acid, Peptide, or Protein> receptor <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> antagonist RU - 486 ( <START=Pharmacologic Substance> mifepristone <END=Pharmacologic Substance> ) significantly counteracted the effect of <START=Pharmacologic Substance> dexamethasone <END=Pharmacologic Substance> on <START=Amino Acid, Peptide, or Protein> <START=Organic Chemical> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> glucocorticoid <END=Organic Chemical> <END=Amino Acid, Peptide, or Protein> receptor <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> activation, indicating that the <START=Pharmacologic Substance> dexamethasone <END=Pharmacologic Substance> effect is specific and is mediated through the <START=Amino Acid, Peptide, or Protein> <START=Organic Chemical> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> glucocorticoid <END=Organic Chemical> <END=Amino Acid, Peptide, or Protein> receptor <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>."}, {"PMID": 23238299, "id": 4, "text": "In addition, chelidonine and the alkaloid extract inhibited the activity of the drug modifying enzymes CYP3A4 and GST in a dose-dependent manner.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [13, 24], "name": "chelidonine", "tok_span": [3, 6], "new_tok_span": [3, 6]}, {"ent_type": "GENE", "char_span": [103, 109], "name": "CYP3A4", "tok_span": [19, 23], "new_tok_span": [19, 23]}, {"ent_type": "GENE", "char_span": [114, 117], "name": "GST", "tok_span": [24, 25], "new_tok_span": [24, 25]}], "relation_list": [{"subject": "chelidonine", "sbj_char_span": [13, 24], "object": "CYP3A4", "obj_char_span": [103, 109], "rel_type": "inhibitor", "sbj_tok_span": [3, 6], "obj_tok_span": [19, 23], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [19, 23]}, {"subject": "chelidonine", "sbj_char_span": [13, 24], "object": "GST", "obj_char_span": [114, 117], "rel_type": "inhibitor", "sbj_tok_span": [3, 6], "obj_tok_span": [24, 25], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [24, 25]}], "umls_entity_list": [], "new_text": "In addition, chelidonine and the alkaloid extract inhibited the activity of the drug modifying enzymes CYP3A4 and GST in a dose - dependent manner."}, {"PMID": 9374794, "id": 5, "text": "Under voltage-clamp conditions, cisapride block of HERG is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [32, 41], "name": "cisapride", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [51, 55], "name": "HERG", "tok_span": [12, 14], "new_tok_span": [15, 17]}], "relation_list": [{"subject": "cisapride", "sbj_char_span": [32, 41], "object": "HERG", "obj_char_span": [51, 55], "rel_type": "inhibitor", "sbj_tok_span": [6, 10], "obj_tok_span": [12, 14], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [15, 17]}], "umls_entity_list": [{"mention": "cisapride", "char_span": [32, 41], "sem_type": "Pharmacologic Substance", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"mention": "HERG", "char_span": [51, 55], "sem_type": "Gene or Genome", "tok_span": [12, 14], "new_tok_span": [15, 17]}], "new_text": "Under voltage - clamp conditions, <START=Pharmacologic Substance> cisapride <END=Pharmacologic Substance> block of <START=Gene or Genome> HERG <END=Gene or Genome> is dose dependent with a half - maximal inhibitory concentration of 6. 5 nM at 22 degrees C ( n = 25 cells )."}, {"PMID": 23374869, "id": 4, "text": "In most instances, C6-substituted phthalides exhibit MAO-B specific inhibition.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [34, 44], "name": "phthalides", "tok_span": [8, 11], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [53, 58], "name": "MAO-B", "tok_span": [12, 16], "new_tok_span": [16, 20]}], "relation_list": [{"subject": "phthalides", "sbj_char_span": [34, 44], "object": "MAO-B", "obj_char_span": [53, 58], "rel_type": "inhibitor", "sbj_tok_span": [8, 11], "obj_tok_span": [12, 16], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [16, 20]}], "umls_entity_list": [{"mention": "phthalide", "char_span": [34, 43], "sem_type": "Organic Chemical", "tok_span": [8, 11], "new_tok_span": [11, 14]}, {"mention": "C6", "char_span": [19, 21], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 6], "new_tok_span": [5, 7]}], "new_text": "In most instances, <START=Amino Acid, Peptide, or Protein> C6 <END=Amino Acid, Peptide, or Protein> - substituted <START=Organic Chemical> phthalides <END=Organic Chemical> exhibit MAO - B specific inhibition."}, {"PMID": 12227806, "id": 0, "text": "Practical asymmetric synthesis of aprepitant, a potent human NK-1 receptor antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [34, 44], "name": "aprepitant", "tok_span": [4, 8], "new_tok_span": [5, 9]}, {"ent_type": "GENE", "char_span": [61, 74], "name": "NK-1 receptor", "tok_span": [12, 16], "new_tok_span": [15, 19]}], "relation_list": [{"subject": "aprepitant", "sbj_char_span": [34, 44], "object": "NK-1 receptor", "obj_char_span": [61, 74], "rel_type": "agonist or antagonist", "sbj_tok_span": [4, 8], "obj_tok_span": [12, 16], "new_sbj_tok_span": [5, 9], "new_obj_tok_span": [15, 19]}], "umls_entity_list": [{"mention": "aprepitant", "char_span": [34, 44], "sem_type": "Pharmacologic Substance", "tok_span": [4, 8], "new_tok_span": [5, 9]}, {"mention": "NK-1 receptor", "char_span": [61, 74], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 16], "new_tok_span": [15, 19]}, {"mention": "cetal", "char_span": [137, 142], "sem_type": "Organic Chemical", "tok_span": [27, 29], "new_tok_span": [32, 34]}], "new_text": "Practical asymmetric synthesis of <START=Pharmacologic Substance> aprepitant <END=Pharmacologic Substance>, a potent human <START=Amino Acid, Peptide, or Protein> NK - 1 receptor <END=Amino Acid, Peptide, or Protein> antagonist, via a stereoselective Lewis acid - catalyzed trans <START=Organic Chemical> acetali <END=Organic Chemical>zation reaction."}, {"PMID": 23583884, "id": 8, "text": "However, Ca(2+) blockers also obviously attenuated NF-κB activation and transnuclear transport induced by TCDD. In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and NF-κB activation induced by TCDD can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 15], "name": "Ca(2+)", "tok_span": [2, 7], "new_tok_span": [2, 7]}, {"ent_type": "CHEMICAL", "char_span": [106, 110], "name": "TCDD", "tok_span": [23, 25], "new_tok_span": [23, 25]}, {"ent_type": "CHEMICAL", "char_span": [238, 242], "name": "TCDD", "tok_span": [51, 53], "new_tok_span": [53, 55]}, {"ent_type": "CHEMICAL", "char_span": [276, 282], "name": "Ca(2+)", "tok_span": [60, 65], "new_tok_span": [62, 67]}, {"ent_type": "GENE", "char_span": [51, 56], "name": "NF-κB", "tok_span": [11, 15], "new_tok_span": [11, 15]}, {"ent_type": "GENE", "char_span": [197, 205], "name": "cytokine", "tok_span": [42, 43], "new_tok_span": [44, 45]}, {"ent_type": "GENE", "char_span": [210, 215], "name": "NF-κB", "tok_span": [44, 48], "new_tok_span": [46, 50]}], "relation_list": [{"subject": "TCDD", "sbj_char_span": [106, 110], "object": "NF-κB", "obj_char_span": [51, 56], "rel_type": "activator", "sbj_tok_span": [23, 25], "obj_tok_span": [11, 15], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [11, 15]}, {"subject": "TCDD", "sbj_char_span": [106, 110], "object": "NF-κB", "obj_char_span": [51, 56], "rel_type": "regulator", "sbj_tok_span": [23, 25], "obj_tok_span": [11, 15], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [11, 15]}, {"subject": "TCDD", "sbj_char_span": [238, 242], "object": "cytokine", "obj_char_span": [197, 205], "rel_type": "activator", "sbj_tok_span": [51, 53], "obj_tok_span": [42, 43], "new_sbj_tok_span": [53, 55], "new_obj_tok_span": [44, 45]}, {"subject": "TCDD", "sbj_char_span": [238, 242], "object": "NF-κB", "obj_char_span": [210, 215], "rel_type": "activator", "sbj_tok_span": [51, 53], "obj_tok_span": [44, 48], "new_sbj_tok_span": [53, 55], "new_obj_tok_span": [46, 50]}], "umls_entity_list": [{"mention": "pro", "char_span": [180, 183], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 40], "new_tok_span": [40, 41]}], "new_text": "However, Ca ( 2 + ) blockers also obviously attenuated NF - κB activation and transnuclear transport induced by TCDD. In concert with these results, we highlighted that the secretion of <START=Amino Acid, Peptide, or Protein> pro <END=Amino Acid, Peptide, or Protein> - inflammatory cytokine and NF - κB activation induced by TCDD can be mediated by elevation of [ Ca ( 2 + ) ] i in HAPI microglial cells."}, {"PMID": 17194761, "id": 1, "text": "Aspartoacylase catalyzes hydrolysis of N-acetyl-l-aspartate to aspartate and acetate in the vertebrate brain.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [39, 59], "name": "N-acetyl-l-aspartate", "tok_span": [10, 18], "new_tok_span": [14, 22]}, {"ent_type": "CHEMICAL", "char_span": [63, 72], "name": "aspartate", "tok_span": [19, 21], "new_tok_span": [23, 25]}, {"ent_type": "CHEMICAL", "char_span": [77, 84], "name": "acetate", "tok_span": [22, 23], "new_tok_span": [27, 28]}, {"ent_type": "GENE", "char_span": [0, 14], "name": "Aspartoacylase", "tok_span": [0, 6], "new_tok_span": [2, 8]}], "relation_list": [{"subject": "N-acetyl-l-aspartate", "sbj_char_span": [39, 59], "object": "Aspartoacylase", "obj_char_span": [0, 14], "rel_type": "product or substrate", "sbj_tok_span": [10, 18], "obj_tok_span": [0, 6], "new_sbj_tok_span": [14, 22], "new_obj_tok_span": [2, 8]}, {"subject": "aspartate", "sbj_char_span": [63, 72], "object": "Aspartoacylase", "obj_char_span": [0, 14], "rel_type": "product or substrate", "sbj_tok_span": [19, 21], "obj_tok_span": [0, 6], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [2, 8]}, {"subject": "acetate", "sbj_char_span": [77, 84], "object": "Aspartoacylase", "obj_char_span": [0, 14], "rel_type": "product or substrate", "sbj_tok_span": [22, 23], "obj_tok_span": [0, 6], "new_sbj_tok_span": [27, 28], "new_obj_tok_span": [2, 8]}], "umls_entity_list": [{"mention": "Aspartoacylase", "char_span": [0, 14], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 6], "new_tok_span": [2, 8]}, {"mention": "Aspartoacylase", "char_span": [0, 14], "sem_type": "Gene or Genome", "tok_span": [0, 6], "new_tok_span": [2, 8]}, {"mention": "acetate", "char_span": [77, 84], "sem_type": "Pharmacologic Substance", "tok_span": [22, 23], "new_tok_span": [27, 28]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Aspartoacylase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> catalyzes hydrolysis of N - acetyl - l - aspartate to aspartate and <START=Pharmacologic Substance> acetate <END=Pharmacologic Substance> in the vertebrate brain."}, {"PMID": 10530931, "id": 0, "text": "Synthesis and antagonistic activity at muscarinic receptor subtypes of some 2-carbonyl derivatives of diphenidol.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [102, 112], "name": "diphenidol", "tok_span": [18, 22], "new_tok_span": [21, 25]}, {"ent_type": "CHEMICAL", "char_span": [76, 86], "name": "2-carbonyl", "tok_span": [13, 16], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [39, 58], "name": "muscarinic receptor", "tok_span": [6, 10], "new_tok_span": [7, 11]}], "relation_list": [{"subject": "2-carbonyl", "sbj_char_span": [76, 86], "object": "muscarinic receptor", "obj_char_span": [39, 58], "rel_type": "agonist or antagonist", "sbj_tok_span": [13, 16], "obj_tok_span": [6, 10], "new_sbj_tok_span": [15, 18], "new_obj_tok_span": [7, 11]}, {"subject": "diphenidol", "sbj_char_span": [102, 112], "object": "muscarinic receptor", "obj_char_span": [39, 58], "rel_type": "agonist or antagonist", "sbj_tok_span": [18, 22], "obj_tok_span": [6, 10], "new_sbj_tok_span": [21, 25], "new_obj_tok_span": [7, 11]}], "umls_entity_list": [{"mention": "muscarinic", "char_span": [39, 49], "sem_type": "Pharmacologic Substance", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"mention": "diphenidol", "char_span": [102, 112], "sem_type": "Pharmacologic Substance", "tok_span": [18, 22], "new_tok_span": [21, 25]}], "new_text": "Synthesis and antagonistic activity at <START=Pharmacologic Substance> muscarinic <END=Pharmacologic Substance> receptor subtypes of some 2 - carbonyl derivatives of <START=Pharmacologic Substance> diphenidol <END=Pharmacologic Substance>."}, {"PMID": 23524313, "id": 6, "text": "In HepG2 cells, fisetin was found to increase the levels of a nuclear form of SREBP2 and LDLR. In conclusion, fisetin supplementation displayed hypocholesterolemic effects by modulating the expression of genes associated with cholesterol and bile acid metabolism.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [226, 237], "name": "cholesterol", "tok_span": [46, 47], "new_tok_span": [50, 51]}, {"ent_type": "CHEMICAL", "char_span": [242, 251], "name": "bile acid", "tok_span": [48, 50], "new_tok_span": [52, 54]}, {"ent_type": "CHEMICAL", "char_span": [16, 23], "name": "fisetin", "tok_span": [5, 8], "new_tok_span": [5, 8]}, {"ent_type": "CHEMICAL", "char_span": [110, 117], "name": "fisetin", "tok_span": [29, 32], "new_tok_span": [33, 36]}, {"ent_type": "GENE", "char_span": [78, 84], "name": "SREBP2", "tok_span": [19, 22], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [89, 93], "name": "LDLR", "tok_span": [23, 25], "new_tok_span": [26, 28]}], "relation_list": [{"subject": "fisetin", "sbj_char_span": [16, 23], "object": "SREBP2", "obj_char_span": [78, 84], "rel_type": "regulator", "sbj_tok_span": [5, 8], "obj_tok_span": [19, 22], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [20, 23]}, {"subject": "fisetin", "sbj_char_span": [16, 23], "object": "LDLR", "obj_char_span": [89, 93], "rel_type": "regulator", "sbj_tok_span": [5, 8], "obj_tok_span": [23, 25], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [26, 28]}], "umls_entity_list": [{"mention": "SREBP2", "char_span": [78, 84], "sem_type": "Gene or Genome", "tok_span": [19, 22], "new_tok_span": [20, 23]}, {"mention": "LDLR", "char_span": [89, 93], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [23, 25], "new_tok_span": [26, 28]}], "new_text": "In HepG2 cells, fisetin was found to increase the levels of a nuclear form of <START=Gene or Genome> SREBP2 <END=Gene or Genome> and <START=Amino Acid, Peptide, or Protein> LDLR <END=Amino Acid, Peptide, or Protein>. In conclusion, fisetin supplementation displayed hypocholesterolemic effects by modulating the expression of genes associated with cholesterol and bile acid metabolism."}, {"PMID": 23416003, "id": 0, "text": "Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [24, 67], "name": "bicyclic pyrazinone and pyrimidinone amides", "tok_span": [4, 17], "new_tok_span": [4, 17]}, {"ent_type": "GENE", "char_span": [78, 80], "name": "TF", "tok_span": [19, 20], "new_tok_span": [26, 27]}, {"ent_type": "GENE", "char_span": [81, 86], "name": "FVIIa", "tok_span": [21, 24], "new_tok_span": [29, 32]}], "relation_list": [{"subject": "bicyclic pyrazinone and pyrimidinone amides", "sbj_char_span": [24, 67], "object": "TF", "obj_char_span": [78, 80], "rel_type": "inhibitor", "sbj_tok_span": [4, 17], "obj_tok_span": [19, 20], "new_sbj_tok_span": [4, 17], "new_obj_tok_span": [26, 27]}, {"subject": "bicyclic pyrazinone and pyrimidinone amides", "sbj_char_span": [24, 67], "object": "FVIIa", "obj_char_span": [81, 86], "rel_type": "inhibitor", "sbj_tok_span": [4, 17], "obj_tok_span": [21, 24], "new_sbj_tok_span": [4, 17], "new_obj_tok_span": [29, 32]}], "umls_entity_list": [{"mention": "pyrimidinone", "char_span": [48, 60], "sem_type": "Organic Chemical", "tok_span": [11, 15], "new_tok_span": [12, 16]}, {"mention": "amides", "char_span": [61, 67], "sem_type": "Organic Chemical", "tok_span": [15, 17], "new_tok_span": [19, 21]}, {"mention": "TF", "char_span": [78, 80], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 20], "new_tok_span": [26, 27]}, {"mention": "amides", "char_span": [61, 67], "sem_type": "Pharmacologic Substance", "tok_span": [15, 17], "new_tok_span": [19, 21]}], "new_text": "Design and synthesis of bicyclic pyrazinone and <START=Organic Chemical> pyrimidinone <END=Organic Chemical> <START=Organic Chemical> <START=Pharmacologic Substance> amides <END=Organic Chemical> <END=Pharmacologic Substance> as potent <START=Amino Acid, Peptide, or Protein> TF <END=Amino Acid, Peptide, or Protein> - FVIIa inhibitors."}, {"PMID": 23273517, "id": 3, "text": "While these analogues were less active than nilotinib toward Abl, their activity toward Kit was comparable, with the monofluorinated analogue being the most active.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [44, 53], "name": "nilotinib", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [61, 64], "name": "Abl", "tok_span": [11, 13], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [88, 91], "name": "Kit", "tok_span": [17, 18], "new_tok_span": [20, 21]}], "relation_list": [{"subject": "nilotinib", "sbj_char_span": [44, 53], "object": "Abl", "obj_char_span": [61, 64], "rel_type": "inhibitor", "sbj_tok_span": [7, 10], "obj_tok_span": [11, 13], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [13, 15]}, {"subject": "nilotinib", "sbj_char_span": [44, 53], "object": "Kit", "obj_char_span": [88, 91], "rel_type": "inhibitor", "sbj_tok_span": [7, 10], "obj_tok_span": [17, 18], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [20, 21]}], "umls_entity_list": [{"mention": "nilotinib", "char_span": [44, 53], "sem_type": "Pharmacologic Substance", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "Kit", "char_span": [88, 91], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 18], "new_tok_span": [20, 21]}], "new_text": "While these analogues were less active than <START=Pharmacologic Substance> nilotinib <END=Pharmacologic Substance> toward Abl, their activity toward <START=Amino Acid, Peptide, or Protein> Kit <END=Amino Acid, Peptide, or Protein> was comparable, with the monofluorinated analogue being the most active."}, {"PMID": 23183084, "id": 6, "text": "The most favorable effects were seen for dydrogesterone and dienogest, where the first, dydrogesterone, significantly reduced SRD5A1, AKR1C2 and AKR1C3 expression, and additionally had a nonsignificant impact on progesterone receptor B (PR-B) protein levels.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [212, 224], "name": "progesterone", "tok_span": [56, 57], "new_tok_span": [62, 63]}, {"ent_type": "CHEMICAL", "char_span": [41, 55], "name": "dydrogesterone", "tok_span": [7, 12], "new_tok_span": [7, 12]}, {"ent_type": "CHEMICAL", "char_span": [60, 69], "name": "dienogest", "tok_span": [13, 16], "new_tok_span": [13, 16]}, {"ent_type": "CHEMICAL", "char_span": [88, 102], "name": "dydrogesterone", "tok_span": [21, 26], "new_tok_span": [21, 26]}, {"ent_type": "GENE", "char_span": [126, 132], "name": "SRD5A1", "tok_span": [29, 34], "new_tok_span": [31, 36]}, {"ent_type": "GENE", "char_span": [134, 140], "name": "AKR1C2", "tok_span": [35, 40], "new_tok_span": [39, 44]}, {"ent_type": "GENE", "char_span": [145, 151], "name": "AKR1C3", "tok_span": [41, 46], "new_tok_span": [45, 50]}, {"ent_type": "GENE", "char_span": [212, 235], "name": "progesterone receptor B", "tok_span": [56, 59], "new_tok_span": [62, 65]}, {"ent_type": "GENE", "char_span": [237, 241], "name": "PR-B", "tok_span": [60, 63], "new_tok_span": [68, 71]}], "relation_list": [{"subject": "dydrogesterone", "sbj_char_span": [88, 102], "object": "SRD5A1", "obj_char_span": [126, 132], "rel_type": "regulator", "sbj_tok_span": [21, 26], "obj_tok_span": [29, 34], "new_sbj_tok_span": [21, 26], "new_obj_tok_span": [31, 36]}, {"subject": "dydrogesterone", "sbj_char_span": [88, 102], "object": "AKR1C2", "obj_char_span": [134, 140], "rel_type": "regulator", "sbj_tok_span": [21, 26], "obj_tok_span": [35, 40], "new_sbj_tok_span": [21, 26], "new_obj_tok_span": [39, 44]}, {"subject": "dydrogesterone", "sbj_char_span": [88, 102], "object": "AKR1C3", "obj_char_span": [145, 151], "rel_type": "regulator", "sbj_tok_span": [21, 26], "obj_tok_span": [41, 46], "new_sbj_tok_span": [21, 26], "new_obj_tok_span": [45, 50]}], "umls_entity_list": [{"mention": "SRD5A1", "char_span": [126, 132], "sem_type": "Gene or Genome", "tok_span": [29, 34], "new_tok_span": [31, 36]}, {"mention": "SRD5A1", "char_span": [126, 132], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 34], "new_tok_span": [31, 36]}, {"mention": "progesterone", "char_span": [212, 224], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 57], "new_tok_span": [62, 63]}, {"mention": "progesterone receptor B", "char_span": [212, 235], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 59], "new_tok_span": [62, 65]}], "new_text": "The most favorable effects were seen for dydrogesterone and dienogest, where the first, dydrogesterone, significantly reduced <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> SRD5A1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, AKR1C2 and AKR1C3 expression, and additionally had a nonsignificant impact on <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> progesterone <END=Amino Acid, Peptide, or Protein> receptor B <END=Amino Acid, Peptide, or Protein> ( PR - B ) protein levels."}, {"PMID": 17112803, "id": 13, "text": "Whereas a nonfunctional MRP2 variant has been described in a patient with severe impairment of methotrexate excretion, our study is the first to suggest that a frequent ABCC2 polymorphism contributes to variability of methotrexate kinetics.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [95, 107], "name": "methotrexate", "tok_span": [18, 20], "new_tok_span": [21, 23]}, {"ent_type": "CHEMICAL", "char_span": [218, 230], "name": "methotrexate", "tok_span": [40, 42], "new_tok_span": [45, 47]}, {"ent_type": "GENE", "char_span": [24, 28], "name": "MRP2", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"ent_type": "GENE", "char_span": [169, 174], "name": "ABCC2", "tok_span": [32, 35], "new_tok_span": [36, 39]}], "relation_list": [{"subject": "methotrexate", "sbj_char_span": [95, 107], "object": "MRP2", "obj_char_span": [24, 28], "rel_type": "product or substrate", "sbj_tok_span": [18, 20], "obj_tok_span": [4, 7], "new_sbj_tok_span": [21, 23], "new_obj_tok_span": [5, 8]}], "umls_entity_list": [{"mention": "MRP2", "char_span": [24, 28], "sem_type": "Gene or Genome", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"mention": "methotrexate", "char_span": [95, 107], "sem_type": "Pharmacologic Substance", "tok_span": [18, 20], "new_tok_span": [21, 23]}, {"mention": "methotrexate", "char_span": [218, 230], "sem_type": "Pharmacologic Substance", "tok_span": [40, 42], "new_tok_span": [45, 47]}], "new_text": "Whereas a nonfunctional <START=Gene or Genome> MRP2 <END=Gene or Genome> variant has been described in a patient with severe impairment of <START=Pharmacologic Substance> methotrexate <END=Pharmacologic Substance> excretion, our study is the first to suggest that a frequent ABCC2 polymorphism contributes to variability of <START=Pharmacologic Substance> methotrexate <END=Pharmacologic Substance> kinetics."}, {"PMID": 2882965, "id": 0, "text": "Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [110, 131], "name": "5-aminosalicylic acid", "tok_span": [21, 28], "new_tok_span": [23, 30]}, {"ent_type": "CHEMICAL", "char_span": [40, 56], "name": "arachidonic acid", "tok_span": [8, 12], "new_tok_span": [10, 14]}, {"ent_type": "CHEMICAL", "char_span": [92, 105], "name": "sulfasalazine", "tok_span": [17, 20], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [14, 28], "name": "5-lipoxygenase", "tok_span": [2, 6], "new_tok_span": [2, 6]}], "relation_list": [{"subject": "arachidonic acid", "sbj_char_span": [40, 56], "object": "5-lipoxygenase", "obj_char_span": [14, 28], "rel_type": "product or substrate", "sbj_tok_span": [8, 12], "obj_tok_span": [2, 6], "new_sbj_tok_span": [10, 14], "new_obj_tok_span": [2, 6]}, {"subject": "sulfasalazine", "sbj_char_span": [92, 105], "object": "5-lipoxygenase", "obj_char_span": [14, 28], "rel_type": "inhibitor", "sbj_tok_span": [17, 20], "obj_tok_span": [2, 6], "new_sbj_tok_span": [19, 22], "new_obj_tok_span": [2, 6]}, {"subject": "5-aminosalicylic acid", "sbj_char_span": [110, 131], "object": "5-lipoxygenase", "obj_char_span": [14, 28], "rel_type": "inhibitor", "sbj_tok_span": [21, 28], "obj_tok_span": [2, 6], "new_sbj_tok_span": [23, 30], "new_obj_tok_span": [2, 6]}], "umls_entity_list": [{"mention": "lipoxygenase", "char_span": [16, 28], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 6], "new_tok_span": [5, 7]}], "new_text": "Inhibition of 5 - <START=Amino Acid, Peptide, or Protein> lipoxygenase <END=Amino Acid, Peptide, or Protein> pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5 - aminosalicylic acid."}, {"PMID": 12170055, "id": 12, "text": "The modeling studies demonstrated that meperidine can fit into the alpha(2B)-adrenoceptor subtype.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [39, 49], "name": "meperidine", "tok_span": [5, 8], "new_tok_span": [5, 8]}, {"ent_type": "GENE", "char_span": [67, 89], "name": "alpha(2B)-adrenoceptor", "tok_span": [12, 21], "new_tok_span": [12, 21]}], "relation_list": [{"subject": "meperidine", "sbj_char_span": [39, 49], "object": "alpha(2B)-adrenoceptor", "obj_char_span": [67, 89], "rel_type": "regulator", "sbj_tok_span": [5, 8], "obj_tok_span": [12, 21], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [12, 21]}], "umls_entity_list": [], "new_text": "The modeling studies demonstrated that meperidine can fit into the alpha ( 2B ) - adrenoceptor subtype."}, {"PMID": 23591590, "id": 7, "text": "An increase in the energy required to remove the same anion from the tridentate receptor when compared to the bidentate and monodentate receptors is explained as being due to the increase in halogen bonding interactions.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [191, 198], "name": "halogen", "tok_span": [40, 42], "new_tok_span": [40, 42]}, {"ent_type": "GENE", "char_span": [69, 88], "name": "tridentate receptor", "tok_span": [13, 18], "new_tok_span": [13, 18]}, {"ent_type": "GENE", "char_span": [110, 145], "name": "bidentate and monodentate receptors", "tok_span": [22, 31], "new_tok_span": [22, 31]}], "relation_list": [{"subject": "halogen", "sbj_char_span": [191, 198], "object": "tridentate receptor", "obj_char_span": [69, 88], "rel_type": "regulator", "sbj_tok_span": [40, 42], "obj_tok_span": [13, 18], "new_sbj_tok_span": [40, 42], "new_obj_tok_span": [13, 18]}], "umls_entity_list": [], "new_text": "An increase in the energy required to remove the same anion from the tridentate receptor when compared to the bidentate and monodentate receptors is explained as being due to the increase in halogen bonding interactions."}, {"PMID": 23572520, "id": 6, "text": "Despite the presence of a GSNO binding site at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using CysNO demonstrate that GSNO binding does not precede S-nitrosation of GSTP1-1.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [202, 203], "name": "S", "tok_span": [44, 45], "new_tok_span": [52, 53]}, {"ent_type": "CHEMICAL", "char_span": [149, 154], "name": "CysNO", "tok_span": [33, 35], "new_tok_span": [41, 43]}, {"ent_type": "GENE", "char_span": [219, 226], "name": "GSTP1-1", "tok_span": [50, 55], "new_tok_span": [62, 67]}, {"ent_type": "GENE", "char_span": [26, 43], "name": "GSNO binding site", "tok_span": [5, 9], "new_tok_span": [5, 9]}, {"ent_type": "GENE", "char_span": [66, 73], "name": "GSTP1-1", "tok_span": [14, 19], "new_tok_span": [18, 23]}], "relation_list": [{"subject": "S", "sbj_char_span": [202, 203], "object": "GSTP1-1", "obj_char_span": [219, 226], "rel_type": "part of", "sbj_tok_span": [44, 45], "obj_tok_span": [50, 55], "new_sbj_tok_span": [52, 53], "new_obj_tok_span": [62, 67]}], "umls_entity_list": [{"mention": "GSTP1", "char_span": [66, 71], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 17], "new_tok_span": [18, 21]}, {"mention": "GSTP1", "char_span": [219, 224], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 53], "new_tok_span": [62, 65]}, {"mention": "GSTP1", "char_span": [66, 71], "sem_type": "Gene or Genome", "tok_span": [14, 17], "new_tok_span": [18, 21]}, {"mention": "GSTP1", "char_span": [219, 224], "sem_type": "Gene or Genome", "tok_span": [50, 53], "new_tok_span": [62, 65]}, {"mention": "GSTP1-1", "char_span": [66, 73], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 19], "new_tok_span": [18, 23]}, {"mention": "GSTP1-1", "char_span": [219, 226], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 55], "new_tok_span": [62, 67]}, {"mention": "GSTP1-1", "char_span": [66, 73], "sem_type": "Gene or Genome", "tok_span": [14, 19], "new_tok_span": [18, 23]}, {"mention": "GSTP1-1", "char_span": [219, 226], "sem_type": "Gene or Genome", "tok_span": [50, 55], "new_tok_span": [62, 67]}], "new_text": "Despite the presence of a GSNO binding site at the active site of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> GSTP1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - 1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, isothermal titration calorimetry as well as nitrosation experiments using CysNO demonstrate that GSNO binding does not precede S - nitrosation of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> GSTP1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - 1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>."}, {"PMID": 9581512, "id": 4, "text": "Ellagic acid is a competitive inhibitor of both cAK and of PKC but piceatannol inhibits these enzymes in a fashion that is competitive and non-competitive, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Ellagic acid", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [67, 78], "name": "piceatannol", "tok_span": [16, 21], "new_tok_span": [18, 23]}, {"ent_type": "GENE", "char_span": [59, 62], "name": "PKC", "tok_span": [14, 15], "new_tok_span": [16, 17]}], "relation_list": [{"subject": "Ellagic acid", "sbj_char_span": [0, 12], "object": "PKC", "obj_char_span": [59, 62], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [14, 15], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [16, 17]}, {"subject": "piceatannol", "sbj_char_span": [67, 78], "object": "PKC", "obj_char_span": [59, 62], "rel_type": "inhibitor", "sbj_tok_span": [16, 21], "obj_tok_span": [14, 15], "new_sbj_tok_span": [18, 23], "new_obj_tok_span": [16, 17]}], "umls_entity_list": [{"mention": "Ellagic acid", "char_span": [0, 12], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "enzymes", "char_span": [94, 101], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [23, 24], "new_tok_span": [26, 27]}], "new_text": "<START=Pharmacologic Substance> Ellagic acid <END=Pharmacologic Substance> is a competitive inhibitor of both cAK and of PKC but piceatannol inhibits these <START=Amino Acid, Peptide, or Protein> enzymes <END=Amino Acid, Peptide, or Protein> in a fashion that is competitive and non - competitive, respectively."}, {"PMID": 9643444, "id": 7, "text": "When given intratracheally with insulin, inhibitors including N-ethylmaleimide, p-chloromercuribenzoic acid, and 1,10-phenanthroline significantly enhanced the absolute bioavailability of insulin and the compound's hypoglycaemic effects.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [62, 78], "name": "N-ethylmaleimide", "tok_span": [11, 16], "new_tok_span": [15, 20]}, {"ent_type": "CHEMICAL", "char_span": [80, 107], "name": "p-chloromercuribenzoic acid", "tok_span": [17, 26], "new_tok_span": [21, 30]}, {"ent_type": "CHEMICAL", "char_span": [113, 132], "name": "1,10-phenanthroline", "tok_span": [28, 36], "new_tok_span": [32, 40]}, {"ent_type": "GENE", "char_span": [32, 39], "name": "insulin", "tok_span": [7, 8], "new_tok_span": [9, 10]}, {"ent_type": "GENE", "char_span": [188, 195], "name": "insulin", "tok_span": [42, 43], "new_tok_span": [48, 49]}], "relation_list": [{"subject": "N-ethylmaleimide", "sbj_char_span": [62, 78], "object": "insulin", "obj_char_span": [188, 195], "rel_type": "regulator", "sbj_tok_span": [11, 16], "obj_tok_span": [42, 43], "new_sbj_tok_span": [15, 20], "new_obj_tok_span": [48, 49]}, {"subject": "p-chloromercuribenzoic acid", "sbj_char_span": [80, 107], "object": "insulin", "obj_char_span": [188, 195], "rel_type": "regulator", "sbj_tok_span": [17, 26], "obj_tok_span": [42, 43], "new_sbj_tok_span": [21, 30], "new_obj_tok_span": [48, 49]}, {"subject": "1,10-phenanthroline", "sbj_char_span": [113, 132], "object": "insulin", "obj_char_span": [188, 195], "rel_type": "regulator", "sbj_tok_span": [28, 36], "obj_tok_span": [42, 43], "new_sbj_tok_span": [32, 40], "new_obj_tok_span": [48, 49]}], "umls_entity_list": [{"mention": "insulin", "char_span": [32, 39], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 8], "new_tok_span": [9, 10]}, {"mention": "insulin", "char_span": [188, 195], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 43], "new_tok_span": [48, 49]}, {"mention": "insulin", "char_span": [32, 39], "sem_type": "Pharmacologic Substance", "tok_span": [7, 8], "new_tok_span": [9, 10]}, {"mention": "insulin", "char_span": [188, 195], "sem_type": "Pharmacologic Substance", "tok_span": [42, 43], "new_tok_span": [48, 49]}], "new_text": "When given intratracheally with <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> insulin <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance>, inhibitors including N - ethylmaleimide, p - chloromercuribenzoic acid, and 1, 10 - phenanthroline significantly enhanced the absolute bioavailability of <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> insulin <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> and the compound's hypoglycaemic effects."}, {"PMID": 7680751, "id": 0, "text": "Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [34, 43], "name": "serotonin", "tok_span": [7, 8], "new_tok_span": [8, 9]}, {"ent_type": "CHEMICAL", "char_span": [76, 85], "name": "tricyclic", "tok_span": [13, 15], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [34, 52], "name": "serotonin receptor", "tok_span": [7, 9], "new_tok_span": [8, 10]}], "relation_list": [{"subject": "tricyclic", "sbj_char_span": [76, 85], "object": "serotonin receptor", "obj_char_span": [34, 52], "rel_type": "regulator", "sbj_tok_span": [13, 15], "obj_tok_span": [7, 9], "new_sbj_tok_span": [15, 17], "new_obj_tok_span": [8, 10]}], "umls_entity_list": [{"mention": "serotonin receptor", "char_span": [34, 52], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"mention": "psychotropic", "char_span": [86, 98], "sem_type": "Pharmacologic Substance", "tok_span": [15, 18], "new_tok_span": [18, 21]}], "new_text": "Cloning and expression of a novel <START=Amino Acid, Peptide, or Protein> serotonin receptor <END=Amino Acid, Peptide, or Protein> with high affinity for tricyclic <START=Pharmacologic Substance> psychotropic <END=Pharmacologic Substance> drugs."}, {"PMID": 16292755, "id": 3, "text": "Vitamin E and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and low-density lipoprotein cholesterol compared to HC-control group.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Vitamin E", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"ent_type": "CHEMICAL", "char_span": [14, 22], "name": "probucol", "tok_span": [3, 6], "new_tok_span": [6, 9]}, {"ent_type": "CHEMICAL", "char_span": [76, 87], "name": "cholesterol", "tok_span": [14, 15], "new_tok_span": [18, 19]}, {"ent_type": "CHEMICAL", "char_span": [126, 137], "name": "cholesterol", "tok_span": [25, 26], "new_tok_span": [29, 30]}, {"ent_type": "GENE", "char_span": [102, 125], "name": "low-density lipoprotein", "tok_span": [21, 25], "new_tok_span": [25, 29]}], "relation_list": [{"subject": "Vitamin E", "sbj_char_span": [0, 9], "object": "low-density lipoprotein", "obj_char_span": [102, 125], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [21, 25], "new_sbj_tok_span": [1, 3], "new_obj_tok_span": [25, 29]}, {"subject": "probucol", "sbj_char_span": [14, 22], "object": "low-density lipoprotein", "obj_char_span": [102, 125], "rel_type": "regulator", "sbj_tok_span": [3, 6], "obj_tok_span": [21, 25], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [25, 29]}], "umls_entity_list": [{"mention": "Vitamin E", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"mention": "probucol", "char_span": [14, 22], "sem_type": "Pharmacologic Substance", "tok_span": [3, 6], "new_tok_span": [6, 9]}, {"mention": "HC", "char_span": [150, 152], "sem_type": "Pharmacologic Substance", "tok_span": [28, 29], "new_tok_span": [34, 35]}, {"mention": "HC", "char_span": [150, 152], "sem_type": "Gene or Genome", "tok_span": [28, 29], "new_tok_span": [34, 35]}], "new_text": "<START=Pharmacologic Substance> Vitamin E <END=Pharmacologic Substance> and <START=Pharmacologic Substance> probucol <END=Pharmacologic Substance> significantly suppressed an increase in plasma total - cholesterol ( total - C ) and low - density lipoprotein cholesterol compared to <START=Pharmacologic Substance> <START=Gene or Genome> HC <END=Pharmacologic Substance> <END=Gene or Genome> - control group."}, {"PMID": 14757700, "id": 1, "text": "TRPM8 (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [97, 107], "name": "eucalyptol", "tok_span": [31, 35], "new_tok_span": [34, 38]}, {"ent_type": "CHEMICAL", "char_span": [112, 118], "name": "icilin", "tok_span": [36, 38], "new_tok_span": [41, 43]}, {"ent_type": "CHEMICAL", "char_span": [18, 24], "name": "Ca(2+)", "tok_span": [10, 15], "new_tok_span": [12, 17]}, {"ent_type": "CHEMICAL", "char_span": [88, 95], "name": "menthol", "tok_span": [28, 30], "new_tok_span": [30, 32]}, {"ent_type": "GENE", "char_span": [7, 11], "name": "CMR1", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"ent_type": "GENE", "char_span": [18, 42], "name": "Ca(2+)-permeable channel", "tok_span": [10, 19], "new_tok_span": [12, 21]}, {"ent_type": "GENE", "char_span": [0, 5], "name": "TRPM8", "tok_span": [0, 3], "new_tok_span": [0, 3]}], "relation_list": [{"subject": "menthol", "sbj_char_span": [88, 95], "object": "TRPM8", "obj_char_span": [0, 5], "rel_type": "activator", "sbj_tok_span": [28, 30], "obj_tok_span": [0, 3], "new_sbj_tok_span": [30, 32], "new_obj_tok_span": [0, 3]}, {"subject": "menthol", "sbj_char_span": [88, 95], "object": "CMR1", "obj_char_span": [7, 11], "rel_type": "activator", "sbj_tok_span": [28, 30], "obj_tok_span": [4, 7], "new_sbj_tok_span": [30, 32], "new_obj_tok_span": [5, 8]}, {"subject": "menthol", "sbj_char_span": [88, 95], "object": "Ca(2+)-permeable channel", "obj_char_span": [18, 42], "rel_type": "activator", "sbj_tok_span": [28, 30], "obj_tok_span": [10, 19], "new_sbj_tok_span": [30, 32], "new_obj_tok_span": [12, 21]}, {"subject": "eucalyptol", "sbj_char_span": [97, 107], "object": "TRPM8", "obj_char_span": [0, 5], "rel_type": "activator", "sbj_tok_span": [31, 35], "obj_tok_span": [0, 3], "new_sbj_tok_span": [34, 38], "new_obj_tok_span": [0, 3]}, {"subject": "eucalyptol", "sbj_char_span": [97, 107], "object": "CMR1", "obj_char_span": [7, 11], "rel_type": "activator", "sbj_tok_span": [31, 35], "obj_tok_span": [4, 7], "new_sbj_tok_span": [34, 38], "new_obj_tok_span": [5, 8]}, {"subject": "eucalyptol", "sbj_char_span": [97, 107], "object": "Ca(2+)-permeable channel", "obj_char_span": [18, 42], "rel_type": "activator", "sbj_tok_span": [31, 35], "obj_tok_span": [10, 19], "new_sbj_tok_span": [34, 38], "new_obj_tok_span": [12, 21]}, {"subject": "icilin", "sbj_char_span": [112, 118], "object": "TRPM8", "obj_char_span": [0, 5], "rel_type": "activator", "sbj_tok_span": [36, 38], "obj_tok_span": [0, 3], "new_sbj_tok_span": [41, 43], "new_obj_tok_span": [0, 3]}, {"subject": "icilin", "sbj_char_span": [112, 118], "object": "CMR1", "obj_char_span": [7, 11], "rel_type": "activator", "sbj_tok_span": [36, 38], "obj_tok_span": [4, 7], "new_sbj_tok_span": [41, 43], "new_obj_tok_span": [5, 8]}, {"subject": "icilin", "sbj_char_span": [112, 118], "object": "Ca(2+)-permeable channel", "obj_char_span": [18, 42], "rel_type": "activator", "sbj_tok_span": [36, 38], "obj_tok_span": [10, 19], "new_sbj_tok_span": [41, 43], "new_obj_tok_span": [12, 21]}], "umls_entity_list": [{"mention": "CMR1", "char_span": [7, 11], "sem_type": "Gene or Genome", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"mention": "eucalyptol", "char_span": [97, 107], "sem_type": "Pharmacologic Substance", "tok_span": [31, 35], "new_tok_span": [34, 38]}, {"mention": "icilin", "char_span": [112, 118], "sem_type": "Organic Chemical", "tok_span": [36, 38], "new_tok_span": [41, 43]}], "new_text": "TRPM8 ( <START=Gene or Genome> CMR1 <END=Gene or Genome> ) is a Ca ( 2 + ) - permeable channel, which can be activated by low temperatures, menthol, <START=Pharmacologic Substance> eucalyptol <END=Pharmacologic Substance> and <START=Organic Chemical> icilin <END=Organic Chemical>."}, {"PMID": 23404093, "id": 3, "text": "Palonosetron, a second-generation 5-HT3 receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Palonosetron", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "GENE", "char_span": [34, 39], "name": "5-HT3", "tok_span": [9, 13], "new_tok_span": [9, 13]}, {"ent_type": "GENE", "char_span": [179, 184], "name": "5-HT3", "tok_span": [37, 41], "new_tok_span": [39, 43]}], "relation_list": [{"subject": "Palonosetron", "sbj_char_span": [0, 12], "object": "5-HT3", "obj_char_span": [34, 39], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 4], "obj_tok_span": [9, 13], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [9, 13]}], "umls_entity_list": [{"mention": "receptor antagonist", "char_span": [40, 59], "sem_type": "Pharmacologic Substance", "tok_span": [13, 15], "new_tok_span": [14, 16]}, {"mention": "receptor antagonist", "char_span": [185, 204], "sem_type": "Pharmacologic Substance", "tok_span": [41, 43], "new_tok_span": [44, 46]}], "new_text": "Palonosetron, a second - generation 5 - HT3 <START=Pharmacologic Substance> receptor antagonist <END=Pharmacologic Substance> with a different half - life, a different binding capacity and a different mechanism of action than the first - generation 5 - HT3 <START=Pharmacologic Substance> receptor antagonists <END=Pharmacologic Substance> appears to be the most effective agent in its class."}, {"PMID": 17289088, "id": 2, "text": "Stimulation of lymphocytes with phytohemagglutinin, which activates T cells via the T cell receptor/CD3 complex, enhances the synthesis and release of ACh and up-regulates expression of ChAT and M(5) mAChR mRNAs. In addition, activation of protein kinase C and increases in intracellular cAMP also enhance cholinergic activity in T cells, and lymphocyte function associated antigen-1 (LFA-1; CD11a/CD18) is an important mediator of leukocyte migration and T cell activation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [151, 154], "name": "ACh", "tok_span": [32, 33], "new_tok_span": [34, 35]}, {"ent_type": "CHEMICAL", "char_span": [288, 292], "name": "cAMP", "tok_span": [63, 64], "new_tok_span": [65, 66]}, {"ent_type": "GENE", "char_span": [32, 50], "name": "phytohemagglutinin", "tok_span": [4, 11], "new_tok_span": [5, 12]}, {"ent_type": "GENE", "char_span": [84, 99], "name": "T cell receptor", "tok_span": [18, 21], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [100, 103], "name": "CD3", "tok_span": [22, 24], "new_tok_span": [24, 26]}, {"ent_type": "GENE", "char_span": [186, 190], "name": "ChAT", "tok_span": [39, 41], "new_tok_span": [41, 43]}, {"ent_type": "GENE", "char_span": [195, 205], "name": "M(5) mAChR", "tok_span": [42, 49], "new_tok_span": [44, 51]}, {"ent_type": "GENE", "char_span": [240, 256], "name": "protein kinase C", "tok_span": [56, 59], "new_tok_span": [58, 61]}, {"ent_type": "GENE", "char_span": [343, 383], "name": "lymphocyte function associated antigen-1", "tok_span": [73, 79], "new_tok_span": [75, 81]}, {"ent_type": "GENE", "char_span": [385, 390], "name": "LFA-1", "tok_span": [80, 84], "new_tok_span": [82, 86]}, {"ent_type": "GENE", "char_span": [392, 397], "name": "CD11a", "tok_span": [85, 88], "new_tok_span": [88, 91]}, {"ent_type": "GENE", "char_span": [398, 402], "name": "CD18", "tok_span": [89, 91], "new_tok_span": [92, 94]}], "relation_list": [{"subject": "cAMP", "sbj_char_span": [288, 292], "object": "lymphocyte function associated antigen-1", "obj_char_span": [343, 383], "rel_type": "regulator", "sbj_tok_span": [63, 64], "obj_tok_span": [73, 79], "new_sbj_tok_span": [65, 66], "new_obj_tok_span": [75, 81]}, {"subject": "cAMP", "sbj_char_span": [288, 292], "object": "LFA-1", "obj_char_span": [385, 390], "rel_type": "regulator", "sbj_tok_span": [63, 64], "obj_tok_span": [80, 84], "new_sbj_tok_span": [65, 66], "new_obj_tok_span": [82, 86]}, {"subject": "cAMP", "sbj_char_span": [288, 292], "object": "CD11a", "obj_char_span": [392, 397], "rel_type": "regulator", "sbj_tok_span": [63, 64], "obj_tok_span": [85, 88], "new_sbj_tok_span": [65, 66], "new_obj_tok_span": [88, 91]}, {"subject": "cAMP", "sbj_char_span": [288, 292], "object": "CD18", "obj_char_span": [398, 402], "rel_type": "regulator", "sbj_tok_span": [63, 64], "obj_tok_span": [89, 91], "new_sbj_tok_span": [65, 66], "new_obj_tok_span": [92, 94]}], "umls_entity_list": [{"mention": "phytohemagglutinin", "char_span": [32, 50], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 11], "new_tok_span": [5, 12]}, {"mention": "CD11a/CD18", "char_span": [392, 402], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [85, 91], "new_tok_span": [88, 94]}, {"mention": "leukocyte", "char_span": [432, 441], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [97, 98], "new_tok_span": [104, 105]}, {"mention": "mediator", "char_span": [420, 428], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [95, 96], "new_tok_span": [100, 101]}], "new_text": "Stimulation of lymphocytes with <START=Amino Acid, Peptide, or Protein> phytohemagglutinin <END=Amino Acid, Peptide, or Protein>, which activates T cells via the T cell receptor / CD3 complex, enhances the synthesis and release of ACh and up - regulates expression of ChAT and M ( 5 ) mAChR mRNAs. In addition, activation of protein kinase C and increases in intracellular cAMP also enhance cholinergic activity in T cells, and lymphocyte function associated antigen - 1 ( LFA - 1 ; <START=Amino Acid, Peptide, or Protein> CD11a / CD18 <END=Amino Acid, Peptide, or Protein> ) is an important <START=Amino Acid, Peptide, or Protein> mediator <END=Amino Acid, Peptide, or Protein> of <START=Amino Acid, Peptide, or Protein> leukocyte <END=Amino Acid, Peptide, or Protein> migration and T cell activation."}, {"PMID": 23220590, "id": 6, "text": "At therapeutic drug levels (0.015 mM) and physiologically relevant concentrations of ethanol (10 mM) and acetaldehyde (10 μM) in target tissues, cimetidine could weakly inhibit (<5%) the activities of ADH1B2 and ADH1B3 in liver, ADH2 in liver and small intestine, ADH4 in stomach, and ALDH1A1 in the three tissues, but not significantly affect ADH1A, ADH1B1, ADH1C1/2, or ALDH2. At higher drug levels, which may accumulate in cells (0.2 mM), the activities of the weakly-inhibited enzymes may be decreased more significantly.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [85, 92], "name": "ethanol", "tok_span": [16, 17], "new_tok_span": [17, 18]}, {"ent_type": "CHEMICAL", "char_span": [105, 117], "name": "acetaldehyde", "tok_span": [22, 24], "new_tok_span": [25, 27]}, {"ent_type": "CHEMICAL", "char_span": [145, 155], "name": "cimetidine", "tok_span": [33, 36], "new_tok_span": [37, 40]}, {"ent_type": "GENE", "char_span": [201, 207], "name": "ADH1B2", "tok_span": [47, 52], "new_tok_span": [51, 56]}, {"ent_type": "GENE", "char_span": [212, 218], "name": "ADH1B3", "tok_span": [53, 58], "new_tok_span": [57, 62]}, {"ent_type": "GENE", "char_span": [229, 233], "name": "ADH2", "tok_span": [61, 64], "new_tok_span": [66, 69]}, {"ent_type": "GENE", "char_span": [264, 268], "name": "ADH4", "tok_span": [70, 73], "new_tok_span": [78, 81]}, {"ent_type": "GENE", "char_span": [285, 292], "name": "ALDH1A1", "tok_span": [77, 82], "new_tok_span": [89, 94]}, {"ent_type": "GENE", "char_span": [344, 349], "name": "ADH1A", "tok_span": [91, 95], "new_tok_span": [106, 110]}, {"ent_type": "GENE", "char_span": [351, 357], "name": "ADH1B1", "tok_span": [96, 101], "new_tok_span": [112, 117]}, {"ent_type": "GENE", "char_span": [359, 367], "name": "ADH1C1/2", "tok_span": [102, 109], "new_tok_span": [118, 125]}, {"ent_type": "GENE", "char_span": [372, 377], "name": "ALDH2", "tok_span": [111, 114], "new_tok_span": [129, 132]}], "relation_list": [{"subject": "ethanol", "sbj_char_span": [85, 92], "object": "ADH1B2", "obj_char_span": [201, 207], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [47, 52], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [51, 56]}, {"subject": "ethanol", "sbj_char_span": [85, 92], "object": "ADH1B3", "obj_char_span": [212, 218], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [53, 58], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [57, 62]}, {"subject": "ethanol", "sbj_char_span": [85, 92], "object": "ADH1A", "obj_char_span": [344, 349], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [91, 95], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [106, 110]}, {"subject": "ethanol", "sbj_char_span": [85, 92], "object": "ADH1B1", "obj_char_span": [351, 357], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [96, 101], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [112, 117]}, {"subject": "ethanol", "sbj_char_span": [85, 92], "object": "ALDH2", "obj_char_span": [372, 377], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [111, 114], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [129, 132]}, {"subject": "ethanol", "sbj_char_span": [85, 92], "object": "ADH2", "obj_char_span": [229, 233], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [61, 64], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [66, 69]}, {"subject": "ethanol", "sbj_char_span": [85, 92], "object": "ADH4", "obj_char_span": [264, 268], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [70, 73], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [78, 81]}, {"subject": "ethanol", "sbj_char_span": [85, 92], "object": "ALDH1A1", "obj_char_span": [285, 292], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [77, 82], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [89, 94]}, {"subject": "acetaldehyde", "sbj_char_span": [105, 117], "object": "ALDH1A1", "obj_char_span": [285, 292], "rel_type": "product or substrate", "sbj_tok_span": [22, 24], "obj_tok_span": [77, 82], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [89, 94]}], "umls_entity_list": [{"mention": "ethanol", "char_span": [85, 92], "sem_type": "Pharmacologic Substance", "tok_span": [16, 17], "new_tok_span": [17, 18]}, {"mention": "acetaldehyde", "char_span": [105, 117], "sem_type": "Organic Chemical", "tok_span": [22, 24], "new_tok_span": [25, 27]}, {"mention": "ADH2", "char_span": [229, 233], "sem_type": "Gene or Genome", "tok_span": [61, 64], "new_tok_span": [66, 69]}, {"mention": "ADH4", "char_span": [264, 268], "sem_type": "Gene or Genome", "tok_span": [70, 73], "new_tok_span": [78, 81]}, {"mention": "ADH4", "char_span": [264, 268], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [70, 73], "new_tok_span": [78, 81]}, {"mention": "ALDH1A1", "char_span": [285, 292], "sem_type": "Gene or Genome", "tok_span": [77, 82], "new_tok_span": [89, 94]}, {"mention": "ALDH1A1", "char_span": [285, 292], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [77, 82], "new_tok_span": [89, 94]}, {"mention": "ADH1A", "char_span": [344, 349], "sem_type": "Gene or Genome", "tok_span": [91, 95], "new_tok_span": [106, 110]}, {"mention": "ALDH2", "char_span": [372, 377], "sem_type": "Gene or Genome", "tok_span": [111, 114], "new_tok_span": [129, 132]}, {"mention": "ALDH2", "char_span": [372, 377], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [111, 114], "new_tok_span": [129, 132]}], "new_text": "At therapeutic drug levels ( 0. 015 mM ) and physiologically relevant concentrations of <START=Pharmacologic Substance> ethanol <END=Pharmacologic Substance> ( 10 mM ) and <START=Organic Chemical> acetaldehyde <END=Organic Chemical> ( 10 μM ) in target tissues, cimetidine could weakly inhibit ( < 5 % ) the activities of ADH1B2 and ADH1B3 in liver, <START=Gene or Genome> ADH2 <END=Gene or Genome> in liver and small intestine, <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ADH4 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> in stomach, and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ALDH1A1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> in the three tissues, but not significantly affect <START=Gene or Genome> ADH1A <END=Gene or Genome>, ADH1B1, ADH1C1 / 2, or <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ALDH2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. At higher drug levels, which may accumulate in cells ( 0. 2 mM ), the activities of the weakly - inhibited enzymes may be decreased more significantly."}, {"PMID": 8666140, "id": 7, "text": "Single-strand conformational analysis and nucleotide sequencing of the entire coding region of the PC3 gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (Arg/Gln53) and 14 (Gln/Glu638), neither of which was associated with NIDDM in this population.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 52], "name": "nucleotide", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "GENE", "char_span": [99, 102], "name": "PC3", "tok_span": [15, 17], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [184, 193], "name": "Arg/Gln53", "tok_span": [34, 39], "new_tok_span": [38, 43]}, {"ent_type": "GENE", "char_span": [203, 213], "name": "Gln/Glu638", "tok_span": [43, 49], "new_tok_span": [50, 56]}], "relation_list": [{"subject": "nucleotide", "sbj_char_span": [42, 52], "object": "PC3", "obj_char_span": [99, 102], "rel_type": "part of", "sbj_tok_span": [6, 7], "obj_tok_span": [15, 17], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [16, 18]}, {"subject": "nucleotide", "sbj_char_span": [42, 52], "object": "Arg/Gln53", "obj_char_span": [184, 193], "rel_type": "part of", "sbj_tok_span": [6, 7], "obj_tok_span": [34, 39], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [38, 43]}, {"subject": "nucleotide", "sbj_char_span": [42, 52], "object": "Gln/Glu638", "obj_char_span": [203, 213], "rel_type": "part of", "sbj_tok_span": [6, 7], "obj_tok_span": [43, 49], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [50, 56]}], "umls_entity_list": [{"mention": "PC3", "char_span": [99, 102], "sem_type": "Gene or Genome", "tok_span": [15, 17], "new_tok_span": [16, 18]}, {"mention": "NIDDM", "char_span": [138, 143], "sem_type": "Gene or Genome", "tok_span": [23, 26], "new_tok_span": [26, 29]}, {"mention": "NIDDM", "char_span": [253, 258], "sem_type": "Gene or Genome", "tok_span": [57, 60], "new_tok_span": [66, 69]}, {"mention": "Gln", "char_span": [188, 191], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 38], "new_tok_span": [41, 43]}, {"mention": "Gln", "char_span": [203, 206], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [43, 45], "new_tok_span": [50, 52]}], "new_text": "Single - strand conformational analysis and nucleotide sequencing of the entire coding region of the <START=Gene or Genome> PC3 <END=Gene or Genome> gene in 102 Japanese subjects with <START=Gene or Genome> NIDDM <END=Gene or Genome> revealed missense mutations in exons 2 ( Arg / <START=Amino Acid, Peptide, or Protein> Gln <END=Amino Acid, Peptide, or Protein>53 ) and 14 ( <START=Amino Acid, Peptide, or Protein> Gln <END=Amino Acid, Peptide, or Protein> / Glu638 ), neither of which was associated with <START=Gene or Genome> NIDDM <END=Gene or Genome> in this population."}, {"PMID": 23261528, "id": 0, "text": "Inhibition of Th1/Th17 responses via suppression of STAT1 and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural flavonoid glucoside icariin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [155, 164], "name": "flavonoid", "tok_span": [29, 31], "new_tok_span": [36, 38]}, {"ent_type": "CHEMICAL", "char_span": [175, 182], "name": "icariin", "tok_span": [33, 36], "new_tok_span": [44, 47]}, {"ent_type": "GENE", "char_span": [52, 57], "name": "STAT1", "tok_span": [11, 13], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [62, 67], "name": "STAT3", "tok_span": [14, 16], "new_tok_span": [20, 22]}], "relation_list": [{"subject": "flavonoid", "sbj_char_span": [155, 164], "object": "STAT1", "obj_char_span": [52, 57], "rel_type": "inhibitor", "sbj_tok_span": [29, 31], "obj_tok_span": [11, 13], "new_sbj_tok_span": [36, 38], "new_obj_tok_span": [15, 17]}, {"subject": "icariin", "sbj_char_span": [175, 182], "object": "STAT1", "obj_char_span": [52, 57], "rel_type": "inhibitor", "sbj_tok_span": [33, 36], "obj_tok_span": [11, 13], "new_sbj_tok_span": [44, 47], "new_obj_tok_span": [15, 17]}, {"subject": "flavonoid", "sbj_char_span": [155, 164], "object": "STAT3", "obj_char_span": [62, 67], "rel_type": "inhibitor", "sbj_tok_span": [29, 31], "obj_tok_span": [14, 16], "new_sbj_tok_span": [36, 38], "new_obj_tok_span": [20, 22]}, {"subject": "icariin", "sbj_char_span": [175, 182], "object": "STAT3", "obj_char_span": [62, 67], "rel_type": "inhibitor", "sbj_tok_span": [33, 36], "obj_tok_span": [14, 16], "new_sbj_tok_span": [44, 47], "new_obj_tok_span": [20, 22]}], "umls_entity_list": [{"mention": "STAT1", "char_span": [52, 57], "sem_type": "Gene or Genome", "tok_span": [11, 13], "new_tok_span": [15, 17]}, {"mention": "STAT1", "char_span": [52, 57], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 13], "new_tok_span": [15, 17]}, {"mention": "via", "char_span": [33, 36], "sem_type": "Gene or Genome", "tok_span": [8, 9], "new_tok_span": [9, 10]}, {"mention": "flavonoid", "char_span": [155, 164], "sem_type": "Organic Chemical", "tok_span": [29, 31], "new_tok_span": [36, 38]}, {"mention": "glucoside", "char_span": [165, 174], "sem_type": "Organic Chemical", "tok_span": [31, 33], "new_tok_span": [40, 42]}, {"mention": "icariin", "char_span": [175, 182], "sem_type": "Organic Chemical", "tok_span": [33, 36], "new_tok_span": [44, 47]}], "new_text": "Inhibition of Th1 / Th17 responses <START=Gene or Genome> via <END=Gene or Genome> suppression of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> STAT1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and STAT3 activation contributes to the amelioration of murine experimental colitis by a natural <START=Organic Chemical> flavonoid <END=Organic Chemical> <START=Organic Chemical> glucoside <END=Organic Chemical> <START=Organic Chemical> icariin <END=Organic Chemical>."}, {"PMID": 3334987, "id": 4, "text": "All tested compounds displaced 17 beta-[3H]estradiol from the cytosolic estrogen receptor, but to varying degrees; and there was no discernible relationship between their ability to compete for this receptor and their efficacy in stimulating DNA synthesis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [31, 52], "name": "17 beta-[3H]estradiol", "tok_span": [4, 12], "new_tok_span": [4, 12]}, {"ent_type": "CHEMICAL", "char_span": [72, 80], "name": "estrogen", "tok_span": [15, 16], "new_tok_span": [17, 18]}, {"ent_type": "GENE", "char_span": [72, 89], "name": "estrogen receptor", "tok_span": [15, 17], "new_tok_span": [17, 19]}], "relation_list": [{"subject": "17 beta-[3H]estradiol", "sbj_char_span": [31, 52], "object": "estrogen receptor", "obj_char_span": [72, 89], "rel_type": "regulator", "sbj_tok_span": [4, 12], "obj_tok_span": [15, 17], "new_sbj_tok_span": [4, 12], "new_obj_tok_span": [17, 19]}], "umls_entity_list": [{"mention": "cytosolic", "char_span": [62, 71], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 15], "new_tok_span": [15, 16]}, {"mention": "receptor", "char_span": [81, 89], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 17], "new_tok_span": [19, 20]}, {"mention": "receptor", "char_span": [199, 207], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 38], "new_tok_span": [42, 43]}], "new_text": "All tested compounds displaced 17 beta - [ 3H ] estradiol from the <START=Amino Acid, Peptide, or Protein> cytosolic <END=Amino Acid, Peptide, or Protein> estrogen <START=Amino Acid, Peptide, or Protein> receptor <END=Amino Acid, Peptide, or Protein>, but to varying degrees ; and there was no discernible relationship between their ability to compete for this <START=Amino Acid, Peptide, or Protein> receptor <END=Amino Acid, Peptide, or Protein> and their efficacy in stimulating DNA synthesis."}, {"PMID": 12531805, "id": 0, "text": "SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 7], "name": "SU11248", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [24, 32], "name": "tyrosine", "tok_span": [9, 10], "new_tok_span": [9, 10]}, {"ent_type": "GENE", "char_span": [19, 23], "name": "FLT3", "tok_span": [6, 9], "new_tok_span": [6, 9]}, {"ent_type": "GENE", "char_span": [24, 39], "name": "tyrosine kinase", "tok_span": [9, 11], "new_tok_span": [9, 11]}], "relation_list": [{"subject": "SU11248", "sbj_char_span": [0, 7], "object": "FLT3", "obj_char_span": [19, 23], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [6, 9], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [6, 9]}, {"subject": "SU11248", "sbj_char_span": [0, 7], "object": "tyrosine kinase", "obj_char_span": [24, 39], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [9, 11], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [9, 11]}], "umls_entity_list": [], "new_text": "SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo."}, {"PMID": 23219887, "id": 3, "text": "Active site aromatic and acidic residues are involved in binding the ω-aminoaldehydes in plant ALDH10 enzymes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [69, 85], "name": "ω-aminoaldehydes", "tok_span": [11, 16], "new_tok_span": [11, 16]}, {"ent_type": "GENE", "char_span": [89, 101], "name": "plant ALDH10", "tok_span": [17, 21], "new_tok_span": [17, 21]}], "relation_list": [{"subject": "ω-aminoaldehydes", "sbj_char_span": [69, 85], "object": "plant ALDH10", "obj_char_span": [89, 101], "rel_type": "regulator", "sbj_tok_span": [11, 16], "obj_tok_span": [17, 21], "new_sbj_tok_span": [11, 16], "new_obj_tok_span": [17, 21]}], "umls_entity_list": [{"mention": "ALDH10", "char_span": [95, 101], "sem_type": "Gene or Genome", "tok_span": [18, 21], "new_tok_span": [19, 22]}], "new_text": "Active site aromatic and acidic residues are involved in binding the ω - aminoaldehydes in plant <START=Gene or Genome> ALDH10 <END=Gene or Genome> enzymes."}, {"PMID": 17112405, "id": 3, "text": "The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [53, 57], "name": "NMDA", "tok_span": [11, 12], "new_tok_span": [16, 17]}, {"ent_type": "CHEMICAL", "char_span": [117, 127], "name": "pranlukast", "tok_span": [24, 29], "new_tok_span": [36, 41]}, {"ent_type": "CHEMICAL", "char_span": [153, 157], "name": "NMDA", "tok_span": [43, 44], "new_tok_span": [56, 57]}, {"ent_type": "CHEMICAL", "char_span": [179, 187], "name": "ketamine", "tok_span": [47, 48], "new_tok_span": [63, 64]}, {"ent_type": "CHEMICAL", "char_span": [220, 229], "name": "edaravone", "tok_span": [59, 63], "new_tok_span": [76, 80]}, {"ent_type": "GENE", "char_span": [15, 30], "name": "CysLT1 receptor", "tok_span": [3, 7], "new_tok_span": [5, 9]}, {"ent_type": "GENE", "char_span": [89, 104], "name": "CysLT1 receptor", "tok_span": [18, 22], "new_tok_span": [26, 30]}, {"ent_type": "GENE", "char_span": [153, 166], "name": "NMDA receptor", "tok_span": [43, 45], "new_tok_span": [56, 58]}], "relation_list": [{"subject": "pranlukast", "sbj_char_span": [117, 127], "object": "CysLT1 receptor", "obj_char_span": [89, 104], "rel_type": "agonist or antagonist", "sbj_tok_span": [24, 29], "obj_tok_span": [18, 22], "new_sbj_tok_span": [36, 41], "new_obj_tok_span": [26, 30]}, {"subject": "ketamine", "sbj_char_span": [179, 187], "object": "NMDA receptor", "obj_char_span": [153, 166], "rel_type": "agonist or antagonist", "sbj_tok_span": [47, 48], "obj_tok_span": [43, 45], "new_sbj_tok_span": [63, 64], "new_obj_tok_span": [56, 58]}], "umls_entity_list": [{"mention": "CysLT1", "char_span": [15, 21], "sem_type": "Gene or Genome", "tok_span": [3, 6], "new_tok_span": [5, 8]}, {"mention": "CysLT1", "char_span": [89, 95], "sem_type": "Gene or Genome", "tok_span": [18, 21], "new_tok_span": [26, 29]}, {"mention": "NMDA", "char_span": [53, 57], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 12], "new_tok_span": [16, 17]}, {"mention": "NMDA", "char_span": [153, 157], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [43, 44], "new_tok_span": [56, 57]}, {"mention": "CysLT1 receptor", "char_span": [15, 30], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 7], "new_tok_span": [5, 9]}, {"mention": "CysLT1 receptor", "char_span": [89, 104], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 22], "new_tok_span": [26, 30]}, {"mention": "receptor antagonist", "char_span": [96, 115], "sem_type": "Pharmacologic Substance", "tok_span": [21, 23], "new_tok_span": [31, 33]}, {"mention": "receptor antagonist", "char_span": [158, 177], "sem_type": "Pharmacologic Substance", "tok_span": [44, 46], "new_tok_span": [59, 61]}, {"mention": "edaravone", "char_span": [220, 229], "sem_type": "Pharmacologic Substance", "tok_span": [59, 63], "new_tok_span": [76, 80]}], "new_text": "The changes in <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> CysLT1 <END=Gene or Genome> receptor <END=Amino Acid, Peptide, or Protein> expression 24 h after <START=Amino Acid, Peptide, or Protein> NMDA <END=Amino Acid, Peptide, or Protein> injection and the effects of a <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> CysLT1 <END=Gene or Genome> <START=Pharmacologic Substance> receptor <END=Amino Acid, Peptide, or Protein> antagonist <END=Pharmacologic Substance>, pranlukast ( 0. 01 and 0. 1 mg / kg ), an <START=Amino Acid, Peptide, or Protein> NMDA <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> receptor antagonist <END=Pharmacologic Substance>, ketamine ( 30 mg / kg ), and an antioxidant, <START=Pharmacologic Substance> edaravone <END=Pharmacologic Substance> ( 9 mg / kg ) were observed."}, {"PMID": 23448346, "id": 5, "text": "Computational docking analysis was conducted to model the interaction of these antagonists with the human ERα and showed that they could tightly bind to the ERα in a manner similar to that of ICI-182,780, a pure ER antagonist.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [192, 203], "name": "ICI-182,780", "tok_span": [35, 42], "new_tok_span": [43, 50]}, {"ent_type": "GENE", "char_span": [100, 109], "name": "human ERα", "tok_span": [14, 17], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [157, 160], "name": "ERα", "tok_span": [26, 28], "new_tok_span": [31, 33]}, {"ent_type": "GENE", "char_span": [212, 214], "name": "ER", "tok_span": [45, 46], "new_tok_span": [54, 55]}], "relation_list": [{"subject": "ICI-182,780", "sbj_char_span": [192, 203], "object": "ER", "obj_char_span": [212, 214], "rel_type": "agonist or antagonist", "sbj_tok_span": [35, 42], "obj_tok_span": [45, 46], "new_sbj_tok_span": [43, 50], "new_obj_tok_span": [54, 55]}], "umls_entity_list": [{"mention": "er", "char_span": [61, 63], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [9, 10]}, {"mention": "ER", "char_span": [106, 108], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 16], "new_tok_span": [18, 19]}, {"mention": "ER", "char_span": [157, 159], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 27], "new_tok_span": [31, 32]}, {"mention": "er", "char_span": [170, 172], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 31], "new_tok_span": [37, 38]}, {"mention": "ER", "char_span": [212, 214], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [45, 46], "new_tok_span": [54, 55]}], "new_text": "Computational docking analysis was conducted to model the <START=Amino Acid, Peptide, or Protein> interaction <END=Amino Acid, Peptide, or Protein> of these antagonists with the human <START=Amino Acid, Peptide, or Protein> ER <END=Amino Acid, Peptide, or Protein>α and showed that they could tightly bind to the <START=Amino Acid, Peptide, or Protein> ER <END=Amino Acid, Peptide, or Protein>α in a <START=Amino Acid, Peptide, or Protein> manner <END=Amino Acid, Peptide, or Protein> similar to that of ICI - 182, 780, a pure <START=Amino Acid, Peptide, or Protein> ER <END=Amino Acid, Peptide, or Protein> antagonist."}, {"PMID": 9730867, "id": 5, "text": "The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [138, 145], "name": "timolol", "tok_span": [42, 45], "new_tok_span": [49, 52]}, {"ent_type": "CHEMICAL", "char_span": [108, 119], "name": "ICI 118,551", "tok_span": [26, 32], "new_tok_span": [31, 37]}, {"ent_type": "GENE", "char_span": [27, 36], "name": "IFN-gamma", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [38, 44], "name": "GM-CSF", "tok_span": [8, 11], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [50, 54], "name": "IL-3", "tok_span": [13, 16], "new_tok_span": [13, 16]}, {"ent_type": "GENE", "char_span": [89, 96], "name": "beta2AR", "tok_span": [22, 25], "new_tok_span": [23, 26]}], "relation_list": [{"subject": "ICI 118,551", "sbj_char_span": [108, 119], "object": "beta2AR", "obj_char_span": [89, 96], "rel_type": "agonist or antagonist", "sbj_tok_span": [26, 32], "obj_tok_span": [22, 25], "new_sbj_tok_span": [31, 37], "new_obj_tok_span": [23, 26]}, {"subject": "timolol", "sbj_char_span": [138, 145], "object": "beta2AR", "obj_char_span": [89, 96], "rel_type": "agonist or antagonist", "sbj_tok_span": [42, 45], "obj_tok_span": [22, 25], "new_sbj_tok_span": [49, 52], "new_obj_tok_span": [23, 26]}, {"subject": "ICI 118,551", "sbj_char_span": [108, 119], "object": "IFN-gamma", "obj_char_span": [27, 36], "rel_type": "regulator", "sbj_tok_span": [26, 32], "obj_tok_span": [4, 7], "new_sbj_tok_span": [31, 37], "new_obj_tok_span": [4, 7]}, {"subject": "ICI 118,551", "sbj_char_span": [108, 119], "object": "GM-CSF", "obj_char_span": [38, 44], "rel_type": "regulator", "sbj_tok_span": [26, 32], "obj_tok_span": [8, 11], "new_sbj_tok_span": [31, 37], "new_obj_tok_span": [8, 11]}, {"subject": "ICI 118,551", "sbj_char_span": [108, 119], "object": "IL-3", "obj_char_span": [50, 54], "rel_type": "regulator", "sbj_tok_span": [26, 32], "obj_tok_span": [13, 16], "new_sbj_tok_span": [31, 37], "new_obj_tok_span": [13, 16]}, {"subject": "timolol", "sbj_char_span": [138, 145], "object": "IFN-gamma", "obj_char_span": [27, 36], "rel_type": "regulator", "sbj_tok_span": [42, 45], "obj_tok_span": [4, 7], "new_sbj_tok_span": [49, 52], "new_obj_tok_span": [4, 7]}, {"subject": "timolol", "sbj_char_span": [138, 145], "object": "GM-CSF", "obj_char_span": [38, 44], "rel_type": "regulator", "sbj_tok_span": [42, 45], "obj_tok_span": [8, 11], "new_sbj_tok_span": [49, 52], "new_obj_tok_span": [8, 11]}, {"subject": "timolol", "sbj_char_span": [138, 145], "object": "IL-3", "obj_char_span": [50, 54], "rel_type": "regulator", "sbj_tok_span": [42, 45], "obj_tok_span": [13, 16], "new_sbj_tok_span": [49, 52], "new_obj_tok_span": [13, 16]}], "umls_entity_list": [{"mention": "beta2AR", "char_span": [89, 96], "sem_type": "Gene or Genome", "tok_span": [22, 25], "new_tok_span": [23, 26]}, {"mention": "ICI 118,551", "char_span": [108, 119], "sem_type": "Pharmacologic Substance", "tok_span": [26, 32], "new_tok_span": [31, 37]}, {"mention": "antagonist", "char_span": [97, 107], "sem_type": "Pharmacologic Substance", "tok_span": [25, 26], "new_tok_span": [28, 29]}, {"mention": "antagonist", "char_span": [173, 183], "sem_type": "Pharmacologic Substance", "tok_span": [58, 59], "new_tok_span": [67, 68]}, {"mention": "timolol", "char_span": [138, 145], "sem_type": "Pharmacologic Substance", "tok_span": [42, 45], "new_tok_span": [49, 52]}], "new_text": "The observed inhibition on IFN - gamma, GM - CSF, and IL - 3 mRNA was blocked by the selective <START=Gene or Genome> beta2AR <END=Gene or Genome> <START=Pharmacologic Substance> antagonist <END=Pharmacologic Substance> <START=Pharmacologic Substance> ICI 118, 551 <END=Pharmacologic Substance> ( 10 ( - 6 ) M ) and by <START=Pharmacologic Substance> timolol <END=Pharmacologic Substance> ( 10 ( - 6 ) M ), a nonselective <START=Pharmacologic Substance> antagonist <END=Pharmacologic Substance>."}, {"PMID": 16543605, "id": 7, "text": "We have cloned and characterized a CYP51 from MAC that functions as a lanosterol 14alpha-demethylase.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [70, 80], "name": "lanosterol", "tok_span": [14, 18], "new_tok_span": [21, 25]}, {"ent_type": "GENE", "char_span": [35, 40], "name": "CYP51", "tok_span": [6, 8], "new_tok_span": [7, 9]}], "relation_list": [{"subject": "lanosterol", "sbj_char_span": [70, 80], "object": "CYP51", "obj_char_span": [35, 40], "rel_type": "product or substrate", "sbj_tok_span": [14, 18], "obj_tok_span": [6, 8], "new_sbj_tok_span": [21, 25], "new_obj_tok_span": [7, 9]}], "umls_entity_list": [{"mention": "CYP51", "char_span": [35, 40], "sem_type": "Gene or Genome", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"mention": "MAC", "char_span": [46, 49], "sem_type": "Gene or Genome", "tok_span": [9, 10], "new_tok_span": [13, 14]}, {"mention": "MAC", "char_span": [46, 49], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 10], "new_tok_span": [13, 14]}, {"mention": "lanosterol", "char_span": [70, 80], "sem_type": "Organic Chemical", "tok_span": [14, 18], "new_tok_span": [21, 25]}, {"mention": "demethylase", "char_span": [89, 100], "sem_type": "Gene or Genome", "tok_span": [21, 24], "new_tok_span": [30, 33]}], "new_text": "We have cloned and characterized a <START=Gene or Genome> CYP51 <END=Gene or Genome> from <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> MAC <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> that functions as a <START=Organic Chemical> lanosterol <END=Organic Chemical> 14alpha - <START=Gene or Genome> demethylase <END=Gene or Genome>."}, {"PMID": 23639191, "id": 10, "text": "Moreover, calycopterin, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and Nrf2, which play an important role in antioxidant capacity of the cell.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [10, 22], "name": "calycopterin", "tok_span": [2, 6], "new_tok_span": [2, 6]}, {"ent_type": "CHEMICAL", "char_span": [39, 43], "name": "H2O2", "tok_span": [10, 14], "new_tok_span": [10, 14]}, {"ent_type": "GENE", "char_span": [135, 139], "name": "CREB", "tok_span": [28, 29], "new_tok_span": [30, 31]}, {"ent_type": "GENE", "char_span": [144, 148], "name": "Nrf2", "tok_span": [30, 32], "new_tok_span": [32, 34]}], "relation_list": [{"subject": "calycopterin", "sbj_char_span": [10, 22], "object": "CREB", "obj_char_span": [135, 139], "rel_type": "regulator", "sbj_tok_span": [2, 6], "obj_tok_span": [28, 29], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [30, 31]}, {"subject": "calycopterin", "sbj_char_span": [10, 22], "object": "Nrf2", "obj_char_span": [144, 148], "rel_type": "regulator", "sbj_tok_span": [2, 6], "obj_tok_span": [30, 32], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [32, 34]}], "umls_entity_list": [{"mention": "transcription factors", "char_span": [112, 133], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 27], "new_tok_span": [26, 28]}, {"mention": "antioxidant", "char_span": [182, 193], "sem_type": "Pharmacologic Substance", "tok_span": [39, 40], "new_tok_span": [42, 43]}], "new_text": "Moreover, calycopterin, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress - sensing <START=Amino Acid, Peptide, or Protein> transcription factors <END=Amino Acid, Peptide, or Protein>, CREB and Nrf2, which play an important role in <START=Pharmacologic Substance> antioxidant <END=Pharmacologic Substance> capacity of the cell."}, {"PMID": 10566562, "id": 3, "text": "In recent studies, the cyclooxygenase-2 (COX-2) inhibitor rofecoxib demonstrated analgesic effects similar to those of NSAIDs in the treatment of acute pain and primary dysmenorrhea.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [58, 67], "name": "rofecoxib", "tok_span": [15, 19], "new_tok_span": [16, 20]}, {"ent_type": "GENE", "char_span": [23, 39], "name": "cyclooxygenase-2", "tok_span": [5, 9], "new_tok_span": [5, 9]}, {"ent_type": "GENE", "char_span": [41, 46], "name": "COX-2", "tok_span": [10, 13], "new_tok_span": [10, 13]}], "relation_list": [{"subject": "rofecoxib", "sbj_char_span": [58, 67], "object": "cyclooxygenase-2", "obj_char_span": [23, 39], "rel_type": "inhibitor", "sbj_tok_span": [15, 19], "obj_tok_span": [5, 9], "new_sbj_tok_span": [16, 20], "new_obj_tok_span": [5, 9]}, {"subject": "rofecoxib", "sbj_char_span": [58, 67], "object": "COX-2", "obj_char_span": [41, 46], "rel_type": "inhibitor", "sbj_tok_span": [15, 19], "obj_tok_span": [10, 13], "new_sbj_tok_span": [16, 20], "new_obj_tok_span": [10, 13]}], "umls_entity_list": [{"mention": "rofecoxib", "char_span": [58, 67], "sem_type": "Pharmacologic Substance", "tok_span": [15, 19], "new_tok_span": [16, 20]}, {"mention": "NSAIDs", "char_span": [119, 125], "sem_type": "Pharmacologic Substance", "tok_span": [26, 28], "new_tok_span": [29, 31]}], "new_text": "In recent studies, the cyclooxygenase - 2 ( COX - 2 ) inhibitor <START=Pharmacologic Substance> rofecoxib <END=Pharmacologic Substance> demonstrated analgesic effects similar to those of <START=Pharmacologic Substance> NSAIDs <END=Pharmacologic Substance> in the treatment of acute pain and primary dysmenorrhea."}, {"PMID": 1647395, "id": 1, "text": "Estramustine is a novel anti-microtubule drug shown to bind MAP-1 and MAP-2 (microtubule-associated proteins) in vitro.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Estramustine", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "GENE", "char_span": [29, 40], "name": "microtubule", "tok_span": [9, 10], "new_tok_span": [9, 10]}, {"ent_type": "GENE", "char_span": [60, 65], "name": "MAP-1", "tok_span": [14, 17], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [70, 75], "name": "MAP-2", "tok_span": [18, 21], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [77, 108], "name": "microtubule-associated proteins", "tok_span": [22, 26], "new_tok_span": [25, 29]}], "relation_list": [{"subject": "Estramustine", "sbj_char_span": [0, 12], "object": "MAP-1", "obj_char_span": [60, 65], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [14, 17], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [15, 18]}, {"subject": "Estramustine", "sbj_char_span": [0, 12], "object": "MAP-2", "obj_char_span": [70, 75], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [18, 21], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [20, 23]}, {"subject": "Estramustine", "sbj_char_span": [0, 12], "object": "microtubule-associated proteins", "obj_char_span": [77, 108], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [22, 26], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [25, 29]}], "umls_entity_list": [{"mention": "MAP-1", "char_span": [60, 65], "sem_type": "Gene or Genome", "tok_span": [14, 17], "new_tok_span": [15, 18]}, {"mention": "microtubule-associated", "char_span": [77, 99], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 25], "new_tok_span": [25, 28]}], "new_text": "Estramustine is a novel anti - microtubule drug shown to bind <START=Gene or Genome> MAP - 1 <END=Gene or Genome> and MAP - 2 ( <START=Amino Acid, Peptide, or Protein> microtubule - associated <END=Amino Acid, Peptide, or Protein> proteins ) in vitro."}, {"PMID": 16781459, "id": 4, "text": "While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [192, 197], "name": "H(2)S", "tok_span": [43, 48], "new_tok_span": [65, 70]}, {"ent_type": "CHEMICAL", "char_span": [221, 223], "name": "NO", "tok_span": [52, 53], "new_tok_span": [78, 79]}, {"ent_type": "CHEMICAL", "char_span": [296, 301], "name": "H(2)S", "tok_span": [65, 70], "new_tok_span": [95, 100]}, {"ent_type": "GENE", "char_span": [25, 27], "name": "HO", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"ent_type": "GENE", "char_span": [44, 46], "name": "HO", "tok_span": [9, 10], "new_tok_span": [12, 13]}, {"ent_type": "GENE", "char_span": [103, 107], "name": "HO-1", "tok_span": [24, 27], "new_tok_span": [32, 35]}, {"ent_type": "GENE", "char_span": [122, 126], "name": "HO-1", "tok_span": [29, 32], "new_tok_span": [41, 44]}, {"ent_type": "GENE", "char_span": [201, 205], "name": "iNOS", "tok_span": [49, 50], "new_tok_span": [73, 74]}, {"ent_type": "GENE", "char_span": [236, 240], "name": "HO-1", "tok_span": [55, 58], "new_tok_span": [83, 86]}], "relation_list": [{"subject": "H(2)S", "sbj_char_span": [192, 197], "object": "iNOS", "obj_char_span": [201, 205], "rel_type": "regulator", "sbj_tok_span": [43, 48], "obj_tok_span": [49, 50], "new_sbj_tok_span": [65, 70], "new_obj_tok_span": [73, 74]}, {"subject": "NO", "sbj_char_span": [221, 223], "object": "iNOS", "obj_char_span": [201, 205], "rel_type": "product or substrate", "sbj_tok_span": [52, 53], "obj_tok_span": [49, 50], "new_sbj_tok_span": [78, 79], "new_obj_tok_span": [73, 74]}], "umls_entity_list": [{"mention": "HO", "char_span": [25, 27], "sem_type": "Gene or Genome", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"mention": "HO", "char_span": [44, 46], "sem_type": "Gene or Genome", "tok_span": [9, 10], "new_tok_span": [12, 13]}, {"mention": "HO", "char_span": [103, 105], "sem_type": "Gene or Genome", "tok_span": [24, 25], "new_tok_span": [32, 33]}, {"mention": "HO", "char_span": [122, 124], "sem_type": "Gene or Genome", "tok_span": [29, 30], "new_tok_span": [41, 42]}, {"mention": "HO", "char_span": [236, 238], "sem_type": "Gene or Genome", "tok_span": [55, 56], "new_tok_span": [83, 84]}, {"mention": "tin protoporphyrin IX", "char_span": [58, 79], "sem_type": "Pharmacologic Substance", "tok_span": [12, 18], "new_tok_span": [17, 23]}, {"mention": "HO-1", "char_span": [103, 107], "sem_type": "Gene or Genome", "tok_span": [24, 27], "new_tok_span": [32, 35]}, {"mention": "HO-1", "char_span": [122, 126], "sem_type": "Gene or Genome", "tok_span": [29, 32], "new_tok_span": [41, 44]}, {"mention": "HO-1", "char_span": [236, 240], "sem_type": "Gene or Genome", "tok_span": [55, 58], "new_tok_span": [83, 86]}, {"mention": "NA", "char_span": [146, 148], "sem_type": "Pharmacologic Substance", "tok_span": [34, 35], "new_tok_span": [50, 51]}, {"mention": "NA", "char_span": [153, 155], "sem_type": "Pharmacologic Substance", "tok_span": [36, 37], "new_tok_span": [56, 57]}, {"mention": "small interfering RNA", "char_span": [127, 148], "sem_type": "Pharmacologic Substance", "tok_span": [32, 35], "new_tok_span": [47, 50]}, {"mention": "siRNA", "char_span": [150, 155], "sem_type": "Pharmacologic Substance", "tok_span": [36, 37], "new_tok_span": [56, 57]}, {"mention": "iNOS", "char_span": [201, 205], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [49, 50], "new_tok_span": [73, 74]}, {"mention": "iNOS", "char_span": [201, 205], "sem_type": "Gene or Genome", "tok_span": [49, 50], "new_tok_span": [73, 74]}], "new_text": "While either blockage of <START=Gene or Genome> HO <END=Gene or Genome> activity by the <START=Gene or Genome> HO <END=Gene or Genome> inhibitor, <START=Pharmacologic Substance> tin protoporphyrin IX <END=Pharmacologic Substance>, or down - regulation of <START=Gene or Genome> <START=Gene or Genome> HO <END=Gene or Genome> - 1 <END=Gene or Genome> expression by <START=Gene or Genome> <START=Gene or Genome> HO <END=Gene or Genome> - 1 <END=Gene or Genome> <START=Pharmacologic Substance> small interfering <START=Pharmacologic Substance> RNA <END=Pharmacologic Substance> <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> <START=Pharmacologic Substance> siRNA <END=Pharmacologic Substance> <END=Pharmacologic Substance> ) reversed the inhibitory effects of H ( 2 ) S on <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> iNOS <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> expression and NO production, <START=Gene or Genome> <START=Gene or Genome> HO <END=Gene or Genome> - 1 <END=Gene or Genome> overexpression produced the same inhibitory effects of H ( 2 ) S."}, {"PMID": 17545671, "id": 1, "text": "We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [137, 147], "name": "fatty acid", "tok_span": [28, 30], "new_tok_span": [30, 32]}, {"ent_type": "CHEMICAL", "char_span": [173, 193], "name": "glycerol 3-phosphate", "tok_span": [33, 37], "new_tok_span": [35, 39]}, {"ent_type": "CHEMICAL", "char_span": [208, 218], "name": "fatty acid", "tok_span": [39, 41], "new_tok_span": [41, 43]}, {"ent_type": "CHEMICAL", "char_span": [23, 32], "name": "aspartate", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"ent_type": "CHEMICAL", "char_span": [302, 318], "name": "[(14)C]aspartate", "tok_span": [60, 68], "new_tok_span": [62, 70]}, {"ent_type": "CHEMICAL", "char_span": [397, 414], "name": "thiazolidinedione", "tok_span": [87, 92], "new_tok_span": [94, 99]}, {"ent_type": "CHEMICAL", "char_span": [416, 419], "name": "TZD", "tok_span": [93, 96], "new_tok_span": [101, 104]}, {"ent_type": "CHEMICAL", "char_span": [421, 434], "name": "rosiglitazone", "tok_span": [97, 102], "new_tok_span": [106, 111]}, {"ent_type": "GENE", "char_span": [13, 49], "name": "cytosolic aspartate aminotransferase", "tok_span": [3, 8], "new_tok_span": [3, 8]}, {"ent_type": "GENE", "char_span": [253, 259], "name": "cAspAT", "tok_span": [48, 52], "new_tok_span": [50, 54]}, {"ent_type": "GENE", "char_span": [358, 363], "name": "F442A", "tok_span": [78, 82], "new_tok_span": [84, 88]}, {"ent_type": "GENE", "char_span": [51, 57], "name": "cAspAT", "tok_span": [9, 13], "new_tok_span": [11, 15]}], "relation_list": [{"subject": "thiazolidinedione", "sbj_char_span": [397, 414], "object": "cAspAT", "obj_char_span": [253, 259], "rel_type": "activator", "sbj_tok_span": [87, 92], "obj_tok_span": [48, 52], "new_sbj_tok_span": [94, 99], "new_obj_tok_span": [50, 54]}, {"subject": "TZD", "sbj_char_span": [416, 419], "object": "cAspAT", "obj_char_span": [253, 259], "rel_type": "activator", "sbj_tok_span": [93, 96], "obj_tok_span": [48, 52], "new_sbj_tok_span": [101, 104], "new_obj_tok_span": [50, 54]}, {"subject": "rosiglitazone", "sbj_char_span": [421, 434], "object": "cAspAT", "obj_char_span": [253, 259], "rel_type": "activator", "sbj_tok_span": [97, 102], "obj_tok_span": [48, 52], "new_sbj_tok_span": [106, 111], "new_obj_tok_span": [50, 54]}], "umls_entity_list": [{"mention": "aspartate", "char_span": [23, 32], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"mention": "aspartate", "char_span": [309, 318], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [66, 68], "new_tok_span": [69, 71]}, {"mention": "lipid", "char_span": [336, 341], "sem_type": "Organic Chemical", "tok_span": [71, 72], "new_tok_span": [76, 77]}, {"mention": "thiazolidinedione", "char_span": [397, 414], "sem_type": "Pharmacologic Substance", "tok_span": [87, 92], "new_tok_span": [94, 99]}, {"mention": "rosiglitazone", "char_span": [421, 434], "sem_type": "Pharmacologic Substance", "tok_span": [97, 102], "new_tok_span": [106, 111]}], "new_text": "We show that cytosolic <START=Amino Acid, Peptide, or Protein> aspartate <END=Amino Acid, Peptide, or Protein> aminotransferase ( cAspAT ) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3 - phosphate formation for fatty acid re - esterification during fasting. cAspAT activity, as well as the incorporation of [ ( 14 ) C ] <START=Amino Acid, Peptide, or Protein> aspartate <END=Amino Acid, Peptide, or Protein> into the neutral <START=Organic Chemical> lipid <END=Organic Chemical> fraction of 3T3 - F442A adipocytes was stimulated by the <START=Pharmacologic Substance> thiazolidinedione <END=Pharmacologic Substance> ( TZD ) <START=Pharmacologic Substance> rosiglitazone <END=Pharmacologic Substance>."}, {"PMID": 16472148, "id": 3, "text": "In this review, the novel action mechanism (s) of cilostazol are overviewed with the focus on the action of cilostazol in in vitro and in vivo studies as a maxi-K channel opener targeting anti-apoptotic signaling pathways.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [50, 60], "name": "cilostazol", "tok_span": [12, 16], "new_tok_span": [13, 17]}, {"ent_type": "CHEMICAL", "char_span": [108, 118], "name": "cilostazol", "tok_span": [26, 30], "new_tok_span": [29, 33]}, {"ent_type": "CHEMICAL", "char_span": [161, 162], "name": "K", "tok_span": [42, 43], "new_tok_span": [46, 47]}, {"ent_type": "GENE", "char_span": [156, 170], "name": "maxi-K channel", "tok_span": [39, 44], "new_tok_span": [43, 48]}], "relation_list": [{"subject": "cilostazol", "sbj_char_span": [108, 118], "object": "maxi-K channel", "obj_char_span": [156, 170], "rel_type": "activator", "sbj_tok_span": [26, 30], "obj_tok_span": [39, 44], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [43, 48]}], "umls_entity_list": [{"mention": "cilostazol", "char_span": [50, 60], "sem_type": "Pharmacologic Substance", "tok_span": [12, 16], "new_tok_span": [13, 17]}, {"mention": "cilostazol", "char_span": [108, 118], "sem_type": "Pharmacologic Substance", "tok_span": [26, 30], "new_tok_span": [29, 33]}], "new_text": "In this review, the novel action mechanism ( s ) of <START=Pharmacologic Substance> cilostazol <END=Pharmacologic Substance> are overviewed with the focus on the action of <START=Pharmacologic Substance> cilostazol <END=Pharmacologic Substance> in in vitro and in vivo studies as a maxi - K channel opener targeting anti - apoptotic signaling pathways."}, {"PMID": 23260350, "id": 0, "text": "Identification of benzofuran central cores for the inhibition of leukotriene A(4) hydrolase.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 28], "name": "benzofuran", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"ent_type": "CHEMICAL", "char_span": [65, 81], "name": "leukotriene A(4)", "tok_span": [11, 18], "new_tok_span": [14, 21]}, {"ent_type": "GENE", "char_span": [65, 91], "name": "leukotriene A(4) hydrolase", "tok_span": [11, 21], "new_tok_span": [14, 24]}], "relation_list": [{"subject": "benzofuran", "sbj_char_span": [18, 28], "object": "leukotriene A(4) hydrolase", "obj_char_span": [65, 91], "rel_type": "inhibitor", "sbj_tok_span": [2, 5], "obj_tok_span": [11, 21], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [14, 24]}], "umls_entity_list": [{"mention": "benzofuran", "char_span": [18, 28], "sem_type": "Organic Chemical", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"mention": "leukotriene A(4) hydrolase", "char_span": [65, 91], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 21], "new_tok_span": [14, 24]}], "new_text": "Identification of <START=Organic Chemical> benzofuran <END=Organic Chemical> central cores for the inhibition of <START=Amino Acid, Peptide, or Protein> leukotriene A ( 4 ) hydrolase <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 7911719, "id": 6, "text": "Schild analysis of 5-methyl-urapidil inhibition experiments in chloroethylclonidine-treated ventricles indicated that only alpha 1A-adrenoceptors mediate the inotropic effects of adrenaline following inactivation of the alpha 1B-adrenoceptors. 5.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [19, 36], "name": "5-methyl-urapidil", "tok_span": [4, 12], "new_tok_span": [4, 12]}, {"ent_type": "CHEMICAL", "char_span": [63, 83], "name": "chloroethylclonidine", "tok_span": [15, 23], "new_tok_span": [18, 26]}, {"ent_type": "CHEMICAL", "char_span": [179, 189], "name": "adrenaline", "tok_span": [44, 46], "new_tok_span": [49, 51]}, {"ent_type": "GENE", "char_span": [123, 145], "name": "alpha 1A-adrenoceptors", "tok_span": [30, 38], "new_tok_span": [34, 42]}, {"ent_type": "GENE", "char_span": [220, 242], "name": "alpha 1B-adrenoceptors", "tok_span": [50, 58], "new_tok_span": [56, 64]}], "relation_list": [{"subject": "chloroethylclonidine", "sbj_char_span": [63, 83], "object": "alpha 1B-adrenoceptors", "obj_char_span": [220, 242], "rel_type": "inhibitor", "sbj_tok_span": [15, 23], "obj_tok_span": [50, 58], "new_sbj_tok_span": [18, 26], "new_obj_tok_span": [56, 64]}, {"subject": "5-methyl-urapidil", "sbj_char_span": [19, 36], "object": "alpha 1A-adrenoceptors", "obj_char_span": [123, 145], "rel_type": "inhibitor", "sbj_tok_span": [4, 12], "obj_tok_span": [30, 38], "new_sbj_tok_span": [4, 12], "new_obj_tok_span": [34, 42]}], "umls_entity_list": [{"mention": "urapidil", "char_span": [28, 36], "sem_type": "Pharmacologic Substance", "tok_span": [8, 12], "new_tok_span": [9, 13]}, {"mention": "chloroethylclonidine", "char_span": [63, 83], "sem_type": "Pharmacologic Substance", "tok_span": [15, 23], "new_tok_span": [18, 26]}, {"mention": "adrenaline", "char_span": [179, 189], "sem_type": "Pharmacologic Substance", "tok_span": [44, 46], "new_tok_span": [49, 51]}], "new_text": "Schild analysis of 5 - methyl - <START=Pharmacologic Substance> urapidil <END=Pharmacologic Substance> inhibition experiments in <START=Pharmacologic Substance> chloroethylclonidine <END=Pharmacologic Substance> - treated ventricles indicated that only alpha 1A - adrenoceptors mediate the inotropic effects of <START=Pharmacologic Substance> adrenaline <END=Pharmacologic Substance> following inactivation of the alpha 1B - adrenoceptors. 5."}, {"PMID": 11488610, "id": 7, "text": "Changes in the accessibility of Trp residues upon pyridoxal-P binding strongly supported a significant conformational change in GAD. Fluorescence intensity measurements were also carried out to investigate the unfolding of GAD using guanidine hydrochloride (GdnHCl) as the denaturant.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [233, 256], "name": "guanidine hydrochloride", "tok_span": [38, 41], "new_tok_span": [41, 44]}, {"ent_type": "CHEMICAL", "char_span": [258, 264], "name": "GdnHCl", "tok_span": [42, 45], "new_tok_span": [46, 49]}, {"ent_type": "CHEMICAL", "char_span": [32, 35], "name": "Trp", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [50, 61], "name": "pyridoxal-P", "tok_span": [8, 14], "new_tok_span": [10, 16]}, {"ent_type": "GENE", "char_span": [128, 131], "name": "GAD", "tok_span": [22, 23], "new_tok_span": [24, 25]}, {"ent_type": "GENE", "char_span": [223, 226], "name": "GAD", "tok_span": [36, 37], "new_tok_span": [38, 39]}], "relation_list": [{"subject": "Trp", "sbj_char_span": [32, 35], "object": "GAD", "obj_char_span": [128, 131], "rel_type": "part of", "sbj_tok_span": [5, 6], "obj_tok_span": [22, 23], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [24, 25]}, {"subject": "pyridoxal-P", "sbj_char_span": [50, 61], "object": "GAD", "obj_char_span": [128, 131], "rel_type": "regulator", "sbj_tok_span": [8, 14], "obj_tok_span": [22, 23], "new_sbj_tok_span": [10, 16], "new_obj_tok_span": [24, 25]}], "umls_entity_list": [{"mention": "Trp", "char_span": [32, 35], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"mention": "guanidine hydrochloride", "char_span": [233, 256], "sem_type": "Pharmacologic Substance", "tok_span": [38, 41], "new_tok_span": [41, 44]}], "new_text": "Changes in the accessibility of <START=Amino Acid, Peptide, or Protein> Trp <END=Amino Acid, Peptide, or Protein> residues upon pyridoxal - P binding strongly supported a significant conformational change in GAD. Fluorescence intensity measurements were also carried out to investigate the unfolding of GAD using <START=Pharmacologic Substance> guanidine hydrochloride <END=Pharmacologic Substance> ( GdnHCl ) as the denaturant."}, {"PMID": 22722028, "id": 8, "text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [158, 171], "name": "valproic acid", "tok_span": [22, 26], "new_tok_span": [22, 26]}, {"ent_type": "CHEMICAL", "char_span": [217, 223], "name": "AMN082", "tok_span": [35, 39], "new_tok_span": [36, 40]}, {"ent_type": "CHEMICAL", "char_span": [238, 247], "name": "glutamate", "tok_span": [42, 43], "new_tok_span": [47, 48]}, {"ent_type": "CHEMICAL", "char_span": [283, 289], "name": "MS-275", "tok_span": [54, 57], "new_tok_span": [60, 63]}, {"ent_type": "CHEMICAL", "char_span": [293, 297], "name": "PEPA", "tok_span": [58, 60], "new_tok_span": [65, 67]}, {"ent_type": "CHEMICAL", "char_span": [299, 303], "name": "AMPA", "tok_span": [61, 63], "new_tok_span": [70, 72]}, {"ent_type": "GENE", "char_span": [198, 202], "name": "HDAC", "tok_span": [31, 32], "new_tok_span": [31, 32]}, {"ent_type": "GENE", "char_span": [225, 258], "name": "metabotropic glutamate receptor 7", "tok_span": [40, 45], "new_tok_span": [44, 49]}, {"ent_type": "GENE", "char_span": [260, 265], "name": "mGlu7", "tok_span": [46, 49], "new_tok_span": [52, 55]}, {"ent_type": "GENE", "char_span": [299, 312], "name": "AMPA receptor", "tok_span": [61, 64], "new_tok_span": [70, 73]}], "relation_list": [{"subject": "valproic acid", "sbj_char_span": [158, 171], "object": "HDAC", "obj_char_span": [198, 202], "rel_type": "inhibitor", "sbj_tok_span": [22, 26], "obj_tok_span": [31, 32], "new_sbj_tok_span": [22, 26], "new_obj_tok_span": [31, 32]}, {"subject": "AMN082", "sbj_char_span": [217, 223], "object": "metabotropic glutamate receptor 7", "obj_char_span": [225, 258], "rel_type": "agonist or antagonist", "sbj_tok_span": [35, 39], "obj_tok_span": [40, 45], "new_sbj_tok_span": [36, 40], "new_obj_tok_span": [44, 49]}, {"subject": "AMN082", "sbj_char_span": [217, 223], "object": "mGlu7", "obj_char_span": [260, 265], "rel_type": "agonist or antagonist", "sbj_tok_span": [35, 39], "obj_tok_span": [46, 49], "new_sbj_tok_span": [36, 40], "new_obj_tok_span": [52, 55]}, {"subject": "MS-275", "sbj_char_span": [283, 289], "object": "AMPA receptor", "obj_char_span": [299, 312], "rel_type": "activator", "sbj_tok_span": [54, 57], "obj_tok_span": [61, 64], "new_sbj_tok_span": [60, 63], "new_obj_tok_span": [70, 73]}, {"subject": "PEPA", "sbj_char_span": [293, 297], "object": "AMPA receptor", "obj_char_span": [299, 312], "rel_type": "activator", "sbj_tok_span": [58, 60], "obj_tok_span": [61, 64], "new_sbj_tok_span": [65, 67], "new_obj_tok_span": [70, 73]}], "umls_entity_list": [{"mention": "AMN082", "char_span": [217, 223], "sem_type": "Organic Chemical", "tok_span": [35, 39], "new_tok_span": [36, 40]}, {"mention": "metabotropic", "char_span": [225, 237], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [40, 42], "new_tok_span": [44, 46]}, {"mention": "metabotropic glutamate receptor 7", "char_span": [225, 258], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [40, 45], "new_tok_span": [44, 49]}, {"mention": "PEPA", "char_span": [293, 297], "sem_type": "Gene or Genome", "tok_span": [58, 60], "new_tok_span": [65, 67]}, {"mention": "AMPA receptor", "char_span": [299, 312], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [61, 64], "new_tok_span": [70, 73]}], "new_text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation / retrieval was achieved with prior extinction training administration of valproic acid ( a GABAergic enhancer and HDAC inhibitor ) or <START=Organic Chemical> AMN082 <END=Organic Chemical> [ <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> metabotropic <END=Amino Acid, Peptide, or Protein> glutamate receptor 7 <END=Amino Acid, Peptide, or Protein> ( mGlu7 ) agonist ], while MS - 275 or <START=Gene or Genome> PEPA <END=Gene or Genome> ( <START=Amino Acid, Peptide, or Protein> AMPA receptor <END=Amino Acid, Peptide, or Protein> potentiator ) failed to affect extinction acquisition in S1 mice."}, {"PMID": 12023506, "id": 9, "text": "Comparing the K(i) values with the therapeutically relevant concentrations of unbound inhibitors in the plasma, probenecid alone was predicted to inhibit hOAT4-mediated organic anion transport in vivo.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [112, 122], "name": "probenecid", "tok_span": [21, 24], "new_tok_span": [21, 24]}, {"ent_type": "GENE", "char_span": [154, 159], "name": "hOAT4", "tok_span": [29, 33], "new_tok_span": [29, 33]}], "relation_list": [{"subject": "probenecid", "sbj_char_span": [112, 122], "object": "hOAT4", "obj_char_span": [154, 159], "rel_type": "inhibitor", "sbj_tok_span": [21, 24], "obj_tok_span": [29, 33], "new_sbj_tok_span": [21, 24], "new_obj_tok_span": [29, 33]}], "umls_entity_list": [], "new_text": "Comparing the K ( i ) values with the therapeutically relevant concentrations of unbound inhibitors in the plasma, probenecid alone was predicted to inhibit hOAT4 - mediated organic anion transport in vivo."}, {"PMID": 23435367, "id": 5, "text": "These results indicate transcription of FDX1 is regulated by the NR5A family and cAMP signaling, and participates in steroid hormone production in ovarian granulosa cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [81, 85], "name": "cAMP", "tok_span": [17, 18], "new_tok_span": [17, 18]}, {"ent_type": "CHEMICAL", "char_span": [117, 124], "name": "steroid", "tok_span": [23, 24], "new_tok_span": [24, 25]}, {"ent_type": "GENE", "char_span": [40, 44], "name": "FDX1", "tok_span": [5, 8], "new_tok_span": [5, 8]}, {"ent_type": "GENE", "char_span": [65, 69], "name": "NR5A", "tok_span": [12, 15], "new_tok_span": [12, 15]}], "relation_list": [{"subject": "steroid", "sbj_char_span": [117, 124], "object": "FDX1", "obj_char_span": [40, 44], "rel_type": "product or substrate", "sbj_tok_span": [23, 24], "obj_tok_span": [5, 8], "new_sbj_tok_span": [24, 25], "new_obj_tok_span": [5, 8]}, {"subject": "cAMP", "sbj_char_span": [81, 85], "object": "FDX1", "obj_char_span": [40, 44], "rel_type": "regulator", "sbj_tok_span": [17, 18], "obj_tok_span": [5, 8], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [5, 8]}], "umls_entity_list": [{"mention": "steroid", "char_span": [117, 124], "sem_type": "Pharmacologic Substance", "tok_span": [23, 24], "new_tok_span": [24, 25]}], "new_text": "These results indicate transcription of FDX1 is regulated by the NR5A family and cAMP signaling, and participates in <START=Pharmacologic Substance> steroid <END=Pharmacologic Substance> hormone production in ovarian granulosa cells."}, {"PMID": 23449888, "id": 8, "text": "Furthermore, we demonstrated that p14ARF binds to both the N-terminal domain and the ligand-binding domain of AR, and the human double minute 2 (HDM2)-binding motif of p14ARF is required for the interaction of p14ARF and AR proteins. p14ARF perturbs the androgen-induced interaction between the N terminus and C terminus of AR. Most importantly, we observed that the expression of PSA is reversely correlated with p14ARF in human prostate tissues.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [59, 60], "name": "N", "tok_span": [13, 14], "new_tok_span": [17, 18]}, {"ent_type": "CHEMICAL", "char_span": [254, 262], "name": "androgen", "tok_span": [66, 67], "new_tok_span": [82, 83]}, {"ent_type": "CHEMICAL", "char_span": [295, 296], "name": "N", "tok_span": [72, 73], "new_tok_span": [88, 89]}, {"ent_type": "CHEMICAL", "char_span": [310, 311], "name": "C", "tok_span": [75, 76], "new_tok_span": [91, 92]}, {"ent_type": "GENE", "char_span": [34, 40], "name": "p14ARF", "tok_span": [5, 9], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [110, 112], "name": "AR", "tok_span": [24, 25], "new_tok_span": [28, 29]}, {"ent_type": "GENE", "char_span": [122, 164], "name": "human double minute 2 (HDM2)-binding motif", "tok_span": [28, 40], "new_tok_span": [32, 44]}, {"ent_type": "GENE", "char_span": [168, 174], "name": "p14ARF", "tok_span": [41, 45], "new_tok_span": [47, 51]}, {"ent_type": "GENE", "char_span": [210, 216], "name": "p14ARF", "tok_span": [51, 55], "new_tok_span": [61, 65]}, {"ent_type": "GENE", "char_span": [221, 223], "name": "AR", "tok_span": [56, 57], "new_tok_span": [68, 69]}, {"ent_type": "GENE", "char_span": [234, 240], "name": "p14ARF", "tok_span": [59, 63], "new_tok_span": [73, 77]}, {"ent_type": "GENE", "char_span": [324, 326], "name": "AR", "tok_span": [78, 79], "new_tok_span": [94, 95]}, {"ent_type": "GENE", "char_span": [381, 384], "name": "PSA", "tok_span": [89, 90], "new_tok_span": [107, 108]}, {"ent_type": "GENE", "char_span": [414, 420], "name": "p14ARF", "tok_span": [95, 99], "new_tok_span": [117, 121]}], "relation_list": [{"subject": "N", "sbj_char_span": [59, 60], "object": "AR", "obj_char_span": [110, 112], "rel_type": "part of", "sbj_tok_span": [13, 14], "obj_tok_span": [24, 25], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [28, 29]}, {"subject": "N", "sbj_char_span": [295, 296], "object": "AR", "obj_char_span": [324, 326], "rel_type": "part of", "sbj_tok_span": [72, 73], "obj_tok_span": [78, 79], "new_sbj_tok_span": [88, 89], "new_obj_tok_span": [94, 95]}, {"subject": "C", "sbj_char_span": [310, 311], "object": "AR", "obj_char_span": [324, 326], "rel_type": "part of", "sbj_tok_span": [75, 76], "obj_tok_span": [78, 79], "new_sbj_tok_span": [91, 92], "new_obj_tok_span": [94, 95]}], "umls_entity_list": [{"mention": "p14ARF", "char_span": [34, 40], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 9], "new_tok_span": [7, 11]}, {"mention": "p14ARF", "char_span": [168, 174], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 45], "new_tok_span": [47, 51]}, {"mention": "p14ARF", "char_span": [210, 216], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [51, 55], "new_tok_span": [61, 65]}, {"mention": "p14ARF", "char_span": [234, 240], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [59, 63], "new_tok_span": [73, 77]}, {"mention": "p14ARF", "char_span": [414, 420], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [95, 99], "new_tok_span": [117, 121]}, {"mention": "p14ARF", "char_span": [34, 40], "sem_type": "Gene or Genome", "tok_span": [5, 9], "new_tok_span": [7, 11]}, {"mention": "p14ARF", "char_span": [168, 174], "sem_type": "Gene or Genome", "tok_span": [41, 45], "new_tok_span": [47, 51]}, {"mention": "p14ARF", "char_span": [210, 216], "sem_type": "Gene or Genome", "tok_span": [51, 55], "new_tok_span": [61, 65]}, {"mention": "p14ARF", "char_span": [234, 240], "sem_type": "Gene or Genome", "tok_span": [59, 63], "new_tok_span": [73, 77]}, {"mention": "p14ARF", "char_span": [414, 420], "sem_type": "Gene or Genome", "tok_span": [95, 99], "new_tok_span": [117, 121]}, {"mention": "PSA", "char_span": [381, 384], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [89, 90], "new_tok_span": [107, 108]}, {"mention": "PSA", "char_span": [381, 384], "sem_type": "Gene or Genome", "tok_span": [89, 90], "new_tok_span": [107, 108]}], "new_text": "Furthermore, we demonstrated that <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> p14ARF <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> binds to both the N - terminal domain and the ligand - binding domain of AR, and the human double minute 2 ( HDM2 ) - binding motif of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> p14ARF <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> is required for the interaction of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> p14ARF <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and AR proteins. <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> p14ARF <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> perturbs the androgen - induced interaction between the N terminus and C terminus of AR. Most importantly, we observed that the expression of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PSA <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> is reversely correlated with <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> p14ARF <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> in human prostate tissues."}, {"PMID": 23183374, "id": 8, "text": "Moreover, we demonstrate that release of AID from nucleoli is dependent on its C-terminal motif.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [79, 80], "name": "C", "tok_span": [16, 17], "new_tok_span": [16, 17]}, {"ent_type": "GENE", "char_span": [41, 44], "name": "AID", "tok_span": [7, 9], "new_tok_span": [7, 9]}], "relation_list": [{"subject": "C", "sbj_char_span": [79, 80], "object": "AID", "obj_char_span": [41, 44], "rel_type": "part of", "sbj_tok_span": [16, 17], "obj_tok_span": [7, 9], "new_sbj_tok_span": [16, 17], "new_obj_tok_span": [7, 9]}], "umls_entity_list": [], "new_text": "Moreover, we demonstrate that release of AID from nucleoli is dependent on its C - terminal motif."}, {"PMID": 10805052, "id": 0, "text": "Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [133, 152], "name": "hydrochlorothiazide", "tok_span": [33, 37], "new_tok_span": [44, 48]}, {"ent_type": "CHEMICAL", "char_span": [40, 61], "name": "candesartan cilexetil", "tok_span": [9, 16], "new_tok_span": [14, 21]}, {"ent_type": "CHEMICAL", "char_span": [86, 96], "name": "lisinopril", "tok_span": [22, 26], "new_tok_span": [31, 35]}, {"ent_type": "GENE", "char_span": [18, 30], "name": "AT1-receptor", "tok_span": [3, 7], "new_tok_span": [5, 9]}, {"ent_type": "GENE", "char_span": [71, 74], "name": "ACE", "tok_span": [19, 20], "new_tok_span": [26, 27]}], "relation_list": [{"subject": "candesartan cilexetil", "sbj_char_span": [40, 61], "object": "AT1-receptor", "obj_char_span": [18, 30], "rel_type": "inhibitor", "sbj_tok_span": [9, 16], "obj_tok_span": [3, 7], "new_sbj_tok_span": [14, 21], "new_obj_tok_span": [5, 9]}, {"subject": "lisinopril", "sbj_char_span": [86, 96], "object": "ACE", "obj_char_span": [71, 74], "rel_type": "inhibitor", "sbj_tok_span": [22, 26], "obj_tok_span": [19, 20], "new_sbj_tok_span": [31, 35], "new_obj_tok_span": [26, 27]}], "umls_entity_list": [{"mention": "AT1", "char_span": [18, 21], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"mention": "AT1", "char_span": [18, 21], "sem_type": "Gene or Genome", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"mention": "candesartan cilexetil", "char_span": [40, 61], "sem_type": "Pharmacologic Substance", "tok_span": [9, 16], "new_tok_span": [14, 21]}, {"mention": "ACE inhibitor", "char_span": [71, 84], "sem_type": "Pharmacologic Substance", "tok_span": [19, 21], "new_tok_span": [26, 28]}, {"mention": "lisinopril", "char_span": [86, 96], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 26], "new_tok_span": [31, 35]}, {"mention": "hydrochlorothiazide", "char_span": [133, 152], "sem_type": "Pharmacologic Substance", "tok_span": [33, 37], "new_tok_span": [44, 48]}], "new_text": "Comparison of the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> AT1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - receptor blocker, <START=Pharmacologic Substance> candesartan cilexetil <END=Pharmacologic Substance>, and the <START=Pharmacologic Substance> ACE inhibitor <END=Pharmacologic Substance>, <START=Amino Acid, Peptide, or Protein> lisinopril <END=Amino Acid, Peptide, or Protein>, in fixed combination with low dose <START=Pharmacologic Substance> hydrochlorothiazide <END=Pharmacologic Substance> in hypertensive patients."}, {"PMID": 23537890, "id": 5, "text": "Quercetin exhibited cytoprotective effects on the liver, as evidenced by decreased aminotransferase plasma levels.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Quercetin", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [83, 99], "name": "aminotransferase", "tok_span": [15, 17], "new_tok_span": [18, 20]}], "relation_list": [{"subject": "Quercetin", "sbj_char_span": [0, 9], "object": "aminotransferase", "obj_char_span": [83, 99], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [15, 17], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [18, 20]}], "umls_entity_list": [{"mention": "Quercetin", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "aminotransferase", "char_span": [83, 99], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 17], "new_tok_span": [18, 20]}, {"mention": "plasma", "char_span": [100, 106], "sem_type": "Pharmacologic Substance", "tok_span": [17, 18], "new_tok_span": [22, 23]}], "new_text": "<START=Pharmacologic Substance> Quercetin <END=Pharmacologic Substance> exhibited cytoprotective effects on the liver, as evidenced by decreased <START=Amino Acid, Peptide, or Protein> aminotransferase <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> plasma <END=Pharmacologic Substance> levels."}, {"PMID": 23512537, "id": 4, "text": "It is possible that variations in cytochrome P450 3A enzyme-mediated metabolism of BDP may contribute to this phenomenon.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [83, 86], "name": "BDP", "tok_span": [16, 18], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [34, 52], "name": "cytochrome P450 3A", "tok_span": [6, 11], "new_tok_span": [7, 12]}], "relation_list": [{"subject": "BDP", "sbj_char_span": [83, 86], "object": "cytochrome P450 3A", "obj_char_span": [34, 52], "rel_type": "product or substrate", "sbj_tok_span": [16, 18], "obj_tok_span": [6, 11], "new_sbj_tok_span": [19, 21], "new_obj_tok_span": [7, 12]}], "umls_entity_list": [{"mention": "cytochrome P450 3A", "char_span": [34, 52], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 11], "new_tok_span": [7, 12]}, {"mention": "BDP", "char_span": [83, 86], "sem_type": "Gene or Genome", "tok_span": [16, 18], "new_tok_span": [19, 21]}], "new_text": "It is possible that variations in <START=Amino Acid, Peptide, or Protein> cytochrome P450 3A <END=Amino Acid, Peptide, or Protein> enzyme - mediated metabolism of <START=Gene or Genome> BDP <END=Gene or Genome> may contribute to this phenomenon."}, {"PMID": 23517912, "id": 6, "text": "The results suggested that fisetin treatment inhibits mTORC1 activity in an Akt-dependent manner.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [27, 34], "name": "fisetin", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [54, 60], "name": "mTORC1", "tok_span": [9, 12], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [76, 79], "name": "Akt", "tok_span": [15, 16], "new_tok_span": [21, 22]}], "relation_list": [{"subject": "fisetin", "sbj_char_span": [27, 34], "object": "mTORC1", "obj_char_span": [54, 60], "rel_type": "inhibitor", "sbj_tok_span": [4, 7], "obj_tok_span": [9, 12], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [11, 14]}, {"subject": "fisetin", "sbj_char_span": [27, 34], "object": "Akt", "obj_char_span": [76, 79], "rel_type": "inhibitor", "sbj_tok_span": [4, 7], "obj_tok_span": [15, 16], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [21, 22]}], "umls_entity_list": [{"mention": "mTORC1", "char_span": [54, 60], "sem_type": "Gene or Genome", "tok_span": [9, 12], "new_tok_span": [11, 14]}, {"mention": "Akt", "char_span": [76, 79], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 16], "new_tok_span": [21, 22]}, {"mention": "Akt", "char_span": [76, 79], "sem_type": "Gene or Genome", "tok_span": [15, 16], "new_tok_span": [21, 22]}, {"mention": "mTORC1", "char_span": [54, 60], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 12], "new_tok_span": [11, 14]}], "new_text": "The results suggested that fisetin treatment inhibits <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> mTORC1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> activity in an <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Akt <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - dependent manner."}, {"PMID": 16014042, "id": 5, "text": "We also measured the uptake of l-cystine in Xenopus oocytes expressing human xCT and/or 4F2hc or xCT and/or rBAT (a heavy chain homologous to 4F2hc).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [31, 40], "name": "l-cystine", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [71, 80], "name": "human xCT", "tok_span": [14, 17], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [88, 93], "name": "4F2hc", "tok_span": [20, 25], "new_tok_span": [22, 27]}, {"ent_type": "GENE", "char_span": [97, 100], "name": "xCT", "tok_span": [26, 28], "new_tok_span": [30, 32]}, {"ent_type": "GENE", "char_span": [108, 112], "name": "rBAT", "tok_span": [31, 34], "new_tok_span": [36, 39]}, {"ent_type": "GENE", "char_span": [142, 147], "name": "4F2hc", "tok_span": [40, 45], "new_tok_span": [50, 55]}], "relation_list": [{"subject": "l-cystine", "sbj_char_span": [31, 40], "object": "human xCT", "obj_char_span": [71, 80], "rel_type": "product or substrate", "sbj_tok_span": [6, 10], "obj_tok_span": [14, 17], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [14, 17]}, {"subject": "l-cystine", "sbj_char_span": [31, 40], "object": "4F2hc", "obj_char_span": [88, 93], "rel_type": "product or substrate", "sbj_tok_span": [6, 10], "obj_tok_span": [20, 25], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [22, 27]}, {"subject": "l-cystine", "sbj_char_span": [31, 40], "object": "xCT", "obj_char_span": [97, 100], "rel_type": "product or substrate", "sbj_tok_span": [6, 10], "obj_tok_span": [26, 28], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [30, 32]}, {"subject": "l-cystine", "sbj_char_span": [31, 40], "object": "rBAT", "obj_char_span": [108, 112], "rel_type": "product or substrate", "sbj_tok_span": [6, 10], "obj_tok_span": [31, 34], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [36, 39]}, {"subject": "l-cystine", "sbj_char_span": [31, 40], "object": "4F2hc", "obj_char_span": [142, 147], "rel_type": "product or substrate", "sbj_tok_span": [6, 10], "obj_tok_span": [40, 45], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [50, 55]}], "umls_entity_list": [{"mention": "rBAT", "char_span": [108, 112], "sem_type": "Gene or Genome", "tok_span": [31, 34], "new_tok_span": [36, 39]}, {"mention": "homologous", "char_span": [128, 138], "sem_type": "Gene or Genome", "tok_span": [38, 39], "new_tok_span": [45, 46]}, {"mention": "4F2hc", "char_span": [88, 93], "sem_type": "Gene or Genome", "tok_span": [20, 25], "new_tok_span": [22, 27]}, {"mention": "4F2hc", "char_span": [142, 147], "sem_type": "Gene or Genome", "tok_span": [40, 45], "new_tok_span": [50, 55]}, {"mention": "4F2hc", "char_span": [88, 93], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 25], "new_tok_span": [22, 27]}, {"mention": "4F2hc", "char_span": [142, 147], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [40, 45], "new_tok_span": [50, 55]}], "new_text": "We also measured the uptake of l - cystine in Xenopus oocytes expressing human xCT and / or <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> 4F2hc <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> or xCT and / or <START=Gene or Genome> rBAT <END=Gene or Genome> ( a heavy chain <START=Gene or Genome> homologous <END=Gene or Genome> to <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> 4F2hc <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> )."}, {"PMID": 23103426, "id": 0, "text": "Mitochondrial electron transfer chain complexes inhibition by different organochalcogens.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [72, 88], "name": "organochalcogens", "tok_span": [8, 12], "new_tok_span": [8, 12]}, {"ent_type": "GENE", "char_span": [0, 47], "name": "Mitochondrial electron transfer chain complexes", "tok_span": [0, 5], "new_tok_span": [0, 5]}], "relation_list": [{"subject": "organochalcogens", "sbj_char_span": [72, 88], "object": "Mitochondrial electron transfer chain complexes", "obj_char_span": [0, 47], "rel_type": "inhibitor", "sbj_tok_span": [8, 12], "obj_tok_span": [0, 5], "new_sbj_tok_span": [8, 12], "new_obj_tok_span": [0, 5]}], "umls_entity_list": [], "new_text": "Mitochondrial electron transfer chain complexes inhibition by different organochalcogens."}, {"PMID": 23395717, "id": 1, "text": "Xestospongin C (XC), which is a group of macrocyclic bis-1-oxaquinolizidines, is a potent inhibitor of sarcoendoplasmic reticulum calcium transport ATPase and IP3 receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 14], "name": "Xestospongin C", "tok_span": [0, 6], "new_tok_span": [0, 6]}, {"ent_type": "CHEMICAL", "char_span": [53, 76], "name": "bis-1-oxaquinolizidines", "tok_span": [19, 30], "new_tok_span": [22, 33]}, {"ent_type": "GENE", "char_span": [103, 154], "name": "sarcoendoplasmic reticulum calcium transport ATPase", "tok_span": [36, 45], "new_tok_span": [40, 49]}, {"ent_type": "GENE", "char_span": [159, 171], "name": "IP3 receptor", "tok_span": [46, 49], "new_tok_span": [56, 59]}], "relation_list": [{"subject": "bis-1-oxaquinolizidines", "sbj_char_span": [53, 76], "object": "sarcoendoplasmic reticulum calcium transport ATPase", "obj_char_span": [103, 154], "rel_type": "inhibitor", "sbj_tok_span": [19, 30], "obj_tok_span": [36, 45], "new_sbj_tok_span": [22, 33], "new_obj_tok_span": [40, 49]}, {"subject": "bis-1-oxaquinolizidines", "sbj_char_span": [53, 76], "object": "IP3 receptor", "obj_char_span": [159, 171], "rel_type": "inhibitor", "sbj_tok_span": [19, 30], "obj_tok_span": [46, 49], "new_sbj_tok_span": [22, 33], "new_obj_tok_span": [56, 59]}, {"subject": "Xestospongin C", "sbj_char_span": [0, 14], "object": "sarcoendoplasmic reticulum calcium transport ATPase", "obj_char_span": [103, 154], "rel_type": "inhibitor", "sbj_tok_span": [0, 6], "obj_tok_span": [36, 45], "new_sbj_tok_span": [0, 6], "new_obj_tok_span": [40, 49]}, {"subject": "Xestospongin C", "sbj_char_span": [0, 14], "object": "IP3 receptor", "obj_char_span": [159, 171], "rel_type": "inhibitor", "sbj_tok_span": [0, 6], "obj_tok_span": [46, 49], "new_sbj_tok_span": [0, 6], "new_obj_tok_span": [56, 59]}], "umls_entity_list": [{"mention": "acrocycl", "char_span": [42, 50], "sem_type": "Organic Chemical", "tok_span": [16, 18], "new_tok_span": [17, 19]}, {"mention": "bis", "char_span": [53, 56], "sem_type": "Gene or Genome", "tok_span": [19, 20], "new_tok_span": [22, 23]}, {"mention": "calcium", "char_span": [130, 137], "sem_type": "Pharmacologic Substance", "tok_span": [42, 43], "new_tok_span": [48, 49]}, {"mention": "ATPase", "char_span": [148, 154], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [44, 45], "new_tok_span": [53, 54]}, {"mention": "calcium", "char_span": [130, 137], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 43], "new_tok_span": [48, 49]}], "new_text": "Xestospongin C ( XC ), which is a group of <START=Organic Chemical> macrocycl <END=Organic Chemical>ic <START=Gene or Genome> bis <END=Gene or Genome> - 1 - oxaquinolizidines, is a potent inhibitor of sarcoendoplasmic reticulum <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> calcium <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> transport <START=Amino Acid, Peptide, or Protein> ATPase <END=Amino Acid, Peptide, or Protein> and IP3 receptor."}, {"PMID": 23585332, "id": 2, "text": "The rate limiting enzyme of beta-oxidation (ACOX1) was significantly over-expressed in the liver with tBHQ treatment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [102, 106], "name": "tBHQ", "tok_span": [22, 25], "new_tok_span": [25, 28]}, {"ent_type": "GENE", "char_span": [44, 49], "name": "ACOX1", "tok_span": [9, 12], "new_tok_span": [10, 13]}], "relation_list": [{"subject": "tBHQ", "sbj_char_span": [102, 106], "object": "ACOX1", "obj_char_span": [44, 49], "rel_type": "regulator", "sbj_tok_span": [22, 25], "obj_tok_span": [9, 12], "new_sbj_tok_span": [25, 28], "new_obj_tok_span": [10, 13]}], "umls_entity_list": [{"mention": "ACOX1", "char_span": [44, 49], "sem_type": "Gene or Genome", "tok_span": [9, 12], "new_tok_span": [10, 13]}, {"mention": "tBHQ", "char_span": [102, 106], "sem_type": "Pharmacologic Substance", "tok_span": [22, 25], "new_tok_span": [25, 28]}], "new_text": "The rate limiting enzyme of beta - oxidation ( <START=Gene or Genome> ACOX1 <END=Gene or Genome> ) was significantly over - expressed in the liver with <START=Pharmacologic Substance> tBHQ <END=Pharmacologic Substance> treatment."}, {"PMID": 23542819, "id": 2, "text": "In a high-throughput screen for modulators of KCNQ2 channel, a fundamental player modulating neuronal excitability, Mancozeb, was found to significantly potentiate KCNQ2 activity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [116, 124], "name": "Mancozeb", "tok_span": [22, 26], "new_tok_span": [25, 29]}, {"ent_type": "GENE", "char_span": [46, 51], "name": "KCNQ2", "tok_span": [9, 13], "new_tok_span": [10, 14]}, {"ent_type": "GENE", "char_span": [164, 169], "name": "KCNQ2", "tok_span": [33, 37], "new_tok_span": [38, 42]}], "relation_list": [{"subject": "Mancozeb", "sbj_char_span": [116, 124], "object": "KCNQ2", "obj_char_span": [164, 169], "rel_type": "activator", "sbj_tok_span": [22, 26], "obj_tok_span": [33, 37], "new_sbj_tok_span": [25, 29], "new_obj_tok_span": [38, 42]}], "umls_entity_list": [{"mention": "KCNQ2", "char_span": [46, 51], "sem_type": "Gene or Genome", "tok_span": [9, 13], "new_tok_span": [10, 14]}, {"mention": "KCNQ2", "char_span": [164, 169], "sem_type": "Gene or Genome", "tok_span": [33, 37], "new_tok_span": [38, 42]}, {"mention": "Mancozeb", "char_span": [116, 124], "sem_type": "Organic Chemical", "tok_span": [22, 26], "new_tok_span": [25, 29]}], "new_text": "In a high - throughput screen for modulators of <START=Gene or Genome> KCNQ2 <END=Gene or Genome> channel, a fundamental player modulating neuronal excitability, <START=Organic Chemical> Mancozeb <END=Organic Chemical>, was found to significantly potentiate <START=Gene or Genome> KCNQ2 <END=Gene or Genome> activity."}, {"PMID": 16232421, "id": 7, "text": "A double mutant of the two fumarate reductase isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [27, 35], "name": "fumarate", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"ent_type": "CHEMICAL", "char_span": [85, 94], "name": "succinate", "tok_span": [23, 25], "new_tok_span": [27, 29]}, {"ent_type": "CHEMICAL", "char_span": [170, 177], "name": "glucose", "tok_span": [39, 40], "new_tok_span": [43, 44]}, {"ent_type": "GENE", "char_span": [27, 45], "name": "fumarate reductase", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [61, 65], "name": "OSM1", "tok_span": [14, 17], "new_tok_span": [18, 21]}, {"ent_type": "GENE", "char_span": [70, 74], "name": "FRDS", "tok_span": [18, 20], "new_tok_span": [22, 24]}], "relation_list": [{"subject": "succinate", "sbj_char_span": [85, 94], "object": "fumarate reductase", "obj_char_span": [27, 45], "rel_type": "product or substrate", "sbj_tok_span": [23, 25], "obj_tok_span": [6, 10], "new_sbj_tok_span": [27, 29], "new_obj_tok_span": [7, 11]}, {"subject": "succinate", "sbj_char_span": [85, 94], "object": "OSM1", "obj_char_span": [61, 65], "rel_type": "product or substrate", "sbj_tok_span": [23, 25], "obj_tok_span": [14, 17], "new_sbj_tok_span": [27, 29], "new_obj_tok_span": [18, 21]}, {"subject": "succinate", "sbj_char_span": [85, 94], "object": "FRDS", "obj_char_span": [70, 74], "rel_type": "product or substrate", "sbj_tok_span": [23, 25], "obj_tok_span": [18, 20], "new_sbj_tok_span": [27, 29], "new_obj_tok_span": [22, 24]}], "umls_entity_list": [{"mention": "fumarate reductase", "char_span": [27, 45], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"mention": "isozyme", "char_span": [46, 53], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"mention": "buffered", "char_span": [178, 186], "sem_type": "Pharmacologic Substance", "tok_span": [41, 42], "new_tok_span": [46, 47]}], "new_text": "A double mutant of the two <START=Amino Acid, Peptide, or Protein> fumarate reductase <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> isozyme <END=Amino Acid, Peptide, or Protein> genes ( OSM1 and FRDS ) showed a succinate productivity of 50 % as compared to the parent when cells were incubated in glucose - <START=Pharmacologic Substance> buffered <END=Pharmacologic Substance> solution."}, {"PMID": 17065073, "id": 1, "text": "Adenosine kinase is a well-known enzyme which catalyzes the phosphorylation of adenosine to AMP: Its metabolic and kinetic properties are well studied.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Adenosine", "tok_span": [0, 2], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [79, 88], "name": "adenosine", "tok_span": [15, 16], "new_tok_span": [25, 26]}, {"ent_type": "CHEMICAL", "char_span": [92, 95], "name": "AMP", "tok_span": [17, 18], "new_tok_span": [31, 32]}, {"ent_type": "GENE", "char_span": [0, 16], "name": "Adenosine kinase", "tok_span": [0, 3], "new_tok_span": [3, 6]}], "relation_list": [{"subject": "adenosine", "sbj_char_span": [79, 88], "object": "Adenosine kinase", "obj_char_span": [0, 16], "rel_type": "product or substrate", "sbj_tok_span": [15, 16], "obj_tok_span": [0, 3], "new_sbj_tok_span": [25, 26], "new_obj_tok_span": [3, 6]}, {"subject": "AMP", "sbj_char_span": [92, 95], "object": "Adenosine kinase", "obj_char_span": [0, 16], "rel_type": "product or substrate", "sbj_tok_span": [17, 18], "obj_tok_span": [0, 3], "new_sbj_tok_span": [31, 32], "new_obj_tok_span": [3, 6]}], "umls_entity_list": [{"mention": "Adenosine", "char_span": [0, 9], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 2], "new_tok_span": [3, 5]}, {"mention": "adenosine", "char_span": [79, 88], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 16], "new_tok_span": [25, 26]}, {"mention": "Adenosine kinase", "char_span": [0, 16], "sem_type": "Gene or Genome", "tok_span": [0, 3], "new_tok_span": [3, 6]}, {"mention": "enzyme", "char_span": [33, 39], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [15, 16]}, {"mention": "Adenosine", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 2], "new_tok_span": [3, 5]}, {"mention": "adenosine", "char_span": [79, 88], "sem_type": "Pharmacologic Substance", "tok_span": [15, 16], "new_tok_span": [25, 26]}, {"mention": "AMP", "char_span": [92, 95], "sem_type": "Gene or Genome", "tok_span": [17, 18], "new_tok_span": [31, 32]}, {"mention": "AMP", "char_span": [92, 95], "sem_type": "Pharmacologic Substance", "tok_span": [17, 18], "new_tok_span": [31, 32]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Pharmacologic Substance> Adenosine <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> kinase <END=Gene or Genome> is a well - known <START=Amino Acid, Peptide, or Protein> enzyme <END=Amino Acid, Peptide, or Protein> which catalyzes the phosphorylation of <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> adenosine <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> to <START=Gene or Genome> <START=Pharmacologic Substance> AMP <END=Gene or Genome> <END=Pharmacologic Substance> : Its metabolic and kinetic properties are well studied."}, {"PMID": 20439738, "id": 4, "text": "Using a high-content screen with cells expressing Smo receptors and a beta-arrestin2-GFP reporter, we identified four FDA-approved drugs, halcinonide, fluticasone, clobetasol, and fluocinonide, as Smo agonists that activate Hedgehog signaling.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [138, 149], "name": "halcinonide", "tok_span": [31, 35], "new_tok_span": [38, 42]}, {"ent_type": "CHEMICAL", "char_span": [151, 162], "name": "fluticasone", "tok_span": [36, 39], "new_tok_span": [44, 47]}, {"ent_type": "CHEMICAL", "char_span": [164, 174], "name": "clobetasol", "tok_span": [40, 44], "new_tok_span": [49, 53]}, {"ent_type": "CHEMICAL", "char_span": [180, 192], "name": "fluocinonide", "tok_span": [46, 50], "new_tok_span": [57, 61]}, {"ent_type": "GENE", "char_span": [50, 63], "name": "Smo receptors", "tok_span": [9, 12], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [70, 84], "name": "beta-arrestin2", "tok_span": [14, 19], "new_tok_span": [18, 23]}, {"ent_type": "GENE", "char_span": [197, 200], "name": "Smo", "tok_span": [52, 54], "new_tok_span": [66, 68]}, {"ent_type": "GENE", "char_span": [224, 232], "name": "Hedgehog", "tok_span": [57, 61], "new_tok_span": [73, 77]}], "relation_list": [{"subject": "halcinonide", "sbj_char_span": [138, 149], "object": "Smo", "obj_char_span": [197, 200], "rel_type": "agonist or antagonist", "sbj_tok_span": [31, 35], "obj_tok_span": [52, 54], "new_sbj_tok_span": [38, 42], "new_obj_tok_span": [66, 68]}, {"subject": "fluticasone", "sbj_char_span": [151, 162], "object": "Smo", "obj_char_span": [197, 200], "rel_type": "agonist or antagonist", "sbj_tok_span": [36, 39], "obj_tok_span": [52, 54], "new_sbj_tok_span": [44, 47], "new_obj_tok_span": [66, 68]}, {"subject": "clobetasol", "sbj_char_span": [164, 174], "object": "Smo", "obj_char_span": [197, 200], "rel_type": "agonist or antagonist", "sbj_tok_span": [40, 44], "obj_tok_span": [52, 54], "new_sbj_tok_span": [49, 53], "new_obj_tok_span": [66, 68]}, {"subject": "fluocinonide", "sbj_char_span": [180, 192], "object": "Smo", "obj_char_span": [197, 200], "rel_type": "agonist or antagonist", "sbj_tok_span": [46, 50], "obj_tok_span": [52, 54], "new_sbj_tok_span": [57, 61], "new_obj_tok_span": [66, 68]}, {"subject": "halcinonide", "sbj_char_span": [138, 149], "object": "Hedgehog", "obj_char_span": [224, 232], "rel_type": "regulator", "sbj_tok_span": [31, 35], "obj_tok_span": [57, 61], "new_sbj_tok_span": [38, 42], "new_obj_tok_span": [73, 77]}, {"subject": "fluticasone", "sbj_char_span": [151, 162], "object": "Hedgehog", "obj_char_span": [224, 232], "rel_type": "regulator", "sbj_tok_span": [36, 39], "obj_tok_span": [57, 61], "new_sbj_tok_span": [44, 47], "new_obj_tok_span": [73, 77]}, {"subject": "clobetasol", "sbj_char_span": [164, 174], "object": "Hedgehog", "obj_char_span": [224, 232], "rel_type": "regulator", "sbj_tok_span": [40, 44], "obj_tok_span": [57, 61], "new_sbj_tok_span": [49, 53], "new_obj_tok_span": [73, 77]}, {"subject": "fluocinonide", "sbj_char_span": [180, 192], "object": "Hedgehog", "obj_char_span": [224, 232], "rel_type": "regulator", "sbj_tok_span": [46, 50], "obj_tok_span": [57, 61], "new_sbj_tok_span": [57, 61], "new_obj_tok_span": [73, 77]}], "umls_entity_list": [{"mention": "Smo", "char_span": [50, 53], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 11], "new_tok_span": [11, 13]}, {"mention": "Smo", "char_span": [197, 200], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [52, 54], "new_tok_span": [66, 68]}, {"mention": "Smo", "char_span": [50, 53], "sem_type": "Gene or Genome", "tok_span": [9, 11], "new_tok_span": [11, 13]}, {"mention": "Smo", "char_span": [197, 200], "sem_type": "Gene or Genome", "tok_span": [52, 54], "new_tok_span": [66, 68]}, {"mention": "GFP", "char_span": [85, 88], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 21], "new_tok_span": [25, 26]}, {"mention": "halcinonide", "char_span": [138, 149], "sem_type": "Pharmacologic Substance", "tok_span": [31, 35], "new_tok_span": [38, 42]}, {"mention": "clobetasol", "char_span": [164, 174], "sem_type": "Pharmacologic Substance", "tok_span": [40, 44], "new_tok_span": [49, 53]}, {"mention": "fluocinonide", "char_span": [180, 192], "sem_type": "Pharmacologic Substance", "tok_span": [46, 50], "new_tok_span": [57, 61]}], "new_text": "Using a high - content screen with cells expressing <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Smo <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> receptors and a beta - arrestin2 - <START=Amino Acid, Peptide, or Protein> GFP <END=Amino Acid, Peptide, or Protein> reporter, we identified four FDA - approved drugs, <START=Pharmacologic Substance> halcinonide <END=Pharmacologic Substance>, fluticasone, <START=Pharmacologic Substance> clobetasol <END=Pharmacologic Substance>, and <START=Pharmacologic Substance> fluocinonide <END=Pharmacologic Substance>, as <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Smo <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> agonists that activate Hedgehog signaling."}, {"PMID": 8836655, "id": 7, "text": "Pretreatment with tropisetron (1 microM), a 5-HT3 antagonist, ketanserin (10 microM), a 5-HT2 antagonist, thioperamide (10 microM), a histamine H3 antagonist, or phentolamine (10 microM), an alpha-adrenergic antagonist, however, had no effect.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 29], "name": "tropisetron", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [62, 72], "name": "ketanserin", "tok_span": [19, 23], "new_tok_span": [21, 25]}, {"ent_type": "CHEMICAL", "char_span": [106, 118], "name": "thioperamide", "tok_span": [36, 39], "new_tok_span": [38, 41]}, {"ent_type": "CHEMICAL", "char_span": [134, 143], "name": "histamine", "tok_span": [46, 47], "new_tok_span": [48, 49]}, {"ent_type": "CHEMICAL", "char_span": [162, 174], "name": "phentolamine", "tok_span": [52, 55], "new_tok_span": [54, 57]}, {"ent_type": "GENE", "char_span": [44, 49], "name": "5-HT3", "tok_span": [13, 17], "new_tok_span": [15, 19]}, {"ent_type": "GENE", "char_span": [88, 93], "name": "5-HT2", "tok_span": [30, 34], "new_tok_span": [32, 36]}, {"ent_type": "GENE", "char_span": [134, 146], "name": "histamine H3", "tok_span": [46, 49], "new_tok_span": [48, 51]}], "relation_list": [{"subject": "tropisetron", "sbj_char_span": [18, 29], "object": "5-HT3", "obj_char_span": [44, 49], "rel_type": "agonist or antagonist", "sbj_tok_span": [3, 6], "obj_tok_span": [13, 17], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [15, 19]}, {"subject": "ketanserin", "sbj_char_span": [62, 72], "object": "5-HT2", "obj_char_span": [88, 93], "rel_type": "agonist or antagonist", "sbj_tok_span": [19, 23], "obj_tok_span": [30, 34], "new_sbj_tok_span": [21, 25], "new_obj_tok_span": [32, 36]}, {"subject": "thioperamide", "sbj_char_span": [106, 118], "object": "histamine H3", "obj_char_span": [134, 146], "rel_type": "agonist or antagonist", "sbj_tok_span": [36, 39], "obj_tok_span": [46, 49], "new_sbj_tok_span": [38, 41], "new_obj_tok_span": [48, 51]}], "umls_entity_list": [{"mention": "tropisetron", "char_span": [18, 29], "sem_type": "Pharmacologic Substance", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "alpha-adrenergic antagonist", "char_span": [191, 218], "sem_type": "Pharmacologic Substance", "tok_span": [62, 67], "new_tok_span": [65, 70]}], "new_text": "Pretreatment with <START=Pharmacologic Substance> tropisetron <END=Pharmacologic Substance> ( 1 microM ), a 5 - HT3 antagonist, ketanserin ( 10 microM ), a 5 - HT2 antagonist, thioperamide ( 10 microM ), a histamine H3 antagonist, or phentolamine ( 10 microM ), an <START=Pharmacologic Substance> alpha - adrenergic antagonist <END=Pharmacologic Substance>, however, had no effect."}, {"PMID": 23607891, "id": 5, "text": "Furthermore, we could show that the GSH level decreased significantly after exposure to magnetite particles, while catalase (CAT) activity was increased.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [36, 39], "name": "GSH", "tok_span": [7, 8], "new_tok_span": [7, 8]}, {"ent_type": "CHEMICAL", "char_span": [88, 97], "name": "magnetite", "tok_span": [14, 16], "new_tok_span": [14, 16]}, {"ent_type": "GENE", "char_span": [115, 123], "name": "catalase", "tok_span": [19, 20], "new_tok_span": [19, 20]}, {"ent_type": "GENE", "char_span": [125, 128], "name": "CAT", "tok_span": [21, 22], "new_tok_span": [21, 22]}], "relation_list": [{"subject": "magnetite", "sbj_char_span": [88, 97], "object": "catalase", "obj_char_span": [115, 123], "rel_type": "activator", "sbj_tok_span": [14, 16], "obj_tok_span": [19, 20], "new_sbj_tok_span": [14, 16], "new_obj_tok_span": [19, 20]}, {"subject": "magnetite", "sbj_char_span": [88, 97], "object": "CAT", "obj_char_span": [125, 128], "rel_type": "activator", "sbj_tok_span": [14, 16], "obj_tok_span": [21, 22], "new_sbj_tok_span": [14, 16], "new_obj_tok_span": [21, 22]}], "umls_entity_list": [], "new_text": "Furthermore, we could show that the GSH level decreased significantly after exposure to magnetite particles, while catalase ( CAT ) activity was increased."}, {"PMID": 23415833, "id": 5, "text": "Of the nine human CYPs studied, only CYPs 3A4, 2B6, and 2C19 were able to metabolize profenofos to BCP. Kinetic studies indicated that CYP 2C19 has the lowest Km, 0.516μM followed by 2B6 (Km=1.02μM) and 3A4 (Km=18.9μM). The Vmax for BCP formation was 47.9, 25.1, and 19.2nmol/min/nmol CYP for CYP2B6, 2C19, and 3A4, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [233, 236], "name": "BCP", "tok_span": [89, 91], "new_tok_span": [103, 105]}, {"ent_type": "CHEMICAL", "char_span": [85, 95], "name": "profenofos", "tok_span": [28, 32], "new_tok_span": [33, 37]}, {"ent_type": "CHEMICAL", "char_span": [99, 102], "name": "BCP", "tok_span": [33, 35], "new_tok_span": [39, 41]}, {"ent_type": "GENE", "char_span": [285, 288], "name": "CYP", "tok_span": [111, 112], "new_tok_span": [126, 127]}, {"ent_type": "GENE", "char_span": [293, 314], "name": "CYP2B6, 2C19, and 3A4", "tok_span": [113, 126], "new_tok_span": [130, 143]}, {"ent_type": "GENE", "char_span": [12, 22], "name": "human CYPs", "tok_span": [3, 6], "new_tok_span": [3, 6]}, {"ent_type": "GENE", "char_span": [37, 60], "name": "CYPs 3A4, 2B6, and 2C19", "tok_span": [9, 23], "new_tok_span": [12, 26]}, {"ent_type": "GENE", "char_span": [135, 143], "name": "CYP 2C19", "tok_span": [42, 46], "new_tok_span": [49, 53]}], "relation_list": [{"subject": "profenofos", "sbj_char_span": [85, 95], "object": "human CYPs", "obj_char_span": [12, 22], "rel_type": "product or substrate", "sbj_tok_span": [28, 32], "obj_tok_span": [3, 6], "new_sbj_tok_span": [33, 37], "new_obj_tok_span": [3, 6]}, {"subject": "BCP", "sbj_char_span": [99, 102], "object": "human CYPs", "obj_char_span": [12, 22], "rel_type": "product or substrate", "sbj_tok_span": [33, 35], "obj_tok_span": [3, 6], "new_sbj_tok_span": [39, 41], "new_obj_tok_span": [3, 6]}, {"subject": "BCP", "sbj_char_span": [233, 236], "object": "CYP", "obj_char_span": [285, 288], "rel_type": "product or substrate", "sbj_tok_span": [89, 91], "obj_tok_span": [111, 112], "new_sbj_tok_span": [103, 105], "new_obj_tok_span": [126, 127]}], "umls_entity_list": [{"mention": "CYP", "char_span": [18, 21], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 5], "new_tok_span": [5, 6]}, {"mention": "CYP", "char_span": [37, 40], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 10], "new_tok_span": [12, 13]}, {"mention": "CYP", "char_span": [135, 138], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 43], "new_tok_span": [49, 50]}, {"mention": "CYP", "char_span": [285, 288], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [111, 112], "new_tok_span": [126, 127]}, {"mention": "CYP", "char_span": [293, 296], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [113, 114], "new_tok_span": [130, 131]}, {"mention": "profenofos", "char_span": [85, 95], "sem_type": "Pharmacologic Substance", "tok_span": [28, 32], "new_tok_span": [33, 37]}, {"mention": "Km", "char_span": [159, 161], "sem_type": "Gene or Genome", "tok_span": [49, 50], "new_tok_span": [58, 59]}, {"mention": "Km", "char_span": [188, 190], "sem_type": "Gene or Genome", "tok_span": [63, 64], "new_tok_span": [74, 75]}, {"mention": "Km", "char_span": [208, 210], "sem_type": "Gene or Genome", "tok_span": [76, 77], "new_tok_span": [89, 90]}], "new_text": "Of the nine human <START=Amino Acid, Peptide, or Protein> CYP <END=Amino Acid, Peptide, or Protein>s studied, only <START=Amino Acid, Peptide, or Protein> CYP <END=Amino Acid, Peptide, or Protein>s 3A4, 2B6, and 2C19 were able to metabolize <START=Pharmacologic Substance> profenofos <END=Pharmacologic Substance> to BCP. Kinetic studies indicated that <START=Amino Acid, Peptide, or Protein> CYP <END=Amino Acid, Peptide, or Protein> 2C19 has the lowest <START=Gene or Genome> Km <END=Gene or Genome>, 0. 516μM followed by 2B6 ( <START=Gene or Genome> Km <END=Gene or Genome> = 1. 02μM ) and 3A4 ( <START=Gene or Genome> Km <END=Gene or Genome> = 18. 9μM ). The Vmax for BCP formation was 47. 9, 25. 1, and 19. 2nmol / min / nmol <START=Amino Acid, Peptide, or Protein> CYP <END=Amino Acid, Peptide, or Protein> for <START=Amino Acid, Peptide, or Protein> CYP <END=Amino Acid, Peptide, or Protein>2B6, 2C19, and 3A4, respectively."}, {"PMID": 15909120, "id": 4, "text": "A glucocorticoid receptor antagonist, mifepristone (RU486), suppressed dexamethasone-induced osteocyte apoptosis, suggesting that it was mediated by glucocorticoid receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [38, 50], "name": "mifepristone", "tok_span": [5, 9], "new_tok_span": [11, 15]}, {"ent_type": "CHEMICAL", "char_span": [52, 57], "name": "RU486", "tok_span": [10, 13], "new_tok_span": [16, 19]}, {"ent_type": "CHEMICAL", "char_span": [71, 84], "name": "dexamethasone", "tok_span": [16, 17], "new_tok_span": [23, 24]}, {"ent_type": "GENE", "char_span": [2, 25], "name": "glucocorticoid receptor", "tok_span": [1, 3], "new_tok_span": [4, 6]}, {"ent_type": "GENE", "char_span": [149, 172], "name": "glucocorticoid receptor", "tok_span": [29, 31], "new_tok_span": [40, 42]}], "relation_list": [{"subject": "mifepristone", "sbj_char_span": [38, 50], "object": "glucocorticoid receptor", "obj_char_span": [2, 25], "rel_type": "agonist or antagonist", "sbj_tok_span": [5, 9], "obj_tok_span": [1, 3], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [4, 6]}, {"subject": "RU486", "sbj_char_span": [52, 57], "object": "glucocorticoid receptor", "obj_char_span": [2, 25], "rel_type": "agonist or antagonist", "sbj_tok_span": [10, 13], "obj_tok_span": [1, 3], "new_sbj_tok_span": [16, 19], "new_obj_tok_span": [4, 6]}], "umls_entity_list": [{"mention": "dexamethasone", "char_span": [71, 84], "sem_type": "Pharmacologic Substance", "tok_span": [16, 17], "new_tok_span": [23, 24]}, {"mention": "glucocorticoid", "char_span": [2, 16], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 2], "new_tok_span": [4, 5]}, {"mention": "glucocorticoid", "char_span": [149, 163], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 30], "new_tok_span": [40, 41]}, {"mention": "glucocorticoid receptor", "char_span": [2, 25], "sem_type": "Gene or Genome", "tok_span": [1, 3], "new_tok_span": [4, 6]}, {"mention": "glucocorticoid receptor", "char_span": [149, 172], "sem_type": "Gene or Genome", "tok_span": [29, 31], "new_tok_span": [40, 42]}, {"mention": "glucocorticoid receptor", "char_span": [2, 25], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 3], "new_tok_span": [4, 6]}, {"mention": "glucocorticoid receptor", "char_span": [149, 172], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 31], "new_tok_span": [40, 42]}], "new_text": "A <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> glucocorticoid <END=Amino Acid, Peptide, or Protein> receptor <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> antagonist, mifepristone ( RU486 ), suppressed <START=Pharmacologic Substance> dexamethasone <END=Pharmacologic Substance> - induced osteocyte apoptosis, suggesting that it was mediated by <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> glucocorticoid <END=Amino Acid, Peptide, or Protein> receptor <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23474889, "id": 7, "text": "This inhibition was blocked when mice were pretreated with the selective H3R agonist R-(alpha)-methyl-histamine (10 mg/kg).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [85, 111], "name": "R-(alpha)-methyl-histamine", "tok_span": [15, 24], "new_tok_span": [15, 24]}, {"ent_type": "GENE", "char_span": [73, 76], "name": "H3R", "tok_span": [11, 14], "new_tok_span": [11, 14]}], "relation_list": [{"subject": "R-(alpha)-methyl-histamine", "sbj_char_span": [85, 111], "object": "H3R", "obj_char_span": [73, 76], "rel_type": "agonist or antagonist", "sbj_tok_span": [15, 24], "obj_tok_span": [11, 14], "new_sbj_tok_span": [15, 24], "new_obj_tok_span": [11, 14]}], "umls_entity_list": [{"mention": "alpha", "char_span": [88, 93], "sem_type": "Pharmacologic Substance", "tok_span": [18, 19], "new_tok_span": [19, 20]}], "new_text": "This inhibition was blocked when mice were pretreated with the selective H3R agonist R - ( <START=Pharmacologic Substance> alpha <END=Pharmacologic Substance> ) - methyl - histamine ( 10 mg / kg )."}, {"PMID": 10085232, "id": 3, "text": "These studies show clearly that, in all three GSTs, an aspartate residue at position 208 is a prerequisite for high activity in aflatoxin-exo-8,9-epoxide conjugation, although this alone is not sufficient; other residues in the vicinity, particularly residues 103-112, are important, perhaps for the optimal orientation of the aflatoxin-exo-8,9-epoxide in the active site for catalysis to occur.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [327, 352], "name": "aflatoxin-exo-8,9-epoxide", "tok_span": [70, 83], "new_tok_span": [81, 94]}, {"ent_type": "CHEMICAL", "char_span": [128, 153], "name": "aflatoxin-exo-8,9-epoxide", "tok_span": [26, 39], "new_tok_span": [33, 46]}, {"ent_type": "GENE", "char_span": [46, 50], "name": "GSTs", "tok_span": [9, 11], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "aflatoxin-exo-8,9-epoxide", "sbj_char_span": [128, 153], "object": "GSTs", "obj_char_span": [46, 50], "rel_type": "regulator", "sbj_tok_span": [26, 39], "obj_tok_span": [9, 11], "new_sbj_tok_span": [33, 46], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [{"mention": "GSTs", "char_span": [46, 50], "sem_type": "Organic Chemical", "tok_span": [9, 11], "new_tok_span": [11, 13]}, {"mention": "GSTs", "char_span": [46, 50], "sem_type": "Gene or Genome", "tok_span": [9, 11], "new_tok_span": [11, 13]}, {"mention": "aspartate", "char_span": [55, 64], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 15], "new_tok_span": [18, 20]}, {"mention": "aflatoxin", "char_span": [128, 137], "sem_type": "Organic Chemical", "tok_span": [26, 29], "new_tok_span": [33, 36]}, {"mention": "aflatoxin", "char_span": [327, 336], "sem_type": "Organic Chemical", "tok_span": [70, 73], "new_tok_span": [81, 84]}, {"mention": "epoxide", "char_span": [146, 153], "sem_type": "Organic Chemical", "tok_span": [37, 39], "new_tok_span": [46, 48]}, {"mention": "epoxide", "char_span": [345, 352], "sem_type": "Organic Chemical", "tok_span": [81, 83], "new_tok_span": [94, 96]}], "new_text": "These studies show clearly that, in all three <START=Organic Chemical> <START=Gene or Genome> GSTs <END=Organic Chemical> <END=Gene or Genome>, an <START=Amino Acid, Peptide, or Protein> aspartate <END=Amino Acid, Peptide, or Protein> residue at position 208 is a prerequisite for high activity in <START=Organic Chemical> aflatoxin <END=Organic Chemical> - exo - 8, 9 - <START=Organic Chemical> epoxide <END=Organic Chemical> conjugation, although this alone is not sufficient ; other residues in the vicinity, particularly residues 103 - 112, are important, perhaps for the optimal orientation of the <START=Organic Chemical> aflatoxin <END=Organic Chemical> - exo - 8, 9 - <START=Organic Chemical> epoxide <END=Organic Chemical> in the active site for catalysis to occur."}, {"PMID": 23319419, "id": 0, "text": "ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "ICA-105574", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"ent_type": "CHEMICAL", "char_span": [113, 122], "name": "potassium", "tok_span": [24, 25], "new_tok_span": [28, 29]}, {"ent_type": "GENE", "char_span": [101, 104], "name": "EAG", "tok_span": [19, 21], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [109, 112], "name": "ERG", "tok_span": [22, 24], "new_tok_span": [26, 28]}, {"ent_type": "GENE", "char_span": [113, 131], "name": "potassium channels", "tok_span": [24, 26], "new_tok_span": [28, 30]}], "relation_list": [{"subject": "ICA-105574", "sbj_char_span": [0, 10], "object": "EAG", "obj_char_span": [101, 104], "rel_type": "activator", "sbj_tok_span": [0, 5], "obj_tok_span": [19, 21], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [22, 24]}, {"subject": "ICA-105574", "sbj_char_span": [0, 10], "object": "ERG", "obj_char_span": [109, 112], "rel_type": "activator", "sbj_tok_span": [0, 5], "obj_tok_span": [22, 24], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [26, 28]}, {"subject": "ICA-105574", "sbj_char_span": [0, 10], "object": "potassium channels", "obj_char_span": [113, 131], "rel_type": "activator", "sbj_tok_span": [0, 5], "obj_tok_span": [24, 26], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [28, 30]}, {"subject": "ICA-105574", "sbj_char_span": [0, 10], "object": "EAG", "obj_char_span": [101, 104], "rel_type": "regulator", "sbj_tok_span": [0, 5], "obj_tok_span": [19, 21], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [22, 24]}, {"subject": "ICA-105574", "sbj_char_span": [0, 10], "object": "ERG", "obj_char_span": [109, 112], "rel_type": "regulator", "sbj_tok_span": [0, 5], "obj_tok_span": [22, 24], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [26, 28]}, {"subject": "ICA-105574", "sbj_char_span": [0, 10], "object": "potassium channels", "obj_char_span": [113, 131], "rel_type": "regulator", "sbj_tok_span": [0, 5], "obj_tok_span": [24, 26], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [28, 30]}], "umls_entity_list": [{"mention": "ICA-105574", "char_span": [0, 10], "sem_type": "Pharmacologic Substance", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"mention": "EAG", "char_span": [101, 104], "sem_type": "Gene or Genome", "tok_span": [19, 21], "new_tok_span": [22, 24]}], "new_text": "<START=Pharmacologic Substance> ICA - 105574 <END=Pharmacologic Substance> interacts with a common binding site to elicit opposite effects on inactivation gating of <START=Gene or Genome> EAG <END=Gene or Genome> and ERG potassium channels."}, {"PMID": 8392199, "id": 8, "text": "The present results further support the previously suggested hypothesis that acute cocaine administration inhibits the 5-HT2-receptor function by increasing the synaptic concentration of norepinephrine and serotonin via inhibition of their uptake and therefore indirectly stimulating the respective inhibitory adrenergic alpha 2- and serotonergic 5-HT1A-receptors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [83, 90], "name": "cocaine", "tok_span": [11, 12], "new_tok_span": [11, 12]}, {"ent_type": "CHEMICAL", "char_span": [187, 201], "name": "norepinephrine", "tok_span": [28, 29], "new_tok_span": [29, 30]}, {"ent_type": "CHEMICAL", "char_span": [206, 215], "name": "serotonin", "tok_span": [30, 31], "new_tok_span": [32, 33]}, {"ent_type": "GENE", "char_span": [119, 124], "name": "5-HT2", "tok_span": [15, 19], "new_tok_span": [15, 19]}, {"ent_type": "GENE", "char_span": [310, 328], "name": "adrenergic alpha 2", "tok_span": [43, 47], "new_tok_span": [46, 50]}, {"ent_type": "GENE", "char_span": [347, 353], "name": "5-HT1A", "tok_span": [51, 56], "new_tok_span": [55, 60]}], "relation_list": [{"subject": "cocaine", "sbj_char_span": [83, 90], "object": "5-HT2", "obj_char_span": [119, 124], "rel_type": "inhibitor", "sbj_tok_span": [11, 12], "obj_tok_span": [15, 19], "new_sbj_tok_span": [11, 12], "new_obj_tok_span": [15, 19]}], "umls_entity_list": [{"mention": "norepinephrine", "char_span": [187, 201], "sem_type": "Pharmacologic Substance", "tok_span": [28, 29], "new_tok_span": [29, 30]}, {"mention": "adrenergic", "char_span": [310, 320], "sem_type": "Pharmacologic Substance", "tok_span": [43, 45], "new_tok_span": [46, 48]}], "new_text": "The present results further support the previously suggested hypothesis that acute cocaine administration inhibits the 5 - HT2 - receptor function by increasing the synaptic concentration of <START=Pharmacologic Substance> norepinephrine <END=Pharmacologic Substance> and serotonin via inhibition of their uptake and therefore indirectly stimulating the respective inhibitory <START=Pharmacologic Substance> adrenergic <END=Pharmacologic Substance> alpha 2 - and serotonergic 5 - HT1A - receptors."}, {"PMID": 21262851, "id": 5, "text": "All GABA(A)R modulators induced a negative shift in the steady-state inactivation curve of Ca(v)1.3 channels, but only BDZs and pentobarbital induced a negative shift in Ca(v)1.2 channel inactivation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [119, 123], "name": "BDZs", "tok_span": [30, 33], "new_tok_span": [30, 33]}, {"ent_type": "CHEMICAL", "char_span": [128, 141], "name": "pentobarbital", "tok_span": [34, 36], "new_tok_span": [34, 36]}, {"ent_type": "GENE", "char_span": [4, 12], "name": "GABA(A)R", "tok_span": [1, 6], "new_tok_span": [1, 6]}, {"ent_type": "GENE", "char_span": [91, 99], "name": "Ca(v)1.3", "tok_span": [19, 26], "new_tok_span": [19, 26]}, {"ent_type": "GENE", "char_span": [170, 178], "name": "Ca(v)1.2", "tok_span": [41, 48], "new_tok_span": [41, 48]}], "relation_list": [{"subject": "BDZs", "sbj_char_span": [119, 123], "object": "Ca(v)1.2", "obj_char_span": [170, 178], "rel_type": "inhibitor", "sbj_tok_span": [30, 33], "obj_tok_span": [41, 48], "new_sbj_tok_span": [30, 33], "new_obj_tok_span": [41, 48]}, {"subject": "pentobarbital", "sbj_char_span": [128, 141], "object": "Ca(v)1.2", "obj_char_span": [170, 178], "rel_type": "inhibitor", "sbj_tok_span": [34, 36], "obj_tok_span": [41, 48], "new_sbj_tok_span": [34, 36], "new_obj_tok_span": [41, 48]}], "umls_entity_list": [], "new_text": "All GABA ( A ) R modulators induced a negative shift in the steady - state inactivation curve of Ca ( v ) 1. 3 channels, but only BDZs and pentobarbital induced a negative shift in Ca ( v ) 1. 2 channel inactivation."}, {"PMID": 23454149, "id": 8, "text": "Western blotting demonstrated that DMBT effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and p-Akt.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [35, 39], "name": "DMBT", "tok_span": [4, 6], "new_tok_span": [4, 6]}, {"ent_type": "GENE", "char_span": [81, 85], "name": "VEGF", "tok_span": [11, 12], "new_tok_span": [12, 13]}, {"ent_type": "GENE", "char_span": [87, 96], "name": "p-VEGFR-2", "tok_span": [13, 19], "new_tok_span": [15, 21]}, {"ent_type": "GENE", "char_span": [98, 104], "name": "p-EGFR", "tok_span": [20, 23], "new_tok_span": [33, 36]}, {"ent_type": "GENE", "char_span": [110, 115], "name": "p-Akt", "tok_span": [25, 28], "new_tok_span": [41, 44]}], "relation_list": [{"subject": "DMBT", "sbj_char_span": [35, 39], "object": "VEGF", "obj_char_span": [81, 85], "rel_type": "regulator", "sbj_tok_span": [4, 6], "obj_tok_span": [11, 12], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [12, 13]}, {"subject": "DMBT", "sbj_char_span": [35, 39], "object": "p-VEGFR-2", "obj_char_span": [87, 96], "rel_type": "regulator", "sbj_tok_span": [4, 6], "obj_tok_span": [13, 19], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [15, 21]}, {"subject": "DMBT", "sbj_char_span": [35, 39], "object": "p-EGFR", "obj_char_span": [98, 104], "rel_type": "regulator", "sbj_tok_span": [4, 6], "obj_tok_span": [20, 23], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [33, 36]}, {"subject": "DMBT", "sbj_char_span": [35, 39], "object": "p-Akt", "obj_char_span": [110, 115], "rel_type": "regulator", "sbj_tok_span": [4, 6], "obj_tok_span": [25, 28], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [41, 44]}], "umls_entity_list": [{"mention": "VEGF", "char_span": [81, 85], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 12], "new_tok_span": [12, 13]}, {"mention": "VEGF", "char_span": [89, 93], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 16], "new_tok_span": [22, 23]}, {"mention": "-", "char_span": [88, 89], "sem_type": "Pharmacologic Substance", "tok_span": [14, 15], "new_tok_span": [17, 18]}, {"mention": "-", "char_span": [94, 95], "sem_type": "Pharmacologic Substance", "tok_span": [17, 18], "new_tok_span": [27, 28]}, {"mention": "-", "char_span": [99, 100], "sem_type": "Pharmacologic Substance", "tok_span": [21, 22], "new_tok_span": [35, 36]}, {"mention": "-", "char_span": [111, 112], "sem_type": "Pharmacologic Substance", "tok_span": [26, 27], "new_tok_span": [43, 44]}, {"mention": "VEGFR", "char_span": [89, 94], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 17], "new_tok_span": [22, 24]}, {"mention": "VEGFR-2", "char_span": [89, 96], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 19], "new_tok_span": [22, 26]}, {"mention": "p-EGFR", "char_span": [98, 104], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 23], "new_tok_span": [33, 36]}, {"mention": "Akt", "char_span": [112, 115], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [47, 48]}, {"mention": "Akt", "char_span": [112, 115], "sem_type": "Gene or Genome", "tok_span": [27, 28], "new_tok_span": [47, 48]}], "new_text": "Western blotting demonstrated that DMBT effectively suppressed the expression of <START=Amino Acid, Peptide, or Protein> VEGF <END=Amino Acid, Peptide, or Protein>, p <START=Pharmacologic Substance> - <END=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> VEGF <END=Amino Acid, Peptide, or Protein>R <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> - <END=Pharmacologic Substance> 2 <END=Amino Acid, Peptide, or Protein>, <START=Amino Acid, Peptide, or Protein> p <START=Pharmacologic Substance> - <END=Pharmacologic Substance> EGFR <END=Amino Acid, Peptide, or Protein>, and p <START=Pharmacologic Substance> - <END=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Akt <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>."}, {"PMID": 11330337, "id": 2, "text": "In the present study, the capacity of acetylcholinesterase inhibitors to interact with muscarinic receptors was assessed by their ability to displace both [3H]-oxotremorine-M and [3H]-quinuclinidyl benzilate binding in rat brain membranes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [155, 174], "name": "[3H]-oxotremorine-M", "tok_span": [28, 40], "new_tok_span": [32, 44]}, {"ent_type": "CHEMICAL", "char_span": [179, 207], "name": "[3H]-quinuclinidyl benzilate", "tok_span": [41, 54], "new_tok_span": [45, 58]}, {"ent_type": "GENE", "char_span": [38, 58], "name": "acetylcholinesterase", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [87, 107], "name": "muscarinic receptors", "tok_span": [15, 19], "new_tok_span": [18, 22]}], "relation_list": [{"subject": "[3H]-oxotremorine-M", "sbj_char_span": [155, 174], "object": "muscarinic receptors", "obj_char_span": [87, 107], "rel_type": "regulator", "sbj_tok_span": [28, 40], "obj_tok_span": [15, 19], "new_sbj_tok_span": [32, 44], "new_obj_tok_span": [18, 22]}, {"subject": "[3H]-quinuclinidyl benzilate", "sbj_char_span": [179, 207], "object": "muscarinic receptors", "obj_char_span": [87, 107], "rel_type": "regulator", "sbj_tok_span": [41, 54], "obj_tok_span": [15, 19], "new_sbj_tok_span": [45, 58], "new_obj_tok_span": [18, 22]}], "umls_entity_list": [{"mention": "acetylcholinesterase", "char_span": [38, 58], "sem_type": "Pharmacologic Substance", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"mention": "muscarinic", "char_span": [87, 97], "sem_type": "Pharmacologic Substance", "tok_span": [15, 18], "new_tok_span": [18, 21]}, {"mention": "benzilate", "char_span": [198, 207], "sem_type": "Organic Chemical", "tok_span": [51, 54], "new_tok_span": [56, 59]}], "new_text": "In the present study, the capacity of <START=Pharmacologic Substance> acetylcholinesterase <END=Pharmacologic Substance> inhibitors to interact with <START=Pharmacologic Substance> muscarinic <END=Pharmacologic Substance> receptors was assessed by their ability to displace both [ 3H ] - oxotremorine - M and [ 3H ] - quinuclinidyl <START=Organic Chemical> benzilate <END=Organic Chemical> binding in rat brain membranes."}, {"PMID": 23386703, "id": 3, "text": "Approximately 20-50% of an apixaban i.v. dose was found in feces of BDC rats and dogs, suggesting IE leading to fecal elimination and intestinal clearance (IC). The fecal elimination, IC, and systemic clearance of apixaban were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with GF-120918, a dual BCRP and P-gp inhibitor).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [329, 338], "name": "GF-120918", "tok_span": [75, 80], "new_tok_span": [80, 85]}, {"ent_type": "CHEMICAL", "char_span": [27, 35], "name": "apixaban", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"ent_type": "CHEMICAL", "char_span": [214, 222], "name": "apixaban", "tok_span": [50, 53], "new_tok_span": [53, 56]}, {"ent_type": "GENE", "char_span": [347, 351], "name": "BCRP", "tok_span": [83, 85], "new_tok_span": [90, 92]}, {"ent_type": "GENE", "char_span": [356, 360], "name": "P-gp", "tok_span": [86, 89], "new_tok_span": [95, 98]}], "relation_list": [{"subject": "GF-120918", "sbj_char_span": [329, 338], "object": "BCRP", "obj_char_span": [347, 351], "rel_type": "inhibitor", "sbj_tok_span": [75, 80], "obj_tok_span": [83, 85], "new_sbj_tok_span": [80, 85], "new_obj_tok_span": [90, 92]}, {"subject": "GF-120918", "sbj_char_span": [329, 338], "object": "P-gp", "obj_char_span": [356, 360], "rel_type": "inhibitor", "sbj_tok_span": [75, 80], "obj_tok_span": [86, 89], "new_sbj_tok_span": [80, 85], "new_obj_tok_span": [95, 98]}], "umls_entity_list": [{"mention": "apixaban", "char_span": [27, 35], "sem_type": "Pharmacologic Substance", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "apixaban", "char_span": [214, 222], "sem_type": "Pharmacologic Substance", "tok_span": [50, 53], "new_tok_span": [53, 56]}, {"mention": "GF", "char_span": [329, 331], "sem_type": "Pharmacologic Substance", "tok_span": [75, 76], "new_tok_span": [80, 81]}, {"mention": "BCRP", "char_span": [347, 351], "sem_type": "Gene or Genome", "tok_span": [83, 85], "new_tok_span": [90, 92]}, {"mention": "P-gp inhibitor", "char_span": [356, 370], "sem_type": "Pharmacologic Substance", "tok_span": [86, 90], "new_tok_span": [95, 99]}], "new_text": "Approximately 20 - 50 % of an <START=Pharmacologic Substance> apixaban <END=Pharmacologic Substance> i. v. dose was found in feces of BDC rats and dogs, suggesting IE leading to fecal elimination and intestinal clearance ( IC ). The fecal elimination, IC, and systemic clearance of <START=Pharmacologic Substance> apixaban <END=Pharmacologic Substance> were increased upon AC administration in both BDC rats and dogs and were decreased in BDC rats dosed with <START=Pharmacologic Substance> GF <END=Pharmacologic Substance> - 120918, a dual <START=Gene or Genome> BCRP <END=Gene or Genome> and <START=Pharmacologic Substance> P - gp inhibitor <END=Pharmacologic Substance> )."}, {"PMID": 17537429, "id": 6, "text": "Neonatal cells had a higher glucose uptake than adult cells and GLUT 1 participated in basal uptake in both cell types.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 35], "name": "glucose", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "GENE", "char_span": [64, 70], "name": "GLUT 1", "tok_span": [12, 14], "new_tok_span": [12, 14]}], "relation_list": [{"subject": "glucose", "sbj_char_span": [28, 35], "object": "GLUT 1", "obj_char_span": [64, 70], "rel_type": "product or substrate", "sbj_tok_span": [6, 7], "obj_tok_span": [12, 14], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [12, 14]}], "umls_entity_list": [], "new_text": "Neonatal cells had a higher glucose uptake than adult cells and GLUT 1 participated in basal uptake in both cell types."}, {"PMID": 18505444, "id": 8, "text": "The Kv channel blockers amiodarone, tetraethylammonium and verapamil, as well as increased extracellular K+ levels, inhibited proliferation of cultured MSC. In MSC treated with Kv channel blockers or an increased extracellular concentration of K+, the proportion of cells in the S phase decreased significantly and the proportion of cells in the G(0)/G(1) phase tended to increase, indicating that the cells were prevented from entering the S phase of the cell cycle.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [105, 107], "name": "K+", "tok_span": [23, 25], "new_tok_span": [29, 31]}, {"ent_type": "CHEMICAL", "char_span": [244, 246], "name": "K+", "tok_span": [46, 48], "new_tok_span": [54, 56]}, {"ent_type": "CHEMICAL", "char_span": [24, 34], "name": "amiodarone", "tok_span": [4, 8], "new_tok_span": [7, 11]}, {"ent_type": "CHEMICAL", "char_span": [36, 54], "name": "tetraethylammonium", "tok_span": [9, 13], "new_tok_span": [14, 18]}, {"ent_type": "CHEMICAL", "char_span": [59, 68], "name": "verapamil", "tok_span": [14, 17], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [177, 187], "name": "Kv channel", "tok_span": [37, 39], "new_tok_span": [43, 45]}, {"ent_type": "GENE", "char_span": [4, 14], "name": "Kv channel", "tok_span": [1, 3], "new_tok_span": [1, 3]}], "relation_list": [{"subject": "amiodarone", "sbj_char_span": [24, 34], "object": "Kv channel", "obj_char_span": [4, 14], "rel_type": "inhibitor", "sbj_tok_span": [4, 8], "obj_tok_span": [1, 3], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [1, 3]}, {"subject": "tetraethylammonium", "sbj_char_span": [36, 54], "object": "Kv channel", "obj_char_span": [4, 14], "rel_type": "inhibitor", "sbj_tok_span": [9, 13], "obj_tok_span": [1, 3], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [1, 3]}, {"subject": "verapamil", "sbj_char_span": [59, 68], "object": "Kv channel", "obj_char_span": [4, 14], "rel_type": "inhibitor", "sbj_tok_span": [14, 17], "obj_tok_span": [1, 3], "new_sbj_tok_span": [20, 23], "new_obj_tok_span": [1, 3]}], "umls_entity_list": [{"mention": "channel", "char_span": [7, 14], "sem_type": "Pharmacologic Substance", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"mention": "channel", "char_span": [180, 187], "sem_type": "Pharmacologic Substance", "tok_span": [38, 39], "new_tok_span": [45, 46]}, {"mention": "amiodarone", "char_span": [24, 34], "sem_type": "Pharmacologic Substance", "tok_span": [4, 8], "new_tok_span": [7, 11]}, {"mention": "tetraethylammonium", "char_span": [36, 54], "sem_type": "Pharmacologic Substance", "tok_span": [9, 13], "new_tok_span": [14, 18]}], "new_text": "The Kv <START=Pharmacologic Substance> channel <END=Pharmacologic Substance> blockers <START=Pharmacologic Substance> amiodarone <END=Pharmacologic Substance>, <START=Pharmacologic Substance> tetraethylammonium <END=Pharmacologic Substance> and verapamil, as well as increased extracellular K + levels, inhibited proliferation of cultured MSC. In MSC treated with Kv <START=Pharmacologic Substance> channel <END=Pharmacologic Substance> blockers or an increased extracellular concentration of K +, the proportion of cells in the S phase decreased significantly and the proportion of cells in the G ( 0 ) / G ( 1 ) phase tended to increase, indicating that the cells were prevented from entering the S phase of the cell cycle."}, {"PMID": 23211707, "id": 4, "text": "We further showed that central administration of an ERα agonist, propyl pyrazole triol, acutely increases physical interaction between SRC1 and ERα in the hypothalamus.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [65, 86], "name": "propyl pyrazole triol", "tok_span": [12, 18], "new_tok_span": [12, 18]}, {"ent_type": "GENE", "char_span": [52, 55], "name": "ERα", "tok_span": [8, 10], "new_tok_span": [8, 10]}, {"ent_type": "GENE", "char_span": [135, 139], "name": "SRC1", "tok_span": [25, 28], "new_tok_span": [27, 30]}, {"ent_type": "GENE", "char_span": [144, 147], "name": "ERα", "tok_span": [29, 31], "new_tok_span": [33, 35]}], "relation_list": [{"subject": "propyl pyrazole triol", "sbj_char_span": [65, 86], "object": "ERα", "obj_char_span": [52, 55], "rel_type": "agonist or antagonist", "sbj_tok_span": [12, 18], "obj_tok_span": [8, 10], "new_sbj_tok_span": [12, 18], "new_obj_tok_span": [8, 10]}], "umls_entity_list": [{"mention": "SRC1", "char_span": [135, 139], "sem_type": "Gene or Genome", "tok_span": [25, 28], "new_tok_span": [27, 30]}, {"mention": "SRC1", "char_span": [135, 139], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 28], "new_tok_span": [27, 30]}], "new_text": "We further showed that central administration of an ERα agonist, propyl pyrazole triol, acutely increases physical interaction between <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> SRC1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and ERα in the hypothalamus."}, {"PMID": 16781459, "id": 8, "text": "Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [39, 44], "name": "H(2)S", "tok_span": [6, 11], "new_tok_span": [8, 13]}, {"ent_type": "CHEMICAL", "char_span": [57, 59], "name": "NO", "tok_span": [13, 14], "new_tok_span": [15, 16]}, {"ent_type": "CHEMICAL", "char_span": [179, 181], "name": "CO", "tok_span": [38, 39], "new_tok_span": [45, 46]}, {"ent_type": "GENE", "char_span": [75, 84], "name": "NF-kappaB", "tok_span": [16, 20], "new_tok_span": [18, 22]}, {"ent_type": "GENE", "char_span": [174, 178], "name": "HO-1", "tok_span": [34, 37], "new_tok_span": [40, 43]}], "relation_list": [{"subject": "H(2)S", "sbj_char_span": [39, 44], "object": "NF-kappaB", "obj_char_span": [75, 84], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [16, 20], "new_sbj_tok_span": [8, 13], "new_obj_tok_span": [18, 22]}, {"subject": "CO", "sbj_char_span": [179, 181], "object": "HO-1", "obj_char_span": [174, 178], "rel_type": "product or substrate", "sbj_tok_span": [38, 39], "obj_tok_span": [34, 37], "new_sbj_tok_span": [45, 46], "new_obj_tok_span": [40, 43]}], "umls_entity_list": [{"mention": "LPS", "char_span": [99, 102], "sem_type": "Organic Chemical", "tok_span": [22, 23], "new_tok_span": [26, 27]}, {"mention": "LPS", "char_span": [99, 102], "sem_type": "Gene or Genome", "tok_span": [22, 23], "new_tok_span": [26, 27]}, {"mention": "Co", "char_span": [0, 2], "sem_type": "Gene or Genome", "tok_span": [0, 1], "new_tok_span": [1, 2]}, {"mention": "CO", "char_span": [179, 181], "sem_type": "Gene or Genome", "tok_span": [38, 39], "new_tok_span": [45, 46]}], "new_text": "<START=Gene or Genome> Collectively <END=Gene or Genome>, our results suggest that H ( 2 ) S can inhibit NO production and NF - kappaB activation in <START=Organic Chemical> <START=Gene or Genome> LPS <END=Organic Chemical> <END=Gene or Genome> - stimulated macrophages through a mechanism that involves the action of HO - 1 / <START=Gene or Genome> CO <END=Gene or Genome>."}, {"PMID": 12927775, "id": 0, "text": "Structure-based design of aliskiren, a novel orally effective renin inhibitor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [26, 35], "name": "aliskiren", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"ent_type": "GENE", "char_span": [62, 67], "name": "renin", "tok_span": [13, 14], "new_tok_span": [17, 18]}], "relation_list": [{"subject": "aliskiren", "sbj_char_span": [26, 35], "object": "renin", "obj_char_span": [62, 67], "rel_type": "inhibitor", "sbj_tok_span": [5, 8], "obj_tok_span": [13, 14], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [17, 18]}], "umls_entity_list": [{"mention": "aliskiren", "char_span": [26, 35], "sem_type": "Pharmacologic Substance", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"mention": "renin", "char_span": [62, 67], "sem_type": "Pharmacologic Substance", "tok_span": [13, 14], "new_tok_span": [17, 18]}, {"mention": "renin inhibitor", "char_span": [62, 77], "sem_type": "Pharmacologic Substance", "tok_span": [13, 15], "new_tok_span": [17, 19]}], "new_text": "Structure - based design of <START=Pharmacologic Substance> aliskiren <END=Pharmacologic Substance>, a novel orally effective <START=Pharmacologic Substance> <START=Pharmacologic Substance> renin <END=Pharmacologic Substance> inhibitor <END=Pharmacologic Substance>."}, {"PMID": 8102973, "id": 4, "text": "It was found that clozapine is selective for the dopamine D4 vs. the D2 receptor by a factor of 2.8.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 27], "name": "clozapine", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [49, 57], "name": "dopamine", "tok_span": [11, 12], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [49, 60], "name": "dopamine D4", "tok_span": [11, 14], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [69, 80], "name": "D2 receptor", "tok_span": [17, 20], "new_tok_span": [20, 23]}], "relation_list": [{"subject": "clozapine", "sbj_char_span": [18, 27], "object": "dopamine D4", "obj_char_span": [49, 60], "rel_type": "agonist or antagonist", "sbj_tok_span": [4, 7], "obj_tok_span": [11, 14], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [11, 14]}], "umls_entity_list": [{"mention": "D4", "char_span": [58, 60], "sem_type": "Gene or Genome", "tok_span": [12, 14], "new_tok_span": [13, 15]}, {"mention": "D2 receptor", "char_span": [69, 80], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 20], "new_tok_span": [20, 23]}], "new_text": "It was found that clozapine is selective for the dopamine <START=Gene or Genome> D4 <END=Gene or Genome> vs. the <START=Amino Acid, Peptide, or Protein> D2 receptor <END=Amino Acid, Peptide, or Protein> by a factor of 2. 8."}, {"PMID": 17603755, "id": 3, "text": "Miglustat, a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step in glycosphingolipid synthesis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Miglustat", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [106, 122], "name": "glucosylceramide", "tok_span": [24, 28], "new_tok_span": [28, 32]}, {"ent_type": "GENE", "char_span": [106, 131], "name": "glucosylceramide synthase", "tok_span": [24, 29], "new_tok_span": [28, 33]}], "relation_list": [{"subject": "Miglustat", "sbj_char_span": [0, 9], "object": "glucosylceramide synthase", "obj_char_span": [106, 131], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [24, 29], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [28, 33]}], "umls_entity_list": [{"mention": "Miglustat", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "glucosylceramide synthase", "char_span": [106, 131], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 29], "new_tok_span": [28, 33]}, {"mention": "glucosylceramide synthase", "char_span": [106, 131], "sem_type": "Gene or Genome", "tok_span": [24, 29], "new_tok_span": [28, 33]}, {"mention": "committed", "char_span": [159, 168], "sem_type": "Pharmacologic Substance", "tok_span": [35, 36], "new_tok_span": [42, 43]}], "new_text": "<START=Pharmacologic Substance> Miglustat <END=Pharmacologic Substance>, a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> glucosylceramide synthase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, which catalyses the first <START=Pharmacologic Substance> committed <END=Pharmacologic Substance> step in glycosphingolipid synthesis."}, {"PMID": 23583931, "id": 9, "text": "Phosphorylation on Ser and Thr residues of pannexin1 was increased during potentiation, possibly mediating HC opening.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [19, 22], "name": "Ser", "tok_span": [3, 4], "new_tok_span": [3, 4]}, {"ent_type": "CHEMICAL", "char_span": [27, 30], "name": "Thr", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"ent_type": "GENE", "char_span": [43, 52], "name": "pannexin1", "tok_span": [8, 11], "new_tok_span": [10, 13]}], "relation_list": [{"subject": "Ser", "sbj_char_span": [19, 22], "object": "pannexin1", "obj_char_span": [43, 52], "rel_type": "part of", "sbj_tok_span": [3, 4], "obj_tok_span": [8, 11], "new_sbj_tok_span": [3, 4], "new_obj_tok_span": [10, 13]}, {"subject": "Thr", "sbj_char_span": [27, 30], "object": "pannexin1", "obj_char_span": [43, 52], "rel_type": "part of", "sbj_tok_span": [5, 6], "obj_tok_span": [8, 11], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [10, 13]}], "umls_entity_list": [{"mention": "Thr", "char_span": [27, 30], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"mention": "HC", "char_span": [107, 109], "sem_type": "Pharmacologic Substance", "tok_span": [18, 19], "new_tok_span": [22, 23]}, {"mention": "HC", "char_span": [107, 109], "sem_type": "Gene or Genome", "tok_span": [18, 19], "new_tok_span": [22, 23]}], "new_text": "Phosphorylation on Ser and <START=Amino Acid, Peptide, or Protein> Thr <END=Amino Acid, Peptide, or Protein> residues of pannexin1 was increased during potentiation, possibly mediating <START=Pharmacologic Substance> <START=Gene or Genome> HC <END=Pharmacologic Substance> <END=Gene or Genome> opening."}, {"PMID": 23165153, "id": 7, "text": "Pretreatment of the resistant cells with a potent proteasome inhibitor Z-Leu-Leu-Leu-al augmented the CDDP sensitization elicited by the AKR inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [71, 87], "name": "Z-Leu-Leu-Leu-al", "tok_span": [11, 20], "new_tok_span": [16, 25]}, {"ent_type": "CHEMICAL", "char_span": [102, 106], "name": "CDDP", "tok_span": [22, 24], "new_tok_span": [29, 31]}, {"ent_type": "GENE", "char_span": [50, 60], "name": "proteasome", "tok_span": [9, 10], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [137, 140], "name": "AKR", "tok_span": [28, 30], "new_tok_span": [36, 38]}], "relation_list": [{"subject": "Z-Leu-Leu-Leu-al", "sbj_char_span": [71, 87], "object": "proteasome", "obj_char_span": [50, 60], "rel_type": "inhibitor", "sbj_tok_span": [11, 20], "obj_tok_span": [9, 10], "new_sbj_tok_span": [16, 25], "new_obj_tok_span": [11, 12]}], "umls_entity_list": [{"mention": "proteasome inhibitor", "char_span": [50, 70], "sem_type": "Pharmacologic Substance", "tok_span": [9, 11], "new_tok_span": [11, 13]}, {"mention": "Z-Leu-Leu-Leu-al", "char_span": [71, 87], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 20], "new_tok_span": [16, 25]}, {"mention": "proteasome inhibitor", "char_span": [50, 70], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 11], "new_tok_span": [11, 13]}, {"mention": "CDDP", "char_span": [102, 106], "sem_type": "Pharmacologic Substance", "tok_span": [22, 24], "new_tok_span": [29, 31]}], "new_text": "Pretreatment of the resistant cells with a potent <START=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> proteasome inhibitor <END=Pharmacologic Substance> <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> Z - Leu - Leu - Leu - al <END=Amino Acid, Peptide, or Protein> augmented the <START=Pharmacologic Substance> CDDP <END=Pharmacologic Substance> sensitization elicited by the AKR inhibitors."}, {"PMID": 23604720, "id": 4, "text": "In the kinetic analyses using Lineweaver-Burk plots of 1/velocity and 1/substrate, methyl-3,5-di-O-caffeoylquinate showed competitive inhibition of rhAR. Furthermore, methyl-3,5-di-O-caffeoylquinate inhibited galactitol formation in the rat lens and in erythrocytes incubated with a high concentration of glucose, indicating that this compound may be effective in preventing diabetic complications.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [167, 198], "name": "methyl-3,5-di-O-caffeoylquinate", "tok_span": [43, 57], "new_tok_span": [43, 57]}, {"ent_type": "CHEMICAL", "char_span": [209, 219], "name": "galactitol", "tok_span": [58, 60], "new_tok_span": [58, 60]}, {"ent_type": "CHEMICAL", "char_span": [305, 312], "name": "glucose", "tok_span": [74, 75], "new_tok_span": [74, 75]}, {"ent_type": "CHEMICAL", "char_span": [83, 114], "name": "methyl-3,5-di-O-caffeoylquinate", "tok_span": [20, 34], "new_tok_span": [20, 34]}, {"ent_type": "GENE", "char_span": [148, 152], "name": "rhAR", "tok_span": [38, 40], "new_tok_span": [38, 40]}], "relation_list": [{"subject": "methyl-3,5-di-O-caffeoylquinate", "sbj_char_span": [83, 114], "object": "rhAR", "obj_char_span": [148, 152], "rel_type": "inhibitor", "sbj_tok_span": [20, 34], "obj_tok_span": [38, 40], "new_sbj_tok_span": [20, 34], "new_obj_tok_span": [38, 40]}], "umls_entity_list": [], "new_text": "In the kinetic analyses using Lineweaver - Burk plots of 1 / velocity and 1 / substrate, methyl - 3, 5 - di - O - caffeoylquinate showed competitive inhibition of rhAR. Furthermore, methyl - 3, 5 - di - O - caffeoylquinate inhibited galactitol formation in the rat lens and in erythrocytes incubated with a high concentration of glucose, indicating that this compound may be effective in preventing diabetic complications."}, {"PMID": 23194750, "id": 7, "text": "Thiazolidinediones decrease vasoconstriction of isolated vessels possibly by inhibiting PI3K/Akt pathway.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 18], "name": "Thiazolidinediones", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "GENE", "char_span": [88, 92], "name": "PI3K", "tok_span": [14, 17], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [93, 96], "name": "Akt", "tok_span": [18, 19], "new_tok_span": [20, 21]}], "relation_list": [{"subject": "Thiazolidinediones", "sbj_char_span": [0, 18], "object": "PI3K", "obj_char_span": [88, 92], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [14, 17], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [14, 17]}, {"subject": "Thiazolidinediones", "sbj_char_span": [0, 18], "object": "Akt", "obj_char_span": [93, 96], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [18, 19], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [20, 21]}], "umls_entity_list": [{"mention": "Akt", "char_span": [93, 96], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 19], "new_tok_span": [20, 21]}, {"mention": "Akt", "char_span": [93, 96], "sem_type": "Gene or Genome", "tok_span": [18, 19], "new_tok_span": [20, 21]}], "new_text": "Thiazolidinediones decrease vasoconstriction of isolated vessels possibly by inhibiting PI3K / <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Akt <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> pathway."}, {"PMID": 23205634, "id": 5, "text": "Both wild-type ABCG2 and its R482G mutant variant require cholesterol for full activity, although they exhibit different cholesterol sensitivities.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [58, 69], "name": "cholesterol", "tok_span": [16, 17], "new_tok_span": [17, 18]}, {"ent_type": "CHEMICAL", "char_span": [121, 132], "name": "cholesterol", "tok_span": [25, 26], "new_tok_span": [28, 29]}, {"ent_type": "GENE", "char_span": [15, 20], "name": "ABCG2", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [29, 34], "name": "R482G", "tok_span": [9, 13], "new_tok_span": [9, 13]}], "relation_list": [{"subject": "cholesterol", "sbj_char_span": [58, 69], "object": "ABCG2", "obj_char_span": [15, 20], "rel_type": "activator", "sbj_tok_span": [16, 17], "obj_tok_span": [4, 7], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [4, 7]}, {"subject": "cholesterol", "sbj_char_span": [58, 69], "object": "R482G", "obj_char_span": [29, 34], "rel_type": "activator", "sbj_tok_span": [16, 17], "obj_tok_span": [9, 13], "new_sbj_tok_span": [17, 18], "new_obj_tok_span": [9, 13]}], "umls_entity_list": [{"mention": "cholesterol", "char_span": [58, 69], "sem_type": "Organic Chemical", "tok_span": [16, 17], "new_tok_span": [17, 18]}, {"mention": "cholesterol", "char_span": [121, 132], "sem_type": "Organic Chemical", "tok_span": [25, 26], "new_tok_span": [28, 29]}], "new_text": "Both wild - type ABCG2 and its R482G mutant variant require <START=Organic Chemical> cholesterol <END=Organic Chemical> for full activity, although they exhibit different <START=Organic Chemical> cholesterol <END=Organic Chemical> sensitivities."}, {"PMID": 23303191, "id": 3, "text": "Hyaluronan synthesis driven by HAS2 was less affected by glucosamine addition, and HAS3 was not affected at all.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [57, 68], "name": "glucosamine", "tok_span": [14, 18], "new_tok_span": [19, 23]}, {"ent_type": "GENE", "char_span": [31, 35], "name": "HAS2", "tok_span": [7, 10], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [83, 87], "name": "HAS3", "tok_span": [21, 24], "new_tok_span": [27, 30]}], "relation_list": [{"subject": "glucosamine", "sbj_char_span": [57, 68], "object": "HAS2", "obj_char_span": [31, 35], "rel_type": "product or substrate", "sbj_tok_span": [14, 18], "obj_tok_span": [7, 10], "new_sbj_tok_span": [19, 23], "new_obj_tok_span": [9, 12]}], "umls_entity_list": [{"mention": "HAS2", "char_span": [31, 35], "sem_type": "Gene or Genome", "tok_span": [7, 10], "new_tok_span": [9, 12]}, {"mention": "HAS2", "char_span": [31, 35], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 10], "new_tok_span": [9, 12]}, {"mention": "glucosamine", "char_span": [57, 68], "sem_type": "Pharmacologic Substance", "tok_span": [14, 18], "new_tok_span": [19, 23]}], "new_text": "Hyaluronan synthesis driven by <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> HAS2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> was less affected by <START=Pharmacologic Substance> glucosamine <END=Pharmacologic Substance> addition, and HAS3 was not affected at all."}, {"PMID": 9013583, "id": 1, "text": "Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) and cyclooxygenase inhibitor that is frequently used as a research tool to study the process of adipocyte differentiation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Indomethacin", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [22, 31], "name": "steroidal", "tok_span": [7, 9], "new_tok_span": [7, 9]}, {"ent_type": "GENE", "char_span": [67, 81], "name": "cyclooxygenase", "tok_span": [18, 20], "new_tok_span": [19, 21]}], "relation_list": [{"subject": "Indomethacin", "sbj_char_span": [0, 12], "object": "cyclooxygenase", "obj_char_span": [67, 81], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [18, 20], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [19, 21]}], "umls_entity_list": [{"mention": "cyclooxygenase inhibitor", "char_span": [67, 91], "sem_type": "Pharmacologic Substance", "tok_span": [18, 21], "new_tok_span": [19, 22]}], "new_text": "Indomethacin is a non - steroidal anti - inflammatory drug ( NSAID ) and <START=Pharmacologic Substance> cyclooxygenase inhibitor <END=Pharmacologic Substance> that is frequently used as a research tool to study the process of adipocyte differentiation."}, {"PMID": 23432095, "id": 5, "text": "Indomethacin, used to inhibit cyclooxygenase, also inhibits AKR1C3 and displays selectivity over AKR1C1/AKR1C2. Parallel synthetic strategies were used to generate libraries of indomethacin analogues, which exhibit reduced cyclooxygenase inhibitory activity but retain AKR1C3 inhibitory potency and selectivity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Indomethacin", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [177, 189], "name": "indomethacin", "tok_span": [42, 45], "new_tok_span": [50, 53]}, {"ent_type": "GENE", "char_span": [30, 44], "name": "cyclooxygenase", "tok_span": [7, 9], "new_tok_span": [7, 9]}, {"ent_type": "GENE", "char_span": [60, 66], "name": "AKR1C3", "tok_span": [12, 17], "new_tok_span": [14, 19]}, {"ent_type": "GENE", "char_span": [97, 103], "name": "AKR1C1", "tok_span": [21, 26], "new_tok_span": [25, 30]}, {"ent_type": "GENE", "char_span": [104, 110], "name": "AKR1C2", "tok_span": [27, 32], "new_tok_span": [33, 38]}, {"ent_type": "GENE", "char_span": [223, 237], "name": "cyclooxygenase", "tok_span": [50, 52], "new_tok_span": [58, 60]}, {"ent_type": "GENE", "char_span": [269, 275], "name": "AKR1C3", "tok_span": [56, 61], "new_tok_span": [66, 71]}], "relation_list": [{"subject": "Indomethacin", "sbj_char_span": [0, 12], "object": "cyclooxygenase", "obj_char_span": [30, 44], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [7, 9], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [7, 9]}, {"subject": "Indomethacin", "sbj_char_span": [0, 12], "object": "AKR1C3", "obj_char_span": [60, 66], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [12, 17], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [14, 19]}, {"subject": "indomethacin", "sbj_char_span": [177, 189], "object": "AKR1C3", "obj_char_span": [269, 275], "rel_type": "inhibitor", "sbj_tok_span": [42, 45], "obj_tok_span": [56, 61], "new_sbj_tok_span": [50, 53], "new_obj_tok_span": [66, 71]}], "umls_entity_list": [{"mention": "AKR1C2", "char_span": [104, 110], "sem_type": "Gene or Genome", "tok_span": [27, 32], "new_tok_span": [33, 38]}, {"mention": "AKR1C2", "char_span": [104, 110], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 32], "new_tok_span": [33, 38]}, {"mention": "AKR1C3", "char_span": [60, 66], "sem_type": "Gene or Genome", "tok_span": [12, 17], "new_tok_span": [14, 19]}, {"mention": "AKR1C3", "char_span": [269, 275], "sem_type": "Gene or Genome", "tok_span": [56, 61], "new_tok_span": [66, 71]}, {"mention": "AKR1C3", "char_span": [60, 66], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 17], "new_tok_span": [14, 19]}, {"mention": "AKR1C3", "char_span": [269, 275], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 61], "new_tok_span": [66, 71]}], "new_text": "Indomethacin, used to inhibit cyclooxygenase, also inhibits <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> AKR1C3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and displays selectivity over AKR1C1 / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> AKR1C2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. Parallel synthetic strategies were used to generate libraries of indomethacin analogues, which exhibit reduced cyclooxygenase inhibitory activity but retain <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> AKR1C3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> inhibitory potency and selectivity."}, {"PMID": 17575107, "id": 2, "text": "We hypothesized that sorafenib, a multikinase inhibitor of the BRaf, vascular endothelial growth factor receptor-2, and platelet-derived growth factor receptor-beta kinase, would decrease tumor growth and angiogenesis in an orthotopic model of ATC. The in vitro antiproliferative and proapoptotic effects of sorafenib on ATC cell lines were examined.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [21, 30], "name": "sorafenib", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [308, 317], "name": "sorafenib", "tok_span": [59, 61], "new_tok_span": [65, 67]}, {"ent_type": "GENE", "char_span": [63, 67], "name": "BRaf", "tok_span": [12, 14], "new_tok_span": [14, 16]}, {"ent_type": "GENE", "char_span": [69, 114], "name": "vascular endothelial growth factor receptor-2", "tok_span": [15, 22], "new_tok_span": [18, 25]}, {"ent_type": "GENE", "char_span": [120, 164], "name": "platelet-derived growth factor receptor-beta", "tok_span": [24, 32], "new_tok_span": [28, 36]}, {"ent_type": "GENE", "char_span": [165, 171], "name": "kinase", "tok_span": [32, 33], "new_tok_span": [37, 38]}], "relation_list": [{"subject": "sorafenib", "sbj_char_span": [21, 30], "object": "BRaf", "obj_char_span": [63, 67], "rel_type": "inhibitor", "sbj_tok_span": [3, 5], "obj_tok_span": [12, 14], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [14, 16]}, {"subject": "sorafenib", "sbj_char_span": [21, 30], "object": "vascular endothelial growth factor receptor-2", "obj_char_span": [69, 114], "rel_type": "inhibitor", "sbj_tok_span": [3, 5], "obj_tok_span": [15, 22], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [18, 25]}, {"subject": "sorafenib", "sbj_char_span": [21, 30], "object": "platelet-derived growth factor receptor-beta", "obj_char_span": [120, 164], "rel_type": "inhibitor", "sbj_tok_span": [3, 5], "obj_tok_span": [24, 32], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [28, 36]}, {"subject": "sorafenib", "sbj_char_span": [21, 30], "object": "kinase", "obj_char_span": [165, 171], "rel_type": "inhibitor", "sbj_tok_span": [3, 5], "obj_tok_span": [32, 33], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [37, 38]}], "umls_entity_list": [{"mention": "vascular", "char_span": [69, 77], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 16], "new_tok_span": [18, 19]}, {"mention": "kinase", "char_span": [39, 45], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [9, 10]}, {"mention": "kinase", "char_span": [165, 171], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 33], "new_tok_span": [37, 38]}], "new_text": "We hypothesized that sorafenib, a multi <START=Amino Acid, Peptide, or Protein>kinase <END=Amino Acid, Peptide, or Protein> inhibitor of the BRaf, <START=Amino Acid, Peptide, or Protein> vascular <END=Amino Acid, Peptide, or Protein> endothelial growth factor receptor - 2, and platelet - derived growth factor receptor - beta <START=Amino Acid, Peptide, or Protein> kinase <END=Amino Acid, Peptide, or Protein>, would decrease tumor growth and angiogenesis in an orthotopic model of ATC. The in vitro antiproliferative and proapoptotic effects of sorafenib on ATC cell lines were examined."}, {"PMID": 16905533, "id": 4, "text": "The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser-776 and Ser-779 were substituted with glutamic acid to mimic phosphorylation exhibited significantly higher activity compared with wild type DGKgamma and an unphosphorylatable DGKgamma mutant.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [102, 105], "name": "Ser", "tok_span": [21, 22], "new_tok_span": [21, 22]}, {"ent_type": "CHEMICAL", "char_span": [114, 117], "name": "Ser", "tok_span": [26, 27], "new_tok_span": [26, 27]}, {"ent_type": "CHEMICAL", "char_span": [144, 157], "name": "glutamic acid", "tok_span": [33, 36], "new_tok_span": [34, 37]}, {"ent_type": "GENE", "char_span": [23, 31], "name": "gammaPKC", "tok_span": [3, 6], "new_tok_span": [3, 6]}, {"ent_type": "GENE", "char_span": [58, 66], "name": "DGKgamma", "tok_span": [10, 13], "new_tok_span": [10, 13]}, {"ent_type": "GENE", "char_span": [77, 85], "name": "DGKgamma", "tok_span": [15, 18], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [247, 255], "name": "DGKgamma", "tok_span": [47, 50], "new_tok_span": [51, 54]}, {"ent_type": "GENE", "char_span": [282, 290], "name": "DGKgamma", "tok_span": [58, 61], "new_tok_span": [62, 65]}], "relation_list": [{"subject": "Ser", "sbj_char_span": [102, 105], "object": "DGKgamma", "obj_char_span": [77, 85], "rel_type": "part of", "sbj_tok_span": [21, 22], "obj_tok_span": [15, 18], "new_sbj_tok_span": [21, 22], "new_obj_tok_span": [15, 18]}, {"subject": "Ser", "sbj_char_span": [114, 117], "object": "DGKgamma", "obj_char_span": [77, 85], "rel_type": "part of", "sbj_tok_span": [26, 27], "obj_tok_span": [15, 18], "new_sbj_tok_span": [26, 27], "new_obj_tok_span": [15, 18]}, {"subject": "glutamic acid", "sbj_char_span": [144, 157], "object": "DGKgamma", "obj_char_span": [77, 85], "rel_type": "part of", "sbj_tok_span": [33, 36], "obj_tok_span": [15, 18], "new_sbj_tok_span": [34, 37], "new_obj_tok_span": [15, 18]}], "umls_entity_list": [{"mention": "glutamic acid", "char_span": [144, 157], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 36], "new_tok_span": [34, 37]}, {"mention": "wild type", "char_span": [237, 246], "sem_type": "Gene or Genome", "tok_span": [45, 47], "new_tok_span": [48, 50]}], "new_text": "The phosphorylation by gammaPKC resulted in activation of DGKgamma because a DGKgamma mutant in which Ser - 776 and Ser - 779 were substituted with <START=Amino Acid, Peptide, or Protein> glutamic acid <END=Amino Acid, Peptide, or Protein> to mimic phosphorylation exhibited significantly higher activity compared with <START=Gene or Genome> wild type <END=Gene or Genome> DGKgamma and an unphosphorylatable DGKgamma mutant."}, {"PMID": 23536517, "id": 6, "text": "Histopathologic scores in the AP + Tau and Tau groups were significantly lower compared with the AP group (both p < 0.001).These results showed that Tau reduces lipid peroxidation, amylase and MPO activities and the concentrations of proinflammatory cytokines secondary to AP and also increases superoxide dismutase and glutathione peroxidase activities in rats with sodium taurocholate-induced AP. It also has a marked ameliorative effect at histopathologic lesions.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [295, 305], "name": "superoxide", "tok_span": [57, 58], "new_tok_span": [74, 75]}, {"ent_type": "CHEMICAL", "char_span": [320, 331], "name": "glutathione", "tok_span": [60, 61], "new_tok_span": [78, 79]}, {"ent_type": "CHEMICAL", "char_span": [367, 386], "name": "sodium taurocholate", "tok_span": [66, 71], "new_tok_span": [85, 90]}, {"ent_type": "CHEMICAL", "char_span": [35, 38], "name": "Tau", "tok_span": [8, 9], "new_tok_span": [11, 12]}, {"ent_type": "CHEMICAL", "char_span": [43, 46], "name": "Tau", "tok_span": [10, 11], "new_tok_span": [15, 16]}, {"ent_type": "CHEMICAL", "char_span": [149, 152], "name": "Tau", "tok_span": [34, 35], "new_tok_span": [43, 44]}, {"ent_type": "GENE", "char_span": [250, 259], "name": "cytokines", "tok_span": [50, 51], "new_tok_span": [64, 65]}, {"ent_type": "GENE", "char_span": [295, 315], "name": "superoxide dismutase", "tok_span": [57, 59], "new_tok_span": [74, 76]}, {"ent_type": "GENE", "char_span": [320, 342], "name": "glutathione peroxidase", "tok_span": [60, 62], "new_tok_span": [78, 80]}], "relation_list": [{"subject": "Tau", "sbj_char_span": [149, 152], "object": "cytokines", "obj_char_span": [250, 259], "rel_type": "regulator", "sbj_tok_span": [34, 35], "obj_tok_span": [50, 51], "new_sbj_tok_span": [43, 44], "new_obj_tok_span": [64, 65]}, {"subject": "Tau", "sbj_char_span": [149, 152], "object": "superoxide dismutase", "obj_char_span": [295, 315], "rel_type": "activator", "sbj_tok_span": [34, 35], "obj_tok_span": [57, 59], "new_sbj_tok_span": [43, 44], "new_obj_tok_span": [74, 76]}, {"subject": "Tau", "sbj_char_span": [149, 152], "object": "glutathione peroxidase", "obj_char_span": [320, 342], "rel_type": "activator", "sbj_tok_span": [34, 35], "obj_tok_span": [60, 62], "new_sbj_tok_span": [43, 44], "new_obj_tok_span": [78, 80]}], "umls_entity_list": [{"mention": "AP", "char_span": [30, 32], "sem_type": "Organic Chemical", "tok_span": [6, 7], "new_tok_span": [7, 8]}, {"mention": "AP", "char_span": [97, 99], "sem_type": "Organic Chemical", "tok_span": [18, 19], "new_tok_span": [25, 26]}, {"mention": "AP", "char_span": [273, 275], "sem_type": "Organic Chemical", "tok_span": [53, 54], "new_tok_span": [68, 69]}, {"mention": "AP", "char_span": [395, 397], "sem_type": "Organic Chemical", "tok_span": [73, 74], "new_tok_span": [96, 97]}, {"mention": "Tau", "char_span": [35, 38], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [11, 12]}, {"mention": "Tau", "char_span": [43, 46], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 11], "new_tok_span": [15, 16]}, {"mention": "Tau", "char_span": [149, 152], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 35], "new_tok_span": [43, 44]}, {"mention": "tau", "char_span": [374, 377], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [67, 68], "new_tok_span": [87, 88]}, {"mention": "amylase", "char_span": [181, 188], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 41], "new_tok_span": [50, 52]}, {"mention": "MPO", "char_span": [193, 196], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 44], "new_tok_span": [55, 57]}, {"mention": "superoxide dismutase", "char_span": [295, 315], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [57, 59], "new_tok_span": [74, 76]}, {"mention": "sodium taurocholate", "char_span": [367, 386], "sem_type": "Pharmacologic Substance", "tok_span": [66, 71], "new_tok_span": [85, 90]}], "new_text": "Histopathologic scores in the <START=Organic Chemical> AP <END=Organic Chemical> + <START=Amino Acid, Peptide, or Protein> Tau <END=Amino Acid, Peptide, or Protein> and <START=Amino Acid, Peptide, or Protein> Tau <END=Amino Acid, Peptide, or Protein> groups were significantly lower compared with the <START=Organic Chemical> AP <END=Organic Chemical> group ( both p < 0. 001 ). These results showed that <START=Amino Acid, Peptide, or Protein> Tau <END=Amino Acid, Peptide, or Protein> reduces lipid peroxidation, <START=Amino Acid, Peptide, or Protein> amylase <END=Amino Acid, Peptide, or Protein> and <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> activities and the concentrations of proinflammatory cytokines secondary to <START=Organic Chemical> AP <END=Organic Chemical> and also increases <START=Amino Acid, Peptide, or Protein> superoxide dismutase <END=Amino Acid, Peptide, or Protein> and glutathione peroxidase activities in rats with <START=Pharmacologic Substance> sodium <START=Amino Acid, Peptide, or Protein> tau <END=Amino Acid, Peptide, or Protein>rocholate <END=Pharmacologic Substance> - induced <START=Organic Chemical> AP <END=Organic Chemical>. It also has a marked ameliorative effect at histopathologic lesions."}, {"PMID": 10841524, "id": 0, "text": "Na(+)-dependent transporters mediate HCO(3)(-) salvage across the luminal membrane of the main pancreatic duct.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 5], "name": "Na(+)", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [37, 46], "name": "HCO(3)(-)", "tok_span": [8, 16], "new_tok_span": [10, 18]}, {"ent_type": "GENE", "char_span": [0, 28], "name": "Na(+)-dependent transporters", "tok_span": [0, 7], "new_tok_span": [0, 7]}], "relation_list": [{"subject": "HCO(3)(-)", "sbj_char_span": [37, 46], "object": "Na(+)-dependent transporters", "obj_char_span": [0, 28], "rel_type": "product or substrate", "sbj_tok_span": [8, 16], "obj_tok_span": [0, 7], "new_sbj_tok_span": [10, 18], "new_obj_tok_span": [0, 7]}], "umls_entity_list": [{"mention": "transporters", "char_span": [16, 28], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 7], "new_tok_span": [7, 8]}], "new_text": "Na ( + ) - dependent <START=Amino Acid, Peptide, or Protein> transporters <END=Amino Acid, Peptide, or Protein> mediate HCO ( 3 ) ( - ) salvage across the luminal membrane of the main pancreatic duct."}, {"PMID": 17032653, "id": 3, "text": "Here we show that RDH12 localizes to the photoreceptor inner segments and that deletion of this gene in mice slows the kinetics of all-trans-retinal reduction, delaying dark adaptation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [131, 148], "name": "all-trans-retinal", "tok_span": [28, 33], "new_tok_span": [28, 33]}, {"ent_type": "GENE", "char_span": [18, 23], "name": "RDH12", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [41, 54], "name": "photoreceptor", "tok_span": [11, 13], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "all-trans-retinal", "sbj_char_span": [131, 148], "object": "RDH12", "obj_char_span": [18, 23], "rel_type": "product or substrate", "sbj_tok_span": [28, 33], "obj_tok_span": [4, 7], "new_sbj_tok_span": [28, 33], "new_obj_tok_span": [4, 7]}], "umls_entity_list": [], "new_text": "Here we show that RDH12 localizes to the photoreceptor inner segments and that deletion of this gene in mice slows the kinetics of all - trans - retinal reduction, delaying dark adaptation."}, {"PMID": 12668769, "id": 3, "text": "An alternative THF-dependent pathway involves the C1-THF synthase/SHMT activities with formate as 1-C source.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [15, 18], "name": "THF", "tok_span": [2, 3], "new_tok_span": [4, 5]}, {"ent_type": "CHEMICAL", "char_span": [50, 52], "name": "C1", "tok_span": [8, 10], "new_tok_span": [10, 12]}, {"ent_type": "CHEMICAL", "char_span": [53, 56], "name": "THF", "tok_span": [11, 12], "new_tok_span": [13, 14]}, {"ent_type": "CHEMICAL", "char_span": [87, 94], "name": "formate", "tok_span": [18, 20], "new_tok_span": [25, 27]}, {"ent_type": "CHEMICAL", "char_span": [98, 101], "name": "1-C", "tok_span": [21, 24], "new_tok_span": [29, 32]}, {"ent_type": "GENE", "char_span": [50, 65], "name": "C1-THF synthase", "tok_span": [8, 13], "new_tok_span": [10, 15]}, {"ent_type": "GENE", "char_span": [66, 70], "name": "SHMT", "tok_span": [14, 16], "new_tok_span": [18, 20]}], "relation_list": [{"subject": "formate", "sbj_char_span": [87, 94], "object": "SHMT", "obj_char_span": [66, 70], "rel_type": "product or substrate", "sbj_tok_span": [18, 20], "obj_tok_span": [14, 16], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [18, 20]}, {"subject": "formate", "sbj_char_span": [87, 94], "object": "C1-THF synthase", "obj_char_span": [50, 65], "rel_type": "product or substrate", "sbj_tok_span": [18, 20], "obj_tok_span": [8, 13], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [10, 15]}], "umls_entity_list": [{"mention": "alternative", "char_span": [3, 14], "sem_type": "Gene or Genome", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"mention": "SHMT", "char_span": [66, 70], "sem_type": "Gene or Genome", "tok_span": [14, 16], "new_tok_span": [18, 20]}, {"mention": "formate", "char_span": [87, 94], "sem_type": "Organic Chemical", "tok_span": [18, 20], "new_tok_span": [25, 27]}, {"mention": "SHMT", "char_span": [66, 70], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 16], "new_tok_span": [18, 20]}], "new_text": "An <START=Gene or Genome> alternative <END=Gene or Genome> THF - dependent pathway involves the C1 - THF synthase / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> SHMT <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> activities with <START=Organic Chemical> formate <END=Organic Chemical> as 1 - C source."}, {"PMID": 10334992, "id": 2, "text": "Results presented here show that bile acids are physiological ligands for the farnesoid X receptor (FXR), an orphan nuclear receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [33, 43], "name": "bile acids", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"ent_type": "GENE", "char_span": [78, 98], "name": "farnesoid X receptor", "tok_span": [12, 17], "new_tok_span": [15, 20]}, {"ent_type": "GENE", "char_span": [100, 103], "name": "FXR", "tok_span": [18, 20], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [109, 132], "name": "orphan nuclear receptor", "tok_span": [23, 27], "new_tok_span": [27, 31]}], "relation_list": [{"subject": "bile acids", "sbj_char_span": [33, 43], "object": "farnesoid X receptor", "obj_char_span": [78, 98], "rel_type": "regulator", "sbj_tok_span": [5, 7], "obj_tok_span": [12, 17], "new_sbj_tok_span": [6, 8], "new_obj_tok_span": [15, 20]}, {"subject": "bile acids", "sbj_char_span": [33, 43], "object": "FXR", "obj_char_span": [100, 103], "rel_type": "regulator", "sbj_tok_span": [5, 7], "obj_tok_span": [18, 20], "new_sbj_tok_span": [6, 8], "new_obj_tok_span": [22, 24]}, {"subject": "bile acids", "sbj_char_span": [33, 43], "object": "orphan nuclear receptor", "obj_char_span": [109, 132], "rel_type": "regulator", "sbj_tok_span": [5, 7], "obj_tok_span": [23, 27], "new_sbj_tok_span": [6, 8], "new_obj_tok_span": [27, 31]}], "umls_entity_list": [{"mention": "bile", "char_span": [33, 37], "sem_type": "Organic Chemical", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"mention": "farnesoid X receptor", "char_span": [78, 98], "sem_type": "Gene or Genome", "tok_span": [12, 17], "new_tok_span": [15, 20]}], "new_text": "Results presented here show that <START=Organic Chemical> bile <END=Organic Chemical> acids are physiological ligands for the <START=Gene or Genome> farnesoid X receptor <END=Gene or Genome> ( FXR ), an orphan nuclear receptor."}, {"PMID": 11695891, "id": 2, "text": "We report the crystal structure of the catalytic heme domain of endothelial NOS complexed with 7-NIBr at 1.65 A resolution.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [95, 101], "name": "7-NIBr", "tok_span": [16, 20], "new_tok_span": [18, 22]}, {"ent_type": "GENE", "char_span": [39, 60], "name": "catalytic heme domain", "tok_span": [7, 10], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [64, 79], "name": "endothelial NOS", "tok_span": [11, 13], "new_tok_span": [13, 15]}], "relation_list": [{"subject": "7-NIBr", "sbj_char_span": [95, 101], "object": "catalytic heme domain", "obj_char_span": [39, 60], "rel_type": "regulator", "sbj_tok_span": [16, 20], "obj_tok_span": [7, 10], "new_sbj_tok_span": [18, 22], "new_obj_tok_span": [7, 10]}, {"subject": "7-NIBr", "sbj_char_span": [95, 101], "object": "endothelial NOS", "obj_char_span": [64, 79], "rel_type": "regulator", "sbj_tok_span": [16, 20], "obj_tok_span": [11, 13], "new_sbj_tok_span": [18, 22], "new_obj_tok_span": [13, 15]}], "umls_entity_list": [{"mention": "heme", "char_span": [49, 53], "sem_type": "Organic Chemical", "tok_span": [8, 9], "new_tok_span": [9, 10]}], "new_text": "We report the crystal structure of the catalytic <START=Organic Chemical> heme <END=Organic Chemical> domain of endothelial NOS complexed with 7 - NIBr at 1. 65 A resolution."}, {"PMID": 11237340, "id": 6, "text": "Both the spectrophotometric and the radiometric methods are based on the conversion of 5-methyltetrahydrofolate to tetrahydrofolate by methionine synthase.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [87, 111], "name": "5-methyltetrahydrofolate", "tok_span": [15, 22], "new_tok_span": [15, 22]}, {"ent_type": "CHEMICAL", "char_span": [115, 131], "name": "tetrahydrofolate", "tok_span": [23, 27], "new_tok_span": [26, 30]}, {"ent_type": "CHEMICAL", "char_span": [135, 145], "name": "methionine", "tok_span": [28, 29], "new_tok_span": [32, 33]}, {"ent_type": "GENE", "char_span": [135, 154], "name": "methionine synthase", "tok_span": [28, 30], "new_tok_span": [32, 34]}], "relation_list": [{"subject": "5-methyltetrahydrofolate", "sbj_char_span": [87, 111], "object": "methionine synthase", "obj_char_span": [135, 154], "rel_type": "product or substrate", "sbj_tok_span": [15, 22], "obj_tok_span": [28, 30], "new_sbj_tok_span": [15, 22], "new_obj_tok_span": [32, 34]}, {"subject": "tetrahydrofolate", "sbj_char_span": [115, 131], "object": "methionine synthase", "obj_char_span": [135, 154], "rel_type": "product or substrate", "sbj_tok_span": [23, 27], "obj_tok_span": [28, 30], "new_sbj_tok_span": [26, 30], "new_obj_tok_span": [32, 34]}], "umls_entity_list": [{"mention": "tetrahydrofolate", "char_span": [95, 111], "sem_type": "Pharmacologic Substance", "tok_span": [18, 22], "new_tok_span": [19, 23]}, {"mention": "tetrahydrofolate", "char_span": [115, 131], "sem_type": "Pharmacologic Substance", "tok_span": [23, 27], "new_tok_span": [26, 30]}], "new_text": "Both the spectrophotometric and the radiometric methods are based on the conversion of 5 - methyl <START=Pharmacologic Substance>tetrahydrofolate <END=Pharmacologic Substance> to <START=Pharmacologic Substance> tetrahydrofolate <END=Pharmacologic Substance> by methionine synthase."}, {"PMID": 16803890, "id": 12, "text": "However, the action of desipramine was independent of its action on ASMase, since neither genetic loss of ASMase (Niemann-Pick fibroblasts) nor knockdown of ASMase using RNA interference affected TNFalpha-induced PGE(2) synthesis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [23, 34], "name": "desipramine", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"ent_type": "CHEMICAL", "char_span": [213, 219], "name": "PGE(2)", "tok_span": [48, 52], "new_tok_span": [52, 56]}, {"ent_type": "GENE", "char_span": [68, 74], "name": "ASMase", "tok_span": [15, 18], "new_tok_span": [17, 20]}, {"ent_type": "GENE", "char_span": [106, 112], "name": "ASMase", "tok_span": [24, 27], "new_tok_span": [26, 29]}, {"ent_type": "GENE", "char_span": [157, 163], "name": "ASMase", "tok_span": [37, 40], "new_tok_span": [39, 42]}, {"ent_type": "GENE", "char_span": [196, 204], "name": "TNFalpha", "tok_span": [44, 46], "new_tok_span": [47, 49]}], "relation_list": [{"subject": "desipramine", "sbj_char_span": [23, 34], "object": "ASMase", "obj_char_span": [68, 74], "rel_type": "inhibitor", "sbj_tok_span": [5, 9], "obj_tok_span": [15, 18], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [17, 20]}], "umls_entity_list": [{"mention": "desipramine", "char_span": [23, 34], "sem_type": "Pharmacologic Substance", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"mention": "TNFalpha", "char_span": [196, 204], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [44, 46], "new_tok_span": [47, 49]}], "new_text": "However, the action of <START=Pharmacologic Substance> desipramine <END=Pharmacologic Substance> was independent of its action on ASMase, since neither genetic loss of ASMase ( Niemann - Pick fibroblasts ) nor knockdown of ASMase using RNA interference affected <START=Amino Acid, Peptide, or Protein> TNFalpha <END=Amino Acid, Peptide, or Protein> - induced PGE ( 2 ) synthesis."}, {"PMID": 9572299, "id": 3, "text": "As seen for spermidine stimulation, high-affinity haloperidol inhibition is governed by the region around amino acid 198, based on results from chimeric murine NR2A/NR2B (epislon1/epsilon2) receptors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [12, 22], "name": "spermidine", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [50, 61], "name": "haloperidol", "tok_span": [10, 13], "new_tok_span": [11, 14]}, {"ent_type": "CHEMICAL", "char_span": [106, 116], "name": "amino acid", "tok_span": [20, 22], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [153, 164], "name": "murine NR2A", "tok_span": [29, 33], "new_tok_span": [31, 35]}, {"ent_type": "GENE", "char_span": [165, 169], "name": "NR2B", "tok_span": [34, 37], "new_tok_span": [42, 45]}, {"ent_type": "GENE", "char_span": [170, 199], "name": "(epislon1/epsilon2) receptors", "tok_span": [37, 48], "new_tok_span": [47, 58]}], "relation_list": [{"subject": "amino acid", "sbj_char_span": [106, 116], "object": "murine NR2A", "obj_char_span": [153, 164], "rel_type": "part of", "sbj_tok_span": [20, 22], "obj_tok_span": [29, 33], "new_sbj_tok_span": [22, 24], "new_obj_tok_span": [31, 35]}, {"subject": "amino acid", "sbj_char_span": [106, 116], "object": "NR2B", "obj_char_span": [165, 169], "rel_type": "part of", "sbj_tok_span": [20, 22], "obj_tok_span": [34, 37], "new_sbj_tok_span": [22, 24], "new_obj_tok_span": [42, 45]}, {"subject": "haloperidol", "sbj_char_span": [50, 61], "object": "murine NR2A", "obj_char_span": [153, 164], "rel_type": "inhibitor", "sbj_tok_span": [10, 13], "obj_tok_span": [29, 33], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [31, 35]}, {"subject": "haloperidol", "sbj_char_span": [50, 61], "object": "NR2B", "obj_char_span": [165, 169], "rel_type": "inhibitor", "sbj_tok_span": [10, 13], "obj_tok_span": [34, 37], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [42, 45]}, {"subject": "haloperidol", "sbj_char_span": [50, 61], "object": "murine NR2A", "obj_char_span": [153, 164], "rel_type": "regulator", "sbj_tok_span": [10, 13], "obj_tok_span": [29, 33], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [31, 35]}, {"subject": "haloperidol", "sbj_char_span": [50, 61], "object": "NR2B", "obj_char_span": [165, 169], "rel_type": "regulator", "sbj_tok_span": [10, 13], "obj_tok_span": [34, 37], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [42, 45]}], "umls_entity_list": [{"mention": "haloperidol", "char_span": [50, 61], "sem_type": "Pharmacologic Substance", "tok_span": [10, 13], "new_tok_span": [11, 14]}, {"mention": "NR2A", "char_span": [160, 164], "sem_type": "Gene or Genome", "tok_span": [30, 33], "new_tok_span": [34, 37]}, {"mention": "NR2B", "char_span": [165, 169], "sem_type": "Gene or Genome", "tok_span": [34, 37], "new_tok_span": [42, 45]}, {"mention": "NR2B", "char_span": [165, 169], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 37], "new_tok_span": [42, 45]}, {"mention": "NR2A", "char_span": [160, 164], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 33], "new_tok_span": [34, 37]}], "new_text": "As seen for spermidine stimulation, high - affinity <START=Pharmacologic Substance> haloperidol <END=Pharmacologic Substance> inhibition is governed by the region around amino acid 198, based on results from chimeric murine <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NR2A <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NR2B <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( epislon1 / epsilon2 ) receptors."}, {"PMID": 23284002, "id": 5, "text": "Treatment with TSA and the Nrf2-ARE activator resulted in increased inhibition of the TGF-β-induced myofibroblast differentiation as compared with treatment with DPI or NAC. Furthermore, TSA also decreased cellular ROS and H(2)O(2) accumulation induced by TGF-β, whereas it elevated intracellular GSH level and cellular total antioxidant capacity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [162, 165], "name": "DPI", "tok_span": [32, 34], "new_tok_span": [36, 38]}, {"ent_type": "CHEMICAL", "char_span": [169, 172], "name": "NAC", "tok_span": [35, 36], "new_tok_span": [39, 40]}, {"ent_type": "CHEMICAL", "char_span": [187, 190], "name": "TSA", "tok_span": [39, 41], "new_tok_span": [45, 47]}, {"ent_type": "CHEMICAL", "char_span": [223, 231], "name": "H(2)O(2)", "tok_span": [46, 54], "new_tok_span": [54, 62]}, {"ent_type": "CHEMICAL", "char_span": [297, 300], "name": "GSH", "tok_span": [65, 66], "new_tok_span": [74, 75]}, {"ent_type": "CHEMICAL", "char_span": [15, 18], "name": "TSA", "tok_span": [2, 4], "new_tok_span": [4, 6]}, {"ent_type": "GENE", "char_span": [256, 261], "name": "TGF-β", "tok_span": [57, 60], "new_tok_span": [65, 68]}, {"ent_type": "GENE", "char_span": [27, 31], "name": "Nrf2", "tok_span": [6, 8], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [32, 35], "name": "ARE", "tok_span": [9, 10], "new_tok_span": [13, 14]}, {"ent_type": "GENE", "char_span": [86, 91], "name": "TGF-β", "tok_span": [17, 20], "new_tok_span": [21, 24]}], "relation_list": [{"subject": "TSA", "sbj_char_span": [15, 18], "object": "TGF-β", "obj_char_span": [86, 91], "rel_type": "inhibitor", "sbj_tok_span": [2, 4], "obj_tok_span": [17, 20], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [21, 24]}, {"subject": "TSA", "sbj_char_span": [187, 190], "object": "TGF-β", "obj_char_span": [256, 261], "rel_type": "inhibitor", "sbj_tok_span": [39, 41], "obj_tok_span": [57, 60], "new_sbj_tok_span": [45, 47], "new_obj_tok_span": [65, 68]}], "umls_entity_list": [{"mention": "TSA", "char_span": [15, 18], "sem_type": "Gene or Genome", "tok_span": [2, 4], "new_tok_span": [4, 6]}, {"mention": "TSA", "char_span": [187, 190], "sem_type": "Gene or Genome", "tok_span": [39, 41], "new_tok_span": [45, 47]}, {"mention": "TSA", "char_span": [15, 18], "sem_type": "Organic Chemical", "tok_span": [2, 4], "new_tok_span": [4, 6]}, {"mention": "TSA", "char_span": [187, 190], "sem_type": "Organic Chemical", "tok_span": [39, 41], "new_tok_span": [45, 47]}, {"mention": "GSH", "char_span": [297, 300], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [65, 66], "new_tok_span": [74, 75]}, {"mention": "antioxidant", "char_span": [326, 337], "sem_type": "Pharmacologic Substance", "tok_span": [70, 71], "new_tok_span": [81, 82]}], "new_text": "Treatment with <START=Gene or Genome> <START=Organic Chemical> TSA <END=Gene or Genome> <END=Organic Chemical> and the Nrf2 - ARE activator resulted in increased inhibition of the TGF - β - induced myofibroblast differentiation as compared with treatment with DPI or NAC. Furthermore, <START=Gene or Genome> <START=Organic Chemical> TSA <END=Gene or Genome> <END=Organic Chemical> also decreased cellular ROS and H ( 2 ) O ( 2 ) accumulation induced by TGF - β, whereas it elevated intracellular <START=Amino Acid, Peptide, or Protein> GSH <END=Amino Acid, Peptide, or Protein> level and cellular total <START=Pharmacologic Substance> antioxidant <END=Pharmacologic Substance> capacity."}, {"PMID": 23395003, "id": 0, "text": "Fbxl10/Kdm2b recruits polycomb repressive complex 1 to CpG islands and regulates H2A ubiquitylation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [55, 58], "name": "CpG", "tok_span": [18, 19], "new_tok_span": [28, 29]}, {"ent_type": "GENE", "char_span": [0, 6], "name": "Fbxl10", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "GENE", "char_span": [22, 51], "name": "polycomb repressive complex 1", "tok_span": [11, 17], "new_tok_span": [19, 25]}, {"ent_type": "GENE", "char_span": [7, 12], "name": "Kdm2b", "tok_span": [5, 9], "new_tok_span": [9, 13]}, {"ent_type": "GENE", "char_span": [81, 84], "name": "H2A", "tok_span": [22, 25], "new_tok_span": [34, 37]}], "relation_list": [{"subject": "CpG", "sbj_char_span": [55, 58], "object": "polycomb repressive complex 1", "obj_char_span": [22, 51], "rel_type": "regulator", "sbj_tok_span": [18, 19], "obj_tok_span": [11, 17], "new_sbj_tok_span": [28, 29], "new_obj_tok_span": [19, 25]}], "umls_entity_list": [{"mention": "Fbxl10", "char_span": [0, 6], "sem_type": "Gene or Genome", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "Kdm2b", "char_span": [7, 12], "sem_type": "Gene or Genome", "tok_span": [5, 9], "new_tok_span": [9, 13]}, {"mention": "polycomb repressive complex 1", "char_span": [22, 51], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 17], "new_tok_span": [19, 25]}, {"mention": "polycomb", "char_span": [22, 30], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 13], "new_tok_span": [19, 21]}, {"mention": "Kdm2b", "char_span": [7, 12], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 9], "new_tok_span": [9, 13]}, {"mention": "H2A", "char_span": [81, 84], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 25], "new_tok_span": [34, 37]}, {"mention": "H2A", "char_span": [81, 84], "sem_type": "Gene or Genome", "tok_span": [22, 25], "new_tok_span": [34, 37]}], "new_text": "<START=Gene or Genome> Fbxl10 <END=Gene or Genome> / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Kdm2b <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> recruits <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> polycomb <END=Amino Acid, Peptide, or Protein> repressive complex 1 <END=Amino Acid, Peptide, or Protein> to CpG islands and regulates <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> H2A <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ubiquitylation."}, {"PMID": 17369473, "id": 5, "text": "In summary, phenformin and metformin increase AMPK activity and phosphorylation in the isolated heart.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [12, 22], "name": "phenformin", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [27, 36], "name": "metformin", "tok_span": [6, 7], "new_tok_span": [7, 8]}, {"ent_type": "GENE", "char_span": [46, 50], "name": "AMPK", "tok_span": [8, 9], "new_tok_span": [10, 11]}], "relation_list": [{"subject": "phenformin", "sbj_char_span": [12, 22], "object": "AMPK", "obj_char_span": [46, 50], "rel_type": "activator", "sbj_tok_span": [3, 5], "obj_tok_span": [8, 9], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [10, 11]}, {"subject": "metformin", "sbj_char_span": [27, 36], "object": "AMPK", "obj_char_span": [46, 50], "rel_type": "activator", "sbj_tok_span": [6, 7], "obj_tok_span": [8, 9], "new_sbj_tok_span": [7, 8], "new_obj_tok_span": [10, 11]}], "umls_entity_list": [{"mention": "metformin", "char_span": [27, 36], "sem_type": "Pharmacologic Substance", "tok_span": [6, 7], "new_tok_span": [7, 8]}], "new_text": "In summary, phenformin and <START=Pharmacologic Substance> metformin <END=Pharmacologic Substance> increase AMPK activity and phosphorylation in the isolated heart."}, {"PMID": 23183186, "id": 9, "text": "Finally, the Pak1(-/-) mice exhibited reduced brainstem gcg level and abolished β-cat Ser675 phosphorylation in brain neurons after insulin treatment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [86, 89], "name": "Ser", "tok_span": [22, 23], "new_tok_span": [28, 29]}, {"ent_type": "GENE", "char_span": [13, 17], "name": "Pak1", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"ent_type": "GENE", "char_span": [80, 85], "name": "β-cat", "tok_span": [19, 22], "new_tok_span": [25, 28]}, {"ent_type": "GENE", "char_span": [132, 139], "name": "insulin", "tok_span": [30, 31], "new_tok_span": [36, 37]}], "relation_list": [{"subject": "Ser", "sbj_char_span": [86, 89], "object": "β-cat", "obj_char_span": [80, 85], "rel_type": "part of", "sbj_tok_span": [22, 23], "obj_tok_span": [19, 22], "new_sbj_tok_span": [28, 29], "new_obj_tok_span": [25, 28]}], "umls_entity_list": [{"mention": "Pak1", "char_span": [13, 17], "sem_type": "Gene or Genome", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"mention": "Pak1", "char_span": [13, 17], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"mention": "gcg", "char_span": [56, 59], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 16], "new_tok_span": [19, 21]}], "new_text": "Finally, the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Pak1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( - / - ) mice exhibited reduced brainstem <START=Amino Acid, Peptide, or Protein> gcg <END=Amino Acid, Peptide, or Protein> level and abolished β - cat Ser675 phosphorylation in brain neurons after insulin treatment."}, {"PMID": 11309248, "id": 4, "text": "Digoxin (10(-5) M) or digitoxin (10(-5) M), but not ouabain, decreased the expression of P450scc and steroidogenic acute regulatory (StAR) protein in rat granulosa cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 7], "name": "Digoxin", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "CHEMICAL", "char_span": [22, 31], "name": "digitoxin", "tok_span": [11, 13], "new_tok_span": [11, 13]}, {"ent_type": "GENE", "char_span": [89, 96], "name": "P450scc", "tok_span": [32, 36], "new_tok_span": [35, 39]}, {"ent_type": "GENE", "char_span": [101, 146], "name": "steroidogenic acute regulatory (StAR) protein", "tok_span": [37, 46], "new_tok_span": [41, 50]}], "relation_list": [{"subject": "Digoxin", "sbj_char_span": [0, 7], "object": "P450scc", "obj_char_span": [89, 96], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [32, 36], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [35, 39]}, {"subject": "digitoxin", "sbj_char_span": [22, 31], "object": "P450scc", "obj_char_span": [89, 96], "rel_type": "regulator", "sbj_tok_span": [11, 13], "obj_tok_span": [32, 36], "new_sbj_tok_span": [11, 13], "new_obj_tok_span": [35, 39]}, {"subject": "Digoxin", "sbj_char_span": [0, 7], "object": "steroidogenic acute regulatory (StAR) protein", "obj_char_span": [101, 146], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [37, 46], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [41, 50]}, {"subject": "digitoxin", "sbj_char_span": [22, 31], "object": "steroidogenic acute regulatory (StAR) protein", "obj_char_span": [101, 146], "rel_type": "regulator", "sbj_tok_span": [11, 13], "obj_tok_span": [37, 46], "new_sbj_tok_span": [11, 13], "new_obj_tok_span": [41, 50]}], "umls_entity_list": [{"mention": "ouabain", "char_span": [52, 59], "sem_type": "Pharmacologic Substance", "tok_span": [24, 27], "new_tok_span": [25, 28]}, {"mention": "P450scc", "char_span": [89, 96], "sem_type": "Gene or Genome", "tok_span": [32, 36], "new_tok_span": [35, 39]}], "new_text": "Digoxin ( 10 ( - 5 ) M ) or digitoxin ( 10 ( - 5 ) M ), but not <START=Pharmacologic Substance> ouabain <END=Pharmacologic Substance>, decreased the expression of <START=Gene or Genome> P450scc <END=Gene or Genome> and steroidogenic acute regulatory ( StAR ) protein in rat granulosa cells."}, {"PMID": 23381882, "id": 0, "text": "Mechanisms of Pharmacokinetic Enhancement Between Ritonavir and Saquinavir; Micro/Small Dosing Tests Using Midazolam (CYP3A4), Fexofenadine (p-Glycoprotein), and Pravastatin (OATP1B1) as Probe Drugs.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [107, 116], "name": "Midazolam", "tok_span": [23, 26], "new_tok_span": [27, 30]}, {"ent_type": "CHEMICAL", "char_span": [127, 139], "name": "Fexofenadine", "tok_span": [33, 38], "new_tok_span": [38, 43]}, {"ent_type": "CHEMICAL", "char_span": [162, 173], "name": "Pravastatin", "tok_span": [46, 50], "new_tok_span": [52, 56]}, {"ent_type": "CHEMICAL", "char_span": [50, 59], "name": "Ritonavir", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"ent_type": "CHEMICAL", "char_span": [64, 74], "name": "Saquinavir", "tok_span": [12, 15], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [118, 124], "name": "CYP3A4", "tok_span": [27, 31], "new_tok_span": [31, 35]}, {"ent_type": "GENE", "char_span": [141, 155], "name": "p-Glycoprotein", "tok_span": [39, 43], "new_tok_span": [45, 49]}, {"ent_type": "GENE", "char_span": [175, 182], "name": "OATP1B1", "tok_span": [51, 56], "new_tok_span": [57, 62]}], "relation_list": [{"subject": "Midazolam", "sbj_char_span": [107, 116], "object": "CYP3A4", "obj_char_span": [118, 124], "rel_type": "product or substrate", "sbj_tok_span": [23, 26], "obj_tok_span": [27, 31], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [31, 35]}, {"subject": "Fexofenadine", "sbj_char_span": [127, 139], "object": "p-Glycoprotein", "obj_char_span": [141, 155], "rel_type": "product or substrate", "sbj_tok_span": [33, 38], "obj_tok_span": [39, 43], "new_sbj_tok_span": [38, 43], "new_obj_tok_span": [45, 49]}, {"subject": "Pravastatin", "sbj_char_span": [162, 173], "object": "OATP1B1", "obj_char_span": [175, 182], "rel_type": "product or substrate", "sbj_tok_span": [46, 50], "obj_tok_span": [51, 56], "new_sbj_tok_span": [52, 56], "new_obj_tok_span": [57, 62]}], "umls_entity_list": [{"mention": "Ritonavir", "char_span": [50, 59], "sem_type": "Pharmacologic Substance", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"mention": "Saquinavir", "char_span": [64, 74], "sem_type": "Pharmacologic Substance", "tok_span": [12, 15], "new_tok_span": [15, 18]}, {"mention": "Fexofenadine", "char_span": [127, 139], "sem_type": "Pharmacologic Substance", "tok_span": [33, 38], "new_tok_span": [38, 43]}, {"mention": "Probe", "char_span": [187, 192], "sem_type": "Gene or Genome", "tok_span": [58, 60], "new_tok_span": [65, 67]}], "new_text": "Mechanisms of Pharmacokinetic Enhancement Between <START=Pharmacologic Substance> Ritonavir <END=Pharmacologic Substance> and <START=Pharmacologic Substance> Saquinavir <END=Pharmacologic Substance> ; Micro / Small Dosing Tests Using Midazolam ( CYP3A4 ), <START=Pharmacologic Substance> Fexofenadine <END=Pharmacologic Substance> ( p - Glycoprotein ), and Pravastatin ( OATP1B1 ) as <START=Gene or Genome> Probe <END=Gene or Genome> Drugs."}, {"PMID": 23519392, "id": 0, "text": "Pregnane X Receptor Mediates Dyslipidemia Induced by the HIV Protease Inhibitor Amprenavir in Mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "Pregnane", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"ent_type": "CHEMICAL", "char_span": [80, 90], "name": "Amprenavir", "tok_span": [18, 22], "new_tok_span": [25, 29]}, {"ent_type": "GENE", "char_span": [0, 19], "name": "Pregnane X Receptor", "tok_span": [0, 5], "new_tok_span": [2, 7]}, {"ent_type": "GENE", "char_span": [57, 69], "name": "HIV Protease", "tok_span": [13, 16], "new_tok_span": [18, 21]}], "relation_list": [{"subject": "Amprenavir", "sbj_char_span": [80, 90], "object": "HIV Protease", "obj_char_span": [57, 69], "rel_type": "inhibitor", "sbj_tok_span": [18, 22], "obj_tok_span": [13, 16], "new_sbj_tok_span": [25, 29], "new_obj_tok_span": [18, 21]}], "umls_entity_list": [{"mention": "Pregnane X Receptor", "char_span": [0, 19], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 5], "new_tok_span": [2, 7]}, {"mention": "Pregnane X Receptor", "char_span": [0, 19], "sem_type": "Gene or Genome", "tok_span": [0, 5], "new_tok_span": [2, 7]}, {"mention": "HIV Protease Inhibitor", "char_span": [57, 79], "sem_type": "Pharmacologic Substance", "tok_span": [13, 18], "new_tok_span": [18, 23]}, {"mention": "Amprenavir", "char_span": [80, 90], "sem_type": "Pharmacologic Substance", "tok_span": [18, 22], "new_tok_span": [25, 29]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Pregnane X Receptor <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> Mediates Dyslipidemia Induced by the <START=Pharmacologic Substance> HIV Protease Inhibitor <END=Pharmacologic Substance> <START=Pharmacologic Substance> Amprenavir <END=Pharmacologic Substance> in Mice."}, {"PMID": 22659088, "id": 4, "text": "Uncoupling from this channel was achieved by co-expression of an mGluR1 C-terminal protein designed to disrupt a previously described direct interaction between these two proteins, suggesting that this interaction allows incorporation of Ca(V2.1) into the mGluR1/Homer signaling complex, thereby preserving modulation in the presence of scaffolding Homer proteins.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [72, 73], "name": "C", "tok_span": [19, 20], "new_tok_span": [27, 28]}, {"ent_type": "CHEMICAL", "char_span": [238, 240], "name": "Ca", "tok_span": [43, 44], "new_tok_span": [53, 54]}, {"ent_type": "GENE", "char_span": [65, 71], "name": "mGluR1", "tok_span": [15, 19], "new_tok_span": [21, 25]}, {"ent_type": "GENE", "char_span": [238, 246], "name": "Ca(V2.1)", "tok_span": [43, 50], "new_tok_span": [53, 60]}, {"ent_type": "GENE", "char_span": [256, 262], "name": "mGluR1", "tok_span": [52, 56], "new_tok_span": [66, 70]}, {"ent_type": "GENE", "char_span": [263, 268], "name": "Homer", "tok_span": [57, 59], "new_tok_span": [75, 77]}, {"ent_type": "GENE", "char_span": [349, 363], "name": "Homer proteins", "tok_span": [71, 74], "new_tok_span": [95, 98]}], "relation_list": [{"subject": "C", "sbj_char_span": [72, 73], "object": "mGluR1", "obj_char_span": [65, 71], "rel_type": "part of", "sbj_tok_span": [19, 20], "obj_tok_span": [15, 19], "new_sbj_tok_span": [27, 28], "new_obj_tok_span": [21, 25]}], "umls_entity_list": [{"mention": "co", "char_span": [2, 4], "sem_type": "Gene or Genome", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"mention": "co", "char_span": [45, 47], "sem_type": "Gene or Genome", "tok_span": [10, 11], "new_tok_span": [13, 14]}, {"mention": "co", "char_span": [223, 225], "sem_type": "Gene or Genome", "tok_span": [41, 42], "new_tok_span": [50, 51]}, {"mention": "co", "char_span": [279, 281], "sem_type": "Gene or Genome", "tok_span": [60, 61], "new_tok_span": [81, 82]}, {"mention": "mGluR1", "char_span": [65, 71], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 19], "new_tok_span": [21, 25]}, {"mention": "mGluR1", "char_span": [256, 262], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [52, 56], "new_tok_span": [66, 70]}, {"mention": "mGluR1", "char_span": [65, 71], "sem_type": "Gene or Genome", "tok_span": [15, 19], "new_tok_span": [21, 25]}, {"mention": "mGluR1", "char_span": [256, 262], "sem_type": "Gene or Genome", "tok_span": [52, 56], "new_tok_span": [66, 70]}, {"mention": "V2", "char_span": [241, 243], "sem_type": "Gene or Genome", "tok_span": [45, 47], "new_tok_span": [56, 58]}, {"mention": "Homer", "char_span": [263, 268], "sem_type": "Gene or Genome", "tok_span": [57, 59], "new_tok_span": [75, 77]}, {"mention": "Homer", "char_span": [349, 354], "sem_type": "Gene or Genome", "tok_span": [71, 73], "new_tok_span": [95, 97]}, {"mention": "Homer", "char_span": [263, 268], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [57, 59], "new_tok_span": [75, 77]}, {"mention": "Homer", "char_span": [349, 354], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [71, 73], "new_tok_span": [95, 97]}], "new_text": "Un <START=Gene or Genome>co <END=Gene or Genome>upling from this channel was achieved by <START=Gene or Genome> co <END=Gene or Genome> - expression of an <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> mGluR1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> C - terminal protein designed to disrupt a previously described direct interaction between these two proteins, suggesting that this interaction allows <START=Gene or Genome> incorporation <END=Gene or Genome> of Ca ( <START=Gene or Genome> V2 <END=Gene or Genome>. 1 ) into the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> mGluR1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Homer <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> signaling <START=Gene or Genome> complex <END=Gene or Genome>, thereby preserving modulation in the presence of scaffolding <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Homer <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> proteins."}, {"PMID": 23453838, "id": 1, "text": "Activated organophosphate (OP) insecticides and chemical agents inhibit acetylcholinesterase (AChE) to form OP-AChE adducts.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [10, 25], "name": "organophosphate", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"ent_type": "GENE", "char_span": [111, 115], "name": "AChE", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"ent_type": "GENE", "char_span": [72, 92], "name": "acetylcholinesterase", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [94, 98], "name": "AChE", "tok_span": [17, 19], "new_tok_span": [21, 23]}], "relation_list": [{"subject": "organophosphate", "sbj_char_span": [10, 25], "object": "acetylcholinesterase", "obj_char_span": [72, 92], "rel_type": "inhibitor", "sbj_tok_span": [2, 4], "obj_tok_span": [13, 16], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [16, 19]}, {"subject": "organophosphate", "sbj_char_span": [10, 25], "object": "AChE", "obj_char_span": [94, 98], "rel_type": "inhibitor", "sbj_tok_span": [2, 4], "obj_tok_span": [17, 19], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [21, 23]}, {"subject": "organophosphate", "sbj_char_span": [10, 25], "object": "AChE", "obj_char_span": [111, 115], "rel_type": "regulator", "sbj_tok_span": [2, 4], "obj_tok_span": [24, 26], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [28, 30]}], "umls_entity_list": [{"mention": "organophosphate", "char_span": [10, 25], "sem_type": "Organic Chemical", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"mention": "acetylcholinesterase", "char_span": [72, 92], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 16], "new_tok_span": [16, 19]}], "new_text": "Activated <START=Organic Chemical> organophosphate <END=Organic Chemical> ( OP ) insecticides and chemical agents inhibit <START=Amino Acid, Peptide, or Protein> acetylcholinesterase <END=Amino Acid, Peptide, or Protein> ( AChE ) to form OP - AChE adducts."}, {"PMID": 12477282, "id": 6, "text": "Experimental manipulation of the intracellular GSSG concentration during inhibition of cellular prooxidant production demonstrated that increased intracellular GSSG is a primary signal that is directly or indirectly required for CpG-induced NF-kappaB activation but is not in itself sufficient to trigger this in the absence of CpG ODN. These data suggest the existence of a second CpG-induced intracellular signal, independent of GSSG, mediating the activation of innate immunity by bacterial DNA.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [47, 51], "name": "GSSG", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"ent_type": "CHEMICAL", "char_span": [160, 164], "name": "GSSG", "tok_span": [19, 21], "new_tok_span": [22, 24]}, {"ent_type": "CHEMICAL", "char_span": [431, 435], "name": "GSSG", "tok_span": [73, 75], "new_tok_span": [78, 80]}, {"ent_type": "GENE", "char_span": [241, 250], "name": "NF-kappaB", "tok_span": [35, 39], "new_tok_span": [39, 43]}], "relation_list": [{"subject": "GSSG", "sbj_char_span": [160, 164], "object": "NF-kappaB", "obj_char_span": [241, 250], "rel_type": "activator", "sbj_tok_span": [19, 21], "obj_tok_span": [35, 39], "new_sbj_tok_span": [22, 24], "new_obj_tok_span": [39, 43]}], "umls_entity_list": [{"mention": "GSSG", "char_span": [47, 51], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"mention": "GSSG", "char_span": [160, 164], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 21], "new_tok_span": [22, 24]}, {"mention": "GSSG", "char_span": [431, 435], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [73, 75], "new_tok_span": [78, 80]}], "new_text": "Experimental manipulation of the intracellular <START=Amino Acid, Peptide, or Protein> GSSG <END=Amino Acid, Peptide, or Protein> concentration during inhibition of cellular prooxidant production demonstrated that increased intracellular <START=Amino Acid, Peptide, or Protein> GSSG <END=Amino Acid, Peptide, or Protein> is a primary signal that is directly or indirectly required for CpG - induced NF - kappaB activation but is not in itself sufficient to trigger this in the absence of CpG ODN. These data suggest the existence of a second CpG - induced intracellular signal, independent of <START=Amino Acid, Peptide, or Protein> GSSG <END=Amino Acid, Peptide, or Protein>, mediating the activation of innate immunity by bacterial DNA."}, {"PMID": 16735460, "id": 0, "text": "Functional roles of cationic amino acid residues in the sodium-dicarboxylate cotransporter 3 (NaDC-3) from winter flounder.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [29, 39], "name": "amino acid", "tok_span": [4, 6], "new_tok_span": [4, 6]}, {"ent_type": "CHEMICAL", "char_span": [56, 76], "name": "sodium-dicarboxylate", "tok_span": [9, 14], "new_tok_span": [10, 15]}, {"ent_type": "GENE", "char_span": [56, 92], "name": "sodium-dicarboxylate cotransporter 3", "tok_span": [9, 17], "new_tok_span": [10, 18]}, {"ent_type": "GENE", "char_span": [94, 100], "name": "NaDC-3", "tok_span": [18, 22], "new_tok_span": [23, 27]}], "relation_list": [{"subject": "amino acid", "sbj_char_span": [29, 39], "object": "sodium-dicarboxylate cotransporter 3", "obj_char_span": [56, 92], "rel_type": "part of", "sbj_tok_span": [4, 6], "obj_tok_span": [9, 17], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [10, 18]}, {"subject": "amino acid", "sbj_char_span": [29, 39], "object": "NaDC-3", "obj_char_span": [94, 100], "rel_type": "part of", "sbj_tok_span": [4, 6], "obj_tok_span": [18, 22], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [23, 27]}], "umls_entity_list": [{"mention": "dicarboxylate", "char_span": [63, 76], "sem_type": "Organic Chemical", "tok_span": [11, 14], "new_tok_span": [14, 17]}, {"mention": "sodium", "char_span": [56, 62], "sem_type": "Pharmacologic Substance", "tok_span": [9, 10], "new_tok_span": [10, 11]}, {"mention": "NaDC", "char_span": [94, 98], "sem_type": "Organic Chemical", "tok_span": [18, 20], "new_tok_span": [23, 25]}], "new_text": "Functional roles of cationic amino acid residues in the <START=Pharmacologic Substance> sodium <END=Pharmacologic Substance> - <START=Organic Chemical> dicarboxylate <END=Organic Chemical> cotransporter 3 ( <START=Organic Chemical> NaDC <END=Organic Chemical> - 3 ) from winter flounder."}, {"PMID": 2521824, "id": 7, "text": "In addition to effects on cell proliferation, DHT increased the percentage of alkaline phosphatase (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [46, 49], "name": "DHT", "tok_span": [8, 10], "new_tok_span": [8, 10]}, {"ent_type": "GENE", "char_span": [78, 98], "name": "alkaline phosphatase", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [100, 103], "name": "ALP", "tok_span": [17, 18], "new_tok_span": [21, 22]}], "relation_list": [{"subject": "DHT", "sbj_char_span": [46, 49], "object": "alkaline phosphatase", "obj_char_span": [78, 98], "rel_type": "regulator", "sbj_tok_span": [8, 10], "obj_tok_span": [14, 16], "new_sbj_tok_span": [8, 10], "new_obj_tok_span": [16, 18]}, {"subject": "DHT", "sbj_char_span": [46, 49], "object": "ALP", "obj_char_span": [100, 103], "rel_type": "regulator", "sbj_tok_span": [8, 10], "obj_tok_span": [17, 18], "new_sbj_tok_span": [8, 10], "new_obj_tok_span": [21, 22]}], "umls_entity_list": [{"mention": "alkaline phosphatase", "char_span": [78, 98], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"mention": "alkaline phosphatase", "char_span": [78, 98], "sem_type": "Organic Chemical", "tok_span": [14, 16], "new_tok_span": [16, 18]}], "new_text": "In addition to effects on cell proliferation, DHT increased the percentage of <START=Amino Acid, Peptide, or Protein> <START=Organic Chemical> alkaline phosphatase <END=Amino Acid, Peptide, or Protein> <END=Organic Chemical> ( ALP ) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens."}, {"PMID": 2125244, "id": 1, "text": "The concentration of estramustine phosphate required to inhibit the assembly or to induce the disassembly of chick brain MAP2:tubulin microtubules is markedly dependent upon the microtubule protein concentration.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [21, 43], "name": "estramustine phosphate", "tok_span": [3, 8], "new_tok_span": [4, 9]}, {"ent_type": "GENE", "char_span": [109, 125], "name": "chick brain MAP2", "tok_span": [20, 24], "new_tok_span": [22, 26]}, {"ent_type": "GENE", "char_span": [126, 133], "name": "tubulin", "tok_span": [25, 26], "new_tok_span": [29, 30]}], "relation_list": [{"subject": "estramustine phosphate", "sbj_char_span": [21, 43], "object": "chick brain MAP2", "obj_char_span": [109, 125], "rel_type": "inhibitor", "sbj_tok_span": [3, 8], "obj_tok_span": [20, 24], "new_sbj_tok_span": [4, 9], "new_obj_tok_span": [22, 26]}, {"subject": "estramustine phosphate", "sbj_char_span": [21, 43], "object": "chick brain MAP2", "obj_char_span": [109, 125], "rel_type": "activator", "sbj_tok_span": [3, 8], "obj_tok_span": [20, 24], "new_sbj_tok_span": [4, 9], "new_obj_tok_span": [22, 26]}, {"subject": "estramustine phosphate", "sbj_char_span": [21, 43], "object": "tubulin", "obj_char_span": [126, 133], "rel_type": "activator", "sbj_tok_span": [3, 8], "obj_tok_span": [25, 26], "new_sbj_tok_span": [4, 9], "new_obj_tok_span": [29, 30]}, {"subject": "estramustine phosphate", "sbj_char_span": [21, 43], "object": "tubulin", "obj_char_span": [126, 133], "rel_type": "inhibitor", "sbj_tok_span": [3, 8], "obj_tok_span": [25, 26], "new_sbj_tok_span": [4, 9], "new_obj_tok_span": [29, 30]}], "umls_entity_list": [{"mention": "estramustine phosphate", "char_span": [21, 43], "sem_type": "Pharmacologic Substance", "tok_span": [3, 8], "new_tok_span": [4, 9]}, {"mention": "MAP2", "char_span": [121, 125], "sem_type": "Gene or Genome", "tok_span": [22, 24], "new_tok_span": [25, 27]}], "new_text": "The concentration of <START=Pharmacologic Substance> estramustine phosphate <END=Pharmacologic Substance> required to inhibit the assembly or to induce the disassembly of chick brain <START=Gene or Genome> MAP2 <END=Gene or Genome> : tubulin microtubules is markedly dependent upon the microtubule protein concentration."}, {"PMID": 2833901, "id": 7, "text": "Felodipine and the p-chloro analogue inhibited Ca2+/calmodulin-dependent caldesmon kinase with similar potencies (IC50 = 17.4 microM), whereas the oxidized and t-butyl analogues caused no inhibition.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [47, 51], "name": "Ca2+", "tok_span": [11, 14], "new_tok_span": [11, 14]}, {"ent_type": "CHEMICAL", "char_span": [160, 167], "name": "t-butyl", "tok_span": [43, 47], "new_tok_span": [45, 49]}, {"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Felodipine", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [19, 27], "name": "p-chloro", "tok_span": [5, 9], "new_tok_span": [5, 9]}, {"ent_type": "GENE", "char_span": [52, 62], "name": "calmodulin", "tok_span": [15, 18], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [73, 89], "name": "caldesmon kinase", "tok_span": [20, 24], "new_tok_span": [21, 25]}], "relation_list": [{"subject": "Felodipine", "sbj_char_span": [0, 10], "object": "caldesmon kinase", "obj_char_span": [73, 89], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [20, 24], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [21, 25]}, {"subject": "p-chloro", "sbj_char_span": [19, 27], "object": "caldesmon kinase", "obj_char_span": [73, 89], "rel_type": "inhibitor", "sbj_tok_span": [5, 9], "obj_tok_span": [20, 24], "new_sbj_tok_span": [5, 9], "new_obj_tok_span": [21, 25]}], "umls_entity_list": [{"mention": "caldesmon kinase", "char_span": [73, 89], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 24], "new_tok_span": [21, 25]}], "new_text": "Felodipine and the p - chloro analogue inhibited Ca2 + / calmodulin - dependent <START=Amino Acid, Peptide, or Protein> caldesmon kinase <END=Amino Acid, Peptide, or Protein> with similar potencies ( IC50 = 17. 4 microM ), whereas the oxidized and t - butyl analogues caused no inhibition."}, {"PMID": 17355872, "id": 4, "text": "To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of SIRT5, one in complex with ADP-ribose, the other bound to suramin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [139, 142], "name": "ADP", "tok_span": [27, 28], "new_tok_span": [31, 32]}, {"ent_type": "CHEMICAL", "char_span": [170, 177], "name": "suramin", "tok_span": [36, 38], "new_tok_span": [40, 42]}, {"ent_type": "GENE", "char_span": [112, 117], "name": "SIRT5", "tok_span": [20, 22], "new_tok_span": [23, 25]}], "relation_list": [{"subject": "ADP", "sbj_char_span": [139, 142], "object": "SIRT5", "obj_char_span": [112, 117], "rel_type": "regulator", "sbj_tok_span": [27, 28], "obj_tok_span": [20, 22], "new_sbj_tok_span": [31, 32], "new_obj_tok_span": [23, 25]}, {"subject": "suramin", "sbj_char_span": [170, 177], "object": "SIRT5", "obj_char_span": [112, 117], "rel_type": "regulator", "sbj_tok_span": [36, 38], "obj_tok_span": [20, 22], "new_sbj_tok_span": [40, 42], "new_obj_tok_span": [23, 25]}], "umls_entity_list": [{"mention": "sirtuin", "char_span": [29, 36], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"mention": "SIRT5", "char_span": [112, 117], "sem_type": "Gene or Genome", "tok_span": [20, 22], "new_tok_span": [23, 25]}], "new_text": "To provide insights into how <START=Amino Acid, Peptide, or Protein> sirtuin <END=Amino Acid, Peptide, or Protein> function is altered by inhibitors, we determined two crystal structures of <START=Gene or Genome> SIRT5 <END=Gene or Genome>, one in complex with ADP - ribose, the other bound to suramin."}, {"PMID": 23623843, "id": 4, "text": "Administration of KBTP (200, 400 and 800mg/kgbw) in mice ahead of CCl4 injection could observably antagonize the CCl4-induced increases in serum ALT, AST, TG and TC, and the hepatic MDA and 8-iso-PGF2a levels, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [66, 70], "name": "CCl4", "tok_span": [20, 23], "new_tok_span": [21, 24]}, {"ent_type": "CHEMICAL", "char_span": [113, 117], "name": "CCl4", "tok_span": [30, 33], "new_tok_span": [33, 36]}, {"ent_type": "CHEMICAL", "char_span": [182, 185], "name": "MDA", "tok_span": [49, 50], "new_tok_span": [53, 54]}, {"ent_type": "CHEMICAL", "char_span": [190, 201], "name": "8-iso-PGF2a", "tok_span": [51, 59], "new_tok_span": [55, 63]}, {"ent_type": "GENE", "char_span": [145, 148], "name": "ALT", "tok_span": [38, 39], "new_tok_span": [42, 43]}, {"ent_type": "GENE", "char_span": [150, 153], "name": "AST", "tok_span": [40, 41], "new_tok_span": [44, 45]}], "relation_list": [{"subject": "CCl4", "sbj_char_span": [113, 117], "object": "ALT", "obj_char_span": [145, 148], "rel_type": "regulator", "sbj_tok_span": [30, 33], "obj_tok_span": [38, 39], "new_sbj_tok_span": [33, 36], "new_obj_tok_span": [42, 43]}, {"subject": "CCl4", "sbj_char_span": [113, 117], "object": "AST", "obj_char_span": [150, 153], "rel_type": "regulator", "sbj_tok_span": [30, 33], "obj_tok_span": [40, 41], "new_sbj_tok_span": [33, 36], "new_obj_tok_span": [44, 45]}], "umls_entity_list": [{"mention": "CCl4", "char_span": [66, 70], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 23], "new_tok_span": [21, 24]}, {"mention": "CCl4", "char_span": [113, 117], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 33], "new_tok_span": [33, 36]}], "new_text": "Administration of KBTP ( 200, 400 and 800mg / kgbw ) in mice ahead of <START=Amino Acid, Peptide, or Protein> CCl4 <END=Amino Acid, Peptide, or Protein> injection could observably antagonize the <START=Amino Acid, Peptide, or Protein> CCl4 <END=Amino Acid, Peptide, or Protein> - induced increases in serum ALT, AST, TG and TC, and the hepatic MDA and 8 - iso - PGF2a levels, respectively."}, {"PMID": 2877081, "id": 0, "text": "Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [11, 21], "name": "nizatidine", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [35, 44], "name": "histamine", "tok_span": [9, 10], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [35, 56], "name": "histamine H2-receptor", "tok_span": [9, 14], "new_tok_span": [11, 16]}], "relation_list": [{"subject": "nizatidine", "sbj_char_span": [11, 21], "object": "histamine H2-receptor", "obj_char_span": [35, 56], "rel_type": "agonist or antagonist", "sbj_tok_span": [3, 6], "obj_tok_span": [9, 14], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [11, 16]}], "umls_entity_list": [{"mention": "nizatidine", "char_span": [11, 21], "sem_type": "Pharmacologic Substance", "tok_span": [3, 6], "new_tok_span": [4, 7]}], "new_text": "Actions of <START=Pharmacologic Substance> nizatidine <END=Pharmacologic Substance>, a selective histamine H2 - receptor antagonist, on gastric acid secretion in dogs, rats and frogs."}, {"PMID": 11785774, "id": 2, "text": "COX-1 and COX-2 inhibitor, piroxicam (0.02 and 0.2 microg) and compound NS-398 (0.01 and 0.1 microg), respectively, were given intracerebroventricularly (i.c.v.) 15 min prior to i.c.v. adrenergic receptor agonists: phenylephrine (30 microg) and clonidine (10 microg), an alpha1- and alpha2-adrenergic agonist, and isoprenaline (20 microg) a non-selective beta-adrenergic agonist and clenbuterol (10 microg) a selective beta2-adrenergic agonist.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [27, 36], "name": "piroxicam", "tok_span": [9, 13], "new_tok_span": [9, 13]}, {"ent_type": "CHEMICAL", "char_span": [72, 78], "name": "NS-398", "tok_span": [26, 30], "new_tok_span": [26, 30]}, {"ent_type": "CHEMICAL", "char_span": [215, 228], "name": "phenylephrine", "tok_span": [76, 79], "new_tok_span": [76, 79]}, {"ent_type": "CHEMICAL", "char_span": [245, 254], "name": "clonidine", "tok_span": [85, 87], "new_tok_span": [85, 87]}, {"ent_type": "CHEMICAL", "char_span": [314, 326], "name": "isoprenaline", "tok_span": [106, 109], "new_tok_span": [106, 109]}, {"ent_type": "CHEMICAL", "char_span": [383, 394], "name": "clenbuterol", "tok_span": [124, 129], "new_tok_span": [126, 131]}, {"ent_type": "GENE", "char_span": [0, 5], "name": "COX-1", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "GENE", "char_span": [10, 15], "name": "COX-2", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [185, 204], "name": "adrenergic receptor", "tok_span": [71, 74], "new_tok_span": [71, 74]}], "relation_list": [{"subject": "piroxicam", "sbj_char_span": [27, 36], "object": "COX-1", "obj_char_span": [0, 5], "rel_type": "inhibitor", "sbj_tok_span": [9, 13], "obj_tok_span": [0, 3], "new_sbj_tok_span": [9, 13], "new_obj_tok_span": [0, 3]}, {"subject": "piroxicam", "sbj_char_span": [27, 36], "object": "COX-2", "obj_char_span": [10, 15], "rel_type": "inhibitor", "sbj_tok_span": [9, 13], "obj_tok_span": [4, 7], "new_sbj_tok_span": [9, 13], "new_obj_tok_span": [4, 7]}, {"subject": "phenylephrine", "sbj_char_span": [215, 228], "object": "adrenergic receptor", "obj_char_span": [185, 204], "rel_type": "agonist or antagonist", "sbj_tok_span": [76, 79], "obj_tok_span": [71, 74], "new_sbj_tok_span": [76, 79], "new_obj_tok_span": [71, 74]}, {"subject": "clonidine", "sbj_char_span": [245, 254], "object": "adrenergic receptor", "obj_char_span": [185, 204], "rel_type": "agonist or antagonist", "sbj_tok_span": [85, 87], "obj_tok_span": [71, 74], "new_sbj_tok_span": [85, 87], "new_obj_tok_span": [71, 74]}, {"subject": "isoprenaline", "sbj_char_span": [314, 326], "object": "adrenergic receptor", "obj_char_span": [185, 204], "rel_type": "agonist or antagonist", "sbj_tok_span": [106, 109], "obj_tok_span": [71, 74], "new_sbj_tok_span": [106, 109], "new_obj_tok_span": [71, 74]}, {"subject": "clenbuterol", "sbj_char_span": [383, 394], "object": "adrenergic receptor", "obj_char_span": [185, 204], "rel_type": "agonist or antagonist", "sbj_tok_span": [124, 129], "obj_tok_span": [71, 74], "new_sbj_tok_span": [126, 131], "new_obj_tok_span": [71, 74]}], "umls_entity_list": [{"mention": "beta-adrenergic agonist", "char_span": [355, 378], "sem_type": "Pharmacologic Substance", "tok_span": [118, 123], "new_tok_span": [119, 124]}, {"mention": "beta2-adrenergic agonist", "char_span": [419, 443], "sem_type": "Pharmacologic Substance", "tok_span": [136, 142], "new_tok_span": [139, 145]}], "new_text": "COX - 1 and COX - 2 inhibitor, piroxicam ( 0. 02 and 0. 2 microg ) and compound NS - 398 ( 0. 01 and 0. 1 microg ), respectively, were given intracerebroventricularly ( i. c. v. ) 15 min prior to i. c. v. adrenergic receptor agonists : phenylephrine ( 30 microg ) and clonidine ( 10 microg ), an alpha1 - and alpha2 - adrenergic agonist, and isoprenaline ( 20 microg ) a non - selective <START=Pharmacologic Substance> beta - adrenergic agonist <END=Pharmacologic Substance> and clenbuterol ( 10 microg ) a selective <START=Pharmacologic Substance> beta2 - adrenergic agonist <END=Pharmacologic Substance>."}, {"PMID": 23261865, "id": 4, "text": "Selective antagonism of A(2A) adenosine receptors by ZM241385 significantly prevents or delays the appearance of AD and protects from the irreversible block of neurotransmission induced by 9-min OGD in the DG. The effects of 9-min OGD on proliferation and maturation of cells localized in the subgranular zone of DG in slices prepared from 5-bromo-2'-deoxyuridine (BrdU) treated rats was investigated.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [340, 363], "name": "5-bromo-2'-deoxyuridine", "tok_span": [72, 84], "new_tok_span": [78, 90]}, {"ent_type": "CHEMICAL", "char_span": [365, 369], "name": "BrdU", "tok_span": [85, 86], "new_tok_span": [91, 92]}, {"ent_type": "CHEMICAL", "char_span": [30, 39], "name": "adenosine", "tok_span": [9, 10], "new_tok_span": [9, 10]}, {"ent_type": "CHEMICAL", "char_span": [53, 61], "name": "ZM241385", "tok_span": [12, 17], "new_tok_span": [13, 18]}, {"ent_type": "GENE", "char_span": [24, 49], "name": "A(2A) adenosine receptors", "tok_span": [4, 11], "new_tok_span": [4, 11]}], "relation_list": [{"subject": "ZM241385", "sbj_char_span": [53, 61], "object": "A(2A) adenosine receptors", "obj_char_span": [24, 49], "rel_type": "agonist or antagonist", "sbj_tok_span": [12, 17], "obj_tok_span": [4, 11], "new_sbj_tok_span": [13, 18], "new_obj_tok_span": [4, 11]}], "umls_entity_list": [{"mention": "ZM241385", "char_span": [53, 61], "sem_type": "Organic Chemical", "tok_span": [12, 17], "new_tok_span": [13, 18]}, {"mention": "OGD", "char_span": [195, 198], "sem_type": "Gene or Genome", "tok_span": [39, 41], "new_tok_span": [42, 44]}, {"mention": "OGD", "char_span": [231, 234], "sem_type": "Gene or Genome", "tok_span": [51, 53], "new_tok_span": [56, 58]}], "new_text": "Selective antagonism of A ( 2A ) adenosine receptors by <START=Organic Chemical> ZM241385 <END=Organic Chemical> significantly prevents or delays the appearance of AD and protects from the irreversible block of neurotransmission induced by 9 - min <START=Gene or Genome> OGD <END=Gene or Genome> in the DG. The effects of 9 - min <START=Gene or Genome> OGD <END=Gene or Genome> on proliferation and maturation of cells localized in the subgranular zone of DG in slices prepared from 5 - bromo - 2'- deoxyuridine ( BrdU ) treated rats was investigated."}, {"PMID": 7994588, "id": 3, "text": "For this purpose, we used hydroxy methyl glutaryl Coenzyme A (HMG-CoA) reductase inhibitors such as lovastatin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [26, 60], "name": "hydroxy methyl glutaryl Coenzyme A", "tok_span": [6, 13], "new_tok_span": [6, 13]}, {"ent_type": "CHEMICAL", "char_span": [62, 69], "name": "HMG-CoA", "tok_span": [14, 19], "new_tok_span": [14, 19]}, {"ent_type": "CHEMICAL", "char_span": [100, 110], "name": "lovastatin", "tok_span": [24, 26], "new_tok_span": [25, 27]}, {"ent_type": "GENE", "char_span": [26, 80], "name": "hydroxy methyl glutaryl Coenzyme A (HMG-CoA) reductase", "tok_span": [6, 21], "new_tok_span": [6, 21]}], "relation_list": [{"subject": "lovastatin", "sbj_char_span": [100, 110], "object": "hydroxy methyl glutaryl Coenzyme A (HMG-CoA) reductase", "obj_char_span": [26, 80], "rel_type": "inhibitor", "sbj_tok_span": [24, 26], "obj_tok_span": [6, 21], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [6, 21]}], "umls_entity_list": [{"mention": "lovastatin", "char_span": [100, 110], "sem_type": "Pharmacologic Substance", "tok_span": [24, 26], "new_tok_span": [25, 27]}], "new_text": "For this purpose, we used hydroxy methyl glutaryl Coenzyme A ( HMG - CoA ) reductase inhibitors such as <START=Pharmacologic Substance> lovastatin <END=Pharmacologic Substance>."}, {"PMID": 11980628, "id": 10, "text": "Furthermore, in rats SOM230 demonstrated a much higher efficacy in lowering plasma insulin-like growth factor-I (IGF-I) levels compared with SMS 201-995.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [21, 27], "name": "SOM230", "tok_span": [4, 7], "new_tok_span": [5, 8]}, {"ent_type": "CHEMICAL", "char_span": [141, 152], "name": "SMS 201-995", "tok_span": [30, 35], "new_tok_span": [32, 37]}, {"ent_type": "GENE", "char_span": [83, 111], "name": "insulin-like growth factor-I", "tok_span": [15, 22], "new_tok_span": [17, 24]}, {"ent_type": "GENE", "char_span": [113, 118], "name": "IGF-I", "tok_span": [23, 26], "new_tok_span": [25, 28]}], "relation_list": [{"subject": "SOM230", "sbj_char_span": [21, 27], "object": "insulin-like growth factor-I", "obj_char_span": [83, 111], "rel_type": "regulator", "sbj_tok_span": [4, 7], "obj_tok_span": [15, 22], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [17, 24]}, {"subject": "SOM230", "sbj_char_span": [21, 27], "object": "IGF-I", "obj_char_span": [113, 118], "rel_type": "regulator", "sbj_tok_span": [4, 7], "obj_tok_span": [23, 26], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [25, 28]}], "umls_entity_list": [{"mention": "SOM230", "char_span": [21, 27], "sem_type": "Organic Chemical", "tok_span": [4, 7], "new_tok_span": [5, 8]}], "new_text": "Furthermore, in rats <START=Organic Chemical> SOM230 <END=Organic Chemical> demonstrated a much higher efficacy in lowering plasma insulin - like growth factor - I ( IGF - I ) levels compared with SMS 201 - 995."}, {"PMID": 17545671, "id": 6, "text": "RORalpha ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by rosiglitazone treatment of adipocytes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [82, 95], "name": "rosiglitazone", "tok_span": [17, 22], "new_tok_span": [18, 23]}, {"ent_type": "CHEMICAL", "char_span": [165, 178], "name": "rosiglitazone", "tok_span": [38, 43], "new_tok_span": [41, 46]}, {"ent_type": "GENE", "char_span": [0, 8], "name": "RORalpha", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "GENE", "char_span": [42, 48], "name": "cAspAT", "tok_span": [8, 12], "new_tok_span": [8, 12]}], "relation_list": [{"subject": "rosiglitazone", "sbj_char_span": [165, 178], "object": "RORalpha", "obj_char_span": [0, 8], "rel_type": "regulator", "sbj_tok_span": [38, 43], "obj_tok_span": [0, 4], "new_sbj_tok_span": [41, 46], "new_obj_tok_span": [0, 4]}, {"subject": "rosiglitazone", "sbj_char_span": [165, 178], "object": "cAspAT", "obj_char_span": [42, 48], "rel_type": "regulator", "sbj_tok_span": [38, 43], "obj_tok_span": [8, 12], "new_sbj_tok_span": [41, 46], "new_obj_tok_span": [8, 12]}], "umls_entity_list": [{"mention": "rosiglitazone", "char_span": [82, 95], "sem_type": "Pharmacologic Substance", "tok_span": [17, 22], "new_tok_span": [18, 23]}, {"mention": "rosiglitazone", "char_span": [165, 178], "sem_type": "Pharmacologic Substance", "tok_span": [38, 43], "new_tok_span": [41, 46]}], "new_text": "RORalpha ectopic expression activated the cAspAT gene transcription in absence of <START=Pharmacologic Substance> rosiglitazone <END=Pharmacologic Substance>, and its protein amount in nuclear extracts is 1. 8 - fold increased by <START=Pharmacologic Substance> rosiglitazone <END=Pharmacologic Substance> treatment of adipocytes."}, {"PMID": 15991886, "id": 1, "text": "Lubiprostone [RU 0211, SPI 0211] is a bicyclic fatty acid that acts as a chloride channel opener, increasing intestinal water secretion.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Lubiprostone", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [14, 21], "name": "RU 0211", "tok_span": [5, 8], "new_tok_span": [8, 11]}, {"ent_type": "CHEMICAL", "char_span": [23, 31], "name": "SPI 0211", "tok_span": [9, 13], "new_tok_span": [14, 18]}, {"ent_type": "CHEMICAL", "char_span": [38, 57], "name": "bicyclic fatty acid", "tok_span": [16, 20], "new_tok_span": [23, 27]}, {"ent_type": "CHEMICAL", "char_span": [73, 81], "name": "chloride", "tok_span": [24, 25], "new_tok_span": [32, 33]}, {"ent_type": "GENE", "char_span": [73, 89], "name": "chloride channel", "tok_span": [24, 26], "new_tok_span": [32, 34]}], "relation_list": [{"subject": "Lubiprostone", "sbj_char_span": [0, 12], "object": "chloride channel", "obj_char_span": [73, 89], "rel_type": "activator", "sbj_tok_span": [0, 4], "obj_tok_span": [24, 26], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [32, 34]}, {"subject": "RU 0211", "sbj_char_span": [14, 21], "object": "chloride channel", "obj_char_span": [73, 89], "rel_type": "activator", "sbj_tok_span": [5, 8], "obj_tok_span": [24, 26], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [32, 34]}, {"subject": "SPI 0211", "sbj_char_span": [23, 31], "object": "chloride channel", "obj_char_span": [73, 89], "rel_type": "activator", "sbj_tok_span": [9, 13], "obj_tok_span": [24, 26], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [32, 34]}, {"subject": "bicyclic fatty acid", "sbj_char_span": [38, 57], "object": "chloride channel", "obj_char_span": [73, 89], "rel_type": "activator", "sbj_tok_span": [16, 20], "obj_tok_span": [24, 26], "new_sbj_tok_span": [23, 27], "new_obj_tok_span": [32, 34]}], "umls_entity_list": [{"mention": "Lubiprostone", "char_span": [0, 12], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "RU", "char_span": [14, 16], "sem_type": "Pharmacologic Substance", "tok_span": [5, 6], "new_tok_span": [8, 9]}, {"mention": "SPI", "char_span": [23, 26], "sem_type": "Pharmacologic Substance", "tok_span": [9, 11], "new_tok_span": [14, 16]}, {"mention": "bicyclic", "char_span": [38, 46], "sem_type": "Organic Chemical", "tok_span": [16, 18], "new_tok_span": [23, 25]}], "new_text": "<START=Pharmacologic Substance> Lubiprostone <END=Pharmacologic Substance> [ <START=Pharmacologic Substance> RU <END=Pharmacologic Substance> 0211, <START=Pharmacologic Substance> SPI <END=Pharmacologic Substance> 0211 ] is a <START=Organic Chemical> bicyclic <END=Organic Chemical> fatty acid that acts as a chloride channel opener, increasing intestinal water secretion."}, {"PMID": 1687367, "id": 8, "text": "At beta 1-adrenoceptors, the affinity of the compound RR-SR was about 3 times that of labetalol.5.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [86, 95], "name": "labetalol", "tok_span": [23, 26], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [3, 23], "name": "beta 1-adrenoceptors", "tok_span": [1, 8], "new_tok_span": [1, 8]}], "relation_list": [{"subject": "labetalol", "sbj_char_span": [86, 95], "object": "beta 1-adrenoceptors", "obj_char_span": [3, 23], "rel_type": "regulator", "sbj_tok_span": [23, 26], "obj_tok_span": [1, 8], "new_sbj_tok_span": [28, 31], "new_obj_tok_span": [1, 8]}], "umls_entity_list": [{"mention": "SR", "char_span": [57, 59], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"mention": "SR", "char_span": [57, 59], "sem_type": "Gene or Genome", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"mention": "labetalol", "char_span": [86, 95], "sem_type": "Pharmacologic Substance", "tok_span": [23, 26], "new_tok_span": [28, 31]}], "new_text": "At beta 1 - adrenoceptors, the affinity of the compound RR - <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> SR <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> was about 3 times that of <START=Pharmacologic Substance> labetalol <END=Pharmacologic Substance>. 5."}, {"PMID": 23542815, "id": 7, "text": "Finally, pretreatment with LY364947, an inhibitor of TGF-β signaling could apparently reverse these changes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [27, 35], "name": "LY364947", "tok_span": [4, 8], "new_tok_span": [4, 8]}, {"ent_type": "GENE", "char_span": [53, 58], "name": "TGF-β", "tok_span": [12, 15], "new_tok_span": [12, 15]}], "relation_list": [{"subject": "LY364947", "sbj_char_span": [27, 35], "object": "TGF-β", "obj_char_span": [53, 58], "rel_type": "regulator", "sbj_tok_span": [4, 8], "obj_tok_span": [12, 15], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [12, 15]}], "umls_entity_list": [], "new_text": "Finally, pretreatment with LY364947, an inhibitor of TGF - β signaling could apparently reverse these changes."}, {"PMID": 23536519, "id": 4, "text": "Resveratrol (100 μM) significantly decreased the glycolytic enzymes (pyruvate kinase and lactate dehydrogenase) in Caco2 cells, while an increase in citrate synthase activity and a decrease in glucose consumption were observed in both cell lines.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Resveratrol", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "CHEMICAL", "char_span": [149, 156], "name": "citrate", "tok_span": [30, 31], "new_tok_span": [32, 33]}, {"ent_type": "CHEMICAL", "char_span": [193, 200], "name": "glucose", "tok_span": [37, 38], "new_tok_span": [39, 40]}, {"ent_type": "GENE", "char_span": [49, 67], "name": "glycolytic enzymes", "tok_span": [10, 13], "new_tok_span": [10, 13]}, {"ent_type": "GENE", "char_span": [69, 84], "name": "pyruvate kinase", "tok_span": [14, 16], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [89, 110], "name": "lactate dehydrogenase", "tok_span": [17, 19], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [149, 165], "name": "citrate synthase", "tok_span": [30, 32], "new_tok_span": [32, 34]}], "relation_list": [{"subject": "Resveratrol", "sbj_char_span": [0, 11], "object": "citrate synthase", "obj_char_span": [149, 165], "rel_type": "activator", "sbj_tok_span": [0, 2], "obj_tok_span": [30, 32], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [32, 34]}], "umls_entity_list": [{"mention": "pyruvate", "char_span": [69, 77], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 15], "new_tok_span": [15, 16]}], "new_text": "Resveratrol ( 100 μM ) significantly decreased the glycolytic enzymes ( <START=Amino Acid, Peptide, or Protein> pyruvate <END=Amino Acid, Peptide, or Protein> kinase and lactate dehydrogenase ) in Caco2 cells, while an increase in citrate synthase activity and a decrease in glucose consumption were observed in both cell lines."}, {"PMID": 17254025, "id": 3, "text": "The latter reaction, catalyzed by aspartoacylase (ASPA), produces acetyl groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [66, 72], "name": "acetyl", "tok_span": [17, 18], "new_tok_span": [21, 22]}, {"ent_type": "CHEMICAL", "char_span": [85, 94], "name": "aspartate", "tok_span": [20, 22], "new_tok_span": [25, 27]}, {"ent_type": "GENE", "char_span": [34, 48], "name": "aspartoacylase", "tok_span": [6, 11], "new_tok_span": [8, 13]}, {"ent_type": "GENE", "char_span": [50, 54], "name": "ASPA", "tok_span": [12, 14], "new_tok_span": [16, 18]}], "relation_list": [{"subject": "acetyl", "sbj_char_span": [66, 72], "object": "aspartoacylase", "obj_char_span": [34, 48], "rel_type": "product or substrate", "sbj_tok_span": [17, 18], "obj_tok_span": [6, 11], "new_sbj_tok_span": [21, 22], "new_obj_tok_span": [8, 13]}, {"subject": "acetyl", "sbj_char_span": [66, 72], "object": "ASPA", "obj_char_span": [50, 54], "rel_type": "product or substrate", "sbj_tok_span": [17, 18], "obj_tok_span": [12, 14], "new_sbj_tok_span": [21, 22], "new_obj_tok_span": [16, 18]}, {"subject": "aspartate", "sbj_char_span": [85, 94], "object": "aspartoacylase", "obj_char_span": [34, 48], "rel_type": "product or substrate", "sbj_tok_span": [20, 22], "obj_tok_span": [6, 11], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [8, 13]}, {"subject": "aspartate", "sbj_char_span": [85, 94], "object": "ASPA", "obj_char_span": [50, 54], "rel_type": "product or substrate", "sbj_tok_span": [20, 22], "obj_tok_span": [12, 14], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [16, 18]}], "umls_entity_list": [{"mention": "aspartoacylase", "char_span": [34, 48], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 11], "new_tok_span": [8, 13]}, {"mention": "aspartoacylase", "char_span": [34, 48], "sem_type": "Gene or Genome", "tok_span": [6, 11], "new_tok_span": [8, 13]}, {"mention": "aspartate", "char_span": [85, 94], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 22], "new_tok_span": [25, 27]}], "new_text": "The latter reaction, catalyzed by <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> aspartoacylase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( ASPA ), produces acetyl groups plus <START=Amino Acid, Peptide, or Protein> aspartate <END=Amino Acid, Peptide, or Protein> and has been proposed to occur in both soluble and membranous subfractions of white matter."}, {"PMID": 23493374, "id": 8, "text": "Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 31], "name": "5-aza-2'-deoxycytidine", "tok_span": [2, 13], "new_tok_span": [2, 13]}, {"ent_type": "CHEMICAL", "char_span": [68, 82], "name": "trichostatin A", "tok_span": [18, 21], "new_tok_span": [21, 24]}, {"ent_type": "CHEMICAL", "char_span": [91, 97], "name": "(m)CpG", "tok_span": [22, 26], "new_tok_span": [26, 30]}, {"ent_type": "CHEMICAL", "char_span": [230, 237], "name": "(m)CpGs", "tok_span": [58, 63], "new_tok_span": [74, 79]}, {"ent_type": "GENE", "char_span": [145, 150], "name": "Mecp2", "tok_span": [32, 35], "new_tok_span": [40, 43]}, {"ent_type": "GENE", "char_span": [155, 160], "name": "Creb1", "tok_span": [36, 39], "new_tok_span": [46, 49]}, {"ent_type": "GENE", "char_span": [194, 199], "name": "Mecp2", "tok_span": [44, 47], "new_tok_span": [56, 59]}, {"ent_type": "GENE", "char_span": [207, 212], "name": "Creb1", "tok_span": [50, 53], "new_tok_span": [64, 67]}, {"ent_type": "GENE", "char_span": [224, 229], "name": "glut3", "tok_span": [55, 57], "new_tok_span": [70, 72]}, {"ent_type": "GENE", "char_span": [246, 251], "name": "glut3", "tok_span": [64, 66], "new_tok_span": [81, 83]}], "relation_list": [{"subject": "5-aza-2'-deoxycytidine", "sbj_char_span": [9, 31], "object": "Mecp2", "obj_char_span": [145, 150], "rel_type": "regulator", "sbj_tok_span": [2, 13], "obj_tok_span": [32, 35], "new_sbj_tok_span": [2, 13], "new_obj_tok_span": [40, 43]}, {"subject": "trichostatin A", "sbj_char_span": [68, 82], "object": "Mecp2", "obj_char_span": [145, 150], "rel_type": "regulator", "sbj_tok_span": [18, 21], "obj_tok_span": [32, 35], "new_sbj_tok_span": [21, 24], "new_obj_tok_span": [40, 43]}, {"subject": "5-aza-2'-deoxycytidine", "sbj_char_span": [9, 31], "object": "Creb1", "obj_char_span": [155, 160], "rel_type": "regulator", "sbj_tok_span": [2, 13], "obj_tok_span": [36, 39], "new_sbj_tok_span": [2, 13], "new_obj_tok_span": [46, 49]}, {"subject": "trichostatin A", "sbj_char_span": [68, 82], "object": "Creb1", "obj_char_span": [155, 160], "rel_type": "regulator", "sbj_tok_span": [18, 21], "obj_tok_span": [36, 39], "new_sbj_tok_span": [21, 24], "new_obj_tok_span": [46, 49]}], "umls_entity_list": [{"mention": "trichostatin A", "char_span": [68, 82], "sem_type": "Organic Chemical", "tok_span": [18, 21], "new_tok_span": [21, 24]}, {"mention": "na", "char_span": [56, 58], "sem_type": "Pharmacologic Substance", "tok_span": [16, 17], "new_tok_span": [17, 18]}, {"mention": "NA", "char_span": [131, 133], "sem_type": "Pharmacologic Substance", "tok_span": [30, 31], "new_tok_span": [35, 36]}, {"mention": "Mecp2", "char_span": [145, 150], "sem_type": "Gene or Genome", "tok_span": [32, 35], "new_tok_span": [40, 43]}, {"mention": "Mecp2", "char_span": [194, 199], "sem_type": "Gene or Genome", "tok_span": [44, 47], "new_tok_span": [56, 59]}, {"mention": "Mecp2", "char_span": [145, 150], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 35], "new_tok_span": [40, 43]}, {"mention": "Mecp2", "char_span": [194, 199], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [44, 47], "new_tok_span": [56, 59]}, {"mention": "glut3", "char_span": [224, 229], "sem_type": "Gene or Genome", "tok_span": [55, 57], "new_tok_span": [70, 72]}, {"mention": "glut3", "char_span": [246, 251], "sem_type": "Gene or Genome", "tok_span": [64, 66], "new_tok_span": [81, 83]}], "new_text": "Separate 5 - aza - 2'- deoxycytidine pretreatment or in <START=Pharmacologic Substance> combination <END=Pharmacologic Substance> with <START=Organic Chemical> trichostatin A <END=Organic Chemical> reduced ( m ) CpG and specific small interference <START=Pharmacologic Substance> RNAs <END=Pharmacologic Substance> targeting <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Mecp2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and Creb1 separately or together depleting <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Mecp2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and / or Creb1 binding of <START=Gene or Genome> glut3 <END=Gene or Genome> - ( m ) CpGs reduced <START=Gene or Genome> glut3 <END=Gene or Genome> expression in HT22 cells."}, {"PMID": 11141093, "id": 1, "text": "In a search for less flexible analogues of caproctamine (1), a diamine diamide endowed with an interesting AChE affinity profile, we discovered compound 2, in which the terminal 2-methoxybenzyl groups of 1 have been incorporated into a tricyclic system.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [178, 193], "name": "2-methoxybenzyl", "tok_span": [41, 47], "new_tok_span": [47, 53]}, {"ent_type": "CHEMICAL", "char_span": [236, 245], "name": "tricyclic", "tok_span": [55, 57], "new_tok_span": [61, 63]}, {"ent_type": "CHEMICAL", "char_span": [43, 55], "name": "caproctamine", "tok_span": [8, 13], "new_tok_span": [9, 14]}, {"ent_type": "CHEMICAL", "char_span": [63, 70], "name": "diamine", "tok_span": [18, 20], "new_tok_span": [21, 23]}, {"ent_type": "CHEMICAL", "char_span": [71, 78], "name": "diamide", "tok_span": [20, 22], "new_tok_span": [25, 27]}, {"ent_type": "GENE", "char_span": [107, 111], "name": "AChE", "tok_span": [27, 29], "new_tok_span": [33, 35]}], "relation_list": [{"subject": "caproctamine", "sbj_char_span": [43, 55], "object": "AChE", "obj_char_span": [107, 111], "rel_type": "regulator", "sbj_tok_span": [8, 13], "obj_tok_span": [27, 29], "new_sbj_tok_span": [9, 14], "new_obj_tok_span": [33, 35]}, {"subject": "diamine", "sbj_char_span": [63, 70], "object": "AChE", "obj_char_span": [107, 111], "rel_type": "regulator", "sbj_tok_span": [18, 20], "obj_tok_span": [27, 29], "new_sbj_tok_span": [21, 23], "new_obj_tok_span": [33, 35]}, {"subject": "diamide", "sbj_char_span": [71, 78], "object": "AChE", "obj_char_span": [107, 111], "rel_type": "regulator", "sbj_tok_span": [20, 22], "obj_tok_span": [27, 29], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [33, 35]}], "umls_entity_list": [{"mention": "caproctamine", "char_span": [43, 55], "sem_type": "Organic Chemical", "tok_span": [8, 13], "new_tok_span": [9, 14]}, {"mention": "diamine", "char_span": [63, 70], "sem_type": "Organic Chemical", "tok_span": [18, 20], "new_tok_span": [21, 23]}, {"mention": "diamide", "char_span": [71, 78], "sem_type": "Pharmacologic Substance", "tok_span": [20, 22], "new_tok_span": [25, 27]}], "new_text": "In a search for less flexible analogues of <START=Organic Chemical> caproctamine <END=Organic Chemical> ( 1 ), a <START=Organic Chemical> diamine <END=Organic Chemical> <START=Pharmacologic Substance> diamide <END=Pharmacologic Substance> endowed with an interesting AChE affinity profile, we discovered compound 2, in which the terminal 2 - methoxybenzyl groups of 1 have been incorporated into a tricyclic system."}, {"PMID": 23266270, "id": 5, "text": "DPEP inhibited LPS-induced phosphorylation of ERK, JNK, and p38.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 4], "name": "DPEP", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [46, 49], "name": "ERK", "tok_span": [8, 9], "new_tok_span": [13, 14]}, {"ent_type": "GENE", "char_span": [51, 54], "name": "JNK", "tok_span": [10, 11], "new_tok_span": [17, 18]}, {"ent_type": "GENE", "char_span": [60, 63], "name": "p38", "tok_span": [13, 15], "new_tok_span": [22, 24]}], "relation_list": [{"subject": "DPEP", "sbj_char_span": [0, 4], "object": "ERK", "obj_char_span": [46, 49], "rel_type": "inhibitor", "sbj_tok_span": [0, 2], "obj_tok_span": [8, 9], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [13, 14]}, {"subject": "DPEP", "sbj_char_span": [0, 4], "object": "JNK", "obj_char_span": [51, 54], "rel_type": "inhibitor", "sbj_tok_span": [0, 2], "obj_tok_span": [10, 11], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [17, 18]}, {"subject": "DPEP", "sbj_char_span": [0, 4], "object": "p38", "obj_char_span": [60, 63], "rel_type": "inhibitor", "sbj_tok_span": [0, 2], "obj_tok_span": [13, 15], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [22, 24]}], "umls_entity_list": [{"mention": "LPS", "char_span": [15, 18], "sem_type": "Organic Chemical", "tok_span": [3, 4], "new_tok_span": [5, 6]}, {"mention": "ERK", "char_span": [46, 49], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [13, 14]}, {"mention": "LPS", "char_span": [15, 18], "sem_type": "Gene or Genome", "tok_span": [3, 4], "new_tok_span": [5, 6]}, {"mention": "JNK", "char_span": [51, 54], "sem_type": "Gene or Genome", "tok_span": [10, 11], "new_tok_span": [17, 18]}, {"mention": "p38", "char_span": [60, 63], "sem_type": "Gene or Genome", "tok_span": [13, 15], "new_tok_span": [22, 24]}], "new_text": "DPEP inhibited <START=Organic Chemical> <START=Gene or Genome> LPS <END=Organic Chemical> <END=Gene or Genome> - induced phosphorylation of <START=Amino Acid, Peptide, or Protein> ERK <END=Amino Acid, Peptide, or Protein>, <START=Gene or Genome> JNK <END=Gene or Genome>, and <START=Gene or Genome> p38 <END=Gene or Genome>."}, {"PMID": 8161345, "id": 0, "text": "5-ethynyl-2(1H)-pyrimidinone: aldehyde oxidase-activation to 5-ethynyluracil, a mechanism-based inactivator of dihydropyrimidine dehydrogenase. 5-Ethynyluracil is a potent mechanism-based inactivator of dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2) in vitro (Porter et al., J Biol Chem 267: 5236-5242, 1992) and in vivo (Spector et al., Biochem Pharmacol, 46: 2243-2248, 1993. 5-Ethynyl-2(1H)-pyrimidinone was rapidly oxidized to 5-ethynyluracil by aldehyde oxidase.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [144, 159], "name": "5-Ethynyluracil", "tok_span": [49, 57], "new_tok_span": [60, 68]}, {"ent_type": "CHEMICAL", "char_span": [381, 409], "name": "5-Ethynyl-2(1H)-pyrimidinone", "tok_span": [132, 148], "new_tok_span": [152, 168]}, {"ent_type": "CHEMICAL", "char_span": [434, 449], "name": "5-ethynyluracil", "tok_span": [152, 160], "new_tok_span": [175, 183]}, {"ent_type": "CHEMICAL", "char_span": [453, 461], "name": "aldehyde", "tok_span": [161, 165], "new_tok_span": [187, 191]}, {"ent_type": "CHEMICAL", "char_span": [203, 220], "name": "dihydropyrimidine", "tok_span": [67, 72], "new_tok_span": [83, 88]}, {"ent_type": "CHEMICAL", "char_span": [0, 28], "name": "5-ethynyl-2(1H)-pyrimidinone", "tok_span": [0, 16], "new_tok_span": [0, 16]}, {"ent_type": "CHEMICAL", "char_span": [111, 128], "name": "dihydropyrimidine", "tok_span": [42, 47], "new_tok_span": [50, 55]}, {"ent_type": "CHEMICAL", "char_span": [30, 38], "name": "aldehyde", "tok_span": [17, 21], "new_tok_span": [19, 23]}, {"ent_type": "CHEMICAL", "char_span": [61, 76], "name": "5-ethynyluracil", "tok_span": [25, 33], "new_tok_span": [28, 36]}, {"ent_type": "GENE", "char_span": [453, 469], "name": "aldehyde oxidase", "tok_span": [161, 166], "new_tok_span": [187, 192]}, {"ent_type": "GENE", "char_span": [203, 234], "name": "dihydropyrimidine dehydrogenase", "tok_span": [67, 73], "new_tok_span": [83, 89]}, {"ent_type": "GENE", "char_span": [236, 239], "name": "DPD", "tok_span": [74, 76], "new_tok_span": [93, 95]}, {"ent_type": "GENE", "char_span": [241, 251], "name": "EC 1.3.1.2", "tok_span": [77, 85], "new_tok_span": [97, 105]}, {"ent_type": "GENE", "char_span": [111, 142], "name": "dihydropyrimidine dehydrogenase", "tok_span": [42, 48], "new_tok_span": [50, 56]}, {"ent_type": "GENE", "char_span": [30, 46], "name": "aldehyde oxidase", "tok_span": [17, 22], "new_tok_span": [19, 24]}], "relation_list": [{"subject": "5-Ethynyluracil", "sbj_char_span": [144, 159], "object": "dihydropyrimidine dehydrogenase", "obj_char_span": [203, 234], "rel_type": "inhibitor", "sbj_tok_span": [49, 57], "obj_tok_span": [67, 73], "new_sbj_tok_span": [60, 68], "new_obj_tok_span": [83, 89]}, {"subject": "5-Ethynyluracil", "sbj_char_span": [144, 159], "object": "DPD", "obj_char_span": [236, 239], "rel_type": "inhibitor", "sbj_tok_span": [49, 57], "obj_tok_span": [74, 76], "new_sbj_tok_span": [60, 68], "new_obj_tok_span": [93, 95]}, {"subject": "5-Ethynyluracil", "sbj_char_span": [144, 159], "object": "EC 1.3.1.2", "obj_char_span": [241, 251], "rel_type": "inhibitor", "sbj_tok_span": [49, 57], "obj_tok_span": [77, 85], "new_sbj_tok_span": [60, 68], "new_obj_tok_span": [97, 105]}, {"subject": "5-Ethynyl-2(1H)-pyrimidinone", "sbj_char_span": [381, 409], "object": "aldehyde oxidase", "obj_char_span": [453, 469], "rel_type": "product or substrate", "sbj_tok_span": [132, 148], "obj_tok_span": [161, 166], "new_sbj_tok_span": [152, 168], "new_obj_tok_span": [187, 192]}, {"subject": "5-ethynyluracil", "sbj_char_span": [434, 449], "object": "aldehyde oxidase", "obj_char_span": [453, 469], "rel_type": "product or substrate", "sbj_tok_span": [152, 160], "obj_tok_span": [161, 166], "new_sbj_tok_span": [175, 183], "new_obj_tok_span": [187, 192]}], "umls_entity_list": [{"mention": "pyrimidinone", "char_span": [16, 28], "sem_type": "Organic Chemical", "tok_span": [12, 16], "new_tok_span": [13, 17]}, {"mention": "pyrimidinone", "char_span": [397, 409], "sem_type": "Organic Chemical", "tok_span": [144, 148], "new_tok_span": [165, 169]}, {"mention": "ethynyluracil", "char_span": [63, 76], "sem_type": "Pharmacologic Substance", "tok_span": [27, 33], "new_tok_span": [31, 37]}, {"mention": "Ethynyluracil", "char_span": [146, 159], "sem_type": "Pharmacologic Substance", "tok_span": [51, 57], "new_tok_span": [63, 69]}, {"mention": "ethynyluracil", "char_span": [436, 449], "sem_type": "Pharmacologic Substance", "tok_span": [154, 160], "new_tok_span": [178, 184]}, {"mention": "dihydropyrimidine dehydrogenase", "char_span": [111, 142], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 48], "new_tok_span": [50, 56]}, {"mention": "dihydropyrimidine dehydrogenase", "char_span": [203, 234], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [67, 73], "new_tok_span": [83, 89]}, {"mention": "dihydropyrimidine dehydrogenase", "char_span": [111, 142], "sem_type": "Gene or Genome", "tok_span": [42, 48], "new_tok_span": [50, 56]}, {"mention": "dihydropyrimidine dehydrogenase", "char_span": [203, 234], "sem_type": "Gene or Genome", "tok_span": [67, 73], "new_tok_span": [83, 89]}, {"mention": "5-ethynyluracil", "char_span": [61, 76], "sem_type": "Pharmacologic Substance", "tok_span": [25, 33], "new_tok_span": [28, 36]}, {"mention": "5-Ethynyluracil", "char_span": [144, 159], "sem_type": "Pharmacologic Substance", "tok_span": [49, 57], "new_tok_span": [60, 68]}, {"mention": "5-ethynyluracil", "char_span": [434, 449], "sem_type": "Pharmacologic Substance", "tok_span": [152, 160], "new_tok_span": [175, 183]}, {"mention": "DPD", "char_span": [236, 239], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [74, 76], "new_tok_span": [93, 95]}], "new_text": "5 - ethynyl - 2 ( 1H ) - <START=Organic Chemical> pyrimidinone <END=Organic Chemical> : aldehyde oxidase - activation to <START=Pharmacologic Substance> 5 - <START=Pharmacologic Substance> ethynyluracil <END=Pharmacologic Substance> <END=Pharmacologic Substance>, a mechanism - based inactivator of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> dihydropyrimidine dehydrogenase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>. <START=Pharmacologic Substance> 5 - <START=Pharmacologic Substance> Ethynyluracil <END=Pharmacologic Substance> <END=Pharmacologic Substance> is a potent mechanism - based inactivator of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> dihydropyrimidine dehydrogenase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( <START=Amino Acid, Peptide, or Protein> DPD <END=Amino Acid, Peptide, or Protein>, EC 1. 3. 1. 2 ) in vitro ( Porter et al., J Biol Chem 267 : 5236 - 5242, 1992 ) and in vivo ( Spector et al., Biochem Pharmacol, 46 : 2243 - 2248, 1993. 5 - Ethynyl - 2 ( 1H ) - <START=Organic Chemical> pyrimidinone <END=Organic Chemical> was rapidly oxidized to <START=Pharmacologic Substance> 5 - <START=Pharmacologic Substance> ethynyluracil <END=Pharmacologic Substance> <END=Pharmacologic Substance> by aldehyde oxidase."}, {"PMID": 23296101, "id": 7, "text": "These results show that phthalate esters activate TRPA1 and TRPV1 with selectivity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [24, 40], "name": "phthalate esters", "tok_span": [4, 8], "new_tok_span": [4, 8]}, {"ent_type": "GENE", "char_span": [50, 55], "name": "TRPA1", "tok_span": [9, 12], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [60, 65], "name": "TRPV1", "tok_span": [13, 16], "new_tok_span": [14, 17]}], "relation_list": [{"subject": "phthalate esters", "sbj_char_span": [24, 40], "object": "TRPA1", "obj_char_span": [50, 55], "rel_type": "activator", "sbj_tok_span": [4, 8], "obj_tok_span": [9, 12], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [9, 12]}, {"subject": "phthalate esters", "sbj_char_span": [24, 40], "object": "TRPV1", "obj_char_span": [60, 65], "rel_type": "activator", "sbj_tok_span": [4, 8], "obj_tok_span": [13, 16], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [14, 17]}], "umls_entity_list": [{"mention": "TRPV1", "char_span": [60, 65], "sem_type": "Gene or Genome", "tok_span": [13, 16], "new_tok_span": [14, 17]}], "new_text": "These results show that phthalate esters activate TRPA1 and <START=Gene or Genome> TRPV1 <END=Gene or Genome> with selectivity."}, {"PMID": 23591777, "id": 3, "text": "In addition, CCl4 treatment led to elevation of hepatic malondialdehyde (MDA) content as well as decrease in superoxide dismutase (SOD) and catalase (CAT) activities.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [13, 17], "name": "CCl4", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [56, 71], "name": "malondialdehyde", "tok_span": [12, 16], "new_tok_span": [17, 21]}, {"ent_type": "CHEMICAL", "char_span": [73, 76], "name": "MDA", "tok_span": [17, 18], "new_tok_span": [23, 24]}, {"ent_type": "CHEMICAL", "char_span": [109, 119], "name": "superoxide", "tok_span": [25, 26], "new_tok_span": [32, 33]}, {"ent_type": "GENE", "char_span": [109, 129], "name": "superoxide dismutase", "tok_span": [25, 27], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [131, 134], "name": "SOD", "tok_span": [28, 29], "new_tok_span": [36, 37]}, {"ent_type": "GENE", "char_span": [140, 148], "name": "catalase", "tok_span": [31, 32], "new_tok_span": [39, 40]}, {"ent_type": "GENE", "char_span": [150, 153], "name": "CAT", "tok_span": [33, 34], "new_tok_span": [41, 42]}], "relation_list": [{"subject": "CCl4", "sbj_char_span": [13, 17], "object": "superoxide dismutase", "obj_char_span": [109, 129], "rel_type": "inhibitor", "sbj_tok_span": [3, 6], "obj_tok_span": [25, 27], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [32, 34]}, {"subject": "CCl4", "sbj_char_span": [13, 17], "object": "SOD", "obj_char_span": [131, 134], "rel_type": "inhibitor", "sbj_tok_span": [3, 6], "obj_tok_span": [28, 29], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [36, 37]}, {"subject": "CCl4", "sbj_char_span": [13, 17], "object": "catalase", "obj_char_span": [140, 148], "rel_type": "inhibitor", "sbj_tok_span": [3, 6], "obj_tok_span": [31, 32], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [39, 40]}, {"subject": "CCl4", "sbj_char_span": [13, 17], "object": "CAT", "obj_char_span": [150, 153], "rel_type": "inhibitor", "sbj_tok_span": [3, 6], "obj_tok_span": [33, 34], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [41, 42]}], "umls_entity_list": [{"mention": "CCl4", "char_span": [13, 17], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "led", "char_span": [28, 31], "sem_type": "Gene or Genome", "tok_span": [7, 8], "new_tok_span": [10, 11]}, {"mention": "malondialdehyde", "char_span": [56, 71], "sem_type": "Organic Chemical", "tok_span": [12, 16], "new_tok_span": [17, 21]}, {"mention": "superoxide dismutase", "char_span": [109, 129], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 27], "new_tok_span": [32, 34]}], "new_text": "In addition, <START=Amino Acid, Peptide, or Protein> CCl4 <END=Amino Acid, Peptide, or Protein> treatment <START=Gene or Genome> led <END=Gene or Genome> to elevation of hepatic <START=Organic Chemical> malondialdehyde <END=Organic Chemical> ( MDA ) content as well as decrease in <START=Amino Acid, Peptide, or Protein> superoxide dismutase <END=Amino Acid, Peptide, or Protein> ( SOD ) and catalase ( CAT ) activities."}, {"PMID": 12063084, "id": 3, "text": "Combined with previous studies demonstrating the potent partial agonism of aripiprazole at dopamine D2 receptors, this study suggests aripiprazole is the first dopamine-serotonin system stabilizer.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [75, 87], "name": "aripiprazole", "tok_span": [11, 15], "new_tok_span": [14, 18]}, {"ent_type": "CHEMICAL", "char_span": [91, 99], "name": "dopamine", "tok_span": [16, 17], "new_tok_span": [21, 22]}, {"ent_type": "CHEMICAL", "char_span": [134, 146], "name": "aripiprazole", "tok_span": [24, 28], "new_tok_span": [31, 35]}, {"ent_type": "CHEMICAL", "char_span": [160, 168], "name": "dopamine", "tok_span": [31, 32], "new_tok_span": [40, 41]}, {"ent_type": "CHEMICAL", "char_span": [169, 178], "name": "serotonin", "tok_span": [33, 34], "new_tok_span": [43, 44]}, {"ent_type": "GENE", "char_span": [91, 112], "name": "dopamine D2 receptors", "tok_span": [16, 20], "new_tok_span": [21, 25]}], "relation_list": [{"subject": "aripiprazole", "sbj_char_span": [75, 87], "object": "dopamine D2 receptors", "obj_char_span": [91, 112], "rel_type": "agonist or antagonist", "sbj_tok_span": [11, 15], "obj_tok_span": [16, 20], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [21, 25]}], "umls_entity_list": [{"mention": "agon", "char_span": [64, 68], "sem_type": "Pharmacologic Substance", "tok_span": [8, 9], "new_tok_span": [9, 10]}, {"mention": "aripiprazole", "char_span": [75, 87], "sem_type": "Pharmacologic Substance", "tok_span": [11, 15], "new_tok_span": [14, 18]}, {"mention": "aripiprazole", "char_span": [134, 146], "sem_type": "Pharmacologic Substance", "tok_span": [24, 28], "new_tok_span": [31, 35]}, {"mention": "dopamine", "char_span": [91, 99], "sem_type": "Pharmacologic Substance", "tok_span": [16, 17], "new_tok_span": [21, 22]}, {"mention": "dopamine", "char_span": [160, 168], "sem_type": "Pharmacologic Substance", "tok_span": [31, 32], "new_tok_span": [40, 41]}], "new_text": "Combined with previous studies demonstrating the potent partial <START=Pharmacologic Substance> agon <END=Pharmacologic Substance>ism of <START=Pharmacologic Substance> aripiprazole <END=Pharmacologic Substance> at <START=Pharmacologic Substance> dopamine <END=Pharmacologic Substance> D2 receptors, this study suggests <START=Pharmacologic Substance> aripiprazole <END=Pharmacologic Substance> is the first <START=Pharmacologic Substance> dopamine <END=Pharmacologic Substance> - serotonin system stabilizer."}, {"PMID": 17308037, "id": 6, "text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [138, 147], "name": "milrinone", "tok_span": [57, 60], "new_tok_span": [63, 66]}, {"ent_type": "CHEMICAL", "char_span": [196, 242], "name": "4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one", "tok_span": [82, 105], "new_tok_span": [92, 115]}, {"ent_type": "CHEMICAL", "char_span": [273, 282], "name": "zaprinast", "tok_span": [118, 121], "new_tok_span": [132, 135]}, {"ent_type": "CHEMICAL", "char_span": [306, 315], "name": "BRL-50481", "tok_span": [131, 137], "new_tok_span": [145, 151]}, {"ent_type": "CHEMICAL", "char_span": [317, 358], "name": "5-nitro-2,N,N-trimethylbenzenesulfonamide", "tok_span": [138, 156], "new_tok_span": [152, 170]}, {"ent_type": "CHEMICAL", "char_span": [18, 61], "name": "8-methoxymethyl-3-isobutyl-1-methylxanthine", "tok_span": [6, 23], "new_tok_span": [9, 26]}, {"ent_type": "CHEMICAL", "char_span": [82, 118], "name": "erythro-9-(2-hydroxy-3-nonyl)adenine", "tok_span": [32, 48], "new_tok_span": [37, 53]}, {"ent_type": "GENE", "char_span": [132, 136], "name": "PDE3", "tok_span": [54, 56], "new_tok_span": [60, 62]}, {"ent_type": "GENE", "char_span": [178, 182], "name": "PDE4", "tok_span": [73, 75], "new_tok_span": [80, 82]}, {"ent_type": "GENE", "char_span": [258, 262], "name": "PDE5", "tok_span": [112, 114], "new_tok_span": [125, 127]}, {"ent_type": "GENE", "char_span": [267, 271], "name": "PDE6", "tok_span": [115, 117], "new_tok_span": [129, 131]}, {"ent_type": "GENE", "char_span": [300, 304], "name": "PDE7", "tok_span": [128, 130], "new_tok_span": [142, 144]}, {"ent_type": "GENE", "char_span": [397, 414], "name": "phosphodiesterase", "tok_span": [169, 173], "new_tok_span": [185, 189]}, {"ent_type": "GENE", "char_span": [12, 16], "name": "PDE1", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"ent_type": "GENE", "char_span": [76, 80], "name": "PDE2", "tok_span": [29, 31], "new_tok_span": [33, 35]}], "relation_list": [{"subject": "8-methoxymethyl-3-isobutyl-1-methylxanthine", "sbj_char_span": [18, 61], "object": "PDE1", "obj_char_span": [12, 16], "rel_type": "inhibitor", "sbj_tok_span": [6, 23], "obj_tok_span": [3, 5], "new_sbj_tok_span": [9, 26], "new_obj_tok_span": [5, 7]}, {"subject": "erythro-9-(2-hydroxy-3-nonyl)adenine", "sbj_char_span": [82, 118], "object": "PDE2", "obj_char_span": [76, 80], "rel_type": "inhibitor", "sbj_tok_span": [32, 48], "obj_tok_span": [29, 31], "new_sbj_tok_span": [37, 53], "new_obj_tok_span": [33, 35]}, {"subject": "milrinone", "sbj_char_span": [138, 147], "object": "PDE3", "obj_char_span": [132, 136], "rel_type": "inhibitor", "sbj_tok_span": [57, 60], "obj_tok_span": [54, 56], "new_sbj_tok_span": [63, 66], "new_obj_tok_span": [60, 62]}, {"subject": "4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one", "sbj_char_span": [196, 242], "object": "PDE4", "obj_char_span": [178, 182], "rel_type": "inhibitor", "sbj_tok_span": [82, 105], "obj_tok_span": [73, 75], "new_sbj_tok_span": [92, 115], "new_obj_tok_span": [80, 82]}, {"subject": "zaprinast", "sbj_char_span": [273, 282], "object": "PDE5", "obj_char_span": [258, 262], "rel_type": "inhibitor", "sbj_tok_span": [118, 121], "obj_tok_span": [112, 114], "new_sbj_tok_span": [132, 135], "new_obj_tok_span": [125, 127]}, {"subject": "zaprinast", "sbj_char_span": [273, 282], "object": "PDE6", "obj_char_span": [267, 271], "rel_type": "inhibitor", "sbj_tok_span": [118, 121], "obj_tok_span": [115, 117], "new_sbj_tok_span": [132, 135], "new_obj_tok_span": [129, 131]}, {"subject": "BRL-50481", "sbj_char_span": [306, 315], "object": "PDE7", "obj_char_span": [300, 304], "rel_type": "inhibitor", "sbj_tok_span": [131, 137], "obj_tok_span": [128, 130], "new_sbj_tok_span": [145, 151], "new_obj_tok_span": [142, 144]}, {"subject": "5-nitro-2,N,N-trimethylbenzenesulfonamide", "sbj_char_span": [317, 358], "object": "PDE7", "obj_char_span": [300, 304], "rel_type": "inhibitor", "sbj_tok_span": [138, 156], "obj_tok_span": [128, 130], "new_sbj_tok_span": [152, 170], "new_obj_tok_span": [142, 144]}], "umls_entity_list": [{"mention": "Blockade", "char_span": [0, 8], "sem_type": "Pharmacologic Substance", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"mention": "8-methoxymethyl-3-isobutyl-1-methylxanthine", "char_span": [18, 61], "sem_type": "Pharmacologic Substance", "tok_span": [6, 23], "new_tok_span": [9, 26]}, {"mention": "erythro", "char_span": [82, 89], "sem_type": "Organic Chemical", "tok_span": [32, 34], "new_tok_span": [37, 39]}, {"mention": "PDE4", "char_span": [178, 182], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [73, 75], "new_tok_span": [80, 82]}, {"mention": "Ro 20-1724", "char_span": [184, 194], "sem_type": "Pharmacologic Substance", "tok_span": [76, 81], "new_tok_span": [85, 90]}, {"mention": "imidazolidin-2-one", "char_span": [224, 242], "sem_type": "Organic Chemical", "tok_span": [97, 105], "new_tok_span": [108, 116]}, {"mention": "PDE5", "char_span": [258, 262], "sem_type": "Gene or Genome", "tok_span": [112, 114], "new_tok_span": [125, 127]}, {"mention": "ecto", "char_span": [392, 396], "sem_type": "Gene or Genome", "tok_span": [166, 168], "new_tok_span": [181, 183]}], "new_text": "<START=Pharmacologic Substance> Blockade <END=Pharmacologic Substance> of PDE1 ( <START=Pharmacologic Substance> 8 - methoxymethyl - 3 - isobutyl - 1 - methylxanthine <END=Pharmacologic Substance>, 100 microM ), PDE2 [ <START=Organic Chemical> erythro <END=Organic Chemical> - 9 - ( 2 - hydroxy - 3 - nonyl ) adenine, 30 microM ], PDE3 ( milrinone, 10 microM ; cGMP, 10 microM ), <START=Amino Acid, Peptide, or Protein> PDE4 <END=Amino Acid, Peptide, or Protein> ( <START=Pharmacologic Substance> Ro 20 - 1724 <END=Pharmacologic Substance> [ 4 - ( 3 - butoxy - 4 - methoxybenzyl ) <START=Organic Chemical> imidazolidin - 2 - one <END=Organic Chemical> ], 100 microM ), <START=Gene or Genome> PDE5 <END=Gene or Genome> and PDE6 ( zaprinast, 30 microM ), and PDE7 [ BRL - 50481 ( 5 - nitro - 2, N, N - trimethylbenzenesulfonamide ), 10 microM ] did not alter renal <START=Gene or Genome> ecto <END=Gene or Genome> - phosphodiesterase activity."}, {"PMID": 23293300, "id": 1, "text": "The inhibitory effect of boceprevir (BOC), an inhibitor of hepatitis C virus nonstructural protein 3 protease was evaluated in vitro against a panel of drug-metabolizing enzymes and transporters.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [25, 35], "name": "boceprevir", "tok_span": [4, 8], "new_tok_span": [5, 9]}, {"ent_type": "CHEMICAL", "char_span": [37, 40], "name": "BOC", "tok_span": [9, 11], "new_tok_span": [11, 13]}, {"ent_type": "GENE", "char_span": [101, 109], "name": "protease", "tok_span": [23, 24], "new_tok_span": [25, 26]}, {"ent_type": "GENE", "char_span": [59, 100], "name": "hepatitis C virus nonstructural protein 3", "tok_span": [16, 23], "new_tok_span": [18, 25]}], "relation_list": [{"subject": "boceprevir", "sbj_char_span": [25, 35], "object": "hepatitis C virus nonstructural protein 3", "obj_char_span": [59, 100], "rel_type": "inhibitor", "sbj_tok_span": [4, 8], "obj_tok_span": [16, 23], "new_sbj_tok_span": [5, 9], "new_obj_tok_span": [18, 25]}, {"subject": "BOC", "sbj_char_span": [37, 40], "object": "hepatitis C virus nonstructural protein 3", "obj_char_span": [59, 100], "rel_type": "inhibitor", "sbj_tok_span": [9, 11], "obj_tok_span": [16, 23], "new_sbj_tok_span": [11, 13], "new_obj_tok_span": [18, 25]}, {"subject": "boceprevir", "sbj_char_span": [25, 35], "object": "protease", "obj_char_span": [101, 109], "rel_type": "inhibitor", "sbj_tok_span": [4, 8], "obj_tok_span": [23, 24], "new_sbj_tok_span": [5, 9], "new_obj_tok_span": [25, 26]}, {"subject": "BOC", "sbj_char_span": [37, 40], "object": "protease", "obj_char_span": [101, 109], "rel_type": "inhibitor", "sbj_tok_span": [9, 11], "obj_tok_span": [23, 24], "new_sbj_tok_span": [11, 13], "new_obj_tok_span": [25, 26]}], "umls_entity_list": [{"mention": "boceprevir", "char_span": [25, 35], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 8], "new_tok_span": [5, 9]}], "new_text": "The inhibitory effect of <START=Amino Acid, Peptide, or Protein> boceprevir <END=Amino Acid, Peptide, or Protein> ( BOC ), an inhibitor of hepatitis C virus nonstructural protein 3 protease was evaluated in vitro against a panel of drug - metabolizing enzymes and transporters."}, {"PMID": 12538485, "id": 6, "text": "In target modulation studies in vivo, SU11248 selectively inhibited Flk-1/KDR (VEGF receptor 2) and PDGF receptor beta phosphorylation (in a time- and dose-dependent manner) when plasma concentrations of inhibitor reached or exceeded 50-100 ng/ml.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [38, 45], "name": "SU11248", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [68, 73], "name": "Flk-1", "tok_span": [12, 16], "new_tok_span": [15, 19]}, {"ent_type": "GENE", "char_span": [74, 77], "name": "KDR", "tok_span": [17, 19], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [79, 94], "name": "VEGF receptor 2", "tok_span": [20, 23], "new_tok_span": [26, 29]}, {"ent_type": "GENE", "char_span": [100, 118], "name": "PDGF receptor beta", "tok_span": [25, 28], "new_tok_span": [31, 34]}], "relation_list": [{"subject": "SU11248", "sbj_char_span": [38, 45], "object": "Flk-1", "obj_char_span": [68, 73], "rel_type": "inhibitor", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 16], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [15, 19]}, {"subject": "SU11248", "sbj_char_span": [38, 45], "object": "KDR", "obj_char_span": [74, 77], "rel_type": "inhibitor", "sbj_tok_span": [7, 10], "obj_tok_span": [17, 19], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [22, 24]}, {"subject": "SU11248", "sbj_char_span": [38, 45], "object": "VEGF receptor 2", "obj_char_span": [79, 94], "rel_type": "inhibitor", "sbj_tok_span": [7, 10], "obj_tok_span": [20, 23], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [26, 29]}, {"subject": "SU11248", "sbj_char_span": [38, 45], "object": "PDGF receptor beta", "obj_char_span": [100, 118], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [25, 28], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [31, 34]}], "umls_entity_list": [{"mention": "SU11248", "char_span": [38, 45], "sem_type": "Pharmacologic Substance", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "Flk-1", "char_span": [68, 73], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 16], "new_tok_span": [15, 19]}, {"mention": "KDR", "char_span": [74, 77], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 19], "new_tok_span": [22, 24]}], "new_text": "In target modulation studies in vivo, <START=Pharmacologic Substance> SU11248 <END=Pharmacologic Substance> selectively inhibited <START=Amino Acid, Peptide, or Protein> Flk - 1 <END=Amino Acid, Peptide, or Protein> / <START=Amino Acid, Peptide, or Protein> KDR <END=Amino Acid, Peptide, or Protein> ( VEGF receptor 2 ) and PDGF receptor beta phosphorylation ( in a time - and dose - dependent manner ) when plasma concentrations of inhibitor reached or exceeded 50 - 100 ng / ml."}, {"PMID": 10823899, "id": 2, "text": "These psychostimulants attenuate DAT clearance efficiency, thereby increasing synaptic dopamine (DA) levels.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [87, 95], "name": "dopamine", "tok_span": [13, 14], "new_tok_span": [20, 21]}, {"ent_type": "CHEMICAL", "char_span": [97, 99], "name": "DA", "tok_span": [15, 16], "new_tok_span": [23, 24]}, {"ent_type": "GENE", "char_span": [33, 36], "name": "DAT", "tok_span": [6, 7], "new_tok_span": [10, 11]}], "relation_list": [{"subject": "dopamine", "sbj_char_span": [87, 95], "object": "DAT", "obj_char_span": [33, 36], "rel_type": "product or substrate", "sbj_tok_span": [13, 14], "obj_tok_span": [6, 7], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [10, 11]}, {"subject": "DA", "sbj_char_span": [97, 99], "object": "DAT", "obj_char_span": [33, 36], "rel_type": "product or substrate", "sbj_tok_span": [15, 16], "obj_tok_span": [6, 7], "new_sbj_tok_span": [23, 24], "new_obj_tok_span": [10, 11]}], "umls_entity_list": [{"mention": "psychostimulants", "char_span": [6, 22], "sem_type": "Pharmacologic Substance", "tok_span": [1, 5], "new_tok_span": [2, 6]}, {"mention": "DAT", "char_span": [33, 36], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 7], "new_tok_span": [10, 11]}, {"mention": "DAT", "char_span": [33, 36], "sem_type": "Gene or Genome", "tok_span": [6, 7], "new_tok_span": [10, 11]}, {"mention": "dopamine", "char_span": [87, 95], "sem_type": "Pharmacologic Substance", "tok_span": [13, 14], "new_tok_span": [20, 21]}], "new_text": "These <START=Pharmacologic Substance> psychostimulants <END=Pharmacologic Substance> attenuate <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> DAT <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> clearance efficiency, thereby increasing synaptic <START=Pharmacologic Substance> dopamine <END=Pharmacologic Substance> ( DA ) levels."}, {"PMID": 23194525, "id": 0, "text": "The nutritional supplement Active Hexose Correlated Compound (AHCC) has direct immunomodulatory actions on intestinal epithelial cells and macrophages involving TLR/MyD88 and NF-κB/MAPK activation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [34, 40], "name": "Hexose", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [161, 164], "name": "TLR", "tok_span": [26, 27], "new_tok_span": [27, 28]}, {"ent_type": "GENE", "char_span": [165, 170], "name": "MyD88", "tok_span": [28, 31], "new_tok_span": [32, 35]}, {"ent_type": "GENE", "char_span": [175, 180], "name": "NF-κB", "tok_span": [32, 36], "new_tok_span": [38, 42]}, {"ent_type": "GENE", "char_span": [181, 185], "name": "MAPK", "tok_span": [37, 38], "new_tok_span": [43, 44]}], "relation_list": [{"subject": "Hexose", "sbj_char_span": [34, 40], "object": "TLR", "obj_char_span": [161, 164], "rel_type": "activator", "sbj_tok_span": [4, 7], "obj_tok_span": [26, 27], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [27, 28]}, {"subject": "Hexose", "sbj_char_span": [34, 40], "object": "MyD88", "obj_char_span": [165, 170], "rel_type": "activator", "sbj_tok_span": [4, 7], "obj_tok_span": [28, 31], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [32, 35]}, {"subject": "Hexose", "sbj_char_span": [34, 40], "object": "NF-κB", "obj_char_span": [175, 180], "rel_type": "activator", "sbj_tok_span": [4, 7], "obj_tok_span": [32, 36], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [38, 42]}, {"subject": "Hexose", "sbj_char_span": [34, 40], "object": "MAPK", "obj_char_span": [181, 185], "rel_type": "activator", "sbj_tok_span": [4, 7], "obj_tok_span": [37, 38], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [43, 44]}], "umls_entity_list": [{"mention": "TLR", "char_span": [161, 164], "sem_type": "Gene or Genome", "tok_span": [26, 27], "new_tok_span": [27, 28]}, {"mention": "MyD88", "char_span": [165, 170], "sem_type": "Gene or Genome", "tok_span": [28, 31], "new_tok_span": [32, 35]}, {"mention": "MyD88", "char_span": [165, 170], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 31], "new_tok_span": [32, 35]}], "new_text": "The nutritional supplement Active Hexose Correlated Compound ( AHCC ) has direct immunomodulatory actions on intestinal epithelial cells and macrophages involving <START=Gene or Genome> TLR <END=Gene or Genome> / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> MyD88 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and NF - κB / MAPK activation."}, {"PMID": 17434872, "id": 7, "text": "Inhibition studies demonstrated that the methyl group on the phenylacetic acid ring is required for COX-2 selectivity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [41, 47], "name": "methyl", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [61, 78], "name": "phenylacetic acid", "tok_span": [9, 12], "new_tok_span": [12, 15]}, {"ent_type": "GENE", "char_span": [100, 105], "name": "COX-2", "tok_span": [16, 19], "new_tok_span": [22, 25]}], "relation_list": [{"subject": "methyl", "sbj_char_span": [41, 47], "object": "COX-2", "obj_char_span": [100, 105], "rel_type": "inhibitor", "sbj_tok_span": [5, 6], "obj_tok_span": [16, 19], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [22, 25]}, {"subject": "phenylacetic acid", "sbj_char_span": [61, 78], "object": "COX-2", "obj_char_span": [100, 105], "rel_type": "inhibitor", "sbj_tok_span": [9, 12], "obj_tok_span": [16, 19], "new_sbj_tok_span": [12, 15], "new_obj_tok_span": [22, 25]}], "umls_entity_list": [{"mention": "methyl", "char_span": [41, 47], "sem_type": "Organic Chemical", "tok_span": [5, 6], "new_tok_span": [6, 7]}, {"mention": "phenylacetic acid", "char_span": [61, 78], "sem_type": "Pharmacologic Substance", "tok_span": [9, 12], "new_tok_span": [12, 15]}, {"mention": "COX-2", "char_span": [100, 105], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 19], "new_tok_span": [22, 25]}, {"mention": "COX-2", "char_span": [100, 105], "sem_type": "Gene or Genome", "tok_span": [16, 19], "new_tok_span": [22, 25]}], "new_text": "Inhibition studies demonstrated that the <START=Organic Chemical> methyl <END=Organic Chemical> group on the <START=Pharmacologic Substance> phenylacetic acid <END=Pharmacologic Substance> ring is required for <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> COX - 2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> selectivity."}, {"PMID": 23295227, "id": 8, "text": "This was due to the presence of the more voluminous Gln-303 side chain (Ser-302 in AR) and of a water molecule buried in a subpocket located at the base of flexible loop A.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [52, 55], "name": "Gln", "tok_span": [12, 14], "new_tok_span": [15, 17]}, {"ent_type": "CHEMICAL", "char_span": [72, 75], "name": "Ser", "tok_span": [20, 21], "new_tok_span": [24, 25]}, {"ent_type": "GENE", "char_span": [83, 85], "name": "AR", "tok_span": [25, 26], "new_tok_span": [29, 30]}], "relation_list": [{"subject": "Ser", "sbj_char_span": [72, 75], "object": "AR", "obj_char_span": [83, 85], "rel_type": "part of", "sbj_tok_span": [20, 21], "obj_tok_span": [25, 26], "new_sbj_tok_span": [24, 25], "new_obj_tok_span": [29, 30]}], "umls_entity_list": [{"mention": "Gln", "char_span": [52, 55], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 14], "new_tok_span": [15, 17]}, {"mention": "was", "char_span": [5, 8], "sem_type": "Gene or Genome", "tok_span": [1, 2], "new_tok_span": [2, 3]}], "new_text": "This <START=Gene or Genome> was <END=Gene or Genome> due to the presence of the more voluminous <START=Amino Acid, Peptide, or Protein> Gln <END=Amino Acid, Peptide, or Protein> - 303 side chain ( Ser - 302 in AR ) and of a water molecule buried in a subpocket located at the base of flexible loop A."}, {"PMID": 23416065, "id": 1, "text": "The cyclooxygenase-2 inhibitor, diflunisal, is used in the clinic for its anti-inflammatory activity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [32, 42], "name": "diflunisal", "tok_span": [7, 11], "new_tok_span": [10, 14]}, {"ent_type": "GENE", "char_span": [4, 20], "name": "cyclooxygenase-2", "tok_span": [1, 5], "new_tok_span": [2, 6]}], "relation_list": [{"subject": "diflunisal", "sbj_char_span": [32, 42], "object": "cyclooxygenase-2", "obj_char_span": [4, 20], "rel_type": "inhibitor", "sbj_tok_span": [7, 11], "obj_tok_span": [1, 5], "new_sbj_tok_span": [10, 14], "new_obj_tok_span": [2, 6]}], "umls_entity_list": [{"mention": "cyclooxygenase-2 inhibitor", "char_span": [4, 30], "sem_type": "Pharmacologic Substance", "tok_span": [1, 6], "new_tok_span": [2, 7]}, {"mention": "diflunisal", "char_span": [32, 42], "sem_type": "Pharmacologic Substance", "tok_span": [7, 11], "new_tok_span": [10, 14]}], "new_text": "The <START=Pharmacologic Substance> cyclooxygenase - 2 inhibitor <END=Pharmacologic Substance>, <START=Pharmacologic Substance> diflunisal <END=Pharmacologic Substance>, is used in the clinic for its anti - inflammatory activity."}, {"PMID": 10626810, "id": 5, "text": "In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [62, 78], "name": "sulindac sulfide", "tok_span": [12, 17], "new_tok_span": [13, 18]}, {"ent_type": "CHEMICAL", "char_span": [109, 118], "name": "exisulind", "tok_span": [28, 32], "new_tok_span": [35, 39]}, {"ent_type": "CHEMICAL", "char_span": [120, 136], "name": "sulindac sulfone", "tok_span": [33, 38], "new_tok_span": [42, 47]}, {"ent_type": "CHEMICAL", "char_span": [205, 230], "name": "nordihydroguaiaretic acid", "tok_span": [53, 61], "new_tok_span": [65, 73]}, {"ent_type": "CHEMICAL", "char_span": [232, 236], "name": "NDGA", "tok_span": [62, 64], "new_tok_span": [74, 76]}, {"ent_type": "GENE", "char_span": [82, 87], "name": "COX-1", "tok_span": [19, 22], "new_tok_span": [22, 25]}, {"ent_type": "GENE", "char_span": [92, 97], "name": "COX-2", "tok_span": [23, 26], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [188, 191], "name": "COX", "tok_span": [49, 50], "new_tok_span": [60, 61]}, {"ent_type": "GENE", "char_span": [241, 253], "name": "lipoxygenase", "tok_span": [67, 69], "new_tok_span": [80, 82]}], "relation_list": [{"subject": "sulindac sulfide", "sbj_char_span": [62, 78], "object": "COX-1", "obj_char_span": [82, 87], "rel_type": "inhibitor", "sbj_tok_span": [12, 17], "obj_tok_span": [19, 22], "new_sbj_tok_span": [13, 18], "new_obj_tok_span": [22, 25]}, {"subject": "sulindac sulfide", "sbj_char_span": [62, 78], "object": "COX-2", "obj_char_span": [92, 97], "rel_type": "inhibitor", "sbj_tok_span": [12, 17], "obj_tok_span": [23, 26], "new_sbj_tok_span": [13, 18], "new_obj_tok_span": [28, 31]}, {"subject": "nordihydroguaiaretic acid", "sbj_char_span": [205, 230], "object": "lipoxygenase", "obj_char_span": [241, 253], "rel_type": "inhibitor", "sbj_tok_span": [53, 61], "obj_tok_span": [67, 69], "new_sbj_tok_span": [65, 73], "new_obj_tok_span": [80, 82]}, {"subject": "NDGA", "sbj_char_span": [232, 236], "object": "lipoxygenase", "obj_char_span": [241, 253], "rel_type": "inhibitor", "sbj_tok_span": [62, 64], "obj_tok_span": [67, 69], "new_sbj_tok_span": [74, 76], "new_obj_tok_span": [80, 82]}], "umls_entity_list": [{"mention": "sulindac sulfide", "char_span": [62, 78], "sem_type": "Pharmacologic Substance", "tok_span": [12, 17], "new_tok_span": [13, 18]}, {"mention": "exisulind", "char_span": [109, 118], "sem_type": "Pharmacologic Substance", "tok_span": [28, 32], "new_tok_span": [35, 39]}, {"mention": "sulindac sulfone", "char_span": [120, 136], "sem_type": "Pharmacologic Substance", "tok_span": [33, 38], "new_tok_span": [42, 47]}, {"mention": "COX", "char_span": [82, 85], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 20], "new_tok_span": [22, 23]}, {"mention": "COX", "char_span": [92, 95], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [23, 24], "new_tok_span": [28, 29]}, {"mention": "COX", "char_span": [188, 191], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [49, 50], "new_tok_span": [60, 61]}, {"mention": "lipoxygenase inhibitor", "char_span": [241, 263], "sem_type": "Pharmacologic Substance", "tok_span": [67, 70], "new_tok_span": [80, 83]}], "new_text": "In this report, we evaluated the growth - inhibitory effects of <START=Pharmacologic Substance> sulindac sulfide <END=Pharmacologic Substance>, a <START=Amino Acid, Peptide, or Protein> COX <END=Amino Acid, Peptide, or Protein> - 1 and <START=Amino Acid, Peptide, or Protein> COX <END=Amino Acid, Peptide, or Protein> - 2 inhibitor ; <START=Pharmacologic Substance> exisulind <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> sulindac sulfone <END=Pharmacologic Substance> ), a novel proapoptotic agent that does not inhibit <START=Amino Acid, Peptide, or Protein> COX <END=Amino Acid, Peptide, or Protein> enzymes ; and nordihydroguaiaretic acid ( NDGA ), a <START=Pharmacologic Substance> lipoxygenase inhibitor <END=Pharmacologic Substance> on human lung cancer cell lines."}, {"PMID": 16901636, "id": 2, "text": "Our purpose was to test the impact of single and/or combined treatment with the AT(1)-receptor blocker candesartan and the HMG-CoA reductase inhibitor rosuvastatin on infarct size and neuroscore in transient cerebral ischemia in rats.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [103, 114], "name": "candesartan", "tok_span": [23, 26], "new_tok_span": [24, 27]}, {"ent_type": "CHEMICAL", "char_span": [123, 130], "name": "HMG-CoA", "tok_span": [28, 33], "new_tok_span": [31, 36]}, {"ent_type": "CHEMICAL", "char_span": [151, 163], "name": "rosuvastatin", "tok_span": [35, 38], "new_tok_span": [40, 43]}, {"ent_type": "GENE", "char_span": [123, 140], "name": "HMG-CoA reductase", "tok_span": [28, 34], "new_tok_span": [31, 37]}, {"ent_type": "GENE", "char_span": [80, 85], "name": "AT(1)", "tok_span": [16, 20], "new_tok_span": [16, 20]}], "relation_list": [{"subject": "candesartan", "sbj_char_span": [103, 114], "object": "AT(1)", "obj_char_span": [80, 85], "rel_type": "inhibitor", "sbj_tok_span": [23, 26], "obj_tok_span": [16, 20], "new_sbj_tok_span": [24, 27], "new_obj_tok_span": [16, 20]}, {"subject": "rosuvastatin", "sbj_char_span": [151, 163], "object": "HMG-CoA reductase", "obj_char_span": [123, 140], "rel_type": "inhibitor", "sbj_tok_span": [35, 38], "obj_tok_span": [28, 34], "new_sbj_tok_span": [40, 43], "new_obj_tok_span": [31, 37]}], "umls_entity_list": [{"mention": "candesartan", "char_span": [103, 114], "sem_type": "Pharmacologic Substance", "tok_span": [23, 26], "new_tok_span": [24, 27]}, {"mention": "HMG-CoA reductase inhibitor", "char_span": [123, 150], "sem_type": "Pharmacologic Substance", "tok_span": [28, 35], "new_tok_span": [31, 38]}, {"mention": "rosuvastatin", "char_span": [151, 163], "sem_type": "Pharmacologic Substance", "tok_span": [35, 38], "new_tok_span": [40, 43]}], "new_text": "Our purpose was to test the impact of single and / or combined treatment with the AT ( 1 ) - receptor blocker <START=Pharmacologic Substance> candesartan <END=Pharmacologic Substance> and the <START=Pharmacologic Substance> HMG - CoA reductase inhibitor <END=Pharmacologic Substance> <START=Pharmacologic Substance> rosuvastatin <END=Pharmacologic Substance> on infarct size and neuroscore in transient cerebral ischemia in rats."}, {"PMID": 15967876, "id": 7, "text": "We found that although inactivation facilitated cisapride block of the HERG K+ current, it was not coupled with cisapride block of HERG when the Cs+ current was recorded.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [76, 78], "name": "K+", "tok_span": [15, 17], "new_tok_span": [19, 21]}, {"ent_type": "CHEMICAL", "char_span": [145, 148], "name": "Cs+", "tok_span": [34, 36], "new_tok_span": [42, 44]}, {"ent_type": "CHEMICAL", "char_span": [48, 57], "name": "cisapride", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [71, 75], "name": "HERG", "tok_span": [13, 15], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [131, 135], "name": "HERG", "tok_span": [30, 32], "new_tok_span": [37, 39]}], "relation_list": [{"subject": "cisapride", "sbj_char_span": [48, 57], "object": "HERG", "obj_char_span": [71, 75], "rel_type": "inhibitor", "sbj_tok_span": [6, 10], "obj_tok_span": [13, 15], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [16, 18]}], "umls_entity_list": [{"mention": "cisapride", "char_span": [48, 57], "sem_type": "Pharmacologic Substance", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"mention": "cisapride", "char_span": [112, 121], "sem_type": "Pharmacologic Substance", "tok_span": [24, 28], "new_tok_span": [29, 33]}, {"mention": "HERG", "char_span": [71, 75], "sem_type": "Gene or Genome", "tok_span": [13, 15], "new_tok_span": [16, 18]}, {"mention": "HERG", "char_span": [131, 135], "sem_type": "Gene or Genome", "tok_span": [30, 32], "new_tok_span": [37, 39]}], "new_text": "We found that although inactivation facilitated <START=Pharmacologic Substance> cisapride <END=Pharmacologic Substance> block of the <START=Gene or Genome> HERG <END=Gene or Genome> K + current, it was not coupled with <START=Pharmacologic Substance> cisapride <END=Pharmacologic Substance> block of <START=Gene or Genome> HERG <END=Gene or Genome> when the Cs + current was recorded."}, {"PMID": 23238299, "id": 3, "text": "Chelidonine and the alkaloid extract inhibited P-gp/MDR1 activity in a concentration-dependent manner in Caco-2 and CEM/ADR5000 and reversed their doxorubicin resistance.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Chelidonine", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [147, 158], "name": "doxorubicin", "tok_span": [39, 40], "new_tok_span": [52, 53]}, {"ent_type": "GENE", "char_span": [47, 51], "name": "P-gp", "tok_span": [10, 13], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [52, 56], "name": "MDR1", "tok_span": [14, 16], "new_tok_span": [25, 27]}], "relation_list": [{"subject": "Chelidonine", "sbj_char_span": [0, 11], "object": "P-gp", "obj_char_span": [47, 51], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 13], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [16, 19]}, {"subject": "Chelidonine", "sbj_char_span": [0, 11], "object": "MDR1", "obj_char_span": [52, 56], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [14, 16], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [25, 27]}], "umls_entity_list": [{"mention": "Chelidonine", "char_span": [0, 11], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "alkaloid", "char_span": [20, 28], "sem_type": "Pharmacologic Substance", "tok_span": [6, 8], "new_tok_span": [10, 12]}, {"mention": "alkaloid", "char_span": [20, 28], "sem_type": "Organic Chemical", "tok_span": [6, 8], "new_tok_span": [10, 12]}, {"mention": "gp", "char_span": [49, 51], "sem_type": "Gene or Genome", "tok_span": [12, 13], "new_tok_span": [20, 21]}, {"mention": "MDR1", "char_span": [52, 56], "sem_type": "Gene or Genome", "tok_span": [14, 16], "new_tok_span": [25, 27]}, {"mention": "gp", "char_span": [49, 51], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 13], "new_tok_span": [20, 21]}, {"mention": "doxorubicin resistance", "char_span": [147, 169], "sem_type": "Gene or Genome", "tok_span": [39, 41], "new_tok_span": [52, 54]}], "new_text": "<START=Pharmacologic Substance> Chelidonine <END=Pharmacologic Substance> and the <START=Pharmacologic Substance> <START=Organic Chemical> alkaloid <END=Pharmacologic Substance> <END=Organic Chemical> extract inhibited P - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> gp <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> / <START=Gene or Genome> MDR1 <END=Gene or Genome> activity in a concentration - dependent manner in Caco - 2 and CEM / ADR5000 and reversed their <START=Gene or Genome> doxorubicin resistance <END=Gene or Genome>."}, {"PMID": 15325927, "id": 4, "text": "After 12 months of treatment, carvedilol significantly improved all end points (plasma concentration of B-type natriuretic peptide [BNP] from 175 (35 to 209) to 106 (52 to 160) pg/ml, mean (95% confidence interval) p <0.01; New York Heart Association functional class from 2.37 (2.13 to 2.61) to 1.56 (1.21 to 1.91), p <0.01; exercise capacity estimated with the Specific Activity Scale from 4.75 (4.50 to 5.00) to 5.68 (5.22 to 6.14) METs, p <0.02), whereas conventional therapy did not (plasma BNP concentration from 150 (114 to 186) to 174 (100 to 248) pg/ml; New York Heart Association functional class from 2.29 (2.08 to 2.50) to 2.11 (1.73 to 2.49); exercise capacity from 4.57 (4.34 to 4.80) to 4.72 (4.41 to 5.03) METs).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [30, 40], "name": "carvedilol", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [104, 130], "name": "B-type natriuretic peptide", "tok_span": [19, 26], "new_tok_span": [19, 26]}, {"ent_type": "GENE", "char_span": [132, 135], "name": "BNP", "tok_span": [27, 29], "new_tok_span": [27, 29]}, {"ent_type": "GENE", "char_span": [489, 499], "name": "plasma BNP", "tok_span": [150, 153], "new_tok_span": [152, 155]}], "relation_list": [{"subject": "carvedilol", "sbj_char_span": [30, 40], "object": "B-type natriuretic peptide", "obj_char_span": [104, 130], "rel_type": "regulator", "sbj_tok_span": [6, 10], "obj_tok_span": [19, 26], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [19, 26]}, {"subject": "carvedilol", "sbj_char_span": [30, 40], "object": "BNP", "obj_char_span": [132, 135], "rel_type": "regulator", "sbj_tok_span": [6, 10], "obj_tok_span": [27, 29], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [27, 29]}], "umls_entity_list": [{"mention": "METs", "char_span": [435, 439], "sem_type": "Gene or Genome", "tok_span": [134, 136], "new_tok_span": [135, 137]}, {"mention": "METs", "char_span": [722, 726], "sem_type": "Gene or Genome", "tok_span": [233, 235], "new_tok_span": [236, 238]}], "new_text": "After 12 months of treatment, carvedilol significantly improved all end points ( plasma concentration of B - type natriuretic peptide [ BNP ] from 175 ( 35 to 209 ) to 106 ( 52 to 160 ) pg / ml, mean ( 95 % confidence interval ) p < 0. 01 ; New York Heart Association functional class from 2. 37 ( 2. 13 to 2. 61 ) to 1. 56 ( 1. 21 to 1. 91 ), p < 0. 01 ; exercise capacity estimated with the Specific Activity Scale from 4. 75 ( 4. 50 to 5. 00 ) to 5. 68 ( 5. 22 to 6. 14 ) <START=Gene or Genome> METs <END=Gene or Genome>, p < 0. 02 ), whereas conventional therapy did not ( plasma BNP concentration from 150 ( 114 to 186 ) to 174 ( 100 to 248 ) pg / ml ; New York Heart Association functional class from 2. 29 ( 2. 08 to 2. 50 ) to 2. 11 ( 1. 73 to 2. 49 ) ; exercise capacity from 4. 57 ( 4. 34 to 4. 80 ) to 4. 72 ( 4. 41 to 5. 03 ) <START=Gene or Genome> METs <END=Gene or Genome> )."}, {"PMID": 8647296, "id": 4, "text": "However, a fundamental difference was found; unlike NTR-1, NTR-2 recognizes, with high affinity, levocabastine, a histamine H1 receptor antagonist previously shown to compete with NT for low-affinity binding sites in brain.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [97, 110], "name": "levocabastine", "tok_span": [24, 29], "new_tok_span": [41, 46]}, {"ent_type": "CHEMICAL", "char_span": [114, 123], "name": "histamine", "tok_span": [31, 32], "new_tok_span": [49, 50]}, {"ent_type": "GENE", "char_span": [52, 57], "name": "NTR-1", "tok_span": [9, 13], "new_tok_span": [16, 20]}, {"ent_type": "GENE", "char_span": [59, 64], "name": "NTR-2", "tok_span": [14, 18], "new_tok_span": [27, 31]}, {"ent_type": "GENE", "char_span": [114, 135], "name": "histamine H1 receptor", "tok_span": [31, 35], "new_tok_span": [49, 53]}, {"ent_type": "GENE", "char_span": [180, 182], "name": "NT", "tok_span": [41, 42], "new_tok_span": [65, 66]}], "relation_list": [{"subject": "levocabastine", "sbj_char_span": [97, 110], "object": "histamine H1 receptor", "obj_char_span": [114, 135], "rel_type": "agonist or antagonist", "sbj_tok_span": [24, 29], "obj_tok_span": [31, 35], "new_sbj_tok_span": [41, 46], "new_obj_tok_span": [49, 53]}], "umls_entity_list": [{"mention": "NTR", "char_span": [52, 55], "sem_type": "Gene or Genome", "tok_span": [9, 11], "new_tok_span": [16, 18]}, {"mention": "NTR", "char_span": [59, 62], "sem_type": "Gene or Genome", "tok_span": [14, 16], "new_tok_span": [27, 29]}, {"mention": "levocabastine", "char_span": [97, 110], "sem_type": "Pharmacologic Substance", "tok_span": [24, 29], "new_tok_span": [41, 46]}, {"mention": "nt", "char_span": [18, 20], "sem_type": "Gene or Genome", "tok_span": [3, 4], "new_tok_span": [5, 6]}, {"mention": "NT", "char_span": [52, 54], "sem_type": "Gene or Genome", "tok_span": [9, 10], "new_tok_span": [16, 17]}, {"mention": "NT", "char_span": [59, 61], "sem_type": "Gene or Genome", "tok_span": [14, 15], "new_tok_span": [27, 28]}, {"mention": "nt", "char_span": [137, 139], "sem_type": "Gene or Genome", "tok_span": [35, 36], "new_tok_span": [55, 56]}, {"mention": "NT", "char_span": [180, 182], "sem_type": "Gene or Genome", "tok_span": [41, 42], "new_tok_span": [65, 66]}, {"mention": "nt", "char_span": [18, 20], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 4], "new_tok_span": [5, 6]}, {"mention": "NT", "char_span": [52, 54], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 10], "new_tok_span": [16, 17]}, {"mention": "NT", "char_span": [59, 61], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 15], "new_tok_span": [27, 28]}, {"mention": "nt", "char_span": [137, 139], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 36], "new_tok_span": [55, 56]}, {"mention": "NT", "char_span": [180, 182], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 42], "new_tok_span": [65, 66]}], "new_text": "However, a <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> fundamental <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> difference was found ; unlike <START=Gene or Genome> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NT <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>R <END=Gene or Genome> - 1, <START=Gene or Genome> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NT <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>R <END=Gene or Genome> - 2 recognizes, with high affinity, <START=Pharmacologic Substance> levocabastine <END=Pharmacologic Substance>, a histamine H1 receptor <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> antagonist <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> previously shown to compete with <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NT <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> for low - affinity binding sites in brain."}, {"PMID": 15224175, "id": 7, "text": "Thus, the cranio-selective vasoconstriction elicited by ergotamine in dogs is predominantly mediated by 5-HT1B receptors as well as alpha2A/2C-adrenoceptor subtypes and, to a lesser extent, by alpha1-adrenoceptors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [56, 66], "name": "ergotamine", "tok_span": [11, 15], "new_tok_span": [12, 16]}, {"ent_type": "GENE", "char_span": [104, 110], "name": "5-HT1B", "tok_span": [21, 26], "new_tok_span": [23, 28]}, {"ent_type": "GENE", "char_span": [132, 155], "name": "alpha2A/2C-adrenoceptor", "tok_span": [30, 40], "new_tok_span": [32, 42]}, {"ent_type": "GENE", "char_span": [193, 213], "name": "alpha1-adrenoceptors", "tok_span": [49, 56], "new_tok_span": [53, 60]}], "relation_list": [{"subject": "ergotamine", "sbj_char_span": [56, 66], "object": "alpha1-adrenoceptors", "obj_char_span": [193, 213], "rel_type": "regulator", "sbj_tok_span": [11, 15], "obj_tok_span": [49, 56], "new_sbj_tok_span": [12, 16], "new_obj_tok_span": [53, 60]}], "umls_entity_list": [{"mention": "ergotamine", "char_span": [56, 66], "sem_type": "Pharmacologic Substance", "tok_span": [11, 15], "new_tok_span": [12, 16]}, {"mention": "adrenoceptor", "char_span": [143, 155], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 40], "new_tok_span": [40, 43]}, {"mention": "adrenoceptor", "char_span": [200, 212], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [52, 55], "new_tok_span": [57, 60]}], "new_text": "Thus, the cranio - selective vasoconstriction elicited by <START=Pharmacologic Substance> ergotamine <END=Pharmacologic Substance> in dogs is predominantly mediated by 5 - HT1B receptors as well as alpha2A / 2C - <START=Amino Acid, Peptide, or Protein> adrenoceptor <END=Amino Acid, Peptide, or Protein> subtypes and, to a lesser extent, by alpha1 - <START=Amino Acid, Peptide, or Protein> adrenoceptor <END=Amino Acid, Peptide, or Protein>s."}, {"PMID": 11270983, "id": 7, "text": "The endothelium-dependent component of the response to lower concentrations of endothelin-1 was inhibited by indometacin and ridogrel, but not by dazoxiben.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [109, 120], "name": "indometacin", "tok_span": [19, 22], "new_tok_span": [19, 22]}, {"ent_type": "CHEMICAL", "char_span": [125, 133], "name": "ridogrel", "tok_span": [23, 25], "new_tok_span": [23, 25]}, {"ent_type": "CHEMICAL", "char_span": [146, 155], "name": "dazoxiben", "tok_span": [29, 33], "new_tok_span": [30, 34]}, {"ent_type": "GENE", "char_span": [79, 91], "name": "endothelin-1", "tok_span": [12, 16], "new_tok_span": [12, 16]}], "relation_list": [{"subject": "indometacin", "sbj_char_span": [109, 120], "object": "endothelin-1", "obj_char_span": [79, 91], "rel_type": "inhibitor", "sbj_tok_span": [19, 22], "obj_tok_span": [12, 16], "new_sbj_tok_span": [19, 22], "new_obj_tok_span": [12, 16]}, {"subject": "ridogrel", "sbj_char_span": [125, 133], "object": "endothelin-1", "obj_char_span": [79, 91], "rel_type": "inhibitor", "sbj_tok_span": [23, 25], "obj_tok_span": [12, 16], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [12, 16]}], "umls_entity_list": [{"mention": "dazoxiben", "char_span": [146, 155], "sem_type": "Pharmacologic Substance", "tok_span": [29, 33], "new_tok_span": [30, 34]}], "new_text": "The endothelium - dependent component of the response to lower concentrations of endothelin - 1 was inhibited by indometacin and ridogrel, but not by <START=Pharmacologic Substance> dazoxiben <END=Pharmacologic Substance>."}, {"PMID": 23144001, "id": 0, "text": "Real-time fluorescence turn-on detection of alkaline phosphatase activity with a novel perylene probe.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [87, 95], "name": "perylene", "tok_span": [15, 17], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [44, 64], "name": "alkaline phosphatase", "tok_span": [9, 11], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "perylene", "sbj_char_span": [87, 95], "object": "alkaline phosphatase", "obj_char_span": [44, 64], "rel_type": "regulator", "sbj_tok_span": [15, 17], "obj_tok_span": [9, 11], "new_sbj_tok_span": [20, 22], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [{"mention": "alkaline phosphatase", "char_span": [44, 64], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 11], "new_tok_span": [11, 13]}, {"mention": "alkaline phosphatase", "char_span": [44, 64], "sem_type": "Organic Chemical", "tok_span": [9, 11], "new_tok_span": [11, 13]}, {"mention": "perylene", "char_span": [87, 95], "sem_type": "Organic Chemical", "tok_span": [15, 17], "new_tok_span": [20, 22]}, {"mention": "probe", "char_span": [96, 101], "sem_type": "Gene or Genome", "tok_span": [17, 18], "new_tok_span": [24, 25]}], "new_text": "Real - time fluorescence turn - on detection of <START=Amino Acid, Peptide, or Protein> <START=Organic Chemical> alkaline phosphatase <END=Amino Acid, Peptide, or Protein> <END=Organic Chemical> activity with a novel <START=Organic Chemical> perylene <END=Organic Chemical> <START=Gene or Genome> probe <END=Gene or Genome>."}, {"PMID": 11578145, "id": 9, "text": "PPG is an effective inhibitor of the pyridoxal 5'-phosphate (PLP)-containing enzyme bacterial L-methionine gamma-lyase (EC 4.4.1.11) contributing to the alpha,gamma-elimination reaction of SeMet and cystathionine gamma-lyase (EC 4.4.1.1) relating to conversion of SeMet to SeCyH.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 3], "name": "PPG", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "CHEMICAL", "char_span": [37, 59], "name": "pyridoxal 5'-phosphate", "tok_span": [8, 16], "new_tok_span": [8, 16]}, {"ent_type": "CHEMICAL", "char_span": [61, 64], "name": "PLP", "tok_span": [17, 19], "new_tok_span": [17, 19]}, {"ent_type": "CHEMICAL", "char_span": [94, 106], "name": "L-methionine", "tok_span": [24, 27], "new_tok_span": [26, 29]}, {"ent_type": "CHEMICAL", "char_span": [189, 194], "name": "SeMet", "tok_span": [51, 53], "new_tok_span": [55, 57]}, {"ent_type": "CHEMICAL", "char_span": [199, 212], "name": "cystathionine", "tok_span": [54, 57], "new_tok_span": [58, 61]}, {"ent_type": "CHEMICAL", "char_span": [264, 269], "name": "SeMet", "tok_span": [75, 77], "new_tok_span": [79, 81]}, {"ent_type": "CHEMICAL", "char_span": [273, 278], "name": "SeCyH", "tok_span": [78, 81], "new_tok_span": [82, 85]}, {"ent_type": "GENE", "char_span": [84, 118], "name": "bacterial L-methionine gamma-lyase", "tok_span": [23, 31], "new_tok_span": [25, 33]}, {"ent_type": "GENE", "char_span": [120, 131], "name": "EC 4.4.1.11", "tok_span": [32, 40], "new_tok_span": [36, 44]}, {"ent_type": "GENE", "char_span": [199, 224], "name": "cystathionine gamma-lyase", "tok_span": [54, 61], "new_tok_span": [58, 65]}, {"ent_type": "GENE", "char_span": [226, 236], "name": "EC 4.4.1.1", "tok_span": [62, 70], "new_tok_span": [66, 74]}], "relation_list": [{"subject": "PPG", "sbj_char_span": [0, 3], "object": "bacterial L-methionine gamma-lyase", "obj_char_span": [84, 118], "rel_type": "inhibitor", "sbj_tok_span": [0, 2], "obj_tok_span": [23, 31], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [25, 33]}, {"subject": "PPG", "sbj_char_span": [0, 3], "object": "EC 4.4.1.11", "obj_char_span": [120, 131], "rel_type": "inhibitor", "sbj_tok_span": [0, 2], "obj_tok_span": [32, 40], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [36, 44]}, {"subject": "SeMet", "sbj_char_span": [189, 194], "object": "bacterial L-methionine gamma-lyase", "obj_char_span": [84, 118], "rel_type": "product or substrate", "sbj_tok_span": [51, 53], "obj_tok_span": [23, 31], "new_sbj_tok_span": [55, 57], "new_obj_tok_span": [25, 33]}, {"subject": "SeMet", "sbj_char_span": [189, 194], "object": "EC 4.4.1.11", "obj_char_span": [120, 131], "rel_type": "product or substrate", "sbj_tok_span": [51, 53], "obj_tok_span": [32, 40], "new_sbj_tok_span": [55, 57], "new_obj_tok_span": [36, 44]}, {"subject": "SeMet", "sbj_char_span": [264, 269], "object": "cystathionine gamma-lyase", "obj_char_span": [199, 224], "rel_type": "product or substrate", "sbj_tok_span": [75, 77], "obj_tok_span": [54, 61], "new_sbj_tok_span": [79, 81], "new_obj_tok_span": [58, 65]}, {"subject": "SeMet", "sbj_char_span": [264, 269], "object": "EC 4.4.1.1", "obj_char_span": [226, 236], "rel_type": "product or substrate", "sbj_tok_span": [75, 77], "obj_tok_span": [62, 70], "new_sbj_tok_span": [79, 81], "new_obj_tok_span": [66, 74]}, {"subject": "SeCyH", "sbj_char_span": [273, 278], "object": "cystathionine gamma-lyase", "obj_char_span": [199, 224], "rel_type": "product or substrate", "sbj_tok_span": [78, 81], "obj_tok_span": [54, 61], "new_sbj_tok_span": [82, 85], "new_obj_tok_span": [58, 65]}, {"subject": "SeCyH", "sbj_char_span": [273, 278], "object": "EC 4.4.1.1", "obj_char_span": [226, 236], "rel_type": "product or substrate", "sbj_tok_span": [78, 81], "obj_tok_span": [62, 70], "new_sbj_tok_span": [82, 85], "new_obj_tok_span": [66, 74]}], "umls_entity_list": [{"mention": "enzyme", "char_span": [77, 83], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 23], "new_tok_span": [23, 24]}, {"mention": "methionine", "char_span": [96, 106], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 27], "new_tok_span": [29, 30]}], "new_text": "PPG is an effective inhibitor of the pyridoxal 5'- phosphate ( PLP ) - containing <START=Amino Acid, Peptide, or Protein> enzyme <END=Amino Acid, Peptide, or Protein> bacterial L - <START=Amino Acid, Peptide, or Protein> methionine <END=Amino Acid, Peptide, or Protein> gamma - lyase ( EC 4. 4. 1. 11 ) contributing to the alpha, gamma - elimination reaction of SeMet and cystathionine gamma - lyase ( EC 4. 4. 1. 1 ) relating to conversion of SeMet to SeCyH."}, {"PMID": 23044489, "id": 2, "text": "Organophosphorus nerve agents (NA), potent irreversible cholinesterase inhibitors, could induce severe seizures, status epilepticus (SE), seizure-related brain damage (SRBD) and lethality.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 16], "name": "Organophosphorus", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "GENE", "char_span": [56, 70], "name": "cholinesterase", "tok_span": [11, 14], "new_tok_span": [14, 17]}], "relation_list": [{"subject": "Organophosphorus", "sbj_char_span": [0, 16], "object": "cholinesterase", "obj_char_span": [56, 70], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [11, 14], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [14, 17]}], "umls_entity_list": [{"mention": "nerve", "char_span": [17, 22], "sem_type": "Organic Chemical", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"mention": "cholinesterase", "char_span": [56, 70], "sem_type": "Pharmacologic Substance", "tok_span": [11, 14], "new_tok_span": [14, 17]}], "new_text": "Organophosphorus <START=Organic Chemical> nerve <END=Organic Chemical> agents ( NA ), potent irreversible <START=Pharmacologic Substance> cholinesterase <END=Pharmacologic Substance> inhibitors, could induce severe seizures, status epilepticus ( SE ), seizure - related brain damage ( SRBD ) and lethality."}, {"PMID": 18574460, "id": 8, "text": "Estimated affinities for the fast-inactivated channel state were 81 nM, 312 nM and 227 nM for 4-iodopropofol, 4-bromopropofol and 4-chloropropofol in Na(V)1.4, and 450 nM for 4-chloropropofol in Na(V)1.2.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [94, 108], "name": "4-iodopropofol", "tok_span": [20, 25], "new_tok_span": [20, 25]}, {"ent_type": "CHEMICAL", "char_span": [110, 125], "name": "4-bromopropofol", "tok_span": [26, 31], "new_tok_span": [27, 32]}, {"ent_type": "CHEMICAL", "char_span": [130, 146], "name": "4-chloropropofol", "tok_span": [32, 37], "new_tok_span": [34, 39]}, {"ent_type": "CHEMICAL", "char_span": [175, 191], "name": "4-chloropropofol", "tok_span": [50, 55], "new_tok_span": [52, 57]}, {"ent_type": "GENE", "char_span": [150, 158], "name": "Na(V)1.4", "tok_span": [38, 45], "new_tok_span": [40, 47]}, {"ent_type": "GENE", "char_span": [195, 203], "name": "Na(V)1.2", "tok_span": [56, 63], "new_tok_span": [58, 65]}], "relation_list": [{"subject": "4-iodopropofol", "sbj_char_span": [94, 108], "object": "Na(V)1.4", "obj_char_span": [150, 158], "rel_type": "regulator", "sbj_tok_span": [20, 25], "obj_tok_span": [38, 45], "new_sbj_tok_span": [20, 25], "new_obj_tok_span": [40, 47]}, {"subject": "4-bromopropofol", "sbj_char_span": [110, 125], "object": "Na(V)1.4", "obj_char_span": [150, 158], "rel_type": "regulator", "sbj_tok_span": [26, 31], "obj_tok_span": [38, 45], "new_sbj_tok_span": [27, 32], "new_obj_tok_span": [40, 47]}, {"subject": "4-chloropropofol", "sbj_char_span": [130, 146], "object": "Na(V)1.4", "obj_char_span": [150, 158], "rel_type": "regulator", "sbj_tok_span": [32, 37], "obj_tok_span": [38, 45], "new_sbj_tok_span": [34, 39], "new_obj_tok_span": [40, 47]}, {"subject": "4-chloropropofol", "sbj_char_span": [175, 191], "object": "Na(V)1.2", "obj_char_span": [195, 203], "rel_type": "regulator", "sbj_tok_span": [50, 55], "obj_tok_span": [56, 63], "new_sbj_tok_span": [52, 57], "new_obj_tok_span": [58, 65]}, {"subject": "4-iodopropofol", "sbj_char_span": [94, 108], "object": "Na(V)1.4", "obj_char_span": [150, 158], "rel_type": "inhibitor", "sbj_tok_span": [20, 25], "obj_tok_span": [38, 45], "new_sbj_tok_span": [20, 25], "new_obj_tok_span": [40, 47]}, {"subject": "4-bromopropofol", "sbj_char_span": [110, 125], "object": "Na(V)1.4", "obj_char_span": [150, 158], "rel_type": "inhibitor", "sbj_tok_span": [26, 31], "obj_tok_span": [38, 45], "new_sbj_tok_span": [27, 32], "new_obj_tok_span": [40, 47]}, {"subject": "4-chloropropofol", "sbj_char_span": [130, 146], "object": "Na(V)1.4", "obj_char_span": [150, 158], "rel_type": "inhibitor", "sbj_tok_span": [32, 37], "obj_tok_span": [38, 45], "new_sbj_tok_span": [34, 39], "new_obj_tok_span": [40, 47]}, {"subject": "4-chloropropofol", "sbj_char_span": [175, 191], "object": "Na(V)1.2", "obj_char_span": [195, 203], "rel_type": "inhibitor", "sbj_tok_span": [50, 55], "obj_tok_span": [56, 63], "new_sbj_tok_span": [52, 57], "new_obj_tok_span": [58, 65]}], "umls_entity_list": [{"mention": "4-bromopropofol", "char_span": [110, 125], "sem_type": "Pharmacologic Substance", "tok_span": [26, 31], "new_tok_span": [27, 32]}], "new_text": "Estimated affinities for the fast - inactivated channel state were 81 nM, 312 nM and 227 nM for 4 - iodopropofol, <START=Pharmacologic Substance> 4 - bromopropofol <END=Pharmacologic Substance> and 4 - chloropropofol in Na ( V ) 1. 4, and 450 nM for 4 - chloropropofol in Na ( V ) 1. 2."}, {"PMID": 23551063, "id": 1, "text": "Abstract 1.  UDP-glucuronosyltransferases (UGTs) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2.  We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs. 3.  We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [13, 16], "name": "UDP", "tok_span": [3, 4], "new_tok_span": [3, 4]}, {"ent_type": "CHEMICAL", "char_span": [257, 292], "name": "7-hydroxy-4-trifluoromethylcoumarin", "tok_span": [53, 65], "new_tok_span": [55, 67]}, {"ent_type": "CHEMICAL", "char_span": [294, 297], "name": "HFC", "tok_span": [66, 68], "new_tok_span": [68, 70]}, {"ent_type": "CHEMICAL", "char_span": [386, 389], "name": "HFC", "tok_span": [91, 93], "new_tok_span": [93, 95]}, {"ent_type": "GENE", "char_span": [13, 41], "name": "UDP-glucuronosyltransferases", "tok_span": [3, 10], "new_tok_span": [3, 10]}, {"ent_type": "GENE", "char_span": [311, 315], "name": "UGTs", "tok_span": [71, 74], "new_tok_span": [73, 76]}, {"ent_type": "GENE", "char_span": [371, 381], "name": "human UGTs", "tok_span": [86, 90], "new_tok_span": [88, 92]}, {"ent_type": "GENE", "char_span": [43, 47], "name": "UGTs", "tok_span": [11, 14], "new_tok_span": [13, 16]}], "relation_list": [{"subject": "7-hydroxy-4-trifluoromethylcoumarin", "sbj_char_span": [257, 292], "object": "UGTs", "obj_char_span": [311, 315], "rel_type": "product or substrate", "sbj_tok_span": [53, 65], "obj_tok_span": [71, 74], "new_sbj_tok_span": [55, 67], "new_obj_tok_span": [73, 76]}, {"subject": "HFC", "sbj_char_span": [294, 297], "object": "UGTs", "obj_char_span": [311, 315], "rel_type": "product or substrate", "sbj_tok_span": [66, 68], "obj_tok_span": [71, 74], "new_sbj_tok_span": [68, 70], "new_obj_tok_span": [73, 76]}, {"subject": "HFC", "sbj_char_span": [386, 389], "object": "human UGTs", "obj_char_span": [371, 381], "rel_type": "product or substrate", "sbj_tok_span": [91, 93], "obj_tok_span": [86, 90], "new_sbj_tok_span": [93, 95], "new_obj_tok_span": [88, 92]}], "umls_entity_list": [{"mention": "glucuronosyltransferase", "char_span": [17, 40], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 9], "new_tok_span": [6, 10]}], "new_text": "Abstract 1. UDP - <START=Amino Acid, Peptide, or Protein> glucuronosyltransferase <END=Amino Acid, Peptide, or Protein>s ( UGTs ) are versatile and important conjugation enzymes in the metabolism of drugs and other xenobiotics. 2. We have developed a convenient quantitative multi - well plate assay to measure the glucuronidation rate of 7 - hydroxy - 4 - trifluoromethylcoumarin ( HFC ) for several UGTs. 3. We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes."}, {"PMID": 2567596, "id": 6, "text": "Moreover, the H2-selective agonist 4-methylhistamine (Ki = 412 microM) was even more potent than its H1-selective 2-methylderivative (Ki = 772 microM). Since several ethylenediamines were also very potent in displacing [3H]mepyramine we suggest the presence of an ethylenediamine recognition site on rat liver plasma membrane which is unrelated to the histamine H1-receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [352, 361], "name": "histamine", "tok_span": [86, 87], "new_tok_span": [98, 99]}, {"ent_type": "CHEMICAL", "char_span": [35, 52], "name": "4-methylhistamine", "tok_span": [8, 13], "new_tok_span": [8, 13]}, {"ent_type": "CHEMICAL", "char_span": [166, 182], "name": "ethylenediamines", "tok_span": [48, 51], "new_tok_span": [53, 56]}, {"ent_type": "CHEMICAL", "char_span": [219, 233], "name": "[3H]mepyramine", "tok_span": [58, 65], "new_tok_span": [66, 73]}, {"ent_type": "CHEMICAL", "char_span": [264, 279], "name": "ethylenediamine", "tok_span": [71, 74], "new_tok_span": [81, 84]}, {"ent_type": "GENE", "char_span": [352, 373], "name": "histamine H1-receptor", "tok_span": [86, 91], "new_tok_span": [98, 103]}, {"ent_type": "GENE", "char_span": [14, 16], "name": "H2", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "GENE", "char_span": [101, 103], "name": "H1", "tok_span": [27, 29], "new_tok_span": [29, 31]}], "relation_list": [{"subject": "4-methylhistamine", "sbj_char_span": [35, 52], "object": "H2", "obj_char_span": [14, 16], "rel_type": "agonist or antagonist", "sbj_tok_span": [8, 13], "obj_tok_span": [3, 5], "new_sbj_tok_span": [8, 13], "new_obj_tok_span": [3, 5]}], "umls_entity_list": [{"mention": "methylhistamine", "char_span": [37, 52], "sem_type": "Organic Chemical", "tok_span": [10, 13], "new_tok_span": [11, 14]}, {"mention": "ethylenediamines", "char_span": [166, 182], "sem_type": "Organic Chemical", "tok_span": [48, 51], "new_tok_span": [53, 56]}, {"mention": "ethylenediamine", "char_span": [166, 181], "sem_type": "Pharmacologic Substance", "tok_span": [48, 51], "new_tok_span": [53, 56]}, {"mention": "ethylenediamine", "char_span": [264, 279], "sem_type": "Pharmacologic Substance", "tok_span": [71, 74], "new_tok_span": [81, 84]}, {"mention": "ethylenediamine", "char_span": [166, 181], "sem_type": "Organic Chemical", "tok_span": [48, 51], "new_tok_span": [53, 56]}, {"mention": "ethylenediamine", "char_span": [264, 279], "sem_type": "Organic Chemical", "tok_span": [71, 74], "new_tok_span": [81, 84]}], "new_text": "Moreover, the H2 - selective agonist 4 - <START=Organic Chemical> methylhistamine <END=Organic Chemical> ( Ki = 412 microM ) was even more potent than its H1 - selective 2 - methylderivative ( Ki = 772 microM ). Since several <START=Organic Chemical> <START=Pharmacologic Substance> <START=Organic Chemical> ethylenediamines <END=Organic Chemical> <END=Pharmacologic Substance> <END=Organic Chemical> were also very potent in displacing [ 3H ] mepyramine we suggest the presence of an <START=Pharmacologic Substance> <START=Organic Chemical> ethylenediamine <END=Pharmacologic Substance> <END=Organic Chemical> recognition site on rat liver plasma membrane which is unrelated to the histamine H1 - receptor."}, {"PMID": 9040115, "id": 11, "text": "Conversely, opioid antagonists such as naloxone and naltrexone (which bind to non-selectively opioid receptors) have been shown to decrease alcohol consumption under various experimental conditions.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [39, 47], "name": "naloxone", "tok_span": [6, 9], "new_tok_span": [9, 12]}, {"ent_type": "CHEMICAL", "char_span": [52, 62], "name": "naltrexone", "tok_span": [10, 14], "new_tok_span": [14, 18]}, {"ent_type": "CHEMICAL", "char_span": [140, 147], "name": "alcohol", "tok_span": [29, 30], "new_tok_span": [33, 34]}, {"ent_type": "GENE", "char_span": [94, 110], "name": "opioid receptors", "tok_span": [21, 23], "new_tok_span": [25, 27]}], "relation_list": [{"subject": "naloxone", "sbj_char_span": [39, 47], "object": "opioid receptors", "obj_char_span": [94, 110], "rel_type": "regulator", "sbj_tok_span": [6, 9], "obj_tok_span": [21, 23], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [25, 27]}, {"subject": "naltrexone", "sbj_char_span": [52, 62], "object": "opioid receptors", "obj_char_span": [94, 110], "rel_type": "regulator", "sbj_tok_span": [10, 14], "obj_tok_span": [21, 23], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [25, 27]}, {"subject": "naloxone", "sbj_char_span": [39, 47], "object": "opioid receptors", "obj_char_span": [94, 110], "rel_type": "agonist or antagonist", "sbj_tok_span": [6, 9], "obj_tok_span": [21, 23], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [25, 27]}, {"subject": "naltrexone", "sbj_char_span": [52, 62], "object": "opioid receptors", "obj_char_span": [94, 110], "rel_type": "activator", "sbj_tok_span": [10, 14], "obj_tok_span": [21, 23], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [25, 27]}], "umls_entity_list": [{"mention": "opioid antagonists", "char_span": [12, 30], "sem_type": "Pharmacologic Substance", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"mention": "naloxone", "char_span": [39, 47], "sem_type": "Organic Chemical", "tok_span": [6, 9], "new_tok_span": [9, 12]}], "new_text": "Conversely, <START=Pharmacologic Substance> opioid antagonists <END=Pharmacologic Substance> such as <START=Organic Chemical> naloxone <END=Organic Chemical> and naltrexone ( which bind to non - selectively opioid receptors ) have been shown to decrease alcohol consumption under various experimental conditions."}, {"PMID": 23500772, "id": 3, "text": "HbA1c level in DM12W group was higher than in DM4W group, HbA1c level in EtOH+DM8W group was lower than in DM8W group.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 77], "name": "EtOH", "tok_span": [23, 25], "new_tok_span": [23, 25]}, {"ent_type": "GENE", "char_span": [0, 5], "name": "HbA1c", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "GENE", "char_span": [58, 63], "name": "HbA1c", "tok_span": [18, 21], "new_tok_span": [18, 21]}], "relation_list": [{"subject": "EtOH", "sbj_char_span": [73, 77], "object": "HbA1c", "obj_char_span": [58, 63], "rel_type": "regulator", "sbj_tok_span": [23, 25], "obj_tok_span": [18, 21], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [18, 21]}], "umls_entity_list": [], "new_text": "HbA1c level in DM12W group was higher than in DM4W group, HbA1c level in EtOH + DM8W group was lower than in DM8W group."}, {"PMID": 23353701, "id": 6, "text": "Interestingly, AdOx disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/PI3K, which is linked to various tumorigenic responses.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [15, 19], "name": "AdOx", "tok_span": [2, 4], "new_tok_span": [2, 4]}, {"ent_type": "GENE", "char_span": [30, 35], "name": "actin", "tok_span": [5, 6], "new_tok_span": [5, 6]}, {"ent_type": "GENE", "char_span": [159, 162], "name": "Src", "tok_span": [24, 25], "new_tok_span": [25, 26]}, {"ent_type": "GENE", "char_span": [167, 170], "name": "p85", "tok_span": [26, 28], "new_tok_span": [30, 32]}, {"ent_type": "GENE", "char_span": [171, 175], "name": "PI3K", "tok_span": [29, 32], "new_tok_span": [37, 40]}], "relation_list": [{"subject": "AdOx", "sbj_char_span": [15, 19], "object": "actin", "obj_char_span": [30, 35], "rel_type": "inhibitor", "sbj_tok_span": [2, 4], "obj_tok_span": [5, 6], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [5, 6]}, {"subject": "AdOx", "sbj_char_span": [15, 19], "object": "Src", "obj_char_span": [159, 162], "rel_type": "regulator", "sbj_tok_span": [2, 4], "obj_tok_span": [24, 25], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [25, 26]}, {"subject": "AdOx", "sbj_char_span": [15, 19], "object": "p85", "obj_char_span": [167, 170], "rel_type": "regulator", "sbj_tok_span": [2, 4], "obj_tok_span": [26, 28], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [30, 32]}, {"subject": "AdOx", "sbj_char_span": [15, 19], "object": "PI3K", "obj_char_span": [171, 175], "rel_type": "regulator", "sbj_tok_span": [2, 4], "obj_tok_span": [29, 32], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [37, 40]}], "umls_entity_list": [{"mention": "Src", "char_span": [159, 162], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 25], "new_tok_span": [25, 26]}, {"mention": "p85", "char_span": [167, 170], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 28], "new_tok_span": [30, 32]}, {"mention": "PI3K", "char_span": [171, 175], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 32], "new_tok_span": [37, 40]}, {"mention": "PI3K", "char_span": [171, 175], "sem_type": "Gene or Genome", "tok_span": [29, 32], "new_tok_span": [37, 40]}, {"mention": "p85", "char_span": [167, 170], "sem_type": "Gene or Genome", "tok_span": [26, 28], "new_tok_span": [30, 32]}], "new_text": "Interestingly, AdOx disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of <START=Amino Acid, Peptide, or Protein> Src <END=Amino Acid, Peptide, or Protein> and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> p85 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> / <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PI3K <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, which is linked to various tumorigenic responses."}, {"PMID": 10667230, "id": 6, "text": "Suramin inhibited the anchorage-independent growth induced by IGF-1 or TGF alpha only at an IC50 of 100 micrograms/ml.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 7], "name": "Suramin", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [62, 67], "name": "IGF-1", "tok_span": [11, 14], "new_tok_span": [12, 15]}, {"ent_type": "GENE", "char_span": [71, 80], "name": "TGF alpha", "tok_span": [15, 17], "new_tok_span": [17, 19]}], "relation_list": [{"subject": "Suramin", "sbj_char_span": [0, 7], "object": "IGF-1", "obj_char_span": [62, 67], "rel_type": "inhibitor", "sbj_tok_span": [0, 2], "obj_tok_span": [11, 14], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [12, 15]}, {"subject": "Suramin", "sbj_char_span": [0, 7], "object": "TGF alpha", "obj_char_span": [71, 80], "rel_type": "inhibitor", "sbj_tok_span": [0, 2], "obj_tok_span": [15, 17], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [17, 19]}], "umls_entity_list": [{"mention": "IGF-1", "char_span": [62, 67], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 14], "new_tok_span": [12, 15]}], "new_text": "Suramin inhibited the anchorage - independent growth induced by <START=Amino Acid, Peptide, or Protein> IGF - 1 <END=Amino Acid, Peptide, or Protein> or TGF alpha only at an IC50 of 100 micrograms / ml."}, {"PMID": 1691366, "id": 5, "text": "Our results suggest that viable adult rat ventricular myocytes may contain two beta 1-adrenoceptor binding sites exhibiting different affinities for bisoprolol, whereas beta 2-adrenergic receptors are completely absent.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [149, 159], "name": "bisoprolol", "tok_span": [24, 27], "new_tok_span": [25, 28]}, {"ent_type": "GENE", "char_span": [79, 112], "name": "beta 1-adrenoceptor binding sites", "tok_span": [12, 20], "new_tok_span": [12, 20]}, {"ent_type": "GENE", "char_span": [169, 196], "name": "beta 2-adrenergic receptors", "tok_span": [29, 35], "new_tok_span": [31, 37]}], "relation_list": [{"subject": "bisoprolol", "sbj_char_span": [149, 159], "object": "beta 1-adrenoceptor binding sites", "obj_char_span": [79, 112], "rel_type": "inhibitor", "sbj_tok_span": [24, 27], "obj_tok_span": [12, 20], "new_sbj_tok_span": [25, 28], "new_obj_tok_span": [12, 20]}], "umls_entity_list": [{"mention": "bisoprolol", "char_span": [149, 159], "sem_type": "Pharmacologic Substance", "tok_span": [24, 27], "new_tok_span": [25, 28]}], "new_text": "Our results suggest that viable adult rat ventricular myocytes may contain two beta 1 - adrenoceptor binding sites exhibiting different affinities for <START=Pharmacologic Substance> bisoprolol <END=Pharmacologic Substance>, whereas beta 2 - adrenergic receptors are completely absent."}, {"PMID": 23557840, "id": 2, "text": "Continuing our previous work, we take the first steps of structure-activity relationship exploration and show that 1,3,4-oxadiazol-2-ones can serve as scaffold for both selective FAAH and MAGL inhibitors, and also function as a dual FAAH/MAGL inhibitor at sub-micromolar IC50 values.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [115, 137], "name": "1,3,4-oxadiazol-2-ones", "tok_span": [20, 33], "new_tok_span": [20, 33]}, {"ent_type": "GENE", "char_span": [179, 183], "name": "FAAH", "tok_span": [40, 42], "new_tok_span": [41, 43]}, {"ent_type": "GENE", "char_span": [188, 192], "name": "MAGL", "tok_span": [43, 45], "new_tok_span": [46, 48]}, {"ent_type": "GENE", "char_span": [233, 237], "name": "FAAH", "tok_span": [53, 55], "new_tok_span": [58, 60]}, {"ent_type": "GENE", "char_span": [238, 242], "name": "MAGL", "tok_span": [56, 58], "new_tok_span": [63, 65]}], "relation_list": [{"subject": "1,3,4-oxadiazol-2-ones", "sbj_char_span": [115, 137], "object": "FAAH", "obj_char_span": [179, 183], "rel_type": "inhibitor", "sbj_tok_span": [20, 33], "obj_tok_span": [40, 42], "new_sbj_tok_span": [20, 33], "new_obj_tok_span": [41, 43]}, {"subject": "1,3,4-oxadiazol-2-ones", "sbj_char_span": [115, 137], "object": "MAGL", "obj_char_span": [188, 192], "rel_type": "inhibitor", "sbj_tok_span": [20, 33], "obj_tok_span": [43, 45], "new_sbj_tok_span": [20, 33], "new_obj_tok_span": [46, 48]}, {"subject": "1,3,4-oxadiazol-2-ones", "sbj_char_span": [115, 137], "object": "MAGL", "obj_char_span": [238, 242], "rel_type": "inhibitor", "sbj_tok_span": [20, 33], "obj_tok_span": [56, 58], "new_sbj_tok_span": [20, 33], "new_obj_tok_span": [63, 65]}, {"subject": "1,3,4-oxadiazol-2-ones", "sbj_char_span": [115, 137], "object": "FAAH", "obj_char_span": [233, 237], "rel_type": "inhibitor", "sbj_tok_span": [20, 33], "obj_tok_span": [53, 55], "new_sbj_tok_span": [20, 33], "new_obj_tok_span": [58, 60]}], "umls_entity_list": [{"mention": "FAAH", "char_span": [179, 183], "sem_type": "Gene or Genome", "tok_span": [40, 42], "new_tok_span": [41, 43]}, {"mention": "FAAH", "char_span": [233, 237], "sem_type": "Gene or Genome", "tok_span": [53, 55], "new_tok_span": [58, 60]}, {"mention": "MAGL", "char_span": [188, 192], "sem_type": "Gene or Genome", "tok_span": [43, 45], "new_tok_span": [46, 48]}, {"mention": "MAGL", "char_span": [238, 242], "sem_type": "Gene or Genome", "tok_span": [56, 58], "new_tok_span": [63, 65]}], "new_text": "Continuing our previous work, we take the first steps of structure - activity relationship exploration and show that 1, 3, 4 - oxadiazol - 2 - ones can serve as scaffold for both selective <START=Gene or Genome> FAAH <END=Gene or Genome> and <START=Gene or Genome> MAGL <END=Gene or Genome> inhibitors, and also function as a dual <START=Gene or Genome> FAAH <END=Gene or Genome> / <START=Gene or Genome> MAGL <END=Gene or Genome> inhibitor at sub - micromolar IC50 values."}, {"PMID": 11270983, "id": 5, "text": "In rings with endothelium of the previously deendothelialized left anterior descending coronary artery, indometacin (inhibitor of cyclooxygenase) and ridogrel (thromboxane A2 receptor antagonist and inhibitor of thromboxane synthase) inhibited contractions to endothelin-1.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [150, 158], "name": "ridogrel", "tok_span": [28, 30], "new_tok_span": [28, 30]}, {"ent_type": "CHEMICAL", "char_span": [160, 174], "name": "thromboxane A2", "tok_span": [31, 36], "new_tok_span": [32, 37]}, {"ent_type": "CHEMICAL", "char_span": [212, 223], "name": "thromboxane", "tok_span": [41, 44], "new_tok_span": [45, 48]}, {"ent_type": "CHEMICAL", "char_span": [104, 115], "name": "indometacin", "tok_span": [18, 21], "new_tok_span": [18, 21]}, {"ent_type": "GENE", "char_span": [130, 144], "name": "cyclooxygenase", "tok_span": [24, 26], "new_tok_span": [24, 26]}, {"ent_type": "GENE", "char_span": [160, 183], "name": "thromboxane A2 receptor", "tok_span": [31, 37], "new_tok_span": [32, 38]}, {"ent_type": "GENE", "char_span": [212, 232], "name": "thromboxane synthase", "tok_span": [41, 45], "new_tok_span": [45, 49]}, {"ent_type": "GENE", "char_span": [260, 272], "name": "endothelin-1", "tok_span": [49, 53], "new_tok_span": [56, 60]}], "relation_list": [{"subject": "indometacin", "sbj_char_span": [104, 115], "object": "cyclooxygenase", "obj_char_span": [130, 144], "rel_type": "inhibitor", "sbj_tok_span": [18, 21], "obj_tok_span": [24, 26], "new_sbj_tok_span": [18, 21], "new_obj_tok_span": [24, 26]}, {"subject": "ridogrel", "sbj_char_span": [150, 158], "object": "thromboxane A2 receptor", "obj_char_span": [160, 183], "rel_type": "agonist or antagonist", "sbj_tok_span": [28, 30], "obj_tok_span": [31, 37], "new_sbj_tok_span": [28, 30], "new_obj_tok_span": [32, 38]}, {"subject": "ridogrel", "sbj_char_span": [150, 158], "object": "thromboxane synthase", "obj_char_span": [212, 232], "rel_type": "inhibitor", "sbj_tok_span": [28, 30], "obj_tok_span": [41, 45], "new_sbj_tok_span": [28, 30], "new_obj_tok_span": [45, 49]}, {"subject": "ridogrel", "sbj_char_span": [150, 158], "object": "endothelin-1", "obj_char_span": [260, 272], "rel_type": "regulator", "sbj_tok_span": [28, 30], "obj_tok_span": [49, 53], "new_sbj_tok_span": [28, 30], "new_obj_tok_span": [56, 60]}], "umls_entity_list": [{"mention": "thromboxane synthase", "char_span": [212, 232], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 45], "new_tok_span": [45, 49]}, {"mention": "thromboxane", "char_span": [160, 171], "sem_type": "Organic Chemical", "tok_span": [31, 34], "new_tok_span": [32, 35]}, {"mention": "thromboxane", "char_span": [212, 223], "sem_type": "Organic Chemical", "tok_span": [41, 44], "new_tok_span": [45, 48]}, {"mention": "endothelin-1", "char_span": [260, 272], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [49, 53], "new_tok_span": [56, 60]}], "new_text": "In rings with endothelium of the previously deendothelialized left anterior descending coronary artery, indometacin ( inhibitor of cyclooxygenase ) and ridogrel ( <START=Organic Chemical> thromboxane <END=Organic Chemical> A2 receptor antagonist and inhibitor of <START=Amino Acid, Peptide, or Protein> <START=Organic Chemical> thromboxane <END=Organic Chemical> synthase <END=Amino Acid, Peptide, or Protein> ) inhibited contractions to <START=Amino Acid, Peptide, or Protein> endothelin - 1 <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 20497523, "id": 4, "text": "The contribution of ERalpha and ERbeta to ER-mediated immune modulation was studied in delayed type hypersensitivity (DTH) and in experimental arthritis METHODS: ER-mediated suppression of rat adjuvant arthritis (AA) was studied using ethinyl-estradiol (EE) and a selective ERbeta agonist (ERB-79).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [235, 252], "name": "ethinyl-estradiol", "tok_span": [45, 50], "new_tok_span": [65, 70]}, {"ent_type": "CHEMICAL", "char_span": [254, 256], "name": "EE", "tok_span": [51, 52], "new_tok_span": [71, 72]}, {"ent_type": "CHEMICAL", "char_span": [290, 296], "name": "ERB-79", "tok_span": [60, 64], "new_tok_span": [85, 89]}, {"ent_type": "GENE", "char_span": [20, 27], "name": "ERalpha", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"ent_type": "GENE", "char_span": [32, 38], "name": "ERbeta", "tok_span": [6, 8], "new_tok_span": [12, 14]}, {"ent_type": "GENE", "char_span": [42, 44], "name": "ER", "tok_span": [9, 10], "new_tok_span": [18, 19]}, {"ent_type": "GENE", "char_span": [162, 164], "name": "ER", "tok_span": [31, 32], "new_tok_span": [48, 49]}, {"ent_type": "GENE", "char_span": [274, 280], "name": "ERbeta", "tok_span": [56, 58], "new_tok_span": [78, 80]}], "relation_list": [{"subject": "ERB-79", "sbj_char_span": [290, 296], "object": "ERbeta", "obj_char_span": [274, 280], "rel_type": "agonist or antagonist", "sbj_tok_span": [60, 64], "obj_tok_span": [56, 58], "new_sbj_tok_span": [85, 89], "new_obj_tok_span": [78, 80]}], "umls_entity_list": [{"mention": "ERalpha", "char_span": [20, 27], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"mention": "ERbeta", "char_span": [32, 38], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 8], "new_tok_span": [12, 14]}, {"mention": "ERbeta", "char_span": [274, 280], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 58], "new_tok_span": [78, 80]}, {"mention": "mediated", "char_span": [45, 53], "sem_type": "Pharmacologic Substance", "tok_span": [11, 12], "new_tok_span": [22, 23]}, {"mention": "mediated", "char_span": [165, 173], "sem_type": "Pharmacologic Substance", "tok_span": [33, 34], "new_tok_span": [52, 53]}, {"mention": "ER", "char_span": [20, 22], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 4], "new_tok_span": [5, 6]}, {"mention": "ER", "char_span": [32, 34], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 7], "new_tok_span": [12, 13]}, {"mention": "ER", "char_span": [42, 44], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 10], "new_tok_span": [18, 19]}, {"mention": "er", "char_span": [103, 105], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 20], "new_tok_span": [32, 33]}, {"mention": "er", "char_span": [133, 135], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [42, 43]}, {"mention": "ER", "char_span": [162, 164], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [31, 32], "new_tok_span": [48, 49]}, {"mention": "ER", "char_span": [274, 276], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 57], "new_tok_span": [78, 79]}, {"mention": "ER", "char_span": [290, 292], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [60, 61], "new_tok_span": [85, 86]}], "new_text": "The contribution of <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> ER <END=Amino Acid, Peptide, or Protein>alpha <END=Amino Acid, Peptide, or Protein> and <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> ER <END=Amino Acid, Peptide, or Protein>beta <END=Amino Acid, Peptide, or Protein> to <START=Amino Acid, Peptide, or Protein> ER <END=Amino Acid, Peptide, or Protein> - <START=Pharmacologic Substance> mediated <END=Pharmacologic Substance> immune modulation was studied in delayed type <START=Amino Acid, Peptide, or Protein> hypers <END=Amino Acid, Peptide, or Protein>ensitivity ( DTH ) and in <START=Amino Acid, Peptide, or Protein> experimental <END=Amino Acid, Peptide, or Protein> arthritis METHODS : <START=Amino Acid, Peptide, or Protein> ER <END=Amino Acid, Peptide, or Protein> - <START=Pharmacologic Substance> mediated <END=Pharmacologic Substance> suppression of rat adjuvant arthritis ( AA ) was studied using ethinyl - estradiol ( EE ) and a selective <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> ER <END=Amino Acid, Peptide, or Protein>beta <END=Amino Acid, Peptide, or Protein> agonist ( <START=Amino Acid, Peptide, or Protein> ER <END=Amino Acid, Peptide, or Protein>B - 79 )."}, {"PMID": 11986668, "id": 6, "text": "Minocycline-mediated inhibition of cytochrome c release is demonstrated in vivo, in cells, and in isolated mitochondria.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Minocycline", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "GENE", "char_span": [35, 47], "name": "cytochrome c", "tok_span": [8, 10], "new_tok_span": [10, 12]}], "relation_list": [{"subject": "Minocycline", "sbj_char_span": [0, 11], "object": "cytochrome c", "obj_char_span": [35, 47], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [8, 10], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [10, 12]}], "umls_entity_list": [{"mention": "Minocyclin", "char_span": [0, 10], "sem_type": "Organic Chemical", "tok_span": [0, 3], "new_tok_span": [1, 4]}], "new_text": "<START=Organic Chemical> Minocyclin <END=Organic Chemical>e - mediated inhibition of cytochrome c release is demonstrated in vivo, in cells, and in isolated mitochondria."}, {"PMID": 17194886, "id": 10, "text": "Triflusal (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Triflusal", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [72, 80], "name": "IL-Ibeta", "tok_span": [16, 20], "new_tok_span": [19, 23]}, {"ent_type": "GENE", "char_span": [89, 111], "name": "nuclear factor kappa B", "tok_span": [22, 26], "new_tok_span": [26, 30]}, {"ent_type": "GENE", "char_span": [115, 142], "name": "tumor necrosis factor-alpha", "tok_span": [27, 32], "new_tok_span": [32, 37]}], "relation_list": [{"subject": "Triflusal", "sbj_char_span": [0, 9], "object": "IL-Ibeta", "obj_char_span": [72, 80], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [16, 20], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [19, 23]}], "umls_entity_list": [{"mention": "Triflusal", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "IL", "char_span": [72, 74], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 17], "new_tok_span": [19, 20]}, {"mention": "il", "char_span": [160, 162], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 36], "new_tok_span": [42, 43]}, {"mention": "tumor necrosis factor-alpha", "char_span": [115, 142], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 32], "new_tok_span": [32, 37]}], "new_text": "<START=Pharmacologic Substance> Triflusal <END=Pharmacologic Substance> ( 30 mg / kg ) also significantly decreased the protein levels of <START=Amino Acid, Peptide, or Protein> IL <END=Amino Acid, Peptide, or Protein> - Ibeta but not nuclear factor kappa B or <START=Amino Acid, Peptide, or Protein> tumor necrosis factor - alpha <END=Amino Acid, Peptide, or Protein> in the cortex <START=Amino Acid, Peptide, or Protein> ipsilateral <END=Amino Acid, Peptide, or Protein> to the middle cerebral artery occlusion."}, {"PMID": 17442055, "id": 4, "text": "The novel KAT had a pH optimum of 8.0 and a low capacity to transaminate glutamine or alpha-aminoadipate (the classic substrates of KAT I and KAT II, respectively).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 82], "name": "glutamine", "tok_span": [20, 21], "new_tok_span": [22, 23]}, {"ent_type": "CHEMICAL", "char_span": [86, 104], "name": "alpha-aminoadipate", "tok_span": [22, 28], "new_tok_span": [24, 30]}, {"ent_type": "GENE", "char_span": [10, 13], "name": "KAT", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"ent_type": "GENE", "char_span": [132, 137], "name": "KAT I", "tok_span": [33, 36], "new_tok_span": [36, 39]}, {"ent_type": "GENE", "char_span": [142, 148], "name": "KAT II", "tok_span": [37, 40], "new_tok_span": [42, 45]}], "relation_list": [{"subject": "glutamine", "sbj_char_span": [73, 82], "object": "KAT", "obj_char_span": [10, 13], "rel_type": "product or substrate", "sbj_tok_span": [20, 21], "obj_tok_span": [2, 4], "new_sbj_tok_span": [22, 23], "new_obj_tok_span": [3, 5]}, {"subject": "alpha-aminoadipate", "sbj_char_span": [86, 104], "object": "KAT", "obj_char_span": [10, 13], "rel_type": "product or substrate", "sbj_tok_span": [22, 28], "obj_tok_span": [2, 4], "new_sbj_tok_span": [24, 30], "new_obj_tok_span": [3, 5]}, {"subject": "glutamine", "sbj_char_span": [73, 82], "object": "KAT I", "obj_char_span": [132, 137], "rel_type": "product or substrate", "sbj_tok_span": [20, 21], "obj_tok_span": [33, 36], "new_sbj_tok_span": [22, 23], "new_obj_tok_span": [36, 39]}, {"subject": "alpha-aminoadipate", "sbj_char_span": [86, 104], "object": "KAT I", "obj_char_span": [132, 137], "rel_type": "product or substrate", "sbj_tok_span": [22, 28], "obj_tok_span": [33, 36], "new_sbj_tok_span": [24, 30], "new_obj_tok_span": [36, 39]}, {"subject": "glutamine", "sbj_char_span": [73, 82], "object": "KAT II", "obj_char_span": [142, 148], "rel_type": "product or substrate", "sbj_tok_span": [20, 21], "obj_tok_span": [37, 40], "new_sbj_tok_span": [22, 23], "new_obj_tok_span": [42, 45]}, {"subject": "alpha-aminoadipate", "sbj_char_span": [86, 104], "object": "KAT II", "obj_char_span": [142, 148], "rel_type": "product or substrate", "sbj_tok_span": [22, 28], "obj_tok_span": [37, 40], "new_sbj_tok_span": [24, 30], "new_obj_tok_span": [42, 45]}], "umls_entity_list": [{"mention": "KAT", "char_span": [10, 13], "sem_type": "Gene or Genome", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"mention": "KAT", "char_span": [132, 135], "sem_type": "Gene or Genome", "tok_span": [33, 35], "new_tok_span": [36, 38]}, {"mention": "KAT", "char_span": [142, 145], "sem_type": "Gene or Genome", "tok_span": [37, 39], "new_tok_span": [42, 44]}], "new_text": "The novel <START=Gene or Genome> KAT <END=Gene or Genome> had a pH optimum of 8. 0 and a low capacity to transaminate glutamine or alpha - aminoadipate ( the classic substrates of <START=Gene or Genome> KAT <END=Gene or Genome> I and <START=Gene or Genome> KAT <END=Gene or Genome> II, respectively )."}, {"PMID": 23607523, "id": 5, "text": "A gene cassette encoding C7-cyclitol biosynthetic enzymes was identified upstream of the benzopyranopyrrole-specific ORFs. Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [365, 367], "name": "C7", "tok_span": [74, 76], "new_tok_span": [88, 90]}, {"ent_type": "CHEMICAL", "char_span": [368, 376], "name": "cyclitol", "tok_span": [77, 79], "new_tok_span": [92, 94]}, {"ent_type": "CHEMICAL", "char_span": [25, 27], "name": "C7", "tok_span": [4, 6], "new_tok_span": [6, 8]}, {"ent_type": "CHEMICAL", "char_span": [28, 36], "name": "cyclitol", "tok_span": [7, 9], "new_tok_span": [10, 12]}, {"ent_type": "CHEMICAL", "char_span": [89, 107], "name": "benzopyranopyrrole", "tok_span": [16, 20], "new_tok_span": [22, 26]}, {"ent_type": "CHEMICAL", "char_span": [168, 169], "name": "N", "tok_span": [33, 34], "new_tok_span": [43, 44]}, {"ent_type": "CHEMICAL", "char_span": [207, 218], "name": "pyralomicin", "tok_span": [44, 48], "new_tok_span": [56, 60]}, {"ent_type": "CHEMICAL", "char_span": [308, 313], "name": "sugar", "tok_span": [65, 66], "new_tok_span": [78, 79]}, {"ent_type": "CHEMICAL", "char_span": [314, 323], "name": "phosphate", "tok_span": [66, 67], "new_tok_span": [79, 80]}, {"ent_type": "GENE", "char_span": [168, 189], "name": "N-glycosyltransferase", "tok_span": [33, 38], "new_tok_span": [43, 48]}, {"ent_type": "GENE", "char_span": [191, 195], "name": "prlH", "tok_span": [39, 42], "new_tok_span": [50, 53]}, {"ent_type": "GENE", "char_span": [261, 265], "name": "PrlA", "tok_span": [54, 57], "new_tok_span": [66, 69]}, {"ent_type": "GENE", "char_span": [308, 331], "name": "sugar phosphate cyclase", "tok_span": [65, 68], "new_tok_span": [78, 81]}], "relation_list": [{"subject": "pyralomicin", "sbj_char_span": [207, 218], "object": "N-glycosyltransferase", "obj_char_span": [168, 189], "rel_type": "product or substrate", "sbj_tok_span": [44, 48], "obj_tok_span": [33, 38], "new_sbj_tok_span": [56, 60], "new_obj_tok_span": [43, 48]}, {"subject": "pyralomicin", "sbj_char_span": [207, 218], "object": "prlH", "obj_char_span": [191, 195], "rel_type": "product or substrate", "sbj_tok_span": [44, 48], "obj_tok_span": [39, 42], "new_sbj_tok_span": [56, 60], "new_obj_tok_span": [50, 53]}, {"subject": "cyclitol", "sbj_char_span": [368, 376], "object": "sugar phosphate cyclase", "obj_char_span": [308, 331], "rel_type": "product or substrate", "sbj_tok_span": [77, 79], "obj_tok_span": [65, 68], "new_sbj_tok_span": [92, 94], "new_obj_tok_span": [78, 81]}, {"subject": "C7", "sbj_char_span": [365, 367], "object": "sugar phosphate cyclase", "obj_char_span": [308, 331], "rel_type": "product or substrate", "sbj_tok_span": [74, 76], "obj_tok_span": [65, 68], "new_sbj_tok_span": [88, 90], "new_obj_tok_span": [78, 81]}, {"subject": "cyclitol", "sbj_char_span": [368, 376], "object": "PrlA", "obj_char_span": [261, 265], "rel_type": "product or substrate", "sbj_tok_span": [77, 79], "obj_tok_span": [54, 57], "new_sbj_tok_span": [92, 94], "new_obj_tok_span": [66, 69]}, {"subject": "C7", "sbj_char_span": [365, 367], "object": "PrlA", "obj_char_span": [261, 265], "rel_type": "product or substrate", "sbj_tok_span": [74, 76], "obj_tok_span": [54, 57], "new_sbj_tok_span": [88, 90], "new_obj_tok_span": [66, 69]}], "umls_entity_list": [{"mention": "gene", "char_span": [2, 6], "sem_type": "Gene or Genome", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"mention": "gene", "char_span": [150, 154], "sem_type": "Gene or Genome", "tok_span": [30, 31], "new_tok_span": [39, 40]}, {"mention": "cyclitol", "char_span": [28, 36], "sem_type": "Organic Chemical", "tok_span": [7, 9], "new_tok_span": [10, 12]}, {"mention": "cyclitol", "char_span": [368, 376], "sem_type": "Organic Chemical", "tok_span": [77, 79], "new_tok_span": [92, 94]}, {"mention": "enzymes", "char_span": [50, 57], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 11], "new_tok_span": [15, 16]}, {"mention": "ORFs", "char_span": [117, 121], "sem_type": "Gene or Genome", "tok_span": [22, 24], "new_tok_span": [29, 31]}, {"mention": "prlH", "char_span": [191, 195], "sem_type": "Gene or Genome", "tok_span": [39, 42], "new_tok_span": [50, 53]}, {"mention": "sugar phosphate", "char_span": [308, 323], "sem_type": "Organic Chemical", "tok_span": [65, 67], "new_tok_span": [78, 80]}], "new_text": "A <START=Gene or Genome> gene <END=Gene or Genome> cassette encoding C7 - <START=Organic Chemical> cyclitol <END=Organic Chemical> biosynthetic <START=Amino Acid, Peptide, or Protein> enzymes <END=Amino Acid, Peptide, or Protein> was identified upstream of the benzopyranopyrrole - specific <START=Gene or Genome> ORFs <END=Gene or Genome>. Targeted disruption of the <START=Gene or Genome> gene <END=Gene or Genome> encoding the N - glycosyltransferase, <START=Gene or Genome> prlH <END=Gene or Genome>, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a <START=Organic Chemical> sugar phosphate <END=Organic Chemical> cyclase involved in the formation of the C7 - <START=Organic Chemical> cyclitol <END=Organic Chemical> moiety."}, {"PMID": 17619763, "id": 2, "text": "The most clinically developed targeted therapies in advanced RCC are those that target the vascular endothelial growth factor (VEGF) ligand or receptor (VEGFR) and therapy directed against the mammalian target of rapamycin (mTOR). Sutent and sorafenib are orally available inhibitors of the VEGFR and platelet derived growth factor receptor (PDGFR). Temsirolimus is an mTOR inhibitor that leads to G1 cell cycle arrest and may affect VEGF production.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [213, 222], "name": "rapamycin", "tok_span": [36, 37], "new_tok_span": [46, 47]}, {"ent_type": "CHEMICAL", "char_span": [231, 237], "name": "Sutent", "tok_span": [41, 44], "new_tok_span": [53, 56]}, {"ent_type": "CHEMICAL", "char_span": [242, 251], "name": "sorafenib", "tok_span": [45, 47], "new_tok_span": [57, 59]}, {"ent_type": "CHEMICAL", "char_span": [350, 362], "name": "Temsirolimus", "tok_span": [66, 69], "new_tok_span": [82, 85]}, {"ent_type": "GENE", "char_span": [91, 125], "name": "vascular endothelial growth factor", "tok_span": [14, 18], "new_tok_span": [17, 21]}, {"ent_type": "GENE", "char_span": [127, 131], "name": "VEGF", "tok_span": [19, 20], "new_tok_span": [23, 24]}, {"ent_type": "GENE", "char_span": [153, 158], "name": "VEGFR", "tok_span": [25, 27], "new_tok_span": [30, 32]}, {"ent_type": "GENE", "char_span": [193, 222], "name": "mammalian target of rapamycin", "tok_span": [33, 37], "new_tok_span": [43, 47]}, {"ent_type": "GENE", "char_span": [224, 228], "name": "mTOR", "tok_span": [38, 39], "new_tok_span": [50, 51]}, {"ent_type": "GENE", "char_span": [291, 296], "name": "VEGFR", "tok_span": [53, 55], "new_tok_span": [66, 68]}, {"ent_type": "GENE", "char_span": [301, 340], "name": "platelet derived growth factor receptor", "tok_span": [56, 61], "new_tok_span": [71, 76]}, {"ent_type": "GENE", "char_span": [342, 347], "name": "PDGFR", "tok_span": [62, 64], "new_tok_span": [78, 80]}, {"ent_type": "GENE", "char_span": [369, 373], "name": "mTOR", "tok_span": [71, 72], "new_tok_span": [87, 88]}, {"ent_type": "GENE", "char_span": [434, 438], "name": "VEGF", "tok_span": [84, 85], "new_tok_span": [100, 101]}], "relation_list": [{"subject": "Sutent", "sbj_char_span": [231, 237], "object": "VEGFR", "obj_char_span": [291, 296], "rel_type": "inhibitor", "sbj_tok_span": [41, 44], "obj_tok_span": [53, 55], "new_sbj_tok_span": [53, 56], "new_obj_tok_span": [66, 68]}, {"subject": "Sutent", "sbj_char_span": [231, 237], "object": "platelet derived growth factor receptor", "obj_char_span": [301, 340], "rel_type": "inhibitor", "sbj_tok_span": [41, 44], "obj_tok_span": [56, 61], "new_sbj_tok_span": [53, 56], "new_obj_tok_span": [71, 76]}, {"subject": "Sutent", "sbj_char_span": [231, 237], "object": "PDGFR", "obj_char_span": [342, 347], "rel_type": "inhibitor", "sbj_tok_span": [41, 44], "obj_tok_span": [62, 64], "new_sbj_tok_span": [53, 56], "new_obj_tok_span": [78, 80]}, {"subject": "sorafenib", "sbj_char_span": [242, 251], "object": "VEGFR", "obj_char_span": [291, 296], "rel_type": "inhibitor", "sbj_tok_span": [45, 47], "obj_tok_span": [53, 55], "new_sbj_tok_span": [57, 59], "new_obj_tok_span": [66, 68]}, {"subject": "sorafenib", "sbj_char_span": [242, 251], "object": "platelet derived growth factor receptor", "obj_char_span": [301, 340], "rel_type": "inhibitor", "sbj_tok_span": [45, 47], "obj_tok_span": [56, 61], "new_sbj_tok_span": [57, 59], "new_obj_tok_span": [71, 76]}, {"subject": "sorafenib", "sbj_char_span": [242, 251], "object": "PDGFR", "obj_char_span": [342, 347], "rel_type": "inhibitor", "sbj_tok_span": [45, 47], "obj_tok_span": [62, 64], "new_sbj_tok_span": [57, 59], "new_obj_tok_span": [78, 80]}, {"subject": "Temsirolimus", "sbj_char_span": [350, 362], "object": "mTOR", "obj_char_span": [369, 373], "rel_type": "inhibitor", "sbj_tok_span": [66, 69], "obj_tok_span": [71, 72], "new_sbj_tok_span": [82, 85], "new_obj_tok_span": [87, 88]}], "umls_entity_list": [{"mention": "RCC", "char_span": [61, 64], "sem_type": "Gene or Genome", "tok_span": [8, 9], "new_tok_span": [9, 10]}, {"mention": "vascular endothelial growth factor", "char_span": [91, 125], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 18], "new_tok_span": [17, 21]}, {"mention": "VEGFR", "char_span": [153, 158], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 27], "new_tok_span": [30, 32]}, {"mention": "VEGFR", "char_span": [291, 296], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [53, 55], "new_tok_span": [66, 68]}, {"mention": "directed", "char_span": [172, 180], "sem_type": "Pharmacologic Substance", "tok_span": [30, 31], "new_tok_span": [37, 38]}, {"mention": "mammalian target of rapamycin", "char_span": [193, 222], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 37], "new_tok_span": [43, 47]}, {"mention": "mammalian target of rapamycin", "char_span": [193, 222], "sem_type": "Gene or Genome", "tok_span": [33, 37], "new_tok_span": [43, 47]}, {"mention": "platelet derived growth factor receptor", "char_span": [301, 340], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 61], "new_tok_span": [71, 76]}], "new_text": "The most clinically developed targeted therapies in advanced <START=Gene or Genome> RCC <END=Gene or Genome> are those that target the <START=Amino Acid, Peptide, or Protein> vascular endothelial growth factor <END=Amino Acid, Peptide, or Protein> ( VEGF ) ligand or receptor ( <START=Amino Acid, Peptide, or Protein> VEGFR <END=Amino Acid, Peptide, or Protein> ) and therapy <START=Pharmacologic Substance> directed <END=Pharmacologic Substance> against the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> mammalian target of rapamycin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( mTOR ). Sutent and sorafenib are orally available inhibitors of the <START=Amino Acid, Peptide, or Protein> VEGFR <END=Amino Acid, Peptide, or Protein> and <START=Amino Acid, Peptide, or Protein> platelet derived growth factor receptor <END=Amino Acid, Peptide, or Protein> ( PDGFR ). Temsirolimus is an mTOR inhibitor that leads to G1 cell cycle arrest and may affect VEGF production."}, {"PMID": 23432095, "id": 3, "text": "AKR1C3 is upregulated in CRPC where it catalyzes the formation of potent androgens.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 82], "name": "androgens", "tok_span": [18, 20], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [0, 6], "name": "AKR1C3", "tok_span": [0, 5], "new_tok_span": [0, 5]}], "relation_list": [{"subject": "androgens", "sbj_char_span": [73, 82], "object": "AKR1C3", "obj_char_span": [0, 6], "rel_type": "product or substrate", "sbj_tok_span": [18, 20], "obj_tok_span": [0, 5], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [0, 5]}], "umls_entity_list": [], "new_text": "AKR1C3 is upregulated in CRPC where it catalyzes the formation of potent androgens."}, {"PMID": 9614060, "id": 6, "text": "However, the apparent affinity for lysine transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of Cat3-mediated transport.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [35, 41], "name": "lysine", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "GENE", "char_span": [75, 79], "name": "Cat1", "tok_span": [15, 17], "new_tok_span": [17, 19]}, {"ent_type": "GENE", "char_span": [156, 160], "name": "Cat3", "tok_span": [34, 36], "new_tok_span": [39, 41]}], "relation_list": [{"subject": "lysine", "sbj_char_span": [35, 41], "object": "Cat3", "obj_char_span": [156, 160], "rel_type": "product or substrate", "sbj_tok_span": [6, 7], "obj_tok_span": [34, 36], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [39, 41]}], "umls_entity_list": [{"mention": "Cat1", "char_span": [75, 79], "sem_type": "Gene or Genome", "tok_span": [15, 17], "new_tok_span": [17, 19]}, {"mention": "Cat1", "char_span": [75, 79], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 17], "new_tok_span": [17, 19]}, {"mention": "Cat3", "char_span": [156, 160], "sem_type": "Gene or Genome", "tok_span": [34, 36], "new_tok_span": [39, 41]}], "new_text": "However, the apparent affinity for lysine transport was 2. 4 times lower in <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Cat1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( - / - ) cells when compared with wild type cells, a property characteristic of <START=Gene or Genome> Cat3 <END=Gene or Genome> - mediated transport."}, {"PMID": 16982784, "id": 7, "text": "Correspondingly, the overall catalytic efficiency (kcat/Km) of hydrolysis for cefotaxime was increased from 0.60 +/- 0.07 microM(-1) s(-1) (mean +/- standard deviation) for Gly238Ser to 1.70 +/- 0.01 microM(-1) s(-1) for the Asp104Lys and Gly238Ser beta-lactamase (threefold increase).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [78, 88], "name": "cefotaxime", "tok_span": [16, 19], "new_tok_span": [17, 20]}, {"ent_type": "GENE", "char_span": [173, 182], "name": "Gly238Ser", "tok_span": [51, 55], "new_tok_span": [53, 57]}, {"ent_type": "GENE", "char_span": [225, 234], "name": "Asp104Lys", "tok_span": [78, 81], "new_tok_span": [80, 83]}, {"ent_type": "GENE", "char_span": [239, 248], "name": "Gly238Ser", "tok_span": [82, 86], "new_tok_span": [84, 88]}, {"ent_type": "GENE", "char_span": [249, 263], "name": "beta-lactamase", "tok_span": [86, 91], "new_tok_span": [89, 94]}], "relation_list": [{"subject": "cefotaxime", "sbj_char_span": [78, 88], "object": "Gly238Ser", "obj_char_span": [173, 182], "rel_type": "product or substrate", "sbj_tok_span": [16, 19], "obj_tok_span": [51, 55], "new_sbj_tok_span": [17, 20], "new_obj_tok_span": [53, 57]}, {"subject": "cefotaxime", "sbj_char_span": [78, 88], "object": "Asp104Lys", "obj_char_span": [225, 234], "rel_type": "product or substrate", "sbj_tok_span": [16, 19], "obj_tok_span": [78, 81], "new_sbj_tok_span": [17, 20], "new_obj_tok_span": [80, 83]}, {"subject": "cefotaxime", "sbj_char_span": [78, 88], "object": "Gly238Ser", "obj_char_span": [239, 248], "rel_type": "product or substrate", "sbj_tok_span": [16, 19], "obj_tok_span": [82, 86], "new_sbj_tok_span": [17, 20], "new_obj_tok_span": [84, 88]}, {"subject": "cefotaxime", "sbj_char_span": [78, 88], "object": "beta-lactamase", "obj_char_span": [249, 263], "rel_type": "product or substrate", "sbj_tok_span": [16, 19], "obj_tok_span": [86, 91], "new_sbj_tok_span": [17, 20], "new_obj_tok_span": [89, 94]}], "umls_entity_list": [{"mention": "cefotaxime", "char_span": [78, 88], "sem_type": "Organic Chemical", "tok_span": [16, 19], "new_tok_span": [17, 20]}, {"mention": "beta-lactamase", "char_span": [249, 263], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [86, 91], "new_tok_span": [89, 94]}], "new_text": "Correspondingly, the overall catalytic efficiency ( kcat / Km ) of hydrolysis for <START=Organic Chemical> cefotaxime <END=Organic Chemical> was increased from 0. 60 + / - 0. 07 microM ( - 1 ) s ( - 1 ) ( mean + / - standard deviation ) for Gly238Ser to 1. 70 + / - 0. 01 microM ( - 1 ) s ( - 1 ) for the Asp104Lys and Gly238Ser <START=Amino Acid, Peptide, or Protein> beta - lactamase <END=Amino Acid, Peptide, or Protein> ( threefold increase )."}, {"PMID": 23046524, "id": 1, "text": "Using paraoxon as a reference acetylcholinesterase (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [6, 14], "name": "paraoxon", "tok_span": [1, 4], "new_tok_span": [2, 5]}, {"ent_type": "GENE", "char_span": [30, 50], "name": "acetylcholinesterase", "tok_span": [7, 10], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [52, 56], "name": "AChE", "tok_span": [11, 13], "new_tok_span": [13, 15]}], "relation_list": [{"subject": "paraoxon", "sbj_char_span": [6, 14], "object": "acetylcholinesterase", "obj_char_span": [30, 50], "rel_type": "inhibitor", "sbj_tok_span": [1, 4], "obj_tok_span": [7, 10], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [9, 12]}, {"subject": "paraoxon", "sbj_char_span": [6, 14], "object": "AChE", "obj_char_span": [52, 56], "rel_type": "inhibitor", "sbj_tok_span": [1, 4], "obj_tok_span": [11, 13], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [13, 15]}], "umls_entity_list": [{"mention": "paraoxon", "char_span": [6, 14], "sem_type": "Organic Chemical", "tok_span": [1, 4], "new_tok_span": [2, 5]}], "new_text": "Using <START=Organic Chemical> paraoxon <END=Organic Chemical> as a reference acetylcholinesterase ( AChE ) inhibitor, the objective of this study was to develop an adverse outcome pathway ( AOP ) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis."}, {"PMID": 23219337, "id": 5, "text": "Wogonin (10-100 μM) also inhibited increases in IL-1β production and cyclooxygenase (COX)-2 expression induced by lipopolysaccharide in THP-1 macrophages.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 7], "name": "Wogonin", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "GENE", "char_span": [48, 53], "name": "IL-1β", "tok_span": [15, 19], "new_tok_span": [17, 21]}, {"ent_type": "GENE", "char_span": [69, 91], "name": "cyclooxygenase (COX)-2", "tok_span": [21, 28], "new_tok_span": [23, 30]}], "relation_list": [{"subject": "Wogonin", "sbj_char_span": [0, 7], "object": "IL-1β", "obj_char_span": [48, 53], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [15, 19], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [17, 21]}, {"subject": "Wogonin", "sbj_char_span": [0, 7], "object": "cyclooxygenase (COX)-2", "obj_char_span": [69, 91], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [21, 28], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [23, 30]}], "umls_entity_list": [{"mention": "Wogonin", "char_span": [0, 7], "sem_type": "Organic Chemical", "tok_span": [0, 4], "new_tok_span": [1, 5]}], "new_text": "<START=Organic Chemical> Wogonin <END=Organic Chemical> ( 10 - 100 μM ) also inhibited increases in IL - 1β production and cyclooxygenase ( COX ) - 2 expression induced by lipopolysaccharide in THP - 1 macrophages."}, {"PMID": 16730121, "id": 1, "text": "Effect of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide (ramelteon, TAK-375), a selective MT1/MT2 receptor agonist, on motor coordination was studied using rota-rod performance in mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [10, 85], "name": "(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide", "tok_span": [2, 48], "new_tok_span": [2, 48]}, {"ent_type": "CHEMICAL", "char_span": [87, 96], "name": "ramelteon", "tok_span": [49, 52], "new_tok_span": [53, 56]}, {"ent_type": "CHEMICAL", "char_span": [98, 105], "name": "TAK-375", "tok_span": [53, 57], "new_tok_span": [57, 61]}, {"ent_type": "GENE", "char_span": [120, 136], "name": "MT1/MT2 receptor", "tok_span": [61, 67], "new_tok_span": [65, 71]}], "relation_list": [{"subject": "TAK-375", "sbj_char_span": [98, 105], "object": "MT1/MT2 receptor", "obj_char_span": [120, 136], "rel_type": "agonist or antagonist", "sbj_tok_span": [53, 57], "obj_tok_span": [61, 67], "new_sbj_tok_span": [57, 61], "new_obj_tok_span": [65, 71]}, {"subject": "ramelteon", "sbj_char_span": [87, 96], "object": "MT1/MT2 receptor", "obj_char_span": [120, 136], "rel_type": "agonist or antagonist", "sbj_tok_span": [49, 52], "obj_tok_span": [61, 67], "new_sbj_tok_span": [53, 56], "new_obj_tok_span": [65, 71]}, {"subject": "(S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno-[5,4-b]furan-8-yl)ethyl]propionamide", "sbj_char_span": [10, 85], "object": "MT1/MT2 receptor", "obj_char_span": [120, 136], "rel_type": "agonist or antagonist", "sbj_tok_span": [2, 48], "obj_tok_span": [61, 67], "new_sbj_tok_span": [2, 48], "new_obj_tok_span": [65, 71]}], "umls_entity_list": [{"mention": "furan", "char_span": [56, 61], "sem_type": "Organic Chemical", "tok_span": [36, 38], "new_tok_span": [37, 39]}, {"mention": "propionamide", "char_span": [73, 85], "sem_type": "Pharmacologic Substance", "tok_span": [45, 48], "new_tok_span": [48, 51]}], "new_text": "Effect of ( S ) - N - [ 2 - ( 1, 6, 7, 8 - tetrahydro - 2H - indeno - [ 5, 4 - b ] <START=Organic Chemical> furan <END=Organic Chemical> - 8 - yl ) ethyl ] <START=Pharmacologic Substance> propionamide <END=Pharmacologic Substance> ( ramelteon, TAK - 375 ), a selective MT1 / MT2 receptor agonist, on motor coordination was studied using rota - rod performance in mice."}, {"PMID": 8646863, "id": 3, "text": "The pharmacologic properties of fluticasone propionate-including high lipophilicity, high selectivity and affinity for the glucocorticoid receptor, low systemic absorption, and rapid metabolism and clearance-combine to give fluticasone propionate a high therapeutic index.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [32, 54], "name": "fluticasone propionate", "tok_span": [5, 11], "new_tok_span": [6, 12]}, {"ent_type": "CHEMICAL", "char_span": [224, 246], "name": "fluticasone propionate", "tok_span": [40, 46], "new_tok_span": [49, 55]}, {"ent_type": "GENE", "char_span": [123, 146], "name": "glucocorticoid receptor", "tok_span": [24, 26], "new_tok_span": [29, 31]}], "relation_list": [{"subject": "fluticasone propionate", "sbj_char_span": [32, 54], "object": "glucocorticoid receptor", "obj_char_span": [123, 146], "rel_type": "regulator", "sbj_tok_span": [5, 11], "obj_tok_span": [24, 26], "new_sbj_tok_span": [6, 12], "new_obj_tok_span": [29, 31]}], "umls_entity_list": [{"mention": "fluticasone propionate", "char_span": [32, 54], "sem_type": "Pharmacologic Substance", "tok_span": [5, 11], "new_tok_span": [6, 12]}, {"mention": "fluticasone propionate", "char_span": [224, 246], "sem_type": "Pharmacologic Substance", "tok_span": [40, 46], "new_tok_span": [49, 55]}, {"mention": "glucocorticoid", "char_span": [123, 137], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 25], "new_tok_span": [29, 30]}, {"mention": "glucocorticoid receptor", "char_span": [123, 146], "sem_type": "Gene or Genome", "tok_span": [24, 26], "new_tok_span": [29, 31]}, {"mention": "glucocorticoid receptor", "char_span": [123, 146], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 26], "new_tok_span": [29, 31]}], "new_text": "The pharmacologic properties of <START=Pharmacologic Substance> fluticasone propionate <END=Pharmacologic Substance> - including high lipophilicity, high selectivity and affinity for the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> glucocorticoid <END=Amino Acid, Peptide, or Protein> receptor <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, low systemic absorption, and rapid metabolism and clearance - combine to give <START=Pharmacologic Substance> fluticasone propionate <END=Pharmacologic Substance> a high therapeutic index."}, {"PMID": 17673606, "id": 3, "text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [91, 94], "name": "DVS", "tok_span": [17, 19], "new_tok_span": [17, 19]}, {"ent_type": "CHEMICAL", "char_span": [115, 124], "name": "[(3)H]NIS", "tok_span": [23, 31], "new_tok_span": [23, 31]}, {"ent_type": "CHEMICAL", "char_span": [150, 153], "name": "DVS", "tok_span": [35, 37], "new_tok_span": [35, 37]}, {"ent_type": "CHEMICAL", "char_span": [159, 162], "name": "DVS", "tok_span": [39, 41], "new_tok_span": [39, 41]}, {"ent_type": "CHEMICAL", "char_span": [170, 243], "name": "rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol", "tok_span": [42, 80], "new_tok_span": [42, 80]}, {"ent_type": "CHEMICAL", "char_span": [245, 253], "name": "WY-46824", "tok_span": [81, 87], "new_tok_span": [83, 89]}, {"ent_type": "CHEMICAL", "char_span": [256, 271], "name": "methylphenidate", "tok_span": [89, 92], "new_tok_span": [92, 95]}, {"ent_type": "CHEMICAL", "char_span": [281, 288], "name": "cocaine", "tok_span": [95, 96], "new_tok_span": [99, 100]}, {"ent_type": "CHEMICAL", "char_span": [296, 358], "name": "3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester", "tok_span": [97, 117], "new_tok_span": [101, 121]}, {"ent_type": "CHEMICAL", "char_span": [360, 366], "name": "RTI-55", "tok_span": [118, 122], "new_tok_span": [125, 129]}, {"ent_type": "CHEMICAL", "char_span": [405, 408], "name": "NIS", "tok_span": [131, 133], "new_tok_span": [139, 141]}, {"ent_type": "CHEMICAL", "char_span": [410, 418], "name": "mazindol", "tok_span": [134, 138], "new_tok_span": [142, 146]}, {"ent_type": "CHEMICAL", "char_span": [420, 429], "name": "tricyclic", "tok_span": [139, 141], "new_tok_span": [147, 149]}, {"ent_type": "CHEMICAL", "char_span": [451, 458], "name": "cocaine", "tok_span": [145, 146], "new_tok_span": [153, 154]}, {"ent_type": "GENE", "char_span": [6, 10], "name": "hNET", "tok_span": [1, 3], "new_tok_span": [1, 3]}, {"ent_type": "GENE", "char_span": [379, 383], "name": "hNET", "tok_span": [125, 127], "new_tok_span": [133, 135]}], "relation_list": [{"subject": "DVS", "sbj_char_span": [91, 94], "object": "hNET", "obj_char_span": [6, 10], "rel_type": "regulator", "sbj_tok_span": [17, 19], "obj_tok_span": [1, 3], "new_sbj_tok_span": [17, 19], "new_obj_tok_span": [1, 3]}, {"subject": "[(3)H]NIS", "sbj_char_span": [115, 124], "object": "hNET", "obj_char_span": [6, 10], "rel_type": "regulator", "sbj_tok_span": [23, 31], "obj_tok_span": [1, 3], "new_sbj_tok_span": [23, 31], "new_obj_tok_span": [1, 3]}, {"subject": "NIS", "sbj_char_span": [405, 408], "object": "hNET", "obj_char_span": [379, 383], "rel_type": "agonist or antagonist", "sbj_tok_span": [131, 133], "obj_tok_span": [125, 127], "new_sbj_tok_span": [139, 141], "new_obj_tok_span": [133, 135]}, {"subject": "mazindol", "sbj_char_span": [410, 418], "object": "hNET", "obj_char_span": [379, 383], "rel_type": "agonist or antagonist", "sbj_tok_span": [134, 138], "obj_tok_span": [125, 127], "new_sbj_tok_span": [142, 146], "new_obj_tok_span": [133, 135]}, {"subject": "tricyclic", "sbj_char_span": [420, 429], "object": "hNET", "obj_char_span": [379, 383], "rel_type": "agonist or antagonist", "sbj_tok_span": [139, 141], "obj_tok_span": [125, 127], "new_sbj_tok_span": [147, 149], "new_obj_tok_span": [133, 135]}, {"subject": "cocaine", "sbj_char_span": [451, 458], "object": "hNET", "obj_char_span": [379, 383], "rel_type": "agonist or antagonist", "sbj_tok_span": [145, 146], "obj_tok_span": [125, 127], "new_sbj_tok_span": [153, 154], "new_obj_tok_span": [133, 135]}, {"subject": "rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol", "sbj_char_span": [170, 243], "object": "hNET", "obj_char_span": [6, 10], "rel_type": "agonist or antagonist", "sbj_tok_span": [42, 80], "obj_tok_span": [1, 3], "new_sbj_tok_span": [42, 80], "new_obj_tok_span": [1, 3]}, {"subject": "WY-46824", "sbj_char_span": [245, 253], "object": "hNET", "obj_char_span": [6, 10], "rel_type": "agonist or antagonist", "sbj_tok_span": [81, 87], "obj_tok_span": [1, 3], "new_sbj_tok_span": [83, 89], "new_obj_tok_span": [1, 3]}, {"subject": "methylphenidate", "sbj_char_span": [256, 271], "object": "hNET", "obj_char_span": [6, 10], "rel_type": "agonist or antagonist", "sbj_tok_span": [89, 92], "obj_tok_span": [1, 3], "new_sbj_tok_span": [92, 95], "new_obj_tok_span": [1, 3]}, {"subject": "cocaine", "sbj_char_span": [281, 288], "object": "hNET", "obj_char_span": [6, 10], "rel_type": "agonist or antagonist", "sbj_tok_span": [95, 96], "obj_tok_span": [1, 3], "new_sbj_tok_span": [99, 100], "new_obj_tok_span": [1, 3]}, {"subject": "3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester", "sbj_char_span": [296, 358], "object": "hNET", "obj_char_span": [6, 10], "rel_type": "agonist or antagonist", "sbj_tok_span": [97, 117], "obj_tok_span": [1, 3], "new_sbj_tok_span": [101, 121], "new_obj_tok_span": [1, 3]}, {"subject": "RTI-55", "sbj_char_span": [360, 366], "object": "hNET", "obj_char_span": [6, 10], "rel_type": "agonist or antagonist", "sbj_tok_span": [118, 122], "obj_tok_span": [1, 3], "new_sbj_tok_span": [125, 129], "new_obj_tok_span": [1, 3]}, {"subject": "DVS", "sbj_char_span": [150, 153], "object": "hNET", "obj_char_span": [6, 10], "rel_type": "agonist or antagonist", "sbj_tok_span": [35, 37], "obj_tok_span": [1, 3], "new_sbj_tok_span": [35, 37], "new_obj_tok_span": [1, 3]}, {"subject": "DVS", "sbj_char_span": [159, 162], "object": "hNET", "obj_char_span": [6, 10], "rel_type": "agonist or antagonist", "sbj_tok_span": [39, 41], "obj_tok_span": [1, 3], "new_sbj_tok_span": [39, 41], "new_obj_tok_span": [1, 3]}], "umls_entity_list": [{"mention": "cyclohexanol", "char_span": [231, 243], "sem_type": "Pharmacologic Substance", "tok_span": [77, 80], "new_tok_span": [78, 81]}, {"mention": "methylphenidate", "char_span": [256, 271], "sem_type": "Pharmacologic Substance", "tok_span": [89, 92], "new_tok_span": [92, 95]}, {"mention": "tropane", "char_span": [316, 323], "sem_type": "Organic Chemical", "tok_span": [106, 108], "new_tok_span": [111, 113]}, {"mention": "RTI-55", "char_span": [360, 366], "sem_type": "Organic Chemical", "tok_span": [118, 122], "new_tok_span": [125, 129]}], "new_text": "Using hNET in transfected human embryonic kidney - 293 cells, this difference in potency for DVS at sites labeled by [ ( 3 ) H ] NIS was found to distinguish DVS, the DVS analog rac - ( 1 - [ 1 - ( 3 - chloro - phenyl ) - 2 - ( 4 - methylpiperazin - 1 - yl ) - ethyl ] <START=Pharmacologic Substance> cyclohexanol <END=Pharmacologic Substance> ( WY - 46824 ), <START=Pharmacologic Substance> methylphenidate <END=Pharmacologic Substance>, and the cocaine analog 3beta - ( 4 - iodophenyl ) <START=Organic Chemical> tropane <END=Organic Chemical> - 2beta - carboxylic acid methyl ester ( <START=Organic Chemical> RTI - 55 <END=Organic Chemical> ) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine."}, {"PMID": 23597450, "id": 8, "text": "Consistent with these results, prunetin significantly reduced serum levels of inflammatory cytokines and mortality in mice challenged with lipopolysaccharide.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [31, 39], "name": "prunetin", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"ent_type": "GENE", "char_span": [91, 100], "name": "cytokines", "tok_span": [14, 15], "new_tok_span": [16, 17]}], "relation_list": [{"subject": "prunetin", "sbj_char_span": [31, 39], "object": "cytokines", "obj_char_span": [91, 100], "rel_type": "regulator", "sbj_tok_span": [5, 8], "obj_tok_span": [14, 15], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [16, 17]}], "umls_entity_list": [{"mention": "prunetin", "char_span": [31, 39], "sem_type": "Pharmacologic Substance", "tok_span": [5, 8], "new_tok_span": [6, 9]}], "new_text": "Consistent with these results, <START=Pharmacologic Substance> prunetin <END=Pharmacologic Substance> significantly reduced serum levels of inflammatory cytokines and mortality in mice challenged with lipopolysaccharide."}, {"PMID": 3139361, "id": 3, "text": "The following ranking (low to high) for the RBA of the nuclear (intact cells) progesterone receptor irrespective of the ligand used is found: norethisterone much less than levonorgestrel less than 3-keto-destogestrel less than gestodene.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [78, 90], "name": "progesterone", "tok_span": [19, 20], "new_tok_span": [22, 23]}, {"ent_type": "CHEMICAL", "char_span": [142, 156], "name": "norethisterone", "tok_span": [29, 33], "new_tok_span": [36, 40]}, {"ent_type": "CHEMICAL", "char_span": [172, 186], "name": "levonorgestrel", "tok_span": [36, 41], "new_tok_span": [45, 50]}, {"ent_type": "CHEMICAL", "char_span": [197, 216], "name": "3-keto-destogestrel", "tok_span": [43, 52], "new_tok_span": [53, 62]}, {"ent_type": "CHEMICAL", "char_span": [227, 236], "name": "gestodene", "tok_span": [54, 57], "new_tok_span": [65, 68]}, {"ent_type": "GENE", "char_span": [78, 99], "name": "progesterone receptor", "tok_span": [19, 21], "new_tok_span": [22, 24]}], "relation_list": [{"subject": "levonorgestrel", "sbj_char_span": [172, 186], "object": "progesterone receptor", "obj_char_span": [78, 99], "rel_type": "regulator", "sbj_tok_span": [36, 41], "obj_tok_span": [19, 21], "new_sbj_tok_span": [45, 50], "new_obj_tok_span": [22, 24]}, {"subject": "gestodene", "sbj_char_span": [227, 236], "object": "progesterone receptor", "obj_char_span": [78, 99], "rel_type": "regulator", "sbj_tok_span": [54, 57], "obj_tok_span": [19, 21], "new_sbj_tok_span": [65, 68], "new_obj_tok_span": [22, 24]}], "umls_entity_list": [{"mention": "progesterone receptor", "char_span": [78, 99], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 21], "new_tok_span": [22, 24]}, {"mention": "progesterone receptor", "char_span": [78, 99], "sem_type": "Gene or Genome", "tok_span": [19, 21], "new_tok_span": [22, 24]}, {"mention": "progesterone", "char_span": [78, 90], "sem_type": "Pharmacologic Substance", "tok_span": [19, 20], "new_tok_span": [22, 23]}, {"mention": "norethisterone", "char_span": [142, 156], "sem_type": "Pharmacologic Substance", "tok_span": [29, 33], "new_tok_span": [36, 40]}, {"mention": "levonorgestrel", "char_span": [172, 186], "sem_type": "Pharmacologic Substance", "tok_span": [36, 41], "new_tok_span": [45, 50]}, {"mention": "gestodene", "char_span": [227, 236], "sem_type": "Pharmacologic Substance", "tok_span": [54, 57], "new_tok_span": [65, 68]}], "new_text": "The following ranking ( low to high ) for the RBA of the nuclear ( intact cells ) <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Pharmacologic Substance> progesterone <END=Pharmacologic Substance> receptor <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> irrespective of the ligand used is found : <START=Pharmacologic Substance> norethisterone <END=Pharmacologic Substance> much less than <START=Pharmacologic Substance> levonorgestrel <END=Pharmacologic Substance> less than 3 - keto - destogestrel less than <START=Pharmacologic Substance> gestodene <END=Pharmacologic Substance>."}, {"PMID": 16395286, "id": 9, "text": "We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the MMP-9 inhibition by tetracyclines.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [130, 143], "name": "tetracyclines", "tok_span": [21, 24], "new_tok_span": [24, 27]}, {"ent_type": "GENE", "char_span": [110, 115], "name": "MMP-9", "tok_span": [16, 19], "new_tok_span": [17, 20]}], "relation_list": [{"subject": "tetracyclines", "sbj_char_span": [130, 143], "object": "MMP-9", "obj_char_span": [110, 115], "rel_type": "inhibitor", "sbj_tok_span": [21, 24], "obj_tok_span": [16, 19], "new_sbj_tok_span": [24, 27], "new_obj_tok_span": [17, 20]}], "umls_entity_list": [{"mention": "MMP-9", "char_span": [110, 115], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 19], "new_tok_span": [17, 20]}, {"mention": "tetracyclines", "char_span": [130, 143], "sem_type": "Organic Chemical", "tok_span": [21, 24], "new_tok_span": [24, 27]}], "new_text": "We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the <START=Amino Acid, Peptide, or Protein> MMP - 9 <END=Amino Acid, Peptide, or Protein> inhibition by <START=Organic Chemical> tetracyclines <END=Organic Chemical>."}, {"PMID": 15985434, "id": 2, "text": "This constitutes an essential step in the synthesis of pyridoxal 5'-phosphate (PLP), the active form of vitamin B6, a cofactor for over 140 enzymes. (R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [55, 77], "name": "pyridoxal 5'-phosphate", "tok_span": [9, 17], "new_tok_span": [9, 17]}, {"ent_type": "CHEMICAL", "char_span": [79, 82], "name": "PLP", "tok_span": [18, 20], "new_tok_span": [18, 20]}, {"ent_type": "CHEMICAL", "char_span": [104, 114], "name": "vitamin B6", "tok_span": [26, 29], "new_tok_span": [26, 29]}, {"ent_type": "CHEMICAL", "char_span": [149, 164], "name": "(R)-Roscovitine", "tok_span": [38, 46], "new_tok_span": [38, 46]}, {"ent_type": "CHEMICAL", "char_span": [166, 172], "name": "CYC202", "tok_span": [47, 50], "new_tok_span": [50, 53]}, {"ent_type": "CHEMICAL", "char_span": [174, 184], "name": "Seliciclib", "tok_span": [51, 55], "new_tok_span": [56, 60]}, {"ent_type": "GENE", "char_span": [225, 249], "name": "cyclin-dependent kinases", "tok_span": [62, 66], "new_tok_span": [68, 72]}, {"ent_type": "GENE", "char_span": [251, 255], "name": "CDKs", "tok_span": [67, 69], "new_tok_span": [73, 75]}], "relation_list": [{"subject": "(R)-Roscovitine", "sbj_char_span": [149, 164], "object": "cyclin-dependent kinases", "obj_char_span": [225, 249], "rel_type": "inhibitor", "sbj_tok_span": [38, 46], "obj_tok_span": [62, 66], "new_sbj_tok_span": [38, 46], "new_obj_tok_span": [68, 72]}, {"subject": "CYC202", "sbj_char_span": [166, 172], "object": "cyclin-dependent kinases", "obj_char_span": [225, 249], "rel_type": "inhibitor", "sbj_tok_span": [47, 50], "obj_tok_span": [62, 66], "new_sbj_tok_span": [50, 53], "new_obj_tok_span": [68, 72]}, {"subject": "Seliciclib", "sbj_char_span": [174, 184], "object": "cyclin-dependent kinases", "obj_char_span": [225, 249], "rel_type": "inhibitor", "sbj_tok_span": [51, 55], "obj_tok_span": [62, 66], "new_sbj_tok_span": [56, 60], "new_obj_tok_span": [68, 72]}, {"subject": "(R)-Roscovitine", "sbj_char_span": [149, 164], "object": "CDKs", "obj_char_span": [251, 255], "rel_type": "inhibitor", "sbj_tok_span": [38, 46], "obj_tok_span": [67, 69], "new_sbj_tok_span": [38, 46], "new_obj_tok_span": [73, 75]}, {"subject": "CYC202", "sbj_char_span": [166, 172], "object": "CDKs", "obj_char_span": [251, 255], "rel_type": "inhibitor", "sbj_tok_span": [47, 50], "obj_tok_span": [67, 69], "new_sbj_tok_span": [50, 53], "new_obj_tok_span": [73, 75]}, {"subject": "Seliciclib", "sbj_char_span": [174, 184], "object": "CDKs", "obj_char_span": [251, 255], "rel_type": "inhibitor", "sbj_tok_span": [51, 55], "obj_tok_span": [67, 69], "new_sbj_tok_span": [56, 60], "new_obj_tok_span": [73, 75]}], "umls_entity_list": [{"mention": "-Roscovitin", "char_span": [152, 163], "sem_type": "Organic Chemical", "tok_span": [41, 46], "new_tok_span": [42, 47]}, {"mention": "CYC202", "char_span": [166, 172], "sem_type": "Organic Chemical", "tok_span": [47, 50], "new_tok_span": [50, 53]}, {"mention": "Seliciclib", "char_span": [174, 184], "sem_type": "Pharmacologic Substance", "tok_span": [51, 55], "new_tok_span": [56, 60]}], "new_text": "This constitutes an essential step in the synthesis of pyridoxal 5'- phosphate ( PLP ), the active form of vitamin B6, a cofactor for over 140 enzymes. ( R ) <START=Organic Chemical> - Roscovitine <END=Organic Chemical> ( <START=Organic Chemical> CYC202 <END=Organic Chemical>, <START=Pharmacologic Substance> Seliciclib <END=Pharmacologic Substance> ) is a relatively selective inhibitor of cyclin - dependent kinases ( CDKs ), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections."}, {"PMID": 23022398, "id": 4, "text": "Other groups received either an infusion of the selective NMDA receptor antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [58, 62], "name": "NMDA", "tok_span": [9, 10], "new_tok_span": [11, 12]}, {"ent_type": "CHEMICAL", "char_span": [84, 87], "name": "AP7", "tok_span": [13, 15], "new_tok_span": [17, 19]}, {"ent_type": "CHEMICAL", "char_span": [138, 142], "name": "PILO", "tok_span": [31, 33], "new_tok_span": [35, 37]}, {"ent_type": "GENE", "char_span": [58, 71], "name": "NMDA receptor", "tok_span": [9, 11], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "AP7", "sbj_char_span": [84, 87], "object": "NMDA receptor", "obj_char_span": [58, 71], "rel_type": "agonist or antagonist", "sbj_tok_span": [13, 15], "obj_tok_span": [9, 11], "new_sbj_tok_span": [17, 19], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [{"mention": "NMDA", "char_span": [58, 62], "sem_type": "Pharmacologic Substance", "tok_span": [9, 10], "new_tok_span": [11, 12]}, {"mention": "NMDA receptor antagonist", "char_span": [58, 82], "sem_type": "Pharmacologic Substance", "tok_span": [9, 12], "new_tok_span": [11, 14]}], "new_text": "Other groups received either an infusion of the selective <START=Pharmacologic Substance> <START=Pharmacologic Substance> NMDA <END=Pharmacologic Substance> receptor antagonist <END=Pharmacologic Substance> ( AP7 ; 10 nmol ; intra - mPFC ) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra - threshold LTD protocol ( 900 pulses, 1 Hz ; LFS900 )."}, {"PMID": 14761877, "id": 9, "text": "In contrast to their opposing actions on cell growth, both activin A and DHT upregulated PSA gene expression and increased PSA secretion by LNCaP cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 76], "name": "DHT", "tok_span": [15, 17], "new_tok_span": [17, 19]}, {"ent_type": "GENE", "char_span": [59, 68], "name": "activin A", "tok_span": [11, 14], "new_tok_span": [12, 15]}, {"ent_type": "GENE", "char_span": [89, 92], "name": "PSA", "tok_span": [18, 19], "new_tok_span": [22, 23]}, {"ent_type": "GENE", "char_span": [123, 126], "name": "PSA", "tok_span": [23, 24], "new_tok_span": [31, 32]}], "relation_list": [{"subject": "DHT", "sbj_char_span": [73, 76], "object": "PSA", "obj_char_span": [89, 92], "rel_type": "regulator", "sbj_tok_span": [15, 17], "obj_tok_span": [18, 19], "new_sbj_tok_span": [17, 19], "new_obj_tok_span": [22, 23]}, {"subject": "DHT", "sbj_char_span": [73, 76], "object": "PSA", "obj_char_span": [123, 126], "rel_type": "regulator", "sbj_tok_span": [15, 17], "obj_tok_span": [23, 24], "new_sbj_tok_span": [17, 19], "new_obj_tok_span": [31, 32]}], "umls_entity_list": [{"mention": "activin A", "char_span": [59, 68], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 14], "new_tok_span": [12, 15]}, {"mention": "PSA", "char_span": [89, 92], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 19], "new_tok_span": [22, 23]}, {"mention": "PSA", "char_span": [123, 126], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [23, 24], "new_tok_span": [31, 32]}, {"mention": "PSA", "char_span": [89, 92], "sem_type": "Gene or Genome", "tok_span": [18, 19], "new_tok_span": [22, 23]}, {"mention": "PSA", "char_span": [123, 126], "sem_type": "Gene or Genome", "tok_span": [23, 24], "new_tok_span": [31, 32]}], "new_text": "In contrast to their opposing actions on cell growth, both <START=Amino Acid, Peptide, or Protein> activin A <END=Amino Acid, Peptide, or Protein> and DHT upregulated <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PSA <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> gene expression and increased <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PSA <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> secretion by LNCaP cells."}, {"PMID": 23319419, "id": 8, "text": "With the exception of three residues, the specific amino acids that form the putative binding pocket for ICA in ERG are conserved in EAG. Mutations introduced into EAG to replicate the ICA binding site in ERG did not alter the functional response to ICA. Together these findings suggest that ICA binds to the same site in EAG and ERG channels to elicit opposite functional effects.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [51, 62], "name": "amino acids", "tok_span": [9, 11], "new_tok_span": [9, 11]}, {"ent_type": "CHEMICAL", "char_span": [105, 108], "name": "ICA", "tok_span": [18, 19], "new_tok_span": [18, 19]}, {"ent_type": "CHEMICAL", "char_span": [185, 188], "name": "ICA", "tok_span": [36, 37], "new_tok_span": [40, 41]}, {"ent_type": "CHEMICAL", "char_span": [250, 253], "name": "ICA", "tok_span": [49, 50], "new_tok_span": [53, 54]}, {"ent_type": "CHEMICAL", "char_span": [292, 295], "name": "ICA", "tok_span": [56, 57], "new_tok_span": [60, 61]}, {"ent_type": "GENE", "char_span": [112, 115], "name": "ERG", "tok_span": [20, 22], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [133, 136], "name": "EAG", "tok_span": [25, 27], "new_tok_span": [26, 28]}, {"ent_type": "GENE", "char_span": [164, 167], "name": "EAG", "tok_span": [31, 33], "new_tok_span": [34, 36]}, {"ent_type": "GENE", "char_span": [205, 208], "name": "ERG", "tok_span": [40, 42], "new_tok_span": [44, 46]}, {"ent_type": "GENE", "char_span": [322, 325], "name": "EAG", "tok_span": [63, 65], "new_tok_span": [68, 70]}, {"ent_type": "GENE", "char_span": [330, 333], "name": "ERG", "tok_span": [66, 68], "new_tok_span": [72, 74]}], "relation_list": [{"subject": "amino acids", "sbj_char_span": [51, 62], "object": "ERG", "obj_char_span": [112, 115], "rel_type": "part of", "sbj_tok_span": [9, 11], "obj_tok_span": [20, 22], "new_sbj_tok_span": [9, 11], "new_obj_tok_span": [20, 22]}, {"subject": "amino acids", "sbj_char_span": [51, 62], "object": "EAG", "obj_char_span": [133, 136], "rel_type": "part of", "sbj_tok_span": [9, 11], "obj_tok_span": [25, 27], "new_sbj_tok_span": [9, 11], "new_obj_tok_span": [26, 28]}, {"subject": "ICA", "sbj_char_span": [105, 108], "object": "ERG", "obj_char_span": [112, 115], "rel_type": "regulator", "sbj_tok_span": [18, 19], "obj_tok_span": [20, 22], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [20, 22]}, {"subject": "ICA", "sbj_char_span": [105, 108], "object": "EAG", "obj_char_span": [133, 136], "rel_type": "regulator", "sbj_tok_span": [18, 19], "obj_tok_span": [25, 27], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [26, 28]}, {"subject": "ICA", "sbj_char_span": [292, 295], "object": "EAG", "obj_char_span": [322, 325], "rel_type": "regulator", "sbj_tok_span": [56, 57], "obj_tok_span": [63, 65], "new_sbj_tok_span": [60, 61], "new_obj_tok_span": [68, 70]}, {"subject": "ICA", "sbj_char_span": [292, 295], "object": "ERG", "obj_char_span": [330, 333], "rel_type": "regulator", "sbj_tok_span": [56, 57], "obj_tok_span": [66, 68], "new_sbj_tok_span": [60, 61], "new_obj_tok_span": [72, 74]}, {"subject": "ICA", "sbj_char_span": [185, 188], "object": "EAG", "obj_char_span": [164, 167], "rel_type": "regulator", "sbj_tok_span": [36, 37], "obj_tok_span": [31, 33], "new_sbj_tok_span": [40, 41], "new_obj_tok_span": [34, 36]}, {"subject": "ICA", "sbj_char_span": [185, 188], "object": "ERG", "obj_char_span": [205, 208], "rel_type": "regulator", "sbj_tok_span": [36, 37], "obj_tok_span": [40, 42], "new_sbj_tok_span": [40, 41], "new_obj_tok_span": [44, 46]}, {"subject": "ICA", "sbj_char_span": [250, 253], "object": "EAG", "obj_char_span": [164, 167], "rel_type": "regulator", "sbj_tok_span": [49, 50], "obj_tok_span": [31, 33], "new_sbj_tok_span": [53, 54], "new_obj_tok_span": [34, 36]}, {"subject": "ICA", "sbj_char_span": [250, 253], "object": "ERG", "obj_char_span": [205, 208], "rel_type": "regulator", "sbj_tok_span": [49, 50], "obj_tok_span": [40, 42], "new_sbj_tok_span": [53, 54], "new_obj_tok_span": [44, 46]}], "umls_entity_list": [{"mention": "EAG", "char_span": [133, 136], "sem_type": "Gene or Genome", "tok_span": [25, 27], "new_tok_span": [26, 28]}, {"mention": "EAG", "char_span": [164, 167], "sem_type": "Gene or Genome", "tok_span": [31, 33], "new_tok_span": [34, 36]}, {"mention": "EAG", "char_span": [322, 325], "sem_type": "Gene or Genome", "tok_span": [63, 65], "new_tok_span": [68, 70]}], "new_text": "With the exception of three residues, the specific amino acids that form the putative binding pocket for ICA in ERG are conserved in <START=Gene or Genome> EAG <END=Gene or Genome>. Mutations introduced into <START=Gene or Genome> EAG <END=Gene or Genome> to replicate the ICA binding site in ERG did not alter the functional response to ICA. Together these findings suggest that ICA binds to the same site in <START=Gene or Genome> EAG <END=Gene or Genome> and ERG channels to elicit opposite functional effects."}, {"PMID": 23263989, "id": 6, "text": "We demonstrate that the PHD1-PHD2 region is essential for viability and that the first PHD finger contributes to the preferred binding of PHD1-PHD2 to lysine 4-methylated histone H3 tails.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [151, 157], "name": "lysine", "tok_span": [37, 38], "new_tok_span": [64, 65]}, {"ent_type": "GENE", "char_span": [24, 33], "name": "PHD1-PHD2", "tok_span": [4, 11], "new_tok_span": [7, 14]}, {"ent_type": "GENE", "char_span": [87, 97], "name": "PHD finger", "tok_span": [20, 23], "new_tok_span": [33, 36]}, {"ent_type": "GENE", "char_span": [138, 147], "name": "PHD1-PHD2", "tok_span": [29, 36], "new_tok_span": [46, 53]}], "relation_list": [{"subject": "lysine", "sbj_char_span": [151, 157], "object": "PHD1-PHD2", "obj_char_span": [138, 147], "rel_type": "regulator", "sbj_tok_span": [37, 38], "obj_tok_span": [29, 36], "new_sbj_tok_span": [64, 65], "new_obj_tok_span": [46, 53]}], "umls_entity_list": [{"mention": "PHD1", "char_span": [24, 28], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 7], "new_tok_span": [7, 10]}, {"mention": "PHD1", "char_span": [138, 142], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 32], "new_tok_span": [46, 49]}, {"mention": "PHD2", "char_span": [29, 33], "sem_type": "Gene or Genome", "tok_span": [8, 11], "new_tok_span": [17, 20]}, {"mention": "PHD2", "char_span": [143, 147], "sem_type": "Gene or Genome", "tok_span": [33, 36], "new_tok_span": [56, 59]}, {"mention": "PHD2", "char_span": [29, 33], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 11], "new_tok_span": [17, 20]}, {"mention": "PHD2", "char_span": [143, 147], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 36], "new_tok_span": [56, 59]}, {"mention": "PHD1", "char_span": [24, 28], "sem_type": "Gene or Genome", "tok_span": [4, 7], "new_tok_span": [7, 10]}, {"mention": "PHD1", "char_span": [138, 142], "sem_type": "Gene or Genome", "tok_span": [29, 32], "new_tok_span": [46, 49]}, {"mention": "PHD", "char_span": [24, 27], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 6], "new_tok_span": [7, 9]}, {"mention": "PHD", "char_span": [29, 32], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 10], "new_tok_span": [17, 19]}, {"mention": "PHD", "char_span": [87, 90], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 22], "new_tok_span": [33, 35]}, {"mention": "PHD", "char_span": [138, 141], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 31], "new_tok_span": [46, 48]}, {"mention": "PHD", "char_span": [143, 146], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 35], "new_tok_span": [56, 58]}, {"mention": "lysine", "char_span": [151, 157], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 38], "new_tok_span": [64, 65]}, {"mention": "methylated", "char_span": [160, 170], "sem_type": "Pharmacologic Substance", "tok_span": [40, 41], "new_tok_span": [69, 70]}, {"mention": "histone", "char_span": [171, 178], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 42], "new_tok_span": [72, 73]}], "new_text": "We demonstrate that the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PHD <END=Amino Acid, Peptide, or Protein>1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> PHD <END=Amino Acid, Peptide, or Protein>2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> region is essential for viability and that the first <START=Amino Acid, Peptide, or Protein> PHD <END=Amino Acid, Peptide, or Protein> finger contributes to the preferred binding of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PHD <END=Amino Acid, Peptide, or Protein>1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> PHD <END=Amino Acid, Peptide, or Protein>2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> to <START=Amino Acid, Peptide, or Protein> lysine <END=Amino Acid, Peptide, or Protein> 4 - <START=Pharmacologic Substance> methylated <END=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> histone <END=Amino Acid, Peptide, or Protein> H3 tails."}, {"PMID": 23345579, "id": 11, "text": "After aging and digestion with pepsin at pH 2, peptide FGES198AGAAS from Sp-tabun thiocholine had a mass of 902.2 m/z in negative mode, indicating that it had aged by deamination, whereas peptide FGES198AGAAS from Rp-tabun thiocholine had a mass of 874.2 m/z in negative mode, indicating that it had aged by O-dealkylation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 93], "name": "Sp-tabun thiocholine", "tok_span": [19, 26], "new_tok_span": [21, 28]}, {"ent_type": "CHEMICAL", "char_span": [214, 234], "name": "Rp-tabun thiocholine", "tok_span": [58, 65], "new_tok_span": [67, 74]}, {"ent_type": "CHEMICAL", "char_span": [308, 309], "name": "O", "tok_span": [86, 87], "new_tok_span": [100, 101]}, {"ent_type": "GENE", "char_span": [31, 37], "name": "pepsin", "tok_span": [5, 8], "new_tok_span": [5, 8]}, {"ent_type": "GENE", "char_span": [55, 67], "name": "FGES198AGAAS", "tok_span": [13, 18], "new_tok_span": [13, 18]}, {"ent_type": "GENE", "char_span": [196, 208], "name": "FGES198AGAAS", "tok_span": [52, 57], "new_tok_span": [60, 65]}], "relation_list": [{"subject": "Sp-tabun thiocholine", "sbj_char_span": [73, 93], "object": "pepsin", "obj_char_span": [31, 37], "rel_type": "product or substrate", "sbj_tok_span": [19, 26], "obj_tok_span": [5, 8], "new_sbj_tok_span": [21, 28], "new_obj_tok_span": [5, 8]}, {"subject": "Rp-tabun thiocholine", "sbj_char_span": [214, 234], "object": "pepsin", "obj_char_span": [31, 37], "rel_type": "product or substrate", "sbj_tok_span": [58, 65], "obj_tok_span": [5, 8], "new_sbj_tok_span": [67, 74], "new_obj_tok_span": [5, 8]}], "umls_entity_list": [{"mention": "Sp", "char_span": [73, 75], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 20], "new_tok_span": [21, 22]}, {"mention": "tabun", "char_span": [76, 81], "sem_type": "Organic Chemical", "tok_span": [21, 23], "new_tok_span": [26, 28]}, {"mention": "tabun", "char_span": [217, 222], "sem_type": "Organic Chemical", "tok_span": [60, 62], "new_tok_span": [71, 73]}, {"mention": "thiocholine", "char_span": [82, 93], "sem_type": "Organic Chemical", "tok_span": [23, 26], "new_tok_span": [30, 33]}, {"mention": "thiocholine", "char_span": [223, 234], "sem_type": "Organic Chemical", "tok_span": [62, 65], "new_tok_span": [75, 78]}, {"mention": "Sp", "char_span": [73, 75], "sem_type": "Gene or Genome", "tok_span": [19, 20], "new_tok_span": [21, 22]}, {"mention": "Rp", "char_span": [214, 216], "sem_type": "Gene or Genome", "tok_span": [58, 59], "new_tok_span": [67, 68]}], "new_text": "After aging and digestion with pepsin at pH 2, peptide FGES198AGAAS from <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Sp <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - <START=Organic Chemical> tabun <END=Organic Chemical> <START=Organic Chemical> thiocholine <END=Organic Chemical> had a mass of 902. 2 m / z in negative mode, indicating that it had aged by deamination, whereas peptide FGES198AGAAS from <START=Gene or Genome> Rp <END=Gene or Genome> - <START=Organic Chemical> tabun <END=Organic Chemical> <START=Organic Chemical> thiocholine <END=Organic Chemical> had a mass of 874. 2 m / z in negative mode, indicating that it had aged by O - dealkylation."}, {"PMID": 23315277, "id": 7, "text": "Moreover, activities of caspase-3 and caspase-9 enzymes were also significantly higher in both kinds of cells exposed to SiO(2) NPs. This study suggested that SiO(2) NPs induce cytotoxicity and apoptosis in A431 and A549 cells, which is likely to be mediated through ROS generation and oxidative stress.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [121, 127], "name": "SiO(2)", "tok_span": [23, 27], "new_tok_span": [25, 29]}, {"ent_type": "CHEMICAL", "char_span": [159, 165], "name": "SiO(2)", "tok_span": [33, 37], "new_tok_span": [37, 41]}, {"ent_type": "GENE", "char_span": [24, 33], "name": "caspase-3", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [38, 47], "name": "caspase-9", "tok_span": [8, 11], "new_tok_span": [9, 12]}], "relation_list": [{"subject": "SiO(2)", "sbj_char_span": [121, 127], "object": "caspase-3", "obj_char_span": [24, 33], "rel_type": "activator", "sbj_tok_span": [23, 27], "obj_tok_span": [4, 7], "new_sbj_tok_span": [25, 29], "new_obj_tok_span": [4, 7]}, {"subject": "SiO(2)", "sbj_char_span": [121, 127], "object": "caspase-9", "obj_char_span": [38, 47], "rel_type": "activator", "sbj_tok_span": [23, 27], "obj_tok_span": [8, 11], "new_sbj_tok_span": [25, 29], "new_obj_tok_span": [9, 12]}], "umls_entity_list": [{"mention": "caspase-9", "char_span": [38, 47], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"mention": "NPs", "char_span": [128, 131], "sem_type": "Gene or Genome", "tok_span": [27, 28], "new_tok_span": [30, 31]}, {"mention": "NPs", "char_span": [166, 169], "sem_type": "Gene or Genome", "tok_span": [37, 38], "new_tok_span": [42, 43]}], "new_text": "Moreover, activities of caspase - 3 and <START=Amino Acid, Peptide, or Protein> caspase - 9 <END=Amino Acid, Peptide, or Protein> enzymes were also significantly higher in both kinds of cells exposed to SiO ( 2 ) <START=Gene or Genome> NPs <END=Gene or Genome>. This study suggested that SiO ( 2 ) <START=Gene or Genome> NPs <END=Gene or Genome> induce cytotoxicity and apoptosis in A431 and A549 cells, which is likely to be mediated through ROS generation and oxidative stress."}, {"PMID": 23008503, "id": 9, "text": "Second, feeding increased both the expression of COX isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with cimetidine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [66, 72], "name": "PGE(2)", "tok_span": [11, 15], "new_tok_span": [13, 17]}, {"ent_type": "CHEMICAL", "char_span": [157, 167], "name": "cimetidine", "tok_span": [30, 33], "new_tok_span": [32, 35]}, {"ent_type": "GENE", "char_span": [49, 52], "name": "COX", "tok_span": [8, 9], "new_tok_span": [9, 10]}], "relation_list": [{"subject": "cimetidine", "sbj_char_span": [157, 167], "object": "COX", "obj_char_span": [49, 52], "rel_type": "regulator", "sbj_tok_span": [30, 33], "obj_tok_span": [8, 9], "new_sbj_tok_span": [32, 35], "new_obj_tok_span": [9, 10]}], "umls_entity_list": [{"mention": "COX", "char_span": [49, 52], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [9, 10]}], "new_text": "Second, feeding increased both the expression of <START=Amino Acid, Peptide, or Protein> COX <END=Amino Acid, Peptide, or Protein> isoforms and PGE ( 2 ) level in the duodenum, and the effects were markedly inhibited by pretreatment with cimetidine."}, {"PMID": 17645691, "id": 5, "text": "Moreover, melatonin (but not silymarin) upregulated several proteins involved in the cellular protection against the oxidative stress in rats with OCP. These included, biliverdin-IX alpha reductase and the sodium-dependent vitamin C transport proteins SVCT1 and SVCT2, whose expression levels were enhanced in maternal and fetal liver by melatonin treatment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [168, 178], "name": "biliverdin", "tok_span": [31, 34], "new_tok_span": [37, 40]}, {"ent_type": "CHEMICAL", "char_span": [206, 212], "name": "sodium", "tok_span": [40, 41], "new_tok_span": [46, 47]}, {"ent_type": "CHEMICAL", "char_span": [223, 232], "name": "vitamin C", "tok_span": [43, 45], "new_tok_span": [49, 51]}, {"ent_type": "CHEMICAL", "char_span": [338, 347], "name": "melatonin", "tok_span": [66, 67], "new_tok_span": [79, 80]}, {"ent_type": "CHEMICAL", "char_span": [10, 19], "name": "melatonin", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"ent_type": "CHEMICAL", "char_span": [29, 38], "name": "silymarin", "tok_span": [6, 9], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [168, 197], "name": "biliverdin-IX alpha reductase", "tok_span": [31, 38], "new_tok_span": [37, 44]}, {"ent_type": "GENE", "char_span": [252, 257], "name": "SVCT1", "tok_span": [47, 50], "new_tok_span": [56, 59]}, {"ent_type": "GENE", "char_span": [262, 267], "name": "SVCT2", "tok_span": [51, 54], "new_tok_span": [62, 65]}], "relation_list": [{"subject": "vitamin C", "sbj_char_span": [223, 232], "object": "SVCT1", "obj_char_span": [252, 257], "rel_type": "product or substrate", "sbj_tok_span": [43, 45], "obj_tok_span": [47, 50], "new_sbj_tok_span": [49, 51], "new_obj_tok_span": [56, 59]}, {"subject": "vitamin C", "sbj_char_span": [223, 232], "object": "SVCT2", "obj_char_span": [262, 267], "rel_type": "product or substrate", "sbj_tok_span": [43, 45], "obj_tok_span": [51, 54], "new_sbj_tok_span": [49, 51], "new_obj_tok_span": [62, 65]}, {"subject": "melatonin", "sbj_char_span": [338, 347], "object": "SVCT1", "obj_char_span": [252, 257], "rel_type": "regulator", "sbj_tok_span": [66, 67], "obj_tok_span": [47, 50], "new_sbj_tok_span": [79, 80], "new_obj_tok_span": [56, 59]}, {"subject": "melatonin", "sbj_char_span": [338, 347], "object": "SVCT2", "obj_char_span": [262, 267], "rel_type": "regulator", "sbj_tok_span": [66, 67], "obj_tok_span": [51, 54], "new_sbj_tok_span": [79, 80], "new_obj_tok_span": [62, 65]}], "umls_entity_list": [{"mention": "silymarin", "char_span": [29, 38], "sem_type": "Pharmacologic Substance", "tok_span": [6, 9], "new_tok_span": [9, 12]}, {"mention": "proteins", "char_span": [60, 68], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 13], "new_tok_span": [17, 18]}, {"mention": "proteins", "char_span": [243, 251], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [46, 47], "new_tok_span": [53, 54]}, {"mention": "SVCT1", "char_span": [252, 257], "sem_type": "Gene or Genome", "tok_span": [47, 50], "new_tok_span": [56, 59]}, {"mention": "SVCT2", "char_span": [262, 267], "sem_type": "Gene or Genome", "tok_span": [51, 54], "new_tok_span": [62, 65]}, {"mention": "melatonin", "char_span": [10, 19], "sem_type": "Pharmacologic Substance", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"mention": "melatonin", "char_span": [338, 347], "sem_type": "Pharmacologic Substance", "tok_span": [66, 67], "new_tok_span": [79, 80]}], "new_text": "Moreover, <START=Pharmacologic Substance> melatonin <END=Pharmacologic Substance> ( but not <START=Pharmacologic Substance> silymarin <END=Pharmacologic Substance> ) upregulated several <START=Amino Acid, Peptide, or Protein> proteins <END=Amino Acid, Peptide, or Protein> involved in the cellular protection against the oxidative stress in rats with OCP. These included, biliverdin - IX alpha reductase and the sodium - dependent vitamin C transport <START=Amino Acid, Peptide, or Protein> proteins <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> SVCT1 <END=Gene or Genome> and <START=Gene or Genome> SVCT2 <END=Gene or Genome>, whose expression levels were enhanced in maternal and fetal liver by <START=Pharmacologic Substance> melatonin <END=Pharmacologic Substance> treatment."}, {"PMID": 23435615, "id": 0, "text": "The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [4, 18], "name": "(R)-omeprazole", "tok_span": [1, 8], "new_tok_span": [1, 8]}, {"ent_type": "GENE", "char_span": [48, 55], "name": "CYP2C19", "tok_span": [12, 16], "new_tok_span": [16, 20]}], "relation_list": [{"subject": "(R)-omeprazole", "sbj_char_span": [4, 18], "object": "CYP2C19", "obj_char_span": [48, 55], "rel_type": "product or substrate", "sbj_tok_span": [1, 8], "obj_tok_span": [12, 16], "new_sbj_tok_span": [1, 8], "new_obj_tok_span": [16, 20]}], "umls_entity_list": [{"mention": "omeprazole", "char_span": [8, 18], "sem_type": "Pharmacologic Substance", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"mention": "CYP2C19", "char_span": [48, 55], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 16], "new_tok_span": [16, 20]}, {"mention": "CYP2C19", "char_span": [48, 55], "sem_type": "Gene or Genome", "tok_span": [12, 16], "new_tok_span": [16, 20]}], "new_text": "The ( R ) - <START=Pharmacologic Substance> omeprazole <END=Pharmacologic Substance> hydroxylation index reflects <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> CYP2C19 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> activity in healthy Japanese volunteers."}, {"PMID": 16530878, "id": 4, "text": "Glutamine synthetase activity and glutamine de novo synthesis were measured using, respectively, a standard enzymatic assay and [13C]-nuclear magnetic resonance spectroscopy.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Glutamine", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "CHEMICAL", "char_span": [34, 43], "name": "glutamine", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [129, 132], "name": "13C", "tok_span": [22, 24], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [0, 20], "name": "Glutamine synthetase", "tok_span": [0, 4], "new_tok_span": [0, 4]}], "relation_list": [{"subject": "glutamine", "sbj_char_span": [34, 43], "object": "Glutamine synthetase", "obj_char_span": [0, 20], "rel_type": "product or substrate", "sbj_tok_span": [6, 7], "obj_tok_span": [0, 4], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [0, 4]}, {"subject": "13C", "sbj_char_span": [129, 132], "object": "Glutamine synthetase", "obj_char_span": [0, 20], "rel_type": "regulator", "sbj_tok_span": [22, 24], "obj_tok_span": [0, 4], "new_sbj_tok_span": [22, 24], "new_obj_tok_span": [0, 4]}], "umls_entity_list": [], "new_text": "Glutamine synthetase activity and glutamine de novo synthesis were measured using, respectively, a standard enzymatic assay and [ 13C ] - nuclear magnetic resonance spectroscopy."}, {"PMID": 15155769, "id": 4, "text": "The M564G mutated CrAT showed higher activity toward longer chain acyl-CoAs: activity toward myristoyl-CoA was 1250-fold higher than that of the wild-type CrAT, and lower activity toward its natural substrate, acetyl-CoA.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [66, 75], "name": "acyl-CoAs", "tok_span": [14, 18], "new_tok_span": [14, 18]}, {"ent_type": "CHEMICAL", "char_span": [93, 106], "name": "myristoyl-CoA", "tok_span": [21, 28], "new_tok_span": [21, 28]}, {"ent_type": "CHEMICAL", "char_span": [210, 220], "name": "acetyl-CoA", "tok_span": [52, 56], "new_tok_span": [52, 56]}, {"ent_type": "GENE", "char_span": [4, 9], "name": "M564G", "tok_span": [1, 5], "new_tok_span": [1, 5]}, {"ent_type": "GENE", "char_span": [18, 22], "name": "CrAT", "tok_span": [6, 8], "new_tok_span": [6, 8]}, {"ent_type": "GENE", "char_span": [155, 159], "name": "CrAT", "tok_span": [41, 43], "new_tok_span": [41, 43]}], "relation_list": [{"subject": "acyl-CoAs", "sbj_char_span": [66, 75], "object": "CrAT", "obj_char_span": [18, 22], "rel_type": "product or substrate", "sbj_tok_span": [14, 18], "obj_tok_span": [6, 8], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [6, 8]}, {"subject": "myristoyl-CoA", "sbj_char_span": [93, 106], "object": "CrAT", "obj_char_span": [18, 22], "rel_type": "product or substrate", "sbj_tok_span": [21, 28], "obj_tok_span": [6, 8], "new_sbj_tok_span": [21, 28], "new_obj_tok_span": [6, 8]}, {"subject": "acyl-CoAs", "sbj_char_span": [66, 75], "object": "M564G", "obj_char_span": [4, 9], "rel_type": "product or substrate", "sbj_tok_span": [14, 18], "obj_tok_span": [1, 5], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [1, 5]}, {"subject": "myristoyl-CoA", "sbj_char_span": [93, 106], "object": "M564G", "obj_char_span": [4, 9], "rel_type": "product or substrate", "sbj_tok_span": [21, 28], "obj_tok_span": [1, 5], "new_sbj_tok_span": [21, 28], "new_obj_tok_span": [1, 5]}, {"subject": "myristoyl-CoA", "sbj_char_span": [93, 106], "object": "CrAT", "obj_char_span": [155, 159], "rel_type": "product or substrate", "sbj_tok_span": [21, 28], "obj_tok_span": [41, 43], "new_sbj_tok_span": [21, 28], "new_obj_tok_span": [41, 43]}, {"subject": "acetyl-CoA", "sbj_char_span": [210, 220], "object": "CrAT", "obj_char_span": [155, 159], "rel_type": "product or substrate", "sbj_tok_span": [52, 56], "obj_tok_span": [41, 43], "new_sbj_tok_span": [52, 56], "new_obj_tok_span": [41, 43]}, {"subject": "acetyl-CoA", "sbj_char_span": [210, 220], "object": "M564G", "obj_char_span": [4, 9], "rel_type": "product or substrate", "sbj_tok_span": [52, 56], "obj_tok_span": [1, 5], "new_sbj_tok_span": [52, 56], "new_obj_tok_span": [1, 5]}, {"subject": "acetyl-CoA", "sbj_char_span": [210, 220], "object": "CrAT", "obj_char_span": [18, 22], "rel_type": "product or substrate", "sbj_tok_span": [52, 56], "obj_tok_span": [6, 8], "new_sbj_tok_span": [52, 56], "new_obj_tok_span": [6, 8]}], "umls_entity_list": [], "new_text": "The M564G mutated CrAT showed higher activity toward longer chain acyl - CoAs : activity toward myristoyl - CoA was 1250 - fold higher than that of the wild - type CrAT, and lower activity toward its natural substrate, acetyl - CoA."}, {"PMID": 23462380, "id": 13, "text": "Recommended management may include use of acetylcholinesterase inhibitors (e.g. neostigmine) and wound care on a case-by-case basis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [80, 91], "name": "neostigmine", "tok_span": [16, 20], "new_tok_span": [19, 23]}, {"ent_type": "GENE", "char_span": [42, 62], "name": "acetylcholinesterase", "tok_span": [7, 10], "new_tok_span": [8, 11]}], "relation_list": [{"subject": "neostigmine", "sbj_char_span": [80, 91], "object": "acetylcholinesterase", "obj_char_span": [42, 62], "rel_type": "inhibitor", "sbj_tok_span": [16, 20], "obj_tok_span": [7, 10], "new_sbj_tok_span": [19, 23], "new_obj_tok_span": [8, 11]}], "umls_entity_list": [{"mention": "acetylcholinesterase", "char_span": [42, 62], "sem_type": "Pharmacologic Substance", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "neostigmine", "char_span": [80, 91], "sem_type": "Pharmacologic Substance", "tok_span": [16, 20], "new_tok_span": [19, 23]}], "new_text": "Recommended management may include use of <START=Pharmacologic Substance> acetylcholinesterase <END=Pharmacologic Substance> inhibitors ( e. g. <START=Pharmacologic Substance> neostigmine <END=Pharmacologic Substance> ) and wound care on a case - by - case basis."}, {"PMID": 23319419, "id": 7, "text": "ICA is a mixed agonist of mutant EAG and EAG/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 3], "name": "ICA", "tok_span": [0, 1], "new_tok_span": [0, 1]}, {"ent_type": "GENE", "char_span": [33, 36], "name": "EAG", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"ent_type": "GENE", "char_span": [41, 44], "name": "EAG", "tok_span": [10, 12], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [45, 48], "name": "ERG", "tok_span": [13, 15], "new_tok_span": [17, 19]}], "relation_list": [{"subject": "ICA", "sbj_char_span": [0, 3], "object": "EAG", "obj_char_span": [33, 36], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 1], "obj_tok_span": [7, 9], "new_sbj_tok_span": [0, 1], "new_obj_tok_span": [8, 10]}, {"subject": "ICA", "sbj_char_span": [0, 3], "object": "EAG", "obj_char_span": [41, 44], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 1], "obj_tok_span": [10, 12], "new_sbj_tok_span": [0, 1], "new_obj_tok_span": [13, 15]}, {"subject": "ICA", "sbj_char_span": [0, 3], "object": "ERG", "obj_char_span": [45, 48], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 1], "obj_tok_span": [13, 15], "new_sbj_tok_span": [0, 1], "new_obj_tok_span": [17, 19]}], "umls_entity_list": [{"mention": "EAG", "char_span": [33, 36], "sem_type": "Gene or Genome", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"mention": "EAG", "char_span": [41, 44], "sem_type": "Gene or Genome", "tok_span": [10, 12], "new_tok_span": [13, 15]}], "new_text": "ICA is a mixed agonist of mutant <START=Gene or Genome> EAG <END=Gene or Genome> and <START=Gene or Genome> EAG <END=Gene or Genome> / ERG chimera channels that inactivate by a combination of slow and fast mechanisms."}, {"PMID": 12662154, "id": 8, "text": "These differences were also present in bovine M-CPT 1, whose N-terminal sequence we determined.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [61, 62], "name": "N", "tok_span": [13, 14], "new_tok_span": [15, 16]}, {"ent_type": "GENE", "char_span": [39, 53], "name": "bovine M-CPT 1", "tok_span": [6, 11], "new_tok_span": [6, 11]}], "relation_list": [{"subject": "N", "sbj_char_span": [61, 62], "object": "bovine M-CPT 1", "obj_char_span": [39, 53], "rel_type": "part of", "sbj_tok_span": [13, 14], "obj_tok_span": [6, 11], "new_sbj_tok_span": [15, 16], "new_obj_tok_span": [6, 11]}], "umls_entity_list": [{"mention": "CPT 1", "char_span": [48, 53], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 11], "new_tok_span": [10, 12]}], "new_text": "These differences were also present in bovine M - <START=Amino Acid, Peptide, or Protein> CPT 1 <END=Amino Acid, Peptide, or Protein>, whose N - terminal sequence we determined."}, {"PMID": 14530799, "id": 9, "text": "Considerable attention has focused on the investigation of theories to explain the better tolerability of memantine over other NMDA receptor antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [106, 115], "name": "memantine", "tok_span": [17, 20], "new_tok_span": [18, 21]}, {"ent_type": "CHEMICAL", "char_span": [127, 131], "name": "NMDA", "tok_span": [22, 23], "new_tok_span": [24, 25]}, {"ent_type": "CHEMICAL", "char_span": [267, 280], "name": "phencyclidine", "tok_span": [45, 48], "new_tok_span": [48, 51]}, {"ent_type": "CHEMICAL", "char_span": [282, 290], "name": "ketamine", "tok_span": [49, 50], "new_tok_span": [54, 55]}, {"ent_type": "CHEMICAL", "char_span": [292, 298], "name": "MK-801", "tok_span": [51, 55], "new_tok_span": [57, 61]}, {"ent_type": "GENE", "char_span": [127, 140], "name": "NMDA receptor", "tok_span": [22, 24], "new_tok_span": [24, 26]}], "relation_list": [{"subject": "memantine", "sbj_char_span": [106, 115], "object": "NMDA receptor", "obj_char_span": [127, 140], "rel_type": "agonist or antagonist", "sbj_tok_span": [17, 20], "obj_tok_span": [22, 24], "new_sbj_tok_span": [18, 21], "new_obj_tok_span": [24, 26]}], "umls_entity_list": [{"mention": "memantine", "char_span": [106, 115], "sem_type": "Pharmacologic Substance", "tok_span": [17, 20], "new_tok_span": [18, 21]}, {"mention": "phencyclidine", "char_span": [267, 280], "sem_type": "Pharmacologic Substance", "tok_span": [45, 48], "new_tok_span": [48, 51]}, {"mention": "ketamine", "char_span": [282, 290], "sem_type": "Pharmacologic Substance", "tok_span": [49, 50], "new_tok_span": [54, 55]}], "new_text": "Considerable attention has focused on the investigation of theories to explain the better tolerability of <START=Pharmacologic Substance> memantine <END=Pharmacologic Substance> over other NMDA receptor antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic - like agents ( <START=Pharmacologic Substance> phencyclidine <END=Pharmacologic Substance>, <START=Pharmacologic Substance> ketamine <END=Pharmacologic Substance>, MK - 801 )."}, {"PMID": 16897483, "id": 9, "text": "Gene expression as well as total ADH activity are strongly inhibited in antisense ACC oxidase melons and in melon fruit treated with the ethylene antagonist 1-methylcyclopropene (1-MCP), indicating a positive regulation by ethylene.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [137, 145], "name": "ethylene", "tok_span": [26, 27], "new_tok_span": [34, 35]}, {"ent_type": "CHEMICAL", "char_span": [157, 177], "name": "1-methylcyclopropene", "tok_span": [28, 34], "new_tok_span": [38, 44]}, {"ent_type": "CHEMICAL", "char_span": [179, 184], "name": "1-MCP", "tok_span": [35, 38], "new_tok_span": [46, 49]}, {"ent_type": "CHEMICAL", "char_span": [223, 231], "name": "ethylene", "tok_span": [45, 46], "new_tok_span": [59, 60]}, {"ent_type": "GENE", "char_span": [33, 36], "name": "ADH", "tok_span": [6, 8], "new_tok_span": [6, 8]}, {"ent_type": "GENE", "char_span": [82, 93], "name": "ACC oxidase", "tok_span": [14, 16], "new_tok_span": [15, 17]}], "relation_list": [{"subject": "1-methylcyclopropene", "sbj_char_span": [157, 177], "object": "ADH", "obj_char_span": [33, 36], "rel_type": "inhibitor", "sbj_tok_span": [28, 34], "obj_tok_span": [6, 8], "new_sbj_tok_span": [38, 44], "new_obj_tok_span": [6, 8]}, {"subject": "1-MCP", "sbj_char_span": [179, 184], "object": "ADH", "obj_char_span": [33, 36], "rel_type": "agonist or antagonist", "sbj_tok_span": [35, 38], "obj_tok_span": [6, 8], "new_sbj_tok_span": [46, 49], "new_obj_tok_span": [6, 8]}, {"subject": "ethylene", "sbj_char_span": [223, 231], "object": "ADH", "obj_char_span": [33, 36], "rel_type": "activator", "sbj_tok_span": [45, 46], "obj_tok_span": [6, 8], "new_sbj_tok_span": [59, 60], "new_obj_tok_span": [6, 8]}, {"subject": "ethylene", "sbj_char_span": [137, 145], "object": "ADH", "obj_char_span": [33, 36], "rel_type": "activator", "sbj_tok_span": [26, 27], "obj_tok_span": [6, 8], "new_sbj_tok_span": [34, 35], "new_obj_tok_span": [6, 8]}], "umls_entity_list": [{"mention": "ACC oxidase", "char_span": [82, 93], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 16], "new_tok_span": [15, 17]}, {"mention": "melon", "char_span": [94, 99], "sem_type": "Organic Chemical", "tok_span": [16, 18], "new_tok_span": [19, 21]}, {"mention": "melon", "char_span": [108, 113], "sem_type": "Organic Chemical", "tok_span": [20, 22], "new_tok_span": [25, 27]}, {"mention": "ethylene", "char_span": [137, 145], "sem_type": "Pharmacologic Substance", "tok_span": [26, 27], "new_tok_span": [34, 35]}, {"mention": "ethylene", "char_span": [223, 231], "sem_type": "Pharmacologic Substance", "tok_span": [45, 46], "new_tok_span": [59, 60]}, {"mention": "ethylene", "char_span": [137, 145], "sem_type": "Organic Chemical", "tok_span": [26, 27], "new_tok_span": [34, 35]}, {"mention": "ethylene", "char_span": [223, 231], "sem_type": "Organic Chemical", "tok_span": [45, 46], "new_tok_span": [59, 60]}, {"mention": "1-MCP", "char_span": [179, 184], "sem_type": "Organic Chemical", "tok_span": [35, 38], "new_tok_span": [46, 49]}], "new_text": "Gene expression as well as total ADH activity are strongly inhibited in antisense <START=Amino Acid, Peptide, or Protein> ACC oxidase <END=Amino Acid, Peptide, or Protein> <START=Organic Chemical> melons <END=Organic Chemical> and in <START=Organic Chemical> melon <END=Organic Chemical> fruit treated with the <START=Pharmacologic Substance> <START=Organic Chemical> ethylene <END=Pharmacologic Substance> <END=Organic Chemical> antagonist 1 - methylcyclopropene ( <START=Organic Chemical> 1 - MCP <END=Organic Chemical> ), indicating a positive regulation by <START=Pharmacologic Substance> <START=Organic Chemical> ethylene <END=Pharmacologic Substance> <END=Organic Chemical>."}, {"PMID": 23434506, "id": 3, "text": "WS-CoQ10 did not alter the mRNA expression levels of Tp53 (at a concentration of 1.0μgmL(-1)) and exhibited neuroprotective activity by stimulating cisplatin-inhibited neurite outgrowth in nerve growth factor (NGF)-differentiated PC12 cells (at a concentration of 0.1μgmL(-1)).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [3, 8], "name": "CoQ10", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"ent_type": "CHEMICAL", "char_span": [148, 157], "name": "cisplatin", "tok_span": [37, 38], "new_tok_span": [42, 43]}, {"ent_type": "GENE", "char_span": [53, 57], "name": "Tp53", "tok_span": [13, 15], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [189, 208], "name": "nerve growth factor", "tok_span": [44, 47], "new_tok_span": [51, 54]}, {"ent_type": "GENE", "char_span": [210, 213], "name": "NGF", "tok_span": [48, 49], "new_tok_span": [56, 57]}], "relation_list": [{"subject": "cisplatin", "sbj_char_span": [148, 157], "object": "nerve growth factor", "obj_char_span": [189, 208], "rel_type": "inhibitor", "sbj_tok_span": [37, 38], "obj_tok_span": [44, 47], "new_sbj_tok_span": [42, 43], "new_obj_tok_span": [51, 54]}, {"subject": "cisplatin", "sbj_char_span": [148, 157], "object": "NGF", "obj_char_span": [210, 213], "rel_type": "inhibitor", "sbj_tok_span": [37, 38], "obj_tok_span": [48, 49], "new_sbj_tok_span": [42, 43], "new_obj_tok_span": [56, 57]}, {"subject": "CoQ10", "sbj_char_span": [3, 8], "object": "nerve growth factor", "obj_char_span": [189, 208], "rel_type": "activator", "sbj_tok_span": [2, 5], "obj_tok_span": [44, 47], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [51, 54]}, {"subject": "CoQ10", "sbj_char_span": [3, 8], "object": "NGF", "obj_char_span": [210, 213], "rel_type": "activator", "sbj_tok_span": [2, 5], "obj_tok_span": [48, 49], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [56, 57]}], "umls_entity_list": [{"mention": "CoQ10", "char_span": [3, 8], "sem_type": "Pharmacologic Substance", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"mention": "Tp53", "char_span": [53, 57], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 15], "new_tok_span": [16, 18]}, {"mention": "cisplatin", "char_span": [148, 157], "sem_type": "Pharmacologic Substance", "tok_span": [37, 38], "new_tok_span": [42, 43]}, {"mention": "nerve growth factor", "char_span": [189, 208], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [44, 47], "new_tok_span": [51, 54]}], "new_text": "WS - <START=Pharmacologic Substance> CoQ10 <END=Pharmacologic Substance> did not alter the mRNA expression levels of <START=Amino Acid, Peptide, or Protein> Tp53 <END=Amino Acid, Peptide, or Protein> ( at a concentration of 1. 0μgmL ( - 1 ) ) and exhibited neuroprotective activity by stimulating <START=Pharmacologic Substance> cisplatin <END=Pharmacologic Substance> - inhibited neurite outgrowth in <START=Amino Acid, Peptide, or Protein> nerve growth factor <END=Amino Acid, Peptide, or Protein> ( NGF ) - differentiated PC12 cells ( at a concentration of 0. 1μgmL ( - 1 ) )."}, {"PMID": 16851960, "id": 3, "text": "The starting point for the calculations is the recent X-ray crystal structure of GNMT complexed with SAM and acetate.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [101, 104], "name": "SAM", "tok_span": [20, 21], "new_tok_span": [22, 23]}, {"ent_type": "GENE", "char_span": [81, 85], "name": "GNMT", "tok_span": [15, 17], "new_tok_span": [16, 18]}], "relation_list": [{"subject": "SAM", "sbj_char_span": [101, 104], "object": "GNMT", "obj_char_span": [81, 85], "rel_type": "product or substrate", "sbj_tok_span": [20, 21], "obj_tok_span": [15, 17], "new_sbj_tok_span": [22, 23], "new_obj_tok_span": [16, 18]}], "umls_entity_list": [{"mention": "GNMT", "char_span": [81, 85], "sem_type": "Gene or Genome", "tok_span": [15, 17], "new_tok_span": [16, 18]}, {"mention": "acetate", "char_span": [109, 116], "sem_type": "Pharmacologic Substance", "tok_span": [22, 23], "new_tok_span": [25, 26]}], "new_text": "The starting point for the calculations is the recent X - ray crystal structure of <START=Gene or Genome> GNMT <END=Gene or Genome> complexed with SAM and <START=Pharmacologic Substance> acetate <END=Pharmacologic Substance>."}, {"PMID": 10579749, "id": 2, "text": "Losartan was the first, but by no means remained the only, AT1 receptor antagonist.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "Losartan", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [59, 62], "name": "AT1", "tok_span": [14, 16], "new_tok_span": [16, 18]}], "relation_list": [{"subject": "Losartan", "sbj_char_span": [0, 8], "object": "AT1", "obj_char_span": [59, 62], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 2], "obj_tok_span": [14, 16], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [16, 18]}], "umls_entity_list": [{"mention": "receptor antagonist", "char_span": [63, 82], "sem_type": "Pharmacologic Substance", "tok_span": [16, 18], "new_tok_span": [21, 23]}, {"mention": "AT1", "char_span": [59, 62], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"mention": "AT1", "char_span": [59, 62], "sem_type": "Gene or Genome", "tok_span": [14, 16], "new_tok_span": [16, 18]}], "new_text": "Losartan was the first, but by no means remained the only, <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> AT1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <START=Pharmacologic Substance> receptor antagonist <END=Pharmacologic Substance>."}, {"PMID": 17067304, "id": 9, "text": "Neonatal quinpirole treatment produced a significant decrease in BDNF and ChAT in the frontal cortex that was unaffected by olanzapine treatment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 19], "name": "quinpirole", "tok_span": [2, 5], "new_tok_span": [2, 5]}, {"ent_type": "CHEMICAL", "char_span": [124, 134], "name": "olanzapine", "tok_span": [23, 26], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [65, 69], "name": "BDNF", "tok_span": [11, 12], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [74, 78], "name": "ChAT", "tok_span": [13, 15], "new_tok_span": [15, 17]}], "relation_list": [{"subject": "quinpirole", "sbj_char_span": [9, 19], "object": "BDNF", "obj_char_span": [65, 69], "rel_type": "regulator", "sbj_tok_span": [2, 5], "obj_tok_span": [11, 12], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [11, 12]}, {"subject": "quinpirole", "sbj_char_span": [9, 19], "object": "ChAT", "obj_char_span": [74, 78], "rel_type": "regulator", "sbj_tok_span": [2, 5], "obj_tok_span": [13, 15], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [15, 17]}], "umls_entity_list": [{"mention": "ChAT", "char_span": [74, 78], "sem_type": "Gene or Genome", "tok_span": [13, 15], "new_tok_span": [15, 17]}, {"mention": "ChAT", "char_span": [74, 78], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 15], "new_tok_span": [15, 17]}, {"mention": "olanzapine", "char_span": [124, 134], "sem_type": "Pharmacologic Substance", "tok_span": [23, 26], "new_tok_span": [28, 31]}], "new_text": "Neonatal quinpirole treatment produced a significant decrease in BDNF and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ChAT <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> in the frontal cortex that was unaffected by <START=Pharmacologic Substance> olanzapine <END=Pharmacologic Substance> treatment."}, {"PMID": 12055598, "id": 14, "text": "Long-term COX-2 deficiency or inhibition is associated with significant intestinal pathology despite normal intestinal PGE(2) levels, suggesting a role for COX-2 in the maintenance of small intestinal integrity in the mouse.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [119, 125], "name": "PGE(2)", "tok_span": [18, 22], "new_tok_span": [20, 24]}, {"ent_type": "GENE", "char_span": [10, 15], "name": "COX-2", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"ent_type": "GENE", "char_span": [156, 161], "name": "COX-2", "tok_span": [28, 31], "new_tok_span": [31, 34]}], "relation_list": [{"subject": "PGE(2)", "sbj_char_span": [119, 125], "object": "COX-2", "obj_char_span": [156, 161], "rel_type": "product or substrate", "sbj_tok_span": [18, 22], "obj_tok_span": [28, 31], "new_sbj_tok_span": [20, 24], "new_obj_tok_span": [31, 34]}], "umls_entity_list": [{"mention": "COX", "char_span": [10, 13], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"mention": "COX", "char_span": [156, 159], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 29], "new_tok_span": [31, 32]}], "new_text": "Long - term <START=Amino Acid, Peptide, or Protein> COX <END=Amino Acid, Peptide, or Protein> - 2 deficiency or inhibition is associated with significant intestinal pathology despite normal intestinal PGE ( 2 ) levels, suggesting a role for <START=Amino Acid, Peptide, or Protein> COX <END=Amino Acid, Peptide, or Protein> - 2 in the maintenance of small intestinal integrity in the mouse."}, {"PMID": 23604717, "id": 0, "text": "Inhibitory action of salicylideneamino-2-thiophenol on NF-κB signaling cascade and cyclooxygenase-2 in HNE-treated endothelial cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [103, 106], "name": "HNE", "tok_span": [28, 30], "new_tok_span": [31, 33]}, {"ent_type": "CHEMICAL", "char_span": [21, 51], "name": "salicylideneamino-2-thiophenol", "tok_span": [4, 15], "new_tok_span": [5, 16]}, {"ent_type": "GENE", "char_span": [55, 60], "name": "NF-κB", "tok_span": [16, 20], "new_tok_span": [18, 22]}, {"ent_type": "GENE", "char_span": [83, 99], "name": "cyclooxygenase-2", "tok_span": [23, 27], "new_tok_span": [25, 29]}], "relation_list": [{"subject": "salicylideneamino-2-thiophenol", "sbj_char_span": [21, 51], "object": "NF-κB", "obj_char_span": [55, 60], "rel_type": "inhibitor", "sbj_tok_span": [4, 15], "obj_tok_span": [16, 20], "new_sbj_tok_span": [5, 16], "new_obj_tok_span": [18, 22]}, {"subject": "salicylideneamino-2-thiophenol", "sbj_char_span": [21, 51], "object": "cyclooxygenase-2", "obj_char_span": [83, 99], "rel_type": "inhibitor", "sbj_tok_span": [4, 15], "obj_tok_span": [23, 27], "new_sbj_tok_span": [5, 16], "new_obj_tok_span": [25, 29]}], "umls_entity_list": [{"mention": "salicylideneamino-2-thiophenol", "char_span": [21, 51], "sem_type": "Organic Chemical", "tok_span": [4, 15], "new_tok_span": [5, 16]}, {"mention": "HNE", "char_span": [103, 106], "sem_type": "Gene or Genome", "tok_span": [28, 30], "new_tok_span": [31, 33]}], "new_text": "Inhibitory action of <START=Organic Chemical> salicylideneamino - 2 - thiophenol <END=Organic Chemical> on NF - κB signaling cascade and cyclooxygenase - 2 in <START=Gene or Genome> HNE <END=Gene or Genome> - treated endothelial cells."}, {"PMID": 11078030, "id": 2, "text": "Rivastigmine also inhibits BuChE, which could lead to additional benefits in late-stage Alzheimer's disease, but also cause more GI side effects at initiation of therapy.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Rivastigmine", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "GENE", "char_span": [27, 32], "name": "BuChE", "tok_span": [7, 10], "new_tok_span": [7, 10]}], "relation_list": [{"subject": "Rivastigmine", "sbj_char_span": [0, 12], "object": "BuChE", "obj_char_span": [27, 32], "rel_type": "inhibitor", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 10], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [7, 10]}], "umls_entity_list": [{"mention": "GI", "char_span": [129, 131], "sem_type": "Gene or Genome", "tok_span": [30, 31], "new_tok_span": [31, 32]}], "new_text": "Rivastigmine also inhibits BuChE, which could lead to additional benefits in late - stage Alzheimer's disease, but also cause more <START=Gene or Genome> GI <END=Gene or Genome> side effects at initiation of therapy."}, {"PMID": 23386702, "id": 1, "text": "Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [101, 109], "name": "alcohols", "tok_span": [23, 25], "new_tok_span": [30, 32]}, {"ent_type": "CHEMICAL", "char_span": [111, 117], "name": "amines", "tok_span": [26, 27], "new_tok_span": [35, 36]}, {"ent_type": "CHEMICAL", "char_span": [123, 129], "name": "thiols", "tok_span": [29, 31], "new_tok_span": [40, 42]}, {"ent_type": "CHEMICAL", "char_span": [28, 34], "name": "esters", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [36, 42], "name": "amides", "tok_span": [8, 10], "new_tok_span": [10, 12]}, {"ent_type": "CHEMICAL", "char_span": [48, 58], "name": "thioesters", "tok_span": [12, 16], "new_tok_span": [17, 21]}, {"ent_type": "CHEMICAL", "char_span": [70, 86], "name": "carboxylic acids", "tok_span": [18, 21], "new_tok_span": [24, 27]}, {"ent_type": "GENE", "char_span": [0, 17], "name": "Carboxylesterases", "tok_span": [0, 4], "new_tok_span": [0, 4]}], "relation_list": [{"subject": "esters", "sbj_char_span": [28, 34], "object": "Carboxylesterases", "obj_char_span": [0, 17], "rel_type": "product or substrate", "sbj_tok_span": [6, 7], "obj_tok_span": [0, 4], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [0, 4]}, {"subject": "amides", "sbj_char_span": [36, 42], "object": "Carboxylesterases", "obj_char_span": [0, 17], "rel_type": "product or substrate", "sbj_tok_span": [8, 10], "obj_tok_span": [0, 4], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [0, 4]}, {"subject": "thioesters", "sbj_char_span": [48, 58], "object": "Carboxylesterases", "obj_char_span": [0, 17], "rel_type": "product or substrate", "sbj_tok_span": [12, 16], "obj_tok_span": [0, 4], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [0, 4]}, {"subject": "carboxylic acids", "sbj_char_span": [70, 86], "object": "Carboxylesterases", "obj_char_span": [0, 17], "rel_type": "product or substrate", "sbj_tok_span": [18, 21], "obj_tok_span": [0, 4], "new_sbj_tok_span": [24, 27], "new_obj_tok_span": [0, 4]}, {"subject": "alcohols", "sbj_char_span": [101, 109], "object": "Carboxylesterases", "obj_char_span": [0, 17], "rel_type": "product or substrate", "sbj_tok_span": [23, 25], "obj_tok_span": [0, 4], "new_sbj_tok_span": [30, 32], "new_obj_tok_span": [0, 4]}, {"subject": "amines", "sbj_char_span": [111, 117], "object": "Carboxylesterases", "obj_char_span": [0, 17], "rel_type": "product or substrate", "sbj_tok_span": [26, 27], "obj_tok_span": [0, 4], "new_sbj_tok_span": [35, 36], "new_obj_tok_span": [0, 4]}, {"subject": "thiols", "sbj_char_span": [123, 129], "object": "Carboxylesterases", "obj_char_span": [0, 17], "rel_type": "product or substrate", "sbj_tok_span": [29, 31], "obj_tok_span": [0, 4], "new_sbj_tok_span": [40, 42], "new_obj_tok_span": [0, 4]}], "umls_entity_list": [{"mention": "amides", "char_span": [36, 42], "sem_type": "Organic Chemical", "tok_span": [8, 10], "new_tok_span": [10, 12]}, {"mention": "amides", "char_span": [36, 42], "sem_type": "Pharmacologic Substance", "tok_span": [8, 10], "new_tok_span": [10, 12]}, {"mention": "thioester", "char_span": [48, 57], "sem_type": "Organic Chemical", "tok_span": [12, 15], "new_tok_span": [17, 20]}, {"mention": "alcohols", "char_span": [101, 109], "sem_type": "Pharmacologic Substance", "tok_span": [23, 25], "new_tok_span": [30, 32]}, {"mention": "amines", "char_span": [111, 117], "sem_type": "Organic Chemical", "tok_span": [26, 27], "new_tok_span": [35, 36]}, {"mention": "thiols", "char_span": [123, 129], "sem_type": "Organic Chemical", "tok_span": [29, 31], "new_tok_span": [40, 42]}], "new_text": "Carboxylesterases hydrolyze esters, <START=Organic Chemical> <START=Pharmacologic Substance> amides <END=Organic Chemical> <END=Pharmacologic Substance>, and <START=Organic Chemical> thioester <END=Organic Chemical>s to produce carboxylic acids and resulting <START=Pharmacologic Substance> alcohols <END=Pharmacologic Substance>, <START=Organic Chemical> amines <END=Organic Chemical>, and <START=Organic Chemical> thiols <END=Organic Chemical>, respectively."}, {"PMID": 2512511, "id": 0, "text": "G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [35, 58], "name": "[125I]iodocyanopindolol", "tok_span": [5, 15], "new_tok_span": [7, 17]}, {"ent_type": "CHEMICAL", "char_span": [63, 80], "name": "+/- cyanopindolol", "tok_span": [16, 24], "new_tok_span": [22, 30]}, {"ent_type": "GENE", "char_span": [0, 9], "name": "G protein", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"ent_type": "GENE", "char_span": [92, 98], "name": "5-HT1B", "tok_span": [26, 31], "new_tok_span": [34, 39]}], "relation_list": [{"subject": "+/- cyanopindolol", "sbj_char_span": [63, 80], "object": "5-HT1B", "obj_char_span": [92, 98], "rel_type": "regulator", "sbj_tok_span": [16, 24], "obj_tok_span": [26, 31], "new_sbj_tok_span": [22, 30], "new_obj_tok_span": [34, 39]}, {"subject": "[125I]iodocyanopindolol", "sbj_char_span": [35, 58], "object": "5-HT1B", "obj_char_span": [92, 98], "rel_type": "regulator", "sbj_tok_span": [5, 15], "obj_tok_span": [26, 31], "new_sbj_tok_span": [7, 17], "new_obj_tok_span": [34, 39]}], "umls_entity_list": [{"mention": "G protein", "char_span": [0, 9], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"mention": "iodocyanopindolol", "char_span": [41, 58], "sem_type": "Organic Chemical", "tok_span": [9, 15], "new_tok_span": [12, 18]}, {"mention": "cyanopindolol", "char_span": [45, 58], "sem_type": "Pharmacologic Substance", "tok_span": [10, 15], "new_tok_span": [14, 19]}, {"mention": "cyanopindolol", "char_span": [67, 80], "sem_type": "Pharmacologic Substance", "tok_span": [19, 24], "new_tok_span": [26, 31]}], "new_text": "<START=Amino Acid, Peptide, or Protein> G protein <END=Amino Acid, Peptide, or Protein> dependent alterations in [ 125I ] <START=Organic Chemical> iod <START=Pharmacologic Substance>ocyanopindolol <END=Organic Chemical> <END=Pharmacologic Substance> and + / - <START=Pharmacologic Substance> cyanopindolol <END=Pharmacologic Substance> binding at 5 - HT1B binding sites in rat brain membranes."}, {"PMID": 11103883, "id": 7, "text": "Ziprasidone exerted a minor preference for 5-HT2A- compared to 5-HT2C-receptor-mediated effects.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Ziprasidone", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "GENE", "char_span": [43, 49], "name": "5-HT2A", "tok_span": [10, 15], "new_tok_span": [10, 15]}, {"ent_type": "GENE", "char_span": [63, 69], "name": "5-HT2C", "tok_span": [18, 23], "new_tok_span": [20, 25]}], "relation_list": [{"subject": "Ziprasidone", "sbj_char_span": [0, 11], "object": "5-HT2A", "obj_char_span": [43, 49], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 5], "obj_tok_span": [10, 15], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [10, 15]}], "umls_entity_list": [{"mention": "HT2A", "char_span": [45, 49], "sem_type": "Gene or Genome", "tok_span": [12, 15], "new_tok_span": [13, 16]}], "new_text": "Ziprasidone exerted a minor preference for 5 - <START=Gene or Genome> HT2A <END=Gene or Genome> - compared to 5 - HT2C - receptor - mediated effects."}, {"PMID": 10351938, "id": 0, "text": "Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [38, 52], "name": "leukotriene C4", "tok_span": [7, 12], "new_tok_span": [8, 13]}, {"ent_type": "CHEMICAL", "char_span": [66, 88], "name": "fluticasone propionate", "tok_span": [14, 20], "new_tok_span": [16, 22]}, {"ent_type": "GENE", "char_span": [14, 19], "name": "cPLA2", "tok_span": [2, 5], "new_tok_span": [2, 5]}], "relation_list": [{"subject": "fluticasone propionate", "sbj_char_span": [66, 88], "object": "cPLA2", "obj_char_span": [14, 19], "rel_type": "regulator", "sbj_tok_span": [14, 20], "obj_tok_span": [2, 5], "new_sbj_tok_span": [16, 22], "new_obj_tok_span": [2, 5]}], "umls_entity_list": [{"mention": "leukotriene", "char_span": [38, 49], "sem_type": "Organic Chemical", "tok_span": [7, 10], "new_tok_span": [8, 11]}], "new_text": "Inhibition of cPLA2 translocation and <START=Organic Chemical> leukotriene <END=Organic Chemical> C4 secretion by fluticasone propionate in exogenously activated human eosinophils."}, {"PMID": 23142599, "id": 6, "text": "These studies demonstrate that 2,3,7,8-TCDD directly inhibits the vitellogenin pathway in vivo through activation of the AHR2. This work provides evidence for AHR2 dependent cross-talk inhibition of vitellogenin genes and offers insight into anti-estrogenic reproductive effects observed in oviparous species exposed to AHR agonist contaminants.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [31, 43], "name": "2,3,7,8-TCDD", "tok_span": [4, 14], "new_tok_span": [4, 14]}, {"ent_type": "GENE", "char_span": [66, 78], "name": "vitellogenin", "tok_span": [17, 21], "new_tok_span": [18, 22]}, {"ent_type": "GENE", "char_span": [121, 125], "name": "AHR2", "tok_span": [28, 31], "new_tok_span": [31, 34]}, {"ent_type": "GENE", "char_span": [159, 163], "name": "AHR2", "tok_span": [37, 40], "new_tok_span": [42, 45]}, {"ent_type": "GENE", "char_span": [199, 211], "name": "vitellogenin", "tok_span": [46, 50], "new_tok_span": [53, 57]}, {"ent_type": "GENE", "char_span": [320, 323], "name": "AHR", "tok_span": [70, 72], "new_tok_span": [79, 81]}], "relation_list": [{"subject": "2,3,7,8-TCDD", "sbj_char_span": [31, 43], "object": "vitellogenin", "obj_char_span": [66, 78], "rel_type": "inhibitor", "sbj_tok_span": [4, 14], "obj_tok_span": [17, 21], "new_sbj_tok_span": [4, 14], "new_obj_tok_span": [18, 22]}, {"subject": "2,3,7,8-TCDD", "sbj_char_span": [31, 43], "object": "AHR2", "obj_char_span": [121, 125], "rel_type": "activator", "sbj_tok_span": [4, 14], "obj_tok_span": [28, 31], "new_sbj_tok_span": [4, 14], "new_obj_tok_span": [31, 34]}], "umls_entity_list": [{"mention": "vitellogenin", "char_span": [66, 78], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 21], "new_tok_span": [18, 22]}, {"mention": "vitellogenin", "char_span": [199, 211], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [46, 50], "new_tok_span": [53, 57]}, {"mention": "AHR", "char_span": [121, 124], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 30], "new_tok_span": [31, 33]}, {"mention": "AHR", "char_span": [159, 162], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 39], "new_tok_span": [42, 44]}, {"mention": "AHR", "char_span": [320, 323], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [70, 72], "new_tok_span": [79, 81]}], "new_text": "These studies demonstrate that 2, 3, 7, 8 - TCDD directly inhibits the <START=Amino Acid, Peptide, or Protein> vitellogenin <END=Amino Acid, Peptide, or Protein> pathway in vivo through activation of the <START=Amino Acid, Peptide, or Protein> AHR <END=Amino Acid, Peptide, or Protein>2. This work provides evidence for <START=Amino Acid, Peptide, or Protein> AHR <END=Amino Acid, Peptide, or Protein>2 dependent cross - talk inhibition of <START=Amino Acid, Peptide, or Protein> vitellogenin <END=Amino Acid, Peptide, or Protein> genes and offers insight into anti - estrogenic reproductive effects observed in oviparous species exposed to <START=Amino Acid, Peptide, or Protein> AHR <END=Amino Acid, Peptide, or Protein> agonist contaminants."}, {"PMID": 23291630, "id": 5, "text": "Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [37, 47], "name": "navitoclax", "tok_span": [8, 12], "new_tok_span": [9, 13]}, {"ent_type": "CHEMICAL", "char_span": [126, 133], "name": "ABT-199", "tok_span": [29, 33], "new_tok_span": [31, 35]}, {"ent_type": "GENE", "char_span": [99, 104], "name": "BCL-2", "tok_span": [22, 25], "new_tok_span": [24, 27]}], "relation_list": [{"subject": "ABT-199", "sbj_char_span": [126, 133], "object": "BCL-2", "obj_char_span": [99, 104], "rel_type": "inhibitor", "sbj_tok_span": [29, 33], "obj_tok_span": [22, 25], "new_sbj_tok_span": [31, 35], "new_obj_tok_span": [24, 27]}, {"subject": "navitoclax", "sbj_char_span": [37, 47], "object": "BCL-2", "obj_char_span": [99, 104], "rel_type": "inhibitor", "sbj_tok_span": [8, 12], "obj_tok_span": [22, 25], "new_sbj_tok_span": [9, 13], "new_obj_tok_span": [24, 27]}], "umls_entity_list": [{"mention": "navitoclax", "char_span": [37, 47], "sem_type": "Pharmacologic Substance", "tok_span": [8, 12], "new_tok_span": [9, 13]}], "new_text": "Here we report the re - engineering of <START=Pharmacologic Substance> navitoclax <END=Pharmacologic Substance> to create a highly potent, orally bioavailable and BCL - 2 - selective inhibitor, ABT - 199."}, {"PMID": 23526814, "id": 1, "text": "Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [112, 131], "name": "tert-butylcarbamate", "tok_span": [33, 40], "new_tok_span": [39, 46]}, {"ent_type": "CHEMICAL", "char_span": [23, 30], "name": "pyrrole", "tok_span": [4, 6], "new_tok_span": [4, 6]}, {"ent_type": "CHEMICAL", "char_span": [36, 43], "name": "benzene", "tok_span": [8, 9], "new_tok_span": [9, 10]}, {"ent_type": "CHEMICAL", "char_span": [50, 62], "name": "hydroxamates", "tok_span": [11, 14], "new_tok_span": [14, 17]}, {"ent_type": "CHEMICAL", "char_span": [75, 91], "name": "2'-aminoanilides", "tok_span": [20, 26], "new_tok_span": [24, 30]}, {"ent_type": "GENE", "char_span": [159, 178], "name": "histone deacetylase", "tok_span": [46, 50], "new_tok_span": [56, 60]}, {"ent_type": "GENE", "char_span": [180, 184], "name": "HDAC", "tok_span": [51, 52], "new_tok_span": [61, 62]}], "relation_list": [{"subject": "pyrrole", "sbj_char_span": [23, 30], "object": "histone deacetylase", "obj_char_span": [159, 178], "rel_type": "inhibitor", "sbj_tok_span": [4, 6], "obj_tok_span": [46, 50], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [56, 60]}, {"subject": "benzene", "sbj_char_span": [36, 43], "object": "histone deacetylase", "obj_char_span": [159, 178], "rel_type": "inhibitor", "sbj_tok_span": [8, 9], "obj_tok_span": [46, 50], "new_sbj_tok_span": [9, 10], "new_obj_tok_span": [56, 60]}, {"subject": "hydroxamates", "sbj_char_span": [50, 62], "object": "histone deacetylase", "obj_char_span": [159, 178], "rel_type": "inhibitor", "sbj_tok_span": [11, 14], "obj_tok_span": [46, 50], "new_sbj_tok_span": [14, 17], "new_obj_tok_span": [56, 60]}, {"subject": "2'-aminoanilides", "sbj_char_span": [75, 91], "object": "histone deacetylase", "obj_char_span": [159, 178], "rel_type": "inhibitor", "sbj_tok_span": [20, 26], "obj_tok_span": [46, 50], "new_sbj_tok_span": [24, 30], "new_obj_tok_span": [56, 60]}, {"subject": "tert-butylcarbamate", "sbj_char_span": [112, 131], "object": "histone deacetylase", "obj_char_span": [159, 178], "rel_type": "inhibitor", "sbj_tok_span": [33, 40], "obj_tok_span": [46, 50], "new_sbj_tok_span": [39, 46], "new_obj_tok_span": [56, 60]}, {"subject": "pyrrole", "sbj_char_span": [23, 30], "object": "HDAC", "obj_char_span": [180, 184], "rel_type": "inhibitor", "sbj_tok_span": [4, 6], "obj_tok_span": [51, 52], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [61, 62]}, {"subject": "benzene", "sbj_char_span": [36, 43], "object": "HDAC", "obj_char_span": [180, 184], "rel_type": "inhibitor", "sbj_tok_span": [8, 9], "obj_tok_span": [51, 52], "new_sbj_tok_span": [9, 10], "new_obj_tok_span": [61, 62]}, {"subject": "hydroxamates", "sbj_char_span": [50, 62], "object": "HDAC", "obj_char_span": [180, 184], "rel_type": "inhibitor", "sbj_tok_span": [11, 14], "obj_tok_span": [51, 52], "new_sbj_tok_span": [14, 17], "new_obj_tok_span": [61, 62]}, {"subject": "2'-aminoanilides", "sbj_char_span": [75, 91], "object": "HDAC", "obj_char_span": [180, 184], "rel_type": "inhibitor", "sbj_tok_span": [20, 26], "obj_tok_span": [51, 52], "new_sbj_tok_span": [24, 30], "new_obj_tok_span": [61, 62]}, {"subject": "tert-butylcarbamate", "sbj_char_span": [112, 131], "object": "HDAC", "obj_char_span": [180, 184], "rel_type": "inhibitor", "sbj_tok_span": [33, 40], "obj_tok_span": [51, 52], "new_sbj_tok_span": [39, 46], "new_obj_tok_span": [61, 62]}], "umls_entity_list": [{"mention": "benzene", "char_span": [36, 43], "sem_type": "Organic Chemical", "tok_span": [8, 9], "new_tok_span": [9, 10]}, {"mention": "hydroxamate", "char_span": [50, 61], "sem_type": "Organic Chemical", "tok_span": [11, 13], "new_tok_span": [14, 16]}, {"mention": "tert", "char_span": [112, 116], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 35], "new_tok_span": [39, 41]}, {"mention": "CAP", "char_span": [145, 148], "sem_type": "Gene or Genome", "tok_span": [43, 44], "new_tok_span": [52, 53]}, {"mention": "tert", "char_span": [112, 116], "sem_type": "Gene or Genome", "tok_span": [33, 35], "new_tok_span": [39, 41]}], "new_text": "Herein we report novel pyrrole - and <START=Organic Chemical> benzene <END=Organic Chemical> - based <START=Organic Chemical> hydroxamate <END=Organic Chemical>s ( 8, 10 ) and 2'- aminoanilides ( 9, 11 ) bearing the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> tert <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - butylcarbamate group at the <START=Gene or Genome> CAP <END=Gene or Genome> moiety as histone deacetylase ( HDAC ) inhibitors."}, {"PMID": 10500149, "id": 3, "text": "Among 22 derivatives/metabolites of dehydroepiandrosterone, we found 4 steroids [no. 4, 1,3,5(10)-estratriene-17alpha-ethynyl-3, 17beta-diol; no. 6, 17alpha-ethynyl-androstene-diol; no. 8, 3beta, 17beta-dihydroxy-androst-5-ene-16-one; and no. 10, 3beta-methylcarbonate-androst-5-ene-7,17-dione] that have no androgenic activity and could also block the Adiol-induced AR transactivation in prostate cancer PC-3 cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [36, 58], "name": "dehydroepiandrosterone", "tok_span": [6, 13], "new_tok_span": [7, 14]}, {"ent_type": "CHEMICAL", "char_span": [71, 79], "name": "steroids", "tok_span": [17, 18], "new_tok_span": [20, 21]}, {"ent_type": "CHEMICAL", "char_span": [85, 140], "name": "4, 1,3,5(10)-estratriene-17alpha-ethynyl-3, 17beta-diol", "tok_span": [21, 50], "new_tok_span": [25, 54]}, {"ent_type": "CHEMICAL", "char_span": [146, 180], "name": "6, 17alpha-ethynyl-androstene-diol", "tok_span": [53, 68], "new_tok_span": [59, 74]}, {"ent_type": "CHEMICAL", "char_span": [186, 233], "name": "8, 3beta, 17beta-dihydroxy-androst-5-ene-16-one", "tok_span": [71, 93], "new_tok_span": [81, 103]}, {"ent_type": "CHEMICAL", "char_span": [243, 293], "name": "10, 3beta-methylcarbonate-androst-5-ene-7,17-dione", "tok_span": [97, 120], "new_tok_span": [107, 130]}, {"ent_type": "CHEMICAL", "char_span": [353, 358], "name": "Adiol", "tok_span": [132, 134], "new_tok_span": [147, 149]}, {"ent_type": "GENE", "char_span": [367, 369], "name": "AR", "tok_span": [136, 137], "new_tok_span": [152, 153]}], "relation_list": [{"subject": "Adiol", "sbj_char_span": [353, 358], "object": "AR", "obj_char_span": [367, 369], "rel_type": "activator", "sbj_tok_span": [132, 134], "obj_tok_span": [136, 137], "new_sbj_tok_span": [147, 149], "new_obj_tok_span": [152, 153]}, {"subject": "dehydroepiandrosterone", "sbj_char_span": [36, 58], "object": "AR", "obj_char_span": [367, 369], "rel_type": "inhibitor", "sbj_tok_span": [6, 13], "obj_tok_span": [136, 137], "new_sbj_tok_span": [7, 14], "new_obj_tok_span": [152, 153]}, {"subject": "steroids", "sbj_char_span": [71, 79], "object": "AR", "obj_char_span": [367, 369], "rel_type": "inhibitor", "sbj_tok_span": [17, 18], "obj_tok_span": [136, 137], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [152, 153]}, {"subject": "4, 1,3,5(10)-estratriene-17alpha-ethynyl-3, 17beta-diol", "sbj_char_span": [85, 140], "object": "AR", "obj_char_span": [367, 369], "rel_type": "inhibitor", "sbj_tok_span": [21, 50], "obj_tok_span": [136, 137], "new_sbj_tok_span": [25, 54], "new_obj_tok_span": [152, 153]}, {"subject": "6, 17alpha-ethynyl-androstene-diol", "sbj_char_span": [146, 180], "object": "AR", "obj_char_span": [367, 369], "rel_type": "inhibitor", "sbj_tok_span": [53, 68], "obj_tok_span": [136, 137], "new_sbj_tok_span": [59, 74], "new_obj_tok_span": [152, 153]}, {"subject": "8, 3beta, 17beta-dihydroxy-androst-5-ene-16-one", "sbj_char_span": [186, 233], "object": "AR", "obj_char_span": [367, 369], "rel_type": "inhibitor", "sbj_tok_span": [71, 93], "obj_tok_span": [136, 137], "new_sbj_tok_span": [81, 103], "new_obj_tok_span": [152, 153]}, {"subject": "10, 3beta-methylcarbonate-androst-5-ene-7,17-dione", "sbj_char_span": [243, 293], "object": "AR", "obj_char_span": [367, 369], "rel_type": "inhibitor", "sbj_tok_span": [97, 120], "obj_tok_span": [136, 137], "new_sbj_tok_span": [107, 130], "new_obj_tok_span": [152, 153]}], "umls_entity_list": [{"mention": "dehydroepiandrosterone", "char_span": [36, 58], "sem_type": "Pharmacologic Substance", "tok_span": [6, 13], "new_tok_span": [7, 14]}, {"mention": "steroids", "char_span": [71, 79], "sem_type": "Pharmacologic Substance", "tok_span": [17, 18], "new_tok_span": [20, 21]}, {"mention": "androstene", "char_span": [165, 175], "sem_type": "Organic Chemical", "tok_span": [62, 65], "new_tok_span": [69, 72]}, {"mention": "diol", "char_span": [136, 140], "sem_type": "Organic Chemical", "tok_span": [48, 50], "new_tok_span": [53, 55]}, {"mention": "diol", "char_span": [176, 180], "sem_type": "Organic Chemical", "tok_span": [66, 68], "new_tok_span": [75, 77]}, {"mention": "diol", "char_span": [354, 358], "sem_type": "Organic Chemical", "tok_span": [132, 134], "new_tok_span": [147, 149]}, {"mention": "androgen", "char_span": [308, 316], "sem_type": "Pharmacologic Substance", "tok_span": [124, 125], "new_tok_span": [136, 137]}, {"mention": "PC-3", "char_span": [405, 409], "sem_type": "Gene or Genome", "tok_span": [142, 145], "new_tok_span": [159, 162]}, {"mention": "androgen", "char_span": [308, 316], "sem_type": "Gene or Genome", "tok_span": [124, 125], "new_tok_span": [136, 137]}], "new_text": "Among 22 derivatives / metabolites of <START=Pharmacologic Substance> dehydroepiandrosterone <END=Pharmacologic Substance>, we found 4 <START=Pharmacologic Substance> steroids <END=Pharmacologic Substance> [ no. 4, 1, 3, 5 ( 10 ) - estratriene - 17alpha - ethynyl - 3, 17beta - <START=Organic Chemical> diol <END=Organic Chemical> ; no. 6, 17alpha - ethynyl - <START=Organic Chemical> androstene <END=Organic Chemical> - <START=Organic Chemical> diol <END=Organic Chemical> ; no. 8, 3beta, 17beta - dihydroxy - androst - 5 - ene - 16 - one ; and no. 10, 3beta - methylcarbonate - androst - 5 - ene - 7, 17 - dione ] that have no <START=Pharmacologic Substance> <START=Gene or Genome> androgen <END=Pharmacologic Substance> <END=Gene or Genome>ic activity and could also block the <START=Organic Chemical> Adiol <END=Organic Chemical> - induced AR transactivation in prostate cancer <START=Gene or Genome> PC - 3 <END=Gene or Genome> cells."}, {"PMID": 22818713, "id": 7, "text": "Moreover, silibinin repressed the phenylephrine-induced phosphorylation of ERK1/2 kinases, while it appeared to inhibit the weakly activated by phenylephrine phosphorylation of Akt.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [10, 19], "name": "silibinin", "tok_span": [2, 5], "new_tok_span": [2, 5]}, {"ent_type": "CHEMICAL", "char_span": [34, 47], "name": "phenylephrine", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"ent_type": "CHEMICAL", "char_span": [144, 157], "name": "phenylephrine", "tok_span": [30, 33], "new_tok_span": [33, 36]}, {"ent_type": "GENE", "char_span": [75, 81], "name": "ERK1/2", "tok_span": [15, 19], "new_tok_span": [17, 21]}, {"ent_type": "GENE", "char_span": [82, 89], "name": "kinases", "tok_span": [19, 20], "new_tok_span": [21, 22]}, {"ent_type": "GENE", "char_span": [177, 180], "name": "Akt", "tok_span": [35, 36], "new_tok_span": [39, 40]}], "relation_list": [{"subject": "phenylephrine", "sbj_char_span": [34, 47], "object": "kinases", "obj_char_span": [82, 89], "rel_type": "activator", "sbj_tok_span": [8, 11], "obj_tok_span": [19, 20], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [21, 22]}, {"subject": "silibinin", "sbj_char_span": [10, 19], "object": "kinases", "obj_char_span": [82, 89], "rel_type": "inhibitor", "sbj_tok_span": [2, 5], "obj_tok_span": [19, 20], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [21, 22]}, {"subject": "phenylephrine", "sbj_char_span": [144, 157], "object": "Akt", "obj_char_span": [177, 180], "rel_type": "activator", "sbj_tok_span": [30, 33], "obj_tok_span": [35, 36], "new_sbj_tok_span": [33, 36], "new_obj_tok_span": [39, 40]}, {"subject": "silibinin", "sbj_char_span": [10, 19], "object": "Akt", "obj_char_span": [177, 180], "rel_type": "inhibitor", "sbj_tok_span": [2, 5], "obj_tok_span": [35, 36], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [39, 40]}], "umls_entity_list": [{"mention": "phenylephrine", "char_span": [34, 47], "sem_type": "Pharmacologic Substance", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"mention": "phenylephrine", "char_span": [144, 157], "sem_type": "Pharmacologic Substance", "tok_span": [30, 33], "new_tok_span": [33, 36]}], "new_text": "Moreover, silibinin repressed the <START=Pharmacologic Substance> phenylephrine <END=Pharmacologic Substance> - induced phosphorylation of ERK1 / 2 kinases, while it appeared to inhibit the weakly activated by <START=Pharmacologic Substance> phenylephrine <END=Pharmacologic Substance> phosphorylation of Akt."}, {"PMID": 14967461, "id": 8, "text": "Agents that have only begun to undergo clinical evaluation include CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, and PKI166 and GW572016, both examples of dual kinase inhibitors (inhibiting epidermal growth factor receptor and Her2).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [67, 74], "name": "CI-1033", "tok_span": [10, 14], "new_tok_span": [11, 15]}, {"ent_type": "CHEMICAL", "char_span": [101, 109], "name": "tyrosine", "tok_span": [21, 22], "new_tok_span": [28, 29]}, {"ent_type": "CHEMICAL", "char_span": [132, 138], "name": "PKI166", "tok_span": [26, 29], "new_tok_span": [35, 38]}, {"ent_type": "CHEMICAL", "char_span": [143, 151], "name": "GW572016", "tok_span": [30, 34], "new_tok_span": [40, 44]}, {"ent_type": "GENE", "char_span": [96, 100], "name": "erbB", "tok_span": [19, 21], "new_tok_span": [24, 26]}, {"ent_type": "GENE", "char_span": [101, 116], "name": "tyrosine kinase", "tok_span": [21, 23], "new_tok_span": [28, 30]}, {"ent_type": "GENE", "char_span": [175, 181], "name": "kinase", "tok_span": [39, 40], "new_tok_span": [49, 50]}, {"ent_type": "GENE", "char_span": [205, 237], "name": "epidermal growth factor receptor", "tok_span": [43, 47], "new_tok_span": [53, 57]}, {"ent_type": "GENE", "char_span": [242, 246], "name": "Her2", "tok_span": [48, 50], "new_tok_span": [58, 60]}], "relation_list": [{"subject": "CI-1033", "sbj_char_span": [67, 74], "object": "erbB", "obj_char_span": [96, 100], "rel_type": "inhibitor", "sbj_tok_span": [10, 14], "obj_tok_span": [19, 21], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [24, 26]}, {"subject": "CI-1033", "sbj_char_span": [67, 74], "object": "tyrosine kinase", "obj_char_span": [101, 116], "rel_type": "inhibitor", "sbj_tok_span": [10, 14], "obj_tok_span": [21, 23], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [28, 30]}, {"subject": "PKI166", "sbj_char_span": [132, 138], "object": "epidermal growth factor receptor", "obj_char_span": [205, 237], "rel_type": "inhibitor", "sbj_tok_span": [26, 29], "obj_tok_span": [43, 47], "new_sbj_tok_span": [35, 38], "new_obj_tok_span": [53, 57]}, {"subject": "GW572016", "sbj_char_span": [143, 151], "object": "epidermal growth factor receptor", "obj_char_span": [205, 237], "rel_type": "inhibitor", "sbj_tok_span": [30, 34], "obj_tok_span": [43, 47], "new_sbj_tok_span": [40, 44], "new_obj_tok_span": [53, 57]}, {"subject": "PKI166", "sbj_char_span": [132, 138], "object": "Her2", "obj_char_span": [242, 246], "rel_type": "inhibitor", "sbj_tok_span": [26, 29], "obj_tok_span": [48, 50], "new_sbj_tok_span": [35, 38], "new_obj_tok_span": [58, 60]}, {"subject": "GW572016", "sbj_char_span": [143, 151], "object": "Her2", "obj_char_span": [242, 246], "rel_type": "inhibitor", "sbj_tok_span": [30, 34], "obj_tok_span": [48, 50], "new_sbj_tok_span": [40, 44], "new_obj_tok_span": [58, 60]}, {"subject": "PKI166", "sbj_char_span": [132, 138], "object": "kinase", "obj_char_span": [175, 181], "rel_type": "inhibitor", "sbj_tok_span": [26, 29], "obj_tok_span": [39, 40], "new_sbj_tok_span": [35, 38], "new_obj_tok_span": [49, 50]}, {"subject": "GW572016", "sbj_char_span": [143, 151], "object": "kinase", "obj_char_span": [175, 181], "rel_type": "inhibitor", "sbj_tok_span": [30, 34], "obj_tok_span": [39, 40], "new_sbj_tok_span": [40, 44], "new_obj_tok_span": [49, 50]}], "umls_entity_list": [{"mention": "CI-1033", "char_span": [67, 74], "sem_type": "Pharmacologic Substance", "tok_span": [10, 14], "new_tok_span": [11, 15]}, {"mention": "tyrosine kinase", "char_span": [101, 116], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 23], "new_tok_span": [28, 30]}, {"mention": "erbB", "char_span": [96, 100], "sem_type": "Gene or Genome", "tok_span": [19, 21], "new_tok_span": [24, 26]}, {"mention": "pan", "char_span": [92, 95], "sem_type": "Gene or Genome", "tok_span": [17, 18], "new_tok_span": [20, 21]}, {"mention": "PKI166", "char_span": [132, 138], "sem_type": "Pharmacologic Substance", "tok_span": [26, 29], "new_tok_span": [35, 38]}], "new_text": "Agents that have only begun to undergo clinical evaluation include <START=Pharmacologic Substance> CI - 1033 <END=Pharmacologic Substance>, an irreversible <START=Gene or Genome> pan <END=Gene or Genome> - <START=Gene or Genome> erbB <END=Gene or Genome> <START=Amino Acid, Peptide, or Protein> tyrosine kinase <END=Amino Acid, Peptide, or Protein> inhibitor, and <START=Pharmacologic Substance> PKI166 <END=Pharmacologic Substance> and GW572016, both examples of dual kinase inhibitors ( inhibiting epidermal growth factor receptor and Her2 )."}, {"PMID": 11438309, "id": 6, "text": "Prucalopride was a 5-HT(4) receptor agonist in the guinea-pig colon, as it induced contractions (pEC(50)=7.48+/-0.06; insensitive to a 5-HT(2A) or 5-HT(3) receptor antagonist, but inhibited by a 5-HT(4) receptor antagonist) as well as the facilitation of electrical stimulation-induced noncholinergic contractions (blocked by a 5-HT(4) receptor antagonist).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Prucalopride", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"ent_type": "GENE", "char_span": [147, 154], "name": "5-HT(3)", "tok_span": [54, 60], "new_tok_span": [58, 64]}, {"ent_type": "GENE", "char_span": [195, 202], "name": "5-HT(4)", "tok_span": [67, 73], "new_tok_span": [73, 79]}, {"ent_type": "GENE", "char_span": [328, 335], "name": "5-HT(4)", "tok_span": [95, 101], "new_tok_span": [103, 109]}, {"ent_type": "GENE", "char_span": [19, 26], "name": "5-HT(4)", "tok_span": [7, 13], "new_tok_span": [9, 15]}, {"ent_type": "GENE", "char_span": [135, 143], "name": "5-HT(2A)", "tok_span": [46, 53], "new_tok_span": [50, 57]}], "relation_list": [{"subject": "Prucalopride", "sbj_char_span": [0, 12], "object": "5-HT(4)", "obj_char_span": [19, 26], "rel_type": "agonist or antagonist", "sbj_tok_span": [0, 5], "obj_tok_span": [7, 13], "new_sbj_tok_span": [1, 6], "new_obj_tok_span": [9, 15]}], "umls_entity_list": [{"mention": "Prucalopride", "char_span": [0, 12], "sem_type": "Pharmacologic Substance", "tok_span": [0, 5], "new_tok_span": [1, 6]}, {"mention": "receptor agonist", "char_span": [27, 43], "sem_type": "Pharmacologic Substance", "tok_span": [13, 15], "new_tok_span": [16, 18]}, {"mention": "receptor antagonist", "char_span": [155, 174], "sem_type": "Pharmacologic Substance", "tok_span": [60, 62], "new_tok_span": [65, 67]}, {"mention": "receptor antagonist", "char_span": [203, 222], "sem_type": "Pharmacologic Substance", "tok_span": [73, 75], "new_tok_span": [80, 82]}, {"mention": "receptor antagonist", "char_span": [336, 355], "sem_type": "Pharmacologic Substance", "tok_span": [101, 103], "new_tok_span": [110, 112]}], "new_text": "<START=Pharmacologic Substance> Prucalopride <END=Pharmacologic Substance> was a 5 - HT ( 4 ) <START=Pharmacologic Substance> receptor agonist <END=Pharmacologic Substance> in the guinea - pig colon, as it induced contractions ( pEC ( 50 ) = 7. 48 + / - 0. 06 ; insensitive to a 5 - HT ( 2A ) or 5 - HT ( 3 ) <START=Pharmacologic Substance> receptor antagonist <END=Pharmacologic Substance>, but inhibited by a 5 - HT ( 4 ) <START=Pharmacologic Substance> receptor antagonist <END=Pharmacologic Substance> ) as well as the facilitation of electrical stimulation - induced noncholinergic contractions ( blocked by a 5 - HT ( 4 ) <START=Pharmacologic Substance> receptor antagonist <END=Pharmacologic Substance> )."}, {"PMID": 9765513, "id": 3, "text": "When expressed in transfected COS cells, HERG is blocked in a concentration-dependent manner by bepridil (EC50 = 0.55 microM), verapamil (EC50 = 0.83 microM), and mibefradil (EC50 = 1.43 microM), whereas nitrendipine and diltiazem have negligible effects.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [96, 104], "name": "bepridil", "tok_span": [18, 21], "new_tok_span": [18, 21]}, {"ent_type": "CHEMICAL", "char_span": [127, 136], "name": "verapamil", "tok_span": [32, 35], "new_tok_span": [32, 35]}, {"ent_type": "CHEMICAL", "char_span": [163, 173], "name": "mibefradil", "tok_span": [47, 52], "new_tok_span": [47, 52]}, {"ent_type": "CHEMICAL", "char_span": [204, 216], "name": "nitrendipine", "tok_span": [64, 67], "new_tok_span": [65, 68]}, {"ent_type": "CHEMICAL", "char_span": [221, 230], "name": "diltiazem", "tok_span": [68, 72], "new_tok_span": [70, 74]}, {"ent_type": "GENE", "char_span": [41, 45], "name": "HERG", "tok_span": [7, 9], "new_tok_span": [7, 9]}], "relation_list": [{"subject": "bepridil", "sbj_char_span": [96, 104], "object": "HERG", "obj_char_span": [41, 45], "rel_type": "inhibitor", "sbj_tok_span": [18, 21], "obj_tok_span": [7, 9], "new_sbj_tok_span": [18, 21], "new_obj_tok_span": [7, 9]}, {"subject": "verapamil", "sbj_char_span": [127, 136], "object": "HERG", "obj_char_span": [41, 45], "rel_type": "inhibitor", "sbj_tok_span": [32, 35], "obj_tok_span": [7, 9], "new_sbj_tok_span": [32, 35], "new_obj_tok_span": [7, 9]}, {"subject": "mibefradil", "sbj_char_span": [163, 173], "object": "HERG", "obj_char_span": [41, 45], "rel_type": "inhibitor", "sbj_tok_span": [47, 52], "obj_tok_span": [7, 9], "new_sbj_tok_span": [47, 52], "new_obj_tok_span": [7, 9]}], "umls_entity_list": [{"mention": "nitrendipine", "char_span": [204, 216], "sem_type": "Pharmacologic Substance", "tok_span": [64, 67], "new_tok_span": [65, 68]}], "new_text": "When expressed in transfected COS cells, HERG is blocked in a concentration - dependent manner by bepridil ( EC50 = 0. 55 microM ), verapamil ( EC50 = 0. 83 microM ), and mibefradil ( EC50 = 1. 43 microM ), whereas <START=Pharmacologic Substance> nitrendipine <END=Pharmacologic Substance> and diltiazem have negligible effects."}, {"PMID": 23540839, "id": 2, "text": "Both 1F1 and 1F1-N bind to the closed form of apo-PR and to pepstatin:PR. In solution, 1F1 and 1F1-N raise the Tm of apo-PR by 3.5-5 °C as assayed by differential scanning fluorimetry (DSF) and show equivalent low-micromolar binding constants to both apo-PR and pepstatin:PR, assayed by backscattering interferometry (BSI). The observed signal intensities in BSI are greater for each fragment upon binding to apo-PR than to pepstatin-bound PR, consistent with greater conformational change in the former binding event.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [60, 69], "name": "pepstatin", "tok_span": [21, 25], "new_tok_span": [22, 26]}, {"ent_type": "CHEMICAL", "char_span": [262, 271], "name": "pepstatin", "tok_span": [81, 85], "new_tok_span": [88, 92]}, {"ent_type": "CHEMICAL", "char_span": [424, 433], "name": "pepstatin", "tok_span": [119, 123], "new_tok_span": [128, 132]}, {"ent_type": "GENE", "char_span": [50, 52], "name": "PR", "tok_span": [18, 19], "new_tok_span": [18, 19]}, {"ent_type": "GENE", "char_span": [70, 72], "name": "PR", "tok_span": [26, 27], "new_tok_span": [28, 29]}, {"ent_type": "GENE", "char_span": [121, 123], "name": "PR", "tok_span": [46, 47], "new_tok_span": [52, 53]}, {"ent_type": "GENE", "char_span": [255, 257], "name": "PR", "tok_span": [79, 80], "new_tok_span": [85, 86]}, {"ent_type": "GENE", "char_span": [272, 274], "name": "PR", "tok_span": [86, 87], "new_tok_span": [94, 95]}, {"ent_type": "GENE", "char_span": [413, 415], "name": "PR", "tok_span": [116, 117], "new_tok_span": [124, 125]}, {"ent_type": "GENE", "char_span": [440, 442], "name": "PR", "tok_span": [125, 126], "new_tok_span": [135, 136]}], "relation_list": [{"subject": "pepstatin", "sbj_char_span": [60, 69], "object": "PR", "obj_char_span": [70, 72], "rel_type": "regulator", "sbj_tok_span": [21, 25], "obj_tok_span": [26, 27], "new_sbj_tok_span": [22, 26], "new_obj_tok_span": [28, 29]}, {"subject": "pepstatin", "sbj_char_span": [262, 271], "object": "PR", "obj_char_span": [272, 274], "rel_type": "regulator", "sbj_tok_span": [81, 85], "obj_tok_span": [86, 87], "new_sbj_tok_span": [88, 92], "new_obj_tok_span": [94, 95]}, {"subject": "pepstatin", "sbj_char_span": [424, 433], "object": "PR", "obj_char_span": [440, 442], "rel_type": "regulator", "sbj_tok_span": [119, 123], "obj_tok_span": [125, 126], "new_sbj_tok_span": [128, 132], "new_obj_tok_span": [135, 136]}], "umls_entity_list": [{"mention": "Tm", "char_span": [111, 113], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 43], "new_tok_span": [46, 47]}, {"mention": "Tm", "char_span": [111, 113], "sem_type": "Gene or Genome", "tok_span": [42, 43], "new_tok_span": [46, 47]}, {"mention": "pepstatin", "char_span": [60, 69], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 25], "new_tok_span": [22, 26]}, {"mention": "pepstatin", "char_span": [262, 271], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [81, 85], "new_tok_span": [88, 92]}, {"mention": "pepstatin", "char_span": [424, 433], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [119, 123], "new_tok_span": [128, 132]}], "new_text": "Both 1F1 and 1F1 - N bind to the closed form of apo - PR and to <START=Amino Acid, Peptide, or Protein> pepstatin <END=Amino Acid, Peptide, or Protein> : PR. In solution, 1F1 and 1F1 - N raise the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Tm <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> of apo - PR by 3. 5 - 5 °C as assayed by differential scanning fluorimetry ( DSF ) and show equivalent low - micromolar binding constants to both apo - PR and <START=Amino Acid, Peptide, or Protein> pepstatin <END=Amino Acid, Peptide, or Protein> : PR, assayed by backscattering interferometry ( BSI ). The observed signal intensities in BSI are greater for each fragment upon binding to apo - PR than to <START=Amino Acid, Peptide, or Protein> pepstatin <END=Amino Acid, Peptide, or Protein> - bound PR, consistent with greater conformational change in the former binding event."}, {"PMID": 23019138, "id": 6, "text": "Methanandamide (10.0 mg/kg) had lesser effect than other CB agonists, and the CB2 agonist AM1241 [1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole], the anandamide transport inhibitor AM404, and the CB antagonist rimonabant did not have diuretic effects.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 14], "name": "Methanandamide", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [90, 96], "name": "AM1241", "tok_span": [25, 28], "new_tok_span": [28, 31]}, {"ent_type": "CHEMICAL", "char_span": [98, 160], "name": "1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole", "tok_span": [29, 59], "new_tok_span": [33, 63]}, {"ent_type": "CHEMICAL", "char_span": [167, 177], "name": "anandamide", "tok_span": [62, 65], "new_tok_span": [73, 76]}, {"ent_type": "CHEMICAL", "char_span": [198, 203], "name": "AM404", "tok_span": [67, 70], "new_tok_span": [82, 85]}, {"ent_type": "CHEMICAL", "char_span": [227, 237], "name": "rimonabant", "tok_span": [75, 79], "new_tok_span": [91, 95]}, {"ent_type": "GENE", "char_span": [78, 81], "name": "CB2", "tok_span": [22, 24], "new_tok_span": [24, 26]}], "relation_list": [{"subject": "AM1241", "sbj_char_span": [90, 96], "object": "CB2", "obj_char_span": [78, 81], "rel_type": "agonist or antagonist", "sbj_tok_span": [25, 28], "obj_tok_span": [22, 24], "new_sbj_tok_span": [28, 31], "new_obj_tok_span": [24, 26]}, {"subject": "1-(methylpiperidin-2-ylmethyl)-3-(2-iodo-5-nitrobenzoyl)indole", "sbj_char_span": [98, 160], "object": "CB2", "obj_char_span": [78, 81], "rel_type": "agonist or antagonist", "sbj_tok_span": [29, 59], "obj_tok_span": [22, 24], "new_sbj_tok_span": [33, 63], "new_obj_tok_span": [24, 26]}, {"subject": "AM404", "sbj_char_span": [198, 203], "object": "CB2", "obj_char_span": [78, 81], "rel_type": "agonist or antagonist", "sbj_tok_span": [67, 70], "obj_tok_span": [22, 24], "new_sbj_tok_span": [82, 85], "new_obj_tok_span": [24, 26]}], "umls_entity_list": [{"mention": "AM1241", "char_span": [90, 96], "sem_type": "Pharmacologic Substance", "tok_span": [25, 28], "new_tok_span": [28, 31]}, {"mention": "iodo", "char_span": [134, 138], "sem_type": "Pharmacologic Substance", "tok_span": [48, 50], "new_tok_span": [53, 55]}, {"mention": "indole", "char_span": [154, 160], "sem_type": "Pharmacologic Substance", "tok_span": [57, 59], "new_tok_span": [65, 67]}, {"mention": "indole", "char_span": [154, 160], "sem_type": "Organic Chemical", "tok_span": [57, 59], "new_tok_span": [65, 67]}, {"mention": "anandamide", "char_span": [4, 14], "sem_type": "Organic Chemical", "tok_span": [1, 4], "new_tok_span": [2, 5]}, {"mention": "anandamide", "char_span": [167, 177], "sem_type": "Organic Chemical", "tok_span": [62, 65], "new_tok_span": [73, 76]}, {"mention": "transport", "char_span": [178, 187], "sem_type": "Pharmacologic Substance", "tok_span": [65, 66], "new_tok_span": [78, 79]}, {"mention": "AM404", "char_span": [198, 203], "sem_type": "Organic Chemical", "tok_span": [67, 70], "new_tok_span": [82, 85]}], "new_text": "Meth <START=Organic Chemical>anandamide <END=Organic Chemical> ( 10. 0 mg / kg ) had lesser effect than other CB agonists, and the CB2 agonist <START=Pharmacologic Substance> AM1241 <END=Pharmacologic Substance> [ 1 - ( methylpiperidin - 2 - ylmethyl ) - 3 - ( 2 - <START=Pharmacologic Substance> iodo <END=Pharmacologic Substance> - 5 - nitrobenzoyl ) <START=Pharmacologic Substance> <START=Organic Chemical> indole <END=Pharmacologic Substance> <END=Organic Chemical> ], the <START=Organic Chemical> anandamide <END=Organic Chemical> <START=Pharmacologic Substance> transport <END=Pharmacologic Substance> inhibitor <START=Organic Chemical> AM404 <END=Organic Chemical>, and the CB antagonist rimonabant did not have diuretic effects."}, {"PMID": 23562072, "id": 2, "text": "Sene et al. (2013) now demonstrate that in aged macrophages decreased ABCA1 expression, regulated by liver X receptor and miR-33, impairs export of intracellular cholesterol, which promotes neovascular AMD.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [162, 173], "name": "cholesterol", "tok_span": [34, 35], "new_tok_span": [36, 37]}, {"ent_type": "GENE", "char_span": [70, 75], "name": "ABCA1", "tok_span": [15, 18], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [101, 117], "name": "liver X receptor", "tok_span": [22, 25], "new_tok_span": [23, 26]}, {"ent_type": "GENE", "char_span": [122, 128], "name": "miR-33", "tok_span": [26, 29], "new_tok_span": [28, 31]}], "relation_list": [{"subject": "cholesterol", "sbj_char_span": [162, 173], "object": "ABCA1", "obj_char_span": [70, 75], "rel_type": "product or substrate", "sbj_tok_span": [34, 35], "obj_tok_span": [15, 18], "new_sbj_tok_span": [36, 37], "new_obj_tok_span": [15, 18]}], "umls_entity_list": [{"mention": "liver X receptor", "char_span": [101, 117], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 25], "new_tok_span": [23, 26]}, {"mention": "AMD", "char_span": [202, 205], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [40, 41], "new_tok_span": [44, 45]}, {"mention": "AMD", "char_span": [202, 205], "sem_type": "Gene or Genome", "tok_span": [40, 41], "new_tok_span": [44, 45]}], "new_text": "Sene et al. ( 2013 ) now demonstrate that in aged macrophages decreased ABCA1 expression, regulated by <START=Amino Acid, Peptide, or Protein> liver X receptor <END=Amino Acid, Peptide, or Protein> and miR - 33, impairs export of intracellular cholesterol, which promotes neovascular <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> AMD <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>."}, {"PMID": 10611634, "id": 7, "text": "In distinction to yohimbine, fluparoxan shows only modest partial agonist actions at h5-HT(1A) sites versus marked antagonist actions at halpha(2)-ARs. While fluparoxan selectively enhances hippocampal noradrenaline (NAD) turnover, yohimbine also enhances striatal dopamine (DA) turnover and suppresses striatal turnover of 5-HT. Further, yohimbine decreases firing of serotonergic neurones in raphe nuclei, an action reversed by WAY100,635.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [158, 168], "name": "fluparoxan", "tok_span": [43, 47], "new_tok_span": [52, 56]}, {"ent_type": "CHEMICAL", "char_span": [202, 215], "name": "noradrenaline", "tok_span": [50, 53], "new_tok_span": [61, 64]}, {"ent_type": "CHEMICAL", "char_span": [217, 220], "name": "NAD", "tok_span": [54, 55], "new_tok_span": [66, 67]}, {"ent_type": "CHEMICAL", "char_span": [232, 241], "name": "yohimbine", "tok_span": [58, 62], "new_tok_span": [71, 75]}, {"ent_type": "CHEMICAL", "char_span": [265, 273], "name": "dopamine", "tok_span": [65, 66], "new_tok_span": [79, 80]}, {"ent_type": "CHEMICAL", "char_span": [275, 277], "name": "DA", "tok_span": [67, 68], "new_tok_span": [81, 82]}, {"ent_type": "CHEMICAL", "char_span": [324, 328], "name": "5-HT", "tok_span": [75, 78], "new_tok_span": [89, 92]}, {"ent_type": "CHEMICAL", "char_span": [339, 348], "name": "yohimbine", "tok_span": [81, 85], "new_tok_span": [96, 100]}, {"ent_type": "CHEMICAL", "char_span": [430, 440], "name": "WAY100,635", "tok_span": [101, 107], "new_tok_span": [117, 123]}, {"ent_type": "CHEMICAL", "char_span": [18, 27], "name": "yohimbine", "tok_span": [3, 7], "new_tok_span": [4, 8]}, {"ent_type": "CHEMICAL", "char_span": [29, 39], "name": "fluparoxan", "tok_span": [8, 12], "new_tok_span": [11, 15]}, {"ent_type": "GENE", "char_span": [85, 94], "name": "h5-HT(1A)", "tok_span": [19, 27], "new_tok_span": [24, 32]}, {"ent_type": "GENE", "char_span": [137, 150], "name": "halpha(2)-ARs", "tok_span": [33, 41], "new_tok_span": [41, 49]}], "relation_list": [{"subject": "yohimbine", "sbj_char_span": [18, 27], "object": "h5-HT(1A)", "obj_char_span": [85, 94], "rel_type": "agonist or antagonist", "sbj_tok_span": [3, 7], "obj_tok_span": [19, 27], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [24, 32]}, {"subject": "fluparoxan", "sbj_char_span": [29, 39], "object": "h5-HT(1A)", "obj_char_span": [85, 94], "rel_type": "agonist or antagonist", "sbj_tok_span": [8, 12], "obj_tok_span": [19, 27], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [24, 32]}, {"subject": "yohimbine", "sbj_char_span": [18, 27], "object": "halpha(2)-ARs", "obj_char_span": [137, 150], "rel_type": "agonist or antagonist", "sbj_tok_span": [3, 7], "obj_tok_span": [33, 41], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [41, 49]}, {"subject": "fluparoxan", "sbj_char_span": [29, 39], "object": "halpha(2)-ARs", "obj_char_span": [137, 150], "rel_type": "agonist or antagonist", "sbj_tok_span": [8, 12], "obj_tok_span": [33, 41], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [41, 49]}], "umls_entity_list": [{"mention": "fluparoxan", "char_span": [29, 39], "sem_type": "Pharmacologic Substance", "tok_span": [8, 12], "new_tok_span": [11, 15]}, {"mention": "fluparoxan", "char_span": [158, 168], "sem_type": "Pharmacologic Substance", "tok_span": [43, 47], "new_tok_span": [52, 56]}, {"mention": "h5", "char_span": [85, 87], "sem_type": "Gene or Genome", "tok_span": [19, 21], "new_tok_span": [24, 26]}, {"mention": "antagonist", "char_span": [115, 125], "sem_type": "Pharmacologic Substance", "tok_span": [30, 31], "new_tok_span": [37, 38]}, {"mention": "noradrenaline", "char_span": [202, 215], "sem_type": "Pharmacologic Substance", "tok_span": [50, 53], "new_tok_span": [61, 64]}, {"mention": "yohimbine", "char_span": [18, 27], "sem_type": "Pharmacologic Substance", "tok_span": [3, 7], "new_tok_span": [4, 8]}, {"mention": "yohimbine", "char_span": [232, 241], "sem_type": "Pharmacologic Substance", "tok_span": [58, 62], "new_tok_span": [71, 75]}, {"mention": "yohimbine", "char_span": [339, 348], "sem_type": "Pharmacologic Substance", "tok_span": [81, 85], "new_tok_span": [96, 100]}], "new_text": "In distinction to <START=Pharmacologic Substance> yohimbine <END=Pharmacologic Substance>, <START=Pharmacologic Substance> fluparoxan <END=Pharmacologic Substance> shows only modest partial agonist actions at <START=Gene or Genome> h5 <END=Gene or Genome> - HT ( 1A ) sites versus marked <START=Pharmacologic Substance> antagonist <END=Pharmacologic Substance> actions at halpha ( 2 ) - ARs. While <START=Pharmacologic Substance> fluparoxan <END=Pharmacologic Substance> selectively enhances hippocampal <START=Pharmacologic Substance> noradrenaline <END=Pharmacologic Substance> ( NAD ) turnover, <START=Pharmacologic Substance> yohimbine <END=Pharmacologic Substance> also enhances striatal dopamine ( DA ) turnover and suppresses striatal turnover of 5 - HT. Further, <START=Pharmacologic Substance> yohimbine <END=Pharmacologic Substance> decreases firing of serotonergic neurones in raphe nuclei, an action reversed by WAY100, 635."}, {"PMID": 17373776, "id": 7, "text": "The E1013N variant exhibited hyperbolic kinetics, but the velocity of glutamine hydrolysis was twice that of glutamate synthesis from 2-oxoglutarate at the synthase site.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [70, 79], "name": "glutamine", "tok_span": [14, 15], "new_tok_span": [14, 15]}, {"ent_type": "CHEMICAL", "char_span": [109, 118], "name": "glutamate", "tok_span": [20, 21], "new_tok_span": [20, 21]}, {"ent_type": "CHEMICAL", "char_span": [134, 148], "name": "2-oxoglutarate", "tok_span": [23, 29], "new_tok_span": [23, 29]}, {"ent_type": "GENE", "char_span": [4, 10], "name": "E1013N", "tok_span": [1, 5], "new_tok_span": [1, 5]}], "relation_list": [{"subject": "glutamine", "sbj_char_span": [70, 79], "object": "E1013N", "obj_char_span": [4, 10], "rel_type": "product or substrate", "sbj_tok_span": [14, 15], "obj_tok_span": [1, 5], "new_sbj_tok_span": [14, 15], "new_obj_tok_span": [1, 5]}, {"subject": "glutamate", "sbj_char_span": [109, 118], "object": "E1013N", "obj_char_span": [4, 10], "rel_type": "product or substrate", "sbj_tok_span": [20, 21], "obj_tok_span": [1, 5], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [1, 5]}, {"subject": "2-oxoglutarate", "sbj_char_span": [134, 148], "object": "E1013N", "obj_char_span": [4, 10], "rel_type": "product or substrate", "sbj_tok_span": [23, 29], "obj_tok_span": [1, 5], "new_sbj_tok_span": [23, 29], "new_obj_tok_span": [1, 5]}], "umls_entity_list": [{"mention": "synthase", "char_span": [156, 164], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [31, 32], "new_tok_span": [32, 33]}], "new_text": "The E1013N variant exhibited hyperbolic kinetics, but the velocity of glutamine hydrolysis was twice that of glutamate synthesis from 2 - oxoglutarate at the <START=Amino Acid, Peptide, or Protein> synthase <END=Amino Acid, Peptide, or Protein> site."}, {"PMID": 17884974, "id": 4, "text": "Ex vivo COX inhibition and pharmacokinetics of acetaminophen were assessed in 5 volunteers receiving single 1000 mg doses orally.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [47, 60], "name": "acetaminophen", "tok_span": [8, 11], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [8, 11], "name": "COX", "tok_span": [2, 3], "new_tok_span": [3, 4]}], "relation_list": [{"subject": "acetaminophen", "sbj_char_span": [47, 60], "object": "COX", "obj_char_span": [8, 11], "rel_type": "inhibitor", "sbj_tok_span": [8, 11], "obj_tok_span": [2, 3], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [3, 4]}], "umls_entity_list": [{"mention": "COX", "char_span": [8, 11], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"mention": "acetaminophen", "char_span": [47, 60], "sem_type": "Pharmacologic Substance", "tok_span": [8, 11], "new_tok_span": [11, 14]}], "new_text": "Ex vivo <START=Amino Acid, Peptide, or Protein> COX <END=Amino Acid, Peptide, or Protein> inhibition and pharmacokinetics of <START=Pharmacologic Substance> acetaminophen <END=Pharmacologic Substance> were assessed in 5 volunteers receiving single 1000 mg doses orally."}, {"PMID": 23643094, "id": 0, "text": "Nordihydroguaiaretic acid induces Nrf2 nuclear translocation in vivo and attenuates renal damage and apoptosis in the ischemia and reperfusion model.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 25], "name": "Nordihydroguaiaretic acid", "tok_span": [0, 9], "new_tok_span": [0, 9]}, {"ent_type": "GENE", "char_span": [34, 38], "name": "Nrf2", "tok_span": [10, 12], "new_tok_span": [10, 12]}], "relation_list": [{"subject": "Nordihydroguaiaretic acid", "sbj_char_span": [0, 25], "object": "Nrf2", "obj_char_span": [34, 38], "rel_type": "activator", "sbj_tok_span": [0, 9], "obj_tok_span": [10, 12], "new_sbj_tok_span": [0, 9], "new_obj_tok_span": [10, 12]}], "umls_entity_list": [], "new_text": "Nordihydroguaiaretic acid induces Nrf2 nuclear translocation in vivo and attenuates renal damage and apoptosis in the ischemia and reperfusion model."}, {"PMID": 10693877, "id": 0, "text": "Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 37], "name": "rofecoxib", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"ent_type": "CHEMICAL", "char_span": [70, 79], "name": "ibuprofen", "tok_span": [17, 21], "new_tok_span": [20, 24]}, {"ent_type": "GENE", "char_span": [41, 57], "name": "cyclooxygenase 2", "tok_span": [11, 14], "new_tok_span": [13, 16]}], "relation_list": [{"subject": "rofecoxib", "sbj_char_span": [28, 37], "object": "cyclooxygenase 2", "obj_char_span": [41, 57], "rel_type": "inhibitor", "sbj_tok_span": [5, 9], "obj_tok_span": [11, 14], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [13, 16]}], "umls_entity_list": [{"mention": "rofecoxib", "char_span": [28, 37], "sem_type": "Pharmacologic Substance", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"mention": "ibuprofen", "char_span": [70, 79], "sem_type": "Pharmacologic Substance", "tok_span": [17, 21], "new_tok_span": [20, 24]}], "new_text": "Comparison of the effect of <START=Pharmacologic Substance> rofecoxib <END=Pharmacologic Substance> ( a cyclooxygenase 2 inhibitor ), <START=Pharmacologic Substance> ibuprofen <END=Pharmacologic Substance>, and placebo on the gastroduodenal mucosa of patients with osteoarthritis : a randomized, double - blind, placebo - controlled trial."}, {"PMID": 23605695, "id": 1, "text": "Pasireotide (Signifor(®)) is a new subcutaneous somatostatin analogue that acts via somatostatin receptors to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Pasireotide", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [13, 21], "name": "Signifor", "tok_span": [4, 7], "new_tok_span": [7, 10]}, {"ent_type": "CHEMICAL", "char_span": [48, 60], "name": "somatostatin", "tok_span": [15, 17], "new_tok_span": [22, 24]}, {"ent_type": "CHEMICAL", "char_span": [84, 96], "name": "somatostatin", "tok_span": [21, 23], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [135, 148], "name": "corticotropin", "tok_span": [29, 31], "new_tok_span": [41, 43]}, {"ent_type": "GENE", "char_span": [48, 60], "name": "somatostatin", "tok_span": [15, 17], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [84, 106], "name": "somatostatin receptors", "tok_span": [21, 24], "new_tok_span": [32, 35]}], "relation_list": [{"subject": "Pasireotide", "sbj_char_span": [0, 11], "object": "somatostatin receptors", "obj_char_span": [84, 106], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [21, 24], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [32, 35]}, {"subject": "Signifor", "sbj_char_span": [13, 21], "object": "somatostatin receptors", "obj_char_span": [84, 106], "rel_type": "regulator", "sbj_tok_span": [4, 7], "obj_tok_span": [21, 24], "new_sbj_tok_span": [7, 10], "new_obj_tok_span": [32, 35]}, {"subject": "Pasireotide", "sbj_char_span": [0, 11], "object": "corticotropin", "obj_char_span": [135, 148], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [29, 31], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [41, 43]}, {"subject": "Signifor", "sbj_char_span": [13, 21], "object": "corticotropin", "obj_char_span": [135, 148], "rel_type": "regulator", "sbj_tok_span": [4, 7], "obj_tok_span": [29, 31], "new_sbj_tok_span": [7, 10], "new_obj_tok_span": [41, 43]}], "umls_entity_list": [{"mention": "Pasireotide", "char_span": [0, 11], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "Signifor", "char_span": [13, 21], "sem_type": "Pharmacologic Substance", "tok_span": [4, 7], "new_tok_span": [7, 10]}, {"mention": "somatostatin analogue", "char_span": [48, 69], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 18], "new_tok_span": [22, 25]}, {"mention": "somatostatin analog", "char_span": [48, 67], "sem_type": "Pharmacologic Substance", "tok_span": [15, 18], "new_tok_span": [22, 25]}, {"mention": "somatostatin analogue", "char_span": [48, 69], "sem_type": "Pharmacologic Substance", "tok_span": [15, 18], "new_tok_span": [22, 25]}, {"mention": "somatostatin receptor", "char_span": [84, 105], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 24], "new_tok_span": [32, 35]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Pasireotide <END=Amino Acid, Peptide, or Protein> ( <START=Pharmacologic Substance> Signifor <END=Pharmacologic Substance> ( ® ) ) is a new subcutaneous <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> <START=Pharmacologic Substance> somatostatin analogue <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> <END=Pharmacologic Substance> that acts via <START=Amino Acid, Peptide, or Protein> somatostatin receptors <END=Amino Acid, Peptide, or Protein> to inhibit the secretion of corticotropin from the pituitary adenoma in patients with Cushing's disease."}, {"PMID": 15748157, "id": 4, "text": "Atorvastatin significantly protected from glutamate-induced excitotoxicity as evidenced by propidium iodide staining, nuclear morphology, release of lactate dehydrogenase, and mitochondrial tetrazolium metabolism, but not from oxygen-glucose deprivation or apoptotic cell death.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Atorvastatin", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [42, 51], "name": "glutamate", "tok_span": [6, 7], "new_tok_span": [7, 8]}, {"ent_type": "CHEMICAL", "char_span": [91, 107], "name": "propidium iodide", "tok_span": [14, 17], "new_tok_span": [17, 20]}, {"ent_type": "CHEMICAL", "char_span": [149, 156], "name": "lactate", "tok_span": [24, 25], "new_tok_span": [29, 30]}, {"ent_type": "CHEMICAL", "char_span": [190, 201], "name": "tetrazolium", "tok_span": [29, 32], "new_tok_span": [36, 39]}, {"ent_type": "CHEMICAL", "char_span": [227, 233], "name": "oxygen", "tok_span": [37, 38], "new_tok_span": [46, 47]}, {"ent_type": "CHEMICAL", "char_span": [234, 241], "name": "glucose", "tok_span": [39, 40], "new_tok_span": [49, 50]}, {"ent_type": "GENE", "char_span": [149, 170], "name": "lactate dehydrogenase", "tok_span": [24, 26], "new_tok_span": [29, 31]}], "relation_list": [{"subject": "Atorvastatin", "sbj_char_span": [0, 12], "object": "lactate dehydrogenase", "obj_char_span": [149, 170], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [24, 26], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [29, 31]}], "umls_entity_list": [{"mention": "glutamate", "char_span": [42, 51], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 7], "new_tok_span": [7, 8]}, {"mention": "propidium iodide", "char_span": [91, 107], "sem_type": "Organic Chemical", "tok_span": [14, 17], "new_tok_span": [17, 20]}, {"mention": "lactate", "char_span": [149, 156], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 25], "new_tok_span": [29, 30]}, {"mention": "tetrazolium", "char_span": [190, 201], "sem_type": "Organic Chemical", "tok_span": [29, 32], "new_tok_span": [36, 39]}, {"mention": "oxygen", "char_span": [227, 233], "sem_type": "Pharmacologic Substance", "tok_span": [37, 38], "new_tok_span": [46, 47]}], "new_text": "Atorvastatin significantly protected from <START=Amino Acid, Peptide, or Protein> glutamate <END=Amino Acid, Peptide, or Protein> - induced excitotoxicity as evidenced by <START=Organic Chemical> propidium iodide <END=Organic Chemical> staining, nuclear morphology, release of <START=Amino Acid, Peptide, or Protein> lactate <END=Amino Acid, Peptide, or Protein> dehydrogenase, and mitochondrial <START=Organic Chemical> tetrazolium <END=Organic Chemical> metabolism, but not from <START=Pharmacologic Substance> oxygen <END=Pharmacologic Substance> - glucose deprivation or apoptotic cell death."}, {"PMID": 15120421, "id": 0, "text": "In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [163, 171], "name": "CDB-2914", "tok_span": [28, 33], "new_tok_span": [29, 34]}, {"ent_type": "CHEMICAL", "char_span": [173, 181], "name": "CDB-4124", "tok_span": [34, 39], "new_tok_span": [37, 42]}, {"ent_type": "CHEMICAL", "char_span": [187, 199], "name": "mifepristone", "tok_span": [41, 45], "new_tok_span": [45, 49]}, {"ent_type": "CHEMICAL", "char_span": [60, 69], "name": "progestin", "tok_span": [13, 16], "new_tok_span": [13, 16]}, {"ent_type": "GENE", "char_span": [60, 69], "name": "progestin", "tok_span": [13, 16], "new_tok_span": [13, 16]}, {"ent_type": "GENE", "char_span": [74, 97], "name": "glucocorticoid receptor", "tok_span": [17, 19], "new_tok_span": [17, 19]}], "relation_list": [{"subject": "CDB-2914", "sbj_char_span": [163, 171], "object": "glucocorticoid receptor", "obj_char_span": [74, 97], "rel_type": "regulator", "sbj_tok_span": [28, 33], "obj_tok_span": [17, 19], "new_sbj_tok_span": [29, 34], "new_obj_tok_span": [17, 19]}, {"subject": "CDB-4124", "sbj_char_span": [173, 181], "object": "glucocorticoid receptor", "obj_char_span": [74, 97], "rel_type": "regulator", "sbj_tok_span": [34, 39], "obj_tok_span": [17, 19], "new_sbj_tok_span": [37, 42], "new_obj_tok_span": [17, 19]}, {"subject": "mifepristone", "sbj_char_span": [187, 199], "object": "glucocorticoid receptor", "obj_char_span": [74, 97], "rel_type": "regulator", "sbj_tok_span": [41, 45], "obj_tok_span": [17, 19], "new_sbj_tok_span": [45, 49], "new_obj_tok_span": [17, 19]}], "umls_entity_list": [{"mention": "CDB", "char_span": [163, 166], "sem_type": "Pharmacologic Substance", "tok_span": [28, 30], "new_tok_span": [29, 31]}, {"mention": "CDB", "char_span": [173, 176], "sem_type": "Pharmacologic Substance", "tok_span": [34, 36], "new_tok_span": [37, 39]}], "new_text": "In vitro antiprogestational / antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of <START=Pharmacologic Substance> CDB <END=Pharmacologic Substance> - 2914, <START=Pharmacologic Substance> CDB <END=Pharmacologic Substance> - 4124, and mifepristone."}, {"PMID": 22422627, "id": 7, "text": "Berberine only suppressed the expression of pp38 among the evaluated signaling molecules.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Berberine", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "GENE", "char_span": [44, 48], "name": "pp38", "tok_span": [8, 10], "new_tok_span": [8, 10]}], "relation_list": [{"subject": "Berberine", "sbj_char_span": [0, 9], "object": "pp38", "obj_char_span": [44, 48], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 10], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [8, 10]}], "umls_entity_list": [], "new_text": "Berberine only suppressed the expression of pp38 among the evaluated signaling molecules."}, {"PMID": 15367040, "id": 2, "text": "Levetiracetam binds selectively and with high affinity to a synaptic vesicle protein known as SV2A, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 13], "name": "Levetiracetam", "tok_span": [0, 6], "new_tok_span": [0, 6]}, {"ent_type": "GENE", "char_span": [60, 84], "name": "synaptic vesicle protein", "tok_span": [14, 17], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [94, 98], "name": "SV2A", "tok_span": [19, 22], "new_tok_span": [19, 22]}], "relation_list": [{"subject": "Levetiracetam", "sbj_char_span": [0, 13], "object": "synaptic vesicle protein", "obj_char_span": [60, 84], "rel_type": "regulator", "sbj_tok_span": [0, 6], "obj_tok_span": [14, 17], "new_sbj_tok_span": [0, 6], "new_obj_tok_span": [14, 17]}, {"subject": "Levetiracetam", "sbj_char_span": [0, 13], "object": "SV2A", "obj_char_span": [94, 98], "rel_type": "regulator", "sbj_tok_span": [0, 6], "obj_tok_span": [19, 22], "new_sbj_tok_span": [0, 6], "new_obj_tok_span": [19, 22]}], "umls_entity_list": [], "new_text": "Levetiracetam binds selectively and with high affinity to a synaptic vesicle protein known as SV2A, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release."}, {"PMID": 17341305, "id": 9, "text": "The expression of ER-alpha and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in progestin-treated BALB/c mice (P < 0.05).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [171, 180], "name": "progestin", "tok_span": [38, 41], "new_tok_span": [57, 60]}, {"ent_type": "GENE", "char_span": [18, 26], "name": "ER-alpha", "tok_span": [3, 6], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [31, 43], "name": "PR isoform A", "tok_span": [7, 10], "new_tok_span": [15, 18]}], "relation_list": [{"subject": "progestin", "sbj_char_span": [171, 180], "object": "ER-alpha", "obj_char_span": [18, 26], "rel_type": "regulator", "sbj_tok_span": [38, 41], "obj_tok_span": [3, 6], "new_sbj_tok_span": [57, 60], "new_obj_tok_span": [8, 11]}, {"subject": "progestin", "sbj_char_span": [171, 180], "object": "PR isoform A", "obj_char_span": [31, 43], "rel_type": "regulator", "sbj_tok_span": [38, 41], "obj_tok_span": [7, 10], "new_sbj_tok_span": [57, 60], "new_obj_tok_span": [15, 18]}], "umls_entity_list": [{"mention": "ER-alpha", "char_span": [18, 26], "sem_type": "Gene or Genome", "tok_span": [3, 6], "new_tok_span": [8, 11]}, {"mention": "isoform", "char_span": [34, 41], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [19, 20]}, {"mention": "pr", "char_span": [6, 8], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 2], "new_tok_span": [3, 4]}, {"mention": "PR", "char_span": [31, 33], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 8], "new_tok_span": [15, 16]}, {"mention": "pr", "char_span": [66, 68], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 16], "new_tok_span": [29, 30]}, {"mention": "pr", "char_span": [171, 173], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [38, 39], "new_tok_span": [57, 58]}, {"mention": "pr", "char_span": [6, 8], "sem_type": "Gene or Genome", "tok_span": [1, 2], "new_tok_span": [3, 4]}, {"mention": "PR", "char_span": [31, 33], "sem_type": "Gene or Genome", "tok_span": [7, 8], "new_tok_span": [15, 16]}, {"mention": "pr", "char_span": [66, 68], "sem_type": "Gene or Genome", "tok_span": [15, 16], "new_tok_span": [29, 30]}, {"mention": "pr", "char_span": [171, 173], "sem_type": "Gene or Genome", "tok_span": [38, 39], "new_tok_span": [57, 58]}, {"mention": "progestin", "char_span": [171, 180], "sem_type": "Pharmacologic Substance", "tok_span": [38, 41], "new_tok_span": [57, 60]}], "new_text": "The <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> expression <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> of <START=Gene or Genome> ER - alpha <END=Gene or Genome> and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PR <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <START=Amino Acid, Peptide, or Protein> isoform <END=Amino Acid, Peptide, or Protein> A in virgin mice was <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> surprisingly <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> much higher in BALB / c than in C57BL / 6 mammary glands, and both receptors were downregulated in <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Pharmacologic Substance> prog <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>estin <END=Pharmacologic Substance> - treated BALB / c mice ( P < 0. 05 )."}, {"PMID": 10688973, "id": 3, "text": "The affinity and functional profile of opioids possessing activity at the nociceptin receptor was determined using [3H]nociceptin and nociceptin-stimulated [35S]GTPgammaS binding.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [156, 170], "name": "[35S]GTPgammaS", "tok_span": [29, 36], "new_tok_span": [41, 48]}, {"ent_type": "GENE", "char_span": [74, 93], "name": "nociceptin receptor", "tok_span": [12, 15], "new_tok_span": [14, 17]}], "relation_list": [{"subject": "[35S]GTPgammaS", "sbj_char_span": [156, 170], "object": "nociceptin receptor", "obj_char_span": [74, 93], "rel_type": "regulator", "sbj_tok_span": [29, 36], "obj_tok_span": [12, 15], "new_sbj_tok_span": [41, 48], "new_obj_tok_span": [14, 17]}], "umls_entity_list": [{"mention": "nociceptin", "char_span": [74, 84], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 14], "new_tok_span": [14, 16]}, {"mention": "nociceptin", "char_span": [119, 129], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 24], "new_tok_span": [28, 30]}, {"mention": "nociceptin", "char_span": [134, 144], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 27], "new_tok_span": [35, 37]}, {"mention": "nociceptin", "char_span": [74, 84], "sem_type": "Gene or Genome", "tok_span": [12, 14], "new_tok_span": [14, 16]}, {"mention": "nociceptin", "char_span": [119, 129], "sem_type": "Gene or Genome", "tok_span": [22, 24], "new_tok_span": [28, 30]}, {"mention": "nociceptin", "char_span": [134, 144], "sem_type": "Gene or Genome", "tok_span": [25, 27], "new_tok_span": [35, 37]}], "new_text": "The affinity and functional profile of opioids possessing activity at the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> nociceptin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> receptor was determined using [ 3H ] <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> nociceptin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> nociceptin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - stimulated [ 35S ] GTPgammaS binding."}, {"PMID": 2922761, "id": 8, "text": "In the high-dose ROAc group, there was a twofold increase in prothrombin times but only after prolonged dosing.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [17, 21], "name": "ROAc", "tok_span": [5, 7], "new_tok_span": [5, 7]}, {"ent_type": "GENE", "char_span": [61, 72], "name": "prothrombin", "tok_span": [15, 19], "new_tok_span": [15, 19]}], "relation_list": [{"subject": "ROAc", "sbj_char_span": [17, 21], "object": "prothrombin", "obj_char_span": [61, 72], "rel_type": "regulator", "sbj_tok_span": [5, 7], "obj_tok_span": [15, 19], "new_sbj_tok_span": [5, 7], "new_obj_tok_span": [15, 19]}], "umls_entity_list": [], "new_text": "In the high - dose ROAc group, there was a twofold increase in prothrombin times but only after prolonged dosing."}, {"PMID": 15016471, "id": 18, "text": "The possibility is discussed that the spontaneous hypertension in rats carrying the GTK/KAT I mutation may be due in part to disruption of glutamine transamination.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [139, 148], "name": "glutamine", "tok_span": [27, 28], "new_tok_span": [30, 31]}, {"ent_type": "GENE", "char_span": [84, 87], "name": "GTK", "tok_span": [12, 14], "new_tok_span": [12, 14]}, {"ent_type": "GENE", "char_span": [88, 93], "name": "KAT I", "tok_span": [15, 18], "new_tok_span": [16, 19]}], "relation_list": [{"subject": "glutamine", "sbj_char_span": [139, 148], "object": "KAT I", "obj_char_span": [88, 93], "rel_type": "product or substrate", "sbj_tok_span": [27, 28], "obj_tok_span": [15, 18], "new_sbj_tok_span": [30, 31], "new_obj_tok_span": [16, 19]}, {"subject": "glutamine", "sbj_char_span": [139, 148], "object": "GTK", "obj_char_span": [84, 87], "rel_type": "product or substrate", "sbj_tok_span": [27, 28], "obj_tok_span": [12, 14], "new_sbj_tok_span": [30, 31], "new_obj_tok_span": [12, 14]}], "umls_entity_list": [{"mention": "KAT", "char_span": [88, 91], "sem_type": "Gene or Genome", "tok_span": [15, 17], "new_tok_span": [16, 18]}, {"mention": "glutamine", "char_span": [139, 148], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [30, 31]}], "new_text": "The possibility is discussed that the spontaneous hypertension in rats carrying the GTK / <START=Gene or Genome> KAT <END=Gene or Genome> I mutation may be due in part to disruption of <START=Amino Acid, Peptide, or Protein> glutamine <END=Amino Acid, Peptide, or Protein> transamination."}, {"PMID": 12213829, "id": 10, "text": "The L0 linker has been reported to be required for glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [51, 64], "name": "glibenclamide", "tok_span": [11, 15], "new_tok_span": [14, 18]}, {"ent_type": "CHEMICAL", "char_span": [146, 171], "name": "(125)I-azidoglibenclamide", "tok_span": [40, 51], "new_tok_span": [50, 61]}, {"ent_type": "CHEMICAL", "char_span": [197, 198], "name": "N", "tok_span": [59, 60], "new_tok_span": [73, 74]}, {"ent_type": "GENE", "char_span": [78, 92], "name": "DeltaNK(IR)6.2", "tok_span": [18, 26], "new_tok_span": [22, 30]}, {"ent_type": "GENE", "char_span": [93, 97], "name": "SUR1", "tok_span": [27, 30], "new_tok_span": [34, 37]}, {"ent_type": "GENE", "char_span": [135, 140], "name": "K(IR)", "tok_span": [35, 39], "new_tok_span": [43, 47]}, {"ent_type": "GENE", "char_span": [191, 196], "name": "K(IR)", "tok_span": [55, 59], "new_tok_span": [67, 71]}, {"ent_type": "GENE", "char_span": [218, 222], "name": "SUR1", "tok_span": [65, 68], "new_tok_span": [80, 83]}], "relation_list": [{"subject": "(125)I-azidoglibenclamide", "sbj_char_span": [146, 171], "object": "K(IR)", "obj_char_span": [135, 140], "rel_type": "regulator", "sbj_tok_span": [40, 51], "obj_tok_span": [35, 39], "new_sbj_tok_span": [50, 61], "new_obj_tok_span": [43, 47]}, {"subject": "(125)I-azidoglibenclamide", "sbj_char_span": [146, 171], "object": "SUR1", "obj_char_span": [93, 97], "rel_type": "regulator", "sbj_tok_span": [40, 51], "obj_tok_span": [27, 30], "new_sbj_tok_span": [50, 61], "new_obj_tok_span": [34, 37]}, {"subject": "(125)I-azidoglibenclamide", "sbj_char_span": [146, 171], "object": "DeltaNK(IR)6.2", "obj_char_span": [78, 92], "rel_type": "regulator", "sbj_tok_span": [40, 51], "obj_tok_span": [18, 26], "new_sbj_tok_span": [50, 61], "new_obj_tok_span": [22, 30]}, {"subject": "N", "sbj_char_span": [197, 198], "object": "K(IR)", "obj_char_span": [191, 196], "rel_type": "part of", "sbj_tok_span": [59, 60], "obj_tok_span": [55, 59], "new_sbj_tok_span": [73, 74], "new_obj_tok_span": [67, 71]}], "umls_entity_list": [{"mention": "glibenclamide", "char_span": [51, 64], "sem_type": "Pharmacologic Substance", "tok_span": [11, 15], "new_tok_span": [14, 18]}, {"mention": "glibenclamide", "char_span": [158, 171], "sem_type": "Pharmacologic Substance", "tok_span": [47, 51], "new_tok_span": [58, 62]}, {"mention": "SUR1", "char_span": [93, 97], "sem_type": "Gene or Genome", "tok_span": [27, 30], "new_tok_span": [34, 37]}, {"mention": "SUR1", "char_span": [218, 222], "sem_type": "Gene or Genome", "tok_span": [65, 68], "new_tok_span": [80, 83]}, {"mention": "ir", "char_span": [42, 44], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 10], "new_tok_span": [10, 11]}, {"mention": "IR", "char_span": [86, 88], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [26, 27]}, {"mention": "IR", "char_span": [137, 139], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 38], "new_tok_span": [46, 47]}, {"mention": "IR", "char_span": [193, 195], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [57, 58], "new_tok_span": [70, 71]}], "new_text": "The L0 linker has been reported to be <START=Amino Acid, Peptide, or Protein> required <END=Amino Acid, Peptide, or Protein> for <START=Pharmacologic Substance> glibenclamide <END=Pharmacologic Substance> binding, and DeltaNK ( <START=Amino Acid, Peptide, or Protein> IR <END=Amino Acid, Peptide, or Protein> ) 6. 2 / <START=Gene or Genome> SUR1 <END=Gene or Genome> channels exhibit reduced labeling of K ( <START=Amino Acid, Peptide, or Protein> IR <END=Amino Acid, Peptide, or Protein> ) with ( 125 ) I - azido <START=Pharmacologic Substance>glibenclamide <END=Pharmacologic Substance>, implying that the K ( <START=Amino Acid, Peptide, or Protein> IR <END=Amino Acid, Peptide, or Protein> ) N terminus and L0 of <START=Gene or Genome> SUR1 <END=Gene or Genome> are in proximity."}, {"PMID": 15078100, "id": 0, "text": "Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [21, 28], "name": "quinone", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"ent_type": "CHEMICAL", "char_span": [85, 95], "name": "quinolines", "tok_span": [21, 24], "new_tok_span": [27, 30]}, {"ent_type": "GENE", "char_span": [21, 45], "name": "quinone oxidoreductase 2", "tok_span": [5, 12], "new_tok_span": [6, 13]}], "relation_list": [{"subject": "quinolines", "sbj_char_span": [85, 95], "object": "quinone oxidoreductase 2", "obj_char_span": [21, 45], "rel_type": "inhibitor", "sbj_tok_span": [21, 24], "obj_tok_span": [5, 12], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [6, 13]}], "umls_entity_list": [{"mention": "quinone oxidoreductase 2", "char_span": [21, 45], "sem_type": "Pharmacologic Substance", "tok_span": [5, 12], "new_tok_span": [6, 13]}, {"mention": "antimalarial", "char_span": [72, 84], "sem_type": "Pharmacologic Substance", "tok_span": [17, 21], "new_tok_span": [20, 24]}, {"mention": "quinolines", "char_span": [85, 95], "sem_type": "Organic Chemical", "tok_span": [21, 24], "new_tok_span": [27, 30]}, {"mention": "quinolines", "char_span": [85, 95], "sem_type": "Pharmacologic Substance", "tok_span": [21, 24], "new_tok_span": [27, 30]}], "new_text": "Kinetic mechanism of <START=Pharmacologic Substance> quinone oxidoreductase 2 <END=Pharmacologic Substance> and its inhibition by the <START=Pharmacologic Substance> antimalarial <END=Pharmacologic Substance> <START=Organic Chemical> <START=Pharmacologic Substance> quinolines <END=Organic Chemical> <END=Pharmacologic Substance>."}, {"PMID": 23547652, "id": 1, "text": "Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have been the most effective histone deacetylase inhibitors (HDACi) to date.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [47, 51], "name": "zinc", "tok_span": [8, 9], "new_tok_span": [10, 11]}, {"ent_type": "GENE", "char_span": [101, 120], "name": "histone deacetylase", "tok_span": [20, 24], "new_tok_span": [23, 27]}, {"ent_type": "GENE", "char_span": [133, 137], "name": "HDAC", "tok_span": [26, 27], "new_tok_span": [30, 31]}], "relation_list": [{"subject": "zinc", "sbj_char_span": [47, 51], "object": "histone deacetylase", "obj_char_span": [101, 120], "rel_type": "inhibitor", "sbj_tok_span": [8, 9], "obj_tok_span": [20, 24], "new_sbj_tok_span": [10, 11], "new_obj_tok_span": [23, 27]}, {"subject": "zinc", "sbj_char_span": [47, 51], "object": "HDAC", "obj_char_span": [133, 137], "rel_type": "inhibitor", "sbj_tok_span": [8, 9], "obj_tok_span": [26, 27], "new_sbj_tok_span": [10, 11], "new_obj_tok_span": [30, 31]}], "umls_entity_list": [{"mention": "hydroxamic acid", "char_span": [24, 39], "sem_type": "Organic Chemical", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "histone deacetylase inhibitors", "char_span": [101, 131], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 25], "new_tok_span": [23, 28]}], "new_text": "Small molecules bearing <START=Organic Chemical> hydroxamic acid <END=Organic Chemical> as the zinc binding group ( ZBG ) have been the most effective <START=Amino Acid, Peptide, or Protein> histone deacetylase inhibitors <END=Amino Acid, Peptide, or Protein> ( HDACi ) to date."}, {"PMID": 23382458, "id": 2, "text": "In human permeability glycoprotein (P-gp)- and breast cancer resistance protein (BCRP)-cDNA-transfected cell monolayers as well as Caco-2 cell monolayers, the apparent efflux ratio of basolateral-to-apical (PcB-A) versus apical-to-basolateral permeability (PcA-B) of apixaban was >10.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [267, 275], "name": "apixaban", "tok_span": [67, 70], "new_tok_span": [80, 83]}, {"ent_type": "GENE", "char_span": [3, 34], "name": "human permeability glycoprotein", "tok_span": [1, 4], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [36, 40], "name": "P-gp", "tok_span": [5, 8], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [47, 79], "name": "breast cancer resistance protein", "tok_span": [11, 15], "new_tok_span": [15, 19]}, {"ent_type": "GENE", "char_span": [81, 85], "name": "BCRP", "tok_span": [16, 18], "new_tok_span": [22, 24]}], "relation_list": [{"subject": "apixaban", "sbj_char_span": [267, 275], "object": "human permeability glycoprotein", "obj_char_span": [3, 34], "rel_type": "product or substrate", "sbj_tok_span": [67, 70], "obj_tok_span": [1, 4], "new_sbj_tok_span": [80, 83], "new_obj_tok_span": [1, 4]}, {"subject": "apixaban", "sbj_char_span": [267, 275], "object": "P-gp", "obj_char_span": [36, 40], "rel_type": "product or substrate", "sbj_tok_span": [67, 70], "obj_tok_span": [5, 8], "new_sbj_tok_span": [80, 83], "new_obj_tok_span": [7, 10]}, {"subject": "apixaban", "sbj_char_span": [267, 275], "object": "breast cancer resistance protein", "obj_char_span": [47, 79], "rel_type": "product or substrate", "sbj_tok_span": [67, 70], "obj_tok_span": [11, 15], "new_sbj_tok_span": [80, 83], "new_obj_tok_span": [15, 19]}, {"subject": "apixaban", "sbj_char_span": [267, 275], "object": "BCRP", "obj_char_span": [81, 85], "rel_type": "product or substrate", "sbj_tok_span": [67, 70], "obj_tok_span": [16, 18], "new_sbj_tok_span": [80, 83], "new_obj_tok_span": [22, 24]}], "umls_entity_list": [{"mention": "glycoprotein", "char_span": [22, 34], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 4], "new_tok_span": [4, 5]}, {"mention": "breast cancer resistance protein", "char_span": [47, 79], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 15], "new_tok_span": [15, 19]}, {"mention": "breast cancer resistance protein", "char_span": [47, 79], "sem_type": "Gene or Genome", "tok_span": [11, 15], "new_tok_span": [15, 19]}, {"mention": "PcB", "char_span": [207, 210], "sem_type": "Organic Chemical", "tok_span": [47, 49], "new_tok_span": [56, 58]}, {"mention": "PcB", "char_span": [207, 210], "sem_type": "Pharmacologic Substance", "tok_span": [47, 49], "new_tok_span": [56, 58]}, {"mention": "PcB", "char_span": [207, 210], "sem_type": "Gene or Genome", "tok_span": [47, 49], "new_tok_span": [56, 58]}, {"mention": "apixaban", "char_span": [267, 275], "sem_type": "Pharmacologic Substance", "tok_span": [67, 70], "new_tok_span": [80, 83]}], "new_text": "In human permeability <START=Amino Acid, Peptide, or Protein> glycoprotein <END=Amino Acid, Peptide, or Protein> ( P - gp ) - and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> breast cancer resistance protein <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( BCRP ) - cDNA - transfected cell monolayers as well as Caco - 2 cell monolayers, the apparent efflux ratio of basolateral - to - apical ( <START=Organic Chemical> <START=Pharmacologic Substance> <START=Gene or Genome> PcB <END=Organic Chemical> <END=Pharmacologic Substance> <END=Gene or Genome> - A ) versus apical - to - basolateral permeability ( PcA - B ) of <START=Pharmacologic Substance> apixaban <END=Pharmacologic Substance> was > 10."}, {"PMID": 16982784, "id": 4, "text": "Unexpectedly, 58% of amino acid variants at position 104 in SHV expressed in Escherichia coli DH10B resulted in beta-lactamases with lowered resistance to ampicillin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [21, 31], "name": "amino acid", "tok_span": [8, 10], "new_tok_span": [8, 10]}, {"ent_type": "CHEMICAL", "char_span": [155, 165], "name": "ampicillin", "tok_span": [35, 37], "new_tok_span": [37, 39]}, {"ent_type": "GENE", "char_span": [60, 63], "name": "SHV", "tok_span": [15, 17], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [112, 127], "name": "beta-lactamases", "tok_span": [26, 31], "new_tok_span": [27, 32]}], "relation_list": [{"subject": "amino acid", "sbj_char_span": [21, 31], "object": "SHV", "obj_char_span": [60, 63], "rel_type": "part of", "sbj_tok_span": [8, 10], "obj_tok_span": [15, 17], "new_sbj_tok_span": [8, 10], "new_obj_tok_span": [15, 17]}], "umls_entity_list": [{"mention": "beta-lactamase", "char_span": [112, 126], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 31], "new_tok_span": [27, 32]}], "new_text": "Unexpectedly, 58 % of amino acid variants at position 104 in SHV expressed in Escherichia coli DH10B resulted in <START=Amino Acid, Peptide, or Protein> beta - lactamases <END=Amino Acid, Peptide, or Protein> with lowered resistance to ampicillin."}, {"PMID": 6311012, "id": 13, "text": "This agent acts synergistically with many penicillins, such as ampicillin, carbenicillin, and the like, and with cephalosporins, cefazolin, cefamandole, or cefoxitin to inhibit gram-negative bacilli, probably on the basis of binding to different proteins needed for the production of the peptidoglycan of the bacterial cell wall.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 53], "name": "penicillins", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"ent_type": "CHEMICAL", "char_span": [63, 73], "name": "ampicillin", "tok_span": [12, 14], "new_tok_span": [15, 17]}, {"ent_type": "CHEMICAL", "char_span": [75, 88], "name": "carbenicillin", "tok_span": [15, 18], "new_tok_span": [20, 23]}, {"ent_type": "CHEMICAL", "char_span": [113, 127], "name": "cephalosporins", "tok_span": [25, 28], "new_tok_span": [32, 35]}, {"ent_type": "CHEMICAL", "char_span": [129, 138], "name": "cefazolin", "tok_span": [29, 32], "new_tok_span": [38, 41]}, {"ent_type": "CHEMICAL", "char_span": [140, 151], "name": "cefamandole", "tok_span": [33, 37], "new_tok_span": [44, 48]}, {"ent_type": "CHEMICAL", "char_span": [156, 165], "name": "cefoxitin", "tok_span": [39, 42], "new_tok_span": [52, 55]}, {"ent_type": "GENE", "char_span": [288, 301], "name": "peptidoglycan", "tok_span": [65, 69], "new_tok_span": [80, 84]}], "relation_list": [{"subject": "penicillins", "sbj_char_span": [42, 53], "object": "peptidoglycan", "obj_char_span": [288, 301], "rel_type": "regulator", "sbj_tok_span": [7, 9], "obj_tok_span": [65, 69], "new_sbj_tok_span": [8, 10], "new_obj_tok_span": [80, 84]}, {"subject": "ampicillin", "sbj_char_span": [63, 73], "object": "peptidoglycan", "obj_char_span": [288, 301], "rel_type": "regulator", "sbj_tok_span": [12, 14], "obj_tok_span": [65, 69], "new_sbj_tok_span": [15, 17], "new_obj_tok_span": [80, 84]}, {"subject": "carbenicillin", "sbj_char_span": [75, 88], "object": "peptidoglycan", "obj_char_span": [288, 301], "rel_type": "regulator", "sbj_tok_span": [15, 18], "obj_tok_span": [65, 69], "new_sbj_tok_span": [20, 23], "new_obj_tok_span": [80, 84]}, {"subject": "cephalosporins", "sbj_char_span": [113, 127], "object": "peptidoglycan", "obj_char_span": [288, 301], "rel_type": "regulator", "sbj_tok_span": [25, 28], "obj_tok_span": [65, 69], "new_sbj_tok_span": [32, 35], "new_obj_tok_span": [80, 84]}, {"subject": "cefazolin", "sbj_char_span": [129, 138], "object": "peptidoglycan", "obj_char_span": [288, 301], "rel_type": "regulator", "sbj_tok_span": [29, 32], "obj_tok_span": [65, 69], "new_sbj_tok_span": [38, 41], "new_obj_tok_span": [80, 84]}, {"subject": "cefamandole", "sbj_char_span": [140, 151], "object": "peptidoglycan", "obj_char_span": [288, 301], "rel_type": "regulator", "sbj_tok_span": [33, 37], "obj_tok_span": [65, 69], "new_sbj_tok_span": [44, 48], "new_obj_tok_span": [80, 84]}, {"subject": "cefoxitin", "sbj_char_span": [156, 165], "object": "peptidoglycan", "obj_char_span": [288, 301], "rel_type": "regulator", "sbj_tok_span": [39, 42], "obj_tok_span": [65, 69], "new_sbj_tok_span": [52, 55], "new_obj_tok_span": [80, 84]}], "umls_entity_list": [{"mention": "penicillins", "char_span": [42, 53], "sem_type": "Organic Chemical", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"mention": "ampicillin", "char_span": [63, 73], "sem_type": "Organic Chemical", "tok_span": [12, 14], "new_tok_span": [15, 17]}, {"mention": "carbenicillin", "char_span": [75, 88], "sem_type": "Organic Chemical", "tok_span": [15, 18], "new_tok_span": [20, 23]}, {"mention": "cephalosporins", "char_span": [113, 127], "sem_type": "Organic Chemical", "tok_span": [25, 28], "new_tok_span": [32, 35]}, {"mention": "cefazolin", "char_span": [129, 138], "sem_type": "Organic Chemical", "tok_span": [29, 32], "new_tok_span": [38, 41]}, {"mention": "cefamandole", "char_span": [140, 151], "sem_type": "Organic Chemical", "tok_span": [33, 37], "new_tok_span": [44, 48]}, {"mention": "cefoxitin", "char_span": [156, 165], "sem_type": "Organic Chemical", "tok_span": [39, 42], "new_tok_span": [52, 55]}, {"mention": "peptidoglycan", "char_span": [288, 301], "sem_type": "Organic Chemical", "tok_span": [65, 69], "new_tok_span": [80, 84]}], "new_text": "This agent acts synergistically with many <START=Organic Chemical> penicillins <END=Organic Chemical>, such as <START=Organic Chemical> ampicillin <END=Organic Chemical>, <START=Organic Chemical> carbenicillin <END=Organic Chemical>, and the like, and with <START=Organic Chemical> cephalosporins <END=Organic Chemical>, <START=Organic Chemical> cefazolin <END=Organic Chemical>, <START=Organic Chemical> cefamandole <END=Organic Chemical>, or <START=Organic Chemical> cefoxitin <END=Organic Chemical> to inhibit gram - negative bacilli, probably on the basis of binding to different proteins needed for the production of the <START=Organic Chemical> peptidoglycan <END=Organic Chemical> of the bacterial cell wall."}, {"PMID": 23515287, "id": 9, "text": "These results indicate that 3β-diol induces OT promoter activity via ER-β-cHRE interactions.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 35], "name": "3β-diol", "tok_span": [4, 9], "new_tok_span": [4, 9]}, {"ent_type": "GENE", "char_span": [44, 55], "name": "OT promoter", "tok_span": [10, 12], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [69, 73], "name": "ER-β", "tok_span": [14, 17], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [74, 78], "name": "cHRE", "tok_span": [18, 21], "new_tok_span": [18, 21]}], "relation_list": [{"subject": "3β-diol", "sbj_char_span": [28, 35], "object": "OT promoter", "obj_char_span": [44, 55], "rel_type": "activator", "sbj_tok_span": [4, 9], "obj_tok_span": [10, 12], "new_sbj_tok_span": [4, 9], "new_obj_tok_span": [10, 12]}, {"subject": "3β-diol", "sbj_char_span": [28, 35], "object": "ER-β", "obj_char_span": [69, 73], "rel_type": "activator", "sbj_tok_span": [4, 9], "obj_tok_span": [14, 17], "new_sbj_tok_span": [4, 9], "new_obj_tok_span": [14, 17]}, {"subject": "3β-diol", "sbj_char_span": [28, 35], "object": "cHRE", "obj_char_span": [74, 78], "rel_type": "activator", "sbj_tok_span": [4, 9], "obj_tok_span": [18, 21], "new_sbj_tok_span": [4, 9], "new_obj_tok_span": [18, 21]}], "umls_entity_list": [], "new_text": "These results indicate that 3β - diol induces OT promoter activity via ER - β - cHRE interactions."}, {"PMID": 15680478, "id": 7, "text": "We found that Ac-[Ser117]Lep116-140-NH2 (V) differentially activates CART neurons through the rostrocaudal extension of the arcuate nucleus.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [36, 39], "name": "NH2", "tok_span": [15, 17], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [69, 73], "name": "CART", "tok_span": [22, 24], "new_tok_span": [32, 34]}], "relation_list": [{"subject": "NH2", "sbj_char_span": [36, 39], "object": "CART", "obj_char_span": [69, 73], "rel_type": "activator", "sbj_tok_span": [15, 17], "obj_tok_span": [22, 24], "new_sbj_tok_span": [19, 21], "new_obj_tok_span": [32, 34]}], "umls_entity_list": [{"mention": "Ac", "char_span": [14, 16], "sem_type": "Gene or Genome", "tok_span": [3, 4], "new_tok_span": [5, 6]}, {"mention": "ac", "char_span": [59, 61], "sem_type": "Gene or Genome", "tok_span": [21, 22], "new_tok_span": [27, 28]}, {"mention": "Ac", "char_span": [14, 16], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 4], "new_tok_span": [5, 6]}, {"mention": "ac", "char_span": [59, 61], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [27, 28]}, {"mention": "CART", "char_span": [69, 73], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 24], "new_tok_span": [32, 34]}, {"mention": "CART", "char_span": [69, 73], "sem_type": "Gene or Genome", "tok_span": [22, 24], "new_tok_span": [32, 34]}], "new_text": "We found that <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Ac <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - [ Ser117 ] Lep116 - 140 - NH2 ( V ) differentially <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> activates <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> CART <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> neurons through the rostrocaudal extension of the arcuate nucleus."}, {"PMID": 23265191, "id": 2, "text": "In eukaryotes, Fe-S clusters are synthesized by the mitochondrial iron-sulfur cluster (ISC) machinery and the cytosolic iron-sulfur assembly (CIA) system.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [66, 77], "name": "iron-sulfur", "tok_span": [12, 15], "new_tok_span": [13, 16]}, {"ent_type": "CHEMICAL", "char_span": [120, 131], "name": "iron-sulfur", "tok_span": [24, 27], "new_tok_span": [29, 32]}, {"ent_type": "CHEMICAL", "char_span": [15, 19], "name": "Fe-S", "tok_span": [3, 6], "new_tok_span": [3, 6]}, {"ent_type": "GENE", "char_span": [52, 85], "name": "mitochondrial iron-sulfur cluster", "tok_span": [11, 16], "new_tok_span": [11, 16]}, {"ent_type": "GENE", "char_span": [87, 90], "name": "ISC", "tok_span": [17, 19], "new_tok_span": [21, 23]}, {"ent_type": "GENE", "char_span": [110, 140], "name": "cytosolic iron-sulfur assembly", "tok_span": [23, 28], "new_tok_span": [27, 32]}, {"ent_type": "GENE", "char_span": [142, 145], "name": "CIA", "tok_span": [29, 31], "new_tok_span": [37, 39]}], "relation_list": [{"subject": "Fe-S", "sbj_char_span": [15, 19], "object": "mitochondrial iron-sulfur cluster", "obj_char_span": [52, 85], "rel_type": "product or substrate", "sbj_tok_span": [3, 6], "obj_tok_span": [11, 16], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [11, 16]}, {"subject": "Fe-S", "sbj_char_span": [15, 19], "object": "ISC", "obj_char_span": [87, 90], "rel_type": "product or substrate", "sbj_tok_span": [3, 6], "obj_tok_span": [17, 19], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [21, 23]}, {"subject": "Fe-S", "sbj_char_span": [15, 19], "object": "cytosolic iron-sulfur assembly", "obj_char_span": [110, 140], "rel_type": "product or substrate", "sbj_tok_span": [3, 6], "obj_tok_span": [23, 28], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [27, 32]}, {"subject": "Fe-S", "sbj_char_span": [15, 19], "object": "CIA", "obj_char_span": [142, 145], "rel_type": "product or substrate", "sbj_tok_span": [3, 6], "obj_tok_span": [29, 31], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [37, 39]}], "umls_entity_list": [{"mention": "iron", "char_span": [66, 70], "sem_type": "Pharmacologic Substance", "tok_span": [12, 13], "new_tok_span": [13, 14]}, {"mention": "iron", "char_span": [120, 124], "sem_type": "Pharmacologic Substance", "tok_span": [24, 25], "new_tok_span": [29, 30]}, {"mention": "sulfur", "char_span": [71, 77], "sem_type": "Pharmacologic Substance", "tok_span": [14, 15], "new_tok_span": [17, 18]}, {"mention": "sulfur", "char_span": [125, 131], "sem_type": "Pharmacologic Substance", "tok_span": [26, 27], "new_tok_span": [33, 34]}], "new_text": "In eukaryotes, Fe - S clusters are synthesized by the mitochondrial <START=Pharmacologic Substance> iron <END=Pharmacologic Substance> - <START=Pharmacologic Substance> sulfur <END=Pharmacologic Substance> cluster ( ISC ) machinery and the cytosolic <START=Pharmacologic Substance> iron <END=Pharmacologic Substance> - <START=Pharmacologic Substance> sulfur <END=Pharmacologic Substance> assembly ( CIA ) system."}, {"PMID": 12213059, "id": 3, "text": "Several compounds, e.g., 3-propylamino- (30), 3-isopropylamino- (34), 3-(S)-sec-butylamino- (37), and 3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (53), which were found to be potent and beta-cell selective activators of K(ATP) channels in vitro, were found to inhibit insulin secretion in rats with minimal effects on blood pressure and to exhibit good oral pharmacokinetic properties.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [70, 90], "name": "3-(S)-sec-butylamino", "tok_span": [29, 40], "new_tok_span": [29, 40]}, {"ent_type": "CHEMICAL", "char_span": [102, 177], "name": "3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "tok_span": [46, 84], "new_tok_span": [46, 84]}, {"ent_type": "CHEMICAL", "char_span": [252, 253], "name": "K", "tok_span": [102, 103], "new_tok_span": [102, 103]}, {"ent_type": "CHEMICAL", "char_span": [254, 257], "name": "ATP", "tok_span": [104, 105], "new_tok_span": [104, 105]}, {"ent_type": "CHEMICAL", "char_span": [25, 38], "name": "3-propylamino", "tok_span": [8, 13], "new_tok_span": [8, 13]}, {"ent_type": "CHEMICAL", "char_span": [46, 62], "name": "3-isopropylamino", "tok_span": [18, 24], "new_tok_span": [18, 24]}, {"ent_type": "GENE", "char_span": [252, 267], "name": "K(ATP) channels", "tok_span": [102, 107], "new_tok_span": [102, 107]}, {"ent_type": "GENE", "char_span": [300, 307], "name": "insulin", "tok_span": [114, 115], "new_tok_span": [114, 115]}], "relation_list": [{"subject": "3-propylamino", "sbj_char_span": [25, 38], "object": "K(ATP) channels", "obj_char_span": [252, 267], "rel_type": "activator", "sbj_tok_span": [8, 13], "obj_tok_span": [102, 107], "new_sbj_tok_span": [8, 13], "new_obj_tok_span": [102, 107]}, {"subject": "3-isopropylamino", "sbj_char_span": [46, 62], "object": "K(ATP) channels", "obj_char_span": [252, 267], "rel_type": "activator", "sbj_tok_span": [18, 24], "obj_tok_span": [102, 107], "new_sbj_tok_span": [18, 24], "new_obj_tok_span": [102, 107]}, {"subject": "3-(S)-sec-butylamino", "sbj_char_span": [70, 90], "object": "K(ATP) channels", "obj_char_span": [252, 267], "rel_type": "activator", "sbj_tok_span": [29, 40], "obj_tok_span": [102, 107], "new_sbj_tok_span": [29, 40], "new_obj_tok_span": [102, 107]}, {"subject": "3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "sbj_char_span": [102, 177], "object": "K(ATP) channels", "obj_char_span": [252, 267], "rel_type": "activator", "sbj_tok_span": [46, 84], "obj_tok_span": [102, 107], "new_sbj_tok_span": [46, 84], "new_obj_tok_span": [102, 107]}, {"subject": "3-propylamino", "sbj_char_span": [25, 38], "object": "insulin", "obj_char_span": [300, 307], "rel_type": "regulator", "sbj_tok_span": [8, 13], "obj_tok_span": [114, 115], "new_sbj_tok_span": [8, 13], "new_obj_tok_span": [114, 115]}, {"subject": "3-isopropylamino", "sbj_char_span": [46, 62], "object": "insulin", "obj_char_span": [300, 307], "rel_type": "regulator", "sbj_tok_span": [18, 24], "obj_tok_span": [114, 115], "new_sbj_tok_span": [18, 24], "new_obj_tok_span": [114, 115]}, {"subject": "3-(S)-sec-butylamino", "sbj_char_span": [70, 90], "object": "insulin", "obj_char_span": [300, 307], "rel_type": "regulator", "sbj_tok_span": [29, 40], "obj_tok_span": [114, 115], "new_sbj_tok_span": [29, 40], "new_obj_tok_span": [114, 115]}, {"subject": "3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "sbj_char_span": [102, 177], "object": "insulin", "obj_char_span": [300, 307], "rel_type": "regulator", "sbj_tok_span": [46, 84], "obj_tok_span": [114, 115], "new_sbj_tok_span": [46, 84], "new_obj_tok_span": [114, 115]}], "umls_entity_list": [], "new_text": "Several compounds, e. g., 3 - propylamino - ( 30 ), 3 - isopropylamino - ( 34 ), 3 - ( S ) - sec - butylamino - ( 37 ), and 3 - ( 1 - methylcyclopropyl ) amino - 4H - thieno [ 3, 2 - e ] - 1, 2, 4 - thiadiazine 1, 1 - dioxide ( 53 ), which were found to be potent and beta - cell selective activators of K ( ATP ) channels in vitro, were found to inhibit insulin secretion in rats with minimal effects on blood pressure and to exhibit good oral pharmacokinetic properties."}, {"PMID": 23259865, "id": 2, "text": "This report documents the design, synthesis, and evaluation of new indenoisoquinolines that are dual inhibitors of both Tdp1 and Top1.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [67, 86], "name": "indenoisoquinolines", "tok_span": [12, 18], "new_tok_span": [12, 18]}, {"ent_type": "GENE", "char_span": [120, 124], "name": "Tdp1", "tok_span": [24, 28], "new_tok_span": [24, 28]}, {"ent_type": "GENE", "char_span": [129, 133], "name": "Top1", "tok_span": [29, 31], "new_tok_span": [29, 31]}], "relation_list": [{"subject": "indenoisoquinolines", "sbj_char_span": [67, 86], "object": "Tdp1", "obj_char_span": [120, 124], "rel_type": "inhibitor", "sbj_tok_span": [12, 18], "obj_tok_span": [24, 28], "new_sbj_tok_span": [12, 18], "new_obj_tok_span": [24, 28]}, {"subject": "indenoisoquinolines", "sbj_char_span": [67, 86], "object": "Top1", "obj_char_span": [129, 133], "rel_type": "inhibitor", "sbj_tok_span": [12, 18], "obj_tok_span": [29, 31], "new_sbj_tok_span": [12, 18], "new_obj_tok_span": [29, 31]}], "umls_entity_list": [], "new_text": "This report documents the design, synthesis, and evaluation of new indenoisoquinolines that are dual inhibitors of both Tdp1 and Top1."}, {"PMID": 8842678, "id": 6, "text": "MAO-B was inhibited by the following drugs (in ascending order of potency): nortriptyline, imipramine, maprotiline, amitriptyline, zimeldine, nomifensine, and viloxazine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [76, 89], "name": "nortriptyline", "tok_span": [18, 22], "new_tok_span": [18, 22]}, {"ent_type": "CHEMICAL", "char_span": [91, 101], "name": "imipramine", "tok_span": [23, 27], "new_tok_span": [23, 27]}, {"ent_type": "CHEMICAL", "char_span": [103, 114], "name": "maprotiline", "tok_span": [28, 32], "new_tok_span": [28, 32]}, {"ent_type": "CHEMICAL", "char_span": [116, 129], "name": "amitriptyline", "tok_span": [33, 38], "new_tok_span": [33, 38]}, {"ent_type": "CHEMICAL", "char_span": [131, 140], "name": "zimeldine", "tok_span": [39, 43], "new_tok_span": [39, 43]}, {"ent_type": "CHEMICAL", "char_span": [142, 153], "name": "nomifensine", "tok_span": [44, 48], "new_tok_span": [44, 48]}, {"ent_type": "CHEMICAL", "char_span": [159, 169], "name": "viloxazine", "tok_span": [50, 54], "new_tok_span": [50, 54]}, {"ent_type": "GENE", "char_span": [0, 5], "name": "MAO-B", "tok_span": [0, 4], "new_tok_span": [0, 4]}], "relation_list": [{"subject": "nortriptyline", "sbj_char_span": [76, 89], "object": "MAO-B", "obj_char_span": [0, 5], "rel_type": "inhibitor", "sbj_tok_span": [18, 22], "obj_tok_span": [0, 4], "new_sbj_tok_span": [18, 22], "new_obj_tok_span": [0, 4]}, {"subject": "imipramine", "sbj_char_span": [91, 101], "object": "MAO-B", "obj_char_span": [0, 5], "rel_type": "inhibitor", "sbj_tok_span": [23, 27], "obj_tok_span": [0, 4], "new_sbj_tok_span": [23, 27], "new_obj_tok_span": [0, 4]}, {"subject": "maprotiline", "sbj_char_span": [103, 114], "object": "MAO-B", "obj_char_span": [0, 5], "rel_type": "inhibitor", "sbj_tok_span": [28, 32], "obj_tok_span": [0, 4], "new_sbj_tok_span": [28, 32], "new_obj_tok_span": [0, 4]}, {"subject": "amitriptyline", "sbj_char_span": [116, 129], "object": "MAO-B", "obj_char_span": [0, 5], "rel_type": "inhibitor", "sbj_tok_span": [33, 38], "obj_tok_span": [0, 4], "new_sbj_tok_span": [33, 38], "new_obj_tok_span": [0, 4]}, {"subject": "zimeldine", "sbj_char_span": [131, 140], "object": "MAO-B", "obj_char_span": [0, 5], "rel_type": "inhibitor", "sbj_tok_span": [39, 43], "obj_tok_span": [0, 4], "new_sbj_tok_span": [39, 43], "new_obj_tok_span": [0, 4]}, {"subject": "nomifensine", "sbj_char_span": [142, 153], "object": "MAO-B", "obj_char_span": [0, 5], "rel_type": "inhibitor", "sbj_tok_span": [44, 48], "obj_tok_span": [0, 4], "new_sbj_tok_span": [44, 48], "new_obj_tok_span": [0, 4]}, {"subject": "viloxazine", "sbj_char_span": [159, 169], "object": "MAO-B", "obj_char_span": [0, 5], "rel_type": "inhibitor", "sbj_tok_span": [50, 54], "obj_tok_span": [0, 4], "new_sbj_tok_span": [50, 54], "new_obj_tok_span": [0, 4]}], "umls_entity_list": [], "new_text": "MAO - B was inhibited by the following drugs ( in ascending order of potency ) : nortriptyline, imipramine, maprotiline, amitriptyline, zimeldine, nomifensine, and viloxazine."}, {"PMID": 23403092, "id": 0, "text": "The food contaminant deoxynivalenol activates the mitogen activated protein kinases in the intestine: interest of ex vivo models as an alternative to in vivo experiments.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [21, 35], "name": "deoxynivalenol", "tok_span": [4, 9], "new_tok_span": [5, 10]}, {"ent_type": "GENE", "char_span": [50, 83], "name": "mitogen activated protein kinases", "tok_span": [11, 15], "new_tok_span": [13, 17]}], "relation_list": [{"subject": "deoxynivalenol", "sbj_char_span": [21, 35], "object": "mitogen activated protein kinases", "obj_char_span": [50, 83], "rel_type": "activator", "sbj_tok_span": [4, 9], "obj_tok_span": [11, 15], "new_sbj_tok_span": [5, 10], "new_obj_tok_span": [13, 17]}], "umls_entity_list": [{"mention": "deoxynivalenol", "char_span": [21, 35], "sem_type": "Organic Chemical", "tok_span": [4, 9], "new_tok_span": [5, 10]}, {"mention": "alternative", "char_span": [135, 146], "sem_type": "Gene or Genome", "tok_span": [26, 27], "new_tok_span": [29, 30]}], "new_text": "The food contaminant <START=Organic Chemical> deoxynivalenol <END=Organic Chemical> activates the mitogen activated protein kinases in the intestine : interest of ex vivo models as an <START=Gene or Genome> alternative <END=Gene or Genome> to in vivo experiments."}, {"PMID": 17082235, "id": 2, "text": "Our work shows that sulfonylureas and glinides additionally bind to PPARgamma and exhibit PPARgamma agonistic activity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [20, 33], "name": "sulfonylureas", "tok_span": [4, 8], "new_tok_span": [4, 8]}, {"ent_type": "CHEMICAL", "char_span": [38, 46], "name": "glinides", "tok_span": [9, 12], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [68, 77], "name": "PPARgamma", "tok_span": [15, 17], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [90, 99], "name": "PPARgamma", "tok_span": [19, 21], "new_tok_span": [19, 21]}], "relation_list": [{"subject": "sulfonylureas", "sbj_char_span": [20, 33], "object": "PPARgamma", "obj_char_span": [68, 77], "rel_type": "regulator", "sbj_tok_span": [4, 8], "obj_tok_span": [15, 17], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [15, 17]}, {"subject": "glinides", "sbj_char_span": [38, 46], "object": "PPARgamma", "obj_char_span": [68, 77], "rel_type": "regulator", "sbj_tok_span": [9, 12], "obj_tok_span": [15, 17], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [15, 17]}, {"subject": "sulfonylureas", "sbj_char_span": [20, 33], "object": "PPARgamma", "obj_char_span": [90, 99], "rel_type": "agonist or antagonist", "sbj_tok_span": [4, 8], "obj_tok_span": [19, 21], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [19, 21]}, {"subject": "glinides", "sbj_char_span": [38, 46], "object": "PPARgamma", "obj_char_span": [90, 99], "rel_type": "agonist or antagonist", "sbj_tok_span": [9, 12], "obj_tok_span": [19, 21], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [19, 21]}], "umls_entity_list": [], "new_text": "Our work shows that sulfonylureas and glinides additionally bind to PPARgamma and exhibit PPARgamma agonistic activity."}, {"PMID": 23591125, "id": 3, "text": "The induced 'ischemic depression' was lasting and sensitive to an acute administration of brain-derived neurotrophic factor or bryostatin-1, a relatively selective activator of protein kinase Cε, during the induction phase.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [127, 139], "name": "bryostatin-1", "tok_span": [22, 28], "new_tok_span": [24, 30]}, {"ent_type": "GENE", "char_span": [90, 123], "name": "brain-derived neurotrophic factor", "tok_span": [15, 21], "new_tok_span": [16, 22]}, {"ent_type": "GENE", "char_span": [177, 194], "name": "protein kinase Cε", "tok_span": [34, 38], "new_tok_span": [36, 40]}], "relation_list": [{"subject": "bryostatin-1", "sbj_char_span": [127, 139], "object": "protein kinase Cε", "obj_char_span": [177, 194], "rel_type": "activator", "sbj_tok_span": [22, 28], "obj_tok_span": [34, 38], "new_sbj_tok_span": [24, 30], "new_obj_tok_span": [36, 40]}], "umls_entity_list": [{"mention": "brain-derived neurotrophic factor", "char_span": [90, 123], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 21], "new_tok_span": [16, 22]}], "new_text": "The induced'ischemic depression'was lasting and sensitive to an acute administration of <START=Amino Acid, Peptide, or Protein> brain - derived neurotrophic factor <END=Amino Acid, Peptide, or Protein> or bryostatin - 1, a relatively selective activator of protein kinase Cε, during the induction phase."}, {"PMID": 17581967, "id": 1, "text": "Kainate-selective ionotropic glutamate receptors (GluRs) require external Na+ and Cl- as well as the neurotransmitter L-glutamate for activation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 7], "name": "Kainate", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "CHEMICAL", "char_span": [118, 129], "name": "L-glutamate", "tok_span": [25, 28], "new_tok_span": [27, 30]}, {"ent_type": "CHEMICAL", "char_span": [29, 38], "name": "glutamate", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [74, 77], "name": "Na+", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"ent_type": "CHEMICAL", "char_span": [82, 85], "name": "Cl-", "tok_span": [17, 19], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [0, 48], "name": "Kainate-selective ionotropic glutamate receptors", "tok_span": [0, 8], "new_tok_span": [0, 8]}, {"ent_type": "GENE", "char_span": [50, 55], "name": "GluRs", "tok_span": [9, 11], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "Na+", "sbj_char_span": [74, 77], "object": "Kainate-selective ionotropic glutamate receptors", "obj_char_span": [0, 48], "rel_type": "activator", "sbj_tok_span": [14, 16], "obj_tok_span": [0, 8], "new_sbj_tok_span": [16, 18], "new_obj_tok_span": [0, 8]}, {"subject": "Cl-", "sbj_char_span": [82, 85], "object": "Kainate-selective ionotropic glutamate receptors", "obj_char_span": [0, 48], "rel_type": "activator", "sbj_tok_span": [17, 19], "obj_tok_span": [0, 8], "new_sbj_tok_span": [19, 21], "new_obj_tok_span": [0, 8]}, {"subject": "L-glutamate", "sbj_char_span": [118, 129], "object": "Kainate-selective ionotropic glutamate receptors", "obj_char_span": [0, 48], "rel_type": "activator", "sbj_tok_span": [25, 28], "obj_tok_span": [0, 8], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [0, 8]}, {"subject": "Na+", "sbj_char_span": [74, 77], "object": "GluRs", "obj_char_span": [50, 55], "rel_type": "activator", "sbj_tok_span": [14, 16], "obj_tok_span": [9, 11], "new_sbj_tok_span": [16, 18], "new_obj_tok_span": [11, 13]}, {"subject": "Cl-", "sbj_char_span": [82, 85], "object": "GluRs", "obj_char_span": [50, 55], "rel_type": "activator", "sbj_tok_span": [17, 19], "obj_tok_span": [9, 11], "new_sbj_tok_span": [19, 21], "new_obj_tok_span": [11, 13]}, {"subject": "L-glutamate", "sbj_char_span": [118, 129], "object": "GluRs", "obj_char_span": [50, 55], "rel_type": "activator", "sbj_tok_span": [25, 28], "obj_tok_span": [9, 11], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [{"mention": "eceptors", "char_span": [40, 48], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 8], "new_tok_span": [8, 9]}], "new_text": "Kainate - selective ionotropic glutamate <START=Amino Acid, Peptide, or Protein> receptors <END=Amino Acid, Peptide, or Protein> ( GluRs ) require external Na + and Cl - as well as the neurotransmitter L - glutamate for activation."}, {"PMID": 23239555, "id": 3, "text": "Here we present boronic and borinic acid derivatives as a new class of potent and nontoxic APT inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [16, 23], "name": "boronic", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [28, 40], "name": "borinic acid", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [91, 94], "name": "APT", "tok_span": [22, 24], "new_tok_span": [24, 26]}], "relation_list": [{"subject": "boronic", "sbj_char_span": [16, 23], "object": "APT", "obj_char_span": [91, 94], "rel_type": "inhibitor", "sbj_tok_span": [3, 5], "obj_tok_span": [22, 24], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [24, 26]}, {"subject": "borinic acid", "sbj_char_span": [28, 40], "object": "APT", "obj_char_span": [91, 94], "rel_type": "inhibitor", "sbj_tok_span": [6, 10], "obj_tok_span": [22, 24], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [24, 26]}], "umls_entity_list": [{"mention": "APT", "char_span": [91, 94], "sem_type": "Pharmacologic Substance", "tok_span": [22, 24], "new_tok_span": [24, 26]}, {"mention": "APT", "char_span": [91, 94], "sem_type": "Gene or Genome", "tok_span": [22, 24], "new_tok_span": [24, 26]}], "new_text": "Here we present boronic and borinic acid derivatives as a new class of potent and nontoxic <START=Pharmacologic Substance> <START=Gene or Genome> APT <END=Pharmacologic Substance> <END=Gene or Genome> inhibitors."}, {"PMID": 10401556, "id": 7, "text": "Combined concentration-ratio analysis demonstrated that tamsulosin, which does not discriminate between alpha 1A- and alpha 1L-adrenoceptors, and RS-17053 competed for binding at the same site in the SMA. 7.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [56, 66], "name": "tamsulosin", "tok_span": [7, 11], "new_tok_span": [7, 11]}, {"ent_type": "CHEMICAL", "char_span": [146, 154], "name": "RS-17053", "tok_span": [32, 36], "new_tok_span": [39, 43]}, {"ent_type": "GENE", "char_span": [104, 112], "name": "alpha 1A", "tok_span": [17, 20], "new_tok_span": [18, 21]}, {"ent_type": "GENE", "char_span": [118, 140], "name": "alpha 1L-adrenoceptors", "tok_span": [22, 30], "new_tok_span": [25, 33]}], "relation_list": [{"subject": "tamsulosin", "sbj_char_span": [56, 66], "object": "alpha 1A", "obj_char_span": [104, 112], "rel_type": "regulator", "sbj_tok_span": [7, 11], "obj_tok_span": [17, 20], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [18, 21]}, {"subject": "tamsulosin", "sbj_char_span": [56, 66], "object": "alpha 1L-adrenoceptors", "obj_char_span": [118, 140], "rel_type": "regulator", "sbj_tok_span": [7, 11], "obj_tok_span": [22, 30], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [25, 33]}, {"subject": "RS-17053", "sbj_char_span": [146, 154], "object": "alpha 1A", "obj_char_span": [104, 112], "rel_type": "regulator", "sbj_tok_span": [32, 36], "obj_tok_span": [17, 20], "new_sbj_tok_span": [39, 43], "new_obj_tok_span": [18, 21]}, {"subject": "RS-17053", "sbj_char_span": [146, 154], "object": "alpha 1L-adrenoceptors", "obj_char_span": [118, 140], "rel_type": "regulator", "sbj_tok_span": [32, 36], "obj_tok_span": [22, 30], "new_sbj_tok_span": [39, 43], "new_obj_tok_span": [25, 33]}], "umls_entity_list": [{"mention": "alpha", "char_span": [104, 109], "sem_type": "Pharmacologic Substance", "tok_span": [17, 18], "new_tok_span": [18, 19]}, {"mention": "alpha", "char_span": [118, 123], "sem_type": "Pharmacologic Substance", "tok_span": [22, 23], "new_tok_span": [25, 26]}, {"mention": "rs", "char_span": [138, 140], "sem_type": "Pharmacologic Substance", "tok_span": [28, 30], "new_tok_span": [33, 35]}, {"mention": "RS", "char_span": [146, 148], "sem_type": "Pharmacologic Substance", "tok_span": [32, 33], "new_tok_span": [39, 40]}, {"mention": "SMA", "char_span": [200, 203], "sem_type": "Gene or Genome", "tok_span": [46, 47], "new_tok_span": [56, 57]}, {"mention": "SMA", "char_span": [200, 203], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [46, 47], "new_tok_span": [56, 57]}], "new_text": "Combined concentration - ratio analysis demonstrated that tamsulosin, which does not discriminate between <START=Pharmacologic Substance> alpha <END=Pharmacologic Substance> 1A - and <START=Pharmacologic Substance> alpha <END=Pharmacologic Substance> 1L - adrenoc <START=Pharmacologic Substance>eptors <END=Pharmacologic Substance>, and <START=Pharmacologic Substance> RS <END=Pharmacologic Substance> - 17053 competed for binding at the same site in the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> SMA <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. 7."}, {"PMID": 11319232, "id": 4, "text": "Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [33, 49], "name": "N-ethylmaleimide", "tok_span": [5, 10], "new_tok_span": [5, 10]}, {"ent_type": "GENE", "char_span": [67, 71], "name": "ACS4", "tok_span": [14, 16], "new_tok_span": [17, 19]}, {"ent_type": "GENE", "char_span": [83, 86], "name": "ACS", "tok_span": [18, 19], "new_tok_span": [26, 27]}], "relation_list": [{"subject": "N-ethylmaleimide", "sbj_char_span": [33, 49], "object": "ACS4", "obj_char_span": [67, 71], "rel_type": "inhibitor", "sbj_tok_span": [5, 10], "obj_tok_span": [14, 16], "new_sbj_tok_span": [5, 10], "new_obj_tok_span": [17, 19]}, {"subject": "N-ethylmaleimide", "sbj_char_span": [33, 49], "object": "ACS", "obj_char_span": [83, 86], "rel_type": "inhibitor", "sbj_tok_span": [5, 10], "obj_tok_span": [18, 19], "new_sbj_tok_span": [5, 10], "new_obj_tok_span": [26, 27]}], "umls_entity_list": [{"mention": "ACS4", "char_span": [67, 71], "sem_type": "Gene or Genome", "tok_span": [14, 16], "new_tok_span": [17, 19]}, {"mention": "ACS", "char_span": [67, 70], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 15], "new_tok_span": [17, 18]}, {"mention": "ACS", "char_span": [83, 86], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 19], "new_tok_span": [26, 27]}, {"mention": "MAM", "char_span": [103, 106], "sem_type": "Gene or Genome", "tok_span": [23, 25], "new_tok_span": [34, 36]}, {"mention": "ACS", "char_span": [67, 70], "sem_type": "Gene or Genome", "tok_span": [14, 15], "new_tok_span": [17, 18]}, {"mention": "ACS", "char_span": [83, 86], "sem_type": "Gene or Genome", "tok_span": [18, 19], "new_tok_span": [26, 27]}], "new_text": "Consistent with these locations, N - ethylmaleimide, an inhibitor of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> ACS <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>4 <END=Gene or Genome>, inhibited <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> ACS <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> activity 47 % in <START=Gene or Genome> MAM <END=Gene or Genome> and 28 % in endoplasmic reticulum."}, {"PMID": 23247010, "id": 5, "text": "In a luciferase reporter gene assay, the promoter region between -2062 bp and the transcription start site of CBR1 was also activated by BHA. The transcription factor Nrf2 is known to be activated by BHA. There are 2 anti-oxidant responsive elements (ARE) that are bound by Nrf2 in this region.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [200, 203], "name": "BHA", "tok_span": [42, 44], "new_tok_span": [63, 65]}, {"ent_type": "GENE", "char_span": [110, 114], "name": "CBR1", "tok_span": [21, 24], "new_tok_span": [31, 34]}, {"ent_type": "GENE", "char_span": [167, 171], "name": "Nrf2", "tok_span": [34, 36], "new_tok_span": [52, 54]}, {"ent_type": "GENE", "char_span": [217, 249], "name": "anti-oxidant responsive elements", "tok_span": [48, 54], "new_tok_span": [71, 77]}, {"ent_type": "GENE", "char_span": [251, 254], "name": "ARE", "tok_span": [55, 56], "new_tok_span": [79, 80]}, {"ent_type": "GENE", "char_span": [274, 278], "name": "Nrf2", "tok_span": [61, 63], "new_tok_span": [87, 89]}], "relation_list": [{"subject": "BHA", "sbj_char_span": [200, 203], "object": "Nrf2", "obj_char_span": [167, 171], "rel_type": "activator", "sbj_tok_span": [42, 44], "obj_tok_span": [34, 36], "new_sbj_tok_span": [63, 65], "new_obj_tok_span": [52, 54]}], "umls_entity_list": [{"mention": "luciferase", "char_span": [5, 15], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"mention": "reporter gene", "char_span": [16, 29], "sem_type": "Gene or Genome", "tok_span": [3, 5], "new_tok_span": [6, 8]}, {"mention": "bp", "char_span": [71, 73], "sem_type": "Gene or Genome", "tok_span": [14, 15], "new_tok_span": [19, 20]}, {"mention": "CBR1", "char_span": [110, 114], "sem_type": "Gene or Genome", "tok_span": [21, 24], "new_tok_span": [31, 34]}, {"mention": "CBR1", "char_span": [110, 114], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 24], "new_tok_span": [31, 34]}, {"mention": "BHA", "char_span": [137, 140], "sem_type": "Pharmacologic Substance", "tok_span": [28, 30], "new_tok_span": [41, 43]}, {"mention": "BHA", "char_span": [200, 203], "sem_type": "Pharmacologic Substance", "tok_span": [42, 44], "new_tok_span": [63, 65]}, {"mention": "transcription", "char_span": [82, 95], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 18], "new_tok_span": [24, 25]}, {"mention": "transcription", "char_span": [146, 159], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 33], "new_tok_span": [47, 48]}, {"mention": "Nrf2", "char_span": [167, 171], "sem_type": "Gene or Genome", "tok_span": [34, 36], "new_tok_span": [52, 54]}, {"mention": "Nrf2", "char_span": [274, 278], "sem_type": "Gene or Genome", "tok_span": [61, 63], "new_tok_span": [87, 89]}, {"mention": "Nrf2", "char_span": [167, 171], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 36], "new_tok_span": [52, 54]}, {"mention": "Nrf2", "char_span": [274, 278], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [61, 63], "new_tok_span": [87, 89]}, {"mention": "anti-oxidant", "char_span": [217, 229], "sem_type": "Pharmacologic Substance", "tok_span": [48, 52], "new_tok_span": [71, 75]}], "new_text": "In a <START=Amino Acid, Peptide, or Protein> luciferase <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> reporter gene <END=Gene or Genome> assay, the promoter region between - 2062 <START=Gene or Genome> bp <END=Gene or Genome> and the <START=Amino Acid, Peptide, or Protein> transcription <END=Amino Acid, Peptide, or Protein> start site of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> CBR1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> was also activated by <START=Pharmacologic Substance> BHA <END=Pharmacologic Substance>. The <START=Amino Acid, Peptide, or Protein> transcription <END=Amino Acid, Peptide, or Protein> factor <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Nrf2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> is known to be activated by <START=Pharmacologic Substance> BHA <END=Pharmacologic Substance>. There are 2 <START=Pharmacologic Substance> anti - oxidant <END=Pharmacologic Substance> responsive elements ( ARE ) that are bound by <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Nrf2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> in this region."}, {"PMID": 16477002, "id": 9, "text": "The IL-2/gamma(c) interface itself exhibits the smallest buried surface and the fewest hydrogen bonds in the complex, which is consistent with its promiscuous use in other cytokine receptor complexes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [87, 95], "name": "hydrogen", "tok_span": [20, 21], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [4, 8], "name": "IL-2", "tok_span": [1, 4], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [172, 189], "name": "cytokine receptor", "tok_span": [37, 39], "new_tok_span": [38, 40]}], "relation_list": [{"subject": "hydrogen", "sbj_char_span": [87, 95], "object": "IL-2", "obj_char_span": [4, 8], "rel_type": "part of", "sbj_tok_span": [20, 21], "obj_tok_span": [1, 4], "new_sbj_tok_span": [20, 21], "new_obj_tok_span": [1, 4]}], "umls_entity_list": [{"mention": "cytokine receptor", "char_span": [172, 189], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 39], "new_tok_span": [38, 40]}], "new_text": "The IL - 2 / gamma ( c ) interface itself exhibits the smallest buried surface and the fewest hydrogen bonds in the complex, which is consistent with its promiscuous use in other <START=Amino Acid, Peptide, or Protein> cytokine receptor <END=Amino Acid, Peptide, or Protein> complexes."}, {"PMID": 14587496, "id": 1, "text": "BACKGROUND: Rivastigmine is a carbamate drug designed to inhibit both acetylcholinesterase and butyrylcholinesterase by reversibly covalently bonding to these enzymes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [12, 24], "name": "Rivastigmine", "tok_span": [2, 7], "new_tok_span": [2, 7]}, {"ent_type": "CHEMICAL", "char_span": [30, 39], "name": "carbamate", "tok_span": [9, 11], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [70, 90], "name": "acetylcholinesterase", "tok_span": [16, 19], "new_tok_span": [18, 21]}, {"ent_type": "GENE", "char_span": [95, 116], "name": "butyrylcholinesterase", "tok_span": [20, 26], "new_tok_span": [22, 28]}], "relation_list": [{"subject": "Rivastigmine", "sbj_char_span": [12, 24], "object": "acetylcholinesterase", "obj_char_span": [70, 90], "rel_type": "inhibitor", "sbj_tok_span": [2, 7], "obj_tok_span": [16, 19], "new_sbj_tok_span": [2, 7], "new_obj_tok_span": [18, 21]}, {"subject": "Rivastigmine", "sbj_char_span": [12, 24], "object": "butyrylcholinesterase", "obj_char_span": [95, 116], "rel_type": "inhibitor", "sbj_tok_span": [2, 7], "obj_tok_span": [20, 26], "new_sbj_tok_span": [2, 7], "new_obj_tok_span": [22, 28]}, {"subject": "carbamate", "sbj_char_span": [30, 39], "object": "acetylcholinesterase", "obj_char_span": [70, 90], "rel_type": "inhibitor", "sbj_tok_span": [9, 11], "obj_tok_span": [16, 19], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [18, 21]}, {"subject": "carbamate", "sbj_char_span": [30, 39], "object": "butyrylcholinesterase", "obj_char_span": [95, 116], "rel_type": "inhibitor", "sbj_tok_span": [9, 11], "obj_tok_span": [20, 26], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [22, 28]}], "umls_entity_list": [{"mention": "carbamate", "char_span": [30, 39], "sem_type": "Organic Chemical", "tok_span": [9, 11], "new_tok_span": [10, 12]}], "new_text": "BACKGROUND : Rivastigmine is a <START=Organic Chemical> carbamate <END=Organic Chemical> drug designed to inhibit both acetylcholinesterase and butyrylcholinesterase by reversibly covalently bonding to these enzymes."}, {"PMID": 1472079, "id": 6, "text": "Cadmium did not increase the breakdown of UDPGA by microsomal UDPGA pyrophosphatase but strongly decreased (30-66%) the synthesis of the cofactor in the cytosol by inhibiting UDP-glucose dehydrogenase (UDPGDH). Cadmium (10-50 microM) was found to inhibit the purified enzyme from bovine liver (EC 1.1.1.22) non-competitively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 47], "name": "UDPGA", "tok_span": [8, 10], "new_tok_span": [8, 10]}, {"ent_type": "CHEMICAL", "char_span": [62, 67], "name": "UDPGA", "tok_span": [13, 15], "new_tok_span": [14, 16]}, {"ent_type": "CHEMICAL", "char_span": [175, 186], "name": "UDP-glucose", "tok_span": [38, 41], "new_tok_span": [41, 44]}, {"ent_type": "CHEMICAL", "char_span": [211, 218], "name": "Cadmium", "tok_span": [48, 50], "new_tok_span": [52, 54]}, {"ent_type": "CHEMICAL", "char_span": [0, 7], "name": "Cadmium", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [68, 83], "name": "pyrophosphatase", "tok_span": [15, 18], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [175, 200], "name": "UDP-glucose dehydrogenase", "tok_span": [38, 42], "new_tok_span": [41, 45]}, {"ent_type": "GENE", "char_span": [202, 208], "name": "UDPGDH", "tok_span": [43, 46], "new_tok_span": [47, 50]}, {"ent_type": "GENE", "char_span": [294, 305], "name": "EC 1.1.1.22", "tok_span": [68, 76], "new_tok_span": [74, 82]}], "relation_list": [{"subject": "Cadmium", "sbj_char_span": [211, 218], "object": "EC 1.1.1.22", "obj_char_span": [294, 305], "rel_type": "inhibitor", "sbj_tok_span": [48, 50], "obj_tok_span": [68, 76], "new_sbj_tok_span": [52, 54], "new_obj_tok_span": [74, 82]}, {"subject": "Cadmium", "sbj_char_span": [0, 7], "object": "UDP-glucose dehydrogenase", "obj_char_span": [175, 200], "rel_type": "inhibitor", "sbj_tok_span": [0, 2], "obj_tok_span": [38, 42], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [41, 45]}, {"subject": "Cadmium", "sbj_char_span": [0, 7], "object": "UDPGDH", "obj_char_span": [202, 208], "rel_type": "inhibitor", "sbj_tok_span": [0, 2], "obj_tok_span": [43, 46], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [47, 50]}, {"subject": "UDPGA", "sbj_char_span": [42, 47], "object": "pyrophosphatase", "obj_char_span": [68, 83], "rel_type": "product or substrate", "sbj_tok_span": [8, 10], "obj_tok_span": [15, 18], "new_sbj_tok_span": [8, 10], "new_obj_tok_span": [16, 19]}], "umls_entity_list": [{"mention": "UDPGA pyrophosphatase", "char_span": [62, 83], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 18], "new_tok_span": [14, 19]}, {"mention": "UDP-glucose dehydrogenase", "char_span": [175, 200], "sem_type": "Gene or Genome", "tok_span": [38, 42], "new_tok_span": [41, 45]}, {"mention": "bovine liver", "char_span": [280, 292], "sem_type": "Pharmacologic Substance", "tok_span": [65, 67], "new_tok_span": [70, 72]}], "new_text": "Cadmium did not increase the breakdown of UDPGA by microsomal <START=Amino Acid, Peptide, or Protein> UDPGA pyrophosphatase <END=Amino Acid, Peptide, or Protein> but strongly decreased ( 30 - 66 % ) the synthesis of the cofactor in the cytosol by inhibiting <START=Gene or Genome> UDP - glucose dehydrogenase <END=Gene or Genome> ( UDPGDH ). Cadmium ( 10 - 50 microM ) was found to inhibit the purified enzyme from <START=Pharmacologic Substance> bovine liver <END=Pharmacologic Substance> ( EC 1. 1. 1. 22 ) non - competitively."}, {"PMID": 23374869, "id": 0, "text": "Inhibition of monoamine oxidase by phthalide analogues.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 23], "name": "monoamine", "tok_span": [2, 4], "new_tok_span": [2, 4]}, {"ent_type": "CHEMICAL", "char_span": [35, 44], "name": "phthalide", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [14, 31], "name": "monoamine oxidase", "tok_span": [2, 5], "new_tok_span": [2, 5]}], "relation_list": [{"subject": "phthalide", "sbj_char_span": [35, 44], "object": "monoamine oxidase", "obj_char_span": [14, 31], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [2, 5], "new_sbj_tok_span": [7, 10], "new_obj_tok_span": [2, 5]}], "umls_entity_list": [{"mention": "phthalide", "char_span": [35, 44], "sem_type": "Organic Chemical", "tok_span": [6, 9], "new_tok_span": [7, 10]}], "new_text": "Inhibition of monoamine oxidase by <START=Organic Chemical> phthalide <END=Organic Chemical> analogues."}, {"PMID": 15206110, "id": 3, "text": "Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an iron analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with transferrin and transferrin receptor-mediated endocytosis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [103, 110], "name": "gallium", "tok_span": [21, 23], "new_tok_span": [21, 23]}, {"ent_type": "CHEMICAL", "char_span": [125, 129], "name": "iron", "tok_span": [26, 27], "new_tok_span": [27, 28]}, {"ent_type": "GENE", "char_span": [257, 268], "name": "transferrin", "tok_span": [47, 49], "new_tok_span": [53, 55]}, {"ent_type": "GENE", "char_span": [273, 293], "name": "transferrin receptor", "tok_span": [50, 53], "new_tok_span": [60, 63]}], "relation_list": [{"subject": "gallium", "sbj_char_span": [103, 110], "object": "transferrin", "obj_char_span": [257, 268], "rel_type": "regulator", "sbj_tok_span": [21, 23], "obj_tok_span": [47, 49], "new_sbj_tok_span": [21, 23], "new_obj_tok_span": [53, 55]}, {"subject": "iron", "sbj_char_span": [125, 129], "object": "transferrin", "obj_char_span": [257, 268], "rel_type": "regulator", "sbj_tok_span": [26, 27], "obj_tok_span": [47, 49], "new_sbj_tok_span": [27, 28], "new_obj_tok_span": [53, 55]}, {"subject": "gallium", "sbj_char_span": [103, 110], "object": "transferrin receptor", "obj_char_span": [273, 293], "rel_type": "regulator", "sbj_tok_span": [21, 23], "obj_tok_span": [50, 53], "new_sbj_tok_span": [21, 23], "new_obj_tok_span": [60, 63]}, {"subject": "iron", "sbj_char_span": [125, 129], "object": "transferrin receptor", "obj_char_span": [273, 293], "rel_type": "regulator", "sbj_tok_span": [26, 27], "obj_tok_span": [50, 53], "new_sbj_tok_span": [27, 28], "new_obj_tok_span": [60, 63]}], "umls_entity_list": [{"mention": "iron", "char_span": [125, 129], "sem_type": "Pharmacologic Substance", "tok_span": [26, 27], "new_tok_span": [27, 28]}, {"mention": "iron", "char_span": [209, 213], "sem_type": "Pharmacologic Substance", "tok_span": [40, 41], "new_tok_span": [43, 44]}, {"mention": "transferrin", "char_span": [257, 268], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [47, 49], "new_tok_span": [53, 55]}, {"mention": "transferrin", "char_span": [273, 284], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 52], "new_tok_span": [60, 62]}, {"mention": "transferrin", "char_span": [257, 268], "sem_type": "Gene or Genome", "tok_span": [47, 49], "new_tok_span": [53, 55]}, {"mention": "transferrin", "char_span": [273, 284], "sem_type": "Gene or Genome", "tok_span": [50, 52], "new_tok_span": [60, 62]}], "new_text": "Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an <START=Pharmacologic Substance> iron <END=Pharmacologic Substance> analogue in every respect, it strongly interferes with cellular acquisition of <START=Pharmacologic Substance> iron <END=Pharmacologic Substance> from blood by competitive interaction with <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> transferrin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> transferrin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> receptor - mediated endocytosis."}, {"PMID": 23201180, "id": 2, "text": "The paraoxonase 1 from human serum (PON1) is a phosphotriesterase (PTE) that hydrolyses several xenobiotics including drugs and organophosphorus compounds (OPs).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [128, 144], "name": "organophosphorus", "tok_span": [33, 36], "new_tok_span": [38, 41]}, {"ent_type": "GENE", "char_span": [4, 17], "name": "paraoxonase 1", "tok_span": [1, 6], "new_tok_span": [1, 6]}, {"ent_type": "GENE", "char_span": [36, 40], "name": "PON1", "tok_span": [10, 13], "new_tok_span": [12, 15]}, {"ent_type": "GENE", "char_span": [47, 65], "name": "phosphotriesterase", "tok_span": [16, 19], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [67, 70], "name": "PTE", "tok_span": [20, 22], "new_tok_span": [24, 26]}], "relation_list": [{"subject": "organophosphorus", "sbj_char_span": [128, 144], "object": "paraoxonase 1", "obj_char_span": [4, 17], "rel_type": "product or substrate", "sbj_tok_span": [33, 36], "obj_tok_span": [1, 6], "new_sbj_tok_span": [38, 41], "new_obj_tok_span": [1, 6]}, {"subject": "organophosphorus", "sbj_char_span": [128, 144], "object": "PON1", "obj_char_span": [36, 40], "rel_type": "product or substrate", "sbj_tok_span": [33, 36], "obj_tok_span": [10, 13], "new_sbj_tok_span": [38, 41], "new_obj_tok_span": [12, 15]}, {"subject": "organophosphorus", "sbj_char_span": [128, 144], "object": "phosphotriesterase", "obj_char_span": [47, 65], "rel_type": "product or substrate", "sbj_tok_span": [33, 36], "obj_tok_span": [16, 19], "new_sbj_tok_span": [38, 41], "new_obj_tok_span": [20, 23]}, {"subject": "organophosphorus", "sbj_char_span": [128, 144], "object": "PTE", "obj_char_span": [67, 70], "rel_type": "product or substrate", "sbj_tok_span": [33, 36], "obj_tok_span": [20, 22], "new_sbj_tok_span": [38, 41], "new_obj_tok_span": [24, 26]}], "umls_entity_list": [{"mention": "PON1", "char_span": [36, 40], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 13], "new_tok_span": [12, 15]}, {"mention": "PON1", "char_span": [36, 40], "sem_type": "Gene or Genome", "tok_span": [10, 13], "new_tok_span": [12, 15]}, {"mention": "organophosphorus", "char_span": [128, 144], "sem_type": "Organic Chemical", "tok_span": [33, 36], "new_tok_span": [38, 41]}, {"mention": "OPs", "char_span": [156, 159], "sem_type": "Gene or Genome", "tok_span": [38, 40], "new_tok_span": [45, 47]}], "new_text": "The paraoxonase 1 from human serum ( <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PON1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ) is a phosphotriesterase ( PTE ) that hydrolyses several xenobiotics including drugs and <START=Organic Chemical> organophosphorus <END=Organic Chemical> compounds ( <START=Gene or Genome> OPs <END=Gene or Genome> )."}, {"PMID": 23305993, "id": 1, "text": "The compound (5Z)-5-[(5-bromo-1H-indol-3-yl)methylene]-3-(4-chlorobenzyl)-thiazolidine-2,4-dione (LYSO-7) was synthesised in order to obtain a new type of anti-inflammatory drug, designed with hybrid features to inhibit cyclooxygenase (COX) and also to activate peroxisome proliferator-activated receptor (PPAR). Results obtained from docking (in silico) studies corroborated with experimental data, showing the potential affinity between the studied ligand and targets.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [13, 96], "name": "(5Z)-5-[(5-bromo-1H-indol-3-yl)methylene]-3-(4-chlorobenzyl)-thiazolidine-2,4-dione", "tok_span": [2, 50], "new_tok_span": [2, 50]}, {"ent_type": "CHEMICAL", "char_span": [98, 104], "name": "LYSO-7", "tok_span": [51, 55], "new_tok_span": [52, 56]}, {"ent_type": "GENE", "char_span": [220, 234], "name": "cyclooxygenase", "tok_span": [78, 80], "new_tok_span": [80, 82]}, {"ent_type": "GENE", "char_span": [236, 239], "name": "COX", "tok_span": [81, 82], "new_tok_span": [83, 84]}, {"ent_type": "GENE", "char_span": [262, 304], "name": "peroxisome proliferator-activated receptor", "tok_span": [87, 94], "new_tok_span": [90, 97]}, {"ent_type": "GENE", "char_span": [306, 310], "name": "PPAR", "tok_span": [95, 96], "new_tok_span": [99, 100]}], "relation_list": [{"subject": "(5Z)-5-[(5-bromo-1H-indol-3-yl)methylene]-3-(4-chlorobenzyl)-thiazolidine-2,4-dione", "sbj_char_span": [13, 96], "object": "cyclooxygenase", "obj_char_span": [220, 234], "rel_type": "inhibitor", "sbj_tok_span": [2, 50], "obj_tok_span": [78, 80], "new_sbj_tok_span": [2, 50], "new_obj_tok_span": [80, 82]}, {"subject": "LYSO-7", "sbj_char_span": [98, 104], "object": "cyclooxygenase", "obj_char_span": [220, 234], "rel_type": "inhibitor", "sbj_tok_span": [51, 55], "obj_tok_span": [78, 80], "new_sbj_tok_span": [52, 56], "new_obj_tok_span": [80, 82]}, {"subject": "(5Z)-5-[(5-bromo-1H-indol-3-yl)methylene]-3-(4-chlorobenzyl)-thiazolidine-2,4-dione", "sbj_char_span": [13, 96], "object": "COX", "obj_char_span": [236, 239], "rel_type": "inhibitor", "sbj_tok_span": [2, 50], "obj_tok_span": [81, 82], "new_sbj_tok_span": [2, 50], "new_obj_tok_span": [83, 84]}, {"subject": "LYSO-7", "sbj_char_span": [98, 104], "object": "COX", "obj_char_span": [236, 239], "rel_type": "inhibitor", "sbj_tok_span": [51, 55], "obj_tok_span": [81, 82], "new_sbj_tok_span": [52, 56], "new_obj_tok_span": [83, 84]}, {"subject": "(5Z)-5-[(5-bromo-1H-indol-3-yl)methylene]-3-(4-chlorobenzyl)-thiazolidine-2,4-dione", "sbj_char_span": [13, 96], "object": "peroxisome proliferator-activated receptor", "obj_char_span": [262, 304], "rel_type": "activator", "sbj_tok_span": [2, 50], "obj_tok_span": [87, 94], "new_sbj_tok_span": [2, 50], "new_obj_tok_span": [90, 97]}, {"subject": "LYSO-7", "sbj_char_span": [98, 104], "object": "peroxisome proliferator-activated receptor", "obj_char_span": [262, 304], "rel_type": "activator", "sbj_tok_span": [51, 55], "obj_tok_span": [87, 94], "new_sbj_tok_span": [52, 56], "new_obj_tok_span": [90, 97]}, {"subject": "(5Z)-5-[(5-bromo-1H-indol-3-yl)methylene]-3-(4-chlorobenzyl)-thiazolidine-2,4-dione", "sbj_char_span": [13, 96], "object": "PPAR", "obj_char_span": [306, 310], "rel_type": "activator", "sbj_tok_span": [2, 50], "obj_tok_span": [95, 96], "new_sbj_tok_span": [2, 50], "new_obj_tok_span": [99, 100]}, {"subject": "LYSO-7", "sbj_char_span": [98, 104], "object": "PPAR", "obj_char_span": [306, 310], "rel_type": "activator", "sbj_tok_span": [51, 55], "obj_tok_span": [95, 96], "new_sbj_tok_span": [52, 56], "new_obj_tok_span": [99, 100]}], "umls_entity_list": [{"mention": "LYSO-7", "char_span": [98, 104], "sem_type": "Pharmacologic Substance", "tok_span": [51, 55], "new_tok_span": [52, 56]}, {"mention": "peroxisome proliferator-activated receptor", "char_span": [262, 304], "sem_type": "Gene or Genome", "tok_span": [87, 94], "new_tok_span": [90, 97]}], "new_text": "The compound ( 5Z ) - 5 - [ ( 5 - bromo - 1H - indol - 3 - yl ) methylene ] - 3 - ( 4 - chlorobenzyl ) - thiazolidine - 2, 4 - dione ( <START=Pharmacologic Substance> LYSO - 7 <END=Pharmacologic Substance> ) was synthesised in order to obtain a new type of anti - inflammatory drug, designed with hybrid features to inhibit cyclooxygenase ( COX ) and also to activate <START=Gene or Genome> peroxisome proliferator - activated receptor <END=Gene or Genome> ( PPAR ). Results obtained from docking ( in silico ) studies corroborated with experimental data, showing the potential affinity between the studied ligand and targets."}, {"PMID": 23085120, "id": 3, "text": "However, the huge discrepancy between the EC50 value and IC50 value of B12H, to protect against neuronal toxicity (0.09μM) and to block the NMDA receptor (21.8μM) respectively, suggests that the neuroprotection of B12H might be not primarily due to the blockade of the NMDA receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [71, 75], "name": "B12H", "tok_span": [15, 18], "new_tok_span": [15, 18]}, {"ent_type": "CHEMICAL", "char_span": [140, 144], "name": "NMDA", "tok_span": [35, 36], "new_tok_span": [35, 36]}, {"ent_type": "CHEMICAL", "char_span": [214, 218], "name": "B12H", "tok_span": [52, 55], "new_tok_span": [52, 55]}, {"ent_type": "CHEMICAL", "char_span": [269, 273], "name": "NMDA", "tok_span": [65, 66], "new_tok_span": [67, 68]}, {"ent_type": "GENE", "char_span": [140, 153], "name": "NMDA receptor", "tok_span": [35, 37], "new_tok_span": [35, 37]}, {"ent_type": "GENE", "char_span": [269, 282], "name": "NMDA receptor", "tok_span": [65, 67], "new_tok_span": [67, 69]}], "relation_list": [{"subject": "B12H", "sbj_char_span": [71, 75], "object": "NMDA receptor", "obj_char_span": [140, 153], "rel_type": "inhibitor", "sbj_tok_span": [15, 18], "obj_tok_span": [35, 37], "new_sbj_tok_span": [15, 18], "new_obj_tok_span": [35, 37]}], "umls_entity_list": [{"mention": "blockade", "char_span": [253, 261], "sem_type": "Pharmacologic Substance", "tok_span": [62, 63], "new_tok_span": [63, 64]}], "new_text": "However, the huge discrepancy between the EC50 value and IC50 value of B12H, to protect against neuronal toxicity ( 0. 09μM ) and to block the NMDA receptor ( 21. 8μM ) respectively, suggests that the neuroprotection of B12H might be not primarily due to the <START=Pharmacologic Substance> blockade <END=Pharmacologic Substance> of the NMDA receptor."}, {"PMID": 15814851, "id": 3, "text": "Inhibition of aromatase is an important approach for reducing growth-stimulatory effects of estrogens in estrogen-dependent breast cancer.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [92, 101], "name": "estrogens", "tok_span": [16, 18], "new_tok_span": [18, 20]}, {"ent_type": "CHEMICAL", "char_span": [105, 113], "name": "estrogen", "tok_span": [19, 20], "new_tok_span": [24, 25]}, {"ent_type": "GENE", "char_span": [14, 23], "name": "aromatase", "tok_span": [2, 4], "new_tok_span": [2, 4]}], "relation_list": [{"subject": "estrogens", "sbj_char_span": [92, 101], "object": "aromatase", "obj_char_span": [14, 23], "rel_type": "product or substrate", "sbj_tok_span": [16, 18], "obj_tok_span": [2, 4], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [2, 4]}, {"subject": "estrogen", "sbj_char_span": [105, 113], "object": "aromatase", "obj_char_span": [14, 23], "rel_type": "product or substrate", "sbj_tok_span": [19, 20], "obj_tok_span": [2, 4], "new_sbj_tok_span": [24, 25], "new_obj_tok_span": [2, 4]}], "umls_entity_list": [{"mention": "estrogens", "char_span": [92, 101], "sem_type": "Pharmacologic Substance", "tok_span": [16, 18], "new_tok_span": [18, 20]}, {"mention": "estrogen", "char_span": [92, 100], "sem_type": "Pharmacologic Substance", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"mention": "estrogen", "char_span": [105, 113], "sem_type": "Pharmacologic Substance", "tok_span": [19, 20], "new_tok_span": [24, 25]}], "new_text": "Inhibition of aromatase is an important approach for reducing growth - stimulatory effects of <START=Pharmacologic Substance> <START=Pharmacologic Substance> estrogen <END=Pharmacologic Substance>s <END=Pharmacologic Substance> in <START=Pharmacologic Substance> estrogen <END=Pharmacologic Substance> - dependent breast cancer."}, {"PMID": 9843368, "id": 0, "text": "Crystallographic analysis of the human phenylalanine hydroxylase catalytic domain with bound catechol inhibitors at 2.0 A resolution.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [39, 52], "name": "phenylalanine", "tok_span": [6, 8], "new_tok_span": [6, 8]}, {"ent_type": "CHEMICAL", "char_span": [93, 101], "name": "catechol", "tok_span": [14, 15], "new_tok_span": [16, 17]}, {"ent_type": "GENE", "char_span": [33, 81], "name": "human phenylalanine hydroxylase catalytic domain", "tok_span": [5, 12], "new_tok_span": [5, 12]}], "relation_list": [{"subject": "catechol", "sbj_char_span": [93, 101], "object": "human phenylalanine hydroxylase catalytic domain", "obj_char_span": [33, 81], "rel_type": "inhibitor", "sbj_tok_span": [14, 15], "obj_tok_span": [5, 12], "new_sbj_tok_span": [16, 17], "new_obj_tok_span": [5, 12]}], "umls_entity_list": [{"mention": "catechol", "char_span": [93, 101], "sem_type": "Organic Chemical", "tok_span": [14, 15], "new_tok_span": [16, 17]}, {"mention": "catechol", "char_span": [93, 101], "sem_type": "Pharmacologic Substance", "tok_span": [14, 15], "new_tok_span": [16, 17]}], "new_text": "Crystallographic analysis of the human phenylalanine hydroxylase catalytic domain with bound <START=Organic Chemical> <START=Pharmacologic Substance> catechol <END=Organic Chemical> <END=Pharmacologic Substance> inhibitors at 2. 0 A resolution."}, {"PMID": 9873034, "id": 7, "text": "Bulky imidazoles like clotrimazole block NO synthesis by inhibiting assembly of the iNOS dimer, revealing a new means to control cellular NO synthesis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [6, 16], "name": "imidazoles", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"ent_type": "CHEMICAL", "char_span": [22, 34], "name": "clotrimazole", "tok_span": [6, 9], "new_tok_span": [9, 12]}, {"ent_type": "CHEMICAL", "char_span": [41, 43], "name": "NO", "tok_span": [10, 11], "new_tok_span": [14, 15]}, {"ent_type": "CHEMICAL", "char_span": [138, 140], "name": "NO", "tok_span": [27, 28], "new_tok_span": [31, 32]}, {"ent_type": "GENE", "char_span": [84, 88], "name": "iNOS", "tok_span": [17, 18], "new_tok_span": [21, 22]}], "relation_list": [{"subject": "NO", "sbj_char_span": [41, 43], "object": "iNOS", "obj_char_span": [84, 88], "rel_type": "product or substrate", "sbj_tok_span": [10, 11], "obj_tok_span": [17, 18], "new_sbj_tok_span": [14, 15], "new_obj_tok_span": [21, 22]}, {"subject": "imidazoles", "sbj_char_span": [6, 16], "object": "iNOS", "obj_char_span": [84, 88], "rel_type": "inhibitor", "sbj_tok_span": [2, 5], "obj_tok_span": [17, 18], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [21, 22]}, {"subject": "clotrimazole", "sbj_char_span": [22, 34], "object": "iNOS", "obj_char_span": [84, 88], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [17, 18], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [21, 22]}], "umls_entity_list": [{"mention": "imidazoles", "char_span": [6, 16], "sem_type": "Pharmacologic Substance", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"mention": "clotrimazole", "char_span": [22, 34], "sem_type": "Pharmacologic Substance", "tok_span": [6, 9], "new_tok_span": [9, 12]}], "new_text": "Bulky <START=Pharmacologic Substance> imidazoles <END=Pharmacologic Substance> like <START=Pharmacologic Substance> clotrimazole <END=Pharmacologic Substance> block NO synthesis by inhibiting assembly of the iNOS dimer, revealing a new means to control cellular NO synthesis."}, {"PMID": 23462233, "id": 10, "text": "Possible AOX involvement in IMI metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 31], "name": "IMI", "tok_span": [5, 7], "new_tok_span": [5, 7]}, {"ent_type": "CHEMICAL", "char_span": [152, 155], "name": "IMI", "tok_span": [30, 32], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [9, 12], "name": "AOX", "tok_span": [1, 3], "new_tok_span": [1, 3]}, {"ent_type": "GENE", "char_span": [74, 77], "name": "AOX", "tok_span": [13, 15], "new_tok_span": [15, 17]}, {"ent_type": "GENE", "char_span": [93, 96], "name": "AOX", "tok_span": [18, 20], "new_tok_span": [20, 22]}], "relation_list": [{"subject": "IMI", "sbj_char_span": [28, 31], "object": "AOX", "obj_char_span": [9, 12], "rel_type": "product or substrate", "sbj_tok_span": [5, 7], "obj_tok_span": [1, 3], "new_sbj_tok_span": [5, 7], "new_obj_tok_span": [1, 3]}, {"subject": "IMI", "sbj_char_span": [28, 31], "object": "AOX", "obj_char_span": [74, 77], "rel_type": "product or substrate", "sbj_tok_span": [5, 7], "obj_tok_span": [13, 15], "new_sbj_tok_span": [5, 7], "new_obj_tok_span": [15, 17]}], "umls_entity_list": [{"mention": "insects", "char_span": [46, 53], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 10], "new_tok_span": [10, 11]}], "new_text": "Possible AOX involvement in IMI metabolism in <START=Amino Acid, Peptide, or Protein> insects <END=Amino Acid, Peptide, or Protein> was evaluated using AOX - expressing and AOX - deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains."}, {"PMID": 23267011, "id": 9, "text": "In contrast to wild-type pol β, the ternary complex of the R283K mutant with an incoming dATP-analogue and templating 8-oxoG resembles a G-A mismatched structure with 8-oxoG adopting an anti-conformation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [89, 93], "name": "dATP", "tok_span": [22, 24], "new_tok_span": [22, 24]}, {"ent_type": "CHEMICAL", "char_span": [118, 124], "name": "8-oxoG", "tok_span": [30, 35], "new_tok_span": [30, 35]}, {"ent_type": "CHEMICAL", "char_span": [167, 173], "name": "8-oxoG", "tok_span": [44, 49], "new_tok_span": [44, 49]}, {"ent_type": "GENE", "char_span": [25, 30], "name": "pol β", "tok_span": [6, 8], "new_tok_span": [6, 8]}, {"ent_type": "GENE", "char_span": [59, 64], "name": "R283K", "tok_span": [14, 18], "new_tok_span": [14, 18]}], "relation_list": [{"subject": "dATP", "sbj_char_span": [89, 93], "object": "R283K", "obj_char_span": [59, 64], "rel_type": "regulator", "sbj_tok_span": [22, 24], "obj_tok_span": [14, 18], "new_sbj_tok_span": [22, 24], "new_obj_tok_span": [14, 18]}, {"subject": "dATP", "sbj_char_span": [89, 93], "object": "pol β", "obj_char_span": [25, 30], "rel_type": "regulator", "sbj_tok_span": [22, 24], "obj_tok_span": [6, 8], "new_sbj_tok_span": [22, 24], "new_obj_tok_span": [6, 8]}, {"subject": "8-oxoG", "sbj_char_span": [118, 124], "object": "R283K", "obj_char_span": [59, 64], "rel_type": "regulator", "sbj_tok_span": [30, 35], "obj_tok_span": [14, 18], "new_sbj_tok_span": [30, 35], "new_obj_tok_span": [14, 18]}, {"subject": "8-oxoG", "sbj_char_span": [167, 173], "object": "R283K", "obj_char_span": [59, 64], "rel_type": "regulator", "sbj_tok_span": [44, 49], "obj_tok_span": [14, 18], "new_sbj_tok_span": [44, 49], "new_obj_tok_span": [14, 18]}], "umls_entity_list": [], "new_text": "In contrast to wild - type pol β, the ternary complex of the R283K mutant with an incoming dATP - analogue and templating 8 - oxoG resembles a G - A mismatched structure with 8 - oxoG adopting an anti - conformation."}, {"PMID": 23643094, "id": 7, "text": "NDGA was able to induce Nrf2 translocation in vivo in kidneys of rats submitted to both U-NX and I/R injury and to protect against renal histological damage and apoptosis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 4], "name": "NDGA", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [24, 28], "name": "Nrf2", "tok_span": [6, 8], "new_tok_span": [6, 8]}], "relation_list": [{"subject": "NDGA", "sbj_char_span": [0, 4], "object": "Nrf2", "obj_char_span": [24, 28], "rel_type": "activator", "sbj_tok_span": [0, 2], "obj_tok_span": [6, 8], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [6, 8]}], "umls_entity_list": [], "new_text": "NDGA was able to induce Nrf2 translocation in vivo in kidneys of rats submitted to both U - NX and I / R injury and to protect against renal histological damage and apoptosis."}, {"PMID": 9669506, "id": 2, "text": "The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 18], "name": "5-HT", "tok_span": [2, 5], "new_tok_span": [2, 5]}, {"ent_type": "CHEMICAL", "char_span": [39, 49], "name": "paroxetine", "tok_span": [9, 12], "new_tok_span": [10, 13]}, {"ent_type": "CHEMICAL", "char_span": [51, 60], "name": "indalpine", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"ent_type": "CHEMICAL", "char_span": [65, 76], "name": "fluvoxamine", "tok_span": [17, 21], "new_tok_span": [22, 26]}, {"ent_type": "CHEMICAL", "char_span": [111, 115], "name": "5-HT", "tok_span": [27, 30], "new_tok_span": [33, 36]}, {"ent_type": "CHEMICAL", "char_span": [141, 155], "name": "norepinephrine", "tok_span": [34, 35], "new_tok_span": [43, 44]}, {"ent_type": "CHEMICAL", "char_span": [175, 186], "name": "desipramine", "tok_span": [39, 43], "new_tok_span": [50, 54]}, {"ent_type": "CHEMICAL", "char_span": [215, 229], "name": "norepinephrine", "tok_span": [49, 50], "new_tok_span": [63, 64]}, {"ent_type": "GENE", "char_span": [111, 127], "name": "5-HT transporter", "tok_span": [27, 31], "new_tok_span": [33, 37]}, {"ent_type": "GENE", "char_span": [215, 241], "name": "norepinephrine transporter", "tok_span": [49, 51], "new_tok_span": [63, 65]}], "relation_list": [{"subject": "paroxetine", "sbj_char_span": [39, 49], "object": "5-HT transporter", "obj_char_span": [111, 127], "rel_type": "regulator", "sbj_tok_span": [9, 12], "obj_tok_span": [27, 31], "new_sbj_tok_span": [10, 13], "new_obj_tok_span": [33, 37]}, {"subject": "indalpine", "sbj_char_span": [51, 60], "object": "5-HT transporter", "obj_char_span": [111, 127], "rel_type": "regulator", "sbj_tok_span": [13, 16], "obj_tok_span": [27, 31], "new_sbj_tok_span": [16, 19], "new_obj_tok_span": [33, 37]}, {"subject": "fluvoxamine", "sbj_char_span": [65, 76], "object": "5-HT transporter", "obj_char_span": [111, 127], "rel_type": "regulator", "sbj_tok_span": [17, 21], "obj_tok_span": [27, 31], "new_sbj_tok_span": [22, 26], "new_obj_tok_span": [33, 37]}, {"subject": "desipramine", "sbj_char_span": [175, 186], "object": "norepinephrine transporter", "obj_char_span": [215, 241], "rel_type": "regulator", "sbj_tok_span": [39, 43], "obj_tok_span": [49, 51], "new_sbj_tok_span": [50, 54], "new_obj_tok_span": [63, 65]}], "umls_entity_list": [{"mention": "paroxetine", "char_span": [39, 49], "sem_type": "Pharmacologic Substance", "tok_span": [9, 12], "new_tok_span": [10, 13]}, {"mention": "indalpine", "char_span": [51, 60], "sem_type": "Pharmacologic Substance", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"mention": "fluvoxamine", "char_span": [65, 76], "sem_type": "Pharmacologic Substance", "tok_span": [17, 21], "new_tok_span": [22, 26]}, {"mention": "transporter", "char_span": [116, 127], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 31], "new_tok_span": [37, 38]}, {"mention": "transporter", "char_span": [230, 241], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 51], "new_tok_span": [65, 66]}, {"mention": "norepinephrine reuptake inhibitor", "char_span": [141, 174], "sem_type": "Pharmacologic Substance", "tok_span": [34, 39], "new_tok_span": [43, 48]}, {"mention": "desipramine", "char_span": [175, 186], "sem_type": "Pharmacologic Substance", "tok_span": [39, 43], "new_tok_span": [50, 54]}, {"mention": "norepinephrine transporter", "char_span": [215, 241], "sem_type": "Gene or Genome", "tok_span": [49, 51], "new_tok_span": [63, 65]}, {"mention": "norepinephrine transporter", "char_span": [215, 241], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [49, 51], "new_tok_span": [63, 65]}], "new_text": "The selective 5 - HT reuptake inhibitors <START=Pharmacologic Substance> paroxetine <END=Pharmacologic Substance>, <START=Pharmacologic Substance> indalpine <END=Pharmacologic Substance> and <START=Pharmacologic Substance> fluvoxamine <END=Pharmacologic Substance> displayed a high affinity for the 5 - HT <START=Amino Acid, Peptide, or Protein> transporter <END=Amino Acid, Peptide, or Protein>, whereas the <START=Pharmacologic Substance> norepinephrine reuptake inhibitor <END=Pharmacologic Substance> <START=Pharmacologic Substance> desipramine <END=Pharmacologic Substance> had a high affinity for the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> norepinephrine <START=Amino Acid, Peptide, or Protein> transporter <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 17234158, "id": 3, "text": "This reduction in TGF-beta2 is biologically relevant since PFD treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [59, 62], "name": "PFD", "tok_span": [11, 13], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [18, 27], "name": "TGF-beta2", "tok_span": [3, 7], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [106, 114], "name": "TGF-beta", "tok_span": [19, 22], "new_tok_span": [28, 31]}], "relation_list": [{"subject": "PFD", "sbj_char_span": [59, 62], "object": "TGF-beta2", "obj_char_span": [18, 27], "rel_type": "regulator", "sbj_tok_span": [11, 13], "obj_tok_span": [3, 7], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [6, 10]}, {"subject": "PFD", "sbj_char_span": [59, 62], "object": "TGF-beta", "obj_char_span": [106, 114], "rel_type": "regulator", "sbj_tok_span": [11, 13], "obj_tok_span": [19, 22], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [28, 31]}], "umls_entity_list": [{"mention": "TGF-beta2", "char_span": [18, 27], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 7], "new_tok_span": [6, 10]}, {"mention": "TGF-beta2", "char_span": [18, 27], "sem_type": "Gene or Genome", "tok_span": [3, 7], "new_tok_span": [6, 10]}, {"mention": "PFD", "char_span": [59, 62], "sem_type": "Gene or Genome", "tok_span": [11, 13], "new_tok_span": [18, 20]}, {"mention": "CCL", "char_span": [125, 128], "sem_type": "Organic Chemical", "tok_span": [24, 25], "new_tok_span": [36, 37]}, {"mention": "CCL", "char_span": [125, 128], "sem_type": "Gene or Genome", "tok_span": [24, 25], "new_tok_span": [36, 37]}, {"mention": "TGF-beta", "char_span": [18, 26], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 6], "new_tok_span": [6, 9]}, {"mention": "TGF-beta", "char_span": [106, 114], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 22], "new_tok_span": [28, 31]}, {"mention": "mediated", "char_span": [138, 146], "sem_type": "Pharmacologic Substance", "tok_span": [28, 29], "new_tok_span": [43, 44]}], "new_text": "This reduction in <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> TGF - beta <END=Amino Acid, Peptide, or Protein>2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> is biologically relevant since <START=Gene or Genome> PFD <END=Gene or Genome> treatment reduces the growth inhibition of <START=Amino Acid, Peptide, or Protein> TGF - beta <END=Amino Acid, Peptide, or Protein> - sensitive <START=Organic Chemical> <START=Gene or Genome> CCL <END=Organic Chemical> <END=Gene or Genome> - 64 cells <START=Pharmacologic Substance> mediated <END=Pharmacologic Substance> by conditioned media of glioma cells."}, {"PMID": 13679187, "id": 0, "text": "Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [47, 57], "name": "ambenonium", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [73, 77], "name": "AChE", "tok_span": [12, 14], "new_tok_span": [14, 16]}], "relation_list": [{"subject": "ambenonium", "sbj_char_span": [47, 57], "object": "AChE", "obj_char_span": [73, 77], "rel_type": "inhibitor", "sbj_tok_span": [7, 10], "obj_tok_span": [12, 14], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [14, 16]}], "umls_entity_list": [{"mention": "ambenonium", "char_span": [47, 57], "sem_type": "Pharmacologic Substance", "tok_span": [7, 10], "new_tok_span": [8, 11]}], "new_text": "Design, synthesis and biological evaluation of <START=Pharmacologic Substance> ambenonium <END=Pharmacologic Substance> derivatives as AChE inhibitors."}, {"PMID": 8052854, "id": 2, "text": "The anti-inflammatory drugs sodium salicylate and aspirin inhibited the activation of NF-kappa B, which further explains the mechanism of action of these drugs.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 45], "name": "sodium salicylate", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"ent_type": "CHEMICAL", "char_span": [50, 57], "name": "aspirin", "tok_span": [10, 11], "new_tok_span": [12, 13]}, {"ent_type": "GENE", "char_span": [86, 96], "name": "NF-kappa B", "tok_span": [15, 19], "new_tok_span": [18, 22]}], "relation_list": [{"subject": "sodium salicylate", "sbj_char_span": [28, 45], "object": "NF-kappa B", "obj_char_span": [86, 96], "rel_type": "inhibitor", "sbj_tok_span": [5, 9], "obj_tok_span": [15, 19], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [18, 22]}, {"subject": "aspirin", "sbj_char_span": [50, 57], "object": "NF-kappa B", "obj_char_span": [86, 96], "rel_type": "inhibitor", "sbj_tok_span": [10, 11], "obj_tok_span": [15, 19], "new_sbj_tok_span": [12, 13], "new_obj_tok_span": [18, 22]}], "umls_entity_list": [{"mention": "sodium salicylate", "char_span": [28, 45], "sem_type": "Pharmacologic Substance", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"mention": "NF-kappa B", "char_span": [86, 96], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 19], "new_tok_span": [18, 22]}], "new_text": "The anti - inflammatory drugs <START=Pharmacologic Substance> sodium salicylate <END=Pharmacologic Substance> and aspirin inhibited the activation of <START=Amino Acid, Peptide, or Protein> NF - kappa B <END=Amino Acid, Peptide, or Protein>, which further explains the mechanism of action of these drugs."}, {"PMID": 23200901, "id": 5, "text": "Bidirectional transport assays of the Aconitum alkaloids were performed with or without P-gp (cyclosporine A and verapamil), BCRP (Ko143) and MRP2 (MK571) inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [38, 56], "name": "Aconitum alkaloids", "tok_span": [6, 11], "new_tok_span": [7, 12]}, {"ent_type": "CHEMICAL", "char_span": [94, 108], "name": "cyclosporine A", "tok_span": [20, 23], "new_tok_span": [28, 31]}, {"ent_type": "CHEMICAL", "char_span": [113, 122], "name": "verapamil", "tok_span": [24, 27], "new_tok_span": [32, 35]}, {"ent_type": "CHEMICAL", "char_span": [131, 136], "name": "Ko143", "tok_span": [32, 35], "new_tok_span": [40, 43]}, {"ent_type": "CHEMICAL", "char_span": [148, 153], "name": "MK571", "tok_span": [41, 44], "new_tok_span": [49, 52]}, {"ent_type": "GENE", "char_span": [88, 92], "name": "P-gp", "tok_span": [16, 19], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [125, 129], "name": "BCRP", "tok_span": [29, 31], "new_tok_span": [37, 39]}, {"ent_type": "GENE", "char_span": [142, 146], "name": "MRP2", "tok_span": [37, 40], "new_tok_span": [45, 48]}], "relation_list": [{"subject": "cyclosporine A", "sbj_char_span": [94, 108], "object": "P-gp", "obj_char_span": [88, 92], "rel_type": "inhibitor", "sbj_tok_span": [20, 23], "obj_tok_span": [16, 19], "new_sbj_tok_span": [28, 31], "new_obj_tok_span": [20, 23]}, {"subject": "verapamil", "sbj_char_span": [113, 122], "object": "P-gp", "obj_char_span": [88, 92], "rel_type": "inhibitor", "sbj_tok_span": [24, 27], "obj_tok_span": [16, 19], "new_sbj_tok_span": [32, 35], "new_obj_tok_span": [20, 23]}, {"subject": "Ko143", "sbj_char_span": [131, 136], "object": "BCRP", "obj_char_span": [125, 129], "rel_type": "inhibitor", "sbj_tok_span": [32, 35], "obj_tok_span": [29, 31], "new_sbj_tok_span": [40, 43], "new_obj_tok_span": [37, 39]}, {"subject": "MK571", "sbj_char_span": [148, 153], "object": "MRP2", "obj_char_span": [142, 146], "rel_type": "inhibitor", "sbj_tok_span": [41, 44], "obj_tok_span": [37, 40], "new_sbj_tok_span": [49, 52], "new_obj_tok_span": [45, 48]}], "umls_entity_list": [{"mention": "alkaloids", "char_span": [47, 56], "sem_type": "Pharmacologic Substance", "tok_span": [9, 11], "new_tok_span": [12, 14]}, {"mention": "Aconitum", "char_span": [38, 46], "sem_type": "Pharmacologic Substance", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"mention": "gp", "char_span": [90, 92], "sem_type": "Gene or Genome", "tok_span": [18, 19], "new_tok_span": [24, 25]}, {"mention": "gp", "char_span": [90, 92], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 19], "new_tok_span": [24, 25]}], "new_text": "Bidirectional transport assays of the <START=Pharmacologic Substance> Aconitum <END=Pharmacologic Substance> <START=Pharmacologic Substance> alkaloids <END=Pharmacologic Substance> were performed with or without P - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> gp <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( cyclosporine A and verapamil ), BCRP ( Ko143 ) and MRP2 ( MK571 ) inhibitors."}, {"PMID": 15236843, "id": 2, "text": "To determine the role played by Tyr(356 (7.43)) in the rat beta(1)-adrenoceptor in binding the antagonists (+/-)cyanopindolol (4-[3-(t-butylamino]-3-(2'-cyano-indoloxy)-2-propanolol) and its iodinated analogue (+/-)[(125)Iodo]cyanopindolol (1-(t-butylamino]-3-(2'-cyano-3'-iodo-indoloxy)-2-propanolol), Tyr(356 (7.43)) was mutated to either Phe or Ala and binding affinities determined for wild type and mutant rat beta(1)-adrenoceptors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [107, 125], "name": "(+/-)cyanopindolol", "tok_span": [31, 41], "new_tok_span": [35, 45]}, {"ent_type": "CHEMICAL", "char_span": [127, 181], "name": "4-[3-(t-butylamino]-3-(2'-cyano-indoloxy)-2-propanolol", "tok_span": [42, 74], "new_tok_span": [48, 80]}, {"ent_type": "CHEMICAL", "char_span": [210, 239], "name": "(+/-)[(125)Iodo]cyanopindolol", "tok_span": [80, 98], "new_tok_span": [88, 106]}, {"ent_type": "CHEMICAL", "char_span": [241, 300], "name": "1-(t-butylamino]-3-(2'-cyano-3'-iodo-indoloxy)-2-propanolol", "tok_span": [99, 134], "new_tok_span": [111, 146]}, {"ent_type": "CHEMICAL", "char_span": [341, 344], "name": "Phe", "tok_span": [150, 151], "new_tok_span": [170, 171]}, {"ent_type": "CHEMICAL", "char_span": [348, 351], "name": "Ala", "tok_span": [152, 153], "new_tok_span": [172, 173]}, {"ent_type": "GENE", "char_span": [411, 436], "name": "rat beta(1)-adrenoceptors", "tok_span": [162, 172], "new_tok_span": [182, 192]}, {"ent_type": "GENE", "char_span": [55, 79], "name": "rat beta(1)-adrenoceptor", "tok_span": [18, 27], "new_tok_span": [22, 31]}], "relation_list": [{"subject": "(+/-)cyanopindolol", "sbj_char_span": [107, 125], "object": "rat beta(1)-adrenoceptor", "obj_char_span": [55, 79], "rel_type": "agonist or antagonist", "sbj_tok_span": [31, 41], "obj_tok_span": [18, 27], "new_sbj_tok_span": [35, 45], "new_obj_tok_span": [22, 31]}, {"subject": "4-[3-(t-butylamino]-3-(2'-cyano-indoloxy)-2-propanolol", "sbj_char_span": [127, 181], "object": "rat beta(1)-adrenoceptor", "obj_char_span": [55, 79], "rel_type": "agonist or antagonist", "sbj_tok_span": [42, 74], "obj_tok_span": [18, 27], "new_sbj_tok_span": [48, 80], "new_obj_tok_span": [22, 31]}, {"subject": "Phe", "sbj_char_span": [341, 344], "object": "rat beta(1)-adrenoceptors", "obj_char_span": [411, 436], "rel_type": "part of", "sbj_tok_span": [150, 151], "obj_tok_span": [162, 172], "new_sbj_tok_span": [170, 171], "new_obj_tok_span": [182, 192]}, {"subject": "Ala", "sbj_char_span": [348, 351], "object": "rat beta(1)-adrenoceptors", "obj_char_span": [411, 436], "rel_type": "part of", "sbj_tok_span": [152, 153], "obj_tok_span": [162, 172], "new_sbj_tok_span": [172, 173], "new_obj_tok_span": [182, 192]}, {"subject": "(+/-)[(125)Iodo]cyanopindolol", "sbj_char_span": [210, 239], "object": "rat beta(1)-adrenoceptor", "obj_char_span": [55, 79], "rel_type": "regulator", "sbj_tok_span": [80, 98], "obj_tok_span": [18, 27], "new_sbj_tok_span": [88, 106], "new_obj_tok_span": [22, 31]}, {"subject": "1-(t-butylamino]-3-(2'-cyano-3'-iodo-indoloxy)-2-propanolol", "sbj_char_span": [241, 300], "object": "rat beta(1)-adrenoceptor", "obj_char_span": [55, 79], "rel_type": "regulator", "sbj_tok_span": [99, 134], "obj_tok_span": [18, 27], "new_sbj_tok_span": [111, 146], "new_obj_tok_span": [22, 31]}], "umls_entity_list": [{"mention": "Tyr", "char_span": [32, 35], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 7], "new_tok_span": [8, 9]}, {"mention": "Tyr", "char_span": [303, 306], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [136, 137], "new_tok_span": [154, 155]}, {"mention": "Tyr", "char_span": [32, 35], "sem_type": "Gene or Genome", "tok_span": [6, 7], "new_tok_span": [8, 9]}, {"mention": "Tyr", "char_span": [303, 306], "sem_type": "Gene or Genome", "tok_span": [136, 137], "new_tok_span": [154, 155]}, {"mention": "propanolol", "char_span": [171, 181], "sem_type": "Pharmacologic Substance", "tok_span": [71, 74], "new_tok_span": [78, 81]}, {"mention": "propanolol", "char_span": [290, 300], "sem_type": "Pharmacologic Substance", "tok_span": [131, 134], "new_tok_span": [146, 149]}, {"mention": "Iodo", "char_span": [221, 225], "sem_type": "Pharmacologic Substance", "tok_span": [89, 92], "new_tok_span": [98, 101]}, {"mention": "iodo", "char_span": [273, 277], "sem_type": "Pharmacologic Substance", "tok_span": [121, 123], "new_tok_span": [134, 136]}, {"mention": "cyanopindolol", "char_span": [112, 125], "sem_type": "Pharmacologic Substance", "tok_span": [36, 41], "new_tok_span": [41, 46]}, {"mention": "cyanopindolol", "char_span": [226, 239], "sem_type": "Pharmacologic Substance", "tok_span": [93, 98], "new_tok_span": [104, 109]}], "new_text": "To determine the role played by <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Tyr <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( 356 ( 7. 43 ) ) in the rat beta ( 1 ) - adrenoceptor in binding the antagonists ( + / - ) <START=Pharmacologic Substance> cyanopindolol <END=Pharmacologic Substance> ( 4 - [ 3 - ( t - butylamino ] - 3 - ( 2'- cyano - indoloxy ) - 2 - <START=Pharmacologic Substance> propanolol <END=Pharmacologic Substance> ) and its iodinated analogue ( + / - ) [ ( 125 ) <START=Pharmacologic Substance> Iodo <END=Pharmacologic Substance> ] <START=Pharmacologic Substance> cyanopindolol <END=Pharmacologic Substance> ( 1 - ( t - butylamino ] - 3 - ( 2'- cyano - 3'- <START=Pharmacologic Substance> iodo <END=Pharmacologic Substance> - indoloxy ) - 2 - <START=Pharmacologic Substance> propanolol <END=Pharmacologic Substance> ), <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Tyr <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( 356 ( 7. 43 ) ) was mutated to either Phe or Ala and binding affinities determined for wild type and mutant rat beta ( 1 ) - adrenoceptors."}, {"PMID": 17570336, "id": 0, "text": "Multiple rat brain calpastatin forms are produced by distinct starting points and alternative splicing of the N-terminal exons. 5'-RACE was performed on rat brain calpastatin mRNA and two new translation initiation ATG's were found.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [110, 111], "name": "N", "tok_span": [19, 20], "new_tok_span": [23, 24]}, {"ent_type": "GENE", "char_span": [153, 174], "name": "rat brain calpastatin", "tok_span": [32, 38], "new_tok_span": [36, 42]}, {"ent_type": "GENE", "char_span": [9, 30], "name": "rat brain calpastatin", "tok_span": [1, 7], "new_tok_span": [1, 7]}], "relation_list": [{"subject": "N", "sbj_char_span": [110, 111], "object": "rat brain calpastatin", "obj_char_span": [9, 30], "rel_type": "part of", "sbj_tok_span": [19, 20], "obj_tok_span": [1, 7], "new_sbj_tok_span": [23, 24], "new_obj_tok_span": [1, 7]}], "umls_entity_list": [{"mention": "calpastatin", "char_span": [19, 30], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 7], "new_tok_span": [5, 9]}, {"mention": "calpastatin", "char_span": [163, 174], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 38], "new_tok_span": [40, 44]}, {"mention": "calpastatin", "char_span": [19, 30], "sem_type": "Gene or Genome", "tok_span": [3, 7], "new_tok_span": [5, 9]}, {"mention": "calpastatin", "char_span": [163, 174], "sem_type": "Gene or Genome", "tok_span": [34, 38], "new_tok_span": [40, 44]}], "new_text": "Multiple rat brain <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> calpastatin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> forms are produced by distinct starting points and alternative splicing of the N - terminal exons. 5'- RACE was performed on rat brain <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> calpastatin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> mRNA and two new translation initiation ATG's were found."}, {"PMID": 10193663, "id": 1, "text": "The affinity of eletriptan ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of 5-HT receptors was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [122, 126], "name": "5-HT", "tok_span": [52, 55], "new_tok_span": [58, 61]}, {"ent_type": "CHEMICAL", "char_span": [16, 26], "name": "eletriptan", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [28, 105], "name": "(R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole", "tok_span": [7, 47], "new_tok_span": [9, 49]}, {"ent_type": "GENE", "char_span": [122, 136], "name": "5-HT receptors", "tok_span": [52, 56], "new_tok_span": [58, 62]}, {"ent_type": "GENE", "char_span": [179, 188], "name": "5-HT1B/1D", "tok_span": [63, 71], "new_tok_span": [69, 77]}], "relation_list": [{"subject": "eletriptan", "sbj_char_span": [16, 26], "object": "5-HT receptors", "obj_char_span": [122, 136], "rel_type": "regulator", "sbj_tok_span": [3, 6], "obj_tok_span": [52, 56], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [58, 62]}, {"subject": "(R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole", "sbj_char_span": [28, 105], "object": "5-HT receptors", "obj_char_span": [122, 136], "rel_type": "regulator", "sbj_tok_span": [7, 47], "obj_tok_span": [52, 56], "new_sbj_tok_span": [9, 49], "new_obj_tok_span": [58, 62]}], "umls_entity_list": [{"mention": "eletriptan", "char_span": [16, 26], "sem_type": "Pharmacologic Substance", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "indole", "char_span": [99, 105], "sem_type": "Pharmacologic Substance", "tok_span": [45, 47], "new_tok_span": [49, 51]}, {"mention": "indole", "char_span": [99, 105], "sem_type": "Organic Chemical", "tok_span": [45, 47], "new_tok_span": [49, 51]}, {"mention": "1D", "char_span": [186, 188], "sem_type": "Gene or Genome", "tok_span": [69, 71], "new_tok_span": [76, 78]}, {"mention": "receptor agonist", "char_span": [189, 205], "sem_type": "Gene or Genome", "tok_span": [71, 73], "new_tok_span": [80, 82]}], "new_text": "The affinity of <START=Pharmacologic Substance> eletriptan <END=Pharmacologic Substance> ( ( R ) - 3 - ( 1 - methyl - 2 - pyrrolidinylmethyl ) - 5 - [ 2 - ( phenylsulphonyl ) ethyl ] - 1H - <START=Pharmacologic Substance> <START=Organic Chemical> indole <END=Pharmacologic Substance> <END=Organic Chemical> ) for a range of 5 - HT receptors was compared to values obtained for other 5 - HT1B / <START=Gene or Genome> 1D <END=Gene or Genome> <START=Gene or Genome> receptor agonists <END=Gene or Genome> known to be effective in the treatment of migraine."}, {"PMID": 23434226, "id": 3, "text": "In addition, this compound inhibited Tyr705 phosphorylation of STAT3 and had no obvious effect on upstream tyrosine kinases.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [37, 40], "name": "Tyr", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [107, 115], "name": "tyrosine", "tok_span": [20, 21], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [63, 68], "name": "STAT3", "tok_span": [11, 13], "new_tok_span": [11, 13]}, {"ent_type": "GENE", "char_span": [107, 123], "name": "tyrosine kinases", "tok_span": [20, 22], "new_tok_span": [20, 22]}], "relation_list": [{"subject": "Tyr", "sbj_char_span": [37, 40], "object": "STAT3", "obj_char_span": [63, 68], "rel_type": "part of", "sbj_tok_span": [6, 7], "obj_tok_span": [11, 13], "new_sbj_tok_span": [6, 7], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [], "new_text": "In addition, this compound inhibited Tyr705 phosphorylation of STAT3 and had no obvious effect on upstream tyrosine kinases."}, {"PMID": 16293341, "id": 1, "text": "MELANOTAN (NDP-MSH) binds the MC1 receptor to significantly increase the eumelanin content of human skin cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "MELANOTAN", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "CHEMICAL", "char_span": [11, 18], "name": "NDP-MSH", "tok_span": [6, 11], "new_tok_span": [7, 12]}, {"ent_type": "GENE", "char_span": [15, 18], "name": "MSH", "tok_span": [9, 11], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [30, 42], "name": "MC1 receptor", "tok_span": [14, 17], "new_tok_span": [16, 19]}], "relation_list": [{"subject": "MELANOTAN", "sbj_char_span": [0, 9], "object": "MC1 receptor", "obj_char_span": [30, 42], "rel_type": "regulator", "sbj_tok_span": [0, 5], "obj_tok_span": [14, 17], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [16, 19]}, {"subject": "NDP-MSH", "sbj_char_span": [11, 18], "object": "MC1 receptor", "obj_char_span": [30, 42], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [14, 17], "new_sbj_tok_span": [7, 12], "new_obj_tok_span": [16, 19]}], "umls_entity_list": [{"mention": "NDP-MSH", "char_span": [11, 18], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 11], "new_tok_span": [7, 12]}, {"mention": "eumelanin", "char_span": [73, 82], "sem_type": "Organic Chemical", "tok_span": [21, 25], "new_tok_span": [24, 28]}, {"mention": "human skin", "char_span": [94, 104], "sem_type": "Organic Chemical", "tok_span": [27, 29], "new_tok_span": [32, 34]}], "new_text": "MELANOTAN ( <START=Amino Acid, Peptide, or Protein> NDP - MSH <END=Amino Acid, Peptide, or Protein> ) binds the MC1 receptor to significantly increase the <START=Organic Chemical> eumelanin <END=Organic Chemical> content of <START=Organic Chemical> human skin <END=Organic Chemical> cells."}, {"PMID": 9622938, "id": 3, "text": "Both patients are homozygous for an L396S substitution, this amino acid being highly conserved across species.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [61, 71], "name": "amino acid", "tok_span": [13, 15], "new_tok_span": [14, 16]}, {"ent_type": "GENE", "char_span": [36, 41], "name": "L396S", "tok_span": [6, 10], "new_tok_span": [6, 10]}], "relation_list": [{"subject": "amino acid", "sbj_char_span": [61, 71], "object": "L396S", "obj_char_span": [36, 41], "rel_type": "part of", "sbj_tok_span": [13, 15], "obj_tok_span": [6, 10], "new_sbj_tok_span": [14, 16], "new_obj_tok_span": [6, 10]}], "umls_entity_list": [{"mention": "amino acid", "char_span": [61, 71], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 15], "new_tok_span": [14, 16]}], "new_text": "Both patients are homozygous for an L396S substitution, this <START=Amino Acid, Peptide, or Protein> amino acid <END=Amino Acid, Peptide, or Protein> being highly conserved across species."}, {"PMID": 12023506, "id": 7, "text": "The K(i) value of probenecid for hOAT2 was 766 microM, whereas those of probenecid, KW-3902, and betamipron for hOAT4 were 54.9, 20.7, and 502 microM, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [72, 82], "name": "probenecid", "tok_span": [24, 27], "new_tok_span": [27, 30]}, {"ent_type": "CHEMICAL", "char_span": [84, 91], "name": "KW-3902", "tok_span": [28, 33], "new_tok_span": [32, 37]}, {"ent_type": "CHEMICAL", "char_span": [97, 107], "name": "betamipron", "tok_span": [35, 39], "new_tok_span": [40, 44]}, {"ent_type": "GENE", "char_span": [33, 38], "name": "hOAT2", "tok_span": [11, 15], "new_tok_span": [13, 17]}, {"ent_type": "GENE", "char_span": [112, 117], "name": "hOAT4", "tok_span": [40, 44], "new_tok_span": [46, 50]}], "relation_list": [{"subject": "probenecid", "sbj_char_span": [72, 82], "object": "hOAT4", "obj_char_span": [112, 117], "rel_type": "inhibitor", "sbj_tok_span": [24, 27], "obj_tok_span": [40, 44], "new_sbj_tok_span": [27, 30], "new_obj_tok_span": [46, 50]}, {"subject": "KW-3902", "sbj_char_span": [84, 91], "object": "hOAT4", "obj_char_span": [112, 117], "rel_type": "inhibitor", "sbj_tok_span": [28, 33], "obj_tok_span": [40, 44], "new_sbj_tok_span": [32, 37], "new_obj_tok_span": [46, 50]}, {"subject": "betamipron", "sbj_char_span": [97, 107], "object": "hOAT4", "obj_char_span": [112, 117], "rel_type": "inhibitor", "sbj_tok_span": [35, 39], "obj_tok_span": [40, 44], "new_sbj_tok_span": [40, 44], "new_obj_tok_span": [46, 50]}], "umls_entity_list": [{"mention": "probenecid", "char_span": [18, 28], "sem_type": "Pharmacologic Substance", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "probenecid", "char_span": [72, 82], "sem_type": "Pharmacologic Substance", "tok_span": [24, 27], "new_tok_span": [27, 30]}, {"mention": "betamipron", "char_span": [97, 107], "sem_type": "Pharmacologic Substance", "tok_span": [35, 39], "new_tok_span": [40, 44]}], "new_text": "The K ( i ) value of <START=Pharmacologic Substance> probenecid <END=Pharmacologic Substance> for hOAT2 was 766 microM, whereas those of <START=Pharmacologic Substance> probenecid <END=Pharmacologic Substance>, KW - 3902, and <START=Pharmacologic Substance> betamipron <END=Pharmacologic Substance> for hOAT4 were 54. 9, 20. 7, and 502 microM, respectively."}, {"PMID": 23430109, "id": 1, "text": "Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Ponatinib", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"ent_type": "CHEMICAL", "char_span": [11, 18], "name": "AP24534", "tok_span": [3, 7], "new_tok_span": [6, 10]}, {"ent_type": "CHEMICAL", "char_span": [86, 94], "name": "tyrosine", "tok_span": [20, 21], "new_tok_span": [26, 27]}, {"ent_type": "GENE", "char_span": [25, 36], "name": "multikinase", "tok_span": [10, 12], "new_tok_span": [14, 16]}, {"ent_type": "GENE", "char_span": [86, 101], "name": "tyrosine kinase", "tok_span": [20, 22], "new_tok_span": [26, 28]}, {"ent_type": "GENE", "char_span": [170, 180], "name": "BCR-ABL KD", "tok_span": [35, 40], "new_tok_span": [44, 49]}], "relation_list": [{"subject": "Ponatinib", "sbj_char_span": [0, 9], "object": "multikinase", "obj_char_span": [25, 36], "rel_type": "inhibitor", "sbj_tok_span": [0, 2], "obj_tok_span": [10, 12], "new_sbj_tok_span": [1, 3], "new_obj_tok_span": [14, 16]}, {"subject": "AP24534", "sbj_char_span": [11, 18], "object": "multikinase", "obj_char_span": [25, 36], "rel_type": "inhibitor", "sbj_tok_span": [3, 7], "obj_tok_span": [10, 12], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [14, 16]}], "umls_entity_list": [{"mention": "Ponatinib", "char_span": [0, 9], "sem_type": "Pharmacologic Substance", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"mention": "AP24534", "char_span": [11, 18], "sem_type": "Pharmacologic Substance", "tok_span": [3, 7], "new_tok_span": [6, 10]}, {"mention": "BCR-ABL", "char_span": [170, 177], "sem_type": "Gene or Genome", "tok_span": [35, 39], "new_tok_span": [44, 48]}, {"mention": "kinase", "char_span": [30, 36], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 12], "new_tok_span": [16, 17]}, {"mention": "kinase", "char_span": [95, 101], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [28, 29]}], "new_text": "<START=Pharmacologic Substance> Ponatinib <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> AP24534 <END=Pharmacologic Substance> ) is a multi <START=Amino Acid, Peptide, or Protein>kinase <END=Amino Acid, Peptide, or Protein> inhibitor with in vitro and clinical activity in tyrosine <START=Amino Acid, Peptide, or Protein> kinase <END=Amino Acid, Peptide, or Protein> inhibitor ( TKI ) - resistant chronic myeloid leukemia, irrespective of <START=Gene or Genome> BCR - ABL <END=Gene or Genome> KD mutation."}, {"PMID": 11980628, "id": 12, "text": "After 126 days of continuous infusion of SOM230 plasma IGF-I levels were decreased by 75% of placebo-treated control animals.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [41, 47], "name": "SOM230", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [55, 60], "name": "IGF-I", "tok_span": [11, 14], "new_tok_span": [13, 16]}], "relation_list": [{"subject": "SOM230", "sbj_char_span": [41, 47], "object": "IGF-I", "obj_char_span": [55, 60], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [11, 14], "new_sbj_tok_span": [8, 11], "new_obj_tok_span": [13, 16]}], "umls_entity_list": [{"mention": "SOM230", "char_span": [41, 47], "sem_type": "Organic Chemical", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "animals", "char_span": [117, 124], "sem_type": "Pharmacologic Substance", "tok_span": [25, 26], "new_tok_span": [28, 29]}], "new_text": "After 126 days of continuous infusion of <START=Organic Chemical> SOM230 <END=Organic Chemical> plasma IGF - I levels were decreased by 75 % of placebo - treated control <START=Pharmacologic Substance> animals <END=Pharmacologic Substance>."}, {"PMID": 17263187, "id": 2, "text": "Prescription medications targeting chronic constipation currently include polyethylene glycol, lactulose and tegaserod, a serotonin type 4 receptor partial agonist.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [95, 104], "name": "lactulose", "tok_span": [13, 15], "new_tok_span": [16, 18]}, {"ent_type": "CHEMICAL", "char_span": [109, 118], "name": "tegaserod", "tok_span": [16, 20], "new_tok_span": [21, 25]}, {"ent_type": "CHEMICAL", "char_span": [122, 131], "name": "serotonin", "tok_span": [22, 23], "new_tok_span": [28, 29]}, {"ent_type": "GENE", "char_span": [122, 147], "name": "serotonin type 4 receptor", "tok_span": [22, 26], "new_tok_span": [28, 32]}], "relation_list": [{"subject": "tegaserod", "sbj_char_span": [109, 118], "object": "serotonin type 4 receptor", "obj_char_span": [122, 147], "rel_type": "agonist or antagonist", "sbj_tok_span": [16, 20], "obj_tok_span": [22, 26], "new_sbj_tok_span": [21, 25], "new_obj_tok_span": [28, 32]}], "umls_entity_list": [{"mention": "Prescription medications", "char_span": [0, 24], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "lactulose", "char_span": [95, 104], "sem_type": "Pharmacologic Substance", "tok_span": [13, 15], "new_tok_span": [16, 18]}, {"mention": "tegaserod", "char_span": [109, 118], "sem_type": "Pharmacologic Substance", "tok_span": [16, 20], "new_tok_span": [21, 25]}], "new_text": "<START=Pharmacologic Substance> Prescription medications <END=Pharmacologic Substance> targeting chronic constipation currently include polyethylene glycol, <START=Pharmacologic Substance> lactulose <END=Pharmacologic Substance> and <START=Pharmacologic Substance> tegaserod <END=Pharmacologic Substance>, a serotonin type 4 receptor partial agonist."}, {"PMID": 23403272, "id": 5, "text": "In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [30, 42], "name": "Paeoniflorin", "tok_span": [6, 11], "new_tok_span": [6, 11]}, {"ent_type": "CHEMICAL", "char_span": [105, 111], "name": "oxygen", "tok_span": [18, 19], "new_tok_span": [20, 21]}, {"ent_type": "CHEMICAL", "char_span": [140, 155], "name": "malondialdehyde", "tok_span": [27, 31], "new_tok_span": [29, 33]}, {"ent_type": "CHEMICAL", "char_span": [157, 160], "name": "MDA", "tok_span": [32, 33], "new_tok_span": [34, 35]}, {"ent_type": "CHEMICAL", "char_span": [166, 173], "name": "lactate", "tok_span": [35, 36], "new_tok_span": [38, 39]}, {"ent_type": "CHEMICAL", "char_span": [259, 270], "name": "glutathione", "tok_span": [50, 51], "new_tok_span": [56, 57]}, {"ent_type": "CHEMICAL", "char_span": [272, 275], "name": "GSH", "tok_span": [52, 53], "new_tok_span": [58, 59]}, {"ent_type": "CHEMICAL", "char_span": [281, 291], "name": "superoxide", "tok_span": [55, 56], "new_tok_span": [62, 63]}, {"ent_type": "GENE", "char_span": [166, 187], "name": "lactate dehydrogenase", "tok_span": [35, 37], "new_tok_span": [38, 40]}, {"ent_type": "GENE", "char_span": [189, 192], "name": "LDH", "tok_span": [38, 39], "new_tok_span": [42, 43]}, {"ent_type": "GENE", "char_span": [281, 301], "name": "superoxide dismutase", "tok_span": [55, 57], "new_tok_span": [62, 64]}, {"ent_type": "GENE", "char_span": [303, 306], "name": "SOD", "tok_span": [58, 59], "new_tok_span": [66, 67]}], "relation_list": [{"subject": "Paeoniflorin", "sbj_char_span": [30, 42], "object": "lactate dehydrogenase", "obj_char_span": [166, 187], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [35, 37], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [38, 40]}, {"subject": "Paeoniflorin", "sbj_char_span": [30, 42], "object": "LDH", "obj_char_span": [189, 192], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [38, 39], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [42, 43]}, {"subject": "Paeoniflorin", "sbj_char_span": [30, 42], "object": "superoxide dismutase", "obj_char_span": [281, 301], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [55, 57], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [62, 64]}, {"subject": "Paeoniflorin", "sbj_char_span": [30, 42], "object": "SOD", "obj_char_span": [303, 306], "rel_type": "regulator", "sbj_tok_span": [6, 11], "obj_tok_span": [58, 59], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [66, 67]}], "umls_entity_list": [{"mention": "lactate", "char_span": [166, 173], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 36], "new_tok_span": [38, 39]}, {"mention": "superoxide dismutase", "char_span": [281, 301], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [55, 57], "new_tok_span": [62, 64]}, {"mention": "ea", "char_span": [97, 99], "sem_type": "Pharmacologic Substance", "tok_span": [17, 18], "new_tok_span": [18, 19]}, {"mention": "ea", "char_span": [195, 197], "sem_type": "Pharmacologic Substance", "tok_span": [40, 41], "new_tok_span": [45, 46]}, {"mention": "EA", "char_span": [311, 313], "sem_type": "Pharmacologic Substance", "tok_span": [61, 62], "new_tok_span": [70, 71]}], "new_text": "In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular <START=Pharmacologic Substance> reactive <END=Pharmacologic Substance> oxygen species ( ROS ), the level of malondialdehyde ( MDA ) and <START=Amino Acid, Peptide, or Protein> lactate <END=Amino Acid, Peptide, or Protein> dehydrogenase ( LDH ) <START=Pharmacologic Substance> leakage <END=Pharmacologic Substance>, and enhanced production of the endogenous antioxidants, glutathione ( GSH ) and <START=Amino Acid, Peptide, or Protein> superoxide dismutase <END=Amino Acid, Peptide, or Protein> ( SOD ) in <START=Pharmacologic Substance> EA <END=Pharmacologic Substance>. hy926 cells."}, {"PMID": 23639191, "id": 12, "text": "In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [19, 23], "name": "H2O2", "tok_span": [4, 8], "new_tok_span": [5, 9]}, {"ent_type": "CHEMICAL", "char_span": [25, 37], "name": "calycopterin", "tok_span": [9, 13], "new_tok_span": [11, 15]}, {"ent_type": "CHEMICAL", "char_span": [60, 63], "name": "GSH", "tok_span": [16, 17], "new_tok_span": [19, 20]}, {"ent_type": "GENE", "char_span": [74, 77], "name": "SOD", "tok_span": [19, 20], "new_tok_span": [23, 24]}], "relation_list": [{"subject": "calycopterin", "sbj_char_span": [25, 37], "object": "SOD", "obj_char_span": [74, 77], "rel_type": "activator", "sbj_tok_span": [9, 13], "obj_tok_span": [19, 20], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [23, 24]}], "umls_entity_list": [{"mention": "H2O2", "char_span": [19, 23], "sem_type": "Pharmacologic Substance", "tok_span": [4, 8], "new_tok_span": [5, 9]}, {"mention": "GSH", "char_span": [60, 63], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 17], "new_tok_span": [19, 20]}], "new_text": "In the presence of <START=Pharmacologic Substance> H2O2 <END=Pharmacologic Substance>, calycopterin inhibited decrease in <START=Amino Acid, Peptide, or Protein> GSH <END=Amino Acid, Peptide, or Protein> level and SOD activity."}, {"PMID": 23384967, "id": 1, "text": "Bisphenol A (BPA) and diethylstilbestrol (DES) are endocrine-disrupting chemicals that interact with the human pregnane X receptor (PXR). CYP3A4 enzyme is essential in the hydroxylation of steroid hormones and is regulated by PXR. In the present study, human and rat hepatoma cell lines were exposed to BPA and DES. Both BPA and DES (10-50μM) caused a significant activation of the CYP3A4 promoter via the PXR in the DPX2 human hepatoma cell line.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Bisphenol A", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [13, 16], "name": "BPA", "tok_span": [5, 7], "new_tok_span": [7, 9]}, {"ent_type": "CHEMICAL", "char_span": [189, 196], "name": "steroid", "tok_span": [50, 51], "new_tok_span": [59, 60]}, {"ent_type": "CHEMICAL", "char_span": [22, 40], "name": "diethylstilbestrol", "tok_span": [9, 15], "new_tok_span": [11, 17]}, {"ent_type": "CHEMICAL", "char_span": [321, 324], "name": "BPA", "tok_span": [80, 82], "new_tok_span": [90, 92]}, {"ent_type": "CHEMICAL", "char_span": [329, 332], "name": "DES", "tok_span": [83, 84], "new_tok_span": [93, 94]}, {"ent_type": "CHEMICAL", "char_span": [42, 45], "name": "DES", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"ent_type": "GENE", "char_span": [105, 130], "name": "human pregnane X receptor", "tok_span": [28, 33], "new_tok_span": [30, 35]}, {"ent_type": "GENE", "char_span": [132, 135], "name": "PXR", "tok_span": [34, 36], "new_tok_span": [40, 42]}, {"ent_type": "GENE", "char_span": [138, 144], "name": "CYP3A4", "tok_span": [38, 42], "new_tok_span": [45, 49]}, {"ent_type": "GENE", "char_span": [226, 229], "name": "PXR", "tok_span": [56, 58], "new_tok_span": [66, 68]}, {"ent_type": "GENE", "char_span": [382, 397], "name": "CYP3A4 promoter", "tok_span": [97, 102], "new_tok_span": [108, 113]}, {"ent_type": "GENE", "char_span": [406, 409], "name": "PXR", "tok_span": [104, 106], "new_tok_span": [118, 120]}], "relation_list": [{"subject": "Bisphenol A", "sbj_char_span": [0, 11], "object": "human pregnane X receptor", "obj_char_span": [105, 130], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [28, 33], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [30, 35]}, {"subject": "BPA", "sbj_char_span": [13, 16], "object": "human pregnane X receptor", "obj_char_span": [105, 130], "rel_type": "regulator", "sbj_tok_span": [5, 7], "obj_tok_span": [28, 33], "new_sbj_tok_span": [7, 9], "new_obj_tok_span": [30, 35]}, {"subject": "diethylstilbestrol", "sbj_char_span": [22, 40], "object": "human pregnane X receptor", "obj_char_span": [105, 130], "rel_type": "regulator", "sbj_tok_span": [9, 15], "obj_tok_span": [28, 33], "new_sbj_tok_span": [11, 17], "new_obj_tok_span": [30, 35]}, {"subject": "DES", "sbj_char_span": [42, 45], "object": "human pregnane X receptor", "obj_char_span": [105, 130], "rel_type": "regulator", "sbj_tok_span": [16, 17], "obj_tok_span": [28, 33], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [30, 35]}, {"subject": "Bisphenol A", "sbj_char_span": [0, 11], "object": "PXR", "obj_char_span": [132, 135], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [34, 36], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [40, 42]}, {"subject": "BPA", "sbj_char_span": [13, 16], "object": "PXR", "obj_char_span": [132, 135], "rel_type": "regulator", "sbj_tok_span": [5, 7], "obj_tok_span": [34, 36], "new_sbj_tok_span": [7, 9], "new_obj_tok_span": [40, 42]}, {"subject": "diethylstilbestrol", "sbj_char_span": [22, 40], "object": "PXR", "obj_char_span": [132, 135], "rel_type": "regulator", "sbj_tok_span": [9, 15], "obj_tok_span": [34, 36], "new_sbj_tok_span": [11, 17], "new_obj_tok_span": [40, 42]}, {"subject": "DES", "sbj_char_span": [42, 45], "object": "PXR", "obj_char_span": [132, 135], "rel_type": "regulator", "sbj_tok_span": [16, 17], "obj_tok_span": [34, 36], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [40, 42]}, {"subject": "steroid", "sbj_char_span": [189, 196], "object": "CYP3A4", "obj_char_span": [138, 144], "rel_type": "product or substrate", "sbj_tok_span": [50, 51], "obj_tok_span": [38, 42], "new_sbj_tok_span": [59, 60], "new_obj_tok_span": [45, 49]}, {"subject": "BPA", "sbj_char_span": [321, 324], "object": "CYP3A4 promoter", "obj_char_span": [382, 397], "rel_type": "activator", "sbj_tok_span": [80, 82], "obj_tok_span": [97, 102], "new_sbj_tok_span": [90, 92], "new_obj_tok_span": [108, 113]}, {"subject": "DES", "sbj_char_span": [329, 332], "object": "CYP3A4 promoter", "obj_char_span": [382, 397], "rel_type": "activator", "sbj_tok_span": [83, 84], "obj_tok_span": [97, 102], "new_sbj_tok_span": [93, 94], "new_obj_tok_span": [108, 113]}, {"subject": "BPA", "sbj_char_span": [321, 324], "object": "PXR", "obj_char_span": [406, 409], "rel_type": "activator", "sbj_tok_span": [80, 82], "obj_tok_span": [104, 106], "new_sbj_tok_span": [90, 92], "new_obj_tok_span": [118, 120]}, {"subject": "DES", "sbj_char_span": [329, 332], "object": "PXR", "obj_char_span": [406, 409], "rel_type": "activator", "sbj_tok_span": [83, 84], "obj_tok_span": [104, 106], "new_sbj_tok_span": [93, 94], "new_obj_tok_span": [118, 120]}], "umls_entity_list": [{"mention": "Bisphenol A", "char_span": [0, 11], "sem_type": "Organic Chemical", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "steroid hormones", "char_span": [189, 205], "sem_type": "Organic Chemical", "tok_span": [50, 52], "new_tok_span": [59, 61]}, {"mention": "pregnane X receptor", "char_span": [111, 130], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 33], "new_tok_span": [33, 37]}, {"mention": "pregnane X receptor", "char_span": [111, 130], "sem_type": "Gene or Genome", "tok_span": [29, 33], "new_tok_span": [33, 37]}, {"mention": "CYP3A4", "char_span": [138, 144], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [38, 42], "new_tok_span": [45, 49]}, {"mention": "CYP3A4", "char_span": [382, 388], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [97, 101], "new_tok_span": [108, 112]}, {"mention": "via", "char_span": [398, 401], "sem_type": "Gene or Genome", "tok_span": [102, 103], "new_tok_span": [115, 116]}], "new_text": "<START=Organic Chemical> Bisphenol A <END=Organic Chemical> ( BPA ) and diethylstilbestrol ( DES ) are endocrine - disrupting chemicals that interact with the human <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> pregnane X receptor <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( PXR ). <START=Amino Acid, Peptide, or Protein> CYP3A4 <END=Amino Acid, Peptide, or Protein> enzyme is essential in the hydroxylation of <START=Organic Chemical> steroid hormones <END=Organic Chemical> and is regulated by PXR. In the present study, human and rat hepatoma cell lines were exposed to BPA and DES. Both BPA and DES ( 10 - 50μM ) caused a significant activation of the <START=Amino Acid, Peptide, or Protein> CYP3A4 <END=Amino Acid, Peptide, or Protein> promoter <START=Gene or Genome> via <END=Gene or Genome> the PXR in the DPX2 human hepatoma cell line."}, {"PMID": 18715952, "id": 7, "text": "EP(1) and EP(3) receptor antagonists ONO-8713 and ONO-AE3-240, but not the EP(4) antagonists ONO-AE3-208 and AH 23848, inhibited tumor cell proliferation, indicating the significance of EP(1) and EP(3) but not EP(4) for MB growth.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [37, 45], "name": "ONO-8713", "tok_span": [11, 16], "new_tok_span": [12, 17]}, {"ent_type": "CHEMICAL", "char_span": [50, 61], "name": "ONO-AE3-240", "tok_span": [17, 24], "new_tok_span": [21, 28]}, {"ent_type": "CHEMICAL", "char_span": [93, 104], "name": "ONO-AE3-208", "tok_span": [33, 40], "new_tok_span": [40, 47]}, {"ent_type": "CHEMICAL", "char_span": [109, 117], "name": "AH 23848", "tok_span": [41, 44], "new_tok_span": [50, 53]}, {"ent_type": "GENE", "char_span": [186, 191], "name": "EP(1)", "tok_span": [54, 58], "new_tok_span": [64, 68]}, {"ent_type": "GENE", "char_span": [196, 201], "name": "EP(3)", "tok_span": [59, 63], "new_tok_span": [69, 73]}, {"ent_type": "GENE", "char_span": [210, 215], "name": "EP(4)", "tok_span": [65, 69], "new_tok_span": [75, 79]}, {"ent_type": "GENE", "char_span": [0, 5], "name": "EP(1)", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "GENE", "char_span": [10, 24], "name": "EP(3) receptor", "tok_span": [5, 10], "new_tok_span": [5, 10]}, {"ent_type": "GENE", "char_span": [75, 80], "name": "EP(4)", "tok_span": [28, 32], "new_tok_span": [34, 38]}], "relation_list": [{"subject": "ONO-8713", "sbj_char_span": [37, 45], "object": "EP(1)", "obj_char_span": [0, 5], "rel_type": "agonist or antagonist", "sbj_tok_span": [11, 16], "obj_tok_span": [0, 4], "new_sbj_tok_span": [12, 17], "new_obj_tok_span": [0, 4]}, {"subject": "ONO-8713", "sbj_char_span": [37, 45], "object": "EP(3) receptor", "obj_char_span": [10, 24], "rel_type": "agonist or antagonist", "sbj_tok_span": [11, 16], "obj_tok_span": [5, 10], "new_sbj_tok_span": [12, 17], "new_obj_tok_span": [5, 10]}, {"subject": "ONO-AE3-240", "sbj_char_span": [50, 61], "object": "EP(1)", "obj_char_span": [0, 5], "rel_type": "agonist or antagonist", "sbj_tok_span": [17, 24], "obj_tok_span": [0, 4], "new_sbj_tok_span": [21, 28], "new_obj_tok_span": [0, 4]}, {"subject": "ONO-AE3-240", "sbj_char_span": [50, 61], "object": "EP(3) receptor", "obj_char_span": [10, 24], "rel_type": "agonist or antagonist", "sbj_tok_span": [17, 24], "obj_tok_span": [5, 10], "new_sbj_tok_span": [21, 28], "new_obj_tok_span": [5, 10]}, {"subject": "ONO-AE3-208", "sbj_char_span": [93, 104], "object": "EP(4)", "obj_char_span": [75, 80], "rel_type": "agonist or antagonist", "sbj_tok_span": [33, 40], "obj_tok_span": [28, 32], "new_sbj_tok_span": [40, 47], "new_obj_tok_span": [34, 38]}, {"subject": "AH 23848", "sbj_char_span": [109, 117], "object": "EP(4)", "obj_char_span": [75, 80], "rel_type": "agonist or antagonist", "sbj_tok_span": [41, 44], "obj_tok_span": [28, 32], "new_sbj_tok_span": [50, 53], "new_obj_tok_span": [34, 38]}], "umls_entity_list": [{"mention": "ONO", "char_span": [37, 40], "sem_type": "Organic Chemical", "tok_span": [11, 13], "new_tok_span": [12, 14]}, {"mention": "ONO", "char_span": [50, 53], "sem_type": "Organic Chemical", "tok_span": [17, 19], "new_tok_span": [21, 23]}, {"mention": "ONO", "char_span": [93, 96], "sem_type": "Organic Chemical", "tok_span": [33, 35], "new_tok_span": [40, 42]}, {"mention": "ONO-AE3-240", "char_span": [50, 61], "sem_type": "Pharmacologic Substance", "tok_span": [17, 24], "new_tok_span": [21, 28]}, {"mention": "AH", "char_span": [109, 111], "sem_type": "Pharmacologic Substance", "tok_span": [41, 42], "new_tok_span": [50, 51]}], "new_text": "EP ( 1 ) and EP ( 3 ) receptor antagonists <START=Organic Chemical> ONO <END=Organic Chemical> - 8713 and <START=Organic Chemical> <START=Pharmacologic Substance> ONO <END=Organic Chemical> - AE3 - 240 <END=Pharmacologic Substance>, but not the EP ( 4 ) antagonists <START=Organic Chemical> ONO <END=Organic Chemical> - AE3 - 208 and <START=Pharmacologic Substance> AH <END=Pharmacologic Substance> 23848, inhibited tumor cell proliferation, indicating the significance of EP ( 1 ) and EP ( 3 ) but not EP ( 4 ) for MB growth."}, {"PMID": 1359745, "id": 1, "text": "The unique role of the enzyme 5-lipoxygenase (5-LO) in the production of leukotrienes (LTs) makes it a likely target for biochemical manipulation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 85], "name": "leukotrienes", "tok_span": [19, 22], "new_tok_span": [25, 28]}, {"ent_type": "CHEMICAL", "char_span": [87, 90], "name": "LTs", "tok_span": [23, 25], "new_tok_span": [29, 31]}, {"ent_type": "GENE", "char_span": [30, 44], "name": "5-lipoxygenase", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [46, 50], "name": "5-LO", "tok_span": [11, 14], "new_tok_span": [15, 18]}], "relation_list": [{"subject": "leukotrienes", "sbj_char_span": [73, 85], "object": "5-lipoxygenase", "obj_char_span": [30, 44], "rel_type": "product or substrate", "sbj_tok_span": [19, 22], "obj_tok_span": [6, 10], "new_sbj_tok_span": [25, 28], "new_obj_tok_span": [6, 10]}, {"subject": "leukotrienes", "sbj_char_span": [73, 85], "object": "5-LO", "obj_char_span": [46, 50], "rel_type": "product or substrate", "sbj_tok_span": [19, 22], "obj_tok_span": [11, 14], "new_sbj_tok_span": [25, 28], "new_obj_tok_span": [15, 18]}, {"subject": "LTs", "sbj_char_span": [87, 90], "object": "5-lipoxygenase", "obj_char_span": [30, 44], "rel_type": "product or substrate", "sbj_tok_span": [23, 25], "obj_tok_span": [6, 10], "new_sbj_tok_span": [29, 31], "new_obj_tok_span": [6, 10]}, {"subject": "LTs", "sbj_char_span": [87, 90], "object": "5-LO", "obj_char_span": [46, 50], "rel_type": "product or substrate", "sbj_tok_span": [23, 25], "obj_tok_span": [11, 14], "new_sbj_tok_span": [29, 31], "new_obj_tok_span": [15, 18]}], "umls_entity_list": [{"mention": "lipoxygenase", "char_span": [32, 44], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 10], "new_tok_span": [9, 11]}, {"mention": "5-LO", "char_span": [46, 50], "sem_type": "Gene or Genome", "tok_span": [11, 14], "new_tok_span": [15, 18]}, {"mention": "5-LO", "char_span": [46, 50], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 14], "new_tok_span": [15, 18]}], "new_text": "The unique role of the enzyme 5 - <START=Amino Acid, Peptide, or Protein> lipoxygenase <END=Amino Acid, Peptide, or Protein> ( <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> 5 - LO <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ) in the production of leukotrienes ( LTs ) makes it a likely target for biochemical manipulation."}, {"PMID": 16627864, "id": 7, "text": "In addition, the HO pathway was blocked after dobutamine pretreatment with 10 micromol/kg tin-mesoporphyrin-IX (Dob/SnMP/Shock) or animals received 100 mg/kg of the carbon monoxide donor dichloromethane (DCM/Shock).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [46, 56], "name": "dobutamine", "tok_span": [9, 12], "new_tok_span": [10, 13]}, {"ent_type": "CHEMICAL", "char_span": [90, 93], "name": "tin", "tok_span": [19, 20], "new_tok_span": [21, 22]}, {"ent_type": "CHEMICAL", "char_span": [94, 110], "name": "mesoporphyrin-IX", "tok_span": [21, 27], "new_tok_span": [24, 30]}, {"ent_type": "CHEMICAL", "char_span": [112, 115], "name": "Dob", "tok_span": [28, 30], "new_tok_span": [34, 36]}, {"ent_type": "CHEMICAL", "char_span": [116, 120], "name": "SnMP", "tok_span": [31, 33], "new_tok_span": [38, 40]}, {"ent_type": "CHEMICAL", "char_span": [165, 180], "name": "carbon monoxide", "tok_span": [46, 50], "new_tok_span": [54, 58]}, {"ent_type": "CHEMICAL", "char_span": [187, 202], "name": "dichloromethane", "tok_span": [51, 53], "new_tok_span": [60, 62]}, {"ent_type": "CHEMICAL", "char_span": [204, 207], "name": "DCM", "tok_span": [54, 55], "new_tok_span": [64, 65]}, {"ent_type": "GENE", "char_span": [17, 19], "name": "HO", "tok_span": [4, 5], "new_tok_span": [4, 5]}], "relation_list": [{"subject": "dobutamine", "sbj_char_span": [46, 56], "object": "HO", "obj_char_span": [17, 19], "rel_type": "inhibitor", "sbj_tok_span": [9, 12], "obj_tok_span": [4, 5], "new_sbj_tok_span": [10, 13], "new_obj_tok_span": [4, 5]}, {"subject": "tin", "sbj_char_span": [90, 93], "object": "HO", "obj_char_span": [17, 19], "rel_type": "inhibitor", "sbj_tok_span": [19, 20], "obj_tok_span": [4, 5], "new_sbj_tok_span": [21, 22], "new_obj_tok_span": [4, 5]}, {"subject": "mesoporphyrin-IX", "sbj_char_span": [94, 110], "object": "HO", "obj_char_span": [17, 19], "rel_type": "inhibitor", "sbj_tok_span": [21, 27], "obj_tok_span": [4, 5], "new_sbj_tok_span": [24, 30], "new_obj_tok_span": [4, 5]}, {"subject": "carbon monoxide", "sbj_char_span": [165, 180], "object": "HO", "obj_char_span": [17, 19], "rel_type": "inhibitor", "sbj_tok_span": [46, 50], "obj_tok_span": [4, 5], "new_sbj_tok_span": [54, 58], "new_obj_tok_span": [4, 5]}, {"subject": "dichloromethane", "sbj_char_span": [187, 202], "object": "HO", "obj_char_span": [17, 19], "rel_type": "inhibitor", "sbj_tok_span": [51, 53], "obj_tok_span": [4, 5], "new_sbj_tok_span": [60, 62], "new_obj_tok_span": [4, 5]}], "umls_entity_list": [{"mention": "dobutamine", "char_span": [46, 56], "sem_type": "Pharmacologic Substance", "tok_span": [9, 12], "new_tok_span": [10, 13]}, {"mention": "IX", "char_span": [108, 110], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 27], "new_tok_span": [31, 32]}, {"mention": "mesoporphyrin", "char_span": [94, 107], "sem_type": "Organic Chemical", "tok_span": [21, 25], "new_tok_span": [24, 28]}, {"mention": "SnMP", "char_span": [116, 120], "sem_type": "Pharmacologic Substance", "tok_span": [31, 33], "new_tok_span": [38, 40]}, {"mention": "dichloromethane", "char_span": [187, 202], "sem_type": "Pharmacologic Substance", "tok_span": [51, 53], "new_tok_span": [60, 62]}], "new_text": "In addition, the HO pathway was blocked after <START=Pharmacologic Substance> dobutamine <END=Pharmacologic Substance> pretreatment with 10 micromol / kg tin - <START=Organic Chemical> mesoporphyrin <END=Organic Chemical> - <START=Amino Acid, Peptide, or Protein> IX <END=Amino Acid, Peptide, or Protein> ( Dob / <START=Pharmacologic Substance> SnMP <END=Pharmacologic Substance> / Shock ) or animals received 100 mg / kg of the carbon monoxide donor <START=Pharmacologic Substance> dichloromethane <END=Pharmacologic Substance> ( DCM / Shock )."}, {"PMID": 16809928, "id": 4, "text": "SSTR2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both octreotide and lanreotide bind preferentially to SSTR2 and, to a lesser extent, to SSTR5. SA inhibitory effects on GH secretion and tumor cell proliferation can occur together or be dissociated events, depending on the tumor expression of SSTR subtypes involved in each mechanism.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [81, 91], "name": "octreotide", "tok_span": [20, 23], "new_tok_span": [36, 39]}, {"ent_type": "CHEMICAL", "char_span": [96, 106], "name": "lanreotide", "tok_span": [24, 28], "new_tok_span": [41, 45]}, {"ent_type": "GENE", "char_span": [0, 5], "name": "SSTR2", "tok_span": [0, 3], "new_tok_span": [3, 6]}, {"ent_type": "GENE", "char_span": [10, 15], "name": "SSTR5", "tok_span": [4, 7], "new_tok_span": [13, 16]}, {"ent_type": "GENE", "char_span": [41, 43], "name": "GH", "tok_span": [11, 12], "new_tok_span": [25, 26]}, {"ent_type": "GENE", "char_span": [130, 135], "name": "SSTR2", "tok_span": [31, 34], "new_tok_span": [52, 55]}, {"ent_type": "GENE", "char_span": [164, 169], "name": "SSTR5", "tok_span": [42, 45], "new_tok_span": [69, 72]}, {"ent_type": "GENE", "char_span": [196, 198], "name": "GH", "tok_span": [50, 51], "new_tok_span": [86, 87]}, {"ent_type": "GENE", "char_span": [320, 324], "name": "SSTR", "tok_span": [70, 72], "new_tok_span": [109, 111]}], "relation_list": [{"subject": "octreotide", "sbj_char_span": [81, 91], "object": "SSTR2", "obj_char_span": [130, 135], "rel_type": "regulator", "sbj_tok_span": [20, 23], "obj_tok_span": [31, 34], "new_sbj_tok_span": [36, 39], "new_obj_tok_span": [52, 55]}, {"subject": "lanreotide", "sbj_char_span": [96, 106], "object": "SSTR2", "obj_char_span": [130, 135], "rel_type": "regulator", "sbj_tok_span": [24, 28], "obj_tok_span": [31, 34], "new_sbj_tok_span": [41, 45], "new_obj_tok_span": [52, 55]}, {"subject": "octreotide", "sbj_char_span": [81, 91], "object": "SSTR5", "obj_char_span": [164, 169], "rel_type": "regulator", "sbj_tok_span": [20, 23], "obj_tok_span": [42, 45], "new_sbj_tok_span": [36, 39], "new_obj_tok_span": [69, 72]}, {"subject": "lanreotide", "sbj_char_span": [96, 106], "object": "SSTR5", "obj_char_span": [164, 169], "rel_type": "regulator", "sbj_tok_span": [24, 28], "obj_tok_span": [42, 45], "new_sbj_tok_span": [41, 45], "new_obj_tok_span": [69, 72]}], "umls_entity_list": [{"mention": "SSTR2", "char_span": [0, 5], "sem_type": "Gene or Genome", "tok_span": [0, 3], "new_tok_span": [3, 6]}, {"mention": "SSTR2", "char_span": [130, 135], "sem_type": "Gene or Genome", "tok_span": [31, 34], "new_tok_span": [52, 55]}, {"mention": "SSTR2", "char_span": [0, 5], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [3, 6]}, {"mention": "SSTR2", "char_span": [130, 135], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [31, 34], "new_tok_span": [52, 55]}, {"mention": "SSTR5", "char_span": [10, 15], "sem_type": "Gene or Genome", "tok_span": [4, 7], "new_tok_span": [13, 16]}, {"mention": "SSTR5", "char_span": [164, 169], "sem_type": "Gene or Genome", "tok_span": [42, 45], "new_tok_span": [69, 72]}, {"mention": "SSTR5", "char_span": [10, 15], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 7], "new_tok_span": [13, 16]}, {"mention": "SSTR5", "char_span": [164, 169], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 45], "new_tok_span": [69, 72]}, {"mention": "GH", "char_span": [41, 43], "sem_type": "Gene or Genome", "tok_span": [11, 12], "new_tok_span": [25, 26]}, {"mention": "GH", "char_span": [196, 198], "sem_type": "Gene or Genome", "tok_span": [50, 51], "new_tok_span": [86, 87]}, {"mention": "GH", "char_span": [41, 43], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [11, 12], "new_tok_span": [25, 26]}, {"mention": "GH", "char_span": [196, 198], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 51], "new_tok_span": [86, 87]}, {"mention": "lanreotide", "char_span": [96, 106], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 28], "new_tok_span": [41, 45]}, {"mention": "SA", "char_span": [171, 173], "sem_type": "Organic Chemical", "tok_span": [46, 47], "new_tok_span": [78, 79]}, {"mention": "SA", "char_span": [171, 173], "sem_type": "Gene or Genome", "tok_span": [46, 47], "new_tok_span": [78, 79]}, {"mention": "SSTR", "char_span": [0, 4], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 2], "new_tok_span": [3, 5]}, {"mention": "SSTR", "char_span": [10, 14], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 6], "new_tok_span": [13, 15]}, {"mention": "SSTR", "char_span": [130, 134], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [31, 33], "new_tok_span": [52, 54]}, {"mention": "SSTR", "char_span": [164, 168], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 44], "new_tok_span": [69, 71]}, {"mention": "SSTR", "char_span": [320, 324], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [70, 72], "new_tok_span": [109, 111]}], "new_text": "<START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> SSTR <END=Amino Acid, Peptide, or Protein>2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> SSTR <END=Amino Acid, Peptide, or Protein>5 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> are usually expressed in <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> GH <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - secreting pituitary tumors, and both octreotide and <START=Amino Acid, Peptide, or Protein> lanreotide <END=Amino Acid, Peptide, or Protein> bind preferentially to <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> SSTR <END=Amino Acid, Peptide, or Protein>2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and, to a lesser extent, to <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> SSTR <END=Amino Acid, Peptide, or Protein>5 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>. <START=Organic Chemical> <START=Gene or Genome> SA <END=Organic Chemical> <END=Gene or Genome> inhibitory effects on <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> GH <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> secretion and tumor cell proliferation can occur together or be dissociated events, depending on the tumor expression of <START=Amino Acid, Peptide, or Protein> SSTR <END=Amino Acid, Peptide, or Protein> subtypes involved in each mechanism."}, {"PMID": 10460702, "id": 1, "text": "Activation of endothelial nitric oxide synthase (eNOS) results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [26, 38], "name": "nitric oxide", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"ent_type": "CHEMICAL", "char_span": [84, 96], "name": "nitric oxide", "tok_span": [14, 16], "new_tok_span": [19, 21]}, {"ent_type": "CHEMICAL", "char_span": [98, 100], "name": "NO", "tok_span": [17, 18], "new_tok_span": [23, 24]}, {"ent_type": "GENE", "char_span": [14, 47], "name": "endothelial nitric oxide synthase", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"ent_type": "GENE", "char_span": [49, 53], "name": "eNOS", "tok_span": [7, 8], "new_tok_span": [11, 12]}], "relation_list": [{"subject": "nitric oxide", "sbj_char_span": [84, 96], "object": "endothelial nitric oxide synthase", "obj_char_span": [14, 47], "rel_type": "product or substrate", "sbj_tok_span": [14, 16], "obj_tok_span": [2, 6], "new_sbj_tok_span": [19, 21], "new_obj_tok_span": [3, 7]}, {"subject": "nitric oxide", "sbj_char_span": [84, 96], "object": "eNOS", "obj_char_span": [49, 53], "rel_type": "product or substrate", "sbj_tok_span": [14, 16], "obj_tok_span": [7, 8], "new_sbj_tok_span": [19, 21], "new_obj_tok_span": [11, 12]}, {"subject": "NO", "sbj_char_span": [98, 100], "object": "endothelial nitric oxide synthase", "obj_char_span": [14, 47], "rel_type": "product or substrate", "sbj_tok_span": [17, 18], "obj_tok_span": [2, 6], "new_sbj_tok_span": [23, 24], "new_obj_tok_span": [3, 7]}, {"subject": "NO", "sbj_char_span": [98, 100], "object": "eNOS", "obj_char_span": [49, 53], "rel_type": "product or substrate", "sbj_tok_span": [17, 18], "obj_tok_span": [7, 8], "new_sbj_tok_span": [23, 24], "new_obj_tok_span": [11, 12]}], "umls_entity_list": [{"mention": "endothelial nitric oxide synthase", "char_span": [14, 47], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"mention": "nitric oxide", "char_span": [26, 38], "sem_type": "Pharmacologic Substance", "tok_span": [3, 5], "new_tok_span": [5, 7]}, {"mention": "nitric oxide", "char_span": [84, 96], "sem_type": "Pharmacologic Substance", "tok_span": [14, 16], "new_tok_span": [19, 21]}], "new_text": "Activation of <START=Amino Acid, Peptide, or Protein> endothelial <START=Pharmacologic Substance> nitric oxide <END=Pharmacologic Substance> synthase <END=Amino Acid, Peptide, or Protein> ( eNOS ) results in the production of <START=Pharmacologic Substance> nitric oxide <END=Pharmacologic Substance> ( NO ) that mediates the vasorelaxing properties of endothelial cells."}, {"PMID": 17929831, "id": 1, "text": "Adenylosuccinate synthetase (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP. AdSS from the thermophilic archaea, Methanocaldococcus jannaschii (MjAdSS) is 345 amino acids long against an average length of 430-457 amino acids for most mesophilic AdSS. This short AdSS has two large deletions that map to the middle and C-terminus of the protein.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 16], "name": "Adenylosuccinate", "tok_span": [0, 6], "new_tok_span": [1, 7]}, {"ent_type": "CHEMICAL", "char_span": [103, 112], "name": "aspartate", "tok_span": [26, 28], "new_tok_span": [35, 37]}, {"ent_type": "CHEMICAL", "char_span": [121, 137], "name": "adenylosuccinate", "tok_span": [30, 36], "new_tok_span": [40, 46]}, {"ent_type": "CHEMICAL", "char_span": [181, 184], "name": "GTP", "tok_span": [45, 46], "new_tok_span": [55, 56]}, {"ent_type": "CHEMICAL", "char_span": [188, 191], "name": "GDP", "tok_span": [47, 48], "new_tok_span": [57, 58]}, {"ent_type": "CHEMICAL", "char_span": [275, 286], "name": "amino acids", "tok_span": [77, 79], "new_tok_span": [88, 90]}, {"ent_type": "CHEMICAL", "char_span": [329, 340], "name": "amino acids", "tok_span": [89, 91], "new_tok_span": [102, 104]}, {"ent_type": "CHEMICAL", "char_span": [434, 435], "name": "C", "tok_span": [112, 113], "new_tok_span": [126, 127]}, {"ent_type": "CHEMICAL", "char_span": [49, 53], "name": "Mg2+", "tok_span": [15, 18], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [0, 27], "name": "Adenylosuccinate synthetase", "tok_span": [0, 8], "new_tok_span": [1, 9]}, {"ent_type": "GENE", "char_span": [193, 197], "name": "AdSS", "tok_span": [49, 51], "new_tok_span": [59, 61]}, {"ent_type": "GENE", "char_span": [260, 266], "name": "MjAdSS", "tok_span": [70, 74], "new_tok_span": [80, 84]}, {"ent_type": "GENE", "char_span": [29, 33], "name": "AdSS", "tok_span": [9, 11], "new_tok_span": [11, 13]}, {"ent_type": "GENE", "char_span": [361, 365], "name": "AdSS", "tok_span": [95, 97], "new_tok_span": [109, 111]}, {"ent_type": "GENE", "char_span": [378, 382], "name": "AdSS", "tok_span": [100, 102], "new_tok_span": [114, 116]}], "relation_list": [{"subject": "adenylosuccinate", "sbj_char_span": [121, 137], "object": "Adenylosuccinate synthetase", "obj_char_span": [0, 27], "rel_type": "product or substrate", "sbj_tok_span": [30, 36], "obj_tok_span": [0, 8], "new_sbj_tok_span": [40, 46], "new_obj_tok_span": [1, 9]}, {"subject": "adenylosuccinate", "sbj_char_span": [121, 137], "object": "AdSS", "obj_char_span": [29, 33], "rel_type": "product or substrate", "sbj_tok_span": [30, 36], "obj_tok_span": [9, 11], "new_sbj_tok_span": [40, 46], "new_obj_tok_span": [11, 13]}, {"subject": "Mg2+", "sbj_char_span": [49, 53], "object": "AdSS", "obj_char_span": [29, 33], "rel_type": "product or substrate", "sbj_tok_span": [15, 18], "obj_tok_span": [9, 11], "new_sbj_tok_span": [19, 22], "new_obj_tok_span": [11, 13]}, {"subject": "amino acids", "sbj_char_span": [275, 286], "object": "MjAdSS", "obj_char_span": [260, 266], "rel_type": "part of", "sbj_tok_span": [77, 79], "obj_tok_span": [70, 74], "new_sbj_tok_span": [88, 90], "new_obj_tok_span": [80, 84]}, {"subject": "amino acids", "sbj_char_span": [275, 286], "object": "AdSS", "obj_char_span": [193, 197], "rel_type": "part of", "sbj_tok_span": [77, 79], "obj_tok_span": [49, 51], "new_sbj_tok_span": [88, 90], "new_obj_tok_span": [59, 61]}, {"subject": "amino acids", "sbj_char_span": [329, 340], "object": "AdSS", "obj_char_span": [361, 365], "rel_type": "part of", "sbj_tok_span": [89, 91], "obj_tok_span": [95, 97], "new_sbj_tok_span": [102, 104], "new_obj_tok_span": [109, 111]}, {"subject": "C", "sbj_char_span": [434, 435], "object": "AdSS", "obj_char_span": [378, 382], "rel_type": "part of", "sbj_tok_span": [112, 113], "obj_tok_span": [100, 102], "new_sbj_tok_span": [126, 127], "new_obj_tok_span": [114, 116]}], "umls_entity_list": [{"mention": "Adenylosuccinate synthetase", "char_span": [0, 27], "sem_type": "Gene or Genome", "tok_span": [0, 8], "new_tok_span": [1, 9]}, {"mention": "Mg2", "char_span": [49, 52], "sem_type": "Gene or Genome", "tok_span": [15, 17], "new_tok_span": [19, 21]}, {"mention": "IMP", "char_span": [94, 97], "sem_type": "Gene or Genome", "tok_span": [24, 25], "new_tok_span": [31, 32]}, {"mention": "Mg2+", "char_span": [49, 53], "sem_type": "Pharmacologic Substance", "tok_span": [15, 18], "new_tok_span": [19, 22]}, {"mention": "aspartate", "char_span": [103, 112], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 28], "new_tok_span": [35, 37]}, {"mention": "amino acids", "char_span": [275, 286], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [77, 79], "new_tok_span": [88, 90]}, {"mention": "amino acids", "char_span": [329, 340], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [89, 91], "new_tok_span": [102, 104]}], "new_text": "<START=Gene or Genome> Adenylosuccinate synthetase <END=Gene or Genome> ( AdSS ) catalyzes the <START=Gene or Genome> <START=Pharmacologic Substance> Mg2 <END=Gene or Genome> + <END=Pharmacologic Substance> dependent condensation of a molecule of <START=Gene or Genome> IMP <END=Gene or Genome> with <START=Amino Acid, Peptide, or Protein> aspartate <END=Amino Acid, Peptide, or Protein> to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP. AdSS from the thermophilic archaea, Methanocaldococcus jannaschii ( MjAdSS ) is 345 <START=Amino Acid, Peptide, or Protein> amino acids <END=Amino Acid, Peptide, or Protein> long against an average length of 430 - 457 <START=Amino Acid, Peptide, or Protein> amino acids <END=Amino Acid, Peptide, or Protein> for most mesophilic AdSS. This short AdSS has two large deletions that map to the middle and C - terminus of the protein."}, {"PMID": 12366848, "id": 1, "text": "The most important group of antifungals is the azoles (e.g. miconazole), which act by inhibiting lanosterol demethylase in the sterol biosynthesis pathway.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [127, 133], "name": "sterol", "tok_span": [35, 37], "new_tok_span": [43, 45]}, {"ent_type": "CHEMICAL", "char_span": [47, 53], "name": "azoles", "tok_span": [9, 11], "new_tok_span": [11, 13]}, {"ent_type": "CHEMICAL", "char_span": [60, 70], "name": "miconazole", "tok_span": [16, 20], "new_tok_span": [19, 23]}, {"ent_type": "CHEMICAL", "char_span": [97, 107], "name": "lanosterol", "tok_span": [26, 30], "new_tok_span": [31, 35]}, {"ent_type": "GENE", "char_span": [97, 119], "name": "lanosterol demethylase", "tok_span": [26, 33], "new_tok_span": [31, 38]}], "relation_list": [{"subject": "azoles", "sbj_char_span": [47, 53], "object": "lanosterol demethylase", "obj_char_span": [97, 119], "rel_type": "inhibitor", "sbj_tok_span": [9, 11], "obj_tok_span": [26, 33], "new_sbj_tok_span": [11, 13], "new_obj_tok_span": [31, 38]}, {"subject": "miconazole", "sbj_char_span": [60, 70], "object": "lanosterol demethylase", "obj_char_span": [97, 119], "rel_type": "inhibitor", "sbj_tok_span": [16, 20], "obj_tok_span": [26, 33], "new_sbj_tok_span": [19, 23], "new_obj_tok_span": [31, 38]}, {"subject": "sterol", "sbj_char_span": [127, 133], "object": "lanosterol demethylase", "obj_char_span": [97, 119], "rel_type": "product or substrate", "sbj_tok_span": [35, 37], "obj_tok_span": [26, 33], "new_sbj_tok_span": [43, 45], "new_obj_tok_span": [31, 38]}], "umls_entity_list": [{"mention": "antifungals", "char_span": [28, 39], "sem_type": "Pharmacologic Substance", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"mention": "miconazol", "char_span": [60, 69], "sem_type": "Pharmacologic Substance", "tok_span": [16, 19], "new_tok_span": [19, 22]}, {"mention": "lanosterol", "char_span": [97, 107], "sem_type": "Organic Chemical", "tok_span": [26, 30], "new_tok_span": [31, 35]}, {"mention": "demethylase", "char_span": [108, 119], "sem_type": "Gene or Genome", "tok_span": [30, 33], "new_tok_span": [37, 40]}], "new_text": "The most important group of <START=Pharmacologic Substance> antifungals <END=Pharmacologic Substance> is the azoles ( e. g. <START=Pharmacologic Substance> miconazol <END=Pharmacologic Substance>e ), which act by inhibiting <START=Organic Chemical> lanosterol <END=Organic Chemical> <START=Gene or Genome> demethylase <END=Gene or Genome> in the sterol biosynthesis pathway."}, {"PMID": 2892392, "id": 1, "text": "The effect of nizatidine, a new histamine H2 receptor antagonist, on gastric secretory function of eight normal subjects stimulated with betazole, was compared with that of cimetidine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [137, 145], "name": "betazole", "tok_span": [25, 28], "new_tok_span": [28, 31]}, {"ent_type": "CHEMICAL", "char_span": [14, 24], "name": "nizatidine", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [173, 183], "name": "cimetidine", "tok_span": [34, 37], "new_tok_span": [39, 42]}, {"ent_type": "CHEMICAL", "char_span": [32, 41], "name": "histamine", "tok_span": [9, 10], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [32, 53], "name": "histamine H2 receptor", "tok_span": [9, 13], "new_tok_span": [11, 15]}], "relation_list": [{"subject": "nizatidine", "sbj_char_span": [14, 24], "object": "histamine H2 receptor", "obj_char_span": [32, 53], "rel_type": "agonist or antagonist", "sbj_tok_span": [3, 6], "obj_tok_span": [9, 13], "new_sbj_tok_span": [4, 7], "new_obj_tok_span": [11, 15]}], "umls_entity_list": [{"mention": "nizatidine", "char_span": [14, 24], "sem_type": "Pharmacologic Substance", "tok_span": [3, 6], "new_tok_span": [4, 7]}, {"mention": "betazole", "char_span": [137, 145], "sem_type": "Pharmacologic Substance", "tok_span": [25, 28], "new_tok_span": [28, 31]}, {"mention": "cimetidine", "char_span": [173, 183], "sem_type": "Pharmacologic Substance", "tok_span": [34, 37], "new_tok_span": [39, 42]}], "new_text": "The effect of <START=Pharmacologic Substance> nizatidine <END=Pharmacologic Substance>, a new histamine H2 receptor antagonist, on gastric secretory function of eight normal subjects stimulated with <START=Pharmacologic Substance> betazole <END=Pharmacologic Substance>, was compared with that of <START=Pharmacologic Substance> cimetidine <END=Pharmacologic Substance>."}, {"PMID": 23567998, "id": 10, "text": "Our data shows that gabapentin is a substrate for the influx transporter LAT1 at therapeutic concentrations.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [20, 30], "name": "gabapentin", "tok_span": [4, 8], "new_tok_span": [4, 8]}, {"ent_type": "GENE", "char_span": [73, 77], "name": "LAT1", "tok_span": [15, 18], "new_tok_span": [15, 18]}], "relation_list": [{"subject": "gabapentin", "sbj_char_span": [20, 30], "object": "LAT1", "obj_char_span": [73, 77], "rel_type": "product or substrate", "sbj_tok_span": [4, 8], "obj_tok_span": [15, 18], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [15, 18]}], "umls_entity_list": [], "new_text": "Our data shows that gabapentin is a substrate for the influx transporter LAT1 at therapeutic concentrations."}, {"PMID": 23154533, "id": 5, "text": "Her MPO-ANCA titer was 21 ELISA units (EUs) before PTU treatment but increased to 259 EUs at 22 days after PTU treatment.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [51, 54], "name": "PTU", "tok_span": [16, 18], "new_tok_span": [18, 20]}, {"ent_type": "CHEMICAL", "char_span": [107, 110], "name": "PTU", "tok_span": [30, 32], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [4, 7], "name": "MPO", "tok_span": [1, 3], "new_tok_span": [2, 4]}], "relation_list": [{"subject": "PTU", "sbj_char_span": [107, 110], "object": "MPO", "obj_char_span": [4, 7], "rel_type": "regulator", "sbj_tok_span": [30, 32], "obj_tok_span": [1, 3], "new_sbj_tok_span": [32, 34], "new_obj_tok_span": [2, 4]}], "umls_entity_list": [{"mention": "MPO", "char_span": [4, 7], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 3], "new_tok_span": [2, 4]}], "new_text": "Her <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> - ANCA titer was 21 ELISA units ( EUs ) before PTU treatment but increased to 259 EUs at 22 days after PTU treatment."}, {"PMID": 8566141, "id": 5, "text": "These results suggest that amantadine induction of Fos in the rat striatum is related to dopamine D1 and NMDA receptors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [27, 37], "name": "amantadine", "tok_span": [4, 8], "new_tok_span": [4, 8]}, {"ent_type": "CHEMICAL", "char_span": [89, 97], "name": "dopamine", "tok_span": [19, 20], "new_tok_span": [19, 20]}, {"ent_type": "CHEMICAL", "char_span": [105, 109], "name": "NMDA", "tok_span": [23, 24], "new_tok_span": [25, 26]}, {"ent_type": "GENE", "char_span": [51, 54], "name": "Fos", "tok_span": [10, 12], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [89, 100], "name": "dopamine D1", "tok_span": [19, 22], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [105, 119], "name": "NMDA receptors", "tok_span": [23, 25], "new_tok_span": [25, 27]}], "relation_list": [{"subject": "amantadine", "sbj_char_span": [27, 37], "object": "Fos", "obj_char_span": [51, 54], "rel_type": "regulator", "sbj_tok_span": [4, 8], "obj_tok_span": [10, 12], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [10, 12]}], "umls_entity_list": [{"mention": "D1", "char_span": [98, 100], "sem_type": "Gene or Genome", "tok_span": [20, 22], "new_tok_span": [21, 23]}], "new_text": "These results suggest that amantadine induction of Fos in the rat striatum is related to dopamine <START=Gene or Genome> D1 <END=Gene or Genome> and NMDA receptors."}, {"PMID": 23237828, "id": 9, "text": "These results imply the functional MEK1/ERK-mediated pathway is necessary for the cycloheximide stimulation of SOCS-3 gene expression.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [82, 95], "name": "cycloheximide", "tok_span": [16, 19], "new_tok_span": [17, 20]}, {"ent_type": "GENE", "char_span": [35, 39], "name": "MEK1", "tok_span": [5, 7], "new_tok_span": [5, 7]}, {"ent_type": "GENE", "char_span": [40, 43], "name": "ERK", "tok_span": [8, 9], "new_tok_span": [8, 9]}, {"ent_type": "GENE", "char_span": [111, 117], "name": "SOCS-3", "tok_span": [21, 25], "new_tok_span": [25, 29]}], "relation_list": [{"subject": "cycloheximide", "sbj_char_span": [82, 95], "object": "SOCS-3", "obj_char_span": [111, 117], "rel_type": "regulator", "sbj_tok_span": [16, 19], "obj_tok_span": [21, 25], "new_sbj_tok_span": [17, 20], "new_obj_tok_span": [25, 29]}], "umls_entity_list": [{"mention": "cycloheximide", "char_span": [82, 95], "sem_type": "Organic Chemical", "tok_span": [16, 19], "new_tok_span": [17, 20]}, {"mention": "SOCS-3", "char_span": [111, 117], "sem_type": "Gene or Genome", "tok_span": [21, 25], "new_tok_span": [25, 29]}, {"mention": "SOCS-3", "char_span": [111, 117], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 25], "new_tok_span": [25, 29]}], "new_text": "These results imply the functional MEK1 / ERK - mediated pathway is necessary for the <START=Organic Chemical> cycloheximide <END=Organic Chemical> stimulation of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> SOCS - 3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> gene expression."}, {"PMID": 8740147, "id": 9, "text": "When MAO-B was also inhibited, 10 nmol/l amezinium caused 84% inhibition of the deamination of noradrenaline by MAO-A in the lungs.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [41, 50], "name": "amezinium", "tok_span": [13, 17], "new_tok_span": [14, 18]}, {"ent_type": "CHEMICAL", "char_span": [95, 108], "name": "noradrenaline", "tok_span": [26, 29], "new_tok_span": [29, 32]}, {"ent_type": "GENE", "char_span": [5, 10], "name": "MAO-B", "tok_span": [1, 5], "new_tok_span": [1, 5]}, {"ent_type": "GENE", "char_span": [112, 117], "name": "MAO-A", "tok_span": [30, 34], "new_tok_span": [36, 40]}], "relation_list": [{"subject": "amezinium", "sbj_char_span": [41, 50], "object": "MAO-A", "obj_char_span": [112, 117], "rel_type": "inhibitor", "sbj_tok_span": [13, 17], "obj_tok_span": [30, 34], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [36, 40]}], "umls_entity_list": [{"mention": "amezinium", "char_span": [41, 50], "sem_type": "Pharmacologic Substance", "tok_span": [13, 17], "new_tok_span": [14, 18]}, {"mention": "noradrenaline", "char_span": [95, 108], "sem_type": "Pharmacologic Substance", "tok_span": [26, 29], "new_tok_span": [29, 32]}, {"mention": "MAO-A", "char_span": [112, 117], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 34], "new_tok_span": [36, 40]}, {"mention": "MAO-A", "char_span": [112, 117], "sem_type": "Gene or Genome", "tok_span": [30, 34], "new_tok_span": [36, 40]}], "new_text": "When MAO - B was also inhibited, 10 nmol / l <START=Pharmacologic Substance> amezinium <END=Pharmacologic Substance> caused 84 % inhibition of the deamination of <START=Pharmacologic Substance> noradrenaline <END=Pharmacologic Substance> by <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> MAO - A <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> in the lungs."}, {"PMID": 12181427, "id": 3, "text": "Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A). In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [60, 69], "name": "milrinone", "tok_span": [21, 24], "new_tok_span": [22, 25]}, {"ent_type": "CHEMICAL", "char_span": [196, 206], "name": "cilostazol", "tok_span": [59, 63], "new_tok_span": [66, 70]}, {"ent_type": "CHEMICAL", "char_span": [367, 377], "name": "cilostazol", "tok_span": [116, 120], "new_tok_span": [129, 133]}, {"ent_type": "CHEMICAL", "char_span": [400, 409], "name": "milrinone", "tok_span": [124, 127], "new_tok_span": [139, 142]}, {"ent_type": "GENE", "char_span": [431, 436], "name": "PDE3A", "tok_span": [130, 133], "new_tok_span": [148, 151]}, {"ent_type": "GENE", "char_span": [8, 13], "name": "Y751A", "tok_span": [2, 6], "new_tok_span": [2, 6]}, {"ent_type": "GENE", "char_span": [15, 20], "name": "D950A", "tok_span": [7, 11], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [26, 32], "name": "F1004A", "tok_span": [13, 17], "new_tok_span": [13, 17]}, {"ent_type": "GENE", "char_span": [121, 126], "name": "PDE3A", "tok_span": [39, 42], "new_tok_span": [43, 46]}, {"ent_type": "GENE", "char_span": [285, 290], "name": "PDE3A", "tok_span": [85, 88], "new_tok_span": [95, 98]}, {"ent_type": "GENE", "char_span": [318, 323], "name": "T844A", "tok_span": [95, 99], "new_tok_span": [107, 111]}, {"ent_type": "GENE", "char_span": [325, 330], "name": "F972A", "tok_span": [100, 104], "new_tok_span": [112, 116]}, {"ent_type": "GENE", "char_span": [335, 340], "name": "Q975A", "tok_span": [105, 109], "new_tok_span": [117, 121]}], "relation_list": [{"subject": "milrinone", "sbj_char_span": [60, 69], "object": "Y751A", "obj_char_span": [8, 13], "rel_type": "inhibitor", "sbj_tok_span": [21, 24], "obj_tok_span": [2, 6], "new_sbj_tok_span": [22, 25], "new_obj_tok_span": [2, 6]}, {"subject": "milrinone", "sbj_char_span": [60, 69], "object": "D950A", "obj_char_span": [15, 20], "rel_type": "inhibitor", "sbj_tok_span": [21, 24], "obj_tok_span": [7, 11], "new_sbj_tok_span": [22, 25], "new_obj_tok_span": [7, 11]}, {"subject": "milrinone", "sbj_char_span": [60, 69], "object": "F1004A", "obj_char_span": [26, 32], "rel_type": "inhibitor", "sbj_tok_span": [21, 24], "obj_tok_span": [13, 17], "new_sbj_tok_span": [22, 25], "new_obj_tok_span": [13, 17]}, {"subject": "milrinone", "sbj_char_span": [60, 69], "object": "PDE3A", "obj_char_span": [121, 126], "rel_type": "inhibitor", "sbj_tok_span": [21, 24], "obj_tok_span": [39, 42], "new_sbj_tok_span": [22, 25], "new_obj_tok_span": [43, 46]}, {"subject": "cilostazol", "sbj_char_span": [196, 206], "object": "PDE3A", "obj_char_span": [285, 290], "rel_type": "inhibitor", "sbj_tok_span": [59, 63], "obj_tok_span": [85, 88], "new_sbj_tok_span": [66, 70], "new_obj_tok_span": [95, 98]}, {"subject": "cilostazol", "sbj_char_span": [367, 377], "object": "T844A", "obj_char_span": [318, 323], "rel_type": "inhibitor", "sbj_tok_span": [116, 120], "obj_tok_span": [95, 99], "new_sbj_tok_span": [129, 133], "new_obj_tok_span": [107, 111]}, {"subject": "cilostazol", "sbj_char_span": [367, 377], "object": "F972A", "obj_char_span": [325, 330], "rel_type": "inhibitor", "sbj_tok_span": [116, 120], "obj_tok_span": [100, 104], "new_sbj_tok_span": [129, 133], "new_obj_tok_span": [112, 116]}, {"subject": "cilostazol", "sbj_char_span": [367, 377], "object": "Q975A", "obj_char_span": [335, 340], "rel_type": "inhibitor", "sbj_tok_span": [116, 120], "obj_tok_span": [105, 109], "new_sbj_tok_span": [129, 133], "new_obj_tok_span": [117, 121]}, {"subject": "cilostazol", "sbj_char_span": [367, 377], "object": "PDE3A", "obj_char_span": [431, 436], "rel_type": "inhibitor", "sbj_tok_span": [116, 120], "obj_tok_span": [130, 133], "new_sbj_tok_span": [129, 133], "new_obj_tok_span": [148, 151]}, {"subject": "milrinone", "sbj_char_span": [400, 409], "object": "PDE3A", "obj_char_span": [431, 436], "rel_type": "inhibitor", "sbj_tok_span": [124, 127], "obj_tok_span": [130, 133], "new_sbj_tok_span": [139, 142], "new_obj_tok_span": [148, 151]}, {"subject": "milrinone", "sbj_char_span": [400, 409], "object": "T844A", "obj_char_span": [318, 323], "rel_type": "inhibitor", "sbj_tok_span": [124, 127], "obj_tok_span": [95, 99], "new_sbj_tok_span": [139, 142], "new_obj_tok_span": [107, 111]}, {"subject": "milrinone", "sbj_char_span": [400, 409], "object": "F972A", "obj_char_span": [325, 330], "rel_type": "inhibitor", "sbj_tok_span": [124, 127], "obj_tok_span": [100, 104], "new_sbj_tok_span": [139, 142], "new_obj_tok_span": [112, 116]}, {"subject": "milrinone", "sbj_char_span": [400, 409], "object": "Q975A", "obj_char_span": [335, 340], "rel_type": "inhibitor", "sbj_tok_span": [124, 127], "obj_tok_span": [105, 109], "new_sbj_tok_span": [139, 142], "new_obj_tok_span": [117, 121]}], "umls_entity_list": [{"mention": "milrinone", "char_span": [60, 69], "sem_type": "Pharmacologic Substance", "tok_span": [21, 24], "new_tok_span": [22, 25]}, {"mention": "milrinone", "char_span": [400, 409], "sem_type": "Pharmacologic Substance", "tok_span": [124, 127], "new_tok_span": [139, 142]}, {"mention": "PDE3A", "char_span": [121, 126], "sem_type": "Gene or Genome", "tok_span": [39, 42], "new_tok_span": [43, 46]}, {"mention": "PDE3A", "char_span": [285, 290], "sem_type": "Gene or Genome", "tok_span": [85, 88], "new_tok_span": [95, 98]}, {"mention": "PDE3A", "char_span": [431, 436], "sem_type": "Gene or Genome", "tok_span": [130, 133], "new_tok_span": [148, 151]}, {"mention": "PDE3A", "char_span": [121, 126], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 42], "new_tok_span": [43, 46]}, {"mention": "PDE3A", "char_span": [285, 290], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [85, 88], "new_tok_span": [95, 98]}, {"mention": "PDE3A", "char_span": [431, 436], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [130, 133], "new_tok_span": [148, 151]}, {"mention": "cilostazol", "char_span": [196, 206], "sem_type": "Pharmacologic Substance", "tok_span": [59, 63], "new_tok_span": [66, 70]}, {"mention": "cilostazol", "char_span": [367, 377], "sem_type": "Pharmacologic Substance", "tok_span": [116, 120], "new_tok_span": [129, 133]}], "new_text": "Mutants Y751A, D950A, and F1004A had reduced sensitivity to <START=Pharmacologic Substance> milrinone <END=Pharmacologic Substance> ( K ( i ) changed from 0. 66 microM for the recombinant <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PDE3A <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> to 7. 5 to 156 microM for the mutants ), and diminished sensitivity to <START=Pharmacologic Substance> cilostazol <END=Pharmacologic Substance> ( K ( i ) of the mutants were 18 - to 371 - fold higher than that of the recombinant <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PDE3A <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ). In contrast, the mutants T844A, F972A and Q975A showed increased K ( i ) for <START=Pharmacologic Substance> cilostazol <END=Pharmacologic Substance> but no difference for <START=Pharmacologic Substance> milrinone <END=Pharmacologic Substance> from the recombinant <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> PDE3A <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23327877, "id": 5, "text": "Compound 6 stimulated OATP1B3-mediated estradiol 17β-glucuronide uptake by increasing the apparent affinity of OATP1B3 for its substrate.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [39, 64], "name": "estradiol 17β-glucuronide", "tok_span": [10, 17], "new_tok_span": [13, 20]}, {"ent_type": "GENE", "char_span": [111, 118], "name": "OATP1B3", "tok_span": [24, 29], "new_tok_span": [31, 36]}, {"ent_type": "GENE", "char_span": [22, 29], "name": "OATP1B3", "tok_span": [3, 8], "new_tok_span": [4, 9]}], "relation_list": [{"subject": "estradiol 17β-glucuronide", "sbj_char_span": [39, 64], "object": "OATP1B3", "obj_char_span": [22, 29], "rel_type": "product or substrate", "sbj_tok_span": [10, 17], "obj_tok_span": [3, 8], "new_sbj_tok_span": [13, 20], "new_obj_tok_span": [4, 9]}, {"subject": "estradiol 17β-glucuronide", "sbj_char_span": [39, 64], "object": "OATP1B3", "obj_char_span": [111, 118], "rel_type": "product or substrate", "sbj_tok_span": [10, 17], "obj_tok_span": [24, 29], "new_sbj_tok_span": [13, 20], "new_obj_tok_span": [31, 36]}], "umls_entity_list": [{"mention": "OATP1B3", "char_span": [22, 29], "sem_type": "Gene or Genome", "tok_span": [3, 8], "new_tok_span": [4, 9]}, {"mention": "OATP1B3", "char_span": [111, 118], "sem_type": "Gene or Genome", "tok_span": [24, 29], "new_tok_span": [31, 36]}, {"mention": "estradiol", "char_span": [39, 48], "sem_type": "Pharmacologic Substance", "tok_span": [10, 11], "new_tok_span": [13, 14]}, {"mention": "glucuronide", "char_span": [53, 64], "sem_type": "Organic Chemical", "tok_span": [14, 17], "new_tok_span": [19, 22]}], "new_text": "Compound 6 stimulated <START=Gene or Genome> OATP1B3 <END=Gene or Genome> - mediated <START=Pharmacologic Substance> estradiol <END=Pharmacologic Substance> 17β - <START=Organic Chemical> glucuronide <END=Organic Chemical> uptake by increasing the apparent affinity of <START=Gene or Genome> OATP1B3 <END=Gene or Genome> for its substrate."}, {"PMID": 17497253, "id": 9, "text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e.g., sotalol or ibutilide in patients with a mutation in the IKr-coding gene KCNH2 (HERG). Quinidine proved to be efficient in prolonging the QT interval and normalizing the effective refractory periods in some patients.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [195, 202], "name": "sotalol", "tok_span": [38, 41], "new_tok_span": [38, 41]}, {"ent_type": "CHEMICAL", "char_span": [206, 215], "name": "ibutilide", "tok_span": [42, 45], "new_tok_span": [43, 46]}, {"ent_type": "CHEMICAL", "char_span": [281, 290], "name": "Quinidine", "tok_span": [65, 69], "new_tok_span": [69, 73]}, {"ent_type": "GENE", "char_span": [251, 254], "name": "IKr", "tok_span": [52, 54], "new_tok_span": [54, 56]}, {"ent_type": "GENE", "char_span": [267, 272], "name": "KCNH2", "tok_span": [57, 60], "new_tok_span": [60, 63]}, {"ent_type": "GENE", "char_span": [274, 278], "name": "HERG", "tok_span": [61, 63], "new_tok_span": [65, 67]}], "relation_list": [{"subject": "sotalol", "sbj_char_span": [195, 202], "object": "IKr", "obj_char_span": [251, 254], "rel_type": "inhibitor", "sbj_tok_span": [38, 41], "obj_tok_span": [52, 54], "new_sbj_tok_span": [38, 41], "new_obj_tok_span": [54, 56]}, {"subject": "sotalol", "sbj_char_span": [195, 202], "object": "KCNH2", "obj_char_span": [267, 272], "rel_type": "inhibitor", "sbj_tok_span": [38, 41], "obj_tok_span": [57, 60], "new_sbj_tok_span": [38, 41], "new_obj_tok_span": [60, 63]}, {"subject": "sotalol", "sbj_char_span": [195, 202], "object": "HERG", "obj_char_span": [274, 278], "rel_type": "inhibitor", "sbj_tok_span": [38, 41], "obj_tok_span": [61, 63], "new_sbj_tok_span": [38, 41], "new_obj_tok_span": [65, 67]}, {"subject": "ibutilide", "sbj_char_span": [206, 215], "object": "IKr", "obj_char_span": [251, 254], "rel_type": "inhibitor", "sbj_tok_span": [42, 45], "obj_tok_span": [52, 54], "new_sbj_tok_span": [43, 46], "new_obj_tok_span": [54, 56]}, {"subject": "ibutilide", "sbj_char_span": [206, 215], "object": "KCNH2", "obj_char_span": [267, 272], "rel_type": "inhibitor", "sbj_tok_span": [42, 45], "obj_tok_span": [57, 60], "new_sbj_tok_span": [43, 46], "new_obj_tok_span": [60, 63]}, {"subject": "ibutilide", "sbj_char_span": [206, 215], "object": "HERG", "obj_char_span": [274, 278], "rel_type": "inhibitor", "sbj_tok_span": [42, 45], "obj_tok_span": [61, 63], "new_sbj_tok_span": [43, 46], "new_obj_tok_span": [65, 67]}], "umls_entity_list": [{"mention": "ibutilide", "char_span": [206, 215], "sem_type": "Pharmacologic Substance", "tok_span": [42, 45], "new_tok_span": [43, 46]}, {"mention": "KCNH2", "char_span": [267, 272], "sem_type": "Gene or Genome", "tok_span": [57, 60], "new_tok_span": [60, 63]}], "new_text": "Pharmacological treatment has been studied and it could be demonstrated, that some mutant currents may be insufficiently suppressed by drugs targeted to block the specific current such as, e. g., sotalol or <START=Pharmacologic Substance> ibutilide <END=Pharmacologic Substance> in patients with a mutation in the IKr - coding gene <START=Gene or Genome> KCNH2 <END=Gene or Genome> ( HERG ). Quinidine proved to be efficient in prolonging the QT interval and normalizing the effective refractory periods in some patients."}, {"PMID": 18079279, "id": 7, "text": "DHEA induced both PPARalpha mRNA and protein levels, as well as PP2A message in primary rat hepatocytes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 4], "name": "DHEA", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [18, 27], "name": "PPARalpha", "tok_span": [4, 6], "new_tok_span": [6, 8]}, {"ent_type": "GENE", "char_span": [64, 68], "name": "PP2A", "tok_span": [14, 17], "new_tok_span": [20, 23]}], "relation_list": [{"subject": "DHEA", "sbj_char_span": [0, 4], "object": "PPARalpha", "obj_char_span": [18, 27], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [4, 6], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [6, 8]}, {"subject": "DHEA", "sbj_char_span": [0, 4], "object": "PP2A", "obj_char_span": [64, 68], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [14, 17], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [20, 23]}], "umls_entity_list": [{"mention": "PPARalpha", "char_span": [18, 27], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 6], "new_tok_span": [6, 8]}, {"mention": "PPARalpha", "char_span": [18, 27], "sem_type": "Gene or Genome", "tok_span": [4, 6], "new_tok_span": [6, 8]}, {"mention": "PP2A", "char_span": [64, 68], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 17], "new_tok_span": [20, 23]}, {"mention": "PP2A", "char_span": [64, 68], "sem_type": "Gene or Genome", "tok_span": [14, 17], "new_tok_span": [20, 23]}], "new_text": "DHEA induced both <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PPARalpha <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> mRNA and protein levels, as well as <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> PP2A <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> message in primary rat hepatocytes."}, {"PMID": 23146838, "id": 6, "text": "In the second experiment, when the ovaries were surgically removed in adult female rats, and local production of estrogens was suppressed with the aromatase inhibitor anastrozole, females fed the saccharin-sweetened yogurt consumed more energy and gained more weight than females fed the glucose-sweetened yogurt.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [113, 122], "name": "estrogens", "tok_span": [20, 22], "new_tok_span": [21, 23]}, {"ent_type": "CHEMICAL", "char_span": [167, 178], "name": "anastrozole", "tok_span": [29, 33], "new_tok_span": [34, 38]}, {"ent_type": "CHEMICAL", "char_span": [196, 205], "name": "saccharin", "tok_span": [37, 40], "new_tok_span": [44, 47]}, {"ent_type": "CHEMICAL", "char_span": [288, 295], "name": "glucose", "tok_span": [57, 58], "new_tok_span": [66, 67]}, {"ent_type": "GENE", "char_span": [147, 156], "name": "aromatase", "tok_span": [26, 28], "new_tok_span": [29, 31]}], "relation_list": [{"subject": "anastrozole", "sbj_char_span": [167, 178], "object": "aromatase", "obj_char_span": [147, 156], "rel_type": "inhibitor", "sbj_tok_span": [29, 33], "obj_tok_span": [26, 28], "new_sbj_tok_span": [34, 38], "new_obj_tok_span": [29, 31]}], "umls_entity_list": [{"mention": "estrogens", "char_span": [113, 122], "sem_type": "Pharmacologic Substance", "tok_span": [20, 22], "new_tok_span": [21, 23]}, {"mention": "aromatase inhibitor", "char_span": [147, 166], "sem_type": "Pharmacologic Substance", "tok_span": [26, 29], "new_tok_span": [29, 32]}, {"mention": "anastrozole", "char_span": [167, 178], "sem_type": "Pharmacologic Substance", "tok_span": [29, 33], "new_tok_span": [34, 38]}, {"mention": "saccharin", "char_span": [196, 205], "sem_type": "Pharmacologic Substance", "tok_span": [37, 40], "new_tok_span": [44, 47]}, {"mention": "glucose", "char_span": [288, 295], "sem_type": "Pharmacologic Substance", "tok_span": [57, 58], "new_tok_span": [66, 67]}], "new_text": "In the second experiment, when the ovaries were surgically removed in adult female rats, and local production of <START=Pharmacologic Substance> estrogens <END=Pharmacologic Substance> was suppressed with the <START=Pharmacologic Substance> aromatase inhibitor <END=Pharmacologic Substance> <START=Pharmacologic Substance> anastrozole <END=Pharmacologic Substance>, females fed the <START=Pharmacologic Substance> saccharin <END=Pharmacologic Substance> - sweetened yogurt consumed more energy and gained more weight than females fed the <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> - sweetened yogurt."}, {"PMID": 23561166, "id": 6, "text": "Enhancement of GLUT4 expression by fisetin was further confirmed in differentiated 3T3-L1 adipocytes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [35, 42], "name": "fisetin", "tok_span": [7, 10], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [15, 20], "name": "GLUT4", "tok_span": [3, 5], "new_tok_span": [4, 6]}], "relation_list": [{"subject": "fisetin", "sbj_char_span": [35, 42], "object": "GLUT4", "obj_char_span": [15, 20], "rel_type": "regulator", "sbj_tok_span": [7, 10], "obj_tok_span": [3, 5], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [4, 6]}], "umls_entity_list": [{"mention": "GLUT4", "char_span": [15, 20], "sem_type": "Gene or Genome", "tok_span": [3, 5], "new_tok_span": [4, 6]}], "new_text": "Enhancement of <START=Gene or Genome> GLUT4 <END=Gene or Genome> expression by fisetin was further confirmed in differentiated 3T3 - L1 adipocytes."}, {"PMID": 17181139, "id": 2, "text": "The introduction of a lipophilic substituent transformed the COX-2 inhibitor carprofen into a potent gamma-secretase modulator.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [77, 86], "name": "carprofen", "tok_span": [14, 17], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [61, 66], "name": "COX-2", "tok_span": [10, 13], "new_tok_span": [10, 13]}, {"ent_type": "GENE", "char_span": [101, 116], "name": "gamma-secretase", "tok_span": [20, 24], "new_tok_span": [23, 27]}], "relation_list": [{"subject": "carprofen", "sbj_char_span": [77, 86], "object": "COX-2", "obj_char_span": [61, 66], "rel_type": "inhibitor", "sbj_tok_span": [14, 17], "obj_tok_span": [10, 13], "new_sbj_tok_span": [15, 18], "new_obj_tok_span": [10, 13]}], "umls_entity_list": [{"mention": "carprofen", "char_span": [77, 86], "sem_type": "Pharmacologic Substance", "tok_span": [14, 17], "new_tok_span": [15, 18]}, {"mention": "gamma-secretase", "char_span": [101, 116], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 24], "new_tok_span": [23, 27]}], "new_text": "The introduction of a lipophilic substituent transformed the COX - 2 inhibitor <START=Pharmacologic Substance> carprofen <END=Pharmacologic Substance> into a potent <START=Amino Acid, Peptide, or Protein> gamma - secretase <END=Amino Acid, Peptide, or Protein> modulator."}, {"PMID": 10485486, "id": 9, "text": "These data suggest that the radiosensitizing effects of caffeine are related to inhibition of the protein kinase activities of ATM and ATR and that both proteins are relevant targets for the development of novel anticancer agents.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [56, 64], "name": "caffeine", "tok_span": [11, 12], "new_tok_span": [12, 13]}, {"ent_type": "GENE", "char_span": [98, 112], "name": "protein kinase", "tok_span": [18, 20], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [127, 130], "name": "ATM", "tok_span": [22, 23], "new_tok_span": [25, 26]}, {"ent_type": "GENE", "char_span": [135, 138], "name": "ATR", "tok_span": [24, 26], "new_tok_span": [28, 30]}], "relation_list": [{"subject": "caffeine", "sbj_char_span": [56, 64], "object": "protein kinase", "obj_char_span": [98, 112], "rel_type": "inhibitor", "sbj_tok_span": [11, 12], "obj_tok_span": [18, 20], "new_sbj_tok_span": [12, 13], "new_obj_tok_span": [20, 22]}, {"subject": "caffeine", "sbj_char_span": [56, 64], "object": "ATM", "obj_char_span": [127, 130], "rel_type": "inhibitor", "sbj_tok_span": [11, 12], "obj_tok_span": [22, 23], "new_sbj_tok_span": [12, 13], "new_obj_tok_span": [25, 26]}, {"subject": "caffeine", "sbj_char_span": [56, 64], "object": "ATR", "obj_char_span": [135, 138], "rel_type": "inhibitor", "sbj_tok_span": [11, 12], "obj_tok_span": [24, 26], "new_sbj_tok_span": [12, 13], "new_obj_tok_span": [28, 30]}], "umls_entity_list": [{"mention": "caffeine", "char_span": [56, 64], "sem_type": "Pharmacologic Substance", "tok_span": [11, 12], "new_tok_span": [12, 13]}, {"mention": "ATM", "char_span": [127, 130], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 23], "new_tok_span": [25, 26]}, {"mention": "anticancer agents", "char_span": [212, 229], "sem_type": "Pharmacologic Substance", "tok_span": [38, 40], "new_tok_span": [43, 45]}], "new_text": "These data suggest that the radiosensitizing effects of <START=Pharmacologic Substance> caffeine <END=Pharmacologic Substance> are related to inhibition of the protein kinase activities of <START=Amino Acid, Peptide, or Protein> ATM <END=Amino Acid, Peptide, or Protein> and ATR and that both proteins are relevant targets for the development of novel <START=Pharmacologic Substance> anticancer agents <END=Pharmacologic Substance>."}, {"PMID": 12623106, "id": 2, "text": "These radiotracers are close analogues of reboxetine, a potent and selective ligand for the norepinephrine transporter (NET). They were examined as potential ligands for imaging NET in vivo by positron emission tomography (PET). The in vivo brain distribution of both [(11)C]-labeled enantiomers were evaluated in rats.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 52], "name": "reboxetine", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"ent_type": "CHEMICAL", "char_span": [92, 106], "name": "norepinephrine", "tok_span": [19, 20], "new_tok_span": [23, 24]}, {"ent_type": "CHEMICAL", "char_span": [269, 274], "name": "(11)C", "tok_span": [52, 56], "new_tok_span": [58, 62]}, {"ent_type": "GENE", "char_span": [92, 118], "name": "norepinephrine transporter", "tok_span": [19, 21], "new_tok_span": [23, 25]}, {"ent_type": "GENE", "char_span": [120, 123], "name": "NET", "tok_span": [22, 23], "new_tok_span": [28, 29]}, {"ent_type": "GENE", "char_span": [178, 181], "name": "NET", "tok_span": [33, 34], "new_tok_span": [39, 40]}], "relation_list": [{"subject": "reboxetine", "sbj_char_span": [42, 52], "object": "norepinephrine transporter", "obj_char_span": [92, 118], "rel_type": "regulator", "sbj_tok_span": [8, 11], "obj_tok_span": [19, 21], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [23, 25]}, {"subject": "reboxetine", "sbj_char_span": [42, 52], "object": "NET", "obj_char_span": [120, 123], "rel_type": "regulator", "sbj_tok_span": [8, 11], "obj_tok_span": [22, 23], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [28, 29]}], "umls_entity_list": [{"mention": "reboxetine", "char_span": [42, 52], "sem_type": "Pharmacologic Substance", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"mention": "norepinephrine transporter", "char_span": [92, 118], "sem_type": "Gene or Genome", "tok_span": [19, 21], "new_tok_span": [23, 25]}, {"mention": "norepinephrine transporter", "char_span": [92, 118], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 21], "new_tok_span": [23, 25]}], "new_text": "These radiotracers are close analogues of <START=Pharmacologic Substance> reboxetine <END=Pharmacologic Substance>, a potent and selective ligand for the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> norepinephrine transporter <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( NET ). They were examined as potential ligands for imaging NET in vivo by positron emission tomography ( PET ). The in vivo brain distribution of both [ ( 11 ) C ] - labeled enantiomers were evaluated in rats."}, {"PMID": 16855072, "id": 5, "text": "Sitagliptin treatment led to approximately 90% inhibition of plasma DPP-4 activity, increased active glucagon-like peptide-1 (GLP-1) levels by 2.7-fold (P < .001), and decreased post-oral glucose tolerance test glucose excursion by 35% (P < .050) compared to placebo.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Sitagliptin", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [188, 195], "name": "glucose", "tok_span": [51, 52], "new_tok_span": [57, 58]}, {"ent_type": "CHEMICAL", "char_span": [211, 218], "name": "glucose", "tok_span": [54, 55], "new_tok_span": [60, 61]}, {"ent_type": "GENE", "char_span": [68, 73], "name": "DPP-4", "tok_span": [13, 16], "new_tok_span": [17, 20]}, {"ent_type": "GENE", "char_span": [101, 124], "name": "glucagon-like peptide-1", "tok_span": [20, 26], "new_tok_span": [25, 31]}, {"ent_type": "GENE", "char_span": [126, 131], "name": "GLP-1", "tok_span": [27, 30], "new_tok_span": [33, 36]}], "relation_list": [{"subject": "Sitagliptin", "sbj_char_span": [0, 11], "object": "DPP-4", "obj_char_span": [68, 73], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [13, 16], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [17, 20]}, {"subject": "Sitagliptin", "sbj_char_span": [0, 11], "object": "glucagon-like peptide-1", "obj_char_span": [101, 124], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [20, 26], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [25, 31]}, {"subject": "Sitagliptin", "sbj_char_span": [0, 11], "object": "GLP-1", "obj_char_span": [126, 131], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [27, 30], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [33, 36]}], "umls_entity_list": [{"mention": "Sitagliptin", "char_span": [0, 11], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "plasma", "char_span": [61, 67], "sem_type": "Pharmacologic Substance", "tok_span": [12, 13], "new_tok_span": [15, 16]}, {"mention": "glucagon-like", "char_span": [101, 114], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 23], "new_tok_span": [25, 28]}], "new_text": "<START=Pharmacologic Substance> Sitagliptin <END=Pharmacologic Substance> treatment led to approximately 90 % inhibition of <START=Pharmacologic Substance> plasma <END=Pharmacologic Substance> DPP - 4 activity, increased active <START=Amino Acid, Peptide, or Protein> glucagon - like <END=Amino Acid, Peptide, or Protein> peptide - 1 ( GLP - 1 ) levels by 2. 7 - fold ( P <. 001 ), and decreased post - oral glucose tolerance test glucose excursion by 35 % ( P <. 050 ) compared to placebo."}, {"PMID": 17273558, "id": 2, "text": "Although iloprost mainly acts as a vasodilator by binding to the I prostanoid (IP) receptor, recent evidence suggests that signaling via this receptor also has antiinflammatory effects through unclear mechanisms.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 17], "name": "iloprost", "tok_span": [1, 3], "new_tok_span": [1, 3]}, {"ent_type": "CHEMICAL", "char_span": [67, 77], "name": "prostanoid", "tok_span": [14, 17], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [65, 91], "name": "I prostanoid (IP) receptor", "tok_span": [13, 21], "new_tok_span": [15, 23]}], "relation_list": [{"subject": "iloprost", "sbj_char_span": [9, 17], "object": "I prostanoid (IP) receptor", "obj_char_span": [65, 91], "rel_type": "regulator", "sbj_tok_span": [1, 3], "obj_tok_span": [13, 21], "new_sbj_tok_span": [1, 3], "new_obj_tok_span": [15, 23]}], "umls_entity_list": [{"mention": "vasodilator", "char_span": [35, 46], "sem_type": "Pharmacologic Substance", "tok_span": [7, 9], "new_tok_span": [8, 10]}], "new_text": "Although iloprost mainly acts as a <START=Pharmacologic Substance> vasodilator <END=Pharmacologic Substance> by binding to the I prostanoid ( IP ) receptor, recent evidence suggests that signaling via this receptor also has antiinflammatory effects through unclear mechanisms."}, {"PMID": 17325510, "id": 7, "text": "CONCLUSIONS: Clinical concentrations of etomidate, but not midazolam, inhibit the KATP channel activity in vascular smooth muscle cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [40, 49], "name": "etomidate", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"ent_type": "CHEMICAL", "char_span": [59, 68], "name": "midazolam", "tok_span": [11, 14], "new_tok_span": [13, 16]}, {"ent_type": "CHEMICAL", "char_span": [82, 86], "name": "KATP", "tok_span": [17, 19], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [82, 94], "name": "KATP channel", "tok_span": [17, 20], "new_tok_span": [19, 22]}], "relation_list": [{"subject": "etomidate", "sbj_char_span": [40, 49], "object": "KATP channel", "obj_char_span": [82, 94], "rel_type": "inhibitor", "sbj_tok_span": [5, 8], "obj_tok_span": [17, 20], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [19, 22]}, {"subject": "midazolam", "sbj_char_span": [59, 68], "object": "KATP channel", "obj_char_span": [82, 94], "rel_type": "inhibitor", "sbj_tok_span": [11, 14], "obj_tok_span": [17, 20], "new_sbj_tok_span": [13, 16], "new_obj_tok_span": [19, 22]}], "umls_entity_list": [{"mention": "etomidate", "char_span": [40, 49], "sem_type": "Pharmacologic Substance", "tok_span": [5, 8], "new_tok_span": [6, 9]}], "new_text": "CONCLUSIONS : Clinical concentrations of <START=Pharmacologic Substance> etomidate <END=Pharmacologic Substance>, but not midazolam, inhibit the KATP channel activity in vascular smooth muscle cells."}, {"PMID": 14504136, "id": 2, "text": "The present study identified the pharmacological profile of this inhibitory action of 5-HT. The inhibition induced by intravenous (i.v.) continuous infusions of 5-HT (5.6 microg x kg-1x min-1) on sympathetically induced tachycardiac responses remained unaltered after i.v. treatment with saline or the antagonists GR 127935 (5-HT1B/1D), the combination of WAY 100635 (5-HT1A) plus GR 127935, ritanserin (5-HT2), tropisetron (5-HT3/4), LY215840 (5-HT7) or a cocktail of antagonists/inhibitors consisting of yohimbine (alpha2), prazosin (alpha1), ritanserin, GR 127935, WAY 100635 and indomethacin (cyclooxygenase), but was abolished by methiothepin (5-HT1/2/6/7 and recombinant 5-ht5A/5B). These drugs, used in doses high enough to block their respective receptors/mechanisms, did not modify the sympathetically induced tachycardiac responses per se.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [86, 90], "name": "5-HT", "tok_span": [12, 15], "new_tok_span": [12, 15]}, {"ent_type": "CHEMICAL", "char_span": [161, 165], "name": "5-HT", "tok_span": [31, 34], "new_tok_span": [31, 34]}, {"ent_type": "CHEMICAL", "char_span": [314, 323], "name": "GR 127935", "tok_span": [71, 75], "new_tok_span": [74, 78]}, {"ent_type": "CHEMICAL", "char_span": [356, 366], "name": "WAY 100635", "tok_span": [89, 94], "new_tok_span": [97, 102]}, {"ent_type": "CHEMICAL", "char_span": [381, 390], "name": "GR 127935", "tok_span": [102, 106], "new_tok_span": [111, 115]}, {"ent_type": "CHEMICAL", "char_span": [392, 402], "name": "ritanserin", "tok_span": [107, 111], "new_tok_span": [118, 122]}, {"ent_type": "CHEMICAL", "char_span": [412, 423], "name": "tropisetron", "tok_span": [118, 121], "new_tok_span": [130, 133]}, {"ent_type": "CHEMICAL", "char_span": [435, 443], "name": "LY215840", "tok_span": [130, 134], "new_tok_span": [143, 147]}, {"ent_type": "CHEMICAL", "char_span": [506, 515], "name": "yohimbine", "tok_span": [150, 154], "new_tok_span": [166, 170]}, {"ent_type": "CHEMICAL", "char_span": [526, 534], "name": "prazosin", "tok_span": [159, 162], "new_tok_span": [175, 178]}, {"ent_type": "CHEMICAL", "char_span": [545, 555], "name": "ritanserin", "tok_span": [167, 171], "new_tok_span": [184, 188]}, {"ent_type": "CHEMICAL", "char_span": [557, 566], "name": "GR 127935", "tok_span": [172, 176], "new_tok_span": [191, 195]}, {"ent_type": "CHEMICAL", "char_span": [568, 578], "name": "WAY 100635", "tok_span": [177, 182], "new_tok_span": [197, 202]}, {"ent_type": "CHEMICAL", "char_span": [583, 595], "name": "indomethacin", "tok_span": [183, 186], "new_tok_span": [203, 206]}, {"ent_type": "CHEMICAL", "char_span": [635, 647], "name": "methiothepin", "tok_span": [195, 199], "new_tok_span": [216, 220]}, {"ent_type": "GENE", "char_span": [325, 334], "name": "5-HT1B/1D", "tok_span": [76, 84], "new_tok_span": [81, 89]}, {"ent_type": "GENE", "char_span": [368, 374], "name": "5-HT1A", "tok_span": [95, 100], "new_tok_span": [103, 108]}, {"ent_type": "GENE", "char_span": [404, 409], "name": "5-HT2", "tok_span": [112, 116], "new_tok_span": [124, 128]}, {"ent_type": "GENE", "char_span": [425, 432], "name": "5-HT3/4", "tok_span": [122, 128], "new_tok_span": [134, 140]}, {"ent_type": "GENE", "char_span": [445, 450], "name": "5-HT7", "tok_span": [135, 139], "new_tok_span": [150, 154]}, {"ent_type": "GENE", "char_span": [597, 611], "name": "cyclooxygenase", "tok_span": [187, 189], "new_tok_span": [207, 209]}, {"ent_type": "GENE", "char_span": [649, 660], "name": "5-HT1/2/6/7", "tok_span": [200, 210], "new_tok_span": [222, 232]}, {"ent_type": "GENE", "char_span": [677, 686], "name": "5-ht5A/5B", "tok_span": [212, 220], "new_tok_span": [234, 242]}], "relation_list": [{"subject": "WAY 100635", "sbj_char_span": [356, 366], "object": "5-HT1A", "obj_char_span": [368, 374], "rel_type": "agonist or antagonist", "sbj_tok_span": [89, 94], "obj_tok_span": [95, 100], "new_sbj_tok_span": [97, 102], "new_obj_tok_span": [103, 108]}, {"subject": "GR 127935", "sbj_char_span": [381, 390], "object": "5-HT2", "obj_char_span": [404, 409], "rel_type": "agonist or antagonist", "sbj_tok_span": [102, 106], "obj_tok_span": [112, 116], "new_sbj_tok_span": [111, 115], "new_obj_tok_span": [124, 128]}, {"subject": "ritanserin", "sbj_char_span": [392, 402], "object": "5-HT2", "obj_char_span": [404, 409], "rel_type": "agonist or antagonist", "sbj_tok_span": [107, 111], "obj_tok_span": [112, 116], "new_sbj_tok_span": [118, 122], "new_obj_tok_span": [124, 128]}, {"subject": "LY215840", "sbj_char_span": [435, 443], "object": "5-HT7", "obj_char_span": [445, 450], "rel_type": "agonist or antagonist", "sbj_tok_span": [130, 134], "obj_tok_span": [135, 139], "new_sbj_tok_span": [143, 147], "new_obj_tok_span": [150, 154]}, {"subject": "ritanserin", "sbj_char_span": [545, 555], "object": "cyclooxygenase", "obj_char_span": [597, 611], "rel_type": "inhibitor", "sbj_tok_span": [167, 171], "obj_tok_span": [187, 189], "new_sbj_tok_span": [184, 188], "new_obj_tok_span": [207, 209]}, {"subject": "GR 127935", "sbj_char_span": [557, 566], "object": "cyclooxygenase", "obj_char_span": [597, 611], "rel_type": "inhibitor", "sbj_tok_span": [172, 176], "obj_tok_span": [187, 189], "new_sbj_tok_span": [191, 195], "new_obj_tok_span": [207, 209]}, {"subject": "WAY 100635", "sbj_char_span": [568, 578], "object": "cyclooxygenase", "obj_char_span": [597, 611], "rel_type": "inhibitor", "sbj_tok_span": [177, 182], "obj_tok_span": [187, 189], "new_sbj_tok_span": [197, 202], "new_obj_tok_span": [207, 209]}, {"subject": "indomethacin", "sbj_char_span": [583, 595], "object": "cyclooxygenase", "obj_char_span": [597, 611], "rel_type": "inhibitor", "sbj_tok_span": [183, 186], "obj_tok_span": [187, 189], "new_sbj_tok_span": [203, 206], "new_obj_tok_span": [207, 209]}], "umls_entity_list": [{"mention": "saline", "char_span": [288, 294], "sem_type": "Pharmacologic Substance", "tok_span": [67, 68], "new_tok_span": [68, 69]}, {"mention": "GR", "char_span": [314, 316], "sem_type": "Pharmacologic Substance", "tok_span": [71, 72], "new_tok_span": [74, 75]}, {"mention": "GR", "char_span": [381, 383], "sem_type": "Pharmacologic Substance", "tok_span": [102, 103], "new_tok_span": [111, 112]}, {"mention": "GR", "char_span": [557, 559], "sem_type": "Pharmacologic Substance", "tok_span": [172, 173], "new_tok_span": [191, 192]}, {"mention": "5-HT1B", "char_span": [325, 331], "sem_type": "Gene or Genome", "tok_span": [76, 81], "new_tok_span": [81, 86]}, {"mention": "1D", "char_span": [332, 334], "sem_type": "Gene or Genome", "tok_span": [82, 84], "new_tok_span": [89, 91]}, {"mention": "ritanserin", "char_span": [392, 402], "sem_type": "Pharmacologic Substance", "tok_span": [107, 111], "new_tok_span": [118, 122]}, {"mention": "ritanserin", "char_span": [545, 555], "sem_type": "Pharmacologic Substance", "tok_span": [167, 171], "new_tok_span": [184, 188]}, {"mention": "LY215840", "char_span": [435, 443], "sem_type": "Pharmacologic Substance", "tok_span": [130, 134], "new_tok_span": [143, 147]}, {"mention": "5-HT7", "char_span": [445, 450], "sem_type": "Gene or Genome", "tok_span": [135, 139], "new_tok_span": [150, 154]}, {"mention": "methiothepin", "char_span": [635, 647], "sem_type": "Pharmacologic Substance", "tok_span": [195, 199], "new_tok_span": [216, 220]}, {"mention": "receptors", "char_span": [754, 763], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [234, 235], "new_tok_span": [257, 258]}], "new_text": "The present study identified the pharmacological profile of this inhibitory action of 5 - HT. The inhibition induced by intravenous ( i. v. ) continuous infusions of 5 - HT ( 5. 6 microg x kg - 1x min - 1 ) on sympathetically induced tachycardiac responses remained unaltered after i. v. treatment with <START=Pharmacologic Substance> saline <END=Pharmacologic Substance> or the antagonists <START=Pharmacologic Substance> GR <END=Pharmacologic Substance> 127935 ( <START=Gene or Genome> 5 - HT1B <END=Gene or Genome> / <START=Gene or Genome> 1D <END=Gene or Genome> ), the combination of WAY 100635 ( 5 - HT1A ) plus <START=Pharmacologic Substance> GR <END=Pharmacologic Substance> 127935, <START=Pharmacologic Substance> ritanserin <END=Pharmacologic Substance> ( 5 - HT2 ), tropisetron ( 5 - HT3 / 4 ), <START=Pharmacologic Substance> LY215840 <END=Pharmacologic Substance> ( <START=Gene or Genome> 5 - HT7 <END=Gene or Genome> ) or a cocktail of antagonists / inhibitors consisting of yohimbine ( alpha2 ), prazosin ( alpha1 ), <START=Pharmacologic Substance> ritanserin <END=Pharmacologic Substance>, <START=Pharmacologic Substance> GR <END=Pharmacologic Substance> 127935, WAY 100635 and indomethacin ( cyclooxygenase ), but was abolished by <START=Pharmacologic Substance> methiothepin <END=Pharmacologic Substance> ( 5 - HT1 / 2 / 6 / 7 and recombinant 5 - ht5A / 5B ). These drugs, used in doses high enough to block their respective <START=Amino Acid, Peptide, or Protein> receptors <END=Amino Acid, Peptide, or Protein> / mechanisms, did not modify the sympathetically induced tachycardiac responses per se."}, {"PMID": 10340919, "id": 3, "text": "METHODS: COX-1 inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [54, 68], "name": "thromboxane B2", "tok_span": [10, 15], "new_tok_span": [10, 15]}, {"ent_type": "CHEMICAL", "char_span": [70, 74], "name": "TXB2", "tok_span": [16, 19], "new_tok_span": [16, 19]}, {"ent_type": "CHEMICAL", "char_span": [162, 171], "name": "meloxicam", "tok_span": [40, 43], "new_tok_span": [43, 46]}, {"ent_type": "CHEMICAL", "char_span": [182, 192], "name": "diclofenac", "tok_span": [46, 50], "new_tok_span": [53, 57]}, {"ent_type": "CHEMICAL", "char_span": [220, 229], "name": "meloxicam", "tok_span": [57, 60], "new_tok_span": [68, 71]}, {"ent_type": "CHEMICAL", "char_span": [247, 257], "name": "diclofenac", "tok_span": [64, 68], "new_tok_span": [79, 83]}, {"ent_type": "GENE", "char_span": [9, 14], "name": "COX-1", "tok_span": [2, 5], "new_tok_span": [2, 5]}], "relation_list": [{"subject": "meloxicam", "sbj_char_span": [162, 171], "object": "COX-1", "obj_char_span": [9, 14], "rel_type": "inhibitor", "sbj_tok_span": [40, 43], "obj_tok_span": [2, 5], "new_sbj_tok_span": [43, 46], "new_obj_tok_span": [2, 5]}, {"subject": "diclofenac", "sbj_char_span": [182, 192], "object": "COX-1", "obj_char_span": [9, 14], "rel_type": "inhibitor", "sbj_tok_span": [46, 50], "obj_tok_span": [2, 5], "new_sbj_tok_span": [53, 57], "new_obj_tok_span": [2, 5]}, {"subject": "meloxicam", "sbj_char_span": [220, 229], "object": "COX-1", "obj_char_span": [9, 14], "rel_type": "inhibitor", "sbj_tok_span": [57, 60], "obj_tok_span": [2, 5], "new_sbj_tok_span": [68, 71], "new_obj_tok_span": [2, 5]}, {"subject": "diclofenac", "sbj_char_span": [247, 257], "object": "COX-1", "obj_char_span": [9, 14], "rel_type": "inhibitor", "sbj_tok_span": [64, 68], "obj_tok_span": [2, 5], "new_sbj_tok_span": [79, 83], "new_obj_tok_span": [2, 5]}], "umls_entity_list": [{"mention": "meloxicam", "char_span": [162, 171], "sem_type": "Pharmacologic Substance", "tok_span": [40, 43], "new_tok_span": [43, 46]}, {"mention": "meloxicam", "char_span": [220, 229], "sem_type": "Pharmacologic Substance", "tok_span": [57, 60], "new_tok_span": [68, 71]}, {"mention": "mg", "char_span": [159, 161], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 40], "new_tok_span": [40, 41]}, {"mention": "mg", "char_span": [179, 181], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [45, 46], "new_tok_span": [50, 51]}, {"mention": "mg", "char_span": [217, 219], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 57], "new_tok_span": [65, 66]}, {"mention": "mg", "char_span": [244, 246], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [63, 64], "new_tok_span": [76, 77]}, {"mention": "diclofenac", "char_span": [182, 192], "sem_type": "Pharmacologic Substance", "tok_span": [46, 50], "new_tok_span": [53, 57]}, {"mention": "diclofenac", "char_span": [247, 257], "sem_type": "Pharmacologic Substance", "tok_span": [64, 68], "new_tok_span": [79, 83]}], "new_text": "METHODS : COX - 1 inhibition was determined by measuring thromboxane B2 ( TXB2 ) - generation from clotting whole blood ex vivo after single oral doses of 7. 5 and 15 <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> meloxicam <END=Pharmacologic Substance> and 75 <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> diclofenac <END=Pharmacologic Substance> and at steady state ( 15 <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> meloxicam <END=Pharmacologic Substance> daily and 150 <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> diclofenac <END=Pharmacologic Substance> daily )."}, {"PMID": 23159329, "id": 10, "text": "Moreover, activation of the ERK and CREB signaling pathway in the hippocampus might be involved in METH-induced spatial memory changes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [99, 103], "name": "METH", "tok_span": [17, 19], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [28, 31], "name": "ERK", "tok_span": [5, 6], "new_tok_span": [5, 6]}, {"ent_type": "GENE", "char_span": [36, 40], "name": "CREB", "tok_span": [7, 8], "new_tok_span": [7, 8]}], "relation_list": [{"subject": "METH", "sbj_char_span": [99, 103], "object": "ERK", "obj_char_span": [28, 31], "rel_type": "activator", "sbj_tok_span": [17, 19], "obj_tok_span": [5, 6], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [5, 6]}, {"subject": "METH", "sbj_char_span": [99, 103], "object": "CREB", "obj_char_span": [36, 40], "rel_type": "activator", "sbj_tok_span": [17, 19], "obj_tok_span": [7, 8], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [7, 8]}], "umls_entity_list": [{"mention": "METH", "char_span": [99, 103], "sem_type": "Pharmacologic Substance", "tok_span": [17, 19], "new_tok_span": [18, 20]}], "new_text": "Moreover, activation of the ERK and CREB signaling pathway in the hippocampus might be involved in <START=Pharmacologic Substance> METH <END=Pharmacologic Substance> - induced spatial memory changes."}, {"PMID": 23238783, "id": 10, "text": "These results suggest that CYP2B6 genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of bupropion.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [171, 180], "name": "bupropion", "tok_span": [34, 37], "new_tok_span": [34, 37]}, {"ent_type": "GENE", "char_span": [27, 33], "name": "CYP2B6", "tok_span": [4, 8], "new_tok_span": [4, 8]}, {"ent_type": "GENE", "char_span": [110, 116], "name": "CYP2B6", "tok_span": [20, 24], "new_tok_span": [20, 24]}], "relation_list": [{"subject": "bupropion", "sbj_char_span": [171, 180], "object": "CYP2B6", "obj_char_span": [27, 33], "rel_type": "product or substrate", "sbj_tok_span": [34, 37], "obj_tok_span": [4, 8], "new_sbj_tok_span": [34, 37], "new_obj_tok_span": [4, 8]}, {"subject": "bupropion", "sbj_char_span": [171, 180], "object": "CYP2B6", "obj_char_span": [110, 116], "rel_type": "product or substrate", "sbj_tok_span": [34, 37], "obj_tok_span": [20, 24], "new_sbj_tok_span": [34, 37], "new_obj_tok_span": [20, 24]}], "umls_entity_list": [], "new_text": "These results suggest that CYP2B6 genotype is the most important patient variable for predicting the level of CYP2B6 activity in women, when measured by the metabolism of bupropion."}, {"PMID": 15192023, "id": 0, "text": "Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [159, 165], "name": "prolyl", "tok_span": [30, 32], "new_tok_span": [33, 35]}, {"ent_type": "CHEMICAL", "char_span": [30, 41], "name": "hydralazine", "tok_span": [5, 9], "new_tok_span": [5, 9]}, {"ent_type": "GENE", "char_span": [159, 178], "name": "prolyl hydroxylases", "tok_span": [30, 34], "new_tok_span": [33, 37]}, {"ent_type": "GENE", "char_span": [56, 87], "name": "hypoxia-inducible factor-1alpha", "tok_span": [12, 19], "new_tok_span": [12, 19]}, {"ent_type": "GENE", "char_span": [89, 123], "name": "vascular endothelial growth factor", "tok_span": [20, 24], "new_tok_span": [21, 25]}], "relation_list": [{"subject": "hydralazine", "sbj_char_span": [30, 41], "object": "prolyl hydroxylases", "obj_char_span": [159, 178], "rel_type": "inhibitor", "sbj_tok_span": [5, 9], "obj_tok_span": [30, 34], "new_sbj_tok_span": [5, 9], "new_obj_tok_span": [33, 37]}, {"subject": "hydralazine", "sbj_char_span": [30, 41], "object": "vascular endothelial growth factor", "obj_char_span": [89, 123], "rel_type": "regulator", "sbj_tok_span": [5, 9], "obj_tok_span": [20, 24], "new_sbj_tok_span": [5, 9], "new_obj_tok_span": [21, 25]}], "umls_entity_list": [{"mention": "vascular endothelial growth factor", "char_span": [89, 123], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 24], "new_tok_span": [21, 25]}, {"mention": "prolyl hydroxylases", "char_span": [159, 178], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 34], "new_tok_span": [33, 37]}], "new_text": "Novel mechanism of action for hydralazine : induction of hypoxia - inducible factor - 1alpha, <START=Amino Acid, Peptide, or Protein> vascular endothelial growth factor <END=Amino Acid, Peptide, or Protein>, and angiogenesis by inhibition of <START=Amino Acid, Peptide, or Protein> prolyl hydroxylases <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23603058, "id": 7, "text": "From the tested clinical-chemical plasma characteristics the total bilirubin concentration and the ASAT activity were strongly elevated by the LPS infusion and additionally increased and decreased by DON, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [67, 76], "name": "bilirubin", "tok_span": [10, 11], "new_tok_span": [10, 11]}, {"ent_type": "CHEMICAL", "char_span": [200, 203], "name": "DON", "tok_span": [30, 32], "new_tok_span": [39, 41]}, {"ent_type": "GENE", "char_span": [99, 103], "name": "ASAT", "tok_span": [14, 16], "new_tok_span": [16, 18]}], "relation_list": [{"subject": "DON", "sbj_char_span": [200, 203], "object": "ASAT", "obj_char_span": [99, 103], "rel_type": "inhibitor", "sbj_tok_span": [30, 32], "obj_tok_span": [14, 16], "new_sbj_tok_span": [39, 41], "new_obj_tok_span": [16, 18]}], "umls_entity_list": [{"mention": "ASAT", "char_span": [99, 103], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"mention": "ASAT", "char_span": [99, 103], "sem_type": "Gene or Genome", "tok_span": [14, 16], "new_tok_span": [16, 18]}, {"mention": "LPS", "char_span": [143, 146], "sem_type": "Organic Chemical", "tok_span": [22, 23], "new_tok_span": [28, 29]}, {"mention": "LPS", "char_span": [143, 146], "sem_type": "Gene or Genome", "tok_span": [22, 23], "new_tok_span": [28, 29]}, {"mention": "DON", "char_span": [200, 203], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 32], "new_tok_span": [39, 41]}], "new_text": "From the tested clinical - chemical plasma characteristics the total bilirubin concentration and the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> ASAT <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> activity were strongly elevated by the <START=Organic Chemical> <START=Gene or Genome> LPS <END=Organic Chemical> <END=Gene or Genome> infusion and additionally increased and decreased by <START=Amino Acid, Peptide, or Protein> DON <END=Amino Acid, Peptide, or Protein>, respectively."}, {"PMID": 23581876, "id": 3, "text": "The effect of sex and cytochrome P450 (P450) enzyme induction on the enantioselective metabolism of PCB 136 was studied using liver tissue slices prepared from naïve control (CTL), phenobarbital (PB; CYP2B inducer) or dexamethasone (DEX; CYP3A inducer) pretreated adult Sprague-Dawley rats.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [100, 107], "name": "PCB 136", "tok_span": [21, 23], "new_tok_span": [22, 24]}, {"ent_type": "CHEMICAL", "char_span": [181, 194], "name": "phenobarbital", "tok_span": [37, 39], "new_tok_span": [39, 41]}, {"ent_type": "CHEMICAL", "char_span": [218, 231], "name": "dexamethasone", "tok_span": [49, 50], "new_tok_span": [52, 53]}, {"ent_type": "CHEMICAL", "char_span": [233, 236], "name": "DEX", "tok_span": [51, 53], "new_tok_span": [56, 58]}, {"ent_type": "GENE", "char_span": [22, 37], "name": "cytochrome P450", "tok_span": [5, 8], "new_tok_span": [5, 8]}, {"ent_type": "GENE", "char_span": [39, 43], "name": "P450", "tok_span": [9, 11], "new_tok_span": [9, 11]}, {"ent_type": "GENE", "char_span": [200, 205], "name": "CYP2B", "tok_span": [42, 45], "new_tok_span": [44, 47]}, {"ent_type": "GENE", "char_span": [238, 243], "name": "CYP3A", "tok_span": [54, 57], "new_tok_span": [60, 63]}], "relation_list": [{"subject": "PCB 136", "sbj_char_span": [100, 107], "object": "cytochrome P450", "obj_char_span": [22, 37], "rel_type": "product or substrate", "sbj_tok_span": [21, 23], "obj_tok_span": [5, 8], "new_sbj_tok_span": [22, 24], "new_obj_tok_span": [5, 8]}, {"subject": "PCB 136", "sbj_char_span": [100, 107], "object": "P450", "obj_char_span": [39, 43], "rel_type": "product or substrate", "sbj_tok_span": [21, 23], "obj_tok_span": [9, 11], "new_sbj_tok_span": [22, 24], "new_obj_tok_span": [9, 11]}], "umls_entity_list": [{"mention": "PCB", "char_span": [100, 103], "sem_type": "Organic Chemical", "tok_span": [21, 22], "new_tok_span": [22, 23]}, {"mention": "dex", "char_span": [218, 221], "sem_type": "Pharmacologic Substance", "tok_span": [49, 50], "new_tok_span": [52, 53]}, {"mention": "DEX", "char_span": [233, 236], "sem_type": "Pharmacologic Substance", "tok_span": [51, 53], "new_tok_span": [56, 58]}], "new_text": "The effect of sex and cytochrome P450 ( P450 ) enzyme induction on the enantioselective metabolism of <START=Organic Chemical> PCB <END=Organic Chemical> 136 was studied using liver tissue slices prepared from naïve control ( CTL ), phenobarbital ( PB ; CYP2B inducer ) or <START=Pharmacologic Substance> dexamethasone <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> DEX <END=Pharmacologic Substance> ; CYP3A inducer ) pretreated adult Sprague - Dawley rats."}, {"PMID": 22982773, "id": 2, "text": "To gain a better understanding of this oxime specificity problem for future design of improved reactivators, we conducted a QSAR analysis for oxime reactivation of AChE inhibited by OP agents and their analogues.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [39, 44], "name": "oxime", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"ent_type": "CHEMICAL", "char_span": [142, 147], "name": "oxime", "tok_span": [27, 29], "new_tok_span": [30, 32]}, {"ent_type": "GENE", "char_span": [164, 168], "name": "AChE", "tok_span": [31, 33], "new_tok_span": [35, 37]}], "relation_list": [{"subject": "oxime", "sbj_char_span": [142, 147], "object": "AChE", "obj_char_span": [164, 168], "rel_type": "activator", "sbj_tok_span": [27, 29], "obj_tok_span": [31, 33], "new_sbj_tok_span": [30, 32], "new_obj_tok_span": [35, 37]}], "umls_entity_list": [{"mention": "oxime", "char_span": [39, 44], "sem_type": "Organic Chemical", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"mention": "oxime", "char_span": [142, 147], "sem_type": "Organic Chemical", "tok_span": [27, 29], "new_tok_span": [30, 32]}], "new_text": "To gain a better understanding of this <START=Organic Chemical> oxime <END=Organic Chemical> specificity problem for future design of improved reactivators, we conducted a QSAR analysis for <START=Organic Chemical> oxime <END=Organic Chemical> reactivation of AChE inhibited by OP agents and their analogues."}, {"PMID": 1315825, "id": 1, "text": "OBJECTIVE: Candoxatril (UK79,300) is an orally available inhibitor of the neutral endopeptidase (E.C.3.4.24.11) which degrades atrial natriuretic factor (ANF). This study was designed to establish initial safety and efficacy data in essential hypertension for this novel class of drug.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [11, 22], "name": "Candoxatril", "tok_span": [2, 7], "new_tok_span": [2, 7]}, {"ent_type": "CHEMICAL", "char_span": [24, 32], "name": "UK79,300", "tok_span": [8, 12], "new_tok_span": [8, 12]}, {"ent_type": "GENE", "char_span": [127, 152], "name": "atrial natriuretic factor", "tok_span": [41, 46], "new_tok_span": [48, 53]}, {"ent_type": "GENE", "char_span": [154, 157], "name": "ANF", "tok_span": [47, 49], "new_tok_span": [57, 59]}, {"ent_type": "GENE", "char_span": [74, 95], "name": "neutral endopeptidase", "tok_span": [20, 25], "new_tok_span": [22, 27]}, {"ent_type": "GENE", "char_span": [97, 110], "name": "E.C.3.4.24.11", "tok_span": [26, 37], "new_tok_span": [30, 41]}], "relation_list": [{"subject": "Candoxatril", "sbj_char_span": [11, 22], "object": "neutral endopeptidase", "obj_char_span": [74, 95], "rel_type": "inhibitor", "sbj_tok_span": [2, 7], "obj_tok_span": [20, 25], "new_sbj_tok_span": [2, 7], "new_obj_tok_span": [22, 27]}, {"subject": "UK79,300", "sbj_char_span": [24, 32], "object": "neutral endopeptidase", "obj_char_span": [74, 95], "rel_type": "inhibitor", "sbj_tok_span": [8, 12], "obj_tok_span": [20, 25], "new_sbj_tok_span": [8, 12], "new_obj_tok_span": [22, 27]}, {"subject": "Candoxatril", "sbj_char_span": [11, 22], "object": "E.C.3.4.24.11", "obj_char_span": [97, 110], "rel_type": "inhibitor", "sbj_tok_span": [2, 7], "obj_tok_span": [26, 37], "new_sbj_tok_span": [2, 7], "new_obj_tok_span": [30, 41]}, {"subject": "UK79,300", "sbj_char_span": [24, 32], "object": "E.C.3.4.24.11", "obj_char_span": [97, 110], "rel_type": "inhibitor", "sbj_tok_span": [8, 12], "obj_tok_span": [26, 37], "new_sbj_tok_span": [8, 12], "new_obj_tok_span": [30, 41]}], "umls_entity_list": [{"mention": "neutral endopeptidase", "char_span": [74, 95], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 25], "new_tok_span": [22, 27]}, {"mention": "neutral endopeptidase", "char_span": [74, 95], "sem_type": "Gene or Genome", "tok_span": [20, 25], "new_tok_span": [22, 27]}, {"mention": "atrial", "char_span": [127, 133], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 42], "new_tok_span": [48, 49]}, {"mention": "atrial natriuretic factor", "char_span": [127, 152], "sem_type": "Gene or Genome", "tok_span": [41, 46], "new_tok_span": [48, 53]}, {"mention": "atrial natriuretic factor", "char_span": [127, 152], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 46], "new_tok_span": [48, 53]}], "new_text": "OBJECTIVE : Candoxatril ( UK79, 300 ) is an orally available inhibitor of the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> neutral endopeptidase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( E. C. 3. 4. 24. 11 ) which degrades <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> atrial <END=Amino Acid, Peptide, or Protein> natriuretic factor <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( ANF ). This study was designed to establish initial safety and efficacy data in essential hypertension for this novel class of drug."}, {"PMID": 18996527, "id": 3, "text": "Homocysteine, the atherogenic product of the NNMT-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Homocysteine", "tok_span": [0, 2], "new_tok_span": [1, 3]}, {"ent_type": "GENE", "char_span": [45, 49], "name": "NNMT", "tok_span": [9, 11], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "Homocysteine", "sbj_char_span": [0, 12], "object": "NNMT", "obj_char_span": [45, 49], "rel_type": "product or substrate", "sbj_tok_span": [0, 2], "obj_tok_span": [9, 11], "new_sbj_tok_span": [1, 3], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [{"mention": "Homocysteine", "char_span": [0, 12], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 2], "new_tok_span": [1, 3]}], "new_text": "<START=Amino Acid, Peptide, or Protein> Homocysteine <END=Amino Acid, Peptide, or Protein>, the atherogenic product of the NNMT - catalyzed reaction, was secreted from 3T3 - L1 cells or adipose tissue cultures."}, {"PMID": 16230360, "id": 4, "text": "At micromolar concentrations, procainamide was found to be a partial competitive inhibitor of DNMT1, reducing the affinity of the enzyme for its two substrates, hemimethylated DNA and S-adenosyl-l-methionine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [30, 42], "name": "procainamide", "tok_span": [5, 8], "new_tok_span": [5, 8]}, {"ent_type": "CHEMICAL", "char_span": [184, 207], "name": "S-adenosyl-l-methionine", "tok_span": [38, 46], "new_tok_span": [38, 46]}, {"ent_type": "GENE", "char_span": [94, 99], "name": "DNMT1", "tok_span": [17, 20], "new_tok_span": [17, 20]}], "relation_list": [{"subject": "procainamide", "sbj_char_span": [30, 42], "object": "DNMT1", "obj_char_span": [94, 99], "rel_type": "inhibitor", "sbj_tok_span": [5, 8], "obj_tok_span": [17, 20], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [17, 20]}, {"subject": "S-adenosyl-l-methionine", "sbj_char_span": [184, 207], "object": "DNMT1", "obj_char_span": [94, 99], "rel_type": "product or substrate", "sbj_tok_span": [38, 46], "obj_tok_span": [17, 20], "new_sbj_tok_span": [38, 46], "new_obj_tok_span": [17, 20]}], "umls_entity_list": [{"mention": "methionine", "char_span": [197, 207], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [45, 46], "new_tok_span": [46, 47]}], "new_text": "At micromolar concentrations, procainamide was found to be a partial competitive inhibitor of DNMT1, reducing the affinity of the enzyme for its two substrates, hemimethylated DNA and S - adenosyl - l - <START=Amino Acid, Peptide, or Protein> methionine <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23607891, "id": 6, "text": "These effects were also dependent on particle size, albeit less pronounced than those observed with EPR. We were able to show that incubation of A549 cells prior to particle treatment with diphenyleneiodonium (DPI), a NADPH-oxidase (NOX) inhibitor, leads to decreased ROS formation, but this effect was not observed for the NOX inhibitor apocynin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [338, 346], "name": "apocynin", "tok_span": [71, 75], "new_tok_span": [82, 86]}, {"ent_type": "CHEMICAL", "char_span": [189, 208], "name": "diphenyleneiodonium", "tok_span": [34, 39], "new_tok_span": [39, 44]}, {"ent_type": "CHEMICAL", "char_span": [210, 213], "name": "DPI", "tok_span": [40, 42], "new_tok_span": [46, 48]}, {"ent_type": "CHEMICAL", "char_span": [218, 223], "name": "NADPH", "tok_span": [45, 46], "new_tok_span": [53, 54]}, {"ent_type": "GENE", "char_span": [324, 327], "name": "NOX", "tok_span": [68, 70], "new_tok_span": [78, 80]}, {"ent_type": "GENE", "char_span": [218, 231], "name": "NADPH-oxidase", "tok_span": [45, 48], "new_tok_span": [53, 56]}, {"ent_type": "GENE", "char_span": [233, 236], "name": "NOX", "tok_span": [49, 51], "new_tok_span": [59, 61]}], "relation_list": [{"subject": "diphenyleneiodonium", "sbj_char_span": [189, 208], "object": "NADPH-oxidase", "obj_char_span": [218, 231], "rel_type": "inhibitor", "sbj_tok_span": [34, 39], "obj_tok_span": [45, 48], "new_sbj_tok_span": [39, 44], "new_obj_tok_span": [53, 56]}, {"subject": "diphenyleneiodonium", "sbj_char_span": [189, 208], "object": "NOX", "obj_char_span": [233, 236], "rel_type": "inhibitor", "sbj_tok_span": [34, 39], "obj_tok_span": [49, 51], "new_sbj_tok_span": [39, 44], "new_obj_tok_span": [59, 61]}, {"subject": "DPI", "sbj_char_span": [210, 213], "object": "NADPH-oxidase", "obj_char_span": [218, 231], "rel_type": "inhibitor", "sbj_tok_span": [40, 42], "obj_tok_span": [45, 48], "new_sbj_tok_span": [46, 48], "new_obj_tok_span": [53, 56]}, {"subject": "DPI", "sbj_char_span": [210, 213], "object": "NOX", "obj_char_span": [233, 236], "rel_type": "inhibitor", "sbj_tok_span": [40, 42], "obj_tok_span": [49, 51], "new_sbj_tok_span": [46, 48], "new_obj_tok_span": [59, 61]}, {"subject": "apocynin", "sbj_char_span": [338, 346], "object": "NOX", "obj_char_span": [324, 327], "rel_type": "inhibitor", "sbj_tok_span": [71, 75], "obj_tok_span": [68, 70], "new_sbj_tok_span": [82, 86], "new_obj_tok_span": [78, 80]}], "umls_entity_list": [{"mention": "diphenyleneiodonium", "char_span": [189, 208], "sem_type": "Pharmacologic Substance", "tok_span": [34, 39], "new_tok_span": [39, 44]}, {"mention": "particle", "char_span": [37, 45], "sem_type": "Gene or Genome", "tok_span": [6, 7], "new_tok_span": [7, 8]}, {"mention": "particle", "char_span": [165, 173], "sem_type": "Gene or Genome", "tok_span": [31, 32], "new_tok_span": [34, 35]}, {"mention": "NADPH", "char_span": [218, 223], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [45, 46], "new_tok_span": [53, 54]}, {"mention": "apocynin", "char_span": [338, 346], "sem_type": "Pharmacologic Substance", "tok_span": [71, 75], "new_tok_span": [82, 86]}, {"mention": "NADPH-oxidase", "char_span": [218, 231], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [45, 48], "new_tok_span": [53, 56]}], "new_text": "These effects were also dependent on <START=Gene or Genome> particle <END=Gene or Genome> size, albeit less pronounced than those observed with EPR. We were able to show that incubation of A549 cells prior to <START=Gene or Genome> particle <END=Gene or Genome> treatment with <START=Pharmacologic Substance> diphenyleneiodonium <END=Pharmacologic Substance> ( DPI ), a <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> NADPH <END=Amino Acid, Peptide, or Protein> - oxidase <END=Amino Acid, Peptide, or Protein> ( NOX ) inhibitor, leads to decreased ROS formation, but this effect was not observed for the NOX inhibitor <START=Pharmacologic Substance> apocynin <END=Pharmacologic Substance>."}, {"PMID": 23561118, "id": 4, "text": "Results showed that EEAP and quercetin but not ferulic acid protected β-cells from glucotoxicity through several mechanisms, including: (1) maintaining β-cell viability; (2) suppressing reactive oxygen species production; (3) reducing characteristic features of apoptosis; (4) inhibiting the activation of caspase-9 and caspase-3 and the cleavage of poly (ADP-ribose) polymerase; (5) upregulating pancreatic and duodenal homeobox 1 gene expression and the insulin secretagogue action of pancreatic β-cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [29, 38], "name": "quercetin", "tok_span": [6, 9], "new_tok_span": [6, 9]}, {"ent_type": "CHEMICAL", "char_span": [47, 59], "name": "ferulic acid", "tok_span": [11, 14], "new_tok_span": [12, 15]}, {"ent_type": "CHEMICAL", "char_span": [195, 201], "name": "oxygen", "tok_span": [41, 42], "new_tok_span": [43, 44]}, {"ent_type": "CHEMICAL", "char_span": [350, 367], "name": "poly (ADP-ribose)", "tok_span": [72, 79], "new_tok_span": [74, 81]}, {"ent_type": "GENE", "char_span": [306, 315], "name": "caspase-9", "tok_span": [61, 64], "new_tok_span": [63, 66]}, {"ent_type": "GENE", "char_span": [320, 329], "name": "caspase-3", "tok_span": [65, 68], "new_tok_span": [67, 70]}, {"ent_type": "GENE", "char_span": [350, 378], "name": "poly (ADP-ribose) polymerase", "tok_span": [72, 80], "new_tok_span": [74, 82]}, {"ent_type": "GENE", "char_span": [421, 431], "name": "homeobox 1", "tok_span": [91, 95], "new_tok_span": [94, 98]}, {"ent_type": "GENE", "char_span": [456, 463], "name": "insulin", "tok_span": [99, 100], "new_tok_span": [103, 104]}], "relation_list": [{"subject": "quercetin", "sbj_char_span": [29, 38], "object": "caspase-9", "obj_char_span": [306, 315], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [61, 64], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [63, 66]}, {"subject": "quercetin", "sbj_char_span": [29, 38], "object": "caspase-3", "obj_char_span": [320, 329], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [65, 68], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [67, 70]}, {"subject": "quercetin", "sbj_char_span": [29, 38], "object": "poly (ADP-ribose) polymerase", "obj_char_span": [350, 378], "rel_type": "inhibitor", "sbj_tok_span": [6, 9], "obj_tok_span": [72, 80], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [74, 82]}, {"subject": "quercetin", "sbj_char_span": [29, 38], "object": "homeobox 1", "obj_char_span": [421, 431], "rel_type": "regulator", "sbj_tok_span": [6, 9], "obj_tok_span": [91, 95], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [94, 98]}, {"subject": "quercetin", "sbj_char_span": [29, 38], "object": "insulin", "obj_char_span": [456, 463], "rel_type": "regulator", "sbj_tok_span": [6, 9], "obj_tok_span": [99, 100], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [103, 104]}], "umls_entity_list": [{"mention": "ferulic acid", "char_span": [47, 59], "sem_type": "Pharmacologic Substance", "tok_span": [11, 14], "new_tok_span": [12, 15]}, {"mention": "pancreatic and duodenal homeobox 1 gene", "char_span": [397, 436], "sem_type": "Gene or Genome", "tok_span": [87, 96], "new_tok_span": [90, 99]}], "new_text": "Results showed that EEAP and quercetin but not <START=Pharmacologic Substance> ferulic acid <END=Pharmacologic Substance> protected β - cells from glucotoxicity through several mechanisms, including : ( 1 ) maintaining β - cell viability ; ( 2 ) suppressing reactive oxygen species production ; ( 3 ) reducing characteristic features of apoptosis ; ( 4 ) inhibiting the activation of caspase - 9 and caspase - 3 and the cleavage of poly ( ADP - ribose ) polymerase ; ( 5 ) upregulating <START=Gene or Genome> pancreatic and duodenal homeobox 1 gene <END=Gene or Genome> expression and the insulin secretagogue action of pancreatic β - cells."}, {"PMID": 11723241, "id": 3, "text": "To gain further insight into the binding site, we examined the minimal structural changes necessary to transform low-affinity binding of dofetilide by the related bovine ether a-go-go channel bEAG to high-affinity binding of HERG. Previously, it was shown that high-affinity binding in HERG required intact C-type inactivation; the bovine ether a-go-go K(+) channel (bEAG), unlike HERG, is noninactivating.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [137, 147], "name": "dofetilide", "tok_span": [23, 27], "new_tok_span": [24, 28]}, {"ent_type": "CHEMICAL", "char_span": [170, 175], "name": "ether", "tok_span": [31, 32], "new_tok_span": [34, 35]}, {"ent_type": "CHEMICAL", "char_span": [339, 344], "name": "ether", "tok_span": [72, 73], "new_tok_span": [77, 78]}, {"ent_type": "CHEMICAL", "char_span": [353, 357], "name": "K(+)", "tok_span": [78, 82], "new_tok_span": [84, 88]}, {"ent_type": "GENE", "char_span": [163, 191], "name": "bovine ether a-go-go channel", "tok_span": [30, 38], "new_tok_span": [32, 40]}, {"ent_type": "GENE", "char_span": [192, 196], "name": "bEAG", "tok_span": [38, 41], "new_tok_span": [42, 45]}, {"ent_type": "GENE", "char_span": [225, 229], "name": "HERG", "tok_span": [47, 49], "new_tok_span": [51, 53]}, {"ent_type": "GENE", "char_span": [286, 290], "name": "HERG", "tok_span": [61, 63], "new_tok_span": [65, 67]}, {"ent_type": "GENE", "char_span": [332, 365], "name": "bovine ether a-go-go K(+) channel", "tok_span": [71, 83], "new_tok_span": [75, 87]}, {"ent_type": "GENE", "char_span": [367, 371], "name": "bEAG", "tok_span": [84, 87], "new_tok_span": [90, 93]}, {"ent_type": "GENE", "char_span": [381, 385], "name": "HERG", "tok_span": [90, 92], "new_tok_span": [96, 98]}], "relation_list": [{"subject": "dofetilide", "sbj_char_span": [137, 147], "object": "bovine ether a-go-go channel", "obj_char_span": [163, 191], "rel_type": "regulator", "sbj_tok_span": [23, 27], "obj_tok_span": [30, 38], "new_sbj_tok_span": [24, 28], "new_obj_tok_span": [32, 40]}, {"subject": "dofetilide", "sbj_char_span": [137, 147], "object": "bEAG", "obj_char_span": [192, 196], "rel_type": "regulator", "sbj_tok_span": [23, 27], "obj_tok_span": [38, 41], "new_sbj_tok_span": [24, 28], "new_obj_tok_span": [42, 45]}, {"subject": "dofetilide", "sbj_char_span": [137, 147], "object": "HERG", "obj_char_span": [225, 229], "rel_type": "regulator", "sbj_tok_span": [23, 27], "obj_tok_span": [47, 49], "new_sbj_tok_span": [24, 28], "new_obj_tok_span": [51, 53]}], "umls_entity_list": [{"mention": "dofetilide", "char_span": [137, 147], "sem_type": "Pharmacologic Substance", "tok_span": [23, 27], "new_tok_span": [24, 28]}, {"mention": "ether", "char_span": [170, 175], "sem_type": "Pharmacologic Substance", "tok_span": [31, 32], "new_tok_span": [34, 35]}, {"mention": "ether", "char_span": [339, 344], "sem_type": "Pharmacologic Substance", "tok_span": [72, 73], "new_tok_span": [77, 78]}], "new_text": "To gain further insight into the binding site, we examined the minimal structural changes necessary to transform low - affinity binding of <START=Pharmacologic Substance> dofetilide <END=Pharmacologic Substance> by the related bovine <START=Pharmacologic Substance> ether <END=Pharmacologic Substance> a - go - go channel bEAG to high - affinity binding of HERG. Previously, it was shown that high - affinity binding in HERG required intact C - type inactivation ; the bovine <START=Pharmacologic Substance> ether <END=Pharmacologic Substance> a - go - go K ( + ) channel ( bEAG ), unlike HERG, is noninactivating."}, {"PMID": 15526107, "id": 7, "text": "Second, we treated volunteers for 7 days with 1 x 20 mg/day carteolol and assessed lymphocyte beta(2)-adrenoceptor density (by (-)-[(125)I]-iodocyanopindolol binding) and functional responsiveness (by 10 muM isoprenaline-induced increase in lymphocyte cyclic AMP content).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [208, 220], "name": "isoprenaline", "tok_span": [60, 63], "new_tok_span": [64, 67]}, {"ent_type": "CHEMICAL", "char_span": [252, 262], "name": "cyclic AMP", "tok_span": [68, 70], "new_tok_span": [72, 74]}, {"ent_type": "CHEMICAL", "char_span": [127, 157], "name": "(-)-[(125)I]-iodocyanopindolol", "tok_span": [33, 50], "new_tok_span": [35, 52]}, {"ent_type": "GENE", "char_span": [94, 114], "name": "beta(2)-adrenoceptor", "tok_span": [22, 30], "new_tok_span": [24, 32]}], "relation_list": [{"subject": "(-)-[(125)I]-iodocyanopindolol", "sbj_char_span": [127, 157], "object": "beta(2)-adrenoceptor", "obj_char_span": [94, 114], "rel_type": "regulator", "sbj_tok_span": [33, 50], "obj_tok_span": [22, 30], "new_sbj_tok_span": [35, 52], "new_obj_tok_span": [24, 32]}], "umls_entity_list": [{"mention": "carteolol", "char_span": [60, 69], "sem_type": "Pharmacologic Substance", "tok_span": [15, 19], "new_tok_span": [16, 20]}, {"mention": "iodocyanopindolol", "char_span": [140, 157], "sem_type": "Organic Chemical", "tok_span": [44, 50], "new_tok_span": [47, 53]}], "new_text": "Second, we treated volunteers for 7 days with 1 x 20 mg / day <START=Pharmacologic Substance> carteolol <END=Pharmacologic Substance> and assessed lymphocyte beta ( 2 ) - adrenoceptor density ( by ( - ) - [ ( 125 ) I ] - <START=Organic Chemical> iodocyanopindolol <END=Organic Chemical> binding ) and functional responsiveness ( by 10 muM isoprenaline - induced increase in lymphocyte cyclic AMP content )."}, {"PMID": 23374869, "id": 1, "text": "Based on recent reports that the small molecules, isatin and phthalimide, are suitable scaffolds for the design of high potency monoamine oxidase (MAO) inhibitors, the present study examines the MAO inhibitory properties of a series of phthalide [2-benzofuran-1(3H)-one] analogues.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [128, 137], "name": "monoamine", "tok_span": [25, 27], "new_tok_span": [28, 30]}, {"ent_type": "CHEMICAL", "char_span": [236, 245], "name": "phthalide", "tok_span": [47, 50], "new_tok_span": [52, 55]}, {"ent_type": "CHEMICAL", "char_span": [247, 269], "name": "2-benzofuran-1(3H)-one", "tok_span": [51, 64], "new_tok_span": [57, 70]}, {"ent_type": "CHEMICAL", "char_span": [50, 56], "name": "isatin", "tok_span": [9, 11], "new_tok_span": [9, 11]}, {"ent_type": "CHEMICAL", "char_span": [61, 72], "name": "phthalimide", "tok_span": [12, 15], "new_tok_span": [13, 16]}, {"ent_type": "GENE", "char_span": [128, 145], "name": "monoamine oxidase", "tok_span": [25, 28], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [147, 150], "name": "MAO", "tok_span": [29, 31], "new_tok_span": [33, 35]}, {"ent_type": "GENE", "char_span": [195, 198], "name": "MAO", "tok_span": [39, 41], "new_tok_span": [43, 45]}], "relation_list": [{"subject": "isatin", "sbj_char_span": [50, 56], "object": "monoamine oxidase", "obj_char_span": [128, 145], "rel_type": "inhibitor", "sbj_tok_span": [9, 11], "obj_tok_span": [25, 28], "new_sbj_tok_span": [9, 11], "new_obj_tok_span": [28, 31]}, {"subject": "isatin", "sbj_char_span": [50, 56], "object": "MAO", "obj_char_span": [147, 150], "rel_type": "inhibitor", "sbj_tok_span": [9, 11], "obj_tok_span": [29, 31], "new_sbj_tok_span": [9, 11], "new_obj_tok_span": [33, 35]}, {"subject": "phthalimide", "sbj_char_span": [61, 72], "object": "monoamine oxidase", "obj_char_span": [128, 145], "rel_type": "inhibitor", "sbj_tok_span": [12, 15], "obj_tok_span": [25, 28], "new_sbj_tok_span": [13, 16], "new_obj_tok_span": [28, 31]}, {"subject": "phthalimide", "sbj_char_span": [61, 72], "object": "MAO", "obj_char_span": [147, 150], "rel_type": "inhibitor", "sbj_tok_span": [12, 15], "obj_tok_span": [29, 31], "new_sbj_tok_span": [13, 16], "new_obj_tok_span": [33, 35]}, {"subject": "phthalide", "sbj_char_span": [236, 245], "object": "MAO", "obj_char_span": [195, 198], "rel_type": "inhibitor", "sbj_tok_span": [47, 50], "obj_tok_span": [39, 41], "new_sbj_tok_span": [52, 55], "new_obj_tok_span": [43, 45]}, {"subject": "2-benzofuran-1(3H)-one", "sbj_char_span": [247, 269], "object": "MAO", "obj_char_span": [195, 198], "rel_type": "inhibitor", "sbj_tok_span": [51, 64], "obj_tok_span": [39, 41], "new_sbj_tok_span": [57, 70], "new_obj_tok_span": [43, 45]}], "umls_entity_list": [{"mention": "phthalimide", "char_span": [61, 72], "sem_type": "Organic Chemical", "tok_span": [12, 15], "new_tok_span": [13, 16]}, {"mention": "monoamine", "char_span": [128, 137], "sem_type": "Pharmacologic Substance", "tok_span": [25, 27], "new_tok_span": [28, 30]}, {"mention": "phthalide", "char_span": [236, 245], "sem_type": "Organic Chemical", "tok_span": [47, 50], "new_tok_span": [52, 55]}, {"mention": "benzofuran", "char_span": [249, 259], "sem_type": "Organic Chemical", "tok_span": [53, 56], "new_tok_span": [60, 63]}], "new_text": "Based on recent reports that the small molecules, isatin and <START=Organic Chemical> phthalimide <END=Organic Chemical>, are suitable scaffolds for the design of high potency <START=Pharmacologic Substance> monoamine <END=Pharmacologic Substance> oxidase ( MAO ) inhibitors, the present study examines the MAO inhibitory properties of a series of <START=Organic Chemical> phthalide <END=Organic Chemical> [ 2 - <START=Organic Chemical> benzofuran <END=Organic Chemical> - 1 ( 3H ) - one ] analogues."}, {"PMID": 17335951, "id": 5, "text": "RESULTS: Duloxetine and fluoxetine both reduced SERT density in cortex and induced anxiolytic-like effects.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 19], "name": "Duloxetine", "tok_span": [2, 5], "new_tok_span": [2, 5]}, {"ent_type": "CHEMICAL", "char_span": [24, 34], "name": "fluoxetine", "tok_span": [6, 9], "new_tok_span": [6, 9]}, {"ent_type": "GENE", "char_span": [48, 52], "name": "SERT", "tok_span": [11, 13], "new_tok_span": [12, 14]}], "relation_list": [{"subject": "fluoxetine", "sbj_char_span": [24, 34], "object": "SERT", "obj_char_span": [48, 52], "rel_type": "regulator", "sbj_tok_span": [6, 9], "obj_tok_span": [11, 13], "new_sbj_tok_span": [6, 9], "new_obj_tok_span": [12, 14]}, {"subject": "Duloxetine", "sbj_char_span": [9, 19], "object": "SERT", "obj_char_span": [48, 52], "rel_type": "regulator", "sbj_tok_span": [2, 5], "obj_tok_span": [11, 13], "new_sbj_tok_span": [2, 5], "new_obj_tok_span": [12, 14]}], "umls_entity_list": [{"mention": "SERT", "char_span": [48, 52], "sem_type": "Gene or Genome", "tok_span": [11, 13], "new_tok_span": [12, 14]}], "new_text": "RESULTS : Duloxetine and fluoxetine both reduced <START=Gene or Genome> SERT <END=Gene or Genome> density in cortex and induced anxiolytic - like effects."}, {"PMID": 23551063, "id": 3, "text": "UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs. 5.  Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates. 6.  This new method is particularly suitable for fast activity screenings of UGTs 1A6, 1A7, 1A10 and 2A1 and HFC glucuronidation activity determination from various samples.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [71, 74], "name": "HFC", "tok_span": [16, 18], "new_tok_span": [18, 20]}, {"ent_type": "CHEMICAL", "char_span": [79, 82], "name": "UDP", "tok_span": [19, 20], "new_tok_span": [21, 22]}, {"ent_type": "CHEMICAL", "char_span": [83, 98], "name": "glucuronic acid", "tok_span": [21, 25], "new_tok_span": [23, 27]}, {"ent_type": "CHEMICAL", "char_span": [187, 190], "name": "HFC", "tok_span": [48, 50], "new_tok_span": [50, 52]}, {"ent_type": "CHEMICAL", "char_span": [331, 334], "name": "HFC", "tok_span": [90, 92], "new_tok_span": [92, 94]}, {"ent_type": "GENE", "char_span": [114, 118], "name": "UGTs", "tok_span": [28, 31], "new_tok_span": [30, 33]}, {"ent_type": "GENE", "char_span": [299, 326], "name": "UGTs 1A6, 1A7, 1A10 and 2A1", "tok_span": [71, 89], "new_tok_span": [73, 91]}, {"ent_type": "GENE", "char_span": [0, 6], "name": "UGT1A6", "tok_span": [0, 5], "new_tok_span": [0, 5]}], "relation_list": [{"subject": "HFC", "sbj_char_span": [71, 74], "object": "UGT1A6", "obj_char_span": [0, 6], "rel_type": "product or substrate", "sbj_tok_span": [16, 18], "obj_tok_span": [0, 5], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [0, 5]}, {"subject": "UDP", "sbj_char_span": [79, 82], "object": "UGT1A6", "obj_char_span": [0, 6], "rel_type": "product or substrate", "sbj_tok_span": [19, 20], "obj_tok_span": [0, 5], "new_sbj_tok_span": [21, 22], "new_obj_tok_span": [0, 5]}, {"subject": "glucuronic acid", "sbj_char_span": [83, 98], "object": "UGT1A6", "obj_char_span": [0, 6], "rel_type": "product or substrate", "sbj_tok_span": [21, 25], "obj_tok_span": [0, 5], "new_sbj_tok_span": [23, 27], "new_obj_tok_span": [0, 5]}, {"subject": "HFC", "sbj_char_span": [71, 74], "object": "UGTs", "obj_char_span": [114, 118], "rel_type": "product or substrate", "sbj_tok_span": [16, 18], "obj_tok_span": [28, 31], "new_sbj_tok_span": [18, 20], "new_obj_tok_span": [30, 33]}, {"subject": "UDP", "sbj_char_span": [79, 82], "object": "UGTs", "obj_char_span": [114, 118], "rel_type": "product or substrate", "sbj_tok_span": [19, 20], "obj_tok_span": [28, 31], "new_sbj_tok_span": [21, 22], "new_obj_tok_span": [30, 33]}, {"subject": "glucuronic acid", "sbj_char_span": [83, 98], "object": "UGTs", "obj_char_span": [114, 118], "rel_type": "product or substrate", "sbj_tok_span": [21, 25], "obj_tok_span": [28, 31], "new_sbj_tok_span": [23, 27], "new_obj_tok_span": [30, 33]}], "umls_entity_list": [{"mention": "Km", "char_span": [49, 51], "sem_type": "Gene or Genome", "tok_span": [12, 13], "new_tok_span": [13, 14]}], "new_text": "UGT1A6 exhibited a significantly higher Vmax and <START=Gene or Genome> Km <END=Gene or Genome> values toward both HFC and UDP - glucuronic acid than the other UGTs. 5. Human, pig and rabbit, but not rat liver microsomes, catalyzed HFC glucuronidation at high rates. 6. This new method is particularly suitable for fast activity screenings of UGTs 1A6, 1A7, 1A10 and 2A1 and HFC glucuronidation activity determination from various samples."}, {"PMID": 23297412, "id": 2, "text": "Here, we show that oral administration of resveratrol, which leads to activation of an NAD(+)-dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 53], "name": "resveratrol", "tok_span": [8, 10], "new_tok_span": [9, 11]}, {"ent_type": "CHEMICAL", "char_span": [87, 93], "name": "NAD(+)", "tok_span": [17, 21], "new_tok_span": [19, 23]}, {"ent_type": "GENE", "char_span": [87, 129], "name": "NAD(+)-dependent protein deacetylase SIRT1", "tok_span": [17, 29], "new_tok_span": [19, 31]}, {"ent_type": "GENE", "char_span": [218, 228], "name": "dystrophin", "tok_span": [42, 45], "new_tok_span": [50, 53]}], "relation_list": [{"subject": "resveratrol", "sbj_char_span": [42, 53], "object": "NAD(+)-dependent protein deacetylase SIRT1", "obj_char_span": [87, 129], "rel_type": "activator", "sbj_tok_span": [8, 10], "obj_tok_span": [17, 29], "new_sbj_tok_span": [9, 11], "new_obj_tok_span": [19, 31]}], "umls_entity_list": [{"mention": "resveratrol", "char_span": [42, 53], "sem_type": "Pharmacologic Substance", "tok_span": [8, 10], "new_tok_span": [9, 11]}, {"mention": "SIRT1", "char_span": [124, 129], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 29], "new_tok_span": [31, 33]}, {"mention": "SIRT1", "char_span": [124, 129], "sem_type": "Gene or Genome", "tok_span": [27, 29], "new_tok_span": [31, 33]}, {"mention": "dystrophin", "char_span": [218, 228], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 45], "new_tok_span": [50, 53]}, {"mention": "dystrophin", "char_span": [218, 228], "sem_type": "Gene or Genome", "tok_span": [42, 45], "new_tok_span": [50, 53]}], "new_text": "Here, we show that oral administration of <START=Pharmacologic Substance> resveratrol <END=Pharmacologic Substance>, which leads to activation of an NAD ( + ) - dependent protein deacetylase <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> SIRT1 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> dystrophin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> - deficient mdx mice."}, {"PMID": 23592746, "id": 13, "text": "Bile acid gavage (TUDCA/UDCA) in diet-induced obese rats, elevated serum TUDCA and concomitantly reduced hepatic steatosis and ER stress (CHOP mRNA). These data demonstrate the ability of alterations in bile acids to recapitulate important metabolic improvements seen after bariatric surgery.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Bile acid", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [18, 23], "name": "TUDCA", "tok_span": [6, 9], "new_tok_span": [10, 13]}, {"ent_type": "CHEMICAL", "char_span": [24, 28], "name": "UDCA", "tok_span": [10, 12], "new_tok_span": [17, 19]}, {"ent_type": "CHEMICAL", "char_span": [73, 78], "name": "TUDCA", "tok_span": [22, 25], "new_tok_span": [34, 37]}, {"ent_type": "CHEMICAL", "char_span": [203, 213], "name": "bile acids", "tok_span": [49, 51], "new_tok_span": [71, 73]}, {"ent_type": "GENE", "char_span": [138, 142], "name": "CHOP", "tok_span": [36, 38], "new_tok_span": [53, 55]}], "relation_list": [{"subject": "Bile acid", "sbj_char_span": [0, 9], "object": "CHOP", "obj_char_span": [138, 142], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [36, 38], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [53, 55]}, {"subject": "TUDCA", "sbj_char_span": [18, 23], "object": "CHOP", "obj_char_span": [138, 142], "rel_type": "regulator", "sbj_tok_span": [6, 9], "obj_tok_span": [36, 38], "new_sbj_tok_span": [10, 13], "new_obj_tok_span": [53, 55]}, {"subject": "UDCA", "sbj_char_span": [24, 28], "object": "CHOP", "obj_char_span": [138, 142], "rel_type": "regulator", "sbj_tok_span": [10, 12], "obj_tok_span": [36, 38], "new_sbj_tok_span": [17, 19], "new_obj_tok_span": [53, 55]}], "umls_entity_list": [{"mention": "bile acids", "char_span": [203, 213], "sem_type": "Organic Chemical", "tok_span": [49, 51], "new_tok_span": [71, 73]}, {"mention": "Bile acid", "char_span": [0, 9], "sem_type": "Organic Chemical", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "bile acid", "char_span": [203, 212], "sem_type": "Organic Chemical", "tok_span": [49, 51], "new_tok_span": [71, 73]}, {"mention": "TUDCA", "char_span": [18, 23], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 9], "new_tok_span": [10, 13]}, {"mention": "TUDCA", "char_span": [73, 78], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 25], "new_tok_span": [34, 37]}, {"mention": "UDCA", "char_span": [19, 23], "sem_type": "Pharmacologic Substance", "tok_span": [6, 9], "new_tok_span": [10, 13]}, {"mention": "UDCA", "char_span": [24, 28], "sem_type": "Pharmacologic Substance", "tok_span": [10, 12], "new_tok_span": [17, 19]}, {"mention": "UDCA", "char_span": [74, 78], "sem_type": "Pharmacologic Substance", "tok_span": [22, 25], "new_tok_span": [34, 37]}, {"mention": "er", "char_span": [68, 70], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [30, 31]}, {"mention": "ER", "char_span": [127, 129], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 34], "new_tok_span": [48, 49]}, {"mention": "er", "char_span": [191, 193], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [47, 48], "new_tok_span": [66, 67]}, {"mention": "er", "char_span": [271, 273], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [59, 60], "new_tok_span": [84, 85]}, {"mention": "er", "char_span": [288, 290], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [62, 63], "new_tok_span": [89, 90]}, {"mention": "CHOP", "char_span": [138, 142], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 38], "new_tok_span": [53, 55]}], "new_text": "<START=Organic Chemical> Bile acid <END=Organic Chemical> gavage ( <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> TUDCA <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> / <START=Pharmacologic Substance> UDCA <END=Pharmacologic Substance> ) in diet - induced obese rats, elevated <START=Amino Acid, Peptide, or Protein> serum <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> TUDCA <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> and concomitantly reduced hepatic steatosis and <START=Amino Acid, Peptide, or Protein> ER <END=Amino Acid, Peptide, or Protein> stress ( <START=Amino Acid, Peptide, or Protein> CHOP <END=Amino Acid, Peptide, or Protein> mRNA ). These data demonstrate the ability of <START=Amino Acid, Peptide, or Protein> alterations <END=Amino Acid, Peptide, or Protein> in <START=Organic Chemical> <START=Organic Chemical> bile acids <END=Organic Chemical> <END=Organic Chemical> to recapitulate important metabolic improvements seen <START=Amino Acid, Peptide, or Protein> after <END=Amino Acid, Peptide, or Protein> bariatric <START=Amino Acid, Peptide, or Protein> surgery <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23301897, "id": 7, "text": "In addition, the new compound perviridicin B (2), three known rocaglate derivatives (9, 11, 12), and a known sesquiterpene, 2-oxaisodauc-5-en-12-al (17), showed significant NF-κB (p65) inhibitory activity in an ELISA assay.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [30, 44], "name": "perviridicin B", "tok_span": [6, 11], "new_tok_span": [6, 11]}, {"ent_type": "CHEMICAL", "char_span": [62, 71], "name": "rocaglate", "tok_span": [17, 21], "new_tok_span": [17, 21]}, {"ent_type": "CHEMICAL", "char_span": [109, 122], "name": "sesquiterpene", "tok_span": [33, 38], "new_tok_span": [34, 39]}, {"ent_type": "CHEMICAL", "char_span": [124, 147], "name": "2-oxaisodauc-5-en-12-al", "tok_span": [39, 53], "new_tok_span": [43, 57]}, {"ent_type": "GENE", "char_span": [173, 178], "name": "NF-κB", "tok_span": [59, 63], "new_tok_span": [65, 69]}, {"ent_type": "GENE", "char_span": [180, 183], "name": "p65", "tok_span": [64, 66], "new_tok_span": [70, 72]}], "relation_list": [{"subject": "perviridicin B", "sbj_char_span": [30, 44], "object": "NF-κB", "obj_char_span": [173, 178], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [59, 63], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [65, 69]}, {"subject": "perviridicin B", "sbj_char_span": [30, 44], "object": "p65", "obj_char_span": [180, 183], "rel_type": "inhibitor", "sbj_tok_span": [6, 11], "obj_tok_span": [64, 66], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [70, 72]}, {"subject": "rocaglate", "sbj_char_span": [62, 71], "object": "NF-κB", "obj_char_span": [173, 178], "rel_type": "inhibitor", "sbj_tok_span": [17, 21], "obj_tok_span": [59, 63], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [65, 69]}, {"subject": "rocaglate", "sbj_char_span": [62, 71], "object": "p65", "obj_char_span": [180, 183], "rel_type": "inhibitor", "sbj_tok_span": [17, 21], "obj_tok_span": [64, 66], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [70, 72]}, {"subject": "sesquiterpene", "sbj_char_span": [109, 122], "object": "NF-κB", "obj_char_span": [173, 178], "rel_type": "inhibitor", "sbj_tok_span": [33, 38], "obj_tok_span": [59, 63], "new_sbj_tok_span": [34, 39], "new_obj_tok_span": [65, 69]}, {"subject": "sesquiterpene", "sbj_char_span": [109, 122], "object": "p65", "obj_char_span": [180, 183], "rel_type": "inhibitor", "sbj_tok_span": [33, 38], "obj_tok_span": [64, 66], "new_sbj_tok_span": [34, 39], "new_obj_tok_span": [70, 72]}, {"subject": "2-oxaisodauc-5-en-12-al", "sbj_char_span": [124, 147], "object": "NF-κB", "obj_char_span": [173, 178], "rel_type": "inhibitor", "sbj_tok_span": [39, 53], "obj_tok_span": [59, 63], "new_sbj_tok_span": [43, 57], "new_obj_tok_span": [65, 69]}, {"subject": "2-oxaisodauc-5-en-12-al", "sbj_char_span": [124, 147], "object": "p65", "obj_char_span": [180, 183], "rel_type": "inhibitor", "sbj_tok_span": [39, 53], "obj_tok_span": [64, 66], "new_sbj_tok_span": [43, 57], "new_obj_tok_span": [70, 72]}], "umls_entity_list": [{"mention": "sesquiterpene", "char_span": [109, 122], "sem_type": "Organic Chemical", "tok_span": [33, 38], "new_tok_span": [34, 39]}, {"mention": "en", "char_span": [119, 121], "sem_type": "Gene or Genome", "tok_span": [36, 37], "new_tok_span": [38, 39]}, {"mention": "en", "char_span": [139, 141], "sem_type": "Gene or Genome", "tok_span": [48, 49], "new_tok_span": [53, 54]}], "new_text": "In addition, the new compound perviridicin B ( 2 ), three known rocaglate derivatives ( 9, 11, 12 ), and a known <START=Organic Chemical> sesquiter <START=Gene or Genome>pen <END=Gene or Genome>e <END=Organic Chemical>, 2 - oxaisodauc - 5 - <START=Gene or Genome> en <END=Gene or Genome> - 12 - al ( 17 ), showed significant NF - κB ( p65 ) inhibitory activity in an ELISA assay."}, {"PMID": 23077105, "id": 1, "text": "Multidrug resistance-associated protein 3 (Mrp3; Abcc3) expression and activity are up-regulated in rat liver after in vivo repeated administration of ethynylestradiol (EE), a cholestatic synthetic estrogen, whereas multidrug resistance-associated protein 2 (Mrp2) is down-regulated.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [151, 167], "name": "ethynylestradiol", "tok_span": [32, 38], "new_tok_span": [45, 51]}, {"ent_type": "CHEMICAL", "char_span": [198, 206], "name": "estrogen", "tok_span": [47, 48], "new_tok_span": [62, 63]}, {"ent_type": "GENE", "char_span": [0, 41], "name": "Multidrug resistance-associated protein 3", "tok_span": [0, 7], "new_tok_span": [3, 10]}, {"ent_type": "GENE", "char_span": [216, 257], "name": "multidrug resistance-associated protein 2", "tok_span": [50, 57], "new_tok_span": [69, 76]}, {"ent_type": "GENE", "char_span": [259, 263], "name": "Mrp2", "tok_span": [58, 61], "new_tok_span": [80, 83]}, {"ent_type": "GENE", "char_span": [43, 47], "name": "Mrp3", "tok_span": [8, 11], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [49, 54], "name": "Abcc3", "tok_span": [12, 15], "new_tok_span": [22, 25]}], "relation_list": [{"subject": "ethynylestradiol", "sbj_char_span": [151, 167], "object": "Multidrug resistance-associated protein 3", "obj_char_span": [0, 41], "rel_type": "regulator", "sbj_tok_span": [32, 38], "obj_tok_span": [0, 7], "new_sbj_tok_span": [45, 51], "new_obj_tok_span": [3, 10]}, {"subject": "ethynylestradiol", "sbj_char_span": [151, 167], "object": "Mrp3", "obj_char_span": [43, 47], "rel_type": "regulator", "sbj_tok_span": [32, 38], "obj_tok_span": [8, 11], "new_sbj_tok_span": [45, 51], "new_obj_tok_span": [15, 18]}, {"subject": "ethynylestradiol", "sbj_char_span": [151, 167], "object": "Abcc3", "obj_char_span": [49, 54], "rel_type": "regulator", "sbj_tok_span": [32, 38], "obj_tok_span": [12, 15], "new_sbj_tok_span": [45, 51], "new_obj_tok_span": [22, 25]}, {"subject": "estrogen", "sbj_char_span": [198, 206], "object": "Multidrug resistance-associated protein 3", "obj_char_span": [0, 41], "rel_type": "regulator", "sbj_tok_span": [47, 48], "obj_tok_span": [0, 7], "new_sbj_tok_span": [62, 63], "new_obj_tok_span": [3, 10]}, {"subject": "estrogen", "sbj_char_span": [198, 206], "object": "Mrp3", "obj_char_span": [43, 47], "rel_type": "regulator", "sbj_tok_span": [47, 48], "obj_tok_span": [8, 11], "new_sbj_tok_span": [62, 63], "new_obj_tok_span": [15, 18]}, {"subject": "estrogen", "sbj_char_span": [198, 206], "object": "Abcc3", "obj_char_span": [49, 54], "rel_type": "regulator", "sbj_tok_span": [47, 48], "obj_tok_span": [12, 15], "new_sbj_tok_span": [62, 63], "new_obj_tok_span": [22, 25]}, {"subject": "ethynylestradiol", "sbj_char_span": [151, 167], "object": "Multidrug resistance-associated protein 3", "obj_char_span": [0, 41], "rel_type": "activator", "sbj_tok_span": [32, 38], "obj_tok_span": [0, 7], "new_sbj_tok_span": [45, 51], "new_obj_tok_span": [3, 10]}, {"subject": "ethynylestradiol", "sbj_char_span": [151, 167], "object": "Mrp3", "obj_char_span": [43, 47], "rel_type": "activator", "sbj_tok_span": [32, 38], "obj_tok_span": [8, 11], "new_sbj_tok_span": [45, 51], "new_obj_tok_span": [15, 18]}, {"subject": "ethynylestradiol", "sbj_char_span": [151, 167], "object": "Abcc3", "obj_char_span": [49, 54], "rel_type": "activator", "sbj_tok_span": [32, 38], "obj_tok_span": [12, 15], "new_sbj_tok_span": [45, 51], "new_obj_tok_span": [22, 25]}, {"subject": "estrogen", "sbj_char_span": [198, 206], "object": "Multidrug resistance-associated protein 3", "obj_char_span": [0, 41], "rel_type": "activator", "sbj_tok_span": [47, 48], "obj_tok_span": [0, 7], "new_sbj_tok_span": [62, 63], "new_obj_tok_span": [3, 10]}, {"subject": "estrogen", "sbj_char_span": [198, 206], "object": "Mrp3", "obj_char_span": [43, 47], "rel_type": "activator", "sbj_tok_span": [47, 48], "obj_tok_span": [8, 11], "new_sbj_tok_span": [62, 63], "new_obj_tok_span": [15, 18]}, {"subject": "estrogen", "sbj_char_span": [198, 206], "object": "Abcc3", "obj_char_span": [49, 54], "rel_type": "activator", "sbj_tok_span": [47, 48], "obj_tok_span": [12, 15], "new_sbj_tok_span": [62, 63], "new_obj_tok_span": [22, 25]}, {"subject": "ethynylestradiol", "sbj_char_span": [151, 167], "object": "multidrug resistance-associated protein 2", "obj_char_span": [216, 257], "rel_type": "regulator", "sbj_tok_span": [32, 38], "obj_tok_span": [50, 57], "new_sbj_tok_span": [45, 51], "new_obj_tok_span": [69, 76]}, {"subject": "estrogen", "sbj_char_span": [198, 206], "object": "multidrug resistance-associated protein 2", "obj_char_span": [216, 257], "rel_type": "regulator", "sbj_tok_span": [47, 48], "obj_tok_span": [50, 57], "new_sbj_tok_span": [62, 63], "new_obj_tok_span": [69, 76]}, {"subject": "ethynylestradiol", "sbj_char_span": [151, 167], "object": "Mrp2", "obj_char_span": [259, 263], "rel_type": "regulator", "sbj_tok_span": [32, 38], "obj_tok_span": [58, 61], "new_sbj_tok_span": [45, 51], "new_obj_tok_span": [80, 83]}, {"subject": "estrogen", "sbj_char_span": [198, 206], "object": "Mrp2", "obj_char_span": [259, 263], "rel_type": "regulator", "sbj_tok_span": [47, 48], "obj_tok_span": [58, 61], "new_sbj_tok_span": [62, 63], "new_obj_tok_span": [80, 83]}, {"subject": "ethynylestradiol", "sbj_char_span": [151, 167], "object": "multidrug resistance-associated protein 2", "obj_char_span": [216, 257], "rel_type": "inhibitor", "sbj_tok_span": [32, 38], "obj_tok_span": [50, 57], "new_sbj_tok_span": [45, 51], "new_obj_tok_span": [69, 76]}, {"subject": "ethynylestradiol", "sbj_char_span": [151, 167], "object": "Mrp2", "obj_char_span": [259, 263], "rel_type": "inhibitor", "sbj_tok_span": [32, 38], "obj_tok_span": [58, 61], "new_sbj_tok_span": [45, 51], "new_obj_tok_span": [80, 83]}, {"subject": "estrogen", "sbj_char_span": [198, 206], "object": "multidrug resistance-associated protein 2", "obj_char_span": [216, 257], "rel_type": "inhibitor", "sbj_tok_span": [47, 48], "obj_tok_span": [50, 57], "new_sbj_tok_span": [62, 63], "new_obj_tok_span": [69, 76]}, {"subject": "estrogen", "sbj_char_span": [198, 206], "object": "Mrp2", "obj_char_span": [259, 263], "rel_type": "inhibitor", "sbj_tok_span": [47, 48], "obj_tok_span": [58, 61], "new_sbj_tok_span": [62, 63], "new_obj_tok_span": [80, 83]}], "umls_entity_list": [{"mention": "Multidrug", "char_span": [0, 9], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 2], "new_tok_span": [3, 5]}, {"mention": "multidrug", "char_span": [216, 225], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 52], "new_tok_span": [69, 71]}, {"mention": "Multidrug resistance-associated protein 3", "char_span": [0, 41], "sem_type": "Gene or Genome", "tok_span": [0, 7], "new_tok_span": [3, 10]}, {"mention": "Multidrug resistance-associated protein 3", "char_span": [0, 41], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 7], "new_tok_span": [3, 10]}, {"mention": "Mrp3", "char_span": [43, 47], "sem_type": "Gene or Genome", "tok_span": [8, 11], "new_tok_span": [15, 18]}, {"mention": "Abcc3", "char_span": [49, 54], "sem_type": "Gene or Genome", "tok_span": [12, 15], "new_tok_span": [22, 25]}, {"mention": "Abcc3", "char_span": [49, 54], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 15], "new_tok_span": [22, 25]}, {"mention": "ethynylestradiol", "char_span": [151, 167], "sem_type": "Pharmacologic Substance", "tok_span": [32, 38], "new_tok_span": [45, 51]}, {"mention": "synthetic estrogen", "char_span": [188, 206], "sem_type": "Pharmacologic Substance", "tok_span": [46, 48], "new_tok_span": [61, 63]}, {"mention": "multidrug resistance-associated protein 2", "char_span": [216, 257], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [50, 57], "new_tok_span": [69, 76]}, {"mention": "multidrug resistance-associated protein 2", "char_span": [216, 257], "sem_type": "Gene or Genome", "tok_span": [50, 57], "new_tok_span": [69, 76]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Multidrug <END=Amino Acid, Peptide, or Protein> resistance - associated protein 3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ( <START=Gene or Genome> Mrp3 <END=Gene or Genome> ; <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Abcc3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ) expression and activity are up - regulated in rat liver after in vivo repeated administration of <START=Pharmacologic Substance> ethynylestradiol <END=Pharmacologic Substance> ( EE ), a cholestatic <START=Pharmacologic Substance> synthetic estrogen <END=Pharmacologic Substance>, whereas <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> multidrug <END=Amino Acid, Peptide, or Protein> resistance - associated protein 2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( Mrp2 ) is down - regulated."}, {"PMID": 19651196, "id": 3, "text": "The mechanism of OP poisoning involves inhibition of acetylcholinesterase (AChE) leading to inactivation of the enzyme which has an important role in neurotransmission.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [17, 19], "name": "OP", "tok_span": [3, 4], "new_tok_span": [3, 4]}, {"ent_type": "GENE", "char_span": [53, 73], "name": "acetylcholinesterase", "tok_span": [8, 11], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [75, 79], "name": "AChE", "tok_span": [12, 14], "new_tok_span": [12, 14]}], "relation_list": [{"subject": "OP", "sbj_char_span": [17, 19], "object": "acetylcholinesterase", "obj_char_span": [53, 73], "rel_type": "inhibitor", "sbj_tok_span": [3, 4], "obj_tok_span": [8, 11], "new_sbj_tok_span": [3, 4], "new_obj_tok_span": [8, 11]}, {"subject": "OP", "sbj_char_span": [17, 19], "object": "AChE", "obj_char_span": [75, 79], "rel_type": "inhibitor", "sbj_tok_span": [3, 4], "obj_tok_span": [12, 14], "new_sbj_tok_span": [3, 4], "new_obj_tok_span": [12, 14]}], "umls_entity_list": [], "new_text": "The mechanism of OP poisoning involves inhibition of acetylcholinesterase ( AChE ) leading to inactivation of the enzyme which has an important role in neurotransmission."}, {"PMID": 2897127, "id": 0, "text": "Interaction of antidepressants and neuroleptics with histamine stimulated parietal cell adenylate cyclase and H+ secretion.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [110, 112], "name": "H+", "tok_span": [18, 20], "new_tok_span": [28, 30]}, {"ent_type": "CHEMICAL", "char_span": [53, 62], "name": "histamine", "tok_span": [10, 11], "new_tok_span": [15, 16]}, {"ent_type": "CHEMICAL", "char_span": [88, 97], "name": "adenylate", "tok_span": [14, 16], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [88, 105], "name": "adenylate cyclase", "tok_span": [14, 17], "new_tok_span": [22, 25]}], "relation_list": [{"subject": "histamine", "sbj_char_span": [53, 62], "object": "adenylate cyclase", "obj_char_span": [88, 105], "rel_type": "activator", "sbj_tok_span": [10, 11], "obj_tok_span": [14, 17], "new_sbj_tok_span": [15, 16], "new_obj_tok_span": [22, 25]}], "umls_entity_list": [{"mention": "antidepressants", "char_span": [15, 30], "sem_type": "Pharmacologic Substance", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"mention": "neuroleptics", "char_span": [35, 47], "sem_type": "Pharmacologic Substance", "tok_span": [5, 9], "new_tok_span": [8, 12]}, {"mention": "histamine", "char_span": [53, 62], "sem_type": "Organic Chemical", "tok_span": [10, 11], "new_tok_span": [15, 16]}, {"mention": "adenylate", "char_span": [88, 97], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 16], "new_tok_span": [22, 24]}, {"mention": "adenylate cyclase", "char_span": [88, 105], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 17], "new_tok_span": [22, 25]}], "new_text": "Interaction of <START=Pharmacologic Substance> antidepressants <END=Pharmacologic Substance> and <START=Pharmacologic Substance> neuroleptics <END=Pharmacologic Substance> with <START=Organic Chemical> histamine <END=Organic Chemical> stimulated parietal cell <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> adenylate <END=Amino Acid, Peptide, or Protein> cyclase <END=Amino Acid, Peptide, or Protein> and H + secretion."}, {"PMID": 17355872, "id": 3, "text": "We identified suramin as a compound that binds to human SIRT5 and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 21], "name": "suramin", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [96, 102], "name": "NAD(+)", "tok_span": [20, 24], "new_tok_span": [26, 30]}, {"ent_type": "GENE", "char_span": [50, 61], "name": "human SIRT5", "tok_span": [10, 13], "new_tok_span": [12, 15]}, {"ent_type": "GENE", "char_span": [90, 124], "name": "SIRT5 NAD(+)-dependent deacetylase", "tok_span": [18, 29], "new_tok_span": [23, 34]}], "relation_list": [{"subject": "suramin", "sbj_char_span": [14, 21], "object": "human SIRT5", "obj_char_span": [50, 61], "rel_type": "regulator", "sbj_tok_span": [2, 4], "obj_tok_span": [10, 13], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [12, 15]}, {"subject": "suramin", "sbj_char_span": [14, 21], "object": "SIRT5 NAD(+)-dependent deacetylase", "obj_char_span": [90, 124], "rel_type": "inhibitor", "sbj_tok_span": [2, 4], "obj_tok_span": [18, 29], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [23, 34]}], "umls_entity_list": [{"mention": "suramin", "char_span": [14, 21], "sem_type": "Pharmacologic Substance", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"mention": "SIRT5", "char_span": [56, 61], "sem_type": "Gene or Genome", "tok_span": [11, 13], "new_tok_span": [14, 16]}, {"mention": "SIRT5", "char_span": [90, 95], "sem_type": "Gene or Genome", "tok_span": [18, 20], "new_tok_span": [23, 25]}], "new_text": "We identified <START=Pharmacologic Substance> suramin <END=Pharmacologic Substance> as a compound that binds to human <START=Gene or Genome> SIRT5 <END=Gene or Genome> and showed that it inhibits <START=Gene or Genome> SIRT5 <END=Gene or Genome> NAD ( + ) - dependent deacetylase activity with an IC ( 50 ) value of 22 microM."}, {"PMID": 12170055, "id": 10, "text": "Meperidine inhibited the production of forskolin-stimulated cyclic adenosine monophosphate mediated by all receptor subtypes but was most effective at the alpha(2B) adrenoceptor (alpha(2B), 0.6 microm; alpha(2A), 1.3 mm; alpha(2C), 0.3 mm), reaching the same level of inhibition (approximately 70%) as achieved with the alpha2-adrenoceptor agonist dexmedetomidine.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Meperidine", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [39, 48], "name": "forskolin", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"ent_type": "CHEMICAL", "char_span": [60, 90], "name": "cyclic adenosine monophosphate", "tok_span": [12, 19], "new_tok_span": [15, 22]}, {"ent_type": "CHEMICAL", "char_span": [348, 363], "name": "dexmedetomidine", "tok_span": [95, 100], "new_tok_span": [104, 109]}, {"ent_type": "GENE", "char_span": [155, 177], "name": "alpha(2B) adrenoceptor", "tok_span": [30, 38], "new_tok_span": [36, 44]}, {"ent_type": "GENE", "char_span": [320, 339], "name": "alpha2-adrenoceptor", "tok_span": [88, 94], "new_tok_span": [94, 100]}], "relation_list": [{"subject": "dexmedetomidine", "sbj_char_span": [348, 363], "object": "alpha2-adrenoceptor", "obj_char_span": [320, 339], "rel_type": "agonist or antagonist", "sbj_tok_span": [95, 100], "obj_tok_span": [88, 94], "new_sbj_tok_span": [104, 109], "new_obj_tok_span": [94, 100]}, {"subject": "Meperidine", "sbj_char_span": [0, 10], "object": "alpha(2B) adrenoceptor", "obj_char_span": [155, 177], "rel_type": "activator", "sbj_tok_span": [0, 3], "obj_tok_span": [30, 38], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [36, 44]}], "umls_entity_list": [{"mention": "forskolin", "char_span": [39, 48], "sem_type": "Pharmacologic Substance", "tok_span": [7, 10], "new_tok_span": [8, 11]}, {"mention": "cyclic adenosine monophosphate", "char_span": [60, 90], "sem_type": "Pharmacologic Substance", "tok_span": [12, 19], "new_tok_span": [15, 22]}, {"mention": "receptor", "char_span": [107, 115], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 23], "new_tok_span": [27, 28]}, {"mention": "dexmedetomidine", "char_span": [348, 363], "sem_type": "Pharmacologic Substance", "tok_span": [95, 100], "new_tok_span": [104, 109]}, {"mention": "adrenoceptor agonist", "char_span": [327, 347], "sem_type": "Pharmacologic Substance", "tok_span": [91, 95], "new_tok_span": [98, 102]}], "new_text": "Meperidine inhibited the production of <START=Pharmacologic Substance> forskolin <END=Pharmacologic Substance> - stimulated <START=Pharmacologic Substance> cyclic adenosine monophosphate <END=Pharmacologic Substance> mediated by all <START=Amino Acid, Peptide, or Protein> receptor <END=Amino Acid, Peptide, or Protein> subtypes but was most effective at the alpha ( 2B ) adrenoceptor ( alpha ( 2B ), 0. 6 microm ; alpha ( 2A ), 1. 3 mm ; alpha ( 2C ), 0. 3 mm ), reaching the same level of inhibition ( approximately 70 % ) as achieved with the alpha2 - <START=Pharmacologic Substance> adrenoceptor agonist <END=Pharmacologic Substance> <START=Pharmacologic Substance> dexmedetomidine <END=Pharmacologic Substance>."}, {"PMID": 23537701, "id": 1, "text": "Tetrahydrocannabinol (THC), the major psychoactive component of marijuana, is a cannabinoid agonist that exerts its effects by activating at least two specific receptors (CB1 and CB2) that belong to the seven transmembrane G-protein coupled receptor (GPCR) family.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 20], "name": "Tetrahydrocannabinol", "tok_span": [0, 6], "new_tok_span": [1, 7]}, {"ent_type": "CHEMICAL", "char_span": [22, 25], "name": "THC", "tok_span": [7, 9], "new_tok_span": [9, 11]}, {"ent_type": "GENE", "char_span": [171, 174], "name": "CB1", "tok_span": [39, 41], "new_tok_span": [48, 50]}, {"ent_type": "GENE", "char_span": [179, 182], "name": "CB2", "tok_span": [42, 44], "new_tok_span": [53, 55]}, {"ent_type": "GENE", "char_span": [223, 249], "name": "G-protein coupled receptor", "tok_span": [51, 56], "new_tok_span": [63, 68]}, {"ent_type": "GENE", "char_span": [251, 255], "name": "GPCR", "tok_span": [57, 59], "new_tok_span": [69, 71]}], "relation_list": [{"subject": "Tetrahydrocannabinol", "sbj_char_span": [0, 20], "object": "CB1", "obj_char_span": [171, 174], "rel_type": "activator", "sbj_tok_span": [0, 6], "obj_tok_span": [39, 41], "new_sbj_tok_span": [1, 7], "new_obj_tok_span": [48, 50]}, {"subject": "Tetrahydrocannabinol", "sbj_char_span": [0, 20], "object": "CB2", "obj_char_span": [179, 182], "rel_type": "activator", "sbj_tok_span": [0, 6], "obj_tok_span": [42, 44], "new_sbj_tok_span": [1, 7], "new_obj_tok_span": [53, 55]}, {"subject": "THC", "sbj_char_span": [22, 25], "object": "CB1", "obj_char_span": [171, 174], "rel_type": "activator", "sbj_tok_span": [7, 9], "obj_tok_span": [39, 41], "new_sbj_tok_span": [9, 11], "new_obj_tok_span": [48, 50]}, {"subject": "THC", "sbj_char_span": [22, 25], "object": "CB2", "obj_char_span": [179, 182], "rel_type": "activator", "sbj_tok_span": [7, 9], "obj_tok_span": [42, 44], "new_sbj_tok_span": [9, 11], "new_obj_tok_span": [53, 55]}], "umls_entity_list": [{"mention": "Tetrahydrocannabinol", "char_span": [0, 20], "sem_type": "Pharmacologic Substance", "tok_span": [0, 6], "new_tok_span": [1, 7]}, {"mention": "marijuana", "char_span": [64, 73], "sem_type": "Pharmacologic Substance", "tok_span": [17, 20], "new_tok_span": [21, 24]}, {"mention": "marijuana", "char_span": [64, 73], "sem_type": "Organic Chemical", "tok_span": [17, 20], "new_tok_span": [21, 24]}, {"mention": "cannabinoid agonist", "char_span": [80, 99], "sem_type": "Pharmacologic Substance", "tok_span": [23, 27], "new_tok_span": [30, 34]}, {"mention": "CB1", "char_span": [171, 174], "sem_type": "Gene or Genome", "tok_span": [39, 41], "new_tok_span": [48, 50]}, {"mention": "CB2", "char_span": [179, 182], "sem_type": "Gene or Genome", "tok_span": [42, 44], "new_tok_span": [53, 55]}], "new_text": "<START=Pharmacologic Substance> Tetrahydrocannabinol <END=Pharmacologic Substance> ( THC ), the major psychoactive component of <START=Pharmacologic Substance> <START=Organic Chemical> marijuana <END=Pharmacologic Substance> <END=Organic Chemical>, is a <START=Pharmacologic Substance> cannabinoid agonist <END=Pharmacologic Substance> that exerts its effects by activating at least two specific receptors ( <START=Gene or Genome> CB1 <END=Gene or Genome> and <START=Gene or Genome> CB2 <END=Gene or Genome> ) that belong to the seven transmembrane G - protein coupled receptor ( GPCR ) family."}, {"PMID": 9336833, "id": 2, "text": "The structures of TK complexed with ADP at the ATP-site and deoxythymidine-5'-monophosphate (dTMP), deoxythymidine (dT), or idoxuridine-5'-phosphate (5-iodo-dUMP) at the substrate-site were refined to 2.75 A, 2.8 A, and 3.0 A resolution, respectively.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [36, 39], "name": "ADP", "tok_span": [7, 8], "new_tok_span": [7, 8]}, {"ent_type": "CHEMICAL", "char_span": [47, 50], "name": "ATP", "tok_span": [10, 11], "new_tok_span": [10, 11]}, {"ent_type": "CHEMICAL", "char_span": [60, 91], "name": "deoxythymidine-5'-monophosphate", "tok_span": [14, 27], "new_tok_span": [14, 27]}, {"ent_type": "CHEMICAL", "char_span": [93, 97], "name": "dTMP", "tok_span": [28, 30], "new_tok_span": [32, 34]}, {"ent_type": "CHEMICAL", "char_span": [100, 114], "name": "deoxythymidine", "tok_span": [32, 36], "new_tok_span": [36, 40]}, {"ent_type": "CHEMICAL", "char_span": [116, 118], "name": "dT", "tok_span": [37, 38], "new_tok_span": [41, 42]}, {"ent_type": "CHEMICAL", "char_span": [124, 148], "name": "idoxuridine-5'-phosphate", "tok_span": [41, 51], "new_tok_span": [46, 56]}, {"ent_type": "CHEMICAL", "char_span": [150, 161], "name": "5-iodo-dUMP", "tok_span": [52, 60], "new_tok_span": [63, 71]}, {"ent_type": "GENE", "char_span": [18, 20], "name": "TK", "tok_span": [3, 4], "new_tok_span": [3, 4]}], "relation_list": [{"subject": "ADP", "sbj_char_span": [36, 39], "object": "TK", "obj_char_span": [18, 20], "rel_type": "regulator", "sbj_tok_span": [7, 8], "obj_tok_span": [3, 4], "new_sbj_tok_span": [7, 8], "new_obj_tok_span": [3, 4]}], "umls_entity_list": [{"mention": "idoxuridine", "char_span": [124, 135], "sem_type": "Pharmacologic Substance", "tok_span": [41, 46], "new_tok_span": [46, 51]}, {"mention": "phosphate", "char_span": [82, 91], "sem_type": "Organic Chemical", "tok_span": [22, 27], "new_tok_span": [24, 29]}, {"mention": "phosphate", "char_span": [139, 148], "sem_type": "Organic Chemical", "tok_span": [50, 51], "new_tok_span": [58, 59]}, {"mention": "phosphate", "char_span": [82, 91], "sem_type": "Pharmacologic Substance", "tok_span": [22, 27], "new_tok_span": [24, 29]}, {"mention": "phosphate", "char_span": [139, 148], "sem_type": "Pharmacologic Substance", "tok_span": [50, 51], "new_tok_span": [58, 59]}, {"mention": "5-iodo-dUMP", "char_span": [150, 161], "sem_type": "Pharmacologic Substance", "tok_span": [52, 60], "new_tok_span": [63, 71]}], "new_text": "The structures of TK complexed with ADP at the ATP - site and deoxythymidine - 5'- <START=Organic Chemical> <START=Pharmacologic Substance> monophosphate <END=Organic Chemical> <END=Pharmacologic Substance> ( dTMP ), deoxythymidine ( dT ), or <START=Pharmacologic Substance> idoxuridine <END=Pharmacologic Substance> - 5'- <START=Organic Chemical> <START=Pharmacologic Substance> phosphate <END=Organic Chemical> <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> 5 - iodo - dUMP <END=Pharmacologic Substance> ) at the substrate - site were refined to 2. 75 A, 2. 8 A, and 3. 0 A resolution, respectively."}, {"PMID": 17620346, "id": 1, "text": "In rats, it has been reported that rofecoxib, a cyclooxygenase-2 (COX-2) inhibitor, reacts with the aldehyde group of allysine in elastin to give a condensation covalent adduct, thereby preventing the formation of cross-linkages in the elastin and causing degradation of the elastic fibers in aortas in vivo.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [100, 108], "name": "aldehyde", "tok_span": [29, 33], "new_tok_span": [32, 36]}, {"ent_type": "CHEMICAL", "char_span": [118, 126], "name": "allysine", "tok_span": [35, 38], "new_tok_span": [40, 43]}, {"ent_type": "CHEMICAL", "char_span": [35, 44], "name": "rofecoxib", "tok_span": [8, 12], "new_tok_span": [8, 12]}, {"ent_type": "GENE", "char_span": [130, 137], "name": "elastin", "tok_span": [39, 41], "new_tok_span": [47, 49]}, {"ent_type": "GENE", "char_span": [236, 243], "name": "elastin", "tok_span": [59, 61], "new_tok_span": [71, 73]}, {"ent_type": "GENE", "char_span": [48, 64], "name": "cyclooxygenase-2", "tok_span": [14, 18], "new_tok_span": [14, 18]}, {"ent_type": "GENE", "char_span": [66, 71], "name": "COX-2", "tok_span": [19, 22], "new_tok_span": [19, 22]}], "relation_list": [{"subject": "rofecoxib", "sbj_char_span": [35, 44], "object": "cyclooxygenase-2", "obj_char_span": [48, 64], "rel_type": "inhibitor", "sbj_tok_span": [8, 12], "obj_tok_span": [14, 18], "new_sbj_tok_span": [8, 12], "new_obj_tok_span": [14, 18]}, {"subject": "rofecoxib", "sbj_char_span": [35, 44], "object": "COX-2", "obj_char_span": [66, 71], "rel_type": "inhibitor", "sbj_tok_span": [8, 12], "obj_tok_span": [19, 22], "new_sbj_tok_span": [8, 12], "new_obj_tok_span": [19, 22]}, {"subject": "aldehyde", "sbj_char_span": [100, 108], "object": "elastin", "obj_char_span": [130, 137], "rel_type": "part of", "sbj_tok_span": [29, 33], "obj_tok_span": [39, 41], "new_sbj_tok_span": [32, 36], "new_obj_tok_span": [47, 49]}, {"subject": "allysine", "sbj_char_span": [118, 126], "object": "elastin", "obj_char_span": [130, 137], "rel_type": "part of", "sbj_tok_span": [35, 38], "obj_tok_span": [39, 41], "new_sbj_tok_span": [40, 43], "new_obj_tok_span": [47, 49]}], "umls_entity_list": [{"mention": "react", "char_span": [84, 89], "sem_type": "Pharmacologic Substance", "tok_span": [25, 26], "new_tok_span": [26, 27]}, {"mention": "aldehyde", "char_span": [100, 108], "sem_type": "Organic Chemical", "tok_span": [29, 33], "new_tok_span": [32, 36]}, {"mention": "allysine", "char_span": [118, 126], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 38], "new_tok_span": [40, 43]}, {"mention": "elastin", "char_span": [130, 137], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 41], "new_tok_span": [47, 49]}, {"mention": "elastin", "char_span": [236, 243], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [59, 61], "new_tok_span": [71, 73]}, {"mention": "elastin", "char_span": [130, 137], "sem_type": "Gene or Genome", "tok_span": [39, 41], "new_tok_span": [47, 49]}, {"mention": "elastin", "char_span": [236, 243], "sem_type": "Gene or Genome", "tok_span": [59, 61], "new_tok_span": [71, 73]}], "new_text": "In rats, it has been reported that rofecoxib, a cyclooxygenase - 2 ( COX - 2 ) inhibitor, <START=Pharmacologic Substance> react <END=Pharmacologic Substance>s with the <START=Organic Chemical> aldehyde <END=Organic Chemical> group of <START=Amino Acid, Peptide, or Protein> allysine <END=Amino Acid, Peptide, or Protein> in <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> elastin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> to give a condensation covalent adduct, thereby preventing the formation of cross - linkages in the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> elastin <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and causing degradation of the elastic fibers in aortas in vivo."}, {"PMID": 12652111, "id": 9, "text": "PDE4 activity in failing human heart was lower than in rabbit heart and there was no significant difference in the inhibition of human cytosolic cAMP-PDE by cilostazol and milrinone.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [145, 149], "name": "cAMP", "tok_span": [25, 26], "new_tok_span": [25, 26]}, {"ent_type": "CHEMICAL", "char_span": [157, 167], "name": "cilostazol", "tok_span": [29, 33], "new_tok_span": [29, 33]}, {"ent_type": "CHEMICAL", "char_span": [172, 181], "name": "milrinone", "tok_span": [34, 37], "new_tok_span": [34, 37]}, {"ent_type": "GENE", "char_span": [0, 4], "name": "PDE4", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [129, 153], "name": "human cytosolic cAMP-PDE", "tok_span": [23, 28], "new_tok_span": [23, 28]}], "relation_list": [{"subject": "cilostazol", "sbj_char_span": [157, 167], "object": "human cytosolic cAMP-PDE", "obj_char_span": [129, 153], "rel_type": "inhibitor", "sbj_tok_span": [29, 33], "obj_tok_span": [23, 28], "new_sbj_tok_span": [29, 33], "new_obj_tok_span": [23, 28]}, {"subject": "milrinone", "sbj_char_span": [172, 181], "object": "human cytosolic cAMP-PDE", "obj_char_span": [129, 153], "rel_type": "inhibitor", "sbj_tok_span": [34, 37], "obj_tok_span": [23, 28], "new_sbj_tok_span": [34, 37], "new_obj_tok_span": [23, 28]}], "umls_entity_list": [], "new_text": "PDE4 activity in failing human heart was lower than in rabbit heart and there was no significant difference in the inhibition of human cytosolic cAMP - PDE by cilostazol and milrinone."}, {"PMID": 23022398, "id": 6, "text": "When applied after LFS600, PILO does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that NMDA receptor pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO. In addition, AP7 effectively blocked the long-lasting LTD induced by LFS900.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [27, 31], "name": "PILO", "tok_span": [7, 9], "new_tok_span": [7, 9]}, {"ent_type": "CHEMICAL", "char_span": [125, 129], "name": "NMDA", "tok_span": [28, 29], "new_tok_span": [30, 31]}, {"ent_type": "CHEMICAL", "char_span": [232, 235], "name": "AP7", "tok_span": [48, 50], "new_tok_span": [54, 56]}, {"ent_type": "CHEMICAL", "char_span": [346, 350], "name": "PILO", "tok_span": [70, 72], "new_tok_span": [76, 78]}, {"ent_type": "CHEMICAL", "char_span": [365, 368], "name": "AP7", "tok_span": [76, 78], "new_tok_span": [82, 84]}, {"ent_type": "GENE", "char_span": [125, 138], "name": "NMDA receptor", "tok_span": [28, 30], "new_tok_span": [30, 32]}], "relation_list": [{"subject": "AP7", "sbj_char_span": [232, 235], "object": "NMDA receptor", "obj_char_span": [125, 138], "rel_type": "inhibitor", "sbj_tok_span": [48, 50], "obj_tok_span": [28, 30], "new_sbj_tok_span": [54, 56], "new_obj_tok_span": [30, 32]}], "umls_entity_list": [{"mention": "NMDA receptor", "char_span": [125, 138], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 30], "new_tok_span": [30, 32]}, {"mention": "NMDA", "char_span": [125, 129], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 29], "new_tok_span": [30, 31]}, {"mention": "muscarinic", "char_span": [174, 184], "sem_type": "Pharmacologic Substance", "tok_span": [37, 40], "new_tok_span": [42, 45]}], "new_text": "When applied after LFS600, PILO does not change either mPFC basal neurotransmission or late LTD. Our data also indicate that <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> NMDA <END=Amino Acid, Peptide, or Protein> receptor <END=Amino Acid, Peptide, or Protein> pre - activation is essential to the <START=Pharmacologic Substance> muscarinic <END=Pharmacologic Substance> enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long - lasting LTD produced by PILO. In addition, AP7 effectively blocked the long - lasting LTD induced by LFS900."}, {"PMID": 17259377, "id": 5, "text": "Oral aspirin (as a representative of the salicylate family) inhibited diabetes-induced increase in NF-kappaB DNA-binding affinity in electrophoretic mobility shift assay and transcription factor array in nuclear extract isolated from whole retina.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [5, 12], "name": "aspirin", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"ent_type": "CHEMICAL", "char_span": [41, 51], "name": "salicylate", "tok_span": [8, 11], "new_tok_span": [10, 13]}, {"ent_type": "GENE", "char_span": [99, 108], "name": "NF-kappaB", "tok_span": [19, 23], "new_tok_span": [21, 25]}], "relation_list": [{"subject": "aspirin", "sbj_char_span": [5, 12], "object": "NF-kappaB", "obj_char_span": [99, 108], "rel_type": "inhibitor", "sbj_tok_span": [1, 2], "obj_tok_span": [19, 23], "new_sbj_tok_span": [2, 3], "new_obj_tok_span": [21, 25]}, {"subject": "salicylate", "sbj_char_span": [41, 51], "object": "NF-kappaB", "obj_char_span": [99, 108], "rel_type": "inhibitor", "sbj_tok_span": [8, 11], "obj_tok_span": [19, 23], "new_sbj_tok_span": [10, 13], "new_obj_tok_span": [21, 25]}], "umls_entity_list": [{"mention": "aspirin", "char_span": [5, 12], "sem_type": "Pharmacologic Substance", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"mention": "transcription", "char_span": [174, 187], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 35], "new_tok_span": [37, 38]}], "new_text": "Oral <START=Pharmacologic Substance> aspirin <END=Pharmacologic Substance> ( as a representative of the salicylate family ) inhibited diabetes - induced increase in NF - kappaB DNA - binding affinity in electrophoretic mobility shift assay and <START=Amino Acid, Peptide, or Protein> transcription <END=Amino Acid, Peptide, or Protein> factor array in nuclear extract isolated from whole retina."}, {"PMID": 23466229, "id": 0, "text": "PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "PF-04859989", "tok_span": [0, 6], "new_tok_span": [1, 7]}, {"ent_type": "CHEMICAL", "char_span": [81, 89], "name": "pyrazole", "tok_span": [19, 21], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [113, 119], "name": "KAT II", "tok_span": [24, 27], "new_tok_span": [29, 32]}], "relation_list": [{"subject": "pyrazole", "sbj_char_span": [81, 89], "object": "KAT II", "obj_char_span": [113, 119], "rel_type": "inhibitor", "sbj_tok_span": [19, 21], "obj_tok_span": [24, 27], "new_sbj_tok_span": [22, 24], "new_obj_tok_span": [29, 32]}, {"subject": "PF-04859989", "sbj_char_span": [0, 11], "object": "KAT II", "obj_char_span": [113, 119], "rel_type": "inhibitor", "sbj_tok_span": [0, 6], "obj_tok_span": [24, 27], "new_sbj_tok_span": [1, 7], "new_obj_tok_span": [29, 32]}], "umls_entity_list": [{"mention": "PF-04859989", "char_span": [0, 11], "sem_type": "Pharmacologic Substance", "tok_span": [0, 6], "new_tok_span": [1, 7]}, {"mention": "pyrazole", "char_span": [81, 89], "sem_type": "Organic Chemical", "tok_span": [19, 21], "new_tok_span": [22, 24]}, {"mention": "KAT", "char_span": [113, 116], "sem_type": "Gene or Genome", "tok_span": [24, 26], "new_tok_span": [29, 31]}], "new_text": "<START=Pharmacologic Substance> PF - 04859989 <END=Pharmacologic Substance> as a template for structure - based drug design : identification of new <START=Organic Chemical> pyrazole <END=Organic Chemical> series of irreversible <START=Gene or Genome> KAT <END=Gene or Genome> II inhibitors with improved lipophilic efficiency."}, {"PMID": 23453071, "id": 4, "text": "Furthermore, BRN-250 inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [13, 20], "name": "BRN-250", "tok_span": [2, 6], "new_tok_span": [2, 6]}, {"ent_type": "CHEMICAL", "char_span": [82, 90], "name": "tyrosine", "tok_span": [14, 15], "new_tok_span": [14, 15]}, {"ent_type": "GENE", "char_span": [35, 39], "name": "VEGF", "tok_span": [8, 9], "new_tok_span": [8, 9]}, {"ent_type": "GENE", "char_span": [82, 97], "name": "tyrosine kinase", "tok_span": [14, 16], "new_tok_span": [14, 16]}, {"ent_type": "GENE", "char_span": [110, 125], "name": "VEGF receptor 2", "tok_span": [18, 21], "new_tok_span": [18, 21]}, {"ent_type": "GENE", "char_span": [127, 133], "name": "VEGFR2", "tok_span": [22, 25], "new_tok_span": [22, 25]}, {"ent_type": "GENE", "char_span": [172, 175], "name": "AKT", "tok_span": [32, 33], "new_tok_span": [32, 33]}], "relation_list": [{"subject": "BRN-250", "sbj_char_span": [13, 20], "object": "tyrosine kinase", "obj_char_span": [82, 97], "rel_type": "inhibitor", "sbj_tok_span": [2, 6], "obj_tok_span": [14, 16], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [14, 16]}, {"subject": "BRN-250", "sbj_char_span": [13, 20], "object": "VEGF receptor 2", "obj_char_span": [110, 125], "rel_type": "inhibitor", "sbj_tok_span": [2, 6], "obj_tok_span": [18, 21], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [18, 21]}, {"subject": "BRN-250", "sbj_char_span": [13, 20], "object": "VEGFR2", "obj_char_span": [127, 133], "rel_type": "inhibitor", "sbj_tok_span": [2, 6], "obj_tok_span": [22, 25], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [22, 25]}, {"subject": "BRN-250", "sbj_char_span": [13, 20], "object": "AKT", "obj_char_span": [172, 175], "rel_type": "inhibitor", "sbj_tok_span": [2, 6], "obj_tok_span": [32, 33], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [32, 33]}], "umls_entity_list": [], "new_text": "Furthermore, BRN - 250 inhibited the VEGF - induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 ( VEGFR2 ) and the activation of its downstream AKT pathway."}, {"PMID": 1407010, "id": 2, "text": "Radioligand binding studies were performed in membranes of rabbit whole brain and striatum using the novel iodinated radioligand for 5-hydroxytryptamine 5-HT1B and 5-HT1D sites, Serotonin-5-O-Carboxymethyl-Glycyl[125I]Tyrosinamide ([125I]GTI). [125I]GTI labelled a finite number of high affinity sites in rabbit brain membranes, Bmax = 191 +/- 47 fmol/mg protein, pKD (-log mol/l) = 8.50 +/- 0.13, n = 5.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [133, 152], "name": "5-hydroxytryptamine", "tok_span": [24, 30], "new_tok_span": [24, 30]}, {"ent_type": "CHEMICAL", "char_span": [178, 230], "name": "Serotonin-5-O-Carboxymethyl-Glycyl[125I]Tyrosinamide", "tok_span": [43, 65], "new_tok_span": [48, 70]}, {"ent_type": "CHEMICAL", "char_span": [232, 241], "name": "[125I]GTI", "tok_span": [66, 72], "new_tok_span": [74, 80]}, {"ent_type": "CHEMICAL", "char_span": [244, 253], "name": "[125I]GTI", "tok_span": [74, 80], "new_tok_span": [82, 88]}, {"ent_type": "GENE", "char_span": [133, 159], "name": "5-hydroxytryptamine 5-HT1B", "tok_span": [24, 35], "new_tok_span": [24, 35]}, {"ent_type": "GENE", "char_span": [164, 170], "name": "5-HT1D", "tok_span": [36, 41], "new_tok_span": [39, 44]}], "relation_list": [{"subject": "Serotonin-5-O-Carboxymethyl-Glycyl[125I]Tyrosinamide", "sbj_char_span": [178, 230], "object": "5-hydroxytryptamine 5-HT1B", "obj_char_span": [133, 159], "rel_type": "regulator", "sbj_tok_span": [43, 65], "obj_tok_span": [24, 35], "new_sbj_tok_span": [48, 70], "new_obj_tok_span": [24, 35]}, {"subject": "Serotonin-5-O-Carboxymethyl-Glycyl[125I]Tyrosinamide", "sbj_char_span": [178, 230], "object": "5-HT1D", "obj_char_span": [164, 170], "rel_type": "regulator", "sbj_tok_span": [43, 65], "obj_tok_span": [36, 41], "new_sbj_tok_span": [48, 70], "new_obj_tok_span": [39, 44]}, {"subject": "[125I]GTI", "sbj_char_span": [232, 241], "object": "5-hydroxytryptamine 5-HT1B", "obj_char_span": [133, 159], "rel_type": "regulator", "sbj_tok_span": [66, 72], "obj_tok_span": [24, 35], "new_sbj_tok_span": [74, 80], "new_obj_tok_span": [24, 35]}, {"subject": "[125I]GTI", "sbj_char_span": [232, 241], "object": "5-HT1D", "obj_char_span": [164, 170], "rel_type": "regulator", "sbj_tok_span": [66, 72], "obj_tok_span": [36, 41], "new_sbj_tok_span": [74, 80], "new_obj_tok_span": [39, 44]}], "umls_entity_list": [{"mention": "hydroxytryptamine", "char_span": [135, 152], "sem_type": "Organic Chemical", "tok_span": [26, 30], "new_tok_span": [27, 31]}, {"mention": "5-HT1D", "char_span": [164, 170], "sem_type": "Gene or Genome", "tok_span": [36, 41], "new_tok_span": [39, 44]}, {"mention": "Serotonin", "char_span": [178, 187], "sem_type": "Organic Chemical", "tok_span": [43, 46], "new_tok_span": [48, 51]}, {"mention": "Tyrosinamide", "char_span": [218, 230], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [62, 65], "new_tok_span": [69, 72]}, {"mention": "mg", "char_span": [352, 354], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [104, 105], "new_tok_span": [113, 114]}, {"mention": "pKD", "char_span": [364, 367], "sem_type": "Gene or Genome", "tok_span": [107, 109], "new_tok_span": [118, 120]}], "new_text": "Radioligand binding studies were performed in membranes of rabbit whole brain and striatum using the novel iodinated radioligand for 5 - <START=Organic Chemical> hydroxytryptamine <END=Organic Chemical> 5 - HT1B and <START=Gene or Genome> 5 - HT1D <END=Gene or Genome> sites, <START=Organic Chemical> Serotonin <END=Organic Chemical> - 5 - O - Carboxymethyl - Glycyl [ 125I ] <START=Amino Acid, Peptide, or Protein> Tyrosinamide <END=Amino Acid, Peptide, or Protein> ( [ 125I ] GTI ). [ 125I ] GTI labelled a finite number of high affinity sites in rabbit brain membranes, Bmax = 191 + / - 47 fmol / <START=Amino Acid, Peptide, or Protein> mg <END=Amino Acid, Peptide, or Protein> protein, <START=Gene or Genome> pKD <END=Gene or Genome> ( - log mol / l ) = 8. 50 + / - 0. 13, n = 5."}, {"PMID": 16803890, "id": 18, "text": "In addition, the results of this study warrant careful reconsideration of desipramine as a specific inhibitor for ASMase.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [74, 85], "name": "desipramine", "tok_span": [14, 18], "new_tok_span": [14, 18]}, {"ent_type": "GENE", "char_span": [114, 120], "name": "ASMase", "tok_span": [23, 26], "new_tok_span": [23, 26]}], "relation_list": [{"subject": "desipramine", "sbj_char_span": [74, 85], "object": "ASMase", "obj_char_span": [114, 120], "rel_type": "inhibitor", "sbj_tok_span": [14, 18], "obj_tok_span": [23, 26], "new_sbj_tok_span": [14, 18], "new_obj_tok_span": [23, 26]}], "umls_entity_list": [], "new_text": "In addition, the results of this study warrant careful reconsideration of desipramine as a specific inhibitor for ASMase."}, {"PMID": 15650315, "id": 1, "text": "BACKGROUND: Pranlukast, a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [12, 22], "name": "Pranlukast", "tok_span": [2, 7], "new_tok_span": [2, 7]}, {"ent_type": "CHEMICAL", "char_span": [26, 47], "name": "cysteinyl leukotriene", "tok_span": [9, 16], "new_tok_span": [10, 17]}, {"ent_type": "GENE", "char_span": [26, 58], "name": "cysteinyl leukotriene receptor 1", "tok_span": [9, 18], "new_tok_span": [10, 19]}, {"ent_type": "GENE", "char_span": [60, 67], "name": "CysLTR1", "tok_span": [19, 23], "new_tok_span": [21, 25]}], "relation_list": [{"subject": "Pranlukast", "sbj_char_span": [12, 22], "object": "cysteinyl leukotriene receptor 1", "obj_char_span": [26, 58], "rel_type": "agonist or antagonist", "sbj_tok_span": [2, 7], "obj_tok_span": [9, 18], "new_sbj_tok_span": [2, 7], "new_obj_tok_span": [10, 19]}, {"subject": "Pranlukast", "sbj_char_span": [12, 22], "object": "CysLTR1", "obj_char_span": [60, 67], "rel_type": "agonist or antagonist", "sbj_tok_span": [2, 7], "obj_tok_span": [19, 23], "new_sbj_tok_span": [2, 7], "new_obj_tok_span": [21, 25]}], "umls_entity_list": [{"mention": "cysteinyl leukotriene receptor 1", "char_span": [26, 58], "sem_type": "Gene or Genome", "tok_span": [9, 18], "new_tok_span": [10, 19]}], "new_text": "BACKGROUND : Pranlukast, a <START=Gene or Genome> cysteinyl leukotriene receptor 1 <END=Gene or Genome> ( CysLTR1 ) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation."}, {"PMID": 1329582, "id": 3, "text": "We also examined the effects of WEB 2086, a platelet-activating factor (PAF) receptor antagonist, in parallel.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [32, 40], "name": "WEB 2086", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [44, 85], "name": "platelet-activating factor (PAF) receptor", "tok_span": [12, 21], "new_tok_span": [15, 24]}], "relation_list": [{"subject": "WEB 2086", "sbj_char_span": [32, 40], "object": "platelet-activating factor (PAF) receptor", "obj_char_span": [44, 85], "rel_type": "agonist or antagonist", "sbj_tok_span": [6, 10], "obj_tok_span": [12, 21], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [15, 24]}], "umls_entity_list": [{"mention": "WEB", "char_span": [32, 35], "sem_type": "Pharmacologic Substance", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"mention": "platelet", "char_span": [44, 52], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 13], "new_tok_span": [15, 16]}], "new_text": "We also examined the effects of <START=Pharmacologic Substance> WEB <END=Pharmacologic Substance> 2086, a <START=Amino Acid, Peptide, or Protein> platelet <END=Amino Acid, Peptide, or Protein> - activating factor ( PAF ) receptor antagonist, in parallel."}, {"PMID": 23148920, "id": 0, "text": "Hydrogen sulfide increases nitric oxide production with calcium-dependent activation of endothelial nitric oxide synthase in endothelial cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 16], "name": "Hydrogen sulfide", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [100, 112], "name": "nitric oxide", "tok_span": [14, 16], "new_tok_span": [19, 21]}, {"ent_type": "CHEMICAL", "char_span": [27, 39], "name": "nitric oxide", "tok_span": [4, 6], "new_tok_span": [4, 6]}, {"ent_type": "CHEMICAL", "char_span": [56, 63], "name": "calcium", "tok_span": [8, 9], "new_tok_span": [10, 11]}, {"ent_type": "GENE", "char_span": [88, 121], "name": "endothelial nitric oxide synthase", "tok_span": [13, 17], "new_tok_span": [18, 22]}], "relation_list": [{"subject": "Hydrogen sulfide", "sbj_char_span": [0, 16], "object": "endothelial nitric oxide synthase", "obj_char_span": [88, 121], "rel_type": "activator", "sbj_tok_span": [0, 3], "obj_tok_span": [13, 17], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [18, 22]}, {"subject": "nitric oxide", "sbj_char_span": [27, 39], "object": "endothelial nitric oxide synthase", "obj_char_span": [88, 121], "rel_type": "product or substrate", "sbj_tok_span": [4, 6], "obj_tok_span": [13, 17], "new_sbj_tok_span": [4, 6], "new_obj_tok_span": [18, 22]}], "umls_entity_list": [{"mention": "calcium", "char_span": [56, 63], "sem_type": "Pharmacologic Substance", "tok_span": [8, 9], "new_tok_span": [10, 11]}, {"mention": "endothelial nitric oxide synthase", "char_span": [88, 121], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 17], "new_tok_span": [18, 22]}, {"mention": "calcium", "char_span": [56, 63], "sem_type": "Gene or Genome", "tok_span": [8, 9], "new_tok_span": [10, 11]}], "new_text": "Hydrogen sulfide increases nitric oxide production with <START=Pharmacologic Substance> <START=Gene or Genome> calcium <END=Pharmacologic Substance> <END=Gene or Genome> - dependent activation of <START=Amino Acid, Peptide, or Protein> endothelial nitric oxide synthase <END=Amino Acid, Peptide, or Protein> in endothelial cells."}, {"PMID": 11393267, "id": 5, "text": "Reactivation potentials of BuChE (the difference between oxime-reactivated and -unreactivated enzyme activity) declined significantly with time after organophosphate ingestion.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [57, 62], "name": "oxime", "tok_span": [11, 13], "new_tok_span": [11, 13]}, {"ent_type": "CHEMICAL", "char_span": [150, 165], "name": "organophosphate", "tok_span": [29, 31], "new_tok_span": [30, 32]}, {"ent_type": "GENE", "char_span": [27, 32], "name": "BuChE", "tok_span": [4, 7], "new_tok_span": [4, 7]}], "relation_list": [{"subject": "oxime", "sbj_char_span": [57, 62], "object": "BuChE", "obj_char_span": [27, 32], "rel_type": "activator", "sbj_tok_span": [11, 13], "obj_tok_span": [4, 7], "new_sbj_tok_span": [11, 13], "new_obj_tok_span": [4, 7]}], "umls_entity_list": [{"mention": "organophosphate", "char_span": [150, 165], "sem_type": "Organic Chemical", "tok_span": [29, 31], "new_tok_span": [30, 32]}], "new_text": "Reactivation potentials of BuChE ( the difference between oxime - reactivated and - unreactivated enzyme activity ) declined significantly with time after <START=Organic Chemical> organophosphate <END=Organic Chemical> ingestion."}, {"PMID": 11980628, "id": 14, "text": "It is important to note that the inhibitory effect of SOM230 was relatively selective for GH and IGF-I in that insulin and glucagon secretion was inhibited only at higher doses of SOM230.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [54, 60], "name": "SOM230", "tok_span": [10, 13], "new_tok_span": [11, 14]}, {"ent_type": "CHEMICAL", "char_span": [180, 186], "name": "SOM230", "tok_span": [35, 38], "new_tok_span": [50, 53]}, {"ent_type": "GENE", "char_span": [90, 92], "name": "GH", "tok_span": [17, 18], "new_tok_span": [21, 22]}, {"ent_type": "GENE", "char_span": [97, 102], "name": "IGF-I", "tok_span": [19, 22], "new_tok_span": [25, 28]}, {"ent_type": "GENE", "char_span": [111, 118], "name": "insulin", "tok_span": [24, 25], "new_tok_span": [32, 33]}, {"ent_type": "GENE", "char_span": [123, 131], "name": "glucagon", "tok_span": [26, 27], "new_tok_span": [36, 37]}], "relation_list": [{"subject": "SOM230", "sbj_char_span": [54, 60], "object": "GH", "obj_char_span": [90, 92], "rel_type": "inhibitor", "sbj_tok_span": [10, 13], "obj_tok_span": [17, 18], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [21, 22]}, {"subject": "SOM230", "sbj_char_span": [54, 60], "object": "IGF-I", "obj_char_span": [97, 102], "rel_type": "inhibitor", "sbj_tok_span": [10, 13], "obj_tok_span": [19, 22], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [25, 28]}, {"subject": "SOM230", "sbj_char_span": [180, 186], "object": "insulin", "obj_char_span": [111, 118], "rel_type": "regulator", "sbj_tok_span": [35, 38], "obj_tok_span": [24, 25], "new_sbj_tok_span": [50, 53], "new_obj_tok_span": [32, 33]}, {"subject": "SOM230", "sbj_char_span": [180, 186], "object": "glucagon", "obj_char_span": [123, 131], "rel_type": "regulator", "sbj_tok_span": [35, 38], "obj_tok_span": [26, 27], "new_sbj_tok_span": [50, 53], "new_obj_tok_span": [36, 37]}], "umls_entity_list": [{"mention": "SOM230", "char_span": [54, 60], "sem_type": "Organic Chemical", "tok_span": [10, 13], "new_tok_span": [11, 14]}, {"mention": "SOM230", "char_span": [180, 186], "sem_type": "Organic Chemical", "tok_span": [35, 38], "new_tok_span": [50, 53]}, {"mention": "GH", "char_span": [90, 92], "sem_type": "Gene or Genome", "tok_span": [17, 18], "new_tok_span": [21, 22]}, {"mention": "gh", "char_span": [166, 168], "sem_type": "Gene or Genome", "tok_span": [32, 33], "new_tok_span": [44, 45]}, {"mention": "GH", "char_span": [90, 92], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 18], "new_tok_span": [21, 22]}, {"mention": "gh", "char_span": [166, 168], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 33], "new_tok_span": [44, 45]}, {"mention": "insulin", "char_span": [111, 118], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 25], "new_tok_span": [32, 33]}, {"mention": "insulin", "char_span": [111, 118], "sem_type": "Pharmacologic Substance", "tok_span": [24, 25], "new_tok_span": [32, 33]}], "new_text": "It is important to note that the inhibitory effect of <START=Organic Chemical> SOM230 <END=Organic Chemical> was relatively selective for <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> GH <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and IGF - I in that <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> insulin <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> and glucagon secretion was inhibited only at <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> higher <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> doses of <START=Organic Chemical> SOM230 <END=Organic Chemical>."}, {"PMID": 9808077, "id": 8, "text": "Furthermore, the inhibition of nitric oxide synthetase by paroxetine, and possibly other SSRIs, may have significant pharmacodynamic effects.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [31, 43], "name": "nitric oxide", "tok_span": [5, 7], "new_tok_span": [5, 7]}, {"ent_type": "CHEMICAL", "char_span": [58, 68], "name": "paroxetine", "tok_span": [10, 13], "new_tok_span": [10, 13]}, {"ent_type": "GENE", "char_span": [31, 54], "name": "nitric oxide synthetase", "tok_span": [5, 9], "new_tok_span": [5, 9]}], "relation_list": [{"subject": "paroxetine", "sbj_char_span": [58, 68], "object": "nitric oxide synthetase", "obj_char_span": [31, 54], "rel_type": "inhibitor", "sbj_tok_span": [10, 13], "obj_tok_span": [5, 9], "new_sbj_tok_span": [10, 13], "new_obj_tok_span": [5, 9]}], "umls_entity_list": [{"mention": "SSRIs", "char_span": [89, 94], "sem_type": "Pharmacologic Substance", "tok_span": [17, 20], "new_tok_span": [18, 21]}], "new_text": "Furthermore, the inhibition of nitric oxide synthetase by paroxetine, and possibly other <START=Pharmacologic Substance> SSRIs <END=Pharmacologic Substance>, may have significant pharmacodynamic effects."}, {"PMID": 12358053, "id": 2, "text": "In addition, we have previously shown an important role for COX-produced prostanoids in recovery of ischaemic-injured equine jejunum.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [73, 84], "name": "prostanoids", "tok_span": [14, 17], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [60, 63], "name": "COX", "tok_span": [11, 12], "new_tok_span": [11, 12]}], "relation_list": [{"subject": "prostanoids", "sbj_char_span": [73, 84], "object": "COX", "obj_char_span": [60, 63], "rel_type": "product or substrate", "sbj_tok_span": [14, 17], "obj_tok_span": [11, 12], "new_sbj_tok_span": [14, 17], "new_obj_tok_span": [11, 12]}], "umls_entity_list": [], "new_text": "In addition, we have previously shown an important role for COX - produced prostanoids in recovery of ischaemic - injured equine jejunum."}, {"PMID": 2833901, "id": 11, "text": "Finally, the effects of felodipine and the three analogues on two processes which are dependent on myosin phosphorylation were examined, namely the actin-activated Mg2+-ATPase activity of myosin and the assembly of myosin filaments.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [24, 34], "name": "felodipine", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"ent_type": "CHEMICAL", "char_span": [164, 168], "name": "Mg2+", "tok_span": [30, 33], "new_tok_span": [38, 41]}, {"ent_type": "GENE", "char_span": [99, 105], "name": "myosin", "tok_span": [20, 21], "new_tok_span": [23, 24]}, {"ent_type": "GENE", "char_span": [148, 153], "name": "actin", "tok_span": [27, 28], "new_tok_span": [32, 33]}, {"ent_type": "GENE", "char_span": [164, 175], "name": "Mg2+-ATPase", "tok_span": [30, 35], "new_tok_span": [38, 43]}, {"ent_type": "GENE", "char_span": [188, 194], "name": "myosin", "tok_span": [37, 38], "new_tok_span": [48, 49]}, {"ent_type": "GENE", "char_span": [215, 221], "name": "myosin", "tok_span": [42, 43], "new_tok_span": [55, 56]}], "relation_list": [{"subject": "felodipine", "sbj_char_span": [24, 34], "object": "myosin", "obj_char_span": [99, 105], "rel_type": "regulator", "sbj_tok_span": [5, 9], "obj_tok_span": [20, 21], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [23, 24]}], "umls_entity_list": [{"mention": "felodipine", "char_span": [24, 34], "sem_type": "Pharmacologic Substance", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"mention": "myosin", "char_span": [99, 105], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 21], "new_tok_span": [23, 24]}, {"mention": "myosin", "char_span": [188, 194], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 38], "new_tok_span": [48, 49]}, {"mention": "myosin", "char_span": [215, 221], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 43], "new_tok_span": [55, 56]}, {"mention": "actin", "char_span": [148, 153], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [32, 33]}, {"mention": "Mg2", "char_span": [164, 167], "sem_type": "Gene or Genome", "tok_span": [30, 32], "new_tok_span": [38, 40]}, {"mention": "Mg2+", "char_span": [164, 168], "sem_type": "Pharmacologic Substance", "tok_span": [30, 33], "new_tok_span": [38, 41]}], "new_text": "Finally, the effects of <START=Pharmacologic Substance> felodipine <END=Pharmacologic Substance> and the three analogues on two processes which are dependent on <START=Amino Acid, Peptide, or Protein> myosin <END=Amino Acid, Peptide, or Protein> phosphorylation were examined, namely the <START=Amino Acid, Peptide, or Protein> actin <END=Amino Acid, Peptide, or Protein> - activated <START=Gene or Genome> <START=Pharmacologic Substance> Mg2 <END=Gene or Genome> + <END=Pharmacologic Substance> - ATPase activity of <START=Amino Acid, Peptide, or Protein> myosin <END=Amino Acid, Peptide, or Protein> and the assembly of <START=Amino Acid, Peptide, or Protein> myosin <END=Amino Acid, Peptide, or Protein> filaments."}, {"PMID": 2833901, "id": 1, "text": "We have examined the effects on the activities of three calmodulin-dependent enzymes (cAMP phosphodiesterase, caldesmon kinase and myosin light chain kinase) of the dihydropyridine Ca2+ channel blocker felodipine and three analogues (p-chloro, oxidized and t-butyl) exhibiting different pharmacological potencies.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [165, 180], "name": "dihydropyridine", "tok_span": [35, 39], "new_tok_span": [46, 50]}, {"ent_type": "CHEMICAL", "char_span": [181, 185], "name": "Ca2+", "tok_span": [39, 42], "new_tok_span": [51, 54]}, {"ent_type": "CHEMICAL", "char_span": [202, 212], "name": "felodipine", "tok_span": [44, 48], "new_tok_span": [59, 63]}, {"ent_type": "CHEMICAL", "char_span": [234, 242], "name": "p-chloro", "tok_span": [52, 56], "new_tok_span": [68, 72]}, {"ent_type": "CHEMICAL", "char_span": [257, 264], "name": "t-butyl", "tok_span": [59, 63], "new_tok_span": [75, 79]}, {"ent_type": "CHEMICAL", "char_span": [86, 90], "name": "cAMP", "tok_span": [17, 18], "new_tok_span": [19, 20]}, {"ent_type": "GENE", "char_span": [110, 126], "name": "caldesmon kinase", "tok_span": [23, 27], "new_tok_span": [26, 30]}, {"ent_type": "GENE", "char_span": [131, 156], "name": "myosin light chain kinase", "tok_span": [28, 32], "new_tok_span": [35, 39]}, {"ent_type": "GENE", "char_span": [181, 193], "name": "Ca2+ channel", "tok_span": [39, 43], "new_tok_span": [51, 55]}, {"ent_type": "GENE", "char_span": [56, 84], "name": "calmodulin-dependent enzymes", "tok_span": [10, 16], "new_tok_span": [11, 17]}, {"ent_type": "GENE", "char_span": [86, 108], "name": "cAMP phosphodiesterase", "tok_span": [17, 22], "new_tok_span": [19, 24]}], "relation_list": [{"subject": "felodipine", "sbj_char_span": [202, 212], "object": "Ca2+ channel", "obj_char_span": [181, 193], "rel_type": "inhibitor", "sbj_tok_span": [44, 48], "obj_tok_span": [39, 43], "new_sbj_tok_span": [59, 63], "new_obj_tok_span": [51, 55]}], "umls_entity_list": [{"mention": "calmodulin", "char_span": [56, 66], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 13], "new_tok_span": [11, 14]}, {"mention": "caldesmon kinase", "char_span": [110, 126], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [23, 27], "new_tok_span": [26, 30]}, {"mention": "myosin", "char_span": [131, 137], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 29], "new_tok_span": [35, 36]}, {"mention": "myosin light chain kinase", "char_span": [131, 156], "sem_type": "Gene or Genome", "tok_span": [28, 32], "new_tok_span": [35, 39]}, {"mention": "myosin light chain kinase", "char_span": [131, 156], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 32], "new_tok_span": [35, 39]}, {"mention": "dihydropyridine", "char_span": [165, 180], "sem_type": "Pharmacologic Substance", "tok_span": [35, 39], "new_tok_span": [46, 50]}, {"mention": "channel blocker", "char_span": [186, 201], "sem_type": "Pharmacologic Substance", "tok_span": [42, 44], "new_tok_span": [55, 57]}, {"mention": "felodipine", "char_span": [202, 212], "sem_type": "Pharmacologic Substance", "tok_span": [44, 48], "new_tok_span": [59, 63]}], "new_text": "We have examined the effects on the activities of three <START=Amino Acid, Peptide, or Protein> calmodulin <END=Amino Acid, Peptide, or Protein> - dependent enzymes ( cAMP phosphodiesterase, <START=Amino Acid, Peptide, or Protein> caldesmon kinase <END=Amino Acid, Peptide, or Protein> and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> myosin <END=Amino Acid, Peptide, or Protein> light chain kinase <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ) of the <START=Pharmacologic Substance> dihydropyridine <END=Pharmacologic Substance> Ca2 + <START=Pharmacologic Substance> channel blocker <END=Pharmacologic Substance> <START=Pharmacologic Substance> felodipine <END=Pharmacologic Substance> and three analogues ( p - chloro, oxidized and t - butyl ) exhibiting different pharmacological potencies."}, {"PMID": 23416065, "id": 3, "text": "The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [44, 54], "name": "fatty acid", "tok_span": [9, 11], "new_tok_span": [10, 12]}, {"ent_type": "CHEMICAL", "char_span": [59, 75], "name": "acetyldiflunisal", "tok_span": [12, 17], "new_tok_span": [15, 20]}, {"ent_type": "CHEMICAL", "char_span": [90, 106], "name": "acetyldiflunisal", "tok_span": [19, 24], "new_tok_span": [24, 29]}, {"ent_type": "CHEMICAL", "char_span": [171, 177], "name": "lysine", "tok_span": [39, 40], "new_tok_span": [46, 47]}, {"ent_type": "GENE", "char_span": [25, 28], "name": "HSA", "tok_span": [4, 6], "new_tok_span": [4, 6]}, {"ent_type": "GENE", "char_span": [120, 133], "name": "IIA subdomain", "tok_span": [27, 31], "new_tok_span": [33, 37]}], "relation_list": [{"subject": "fatty acid", "sbj_char_span": [44, 54], "object": "HSA", "obj_char_span": [25, 28], "rel_type": "regulator", "sbj_tok_span": [9, 11], "obj_tok_span": [4, 6], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [4, 6]}, {"subject": "acetyldiflunisal", "sbj_char_span": [59, 75], "object": "HSA", "obj_char_span": [25, 28], "rel_type": "regulator", "sbj_tok_span": [12, 17], "obj_tok_span": [4, 6], "new_sbj_tok_span": [15, 20], "new_obj_tok_span": [4, 6]}, {"subject": "acetyldiflunisal", "sbj_char_span": [90, 106], "object": "IIA subdomain", "obj_char_span": [120, 133], "rel_type": "regulator", "sbj_tok_span": [19, 24], "obj_tok_span": [27, 31], "new_sbj_tok_span": [24, 29], "new_obj_tok_span": [33, 37]}, {"subject": "lysine", "sbj_char_span": [171, 177], "object": "IIA subdomain", "obj_char_span": [120, 133], "rel_type": "part of", "sbj_tok_span": [39, 40], "obj_tok_span": [27, 31], "new_sbj_tok_span": [46, 47], "new_obj_tok_span": [33, 37]}], "umls_entity_list": [{"mention": "fatty acid", "char_span": [44, 54], "sem_type": "Organic Chemical", "tok_span": [9, 11], "new_tok_span": [10, 12]}, {"mention": "acetyldiflunisal", "char_span": [59, 75], "sem_type": "Pharmacologic Substance", "tok_span": [12, 17], "new_tok_span": [15, 20]}, {"mention": "acetyldiflunisal", "char_span": [90, 106], "sem_type": "Pharmacologic Substance", "tok_span": [19, 24], "new_tok_span": [24, 29]}, {"mention": "lysine", "char_span": [171, 177], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [39, 40], "new_tok_span": [46, 47]}], "new_text": "The crystal structure of HSA complexed with <START=Organic Chemical> fatty acid <END=Organic Chemical> and <START=Pharmacologic Substance> acetyldiflunisal <END=Pharmacologic Substance> revealed that <START=Pharmacologic Substance> acetyldiflunisal <END=Pharmacologic Substance> binds to the IIA subdomain and that upon binding, it acetylates <START=Amino Acid, Peptide, or Protein> lysine <END=Amino Acid, Peptide, or Protein> 199."}, {"PMID": 10353334, "id": 2, "text": "Arginine, the substrate of nitric oxide synthases, might be recycled from the citrulline produced with NO by argininosuccinate synthetase (AS) and argininosuccinate lyase (AL). The regulation of AS and AL genes during hyperammonemia is unknown in the brain.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [27, 39], "name": "nitric oxide", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"ent_type": "CHEMICAL", "char_span": [78, 88], "name": "citrulline", "tok_span": [18, 21], "new_tok_span": [20, 23]}, {"ent_type": "CHEMICAL", "char_span": [103, 105], "name": "NO", "tok_span": [23, 24], "new_tok_span": [25, 26]}, {"ent_type": "CHEMICAL", "char_span": [109, 126], "name": "argininosuccinate", "tok_span": [25, 31], "new_tok_span": [30, 36]}, {"ent_type": "CHEMICAL", "char_span": [147, 164], "name": "argininosuccinate", "tok_span": [37, 43], "new_tok_span": [47, 53]}, {"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "Arginine", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [27, 49], "name": "nitric oxide synthases", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [109, 137], "name": "argininosuccinate synthetase", "tok_span": [25, 33], "new_tok_span": [30, 38]}, {"ent_type": "GENE", "char_span": [139, 141], "name": "AS", "tok_span": [34, 35], "new_tok_span": [42, 43]}, {"ent_type": "GENE", "char_span": [147, 170], "name": "argininosuccinate lyase", "tok_span": [37, 45], "new_tok_span": [47, 55]}, {"ent_type": "GENE", "char_span": [172, 174], "name": "AL", "tok_span": [46, 47], "new_tok_span": [58, 59]}, {"ent_type": "GENE", "char_span": [195, 197], "name": "AS", "tok_span": [52, 53], "new_tok_span": [64, 65]}, {"ent_type": "GENE", "char_span": [202, 204], "name": "AL", "tok_span": [54, 55], "new_tok_span": [66, 67]}], "relation_list": [{"subject": "Arginine", "sbj_char_span": [0, 8], "object": "nitric oxide synthases", "obj_char_span": [27, 49], "rel_type": "product or substrate", "sbj_tok_span": [0, 2], "obj_tok_span": [6, 10], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [7, 11]}, {"subject": "citrulline", "sbj_char_span": [78, 88], "object": "argininosuccinate synthetase", "obj_char_span": [109, 137], "rel_type": "product or substrate", "sbj_tok_span": [18, 21], "obj_tok_span": [25, 33], "new_sbj_tok_span": [20, 23], "new_obj_tok_span": [30, 38]}, {"subject": "citrulline", "sbj_char_span": [78, 88], "object": "AS", "obj_char_span": [139, 141], "rel_type": "product or substrate", "sbj_tok_span": [18, 21], "obj_tok_span": [34, 35], "new_sbj_tok_span": [20, 23], "new_obj_tok_span": [42, 43]}, {"subject": "citrulline", "sbj_char_span": [78, 88], "object": "argininosuccinate lyase", "obj_char_span": [147, 170], "rel_type": "product or substrate", "sbj_tok_span": [18, 21], "obj_tok_span": [37, 45], "new_sbj_tok_span": [20, 23], "new_obj_tok_span": [47, 55]}, {"subject": "citrulline", "sbj_char_span": [78, 88], "object": "AL", "obj_char_span": [172, 174], "rel_type": "product or substrate", "sbj_tok_span": [18, 21], "obj_tok_span": [46, 47], "new_sbj_tok_span": [20, 23], "new_obj_tok_span": [58, 59]}, {"subject": "NO", "sbj_char_span": [103, 105], "object": "argininosuccinate synthetase", "obj_char_span": [109, 137], "rel_type": "product or substrate", "sbj_tok_span": [23, 24], "obj_tok_span": [25, 33], "new_sbj_tok_span": [25, 26], "new_obj_tok_span": [30, 38]}, {"subject": "NO", "sbj_char_span": [103, 105], "object": "AS", "obj_char_span": [139, 141], "rel_type": "product or substrate", "sbj_tok_span": [23, 24], "obj_tok_span": [34, 35], "new_sbj_tok_span": [25, 26], "new_obj_tok_span": [42, 43]}, {"subject": "NO", "sbj_char_span": [103, 105], "object": "argininosuccinate lyase", "obj_char_span": [147, 170], "rel_type": "product or substrate", "sbj_tok_span": [23, 24], "obj_tok_span": [37, 45], "new_sbj_tok_span": [25, 26], "new_obj_tok_span": [47, 55]}, {"subject": "NO", "sbj_char_span": [103, 105], "object": "AL", "obj_char_span": [172, 174], "rel_type": "product or substrate", "sbj_tok_span": [23, 24], "obj_tok_span": [46, 47], "new_sbj_tok_span": [25, 26], "new_obj_tok_span": [58, 59]}], "umls_entity_list": [{"mention": "nitric oxide synthases", "char_span": [27, 49], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"mention": "argininosuccinate", "char_span": [109, 126], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 31], "new_tok_span": [30, 36]}, {"mention": "argininosuccinate", "char_span": [147, 164], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 43], "new_tok_span": [47, 53]}, {"mention": "argininosuccinate lyase", "char_span": [147, 170], "sem_type": "Gene or Genome", "tok_span": [37, 45], "new_tok_span": [47, 55]}, {"mention": "argininosuccinate synthetase", "char_span": [109, 137], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 33], "new_tok_span": [30, 38]}, {"mention": "argininosuccinate synthetase", "char_span": [109, 137], "sem_type": "Gene or Genome", "tok_span": [25, 33], "new_tok_span": [30, 38]}, {"mention": "unknown", "char_span": [236, 243], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [62, 63], "new_tok_span": [75, 76]}], "new_text": "Arginine, the substrate of <START=Amino Acid, Peptide, or Protein> nitric oxide synthases <END=Amino Acid, Peptide, or Protein>, might be recycled from the citrulline produced with NO by <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> argininosuccinate <END=Amino Acid, Peptide, or Protein> synthetase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> ( AS ) and <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> argininosuccinate <END=Amino Acid, Peptide, or Protein> lyase <END=Gene or Genome> ( AL ). The regulation of AS and AL genes during hyperammonemia is <START=Amino Acid, Peptide, or Protein> unknown <END=Amino Acid, Peptide, or Protein> in the brain."}, {"PMID": 9760035, "id": 2, "text": "Apart from the parent compound two metabolites were identified namely desGlyNH2-carbetocin (carbetocin metabolite I) and desLeuGlyNH2-carbetocin (carbetocin metabolite II). Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as oxytocin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [70, 79], "name": "desGlyNH2", "tok_span": [10, 14], "new_tok_span": [10, 14]}, {"ent_type": "CHEMICAL", "char_span": [80, 90], "name": "carbetocin", "tok_span": [15, 18], "new_tok_span": [16, 19]}, {"ent_type": "CHEMICAL", "char_span": [92, 102], "name": "carbetocin", "tok_span": [19, 22], "new_tok_span": [22, 25]}, {"ent_type": "CHEMICAL", "char_span": [121, 133], "name": "desLeuGlyNH2", "tok_span": [26, 32], "new_tok_span": [30, 36]}, {"ent_type": "CHEMICAL", "char_span": [134, 144], "name": "carbetocin", "tok_span": [33, 36], "new_tok_span": [38, 41]}, {"ent_type": "CHEMICAL", "char_span": [146, 156], "name": "carbetocin", "tok_span": [37, 40], "new_tok_span": [44, 47]}, {"ent_type": "CHEMICAL", "char_span": [178, 188], "name": "carbetocin", "tok_span": [45, 48], "new_tok_span": [54, 57]}, {"ent_type": "CHEMICAL", "char_span": [190, 200], "name": "carbetocin", "tok_span": [49, 52], "new_tok_span": [60, 63]}, {"ent_type": "CHEMICAL", "char_span": [218, 228], "name": "carbetocin", "tok_span": [55, 58], "new_tok_span": [68, 71]}, {"ent_type": "CHEMICAL", "char_span": [290, 298], "name": "oxytocin", "tok_span": [68, 71], "new_tok_span": [83, 86]}, {"ent_type": "CHEMICAL", "char_span": [334, 342], "name": "oxytocin", "tok_span": [77, 80], "new_tok_span": [94, 97]}, {"ent_type": "GENE", "char_span": [290, 307], "name": "oxytocin receptor", "tok_span": [68, 72], "new_tok_span": [83, 87]}, {"ent_type": "GENE", "char_span": [334, 342], "name": "oxytocin", "tok_span": [77, 80], "new_tok_span": [94, 97]}], "relation_list": [{"subject": "carbetocin", "sbj_char_span": [178, 188], "object": "oxytocin receptor", "obj_char_span": [290, 307], "rel_type": "regulator", "sbj_tok_span": [45, 48], "obj_tok_span": [68, 72], "new_sbj_tok_span": [54, 57], "new_obj_tok_span": [83, 87]}, {"subject": "carbetocin", "sbj_char_span": [190, 200], "object": "oxytocin receptor", "obj_char_span": [290, 307], "rel_type": "regulator", "sbj_tok_span": [49, 52], "obj_tok_span": [68, 72], "new_sbj_tok_span": [60, 63], "new_obj_tok_span": [83, 87]}, {"subject": "carbetocin", "sbj_char_span": [218, 228], "object": "oxytocin receptor", "obj_char_span": [290, 307], "rel_type": "regulator", "sbj_tok_span": [55, 58], "obj_tok_span": [68, 72], "new_sbj_tok_span": [68, 71], "new_obj_tok_span": [83, 87]}], "umls_entity_list": [{"mention": "carbetocin", "char_span": [80, 90], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 18], "new_tok_span": [16, 19]}, {"mention": "carbetocin", "char_span": [92, 102], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 22], "new_tok_span": [22, 25]}, {"mention": "carbetocin", "char_span": [134, 144], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 36], "new_tok_span": [38, 41]}, {"mention": "carbetocin", "char_span": [146, 156], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 40], "new_tok_span": [44, 47]}, {"mention": "carbetocin", "char_span": [178, 188], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [45, 48], "new_tok_span": [54, 57]}, {"mention": "carbetocin", "char_span": [190, 200], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [49, 52], "new_tok_span": [60, 63]}, {"mention": "carbetocin", "char_span": [218, 228], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [55, 58], "new_tok_span": [68, 71]}, {"mention": "oxytocin", "char_span": [290, 298], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [68, 71], "new_tok_span": [83, 86]}, {"mention": "oxytocin", "char_span": [334, 342], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [77, 80], "new_tok_span": [94, 97]}], "new_text": "Apart from the parent compound two metabolites were identified namely desGlyNH2 - <START=Amino Acid, Peptide, or Protein> carbetocin <END=Amino Acid, Peptide, or Protein> ( <START=Amino Acid, Peptide, or Protein> carbetocin <END=Amino Acid, Peptide, or Protein> metabolite I ) and desLeuGlyNH2 - <START=Amino Acid, Peptide, or Protein> carbetocin <END=Amino Acid, Peptide, or Protein> ( <START=Amino Acid, Peptide, or Protein> carbetocin <END=Amino Acid, Peptide, or Protein> metabolite II ). Both <START=Amino Acid, Peptide, or Protein> carbetocin <END=Amino Acid, Peptide, or Protein>, <START=Amino Acid, Peptide, or Protein> carbetocin <END=Amino Acid, Peptide, or Protein> metabolite I and <START=Amino Acid, Peptide, or Protein> carbetocin <END=Amino Acid, Peptide, or Protein> metabolite II displayed binding affinities to the myometrial <START=Amino Acid, Peptide, or Protein> oxytocin <END=Amino Acid, Peptide, or Protein> receptor of a similar magnitude as <START=Amino Acid, Peptide, or Protein> oxytocin <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 8589992, "id": 2, "text": "This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [48, 58], "name": "nucleotide", "tok_span": [14, 15], "new_tok_span": [16, 17]}, {"ent_type": "CHEMICAL", "char_span": [170, 175], "name": "amino", "tok_span": [42, 43], "new_tok_span": [50, 51]}, {"ent_type": "CHEMICAL", "char_span": [180, 187], "name": "carboxy", "tok_span": [44, 46], "new_tok_span": [53, 55]}, {"ent_type": "GENE", "char_span": [28, 33], "name": "EAA3a", "tok_span": [5, 9], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [97, 109], "name": "rat GluR5-2b", "tok_span": [20, 27], "new_tok_span": [22, 29]}, {"ent_type": "GENE", "char_span": [148, 162], "name": "human GluR5-1d", "tok_span": [33, 40], "new_tok_span": [37, 44]}], "relation_list": [{"subject": "nucleotide", "sbj_char_span": [48, 58], "object": "EAA3a", "obj_char_span": [28, 33], "rel_type": "part of", "sbj_tok_span": [14, 15], "obj_tok_span": [5, 9], "new_sbj_tok_span": [16, 17], "new_obj_tok_span": [7, 11]}, {"subject": "nucleotide", "sbj_char_span": [48, 58], "object": "rat GluR5-2b", "obj_char_span": [97, 109], "rel_type": "part of", "sbj_tok_span": [14, 15], "obj_tok_span": [20, 27], "new_sbj_tok_span": [16, 17], "new_obj_tok_span": [22, 29]}, {"subject": "amino", "sbj_char_span": [170, 175], "object": "human GluR5-1d", "obj_char_span": [148, 162], "rel_type": "part of", "sbj_tok_span": [42, 43], "obj_tok_span": [33, 40], "new_sbj_tok_span": [50, 51], "new_obj_tok_span": [37, 44]}, {"subject": "carboxy", "sbj_char_span": [180, 187], "object": "human GluR5-1d", "obj_char_span": [148, 162], "rel_type": "part of", "sbj_tok_span": [44, 46], "obj_tok_span": [33, 40], "new_sbj_tok_span": [53, 55], "new_obj_tok_span": [37, 44]}], "umls_entity_list": [{"mention": "designated", "char_span": [17, 27], "sem_type": "Pharmacologic Substance", "tok_span": [4, 5], "new_tok_span": [5, 6]}, {"mention": "GluR5", "char_span": [101, 106], "sem_type": "Gene or Genome", "tok_span": [21, 24], "new_tok_span": [24, 27]}, {"mention": "GluR5", "char_span": [154, 159], "sem_type": "Gene or Genome", "tok_span": [34, 37], "new_tok_span": [39, 42]}, {"mention": "1d", "char_span": [160, 162], "sem_type": "Gene or Genome", "tok_span": [38, 40], "new_tok_span": [45, 47]}, {"mention": "carboxy", "char_span": [180, 187], "sem_type": "Organic Chemical", "tok_span": [44, 46], "new_tok_span": [53, 55]}], "new_text": "This cDNA clone, <START=Pharmacologic Substance> designated <END=Pharmacologic Substance> EAA3a, shares a 90 % nucleotide identity with the previously reported rat <START=Gene or Genome> GluR5 <END=Gene or Genome> - 2b cDNA splice variant and differed from human <START=Gene or Genome> GluR5 <END=Gene or Genome> - <START=Gene or Genome> 1d <END=Gene or Genome> in the amino and <START=Organic Chemical> carboxy <END=Organic Chemical> terminal regions."}, {"PMID": 23517028, "id": 0, "text": "Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [94, 108], "name": "Arylpiperazine", "tok_span": [21, 26], "new_tok_span": [23, 28]}, {"ent_type": "GENE", "char_span": [38, 60], "name": "β1-Adrenergic Receptor", "tok_span": [7, 15], "new_tok_span": [7, 15]}], "relation_list": [{"subject": "Arylpiperazine", "sbj_char_span": [94, 108], "object": "β1-Adrenergic Receptor", "obj_char_span": [38, 60], "rel_type": "regulator", "sbj_tok_span": [21, 26], "obj_tok_span": [7, 15], "new_sbj_tok_span": [23, 28], "new_obj_tok_span": [7, 15]}], "umls_entity_list": [{"mention": "Adrenergic", "char_span": [41, 51], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 14], "new_tok_span": [11, 15]}], "new_text": "Biophysical Fragment Screening of the β1 - <START=Amino Acid, Peptide, or Protein> Adrenergic <END=Amino Acid, Peptide, or Protein> Receptor : Identification of High Affinity Arylpiperazine Leads Using Structure - Based Drug Design."}, {"PMID": 21084778, "id": 3, "text": "The most frequent DHPS mutations occur at nucleotide positions 165 and 171, which lead to an amino acid change at positions 55 and 57.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 52], "name": "nucleotide", "tok_span": [8, 9], "new_tok_span": [10, 11]}, {"ent_type": "CHEMICAL", "char_span": [93, 103], "name": "amino acid", "tok_span": [18, 20], "new_tok_span": [20, 22]}, {"ent_type": "GENE", "char_span": [18, 22], "name": "DHPS", "tok_span": [3, 5], "new_tok_span": [4, 6]}], "relation_list": [{"subject": "nucleotide", "sbj_char_span": [42, 52], "object": "DHPS", "obj_char_span": [18, 22], "rel_type": "part of", "sbj_tok_span": [8, 9], "obj_tok_span": [3, 5], "new_sbj_tok_span": [10, 11], "new_obj_tok_span": [4, 6]}, {"subject": "amino acid", "sbj_char_span": [93, 103], "object": "DHPS", "obj_char_span": [18, 22], "rel_type": "part of", "sbj_tok_span": [18, 20], "obj_tok_span": [3, 5], "new_sbj_tok_span": [20, 22], "new_obj_tok_span": [4, 6]}], "umls_entity_list": [{"mention": "DHPS", "char_span": [18, 22], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 5], "new_tok_span": [4, 6]}], "new_text": "The most frequent <START=Amino Acid, Peptide, or Protein> DHPS <END=Amino Acid, Peptide, or Protein> mutations occur at nucleotide positions 165 and 171, which lead to an amino acid change at positions 55 and 57."}, {"PMID": 23261715, "id": 3, "text": "In this study, we found that the reductase activity of AKR1B19 was activated to about 5-fold immediately after the addition of 10 μM SH-reagents (p-chloromercuriphenylsulfonic acid and p-chloromercuribenzoic acid) in the absence or presence of NADPH. In addition, a maximum of 3-fold activation of AKR1B19 was induced by incubation with glutathione disulfide (GSSG) for 1h.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [133, 135], "name": "SH", "tok_span": [31, 32], "new_tok_span": [32, 33]}, {"ent_type": "CHEMICAL", "char_span": [146, 180], "name": "p-chloromercuriphenylsulfonic acid", "tok_span": [35, 46], "new_tok_span": [37, 48]}, {"ent_type": "CHEMICAL", "char_span": [185, 212], "name": "p-chloromercuribenzoic acid", "tok_span": [47, 56], "new_tok_span": [50, 59]}, {"ent_type": "CHEMICAL", "char_span": [244, 249], "name": "NADPH", "tok_span": [63, 64], "new_tok_span": [67, 68]}, {"ent_type": "CHEMICAL", "char_span": [337, 358], "name": "glutathione disulfide", "tok_span": [86, 88], "new_tok_span": [91, 93]}, {"ent_type": "CHEMICAL", "char_span": [360, 364], "name": "GSSG", "tok_span": [89, 91], "new_tok_span": [96, 98]}, {"ent_type": "GENE", "char_span": [33, 42], "name": "reductase", "tok_span": [8, 9], "new_tok_span": [8, 9]}, {"ent_type": "GENE", "char_span": [55, 62], "name": "AKR1B19", "tok_span": [11, 16], "new_tok_span": [11, 16]}, {"ent_type": "GENE", "char_span": [298, 305], "name": "AKR1B19", "tok_span": [76, 81], "new_tok_span": [80, 85]}], "relation_list": [{"subject": "glutathione disulfide", "sbj_char_span": [337, 358], "object": "AKR1B19", "obj_char_span": [298, 305], "rel_type": "activator", "sbj_tok_span": [86, 88], "obj_tok_span": [76, 81], "new_sbj_tok_span": [91, 93], "new_obj_tok_span": [80, 85]}, {"subject": "GSSG", "sbj_char_span": [360, 364], "object": "AKR1B19", "obj_char_span": [298, 305], "rel_type": "activator", "sbj_tok_span": [89, 91], "obj_tok_span": [76, 81], "new_sbj_tok_span": [96, 98], "new_obj_tok_span": [80, 85]}, {"subject": "SH", "sbj_char_span": [133, 135], "object": "reductase", "obj_char_span": [33, 42], "rel_type": "activator", "sbj_tok_span": [31, 32], "obj_tok_span": [8, 9], "new_sbj_tok_span": [32, 33], "new_obj_tok_span": [8, 9]}, {"subject": "SH", "sbj_char_span": [133, 135], "object": "AKR1B19", "obj_char_span": [55, 62], "rel_type": "activator", "sbj_tok_span": [31, 32], "obj_tok_span": [11, 16], "new_sbj_tok_span": [32, 33], "new_obj_tok_span": [11, 16]}, {"subject": "p-chloromercuriphenylsulfonic acid", "sbj_char_span": [146, 180], "object": "reductase", "obj_char_span": [33, 42], "rel_type": "activator", "sbj_tok_span": [35, 46], "obj_tok_span": [8, 9], "new_sbj_tok_span": [37, 48], "new_obj_tok_span": [8, 9]}, {"subject": "p-chloromercuriphenylsulfonic acid", "sbj_char_span": [146, 180], "object": "AKR1B19", "obj_char_span": [55, 62], "rel_type": "activator", "sbj_tok_span": [35, 46], "obj_tok_span": [11, 16], "new_sbj_tok_span": [37, 48], "new_obj_tok_span": [11, 16]}, {"subject": "p-chloromercuribenzoic acid", "sbj_char_span": [185, 212], "object": "reductase", "obj_char_span": [33, 42], "rel_type": "activator", "sbj_tok_span": [47, 56], "obj_tok_span": [8, 9], "new_sbj_tok_span": [50, 59], "new_obj_tok_span": [8, 9]}, {"subject": "p-chloromercuribenzoic acid", "sbj_char_span": [185, 212], "object": "AKR1B19", "obj_char_span": [55, 62], "rel_type": "activator", "sbj_tok_span": [47, 56], "obj_tok_span": [11, 16], "new_sbj_tok_span": [50, 59], "new_obj_tok_span": [11, 16]}], "umls_entity_list": [{"mention": "SH-reagents", "char_span": [133, 144], "sem_type": "Pharmacologic Substance", "tok_span": [31, 34], "new_tok_span": [32, 35]}, {"mention": "p-chloromercuribenzoic", "char_span": [185, 207], "sem_type": "Organic Chemical", "tok_span": [47, 55], "new_tok_span": [50, 58]}, {"mention": "glutathione disulfide", "char_span": [337, 358], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [86, 88], "new_tok_span": [91, 93]}, {"mention": "GSSG", "char_span": [360, 364], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [89, 91], "new_tok_span": [96, 98]}], "new_text": "In this study, we found that the reductase activity of AKR1B19 was activated to about 5 - fold immediately after the addition of 10 μM <START=Pharmacologic Substance> SH - reagents <END=Pharmacologic Substance> ( p - chloromercuriphenylsulfonic acid and <START=Organic Chemical> p - chloromercuribenzoic <END=Organic Chemical> acid ) in the absence or presence of NADPH. In addition, a maximum of 3 - fold activation of AKR1B19 was induced by incubation with <START=Amino Acid, Peptide, or Protein> glutathione disulfide <END=Amino Acid, Peptide, or Protein> ( <START=Amino Acid, Peptide, or Protein> GSSG <END=Amino Acid, Peptide, or Protein> ) for 1h."}, {"PMID": 23633618, "id": 0, "text": "A Structural Snapshot of Cytochrome P450 2B4 in Complex with Paroxetine Provides Insights into Ligand Binding and Clusters of Conformational States.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [61, 71], "name": "Paroxetine", "tok_span": [16, 19], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [25, 44], "name": "Cytochrome P450 2B4", "tok_span": [6, 13], "new_tok_span": [7, 14]}], "relation_list": [{"subject": "Paroxetine", "sbj_char_span": [61, 71], "object": "Cytochrome P450 2B4", "obj_char_span": [25, 44], "rel_type": "regulator", "sbj_tok_span": [16, 19], "obj_tok_span": [6, 13], "new_sbj_tok_span": [19, 22], "new_obj_tok_span": [7, 14]}], "umls_entity_list": [{"mention": "Cytochrome P450 2B4", "char_span": [25, 44], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 13], "new_tok_span": [7, 14]}, {"mention": "Paroxetine", "char_span": [61, 71], "sem_type": "Pharmacologic Substance", "tok_span": [16, 19], "new_tok_span": [19, 22]}], "new_text": "A Structural Snapshot of <START=Amino Acid, Peptide, or Protein> Cytochrome P450 2B4 <END=Amino Acid, Peptide, or Protein> in Complex with <START=Pharmacologic Substance> Paroxetine <END=Pharmacologic Substance> Provides Insights into Ligand Binding and Clusters of Conformational States."}, {"PMID": 15936988, "id": 3, "text": "Moreover, simvastatin concentration-dependently inhibited the expression of ICAM-1 and induced the expression of CD40 on monocytes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [10, 21], "name": "simvastatin", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"ent_type": "GENE", "char_span": [76, 82], "name": "ICAM-1", "tok_span": [12, 15], "new_tok_span": [14, 17]}, {"ent_type": "GENE", "char_span": [113, 117], "name": "CD40", "tok_span": [20, 22], "new_tok_span": [22, 24]}], "relation_list": [{"subject": "simvastatin", "sbj_char_span": [10, 21], "object": "ICAM-1", "obj_char_span": [76, 82], "rel_type": "regulator", "sbj_tok_span": [2, 4], "obj_tok_span": [12, 15], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [14, 17]}, {"subject": "simvastatin", "sbj_char_span": [10, 21], "object": "CD40", "obj_char_span": [113, 117], "rel_type": "regulator", "sbj_tok_span": [2, 4], "obj_tok_span": [20, 22], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [22, 24]}], "umls_entity_list": [{"mention": "simvastatin", "char_span": [10, 21], "sem_type": "Pharmacologic Substance", "tok_span": [2, 4], "new_tok_span": [3, 5]}], "new_text": "Moreover, <START=Pharmacologic Substance> simvastatin <END=Pharmacologic Substance> concentration - dependently inhibited the expression of ICAM - 1 and induced the expression of CD40 on monocytes."}, {"PMID": 23583910, "id": 0, "text": "Aminopropylindenes derived from Grundmann's ketone as a novel chemotype of oxidosqualene cyclase inhibitors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 18], "name": "Aminopropylindenes", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [32, 50], "name": "Grundmann's ketone", "tok_span": [6, 12], "new_tok_span": [6, 12]}, {"ent_type": "GENE", "char_span": [75, 96], "name": "oxidosqualene cyclase", "tok_span": [18, 23], "new_tok_span": [21, 26]}], "relation_list": [{"subject": "Aminopropylindenes", "sbj_char_span": [0, 18], "object": "oxidosqualene cyclase", "obj_char_span": [75, 96], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [18, 23], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [21, 26]}, {"subject": "Grundmann's ketone", "sbj_char_span": [32, 50], "object": "oxidosqualene cyclase", "obj_char_span": [75, 96], "rel_type": "inhibitor", "sbj_tok_span": [6, 12], "obj_tok_span": [18, 23], "new_sbj_tok_span": [6, 12], "new_obj_tok_span": [21, 26]}], "umls_entity_list": [{"mention": "ketone", "char_span": [44, 50], "sem_type": "Organic Chemical", "tok_span": [10, 12], "new_tok_span": [11, 13]}, {"mention": "oxidosqualene cyclase", "char_span": [75, 96], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 23], "new_tok_span": [21, 26]}], "new_text": "Aminopropylindenes derived from Grundmann's <START=Organic Chemical> ketone <END=Organic Chemical> as a novel chemotype of <START=Amino Acid, Peptide, or Protein> oxidosqualene cyclase <END=Amino Acid, Peptide, or Protein> inhibitors."}, {"PMID": 22659408, "id": 6, "text": "NAAG can activate these presynaptic receptors with extremely high affinity and with characteristics compatible with the reported mGluR3 pharmacology.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 4], "name": "NAAG", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "GENE", "char_span": [129, 135], "name": "mGluR3", "tok_span": [18, 22], "new_tok_span": [22, 26]}], "relation_list": [{"subject": "NAAG", "sbj_char_span": [0, 4], "object": "mGluR3", "obj_char_span": [129, 135], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [18, 22], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [22, 26]}, {"subject": "NAAG", "sbj_char_span": [0, 4], "object": "mGluR3", "obj_char_span": [129, 135], "rel_type": "activator", "sbj_tok_span": [0, 2], "obj_tok_span": [18, 22], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [22, 26]}], "umls_entity_list": [{"mention": "presynaptic receptors", "char_span": [24, 45], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 7], "new_tok_span": [6, 8]}, {"mention": "mGluR3", "char_span": [129, 135], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 22], "new_tok_span": [22, 26]}, {"mention": "mGluR3", "char_span": [129, 135], "sem_type": "Gene or Genome", "tok_span": [18, 22], "new_tok_span": [22, 26]}], "new_text": "NAAG can activate these <START=Amino Acid, Peptide, or Protein> presynaptic receptors <END=Amino Acid, Peptide, or Protein> with extremely high affinity and with characteristics compatible with the reported <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> mGluR3 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> pharmacology."}, {"PMID": 6433001, "id": 10, "text": "However, calmodulin antagonists were found to inhibit [3H]nitrendipine binding with the order of potency: pimozide greater than less than calmidazolium (R 24571) greater than trifluoperazine greater than chlorpromazine greater than promethazine greater than chlorpromazine sulfoxide, that correlates quite well with the potency of these drugs as inhibitors of calmodulin-dependent processes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [54, 70], "name": "[3H]nitrendipine", "tok_span": [10, 17], "new_tok_span": [16, 23]}, {"ent_type": "CHEMICAL", "char_span": [106, 114], "name": "pimozide", "tok_span": [24, 28], "new_tok_span": [39, 43]}, {"ent_type": "CHEMICAL", "char_span": [138, 151], "name": "calmidazolium", "tok_span": [32, 36], "new_tok_span": [53, 57]}, {"ent_type": "CHEMICAL", "char_span": [153, 160], "name": "R 24571", "tok_span": [37, 40], "new_tok_span": [60, 63]}, {"ent_type": "CHEMICAL", "char_span": [175, 190], "name": "trifluoperazine", "tok_span": [43, 48], "new_tok_span": [73, 78]}, {"ent_type": "CHEMICAL", "char_span": [204, 218], "name": "chlorpromazine", "tok_span": [50, 53], "new_tok_span": [90, 93]}, {"ent_type": "CHEMICAL", "char_span": [232, 244], "name": "promethazine", "tok_span": [55, 58], "new_tok_span": [105, 108]}, {"ent_type": "CHEMICAL", "char_span": [258, 282], "name": "chlorpromazine sulfoxide", "tok_span": [60, 65], "new_tok_span": [119, 124]}, {"ent_type": "GENE", "char_span": [9, 19], "name": "calmodulin", "tok_span": [2, 5], "new_tok_span": [5, 8]}, {"ent_type": "GENE", "char_span": [360, 370], "name": "calmodulin", "tok_span": [79, 82], "new_tok_span": [152, 155]}], "relation_list": [{"subject": "[3H]nitrendipine", "sbj_char_span": [54, 70], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "regulator", "sbj_tok_span": [10, 17], "obj_tok_span": [2, 5], "new_sbj_tok_span": [16, 23], "new_obj_tok_span": [5, 8]}, {"subject": "pimozide", "sbj_char_span": [106, 114], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "regulator", "sbj_tok_span": [24, 28], "obj_tok_span": [2, 5], "new_sbj_tok_span": [39, 43], "new_obj_tok_span": [5, 8]}, {"subject": "calmidazolium", "sbj_char_span": [138, 151], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "regulator", "sbj_tok_span": [32, 36], "obj_tok_span": [2, 5], "new_sbj_tok_span": [53, 57], "new_obj_tok_span": [5, 8]}, {"subject": "R 24571", "sbj_char_span": [153, 160], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "regulator", "sbj_tok_span": [37, 40], "obj_tok_span": [2, 5], "new_sbj_tok_span": [60, 63], "new_obj_tok_span": [5, 8]}, {"subject": "trifluoperazine", "sbj_char_span": [175, 190], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "regulator", "sbj_tok_span": [43, 48], "obj_tok_span": [2, 5], "new_sbj_tok_span": [73, 78], "new_obj_tok_span": [5, 8]}, {"subject": "chlorpromazine", "sbj_char_span": [204, 218], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "regulator", "sbj_tok_span": [50, 53], "obj_tok_span": [2, 5], "new_sbj_tok_span": [90, 93], "new_obj_tok_span": [5, 8]}, {"subject": "promethazine", "sbj_char_span": [232, 244], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "regulator", "sbj_tok_span": [55, 58], "obj_tok_span": [2, 5], "new_sbj_tok_span": [105, 108], "new_obj_tok_span": [5, 8]}, {"subject": "chlorpromazine sulfoxide", "sbj_char_span": [258, 282], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "regulator", "sbj_tok_span": [60, 65], "obj_tok_span": [2, 5], "new_sbj_tok_span": [119, 124], "new_obj_tok_span": [5, 8]}, {"subject": "pimozide", "sbj_char_span": [106, 114], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "agonist or antagonist", "sbj_tok_span": [24, 28], "obj_tok_span": [2, 5], "new_sbj_tok_span": [39, 43], "new_obj_tok_span": [5, 8]}, {"subject": "calmidazolium", "sbj_char_span": [138, 151], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "agonist or antagonist", "sbj_tok_span": [32, 36], "obj_tok_span": [2, 5], "new_sbj_tok_span": [53, 57], "new_obj_tok_span": [5, 8]}, {"subject": "R 24571", "sbj_char_span": [153, 160], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "agonist or antagonist", "sbj_tok_span": [37, 40], "obj_tok_span": [2, 5], "new_sbj_tok_span": [60, 63], "new_obj_tok_span": [5, 8]}, {"subject": "trifluoperazine", "sbj_char_span": [175, 190], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "agonist or antagonist", "sbj_tok_span": [43, 48], "obj_tok_span": [2, 5], "new_sbj_tok_span": [73, 78], "new_obj_tok_span": [5, 8]}, {"subject": "chlorpromazine", "sbj_char_span": [204, 218], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "agonist or antagonist", "sbj_tok_span": [50, 53], "obj_tok_span": [2, 5], "new_sbj_tok_span": [90, 93], "new_obj_tok_span": [5, 8]}, {"subject": "promethazine", "sbj_char_span": [232, 244], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "agonist or antagonist", "sbj_tok_span": [55, 58], "obj_tok_span": [2, 5], "new_sbj_tok_span": [105, 108], "new_obj_tok_span": [5, 8]}, {"subject": "chlorpromazine sulfoxide", "sbj_char_span": [258, 282], "object": "calmodulin", "obj_char_span": [9, 19], "rel_type": "agonist or antagonist", "sbj_tok_span": [60, 65], "obj_tok_span": [2, 5], "new_sbj_tok_span": [119, 124], "new_obj_tok_span": [5, 8]}, {"subject": "pimozide", "sbj_char_span": [106, 114], "object": "calmodulin", "obj_char_span": [360, 370], "rel_type": "inhibitor", "sbj_tok_span": [24, 28], "obj_tok_span": [79, 82], "new_sbj_tok_span": [39, 43], "new_obj_tok_span": [152, 155]}, {"subject": "calmidazolium", "sbj_char_span": [138, 151], "object": "calmodulin", "obj_char_span": [360, 370], "rel_type": "inhibitor", "sbj_tok_span": [32, 36], "obj_tok_span": [79, 82], "new_sbj_tok_span": [53, 57], "new_obj_tok_span": [152, 155]}, {"subject": "R 24571", "sbj_char_span": [153, 160], "object": "calmodulin", "obj_char_span": [360, 370], "rel_type": "inhibitor", "sbj_tok_span": [37, 40], "obj_tok_span": [79, 82], "new_sbj_tok_span": [60, 63], "new_obj_tok_span": [152, 155]}, {"subject": "trifluoperazine", "sbj_char_span": [175, 190], "object": "calmodulin", "obj_char_span": [360, 370], "rel_type": "inhibitor", "sbj_tok_span": [43, 48], "obj_tok_span": [79, 82], "new_sbj_tok_span": [73, 78], "new_obj_tok_span": [152, 155]}, {"subject": "chlorpromazine", "sbj_char_span": [204, 218], "object": "calmodulin", "obj_char_span": [360, 370], "rel_type": "inhibitor", "sbj_tok_span": [50, 53], "obj_tok_span": [79, 82], "new_sbj_tok_span": [90, 93], "new_obj_tok_span": [152, 155]}, {"subject": "promethazine", "sbj_char_span": [232, 244], "object": "calmodulin", "obj_char_span": [360, 370], "rel_type": "inhibitor", "sbj_tok_span": [55, 58], "obj_tok_span": [79, 82], "new_sbj_tok_span": [105, 108], "new_obj_tok_span": [152, 155]}, {"subject": "chlorpromazine sulfoxide", "sbj_char_span": [258, 282], "object": "calmodulin", "obj_char_span": [360, 370], "rel_type": "inhibitor", "sbj_tok_span": [60, 65], "obj_tok_span": [79, 82], "new_sbj_tok_span": [119, 124], "new_obj_tok_span": [152, 155]}], "umls_entity_list": [{"mention": "calmodulin", "char_span": [9, 19], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 5], "new_tok_span": [5, 8]}, {"mention": "calmodulin", "char_span": [360, 370], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [79, 82], "new_tok_span": [152, 155]}, {"mention": "nitrendipine", "char_span": [58, 70], "sem_type": "Pharmacologic Substance", "tok_span": [14, 17], "new_tok_span": [22, 25]}, {"mention": "pimozide", "char_span": [106, 114], "sem_type": "Pharmacologic Substance", "tok_span": [24, 28], "new_tok_span": [39, 43]}, {"mention": "calmidazolium", "char_span": [138, 151], "sem_type": "Pharmacologic Substance", "tok_span": [32, 36], "new_tok_span": [53, 57]}, {"mention": "r", "char_span": [6, 7], "sem_type": "Pharmacologic Substance", "tok_span": [0, 1], "new_tok_span": [1, 2]}, {"mention": "r", "char_span": [34, 35], "sem_type": "Pharmacologic Substance", "tok_span": [6, 7], "new_tok_span": [11, 12]}, {"mention": "r", "char_span": [61, 62], "sem_type": "Pharmacologic Substance", "tok_span": [14, 15], "new_tok_span": [22, 23]}, {"mention": "r", "char_span": [89, 90], "sem_type": "Pharmacologic Substance", "tok_span": [20, 21], "new_tok_span": [32, 33]}, {"mention": "r", "char_span": [92, 93], "sem_type": "Pharmacologic Substance", "tok_span": [20, 21], "new_tok_span": [32, 33]}, {"mention": "r", "char_span": [116, 117], "sem_type": "Pharmacologic Substance", "tok_span": [28, 29], "new_tok_span": [46, 47]}, {"mention": "r", "char_span": [121, 122], "sem_type": "Pharmacologic Substance", "tok_span": [28, 29], "new_tok_span": [46, 47]}, {"mention": "R", "char_span": [153, 154], "sem_type": "Pharmacologic Substance", "tok_span": [37, 38], "new_tok_span": [60, 61]}, {"mention": "r", "char_span": [163, 164], "sem_type": "Pharmacologic Substance", "tok_span": [41, 42], "new_tok_span": [67, 68]}, {"mention": "r", "char_span": [168, 169], "sem_type": "Pharmacologic Substance", "tok_span": [41, 42], "new_tok_span": [67, 68]}, {"mention": "r", "char_span": [176, 177], "sem_type": "Pharmacologic Substance", "tok_span": [43, 44], "new_tok_span": [73, 74]}, {"mention": "r", "char_span": [184, 185], "sem_type": "Pharmacologic Substance", "tok_span": [46, 47], "new_tok_span": [78, 79]}, {"mention": "r", "char_span": [192, 193], "sem_type": "Pharmacologic Substance", "tok_span": [48, 49], "new_tok_span": [84, 85]}, {"mention": "r", "char_span": [197, 198], "sem_type": "Pharmacologic Substance", "tok_span": [48, 49], "new_tok_span": [84, 85]}, {"mention": "r", "char_span": [208, 209], "sem_type": "Pharmacologic Substance", "tok_span": [50, 51], "new_tok_span": [90, 91]}, {"mention": "r", "char_span": [210, 211], "sem_type": "Pharmacologic Substance", "tok_span": [51, 52], "new_tok_span": [93, 94]}, {"mention": "r", "char_span": [220, 221], "sem_type": "Pharmacologic Substance", "tok_span": [53, 54], "new_tok_span": [99, 100]}, {"mention": "r", "char_span": [225, 226], "sem_type": "Pharmacologic Substance", "tok_span": [53, 54], "new_tok_span": [99, 100]}, {"mention": "r", "char_span": [233, 234], "sem_type": "Pharmacologic Substance", "tok_span": [55, 56], "new_tok_span": [105, 106]}, {"mention": "r", "char_span": [246, 247], "sem_type": "Pharmacologic Substance", "tok_span": [58, 59], "new_tok_span": [112, 113]}, {"mention": "r", "char_span": [251, 252], "sem_type": "Pharmacologic Substance", "tok_span": [58, 59], "new_tok_span": [112, 113]}, {"mention": "r", "char_span": [262, 263], "sem_type": "Pharmacologic Substance", "tok_span": [60, 61], "new_tok_span": [119, 120]}, {"mention": "r", "char_span": [264, 265], "sem_type": "Pharmacologic Substance", "tok_span": [61, 62], "new_tok_span": [122, 123]}, {"mention": "r", "char_span": [291, 292], "sem_type": "Pharmacologic Substance", "tok_span": [67, 68], "new_tok_span": [133, 134]}, {"mention": "r", "char_span": [292, 293], "sem_type": "Pharmacologic Substance", "tok_span": [67, 68], "new_tok_span": [133, 134]}, {"mention": "r", "char_span": [338, 339], "sem_type": "Pharmacologic Substance", "tok_span": [75, 76], "new_tok_span": [144, 145]}, {"mention": "r", "char_span": [354, 355], "sem_type": "Pharmacologic Substance", "tok_span": [77, 78], "new_tok_span": [148, 149]}, {"mention": "r", "char_span": [382, 383], "sem_type": "Pharmacologic Substance", "tok_span": [84, 85], "new_tok_span": [159, 160]}, {"mention": "trifluoperazine", "char_span": [175, 190], "sem_type": "Pharmacologic Substance", "tok_span": [43, 48], "new_tok_span": [73, 78]}, {"mention": "chlorpromazine", "char_span": [204, 218], "sem_type": "Pharmacologic Substance", "tok_span": [50, 53], "new_tok_span": [90, 93]}, {"mention": "chlorpromazine", "char_span": [258, 272], "sem_type": "Pharmacologic Substance", "tok_span": [60, 63], "new_tok_span": [119, 122]}, {"mention": "promethazine", "char_span": [232, 244], "sem_type": "Pharmacologic Substance", "tok_span": [55, 58], "new_tok_span": [105, 108]}, {"mention": "chlorpromazine sulfoxide", "char_span": [258, 282], "sem_type": "Organic Chemical", "tok_span": [60, 65], "new_tok_span": [119, 124]}], "new_text": "<START=Pharmacologic Substance> However <END=Pharmacologic Substance>, <START=Amino Acid, Peptide, or Protein> calmodulin <END=Amino Acid, Peptide, or Protein> antagonists <START=Pharmacologic Substance> were <END=Pharmacologic Substance> found to inhibit [ 3H ] <START=Pharmacologic Substance> <START=Pharmacologic Substance> nitr <END=Pharmacologic Substance>endipine <END=Pharmacologic Substance> binding with the <START=Pharmacologic Substance> <START=Pharmacologic Substance> order <END=Pharmacologic Substance> <END=Pharmacologic Substance> of potency : <START=Pharmacologic Substance> pimozide <END=Pharmacologic Substance> <START=Pharmacologic Substance> <START=Pharmacologic Substance> greater <END=Pharmacologic Substance> <END=Pharmacologic Substance> than less than <START=Pharmacologic Substance> calmidazolium <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> R <END=Pharmacologic Substance> 24571 ) <START=Pharmacologic Substance> <START=Pharmacologic Substance> greater <END=Pharmacologic Substance> <END=Pharmacologic Substance> than <START=Pharmacologic Substance> <START=Pharmacologic Substance> tri <END=Pharmacologic Substance>fluo <START=Pharmacologic Substance>per <END=Pharmacologic Substance>azine <END=Pharmacologic Substance> <START=Pharmacologic Substance> <START=Pharmacologic Substance> greater <END=Pharmacologic Substance> <END=Pharmacologic Substance> than <START=Pharmacologic Substance> <START=Pharmacologic Substance> chlor <END=Pharmacologic Substance> <START=Pharmacologic Substance>prom <END=Pharmacologic Substance>azine <END=Pharmacologic Substance> <START=Pharmacologic Substance> <START=Pharmacologic Substance> greater <END=Pharmacologic Substance> <END=Pharmacologic Substance> than <START=Pharmacologic Substance> <START=Pharmacologic Substance> prom <END=Pharmacologic Substance>ethazine <END=Pharmacologic Substance> <START=Pharmacologic Substance> <START=Pharmacologic Substance> greater <END=Pharmacologic Substance> <END=Pharmacologic Substance> than <START=Pharmacologic Substance> <START=Pharmacologic Substance> <START=Organic Chemical> chlor <END=Pharmacologic Substance> <START=Pharmacologic Substance>prom <END=Pharmacologic Substance>azine <END=Pharmacologic Substance> sulfoxide <END=Organic Chemical>, that <START=Pharmacologic Substance> <START=Pharmacologic Substance> correlates <END=Pharmacologic Substance> <END=Pharmacologic Substance> quite well with the potency of these <START=Pharmacologic Substance> drugs <END=Pharmacologic Substance> as <START=Pharmacologic Substance> inhibitors <END=Pharmacologic Substance> of <START=Amino Acid, Peptide, or Protein> calmodulin <END=Amino Acid, Peptide, or Protein> - dependent <START=Pharmacologic Substance> processes <END=Pharmacologic Substance>."}, {"PMID": 23583258, "id": 3, "text": "This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and IL-8, caused by a mixture of oxysterols representative of a high cholesterol diet.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [172, 182], "name": "oxysterols", "tok_span": [37, 40], "new_tok_span": [40, 43]}, {"ent_type": "CHEMICAL", "char_span": [208, 219], "name": "cholesterol", "tok_span": [44, 45], "new_tok_span": [48, 49]}, {"ent_type": "GENE", "char_span": [120, 132], "name": "interleukins", "tok_span": [21, 23], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [134, 138], "name": "IL-6", "tok_span": [24, 27], "new_tok_span": [26, 29]}, {"ent_type": "GENE", "char_span": [143, 147], "name": "IL-8", "tok_span": [28, 31], "new_tok_span": [30, 33]}], "relation_list": [{"subject": "oxysterols", "sbj_char_span": [172, 182], "object": "interleukins", "obj_char_span": [120, 132], "rel_type": "regulator", "sbj_tok_span": [37, 40], "obj_tok_span": [21, 23], "new_sbj_tok_span": [40, 43], "new_obj_tok_span": [22, 24]}, {"subject": "oxysterols", "sbj_char_span": [172, 182], "object": "IL-6", "obj_char_span": [134, 138], "rel_type": "regulator", "sbj_tok_span": [37, 40], "obj_tok_span": [24, 27], "new_sbj_tok_span": [40, 43], "new_obj_tok_span": [26, 29]}, {"subject": "oxysterols", "sbj_char_span": [172, 182], "object": "IL-8", "obj_char_span": [143, 147], "rel_type": "regulator", "sbj_tok_span": [37, 40], "obj_tok_span": [28, 31], "new_sbj_tok_span": [40, 43], "new_obj_tok_span": [30, 33]}, {"subject": "cholesterol", "sbj_char_span": [208, 219], "object": "interleukins", "obj_char_span": [120, 132], "rel_type": "regulator", "sbj_tok_span": [44, 45], "obj_tok_span": [21, 23], "new_sbj_tok_span": [48, 49], "new_obj_tok_span": [22, 24]}, {"subject": "cholesterol", "sbj_char_span": [208, 219], "object": "IL-6", "obj_char_span": [134, 138], "rel_type": "regulator", "sbj_tok_span": [44, 45], "obj_tok_span": [24, 27], "new_sbj_tok_span": [48, 49], "new_obj_tok_span": [26, 29]}, {"subject": "cholesterol", "sbj_char_span": [208, 219], "object": "IL-8", "obj_char_span": [143, 147], "rel_type": "regulator", "sbj_tok_span": [44, 45], "obj_tok_span": [28, 31], "new_sbj_tok_span": [48, 49], "new_obj_tok_span": [30, 33]}], "umls_entity_list": [{"mention": "interleukins", "char_span": [120, 132], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 23], "new_tok_span": [22, 24]}, {"mention": "oxysterols", "char_span": [172, 182], "sem_type": "Organic Chemical", "tok_span": [37, 40], "new_tok_span": [40, 43]}], "new_text": "This report concerns the marked up - regulation in differentiated CaCo - 2 colonic epithelial cells of two key inflammatory <START=Amino Acid, Peptide, or Protein> interleukins <END=Amino Acid, Peptide, or Protein>, IL - 6 and IL - 8, caused by a mixture of <START=Organic Chemical> oxysterols <END=Organic Chemical> representative of a high cholesterol diet."}, {"PMID": 23567998, "id": 6, "text": "At physiological concentrations of gabapentin, LAT1 mediated transport was 3 or ~10-fold higher than the other transport processes in the two systems, respectively, demonstrating clear selectivity for gabapentin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [35, 45], "name": "gabapentin", "tok_span": [4, 8], "new_tok_span": [5, 9]}, {"ent_type": "CHEMICAL", "char_span": [201, 211], "name": "gabapentin", "tok_span": [38, 42], "new_tok_span": [41, 45]}, {"ent_type": "GENE", "char_span": [47, 51], "name": "LAT1", "tok_span": [9, 12], "new_tok_span": [11, 14]}], "relation_list": [{"subject": "gabapentin", "sbj_char_span": [35, 45], "object": "LAT1", "obj_char_span": [47, 51], "rel_type": "product or substrate", "sbj_tok_span": [4, 8], "obj_tok_span": [9, 12], "new_sbj_tok_span": [5, 9], "new_obj_tok_span": [11, 14]}, {"subject": "gabapentin", "sbj_char_span": [201, 211], "object": "LAT1", "obj_char_span": [47, 51], "rel_type": "product or substrate", "sbj_tok_span": [38, 42], "obj_tok_span": [9, 12], "new_sbj_tok_span": [41, 45], "new_obj_tok_span": [11, 14]}], "umls_entity_list": [{"mention": "gabapentin", "char_span": [35, 45], "sem_type": "Pharmacologic Substance", "tok_span": [4, 8], "new_tok_span": [5, 9]}, {"mention": "gabapentin", "char_span": [201, 211], "sem_type": "Pharmacologic Substance", "tok_span": [38, 42], "new_tok_span": [41, 45]}], "new_text": "At physiological concentrations of <START=Pharmacologic Substance> gabapentin <END=Pharmacologic Substance>, LAT1 mediated transport was 3 or ~ 10 - fold higher than the other transport processes in the two systems, respectively, demonstrating clear selectivity for <START=Pharmacologic Substance> gabapentin <END=Pharmacologic Substance>."}, {"PMID": 11398914, "id": 2, "text": "Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Rofecoxib", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "CHEMICAL", "char_span": [49, 58], "name": "celecoxib", "tok_span": [12, 16], "new_tok_span": [12, 16]}, {"ent_type": "CHEMICAL", "char_span": [60, 69], "name": "meloxicam", "tok_span": [17, 20], "new_tok_span": [17, 20]}, {"ent_type": "CHEMICAL", "char_span": [71, 81], "name": "diclofenac", "tok_span": [21, 25], "new_tok_span": [21, 25]}, {"ent_type": "CHEMICAL", "char_span": [86, 98], "name": "indomethacin", "tok_span": [26, 29], "new_tok_span": [26, 29]}, {"ent_type": "GENE", "char_span": [38, 43], "name": "COX-2", "tok_span": [8, 11], "new_tok_span": [8, 11]}], "relation_list": [{"subject": "Rofecoxib", "sbj_char_span": [0, 9], "object": "COX-2", "obj_char_span": [38, 43], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [8, 11], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [8, 11]}], "umls_entity_list": [], "new_text": "Rofecoxib has greater selectivity for COX - 2 than celecoxib, meloxicam, diclofenac and indomethacin."}, {"PMID": 15740719, "id": 11, "text": "For the vasopressin V1A/oxytocin receptor antagonist atosiban, none of the receptor constructs were able to provide a binding with higher affinity than the starting vasopressin V2 receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [8, 19], "name": "vasopressin", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"ent_type": "CHEMICAL", "char_span": [24, 32], "name": "oxytocin", "tok_span": [9, 12], "new_tok_span": [12, 15]}, {"ent_type": "CHEMICAL", "char_span": [53, 61], "name": "atosiban", "tok_span": [14, 17], "new_tok_span": [19, 22]}, {"ent_type": "CHEMICAL", "char_span": [165, 176], "name": "vasopressin", "tok_span": [35, 38], "new_tok_span": [44, 47]}, {"ent_type": "GENE", "char_span": [8, 41], "name": "vasopressin V1A/oxytocin receptor", "tok_span": [2, 13], "new_tok_span": [3, 14]}, {"ent_type": "GENE", "char_span": [165, 188], "name": "vasopressin V2 receptor", "tok_span": [35, 41], "new_tok_span": [44, 50]}], "relation_list": [{"subject": "atosiban", "sbj_char_span": [53, 61], "object": "vasopressin V1A/oxytocin receptor", "obj_char_span": [8, 41], "rel_type": "agonist or antagonist", "sbj_tok_span": [14, 17], "obj_tok_span": [2, 13], "new_sbj_tok_span": [19, 22], "new_obj_tok_span": [3, 14]}, {"subject": "atosiban", "sbj_char_span": [53, 61], "object": "vasopressin V2 receptor", "obj_char_span": [165, 188], "rel_type": "regulator", "sbj_tok_span": [14, 17], "obj_tok_span": [35, 41], "new_sbj_tok_span": [19, 22], "new_obj_tok_span": [44, 50]}], "umls_entity_list": [{"mention": "oxytocin", "char_span": [24, 32], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [9, 12], "new_tok_span": [12, 15]}, {"mention": "atosiban", "char_span": [53, 61], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [14, 17], "new_tok_span": [19, 22]}, {"mention": "vasopressin", "char_span": [8, 19], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [2, 5], "new_tok_span": [3, 6]}, {"mention": "vasopressin", "char_span": [165, 176], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 38], "new_tok_span": [44, 47]}, {"mention": "vasopressin V2 receptor", "char_span": [165, 188], "sem_type": "Gene or Genome", "tok_span": [35, 41], "new_tok_span": [44, 50]}, {"mention": "vasopressin V2 receptor", "char_span": [165, 188], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 41], "new_tok_span": [44, 50]}], "new_text": "For the <START=Amino Acid, Peptide, or Protein> vasopressin <END=Amino Acid, Peptide, or Protein> V1A / <START=Amino Acid, Peptide, or Protein> oxytocin <END=Amino Acid, Peptide, or Protein> receptor antagonist <START=Amino Acid, Peptide, or Protein> atosiban <END=Amino Acid, Peptide, or Protein>, none of the receptor constructs were able to provide a binding with higher affinity than the starting <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> vasopressin <END=Amino Acid, Peptide, or Protein> V2 receptor <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 12601049, "id": 7, "text": "RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEGF mRNA expression.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 5], "name": "RU486", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "CHEMICAL", "char_span": [26, 36], "name": "budesonide", "tok_span": [5, 9], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [60, 64], "name": "VEGF", "tok_span": [13, 14], "new_tok_span": [16, 17]}, {"ent_type": "GENE", "char_span": [79, 83], "name": "VEGF", "tok_span": [16, 17], "new_tok_span": [21, 22]}], "relation_list": [{"subject": "budesonide", "sbj_char_span": [26, 36], "object": "VEGF", "obj_char_span": [60, 64], "rel_type": "regulator", "sbj_tok_span": [5, 9], "obj_tok_span": [13, 14], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [16, 17]}, {"subject": "budesonide", "sbj_char_span": [26, 36], "object": "VEGF", "obj_char_span": [79, 83], "rel_type": "regulator", "sbj_tok_span": [5, 9], "obj_tok_span": [16, 17], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [21, 22]}, {"subject": "RU486", "sbj_char_span": [0, 5], "object": "VEGF", "obj_char_span": [60, 64], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [13, 14], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [16, 17]}, {"subject": "RU486", "sbj_char_span": [0, 5], "object": "VEGF", "obj_char_span": [79, 83], "rel_type": "regulator", "sbj_tok_span": [0, 3], "obj_tok_span": [16, 17], "new_sbj_tok_span": [1, 4], "new_obj_tok_span": [21, 22]}], "umls_entity_list": [{"mention": "RU486", "char_span": [0, 5], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "VEGF", "char_span": [60, 64], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 14], "new_tok_span": [16, 17]}, {"mention": "VEGF", "char_span": [79, 83], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 17], "new_tok_span": [21, 22]}], "new_text": "<START=Pharmacologic Substance> RU486 <END=Pharmacologic Substance> treatment prevented budesonide - mediated inhibition of <START=Amino Acid, Peptide, or Protein> VEGF <END=Amino Acid, Peptide, or Protein> secretion and <START=Amino Acid, Peptide, or Protein> VEGF <END=Amino Acid, Peptide, or Protein> mRNA expression."}, {"PMID": 23500491, "id": 2, "text": "By combining our structure with previously solved KIF1A structures complexed with two ATP analogs, molecular snapshots during ATP binding reveal that the closure of the nucleotide-binding pocket during ATP binding is achieved by closure of the backdoor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [86, 89], "name": "ATP", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"ent_type": "CHEMICAL", "char_span": [126, 129], "name": "ATP", "tok_span": [23, 24], "new_tok_span": [25, 26]}, {"ent_type": "CHEMICAL", "char_span": [169, 179], "name": "nucleotide", "tok_span": [31, 32], "new_tok_span": [33, 34]}, {"ent_type": "CHEMICAL", "char_span": [202, 205], "name": "ATP", "tok_span": [36, 37], "new_tok_span": [38, 39]}, {"ent_type": "GENE", "char_span": [50, 55], "name": "KIF1A", "tok_span": [7, 11], "new_tok_span": [8, 12]}], "relation_list": [{"subject": "ATP", "sbj_char_span": [86, 89], "object": "KIF1A", "obj_char_span": [50, 55], "rel_type": "regulator", "sbj_tok_span": [16, 17], "obj_tok_span": [7, 11], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [8, 12]}], "umls_entity_list": [{"mention": "KIF1A", "char_span": [50, 55], "sem_type": "Gene or Genome", "tok_span": [7, 11], "new_tok_span": [8, 12]}], "new_text": "By combining our structure with previously solved <START=Gene or Genome> KIF1A <END=Gene or Genome> structures complexed with two ATP analogs, molecular snapshots during ATP binding reveal that the closure of the nucleotide - binding pocket during ATP binding is achieved by closure of the backdoor."}, {"PMID": 22966070, "id": 7, "text": "In hypothalamus of mice administered a high-fat diet, there is a reduction in leptin and insulin-induced Tub-p-tyr and nuclear translocation, which is reversed by reducing protein tyrosine phosphatase 1B expression.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [111, 114], "name": "tyr", "tok_span": [26, 28], "new_tok_span": [32, 34]}, {"ent_type": "CHEMICAL", "char_span": [180, 188], "name": "tyrosine", "tok_span": [38, 39], "new_tok_span": [45, 46]}, {"ent_type": "GENE", "char_span": [78, 84], "name": "leptin", "tok_span": [16, 17], "new_tok_span": [16, 17]}, {"ent_type": "GENE", "char_span": [89, 96], "name": "insulin", "tok_span": [18, 19], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [105, 108], "name": "Tub", "tok_span": [21, 23], "new_tok_span": [26, 28]}, {"ent_type": "GENE", "char_span": [172, 203], "name": "protein tyrosine phosphatase 1B", "tok_span": [37, 42], "new_tok_span": [44, 49]}], "relation_list": [{"subject": "tyr", "sbj_char_span": [111, 114], "object": "Tub", "obj_char_span": [105, 108], "rel_type": "part of", "sbj_tok_span": [26, 28], "obj_tok_span": [21, 23], "new_sbj_tok_span": [32, 34], "new_obj_tok_span": [26, 28]}], "umls_entity_list": [{"mention": "insulin", "char_span": [89, 96], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 19], "new_tok_span": [20, 21]}, {"mention": "Tub", "char_span": [105, 108], "sem_type": "Gene or Genome", "tok_span": [21, 23], "new_tok_span": [26, 28]}, {"mention": "insulin", "char_span": [89, 96], "sem_type": "Pharmacologic Substance", "tok_span": [18, 19], "new_tok_span": [20, 21]}, {"mention": "protein tyrosine phosphatase 1B", "char_span": [172, 203], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [37, 42], "new_tok_span": [44, 49]}], "new_text": "In hypothalamus of mice administered a high - fat diet, there is a reduction in leptin and <START=Amino Acid, Peptide, or Protein> <START=Pharmacologic Substance> insulin <END=Amino Acid, Peptide, or Protein> <END=Pharmacologic Substance> - induced <START=Gene or Genome> Tub <END=Gene or Genome> - p - tyr and nuclear translocation, which is reversed by reducing <START=Amino Acid, Peptide, or Protein> protein tyrosine phosphatase 1B <END=Amino Acid, Peptide, or Protein> expression."}, {"PMID": 23312283, "id": 6, "text": "FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [38, 48], "name": "bile acids", "tok_span": [8, 10], "new_tok_span": [11, 13]}, {"ent_type": "CHEMICAL", "char_span": [112, 121], "name": "bile acid", "tok_span": [27, 29], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [0, 4], "name": "FMO3", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"ent_type": "GENE", "char_span": [82, 102], "name": "farnesoid X receptor", "tok_span": [16, 21], "new_tok_span": [20, 25]}, {"ent_type": "GENE", "char_span": [104, 107], "name": "FXR", "tok_span": [22, 24], "new_tok_span": [26, 28]}], "relation_list": [{"subject": "bile acids", "sbj_char_span": [38, 48], "object": "FMO3", "obj_char_span": [0, 4], "rel_type": "regulator", "sbj_tok_span": [8, 10], "obj_tok_span": [0, 3], "new_sbj_tok_span": [11, 13], "new_obj_tok_span": [1, 4]}, {"subject": "bile acid", "sbj_char_span": [112, 121], "object": "farnesoid X receptor", "obj_char_span": [82, 102], "rel_type": "activator", "sbj_tok_span": [27, 29], "obj_tok_span": [16, 21], "new_sbj_tok_span": [32, 34], "new_obj_tok_span": [20, 25]}, {"subject": "bile acid", "sbj_char_span": [112, 121], "object": "FXR", "obj_char_span": [104, 107], "rel_type": "activator", "sbj_tok_span": [27, 29], "obj_tok_span": [22, 24], "new_sbj_tok_span": [32, 34], "new_obj_tok_span": [26, 28]}], "umls_entity_list": [{"mention": "FMO3", "char_span": [0, 4], "sem_type": "Pharmacologic Substance", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "bile", "char_span": [38, 42], "sem_type": "Organic Chemical", "tok_span": [8, 9], "new_tok_span": [11, 12]}, {"mention": "bile", "char_span": [112, 116], "sem_type": "Organic Chemical", "tok_span": [27, 28], "new_tok_span": [32, 33]}], "new_text": "<START=Pharmacologic Substance> FMO3 <END=Pharmacologic Substance> expression is induced by dietary <START=Organic Chemical> bile <END=Organic Chemical> acids by a mechanism that involves the farnesoid X receptor ( FXR ), a <START=Organic Chemical> bile <END=Organic Chemical> acid - activated nuclear receptor."}, {"PMID": 12142814, "id": 6, "text": "However, those for P4-H activity remained uniformly elevated after one hundred days on NTBC, the PIIINP biomarker even increasing above its grossly abnormal, initial level.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [87, 91], "name": "NTBC", "tok_span": [17, 19], "new_tok_span": [19, 21]}, {"ent_type": "GENE", "char_span": [19, 23], "name": "P4-H", "tok_span": [4, 8], "new_tok_span": [5, 9]}, {"ent_type": "GENE", "char_span": [97, 103], "name": "PIIINP", "tok_span": [21, 24], "new_tok_span": [24, 27]}], "relation_list": [{"subject": "NTBC", "sbj_char_span": [87, 91], "object": "P4-H", "obj_char_span": [19, 23], "rel_type": "activator", "sbj_tok_span": [17, 19], "obj_tok_span": [4, 8], "new_sbj_tok_span": [19, 21], "new_obj_tok_span": [5, 9]}], "umls_entity_list": [{"mention": "P4", "char_span": [19, 21], "sem_type": "Gene or Genome", "tok_span": [4, 6], "new_tok_span": [5, 7]}, {"mention": "PIIINP", "char_span": [97, 103], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 24], "new_tok_span": [24, 27]}], "new_text": "However, those for <START=Gene or Genome> P4 <END=Gene or Genome> - H activity remained uniformly elevated after one hundred days on NTBC, the <START=Amino Acid, Peptide, or Protein> PIIINP <END=Amino Acid, Peptide, or Protein> biomarker even increasing above its grossly abnormal, initial level."}, {"PMID": 7582530, "id": 3, "text": "BMY 7378 displayed high affinity for cloned human alpha 1D-adrenoceptors (pKi = 8.2 +/- 0.10) and was selective over alpha 1A (pKi = 6.2 +/- 0.10) and alpha 1B subtypes (6.7 +/- 0.11).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 8], "name": "BMY 7378", "tok_span": [0, 4], "new_tok_span": [0, 4]}, {"ent_type": "GENE", "char_span": [44, 72], "name": "human alpha 1D-adrenoceptors", "tok_span": [9, 18], "new_tok_span": [9, 18]}], "relation_list": [{"subject": "BMY 7378", "sbj_char_span": [0, 8], "object": "human alpha 1D-adrenoceptors", "obj_char_span": [44, 72], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [9, 18], "new_sbj_tok_span": [0, 4], "new_obj_tok_span": [9, 18]}], "umls_entity_list": [], "new_text": "BMY 7378 displayed high affinity for cloned human alpha 1D - adrenoceptors ( pKi = 8. 2 + / - 0. 10 ) and was selective over alpha 1A ( pKi = 6. 2 + / - 0. 10 ) and alpha 1B subtypes ( 6. 7 + / - 0. 11 )."}, {"PMID": 23266270, "id": 7, "text": "Taken together, the results of this study demonstrate that DPEP inhibits LPS-stimulated inflammation by blocking the NF-κB and MAPK pathways in macrophages.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [59, 63], "name": "DPEP", "tok_span": [10, 12], "new_tok_span": [10, 12]}, {"ent_type": "GENE", "char_span": [117, 122], "name": "NF-κB", "tok_span": [20, 24], "new_tok_span": [20, 24]}, {"ent_type": "GENE", "char_span": [127, 131], "name": "MAPK", "tok_span": [25, 26], "new_tok_span": [25, 26]}], "relation_list": [{"subject": "DPEP", "sbj_char_span": [59, 63], "object": "NF-κB", "obj_char_span": [117, 122], "rel_type": "inhibitor", "sbj_tok_span": [10, 12], "obj_tok_span": [20, 24], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [20, 24]}, {"subject": "DPEP", "sbj_char_span": [59, 63], "object": "MAPK", "obj_char_span": [127, 131], "rel_type": "inhibitor", "sbj_tok_span": [10, 12], "obj_tok_span": [25, 26], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [25, 26]}], "umls_entity_list": [], "new_text": "Taken together, the results of this study demonstrate that DPEP inhibits LPS - stimulated inflammation by blocking the NF - κB and MAPK pathways in macrophages."}, {"PMID": 11785774, "id": 1, "text": "The involvement of prostaglandins synthesized by constitutive (COX-1) and inducible cyclooxygenase (COX-2) in central stimulation of the hypothalamic-pituitary-adrenal (HPA) axis by adrenergic receptor agonists was investigated in conscious rats.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [19, 33], "name": "prostaglandins", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "GENE", "char_span": [100, 105], "name": "COX-2", "tok_span": [18, 21], "new_tok_span": [20, 23]}, {"ent_type": "GENE", "char_span": [63, 68], "name": "COX-1", "tok_span": [9, 12], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [84, 98], "name": "cyclooxygenase", "tok_span": [15, 17], "new_tok_span": [16, 18]}], "relation_list": [{"subject": "prostaglandins", "sbj_char_span": [19, 33], "object": "COX-1", "obj_char_span": [63, 68], "rel_type": "product or substrate", "sbj_tok_span": [3, 5], "obj_tok_span": [9, 12], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [9, 12]}, {"subject": "prostaglandins", "sbj_char_span": [19, 33], "object": "cyclooxygenase", "obj_char_span": [84, 98], "rel_type": "product or substrate", "sbj_tok_span": [3, 5], "obj_tok_span": [15, 17], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [16, 18]}, {"subject": "prostaglandins", "sbj_char_span": [19, 33], "object": "COX-2", "obj_char_span": [100, 105], "rel_type": "product or substrate", "sbj_tok_span": [3, 5], "obj_tok_span": [18, 21], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [20, 23]}], "umls_entity_list": [{"mention": "cyclooxygenase", "char_span": [84, 98], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 17], "new_tok_span": [16, 18]}], "new_text": "The involvement of prostaglandins synthesized by constitutive ( COX - 1 ) and inducible <START=Amino Acid, Peptide, or Protein> cyclooxygenase <END=Amino Acid, Peptide, or Protein> ( COX - 2 ) in central stimulation of the hypothalamic - pituitary - adrenal ( HPA ) axis by adrenergic receptor agonists was investigated in conscious rats."}, {"PMID": 15887238, "id": 10, "text": "Although, imatinib primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [10, 18], "name": "imatinib", "tok_span": [2, 4], "new_tok_span": [2, 4]}, {"ent_type": "CHEMICAL", "char_span": [96, 104], "name": "tyrosine", "tok_span": [16, 17], "new_tok_span": [16, 17]}, {"ent_type": "GENE", "char_span": [38, 54], "name": "tyrosine kinases", "tok_span": [6, 8], "new_tok_span": [6, 8]}, {"ent_type": "GENE", "char_span": [91, 95], "name": "EGFR", "tok_span": [15, 16], "new_tok_span": [15, 16]}, {"ent_type": "GENE", "char_span": [96, 111], "name": "tyrosine kinase", "tok_span": [16, 18], "new_tok_span": [16, 18]}], "relation_list": [{"subject": "imatinib", "sbj_char_span": [10, 18], "object": "tyrosine kinases", "obj_char_span": [38, 54], "rel_type": "inhibitor", "sbj_tok_span": [2, 4], "obj_tok_span": [6, 8], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [6, 8]}, {"subject": "imatinib", "sbj_char_span": [10, 18], "object": "EGFR", "obj_char_span": [91, 95], "rel_type": "activator", "sbj_tok_span": [2, 4], "obj_tok_span": [15, 16], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [15, 16]}, {"subject": "imatinib", "sbj_char_span": [10, 18], "object": "tyrosine kinase", "obj_char_span": [96, 111], "rel_type": "activator", "sbj_tok_span": [2, 4], "obj_tok_span": [16, 18], "new_sbj_tok_span": [2, 4], "new_obj_tok_span": [16, 18]}], "umls_entity_list": [], "new_text": "Although, imatinib primarily inhibits tyrosine kinases, it also stimulates the activity of EGFR tyrosine kinase in head and neck squamous tumors."}, {"PMID": 23147417, "id": 7, "text": "Microinjection into the RVLM of both control and SIHR groups of 7-Ni (0.05 pmol/100 nl, nNOS inhibitor) or Methylene Blue [100 pmol/100 nl, an inhibitor of soluble guanylate cyclase (sGC)] suppressed the OXA-induced increase of SBP and HR, whereas microinjection of AG (1, 10, 100 pmol/100 nl) had no obvious effects on the OXA-induced increase of SBP and HR. Our results indicate that OXA in the RVLM may participate in the central regulation of cardiovascular activities in SIHR, and OX1R and OX2R both have important roles in it.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [107, 121], "name": "Methylene Blue", "tok_span": [31, 34], "new_tok_span": [36, 39]}, {"ent_type": "CHEMICAL", "char_span": [164, 173], "name": "guanylate", "tok_span": [45, 47], "new_tok_span": [52, 54]}, {"ent_type": "GENE", "char_span": [88, 92], "name": "nNOS", "tok_span": [26, 28], "new_tok_span": [28, 30]}, {"ent_type": "GENE", "char_span": [156, 181], "name": "soluble guanylate cyclase", "tok_span": [44, 48], "new_tok_span": [51, 55]}, {"ent_type": "GENE", "char_span": [183, 186], "name": "sGC", "tok_span": [49, 51], "new_tok_span": [57, 59]}, {"ent_type": "GENE", "char_span": [204, 207], "name": "OXA", "tok_span": [55, 57], "new_tok_span": [63, 65]}, {"ent_type": "GENE", "char_span": [324, 327], "name": "OXA", "tok_span": [87, 89], "new_tok_span": [97, 99]}, {"ent_type": "GENE", "char_span": [386, 389], "name": "OXA", "tok_span": [101, 103], "new_tok_span": [111, 113]}, {"ent_type": "GENE", "char_span": [486, 490], "name": "OX1R", "tok_span": [121, 124], "new_tok_span": [132, 135]}, {"ent_type": "GENE", "char_span": [495, 499], "name": "OX2R", "tok_span": [125, 128], "new_tok_span": [138, 141]}], "relation_list": [{"subject": "Methylene Blue", "sbj_char_span": [107, 121], "object": "soluble guanylate cyclase", "obj_char_span": [156, 181], "rel_type": "inhibitor", "sbj_tok_span": [31, 34], "obj_tok_span": [44, 48], "new_sbj_tok_span": [36, 39], "new_obj_tok_span": [51, 55]}, {"subject": "Methylene Blue", "sbj_char_span": [107, 121], "object": "sGC", "obj_char_span": [183, 186], "rel_type": "inhibitor", "sbj_tok_span": [31, 34], "obj_tok_span": [49, 51], "new_sbj_tok_span": [36, 39], "new_obj_tok_span": [57, 59]}, {"subject": "Methylene Blue", "sbj_char_span": [107, 121], "object": "OXA", "obj_char_span": [204, 207], "rel_type": "inhibitor", "sbj_tok_span": [31, 34], "obj_tok_span": [55, 57], "new_sbj_tok_span": [36, 39], "new_obj_tok_span": [63, 65]}], "umls_entity_list": [{"mention": "nNOS", "char_span": [88, 92], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 28], "new_tok_span": [28, 30]}, {"mention": "nNOS", "char_span": [88, 92], "sem_type": "Gene or Genome", "tok_span": [26, 28], "new_tok_span": [28, 30]}, {"mention": "Methylene Blue", "char_span": [107, 121], "sem_type": "Organic Chemical", "tok_span": [31, 34], "new_tok_span": [36, 39]}, {"mention": "soluble guanylate cyclase", "char_span": [156, 181], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [44, 48], "new_tok_span": [51, 55]}, {"mention": "AG", "char_span": [266, 268], "sem_type": "Organic Chemical", "tok_span": [69, 70], "new_tok_span": [78, 79]}, {"mention": "OX1R", "char_span": [486, 490], "sem_type": "Gene or Genome", "tok_span": [121, 124], "new_tok_span": [132, 135]}, {"mention": "OX2R", "char_span": [495, 499], "sem_type": "Gene or Genome", "tok_span": [125, 128], "new_tok_span": [138, 141]}], "new_text": "Microinjection into the RVLM of both control and SIHR groups of 7 - Ni ( 0. 05 pmol / 100 nl, <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> nNOS <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> inhibitor ) or <START=Organic Chemical> Methylene Blue <END=Organic Chemical> [ 100 pmol / 100 nl, an inhibitor of <START=Amino Acid, Peptide, or Protein> soluble guanylate cyclase <END=Amino Acid, Peptide, or Protein> ( sGC ) ] suppressed the OXA - induced increase of SBP and HR, whereas microinjection of <START=Organic Chemical> AG <END=Organic Chemical> ( 1, 10, 100 pmol / 100 nl ) had no obvious effects on the OXA - induced increase of SBP and HR. Our results indicate that OXA in the RVLM may participate in the central regulation of cardiovascular activities in SIHR, and <START=Gene or Genome> OX1R <END=Gene or Genome> and <START=Gene or Genome> OX2R <END=Gene or Genome> both have important roles in it."}, {"PMID": 23474389, "id": 1, "text": "A series of substituted 3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines has been synthesised and tested in vitro as potential pro-apoptotic Bcl-2-inhibitory anticancer agents.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [24, 82], "name": "3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines", "tok_span": [4, 42], "new_tok_span": [4, 42]}, {"ent_type": "GENE", "char_span": [151, 156], "name": "Bcl-2", "tok_span": [55, 58], "new_tok_span": [60, 63]}], "relation_list": [{"subject": "3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines", "sbj_char_span": [24, 82], "object": "Bcl-2", "obj_char_span": [151, 156], "rel_type": "inhibitor", "sbj_tok_span": [4, 42], "obj_tok_span": [55, 58], "new_sbj_tok_span": [4, 42], "new_obj_tok_span": [60, 63]}], "umls_entity_list": [{"mention": "amines", "char_span": [76, 82], "sem_type": "Organic Chemical", "tok_span": [41, 42], "new_tok_span": [42, 43]}, {"mention": "pro", "char_span": [137, 140], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [52, 53], "new_tok_span": [55, 56]}, {"mention": "Bcl-2", "char_span": [151, 156], "sem_type": "Gene or Genome", "tok_span": [55, 58], "new_tok_span": [60, 63]}, {"mention": "anticancer agents", "char_span": [168, 185], "sem_type": "Pharmacologic Substance", "tok_span": [60, 62], "new_tok_span": [67, 69]}], "new_text": "A series of substituted 3 - ( benzylthio ) - 5 - ( 1H - indol - 3 - yl ) - 4H - 1, 2, 4 - triazol - 4 - <START=Organic Chemical> amines <END=Organic Chemical> has been synthesised and tested in vitro as potential <START=Amino Acid, Peptide, or Protein> pro <END=Amino Acid, Peptide, or Protein> - apoptotic <START=Gene or Genome> Bcl - 2 <END=Gene or Genome> - inhibitory <START=Pharmacologic Substance> anticancer agents <END=Pharmacologic Substance>."}, {"PMID": 23306944, "id": 4, "text": "MC3T3-E1 was cultured as mature osteoblasts and treated with sodium metasilicate (0, 1, 5, 10, 25, 50, and 100 μM) as a source of Si. After 7 days of treatment, 5 and 10 μM of sodium metasilicate significantly increased intracellular alkaline phosphatase activity (p < 0.05) when compared to the control.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [61, 80], "name": "sodium metasilicate", "tok_span": [15, 19], "new_tok_span": [17, 21]}, {"ent_type": "CHEMICAL", "char_span": [130, 132], "name": "Si", "tok_span": [41, 42], "new_tok_span": [43, 44]}, {"ent_type": "CHEMICAL", "char_span": [176, 195], "name": "sodium metasilicate", "tok_span": [55, 59], "new_tok_span": [57, 61]}, {"ent_type": "GENE", "char_span": [234, 254], "name": "alkaline phosphatase", "tok_span": [62, 64], "new_tok_span": [64, 66]}], "relation_list": [{"subject": "sodium metasilicate", "sbj_char_span": [176, 195], "object": "alkaline phosphatase", "obj_char_span": [234, 254], "rel_type": "activator", "sbj_tok_span": [55, 59], "obj_tok_span": [62, 64], "new_sbj_tok_span": [57, 61], "new_obj_tok_span": [64, 66]}], "umls_entity_list": [{"mention": "E1", "char_span": [6, 8], "sem_type": "Gene or Genome", "tok_span": [5, 7], "new_tok_span": [6, 8]}], "new_text": "MC3T3 - <START=Gene or Genome> E1 <END=Gene or Genome> was cultured as mature osteoblasts and treated with sodium metasilicate ( 0, 1, 5, 10, 25, 50, and 100 μM ) as a source of Si. After 7 days of treatment, 5 and 10 μM of sodium metasilicate significantly increased intracellular alkaline phosphatase activity ( p < 0. 05 ) when compared to the control."}, {"PMID": 12531805, "id": 9, "text": "We show that SU11248 (20 mg/kg/d) dramatically regresses FLT3-ITD tumors in the subcutaneous tumor xenograft model and prolongs survival in the bone marrow engraftment model.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [13, 20], "name": "SU11248", "tok_span": [3, 6], "new_tok_span": [3, 6]}, {"ent_type": "GENE", "char_span": [57, 61], "name": "FLT3", "tok_span": [17, 20], "new_tok_span": [17, 20]}], "relation_list": [{"subject": "SU11248", "sbj_char_span": [13, 20], "object": "FLT3", "obj_char_span": [57, 61], "rel_type": "inhibitor", "sbj_tok_span": [3, 6], "obj_tok_span": [17, 20], "new_sbj_tok_span": [3, 6], "new_obj_tok_span": [17, 20]}], "umls_entity_list": [], "new_text": "We show that SU11248 ( 20 mg / kg / d ) dramatically regresses FLT3 - ITD tumors in the subcutaneous tumor xenograft model and prolongs survival in the bone marrow engraftment model."}, {"PMID": 17673606, "id": 2, "text": "Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the hNET expressed in membranes compared with whole cells when competing for [(3)H]nisoxetine (NIS) binding.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [56, 59], "name": "DVS", "tok_span": [7, 9], "new_tok_span": [7, 9]}, {"ent_type": "CHEMICAL", "char_span": [221, 237], "name": "[(3)H]nisoxetine", "tok_span": [42, 52], "new_tok_span": [46, 56]}, {"ent_type": "CHEMICAL", "char_span": [239, 242], "name": "NIS", "tok_span": [53, 55], "new_tok_span": [59, 61]}, {"ent_type": "GENE", "char_span": [148, 152], "name": "hNET", "tok_span": [30, 32], "new_tok_span": [32, 34]}], "relation_list": [{"subject": "[(3)H]nisoxetine", "sbj_char_span": [221, 237], "object": "hNET", "obj_char_span": [148, 152], "rel_type": "regulator", "sbj_tok_span": [42, 52], "obj_tok_span": [30, 32], "new_sbj_tok_span": [46, 56], "new_obj_tok_span": [32, 34]}, {"subject": "NIS", "sbj_char_span": [239, 242], "object": "hNET", "obj_char_span": [148, 152], "rel_type": "regulator", "sbj_tok_span": [53, 55], "obj_tok_span": [30, 32], "new_sbj_tok_span": [59, 61], "new_obj_tok_span": [32, 34]}], "umls_entity_list": [{"mention": "Exp", "char_span": [73, 76], "sem_type": "Gene or Genome", "tok_span": [12, 13], "new_tok_span": [13, 14]}, {"mention": "exp", "char_span": [153, 156], "sem_type": "Gene or Genome", "tok_span": [32, 33], "new_tok_span": [35, 36]}, {"mention": "nisoxetine", "char_span": [227, 237], "sem_type": "Pharmacologic Substance", "tok_span": [48, 52], "new_tok_span": [53, 57]}], "new_text": "Initial evaluation of the pharmacological properties of DVS ( J Pharmacol <START=Gene or Genome> Exp <END=Gene or Genome> Ther 318 : 657 - 665, 2006 ) revealed significantly reduced potency for the hNET <START=Gene or Genome> expressed <END=Gene or Genome> in membranes compared with whole cells when competing for [ ( 3 ) H ] <START=Pharmacologic Substance> nisoxetine <END=Pharmacologic Substance> ( NIS ) binding."}, {"PMID": 23415833, "id": 1, "text": "Profenofos is a direct acting phosphorothioate organophosphorus (OP) pesticide capable of inhibiting β-esterases such as acetylcholinesterase, butyrylcholinesterase, and carboxylesterase.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Profenofos", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"ent_type": "CHEMICAL", "char_span": [30, 46], "name": "phosphorothioate", "tok_span": [8, 13], "new_tok_span": [10, 15]}, {"ent_type": "CHEMICAL", "char_span": [47, 63], "name": "organophosphorus", "tok_span": [13, 16], "new_tok_span": [15, 18]}, {"ent_type": "GENE", "char_span": [101, 112], "name": "β-esterases", "tok_span": [23, 27], "new_tok_span": [25, 29]}, {"ent_type": "GENE", "char_span": [121, 141], "name": "acetylcholinesterase", "tok_span": [29, 32], "new_tok_span": [31, 34]}, {"ent_type": "GENE", "char_span": [143, 164], "name": "butyrylcholinesterase", "tok_span": [33, 39], "new_tok_span": [35, 41]}, {"ent_type": "GENE", "char_span": [170, 186], "name": "carboxylesterase", "tok_span": [41, 44], "new_tok_span": [44, 47]}], "relation_list": [{"subject": "Profenofos", "sbj_char_span": [0, 10], "object": "β-esterases", "obj_char_span": [101, 112], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [23, 27], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [25, 29]}, {"subject": "phosphorothioate", "sbj_char_span": [30, 46], "object": "β-esterases", "obj_char_span": [101, 112], "rel_type": "inhibitor", "sbj_tok_span": [8, 13], "obj_tok_span": [23, 27], "new_sbj_tok_span": [10, 15], "new_obj_tok_span": [25, 29]}, {"subject": "organophosphorus", "sbj_char_span": [47, 63], "object": "β-esterases", "obj_char_span": [101, 112], "rel_type": "inhibitor", "sbj_tok_span": [13, 16], "obj_tok_span": [23, 27], "new_sbj_tok_span": [15, 18], "new_obj_tok_span": [25, 29]}, {"subject": "Profenofos", "sbj_char_span": [0, 10], "object": "acetylcholinesterase", "obj_char_span": [121, 141], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [29, 32], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [31, 34]}, {"subject": "Profenofos", "sbj_char_span": [0, 10], "object": "butyrylcholinesterase", "obj_char_span": [143, 164], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [33, 39], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [35, 41]}, {"subject": "Profenofos", "sbj_char_span": [0, 10], "object": "carboxylesterase", "obj_char_span": [170, 186], "rel_type": "inhibitor", "sbj_tok_span": [0, 4], "obj_tok_span": [41, 44], "new_sbj_tok_span": [1, 5], "new_obj_tok_span": [44, 47]}], "umls_entity_list": [{"mention": "Profenofos", "char_span": [0, 10], "sem_type": "Pharmacologic Substance", "tok_span": [0, 4], "new_tok_span": [1, 5]}, {"mention": "carboxylesterase", "char_span": [170, 186], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [41, 44], "new_tok_span": [44, 47]}], "new_text": "<START=Pharmacologic Substance> Profenofos <END=Pharmacologic Substance> is a direct acting phosphorothioate organophosphorus ( OP ) pesticide capable of inhibiting β - esterases such as acetylcholinesterase, butyrylcholinesterase, and <START=Amino Acid, Peptide, or Protein> carboxylesterase <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23411241, "id": 2, "text": "Oral administration of APP at 250 and 500 mg/kg bw in mice was shown to be as effective as AFP in lowering the CCl(4)-caused increases of serum alanine aminotransferase, aspartate aminotransferase and lactic dehydrogenase activities, and hepatic malondialdehyde level, and antagonising the decreases in antioxidant superoxide dismutase and glutathione peroxidase activities caused by CCl(4) (p<0.05).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [111, 117], "name": "CCl(4)", "tok_span": [27, 32], "new_tok_span": [31, 36]}, {"ent_type": "CHEMICAL", "char_span": [144, 151], "name": "alanine", "tok_span": [37, 38], "new_tok_span": [44, 45]}, {"ent_type": "CHEMICAL", "char_span": [170, 179], "name": "aspartate", "tok_span": [41, 43], "new_tok_span": [49, 51]}, {"ent_type": "CHEMICAL", "char_span": [246, 261], "name": "malondialdehyde", "tok_span": [52, 56], "new_tok_span": [61, 65]}, {"ent_type": "CHEMICAL", "char_span": [315, 325], "name": "superoxide", "tok_span": [65, 66], "new_tok_span": [78, 79]}, {"ent_type": "CHEMICAL", "char_span": [340, 351], "name": "glutathione", "tok_span": [68, 69], "new_tok_span": [82, 83]}, {"ent_type": "CHEMICAL", "char_span": [384, 390], "name": "CCl(4)", "tok_span": [73, 78], "new_tok_span": [89, 94]}, {"ent_type": "GENE", "char_span": [138, 168], "name": "serum alanine aminotransferase", "tok_span": [36, 40], "new_tok_span": [43, 47]}, {"ent_type": "GENE", "char_span": [170, 196], "name": "aspartate aminotransferase", "tok_span": [41, 45], "new_tok_span": [49, 53]}, {"ent_type": "GENE", "char_span": [201, 221], "name": "lactic dehydrogenase", "tok_span": [46, 48], "new_tok_span": [54, 56]}, {"ent_type": "GENE", "char_span": [315, 335], "name": "superoxide dismutase", "tok_span": [65, 67], "new_tok_span": [78, 80]}, {"ent_type": "GENE", "char_span": [340, 362], "name": "glutathione peroxidase", "tok_span": [68, 70], "new_tok_span": [82, 84]}], "relation_list": [{"subject": "CCl(4)", "sbj_char_span": [111, 117], "object": "serum alanine aminotransferase", "obj_char_span": [138, 168], "rel_type": "activator", "sbj_tok_span": [27, 32], "obj_tok_span": [36, 40], "new_sbj_tok_span": [31, 36], "new_obj_tok_span": [43, 47]}, {"subject": "CCl(4)", "sbj_char_span": [111, 117], "object": "aspartate aminotransferase", "obj_char_span": [170, 196], "rel_type": "activator", "sbj_tok_span": [27, 32], "obj_tok_span": [41, 45], "new_sbj_tok_span": [31, 36], "new_obj_tok_span": [49, 53]}, {"subject": "CCl(4)", "sbj_char_span": [111, 117], "object": "lactic dehydrogenase", "obj_char_span": [201, 221], "rel_type": "activator", "sbj_tok_span": [27, 32], "obj_tok_span": [46, 48], "new_sbj_tok_span": [31, 36], "new_obj_tok_span": [54, 56]}, {"subject": "CCl(4)", "sbj_char_span": [384, 390], "object": "superoxide dismutase", "obj_char_span": [315, 335], "rel_type": "inhibitor", "sbj_tok_span": [73, 78], "obj_tok_span": [65, 67], "new_sbj_tok_span": [89, 94], "new_obj_tok_span": [78, 80]}, {"subject": "CCl(4)", "sbj_char_span": [384, 390], "object": "glutathione peroxidase", "obj_char_span": [340, 362], "rel_type": "inhibitor", "sbj_tok_span": [73, 78], "obj_tok_span": [68, 70], "new_sbj_tok_span": [89, 94], "new_obj_tok_span": [82, 84]}], "umls_entity_list": [{"mention": "AFP", "char_span": [91, 94], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 24], "new_tok_span": [23, 25]}, {"mention": "CCl", "char_span": [111, 114], "sem_type": "Organic Chemical", "tok_span": [27, 29], "new_tok_span": [31, 33]}, {"mention": "CCl", "char_span": [384, 387], "sem_type": "Organic Chemical", "tok_span": [73, 75], "new_tok_span": [89, 91]}, {"mention": "serum alanine aminotransferase", "char_span": [138, 168], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 40], "new_tok_span": [43, 47]}, {"mention": "CCl", "char_span": [111, 114], "sem_type": "Gene or Genome", "tok_span": [27, 29], "new_tok_span": [31, 33]}, {"mention": "CCl", "char_span": [384, 387], "sem_type": "Gene or Genome", "tok_span": [73, 75], "new_tok_span": [89, 91]}, {"mention": "malondialdehyde", "char_span": [246, 261], "sem_type": "Organic Chemical", "tok_span": [52, 56], "new_tok_span": [61, 65]}, {"mention": "antioxidant", "char_span": [303, 314], "sem_type": "Pharmacologic Substance", "tok_span": [64, 65], "new_tok_span": [75, 76]}, {"mention": "superoxide dismutase", "char_span": [315, 335], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [65, 67], "new_tok_span": [78, 80]}], "new_text": "Oral administration of APP at 250 and 500 mg / kg bw in mice was shown to be as effective as <START=Amino Acid, Peptide, or Protein> AFP <END=Amino Acid, Peptide, or Protein> in lowering the <START=Organic Chemical> <START=Gene or Genome> CCl <END=Organic Chemical> <END=Gene or Genome> ( 4 ) - caused increases of <START=Amino Acid, Peptide, or Protein> serum alanine aminotransferase <END=Amino Acid, Peptide, or Protein>, aspartate aminotransferase and lactic dehydrogenase activities, and hepatic <START=Organic Chemical> malondialdehyde <END=Organic Chemical> level, and antagonising the decreases in <START=Pharmacologic Substance> antioxidant <END=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> superoxide dismutase <END=Amino Acid, Peptide, or Protein> and glutathione peroxidase activities caused by <START=Organic Chemical> <START=Gene or Genome> CCl <END=Organic Chemical> <END=Gene or Genome> ( 4 ) ( p < 0. 05 )."}, {"PMID": 22064666, "id": 2, "text": "Although genetic polymorphisms in the endothelial nitric oxide synthase (eNOS) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [50, 62], "name": "nitric oxide", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"ent_type": "CHEMICAL", "char_span": [106, 108], "name": "NO", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"ent_type": "CHEMICAL", "char_span": [216, 226], "name": "sildenafil", "tok_span": [33, 36], "new_tok_span": [35, 38]}, {"ent_type": "GENE", "char_span": [38, 71], "name": "endothelial nitric oxide synthase", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [73, 77], "name": "eNOS", "tok_span": [10, 11], "new_tok_span": [12, 13]}, {"ent_type": "GENE", "char_span": [158, 162], "name": "eNOS", "tok_span": [25, 26], "new_tok_span": [27, 28]}], "relation_list": [{"subject": "NO", "sbj_char_span": [106, 108], "object": "endothelial nitric oxide synthase", "obj_char_span": [38, 71], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [5, 9], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [6, 10]}, {"subject": "NO", "sbj_char_span": [106, 108], "object": "eNOS", "obj_char_span": [73, 77], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [10, 11], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [12, 13]}], "umls_entity_list": [{"mention": "endothelial nitric oxide synthase", "char_span": [38, 71], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 9], "new_tok_span": [6, 10]}], "new_text": "Although genetic polymorphisms in the <START=Amino Acid, Peptide, or Protein> endothelial nitric oxide synthase <END=Amino Acid, Peptide, or Protein> ( eNOS ) gene may impair endogenous NO formation, there is little information about how eNOS polymorphisms and haplotypes affect the responses to sildenafil."}, {"PMID": 17112405, "id": 5, "text": "Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the CysLT1 receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 10], "name": "Pranlukast", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "CHEMICAL", "char_span": [12, 20], "name": "ketamine", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [25, 34], "name": "edaravone", "tok_span": [8, 12], "new_tok_span": [9, 13]}, {"ent_type": "CHEMICAL", "char_span": [45, 49], "name": "NMDA", "tok_span": [13, 14], "new_tok_span": [16, 17]}, {"ent_type": "CHEMICAL", "char_span": [66, 76], "name": "pranlukast", "tok_span": [18, 23], "new_tok_span": [22, 27]}, {"ent_type": "CHEMICAL", "char_span": [93, 101], "name": "ketamine", "tok_span": [32, 33], "new_tok_span": [36, 37]}, {"ent_type": "GENE", "char_span": [146, 161], "name": "CysLT1 receptor", "tok_span": [39, 43], "new_tok_span": [43, 47]}], "relation_list": [{"subject": "ketamine", "sbj_char_span": [93, 101], "object": "CysLT1 receptor", "obj_char_span": [146, 161], "rel_type": "regulator", "sbj_tok_span": [32, 33], "obj_tok_span": [39, 43], "new_sbj_tok_span": [36, 37], "new_obj_tok_span": [43, 47]}, {"subject": "pranlukast", "sbj_char_span": [66, 76], "object": "CysLT1 receptor", "obj_char_span": [146, 161], "rel_type": "regulator", "sbj_tok_span": [18, 23], "obj_tok_span": [39, 43], "new_sbj_tok_span": [22, 27], "new_obj_tok_span": [43, 47]}], "umls_entity_list": [{"mention": "edaravone", "char_span": [25, 34], "sem_type": "Pharmacologic Substance", "tok_span": [8, 12], "new_tok_span": [9, 13]}, {"mention": "NMDA", "char_span": [45, 49], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [13, 14], "new_tok_span": [16, 17]}], "new_text": "Pranlukast, ketamine and <START=Pharmacologic Substance> edaravone <END=Pharmacologic Substance> decreased <START=Amino Acid, Peptide, or Protein> NMDA <END=Amino Acid, Peptide, or Protein> - induced injury ; pranlukast ( 0. 1 mg / kg ) and ketamine inhibited the upregulated expression of the CysLT1 receptor."}, {"PMID": 23234246, "id": 0, "text": "Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [27, 29], "name": "Re", "tok_span": [5, 6], "new_tok_span": [7, 8]}, {"ent_type": "CHEMICAL", "char_span": [30, 35], "name": "99mTc", "tok_span": [7, 10], "new_tok_span": [9, 12]}, {"ent_type": "CHEMICAL", "char_span": [44, 62], "name": "benzenesulfonamide", "tok_span": [12, 17], "new_tok_span": [15, 20]}, {"ent_type": "GENE", "char_span": [63, 84], "name": "carbonic anhydrase IX", "tok_span": [17, 23], "new_tok_span": [23, 29]}], "relation_list": [{"subject": "99mTc", "sbj_char_span": [30, 35], "object": "carbonic anhydrase IX", "obj_char_span": [63, 84], "rel_type": "inhibitor", "sbj_tok_span": [7, 10], "obj_tok_span": [17, 23], "new_sbj_tok_span": [9, 12], "new_obj_tok_span": [23, 29]}, {"subject": "Re", "sbj_char_span": [27, 29], "object": "carbonic anhydrase IX", "obj_char_span": [63, 84], "rel_type": "inhibitor", "sbj_tok_span": [5, 6], "obj_tok_span": [17, 23], "new_sbj_tok_span": [7, 8], "new_obj_tok_span": [23, 29]}, {"subject": "benzenesulfonamide", "sbj_char_span": [44, 62], "object": "carbonic anhydrase IX", "obj_char_span": [63, 84], "rel_type": "inhibitor", "sbj_tok_span": [12, 17], "obj_tok_span": [17, 23], "new_sbj_tok_span": [15, 20], "new_obj_tok_span": [23, 29]}], "umls_entity_list": [{"mention": "SAR", "char_span": [14, 17], "sem_type": "Gene or Genome", "tok_span": [2, 3], "new_tok_span": [3, 4]}, {"mention": "benzenesulfonamide", "char_span": [44, 62], "sem_type": "Pharmacologic Substance", "tok_span": [12, 17], "new_tok_span": [15, 20]}, {"mention": "carbonic anhydrase IX", "char_span": [63, 84], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 23], "new_tok_span": [23, 29]}, {"mention": "carbonic", "char_span": [63, 71], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 19], "new_tok_span": [23, 25]}, {"mention": "IX", "char_span": [82, 84], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 23], "new_tok_span": [30, 31]}], "new_text": "Synthesis and <START=Gene or Genome> SAR <END=Gene or Genome> of novel Re / 99mTc - labeled <START=Pharmacologic Substance> benzenesulfonamide <END=Pharmacologic Substance> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> carbonic <END=Amino Acid, Peptide, or Protein> anhydrase <START=Amino Acid, Peptide, or Protein> IX <END=Amino Acid, Peptide, or Protein> <END=Amino Acid, Peptide, or Protein> inhibitors for molecular imaging of tumor hypoxia."}, {"PMID": 23358258, "id": 1, "text": "A series of xanthine derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4) for the treatment of type 2 diabetes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [12, 20], "name": "xanthine", "tok_span": [3, 6], "new_tok_span": [5, 8]}, {"ent_type": "CHEMICAL", "char_span": [44, 53], "name": "methylene", "tok_span": [10, 12], "new_tok_span": [15, 17]}, {"ent_type": "CHEMICAL", "char_span": [84, 92], "name": "xanthine", "tok_span": [18, 21], "new_tok_span": [25, 28]}, {"ent_type": "GENE", "char_span": [149, 171], "name": "dipeptidyl peptidase 4", "tok_span": [29, 36], "new_tok_span": [37, 44]}, {"ent_type": "GENE", "char_span": [173, 178], "name": "DPP-4", "tok_span": [37, 40], "new_tok_span": [45, 48]}], "relation_list": [{"subject": "xanthine", "sbj_char_span": [12, 20], "object": "dipeptidyl peptidase 4", "obj_char_span": [149, 171], "rel_type": "inhibitor", "sbj_tok_span": [3, 6], "obj_tok_span": [29, 36], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [37, 44]}, {"subject": "xanthine", "sbj_char_span": [12, 20], "object": "DPP-4", "obj_char_span": [173, 178], "rel_type": "inhibitor", "sbj_tok_span": [3, 6], "obj_tok_span": [37, 40], "new_sbj_tok_span": [5, 8], "new_obj_tok_span": [45, 48]}, {"subject": "xanthine", "sbj_char_span": [84, 92], "object": "dipeptidyl peptidase 4", "obj_char_span": [149, 171], "rel_type": "inhibitor", "sbj_tok_span": [18, 21], "obj_tok_span": [29, 36], "new_sbj_tok_span": [25, 28], "new_obj_tok_span": [37, 44]}, {"subject": "xanthine", "sbj_char_span": [84, 92], "object": "DPP-4", "obj_char_span": [173, 178], "rel_type": "inhibitor", "sbj_tok_span": [18, 21], "obj_tok_span": [37, 40], "new_sbj_tok_span": [25, 28], "new_obj_tok_span": [45, 48]}], "umls_entity_list": [{"mention": "xanthine", "char_span": [12, 20], "sem_type": "Organic Chemical", "tok_span": [3, 6], "new_tok_span": [5, 8]}, {"mention": "xanthine", "char_span": [84, 92], "sem_type": "Organic Chemical", "tok_span": [18, 21], "new_tok_span": [25, 28]}, {"mention": "xanthine derivatives", "char_span": [12, 32], "sem_type": "Pharmacologic Substance", "tok_span": [3, 7], "new_tok_span": [5, 9]}, {"mention": "methylene", "char_span": [44, 53], "sem_type": "Pharmacologic Substance", "tok_span": [10, 12], "new_tok_span": [15, 17]}], "new_text": "A series of <START=Organic Chemical> <START=Pharmacologic Substance> xanthine <END=Organic Chemical> derivatives <END=Pharmacologic Substance> in which a <START=Pharmacologic Substance> methylene <END=Pharmacologic Substance> was inserted at position 8 of <START=Organic Chemical> xanthine <END=Organic Chemical> scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 ( DPP - 4 ) for the treatment of type 2 diabetes."}, {"PMID": 23567241, "id": 3, "text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ERα and ERβ agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 17], "name": "parabens", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [30, 35], "name": "alkyl", "tok_span": [6, 7], "new_tok_span": [9, 10]}, {"ent_type": "CHEMICAL", "char_span": [77, 90], "name": "heptylparaben", "tok_span": [18, 23], "new_tok_span": [23, 28]}, {"ent_type": "CHEMICAL", "char_span": [100, 113], "name": "pentylparaben", "tok_span": [28, 32], "new_tok_span": [34, 38]}, {"ent_type": "GENE", "char_span": [142, 145], "name": "ERα", "tok_span": [40, 42], "new_tok_span": [48, 50]}, {"ent_type": "GENE", "char_span": [150, 153], "name": "ERβ", "tok_span": [43, 45], "new_tok_span": [51, 53]}], "relation_list": [{"subject": "parabens", "sbj_char_span": [9, 17], "object": "ERα", "obj_char_span": [142, 145], "rel_type": "agonist or antagonist", "sbj_tok_span": [2, 4], "obj_tok_span": [40, 42], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [48, 50]}, {"subject": "alkyl", "sbj_char_span": [30, 35], "object": "ERα", "obj_char_span": [142, 145], "rel_type": "agonist or antagonist", "sbj_tok_span": [6, 7], "obj_tok_span": [40, 42], "new_sbj_tok_span": [9, 10], "new_obj_tok_span": [48, 50]}, {"subject": "heptylparaben", "sbj_char_span": [77, 90], "object": "ERα", "obj_char_span": [142, 145], "rel_type": "agonist or antagonist", "sbj_tok_span": [18, 23], "obj_tok_span": [40, 42], "new_sbj_tok_span": [23, 28], "new_obj_tok_span": [48, 50]}, {"subject": "pentylparaben", "sbj_char_span": [100, 113], "object": "ERα", "obj_char_span": [142, 145], "rel_type": "agonist or antagonist", "sbj_tok_span": [28, 32], "obj_tok_span": [40, 42], "new_sbj_tok_span": [34, 38], "new_obj_tok_span": [48, 50]}, {"subject": "parabens", "sbj_char_span": [9, 17], "object": "ERβ", "obj_char_span": [150, 153], "rel_type": "agonist or antagonist", "sbj_tok_span": [2, 4], "obj_tok_span": [43, 45], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [51, 53]}, {"subject": "alkyl", "sbj_char_span": [30, 35], "object": "ERβ", "obj_char_span": [150, 153], "rel_type": "agonist or antagonist", "sbj_tok_span": [6, 7], "obj_tok_span": [43, 45], "new_sbj_tok_span": [9, 10], "new_obj_tok_span": [51, 53]}, {"subject": "heptylparaben", "sbj_char_span": [77, 90], "object": "ERβ", "obj_char_span": [150, 153], "rel_type": "agonist or antagonist", "sbj_tok_span": [18, 23], "obj_tok_span": [43, 45], "new_sbj_tok_span": [23, 28], "new_obj_tok_span": [51, 53]}, {"subject": "pentylparaben", "sbj_char_span": [100, 113], "object": "ERβ", "obj_char_span": [150, 153], "rel_type": "agonist or antagonist", "sbj_tok_span": [28, 32], "obj_tok_span": [43, 45], "new_sbj_tok_span": [34, 38], "new_obj_tok_span": [51, 53]}], "umls_entity_list": [{"mention": "parabens", "char_span": [9, 17], "sem_type": "Pharmacologic Substance", "tok_span": [2, 4], "new_tok_span": [3, 5]}, {"mention": "alkyl", "char_span": [30, 35], "sem_type": "Organic Chemical", "tok_span": [6, 7], "new_tok_span": [9, 10]}, {"mention": "alkyl", "char_span": [281, 286], "sem_type": "Organic Chemical", "tok_span": [78, 79], "new_tok_span": [89, 90]}, {"mention": "heptylparaben", "char_span": [77, 90], "sem_type": "Organic Chemical", "tok_span": [18, 23], "new_tok_span": [23, 28]}, {"mention": "C5", "char_span": [115, 117], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [33, 35], "new_tok_span": [40, 42]}, {"mention": "gonist", "char_span": [155, 161], "sem_type": "Pharmacologic Substance", "tok_span": [45, 46], "new_tok_span": [54, 55]}], "new_text": "Among 12 <START=Pharmacologic Substance> parabens <END=Pharmacologic Substance> with linear <START=Organic Chemical> alkyl <END=Organic Chemical> chains ranging in length from C1 to C12, <START=Organic Chemical> heptylparaben <END=Organic Chemical> ( C7 ) and pentylparaben ( <START=Amino Acid, Peptide, or Protein> C5 <END=Amino Acid, Peptide, or Protein> ) showed the most potent ERα and ERβ <START=Pharmacologic Substance> agonist <END=Pharmacologic Substance>ic activity in the order of 10 ( - 7 ) M and 10 ( - 8 ) M, respectively, and the activities decreased in a stepwise manner as the <START=Organic Chemical> alkyl <END=Organic Chemical> chain was shortened to C1 or lengthened to C12."}, {"PMID": 23195954, "id": 7, "text": "Calnuc, therefore, exists dynamically in two different forms, (i) as a Ca(2+)-binding protein in Zn(2+)-bound form and (ii) as a protease in Zn(2+)-free form, commissioning it to perform multiple functions.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [71, 77], "name": "Ca(2+)", "tok_span": [18, 23], "new_tok_span": [18, 23]}, {"ent_type": "CHEMICAL", "char_span": [97, 103], "name": "Zn(2+)", "tok_span": [27, 32], "new_tok_span": [29, 34]}, {"ent_type": "CHEMICAL", "char_span": [141, 147], "name": "Zn(2+)", "tok_span": [43, 48], "new_tok_span": [45, 50]}, {"ent_type": "GENE", "char_span": [0, 6], "name": "Calnuc", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "GENE", "char_span": [71, 93], "name": "Ca(2+)-binding protein", "tok_span": [18, 26], "new_tok_span": [18, 26]}, {"ent_type": "GENE", "char_span": [129, 137], "name": "protease", "tok_span": [41, 42], "new_tok_span": [43, 44]}], "relation_list": [{"subject": "Zn(2+)", "sbj_char_span": [97, 103], "object": "Calnuc", "obj_char_span": [0, 6], "rel_type": "regulator", "sbj_tok_span": [27, 32], "obj_tok_span": [0, 3], "new_sbj_tok_span": [29, 34], "new_obj_tok_span": [0, 3]}], "umls_entity_list": [{"mention": "binding protein", "char_span": [78, 93], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 26], "new_tok_span": [25, 27]}], "new_text": "Calnuc, therefore, exists dynamically in two different forms, ( i ) as a Ca ( 2 + ) - <START=Amino Acid, Peptide, or Protein> binding protein <END=Amino Acid, Peptide, or Protein> in Zn ( 2 + ) - bound form and ( ii ) as a protease in Zn ( 2 + ) - free form, commissioning it to perform multiple functions."}, {"PMID": 23260346, "id": 3, "text": "Several inhibitors of Lp-PLA(2) have been described, including darapladib, which is currently in phase 3 clinical development for the treatment of atherosclerosis.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [63, 73], "name": "darapladib", "tok_span": [14, 18], "new_tok_span": [17, 21]}, {"ent_type": "GENE", "char_span": [22, 31], "name": "Lp-PLA(2)", "tok_span": [3, 9], "new_tok_span": [4, 10]}], "relation_list": [{"subject": "darapladib", "sbj_char_span": [63, 73], "object": "Lp-PLA(2)", "obj_char_span": [22, 31], "rel_type": "inhibitor", "sbj_tok_span": [14, 18], "obj_tok_span": [3, 9], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [4, 10]}], "umls_entity_list": [{"mention": "Lp-PLA(2)", "char_span": [22, 31], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [3, 9], "new_tok_span": [4, 10]}, {"mention": "darapladib", "char_span": [63, 73], "sem_type": "Pharmacologic Substance", "tok_span": [14, 18], "new_tok_span": [17, 21]}], "new_text": "Several inhibitors of <START=Amino Acid, Peptide, or Protein> Lp - PLA ( 2 ) <END=Amino Acid, Peptide, or Protein> have been described, including <START=Pharmacologic Substance> darapladib <END=Pharmacologic Substance>, which is currently in phase 3 clinical development for the treatment of atherosclerosis."}, {"PMID": 16973691, "id": 7, "text": "At 3 mmol kg(-1), all agonists induced apoptosis (fenoterol, 1.1 +/- 0.1%; isoprenaline, 0.9 +/- 0.8%; and clenbuterol, 0.4 +/- 0.07%; P < 0.05). beta(1)-Adrenoceptor antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [50, 59], "name": "fenoterol", "tok_span": [14, 17], "new_tok_span": [14, 17]}, {"ent_type": "CHEMICAL", "char_span": [75, 87], "name": "isoprenaline", "tok_span": [29, 32], "new_tok_span": [29, 32]}, {"ent_type": "CHEMICAL", "char_span": [107, 118], "name": "clenbuterol", "tok_span": [45, 50], "new_tok_span": [46, 51]}, {"ent_type": "CHEMICAL", "char_span": [192, 202], "name": "bisoprolol", "tok_span": [88, 91], "new_tok_span": [90, 93]}, {"ent_type": "CHEMICAL", "char_span": [277, 288], "name": "clenbuterol", "tok_span": [111, 116], "new_tok_span": [114, 119]}, {"ent_type": "GENE", "char_span": [146, 166], "name": "beta(1)-Adrenoceptor", "tok_span": [69, 78], "new_tok_span": [71, 80]}, {"ent_type": "GENE", "char_span": [352, 362], "name": "beta(2)-AR", "tok_span": [134, 140], "new_tok_span": [138, 144]}], "relation_list": [{"subject": "bisoprolol", "sbj_char_span": [192, 202], "object": "beta(1)-Adrenoceptor", "obj_char_span": [146, 166], "rel_type": "agonist or antagonist", "sbj_tok_span": [88, 91], "obj_tok_span": [69, 78], "new_sbj_tok_span": [90, 93], "new_obj_tok_span": [71, 80]}], "umls_entity_list": [{"mention": "clenbuterol", "char_span": [107, 118], "sem_type": "Pharmacologic Substance", "tok_span": [45, 50], "new_tok_span": [46, 51]}, {"mention": "clenbuterol", "char_span": [277, 288], "sem_type": "Pharmacologic Substance", "tok_span": [111, 116], "new_tok_span": [114, 119]}], "new_text": "At 3 mmol kg ( - 1 ), all agonists induced apoptosis ( fenoterol, 1. 1 + / - 0. 1 % ; isoprenaline, 0. 9 + / - 0. 8 % ; and <START=Pharmacologic Substance> clenbuterol <END=Pharmacologic Substance>, 0. 4 + / - 0. 07 % ; P < 0. 05 ). beta ( 1 ) - Adrenoceptor antagonism ( 10 mg kg ( - 1 ) bisoprolol ) prevented 92 % ( P < 0. 05 ) of apoptosis induced by all three agonists, but <START=Pharmacologic Substance> clenbuterol <END=Pharmacologic Substance> - induced apoptosis could also be prevented by 96 % ( P < 0. 05 ) by beta ( 2 ) - AR antagonism ( 10 mg kg ( - 1 ) ICI 118 551 )."}, {"PMID": 12063169, "id": 5, "text": "The OTA uptakes were inhibited by several substrates for the OATs. Probenecid, piroxicam, octanoate and citrinin inhibited OTA uptake by hOAT4 in a competitive manner (K(i)=44.4-336.4 microM), with the following order of potency: probenecid > piroxicam > octanoate >citrinin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [4, 7], "name": "OTA", "tok_span": [1, 3], "new_tok_span": [1, 3]}, {"ent_type": "CHEMICAL", "char_span": [67, 77], "name": "Probenecid", "tok_span": [15, 19], "new_tok_span": [17, 21]}, {"ent_type": "CHEMICAL", "char_span": [79, 88], "name": "piroxicam", "tok_span": [20, 24], "new_tok_span": [22, 26]}, {"ent_type": "CHEMICAL", "char_span": [90, 99], "name": "octanoate", "tok_span": [25, 28], "new_tok_span": [28, 31]}, {"ent_type": "CHEMICAL", "char_span": [104, 112], "name": "citrinin", "tok_span": [29, 31], "new_tok_span": [34, 36]}, {"ent_type": "CHEMICAL", "char_span": [123, 126], "name": "OTA", "tok_span": [32, 34], "new_tok_span": [38, 40]}, {"ent_type": "CHEMICAL", "char_span": [230, 240], "name": "probenecid", "tok_span": [68, 71], "new_tok_span": [74, 77]}, {"ent_type": "CHEMICAL", "char_span": [243, 252], "name": "piroxicam", "tok_span": [72, 76], "new_tok_span": [78, 82]}, {"ent_type": "CHEMICAL", "char_span": [255, 264], "name": "octanoate", "tok_span": [77, 80], "new_tok_span": [84, 87]}, {"ent_type": "CHEMICAL", "char_span": [266, 274], "name": "citrinin", "tok_span": [81, 83], "new_tok_span": [90, 92]}, {"ent_type": "GENE", "char_span": [61, 65], "name": "OATs", "tok_span": [12, 14], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [137, 142], "name": "hOAT4", "tok_span": [36, 40], "new_tok_span": [42, 46]}], "relation_list": [{"subject": "OTA", "sbj_char_span": [4, 7], "object": "OATs", "obj_char_span": [61, 65], "rel_type": "product or substrate", "sbj_tok_span": [1, 3], "obj_tok_span": [12, 14], "new_sbj_tok_span": [1, 3], "new_obj_tok_span": [13, 15]}, {"subject": "OTA", "sbj_char_span": [123, 126], "object": "hOAT4", "obj_char_span": [137, 142], "rel_type": "product or substrate", "sbj_tok_span": [32, 34], "obj_tok_span": [36, 40], "new_sbj_tok_span": [38, 40], "new_obj_tok_span": [42, 46]}, {"subject": "Probenecid", "sbj_char_span": [67, 77], "object": "hOAT4", "obj_char_span": [137, 142], "rel_type": "regulator", "sbj_tok_span": [15, 19], "obj_tok_span": [36, 40], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [42, 46]}, {"subject": "piroxicam", "sbj_char_span": [79, 88], "object": "hOAT4", "obj_char_span": [137, 142], "rel_type": "regulator", "sbj_tok_span": [20, 24], "obj_tok_span": [36, 40], "new_sbj_tok_span": [22, 26], "new_obj_tok_span": [42, 46]}, {"subject": "octanoate", "sbj_char_span": [90, 99], "object": "hOAT4", "obj_char_span": [137, 142], "rel_type": "regulator", "sbj_tok_span": [25, 28], "obj_tok_span": [36, 40], "new_sbj_tok_span": [28, 31], "new_obj_tok_span": [42, 46]}, {"subject": "citrinin", "sbj_char_span": [104, 112], "object": "hOAT4", "obj_char_span": [137, 142], "rel_type": "regulator", "sbj_tok_span": [29, 31], "obj_tok_span": [36, 40], "new_sbj_tok_span": [34, 36], "new_obj_tok_span": [42, 46]}, {"subject": "probenecid", "sbj_char_span": [230, 240], "object": "hOAT4", "obj_char_span": [137, 142], "rel_type": "regulator", "sbj_tok_span": [68, 71], "obj_tok_span": [36, 40], "new_sbj_tok_span": [74, 77], "new_obj_tok_span": [42, 46]}, {"subject": "piroxicam", "sbj_char_span": [243, 252], "object": "hOAT4", "obj_char_span": [137, 142], "rel_type": "regulator", "sbj_tok_span": [72, 76], "obj_tok_span": [36, 40], "new_sbj_tok_span": [78, 82], "new_obj_tok_span": [42, 46]}, {"subject": "octanoate", "sbj_char_span": [255, 264], "object": "hOAT4", "obj_char_span": [137, 142], "rel_type": "regulator", "sbj_tok_span": [77, 80], "obj_tok_span": [36, 40], "new_sbj_tok_span": [84, 87], "new_obj_tok_span": [42, 46]}, {"subject": "citrinin", "sbj_char_span": [266, 274], "object": "hOAT4", "obj_char_span": [137, 142], "rel_type": "regulator", "sbj_tok_span": [81, 83], "obj_tok_span": [36, 40], "new_sbj_tok_span": [90, 92], "new_obj_tok_span": [42, 46]}], "umls_entity_list": [{"mention": "OATs", "char_span": [61, 65], "sem_type": "Pharmacologic Substance", "tok_span": [12, 14], "new_tok_span": [13, 15]}, {"mention": "octanoate", "char_span": [90, 99], "sem_type": "Pharmacologic Substance", "tok_span": [25, 28], "new_tok_span": [28, 31]}, {"mention": "octanoate", "char_span": [255, 264], "sem_type": "Pharmacologic Substance", "tok_span": [77, 80], "new_tok_span": [84, 87]}, {"mention": "citrinin", "char_span": [104, 112], "sem_type": "Organic Chemical", "tok_span": [29, 31], "new_tok_span": [34, 36]}, {"mention": "citrinin", "char_span": [266, 274], "sem_type": "Organic Chemical", "tok_span": [81, 83], "new_tok_span": [90, 92]}], "new_text": "The OTA uptakes were inhibited by several substrates for the <START=Pharmacologic Substance> OATs <END=Pharmacologic Substance>. Probenecid, piroxicam, <START=Pharmacologic Substance> octanoate <END=Pharmacologic Substance> and <START=Organic Chemical> citrinin <END=Organic Chemical> inhibited OTA uptake by hOAT4 in a competitive manner ( K ( i ) = 44. 4 - 336. 4 microM ), with the following order of potency : probenecid > piroxicam > <START=Pharmacologic Substance> octanoate <END=Pharmacologic Substance> > <START=Organic Chemical> citrinin <END=Organic Chemical>."}, {"PMID": 17442055, "id": 1, "text": "The tryptophan metabolite kynurenic acid (KYNA), which is produced enzymatically by the irreversible transamination of l-kynurenine, is an antagonist of alpha7 nicotinic and NMDA receptors and may thus modulate cholinergic and glutamatergic neurotransmission.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [119, 131], "name": "l-kynurenine", "tok_span": [24, 30], "new_tok_span": [28, 34]}, {"ent_type": "CHEMICAL", "char_span": [174, 178], "name": "NMDA", "tok_span": [40, 41], "new_tok_span": [47, 48]}, {"ent_type": "CHEMICAL", "char_span": [227, 240], "name": "glutamatergic", "tok_span": [48, 51], "new_tok_span": [58, 61]}, {"ent_type": "CHEMICAL", "char_span": [26, 40], "name": "kynurenic acid", "tok_span": [3, 8], "new_tok_span": [6, 11]}, {"ent_type": "CHEMICAL", "char_span": [4, 14], "name": "tryptophan", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"ent_type": "CHEMICAL", "char_span": [42, 46], "name": "KYNA", "tok_span": [9, 11], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [153, 188], "name": "alpha7 nicotinic and NMDA receptors", "tok_span": [35, 42], "new_tok_span": [41, 48]}], "relation_list": [{"subject": "kynurenic acid", "sbj_char_span": [26, 40], "object": "alpha7 nicotinic and NMDA receptors", "obj_char_span": [153, 188], "rel_type": "agonist or antagonist", "sbj_tok_span": [3, 8], "obj_tok_span": [35, 42], "new_sbj_tok_span": [6, 11], "new_obj_tok_span": [41, 48]}, {"subject": "KYNA", "sbj_char_span": [42, 46], "object": "alpha7 nicotinic and NMDA receptors", "obj_char_span": [153, 188], "rel_type": "agonist or antagonist", "sbj_tok_span": [9, 11], "obj_tok_span": [35, 42], "new_sbj_tok_span": [13, 15], "new_obj_tok_span": [41, 48]}], "umls_entity_list": [{"mention": "tryptophan", "char_span": [4, 14], "sem_type": "Organic Chemical", "tok_span": [1, 2], "new_tok_span": [2, 3]}, {"mention": "kynurenic", "char_span": [26, 35], "sem_type": "Pharmacologic Substance", "tok_span": [3, 7], "new_tok_span": [6, 10]}, {"mention": "kynurenine", "char_span": [121, 131], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 30], "new_tok_span": [31, 35]}, {"mention": "NMDA receptors", "char_span": [174, 188], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [40, 42], "new_tok_span": [47, 49]}, {"mention": "cholinergic", "char_span": [211, 222], "sem_type": "Pharmacologic Substance", "tok_span": [46, 47], "new_tok_span": [55, 56]}], "new_text": "The <START=Organic Chemical> tryptophan <END=Organic Chemical> metabolite <START=Pharmacologic Substance> kynurenic <END=Pharmacologic Substance> acid ( KYNA ), which is produced enzymatically by the irreversible transamination of l - <START=Amino Acid, Peptide, or Protein> kynurenine <END=Amino Acid, Peptide, or Protein>, is an antagonist of alpha7 nicotinic and <START=Amino Acid, Peptide, or Protein> NMDA receptors <END=Amino Acid, Peptide, or Protein> and may thus modulate <START=Pharmacologic Substance> cholinergic <END=Pharmacologic Substance> and glutamatergic neurotransmission."}, {"PMID": 12601049, "id": 3, "text": "To determine the involvement of glucocorticoid receptor in the observed effects of budesonide, secretion and mRNA expression studies were also performed in the presence of a glucocorticoid receptor antagonist (RU486).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [83, 93], "name": "budesonide", "tok_span": [12, 16], "new_tok_span": [13, 17]}, {"ent_type": "CHEMICAL", "char_span": [210, 215], "name": "RU486", "tok_span": [34, 37], "new_tok_span": [37, 40]}, {"ent_type": "GENE", "char_span": [32, 55], "name": "glucocorticoid receptor", "tok_span": [5, 7], "new_tok_span": [5, 7]}, {"ent_type": "GENE", "char_span": [174, 197], "name": "glucocorticoid receptor", "tok_span": [30, 32], "new_tok_span": [32, 34]}], "relation_list": [{"subject": "RU486", "sbj_char_span": [210, 215], "object": "glucocorticoid receptor", "obj_char_span": [174, 197], "rel_type": "agonist or antagonist", "sbj_tok_span": [34, 37], "obj_tok_span": [30, 32], "new_sbj_tok_span": [37, 40], "new_obj_tok_span": [32, 34]}], "umls_entity_list": [{"mention": "budesonide", "char_span": [83, 93], "sem_type": "Pharmacologic Substance", "tok_span": [12, 16], "new_tok_span": [13, 17]}, {"mention": "RU486", "char_span": [210, 215], "sem_type": "Pharmacologic Substance", "tok_span": [34, 37], "new_tok_span": [37, 40]}], "new_text": "To determine the involvement of glucocorticoid receptor in the observed effects of <START=Pharmacologic Substance> budesonide <END=Pharmacologic Substance>, secretion and mRNA expression studies were also performed in the presence of a glucocorticoid receptor antagonist ( <START=Pharmacologic Substance> RU486 <END=Pharmacologic Substance> )."}, {"PMID": 17369473, "id": 7, "text": "Cytosolic [AMP] reported metabolically active AMP, which triggered increased AMPK activity, but measures of total AMP did not.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [11, 14], "name": "AMP", "tok_span": [4, 5], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [46, 49], "name": "AMP", "tok_span": [10, 11], "new_tok_span": [16, 17]}, {"ent_type": "CHEMICAL", "char_span": [114, 117], "name": "AMP", "tok_span": [22, 23], "new_tok_span": [36, 37]}, {"ent_type": "GENE", "char_span": [77, 81], "name": "AMPK", "tok_span": [15, 16], "new_tok_span": [25, 26]}], "relation_list": [{"subject": "AMP", "sbj_char_span": [46, 49], "object": "AMPK", "obj_char_span": [77, 81], "rel_type": "activator", "sbj_tok_span": [10, 11], "obj_tok_span": [15, 16], "new_sbj_tok_span": [16, 17], "new_obj_tok_span": [25, 26]}], "umls_entity_list": [{"mention": "AMP", "char_span": [11, 14], "sem_type": "Gene or Genome", "tok_span": [4, 5], "new_tok_span": [6, 7]}, {"mention": "AMP", "char_span": [46, 49], "sem_type": "Gene or Genome", "tok_span": [10, 11], "new_tok_span": [16, 17]}, {"mention": "AMP", "char_span": [77, 80], "sem_type": "Gene or Genome", "tok_span": [15, 16], "new_tok_span": [25, 26]}, {"mention": "AMP", "char_span": [114, 117], "sem_type": "Gene or Genome", "tok_span": [22, 23], "new_tok_span": [36, 37]}, {"mention": "AMP", "char_span": [11, 14], "sem_type": "Pharmacologic Substance", "tok_span": [4, 5], "new_tok_span": [6, 7]}, {"mention": "AMP", "char_span": [46, 49], "sem_type": "Pharmacologic Substance", "tok_span": [10, 11], "new_tok_span": [16, 17]}, {"mention": "AMP", "char_span": [77, 80], "sem_type": "Pharmacologic Substance", "tok_span": [15, 16], "new_tok_span": [25, 26]}, {"mention": "AMP", "char_span": [114, 117], "sem_type": "Pharmacologic Substance", "tok_span": [22, 23], "new_tok_span": [36, 37]}], "new_text": "Cytosolic [ <START=Gene or Genome> <START=Pharmacologic Substance> AMP <END=Gene or Genome> <END=Pharmacologic Substance> ] reported metabolically active <START=Gene or Genome> <START=Pharmacologic Substance> AMP <END=Gene or Genome> <END=Pharmacologic Substance>, which triggered increased <START=Gene or Genome> <START=Pharmacologic Substance> AMPK <END=Gene or Genome> <END=Pharmacologic Substance> activity, but measures of total <START=Gene or Genome> <START=Pharmacologic Substance> AMP <END=Gene or Genome> <END=Pharmacologic Substance> did not."}, {"PMID": 17513393, "id": 7, "text": "Because Cu deficiency results in upregulation of Gclc and an increase in the biosynthesis of glutathione, it is plausible that the net flux of homocysteine through the transsulfuration pathway is increased.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [93, 104], "name": "glutathione", "tok_span": [17, 18], "new_tok_span": [21, 22]}, {"ent_type": "CHEMICAL", "char_span": [143, 155], "name": "homocysteine", "tok_span": [27, 29], "new_tok_span": [32, 34]}, {"ent_type": "CHEMICAL", "char_span": [8, 10], "name": "Cu", "tok_span": [1, 2], "new_tok_span": [1, 2]}, {"ent_type": "GENE", "char_span": [49, 53], "name": "Gclc", "tok_span": [7, 10], "new_tok_span": [9, 12]}], "relation_list": [{"subject": "glutathione", "sbj_char_span": [93, 104], "object": "Gclc", "obj_char_span": [49, 53], "rel_type": "product or substrate", "sbj_tok_span": [17, 18], "obj_tok_span": [7, 10], "new_sbj_tok_span": [21, 22], "new_obj_tok_span": [9, 12]}, {"subject": "homocysteine", "sbj_char_span": [143, 155], "object": "Gclc", "obj_char_span": [49, 53], "rel_type": "product or substrate", "sbj_tok_span": [27, 29], "obj_tok_span": [7, 10], "new_sbj_tok_span": [32, 34], "new_obj_tok_span": [9, 12]}], "umls_entity_list": [{"mention": "Gclc", "char_span": [49, 53], "sem_type": "Gene or Genome", "tok_span": [7, 10], "new_tok_span": [9, 12]}, {"mention": "Gclc", "char_span": [49, 53], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [7, 10], "new_tok_span": [9, 12]}, {"mention": "homocysteine", "char_span": [143, 155], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 29], "new_tok_span": [32, 34]}], "new_text": "Because Cu deficiency results in upregulation of <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> Gclc <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and an increase in the biosynthesis of glutathione, it is plausible that the net flux of <START=Amino Acid, Peptide, or Protein> homocysteine <END=Amino Acid, Peptide, or Protein> through the transsulfuration pathway is increased."}, {"PMID": 10898598, "id": 6, "text": "Most importantly, POCl(3)-induced electric eel AChE inhibition prevents postlabeling with [(3)H]diisopropyl phosphorofluoridate; i.e., both compounds phosphorylate at Ser-200 in the catalytic triad.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [18, 25], "name": "POCl(3)", "tok_span": [3, 8], "new_tok_span": [3, 8]}, {"ent_type": "CHEMICAL", "char_span": [90, 127], "name": "[(3)H]diisopropyl phosphorofluoridate", "tok_span": [21, 35], "new_tok_span": [21, 35]}, {"ent_type": "CHEMICAL", "char_span": [167, 170], "name": "Ser", "tok_span": [46, 47], "new_tok_span": [48, 49]}, {"ent_type": "GENE", "char_span": [34, 51], "name": "electric eel AChE", "tok_span": [10, 15], "new_tok_span": [10, 15]}], "relation_list": [{"subject": "POCl(3)", "sbj_char_span": [18, 25], "object": "electric eel AChE", "obj_char_span": [34, 51], "rel_type": "inhibitor", "sbj_tok_span": [3, 8], "obj_tok_span": [10, 15], "new_sbj_tok_span": [3, 8], "new_obj_tok_span": [10, 15]}, {"subject": "Ser", "sbj_char_span": [167, 170], "object": "electric eel AChE", "obj_char_span": [34, 51], "rel_type": "part of", "sbj_tok_span": [46, 47], "obj_tok_span": [10, 15], "new_sbj_tok_span": [48, 49], "new_obj_tok_span": [10, 15]}, {"subject": "[(3)H]diisopropyl phosphorofluoridate", "sbj_char_span": [90, 127], "object": "electric eel AChE", "obj_char_span": [34, 51], "rel_type": "regulator", "sbj_tok_span": [21, 35], "obj_tok_span": [10, 15], "new_sbj_tok_span": [21, 35], "new_obj_tok_span": [10, 15]}], "umls_entity_list": [{"mention": "diisopropyl phosphorofluoridate", "char_span": [96, 127], "sem_type": "Pharmacologic Substance", "tok_span": [27, 35], "new_tok_span": [28, 36]}], "new_text": "Most importantly, POCl ( 3 ) - induced electric eel AChE inhibition prevents postlabeling with [ ( 3 ) H ] <START=Pharmacologic Substance> diisopropyl phosphorofluoridate <END=Pharmacologic Substance> ; i. e., both compounds phosphorylate at Ser - 200 in the catalytic triad."}, {"PMID": 15481993, "id": 2, "text": "The synthesis and pharmacological evaluation of new water-soluble phosphoramidate derivatives of the COX-2 selective inhibitor cimicoxib (4) are described.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [127, 136], "name": "cimicoxib", "tok_span": [21, 25], "new_tok_span": [24, 28]}, {"ent_type": "CHEMICAL", "char_span": [66, 81], "name": "phosphoramidate", "tok_span": [10, 13], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [101, 106], "name": "COX-2", "tok_span": [16, 19], "new_tok_span": [18, 21]}], "relation_list": [{"subject": "phosphoramidate", "sbj_char_span": [66, 81], "object": "COX-2", "obj_char_span": [101, 106], "rel_type": "inhibitor", "sbj_tok_span": [10, 13], "obj_tok_span": [16, 19], "new_sbj_tok_span": [11, 14], "new_obj_tok_span": [18, 21]}, {"subject": "cimicoxib", "sbj_char_span": [127, 136], "object": "COX-2", "obj_char_span": [101, 106], "rel_type": "inhibitor", "sbj_tok_span": [21, 25], "obj_tok_span": [16, 19], "new_sbj_tok_span": [24, 28], "new_obj_tok_span": [18, 21]}], "umls_entity_list": [{"mention": "phosphoramidate", "char_span": [66, 81], "sem_type": "Pharmacologic Substance", "tok_span": [10, 13], "new_tok_span": [11, 14]}, {"mention": "cimicoxib", "char_span": [127, 136], "sem_type": "Pharmacologic Substance", "tok_span": [21, 25], "new_tok_span": [24, 28]}], "new_text": "The synthesis and pharmacological evaluation of new water - soluble <START=Pharmacologic Substance> phosphoramidate <END=Pharmacologic Substance> derivatives of the COX - 2 selective inhibitor <START=Pharmacologic Substance> cimicoxib <END=Pharmacologic Substance> ( 4 ) are described."}, {"PMID": 15169831, "id": 3, "text": "We evaluated the effects of systemic ethanol (0.05-2.0 g/kg i.p.), the N-methyl-D-aspartate (NMDA) receptor antagonist dizocilpine (MK-801; 0.05-0.2 mg/kg i.v.), the connexin-36 gap junction blocker quinidine (5-20 mg/kg i.v.), the fast-acting barbiturate methohexital (Brevital; 5-10 mg/kg i.v.), and the benzodiazepine chlordiazepoxide (Librium; 5-10 mg/kg i.v.), as well as in situ VTA administration of NMDA and the GABA(A) receptor agonist muscimol, on VTA GABA neuron spontaneous activity and internal capsule stimulus-induced poststimulus spike discharges (ICPSDs).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [37, 44], "name": "ethanol", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [71, 91], "name": "N-methyl-D-aspartate", "tok_span": [25, 33], "new_tok_span": [27, 35]}, {"ent_type": "CHEMICAL", "char_span": [93, 97], "name": "NMDA", "tok_span": [34, 35], "new_tok_span": [38, 39]}, {"ent_type": "CHEMICAL", "char_span": [119, 130], "name": "dizocilpine", "tok_span": [38, 43], "new_tok_span": [43, 48]}, {"ent_type": "CHEMICAL", "char_span": [132, 138], "name": "MK-801", "tok_span": [44, 48], "new_tok_span": [50, 54]}, {"ent_type": "CHEMICAL", "char_span": [199, 208], "name": "quinidine", "tok_span": [74, 76], "new_tok_span": [83, 85]}, {"ent_type": "CHEMICAL", "char_span": [244, 255], "name": "barbiturate", "tok_span": [93, 96], "new_tok_span": [106, 109]}, {"ent_type": "CHEMICAL", "char_span": [256, 268], "name": "methohexital", "tok_span": [96, 100], "new_tok_span": [111, 115]}, {"ent_type": "CHEMICAL", "char_span": [306, 320], "name": "benzodiazepine", "tok_span": [119, 123], "new_tok_span": [140, 144]}, {"ent_type": "CHEMICAL", "char_span": [321, 337], "name": "chlordiazepoxide", "tok_span": [123, 127], "new_tok_span": [146, 150]}, {"ent_type": "CHEMICAL", "char_span": [339, 346], "name": "Librium", "tok_span": [128, 131], "new_tok_span": [153, 156]}, {"ent_type": "CHEMICAL", "char_span": [407, 411], "name": "NMDA", "tok_span": [153, 154], "new_tok_span": [181, 182]}, {"ent_type": "CHEMICAL", "char_span": [462, 466], "name": "GABA", "tok_span": [169, 170], "new_tok_span": [199, 200]}, {"ent_type": "GENE", "char_span": [71, 107], "name": "N-methyl-D-aspartate (NMDA) receptor", "tok_span": [25, 37], "new_tok_span": [27, 39]}, {"ent_type": "GENE", "char_span": [166, 177], "name": "connexin-36", "tok_span": [66, 71], "new_tok_span": [74, 79]}, {"ent_type": "GENE", "char_span": [407, 436], "name": "NMDA and the GABA(A) receptor", "tok_span": [153, 161], "new_tok_span": [181, 189]}], "relation_list": [{"subject": "dizocilpine", "sbj_char_span": [119, 130], "object": "N-methyl-D-aspartate (NMDA) receptor", "obj_char_span": [71, 107], "rel_type": "agonist or antagonist", "sbj_tok_span": [38, 43], "obj_tok_span": [25, 37], "new_sbj_tok_span": [43, 48], "new_obj_tok_span": [27, 39]}, {"subject": "MK-801", "sbj_char_span": [132, 138], "object": "N-methyl-D-aspartate (NMDA) receptor", "obj_char_span": [71, 107], "rel_type": "agonist or antagonist", "sbj_tok_span": [44, 48], "obj_tok_span": [25, 37], "new_sbj_tok_span": [50, 54], "new_obj_tok_span": [27, 39]}, {"subject": "quinidine", "sbj_char_span": [199, 208], "object": "connexin-36", "obj_char_span": [166, 177], "rel_type": "inhibitor", "sbj_tok_span": [74, 76], "obj_tok_span": [66, 71], "new_sbj_tok_span": [83, 85], "new_obj_tok_span": [74, 79]}], "umls_entity_list": [{"mention": "g i", "char_span": [58, 61], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 19], "new_tok_span": [18, 20]}, {"mention": "g i", "char_span": [153, 156], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [58, 60], "new_tok_span": [65, 67]}, {"mention": "g i", "char_span": [219, 222], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [82, 84], "new_tok_span": [93, 95]}, {"mention": "g i", "char_span": [289, 292], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [110, 112], "new_tok_span": [129, 131]}, {"mention": "g i", "char_span": [357, 360], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [137, 139], "new_tok_span": [164, 166]}, {"mention": "dizocilpine", "char_span": [119, 130], "sem_type": "Pharmacologic Substance", "tok_span": [38, 43], "new_tok_span": [43, 48]}, {"mention": "quinidine", "char_span": [199, 208], "sem_type": "Pharmacologic Substance", "tok_span": [74, 76], "new_tok_span": [83, 85]}, {"mention": "barbiturate", "char_span": [244, 255], "sem_type": "Pharmacologic Substance", "tok_span": [93, 96], "new_tok_span": [106, 109]}, {"mention": "methohexital", "char_span": [256, 268], "sem_type": "Pharmacologic Substance", "tok_span": [96, 100], "new_tok_span": [111, 115]}, {"mention": "Brevital", "char_span": [270, 278], "sem_type": "Pharmacologic Substance", "tok_span": [101, 104], "new_tok_span": [118, 121]}, {"mention": "benzodiazepine", "char_span": [306, 320], "sem_type": "Pharmacologic Substance", "tok_span": [119, 123], "new_tok_span": [140, 144]}, {"mention": "chlordiazepoxide", "char_span": [321, 337], "sem_type": "Pharmacologic Substance", "tok_span": [123, 127], "new_tok_span": [146, 150]}, {"mention": "Librium", "char_span": [339, 346], "sem_type": "Pharmacologic Substance", "tok_span": [128, 131], "new_tok_span": [153, 156]}, {"mention": "methyl", "char_span": [73, 79], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [30, 31]}, {"mention": "muscimol", "char_span": [445, 453], "sem_type": "Pharmacologic Substance", "tok_span": [162, 165], "new_tok_span": [191, 194]}], "new_text": "We evaluated the effects of systemic ethanol ( 0. 05 - 2. 0 g / <START=Amino Acid, Peptide, or Protein> kg i <END=Amino Acid, Peptide, or Protein>. p. ), the N - <START=Amino Acid, Peptide, or Protein> methyl <END=Amino Acid, Peptide, or Protein> - D - aspartate ( NMDA ) receptor antagonist <START=Pharmacologic Substance> dizocilpine <END=Pharmacologic Substance> ( MK - 801 ; 0. 05 - 0. 2 mg / <START=Amino Acid, Peptide, or Protein> kg i <END=Amino Acid, Peptide, or Protein>. v. ), the connexin - 36 gap junction blocker <START=Pharmacologic Substance> quinidine <END=Pharmacologic Substance> ( 5 - 20 mg / <START=Amino Acid, Peptide, or Protein> kg i <END=Amino Acid, Peptide, or Protein>. v. ), the fast - acting <START=Pharmacologic Substance> barbiturate <END=Pharmacologic Substance> <START=Pharmacologic Substance> methohexital <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> Brevital <END=Pharmacologic Substance> ; 5 - 10 mg / <START=Amino Acid, Peptide, or Protein> kg i <END=Amino Acid, Peptide, or Protein>. v. ), and the <START=Pharmacologic Substance> benzodiazepine <END=Pharmacologic Substance> <START=Pharmacologic Substance> chlordiazepoxide <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> Librium <END=Pharmacologic Substance> ; 5 - 10 mg / <START=Amino Acid, Peptide, or Protein> kg i <END=Amino Acid, Peptide, or Protein>. v. ), as well as in situ VTA administration of NMDA and the GABA ( A ) receptor agonist <START=Pharmacologic Substance> muscimol <END=Pharmacologic Substance>, on VTA GABA neuron spontaneous activity and internal capsule stimulus - induced poststimulus spike discharges ( ICPSDs )."}, {"PMID": 23611835, "id": 5, "text": "Molecular docking studies suggested that SB has a good affinity towards vinblastine-binding site on β-tubulin subunit.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [72, 83], "name": "vinblastine", "tok_span": [11, 15], "new_tok_span": [12, 16]}, {"ent_type": "GENE", "char_span": [100, 109], "name": "β-tubulin", "tok_span": [19, 22], "new_tok_span": [21, 24]}], "relation_list": [{"subject": "vinblastine", "sbj_char_span": [72, 83], "object": "β-tubulin", "obj_char_span": [100, 109], "rel_type": "regulator", "sbj_tok_span": [11, 15], "obj_tok_span": [19, 22], "new_sbj_tok_span": [12, 16], "new_obj_tok_span": [21, 24]}], "umls_entity_list": [{"mention": "vinblastine", "char_span": [72, 83], "sem_type": "Pharmacologic Substance", "tok_span": [11, 15], "new_tok_span": [12, 16]}, {"mention": "tubulin", "char_span": [102, 109], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [24, 25]}], "new_text": "Molecular docking studies suggested that SB has a good affinity towards <START=Pharmacologic Substance> vinblastine <END=Pharmacologic Substance> - binding site on β - <START=Amino Acid, Peptide, or Protein> tubulin <END=Amino Acid, Peptide, or Protein> subunit."}, {"PMID": 17595315, "id": 2, "text": "We have studied the impact of P450 reductase mutations on the activity of CYP19A1. POR supported CYP19A1 activity with a calculated Km of 126 nm for androstenedione and a Vmax of 1.7 pmol/min.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [149, 164], "name": "androstenedione", "tok_span": [35, 39], "new_tok_span": [50, 54]}, {"ent_type": "GENE", "char_span": [30, 44], "name": "P450 reductase", "tok_span": [6, 9], "new_tok_span": [7, 10]}, {"ent_type": "GENE", "char_span": [74, 81], "name": "CYP19A1", "tok_span": [14, 18], "new_tok_span": [18, 22]}, {"ent_type": "GENE", "char_span": [83, 86], "name": "POR", "tok_span": [19, 21], "new_tok_span": [25, 27]}, {"ent_type": "GENE", "char_span": [97, 104], "name": "CYP19A1", "tok_span": [22, 26], "new_tok_span": [34, 38]}], "relation_list": [{"subject": "androstenedione", "sbj_char_span": [149, 164], "object": "CYP19A1", "obj_char_span": [97, 104], "rel_type": "product or substrate", "sbj_tok_span": [35, 39], "obj_tok_span": [22, 26], "new_sbj_tok_span": [50, 54], "new_obj_tok_span": [34, 38]}, {"subject": "androstenedione", "sbj_char_span": [149, 164], "object": "POR", "obj_char_span": [83, 86], "rel_type": "product or substrate", "sbj_tok_span": [35, 39], "obj_tok_span": [19, 21], "new_sbj_tok_span": [50, 54], "new_obj_tok_span": [25, 27]}], "umls_entity_list": [{"mention": "P450", "char_span": [30, 34], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 8], "new_tok_span": [7, 9]}, {"mention": "reductase", "char_span": [35, 44], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 9], "new_tok_span": [11, 12]}, {"mention": "POR", "char_span": [83, 86], "sem_type": "Gene or Genome", "tok_span": [19, 21], "new_tok_span": [25, 27]}, {"mention": "por", "char_span": [90, 93], "sem_type": "Gene or Genome", "tok_span": [21, 22], "new_tok_span": [31, 32]}, {"mention": "POR", "char_span": [83, 86], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 21], "new_tok_span": [25, 27]}, {"mention": "por", "char_span": [90, 93], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [31, 32]}, {"mention": "Km", "char_span": [132, 134], "sem_type": "Gene or Genome", "tok_span": [30, 31], "new_tok_span": [43, 44]}, {"mention": "androstenedione", "char_span": [149, 164], "sem_type": "Pharmacologic Substance", "tok_span": [35, 39], "new_tok_span": [50, 54]}], "new_text": "We have studied the impact of <START=Amino Acid, Peptide, or Protein> P450 <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> reductase <END=Amino Acid, Peptide, or Protein> mutations on the activity of CYP19A1. <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> POR <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> supported <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> CYP19A1 activity with a calculated <START=Gene or Genome> Km <END=Gene or Genome> of 126 nm for <START=Pharmacologic Substance> androstenedione <END=Pharmacologic Substance> and a Vmax of 1. 7 pmol / min."}, {"PMID": 23500772, "id": 1, "text": "This study assessed changes in myocardial ALDH2 expression in the diabetic rat, in particular the diabetic rat pretreated with ALDH2 activator ethanol (EtOH). The rats were divided into six groups: control, EtOH control, diabetic rat at 4th week (DM4W), 8th week (DM8W), 12th week (DM12W) and EtOH+DM8W groups.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [143, 150], "name": "ethanol", "tok_span": [26, 27], "new_tok_span": [35, 36]}, {"ent_type": "CHEMICAL", "char_span": [152, 156], "name": "EtOH", "tok_span": [28, 30], "new_tok_span": [38, 40]}, {"ent_type": "CHEMICAL", "char_span": [207, 211], "name": "EtOH", "tok_span": [42, 44], "new_tok_span": [52, 54]}, {"ent_type": "CHEMICAL", "char_span": [293, 297], "name": "EtOH", "tok_span": [76, 78], "new_tok_span": [86, 88]}, {"ent_type": "GENE", "char_span": [127, 132], "name": "ALDH2", "tok_span": [22, 25], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [42, 47], "name": "ALDH2", "tok_span": [6, 9], "new_tok_span": [8, 11]}], "relation_list": [{"subject": "ethanol", "sbj_char_span": [143, 150], "object": "ALDH2", "obj_char_span": [127, 132], "rel_type": "activator", "sbj_tok_span": [26, 27], "obj_tok_span": [22, 25], "new_sbj_tok_span": [35, 36], "new_obj_tok_span": [28, 31]}, {"subject": "EtOH", "sbj_char_span": [152, 156], "object": "ALDH2", "obj_char_span": [127, 132], "rel_type": "activator", "sbj_tok_span": [28, 30], "obj_tok_span": [22, 25], "new_sbj_tok_span": [38, 40], "new_obj_tok_span": [28, 31]}], "umls_entity_list": [{"mention": "ALDH2", "char_span": [42, 47], "sem_type": "Gene or Genome", "tok_span": [6, 9], "new_tok_span": [8, 11]}, {"mention": "ALDH2", "char_span": [127, 132], "sem_type": "Gene or Genome", "tok_span": [22, 25], "new_tok_span": [28, 31]}, {"mention": "ALDH2", "char_span": [42, 47], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 9], "new_tok_span": [8, 11]}, {"mention": "ALDH2", "char_span": [127, 132], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [22, 25], "new_tok_span": [28, 31]}, {"mention": "ethanol", "char_span": [143, 150], "sem_type": "Pharmacologic Substance", "tok_span": [26, 27], "new_tok_span": [35, 36]}], "new_text": "This study assessed changes in myocardial <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ALDH2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> expression in the diabetic rat, in particular the diabetic rat pretreated with <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ALDH2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> activator <START=Pharmacologic Substance> ethanol <END=Pharmacologic Substance> ( EtOH ). The rats were divided into six groups : control, EtOH control, diabetic rat at 4th week ( DM4W ), 8th week ( DM8W ), 12th week ( DM12W ) and EtOH + DM8W groups."}, {"PMID": 23604717, "id": 5, "text": "SAL-2 also downregulated COX-2 and iNOS expression induced by HNE, but salicylate did not.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 5], "name": "SAL-2", "tok_span": [0, 4], "new_tok_span": [2, 6]}, {"ent_type": "CHEMICAL", "char_span": [62, 65], "name": "HNE", "tok_span": [14, 16], "new_tok_span": [23, 25]}, {"ent_type": "CHEMICAL", "char_span": [71, 81], "name": "salicylate", "tok_span": [18, 21], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [25, 30], "name": "COX-2", "tok_span": [6, 9], "new_tok_span": [12, 15]}, {"ent_type": "GENE", "char_span": [35, 39], "name": "iNOS", "tok_span": [10, 11], "new_tok_span": [18, 19]}], "relation_list": [{"subject": "SAL-2", "sbj_char_span": [0, 5], "object": "COX-2", "obj_char_span": [25, 30], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [6, 9], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [12, 15]}, {"subject": "SAL-2", "sbj_char_span": [0, 5], "object": "iNOS", "obj_char_span": [35, 39], "rel_type": "regulator", "sbj_tok_span": [0, 4], "obj_tok_span": [10, 11], "new_sbj_tok_span": [2, 6], "new_obj_tok_span": [18, 19]}, {"subject": "HNE", "sbj_char_span": [62, 65], "object": "COX-2", "obj_char_span": [25, 30], "rel_type": "regulator", "sbj_tok_span": [14, 16], "obj_tok_span": [6, 9], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [12, 15]}, {"subject": "HNE", "sbj_char_span": [62, 65], "object": "iNOS", "obj_char_span": [35, 39], "rel_type": "regulator", "sbj_tok_span": [14, 16], "obj_tok_span": [10, 11], "new_sbj_tok_span": [23, 25], "new_obj_tok_span": [18, 19]}], "umls_entity_list": [{"mention": "SAL-2", "char_span": [0, 5], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 4], "new_tok_span": [2, 6]}, {"mention": "COX-2", "char_span": [25, 30], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [6, 9], "new_tok_span": [12, 15]}, {"mention": "COX-2", "char_span": [25, 30], "sem_type": "Gene or Genome", "tok_span": [6, 9], "new_tok_span": [12, 15]}, {"mention": "SAL-2", "char_span": [0, 5], "sem_type": "Gene or Genome", "tok_span": [0, 4], "new_tok_span": [2, 6]}, {"mention": "HNE", "char_span": [62, 65], "sem_type": "Gene or Genome", "tok_span": [14, 16], "new_tok_span": [23, 25]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> SAL - 2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> also downregulated <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> COX - 2 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> and iNOS expression induced by <START=Gene or Genome> HNE <END=Gene or Genome>, but salicylate did not."}, {"PMID": 23416191, "id": 4, "text": "The most potent compound 5 (HJC0123) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [28, 35], "name": "HJC0123", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"ent_type": "GENE", "char_span": [65, 79], "name": "STAT3 promoter", "tok_span": [15, 18], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [122, 127], "name": "STAT3", "tok_span": [24, 26], "new_tok_span": [32, 34]}, {"ent_type": "GENE", "char_span": [164, 173], "name": "caspase-3", "tok_span": [32, 35], "new_tok_span": [43, 46]}], "relation_list": [{"subject": "HJC0123", "sbj_char_span": [28, 35], "object": "STAT3 promoter", "obj_char_span": [65, 79], "rel_type": "inhibitor", "sbj_tok_span": [6, 10], "obj_tok_span": [15, 18], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [19, 22]}, {"subject": "HJC0123", "sbj_char_span": [28, 35], "object": "STAT3", "obj_char_span": [122, 127], "rel_type": "inhibitor", "sbj_tok_span": [6, 10], "obj_tok_span": [24, 26], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [32, 34]}, {"subject": "HJC0123", "sbj_char_span": [28, 35], "object": "caspase-3", "obj_char_span": [164, 173], "rel_type": "regulator", "sbj_tok_span": [6, 10], "obj_tok_span": [32, 35], "new_sbj_tok_span": [7, 11], "new_obj_tok_span": [43, 46]}], "umls_entity_list": [{"mention": "HJC0123", "char_span": [28, 35], "sem_type": "Pharmacologic Substance", "tok_span": [6, 10], "new_tok_span": [7, 11]}, {"mention": "STAT3", "char_span": [65, 70], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [15, 17], "new_tok_span": [19, 21]}, {"mention": "STAT3", "char_span": [122, 127], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 26], "new_tok_span": [32, 34]}, {"mention": "STAT3", "char_span": [65, 70], "sem_type": "Gene or Genome", "tok_span": [15, 17], "new_tok_span": [19, 21]}, {"mention": "STAT3", "char_span": [122, 127], "sem_type": "Gene or Genome", "tok_span": [24, 26], "new_tok_span": [32, 34]}, {"mention": "caspase-3", "char_span": [164, 173], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [32, 35], "new_tok_span": [43, 46]}, {"mention": "pancreatic", "char_span": [242, 252], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [46, 47], "new_tok_span": [59, 60]}], "new_text": "The most potent compound 5 ( <START=Pharmacologic Substance> HJC0123 <END=Pharmacologic Substance> ) has demonstrated to inhibit <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> STAT3 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> promoter activity, downregulate phosphorylation of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> STAT3 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, increase the expression of cleaved <START=Amino Acid, Peptide, or Protein> caspase - 3 <END=Amino Acid, Peptide, or Protein>, inhibit cell cycle progression and promote apoptosis in breast and <START=Amino Acid, Peptide, or Protein> pancreatic <END=Amino Acid, Peptide, or Protein> cancer cells with low micromolar to nanomolar IC50 values."}, {"PMID": 15740719, "id": 10, "text": "For both agonists, important binding domains were the extracellular N-terminus (=E1) and the extracellular loops E2 and E3 from the oxytocin receptor.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [68, 69], "name": "N", "tok_span": [10, 11], "new_tok_span": [10, 11]}, {"ent_type": "CHEMICAL", "char_span": [132, 140], "name": "oxytocin", "tok_span": [29, 32], "new_tok_span": [35, 38]}, {"ent_type": "GENE", "char_span": [132, 149], "name": "oxytocin receptor", "tok_span": [29, 33], "new_tok_span": [35, 39]}], "relation_list": [{"subject": "N", "sbj_char_span": [68, 69], "object": "oxytocin receptor", "obj_char_span": [132, 149], "rel_type": "part of", "sbj_tok_span": [10, 11], "obj_tok_span": [29, 33], "new_sbj_tok_span": [10, 11], "new_obj_tok_span": [35, 39]}], "umls_entity_list": [{"mention": "E2", "char_span": [113, 115], "sem_type": "Gene or Genome", "tok_span": [22, 24], "new_tok_span": [23, 25]}, {"mention": "oxytocin", "char_span": [132, 140], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [29, 32], "new_tok_span": [35, 38]}, {"mention": "oxytocin receptor", "char_span": [132, 149], "sem_type": "Gene or Genome", "tok_span": [29, 33], "new_tok_span": [35, 39]}, {"mention": "E3", "char_span": [120, 122], "sem_type": "Gene or Genome", "tok_span": [25, 27], "new_tok_span": [28, 30]}], "new_text": "For both agonists, important binding domains were the extracellular N - terminus ( = E1 ) and the extracellular loops <START=Gene or Genome> E2 <END=Gene or Genome> and <START=Gene or Genome> E3 <END=Gene or Genome> from the <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> oxytocin <END=Amino Acid, Peptide, or Protein> receptor <END=Gene or Genome>."}, {"PMID": 23639801, "id": 4, "text": "In yeast cells expressing human GPR55, CID16020046 antagonized agonist-induced receptor activation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [39, 50], "name": "CID16020046", "tok_span": [9, 14], "new_tok_span": [12, 17]}, {"ent_type": "GENE", "char_span": [26, 37], "name": "human GPR55", "tok_span": [4, 8], "new_tok_span": [4, 8]}], "relation_list": [{"subject": "CID16020046", "sbj_char_span": [39, 50], "object": "human GPR55", "obj_char_span": [26, 37], "rel_type": "agonist or antagonist", "sbj_tok_span": [9, 14], "obj_tok_span": [4, 8], "new_sbj_tok_span": [12, 17], "new_obj_tok_span": [4, 8]}], "umls_entity_list": [{"mention": "GPR55", "char_span": [32, 37], "sem_type": "Gene or Genome", "tok_span": [5, 8], "new_tok_span": [6, 9]}, {"mention": "CID16020046", "char_span": [39, 50], "sem_type": "Pharmacologic Substance", "tok_span": [9, 14], "new_tok_span": [12, 17]}], "new_text": "In yeast cells expressing human <START=Gene or Genome> GPR55 <END=Gene or Genome>, <START=Pharmacologic Substance> CID16020046 <END=Pharmacologic Substance> antagonized agonist - induced receptor activation."}, {"PMID": 15972446, "id": 3, "text": "We treated a patient with MCL (with an associated myelodysplastic syndrome (MDS)/myeloproliferative disorder [MPD]) based on in vitro studies demonstrating that PKC412 could inhibit D816V KIT-transformed Ba/F3 cell growth with a 50% inhibitory concentration (IC50) of 30 nM to 40 nM.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [161, 167], "name": "PKC412", "tok_span": [36, 39], "new_tok_span": [36, 39]}, {"ent_type": "GENE", "char_span": [182, 187], "name": "D816V", "tok_span": [41, 45], "new_tok_span": [41, 45]}, {"ent_type": "GENE", "char_span": [188, 191], "name": "KIT", "tok_span": [45, 47], "new_tok_span": [45, 47]}], "relation_list": [{"subject": "PKC412", "sbj_char_span": [161, 167], "object": "D816V", "obj_char_span": [182, 187], "rel_type": "inhibitor", "sbj_tok_span": [36, 39], "obj_tok_span": [41, 45], "new_sbj_tok_span": [36, 39], "new_obj_tok_span": [41, 45]}, {"subject": "PKC412", "sbj_char_span": [161, 167], "object": "KIT", "obj_char_span": [188, 191], "rel_type": "inhibitor", "sbj_tok_span": [36, 39], "obj_tok_span": [45, 47], "new_sbj_tok_span": [36, 39], "new_obj_tok_span": [45, 47]}], "umls_entity_list": [{"mention": "F3", "char_span": [207, 209], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [51, 53], "new_tok_span": [52, 54]}], "new_text": "We treated a patient with MCL ( with an associated myelodysplastic syndrome ( MDS ) / myeloproliferative disorder [ MPD ] ) based on in vitro studies demonstrating that PKC412 could inhibit D816V KIT - transformed Ba / <START=Amino Acid, Peptide, or Protein> F3 <END=Amino Acid, Peptide, or Protein> cell growth with a 50 % inhibitory concentration ( IC50 ) of 30 nM to 40 nM."}, {"PMID": 19930708, "id": 2, "text": "In the current study we investigated the activity of the aromatase inhibitor exemestane in human NSCLC cell lines H23 and A549.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [77, 87], "name": "exemestane", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"ent_type": "GENE", "char_span": [57, 66], "name": "aromatase", "tok_span": [10, 12], "new_tok_span": [11, 13]}], "relation_list": [{"subject": "exemestane", "sbj_char_span": [77, 87], "object": "aromatase", "obj_char_span": [57, 66], "rel_type": "inhibitor", "sbj_tok_span": [13, 16], "obj_tok_span": [10, 12], "new_sbj_tok_span": [16, 19], "new_obj_tok_span": [11, 13]}], "umls_entity_list": [{"mention": "exemestane", "char_span": [77, 87], "sem_type": "Pharmacologic Substance", "tok_span": [13, 16], "new_tok_span": [16, 19]}, {"mention": "aromatase inhibitor", "char_span": [57, 76], "sem_type": "Pharmacologic Substance", "tok_span": [10, 13], "new_tok_span": [11, 14]}], "new_text": "In the current study we investigated the activity of the <START=Pharmacologic Substance> aromatase inhibitor <END=Pharmacologic Substance> <START=Pharmacologic Substance> exemestane <END=Pharmacologic Substance> in human NSCLC cell lines H23 and A549."}, {"PMID": 16230360, "id": 2, "text": "Procainamide has been shown to inhibit DNA methyltransferase activity and reactivate silenced gene expression in cancer cells by reversing CpG island hypermethylation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 12], "name": "Procainamide", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "GENE", "char_span": [39, 60], "name": "DNA methyltransferase", "tok_span": [8, 11], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [139, 149], "name": "CpG island", "tok_span": [26, 28], "new_tok_span": [26, 28]}], "relation_list": [{"subject": "Procainamide", "sbj_char_span": [0, 12], "object": "DNA methyltransferase", "obj_char_span": [39, 60], "rel_type": "inhibitor", "sbj_tok_span": [0, 3], "obj_tok_span": [8, 11], "new_sbj_tok_span": [0, 3], "new_obj_tok_span": [8, 11]}], "umls_entity_list": [], "new_text": "Procainamide has been shown to inhibit DNA methyltransferase activity and reactivate silenced gene expression in cancer cells by reversing CpG island hypermethylation."}, {"PMID": 17124432, "id": 1, "text": "BACKGROUND: Norepinephrine transporter (NET) is involved in the regulation of norepinephrine (NE) turnover and metabolism.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [12, 26], "name": "Norepinephrine", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"ent_type": "CHEMICAL", "char_span": [78, 92], "name": "norepinephrine", "tok_span": [16, 17], "new_tok_span": [19, 20]}, {"ent_type": "CHEMICAL", "char_span": [94, 96], "name": "NE", "tok_span": [18, 19], "new_tok_span": [22, 23]}, {"ent_type": "GENE", "char_span": [12, 38], "name": "Norepinephrine transporter", "tok_span": [2, 7], "new_tok_span": [3, 8]}, {"ent_type": "GENE", "char_span": [40, 43], "name": "NET", "tok_span": [8, 9], "new_tok_span": [10, 11]}], "relation_list": [{"subject": "norepinephrine", "sbj_char_span": [78, 92], "object": "Norepinephrine transporter", "obj_char_span": [12, 38], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [2, 7], "new_sbj_tok_span": [19, 20], "new_obj_tok_span": [3, 8]}, {"subject": "norepinephrine", "sbj_char_span": [78, 92], "object": "NET", "obj_char_span": [40, 43], "rel_type": "product or substrate", "sbj_tok_span": [16, 17], "obj_tok_span": [8, 9], "new_sbj_tok_span": [19, 20], "new_obj_tok_span": [10, 11]}, {"subject": "NE", "sbj_char_span": [94, 96], "object": "Norepinephrine transporter", "obj_char_span": [12, 38], "rel_type": "product or substrate", "sbj_tok_span": [18, 19], "obj_tok_span": [2, 7], "new_sbj_tok_span": [22, 23], "new_obj_tok_span": [3, 8]}, {"subject": "NE", "sbj_char_span": [94, 96], "object": "NET", "obj_char_span": [40, 43], "rel_type": "product or substrate", "sbj_tok_span": [18, 19], "obj_tok_span": [8, 9], "new_sbj_tok_span": [22, 23], "new_obj_tok_span": [10, 11]}], "umls_entity_list": [{"mention": "Norepinephrine", "char_span": [12, 26], "sem_type": "Pharmacologic Substance", "tok_span": [2, 6], "new_tok_span": [3, 7]}, {"mention": "norepinephrine", "char_span": [78, 92], "sem_type": "Pharmacologic Substance", "tok_span": [16, 17], "new_tok_span": [19, 20]}], "new_text": "BACKGROUND : <START=Pharmacologic Substance> Norepinephrine <END=Pharmacologic Substance> transporter ( NET ) is involved in the regulation of <START=Pharmacologic Substance> norepinephrine <END=Pharmacologic Substance> ( NE ) turnover and metabolism."}, {"PMID": 11861317, "id": 5, "text": "Whereas PS potentiated NMDA-, glutamate-, and glycine-induced currents of NR1/NR2A and NR1/NR2B receptors, it was inhibitory at NR1/NR2C and NR1/NR2D receptors. 3.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [8, 10], "name": "PS", "tok_span": [1, 2], "new_tok_span": [1, 2]}, {"ent_type": "CHEMICAL", "char_span": [23, 27], "name": "NMDA", "tok_span": [4, 5], "new_tok_span": [4, 5]}, {"ent_type": "CHEMICAL", "char_span": [30, 39], "name": "glutamate", "tok_span": [7, 8], "new_tok_span": [7, 8]}, {"ent_type": "CHEMICAL", "char_span": [46, 53], "name": "glycine", "tok_span": [11, 12], "new_tok_span": [11, 12]}, {"ent_type": "GENE", "char_span": [74, 77], "name": "NR1", "tok_span": [16, 18], "new_tok_span": [16, 18]}, {"ent_type": "GENE", "char_span": [78, 82], "name": "NR2A", "tok_span": [19, 22], "new_tok_span": [21, 24]}, {"ent_type": "GENE", "char_span": [87, 90], "name": "NR1", "tok_span": [23, 25], "new_tok_span": [27, 29]}, {"ent_type": "GENE", "char_span": [91, 95], "name": "NR2B", "tok_span": [26, 29], "new_tok_span": [32, 35]}, {"ent_type": "GENE", "char_span": [128, 131], "name": "NR1", "tok_span": [35, 37], "new_tok_span": [43, 45]}, {"ent_type": "GENE", "char_span": [132, 136], "name": "NR2C", "tok_span": [38, 41], "new_tok_span": [47, 50]}, {"ent_type": "GENE", "char_span": [141, 144], "name": "NR1", "tok_span": [42, 44], "new_tok_span": [52, 54]}, {"ent_type": "GENE", "char_span": [145, 149], "name": "NR2D", "tok_span": [45, 48], "new_tok_span": [56, 59]}], "relation_list": [{"subject": "PS", "sbj_char_span": [8, 10], "object": "NR1", "obj_char_span": [128, 131], "rel_type": "inhibitor", "sbj_tok_span": [1, 2], "obj_tok_span": [35, 37], "new_sbj_tok_span": [1, 2], "new_obj_tok_span": [43, 45]}, {"subject": "PS", "sbj_char_span": [8, 10], "object": "NR2C", "obj_char_span": [132, 136], "rel_type": "inhibitor", "sbj_tok_span": [1, 2], "obj_tok_span": [38, 41], "new_sbj_tok_span": [1, 2], "new_obj_tok_span": [47, 50]}, {"subject": "PS", "sbj_char_span": [8, 10], "object": "NR1", "obj_char_span": [141, 144], "rel_type": "inhibitor", "sbj_tok_span": [1, 2], "obj_tok_span": [42, 44], "new_sbj_tok_span": [1, 2], "new_obj_tok_span": [52, 54]}, {"subject": "PS", "sbj_char_span": [8, 10], "object": "NR2D", "obj_char_span": [145, 149], "rel_type": "inhibitor", "sbj_tok_span": [1, 2], "obj_tok_span": [45, 48], "new_sbj_tok_span": [1, 2], "new_obj_tok_span": [56, 59]}], "umls_entity_list": [{"mention": "NR2A", "char_span": [78, 82], "sem_type": "Gene or Genome", "tok_span": [19, 22], "new_tok_span": [21, 24]}, {"mention": "NR2A", "char_span": [78, 82], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [19, 22], "new_tok_span": [21, 24]}, {"mention": "NR2B", "char_span": [91, 95], "sem_type": "Gene or Genome", "tok_span": [26, 29], "new_tok_span": [32, 35]}, {"mention": "NR2B", "char_span": [91, 95], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [26, 29], "new_tok_span": [32, 35]}, {"mention": "NR2C", "char_span": [132, 136], "sem_type": "Gene or Genome", "tok_span": [38, 41], "new_tok_span": [47, 50]}, {"mention": "NR2D", "char_span": [145, 149], "sem_type": "Gene or Genome", "tok_span": [45, 48], "new_tok_span": [56, 59]}], "new_text": "Whereas PS potentiated NMDA -, glutamate -, and glycine - induced currents of NR1 / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NR2A <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> and NR1 / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> NR2B <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> receptors, it was inhibitory at NR1 / <START=Gene or Genome> NR2C <END=Gene or Genome> and NR1 / <START=Gene or Genome> NR2D <END=Gene or Genome> receptors. 3."}, {"PMID": 23521080, "id": 3, "text": "One exception is tranexamic acid (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to fibrin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [17, 32], "name": "tranexamic acid", "tok_span": [3, 7], "new_tok_span": [4, 8]}, {"ent_type": "CHEMICAL", "char_span": [34, 37], "name": "TXA", "tok_span": [8, 10], "new_tok_span": [10, 12]}, {"ent_type": "CHEMICAL", "char_span": [52, 58], "name": "lysine", "tok_span": [16, 17], "new_tok_span": [18, 19]}, {"ent_type": "GENE", "char_span": [88, 99], "name": "plasminogen", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"ent_type": "GENE", "char_span": [103, 109], "name": "fibrin", "tok_span": [27, 28], "new_tok_span": [34, 35]}], "relation_list": [{"subject": "TXA", "sbj_char_span": [34, 37], "object": "plasminogen", "obj_char_span": [88, 99], "rel_type": "inhibitor", "sbj_tok_span": [8, 10], "obj_tok_span": [24, 26], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [28, 30]}, {"subject": "tranexamic acid", "sbj_char_span": [17, 32], "object": "plasminogen", "obj_char_span": [88, 99], "rel_type": "inhibitor", "sbj_tok_span": [3, 7], "obj_tok_span": [24, 26], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [28, 30]}, {"subject": "lysine", "sbj_char_span": [52, 58], "object": "plasminogen", "obj_char_span": [88, 99], "rel_type": "inhibitor", "sbj_tok_span": [16, 17], "obj_tok_span": [24, 26], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [28, 30]}, {"subject": "tranexamic acid", "sbj_char_span": [17, 32], "object": "fibrin", "obj_char_span": [103, 109], "rel_type": "inhibitor", "sbj_tok_span": [3, 7], "obj_tok_span": [27, 28], "new_sbj_tok_span": [4, 8], "new_obj_tok_span": [34, 35]}, {"subject": "TXA", "sbj_char_span": [34, 37], "object": "fibrin", "obj_char_span": [103, 109], "rel_type": "inhibitor", "sbj_tok_span": [8, 10], "obj_tok_span": [27, 28], "new_sbj_tok_span": [10, 12], "new_obj_tok_span": [34, 35]}, {"subject": "lysine", "sbj_char_span": [52, 58], "object": "fibrin", "obj_char_span": [103, 109], "rel_type": "inhibitor", "sbj_tok_span": [16, 17], "obj_tok_span": [27, 28], "new_sbj_tok_span": [18, 19], "new_obj_tok_span": [34, 35]}], "umls_entity_list": [{"mention": "tranexamic acid", "char_span": [17, 32], "sem_type": "Pharmacologic Substance", "tok_span": [3, 7], "new_tok_span": [4, 8]}, {"mention": "plasminogen", "char_span": [88, 99], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"mention": "plasminogen", "char_span": [88, 99], "sem_type": "Gene or Genome", "tok_span": [24, 26], "new_tok_span": [28, 30]}, {"mention": "fibrin", "char_span": [103, 109], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 28], "new_tok_span": [34, 35]}], "new_text": "One exception is <START=Pharmacologic Substance> tranexamic acid <END=Pharmacologic Substance> ( TXA ), which, as a lysine mimetic, inhibits binding of <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> plasminogen <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> to <START=Amino Acid, Peptide, or Protein> fibrin <END=Amino Acid, Peptide, or Protein>."}, {"PMID": 23432095, "id": 6, "text": "The lead compounds inhibited AKR1C3 with nanomolar potency, displayed >100-fold selectivity over AKR1C1/AKR1C2, and blocked testosterone formation in LNCaP-AKR1C3 cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [124, 136], "name": "testosterone", "tok_span": [35, 36], "new_tok_span": [47, 48]}, {"ent_type": "GENE", "char_span": [29, 35], "name": "AKR1C3", "tok_span": [4, 9], "new_tok_span": [6, 11]}, {"ent_type": "GENE", "char_span": [97, 103], "name": "AKR1C1", "tok_span": [21, 26], "new_tok_span": [27, 32]}, {"ent_type": "GENE", "char_span": [104, 110], "name": "AKR1C2", "tok_span": [27, 32], "new_tok_span": [37, 42]}, {"ent_type": "GENE", "char_span": [156, 162], "name": "AKR1C3", "tok_span": [42, 47], "new_tok_span": [56, 61]}], "relation_list": [{"subject": "testosterone", "sbj_char_span": [124, 136], "object": "AKR1C3", "obj_char_span": [29, 35], "rel_type": "product or substrate", "sbj_tok_span": [35, 36], "obj_tok_span": [4, 9], "new_sbj_tok_span": [47, 48], "new_obj_tok_span": [6, 11]}], "umls_entity_list": [{"mention": "AKR1C3", "char_span": [29, 35], "sem_type": "Gene or Genome", "tok_span": [4, 9], "new_tok_span": [6, 11]}, {"mention": "AKR1C3", "char_span": [156, 162], "sem_type": "Gene or Genome", "tok_span": [42, 47], "new_tok_span": [56, 61]}, {"mention": "AKR1C3", "char_span": [29, 35], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [4, 9], "new_tok_span": [6, 11]}, {"mention": "AKR1C3", "char_span": [156, 162], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 47], "new_tok_span": [56, 61]}, {"mention": "AKR1C1", "char_span": [97, 103], "sem_type": "Gene or Genome", "tok_span": [21, 26], "new_tok_span": [27, 32]}, {"mention": "AKR1C2", "char_span": [104, 110], "sem_type": "Gene or Genome", "tok_span": [27, 32], "new_tok_span": [37, 42]}, {"mention": "AKR1C2", "char_span": [104, 110], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [27, 32], "new_tok_span": [37, 42]}, {"mention": "AKR1C1", "char_span": [97, 103], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 26], "new_tok_span": [27, 32]}], "new_text": "The lead compounds inhibited <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> AKR1C3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> with nanomolar potency, displayed > 100 - fold selectivity over <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> AKR1C1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> AKR1C2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, and blocked testosterone formation in LNCaP - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> AKR1C3 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> cells."}, {"PMID": 16675639, "id": 3, "text": "DVS showed weak binding affinity (62% inhibition at 100 microM) at the human dopamine (DA) transporter.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 3], "name": "DVS", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "CHEMICAL", "char_span": [77, 85], "name": "dopamine", "tok_span": [18, 19], "new_tok_span": [18, 19]}, {"ent_type": "CHEMICAL", "char_span": [87, 89], "name": "DA", "tok_span": [20, 21], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [71, 102], "name": "human dopamine (DA) transporter", "tok_span": [17, 23], "new_tok_span": [17, 23]}], "relation_list": [{"subject": "DVS", "sbj_char_span": [0, 3], "object": "human dopamine (DA) transporter", "obj_char_span": [71, 102], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [17, 23], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [17, 23]}], "umls_entity_list": [], "new_text": "DVS showed weak binding affinity ( 62 % inhibition at 100 microM ) at the human dopamine ( DA ) transporter."}, {"PMID": 15379894, "id": 5, "text": "The arachidonic acid 5-lipoxygenase (5LOX) and tyrosine kinase inhibitor nordihydroguaiaretic acid (NDGA), a natural dicatechol, was one of the most potent non-cytotoxic antagonists tested (IC50 8 +/- 3 microm).", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [4, 20], "name": "arachidonic acid", "tok_span": [1, 5], "new_tok_span": [2, 6]}, {"ent_type": "CHEMICAL", "char_span": [47, 55], "name": "tyrosine", "tok_span": [15, 16], "new_tok_span": [18, 19]}, {"ent_type": "CHEMICAL", "char_span": [73, 98], "name": "nordihydroguaiaretic acid", "tok_span": [18, 26], "new_tok_span": [23, 31]}, {"ent_type": "CHEMICAL", "char_span": [100, 104], "name": "NDGA", "tok_span": [27, 29], "new_tok_span": [33, 35]}, {"ent_type": "CHEMICAL", "char_span": [117, 127], "name": "dicatechol", "tok_span": [33, 36], "new_tok_span": [39, 42]}, {"ent_type": "GENE", "char_span": [21, 35], "name": "5-lipoxygenase", "tok_span": [5, 9], "new_tok_span": [6, 10]}, {"ent_type": "GENE", "char_span": [37, 41], "name": "5LOX", "tok_span": [10, 13], "new_tok_span": [12, 15]}, {"ent_type": "GENE", "char_span": [47, 62], "name": "tyrosine kinase", "tok_span": [15, 17], "new_tok_span": [18, 20]}], "relation_list": [{"subject": "nordihydroguaiaretic acid", "sbj_char_span": [73, 98], "object": "tyrosine kinase", "obj_char_span": [47, 62], "rel_type": "inhibitor", "sbj_tok_span": [18, 26], "obj_tok_span": [15, 17], "new_sbj_tok_span": [23, 31], "new_obj_tok_span": [18, 20]}, {"subject": "NDGA", "sbj_char_span": [100, 104], "object": "tyrosine kinase", "obj_char_span": [47, 62], "rel_type": "inhibitor", "sbj_tok_span": [27, 29], "obj_tok_span": [15, 17], "new_sbj_tok_span": [33, 35], "new_obj_tok_span": [18, 20]}, {"subject": "dicatechol", "sbj_char_span": [117, 127], "object": "tyrosine kinase", "obj_char_span": [47, 62], "rel_type": "inhibitor", "sbj_tok_span": [33, 36], "obj_tok_span": [15, 17], "new_sbj_tok_span": [39, 42], "new_obj_tok_span": [18, 20]}, {"subject": "nordihydroguaiaretic acid", "sbj_char_span": [73, 98], "object": "5-lipoxygenase", "obj_char_span": [21, 35], "rel_type": "inhibitor", "sbj_tok_span": [18, 26], "obj_tok_span": [5, 9], "new_sbj_tok_span": [23, 31], "new_obj_tok_span": [6, 10]}, {"subject": "NDGA", "sbj_char_span": [100, 104], "object": "5-lipoxygenase", "obj_char_span": [21, 35], "rel_type": "inhibitor", "sbj_tok_span": [27, 29], "obj_tok_span": [5, 9], "new_sbj_tok_span": [33, 35], "new_obj_tok_span": [6, 10]}, {"subject": "dicatechol", "sbj_char_span": [117, 127], "object": "5-lipoxygenase", "obj_char_span": [21, 35], "rel_type": "inhibitor", "sbj_tok_span": [33, 36], "obj_tok_span": [5, 9], "new_sbj_tok_span": [39, 42], "new_obj_tok_span": [6, 10]}, {"subject": "nordihydroguaiaretic acid", "sbj_char_span": [73, 98], "object": "5LOX", "obj_char_span": [37, 41], "rel_type": "inhibitor", "sbj_tok_span": [18, 26], "obj_tok_span": [10, 13], "new_sbj_tok_span": [23, 31], "new_obj_tok_span": [12, 15]}, {"subject": "NDGA", "sbj_char_span": [100, 104], "object": "5LOX", "obj_char_span": [37, 41], "rel_type": "inhibitor", "sbj_tok_span": [27, 29], "obj_tok_span": [10, 13], "new_sbj_tok_span": [33, 35], "new_obj_tok_span": [12, 15]}, {"subject": "dicatechol", "sbj_char_span": [117, 127], "object": "5LOX", "obj_char_span": [37, 41], "rel_type": "inhibitor", "sbj_tok_span": [33, 36], "obj_tok_span": [10, 13], "new_sbj_tok_span": [39, 42], "new_obj_tok_span": [12, 15]}], "umls_entity_list": [{"mention": "arachidonic acid 5-lipoxygenase", "char_span": [4, 35], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [1, 9], "new_tok_span": [2, 10]}, {"mention": "tyrosine kinase inhibitor", "char_span": [47, 72], "sem_type": "Pharmacologic Substance", "tok_span": [15, 18], "new_tok_span": [18, 21]}, {"mention": "nordihydroguaiaretic acid", "char_span": [73, 98], "sem_type": "Pharmacologic Substance", "tok_span": [18, 26], "new_tok_span": [23, 31]}], "new_text": "The <START=Amino Acid, Peptide, or Protein> arachidonic acid 5 - lipoxygenase <END=Amino Acid, Peptide, or Protein> ( 5LOX ) and <START=Pharmacologic Substance> tyrosine kinase inhibitor <END=Pharmacologic Substance> <START=Pharmacologic Substance> nordihydroguaiaretic acid <END=Pharmacologic Substance> ( NDGA ), a natural dicatechol, was one of the most potent non - cytotoxic antagonists tested ( IC50 8 + / - 3 microm )."}, {"PMID": 19837759, "id": 5, "text": "RESULTS: (18)F-AV-45 displayed a high binding affinity and specificity to Abeta plaques (K(d), 3.72 +/- 0.30 nM). In vitro autoradiography of postmortem human brain sections showed substantial plaque labeling in AD brains and not in the control brains.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [9, 20], "name": "(18)F-AV-45", "tok_span": [2, 10], "new_tok_span": [2, 10]}, {"ent_type": "GENE", "char_span": [74, 79], "name": "Abeta", "tok_span": [18, 20], "new_tok_span": [19, 21]}], "relation_list": [{"subject": "(18)F-AV-45", "sbj_char_span": [9, 20], "object": "Abeta", "obj_char_span": [74, 79], "rel_type": "regulator", "sbj_tok_span": [2, 10], "obj_tok_span": [18, 20], "new_sbj_tok_span": [2, 10], "new_obj_tok_span": [19, 21]}], "umls_entity_list": [{"mention": "Abeta", "char_span": [74, 79], "sem_type": "Gene or Genome", "tok_span": [18, 20], "new_tok_span": [19, 21]}], "new_text": "RESULTS : ( 18 ) F - AV - 45 displayed a high binding affinity and specificity to <START=Gene or Genome> Abeta <END=Gene or Genome> plaques ( K ( d ), 3. 72 + / - 0. 30 nM ). In vitro autoradiography of postmortem human brain sections showed substantial plaque labeling in AD brains and not in the control brains."}, {"PMID": 23314308, "id": 6, "text": "Inositol triphosphate (InsP3) receptor antagonist 2-APB (10(-4)M) significantly reduced, and high concentration of caffeine (20mM) almost totally suppressed the contractions.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [50, 55], "name": "2-APB", "tok_span": [15, 19], "new_tok_span": [17, 21]}, {"ent_type": "CHEMICAL", "char_span": [115, 123], "name": "caffeine", "tok_span": [34, 35], "new_tok_span": [38, 39]}, {"ent_type": "CHEMICAL", "char_span": [0, 21], "name": "Inositol triphosphate", "tok_span": [0, 8], "new_tok_span": [1, 9]}, {"ent_type": "GENE", "char_span": [0, 38], "name": "Inositol triphosphate (InsP3) receptor", "tok_span": [0, 14], "new_tok_span": [1, 15]}], "relation_list": [{"subject": "2-APB", "sbj_char_span": [50, 55], "object": "Inositol triphosphate (InsP3) receptor", "obj_char_span": [0, 38], "rel_type": "agonist or antagonist", "sbj_tok_span": [15, 19], "obj_tok_span": [0, 14], "new_sbj_tok_span": [17, 21], "new_obj_tok_span": [1, 15]}], "umls_entity_list": [{"mention": "Inositol", "char_span": [0, 8], "sem_type": "Organic Chemical", "tok_span": [0, 3], "new_tok_span": [1, 4]}, {"mention": "APB", "char_span": [52, 55], "sem_type": "Gene or Genome", "tok_span": [17, 19], "new_tok_span": [20, 22]}], "new_text": "<START=Organic Chemical> Inositol <END=Organic Chemical> triphosphate ( InsP3 ) receptor antagonist 2 - <START=Gene or Genome> APB <END=Gene or Genome> ( 10 ( - 4 ) M ) significantly reduced, and high concentration of caffeine ( 20mM ) almost totally suppressed the contractions."}, {"PMID": 15572277, "id": 4, "text": "Aminophylline and DPCPX but not 8pSPT also reversed the protective action of A1/A2 adenosine receptor agonist, 2-chloroadenosine (2-CADO) and selective A1 adenosine receptor agonist, R-N6-phenylisopropyloadenosine (R-PIA), against 3-NPA-evoked convulsions.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 13], "name": "Aminophylline", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "CHEMICAL", "char_span": [18, 23], "name": "DPCPX", "tok_span": [4, 7], "new_tok_span": [4, 7]}, {"ent_type": "CHEMICAL", "char_span": [32, 37], "name": "8pSPT", "tok_span": [9, 13], "new_tok_span": [9, 13]}, {"ent_type": "CHEMICAL", "char_span": [83, 92], "name": "adenosine", "tok_span": [24, 25], "new_tok_span": [25, 26]}, {"ent_type": "CHEMICAL", "char_span": [111, 128], "name": "2-chloroadenosine", "tok_span": [28, 34], "new_tok_span": [31, 37]}, {"ent_type": "CHEMICAL", "char_span": [130, 136], "name": "2-CADO", "tok_span": [35, 39], "new_tok_span": [41, 45]}, {"ent_type": "CHEMICAL", "char_span": [155, 164], "name": "adenosine", "tok_span": [44, 45], "new_tok_span": [51, 52]}, {"ent_type": "CHEMICAL", "char_span": [183, 213], "name": "R-N6-phenylisopropyloadenosine", "tok_span": [48, 60], "new_tok_span": [56, 68]}, {"ent_type": "CHEMICAL", "char_span": [215, 220], "name": "R-PIA", "tok_span": [61, 65], "new_tok_span": [71, 75]}, {"ent_type": "CHEMICAL", "char_span": [231, 236], "name": "3-NPA", "tok_span": [68, 72], "new_tok_span": [78, 82]}, {"ent_type": "GENE", "char_span": [77, 101], "name": "A1/A2 adenosine receptor", "tok_span": [19, 26], "new_tok_span": [19, 26]}, {"ent_type": "GENE", "char_span": [152, 173], "name": "A1 adenosine receptor", "tok_span": [42, 46], "new_tok_span": [48, 52]}], "relation_list": [{"subject": "R-N6-phenylisopropyloadenosine", "sbj_char_span": [183, 213], "object": "A1 adenosine receptor", "obj_char_span": [152, 173], "rel_type": "agonist or antagonist", "sbj_tok_span": [48, 60], "obj_tok_span": [42, 46], "new_sbj_tok_span": [56, 68], "new_obj_tok_span": [48, 52]}, {"subject": "R-PIA", "sbj_char_span": [215, 220], "object": "A1 adenosine receptor", "obj_char_span": [152, 173], "rel_type": "agonist or antagonist", "sbj_tok_span": [61, 65], "obj_tok_span": [42, 46], "new_sbj_tok_span": [71, 75], "new_obj_tok_span": [48, 52]}], "umls_entity_list": [{"mention": "2-chloroadenosine", "char_span": [111, 128], "sem_type": "Pharmacologic Substance", "tok_span": [28, 34], "new_tok_span": [31, 37]}, {"mention": "adenosine", "char_span": [83, 92], "sem_type": "Pharmacologic Substance", "tok_span": [24, 25], "new_tok_span": [25, 26]}, {"mention": "adenosine", "char_span": [119, 128], "sem_type": "Pharmacologic Substance", "tok_span": [31, 34], "new_tok_span": [35, 38]}, {"mention": "adenosine", "char_span": [155, 164], "sem_type": "Pharmacologic Substance", "tok_span": [44, 45], "new_tok_span": [51, 52]}, {"mention": "adenosine", "char_span": [204, 213], "sem_type": "Pharmacologic Substance", "tok_span": [57, 60], "new_tok_span": [66, 69]}], "new_text": "Aminophylline and DPCPX but not 8pSPT also reversed the protective action of A1 / A2 <START=Pharmacologic Substance> adenosine <END=Pharmacologic Substance> receptor agonist, <START=Pharmacologic Substance> 2 - chlor <START=Pharmacologic Substance>oadenosine <END=Pharmacologic Substance> <END=Pharmacologic Substance> ( 2 - CADO ) and selective A1 <START=Pharmacologic Substance> adenosine <END=Pharmacologic Substance> receptor agonist, R - N6 - phenylisopropyl <START=Pharmacologic Substance>oadenosine <END=Pharmacologic Substance> ( R - PIA ), against 3 - NPA - evoked convulsions."}, {"PMID": 14693528, "id": 1, "text": "This study compared the plasma amprenavir pharmacokinetics of the human immunodeficiency virus (HIV) protease inhibitors amprenavir (Agenerase) 1,200 mg twice daily (BID) and the amprenavir prodrug GW433908, a formulation that substantially reduces the number of tablets per dose compared with amprenavir, at doses of 1,395 mg and 1,860 mg BID, in combination with abacavir 300 mg BID and lamivudine 150 mg BID in patients with HIV infection.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [121, 131], "name": "amprenavir", "tok_span": [21, 24], "new_tok_span": [26, 29]}, {"ent_type": "CHEMICAL", "char_span": [133, 142], "name": "Agenerase", "tok_span": [25, 28], "new_tok_span": [32, 35]}, {"ent_type": "CHEMICAL", "char_span": [179, 189], "name": "amprenavir", "tok_span": [41, 44], "new_tok_span": [52, 55]}, {"ent_type": "CHEMICAL", "char_span": [198, 206], "name": "GW433908", "tok_span": [47, 51], "new_tok_span": [60, 64]}, {"ent_type": "CHEMICAL", "char_span": [294, 304], "name": "amprenavir", "tok_span": [65, 68], "new_tok_span": [80, 83]}, {"ent_type": "CHEMICAL", "char_span": [31, 41], "name": "amprenavir", "tok_span": [5, 8], "new_tok_span": [8, 11]}, {"ent_type": "CHEMICAL", "char_span": [365, 373], "name": "abacavir", "tok_span": [89, 92], "new_tok_span": [107, 110]}, {"ent_type": "CHEMICAL", "char_span": [389, 399], "name": "lamivudine", "tok_span": [97, 101], "new_tok_span": [117, 121]}, {"ent_type": "GENE", "char_span": [66, 109], "name": "human immunodeficiency virus (HIV) protease", "tok_span": [12, 20], "new_tok_span": [16, 24]}], "relation_list": [{"subject": "amprenavir", "sbj_char_span": [121, 131], "object": "human immunodeficiency virus (HIV) protease", "obj_char_span": [66, 109], "rel_type": "inhibitor", "sbj_tok_span": [21, 24], "obj_tok_span": [12, 20], "new_sbj_tok_span": [26, 29], "new_obj_tok_span": [16, 24]}, {"subject": "Agenerase", "sbj_char_span": [133, 142], "object": "human immunodeficiency virus (HIV) protease", "obj_char_span": [66, 109], "rel_type": "inhibitor", "sbj_tok_span": [25, 28], "obj_tok_span": [12, 20], "new_sbj_tok_span": [32, 35], "new_obj_tok_span": [16, 24]}, {"subject": "amprenavir", "sbj_char_span": [179, 189], "object": "human immunodeficiency virus (HIV) protease", "obj_char_span": [66, 109], "rel_type": "inhibitor", "sbj_tok_span": [41, 44], "obj_tok_span": [12, 20], "new_sbj_tok_span": [52, 55], "new_obj_tok_span": [16, 24]}, {"subject": "GW433908", "sbj_char_span": [198, 206], "object": "human immunodeficiency virus (HIV) protease", "obj_char_span": [66, 109], "rel_type": "inhibitor", "sbj_tok_span": [47, 51], "obj_tok_span": [12, 20], "new_sbj_tok_span": [60, 64], "new_obj_tok_span": [16, 24]}, {"subject": "abacavir", "sbj_char_span": [365, 373], "object": "human immunodeficiency virus (HIV) protease", "obj_char_span": [66, 109], "rel_type": "inhibitor", "sbj_tok_span": [89, 92], "obj_tok_span": [12, 20], "new_sbj_tok_span": [107, 110], "new_obj_tok_span": [16, 24]}, {"subject": "lamivudine", "sbj_char_span": [389, 399], "object": "human immunodeficiency virus (HIV) protease", "obj_char_span": [66, 109], "rel_type": "inhibitor", "sbj_tok_span": [97, 101], "obj_tok_span": [12, 20], "new_sbj_tok_span": [117, 121], "new_obj_tok_span": [16, 24]}], "umls_entity_list": [{"mention": "amprenavir", "char_span": [31, 41], "sem_type": "Pharmacologic Substance", "tok_span": [5, 8], "new_tok_span": [8, 11]}, {"mention": "amprenavir", "char_span": [121, 131], "sem_type": "Pharmacologic Substance", "tok_span": [21, 24], "new_tok_span": [26, 29]}, {"mention": "amprenavir", "char_span": [179, 189], "sem_type": "Pharmacologic Substance", "tok_span": [41, 44], "new_tok_span": [52, 55]}, {"mention": "amprenavir", "char_span": [294, 304], "sem_type": "Pharmacologic Substance", "tok_span": [65, 68], "new_tok_span": [80, 83]}, {"mention": "plasma", "char_span": [24, 30], "sem_type": "Pharmacologic Substance", "tok_span": [4, 5], "new_tok_span": [5, 6]}, {"mention": "Agenerase", "char_span": [133, 142], "sem_type": "Pharmacologic Substance", "tok_span": [25, 28], "new_tok_span": [32, 35]}, {"mention": "BID", "char_span": [166, 169], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [36, 38], "new_tok_span": [45, 47]}, {"mention": "BID", "char_span": [340, 343], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [83, 85], "new_tok_span": [100, 102]}, {"mention": "BID", "char_span": [381, 384], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [94, 96], "new_tok_span": [113, 115]}, {"mention": "BID", "char_span": [407, 410], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [103, 105], "new_tok_span": [124, 126]}, {"mention": "GW433908", "char_span": [198, 206], "sem_type": "Pharmacologic Substance", "tok_span": [47, 51], "new_tok_span": [60, 64]}], "new_text": "This study compared the <START=Pharmacologic Substance> plasma <END=Pharmacologic Substance> <START=Pharmacologic Substance> amprenavir <END=Pharmacologic Substance> pharmacokinetics of the human immunodeficiency virus ( HIV ) protease inhibitors <START=Pharmacologic Substance> amprenavir <END=Pharmacologic Substance> ( <START=Pharmacologic Substance> Agenerase <END=Pharmacologic Substance> ) 1, 200 mg twice daily ( <START=Amino Acid, Peptide, or Protein> BID <END=Amino Acid, Peptide, or Protein> ) and the <START=Pharmacologic Substance> amprenavir <END=Pharmacologic Substance> prodrug <START=Pharmacologic Substance> GW433908 <END=Pharmacologic Substance>, a formulation that substantially reduces the number of tablets per dose compared with <START=Pharmacologic Substance> amprenavir <END=Pharmacologic Substance>, at doses of 1, 395 mg and 1, 860 mg <START=Amino Acid, Peptide, or Protein> BID <END=Amino Acid, Peptide, or Protein>, in combination with abacavir 300 mg <START=Amino Acid, Peptide, or Protein> BID <END=Amino Acid, Peptide, or Protein> and lamivudine 150 mg <START=Amino Acid, Peptide, or Protein> BID <END=Amino Acid, Peptide, or Protein> in patients with HIV infection."}, {"PMID": 17334413, "id": 1, "text": "Histamine regulates many functions by binding to four histamine G-coupled receptor proteins (H1R, H2R, H3R and H4R). As H3R exerts their effects by coupling to Galpha(i/o) proteins reducing adenosine 3', 5'-monophosphate (cAMP) levels (a key player in the modulation of cholangiocyte hyperplasia/damage), we evaluated the role of H3R in the regulation of biliary growth.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 9], "name": "Histamine", "tok_span": [0, 2], "new_tok_span": [0, 2]}, {"ent_type": "CHEMICAL", "char_span": [190, 220], "name": "adenosine 3', 5'-monophosphate", "tok_span": [52, 64], "new_tok_span": [60, 72]}, {"ent_type": "CHEMICAL", "char_span": [222, 226], "name": "cAMP", "tok_span": [65, 66], "new_tok_span": [73, 74]}, {"ent_type": "CHEMICAL", "char_span": [54, 63], "name": "histamine", "tok_span": [9, 10], "new_tok_span": [9, 10]}, {"ent_type": "GENE", "char_span": [103, 106], "name": "H3R", "tok_span": [24, 27], "new_tok_span": [30, 33]}, {"ent_type": "GENE", "char_span": [111, 114], "name": "H4R", "tok_span": [28, 31], "new_tok_span": [35, 38]}, {"ent_type": "GENE", "char_span": [120, 123], "name": "H3R", "tok_span": [34, 37], "new_tok_span": [42, 45]}, {"ent_type": "GENE", "char_span": [160, 171], "name": "Galpha(i/o)", "tok_span": [43, 50], "new_tok_span": [51, 58]}, {"ent_type": "GENE", "char_span": [330, 333], "name": "H3R", "tok_span": [89, 92], "new_tok_span": [97, 100]}, {"ent_type": "GENE", "char_span": [54, 91], "name": "histamine G-coupled receptor proteins", "tok_span": [9, 15], "new_tok_span": [9, 15]}, {"ent_type": "GENE", "char_span": [93, 96], "name": "H1R", "tok_span": [16, 19], "new_tok_span": [17, 20]}, {"ent_type": "GENE", "char_span": [98, 101], "name": "H2R", "tok_span": [20, 23], "new_tok_span": [24, 27]}], "relation_list": [{"subject": "Histamine", "sbj_char_span": [0, 9], "object": "histamine G-coupled receptor proteins", "obj_char_span": [54, 91], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [9, 15], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [9, 15]}, {"subject": "Histamine", "sbj_char_span": [0, 9], "object": "H1R", "obj_char_span": [93, 96], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [16, 19], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [17, 20]}, {"subject": "Histamine", "sbj_char_span": [0, 9], "object": "H2R", "obj_char_span": [98, 101], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [20, 23], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [24, 27]}, {"subject": "Histamine", "sbj_char_span": [0, 9], "object": "H3R", "obj_char_span": [103, 106], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [24, 27], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [30, 33]}, {"subject": "Histamine", "sbj_char_span": [0, 9], "object": "H4R", "obj_char_span": [111, 114], "rel_type": "regulator", "sbj_tok_span": [0, 2], "obj_tok_span": [28, 31], "new_sbj_tok_span": [0, 2], "new_obj_tok_span": [35, 38]}], "umls_entity_list": [{"mention": "H1R", "char_span": [93, 96], "sem_type": "Gene or Genome", "tok_span": [16, 19], "new_tok_span": [17, 20]}, {"mention": "H2R", "char_span": [98, 101], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 23], "new_tok_span": [24, 27]}, {"mention": "H2R", "char_span": [98, 101], "sem_type": "Gene or Genome", "tok_span": [20, 23], "new_tok_span": [24, 27]}, {"mention": "H4R", "char_span": [111, 114], "sem_type": "Gene or Genome", "tok_span": [28, 31], "new_tok_span": [35, 38]}], "new_text": "Histamine regulates many functions by binding to four histamine G - coupled receptor proteins ( <START=Gene or Genome> H1R <END=Gene or Genome>, <START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> H2R <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome>, H3R and <START=Gene or Genome> H4R <END=Gene or Genome> ). As H3R exerts their effects by coupling to Galpha ( i / o ) proteins reducing adenosine 3 ', 5'- monophosphate ( cAMP ) levels ( a key player in the modulation of cholangiocyte hyperplasia / damage ), we evaluated the role of H3R in the regulation of biliary growth."}, {"PMID": 23402371, "id": 8, "text": "This study demonstrates, for the first time, that inhibition of CDCF uptake in MDCKII-ABCC2 vesicles not only provides a screening assay to assess MRP2 drug-drug interaction potential, but is also predictive of human MRP2-mediated biliary excretion.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [64, 68], "name": "CDCF", "tok_span": [12, 14], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [86, 91], "name": "ABCC2", "tok_span": [20, 23], "new_tok_span": [24, 27]}, {"ent_type": "GENE", "char_span": [147, 151], "name": "MRP2", "tok_span": [32, 35], "new_tok_span": [39, 42]}, {"ent_type": "GENE", "char_span": [211, 221], "name": "human MRP2", "tok_span": [46, 50], "new_tok_span": [54, 58]}], "relation_list": [{"subject": "CDCF", "sbj_char_span": [64, 68], "object": "ABCC2", "obj_char_span": [86, 91], "rel_type": "product or substrate", "sbj_tok_span": [12, 14], "obj_tok_span": [20, 23], "new_sbj_tok_span": [13, 15], "new_obj_tok_span": [24, 27]}, {"subject": "CDCF", "sbj_char_span": [64, 68], "object": "MRP2", "obj_char_span": [147, 151], "rel_type": "product or substrate", "sbj_tok_span": [12, 14], "obj_tok_span": [32, 35], "new_sbj_tok_span": [13, 15], "new_obj_tok_span": [39, 42]}, {"subject": "CDCF", "sbj_char_span": [64, 68], "object": "human MRP2", "obj_char_span": [211, 221], "rel_type": "product or substrate", "sbj_tok_span": [12, 14], "obj_tok_span": [46, 50], "new_sbj_tok_span": [13, 15], "new_obj_tok_span": [54, 58]}], "umls_entity_list": [{"mention": "CDCF", "char_span": [64, 68], "sem_type": "Organic Chemical", "tok_span": [12, 14], "new_tok_span": [13, 15]}, {"mention": "ABCC2", "char_span": [86, 91], "sem_type": "Gene or Genome", "tok_span": [20, 23], "new_tok_span": [24, 27]}, {"mention": "ABCC2", "char_span": [86, 91], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 23], "new_tok_span": [24, 27]}, {"mention": "MRP2", "char_span": [147, 151], "sem_type": "Gene or Genome", "tok_span": [32, 35], "new_tok_span": [39, 42]}, {"mention": "MRP2", "char_span": [217, 221], "sem_type": "Gene or Genome", "tok_span": [47, 50], "new_tok_span": [56, 59]}], "new_text": "This study demonstrates, for the first time, that inhibition of <START=Organic Chemical> CDCF <END=Organic Chemical> uptake in MDCKII - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ABCC2 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> vesicles not only provides a screening assay to assess <START=Gene or Genome> MRP2 <END=Gene or Genome> drug - drug interaction potential, but is also predictive of human <START=Gene or Genome> MRP2 <END=Gene or Genome> - mediated biliary excretion."}, {"PMID": 17119350, "id": 2, "text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [117, 123], "name": "serine", "tok_span": [21, 22], "new_tok_span": [26, 27]}, {"ent_type": "CHEMICAL", "char_span": [138, 141], "name": "NH2", "tok_span": [26, 28], "new_tok_span": [32, 34]}, {"ent_type": "CHEMICAL", "char_span": [378, 388], "name": "paclitaxel", "tok_span": [75, 76], "new_tok_span": [92, 93]}, {"ent_type": "GENE", "char_span": [56, 102], "name": "Fas-associated death domain-containing protein", "tok_span": [7, 15], "new_tok_span": [7, 15]}, {"ent_type": "GENE", "char_span": [104, 108], "name": "FADD", "tok_span": [16, 18], "new_tok_span": [18, 20]}, {"ent_type": "GENE", "char_span": [132, 157], "name": "c-jun NH2-terminal kinase", "tok_span": [23, 31], "new_tok_span": [29, 37]}, {"ent_type": "GENE", "char_span": [159, 162], "name": "JNK", "tok_span": [32, 33], "new_tok_span": [39, 40]}, {"ent_type": "GENE", "char_span": [279, 284], "name": "Bcl-2", "tok_span": [56, 59], "new_tok_span": [65, 68]}, {"ent_type": "GENE", "char_span": [315, 318], "name": "JNK", "tok_span": [62, 63], "new_tok_span": [73, 74]}, {"ent_type": "GENE", "char_span": [319, 323], "name": "FADD", "tok_span": [64, 66], "new_tok_span": [78, 80]}], "relation_list": [{"subject": "serine", "sbj_char_span": [117, 123], "object": "Fas-associated death domain-containing protein", "obj_char_span": [56, 102], "rel_type": "part of", "sbj_tok_span": [21, 22], "obj_tok_span": [7, 15], "new_sbj_tok_span": [26, 27], "new_obj_tok_span": [7, 15]}, {"subject": "serine", "sbj_char_span": [117, 123], "object": "FADD", "obj_char_span": [104, 108], "rel_type": "part of", "sbj_tok_span": [21, 22], "obj_tok_span": [16, 18], "new_sbj_tok_span": [26, 27], "new_obj_tok_span": [18, 20]}, {"subject": "paclitaxel", "sbj_char_span": [378, 388], "object": "FADD", "obj_char_span": [319, 323], "rel_type": "activator", "sbj_tok_span": [75, 76], "obj_tok_span": [64, 66], "new_sbj_tok_span": [92, 93], "new_obj_tok_span": [78, 80]}, {"subject": "paclitaxel", "sbj_char_span": [378, 388], "object": "JNK", "obj_char_span": [315, 318], "rel_type": "activator", "sbj_tok_span": [75, 76], "obj_tok_span": [62, 63], "new_sbj_tok_span": [92, 93], "new_obj_tok_span": [73, 74]}, {"subject": "paclitaxel", "sbj_char_span": [378, 388], "object": "c-jun NH2-terminal kinase", "obj_char_span": [132, 157], "rel_type": "activator", "sbj_tok_span": [75, 76], "obj_tok_span": [23, 31], "new_sbj_tok_span": [92, 93], "new_obj_tok_span": [29, 37]}, {"subject": "paclitaxel", "sbj_char_span": [378, 388], "object": "JNK", "obj_char_span": [159, 162], "rel_type": "activator", "sbj_tok_span": [75, 76], "obj_tok_span": [32, 33], "new_sbj_tok_span": [92, 93], "new_obj_tok_span": [39, 40]}, {"subject": "paclitaxel", "sbj_char_span": [378, 388], "object": "Fas-associated death domain-containing protein", "obj_char_span": [56, 102], "rel_type": "activator", "sbj_tok_span": [75, 76], "obj_tok_span": [7, 15], "new_sbj_tok_span": [92, 93], "new_obj_tok_span": [7, 15]}, {"subject": "paclitaxel", "sbj_char_span": [378, 388], "object": "FADD", "obj_char_span": [104, 108], "rel_type": "activator", "sbj_tok_span": [75, 76], "obj_tok_span": [16, 18], "new_sbj_tok_span": [92, 93], "new_obj_tok_span": [18, 20]}], "umls_entity_list": [{"mention": "FADD", "char_span": [104, 108], "sem_type": "Gene or Genome", "tok_span": [16, 18], "new_tok_span": [18, 20]}, {"mention": "FADD", "char_span": [319, 323], "sem_type": "Gene or Genome", "tok_span": [64, 66], "new_tok_span": [78, 80]}, {"mention": "FADD", "char_span": [104, 108], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 18], "new_tok_span": [18, 20]}, {"mention": "FADD", "char_span": [319, 323], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [64, 66], "new_tok_span": [78, 80]}, {"mention": "serine", "char_span": [117, 123], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [21, 22], "new_tok_span": [26, 27]}, {"mention": "Bcl-2", "char_span": [279, 284], "sem_type": "Gene or Genome", "tok_span": [56, 59], "new_tok_span": [65, 68]}, {"mention": "JNK", "char_span": [159, 162], "sem_type": "Gene or Genome", "tok_span": [32, 33], "new_tok_span": [39, 40]}, {"mention": "JNK", "char_span": [315, 318], "sem_type": "Gene or Genome", "tok_span": [62, 63], "new_tok_span": [73, 74]}, {"mention": "paclitaxel", "char_span": [378, 388], "sem_type": "Pharmacologic Substance", "tok_span": [75, 76], "new_tok_span": [92, 93]}], "new_text": "We have previously demonstrated that phosphorylation of Fas - associated death domain - containing protein ( <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> FADD <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ) at 194 <START=Amino Acid, Peptide, or Protein> serine <END=Amino Acid, Peptide, or Protein> through c - jun NH2 - terminal kinase ( <START=Gene or Genome> JNK <END=Gene or Genome> ) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2 / M, and that <START=Gene or Genome> Bcl - 2 <END=Gene or Genome> phosphorylation downstream of <START=Gene or Genome> JNK <END=Gene or Genome> / <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> FADD <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> plays an important role in cell growth suppression by <START=Pharmacologic Substance> paclitaxel <END=Pharmacologic Substance>."}, {"PMID": 18237195, "id": 4, "text": "In the presence of chloride (Cl-), melatonin inactivated MPO at two points in the classic peroxidase cycle through binding to MPO to form an inactive complex, melatonin-MPO-Cl, and accelerating MPO compound II formation, an inactive form of MPO. Inactivation of MPO was mirrored by the direct conversion of MPO-Fe(III) to MPO compound II without any sign of compound I accumulation.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [19, 27], "name": "chloride", "tok_span": [4, 5], "new_tok_span": [4, 5]}, {"ent_type": "CHEMICAL", "char_span": [29, 32], "name": "Cl-", "tok_span": [6, 8], "new_tok_span": [6, 8]}, {"ent_type": "CHEMICAL", "char_span": [35, 44], "name": "melatonin", "tok_span": [10, 11], "new_tok_span": [10, 11]}, {"ent_type": "CHEMICAL", "char_span": [159, 168], "name": "melatonin", "tok_span": [33, 34], "new_tok_span": [39, 40]}, {"ent_type": "CHEMICAL", "char_span": [173, 175], "name": "Cl", "tok_span": [38, 39], "new_tok_span": [46, 47]}, {"ent_type": "CHEMICAL", "char_span": [311, 318], "name": "Fe(III)", "tok_span": [71, 75], "new_tok_span": [93, 97]}, {"ent_type": "GENE", "char_span": [57, 60], "name": "MPO", "tok_span": [12, 14], "new_tok_span": [13, 15]}, {"ent_type": "GENE", "char_span": [90, 100], "name": "peroxidase", "tok_span": [20, 21], "new_tok_span": [23, 24]}, {"ent_type": "GENE", "char_span": [126, 129], "name": "MPO", "tok_span": [25, 27], "new_tok_span": [30, 32]}, {"ent_type": "GENE", "char_span": [169, 172], "name": "MPO", "tok_span": [35, 37], "new_tok_span": [42, 44]}, {"ent_type": "GENE", "char_span": [194, 197], "name": "MPO", "tok_span": [42, 44], "new_tok_span": [51, 53]}, {"ent_type": "GENE", "char_span": [241, 244], "name": "MPO", "tok_span": [52, 54], "new_tok_span": [69, 71]}, {"ent_type": "GENE", "char_span": [262, 265], "name": "MPO", "tok_span": [58, 60], "new_tok_span": [77, 79]}, {"ent_type": "GENE", "char_span": [307, 310], "name": "MPO", "tok_span": [68, 70], "new_tok_span": [89, 91]}, {"ent_type": "GENE", "char_span": [322, 325], "name": "MPO", "tok_span": [76, 78], "new_tok_span": [107, 109]}], "relation_list": [{"subject": "melatonin", "sbj_char_span": [35, 44], "object": "MPO", "obj_char_span": [57, 60], "rel_type": "inhibitor", "sbj_tok_span": [10, 11], "obj_tok_span": [12, 14], "new_sbj_tok_span": [10, 11], "new_obj_tok_span": [13, 15]}, {"subject": "melatonin", "sbj_char_span": [35, 44], "object": "MPO", "obj_char_span": [126, 129], "rel_type": "regulator", "sbj_tok_span": [10, 11], "obj_tok_span": [25, 27], "new_sbj_tok_span": [10, 11], "new_obj_tok_span": [30, 32]}, {"subject": "melatonin", "sbj_char_span": [159, 168], "object": "MPO", "obj_char_span": [169, 172], "rel_type": "regulator", "sbj_tok_span": [33, 34], "obj_tok_span": [35, 37], "new_sbj_tok_span": [39, 40], "new_obj_tok_span": [42, 44]}, {"subject": "Cl", "sbj_char_span": [173, 175], "object": "MPO", "obj_char_span": [169, 172], "rel_type": "regulator", "sbj_tok_span": [38, 39], "obj_tok_span": [35, 37], "new_sbj_tok_span": [46, 47], "new_obj_tok_span": [42, 44]}, {"subject": "Fe(III)", "sbj_char_span": [311, 318], "object": "MPO", "obj_char_span": [307, 310], "rel_type": "regulator", "sbj_tok_span": [71, 75], "obj_tok_span": [68, 70], "new_sbj_tok_span": [93, 97], "new_obj_tok_span": [89, 91]}], "umls_entity_list": [{"mention": "MPO", "char_span": [57, 60], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [12, 14], "new_tok_span": [13, 15]}, {"mention": "MPO", "char_span": [126, 129], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [25, 27], "new_tok_span": [30, 32]}, {"mention": "MPO", "char_span": [169, 172], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [35, 37], "new_tok_span": [42, 44]}, {"mention": "MPO", "char_span": [194, 197], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [42, 44], "new_tok_span": [51, 53]}, {"mention": "mpo", "char_span": [200, 203], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [44, 45], "new_tok_span": [55, 56]}, {"mention": "MPO", "char_span": [241, 244], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [52, 54], "new_tok_span": [69, 71]}, {"mention": "MPO", "char_span": [262, 265], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [58, 60], "new_tok_span": [77, 79]}, {"mention": "MPO", "char_span": [307, 310], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [68, 70], "new_tok_span": [89, 91]}, {"mention": "MPO", "char_span": [322, 325], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [76, 78], "new_tok_span": [107, 109]}, {"mention": "mpo", "char_span": [328, 331], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [78, 79], "new_tok_span": [111, 112]}, {"mention": "mpo", "char_span": [360, 363], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [84, 85], "new_tok_span": [123, 124]}, {"mention": "peroxidase", "char_span": [90, 100], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [20, 21], "new_tok_span": [23, 24]}, {"mention": "II", "char_span": [207, 209], "sem_type": "Gene or Genome", "tok_span": [45, 46], "new_tok_span": [59, 60]}, {"mention": "II", "char_span": [314, 316], "sem_type": "Gene or Genome", "tok_span": [73, 74], "new_tok_span": [99, 100]}, {"mention": "II", "char_span": [315, 317], "sem_type": "Gene or Genome", "tok_span": [73, 74], "new_tok_span": [99, 100]}, {"mention": "II", "char_span": [335, 337], "sem_type": "Gene or Genome", "tok_span": [79, 80], "new_tok_span": [115, 116]}, {"mention": "II", "char_span": [207, 209], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [45, 46], "new_tok_span": [59, 60]}, {"mention": "II", "char_span": [314, 316], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [73, 74], "new_tok_span": [99, 100]}, {"mention": "II", "char_span": [315, 317], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [73, 74], "new_tok_span": [99, 100]}, {"mention": "II", "char_span": [335, 337], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [79, 80], "new_tok_span": [115, 116]}], "new_text": "In the presence of chloride ( Cl - ), melatonin inactivated <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> at two points in the classic <START=Amino Acid, Peptide, or Protein> peroxidase <END=Amino Acid, Peptide, or Protein> cycle through binding to <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> to form an inactive complex, melatonin - <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> - Cl, and accelerating <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> compound <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> II <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> formation, an inactive form of <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein>. Inactivation of <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> was mirrored by the direct conversion of <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> - Fe ( <START=Gene or Genome> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> III <END=Gene or Genome> <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> <END=Amino Acid, Peptide, or Protein> ) to <START=Amino Acid, Peptide, or Protein> MPO <END=Amino Acid, Peptide, or Protein> <START=Amino Acid, Peptide, or Protein> compound <END=Amino Acid, Peptide, or Protein> <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> II <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> without any sign of <START=Amino Acid, Peptide, or Protein> compound <END=Amino Acid, Peptide, or Protein> I accumulation."}, {"PMID": 22614004, "id": 3, "text": "We have previously shown that the inhibitor of pyruvate dehydrogenase kinase (PDK) dichloroacetate (DCA) activates glucose oxidation and induces apoptosis in cancer cells in vitro and in vivo.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [47, 55], "name": "pyruvate", "tok_span": [8, 9], "new_tok_span": [9, 10]}, {"ent_type": "CHEMICAL", "char_span": [83, 98], "name": "dichloroacetate", "tok_span": [15, 20], "new_tok_span": [18, 23]}, {"ent_type": "CHEMICAL", "char_span": [100, 103], "name": "DCA", "tok_span": [21, 23], "new_tok_span": [25, 27]}, {"ent_type": "CHEMICAL", "char_span": [115, 122], "name": "glucose", "tok_span": [25, 26], "new_tok_span": [29, 30]}, {"ent_type": "GENE", "char_span": [47, 76], "name": "pyruvate dehydrogenase kinase", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"ent_type": "GENE", "char_span": [78, 81], "name": "PDK", "tok_span": [12, 14], "new_tok_span": [14, 16]}], "relation_list": [{"subject": "dichloroacetate", "sbj_char_span": [83, 98], "object": "pyruvate dehydrogenase kinase", "obj_char_span": [47, 76], "rel_type": "inhibitor", "sbj_tok_span": [15, 20], "obj_tok_span": [8, 11], "new_sbj_tok_span": [18, 23], "new_obj_tok_span": [9, 12]}, {"subject": "dichloroacetate", "sbj_char_span": [83, 98], "object": "PDK", "obj_char_span": [78, 81], "rel_type": "inhibitor", "sbj_tok_span": [15, 20], "obj_tok_span": [12, 14], "new_sbj_tok_span": [18, 23], "new_obj_tok_span": [14, 16]}, {"subject": "DCA", "sbj_char_span": [100, 103], "object": "pyruvate dehydrogenase kinase", "obj_char_span": [47, 76], "rel_type": "inhibitor", "sbj_tok_span": [21, 23], "obj_tok_span": [8, 11], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [9, 12]}, {"subject": "DCA", "sbj_char_span": [100, 103], "object": "PDK", "obj_char_span": [78, 81], "rel_type": "inhibitor", "sbj_tok_span": [21, 23], "obj_tok_span": [12, 14], "new_sbj_tok_span": [25, 27], "new_obj_tok_span": [14, 16]}], "umls_entity_list": [{"mention": "pyruvate dehydrogenase kinase", "char_span": [47, 76], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [8, 11], "new_tok_span": [9, 12]}, {"mention": "dichloroacetate", "char_span": [83, 98], "sem_type": "Pharmacologic Substance", "tok_span": [15, 20], "new_tok_span": [18, 23]}], "new_text": "We have previously shown that the inhibitor of <START=Amino Acid, Peptide, or Protein> pyruvate dehydrogenase kinase <END=Amino Acid, Peptide, or Protein> ( PDK ) <START=Pharmacologic Substance> dichloroacetate <END=Pharmacologic Substance> ( DCA ) activates glucose oxidation and induces apoptosis in cancer cells in vitro and in vivo."}, {"PMID": 17046555, "id": 5, "text": "Treatment of the cells with the NADPH oxidase inhibitors, apocynin and diphenylene iodonium, inhibited these effects.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [32, 37], "name": "NADPH", "tok_span": [6, 7], "new_tok_span": [6, 7]}, {"ent_type": "CHEMICAL", "char_span": [58, 66], "name": "apocynin", "tok_span": [10, 14], "new_tok_span": [11, 15]}, {"ent_type": "CHEMICAL", "char_span": [71, 91], "name": "diphenylene iodonium", "tok_span": [15, 20], "new_tok_span": [17, 22]}, {"ent_type": "GENE", "char_span": [32, 45], "name": "NADPH oxidase", "tok_span": [6, 8], "new_tok_span": [6, 8]}], "relation_list": [{"subject": "apocynin", "sbj_char_span": [58, 66], "object": "NADPH oxidase", "obj_char_span": [32, 45], "rel_type": "inhibitor", "sbj_tok_span": [10, 14], "obj_tok_span": [6, 8], "new_sbj_tok_span": [11, 15], "new_obj_tok_span": [6, 8]}, {"subject": "diphenylene iodonium", "sbj_char_span": [71, 91], "object": "NADPH oxidase", "obj_char_span": [32, 45], "rel_type": "inhibitor", "sbj_tok_span": [15, 20], "obj_tok_span": [6, 8], "new_sbj_tok_span": [17, 22], "new_obj_tok_span": [6, 8]}], "umls_entity_list": [{"mention": "apocynin", "char_span": [58, 66], "sem_type": "Pharmacologic Substance", "tok_span": [10, 14], "new_tok_span": [11, 15]}], "new_text": "Treatment of the cells with the NADPH oxidase inhibitors, <START=Pharmacologic Substance> apocynin <END=Pharmacologic Substance> and diphenylene iodonium, inhibited these effects."}, {"PMID": 17034761, "id": 7, "text": "IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by auranofin.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [108, 117], "name": "auranofin", "tok_span": [24, 27], "new_tok_span": [39, 42]}, {"ent_type": "GENE", "char_span": [0, 4], "name": "IRF3", "tok_span": [0, 2], "new_tok_span": [2, 4]}, {"ent_type": "GENE", "char_span": [27, 32], "name": "MyD88", "tok_span": [5, 8], "new_tok_span": [11, 14]}, {"ent_type": "GENE", "char_span": [67, 71], "name": "TRIF", "tok_span": [13, 15], "new_tok_span": [22, 24]}, {"ent_type": "GENE", "char_span": [76, 80], "name": "TBK1", "tok_span": [16, 19], "new_tok_span": [28, 31]}], "relation_list": [{"subject": "auranofin", "sbj_char_span": [108, 117], "object": "TRIF", "obj_char_span": [67, 71], "rel_type": "regulator", "sbj_tok_span": [24, 27], "obj_tok_span": [13, 15], "new_sbj_tok_span": [39, 42], "new_obj_tok_span": [22, 24]}, {"subject": "auranofin", "sbj_char_span": [108, 117], "object": "TBK1", "obj_char_span": [76, 80], "rel_type": "regulator", "sbj_tok_span": [24, 27], "obj_tok_span": [16, 19], "new_sbj_tok_span": [39, 42], "new_obj_tok_span": [28, 31]}], "umls_entity_list": [{"mention": "IRF3", "char_span": [0, 4], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 2], "new_tok_span": [2, 4]}, {"mention": "IRF3", "char_span": [0, 4], "sem_type": "Gene or Genome", "tok_span": [0, 2], "new_tok_span": [2, 4]}, {"mention": "MyD88", "char_span": [27, 32], "sem_type": "Gene or Genome", "tok_span": [5, 8], "new_tok_span": [11, 14]}, {"mention": "MyD88", "char_span": [27, 32], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 8], "new_tok_span": [11, 14]}, {"mention": "TRIF", "char_span": [67, 71], "sem_type": "Gene or Genome", "tok_span": [13, 15], "new_tok_span": [22, 24]}, {"mention": "TBK1", "char_span": [76, 80], "sem_type": "Gene or Genome", "tok_span": [16, 19], "new_tok_span": [28, 31]}, {"mention": "TBK1", "char_span": [76, 80], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [16, 19], "new_tok_span": [28, 31]}, {"mention": "auranofin", "char_span": [108, 117], "sem_type": "Pharmacologic Substance", "tok_span": [24, 27], "new_tok_span": [39, 42]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> IRF3 <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> activation induced by <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> MyD88 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> - independent signaling components, <START=Gene or Genome> TRIF <END=Gene or Genome> and <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> TBK1 <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein>, was also downregulated by <START=Pharmacologic Substance> auranofin <END=Pharmacologic Substance>."}, {"PMID": 3094574, "id": 0, "text": "Tyrosinase catalyzes an unusual oxidative decarboxylation of 3,4-dihydroxymandelate.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [61, 83], "name": "3,4-dihydroxymandelate", "tok_span": [12, 21], "new_tok_span": [18, 27]}, {"ent_type": "GENE", "char_span": [0, 10], "name": "Tyrosinase", "tok_span": [0, 3], "new_tok_span": [2, 5]}], "relation_list": [{"subject": "3,4-dihydroxymandelate", "sbj_char_span": [61, 83], "object": "Tyrosinase", "obj_char_span": [0, 10], "rel_type": "product or substrate", "sbj_tok_span": [12, 21], "obj_tok_span": [0, 3], "new_sbj_tok_span": [18, 27], "new_obj_tok_span": [2, 5]}], "umls_entity_list": [{"mention": "Tyrosinase", "char_span": [0, 10], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"mention": "Tyrosinase", "char_span": [0, 10], "sem_type": "Gene or Genome", "tok_span": [0, 3], "new_tok_span": [2, 5]}, {"mention": "an", "char_span": [21, 23], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [5, 6], "new_tok_span": [10, 11]}, {"mention": "an", "char_span": [75, 77], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [18, 19], "new_tok_span": [25, 26]}], "new_text": "<START=Amino Acid, Peptide, or Protein> <START=Gene or Genome> Tyrosinase <END=Amino Acid, Peptide, or Protein> <END=Gene or Genome> catalyzes <START=Amino Acid, Peptide, or Protein> an <END=Amino Acid, Peptide, or Protein> unusual oxidative decarboxylation of 3, 4 - dihydroxy <START=Amino Acid, Peptide, or Protein>man <END=Amino Acid, Peptide, or Protein>delate."}, {"PMID": 23523950, "id": 4, "text": "We found that AVM induced upregulation of P-gp protein expression, increased P-gp ATPase activity and enhanced cellular efflux of the P-gp substrate rhodamine 123 from cells.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [14, 17], "name": "AVM", "tok_span": [3, 5], "new_tok_span": [3, 5]}, {"ent_type": "CHEMICAL", "char_span": [149, 162], "name": "rhodamine 123", "tok_span": [30, 33], "new_tok_span": [43, 46]}, {"ent_type": "GENE", "char_span": [42, 46], "name": "P-gp", "tok_span": [8, 11], "new_tok_span": [8, 11]}, {"ent_type": "GENE", "char_span": [77, 81], "name": "P-gp", "tok_span": [15, 18], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [82, 88], "name": "ATPase", "tok_span": [18, 19], "new_tok_span": [26, 27]}, {"ent_type": "GENE", "char_span": [134, 138], "name": "P-gp", "tok_span": [26, 29], "new_tok_span": [34, 37]}], "relation_list": [{"subject": "AVM", "sbj_char_span": [14, 17], "object": "P-gp", "obj_char_span": [42, 46], "rel_type": "regulator", "sbj_tok_span": [3, 5], "obj_tok_span": [8, 11], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [8, 11]}, {"subject": "AVM", "sbj_char_span": [14, 17], "object": "P-gp", "obj_char_span": [77, 81], "rel_type": "activator", "sbj_tok_span": [3, 5], "obj_tok_span": [15, 18], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [19, 22]}, {"subject": "AVM", "sbj_char_span": [14, 17], "object": "ATPase", "obj_char_span": [82, 88], "rel_type": "activator", "sbj_tok_span": [3, 5], "obj_tok_span": [18, 19], "new_sbj_tok_span": [3, 5], "new_obj_tok_span": [26, 27]}, {"subject": "rhodamine 123", "sbj_char_span": [149, 162], "object": "P-gp", "obj_char_span": [134, 138], "rel_type": "product or substrate", "sbj_tok_span": [30, 33], "obj_tok_span": [26, 29], "new_sbj_tok_span": [43, 46], "new_obj_tok_span": [34, 37]}], "umls_entity_list": [{"mention": "gp", "char_span": [44, 46], "sem_type": "Gene or Genome", "tok_span": [10, 11], "new_tok_span": [12, 13]}, {"mention": "gp", "char_span": [79, 81], "sem_type": "Gene or Genome", "tok_span": [17, 18], "new_tok_span": [23, 24]}, {"mention": "gp", "char_span": [136, 138], "sem_type": "Gene or Genome", "tok_span": [28, 29], "new_tok_span": [38, 39]}, {"mention": "gp", "char_span": [44, 46], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [10, 11], "new_tok_span": [12, 13]}, {"mention": "gp", "char_span": [79, 81], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [17, 18], "new_tok_span": [23, 24]}, {"mention": "gp", "char_span": [136, 138], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [28, 29], "new_tok_span": [38, 39]}, {"mention": "rhodamine", "char_span": [149, 158], "sem_type": "Organic Chemical", "tok_span": [30, 32], "new_tok_span": [43, 45]}], "new_text": "We found that AVM induced upregulation of P - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> gp <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> protein expression, increased P - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> gp <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> ATPase activity and enhanced cellular efflux of the P - <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> gp <END=Gene or Genome> <END=Amino Acid, Peptide, or Protein> substrate <START=Organic Chemical> rhodamine <END=Organic Chemical> 123 from cells."}, {"PMID": 10432475, "id": 2, "text": "The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [42, 52], "name": "WAY100,635", "tok_span": [10, 16], "new_tok_span": [12, 18]}, {"ent_type": "CHEMICAL", "char_span": [78, 90], "name": "(-)-pindolol", "tok_span": [20, 28], "new_tok_span": [22, 30]}, {"ent_type": "CHEMICAL", "char_span": [111, 113], "name": "DA", "tok_span": [32, 33], "new_tok_span": [36, 37]}, {"ent_type": "CHEMICAL", "char_span": [118, 121], "name": "NAD", "tok_span": [34, 35], "new_tok_span": [38, 39]}, {"ent_type": "CHEMICAL", "char_span": [169, 178], "name": "SB224,289", "tok_span": [47, 53], "new_tok_span": [51, 57]}, {"ent_type": "GENE", "char_span": [14, 20], "name": "5-HT1A", "tok_span": [2, 7], "new_tok_span": [2, 7]}, {"ent_type": "GENE", "char_span": [150, 156], "name": "5-HT1B", "tok_span": [40, 45], "new_tok_span": [44, 49]}], "relation_list": [{"subject": "WAY100,635", "sbj_char_span": [42, 52], "object": "5-HT1A", "obj_char_span": [14, 20], "rel_type": "agonist or antagonist", "sbj_tok_span": [10, 16], "obj_tok_span": [2, 7], "new_sbj_tok_span": [12, 18], "new_obj_tok_span": [2, 7]}, {"subject": "SB224,289", "sbj_char_span": [169, 178], "object": "5-HT1B", "obj_char_span": [150, 156], "rel_type": "agonist or antagonist", "sbj_tok_span": [47, 53], "obj_tok_span": [40, 45], "new_sbj_tok_span": [51, 57], "new_obj_tok_span": [44, 49]}], "umls_entity_list": [{"mention": "receptor antagonist", "char_span": [21, 40], "sem_type": "Pharmacologic Substance", "tok_span": [7, 9], "new_tok_span": [8, 10]}, {"mention": "pindolol", "char_span": [82, 90], "sem_type": "Pharmacologic Substance", "tok_span": [24, 28], "new_tok_span": [27, 31]}], "new_text": "The selective 5 - HT1A <START=Pharmacologic Substance> receptor antagonist <END=Pharmacologic Substance>, WAY100, 635, slightly attenuated the ( - ) - <START=Pharmacologic Substance> pindolol <END=Pharmacologic Substance> - induced increase in DA and NAD levels, while the selective 5 - HT1B antagonist, SB224, 289, was ineffective."}, {"PMID": 23583259, "id": 5, "text": "Rilpivirine, etravirine, and efavirenz, but not nevirapine or delavirdine, increased hPXR target gene (CYP3A4) expression in primary cultures of human hepatocytes.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [0, 11], "name": "Rilpivirine", "tok_span": [0, 5], "new_tok_span": [0, 5]}, {"ent_type": "CHEMICAL", "char_span": [13, 23], "name": "etravirine", "tok_span": [6, 10], "new_tok_span": [6, 10]}, {"ent_type": "CHEMICAL", "char_span": [29, 38], "name": "efavirenz", "tok_span": [12, 15], "new_tok_span": [12, 15]}, {"ent_type": "CHEMICAL", "char_span": [48, 58], "name": "nevirapine", "tok_span": [18, 21], "new_tok_span": [18, 21]}, {"ent_type": "CHEMICAL", "char_span": [62, 73], "name": "delavirdine", "tok_span": [22, 26], "new_tok_span": [22, 26]}, {"ent_type": "GENE", "char_span": [85, 89], "name": "hPXR", "tok_span": [28, 31], "new_tok_span": [28, 31]}, {"ent_type": "GENE", "char_span": [103, 109], "name": "CYP3A4", "tok_span": [34, 38], "new_tok_span": [36, 40]}], "relation_list": [{"subject": "Rilpivirine", "sbj_char_span": [0, 11], "object": "hPXR", "obj_char_span": [85, 89], "rel_type": "activator", "sbj_tok_span": [0, 5], "obj_tok_span": [28, 31], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [28, 31]}, {"subject": "etravirine", "sbj_char_span": [13, 23], "object": "hPXR", "obj_char_span": [85, 89], "rel_type": "activator", "sbj_tok_span": [6, 10], "obj_tok_span": [28, 31], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [28, 31]}, {"subject": "efavirenz", "sbj_char_span": [29, 38], "object": "hPXR", "obj_char_span": [85, 89], "rel_type": "activator", "sbj_tok_span": [12, 15], "obj_tok_span": [28, 31], "new_sbj_tok_span": [12, 15], "new_obj_tok_span": [28, 31]}, {"subject": "Rilpivirine", "sbj_char_span": [0, 11], "object": "CYP3A4", "obj_char_span": [103, 109], "rel_type": "regulator", "sbj_tok_span": [0, 5], "obj_tok_span": [34, 38], "new_sbj_tok_span": [0, 5], "new_obj_tok_span": [36, 40]}, {"subject": "etravirine", "sbj_char_span": [13, 23], "object": "CYP3A4", "obj_char_span": [103, 109], "rel_type": "regulator", "sbj_tok_span": [6, 10], "obj_tok_span": [34, 38], "new_sbj_tok_span": [6, 10], "new_obj_tok_span": [36, 40]}, {"subject": "efavirenz", "sbj_char_span": [29, 38], "object": "CYP3A4", "obj_char_span": [103, 109], "rel_type": "regulator", "sbj_tok_span": [12, 15], "obj_tok_span": [34, 38], "new_sbj_tok_span": [12, 15], "new_obj_tok_span": [36, 40]}], "umls_entity_list": [{"mention": "target gene", "char_span": [90, 101], "sem_type": "Gene or Genome", "tok_span": [31, 33], "new_tok_span": [32, 34]}], "new_text": "Rilpivirine, etravirine, and efavirenz, but not nevirapine or delavirdine, increased hPXR <START=Gene or Genome> target gene <END=Gene or Genome> ( CYP3A4 ) expression in primary cultures of human hepatocytes."}, {"PMID": 23541371, "id": 3, "text": "Nax channels began to open when [Na(+)]o exceeded ∼150 mM without ET-3, but opened fully at a physiological [Na(+)]o (135-145 mM) with 1 nM ET-3.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [33, 38], "name": "Na(+)", "tok_span": [8, 12], "new_tok_span": [8, 12]}, {"ent_type": "CHEMICAL", "char_span": [109, 114], "name": "Na(+)", "tok_span": [30, 34], "new_tok_span": [30, 34]}, {"ent_type": "GENE", "char_span": [0, 12], "name": "Nax channels", "tok_span": [0, 3], "new_tok_span": [0, 3]}, {"ent_type": "GENE", "char_span": [66, 70], "name": "ET-3", "tok_span": [19, 22], "new_tok_span": [19, 22]}, {"ent_type": "GENE", "char_span": [140, 144], "name": "ET-3", "tok_span": [45, 48], "new_tok_span": [45, 48]}], "relation_list": [{"subject": "Na(+)", "sbj_char_span": [33, 38], "object": "Nax channels", "obj_char_span": [0, 12], "rel_type": "product or substrate", "sbj_tok_span": [8, 12], "obj_tok_span": [0, 3], "new_sbj_tok_span": [8, 12], "new_obj_tok_span": [0, 3]}, {"subject": "Na(+)", "sbj_char_span": [109, 114], "object": "Nax channels", "obj_char_span": [0, 12], "rel_type": "product or substrate", "sbj_tok_span": [30, 34], "obj_tok_span": [0, 3], "new_sbj_tok_span": [30, 34], "new_obj_tok_span": [0, 3]}], "umls_entity_list": [], "new_text": "Nax channels began to open when [ Na ( + ) ] o exceeded ∼150 mM without ET - 3, but opened fully at a physiological [ Na ( + ) ] o ( 135 - 145 mM ) with 1 nM ET - 3."}, {"PMID": 23200945, "id": 1, "text": "Previous studies showed that fitter yeast (Saccharomyces cerevisiae) that can grow by fermenting glucose in the presence of allyl alcohol, which is oxidized by alcohol dehydrogenase I (ADH1) to toxic acrolein, had mutations in the ADH1 gene that led to decreased ADH activity.", "entity_list": [{"ent_type": "CHEMICAL", "char_span": [124, 137], "name": "allyl alcohol", "tok_span": [22, 25], "new_tok_span": [26, 29]}, {"ent_type": "CHEMICAL", "char_span": [160, 167], "name": "alcohol", "tok_span": [30, 31], "new_tok_span": [37, 38]}, {"ent_type": "CHEMICAL", "char_span": [200, 208], "name": "acrolein", "tok_span": [40, 43], "new_tok_span": [53, 56]}, {"ent_type": "CHEMICAL", "char_span": [97, 104], "name": "glucose", "tok_span": [17, 18], "new_tok_span": [20, 21]}, {"ent_type": "GENE", "char_span": [160, 183], "name": "alcohol dehydrogenase I", "tok_span": [30, 33], "new_tok_span": [37, 40]}, {"ent_type": "GENE", "char_span": [185, 189], "name": "ADH1", "tok_span": [34, 37], "new_tok_span": [44, 47]}, {"ent_type": "GENE", "char_span": [231, 235], "name": "ADH1", "tok_span": [48, 51], "new_tok_span": [64, 67]}, {"ent_type": "GENE", "char_span": [263, 266], "name": "ADH", "tok_span": [56, 58], "new_tok_span": [77, 79]}], "relation_list": [{"subject": "allyl alcohol", "sbj_char_span": [124, 137], "object": "alcohol dehydrogenase I", "obj_char_span": [160, 183], "rel_type": "product or substrate", "sbj_tok_span": [22, 25], "obj_tok_span": [30, 33], "new_sbj_tok_span": [26, 29], "new_obj_tok_span": [37, 40]}, {"subject": "allyl alcohol", "sbj_char_span": [124, 137], "object": "ADH1", "obj_char_span": [185, 189], "rel_type": "product or substrate", "sbj_tok_span": [22, 25], "obj_tok_span": [34, 37], "new_sbj_tok_span": [26, 29], "new_obj_tok_span": [44, 47]}, {"subject": "acrolein", "sbj_char_span": [200, 208], "object": "alcohol dehydrogenase I", "obj_char_span": [160, 183], "rel_type": "product or substrate", "sbj_tok_span": [40, 43], "obj_tok_span": [30, 33], "new_sbj_tok_span": [53, 56], "new_obj_tok_span": [37, 40]}, {"subject": "acrolein", "sbj_char_span": [200, 208], "object": "ADH1", "obj_char_span": [185, 189], "rel_type": "product or substrate", "sbj_tok_span": [40, 43], "obj_tok_span": [34, 37], "new_sbj_tok_span": [53, 56], "new_obj_tok_span": [44, 47]}], "umls_entity_list": [{"mention": "yeast", "char_span": [36, 41], "sem_type": "Pharmacologic Substance", "tok_span": [6, 7], "new_tok_span": [7, 8]}, {"mention": "glucose", "char_span": [97, 104], "sem_type": "Pharmacologic Substance", "tok_span": [17, 18], "new_tok_span": [20, 21]}, {"mention": "alcohol", "char_span": [130, 137], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [24, 25], "new_tok_span": [29, 30]}, {"mention": "alcohol", "char_span": [160, 167], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [30, 31], "new_tok_span": [37, 38]}, {"mention": "ADH1", "char_span": [185, 189], "sem_type": "Gene or Genome", "tok_span": [34, 37], "new_tok_span": [44, 47]}, {"mention": "ADH1", "char_span": [231, 235], "sem_type": "Gene or Genome", "tok_span": [48, 51], "new_tok_span": [64, 67]}, {"mention": "acrolein", "char_span": [200, 208], "sem_type": "Organic Chemical", "tok_span": [40, 43], "new_tok_span": [53, 56]}, {"mention": "led", "char_span": [246, 249], "sem_type": "Gene or Genome", "tok_span": [53, 54], "new_tok_span": [72, 73]}, {"mention": "ADH", "char_span": [185, 188], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [34, 36], "new_tok_span": [44, 46]}, {"mention": "ADH", "char_span": [231, 234], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [48, 50], "new_tok_span": [64, 66]}, {"mention": "ADH", "char_span": [263, 266], "sem_type": "Amino Acid, Peptide, or Protein", "tok_span": [56, 58], "new_tok_span": [77, 79]}], "new_text": "Previous studies showed that fitter <START=Pharmacologic Substance> yeast <END=Pharmacologic Substance> ( Saccharomyces cerevisiae ) that can grow by fermenting <START=Pharmacologic Substance> glucose <END=Pharmacologic Substance> in the presence of allyl <START=Amino Acid, Peptide, or Protein> alcohol <END=Amino Acid, Peptide, or Protein>, which is oxidized by <START=Amino Acid, Peptide, or Protein> alcohol <END=Amino Acid, Peptide, or Protein> dehydrogenase I ( <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ADH <END=Amino Acid, Peptide, or Protein>1 <END=Gene or Genome> ) to toxic <START=Organic Chemical> acrolein <END=Organic Chemical>, had mutations in the <START=Gene or Genome> <START=Amino Acid, Peptide, or Protein> ADH <END=Amino Acid, Peptide, or Protein>1 <END=Gene or Genome> gene that <START=Gene or Genome> led <END=Gene or Genome> to decreased <START=Amino Acid, Peptide, or Protein> ADH <END=Amino Acid, Peptide, or Protein> activity."}]